<SEC-DOCUMENT>0001193125-24-244123.txt : 20241025
<SEC-HEADER>0001193125-24-244123.hdr.sgml : 20241025
<ACCEPTANCE-DATETIME>20241025160608
ACCESSION NUMBER:		0001193125-24-244123
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		24
FILED AS OF DATE:		20241025
DATE AS OF CHANGE:		20241025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Septerna, Inc.
		CENTRAL INDEX KEY:			0001984086
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				843891440
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282469
		FILM NUMBER:		241397111

	BUSINESS ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE, SUITE 65
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-338-3533

	MAIL ADDRESS:	
		STREET 1:		250 EAST GRAND AVENUE, SUITE 65
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d762905d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4) <BR> Registration Nos. 333-282469 and 333-282824<BR>
</B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>16,000,000 Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g00w02.jpg" ALT="LOGO" STYLE="width:1.93125in;height:0.453125in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is an
initial public offering of shares of common stock of Septerna, Inc. </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering 16,000,000 shares of our common stock. Prior to this
offering, there has been no public market for our common stock. The initial public offering price per share is $18.00. Our common stock has been approved for listing on the Nasdaq Global Market under the symbol of &#147;SEPN.&#148; </P>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under U.S. federal securities laws and,
as such, we have elected to comply with certain reduced public company reporting requirements. </P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Investing in
our common stock involves a high degree of risk. See the section titled &#147;<A HREF="#tx762905_4">Risk Factors</A>&#148; beginning on page 14. </B></P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,840,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See the section titled &#147;Underwriting&#148; for additional disclosure regarding the underwriting
discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted the underwriters an option for a period of
30&nbsp;days to purchase up to an additional 2,400,000 shares of our common stock. </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters expect to deliver the shares of
common stock to purchasers on October&nbsp;28, 2024. </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>TD Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is October 24, 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_14">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_18">Shares Eligible For Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_19">Material U.S. Federal Income Tax Considerations For <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_23">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx762905_24">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other
than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common stock offered hereby, but only under circumstances and in jurisdictions where it is
lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our
common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this
offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Market data and certain other statistical information used throughout this prospectus are based on independent industry
publications, governmental publications, reports by market research firms, including, but not limited to, Clarivate<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, or other independent sources that we believe to be reliable sources.
Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
In some cases, we do not expressly refer to the sources from which this data is derived. We are responsible for all of the disclosure contained in this prospectus, and we believe that these sources are reliable. While we are not aware of any
misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on
various factors, including those discussed under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Some data are also based on our good faith estimates. The content of, or accessibility through, the below sources, except
to the extent specifically set forth in this prospectus, does not constitute a portion of this prospectus and is not incorporated herein and any websites are an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The source of certain statistical data, estimates, and forecasts contained in this prospectus are the following independent
industry publications or reports: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pokhrel B, Bhusal K.&nbsp;Graves Disease. Treasure Island (FL): StatPearls Publishing; January&nbsp;2024.
Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License <FONT STYLE="white-space:nowrap">(CC&nbsp;BY-NC-ND&nbsp;4.0);</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Guillen-Aguinaga, S., et al. Updosing nonsedating antihistamines in patients with chronic spontaneous
urticaria: a systematic review and meta-analysis. British Journal of Dermatology 175.6&nbsp;(2016); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Davies, M., et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American
Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45.11 (2022). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights information contained in greater detail elsewhere in this prospectus and does not contain all of
the information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding
Forward-Looking Statements,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our financial statements and the related notes thereto included elsewhere in this prospectus. Except
where the context otherwise requires or where otherwise indicated, the terms &#147;Septerna,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;our company,&#148; &#147;the company,&#148; and &#147;our business&#148; refer to Septerna,
Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule
drug discovery powered by our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development
of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every
organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of all U.S.
Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125&nbsp;billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75%
of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have
been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug
discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous
ligands). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> replicates the
natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins
within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our
Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including
agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat
diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, summarized in the figure below, is focused initially on three therapeutic areas: </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women&#146;s health, cardiovascular,
and respiratory disease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g59y26.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.39853in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Leveraging our team, scientific and technical advisors, and our proprietary Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Aims to Unlock the Full Therapeutic Potential of GPCRs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past decade, drug discovery across various target classes has been revolutionized by a variety of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> tools and technologies. These innovations include structure-based drug design, computational docking, and <FONT
STYLE="white-space:nowrap">DNA-encoded</FONT> libraries (DELs). However, the utilization of these technologies has been limited for discovering oral small molecules targeting GPCRs due to the inability to isolate functional native GPCR proteins
outside of a cellular context. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With our proprietary Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we can purify GPCRs outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous
or synthetic), all housed within a well-defined lipid bilayer environment. These Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery tools and
technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we are advancing a new approach to GPCR drug discovery, designed to expand the
landscape of druggable GPCR targets with novel oral small molecule medicines for patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> is powered by a suite of tools and technologies that we have optimized and integrated into a proprietary and industrialized workflow, and together form an efficient and iterative discovery process
for identification and optimization of novel small molecule product candidates targeting high-value GPCRs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex biochemistry and structural biology:</I></B> Our Native Complexes reconstitute native
GPCR function in a purified biochemical format, which enables efficient high-resolution, three-dimensional structure determination using cryogenic electron microscopy (cryo-EM). This can reveal receptor binding pockets that we can target with a
range of pharmacologies (agonists, antagonists, and allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex-driven hit identification and optimization:</I></B> We virtually screen our GPCR
structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to
screen billions of candidate molecules simultaneously, and we have </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
developed proprietary technologies to discover and optimize compounds with a variety of modes of action. In addition, we use our proprietary Native Complex biochemical screens in our hit
identification and optimization processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced cellular and in vivo pharmacology models: </I></B>We efficiently evaluate hits and lead
compounds through the integration of advanced cellular and <I>in vivo</I> pharmacology models. Prioritized compounds with desired pharmacologies are then either advanced as potential drug candidates or fed back into the process for additional Native
Complex-driven compound optimization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our oral small molecule drug discovery process, powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, is depicted in the figure below. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g15a01.jpg" ALT="LOGO" STYLE="width:5.83333in;height:3.24245in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our industrial-scale Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies to achieve desired
therapeutic effects. Our platform has led to the discovery and development of a pipeline of novel, highly potent and selective oral small molecules, and for our most advanced programs, optimized them into clinical development candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SEP-786</FONT> &#150; Oral Small Molecule PTH1R Agonist for Hypoparathyroidism
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of parathyroid hormone (PTH)
that affects approximately 70,000 patients in the United States and approximately 140,000 patients in Europe. Patients with hypoparathyroidism are at risk of both short-term and long-term complications, including muscle cramps, fatigue, cognitive
dysfunction, and life-threatening complications, such as cardiac arrhythmias, seizures, and renal failure. The goal of treatment is to relieve symptoms and restore calcium and phosphate levels to normal. Current standard of care consists of
high-dose calcium supplements and activated vitamin D (calcitriol); however, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis or address all of the symptoms experienced by patients. Hormone
replacement with injectable PTH peptides, either marketed or in clinical development, may improve blood chemistry profiles of patients via PTH1R activation but will require life-long daily injections. We believe there is a substantial opportunity
for an oral small molecule therapy that offers convenience, improved compliance, and potentially superior efficacy. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT>
is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. PTH1R is a historically <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-drug</FONT></FONT> small molecule
target, yet we effectively leveraged our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to discover and optimize <FONT STYLE="white-space:nowrap">SEP-786</FONT> with desired drug-like properties. We have successfully
completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> We expect to report data from this trial
in mid-2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I></I><B><I><FONT STYLE="white-space:nowrap">SEP-631</FONT> &#150; Oral Small Molecule MRGPRX2 NAM for CSU and Other Mast
Cell Diseases</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chronic spontaneous urticaria (CSU) is a systemic inflammatory skin disease characterized by
the spontaneous and persistent recurrence of itchy, painful hives, known as wheals, on the skin and angioedema, or swelling, that affects approximately 1.5 million patients in the United States. While there is no known trigger, the degranulation of
mast cells and release of histamine and other inflammatory mediators lead to these debilitating symptoms. Patients are treated initially with antihistamines and <FONT STYLE="white-space:nowrap">non-responders</FONT> may be treated with Xolair
(omalizumab), an injectable <FONT STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody. The targeting and blocking of IgE-mediated inflammation can effectively address symptoms; however, only an estimated 36% of these
antihistamine-refractory patients respond to anti-IgE therapy. <FONT STYLE="white-space:nowrap">Mas-related</FONT> <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptor member X2 (MRGPRX2) plays an important role in mast cell activation
and degranulation. We believe an oral therapy that inhibits MRGPRX2 could provide a differentiated treatment option for patients with CSU given the selective inhibition of mast cells and potential for combination therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> is a selective, oral small molecule MRGPRX2 negative allosteric modulator
(NAM) that we are developing initially for the treatment of CSU. We have initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">SEP-631</FONT> and upon completion, we anticipate submitting for
regulatory clearance to initiate a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to CSU, we may develop
<FONT STYLE="white-space:nowrap">SEP-631</FONT> for the treatment of other mast cell diseases. MRGPRX2 is highly and uniquely expressed on mast cells that drive multiple prevalent diseases, including allergic asthma, atopic dermatitis, interstitial
cystitis, migraine, and prurigo nodularis. We believe <FONT STYLE="white-space:nowrap">SEP-631</FONT> could offer a novel oral treatment option for these patient populations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I></I><B><I>TSHR Program &#150; Oral Small Molecule TSHR NAM for Graves&#146; Disease and TED</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Graves&#146; disease is one of the most prevalent autoimmune conditions affecting over 2 million patients in the United States
and is the leading cause of hyperthyroidism, resulting in symptoms including anxiety, irritability, tremor, and fatigue. Treatments have remained largely unchanged over the past 70 years, and include anti-thyroid medications, radioactive iodine
therapy to ablate thyroid gland function, and thyroidectomy surgery. These treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression to thyroid eye disease (TED) for
approximately 50% of Graves&#146; disease patients. TED is a serious, progressive and vision-threatening autoimmune condition that can lead to eye bulging, swelling, pain and blurred or double vision. Current treatments for TED, such as TEPEZZA
(teprotumumab-trbw), an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IGF-1R</FONT></FONT> human monoclonal antibody, are designed to help manage symptoms. Despite reaching global sales of $2.0&nbsp;billion in 2022, TEPEZZA
requires several intravenous (IV)&nbsp;infusions over several months and has risks of serious side effects, including hearing loss and metabolic issues, such as increased blood glucose or hyperglycemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These autoimmune conditions are caused by autoantibodies that bind to and activate the thyroid stimulating hormone receptor
(TSHR) on thyroid cells in the thyroid gland (leading to Graves&#146; disease) and other cells including fibroblasts located behind the eyes (leading to TED). We believe an oral small molecule TSHR NAM could offer a novel disease-modifying treatment
approach that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#146; autoantibodies. We are advancing several lead compounds towards selection of a development candidate for IND-enabling
studies. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incretin Programs - Oral Small Molecule Single- and Multi-Incretin Receptor Agonists for Metabolic
Disorders Including Obesity and T2D </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obesity and diabetes are two of the most prevalent diseases in the world,
affecting a combined total of more than 800&nbsp;million people, and are associated with severe health complications, including cardiovascular disease and kidney failure, as well as an increased risk of death. Weight reduction is seen as an
important treatment goal for patients with either condition. In recent years, several injectable peptide agonists targeting select metabolic hormone receptors, or incretin receptors, have been approved for the treatment of T2D and obesity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Three incretins play significant roles in glucose metabolism and homeostasis: glucagon-like
<FONT STYLE="white-space:nowrap">peptide-1</FONT> <FONT STYLE="white-space:nowrap">(GLP-1),</FONT> gastric inhibitory polypeptide (GIP), and glucagon. Third-party clinical data with incretin-targeted therapeutics have demonstrated substantial and
sustained reductions in body weight, as well as the ability to lower blood glucose and improve glycated hemoglobin (HbA1c). Global sales in 2023 for Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk), and Mounjaro and Zepbound
(tirzepatide, each marketed by Eli Lilly and Company) were $18.4&nbsp;billion and $5.3&nbsp;billion, respectively. As a class, the marketed GLP-1 and GLP-1/GIP products generated $36 billion in global sales in 2023. Despite these advancements in the
treatment of obesity and T2D, a number of key limitations remain for the incretin therapeutic class, including tolerability, prolonged titration schemes, injection administration, and supply challenges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on unique chemical and structural insights obtained with our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, we believe we have an opportunity to discover and develop novel, next-generation, oral small molecules as selective single- or multi-acting <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP,
glucagon receptor agonists. We are advancing several lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Summary of Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Investment in our common stock involves substantial risks and uncertainties, and our ability to execute on our business
strategy is subject to a number of risks, which are discussed more fully in the section titled &#147;Risk Factors.&#148; You should carefully consider these risks before making an investment in our common stock. If any of these risks or
uncertainties actually occur, our business, financial condition, or results of operations could be materially and adversely affected. In such case, the trading price of our common stock would likely decline, and you could lose all or part of your
investment. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant operating losses since our inception and expect
to incur significant losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional funding in order to finance our
operations. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other
operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are early in our development efforts. We have only recently initiated early clinical studies, and as a
result it will be years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them,
or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and
outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our
future therapeutic candidates on a timely basis or at all. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical
trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may
be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval,
revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates are subject to extensive regulation and compliance obligations, which is costly and
time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could
be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is based on
novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory
approval, and we may not be successful in our efforts to expand our development portfolio of product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We currently have no marketing and sales organization and have no experience as a company in commercializing
products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing, sales or distribution capabilities or enter into agreements with third parties to market and sell our products, we may not be
able to generate product revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if any of our current or future product candidates receive marketing approval, such product candidate may
fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing
products before or more successfully than us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third-party manufacturers, clinical research organizations (CROs), contract manufacturing
organizations (CMOs), and suppliers to supply, develop and test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply
sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional
risks and uncertainties not presently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future, growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Corporate and Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our
name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California 94080, and our telephone number is (650) <FONT STYLE="white-space:nowrap">338-3533.</FONT>
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Our website address is <I>www.septerna.com</I>. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this
prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
prospectus includes our trademarks and trade names which are protected under applicable intellectual property laws and are our property. This prospectus also contains trademarks, trade names and service marks of other companies, which are the
property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus may appear without the&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,&nbsp;<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&nbsp;or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted under applicable law, our rights or the right of the
applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#146; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a
relationship with, or endorsement or sponsorship of us by, these other parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Implications of Being an Emerging Growth Company and a
Smaller Reporting Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our
Business Startups Act of 2012, as amended (JOBS Act). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold nonbinding advisory votes on executive compensation or to obtain stockholder
approval of any golden parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth
company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.235&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal
year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we
are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (SEC). We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage
of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that
are not emerging growth companies. As a result of this </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may
choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company&#148; as defined in the Securities Exchange Act of 1934, as amended (Exchange
Act), meaning that the market value of our shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue
was less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue was less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure
requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_2"></A>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,000,000&nbsp;shares. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have granted the underwriters an option for a period of 30 days to purchase up to 2,400,000 additional shares of our common stock
from us at the public offering price, less underwriting discounts and commissions on the same terms as set forth in this prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">42,002,794&nbsp;shares (or 44,402,794 shares if the underwriters exercise their option to purchase additional shares in full).
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that the net proceeds to us from this offering will be approximately $262.0 million (or approximately $302.2 million if the
underwriters exercise their option to purchase additional shares in full), based on the initial public offering price of $18.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We currently intend to use the net proceeds from this offering, together with our existing cash, cash
equivalents, and marketable securities, as follows: approximately $117&nbsp;million to advance the continued development of SEP-786, our lead product candidate from our PTH1R program through completion of a Phase 2 clinical trial in
hypoparathyroidism patients and initiation of a Phase 3 clinical trial, and additional molecules targeting PTH1R; approximately $37&nbsp;million to advance the development of SEP-631 through completion of a Phase 1 clinical trial and initiation of
Phase 2 clinical studies, and additional small molecules within our MRGPRX2 program; approximately $57&nbsp;million for other research and development activities, including our TSHR and incretin receptor programs, other new GPCR programs, and
continued innovation of our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>; and the remainder to fund working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investing in our common stock involves a high degree of risk. You should read the section titled &#147;Risk Factors&#148; and other
information included in this prospectus before investing in our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq trading symbol </P></TD>
<TD> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;SEPN&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering is based on 3,163,020 shares of our common
stock (which includes 784,550&nbsp;shares of unvested restricted common stock subject to repurchase or forfeiture) outstanding as of June&nbsp;30, 2024, and assumes the automatic conversion of all outstanding shares of our convertible preferred
stock into an aggregate of 22,839,774 shares of our common stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,796,272&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of
June&nbsp;30, 2024 under our 2021 Stock Option and Grant Plan, as amended from time to time (2021 Plan), with a weighted-average exercise price of $2.68 per share; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,228,574 shares of our common stock issuable upon the exercise of stock options granted after June&nbsp;30,
2024 pursuant to the 2021 Plan, with a weighted-average exercise price of $6.81 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,690,000 shares of our common stock that became available for future issuance under our 2024 Stock Option and
Incentive Plan (2024 Plan), which became effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock
reserved for future issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">369,402 shares of our common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan
(ESPP), which became effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future
issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, all information in this prospectus reflects or
assumes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-for-8.6103</FONT> reverse stock split of our common stock, which we
effected on October&nbsp;18, 2024 and a corresponding adjustment to the ratio at which our convertible preferred stock will convert into common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock as of June&nbsp;30, 2024
into an aggregate of 22,839,774 shares of our common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">784,550 shares of unvested restricted common stock subject to repurchase or forfeiture as of June&nbsp;30,
2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding stock options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase up to an additional 2,400,000 shares of our common
stock in this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the
completion of this offering and the effectiveness of our amended and restated bylaws upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables summarize our financial data for Septerna, Inc. You should read the following summary financial data
together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes thereto included elsewhere in this prospectus. We have derived
the summary statements of operations and comprehensive (loss) income data for the years ended December&nbsp;31, 2022 and 2023 from our audited financial statements included elsewhere in this prospectus. We have derived the summary statements of
operations and comprehensive (loss) income data for the six months ended June&nbsp;30, 2023 and 2024, and the summary balance sheet data as of June&nbsp;30, 2024, from our unaudited interim condensed financial statements included elsewhere in this
prospectus. Our unaudited interim condensed financial statements were prepared on a basis consistent with our audited financial statements and include, in our opinion, all adjustments of a normal and recurring nature that are necessary for the fair
statement of the financial information set forth in those statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in any future period and our interim results are
not necessarily indicative of results that may be expected for the full year. The summary financial data included in this section are not intended to replace the audited financial statements and the related notes thereto included elsewhere in this
prospectus and are qualified in their entirety by our financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations and Comprehensive (Loss) Income Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&#8194;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income before (provision) benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Provision) benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share attributable to common stockholders<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net (loss) income per share attributable to
common stockholders<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,928,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,284,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,177,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,284,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net (loss) income per share attributable to common stockholders (unaudited)<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding used in computing net (loss) income per share
attributable to common stockholders (unaudited)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,225,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,495,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,473,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,495,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See Note 13 to our audited financial statements and Note 10 to our unaudited interim condensed financial
statements included elsewhere in this prospectus for details on the calculation of basic and diluted net (loss) income per share attributable to common stockholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The unaudited pro forma basic and diluted net (loss) income per share were computed using the
weighted-average number of shares of common stock outstanding, including the pro forma effect of the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock as of the beginning of the period, or the
issuance dates of the respective convertible preferred stock, if later. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands, except for share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Condensed Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">393,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">438,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">418,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma balance sheet data gives effect to the automatic conversion of all outstanding shares of our
outstanding convertible preferred stock as of June&nbsp;30, 2024 into an aggregate of 22,839,774 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity, each of which
will occur immediately prior to the completion of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma as adjusted balance sheet data gives effect to (i)&nbsp;the pro forma adjustments set forth in
footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of 16,000,000 shares of our common stock in this offering at the initial public offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our unaudited interim condensed
financial statements and the related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties
described below together with all of the other information contained in this prospectus, including our financial statements and related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any of the
events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment.
The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Limited Operating History, Financial Position and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a limited operating history and have incurred significant operating losses since our inception and expect to incur significant
losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pharmaceutical product development is a highly speculative undertaking and
involves a substantial degree of risk. We are a clinical-stage biotechnology company with a limited operating history<I>,</I>&nbsp;which may make it difficult to evaluate the success of our business to date and assess our future viability. Since our
inception in December 2019, we have focused primarily on organizing and staffing our company, business planning, establishing our intellectual property portfolio, raising capital, developing our proprietary and structure-based drug discovery
platform, identifying and developing our product candidates, conducting research and preclinical studies, including <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, initiating and conducting clinical trials, and providing general and
administrative support for these operations. Our approach to the discovery and development of product candidates based on our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is unproven, and we do not know whether we
will be able to develop any product candidates that succeed in clinical development or commercially. Further, our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is in early clinical development and our other product
candidates and development programs are in preclinical development or in the drug discovery stages. Accordingly, we have not yet completed any clinical trials, demonstrated an ability to successfully obtain regulatory approvals, manufactured a
clinical- or commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success
or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we
continue to incur significant research and development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred significant losses since our inception, with
the exception of the year ended December&nbsp;31, 2023, and negative cash flows from operating activities and capital expenditures and expect to continue to incur significant and increasing operating losses for at least the next several&nbsp;years.
If our product candidates are not successfully developed and approved, we may never generate any significant revenue. Our net loss was $27.7&nbsp;million for the year ended December&nbsp;31, 2022 and net income was $4.2&nbsp;million for
the&nbsp;year ended December&nbsp;31, 2023. For the six months ended June 30, 2024, our net loss was $30.6 million. As of June&nbsp;30, 2024, we had an accumulated deficit of $77.2&nbsp;million. Substantially all of our losses have resulted from
expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources
before we would be able to apply for or receive marketing approvals and begin generating revenue from product sales. We expect to continue to incur significant losses for the foreseeable future, and we expect that our expenses will increase
substantially as we continue our development of, seek marketing approval for and potentially commercialize any of our product candidates, recruit and maintain key personnel and seek to identify, assess, acquire,
<FONT STYLE="white-space:nowrap">in-license</FONT> or develop additional product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we succeed in
developing and obtaining marketing approval for one or more of our current or future product candidates, we may never generate revenue that is significant enough to achieve profitability. If we do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other
expenditures to develop and market additional product candidates. Our failure to become and remain profitable could decrease the value of our common stock and impair our ability to raise capital, maintain our research and development efforts, expand
our business or continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if this offering is successful, we will require substantial additional funding in
order to finance our operations. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future
commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development of pharmaceutical product candidates, including
conducting preclinical studies and clinical trials, is a very time-consuming, capital-intensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses
to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate and conduct clinical trials of, and seek regulatory approval for, <FONT STYLE="white-space:nowrap">SEP-786</FONT>
and any additional product candidates we may identify. In addition, if we obtain regulatory approval for any product candidates we may identify, we expect to incur significant commercialization expenses related to product sales, marketing,
manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility of a collaborator. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot
reasonably estimate the actual amount of capital necessary to successfully complete the development and commercialization of our product candidates. Other unanticipated costs may also arise. Furthermore, upon the completion of this offering, we
expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on
acceptable terms, we would be forced to delay, reduce, or eliminate our research and product development programs, future commercialization efforts or other operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June 30, 2024, we had $155.7 million in cash, cash equivalents and marketable securities. We expect that the net
proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2027. However, we have based this
estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of factors currently unknown to us, and we may need to seek funding sooner than planned. Our future capital requirements will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of research and development, preclinical and clinical development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number, scope and duration of clinical trials required for regulatory approval of our current or future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our current or future product candidates in any
jurisdictions in which we or our current or any future collaborators may seek approval for our current or future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing clinical and commercial supplies of our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales
and distribution, for any of our current or future product candidates for which we receive regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting our patent applications, maintaining and enforcing our patents
and other intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other
arrangements, and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaboration and license agreements on favorable terms, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates
and technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our current or future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our implementation of various computerized informational systems and efforts to enhance operational systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products, and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of global economic uncertainty and geopolitical tensions, which may exacerbate the magnitude of the
factors discussed above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our expenses to continue to increase in connection with our ongoing
activities, particularly as we identify, continue the research and development of, initiate preclinical studies and clinical trials of, and seek marketing approval for, product candidates, and we may never generate the necessary data or results
required to obtain regulatory approval and achieve product sales. In addition, our current or future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we
do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable
terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, and possibly
other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any additional fundraising efforts may divert our management from their <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. We have no committed sources of additional capital and, if
we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our current or future product candidates or other
research and development initiatives. Without sufficient funding, our license agreements and any future collaboration agreements may also be terminated if we are unable to meet the payment or other obligations under such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit,
reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Additionally, if we raise funds through
additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates we develop, or we may have
to grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have never
generated revenue from product sales and may never be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to generate revenue from product
sales and achieve profitability depends on our ability, alone or with collaborative partners, to successfully complete the development of, obtain the regulatory approvals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
necessary to commercialize and eventually commercialize, product candidates we may identify for development. We may not generate revenues from product sales for many years, if ever. Our ability
to generate future revenues from product sales depends heavily on our or our collaborators&#146; ability to successfully: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify product candidates and successfully complete research and development of any product candidates we
may identify; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our product candidates through preclinical and clinical development, including as we advance <FONT
STYLE="white-space:nowrap">SEP-786</FONT> into later-stage clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek and obtain regulatory approvals for any product candidates for which we successfully complete clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch and commercialize any product candidates for which we may obtain regulatory approval by establishing a
sales force, marketing and distribution infrastructure, or alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualify for adequate coverage and reimbursement by government and third-party payors for any product
candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in
both amount and quality, products and services to support clinical development and the market demand for any product candidates for which we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop, maintain and enhance a sustainable, scalable, reproducible and transferable manufacturing process for
the product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">address competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and
performing our obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive market acceptance by physicians, patients, healthcare payors, and others in the medical community;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive coverage and adequate reimbursement by healthcare payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect, enforce, defend and expand our portfolio of intellectual property and other proprietary
rights, including patents, trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against third-party intellectual property claims of infringement, misappropriation or other violation;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our expenses could increase beyond expectations if we are required by the FDA, European Medicines Agency (EMA), the competent
authorities of individual European Union (EU) Member States, or other comparable foreign regulatory authorities to perform preclinical studies or clinical trials in addition to those that we currently anticipate. Even if one or more of the product
candidates we may develop are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Additionally, such products may become subject to unfavorable pricing regulations,
third-party reimbursement practices or healthcare reform initiatives. Even if we are able to generate revenues from the sale of any approved product candidates, we may not become profitable and may need to obtain additional funding to continue
operations. Our failure to become and remain profitable may have an adverse effect on the value of our company and depress the market price of our common stock and could impair our ability to raise capital, expand our business, maintain our research
and development efforts, diversify our product candidate pipeline, achieve our strategic objectives or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Discovery, Development and Regulatory Approval of Product Candidates
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are early in our development efforts. We have only recently initiated early clinical studies, and as a result it will be
years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience
significant delays in doing so, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The success of our business depends
primarily upon our ability to identify, develop and commercialize product candidates. We are early in our development efforts and our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is in early clinical development and our
other product candidates and development programs are in preclinical development or in the drug discovery stages. We have invested substantially all of our research efforts to date in developing our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, identifying potential product candidates and conducting preclinical and clinical studies. As an organization, we have limited experience in conducting and managing clinical trials necessary to
obtain regulatory approvals, and we may be unable to do so for our product candidates. While we have successfully completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">SEP-786,</FONT> our lead
product candidate from our PTH1R program, and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786,</FONT> we have not yet completed any clinical trials for <FONT
STYLE="white-space:nowrap">SEP-786</FONT> or any of our product candidates to date. Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery or preclinical development and may never advance to clinical-stage
development. If we are able to advance these other targets and programs into clinical development, we do not have experience managing multiple clinical trials simultaneously, working with global clinical trials, or working in multiple different
disease indications. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing our product candidates, either alone or with third parties, and we cannot guarantee you that we
will ever obtain regulatory approval for any of our product candidates. Before obtaining regulatory approval for the commercial distribution of our product candidates, we must conduct extensive preclinical tests and clinical trials to demonstrate
the safety and efficacy in humans of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not have the financial resources to continue
development of, or the ability to enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful
or problematic side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product
candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product-related side effects experienced by patients in our clinical trials or by individuals using product
similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party manufacturers&#146; inability to successfully manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and
those of our collaborators to supply the needs of clinical trials or commercial sales; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in submitting INDs or other comparable foreign applications or delays or failures in obtaining the
necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical studies conducted outside of the United States may be affected by tariffs or import/export
restrictions imposed by the United States or other foreign governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions imposed by the FDA, EMA or other comparable foreign regulatory authorities regarding the scope or
design of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">high <FONT STYLE="white-space:nowrap">drop-out</FONT> rates of our clinical trial patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the
conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to obtain alternative sources of supply for which we have a single source for product candidate
components or materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater than anticipated costs of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that no longer make
a product candidate economically feasible; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate a benefit-risk profile acceptable to the FDA, EMA, or other comparable foreign
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA, EMA, or other comparable foreign regulatory authority inspection and review of any of the
clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise
meet their contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">varying interpretations of our data by the FDA, EMA, and similar foreign regulatory authorities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our inability to complete development of, or commercialize our product candidates, or significant
delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical
studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our therapeutic candidates or any of our future therapeutic candidates
on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Successful development of pharmaceutical products involves a lengthy and expensive
process, is highly uncertain, and is dependent on numerous factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial results may show the product candidates to be less effective than expected (for example, a
clinical trial could fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among
other things, may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to <FONT STYLE="white-space:nowrap">follow-up,</FONT> length of time to achieve trial
endpoints, additional time requirements for data analysis or New Drug Application (NDA) or similar foreign application preparation, discussions with the FDA, EMA or other comparable foreign regulatory authorities, including FDA, EMA or other
comparable foreign regulatory authorities requesting additional preclinical or clinical data (such as long-term toxicology studies), or encountering unexpected safety or manufacturing issues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful <FONT
STYLE="white-space:nowrap">on-target</FONT> or <FONT STYLE="white-space:nowrap">off-target</FONT> side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of extensive post-marketing approval requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proprietary rights of others and their competing products and technologies that may prevent our product
candidates from being commercialized. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, the length of time necessary to complete clinical
trials and submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict. Even
if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as
the Medicare and Medicaid programs and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may be affected by existing and future healthcare reform measures designed to reduce
the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources.
If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced. Even if we are able to obtain coverage and adequate
reimbursement for our products once approved, there may be features or characteristics of our products, such as dose preparation requirements, that prevent our products from achieving market acceptance by the healthcare or patient communities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory
obligations regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with current Good Manufacturing Practice (cGMPs)
and Good Clinical Practice (GCPs) for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with a product post-approval,
such as AEs of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may encounter substantial delays in the commencement, enrollment or completion of our planned clinical
trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, which could prevent us from commercializing any product candidates we determine to develop on a timely basis, if at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The risk of failure in developing product candidates is high. It is impossible to predict when or if any product candidate
would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development, submit an IND or comparable
foreign application to permit initiation of clinical studies, and then conduct extensive clinical trials to demonstrate the safety and efficacy of product candidates in humans. We have not yet completed a clinical trial of any product candidate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and
studies that support our INDs and other regulatory filings. We cannot be certain of the timely identification of a product candidate or the completion or outcome of our preclinical testing and studies and cannot predict whether the FDA, EMA or other
comparable foreign regulatory authorities will accept our proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of any product candidates. Conducting preclinical
testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. As a result, we cannot be sure
that we will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be able to submit INDs or other comparable foreign regulatory submissions for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs will
result in the FDA, EMA, or other comparable foreign regulatory authority allowing clinical trials to begin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore,
product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could
impact our ability to continue to conduct our clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical testing is expensive, is difficult to design and
implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage
of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other events that may prevent successful enrollment, initiation or timely completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to generate sufficient preclinical, toxicology or other <I>in vivo</I> or <I>in vitro</I>
data to support the initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with applicable regulatory authorities on trial design or implementation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining regulatory authorization to commence a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs, other vendors, or clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different vendors and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining approval from one or more institutional review boards (IRB) refusing to approve,
suspending or terminating the trial at an investigational site, precluding enrollment of additional participants, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our ongoing and planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol such as the data collection omission we experienced at a clinical
site as discussed above or dropping out of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing sufficient quantities of our product candidates for use in clinical trials, or delays
in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having our product candidates being shipped on time, clearing customs and arriving at clinical trial
sites intact; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participants choosing an alternative treatment for the indication for which we are developing our product
candidates, or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of AEs or serious adverse events (SAEs) associated with the product candidate that are viewed to
outweigh its potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of SAEs in clinical trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory authorities; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical trial end points that require prolonged periods of clinical observation or analysis of
the resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials producing negative or inconclusive results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA or
comparable foreign authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or contamination or cross-contaminations of product candidates in the manufacturing process;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials,
not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol or other regulatory requirements or committing fraud; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements, guidance, or feedback from regulatory agencies that require amending or
submitting new clinical protocols or otherwise modifying the design of our clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could
also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs overseeing the conduct of such trials, by a Data Safety Monitoring Board for such trial or by the FDA, EMA, or other comparable foreign regulatory authorities.
Such regulatory authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by the FDA, EMA, or other comparable regulatory foreign authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to
comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination and approval, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks
that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional
administrative burdens associated with foreign regulatory requirements, as well as political, currency exchange and other economic risks relevant to such foreign countries. Investigators and patients may not be able to comply with clinical trial
protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff which in turn could adversely impact our clinical trial operations.
Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments,
employers and others in connection with public health concerns. We may face delays in meeting our anticipated timelines for our ongoing and planned clinical trials, which could adversely affect our business, financial condition, results of
operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any inability to successfully complete preclinical and clinical development could result
in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to
conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow
our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Serious adverse events, undesirable side effects or other unexpected properties of our
product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following
marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have not completed the evaluation of any product candidates in human clinical trials. It is impossible to predict
when or if any product candidates we may develop will ultimately prove safe in humans. As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates&#146; use.
Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In
addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials with a broader group of patients, or as use of these product candidates becomes more widespread if they receive marketing approval,
illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants. Many times, side effects are only detectable after
investigational product candidates are tested in large-scale, Phase&nbsp;3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current
or future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has
received marketing approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition. In particular, because we are developing our product candidates for chronic indications, the FDA, EMA,
and other comparable foreign regulatory authorities will likely require that our product candidates demonstrate a higher level of safety over a longer period of time than would be the case for product candidates intended for short-term use.
Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be
delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics
that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a
risk-benefit perspective, which may limit the commercial value for the product candidate if approved. We may also be required to modify our trial plans based on findings after we commence our clinical trials. Many compounds that initially showed
promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if any of our product candidates receive marketing approval, the FDA could require us to include a boxed warning
in our label or adopt a REMS, to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care
practitioners. For example, the FDA required that the product label for NATPARA, an approved, injectable parathyroid hormone product targeting PTH1R for the management of hypoparathyroidism include a boxed warning related to the risk of osteosarcoma
based on rodent carcinogenicity studies and also implemented a REMS Program to ensure patients and prescribers were appropriately counseled on the benefits and risks of the drug. Similarly, the FDA initially included boxed warnings for FORTEO and
TYMLOS, injectable PTH peptides approved for osteoporosis due to the risk of osteosarcoma. While we have not yet conducted carcinogenicity studies for <FONT STYLE="white-space:nowrap">SEP-786,</FONT> because it also targets PTH1R, it is possible
that absent compelling data to the contrary, the FDA, EMA, and other comparable foreign regulatory authorities will similarly require a boxed warning for <FONT STYLE="white-space:nowrap">SEP-786</FONT> if it is approved for marketing. Furthermore,
if we or others later identify undesirable side effects caused by our product candidates, several other potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend or withdraw approvals of such product candidate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, including &#147;boxed&#148; warnings, or
issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product candidate is administered or conduct additional clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to conduct a recall; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product may become less competitive, and our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could
significantly harm our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our product candidates are subject to
extensive regulation and compliance obligations, which is costly and time-consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The research, clinical development, testing, quality control, safety, effectiveness, manufacturing, labeling, packaging,
storage, record-keeping, advertising, promotion, marketing, import, export, distribution, post-approval monitoring, and post-approval reporting of our product candidates are subject to extensive regulation by the FDA in the United States and by
comparable foreign regulatory authorities in foreign markets. In the United States, neither we nor any future collaborators are permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining
regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and
patient population. Approval policies or regulations may change, new relevant statutes or regulations may be enacted, and the FDA, EMA and other comparable foreign regulatory authorities have substantial discretion in the drug approval process,
including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our potential future
collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities, that such product candidates are safe and
effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be
sufficient to support approval by the FDA, EMA and other comparable foreign regulatory authorities, which could require us to delay or abandon clinical development plans. In addition, regulatory authorities may require us to conduct further
preclinical studies before evaluating our product candidate in a clinical trial. Once we initiate clinical trials, the FDA, EMA, or other comparable foreign regulatory authorities may require additional clinical trials or suggest changes to our
planned clinical trials, prior to and in support of the approval of a NDA or equivalent foreign marketing application. Changes to data requirements by the FDA, EMA, or other comparable foreign regulatory authorities during the development of our
product candidates may cause the applicable regulatory authorities to require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or regulatory authorities may object to
elements of our clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA, EMA or other comparable foreign regulatory authorities can delay,
limit or deny approval of a product candidate for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical
significance required by the FDA, EMA or other comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or
by individuals using drugs similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety
in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in
countries where the standard of care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate is safe and effective, and that a product
candidate&#146;s clinical and other benefits outweigh its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with our interpretation or analysis of data from preclinical studies or clinical
trials; such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States
or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or
with other significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our
third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or
any of our potential future collaborators&#146; clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect
to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising
questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory
considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of the large number of drugs in development, only a small percentage successfully complete the
FDA, EMA, or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product
candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Enrollment and
retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, which could adversely affect our business, operating results and
prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patient enrollment and retention in clinical trials is a significant factor in the timing of clinical
trials and depends on many factors, including the size and nature of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data with respect to the study drug, the number, nature and duration of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical trial sites and the eligibility criteria for the clinical trial.
As we progress our programs we may not be able to initiate or continue clinical trials for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as
required by the FDA, EMA, or other comparable foreign authorities, or as needed to provide appropriate statistical power for a given trial. For certain of our product candidates, the conditions which we may evaluate include rare diseases with
limited patient pools from which to draw. In some cases, patient populations for rare diseases are located at specific academic sites focused on such indications, often with multiple competing clinical trials. Potential patients for any planned
clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. We also may encounter difficulties in identifying and enrolling patients with a stage of
disease appropriate for our planned clinical trials and monitoring such patients adequately during and after treatment. As noted above, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these
patient populations, which may make it more difficult to fully enroll our clinical trials. In addition, the process of finding and diagnosing patients may prove costly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.
If the actual number of patients with these diseases is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even
once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The timely
completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment
or retention in our clinical trials for a variety of reasons. Patient enrollment and retention in clinical trials depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population, in particular for rare diseases such as the diseases on which
we are focused initially, and process for identifying patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existing body of safety and efficacy data for the product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same
indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity and availability of clinical trial sites for patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the complexity of the trial, including number of office visits, lab tests, patient evaluations, and dosing
regimens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to adequately monitor patients during a trial, clinicians&#146; and patients&#146; perceptions as
to the potential advantages of the product candidate being studied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that enrolled patients will drop out of a trial before completing all site visits; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in
relation to other available therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, our efforts to build relationships with patient
communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned
patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. Further, if patients drop out
of our clinical trials, miss scheduled doses or <FONT STYLE="white-space:nowrap">follow-up</FONT> visits, or otherwise fail to follow clinical trial protocols, the integrity of data from our clinical trials may be compromised or not accepted by the
FDA, EMA, or other comparable foreign regulatory authorities, which would represent a significant setback for the applicable program. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future
clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance. Such delays or failures could adversely affect our business, operating results and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations
and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United
States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA, EMA and other comparable foreign
regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject
to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must
continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated
uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product
candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also require a risk
evaluation and mitigation strategies (REMS) program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician
communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or other comparable foreign regulatory authority approves our
product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events (AEs) of unanticipated severity or frequency, or with our third-party
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or
voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or withdrawal of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, under the Food and Drug Omnibus Reform Act (FDORA) sponsors of approved drugs and biologics must provide six
months&#146; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#146;s ability
to be marketed. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved
label. The policies of the FDA, EMA and other comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. In addition,
the U.S. Supreme Court&#146;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#146; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#146;s
regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. As a result of the Supreme Court&#146;s decision, the FDA and other agencies may be less inclined to engage in formal regulation and may
rely to a greater degree on informal guidance, which may not always be susceptible to immediate challenge. We cannot predict the likelihood, nature or extent of government regulation or guidance that may arise from future court decisions,
legislation, or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or guidance or the adoption of new requirements, guidance, or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our
therapeutics may be delayed and, as a result, our stock price may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we estimate the
timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include our expectations regarding the commencement or
completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial or the
initiation of other clinical programs. All of these milestones are and will be based on numerous assumptions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our available capital resources or capital constraints we experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate of progress, costs and results of our clinical trials and research and development activities,
including the extent of scheduling conflicts with participating clinicians and collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and enroll patients who meet clinical trial eligibility criteria;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our receipt of approvals by the FDA, EMA, and other comparable foreign regulatory authorities and the timing
thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other actions, decisions or rules issued by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our
product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts of our collaborators with respect to the commercialization of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales
and marketing activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">securing product reimbursement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our
control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our product candidates may be delayed or never achieved and, as a result, our stock price may decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Results of preclinical studies and early clinical trials on any of our product candidates may not be predictive of results of future
clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The outcome of preclinical studies and early clinical trials may not be predictive of the success
of later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that
we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including
previously unreported adverse events. In addition, while the animal models used in preclinical studies are designed to be representative of disease states in humans, these preclinical models may not be able to accurately predict the way a product
candidate will affect patients in clinical trials. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. In addition, preclinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some instances, there can be significant variability in safety or efficacy results between
different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing
regimen, product formulation and other clinical trial protocols and the rate of dropout among clinical trial patients. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory
approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications
that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have limited financial and
managerial resources, and to date, we have focused on research programs and product candidates within the endocrinology, immunology and inflammation, neurology and metabolic therapeutic areas, with a particular focus on our lead product candidate, <FONT
STYLE="white-space:nowrap">SEP-786.</FONT> Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we believe could be pursued by
leveraging our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. As a result, we may forgo or delay pursuit of opportunities with other product candidates or in other therapeutic areas that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product
candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product
candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
sole development and commercialization rights to such product candidate. We must continually assess the potential commercial viability of our research programs and product candidates, and we may
decide to pause or discontinue development of any of our product candidates based upon such assessments, even if we obtain positive data from our product candidates in preclinical studies and clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is based on novel technologies that are
unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be
successful in our efforts to expand our development portfolio of product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key element of our strategy
is to use our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to overcome the historical limitations of G protein-coupled receptor (GPCR) drug development, including the isolation, purification and
stabilization of GPCRs in their native forms, in order to build a robust and diverse portfolio of potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> oral small molecule therapies that address both well-validated and novel GPCR targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have only recently commenced our first clinical trial of the first candidate developed with our platform. The scientific
research that forms the basis of our efforts to develop product candidates with our platform is still ongoing. We are not aware of any FDA approved therapeutics utilizing the technology underlying our platform. Further, the scientific evidence to
support the feasibility of developing therapeutic treatments based on our platform is both preliminary and limited. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we
may encounter during development of our product candidates. For example, we have not yet generated any meaningful clinical data on any of the product candidates being developed using our platform, and our current data is limited to animal models and
preclinical cell lines, the results of which may not translate into humans. Further, relevant animal models and assays may not accurately predict the safety and efficacy of our product candidates in humans, and we may encounter significant
challenges creating appropriate models and assays for demonstrating the safety and purity of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the novelty of our technology, we intend to work closely with the FDA and comparable foreign regulatory authorities to
perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory
authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory authorities may lack experience in evaluating
the safety and efficacy of product candidates like those developed using our platform, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our
product candidates. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although our research and development efforts to date have resulted in a development portfolio of potential programs and
product candidates, we may not be able to discover or identify novel chemical matter to new GPCR targets and thus not be able to develop product candidates to expand our development portfolio. We may also pursue opportunities to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> additional businesses, technologies or products, form strategic alliances or create joint ventures with third parties to complement or augment our existing business. However, we may not be able to
identify any product candidates through such acquisition or <FONT STYLE="white-space:nowrap">in-license.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if
we are successful in continuing to build and expand our development portfolio, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to have harmful side effects or other
characteristics that indicate that they are unlikely to be drugs that will be successful in clinical trials or receive marketing approval and achieve market acceptance. If we do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
successfully develop and commercialize product candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position
and adversely affect our stock price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preliminary, topline and interim data from our clinical trials that we announce or publish
from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and planned
clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial.
We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that
we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit
and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously made public. As a result, topline and preliminary data should be viewed with caution until the final data are
available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data become available. Adverse differences between topline, preliminary or interim data and final data could significantly harm our business prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations,
conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in
general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or
otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a
particular product, product candidate or our business. If the topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may develop our current or future product candidates in combination with other therapies, which would expose us to additional risks.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may develop our current or potential future product candidates in combination with one or more currently
approved therapies or therapies in development. Even if any of our current or future product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to
the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these
existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify
other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also evaluate our current or future product candidates in combination with one or more other therapies that have not
yet been approved for marketing by the FDA, EMA or other comparable foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
regulatory authorities. We will not be able to market and sell any product candidate in combination with any such unapproved therapies that do not ultimately obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, we cannot be certain that we will be able to obtain a steady supply of such therapies for use in developing
combinations with our product candidates on commercially reasonable terms or at all. Any failure to obtain such therapies for use in clinical development and the expense of purchasing therapies in the market may delay our development timelines,
increase our costs and jeopardize our ability to develop our product candidates as commercially viable therapies. If the FDA, EMA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies,
or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future product candidates, we may be unable to obtain approval of or successfully
market any one or all of the current or future product candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future product candidates are unable to produce
sufficient quantities for clinical trials or for commercialization of our current or future product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would
have an adverse effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to
Commercialization, Marketing and Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently have no marketing and sales organization and have no experience as a
company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketing, sales or distribution capabilities or enter into agreements with third parties to market and sell
our products, we may not be able to generate product revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no internal sales, marketing or distribution
capabilities, nor have we as a company commercialized a product. If any of our product candidates ultimately receives marketing approval, we will be required to build a marketing and sales organization with technical expertise and supporting
distribution capabilities to commercialize each such product in the markets that we target, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to
augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant
risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively
manage a geographically dispersed sales and marketing team. Furthermore, we are currently developing products for multiple indications in different medical specialties, which will require us to build different sales and marketing capabilities that
are tailored to a given product or medical specialty. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter
into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower
if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary
resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future
product revenue and we would incur significant additional losses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if any of our current or future product candidates receive marketing approval,
such product candidate may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become
profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never commercialized a product, and even if any of our current or future product candidates
are approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Historically, several
injectable PTH peptides have been approved by the FDA and other regulatory authorities for treatment of hypoparathyroidism and osteoporosis. However, our lead product candidate is an oral small molecule agonist; to date, no such oral small molecule
in this indication has been approved by the FDA or any other regulatory agency. Market participants with significant influence over acceptance of new treatments, such as clinicians and third-party payors, may not adopt new oral treatments for
hypoparathyroidism or osteoporosis, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing or future
collaborators. If our current or future product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our current or future
product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications and patient populations for which the product candidate is approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety, efficacy and potential advantages compared to alternative treatments and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of the product as well as competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of our relationships with patient communities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments and therapies, including any similar generic
treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer such product for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inclusion of any REMS program or other restrictions included by the regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of the product together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our
product candidates may require significant resources and may never be successful. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product
candidates, if approved, to find market acceptance would harm our business and could require us to seek additional financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we are able to commercialize any product candidate, the third-party payor
coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to
generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The availability and adequacy of coverage and reimbursement by governmental healthcare programs
such as Medicare and Medicaid, private health insurers and other third-party payors in the United States are essential for most patients to be able to afford treatments such as our products or product candidates, if approved. Our ability to achieve
acceptable levels of coverage and reimbursement for drug treatments by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our products, and potentially attract
additional collaboration partners to invest in the development of our product candidates. We cannot be sure that adequate coverage and reimbursement in the United States, the EU, Australia or elsewhere will be available for our products or any
products that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. For more information, see the section titled &#147;Business&#150;Government Regulation&#150;Coverage and Reimbursement.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third-party payors increasingly are challenging prices charged for pharmaceutical products, medical devices and services,
and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug is available. It is possible that a third-party payor may consider our products or product candidates, if approved, and
the generic or biosimilar parent drug as substitutable and only offer to reimburse patients for the generic drug. Even if we show improved efficacy or safety or improved convenience of administration with our products or product candidates, if
approved, pricing of the existing parent drug may limit the amount we will be able to charge for such product. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products or
product candidates, and may not be able to obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an
important role in determining the extent to which new drugs, biologics and medical devices will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their
coverage and reimbursement policies for drugs, biologics and medical devices. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, international operations are generally subject to extensive governmental price controls and other
market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our products and product candidates, if approved, and
on related parent drugs. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Many countries, including the EU Member States, established complex and lengthy procedures
to obtain price approvals, coverage and reimbursement. These procedures vary from country to country but are commonly initiated after grant of the related marketing authorization. More particularly, in the EU, potential reductions in prices and
changes in reimbursement levels could be the result of different factors, including reference pricing systems. It could also result from the application of external reference pricing mechanisms, which consist of arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced countries. Reductions in the pricing of our medicinal products in one EU Member State could affect the price in other EU Member States and, thus, have a negative impact on our financial
results. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to
charge for our products or product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue
and profits. As an example, many EU Member States </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">review periodically their decisions concerning the pricing and reimbursement of
medicinal products. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outcome of these reviews cannot be predicted and could have adverse effects on the pricing and reimbursement of our medicinal products in the EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce
healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our products or product candidates. We expect to
experience pricing pressures in connection with the sale of our products and product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The
downward pressure on healthcare costs in general, particularly prescription drugs, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products before or
more successfully than us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The biotechnology and pharmaceutical industries are characterized by rapidly advancing
technologies, intense competition, and a strong emphasis on proprietary and novel products and product candidates. While we believe our product candidates, platform, knowledge, experience and scientific personnel provide us with several key
competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our future success will depend in part on our
ability to maintain a competitive position with our structure-based drug discovery platform. If we fail to stay at the forefront of technological change in utilizing our platform to create and develop product candidates, we may be unable to compete
effectively. Our competitors may render our approach obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we
derive from our research approach and platform. Several other companies also focus on GPCRs and have platform technologies that are distinct from the Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, including Nxera
Pharma (formerly Sosei Heptares), Structure Therapeutics, Tectonic Therapeutics, and Confo Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we
face competition with respect to our current product candidates and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the
indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are aware of several pharmaceutical
companies that have commenced clinical trials of product candidates or have successfully commercialized products addressing areas that we are targeting. Takeda owns the rights to parathyroid hormone product (brand name NATPARA) for the treatment of
hypoparathyroidism. NATPARA was voluntarily recalled due to manufacturing issues in September 2019 in the United States and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer. In October
2022, Takeda announced manufacturing of all strengths of NATPARA will be discontinued globally by the end of 2024. Ascendis Pharma received regulatory approval for a proprietary once-daily injectable PTH peptide, palopegteriparatide (brand name
YORVIPATH), in Europe and the United States. In March 2024, AstraZeneca acquired Amolyt Pharma, who was developing eneboparatide, a proprietary, once-daily injectable PTH peptide, for hypoparathyroidism, currently in Phase 3 studies. In addition, we
are aware of several academic groups and companies working on making longer-acting agonists of the PTH1R. Other companies and groups are developing or commercializing therapies for hypoparathyroidism, including Calcilytix (a BridgeBio company),
Entera Bio, Extend Biosciences, and MBX Biosciences. Several companies are developing clinical-stage small molecule MRGPRX2 inhibitors, including Escient Pharmaceuticals (acquired by Incyte Pharmaceuticals in April
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
2024), Evommune, and BioArdis. Further there are several other companies pursuing therapies for CSU addressing other receptors of interest, such a Genentech, Sanofi, Celldex Therapeutics, Jasper
Therapeutics, Acelyrin, Allakos, Novartis, Third Harmonic Bio, and Blueprint Medicines. For TSHR, we are aware that Byondis and Crinetics are also working on research stage compounds, but they have not yet entered clinical development. In addition
several companies are working on other mechanisms to address Graves&#146; disease, such as Immunovant, and TED, including Amgen, Viridian, Argenx, Roche, Lassen Therapeutics, Tourmaline Bio, Sling Therapeutics, and Acelyrin. There are also several
currently approved injectable products targeting incretin receptors for the treatment of obesity or T2D. These include, but are not limited to, products such as Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk) for T2D and obesity,
respectively, Trulicity (dulaglutide, marketed by Eli Lilly and Company) for T2D, and Mounjaro and Zepbound (tirzepatide, each marketed by Eli Lilly and Company) for T2D and obesity, respectively. There are also several injectable peptide products
in development pursuing similar indications with similar mechanism of actions along with combination products, including those being developed by Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, and Viking, among
others. In addition, there are oral products such as Rybelsus (semaglutide, marketed by Novo Nordisk) approved for patients with T2D and other oral products in development for treating obesity or T2D, including those being developed by AstraZeneca,
Eli Lilly and Company, Pfizer, Roche, Structure, and Terns. Based on our continuing evaluations of the competitive landscape, we may decide to reallocate resources and reprioritize our development programs if we determine that a particular product
candidate or target indication is no longer commercially viable or advantageous. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our competitors, either alone or
with their collaborators, have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on
many different factors, including the safety and effectiveness of our products, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement
coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop.
Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue
from the sale of our products we may develop, if approved, could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mergers and acquisitions in the
pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Any failure to compete effectively could harm our business, financial condition and operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the
EU Member States. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to seek approval to market our product candidates in both the United States and in
selected foreign jurisdictions, including the EU. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly
those in the EU, the pricing of products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental
authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement
from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Much like the federal Anti-Kickback Statute prohibition in the United
States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or
advantages to reward improper performance is typically governed by the national anti-bribery laws of EU Member States and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in substantial fines and imprisonment. EU
Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or
benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains
applicable in the United Kingdom despite its departure from the EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payments made to physicians in certain EU Member
States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities
of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational
risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in some foreign countries,
including some countries in the EU, the proposed pricing for a product must be approved before it may be lawfully marketed. The requirements governing product pricing and reimbursement vary widely from country to country. For example, some EU Member
States have the option to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member
States and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the
cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for
pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be
significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels
or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining marketing approval of our product candidates in one jurisdiction does not mean that we will be successful in
obtaining marketing approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining and maintaining marketing
approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, it does
not mean that comparable foreign regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining
marketing approval in one jurisdiction may negatively impact the marketing approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United
States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining foreign marketing approvals and establishing and maintaining
compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with
the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, which would
adversely affect our business, prospects, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future growth may depend, in part, on
our ability to commercialize products in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets.
We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product
candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, manufacturing, commercial
sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and
other obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from pandemics or similar public health crises. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the market opportunities for any of our product candidates are smaller than we estimate, even assuming approval of a product
candidate, our revenue may be adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The precise incidence and
prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit
from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may
prove to be incorrect. Further, new information may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis
criteria included in the final label for each of our product candidates approved for sale for these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical
community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our
products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Business Operation and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our
operating results to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our quarterly and annual operating
results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, degree of success and cost of, and level of investment in, research, development, regulatory
approval and commercialization activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our current and future product candidates, which may vary depending on FDA, EMA or
other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with third-party manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies or other assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be
difficult to predict; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations, licensing or other arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to adequately support future growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials or regulatory approval for our
product candidates or any competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which
we may become involved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential unforeseen business disruptions that increase our costs or expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of macro events, such as inflation, geopolitical conflicts, pandemics, natural disasters and supply
chain issues, on our business and operations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the changing and volatile global economic and political environment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, from time to time, we may enter into license or collaboration agreements or strategic partnerships with other
companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and
any such variance could cause a significant fluctuation in our operating results from one period to the next. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cumulative effects of these factors could result in large fluctuations
and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful.
Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period.
If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price
of our common stock could decline substantially. Such a price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had 68 full-time employees. As we advance our research and development
programs, we may need to further increase the number of our employees and the scope of our operations, particularly in the areas of clinical development, biology, chemistry, manufacturing, general and administrative matters related to being a public
company, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our general and administrative functions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify, recruit, integrate, maintain and motivate additional qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manage our development efforts effectively, including the initiation and conduct of clinical trials for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and build a marketing and commercial organization; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improve our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future financial performance and our ability to develop, manufacture and commercialize our product
candidates, if approved, will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other resources, and a disproportionate amount of its attention away from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, to managing these growth activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and
contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are highly dependent on the services of our senior management team and if we are not able to retain these members of our management
team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are highly dependent on our senior management team. In particular, we are highly dependent on the development and management
expertise of Jeffrey Finer, M.D., Ph.D., our Chief Executive Officer, as the other principal members of our management, scientific and clinical team. The employment agreements we have with these officers do not prevent such persons from terminating
their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. In addition, we will need to attract, retain and motivate highly
qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on terms acceptable to us, additional qualified personnel necessary for the continued development of our business, we may
not be able to sustain our operations or grow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to attract or retain qualified personnel in the future
due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and other resources, different risk profiles and a longer operating history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement.
Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives,
the rate and success at which we can discover and develop product candidates and our business will be limited and we may experience constraints on our development objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock
options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative
offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. For example, employment of our key employees is <FONT
STYLE="white-space:nowrap">at-will,</FONT> which means that any of our employees could leave our employment at any time, with or without notice. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist
us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit
their availability to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future performance will also depend, in part, on our ability to successfully integrate
newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other
members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future marketing approvals, sales of our product candidates and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include
intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)&nbsp;FDA, the national competent authorities of individual EU Member States, or comparable foreign regulations, including those laws that require the
reporting of true, complete and accurate information to the FDA, EMA, or other comparable foreign regulatory authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;U.S. federal and state fraud and abuse and other healthcare laws and regulations,
including foreign requirements; or (iv)&nbsp;laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials or falsification of clinical trial data, which could result in regulatory sanctions and serious harm to
our reputation. It is not always possible to identify and deter misconduct by employees and other third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud
or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the
imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal or non U.S. healthcare
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to
operate our business and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in U.S. and international trade policies, particularly with respect to
China, may adversely impact our business and operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. government has recently made statements
and taken certain actions that may lead to potential changes to U.S. and international trade policies, including imposing several rounds of tariffs and export control and sanctions restrictions affecting certain products manufactured in China. Both
China and the United States have each imposed tariffs indicating the potential for further trade barriers, including the U.S. Commerce Department adding numerous Chinese entities to its Unverified List, which requires U.S. exporters to go through
more procedures before exporting goods to such entities. It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry.
Most recently, legislation pending in Congress called the BIOSECURE Act would, among other things, prohibit U.S. federal government contracts, grants, and loans in connection with biotechnology equipment or services provided or produced by certain
named Chinese &#147;biotechnology companies of concern,&#148; which include WuXi AppTec and WuXi Biologics, or collectively WuXi. See the risk factor titled &#147;Risks Related to Government Regulatory and Legal Requirements&#151;We rely on
third-party manufacturers, CROs, CMOs, and suppliers to supply, develop and test components of our product candidates. The loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory
requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product candidate manufacturing, development or formulation would materially and adversely affect our business.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any unfavorable government policies on international trade, such as export controls, economic, sanctions, capital controls or
tariffs, may increase the cost of manufacturing our product candidates and platform materials, affect our ability to commercialize our product candidates if approved, the competitive position of our product candidates, and import or export of raw
materials and finished product candidate used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including pursuant to our service arrangements with WuXi. If
any new tariffs, export controls, sanctions, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if either the U.S. or Chinese government takes retaliatory trade actions due to the
recent trade tensions, such changes could have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and
could limit commercialization of any product candidates we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will face an inherent risk of clinical
trial and product liability exposure related to the testing of any product candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have not
completed the evaluation of any product candidates in human clinical trials or that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may
expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product
candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants and inability to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant time and costs to defend any related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidates that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in price of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need to increase our insurance coverage if we continue to commence clinical trials or if we commence commercialization
of any product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If and when coverage is secured, our
insurance policies may also have various exclusions and we may be subject to a product liability claim for which we have no coverage. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such
indemnification may not be available or adequate should any claim arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets
may not be sufficient to cover such claims and our business operations could be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we or any contract manufacturers and
suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including
those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or
injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance. Under certain environmental laws, we could be held responsible
for costs relating to any contamination at our current or past facilities and at third-party facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We could incur
significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage
and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and
regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance
to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for
environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. In the event of contamination or injury, we could be held liable for damages
or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may incur substantial costs in order to comply with current
or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future ability to utilize our
net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have
incurred losses and we may never achieve profitability. As of December&nbsp;31, 2023, we had $14.6 million of federal net operating loss (NOL) carryforwards and $28.9 million of state NOL carryforwards, available to reduce future taxable income. To
the extent that we continue to generate taxable losses, under current law, our unused U.S. NOLs may be carried forward to offset a portion of future taxable income, if any. Additionally, we continue to generate business tax credits, including
research and development tax credits, which generally may be carried forward to offset a portion of future taxable income, if any, subject to expiration of such credit carryforwards. Under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended (Code), if a corporation undergoes an &#147;ownership change,&#148; generally defined as one or more stockholders or groups of stockholders who own at least 5% of the corporation&#146;s equity increasing their equity ownership in the
aggregate by more than 50 percentage points (by value) over a three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax
attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Similar rules may apply under state tax laws. Our prior equity offerings and other changes in our stock ownership may have resulted
in such ownership changes in the past. In addition, we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net
taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs or other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset U.S. federal taxable income may be subject to limitations, which
could potentially result in increased future tax liability to us and could require us to pay U.S. federal income taxes earlier than would be required if such limitations were not in effect. Additional limitations on our ability to utilize our NOLs
to offset future taxable income may arise as a result of our corporate structure whereby NOLs generated by our subsidiary may not be available to offset taxable income earned by our subsidiary. There is a risk that due to changes under the tax law,
regulatory changes or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or
business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, under Senate Bill 167 enacted by California in June 2024, generally, there is a suspension of the NOL deduction for
tax years beginning on or after January&nbsp;1, 2024, and before January&nbsp;1, 2027 for individual and corporate taxpayers with net business income or modified adjusted gross income of $1&nbsp;million or more, and a limit of $5&nbsp;million of
business credits on the aggregate use of otherwise allowable business tax credits that any individual or corporate taxpayer could claim for tax years beginning on or after January&nbsp;1, 2024, and before January&nbsp;1, 2027. For these reasons, we
may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have and may
in the future engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have and in the future, we may consider strategic transactions, such as acquisitions of companies, asset purchases, and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> or <FONT STYLE="white-space:nowrap">out-licensing</FONT> of products, product candidates or technologies from time to time. Additional potential transactions that we may consider include a variety of
different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our senior management or business, which could adversely affect our
operations and financial results. For example, these transactions may entail numerous operational and financial risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">up-front,</FONT> milestone and royalty payments, equity investments and
financial support of new research and development candidates including increase of personnel, all of which may be substantial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exposure to unknown liabilities, including potential indemnification claims from a potential <FONT
STYLE="white-space:nowrap">spin-off</FONT> or <FONT STYLE="white-space:nowrap">out-license</FONT> of certain of our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption of our business and diversion of our management&#146;s time and attention to develop acquired
products, product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher than expected costs in risk-sharing collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">higher-than-expected acquisition and integration costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower-than-expected benefits, from <FONT STYLE="white-space:nowrap">out-licensing</FONT> or selling our
technology, intellectual property or any of our subsidiaries or, from <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property or purchasing assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">write-downs of assets or goodwill or impairment charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty and cost in combining or separating the operations and personnel of any acquired or sold businesses
with our existing operations and personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may disagree with our strategic partners about decisions affecting the business, which could result in
litigation or arbitration that increases our expenses, distracts our officers and directors and disrupts the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the strategic venture, including by
delaying important decisions until the dispute is resolved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategic partners may take actions that we oppose; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our strategic partners might experience financial distress or become bankrupt; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of relationships with key suppliers or customers of any acquired or sold businesses due to changes
in our senior management and ownership; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to retain key employees of any acquired businesses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, to the extent we enter into a strategic transaction that includes ongoing operations or shared ownership and
management, our strategic partners may take actions that we oppose or we may disagree with our strategic partners about decisions affecting the business, which could result in litigation or arbitration, distract our officers and directors and
otherwise disrupt the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of our business and the business of the strategic partner or entity. Furthermore, to the extent that our directors and
officers serve on the boards of our strategic partners, such directors may be required to abstain from board decision-making in the event of a conflict of interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, although we cannot be certain that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks, and could harm our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are conducting, and will continue to conduct, clinical trials for our current product candidates outside of the United States, and we
may do so for our other product candidates. However, conducting trials outside of the United States exposes us to additional risks, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are conducting, and may in the future conduct, certain of our clinical trials at centers outside of the United States. The
acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or another comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. For example,
in cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are
applicable to the U.S. population and U.S. medical practice; (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii)&nbsp;the data may be considered valid without the need for
an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. In
addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in
accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would
be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. If the FDA, the EMA, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), or other foreign regulatory authorities do not accept any
data generated from other jurisdictions, we would likely be required to conduct additional clinical trials, which would be costly and time consuming, and delay aspects of our development plan, which could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Conducting trials outside the United States also exposes us to additional risks, including risks associated with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our information systems or data, or those of third parties with whom we work, are or were compromised, we
could experience adverse consequences from such compromises, such as damage our reputation, significant financial and legal exposure, or other adverse effects to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely on information technology systems that we or third parties with whom<B><I> </I></B>we work, operate to process,
transmit and store electronic information, including sensitive information, in our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. For example, in connection with our product development
efforts, we may collect and process a variety of personal data, proprietary information, trade secrets, and clinical trial information. As a result, we and the third parties with whom<B><I> </I></B>we work, face a variety of evolving threats that
could cause security incidents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cyberattacks, malicious internet-based activity, online and offline fraud, and other
similar activities could result in the theft or destruction of intellectual property, personal data, or other misappropriation of assets, or otherwise threaten to compromise our confidential or proprietary information and disrupt our operations.
Such threats are increasing in their frequency, sophistication, and intensity, have become increasingly difficult to detect, and come from a variety of sources, including traditional computer &#147;hackers,&#148; threat actors,
&#147;hacktivists,&#148; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks,
including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities, wrongful conduct by hostile foreign governments and industrial espionage. During times of war and other
major conflicts, we and the third parties upon which we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to
produce, sell and distribute our services.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and the third parties with whom<B><I> </I></B>we work are subject to a
variety of evolving threats, including but not limited to the deployment of harmful malware (including as a result of advanced persistent threat intrusions), ransomware,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service,</FONT></FONT> credential stuffing, credential harvesting, social engineering fraud (including through deep fakes, which may be increasingly more difficult to
identify as fake, and phishing attacks), malicious code (such as viruses and worms), personnel misconduct or error, ransomware attacks, supply-chain attacks, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures,
earthquakes, fires, floods, and other similar threats. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In particular, severe ransomware attacks are becoming increasingly
prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of
a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of
operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems,
there can be no assurance that our efforts will prevent information cybersecurity incidents or breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations
and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Remote work has become more common and has increased risks to our information technology systems
and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as
acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#146; systems and technologies.
Furthermore, we may discover security issues or other constraints not found during due diligence of such acquired or integrated entities, creating additional challenges to integrate said information systems into our information technology
environment and security program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we have implemented security measures designed to protect against security
incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate known vulnerabilities in our information systems (such as our hardware and/or software, including that of third
parties with whom we work). We may not, however, detect and remediate all such vulnerabilities on a timely basis for various reasons including but not limited to the impact on the functional operations of affected information systems or the
availability of a solution for the impacted technology. While remedial measures and/or patches designed to address identified vulnerabilities are being developed and/or implemented, these vulnerabilities could be exploited and result in a security
incident. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including
affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. Additionally, laws in all 50
states require businesses to provide notice to customers whose personal data has been disclosed as a result of a data breach. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. We
also may be contractually required to notify patients or other counterparties of a cybersecurity incident or breach. Although we may have contractual protections with our service providers, any actual or perceived cybersecurity incident or breach
could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach. Any contractual protections we may have from our service
providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. In addition to government regulation, privacy advocates and industry groups have and may
in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards. Determining whether personal data has been handled in
compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we maintain insurance coverage, we cannot assure that such coverage
will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or material adverse effects arising out
of our data protection, privacy, and security practices, or that such coverage will continue to be available on acceptable terms or at all. The successful assertion of one or more large claims against us that exceeds our available insurance
coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements), could have an adverse effect on our business. In
addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Threat actors and their techniques change frequently, are often sophisticated in nature, and may not be detected until after a
cybersecurity incident has occurred. Any failure to prevent or mitigate cybersecurity incidents, breaches or other improper access to, use of, or disclosure of our clinical data or patients&#146; personal data could result in significant liability
under state (e.g., state breach notification laws), federal (e.g., HIPAA), and foreign (e.g., the GDPR) laws, and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our reliance on the computer systems of various third parties with whom we work, including our CROs and
other contractors, introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on our third-party partners to implement effective security measures and identify and
correct for any such failures, deficiencies or breaches. However, our ability to monitor these third parties&#146; information security practices is limited, and these third parties may not have adequate information security measures in place. While
we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.<B><I> </I></B>In
addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#146; infrastructure in our supply chain or that of the third parties with whom we work have not been compromised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we or our third-party partners fail to maintain or protect our information technology systems and data integrity
effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party partners could have difficulty preventing, detecting and controlling such cyberattacks and any such attacks
could result in disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on
our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate cybersecurity incidents, breaches or other improper access to or disclosure of such information could have
similarly adverse consequences for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to experiencing a security incident, third parties may gather,
collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.
Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#146;, personnel&#146;s, or vendors&#146; use of generative artificial intelligence technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in
unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. A
security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Government Regulatory and Legal Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to
hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the FDA, EMA, and other comparable foreign regulatory authorities to review and approve new products can be
affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have
fluctuated in recent&nbsp;years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business. For example, over the last several&nbsp;years, the U.S. government shut down several times and certain regulatory agencies, such as the FDA, furloughed critical employees and
ceased critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA, EMA, or other comparable foreign
regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA, EMA, or other comparable foreign regulatory authorities to timely review and process our
regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to obtain orphan drug
designation or exclusivity for our product candidates, and even if we do, that designation may not provide an expedited development or regulatory review or approval process and any orphan drug exclusivity we may receive for approved products may not
prevent the FDA or the EMA from approving other competing products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may
designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition. A similar regulatory scheme governs the designation of orphan product candidates by the EMA in the EU. Generally, if a product with an orphan
drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA (as applicable) from
approving another marketing authorization application for another similar product candidate for the same orphan therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the EU (which can
be extended to 12 years if the sponsor complies with an agreed-upon pediatric investigation plan). The exclusivity period in the EU can be reduced to six years if at the end of the fifth year it is determined that a product no longer meets the
criteria for orphan designation, including if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order for the FDA to grant orphan drug exclusivity to one of our product candidates, the agency must find that the product
candidate is indicated for the treatment of a condition or disease that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making the product candidate available for the disease or condition will be recovered from sales of the product in the United States. Hypoparathyroidism is a disease that affects approximately 70,000 individuals in
the United States, and accordingly, SEP-786, our small molecule agonist to PTH1R, in development for hypoparathyroidism, may qualify for orphan drug designation. The FDA may conclude that the condition or disease for which we seek orphan drug
exclusivity does not meet this standard. In the EU, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
prevention or treatment of a life-threatening or chronically debilitating condition; (2)&nbsp;either (a) such condition affects no more than five in 10,000 persons in the EU when the application
is made, or (b)&nbsp;it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EU to justify the necessary investment in its development; and (3)&nbsp;there exists no satisfactory
method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition. Even if we obtain orphan drug exclusivity
for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different product candidates can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA or
the EMA can subsequently approve the same product candidate for the same condition if the FDA or EMA (as applicable) concludes that the later product candidate is clinically superior in that it is shown to be safer, more effective or makes a major
contribution to patient care compared with the product that has orphan exclusivity. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to
assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>While we may in the
future seek designations for our product candidates with the FDA, EMA and other comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory
exclusivity, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such
designations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA, EMA, and other comparable foreign regulatory authorities offer certain designations for
product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction
with regulatory authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations
could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, we may seek a Fast Track Designation for our lead product candidate, SEP-786, and one or more of our product
candidates. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast
Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we
do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer
supported by data from our clinical development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, we may seek to participate in the PRIority
Medicines (PRIME) scheme for our potential product candidates. The PRIME scheme is intended to encourage development of product candidates in areas of unmet medical need and provides accelerated assessment of product candidates representing
substantial innovation, where the marketing authorization application will be made through the centralized procedure in the EU. Eligible products must target conditions for which there is an unmet medical need (i.e. no treatment option exists in the
European Union or, they can offer a major therapeutic advantage over existing treatments). Many benefits accrue to sponsors of product candidates with access to the PRIME scheme, including but not limited to, early and proactive regulatory dialogue
with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. There is no guarantee, however, that our potential
product candidate would be deemed eligible for the PRIME scheme and even if we do participate in the PRIME scheme, where during the course of development a product no longer meets the eligibility criteria, support under the PRIME scheme may be
withdrawn. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may seek Breakthrough Therapy Designation for one or more of our product
candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug
may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as
breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.
Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval and priority review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate
we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy Designation for a product candidate may not result in
a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we develop qualifies as a
breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at
the time of submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared
with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement
of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such
applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Where appropriate, we may secure approval from the FDA, EMA, or other comparable foreign regulatory authorities through the use of
expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense
of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA, or other comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we
do not comply with rigorous post-marketing requirements, the FDA, EMA, or other comparable foreign regulatory authorities may seek to withdraw the accelerated approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated
approval pathway for our one or more of our product candidates from the FDA, EMA, or other comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#146;s
implementing regulations, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the
product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful
in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is
thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the
sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#146;s clinical benefit. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval
confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or
biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval
studies fail to verify the drug&#146;s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to
the agency on their progress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA, or other
comparable foreign regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or
submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA, or other comparable foreign regulatory authorities,
we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can
be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA, or other comparable foreign regulatory authorities could also require us to conduct further studies prior to
considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any
other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm
our competitive position in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to stringent and evolving U.S. and foreign laws, rules, regulations,
policies, industry standards, contractual requirements, and other obligations related to data protection, privacy, and security. Our actual or perceived failure to comply with such obligations could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to various data protection, privacy, and security laws, rules, regulations, policies, industry standards,
contractual requirements, and other obligations that apply to our collection, transmission, storage, use, disclosure, transfer, maintenance and other processing of sensitive information, including personal data. The legislative and regulatory
landscape for data protection, privacy, and security continues to evolve across jurisdictions worldwide. For example, in the United States, federal, state, and local governments have enacted numerous data protection, privacy, and security laws,
including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In particular, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as
amended by the Health Information Technology for Economic and Clinical Health Act (HITECH), and implementing regulations, establish stringent privacy and security standards that limit the use and disclosure of individually identifiable health
information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability
of electronic protected health information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Data protection, privacy, and security obligations remain an evolving
landscape at both the domestic and foreign level, with new laws, rules and regulations coming into effect, posing continued legal and compliance challenges. For example, in the past few years, numerous U.S. states&#151;including California,
Virginia, Colorado, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Connecticut, and Utah&#151;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording
residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain data processing
activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to conduct our operations. Certain states also impose stricter requirements for processing certain
personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, in California, the California Consumer Privacy Act of 2018, as amended by
the California Privacy Rights Act of 2020 (CPRA) (collectively, CCPA), provides for fines of up to $7,500 per intentional violation and allows privacy litigants affected by certain data breaches to recover significant statutory damages. The CCPA and
other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties with
whom we work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar laws are being proposed in numerous other states and at the federal level. Proposed legislation, if
enacted, may add additional complexity, variation in requirements, processing restrictions, potential legal risk, require additional investment of resources, impact business strategies, and could result in increased compliance costs and/or changes
in business practices and policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are also states that specifically regulate consumer health information. For
example, Washington has enacted a consumer health privacy law, the My Health My Data Act (MHMD), that regulates the collection and sharing of consumer health information. MHMD places restrictions on processing consumer health data (including
imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law, which further increases the relevant
compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United
States, an increasing number of laws, regulations, and industry standards govern data protection, privacy, and security. For example, if we conduct clinical trials in the European Economic Area (EEA) and/or the United Kingdom (U.K.), we may become
subject to additional privacy laws in those jurisdictions, such as the EU General Data Protection Regulation (EU GDPR) and the EU GDPR as incorporated into U.K. domestic law post-Brexit (U.K. GDPR and, together with the EU GDPR, GDPR), both of which
impose strict requirements for processing personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, under the GDPR, data protection authorities may
impose large penalties for violations of the GDPR, including potential fines of up to &#128;20&nbsp;million (&pound;17.5&nbsp;million GBP) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data
subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> could also
result in the imposition of orders to stop data processing activities, which could have a material adverse effect on our business, financial position, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may be unable to transfer personal data from the EEA, U.K., and other jurisdictions to the U.S. or other
countries due to data localization requirements or limitations on cross-border data flows. Although there are various mechanisms that may be used in some cases to lawfully transfer personal data to the U.S. or other countries, these mechanisms are
subject to legal challenges and may not always be available to us. For example, the GDPR requires certain adequate safeguards to enable the transfer of personal data outside of the EEA or the U.K., in particular to the U.S., such as the EU standard
contractual clauses, U.K. International Data Transfer Addendum/Agreement, and the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Data Privacy Framework (Framework) and the UK extension thereto (which allows for transfers to relevant U.S.-based
organizations who self-certify compliance and participate in the Framework). However, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the
U.S. If there is no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
lawful manner for us to transfer personal data from the EEA, the U.K. or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face
significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense,
increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to
operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, if we fail, or are perceived to have failed, to comply with applicable data
protection, privacy, and security laws, including applicable HIPAA privacy and security standards, we could face significant administrative, civil and criminal penalties. For example, HHS has the discretion to impose significant penalties, and such
enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking
either injunctions or damages in response to violations that threaten the data protection, privacy, or security of the personal data of state residents. We cannot be sure how these laws, rules and regulations will be interpreted, enforced, or
applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws, rules and regulations at the international, federal and state level
may be costly and require ongoing modifications to our policies, procedures and systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we rely on certain
third-party vendors to process certain confidential, sensitive, or personal data on our behalf. Failure by us or our third-party vendors to comply with any of these laws, rules, regulations, contractual requirements, industry standards, or other
obligations could result in notification obligations, enforcement actions, regulatory investigations or inquiries, significant fines, imprisonment of company officials and public censure, litigation and claims for damages by affected individuals,
customers or business partners, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our employees and personnel use generative artificial intelligence technologies to perform their work, and the disclosure and
use of personal data in generative artificial intelligence technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative artificial intelligence.
Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative artificial intelligence, it could make our business less efficient and result in
competitive disadvantages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also make public statements about our use, collection, disclosure, and other processing of
personal data through our privacy policies and information provided on our website. Although we endeavor to comply with our public statements and documentation, we may at times fail to do so or be alleged to have failed to do so. The publication of
our privacy policies and other statements that provide promises and assurances about data protection, privacy, and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our
actual practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to data protection, privacy, and security laws, we are contractually subject to industry
standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data protection, privacy, and security, and our efforts to comply with such obligations may
not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obligations related to data protection, privacy, and security (and consumers&#146; data privacy
expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions.
Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data
on our behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of these compliance and operational requirements impose significant
costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. Our efforts to comply with the evolving
data protection, privacy, and security laws, rules, regulations, and other obligations may be unsuccessful. It is </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">possible that these
various obligations may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection, privacy, and security obligations may be unsuccessful. We may need to devote
significant resources to understanding and complying with this changing landscape. In addition, such requirements may require us to modify our data processing practices and policies, utilize management&#146;s time and/or divert resources from other
initiatives and projects. Any actual or perceived failure by us or our third-party partners to comply with such laws, rules, regulations, and other obligations regarding data protection, privacy, and security could result in significant
government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely
affect our business. Even if we are not determined to have violated these laws, rules or regulations, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity. Further,
any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Healthcare legislative reform measures may have a negative impact on our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory
changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for
which we obtain marketing approval. For more information, see the section titled &#147;Business&#150;Government Regulation&#150;Current and Future U.S. Healthcare Reform.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by
major legislative initiatives. In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA) was passed, which substantially changed the way healthcare is financed by
both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The continuing
efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for any of our product candidates, if approved;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to set a price that we believe is fair for any of our product candidates, if
approved;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenues and achieve or maintain profitability;</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital.</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional
activities for pharmaceutical and biologic products. In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S.
Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into
law. The IRA includes several provisions that may impact our business, depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government to negotiate Medicare Part B and
Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay until January&nbsp;1, 2032 the
implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan
designation and for which the only approved indication is for that disease or condition. If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of
the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#146;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#146;s approval process may significantly delay or
prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot predict what healthcare reform initiatives may be adopted in the future. We expect that these and other healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our
drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and
state healthcare fraud and abuse laws, false claims laws, other healthcare laws and regulations and health data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not
fully complied, with such laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Healthcare providers and third-party payors
in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal
investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal
false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, as well as our proposed sales and marketing programs. In addition, we may
be subject to health information privacy and security laws by the federal government, the states and other jurisdictions in which we may conduct our business. For more information, see the section titled &#147;Business&#150;Government
Regulation&#150;Other Healthcare Laws.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the breadth of these laws and the limited statutory exceptions
and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and
regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with
different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to
us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting
requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and the curtailment or restructuring of our
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Legislation or other changes in U.S. tax law may have a material adverse effect on our business, cash flow, financial
condition, or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The rules dealing with U.S. federal, state, and local income taxation are
constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of
our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. For example, under Section&nbsp;174 of the Code, in taxable years beginning after December&nbsp;31,
2021, expenses that are incurred for research and development in the United States will be capitalized and amortized, which may have an adverse effect on our cash flow. Future changes in tax laws could have a material adverse effect on our business,
cash flow, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It cannot be predicted whether, when, in what form, or with what
effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#146; tax liability or require changes in the
manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in
tax laws on an investment in our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions,
embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could hinder our ability to compete in certain markets. We can face criminal liability and other serious consequences for
violations, which can harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations are subject to U.S. and foreign anti-corruption,
anti-money laundering, export control, sanctions and other trade laws and regulations. Anti-corruption laws generally prohibit us and our employees, officers, CROs, consultants, contractors and other partners and agents from authorizing, promising,
offering, providing, soliciting, or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. We have direct or indirect interactions with officials and employees
of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase over time. We expect to rely on third parties for research,
preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even
if we do not explicitly authorize or have prior knowledge of such activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also subject to U.S. and foreign
export controls, trade sanctions, and import laws and regulations. Such laws may prevent or prohibit the export or provision of certain products and services to countries, governments, and persons targeted by sanctions. Violations of these above
laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, breach of contract and fraud litigation, reputational harm and other consequences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Third Party Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may depend on collaborations with third parties for the discovery, development and commercialization of our product candidates. If any
of these collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may in the future seek third-party collaborators for research, development and commercialization of our product candidates.
Pharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or
at all, or such collaborations are not successful, we may not be able to execute our strategy to develop certain targets, product candidates or disease areas that we believe could benefit from the resources of either larger pharmaceutical companies
or those specialized in a particular area of relevance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to any future collaboration agreements, we expect to
have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our current or future product candidates. Moreover, our ability to generate revenues from these arrangements will
depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Collaborations involving our current or future product candidates may pose the following risks to us: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to
these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors such as an acquisition that diverts
resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our current or future product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient
resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to
litigation and potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research,
development or commercialization of our current or future product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of the
foregoing, any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a future collaborator of ours </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
were to be involved in a business combination, the continued pursuit and emphasis on our current or future product development or commercialization program could be delayed, diminished or
terminated. Any failure to successfully develop or commercialize our product candidates pursuant to any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, to the extent that any of our future collaborators were to terminate a collaboration agreement, we
may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon
product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third-party manufacturers, CROs, CMOs, and suppliers to supply, develop and test components of our product candidates. The
loss of our third-party manufacturers, CROs, CMOs, or suppliers, their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, or changes in methods of product
candidate manufacturing, development or formulation would materially and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not
own or operate facilities for drug manufacturing, storage, distribution or quality testing. We currently rely, and may continue to rely, on third-party contract manufacturers, including in China, to manufacture and test bulk drug substances, drug
products, raw materials, samples, components, or other materials and reports. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There can be no assurance that our
preclinical and clinical development product supplies will not be limited, interrupted, terminated or of satisfactory quality or continue to be available at acceptable prices. In addition, any replacement of our manufacturer could require
significant effort and expertise because there may be a limited number of qualified replacements.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The manufacturing
process for a product candidate is subject to FDA, EMA and foreign regulatory authority review. In some cases, we, and our suppliers and manufacturers, some of which may be our sole source of supply, must meet applicable manufacturing requirements
and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. Securing marketing approval also requires the submission of information about the product
manufacturing process to, and inspection of manufacturing facilities by, the FDA, EMA, and other comparable foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications
and the strict regulatory requirements of the FDA, EMA, and other comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates. Moreover, we do not
control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform
its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not
be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to
another third party.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These factors would increase our reliance on such manufacturer or require us to obtain a license from
such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and
procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively
affect our ability to develop product candidates in a timely manner or within budget.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to rely on third-party manufacturers if we receive
regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent
with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the FDA and foreign regulatory
authorities, including for continued compliance with cGMP requirements, quality control, quality assurance and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product
candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#146;s failure to execute on our manufacturing requirements, comply with cGMPs or
maintain a compliance status acceptable to the FDA or foreign regulatory authorities could adversely affect our business in a number of ways, including:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in the progress on certain research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or continue clinical trials of product candidates under development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of the cooperation of existing or future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease distribution or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial
demands for our therapeutics. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our contract manufacturers may experience manufacturing
difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in
preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, we currently rely on foreign CROs and CMOs, including WuXi AppTec (HongKong) Limited, for manufacturing and development activities and will likely continue to rely on foreign CROs and CMOs in the future. Foreign CMOs may be subject to U.S.
legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our
ability to secure significant commitments from governments to purchase our potential therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, if enacted,
legislation pending in Congress known as the BIOSECURE Act would prohibit U.S. federal agencies from entering into or renewing a contract with any company that uses biotechnology equipment or services produced or provided by a &#147;biotechnology
company of concern&#148; in the performance of that contract. It would also prohibit loans or grant funding from U.S. federal agencies to entities that use any biotechnology equipment or services produced or provided by a &#147;biotechnology company
of concern&#148; in the performance of the government grant or loan. The effects of this legislation, if enacted, is unknown; however, it could have the downstream effect of restricting the ability of pharmaceutical companies that enter into
contracts with or receive funding from U.S. federal agencies from purchasing services or equipment from certain Chinese biotechnology companies, including those that are specifically named in the proposed BIOSECURE Act, as well as supply chain
disruptions or delays. The current version of the BIOSECURE Act introduced in the House of Representatives names WuXi Biologics and WuXi AppTec as &#147;biotechnology companies of concern&#148; and includes a grandfathering provision allowing
biotechnology equipment and services provided or produced by named &#147;biotechnology companies of concern&#148; under a contract or agreement entered into before the effective date until January&nbsp;1, 2032.<B></B><B>&nbsp;</B>Depending on
whether the BIOSECURE Act becomes law, what the final language of the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing U.S. federal government business or government
reimbursement for our products in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
future if we continue to use WuXi Biologics, WuXi AppTec or other suppliers or partners identified as &#147;biotechnology companies of concern&#148; beyond this grandfathering period. In addition
to the BIOSECURE Act, any additional executive action, legislative action, or potential sanctions with China could materially impact our work with WuXi STA. U.S. executive agencies have the ability to designate entities and individuals on various
governmental prohibited and restricted parties lists. Depending on the designation, potential consequences can range from a comprehensive prohibition on all transactions or dealings with designated parties, or a limited prohibition on certain types
of activities, such as exports and financing activities, with designated parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, the pharmaceutical
industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting pharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which
could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#146;s public health, economic, political, and social conditions and the uncertainty around China&#146;s relationship
with other governments, such as the U.S. and the United Kingdom, or U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government
funding, which could adversely affect our financial condition and cause us to delay our clinical development programs. Any of the foregoing factors could have a material adverse effect on our business, results of operations, or financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, as product candidates progress through preclinical and clinical trials to marketing approval and
commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve
consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of current or future clinical
trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our
product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may in
the future enter into collaboration agreements and strategic alliances to maximize the potential of our structure-based drug discovery platform and product candidates, and we may not realize the anticipated benefits of such collaborations or
alliances. We expect to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and
commercialization plans. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Part of our business strategy is to explore additional collaborations with third parties
to further utilize our platform capabilities on additional novel GPCR targets and to leverage partners additional disease biology understanding, development and commercial expertise, regional insights or other complementary capabilities to existing
or future Septerna programs. We may therefore form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our
development and commercialization efforts with respect to our structure-based drug discovery platform or our current or future product candidates that we may develop. These transactions can entail numerous operational and financial risks, including
exposure to unknown liabilities, disruption of our business and diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt
or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses,
difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in
management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or license agreements or strategic partnerships, we may not be able to realize </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">the benefit of such transactions if we are unable to successfully integrate them with our existing operations and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
company culture. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or other anticipated benefits that led us to enter into the arrangement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development collaborations are subject to numerous risks, which may include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a
collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources causing delays or termination of the research; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our structure-based drug discovery platform
or collaboration product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results or changes in their strategic focus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for
collaboration product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could develop or acquire products outside of the collaboration that compete directly or
indirectly with our products or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual
property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between us and a collaborator that cause the delay or termination of the research,
development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel
to pursue further development or commercialization of our structure-based drug discovery platform or the applicable product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we could face significant competition in seeking appropriate strategic partners and the negotiation process is
time-consuming, expensive, and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our structure-based drug discovery platform or product candidates because they may be deemed
to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate their desired safety and efficacy profile. If and when we collaborate with a
third party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of our technologies,
product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us for our product candidate. We may also be restricted under any license agreements from entering into additional agreements on certain terms or at all with other potential collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result of these risks, we may not be able to realize the benefit of any future collaborations or licensing agreements we
may enter into. In addition, we may face regulatory obstacles in completing such transactions. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our
expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain
additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our structure-based drug discovery platform or product candidates or bring them to market
and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical
research or development under written agreements with these institutions. If collaborations occur, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the
collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon
development of such program and our business and financial condition could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our products require specific
constituents to work effectively and efficiently, and rights to those constituents are, and in the future may be, held by others. We may also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> third-party technologies to enhance our Native
Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. We may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> any rights from constituents, methods of use, processes or other third-party intellectual property rights
from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which could harm our business. Even if we are able to obtain a license, it may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement
technology in order to establish or maintain our competitive position in the market. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates or our structure-based drug discovery platform
could delay the development and commercialization of our product candidates in certain geographies or limit our ability to discover and develop new product candidates, which could harm our business prospects, financial condition, and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The manufacturing of our product candidates is complex, and our third-party manufacturers may encounter difficulties in
production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our
products for patients, if approved, could be delayed or stopped. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The process of manufacturing pharmaceuticals is
complex, time-consuming, highly regulated and subject to multiple risks. Our contract manufacturers must comply with legal requirements, cGMPs and guidelines for the manufacturing of pharmaceuticals used in clinical trials and, if approved, marketed
products. Our contract manufacturers may have limited experience in the manufacturing of cGMP batches.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Manufacturing
pharmaceuticals is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and
difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are
discovered at our third-party manufacturers&#146; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including,
among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if we or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our future collaborators obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product to specifications
acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If manufacturers are unable to produce sufficient
quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Scaling up a pharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not
have the necessary capabilities to complete the implementation, manufacturing and development process. If we are unable to adequately validate or <FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacturing process at our current
manufacturers&#146; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and <FONT STYLE="white-space:nowrap">scale-up</FONT> the
manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms
acceptable to us.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure that any stability or other issues relating to the manufacture of any of our current or
future product candidates will not occur in the future. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once
approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the
period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates or products may result in
shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for
product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect
our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial condition and results of operations.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of our process development efforts, we also may make changes to the manufacturing processes at various points during
development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and
any of these changes could cause our current or future product candidates to perform differently and affect the results of our current or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform
<I>ex vivo</I> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the
comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third
parties perform in an unsatisfactory manner, it may harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not currently have the ability to
independently conduct preclinical studies or clinical trials required to develop our product candidates. We intend to rely on CROs, clinical trial sites and other third parties to ensure the proper and timely conduct of our preclinical studies and
clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs and others for the execution of future nonclinical studies and to monitor, manage and report data for our clinical trials. We expect
to control only certain aspects of our CROs&#146; and others&#146; activities. Nevertheless, we will be responsible for ensuring that each of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs and others does not
relieve us of our regulatory responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, our CROs and other third parties we might engage will be required to
comply with good laboratory practices (GLPs) and GCPs, which are regulations and guidelines enforced by the FDA, EMA, and other comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of
our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs and
others to conduct <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and
protocol and applicable laws and regulations, and our reliance on the CROs and others does not relieve us of our regulatory responsibilities. If we, our CROs and other third parties we engage fail to comply with GCPs, the clinical data generated in
our clinical trials may be deemed unreliable and the FDA, EMA, or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs or others
fail to comply with these regulations or fail to recruit a sufficient number of participants, we may be required to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we will have agreements governing their activities, our CROs and other third parties we engage will not be our
employees, and we will not control whether or not they devote sufficient time and resources to our future nonclinical and clinical programs. These CROs and others may also have relationships with other commercial entities, including our competitors,
for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and others,
which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. In addition, certain of our agreements with CROs and other third parties currently or will provide for monetary and
other limitations on their liability. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the preclinical or clinical data they obtain is compromised
due to the failure to adhere to our protocols or regulatory requirements or for any other reasons, our preclinical or clinical programs may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully
commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be
delayed, decreased or eliminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our relationship with these CROs terminates, we may not be able to enter into
arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO
commences work. As a result, delays occur, which can negatively impact our ability to meet our desired development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter
challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time
to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal
investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself
may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently depend and in the future may continue to depend on single- or
limited-source suppliers for some of the components and materials used in the product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently depend and in the future may continue to depend on single- or limited-source suppliers for some of the components
and materials used in any product candidates we may develop. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our
competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply,
price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale.
Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in
supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be
interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly or at all. If we are able to find a replacement supplier, the replacement
supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our therapeutics,
any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for our current or any future
product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate that we will file additional patent applications both in the United States and in other jurisdictions, as
appropriate. However, we cannot predict: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if and when any patents will issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree and scope of protection any issued patents will afford us against competitors, including whether
third parties will find ways to invalidate or otherwise circumvent our patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and
patent applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which
may be costly whether we win or lose; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the patent applications that we own, or may <FONT STYLE="white-space:nowrap">in-license,</FONT> will
result in issued patents with claims that cover our current or future product candidates or uses thereof in the United States or in foreign jurisdictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely, and may in the future rely, upon a combination of patent, trade secret and trademark protection for our current and
any future product candidates and proprietary technologies to prevent third parties from exploiting our achievements, thus eroding our competitive position in our market. These legal measures afford only limited protection, and competitors or others
may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain, expand, enforce, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and defend the scope, ownership or control, validity and enforceability of our intellectual property protection in the United States and other countries with respect to our current and any future
product candidates and other proprietary technologies we may develop. Our commercial success depends in large part on our ability to obtain and maintain patent protection in the United States and other jurisdictions with respect to our current and
any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and product candidates. The patent prosecution process is
expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner, including as a result of factors impacting our, our licensors&#146; or governmental
patent offices&#146; operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that we will fail to identify patentable aspects of our research and
development output before it is too late to obtain patent protection. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our current or any future
product candidates in the United States or in foreign jurisdictions. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been or will be found, which unknown prior art can
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do issue and even if such patents cover our current or any future product candidates, third parties may challenge their scope, validity, or
enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to&nbsp;us could deprive us of rights necessary for the
successful commercialization of any current or future product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could
be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the patent applications we hold or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect
to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for current or any future product candidates, it could dissuade companies from collaborating with us
to develop product candidates, and threaten our ability to commercialize, future drug products. Any such outcome could have a negative effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Composition of matter patents for pharmaceutical products provide intellectual property protection for those types of
products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of any of our current or future product candidates
will be considered patentable by the U.S. Patent and Trademark Office (USPTO), or by patent offices in foreign jurisdictions, or that the claims in any of our patents that may issue will be considered valid and enforceable by courts in the United
States or foreign jurisdictions. Method of use patents protect the use of a product for the specified method. We cannot be certain, however, that the claims in our pending patent applications covering methods of use of our current or future product
candidates will be considered patentable by the USPTO, or by patent offices in foreign jurisdictions, or that the claims in any of our patents that may issue will be considered valid and enforceable by courts in the United States or foreign
jurisdictions. Further, this type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not
actively promote their product for our targeted indications, once approved for therapeutic use by FDA. or counterpart foreign regulatory authorities, physicians may prescribe these products
<FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> for those uses that are covered by our method of use patents. Although <FONT STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of
method of use patents, the practice is common and such infringement is difficult to prevent or enforce against. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign jurisdictions may
not protect our rights to the same extent as the laws of the United States. Patent applications in the United States and certain other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we
cannot know with certainty whether we were the first to file for patent protection. As a result, the issuance, scope, validity, enforceability and commercial value of our patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively
prevent others from commercializing competitive technologies or products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the patent laws or
interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patents or narrow the scope of our patent protection. These changes could increase the uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents, all of which could have a negative effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, we may be subject to a third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to
the USPTO or another patent office or become involved in opposition, derivation, reexamination, <I>inter partes</I> review (IPR), post-grant review (PGR) or interference proceedings challenging our patent rights or the patent rights of others. An
adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or
result in our inability to manufacture or commercialize drugs without infringing third-party patent rights or obtaining a costly license from a third party. In addition, if the breadth or strength of protection provided by our patents and patent
applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and
licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held
unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology, products or methods, or limit the duration of the patent protection of our technology, products or
methods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the
natural expiration of a patent is generally 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Various extensions may be available; however, the life of a patent, and the
protection it affords, is limited. For instance, a patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only
once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not necessarily extend to all claims, but instead only to claims that read on the product as approved. Laws governing analogous patent
term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing
phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or
the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration
and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. In
addition, although upon issuance in the United States a patent&#146;s term can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent
prosecution. Without patent protection for our current or future product candidates, including once the patent life has expired even if patents covering our product candidates are obtained, we may be open to competition from generic versions of such
drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Even if patents
covering our current or future product candidates are obtained, once the patent term has expired for a product, we may be open to competition from generic medications. As a result, our owned and licensed patent portfolio may not provide us with
sufficient rights to exclude others from commercializing drugs similar or identical to ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if we have or obtain patents covering our products or methods, we may
still be barred from making, using and selling such products or methods because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or
identical to ours, which could materially affect our ability to successfully develop our technology or to successfully commercialize any approved products alone or with collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patent applications in the United States and elsewhere are generally published approximately 18 months after the earliest
filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our methods and current or future product candidates could have been filed by others
without our knowledge. Additionally, pending claims in patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies or related products. These patent
applications may have priority over patent applications filed by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims challenging the inventorship or
ownership of our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be subject to claims that former employees,
collaborators or other third parties have an interest in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property as an inventor, <FONT STYLE="white-space:nowrap">co-inventor,</FONT>
owner or <FONT STYLE="white-space:nowrap">co-owner.</FONT> For example, we or our licensors may have inventorship or ownership disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our current
or future product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#146; ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade
secrets or other intellectual property. If we or our licensors fail in defending any such claims, we may be required to pay monetary damages and we may also lose valuable intellectual property rights, such as exclusive ownership of, or right to use,
intellectual property that is important to our current or future product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any
of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If
we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our current or future product
candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated their intellectual property. Litigation or other legal proceedings relating to
intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our
technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such
litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or
other proceedings could have a material adverse effect on our ability to compete in the marketplace.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is a
substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with
respect to our current or future product candidates. We cannot be certain that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
owned by third parties. Third parties may assert infringement claims against us based on existing or future intellectual property rights. In the United States, proving invalidity in court
requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to
cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing,
manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we
are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our investigational products or force us to cease some of our business operations, which could materially harm our business.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields
in which we are developing our product candidates, might assert are infringed by our current or future product candidates, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product
candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by one or
more of our current or future product candidates. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our current or future product
candidates may infringe. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained
or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our current or future product candidates. The pharmaceutical and biotechnology industries have produced a
considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the
interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our current or future product candidates, products or methods either do not infringe the patent claims of the relevant patent or that
the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome
the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial
costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. Furthermore, because of the substantial amount of
discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, we may not have sufficient resources to bring these
actions to a successful conclusion.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may choose to challenge the enforceability or validity of claims in a third
party&#146;s U.S. patent by requesting that the USPTO review the patent claims in an <I>ex parte</I> <FONT STYLE="white-space:nowrap">re-examination,</FONT> IPR or PGR proceeding. These proceedings are expensive and may consume our time or other
resources. We may choose to challenge a third party&#146;s patent in patent opposition proceedings in the European Patent Office (EPO), or other foreign patent office. The costs of these opposition proceedings could be substantial and may consume
our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office, then we may be exposed to litigation by a third party alleging that the patent may be infringed by our current or future product
candidates or proprietary technologies.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are found to infringe a third-party&#146;s intellectual property rights, we
could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third-party in order to use the infringing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at
all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary
damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business
operations, and could divert the time and attention of our technical personnel and management, cause development delays, and/or require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a
cost-effective basis, any of which could materially harm our business. In the event of a successful claim of infringement against us, we may have to pay substantial monetary damages, including treble damages and attorneys&#146; fees for willful
infringement, pay royalties and other fees, redesign our infringing drug or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our technology licensed from various third parties may be subject to retained rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying
technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is
difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance
under the Patent and Trademark Law Amendments Act (Bayh-Dole Act). The federal government retains a &#147;nonexclusive, nontransferable, irrevocable, <FONT STYLE="white-space:nowrap">paid-up</FONT> license&#148; for its own benefit. The Bayh-Dole
Act also provides federal agencies with <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights.&#148; <FONT STYLE="white-space:nowrap">March-in</FONT> rights allow the government, in specified circumstances, to require the contractor or
successors in title to the patent to grant a &#147;nonexclusive, partially exclusive, or exclusive license&#148; to a &#147;responsible applicant or applicants.&#148; If the patent owner refuses to do so, the government may grant the license itself.
We sometimes collaborate with academic institutions to accelerate our preclinical research or development, creating a risk that federal funds may be commingled. Therefore, we cannot be sure that any intellectual property co-developed from a
collaboration with an academic institution will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we <FONT STYLE="white-space:nowrap">co-own</FONT> or license in technology which is critical to our business that is
developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration date of a third-party
patent, which might adversely affect our ability to develop and market our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have reviewed certain
third-party patents and patent filings that we believe may be relevant to our product candidates; and on August&nbsp;1, 2024, we completed freedom-to-operate searches for the exact structures of SEP-786 and SEP-631, which did not identify any
third-party patents and patent filings that we believe are relevant to our product candidates. Nevertheless, we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product
candidates. Thus, we cannot guarantee that our current or future product candidates, or our commercialization thereof, do not and will not infringe any third party&#146;s intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that any patent searches or analyses that are performed, including the identification of relevant patents,
the scope of patent claims or the expiration dates of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is
relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may
negatively impact our ability to market our future products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#146;s pending application will issue with claims of
relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to
identify and correctly interpret relevant patents may negatively impact our ability to develop and market our future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">One aspect of the determination of patentability of our inventions depends on the scope and content of the &#147;prior
art,&#148; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent
claims or, if issued, affect the validity or enforceability of a patent claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The landscape of intellectual property
related to our current or future product candidates and future products is constantly changing. Therefore, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and
as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly
uncertain. Because patent applications in the United States and certain other jurisdictions are confidential for typically a period of at least 18 months after their priority date, or may not be published at all, we cannot be certain that we were
the first to file any patent application related to our current or future product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, for U.S. applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an
interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not
entitled to priority before March&nbsp;16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new
procedures for challenging pending patent applications and issued patents. Should we fail to win an interference challenge, a third party may obtain rights to intellectual property related to our current or future product candidates and future
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and <FONT
STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because our programs may in the future require the use of
proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. We may be unable to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of
third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to
assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would&nbsp;allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain
rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on
our business, financial condition, results of operations, and prospects.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we normally seek to obtain the right to control prosecution,
maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our future
licensors or collaboration partners. If any of our future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may
be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and
from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may enter into license agreements in the future with others to advance our existing or future research or allow
commercialization of our current or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or
commercialize our technology platform or product candidates in the future.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, subject to the terms of any such
license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we
cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain,
enforce, and defend such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our current or future
product candidates that are subject of such licensed rights could be adversely affected.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future licensors may rely on
third-party consultants or collaborators or on funds from third parties such that our future licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-license.</FONT> If other third parties have ownership
rights to our future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse
effect on our competitive position, business, financial conditions, results of operations, and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible
that we may be unable to obtain necessary licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors
access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement
technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of
operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products
resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting
from the joint creation or use of intellectual property by our future licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and
certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual
property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and
prospects. Moreover, if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might
therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated, or if the
underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products<B> </B>identical to ours. This could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may be required to license
technologies relating to our programs from additional third parties to further develop or commercialize our current or future product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents
required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our
product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be
involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to
file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our
potential future collaborators were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent is invalid and/or unenforceable in whole or in part.
In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including but
not limited to lack of novelty, obviousness, or insufficient written description or enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information
from the USPTO or made a misleading statement during prosecution.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third parties may also raise similar invalidity claims
before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> PGR, IPR, derivation proceedings, interference proceedings, and equivalent proceedings
in foreign jurisdictions (e.g., opposition proceedings). Such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
proceedings could result in loss of rights to, the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our technology or platform, or any product
candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we
and the patent examiner were unaware during prosecution. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent
applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a patent claim. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps
all, of the patent protection on our product candidates or other intellectual property that we may develop. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened or questioned, it could
dissuade companies from collaborating with us to&nbsp;license, develop or commercialize our current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of
operations and prospects.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if resolved in our favor, litigation or other legal proceedings relating to our
intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other
proceedings. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial
adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because
of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims that we or our employees have misappropriated the intellectual property, including confidential information,
<FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets, of a third-party, or claiming ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and
<FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property, proprietary information, <FONT
STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or these employees, consultants or contractors have used
or disclosed such third-party intellectual property, including <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets or other proprietary information, to us. Litigation may be necessary to defend against these claims. If we fail in
defending any such claims, it may a have negative impact on our business and our ability to develop product candidates or commercialize our technology. In addition to paying substantial monetary damages, we may lose valuable intellectual property
rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could incur substantial costs and be a distraction to management and scientific personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in
claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our
senior management and scientific personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may license intellectual property rights from third parties. Such licenses may be
subject to early termination if we fail to comply with our obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may become a party to licenses that give us rights to third-party intellectual property or technology that is necessary or
useful for our business, and we may enter into additional licenses in the future. Under these license agreements, we are or may become obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a
percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. These fees may be significant, which could make it difficult for us to achieve or maintain profitability. In addition, under certain of such
agreements, we are or may become required to diligently pursue the development of products using the licensed technology. If we fail to comply with these obligations, including due to our use of the intellectual property licensed to us in an
unauthorized manner, and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business,
harming our ability to develop, manufacture and/or commercialize our platform, products or product candidates.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, the agreements under which we license intellectual property or technology to or from third-parties can be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant
agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be
more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates.
More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully
complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. The failure to obtain or <FONT STYLE="white-space:nowrap">in-license</FONT> any
compositions, methods of use, processes or other third-party intellectual property rights at a reasonable cost or on reasonable terms, could harm our business. If we fail to obtain licenses to necessary third-party intellectual property rights, we
may need to cease use of the compositions or methods covered by such third-party intellectual property rights. Furthermore, we may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may
entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving
our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be
due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside
counsel, patent annuity service providers, or our licensing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
partners to pay these fees due to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. If these fees are not paid to the USPTO or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
patent agencies when due, our rights to such patents or patent applications may be abandoned or otherwise materially impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies require compliance with
numerous procedural, documentary, and other similar provisions during the patent application process. For example, many jurisdictions, including the U.S. and China, require a foreign filing license before seeking patent protection in a jurisdiction
outside of the jurisdiction of which the inventor is a citizen or in which the invention was made. Each jurisdiction&#146;s laws regarding foreign filing licenses vary and may even conflict. We employ reputable law firms in foreign jurisdictions and
other professionals to help us comply and we are also dependent on any licensors to take the necessary action to comply with these requirements with respect to our intellectual property. In many cases, an inadvertent lapse can be cured by payment of
a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additional
<FONT STYLE="white-space:nowrap">non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting, maintaining, enforcing, and defending patent applications and patents covering our current
and any future product candidates worldwide is prohibitively expensive, so we will pursue patents in a limited number of jurisdictions. Moreover, our intellectual property rights in some jurisdictions outside the United States can have a different
scope and strength than do those in the United States. Consequently, we will not be able to prevent third parties from practicing our inventions in all jurisdictions, or from selling or importing in and into various jurisdictions products made using
our inventions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and, further, may export otherwise infringing product candidates to territories where we may
obtain patent protection, but where patent enforcement is not as strong as that in the United States. Further, these product candidates may compete with our product candidates in jurisdictions where we do not have any issued or licensed patents and
any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many companies have encountered significant problems protecting and defending intellectual property rights in jurisdictions
outside the United States. The legal systems of certain jurisdictions do not favor the enforcement of patents, trade secrets and other intellectual property rights, particularly those relating to pharmaceutical products, which could make it
difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, including the marketing of competing products in violation of our proprietary rights. Proceedings to enforce
our patents and other intellectual property rights in jurisdictions outside the United States could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our
patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not
prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our
proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in
intellectual property laws in the United States and around the world. For example, in Europe, a new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
unitary patent system took effect June&nbsp;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent
system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court,
increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under
the jurisdiction of the UPC will be potentially vulnerable to a single <FONT STYLE="white-space:nowrap">UPC-based</FONT> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot
predict with certainty the long-term effects of any potential changes. Certain jurisdictions, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties under certain
circumstances. In those jurisdictions, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents.
In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates
we may develop and our technology, one or more U.S. patents that we license or may own in the future may be eligible for limited patent term extension under the Hatch-Waxman Amendments. Under certain circumstances the Hatch-Waxman Amendments permit
a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the term of a patent beyond a total of 14 years from the date of product approval, only
one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for
which extension is sought and within 60 days of FDA approval. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of,
for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable
requirements. Moreover, the applicable patent term extension or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT
STYLE="white-space:nowrap">in-license</FONT> from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, we may be open earlier
than projected to competition from competitive products, including generics or biosimilars following our patent expiration, and our revenue could be reduced earlier than projected. Any of the foregoing could have a material adverse effect on our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Confidentiality agreements with employees and third parties may
not prevent unauthorized disclosure of our trade secrets and other proprietary information. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to
protect proprietary information and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> that we elect not to patent, including processes for which patents are difficult to enforce, and any other elements of our current or future product
candidates, technology and product discovery, development processes and drug discovery platform that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents. In particular, our
trade secrets, confidential know-how and other proprietary information includes our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> drug discovery platform, which we do not plan to patent. Any disclosure,
either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research,
clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological
achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third
parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Trade secrets, confidential know-how and proprietary information, however, may be difficult to protect. We seek to protect our
trade secrets, confidential know-how and proprietary information, including our proprietary processes and drug discovery platform, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors,
contractors, and collaborators. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Although we use reasonable efforts to protect our trade secrets, we cannot
provide any assurances that all such agreements have been duly executed, and notwithstanding the existence of a confidentiality agreement our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or
inadvertently disclose our trade secret information, including to competitors. In addition, competitors or other third parties may otherwise gain access to our trade secrets or independently develop substantially equivalent information and
techniques. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a
party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other
third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign jurisdictions do not protect proprietary rights to the same extent or in the same manner as the
laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our
intellectual property to third parties, or misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business,
operating results, and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our intellectual property rights do not necessarily protect against all potential
threats to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection afforded by our intellectual property rights is uncertain
because intellectual property rights have limitations, and may not adequately protect our business. These risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds or formulations that are similar to our current or future product
candidates but that are not covered by the claims of any patents, should they issue, that we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any strategic partners might not have been the first to make the inventions covered by the issued
patents or pending patent applications that we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might not have been the first to file patent applications covering certain of our current or future product
candidates or inventions we own or control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pending patent applications that we own or control may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or control may be held invalid or unenforceable as a result of legal challenges;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in the United States and other jurisdictions
that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in jurisdictions where we do not have patent rights and then use the information learned from such activities to develop
competitive drugs for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest
and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current or future trademarks or trade names may be challenged,
opposed, infringed, circumvented, invalidated, cancelled, declared generic, determined to be not entitled to registration, or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our
applications by the USPTO or in foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many other
jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not
survive such proceedings. Trademark litigation could be expensive. In addition, we could be found liable for significant monetary damages, including treble damages, disgorgement of profits and attorneys&#146; fees, if we are found to have willfully
infringed a trademark. We may not be able to protect our exclusive right to trademarks or trade names or may be forced to stop using these names, which we need for name recognition by potential collaborators or customers in our markets of interest.
If we are unable to establish name recognition based on our trademarks or trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks or trade names to third parties, such as
distributors. Though these agreements may provide guidelines for how our trademarks or trade names may be used, a breach of these agreements or misuse of our trademarks or tradenames by third parties may jeopardize our rights in or diminish the
goodwill associated with our trademarks or trade names. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, any name we have proposed to use with our product
candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential
for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort
to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or equivalent body. Furthermore, in many jurisdictions, owning and maintaining
a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among
potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market
confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names.
Furthermore, assertions of potential trademark infringement or possible market confusion may lead to coexistence agreements in order to avoid costly disputes related to our trademarks. As a consequence, we may be forced to amend the list of goods
and services covered by our trademarks more narrowly than as originally filed and intended, which could adversely affect our ability to establish name recognition. Over the long term, if we are unable to establish name recognition based on our
trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Rights to improvements to our product candidates may be held by third parties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the course of testing our current or future product candidates, we may enter into agreements with third parties to conduct
clinical testing, which may provide that improvements to our product candidates may be owned solely by a third party or jointly between the parties. If we determine that rights to such improvements owned solely by a third party are necessary to
commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing the product candidates. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on <FONT STYLE="white-space:nowrap">non-exclusive</FONT> terms, thereby giving our
competitors and other third parties access to the same technologies licensed to us. Failure to obtain a license on commercially reasonable terms or at all, or to obtain an exclusive license, could prevent us from commercializing our current or
future product candidates or force us to cease some of our business operations, which could materially harm our business. If we determine that rights to improvements jointly owned between us and a third party are necessary to commercialize our
product candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party. If we are unable to obtain an exclusive license to any such third-party
<FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such improvements, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other parties, including our competitors, and our competitors could
market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our intellectual property in order to enforce such intellectual property against other parties, and
such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The use of new and evolving technologies, such as artificial intelligence, in our offerings may present risks and challenges that can
impact our business including by posing security risks to our confidential information, proprietary information, and personal data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Issues in the development and use of artificial intelligence, combined with an uncertain regulatory environment, may result in
reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence presents risks and challenges that could impact our business. We may adopt and integrate
artificial intelligence tools into our processes for specific use cases reviewed by legal and information security. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or
reputational harm, competitive harm or legal liability. The use of certain artificial intelligence technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property
infringement. Additionally, we expect to see increasing government and supranational regulation related to artificial intelligence use and ethics, which may also significantly increase the burden and cost of research, development and compliance in
this area. For example, several jurisdictions around the globe, including Europe and certain U.S. states, have proposed enacted, or are considering laws governing the development and use of artificial intelligence, such as the EU&#146;s AI Act. We
expect other jurisdictions will adopt similar laws. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal data) and regulate automated decision making, which may be incompatible with our use
artificial intelligence. These obligations may make it harder for us to conduct our business using artificial intelligence, lead to regulatory fines or penalties, require us to change our business practices, retrain our artificial intelligence, or
prevent or limit our use of artificial intelligence. For example, the FTC has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of artificial intelligence where they allege the company has
violated privacy and consumer protection laws. If we cannot use artificial intelligence or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage. The rapid evolution of artificial intelligence will
require the application of significant resources to design, develop, test and maintain our products and services to help ensure that artificial intelligence is implemented in accordance with applicable law and regulation and in a socially
responsible manner and to minimize any real or perceived </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
unintended harmful impacts. Our vendors may in turn incorporate artificial intelligence tools into their own offerings, and the providers of these artificial intelligence tools may not meet
existing or rapidly evolving regulatory or industry standards, including with respect to data protection, privacy, and security. Further, bad actors around the world use increasingly sophisticated methods, including the use of artificial
intelligence, to engage in illegal activities involving the theft and misuse of personal data, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and
information, cause us to breach applicable laws and regulations, and adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Risks Related to this Offering,
Ownership of Our Common Stock, and Operating as a Public Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not know whether an active, liquid and orderly trading
market will develop for our common stock or what the market price of our common stock will be, and, as a result, it may be difficult for you to sell your shares of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there was no public trading market for our common stock. If a market for our common stock does not
develop or is not sustained, it may be difficult for you to sell your shares of our common stock at an attractive price or at all. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods
our results of operations may be below the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. An inactive market may also impair our ability to raise capital by
selling our common stock and our ability to acquire other companies, products, or technologies by using our common stock as consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you purchase common stock in this offering, you will incur immediate and substantial dilution of approximately $8.05 per
share, representing the difference between the initial public offering price of $18.00 per share, and our pro forma as adjusted net tangible book value per share as of June&nbsp;30, 2024 and assumes the automatic conversion of all outstanding shares
of our convertible preferred stock upon the closing of this offering. That is because the price that you pay will be substantially greater than the pro forma as adjusted net tangible book value per share of the common stock that you acquire. This
dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution if the underwriters
exercise their option to purchase additional shares in this offering, when those holding stock options exercise their right to purchase common stock under our equity incentive plans, upon the vesting of outstanding restricted stock awards or when we
otherwise issue additional shares of our common stock. See the section titled &#147;Dilution&#148; for a further description of the dilution you will experience immediately after this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The market price of our common stock may be volatile, which could result in substantial losses for investors purchasing shares in this
offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial public offering price for our common stock was determined through negotiations with the
underwriters. This initial public offering price may vary from the market price of our common stock after the offering. As a result, you may not be able to sell your common stock at or above the initial public offering price. The market price for
our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, some of which may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of existing or new competitive product candidates or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment, completion and results of preclinical studies and clinical trials for our
current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to our current or future product candidates
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing
clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our current or future
product candidates or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to commercialize our current or future product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of any preclinical studies, clinical trials or regulatory approvals of product candidates of our
competitors, or announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement or termination of collaborations for our product development and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other intellectual property or
proprietary rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our research programs, clinical development programs or product
candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations
by securities analysts, if any, that cover our stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">market&nbsp;stand-off&nbsp;or&nbsp;lock-up&nbsp;agreements;</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide
to the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, political, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. If the
market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action
litigation has often been instituted against companies following periods of volatility in the market price of a company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#146;s
attention and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have wide discretion in the use of the net proceeds from this offering and may not use them
effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot specify with certainty the particular uses of the net proceeds we will receive from this
offering. Our management will have wide discretion in the application of the net proceeds, including for any of the purposes described in &#147;Use of Proceeds.&#148; Accordingly, you will have to rely upon the judgment of our management with
respect to the use of the proceeds, with only limited information concerning management&#146;s specific intentions. Our management may spend a portion or all of the net proceeds from this offering in ways that our stockholders may not desire or that
may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from this offering
in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Future sales of our common stock in the public market could cause our
stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our stock price could decline as a result of sales of a large number of shares of our common
stock after this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we
deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, 42,002,794 shares of our common stock will be outstanding (or
44,402,794 shares of common stock will be outstanding assuming exercise in full of the underwriters&#146; option to purchase additional shares), based on our shares outstanding as of June&nbsp;30, 2024. All shares of our common stock expected to be
sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless held by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The resale of the remaining
25,971,648 shares, or 61.8% of our outstanding shares after this offering, is currently prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by our stockholders with us or <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters. However, subject to applicable securities law restrictions and excluding shares of our restricted stock that will remain unvested, these
shares will be able to be sold in the public market beginning 180 days after the date of this prospectus. Shares of our unvested restricted stock subject to repurchase or forfeiture that were issued and outstanding as of the date of this prospectus
will become available for sale immediately upon the vesting of such shares, as applicable, and the expiration of any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements.
Shares issued upon the exercise of stock options pursuant to future awards that may be granted under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent
permitted by the provisions of applicable vesting schedules, any applicable market <FONT STYLE="white-space:nowrap">stand-off</FONT> and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act.
For more information see the section titled &#147;Shares Eligible for Future Sale&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, the holders of approximately 23,894,092 shares, or 56.9%, of our common stock, will have
rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to
register the offer and sale of all shares of our common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rights and shares to be issued under our equity incentive plans, they can be freely sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described in the section titled &#147;Underwriting&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition,
in the future, we may issue additional shares of our common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such
issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an
&#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. For as long as we continue to be an
emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor
attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding
a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial
statements in this prospectus. We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us to lose that status earlier, including if we are deemed to be a &#147;large
accelerated filer,&#148; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the prior June&nbsp;30, or if we have total annual gross revenue
of $1.235&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&nbsp;31, or if we issue more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. For so long as we remain an emerging growth company, we are permitted
and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the requirements of the Public Company Accounting Oversight Board regarding
the communication of critical audit matters in the auditor&#146;s report on the financial statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing only two years of audited financial statements in addition to any required unaudited interim
financial statements and a correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
stockholder approval of any golden parachute payments not previously approved. In this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even after we no longer qualify as an emerging growth company, we could still qualify as a
&#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports
and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
for our common stock and our share price may be more volatile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the JOBS Act provides that an emerging growth company can also
take advantage of an extended transition period for complying with new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting
standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting
company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our
common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year and our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote
substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we will
incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual,
quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Market (Nasdaq) to implement provisions of the
Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010,
the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules
and regulations in these areas such as &#147;say on pay&#148; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering.
Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and
impact the manner in which we operate our business in ways we cannot currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect the rules and
regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from
other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our
products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or
similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons
to serve on our board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Insiders will continue to have substantial
influence over us after this offering, which could limit your ability to affect the outcome of key transactions, including a change of control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After this offering, our directors and executive officers and their affiliates will beneficially own shares representing
approximately&nbsp;30.3% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval. For example, these stockholders may
be able to control elections of directors, amendments of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
organizational documents or approval of any merger, sale of assets or other major corporate transaction. This concentration of ownership may have the effect of delaying or preventing a change in
control of our company and might affect the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not expect to pay any dividends for the
foreseeable future. Investors in this offering may never obtain a return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">You should not rely
on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our
existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after
price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our
ability to operate our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ensuring that we have adequate internal financial and accounting
controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to <FONT STYLE="white-space:nowrap">be&nbsp;re-evaluated&nbsp;frequently.</FONT> Our internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In
connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management
assessment of the effectiveness of our internal control over financial reporting starting with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial
costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy or consequent inability to
produce accurate financial statements on a timely basis could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial
statements on a timely basis cause investors to lose confidence in the accuracy and completeness of our financial reports and could cause the market price of our common stock to decline significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the&nbsp;Exchange Act. We
designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the&nbsp;Exchange Act&nbsp;is accumulated and communicated to management, and recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These inherent limitations include the realities
that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an
unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we experience material weaknesses in the future or otherwise fail to maintain an
effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common
stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may in the future discover material weaknesses in our system of internal financial and accounting
controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and
operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, and our independent registered public accounting firm, were not required to perform an evaluation of our internal control
over financial reporting as of December&nbsp;31, 2023 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we will not in the future identify material weaknesses. Material weaknesses may exist when we
become required to report on the effectiveness of our internal control over financial reporting under Section&nbsp;404 of the Sarbanes-Oxley Act after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we
are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial
information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provisions in our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of
this offering, and amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part, and Delaware law may have anti-takeover effects that could discourage an acquisition
of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this
offering, and amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part, and Delaware law contain provisions that may have the effect of discouraging, delaying or
preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation
and amended and restated bylaws include provisions that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize &#147;blank check&#148; preferred stock, which could be issued by our board of directors without
stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create a classified board of directors whose members serve staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that special meetings of our stockholders can be called only by our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may be removed only for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">specify that no stockholder is permitted to cumulate votes at any election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expressly authorized our board of directors to make, alter, amend or repeal our amended and restated bylaws;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended
and restated certificate of incorporation and amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions, alone or
together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby
depressing the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, because we are incorporated in the State of Delaware, we
are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law (DGCL), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after
the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has
the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our amended and restated bylaws which became effective upon the effectiveness of this registration statement of which this
prospectus forms a part designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial
forum for disputes with us or our directors, officers, or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws which became
effective upon effectiveness of the registration statement of which this prospectus forms a part provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum
for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and
employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws
(including the interpretation, validity or enforceability thereof) or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine (Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of
action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the
sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or
otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal
securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Delaware Forum Provision and the Federal Forum Provision in
our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a
claim in a judicial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an
action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be
brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters.
The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States
may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us
than our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>General Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The global credit and financial markets have experienced extreme volatility and disruptions (including as a result
of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation,
uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict,
including the ongoing conflicts between Russia and Ukraine, and Israel and Hamas, terrorism, or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may
also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further
deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our product
candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. There are also current geopolitical tensions with China that may affect our operations. For example, there has been proposed United States
legislation, such as the bill titled the BIOSECURE Act, that may restrict the ability of United States pharmaceutical companies to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies of concern
without losing the ability to contract with, or otherwise receive funding from, the United States government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships.
Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical
trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending
commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity,
defaults, or <FONT STYLE="white-space:nowrap">non-performance</FONT> by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Actual events involving limited liquidity, defaults,
<FONT STYLE="white-space:nowrap">non-performance</FONT> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry
generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we assess our banking and customer relationships as we believe
necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect our
Company, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures,
the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the
prospects for companies in the financial services industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results of events or concerns that involve one or more of
these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial
assets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential or actual breach of statutory, regulatory or contractual obligations, including obligations that
require us to maintain letters of credit or other credit support arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash
management arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, investor concerns regarding the United States or international
financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it
more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial
obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors
described above or other related or similar factors not described above, could have material adverse impacts on our liquidity, our current and/or planned business operations, and our current or projected financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead
to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or planned business operations and our current or projected results of operations and financial condition. For example, a customer may
fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy, or a supplier may determine that it will no longer deal with us as a customer. In addition, a customer or supplier could be adversely
affected by any of the liquidity or other risks that are described above as factors that could result in material adverse impacts on the Company, including but not limited to delayed access or loss of access to uninsured deposits or loss of the
ability to draw on existing credit facilities involving a troubled or failed financial institution. Any customer, collaborator or supplier bankruptcy or insolvency, or the failure of any customer or collaborator to make payments when due, or any
breach or default by a customer, collaborator or supplier, or the loss of any significant supplier or collaborator relationships, could result in material losses to the Company and may have a material adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to satisfy listing requirements of Nasdaq or obtain or maintain a listing of our common stock on Nasdaq. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, after listing, we fail to satisfy Nasdaq&#146;s continued listing requirements, such as the corporate governance
requirements or the minimum closing bid price requirement. Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our
common stock when you wish to do so. In the event of a delisting, we can provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity
of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the
price of our stock could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our common stock will rely in part on the research and
reports that industry or financial analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our
stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover
our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may
become involved in litigation that could divert management&#146;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time we may be subject to litigation claims through the ordinary course of our business operations regarding, but
not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations with collaborators and licensors and intellectual property rights. In the past, securities class action litigation has
often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, the announcement of negative events, such as negative results from clinical trials, or periods of volatility
in the market price of a company&#146;s securities. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations
are usually expensive and divert management&#146;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive
in any such transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our insurance policies are expensive and only protect us from some business risks, which will leave us
exposed to significant uninsured liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we maintain commercial insurance at a level we believe is
appropriate against certain risks commonly insured in the industry in which we operate, there is no guarantee that our insurer will cover costs or that we will be able to obtain the desired level of coverage on acceptable terms in the future. Some
of the policies we currently maintain include property, general liability, crime insurance, workers&#146; compensation, and directors&#146; and officers&#146;, employment practices and fiduciary liability insurance, clinical trial insurance,
transportation insurance and umbrella insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Changes in the market conditions and our business operations may necessitate the addition of new
insurance policies or change of our existing insurance policies. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also expect that operating as a U.S. public company will make it more difficult and more expensive for us to obtain
director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and
retain qualified people to serve on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured
liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our operations are vulnerable to interruption by disasters, terrorist activity,
pandemics and other events beyond our control, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our facilities are located in
California. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, power loss, terrorist activity, pandemics or other regional or global disasters and generally do not
have a recovery plan for such events. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The
occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Increased attention to, and evolving expectations for, environmental, climate change, social, and governance initiatives could increase
our costs, harm our reputation, or otherwise adversely impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Companies across industries are facing
increasing scrutiny from a variety of stakeholders related to their environmental, climate change, social, and governance (ESG) and sustainability practices. Expectations regarding voluntary ESG initiatives and disclosures may result in increased
costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While we may at times engage in voluntary initiatives (such as voluntary disclosures, certifications, or
goals, among others) to improve the ESG profile of the Company, such initiatives may be costly and may not have the desired effect. Moreover, we may not be able to successfully complete such initiatives due to factors that are within or outside of
our control. Even if this is not the case, our actions may subsequently be determined to be insufficient by various stakeholders, and we may be subject to investor or regulator engagement on our ESG efforts, even if such initiatives are currently
voluntary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain market participants, including major institutional investors and capital providers, use third-party
benchmarks and scores to assess companies&#146; ESG profiles in making investment or voting decisions. Unfavorable ESG ratings could lead to increased negative investor sentiment towards us, which could negatively impact our share price as well as
our access to and cost of capital. To the extent ESG matters negatively impact our reputation, it may also impede our ability to compete as effectively to attract and retain employees, which may adversely impact our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we expect there will likely be increasing levels of regulation, disclosure-related and otherwise, with respect to
ESG matters. For example, the SEC has issued rules that require companies to provide significantly expanded climate-related disclosures in their periodic reporting, which may require us to incur significant additional costs to comply, including the
implementation of significant additional internal controls processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors. These
and other changes in stakeholder expectations will likely lead to increased costs as well as scrutiny that could heighten all of the risks identified in this risk factor. Additionally, our business partners may be subject to similar expectations,
which may augment or create additional risks, including risks that may not be known to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus, including the sections titled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions
and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial
performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
these forward-looking statements. Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, results and costs of conducting our research and development programs and
our current and future preclinical studies and anticipated clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials
will become available, and our current and future programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate, and the timing of, preclinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I> and <I>ex vivo </I>for multiple programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance any product candidates that we may identify and successfully complete any clinical
studies, including the manufacture of any such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope and likelihood of regulatory filings and approvals, including timing of INDs or comparable
foreign applications, and final FDA approval of our current product candidates or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope or likelihood of foreign regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, and strategic plans for our business, product candidates, and
technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or
otherwise violate any third-party intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to leverage programs within our initial target indications and to progress additional programs to
further develop our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our product
candidates, and other positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify and enter into future license agreements and collaborations and the potential benefits
of such agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to rely on third-party manufacturers and successfully manufacture product candidates for
preclinical use, clinical trials and on a larger scale for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to realize the benefits of collaborations for the development and commercialization of current and
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize any current and future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our proprietary Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations necessary to complete further development and
commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth potential of the markets for our current and future product candidates and our ability to
serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will remain an emerging growth company under the JOBS
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of proceeds from this offering, estimates of our expenses, capital requirements, and needs
for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of global economic and political developments on our business, including rising inflation and
capital market disruptions, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access
capital markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ultimate impact of health epidemics, pandemics, and other widespread outbreaks of contagious disease,
including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical trials, our research programs, healthcare systems or the global economy as a whole; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the section titled &#147;Risk Factors.&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some cases, you can identify forward-looking statements by terminology such as
&#147;anticipates,&#148; &#147;believes,&#148; &#147;continue,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;should&#148; or the negative
of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in
some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk
Factors&#148; and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the
forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
statement, of which this prospectus forms a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. Statements that
contain &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant
information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any
date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus also contains estimates, projections and other
information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are
assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by
market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their
estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#147;Risk
Factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds to us from the sale of 16,000,000 shares of our common stock in this offering will be
approximately $262.0&nbsp;million (or approximately $302.2&nbsp;million if the underwriters exercise their option to purchase additional shares in full), based on the initial public offering price of $18.00 per share, and after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Combined with our cash, cash
equivalents, and marketable securities as of October&nbsp;1, 2024, this additional $262.0&nbsp;million will provide for capital resources of approximately $398.3&nbsp;million. This estimate of our capital resources was prepared by management based
upon internal reporting, is preliminary and unaudited, and may be revised as a result of management&#146;s further review of our results as of and for the quarter ended September&nbsp;30, 2024, as well as the actual net proceeds received from this
offering. We have not yet completed our normal interim review procedures as of and for the quarter ended September&nbsp;30, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and
marketable securities, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $117&nbsp;million to advance the continued development of SEP-786, our lead product candidate
from our PTH1R program through completion of a Phase 2 clinical trial in hypoparathyroidism patients and initiation of a Phase 3 clinical trial, and additional molecules targeting PTH1R; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $37&nbsp;million to advance the development of SEP-631 through completion of a Phase 1 clinical
trial and initiation of Phase 2 clinical studies, and additional small molecules within our MRGPRX2 program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $57&nbsp;million for other research and development activities, including our TSHR and incretin
receptor programs, other new GPCR programs, and continued innovation of our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had $155.7&nbsp;million in cash, cash equivalents, and marketable securities. Based on our
current plans, we believe our existing cash, cash equivalents, and marketable securities, together with the net&nbsp;proceeds from this offering, will be sufficient to fund our operations and capital expenditure requirements into the second half of
2027. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The expected use of the net proceeds from this offering represents our intentions based upon our current plans and
business conditions, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion
of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development,
the addition of new programs or changes to plans for existing programs, as well as any collaborations that we may enter into with third parties or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our
management will retain broad discretion over the allocation of the net proceeds from this offering. We expect the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, will not be sufficient
for us to advance any of our programs through regulatory approval, and we will need to raise additional capital to complete the development and potential commercialization of any of our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will retain broad discretion in the application of the net proceeds we receive from our initial public
offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pending our use of the net proceeds from this offering, we intend to invest
the net proceeds in a variety of capital preservation instruments, including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the United States government. We cannot predict
whether the proceeds invested will yield a favorable return. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and
any future earnings to fund the development and expansion of our business, and therefore we do not anticipate paying cash dividends on our common stock in the foreseeable future. Any future determination regarding the declaration and payment of
dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements,
business prospects, and other factors our board of directors may deem relevant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our ability to pay cash
dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash, cash equivalents, and marketable securities and our capitalization as of June 30,
2024: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i) the automatic conversion of all outstanding shares of our
convertible preferred stock into an aggregate of 22,839,774 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity, each of which will occur immediately prior to the
completion of this offering, and (ii) the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the completion of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to reflect: (i) the pro forma adjustments set forth above, and (ii) the
issuance and sale of 16,000,000 shares of our common stock in this offering at the initial public offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma and pro forma as adjusted information below is illustrative only, and our capitalization
following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read the information in this table together with the sections titled
&#147;Prospectus Summary&#151;Summary Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">393,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, non-current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">417,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value; 196,657,452 shares authorized;
196,657,452&nbsp;shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value; no shares authorized, issued or outstanding,
actual; 10,000,000 authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 260,590,689 shares authorized; 3,163,020 shares issued and
outstanding; 784,550 shares subject to repurchase, actual; 500,000,000 shares authorized, 26,002,794 shares issued and outstanding; 784,550 shares subject to repurchase, pro forma; 500,000,000 shares authorized, 42,002,794 shares issued and
outstanding; 784,550 shares subject to repurchase, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;for&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">495,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">418,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">418,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our common stock in
full, our pro forma as adjusted cash, cash equivalents, and marketable securities, additional paid-in capital, total stockholders&#146; equity (deficit), total capitalization, and shares of our common stock outstanding as of June 30, 2024 would be
$457.9&nbsp;million, $535.8&nbsp;million, $458.6&nbsp;million, $458.6&nbsp;million, and 44,402,794 shares, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock issued and outstanding, pro forma and pro forma as adjusted, in the table above is
based on 3,163,020 shares (which includes 784,550&nbsp;shares of unvested restricted common stock subject to repurchase or forfeiture) of our common stock outstanding as of June 30, 2024, and assumes the automatic conversion of all outstanding
shares of our convertible preferred stock into an aggregate of 22,839,774&nbsp;shares of our common stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,796,272 shares of our common stock issuable upon the exercise of stock options outstanding as of
June&nbsp;30, 2024 under the 2021 Plan, with a weighted-average exercise price of $2.68&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,228,574&nbsp;shares of our common stock issuable upon the exercise of stock options granted after
June&nbsp;30, 2024 pursuant to the 2021 Plan, with a weighted-average exercise price of $6.81&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,690,000 shares of our common stock that became available for future issuance under the 2024 Plan, which
became effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future issuance
under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">369,402 shares of our common stock reserved for future issuance under the ESPP, which became effective on the
date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the
difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our historical net tangible book deficit as of June&nbsp;30, 2024 was $68.2 million, or $21.55 per share of our common stock.
Our historical net tangible book deficit per share is the amount of our total tangible assets less our total liabilities and the carrying values of our convertible preferred stock, which is not included within stockholders&#146; deficit. Our
historical net tangible book deficit per share represents historical net tangible book deficit divided by the 3,163,020 shares (which includes 784,550 shares of unvested restricted common stock subject to repurchase or forfeiture) of our common
stock outstanding as of June&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our pro forma net tangible book value as of June&nbsp;30, 2024 was $156.0
million, or $6.00 per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to the automatic conversion of all outstanding shares of our
convertible preferred stock into an aggregate of 22,839,774 shares of our common stock immediately prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the
total number of shares outstanding as of June&nbsp;30, 2024, after giving effect to the pro forma adjustment described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving further effect to the issuance and sale of 16,000,000 shares of our common stock in this offering at the initial
public offering price of $18.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2024 would have been
$418.0&nbsp;million, or $9.95 per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value per share of $3.95 to our existing stockholders and immediate dilution of $8.05 in pro forma as adjusted net
tangible book value per share to new investors purchasing shares of our common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dilution per share
to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per
share basis (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book deficit per share as of June&nbsp;30, <BR>2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;(21.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share as of June&nbsp;30, 2024
attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share <BR>attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this <BR>offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise in full their option to purchase additional shares, our pro forma
as adjusted net tangible book value per share after this offering would be $10.32, representing an immediate increase in pro forma as adjusted net tangible book value per share of $0.37 to existing stockholders and immediate dilution in pro forma as
adjusted net tangible book value per share of $7.68 to new investors purchasing common stock in this offering, based on the initial public offering price of $18.00 per share and after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table as of June&nbsp;30, 2024 summarizes on the pro forma as
adjusted basis described above, the total number of shares of our common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid, and the average price per share paid or to be paid by existing
stockholders and by new investors in this offering at the initial public offering price of $18.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by us. As the table shows, new investors
purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,002,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,002,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">513,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The table above assumes no exercise of the underwriters&#146; option to purchase additional
shares in this offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to 59% of the total number of shares of our common
stock outstanding after this offering, and the number of shares of our common stock held by new investors purchasing common stock in this offering would be increased to 41% of the total number of shares of our common stock outstanding after this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing tables and calculations (other than the historical net tangible book value calculations) are
based on 3,163,020 shares (which includes 784,550 shares of unvested restricted common stock subject to repurchase or forfeiture) of our common stock outstanding as of June&nbsp;30, 2024, and assumes the automatic conversion of all outstanding
shares of our convertible preferred stock into an aggregate of 22,839,774 shares of our common stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,796,272&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of
June&nbsp;30, 2024 under the 2021 Plan, with a weighted-average exercise price of $2.68&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,228,574&nbsp;shares of our common stock issuable upon the exercise of stock options granted after
June&nbsp;30, 2024 pursuant to the 2021 Plan, with a weighted-average exercise price of $6.81&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,690,000&nbsp;shares of our common stock that became available for future issuance under the 2024 Plan, which
became effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future issuance
under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">369,402&nbsp;shares of our common stock reserved for future issuance under the ESPP, which became effective on
the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent that new stock options or other equity awards are issued or any outstanding stock options
are exercised, or we issue additional shares of our common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if
we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial condition and
results of operations together with our audited financial statements and unaudited interim condensed financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this prospectus contain
forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements of our plans, objectives,
expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors including, but not limited to,
those set forth under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and you should carefully read
the section titled &#147;Risk Factors&#148; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#147;Special Note Regarding
Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of
product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within
ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-</FONT></FONT></FONT> art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our
Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including
agonists (which activate GPCR signaling), antagonists (which inhibit GPCR signaling), and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands), to affect GPCR signaling in different ways to
achieve desired therapeutic effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with
novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is summarized in the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g59y26.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.39853in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing our lead product candidate,
<FONT STYLE="white-space:nowrap">SEP-786,</FONT> an oral small molecule agonist targeting the Parathyroid Hormone 1 Receptor (PTH1R) for the treatment of hypoparathyroidism. Leveraging our team, scientific and technical advisors, and our proprietary
Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, we changed our name to
Septerna, Inc. We are headquartered in South San Francisco, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred significant operating losses
since our inception, except for the year ended December&nbsp;31, 2023 when we recorded net income of $4.2 million. Our revenue to date has been generated solely from research services. Since our founding, we have devoted substantially all of our
resources to organizing and staffing our company, business planning, raising capital, developing our proprietary and structure-based drug discovery platform, identifying and discovering our product candidates, establishing our intellectual property
portfolio, conducting research and preclinical studies, including <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, initiating and conducting clinical trials, establishing arrangements with third parties for the manufacture of our
product candidates and related raw materials, and providing general and administrative support for these operations. We have not had any products approved for sale and have not generated any revenue from product sales. Further, we do not expect to
generate revenue from commercial product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one or more of our product candidates. Our ability to generate product revenue will
depend on the successful development and eventual commercialization of one or more of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have
incurred net losses in each year since inception, except for the year ended December&nbsp;31, 2023. During the year ended December&nbsp;31, 2023, we recorded a gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of
$47.6&nbsp;million for the sale of an <FONT STYLE="white-space:nowrap">in-progress</FONT> research and development (IPR&amp;D) asset related to a GPCR program and $0.2&nbsp;million in revenue related to research services resulting in net income of
$4.2&nbsp;million for the year then-ended compared to net loss of $27.7&nbsp;million for the year ended December&nbsp;31, 2022. Of the $47.6&nbsp;million gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, $25.0&nbsp;million
was received in cash in September 2023 and $22.6&nbsp;million was received during the six months ended June&nbsp;30, 2024. Our net losses were $19.8&nbsp;million and $30.6&nbsp;million for the six months ended June&nbsp;30, 2023 and 2024,
respectively. As of June&nbsp;30, 2024, we had an accumulated deficit of $77.2&nbsp;million. We expect to continue to incur net losses for the foreseeable future. Our net losses may fluctuate significantly from period to period, depending on the
timing and expenditures of our operational activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to continue to incur significant and increasing net
operating losses for the next several years as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance our product candidates through preclinical studies and into clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain additional personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operate as a public company, including expenses related to compliance with the rules and regulations of the
SEC and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and development efforts and expand our pipeline of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, discover, validate, and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the manufacture of supplies for our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, expand, and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement operational, financial and information management systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make royalty, milestone or other payments under any future, license or collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially seek to identify, assess, acquire, or <FONT STYLE="white-space:nowrap">in-license</FONT> or
develop new technologies or additional product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially experience any delays, challenges, or other issues associated with the clinical development of our
product candidates, including with respect to our regulatory strategies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue regulatory approval of product candidates that successfully complete clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which
we may obtain marketing approval and related commercial manufacturing <FONT STYLE="white-space:nowrap">build-out.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our net losses may fluctuate significantly from period to period, depending upon the timing of our expenditures on research
and development activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses and other current liabilities, which includes accrued
research and development, in the statements of cash flows in our audited and interim unaudited condensed financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a result, we will require substantial additional funding to further develop our product candidates and support our
continuing operations. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing,
distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#146; ownership interests will be diluted, and the terms of these securities may
include liquidation or other preferences that adversely affect existing stockholders&#146; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing,
distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If
we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant
rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have
historically financed our operations primarily through the issuances of convertible promissory notes and convertible preferred stock. In November 2021, we entered into a total of $100.0&nbsp;million of Series A convertible preferred stock financing
which was divided into two tranches. The initial tranche was completed in November 2021 for net proceeds of $44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of
the then outstanding convertible promissory notes plus accrued interest. In November 2022, we executed the second tranche for net cash proceeds of $30.0&nbsp;million. The Series A convertible preferred stock agreement was subsequently amended to
cancel the remaining 25.0&nbsp;million unissued shares of Series A convertible preferred stock in June 2023, upon entering into the Series B convertible preferred stock financing. In June 2023, we entered into a total of $150.0&nbsp;million of
Series B convertible preferred stock financing, which was divided into two tranches of equal amounts. The first tranche, which was the issuance of $75.0&nbsp;million of Series B convertible preferred stock, was completed in June and July 2023 for
total net proceeds of $74.5&nbsp;million. The second tranche, which was for the issuance of the remaining $75.0&nbsp;million, was completed in May 2024 for net proceeds of $74.9&nbsp;million. Since our inception, we have devoted substantially all of
our resources to raising capital, organizing and staffing our company, business and scientific planning, conducting discovery and research and development activities, establishing and protecting our intellectual property portfolio, developing and
progressing our product candidates and preparing for clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and component materials, engaging in collaboration activities, and providing general and
administrative support for these operations. Based on our current plans, we believe our existing cash, cash equivalents, and marketable securities, together with the net proceeds from this offering, will be sufficient to fund our operations and
capital expenditure requirements into the second half of 2027. See the subsection titled &#147;&#151;Liquidity and Capital Resources&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use contract research and development organizations to conduct our preclinical works and clinical trials. Additionally, we
utilize third-party contract manufacturing organizations (CMOs), to manufacture and supply our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
preclinical and clinical materials during the development of our product candidates. We expect to use similar contract resources for the commercialization of our products, at least until our
resources and operations are at a scale that justifies investment in internal manufacturing capabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Vertex Asset Purchase and
Service Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Asset Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2023, we entered into an asset purchase agreement with Vertex Pharmaceuticals Incorporated (Vertex) for a total of
$47.6&nbsp;million under which Vertex acquired all of our IPR&amp;D asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (Vertex purchase agreement). Of the $47.6&nbsp;million,
$25.0&nbsp;million was received in cash in September 2023 and $22.6&nbsp;million was received in the first half of 2024. Additionally, as part of the agreement, Vertex assumed all claims, counterclaims and credits associated with the program, and we
gave up all rights to the intellectual property. The transfer of the IPR&amp;D asset to Vertex was completed in November 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the same time in September 2023, we entered into a research service agreement with Vertex under which we agreed to perform
certain exploratory research activities for Vertex. See the subsection titled &#147;&#151;Service Agreement&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Vertex purchase agreement also provides for a potential milestone payment payable to us contingent upon achievement of a
certain research milestone. The milestone payment amount is determined based on the timing of achievement of the research milestone. The variable consideration related to this milestone payment was determined to be improbable of receipt at this
time. As a result, the milestone payment was excluded from the transaction price. After the potential milestone payment, we will not receive any other payments or future royalties related to this IPR&amp;D asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Service Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the Vertex purchase agreement, we also entered into a research service agreement with Vertex (Vertex service
agreement) under which we agreed to perform certain exploratory research activities for Vertex. The Vertex service agreement is for a <FONT STYLE="white-space:nowrap">two-year</FONT> term, however, Vertex has the ability to terminate the agreement
with a <FONT STYLE="white-space:nowrap">30-day</FONT> notice at any time. As a result, we concluded that the contract duration is 30 days, representing a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT>
service contract. We recognize revenue associated with the Vertex service agreement over the performance period of the research services as the services are provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have not generated any revenue from product sales and do not expect to do so in the foreseeable future. Our ability to
generate product revenue, if ever, will depend on the successful development and eventual commercialization of any product candidates that we identify. If we fail to complete the development of any future product candidates in a timely manner or to
obtain regulatory approval for such product candidates, our ability to generate future revenue and our results of operations and financial position would be materially adversely affected. Our revenues to date have been exclusively related to
research services. We recognize revenue as specified research services are performed and the results of the research and development services are provided to the customer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operating expenses consist of (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative
expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expenses account for the largest component of our total operating expenses. Research and development
expenses consist primarily of direct and unallocated costs incurred for the research and development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our research and development expenses consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development costs related to (i)&nbsp;the production of preclinical materials, including
fees and milestones paid to contract manufacturers and (ii)&nbsp;agreements with contract development organizations, consultants and other third-party contract organizations to conduct our preclinical studies and other research and development
activities on our behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external costs to conduct clinical trials, including costs paid to clinical research organizations (CROs), the
production of clinical materials and fees paid to contract manufacturers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs incurred in connection with laboratory operations, materials and supplies, and other preclinical
studies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unallocated costs, including: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related costs, including salaries, benefits and stock-based compensation for employees engaged in
research and development activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development costs, including contract research and development and professional service
fees for consulting and related services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facility-related and office costs, including lease/rent, building-related expenses, facility-related overhead,
and depreciation expense; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other costs, including expenses related to our funded, sponsored research activities and technology licenses,
laboratory operations, information technology (IT)-related expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expense all research and
development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and
third-party service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A significant portion of our research and development costs have been external costs,
which we track by stage of development. However, we do not track our unallocated costs on a program specific basis because these costs are deployed across multiple projects and, as such, are not separately classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be
necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect that our research and development expenses will increase substantially in absolute dollars for the foreseeable future as we
continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct clinical trials, as we seek regulatory approvals for
any product candidates that successfully complete clinical trials, and as we incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to
obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing product candidates, many of which
are outside of our control, including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current research and development programs and to establish new ones;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing an appropriate safety profile with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites and patients included in the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the clinical trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in, and the initiation of, clinical trials, as well as drop out or
discontinuation rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are
satisfactory to the FDA, EMA, or any other comparable foreign regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and terms of any regulatory approvals from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance of any future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of any business interruptions to our operations or to those of the third parties with whom we work;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with
others; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of the product candidates following approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any changes in the outcome of any of these variables could mean a significant change in the costs and
timing associated with the development of our product candidates. For example, if the FDA, EMA or any other comparable foreign regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for
the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and
time on the completion of clinical development. We may never obtain regulatory approval for any of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and
Administrative </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of personnel-related costs, costs related to
maintenance and filing of intellectual property, legal fees related to corporate matters, professional fees paid for accounting, auditing, consulting, tax and investor relations services, insurance costs, general corporate expenses, and <FONT
STYLE="white-space:nowrap">IT-related</FONT> and facility-related costs not otherwise included in research and development expenses. Personnel-related costs include salaries, benefits, and stock-based compensation for our personnel in executive,
legal, finance and accounting, human resources, and other administrative functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that our general and
administrative expenses will increase substantially in absolute dollars for the foreseeable future as we continue to increase our headcount to support our business growth. We also anticipate that we will incur increased expenses as a result of our
preparation of becoming and, ultimately, operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and expenses related to audit, legal, regulatory services associated with maintaining
compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Income (Expense), Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income consists of interest earned on our cash, cash equivalents, and marketable securities during the period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Income (Expense), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other income (expense), net consists primarily of changes in the fair value of our cash equivalents held in money market funds
and loss on disposal of our fixed assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to corporate United States federal and state income taxation. As of December&nbsp;31, 2023, we had
$14.6&nbsp;million of federal NOL carryforwards and $28.9&nbsp;million of state NOL carryforwards, available to reduce future taxable income. Of the federal NOL carryforwards, $14.6&nbsp;million will carryforward indefinitely. The state NOL
carryforwards will begin to expire in 2041, if not utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section 382 of the Code (Section 382) places a limitation,
referred to as the Section&nbsp;382 limitation, on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules.
When an ownership change occurs, Section&nbsp;382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax attributes in one year but the
identified ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. We establish a valuation allowance against all of our net deferred tax assets. We consider all
available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and
uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we had federal and state research and development tax credits carryforwards of $2.0&nbsp;million and $1.8
million, respectively, as of December&nbsp;31, 2023 available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2041 if not utilized. The state research and development tax credits have no
expiration date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We record liabilities related to uncertain tax positions in accordance with the guidance that clarifies
the accounting for uncertainty in income taxes recognized in an enterprise&#146;s financial statements by prescribing a minimum recognition threshold and measurement attribute for purposes of financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. As of December&nbsp;31, 2022 and 2023, we had unrecognized tax benefits of $1.8&nbsp;million and $2.5&nbsp;million, respectively, all of which would affect our income tax expense if recognized,
before consideration of our valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Six Months Ended June&nbsp;30, 2023 and 2024 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations for each of the periods indicated are summarized in the table below (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8201;&#8195;2023&#8201;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8201;&#8195;2024&#8201;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Loss before benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our revenue of $0.7&nbsp;million for the six months ended June&nbsp;30, 2024 was generated from the services provided to Vertex
while no revenue was recorded for the six months ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses for each of the periods indicated by direct and
unallocated costs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SEP-786</FONT> (PTH1R)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SEP-631</FONT> (MRGPRX2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TSHR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility-related and office costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expense was $16.4&nbsp;million and $28.2&nbsp;million for the six
months ended June&nbsp;30, 2023 and 2024, respectively. The increase was primarily due to (i) $2.6&nbsp;million of higher direct costs mainly attributable to our preclinical programs, (ii) $2.4&nbsp;million of higher employee-related costs as a
result of increased </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
headcount, (iii) $5.1&nbsp;million of higher expenses associated with external research and development costs, and (iv) $0.9&nbsp;million of higher facility-related and office costs as we
continue to expand our office space to accommodate higher occupancy and larger operational activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and Administrative
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $3.8&nbsp;million and $6.1&nbsp;million for the six months ended
June&nbsp;30, 2023 and 2024, respectively. The increase was primarily due to (i) $0.8&nbsp;million of higher employee-related costs as a result of increased headcount, (ii) $0.6&nbsp;million of higher legal fees, (iii) $0.4&nbsp;million of higher
audit and accounting-related fees, and (iv) $0.2&nbsp;million of higher facility-related and office costs as we continue to expand our office space to accommodate higher headcount, higher occupancy, and larger operational activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income was $0.4&nbsp;million and $2.8&nbsp;million for the six months ended June&nbsp;30, 2023 and 2024, respectively.
The increase was due to higher interest rates and higher balances of invested cash in our cash equivalents, and marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Expense, net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the six months ended June&nbsp;30, 2023 and 2024, our other expense, net was immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Benefit for Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recognized $0.2&nbsp;million of benefit for income taxes for the six months ended June&nbsp;30, 2024. We did not record any
benefit or provision for income taxes for the six months ended June&nbsp;30, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Comparison of the Years Ended December&nbsp;31,
2022 and 2023 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our results of operations for each of the periods indicated are summarized in the table below (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8201;&#8195;2022&#8201;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8201;&#8195;2023&#8201;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating expenses (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total operating expenses (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">(Loss) income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our revenue of $0.2&nbsp;million for the year ended December&nbsp;31, 2023 was generated from the services provided to Vertex
while no revenue was recorded for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Operating Expenses (Income) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our research and development expenses for the periods indicated by direct and unallocated costs
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">SEP-786 (PTH1R)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">SEP-631 (MRGPRX2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">TSHR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Unallocated costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Employee-related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">External research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Facility-related and office costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development expense was $22.0&nbsp;million and $36.0&nbsp;million for the years
ended December&nbsp;31, 2022 and 2023, respectively. The increase was primarily due to (i) $4.0&nbsp;million of higher direct costs attributable to our preclinical programs, (ii) $4.4&nbsp;million of higher employee-related costs as a result of
increased headcount, (iii) $2.7&nbsp;million of higher expenses associated with external research and development costs, and (iv) $1.5&nbsp;million of higher facility-related and office costs as we continue to expand our office space to accommodate
higher occupancy and larger operational activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $5.9&nbsp;million and $9.7&nbsp;million for the years ended December&nbsp;31, 2022 and
2023, respectively. The increase was primarily due to (i) $2.2&nbsp;million of higher employee-related costs a result of increased headcount, (ii) $0.9&nbsp;million of higher legal fees, and (iii) $0.8&nbsp;million of higher consulting expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Gain on Sale of <FONT STYLE="white-space:nowrap">Non-Financial</FONT> Asset </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million was attributable to the sale
of our IPR&amp;D asset related to a GPCR program to Vertex during the year ended December&nbsp;31, 2023. No gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset was recorded during the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest income was $0.3&nbsp;million and $2.8&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively.
The increase was due to higher interest rates and higher balances of our cash and cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Other Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the year ended December&nbsp;31, 2023, our other income and expense was immaterial. For the year ended December&nbsp;31,
2022, we did not record other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provision for Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Provision for income taxes of $0.7&nbsp;million for the year ended December&nbsp;31, 2023 was primarily due to the gain on sale
of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, which resulted in net income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred significant operating losses for each year since our inception, except for the year ended December&nbsp;31,
2023 when we recorded net income of $4.2 million. Our revenue to date has been generated solely from research services. Since our founding, we have devoted substantially all of our resources to organizing and staffing our company, business planning,
raising capital, developing our proprietary and structure-based drug discovery platform, identifying and discovering our product candidates, establishing our intellectual property portfolio, conducting research and preclinical studies, including <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies, initiating and conducting clinical trials, establishing arrangements with third parties for the manufacture of our product candidates and related raw materials, and providing general and
administrative support for these operations. We have not had any products approved for sale and have not generated any revenue from product sales. Further, we do not expect to generate revenue from product sales until such time, if ever, that we are
able to successfully complete the development and obtain marketing approval for one or more of our product candidates. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred net losses in each year since inception, except for the year ended
December&nbsp;31, 2023 when we recorded net income of $4.2&nbsp;million. For the six months ended June&nbsp;30, 2024, we incurred a net loss of $30.6&nbsp;million. We expect to incur substantial expenses when we operate as a public company, advance
our product candidates into clinical development, undergo the regulatory approval process, engage in other research and development activities to expand our pipeline of product candidates, expand our operations and headcount, maintain and expand our
intellectual property portfolio and, if we obtain approval for one or more of our product candidates, launch commercial activities. Specifically, in the near term we expect to incur substantial expenses relating to initiating and completing our
clinical trials and our other product development activities. Furthermore, upon the successful completion of this offering, we expect to incur incremental costs associated with operating as a public company, including significant legal, accounting,
investor relations, director and officer insurance and other expenses. As of June&nbsp;30, 2024, we had an accumulated deficit of $77.2&nbsp;million. We expect to continue to incur net losses for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically financed our operations primarily through the issuances of convertible promissory notes and convertible
preferred stock. In November 2021, we entered into a total of $100.0&nbsp;million of Series A convertible preferred stock financing which was divided into two tranches. The initial tranche was completed in November 2021 for net proceeds of
$44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. In November 2022, we executed the
second tranche for net cash proceeds of $30.0&nbsp;million. The Series A convertible preferred stock agreement was subsequently amended to cancel the remaining 25.0&nbsp;million unissued shares of Series A convertible preferred stock in June 2023,
upon entering into the Series B convertible preferred stock financing. In June 2023, we entered into a total of $150.0&nbsp;million of Series B convertible preferred stock financing, which was divided into two tranches of equal amounts. The first
tranche, which was the issuance of $75.0&nbsp;million of Series B convertible preferred stock, was completed in June and July 2023 for total net proceeds of $74.5&nbsp;million. The second tranche, which was for the issuance of the remaining
$75.0&nbsp;million, was completed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
in May 2024 for net proceeds of $74.9&nbsp;million. During the year ended December&nbsp;31, 2023, we recorded a gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of
$47.6&nbsp;million for the sale of an IPR&amp;D asset related to a GPCR program and $0.2&nbsp;million in revenue related to research services resulting in net income of $4.2&nbsp;million for the year then-ended compared to net loss of
$27.7&nbsp;million for the year ended December&nbsp;31, 2022. Of the $47.6&nbsp;million gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, $25.0&nbsp;million was received in cash at the closing of the Vertex purchase
agreement in September 2023 and $22.6&nbsp;million was received during the six months ended June&nbsp;30, 2024. As of June&nbsp;30, 2024, we had $155.7&nbsp;million in cash, cash equivalents, and marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our cash flows for each of the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in operating activities was $20.0&nbsp;million and $29.7&nbsp;million for the six months ended June&nbsp;30, 2023
and 2024, respectively. The net cash used in operating activities for the six months ended June&nbsp;30, 2023 was attributable to our net loss of $19.8&nbsp;million, and $1.6&nbsp;million of net change in operating assets and liabilities, partially
offset by $1.4&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, stock-based compensation and <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense. The net cash used in
operating activities for the six months ended June&nbsp;30, 2024 was attributable to our net loss of $30.6&nbsp;million, and $1.0&nbsp;million of net change in operating assets and liabilities, partially offset by $1.9&nbsp;million of <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense, deferred income tax and accretion of discounts on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net
cash used in operating activities was $23.3&nbsp;million and $38.7&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. The net cash used in operating activities for the year ended December&nbsp;31, 2022 was attributable
to our net loss of $27.7&nbsp;million, partially offset by $2.6&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, stock-based compensation and <FONT STYLE="white-space:nowrap">non-cash</FONT>
operating lease expense, and $1.7&nbsp;million of net change in operating assets and liabilities. The net cash used in operating activities for the year ended December&nbsp;31, 2023 was attributable to $47.6&nbsp;million of <FONT
STYLE="white-space:nowrap">non-cash</FONT> adjustment related to gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, partially offset by (i)&nbsp;our net income of $4.2&nbsp;million, (ii) $3.8&nbsp;million of <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease expense and deferred income tax, and (iii) $0.9&nbsp;million of net
change in operating assets and liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Cash (Used in) Provided by Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities of $1.2&nbsp;million for the six months ended June&nbsp;30, 2023 was attributable to
purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities of $2.6&nbsp;million for the six months ended
June&nbsp;30, 2024 was attributable to $32.2&nbsp;million of purchases of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities and $0.9&nbsp;million of purchases of property and
equipment, partially offset by the receipt of the remaining $22.6&nbsp;million from the sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset in 2023 and the maturity of $7.9&nbsp;million of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash used in investing activities of $1.3&nbsp;million for the year
ended December&nbsp;31, 2022 was attributable to purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by investing
activities of $22.1&nbsp;million for the year ended December&nbsp;31, 2023 was attributable to $25.0&nbsp;million proceeds from the sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset, partially offset by $2.9&nbsp;million of
purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Net Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $71.5&nbsp;million and $75.0&nbsp;million for the six months ended June&nbsp;30,
2023 and 2024, respectively. Net cash provided by financing activities for the six months ended June&nbsp;30, 2023 and 2024 was primarily attributable to net proceeds from the sale and issuance of our Series B convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Net cash provided by financing activities was $30.1&nbsp;million and $74.5&nbsp;million for the years ended December&nbsp;31,
2022 and 2023, respectively. Net cash provided by financing activities for the year ended December&nbsp;31, 2022 was primarily attributable to net proceeds from the sale and issuance of our Series A convertible preferred stock. Net cash provided by
financing activities for the year ended December&nbsp;31, 2023 was primarily attributable to net proceeds from the sale and issuance of our Series B convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our primary use of cash is to fund our operations, primarily research and development expenditures. Cash used for operating
expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical
products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical
trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing
approval and commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order
to further develop our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses and fees associated with the discovery, acquisition or
<FONT STYLE="white-space:nowrap">in-license</FONT> of additional product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish additional collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of future commercialization activities, if any, including establishing sales, marketing,
manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue, if any, received from commercial sales of our product candidates, should any of our product
candidates receive marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need additional funds to meet operational needs and
capital requirements for clinical trials, other research and development expenditures, and business development activities. Because of the numerous risks and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures
associated with our current and anticipated clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial
product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional
capital through the sale of equity or convertible debt securities, existing stockholders&#146; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect existing
stockholders&#146; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other
arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have historically financed our operations primarily through the issuances of convertible
promissory notes and convertible preferred stock. In June 2023, we entered into a total of $150.0&nbsp;million of Series B convertible preferred stock financing, which was divided into two tranches of equal amounts. The first tranche, which was the
issuance of $75.0&nbsp;million of Series B convertible preferred stock, was completed in June and July 2023 for total net proceeds of $74.5&nbsp;million. The second tranche, which was the issuance of the remaining $75.0&nbsp;million, was completed
in May 2024 for net proceeds of $74.9&nbsp;million. Since our inception, we have devoted substantially all of our resources to raising capital, organizing and staffing our company, business and scientific planning, conducting discovery and research
and development activities, establishing, maintaining, and protecting our intellectual property portfolio, developing and progressing our product candidates and preparing for clinical trials, establishing arrangements with third parties for the
manufacture of our product candidates and component materials, engaging in collaboration activities, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current plans, we believe our existing cash, cash equivalents, and marketable securities, together with the net
proceeds from this offering, will be sufficient to fund our operations and capital expenditure requirements into the second half of 2027. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our future cash outflows for contractual obligations as of June&nbsp;30, 2024 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;Years</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations, including interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We lease certain office space in South San Francisco under a lease that expires in July 2032.
See Note 6 to our audited financial statements included elsewhere in this prospectus for more information on our lease obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into contracts in the normal course of business for contract research services, contract manufacturing services,
professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts and not included in the table above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements other than our indemnification
agreements as described in Note 7 to our audited financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Critical Accounting
Estimates, Significant Judgments and Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Management&#146;s discussion and analysis of our financial
condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). The preparation of these financial statements requires
us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses
incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the
accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generated revenue for the six months ended June&nbsp;30, 2024 and the year ended December&nbsp;31, 2023 from service revenue
for research activities performed related to an agreement with Vertex. We consider revenue to be earned when all of the following criteria are met: (i)&nbsp;we have a contract with a customer that creates enforceable rights and obligations;
(ii)&nbsp;promised products or services are identified; (iii)&nbsp;the transaction price, or the amount we expect to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that
would result in a significant reversal upon resolution of the uncertainty, is determinable; (iv)&nbsp;and we have transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct
good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration we expect to receive in exchange for the goods and services expected to be transferred.
When a contract contains variable consideration and the variable consideration is constrained to the extent that it is not probable that it will be received, it is excluded from the transaction price. A contract&#146;s transaction price is allocated
to each distinct performance obligation on a relative standalone selling price basis and recognized as revenue when, or as, control of the distinct good or service is transferred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation is measured based on the estimated grant date fair value of the award and is recognized as expense on
a straight-line basis over the requisite service period (usually the vesting period). Forfeitures are accounted for in the period in which they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In determining the fair value of the options granted, we use the Black Scholes option pricing model and assumptions discussed
below. Each of these inputs is subjective and generally requires significant judgment to determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fair Value of
Common Stock</I> &#151; See the subsection titled &#147;&#151;Fair Value of Common Stock&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected
Term</I> &#151; The expected term represents the period that our stock options granted are expected to be outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting
date and the end of the contractual term). We have very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. We will continue
to apply this process until a sufficient amount of historical information regarding employee exercise patterns and post-vesting employment termination behavior becomes available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Volatility</I> &#151; Since we are not a public company and have
no trading history for our common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal to the expected term of the stock option
grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Risk-free Interest Rate</I> &#151; The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect
at the time of grant for periods corresponding with the expected term of the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Expected Dividend</I> &#151; We
have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recorded stock-based compensation of $0.7&nbsp;million and $1.2&nbsp;million for the six months ended June&nbsp;30, 2023
and 2024, respectively. We recorded stock-based compensation of $1.5&nbsp;million and $1.6&nbsp;million for the years ended December&nbsp;31, 2022 and 2023, respectively. As of June&nbsp;30, 2024, total unrecognized stock-based compensation expense
related to unvested restricted stock awards and unvested stock options was $5.9&nbsp;million, which is expected to be recognized over a weighted-average period of 2.8 years. As of June&nbsp;30, 2024, total unrecognized stock-based compensation
expense related to unvested restricted stock awards subject to performance conditions, which were improbable of achievement, was $0.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The intrinsic value of all outstanding incentive awards as of June 30, 2024 was $39.5&nbsp;million based on the initial public
offering price of $18.00 per share, of which $3.9&nbsp;million was related to vested stock options and $35.6&nbsp;million was related to unvested stock options and restricted stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Fair Value of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, for all periods prior to this offering, the grant-date fair market value of our common stock underlying stock
options has been determined by our board of directors with assistance of unrelated third-party valuation specialists. Because there has been no public market for our common stock, our board of directors have exercised reasonable judgment and
considered a number of objective and subjective factors to determine the best estimate of the fair market value, which include important developments in our operations, the prices at which we sold shares of our convertible preferred stock, the
rights, preferences and privileges of our convertible preferred stock relative to those of common stock, actual operating results, financial performance, external market conditions in the life sciences industry, general U.S. market conditions,
equity market conditions of comparable public companies, and the lack of marketability of our common stock. Given the absence of a public trading market for our common stock, our board of directors exercised reasonable judgment and considered a
number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including: our stage of development and material risks related to our business; the progress of our research and development programs;
sales of our preferred stock; the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock; the lack of marketability of our securities; our financial condition and operating results, including our
levels of available capital resources; the likelihood of achieving a liquidity event such as an initial public offering in light of prevailing market conditions; equity market conditions affecting comparable public companies; the trends,
developments and conditions in the life sciences and biotechnology industry sectors; and general U.S. market and economic conditions. Valuations of our common stock were prepared by an unrelated third-party valuation firm in accordance with the
guidance provided by the American Institute of Certified Public Accountants 2013 Practice Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>, referred to as the &#147;Practice Aid.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Practice Aid, prior to April 2024, the fair value of our common stock was determined using the Option
Pricing Method (OPM) method as we determined the OPM method was the most appropriate method to utilize based on our stage of development and other relevant factors. The OPM uses the preferred stockholders&#146; liquidation preferences, participation
rights, dividend policy, and conversion rights to determine </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
how proceeds from a liquidity event shall be distributed among the various ownership classes at a future date. Starting April 2024, in accordance with the Practice Aid, we determined the hybrid
probability-weighted expected return method (PWERM) method was the most appropriate method for determining the fair value of our common stock based on our stage of development and other relevant factors. The hybrid PWERM is a scenario-based
methodology that estimates the fair value of common stock based upon an analysis of future values for our company, assuming various outcomes with one of those outcomes incorporating the OPM method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the equity value was determined and allocated to the various classes of equity securities, a discount for lack of
marketability (DLOM) was applied to arrive at the fair value of common stock on a <FONT STYLE="white-space:nowrap">non-marketable</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A DLOM is applied based on the theory that as an owner of a private company stock, the holder has limited information and
opportunities to sell the stock. A market participant that would purchase this stock would recognize this risk and thereby require a higher rate of return, which would reduce the overall fair market value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The assumptions underlying these valuations represented management&#146;s best estimates, which involved inherent
uncertainties and the application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially
different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once a public trading market for our common stock has been established in connection with the completion of
this offering, it will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common
stock will be determined based on the quoted market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Research and Development Costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development costs are expensed as incurred. Research and development expenses consist primarily of
employee-related costs, including salaries, benefits, and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies, production of preclinical materials, <FONT
STYLE="white-space:nowrap">IT-related</FONT> costs, allocated overhead costs including facility-related expenses, contract manufacturing, consulting fees, costs related to laboratory operations, and fees paid to other entities that conduct certain
research and development activities on our behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or
services are rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into various agreements with outsourced contract manufacturing and development
vendors. We estimate accrued research and development expenses as of each balance sheet date based on facts and circumstances known at that time. We periodically confirm the accuracy of our estimates with internal management personnel and external
service providers, and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The
estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original
estimates, we will adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Recent Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note 2 to our audited financial statements included elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Interest Rate Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate
sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
We also seek to maximize income from our marketable securities without assuming significant risk. To achieve our objectives, we maintain a portfolio of marketable securities in a variety of
securities of high credit quality and short-term duration, invested in compliance with our policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We had cash and cash
equivalents of $88.5&nbsp;million and $131.2&nbsp;million as of December&nbsp;31, 2023 and June&nbsp;30, 2024, respectively. Our cash equivalents as of December&nbsp;31, 2023 consisted of money market funds, while as of June&nbsp;30, 2024, our cash
equivalents consisted of money market funds and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities with maturity dates of 90 days or less. As of June&nbsp;30, 2024, we had
marketable securities of $24.5 million, which consisted of U.S. treasury securities, U.S. government agency securities and corporate debt securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical
fluctuations in interest income have not been significant for us. Due to the nature of these cash equivalents and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities, we believe
that a hypothetical 100 basis point increase or decrease in interest rates during any of the periods presented would not have had a material effect on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our employees and our operations are currently located in the United States and our expenses are generally denominated
in U.S. dollars. However, we do use research and development vendors outside of the United States. As such, our expenses are denominated in both U.S. dollars and foreign currencies. Therefore, our operations are and will continue to be subject to
fluctuations in foreign currency exchange rates. To date, foreign currency transaction gains and losses have not been material to our financial statements. We believe that a hypothetical 100 basis point increase or decrease in exchange rates during
any of the periods presented would not have had a material effect on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had
a material effect on our financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Emerging Growth Company Status and Smaller
Reporting Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as &#147;emerging growth company&#148; under the JOBS Act, which permits us to
take advantage of an extended transition period to comply with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and
private companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of
public company effective dates. We could be an emerging growth company until the earliest to occur: (i)&nbsp;the last day of the fiscal year in which we have more than $1.235&nbsp;billion in annual gross revenue; (ii)&nbsp;the date we qualify as a
&#147;large accelerated filers&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, with at least $700.0&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT>
(iii)&nbsp;the issuance, in any three-year period, by us of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; or (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of
this offering. Even after we no longer qualify as an emerging growth company, we may continue to qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements
including reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, if either (i)&nbsp;the market value of our stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a smaller reporting company as defined in the Exchange Act. We
may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these
scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our
second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule
drug discovery powered by our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development
of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every
organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of all U.S.
Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125&nbsp;billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75%
of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have
been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug
discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within
ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our
Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists
(which activate GPCR signaling), antagonists (which inhibit GPCR signaling), and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands), to affect GPCR signaling in different ways to achieve
desired therapeutic effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of oral small molecule GPCR-targeted
programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, summarized in the figure below, is focused initially on three therapeutic areas:
endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women&#146;s health, cardiovascular, and respiratory disease. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g46d29.jpg" ALT="LOGO" STYLE="width:6.33167in;height:4.40643in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing our lead product candidate, SEP-786, an oral small molecule agonist
targeting the Parathyroid Hormone 1 Receptor (PTH1R) for the treatment of hypoparathyroidism. While there are peptide products approved and in development for hypoparathyroidism that target PTH1R, to our knowledge, SEP-786 is the only clinical-stage
oral small molecule PTH1R agonist today. We have initiated a Phase&nbsp;1 clinical trial to assess preliminary safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SEP-786, and expect to report data from this trial in mid-2025.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>GPCRs as Therapeutic Targets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are the most targeted drug class due to their significant role in human diseases and their pharmacological tractability.
GPCRs are characterized by their seven transmembrane domains, and function in ternary complexes that form with extracellular ligands and intracellular transducer proteins which modulate cellular signaling pathways in response to ligand binding.
Different GPCRs play vital roles in a variety of physiologic processes of every major organ system including the central nervous system (CNS), cardiovascular, respiratory, metabolic and urogenital systems, making them key therapeutic targets. Today,
many GPCR-targeted drugs have established market-leading positions across a variety of therapeutic areas, including Ozempic and Wegovy (each marketed by Novo Nordisk) for the treatment of type 2 diabetes (T2D), and obesity, respectively, and Nurtec
ODT (marketed by Pfizer) for the acute treatment of migraine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Historically, GPCR oral small molecule drug discovery has been highly
concentrated on a small number of targets &#150; despite GPCRs constituting the largest human membrane protein family &#150; as GPCRs are difficult to isolate in their native functional form outside of a cellular context, which has limited the
utilization of modern drug discovery tools and technologies. As a result, about 75% of GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> Aims to Unlock the Full Therapeutic Potential of GPCRs
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past decade, drug discovery across various target classes has been revolutionized by a variety of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> tools and technologies. These innovations include structure-based drug design, computational docking, and <FONT
STYLE="white-space:nowrap">DNA-encoded</FONT> libraries (DELs). However, the utilization of these technologies has been limited for discovering oral small molecules targeting GPCRs due to the inability to isolate functional native GPCR proteins
outside of a cellular context. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With our proprietary Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we can purify GPCRs outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous
or synthetic), all housed within a well-defined lipid bilayer environment (Figure 1). These Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery
tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we are advancing a new approach to GPCR drug discovery, designed to expand
the landscape of druggable GPCR targets with novel oral small molecule medicines for patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g98o86.jpg" ALT="LOGO" STYLE="width:3.70848in;height:2.56168in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 1. </B>Native Complexes consist of full-length, properly folded GPCR proteins
reconstituted with a ligand and/or a transducer protein such as a G protein in a lipid bilayer that mimics the cell membrane. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is powered by a suite of tools and
technologies that we have optimized and integrated into a proprietary and industrialized workflow, and together form an efficient and iterative discovery process for identification and optimization of novel small molecule product candidates
targeting high-value GPCRs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex biochemistry and structural biology:</I></B> Our Native Complexes reconstitute native
GPCR function in a purified biochemical format, which enables efficient high-resolution, three-dimensional structure determination using cryogenic electron microscopy (cryo-EM). This can reveal receptor binding pockets that we can target with a
range of pharmacologies (e.g., agonists, antagonists, and allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex-driven hit identification and optimization:</I></B> We virtually screen our GPCR
structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to
screen billions of candidate molecules simultaneously, and we have developed proprietary technologies to discover and optimize compounds with a variety of modes of action. In addition, we use our proprietary Native Complex biochemical screens in our
hit identification and optimization processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced cellular and in vivo pharmacology models: </I></B>We efficiently evaluate hits and lead
compounds through the integration of advanced cellular and <I>in vivo</I> pharmacology models. Prioritized compounds with desired pharmacologies are then either advanced as potential drug candidates or fed back into the process for additional Native
Complex-driven compound optimization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our oral small molecule drug discovery process, powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, is depicted in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g15a01.jpg" ALT="LOGO" STYLE="width:5.83333in;height:3.24245in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our industrial-scale Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies to achieve desired
therapeutic effects. Our platform has led to the discovery and development of a pipeline of novel, highly potent and selective oral small molecules, and for our most advanced programs, optimized them into clinical development candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Pipeline and Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our wholly-owned pipeline, summarized in the figure below, is focused initially on three therapeutic areas: endocrinology,
immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women&#146;s health, cardiovascular, and respiratory disease. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g59y26.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.39853in;">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SEP-786</FONT> &#150; Oral Small Molecule PTH1R Agonist for
Hypoparathyroidism </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of
parathyroid hormone (PTH) that affects approximately 70,000 patients in the United States and approximately 140,000 patients in Europe. Patients with hypoparathyroidism are at risk of both short-term and long-term complications, including muscle
cramps, fatigue, cognitive dysfunction, and life-threatening complications, such as cardiac arrhythmias, seizures, and renal failure. The goal of treatment is to relieve symptoms and restore calcium and phosphate levels to normal. Current standard
of care consists of high-dose calcium supplements and activated vitamin D (calcitriol); however, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis or address all of the symptoms experienced by
patients. Hormone replacement with injectable PTH peptides, either marketed or in clinical development, may improve blood chemistry profiles of patients via PTH1R activation but will require life-long daily injections. We believe there is a
substantial opportunity for an oral small molecule therapy that offers convenience, improved compliance, and potentially superior efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is a clinical-stage, oral small molecule agonist
targeting PTH1R for the treatment of hypoparathyroidism. PTH1R is a historically <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-drug</FONT></FONT> small molecule target, yet we effectively leveraged our Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to discover and optimize <FONT STYLE="white-space:nowrap">SEP-786</FONT> with desired drug-like properties. In preclinical studies, <FONT STYLE="white-space:nowrap">SEP-786</FONT> has
been observed to be generally well-tolerated and has demonstrated potent and selective activation of PTH1R in human, dog, and rat receptor <I>in vitro</I> models. In a preclinical animal model of hypoparathyroidism,
<FONT STYLE="white-space:nowrap">SEP-786</FONT> controlled serum calcium levels within the normal range over a <FONT STYLE="white-space:nowrap">28-day</FONT> dosing period. We have successfully completed Investigational New Drug (IND)-enabling
studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> We expect to report data from this trial in mid-2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">SEP-631</FONT> &#150; Oral Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell Diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chronic spontaneous urticaria (CSU) is a systemic inflammatory skin disease characterized by the spontaneous and persistent
recurrence of itchy, painful hives, known as wheals, on the skin and angioedema, or swelling, that affects approximately 1.5&nbsp;million patients in the United States. While there is no known trigger, the degranulation of mast cells and release of
histamine and other inflammatory mediators lead to these debilitating symptoms. Patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
are treated initially with antihistamines and <FONT STYLE="white-space:nowrap">non-responders</FONT> may be treated with Xolair (omalizumab), an injectable
<FONT STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody. The targeting and blocking of <FONT STYLE="white-space:nowrap">IgE-mediated</FONT> inflammation can effectively address symptoms; however, only an estimated 36% of these
antihistamine- refractory patients respond to <FONT STYLE="white-space:nowrap">anti-IgE</FONT> therapy. <FONT STYLE="white-space:nowrap">Mas-related</FONT> <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptor member X2 (MRGPRX2) plays
an important role in mast cell activation and degranulation. We believe an oral therapy that inhibits MRGPRX2 could provide a differentiated treatment option for patients with CSU given the selective inhibition of mast cells and potential for
combination therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> is a selective, oral small molecule MRGPRX2 negative
allosteric modulator (NAM) that we are developing initially for the treatment of CSU. In preclinical studies, <FONT STYLE="white-space:nowrap">SEP-631</FONT> demonstrated potent and long-lasting inhibition of MRGPRX2 and blocked mediator-induced
angioedema in mice engineered to express the human MRGPRX2 receptor. We have initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies of <FONT STYLE="white-space:nowrap">SEP-631</FONT> and upon completion, we anticipate submitting for
regulatory clearance to initiate a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to CSU, we may develop
<FONT STYLE="white-space:nowrap">SEP-631</FONT> for the treatment of other mast cell diseases. MRGPRX2 is highly and uniquely expressed on mast cells that drive multiple prevalent diseases, including allergic asthma, atopic dermatitis, interstitial
cystitis, migraine, and prurigo nodularis. We believe <FONT STYLE="white-space:nowrap">SEP-631</FONT> could offer a novel oral treatment option for these patient populations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>TSHR Program &#150; Oral Small Molecule TSHR NAM for Graves&#146; Disease and TED </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Graves&#146; disease is one of the most prevalent autoimmune conditions affecting over 2&nbsp;million patients in the United
States and is the leading cause of hyperthyroidism, resulting in symptoms including anxiety, irritability, tremor, and fatigue. Treatments have remained largely unchanged over the past 70&nbsp;years, and include anti-thyroid medications, radioactive
iodine therapy to ablate thyroid gland function, and thyroidectomy surgery. These treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression to thyroid eye disease (TED)
for approximately 50% of Graves&#146; disease patients. TED is a serious, progressive and vision-threatening autoimmune condition that can lead to eye bulging, swelling, pain and blurred or double vision. Current treatments for TED, such as TEPEZZA
(teprotumumab-trbw), an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IGF-1R</FONT></FONT> human monoclonal antibody, are designed to help manage symptoms. Despite reaching global sales of $2.0&nbsp;billion in 2022, TEPEZZA
requires several intravenous (IV)&nbsp;infusions over several months and has risks of serious side effects, including hearing loss and metabolic issues, such as increased blood glucose or hyperglycemia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These autoimmune conditions are caused by autoantibodies that bind to and activate the thyroid stimulating hormone receptor
(TSHR) on thyroid cells in the thyroid gland (leading to Graves&#146; disease) and other cells including orbital fibroblasts located behind the eyes (leading to TED). We believe an oral small molecule TSHR NAM could offer a novel disease-modifying
treatment approach that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#146; autoantibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In our preclinical studies, we have demonstrated that a TSHR NAM can reverse hyperthyroidism and proptosis in a novel mouse
model of Graves&#146; disease and inhibits multiple Graves&#146; disease patient TSHR activating autoantibodies in cell-based assays using primary human cells. We are advancing several lead compounds towards selection of a development candidate for <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Incretin Programs &#150; Oral Small Molecule Single- and Multi-Incretin
Receptor Agonists for Metabolic Disorders Including Obesity and T2D </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obesity and diabetes are two of the most
prevalent diseases in the world, affecting a combined total of more than 800&nbsp;million people, and are associated with severe health complications, including cardiovascular disease and kidney failure, as well as an increased risk of death. Weight
reduction is seen as an important treatment goal for patients with either condition. In recent years, several injectable peptide agonists targeting select metabolic hormone receptors, or incretin receptors, have been approved for the treatment of
T2D and obesity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Three incretins play significant roles in glucose metabolism and
homeostasis: glucagon-like <FONT STYLE="white-space:nowrap">peptide-1</FONT> <FONT STYLE="white-space:nowrap">(GLP-1),</FONT> gastric inhibitory polypeptide (GIP), and glucagon. Third-party clinical data with incretin-targeted therapeutics have
demonstrated substantial and sustained reductions in body weight, as well as the ability to lower blood glucose and improve glycated hemoglobin (HbA1c). Global sales in 2023 for Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk), and
Mounjaro and Zepbound (tirzepatide, each marketed by Eli&nbsp;Lilly and Company) were $18.4&nbsp;billion and $5.3&nbsp;billion, respectively. As a class, the marketed GLP-1 and <FONT STYLE="white-space:nowrap">GLP-1/GIP</FONT> products generated $36
billion in global sales in 2023. Despite these advancements in the treatment of obesity and T2D, a number of key limitations remain for the incretin therapeutic class, including tolerability, prolonged titration schemes, injection administration,
and supply challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on unique chemical and structural insights obtained with our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, we believe we have an opportunity to discover and develop novel, next-generation, oral small molecules as selective single- or multi-acting <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP,
glucagon receptor agonists. We are advancing several lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have built a strong values-driven organization, and are leveraging our industrial-scale Native Complax Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> to develop a broad and deep portfolio of GPCR-targeted programs for patients. We were founded by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural
biology, and pharmacology of GPCRs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Robert Lefkowitz, M.D., </B>James B. Duke Professor of Medicine and Professor of Biochemistry and Chemistry
at Duke University and an Investigator of the Howard Hughes Medical Institute. Dr.&nbsp;Lefkowitz is globally recognized for his groundbreaking discoveries that reveal the inner workings of GPCRs, for which he was awarded the 2012 Nobel Prize in
Chemistry and elections to both the National Academy of Sciences and the National Academy of Medicine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Arthur Christopoulos, Ph.D., </B>Professor of Analytical Pharmacology, Dean of the Faculty of
Pharmacy&nbsp;&amp; Pharmaceutical Sciences, and Director of the Neuromedicines Discovery Centre at Monash University in Australia. Dr.&nbsp;Christopoulos is a world-leading expert in GPCR molecular pharmacology and responsible for several seminal
discoveries of allosteric modulation of GPCRs, for which he has been elected to both the Australian Academy of Science and the Australian Academy of Health and Medical Sciences. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patrick Sexton, Ph.D., D.Sc., </B>Professor, Drug Discovery Biology at Monash University and Director of
the ARC Centre for Cryo-electron Microscopy of Membrane Proteins. Dr.&nbsp;Sexton is an international leader in GPCR biochemistry, pharmacology, and structural biology and his team is at the forefront of using
<FONT STYLE="white-space:nowrap">cryo-EM</FONT> to elucidate the structure and dynamics of GPCRs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Jeffrey Finer, M.D., Ph.D.</B>, our President and Chief Executive Officer. Dr.&nbsp;Finer has more than
35&nbsp;years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drugs
into clinical trials, developing novel technology platforms that integrate science and engineering, and new company creation. Dr. Finer has been a Venture Partner at Third Rock Ventures, LLC (Third Rock Ventures) since 2016, where prior to joining
Septerna, he was involved in the founding and launching of multiple biotech companies, including Maze Therapeutics, Inc. and Ambys Medicines, Inc., serving as interim Chief Technology Officer at both. Previously, Dr.&nbsp;Finer spent several years
in research and development leadership positions, including Vice President, Research Technology at Theravance Biopharma, Inc. (Theravance Biopharma), Vice President, Discovery at Five Prime Therapeutics, Inc., and Director, Drug Discovery
Technologies at Cytokinetics, Inc. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we have established a team of experienced biotechnology leaders
with deep expertise in company building, drug discovery, and clinical advancement of novel medicines. Our senior leadership team includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Elizabeth (Liz) Bhatt, M.S., M.B.A.</B>, our Chief Operating Officer, who has more than 30&nbsp;years of
strategy, deal-making and company-building experience across a range of biotech and pharmaceutical companies, including Applied Molecular Transport Inc., Achaogen, Inc., Gilead Sciences, Inc., Eli Lilly and Company, and Maxygen, Inc.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Jae B. Kim, M.D.</B>, our Chief Medical Officer, is a highly accomplished healthcare executive with
extensive experience in advancing novel therapies across multiple therapeutic areas. Prior to joining us, Dr. Kim served as Chief Medical Officer at Design Therapeutics, where he led the clinical advancement of the company&#146;s pipeline of small
molecule genomic medicines, and as Chief Medical Officer at Avidity Biosciences. Dr. Kim served as Clinical Research Head, Chair of the Clinical Trial Review Board and Vice President of Clinical Development at Alnylam Pharmaceuticals, where he
oversaw the development of multiple clinical assets across inborn errors of metabolism, cardiology, neurology and infectious disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Samira Shaikhly</B>, our Chief People Officer, is a human resources leader with more than 25&nbsp;years of
experience enabling organizational effectiveness in high-growth companies across multiple human resource disciplines including a 15-year tenure at Gilead Sciences, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Ran Xiao, M.B.A.</B><B>, CFA</B>, our Interim Chief Financial Officer and Vice President of Finance and
Business Operations, has more than 20 years of experience in corporate accounting, finance, and business operations in the biotech industry. Earlier in her career, Ms. Xiao held positions as Vice President of Finance and Corporate Controller at
Ambys Medicines, as Corporate Controller at Corvus Pharmaceuticals, where she played a key role in the company&#146;s initial public offering, and served in roles of increasing responsibility at InterMune, where she was part of the team responsible
for accounting operations, financial planning, system implementation and business acquisition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Uwe Klein, Ph.D.</B>, our Senior Vice President, Biological Sciences, has deep expertise in GPCR biology
and over 25&nbsp;years of experience in small molecule drug discovery across a range of biotech and pharmaceutical companies, including MyoKardia, Inc. (acquired by Bristol-Myers Squibb (BMS)). Earlier in his career, Dr.&nbsp;Klein held positions as
Vice President, Biology at Numerate, Inc. (acquired by Valo Health, Inc.) and as Senior Director, Molecular&nbsp;&amp; Cellular Biology at Theravance Biopharma, where he led a team of biologists and two cross-functional project teams in the
discovery of numerous development candidates and several clinical compounds across different therapeutic areas and target classes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Daniel Long, D.Phil.</B>, our Senior Vice President, Drug Discovery, is a highly experienced drug hunter
with a track record of leading high-performing teams that discover drug candidates and advance them through preclinical development to IND and into clinical trials. Dr.&nbsp;Long spent more 20&nbsp;years at Theravance Biopharma, where he held
numerous scientist positions, including as Vice President, Head of Medicinal Chemistry, Biology and Pharmacology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors is composed of accomplished leaders in the life sciences industry, including our board chairman,
Jeffrey Tong, Ph.D., a Partner at Third Rock Ventures; Abraham Bassan, M.S., a Principal at Samsara BioCapital L.P. (Samsara); Bernard Coulie, M.D., Ph.D., M.B.A., President and Chief Executive Officer of Pliant Therapeutics, Inc.;
Dr.&nbsp;Ezekowitz, an Advisory Partner at Third Rock Ventures; Shalini Sharp, M.B.A., a member of the boards of directors of BeiGene, Ltd., Neurocrine Biosciences, Inc. and Organon&nbsp;&amp; Co. and former Chief Financial Officer and Executive
Vice President at Ultragenyx Pharmaceuticals Inc.; Jake Simson, Ph.D., a Partner at RA Capital Management, L.P. (RA Capital) and member of the board of directors of Bicara Therapeutics Inc., and Dr. Finer, our Chief Executive Officer. Further, we
have assembled a cross-functional scientific and drug discovery advisory board, comprised of seasoned drug hunters and leading academic scientists at the forefront of GPCR biology and pharmacology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have raised net proceeds of approximately
$224.2&nbsp;million in equity capital from a syndicate of premier life sciences investors. Potential investors should not consider investments made by our existing investors as a factor when making a decision to purchase shares in this offering
since our existing investors likely have different risk tolerances and paid significantly less per share than the price at which the shares are being offered in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our goal is to develop life-changing GPCR-targeted medicines for patients with significant unmet medical needs. We plan to
achieve this goal by pursuing the following strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Efficiently advance our portfolio of GPCR-targeted programs, led by
<FONT STYLE="white-space:nowrap">SEP-786.</FONT> </B>Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is, to our knowledge, the only clinical-stage, oral small molecule agonist of PTH1R for hypoparathyroidism. We have
initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of <FONT STYLE="white-space:nowrap">SEP-786,</FONT> and we expect to report data from this trial in mid-2025. Our second most advanced candidate, <FONT
STYLE="white-space:nowrap">SEP-631,</FONT> an oral small molecule MRGPRX2 NAM that we are developing initially for the treatment of CSU, is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. We believe <FONT
STYLE="white-space:nowrap">SEP-631</FONT> represents a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pipeline-in-a-product</FONT></FONT></FONT> opportunity to treat multiple mast cell-driven
diseases. We also plan to continue advancing our TSHR and incretin programs toward selection of development candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to expand our differentiated GPCR-targeted pipeline focused on indications with significant unmet
needs. </B>We are leveraging our GPCR biology and pharmacology <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to address a diverse range of diseases.
For each of our programs to date, we have advanced from initiation of medicinal chemistry to potent drug-like compounds with activity in animal models in less than one year. We are focused initially on developing our novel GPCR-targeted drug
candidates in three therapeutic areas &#150; endocrinology, immunology and inflammation, and metabolic diseases &#150; and intend to expand into other therapeutic areas. We will continue to focus on indications with well understood biology,
predictive biomarkers for early <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> efficient clinical development pathways, and high unmet medical need. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the potential of our Native Complex
Platform</B><B><SUP STYLE="font-size:75%; vertical-align:top">TM</SUP></B><B> through continued innovation and investment. </B>Using our industrial-scale platform, we are pioneering a new era of GPCR drug discovery and development. We have
thoughtfully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art,</FONT></FONT></FONT> high-resolution structural biology with large-scale screening and functional testing to
accelerate the discovery and optimization of high-quality lead compounds. In under three years, our platform has allowed us to determine more than 80 high-resolution, three-dimensional GPCR structures with bound small molecules spanning multiple
pharmacological mechanisms, and we have screened over 10&nbsp;billion compounds across our targets which led to the discovery of our existing portfolio of novel compounds. We plan to continually enhance our
<FONT STYLE="white-space:nowrap">in-house</FONT> capabilities, tools, and technologies to further leverage our platform and expand our competitive advantages. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Evaluate and selectively execute value-creating strategic partnerships. </B>We currently own full worldwide
rights across our portfolio, and we intend to build out a commercial presence in select major markets. Our industrialized drug discovery platform has generated, and we believe will continue to generate, numerous novel GPCR-targeted product
candidates, some of which we will independently develop and commercialize, and others that may benefit from a strategic partner&#146;s development and commercial expertise, infrastructure, and financial resources. For example, in September 2023, we
entered into an asset purchase agreement with Vertex Pharmaceuticals Incorporated (Vertex), under which Vertex acquired an undisclosed discovery-stage GPCR program from us and will be solely responsible for continuing the associated research and
development efforts. We intend to explore additional opportunities with partners that we believe will meaningfully enhance the overall potential of our programs and allow us to further leverage our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Pioneering Approach to Unlock the Full Therapeutic Potential of
GPCRs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Using our industrial-scale Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we
are advancing a new approach to GPCR drug discovery and development. We have developed technologies aimed at unlocking GPCRs that have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
historically difficult to drug with oral small molecules, which may allow us to access certain high value GPCRs within the approximately 75% of untapped GPCR therapeutic targets. Our GPCR Native
Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is built upon world-class expertise and leverages proprietary tools and technologies designed to overcome the historical limitations of GPCR drug discovery, including the
isolation, purification, and stabilization of GPCRs in their native forms. Our approach has led to the discovery and development of a deep portfolio of novel oral small molecule GPCR-targeted programs that we are advancing into clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>GPCRs as Therapeutic Targets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs regulate physiological processes in nearly every organ system of the human body and are the most targeted drug class due
to their significant role in human diseases and their pharmacological tractability. Nearly one-third of all <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs in the United States, representing approximately 500 products, target
GPCR-associated pathways. In fact, GPCR-related drugs comprise approximately 27% of global pharmaceutical sales and generated over $125&nbsp;billion in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs are proteins that span the cell membrane seven times, and their primary function is to recognize extracellular
substances, or ligands, and transmit signals across the cell membrane to the inside of the cell. Ligand binding induces conformational changes in GPCRs, forming complexes with signal transducers, including G proteins. These transducers interact with
second messengers, modulating various cellular processes. Certain GPCR ligands are capable of activating multiple pathways through different transducers, leading to diverse physiological and pathological effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">GPCRs constitute the largest and most diverse family of cell membrane receptors, with around 800 identified members. GPCRs are
key therapeutic targets due to their vital roles in a variety of physiologic processes including immune regulation, nervous system transmission, mood and behavior regulation, sensory transmission, and maintaining cardiovascular and gastrointestinal
homeostasis. Despite the pharmacological and commercial success of GPCR-targeted agents, a majority of GPCR therapeutic targets remain undrugged. Each step in GPCR activation involves subtle conformational changes that have been historically
challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug
discovery, particularly the development of novel oral small molecules, such as agonists for peptide GPCRs and allosteric modulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, drug discovery has been highly concentrated on a small number of GPCRs. More than 70% of current GPCR-related drugs
target only six subfamilies of GPCRs. There are about 400 known <FONT STYLE="white-space:nowrap">non-olfactory</FONT> GPCRs, each represented as a branch on the phylogenetic tree in Figure&nbsp;2 below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g01n96.jpg" ALT="LOGO" STYLE="width:4.445in;height:3.3725in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Figure 2.</B> GPCR phylogenetic tree highlighting the number of FDA-approved drugs for each GPCR as of
February 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Today, approximately 75% of potential GPCR therapeutic targets remain undrugged, representing significant
opportunity to address a vast range of therapeutic areas and diseases. And, even for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past decade, the landscape of drug discovery has been revolutionized by advanced technologies that significantly impact
small molecule drug discovery across various target classes. These innovations include structure-based drug design, computational docking, and <FONT STYLE="white-space:nowrap">DNA-encoded</FONT> libraries (DELs). However, the full potential of these
technologies has remained largely untapped for GPCRs due to challenges with isolating functional native GPCR proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we can purify GPCRs
outside of cells and reconstitute them into fully functional ternary complexes with transducer proteins (e.g., G proteins, beta-arrestins) and ligands (endogenous or synthetic), all housed within a well-defined lipid bilayer environment. These
Native Complexes are full-length, properly folded GPCRs that retain their natural structure, function, and dynamics. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally
design, screen for, and optimize potential product candidates. Leveraging our platform, we are able to conduct GPCR oral small molecule drug discovery for a broad array of GPCR targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is powered by a suite of tools and
technologies that we have optimized and integrated into a proprietary and industrialized workflow, and together form an efficient and iterative discovery process for identification and optimization of novel small molecule drug candidates targeting
high-value GPCRs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex biochemistry and structural biology:</I></B> Our Native Complexes reconstitute native
GPCR function in a purified biochemical format, which enables efficient high-resolution, three-dimensional structure determination with cryo-EM. This can reveal receptor binding pockets that we can target with a range of pharmacologies (agonists,
antagonists, and allosteric modulators) as well as novel insights into mechanisms for GPCR modulation.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Native Complex-driven hit identification and optimization:</I></B> We virtually screen our GPCR
structures against ultra-large-scale computational databases containing billions of candidate molecules to identify the most promising small molecule compounds that bind in pockets on the GPCR structure. We use technologies, including DELs, to
screen billions of candidate molecules simultaneously, and we have developed proprietary technologies to discover and optimize compounds with a variety of modes of action. In addition, we use our proprietary Native Complex biochemical screens in our
hit identification and optimization processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advanced cellular and in vivo pharmacology models: </I></B>We efficiently evaluate hits and lead
compounds through the integration of advanced cellular and <I>in vivo</I> pharmacology models. Prioritized compounds with desired pharmacologies are then either advanced as potential drug candidates or fed back into the process for additional Native
Complex-driven compound optimization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our oral small molecule drug discovery process, powered by our
proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, is depicted in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g15a01.jpg" ALT="LOGO" STYLE="width:5.83333in;height:3.24245in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our industrial-scale Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists,
antagonists, and allosteric modulators, to achieve desired therapeutic effects. We have successfully applied the technologies of our platform to identify novel, highly potent and selective oral small molecules, and for our most advanced programs,
optimized them into clinical development candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Native Complex Biochemistry and Structural Biology Capabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have developed an industrialized workflow for creating Native Complexes, which involves reconstituting fully functional
GPCRs outside their cellular context. As illustrated in the figure below, our process for creating a Native Complex begins with a human cell expression system that allows us to express GPCRs at high levels. We then extract these GPCRs using
proprietary solubilization and purification protocols that maintain their stability and prevent denaturation. Following extraction, we reconstitute the GPCRs in an artificial lipid bilayer that closely mimics the natural cell membrane. These
reconstituted GPCRs can be combined with ligands and/or separately purified transducers such as G proteins and beta-arrestins. These Native Complexes are modular assemblies, and a variety of different receptor states can be created by using
different combinations of transducers and ligands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g00b98.jpg" ALT="LOGO" STYLE="width:6.145in;height:1.92855in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once we have isolated a Native Complex, we determine the high-resolution, three-dimensional
structure of the GPCR and a bound compound using cryo-EM. Our <FONT STYLE="white-space:nowrap">in-house</FONT> capabilities, tools, and technologies enable us to identify the precise binding orientation of a drug candidate with exceptional
resolution. After generating the initial Native Complex structure, our advanced technologies enable us to efficiently produce subsequent high-resolution structures. To date, we have successfully determined the structures of over 80 high-resolution,
three-dimensional GPCR structures with bound small molecule ligands spanning multiple mechanisms including agonists, antagonists, and allosteric modulators. Our structure-based drug discovery approach also allows us to uncover novel binding pockets
on validated GPCRs that may offer enhanced therapeutic benefits. In a single lead optimization campaign, we typically generate <FONT STYLE="white-space:nowrap">10-20</FONT> high-resolution structures, and our ability to generate new small molecule
ligand-bound structures as quickly as within 1-2 weeks has allowed us to rapidly iterate and optimize our compounds efficiently into lead drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Native Complex-Driven Hit Identification and Optimization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once we have determined Native Complex structures and identified binding pockets of interest, we employ ultra-large scale
virtual screening using extensive computational databases of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">make-on-demand</FONT></FONT> compounds. To date, we have screened over 10&nbsp;billion such compounds, computationally
docking them into the binding pockets of our high-resolution, three-dimensional GPCR structures using proprietary algorithms and cloud-based computing. Upon identifying candidate compounds with optimal binding poses, we proceed to synthesize and
test these compounds in functional assays to evaluate whether they exhibit the desired molecular pharmacology attributes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, we combine our Native Complexes with DELs to select for GPCR binders with specific functional profiles. DELs are
combinatorial libraries of billions of small molecules synthesized with an added DNA barcode, and we leverage next-generation sequencing technologies to identify high-affinity binders that are optimally suited to modulate specific GPCRs of interest
with desired mechanisms of action. We have developed proprietary DEL screening workflows and analysis methods to discover novel compounds with a wide spectrum of activities including agonists, antagonists, and allosteric modulators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">By integrating these advanced screening techniques into our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>, we have been able to significantly enhance the efficiency and precision of our drug discovery efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Advanced Cellular and In Vivo Pharmacology Models </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon identifying highly potent, novel compounds, we proceed to test these compounds in novel cell-based assays and <I>in
vivo</I> pharmacology models to evaluate whether the compounds exhibit desired drug-like properties. Only the most promising candidates that demonstrate the intended pharmacologic activity move forward into lead optimization campaigns. Other
candidate compounds are fed back into our drug discovery process for additional Native Complex-driven compound optimization. For each of our programs, we have advanced from initiation of medicinal chemistry to potent drug-like compounds with
activity in animal models in less than one year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our proprietary Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP> enables iterative structure-based GPCR drug design for what we believe is the first time at scale. Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#146;s
integrated approach of combining high-resolution structural insights with large-scale screening and rapid functional testing accelerates the discovery and optimization of new therapeutic compounds. Our industrial-scale platform aims to unlock the
full potential of GPCR therapies and has led to the discovery and development of our pipeline of product candidates focused on treating patients across a variety of therapeutic areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Portfolio Opportunities Targeting the Full Breadth of GPCRs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are significant unmet medical needs across numerous GPCR-driven diseases. Our portfolio is focused initially on three
therapeutic areas with the potential to expand to additional therapeutic areas in the future: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Endocrinology</I></B><I>:</I> The endocrine system involves glands that secrete hormones into the
bloodstream that have effects on other tissues. Central to this system are GPCRs, which serve as primary receptors for many circulating hormones. GPCR biology is at the center of endocrine diseases, such as hypoparathyroidism and Graves&#146;
disease, highlighting the urgency for therapeutic interventions targeting GPCR-mediated endocrine disorders. Other endocrine disorders, like osteoporosis, impacts more than 10&nbsp;million older adults in the United States and could benefit from a
small molecule GPCR-directed therapy to help rebuild bone mass. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Immunology</I></B><B><I></I></B><B><I>&nbsp;&amp; inflammation</I></B><I>: </I>GPCRs serve as key
signaling molecules in various cellular processes, including involvement in the regulation of immune responses and the activation of immune cells such as macrophages, T cells, and dendritic cells. Upon activation by extracellular ligands, GPCRs
initiate intracellular signaling cascades that modulate cytokine production, leukocyte trafficking, and inflammatory mediator release. Dysregulation of GPCR signaling pathways is implicated in numerous inflammatory and autoimmune diseases, such as
CSU, making them attractive targets for therapeutic intervention. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Metabolic diseases</I></B><I>: </I>GPCRs are known to regulate various physiological processes such as
energy metabolism, glucose homeostasis, and lipid metabolism. These receptors are involved in sensing nutrients, hormones, and other signaling molecules, thereby influencing appetite, insulin secretion, and lipid storage. Dysregulation of GPCR
signaling pathways is associated with metabolic disorders, such as obesity and T2D. For instance, GPCRs like adrenergic receptors regulate lipolysis and thermogenesis, while receptors such as the <FONT STYLE="white-space:nowrap">GLP-1</FONT>
receptor modulate insulin secretion and satiety. Targeting GPCRs is a clinically and commercially validated approach for the development of therapeutics that manage metabolic disorders, offering the potential to manage glucose levels, promote weight
loss, and improve metabolic health. </P></TD></TR></TABLE> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond our initial therapeutic areas of focus, we intend to
evaluate opportunities in additional therapeutic areas where GPCRs are directly connected to disease pathology, including in areas of neurology, women&#146;s health, cardiovascular disease, and respiratory disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are advancing a deep portfolio of highly potent and selective oral small molecule GPCR-targeted programs with novel
mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline is focused initially on three therapeutic areas &#150; endocrinology, immunology and inflammation, and
metabolic diseases &#150; and is summarized in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g59y26.jpg" ALT="LOGO" STYLE="width:6.25in;height:2.39853in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our target selection process considers the validation level of the GPCR and existing
preclinical and/or clinical data demonstrating desired biological outcomes upon target modulation for a variety of different indications. We have prioritized indications with well-defined biomarkers to streamline the path to clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data, high unmet medical need and significant market opportunities. When analogous molecules exist that are approved or in clinical development, we explore
differentiation opportunities and leverage our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to address known limitations. We also leverage regulatory insights from established precedents to guide each program&#146;s
development strategy. As we expand our portfolio of GPCR-targeted programs, we will continue to focus on targets and indications with well understood biology, predictive biomarkers for early <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> efficient clinical development pathways, and high unmet medical need. We are building a deep portfolio comprised of programs that we can independently develop and commercialize upon
regulatory approval, alongside select programs that may benefit from the development and commercial expertise, infrastructure and financial support of a strategic partner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">SEP-786:</FONT> Oral Small Molecule PTH1R for Hypoparathyroidism </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our lead product candidate, <FONT STYLE="white-space:nowrap">SEP-786,</FONT> is an oral small molecule agonist targeting PTH1R
that we are developing for the treatment of hypoparathyroidism. While there are peptide products approved and in development for hypoparathyroidism that target PTH1R, to our knowledge, SEP-786 is the only clinical-stage oral small molecule PTH1R
agonist today. We discovered and designed <FONT STYLE="white-space:nowrap">SEP-786</FONT> to have potent and selective activation of PTH1R, a GPCR highly involved in blood calcium control, with an optimized profile that achieves sustained
normalization of serum calcium and phosphate upon once-daily or twice-daily oral dosing. Based on preclinical data observed to date, we believe <FONT STYLE="white-space:nowrap">SEP-786</FONT> has the potential to be a differentiated treatment for
hypoparathyroidism. We have successfully completed <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of
<FONT STYLE="white-space:nowrap">SEP-786.</FONT> We expect to report data from this trial in <FONT STYLE="white-space:nowrap">mid-2025.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of Hypoparathyroidism </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of PTH1R </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of PTH that affects approximately 70,000
patients in the United States and 140,000 patients in Europe. PTH is a critical hormone for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
calcium and phosphate homeostasis and functions through the activation of PTH1R. Under normal physiological conditions, PTH is released from the parathyroid glands when circulating calcium levels
are reduced and will act on PTH1R expressed on bone and kidney cells to increase calcium levels (see Figure 3). Most patients with hypoparathyroidism develop the condition following damage to or accidental removal of the parathyroid glands during
thyroid surgery, while other etiologies include autoimmune and genetic disorders. Patients with hypoparathyroidism are at risk of both short-term and long-term complications and comorbidities, such as tingling or burning of the extremities, muscle
cramps and spasms, abdominal pain, abnormal heart rhythm, cataracts, and fatigue and muscle weakness. Chronic hypoparathyroidism is associated with cognitive and emotional symptoms, such as mental lethargy, inability to concentrate, memory loss or
forgetfulness, anxiety and depression. Many patients experience persistent symptoms that negatively impact quality of life and reduce work productivity. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g02n01.jpg" ALT="LOGO" STYLE="width:6.32in;height:3.9in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 3. </B>Overview of parathyroid hormone physiology, hypoparathyroidism, and our
strategy to develop an oral small molecule PTH1R agonist to restore calcium homeostasis in patients with hypoparathyroidism. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current
Treatment Options and Their Limitations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The standard treatment for hypoparathyroidism consists of high-dose calcium
supplements and activated vitamin D (calcitriol) several times a day, which aim to correct serum calcium levels. However, these therapies do not replace other functions of PTH to restore physiological mineral homeostasis, resulting in an increased
risk of physical symptoms, including fatigue, paraesthesia, muscle cramping, tetany, and joint or bone pain, as well as <FONT STYLE="white-space:nowrap">long-term</FONT> complications, such as <FONT STYLE="white-space:nowrap">soft-tissue</FONT>
calcifications and impaired renal function. For some patients with chronic hypoparathyroidism, a managed transition from a high daily calcium intake to a <FONT STYLE="white-space:nowrap">no-</FONT> or
<FONT STYLE="white-space:nowrap">low-calcium</FONT> treatment regimen may reduce adverse events or complications, including kidney stones and hospitalization due to <FONT STYLE="white-space:nowrap">hyper-</FONT> or hypocalcemia. Even among patients
on conventional treatments whose serum calcium levels are within the normal range, these side effects limit the ability of currently available treatments to be safe and effective options for chronic long-term use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Injectable synthetic PTH peptides have been validated in clinical trials to increase serum calcium and provide a more
physiological alternative to conventional therapy. These therapies are designed to sustain PTH in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the normal physiological range, thereby more fully addressing the underlying condition. In 2015, NATPARA (parathyroid hormone) became the first and only
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> prescription PTH injection that is taken with calcium and vitamin D to control hypocalcemia in adults with hypoparathyroidism. Since then, manufacturer Takeda voluntarily recalled NATPARA in the
United States due to manufacturing issues and announced that it will discontinue global manufacturing of NATPARA by the end of 2024. Palopegteriparatide (marketed as YORVIPATH by Ascendis Pharma), an investigational prodrug of active PTH <FONT
STYLE="white-space:nowrap">(1-34),</FONT> received regulatory approval in the EU in 2023 and in the United States in 2024, as a hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. While hormone
replacement with injectable PTH peptides, either marketed or in clinical development, may effectively normalize calcium levels and manage disease complications, they require life-long daily injections. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule PTH1R Agonist </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there is an unmet need for an oral small molecule PTH1R agonist that offers hypoparathyroidism patients a
convenient, more physiological treatment option. Since conventional therapies, such as calcium and vitamin D, have limitations and do not restore other actions of PTH, such as bone turnover or renal calcium reabsorption, we believe an oral option
that can increase serum calcium and replace the other functions of PTH, is needed for patients. Our potent and selective PTH1R agonist is designed to address all patients with hypoparathyroidism. This includes the most severe patients, who may start
injectable PTH peptide therapy, as well as mild-to-moderate patients who are currently on high doses of calcium and vitamin D and may be less interested in an injectable PTH peptide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> affords us the opportunity to
continuously iterate and optimize additional oral small molecule PTH1R agonists. We may develop additional molecules for hypoparathyroidism or for other indications where PTH1R agonists can address disease pathology, such as osteoporosis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical Activity of <FONT STYLE="white-space:nowrap">SEP-786</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> was applied to PTH1R and yielded multiple
tractable chemical series of small molecule PTH1R agonists with distinct binding sites. Iterative structure-based design for one of the chemical series and further lead optimization yielded our lead product candidate,
<FONT STYLE="white-space:nowrap">SEP-786,</FONT> for which we have initiated a Phase 1 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT
STYLE="white-space:nowrap">SEP-786</FONT> has demonstrated potent and selective activation of PTH1R in human, dog, and rat receptor <I>in vitro</I> models. <I>In vivo</I>, <FONT STYLE="white-space:nowrap">SEP-786</FONT> was generally well-tolerated
and showed activity in a translational rat thyroparathyroidectomy (TPTx) model of hypoparathyroidism (Figure 4.A). In this model, surgical removal of the parathyroid glands replicates the human disease of hypoparathyroidism with a reduction in serum
calcium from the normal range. To assess the activity of PTH1R agonists, compounds are dosed orally for small molecules or subcutaneously for peptides, which results in dose-dependent increases in serum calcium allowing for an assessment of compound
activity and PK/PD relationships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Single oral doses of <FONT STYLE="white-space:nowrap">SEP-786</FONT> were compared to
single subcutaneous doses of a long-acting PTH peptide <FONT STYLE="white-space:nowrap">(LA-PTH)</FONT> in the TPTx model (Figure 4.B). The 30 mg/kg oral dose of <FONT STYLE="white-space:nowrap">SEP-786</FONT> demonstrated a similar time-dependent
increase in serum calcium levels to a 2 nmol/kg subcutaneous dose of <FONT STYLE="white-space:nowrap">LA-PTH</FONT> with both doses resulting in serum calcium levels exceeding the normal serum calcium range
<FONT STYLE="white-space:nowrap">(2.0-2.6</FONT> mmol/L). <FONT STYLE="white-space:nowrap">SEP-786</FONT> demonstrated dose-dependent serum calcium increase with oral doses of 3 mg/kg and 10 mg/kg resulting in serum calcium levels within the normal
range. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In a <FONT STYLE="white-space:nowrap">28-day</FONT> repeat dose study
(Figure 4.C), <FONT STYLE="white-space:nowrap">SEP-786</FONT> at 3 mg/kg dosed orally twice-daily provided sustained increases in serum calcium to within the normal range over the entire <FONT STYLE="white-space:nowrap">28-day</FONT> dosing period.
SEP-786 also normalized phosphate levels, improved bone turnover markers, and increased active vitamin D production in this study. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g10t06.jpg" ALT="LOGO" STYLE="width:5.95833in;height:5.42883in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 4. </B>(A)<B> </B>Rat hypoparathyroidism disease model (thyroid-parathyroidectomy
model, TPTx). (B) Single oral doses of <FONT STYLE="white-space:nowrap">SEP-786</FONT> in the TPTx model show dose-dependent increase in serum calcium. (C)&nbsp;Repeat twice-daily oral dosing of <FONT STYLE="white-space:nowrap">SEP-786</FONT> in the
TPTx model shows sustained calcium control over 28 days of dosing. PO = oral; SC = subcutaneous; BID = twice-daily. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical
Studies to Support Clinical Advancement of <FONT STYLE="white-space:nowrap">SEP-786</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The PK profile of SEP-786
across multiple species was determined (Figure 5), to support human PK projections based upon allometric scaling of the nonclinical PK parameters, in addition to in vitro-in vivo extrapolation (IVIVE) of intrinsic clearance in human hepatocytes.
These human PK models projected that SEP-786 will have a human half-life in the range of 9-27 hours following oral dosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A translational PK/PD model for <FONT STYLE="white-space:nowrap">SEP-786</FONT> was developed utilizing the serum calcium
PK/PD relationship in TPTx rats and the predicted human PK. We believe this model supports a projection that once-daily or twice-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
daily oral dosing of <FONT STYLE="white-space:nowrap">SEP-786</FONT> could lead to control of serum calcium within the normal range in patients with hypoparathyroidism. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g76a01.jpg" ALT="LOGO" STYLE="width:4.8683in;height:0.922743in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 5</B><B>.</B> Preclinical pharmacokinetic summary for SEP-786 across species. PO
= oral; cyno = cynomolgus monkey. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>In</I><I></I><I>&nbsp;vitro </I>and<I> in vivo </I>safety studies support that <FONT
STYLE="white-space:nowrap">SEP-786</FONT> has a favorable safety pharmacology profile. In <FONT STYLE="white-space:nowrap">28-day,</FONT> repeat, oral dose Good Laboratory Practice (GLP) toxicology studies in rats and dogs, <FONT
STYLE="white-space:nowrap">SEP-786</FONT> was generally well-tolerated. At doses significantly higher than projected human efficacious doses, sustained hypercalcemic effects on bone and kidney were observed that are consistent with exaggerated <FONT
STYLE="white-space:nowrap">on-target</FONT> pharmacology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical Development Plan and Status of
<FONT STYLE="white-space:nowrap">SEP-786</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have submitted a Clinical Trial Notification (CTN) in Australia and
have initiated a randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) Phase 1 clinical trial in up to 180 healthy adult participants designed to assess preliminary safety, tolerability, PK, and PD of <FONT
STYLE="white-space:nowrap">SEP-786.</FONT> In the SAD portion of the trial, we are evaluating the safety and tolerability of escalating oral doses of <FONT STYLE="white-space:nowrap">SEP-786.</FONT> The MAD portion of the trial will evaluate
once-daily and twice-daily oral dosing of <FONT STYLE="white-space:nowrap">SEP-786</FONT> for five days to evaluate safety and determine the optimal dosing regimen for serum calcium control. Secondary endpoints include PK, serum calcium, urinary
calcium, and other biomarkers. We have initiated the Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SEP-786</FONT> and expect to report data from this trial in mid-2025. We currently intend to conduct Phase 2 and Phase 3 clinical trials
in the United States and globally in select foreign jurisdictions, including at sites in Europe and Canada. We intend to seek approval for SEP-786 in Australia in the future. For more information, see the section titled &#147;&#150;Government
Regulation&#150;Review and Approval of Medicinal Products in Australia.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">SEP-631:</FONT> Oral
Small Molecule MRGPRX2 NAM for CSU and Other Mast Cell Diseases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing
<FONT STYLE="white-space:nowrap">SEP-631,</FONT> a selective, oral small molecule MRGPRX2 NAM, initially for the treatment of CSU. In preclinical studies, <FONT STYLE="white-space:nowrap">SEP-631</FONT> demonstrated potent and long-lasting
inhibition of MRGPRX2, which is a highly and uniquely expressed receptor on mast cells and when activated is a key driver of CSU and other prevalent mast cell diseases. We have initiated <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies
of <FONT STYLE="white-space:nowrap">SEP-631</FONT> and upon completion, we anticipate submitting for regulatory clearance to initiate a clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of CSU </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of MRGPRX2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">CSU is a systemic inflammatory skin disease characterized by the spontaneous and recurrent appearance of itchy, painful hives,
known as wheals, on the skin and angioedema, or swelling, that affects approximately 1.5&nbsp;million patients in the United States. These chronic symptoms, which typically last between two and five years, can interfere with daily living, including
the ability to work, and are frequently associated with psychiatric comorbidities, including depression and anxiety. Some patients with CSU report associated systemic symptoms including headache and fatigue, wheezing, flushing, palpitations, and
gastrointestinal symptoms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While there is no known trigger, the activation and degranulation of mast cells and release of
histamine and other inflammatory mediators lead to these debilitating symptoms of CSU. Two canonical pathways represent the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
primary mechanisms for activation and degranulation of mast cells: activation of the IgE pathway via receptor cross-linking by antibodies targeting the high-affinity IgE receptor (Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#101;</FONT>RI) or IgE itself, and activation of an <FONT STYLE="white-space:nowrap">IgE-independent</FONT> pathway via MRGPRX2. As depicted in Figure 6 below, upon activation, mast cells release a plethora of mediators
leading to the hallmark symptoms of itching, redness, and swelling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MRGPRX2 is highly expressed on the surface of mast
cells and plays a critical role in mast cell activation and degranulation. This receptor is activated by a variety of stimuli, including neuropeptides, antimicrobial peptides, and certain drugs. Upon activation, MRGPRX2 triggers a signaling cascade
that leads to the rapid release of <FONT STYLE="white-space:nowrap">pre-stored</FONT> mediators such as histamine, proteases, and cytokines from mast cell granules. This degranulation process contributes to immediate hypersensitivity reactions and
various inflammatory conditions. The unique ability of MRGPRX2 to respond to a broad range of ligands highlights its importance in host defense mechanisms and its potential as a therapeutic target for treating allergic and inflammatory diseases.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g73h34.jpg" ALT="LOGO" STYLE="width:5.9in;height:3.4325in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 6. </B>Overview of mast cell activation including the <FONT
STYLE="white-space:nowrap">IgE-mediated</FONT> and MRGPRX2-mediated degranulation pathways, physiologic effects of mast cell degranulation, and our strategy to develop a MRGPRX2 NAM to stop MRGPRX2-mediated mast cell degranulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current Treatment Options and Their Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients suffering from CSU are treated initially with antihistamines to control symptoms; however, approximately 37% of
patients are inadequately controlled in this first-line setting. In the antihistamine-refractory setting, patients may be treated with omalizumab (marketed as Xolair by Novartis and Genentech), which is an injectable
<FONT STYLE="white-space:nowrap">anti-IgE</FONT> monoclonal antibody approved by the FDA as an <FONT STYLE="white-space:nowrap">add-on</FONT> therapy for CSU in patients ages 12 years and older. The targeting and blocking of <FONT
STYLE="white-space:nowrap">IgE-mediated</FONT> inflammation can effectively address symptoms; however, only an estimated 36% of these antihistamine-refractory patients respond to <FONT STYLE="white-space:nowrap">anti-IgE</FONT> therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A significant proportion of patients have persistent symptoms with antihistamines and/or Xolair, highlighting substantial need
for additional treatment options. With the expanding knowledge of the pathogenesis of CSU and the role of mast cells, novel therapeutic agents targeting distinct drivers of CSU are in development. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are aware of several new mechanisms, and programs are being explored in clinical trials, such as
<FONT STYLE="white-space:nowrap">anti-Kit</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
antibodies barzolvolimab and briquilimimab, Bruton&#146;s tyrosine kinase inhibitor remibrutinib, and antibody to sialic acid-binding immunoglobulin-like lectin lirentelimab. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule MRGPRX2 NAM </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe an oral small molecule that targets MRGPRX2 could provide a differentiated treatment option for patients with CSU.
Our MRGPRX2 NAM program is designed to selectively inhibit mast cells, minimizing the risk of broad immunosuppression, which might be observed with other mechanistic approaches that either eradicate mast cells or inhibit multiple immune cell types.
We believe selective mast cell inhibitors have the potential to be safer treatment alternatives and could be used for both monotherapy and combination therapy. With our NAM, we believe that we may be able to universally block all endogenous MRGPRX2
and prevent MRGPRX2 activation even in the presence of high concentrations of MRGPRX2 agonists. We believe that with this combination of features, our NAM could have the potential to control patient symptoms and protect against disease flares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing <FONT STYLE="white-space:nowrap">SEP-631</FONT> initially for the treatment of CSU, as we believe this may
provide an efficient path to clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept.</FONT></FONT> There remains a significant unmet need in CSU, since antihistamine-refractory patients have few oral treatment
alternatives. Because multiple diseases are driven by activated mast cells, we believe there is an opportunity to expand into indications across several therapeutic areas, such as allergic asthma, atopic dermatitis, interstitial cystitis, migraine,
and prurigo nodularis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical Activity of <FONT STYLE="white-space:nowrap">SEP-631</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> has been demonstrated to potently block the activation of intracellular
signaling in HEK293 cells with overexpressed human MRGPRX2 stimulated by <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 1.6 nM). Experiments using a matrix of different
concentrations of <FONT STYLE="white-space:nowrap">SEP-631</FONT> versus different concentrations of <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> showed strong suppression of maximal agonist effects (Figure 7), which we believe
demonstrates <FONT STYLE="white-space:nowrap">SEP-631</FONT> has the potential to be a NAM which, when bound to MRGPRX2, cannot be outcompeted by excess amounts of an MRGPRX2 agonist. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g35e11.jpg" ALT="LOGO" STYLE="width:4.50415in;height:2.6382in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 7. </B><FONT STYLE="white-space:nowrap">SEP-631</FONT> shows strong negative
allosteric modulation of <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> activation of MRGPRX2 in HEK293 cells expressing MRGPRX2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">SEP-631</FONT> can block IP1 accumulation
in HEK293 cells expressing MRGPRX2 in response to activation by several clinically relevant endogenous MRGPRX2 agonists (Figure 8), demonstrating that its inhibitory effect is independent of the activating agonist (i.e., the inhibitor does not show
probe dependence). </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g02n07.jpg" ALT="LOGO" STYLE="width:4.61179in;height:2.47586in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 8. </B><FONT STYLE="white-space:nowrap">SEP-631</FONT> potently inhibits the
activation of MRGPRX2 by a range of endogenous MRGPRX2 agonists. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In different <I>in vitro </I>cellular models of mast
cell degranulation, SEP-631 was shown to be a potent inhibitor of activation and degranulation in LAD2 cells (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 2.3 nM) and primary human cord blood-derived mast cells (IC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 0.72 nM). In typical experiments on primary human skin mast cells, SEP-631 fully and potently inhibited tryptase release triggered by an
EC<SUB STYLE="font-size:75%; vertical-align:bottom">90</SUB> concentration of Substance P (IC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 12 nM) (Figure 9). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g14g14.jpg" ALT="LOGO" STYLE="width:3.12215in;height:2.47586in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 9. </B>In typical experiments on human skin mast cells, SEP-631 potently
inhibited Substance P-stimulated tryptase release from primary human skin mast cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key feature of <FONT
STYLE="white-space:nowrap">SEP-631</FONT> compared to other third-party MRGPRX2 inhibitors is its long target residence time or slow <FONT STYLE="white-space:nowrap">off-rate</FONT> of inhibition, meaning it takes a long time for the receptor-ligand
complex to dissociate and for the receptor to become activatable again. Two experimental approaches were taken to determine the half-life of the receptor-ligand complex: radioligand binding experiments and one surface plasmon resonance (SPR) study
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">demonstrated long half-lives of 124&nbsp;minutes (with a standard deviation of 20&nbsp;minutes) and 50 minutes,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
respectively. Long target residence times of receptor ligands are recognized as being potentially advantageous for prolonged drug action <I>in vivo</I>, which have been shown to translate to
enhanced clinical activity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For characterization of <FONT STYLE="white-space:nowrap">SEP-631</FONT><I> in vivo</I>, we
developed a transgenic <FONT STYLE="white-space:nowrap">knock-in</FONT> (KI) mouse model in which the coding region of the endogenous mouse MRGPRB2 receptor was replaced with the human MRGPRX2 receptor, due to the low sequence homology shared
between the mouse and human orthologs. In this model, MRGPRX2 agonist ligands such as substance P or <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> stimulate robust plasma extravasation, or edema, when injected into the skin. Extravasation
can be quantitated by following the redistribution of Evans Blue dye from the circulation into skin tissue (Figure&nbsp;10.A). In the MRGPRX2 KI mouse model, <FONT STYLE="white-space:nowrap">SEP-631</FONT> robustly inhibited skin extravasation when
dosed orally prior to the <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> skin challenge, demonstrating complete blockade of skin mast cell degranulation at an oral dose of 3 mg/kg (Figure&nbsp;10.B). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g99m62.jpg" ALT="LOGO" STYLE="width:5.9575in;height:2.595in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;10. </B>(A)<B> </B>Human MRGPRX2 KI mouse model of plasma extravasation into
skin. <FONT STYLE="white-space:nowrap">(B)&nbsp;SEP-631</FONT> potently inhibited <FONT STYLE="white-space:nowrap">cortistatin-14</FONT> mediated plasma extravasation into skin in a human MRGPRX2 KI mouse model. PO&nbsp;=&nbsp;oral. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Preclinical Studies to Support Clinical Advancement of <FONT STYLE="white-space:nowrap">SEP-631</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preclinical drug metabolism and PK profile of <FONT STYLE="white-space:nowrap">SEP-631</FONT> across multiple species was
determined to support human PK projections. <FONT STYLE="white-space:nowrap">SEP-631</FONT> has the potential to be highly orally bioavailable with low clearance and a projected half-life consistent with once-daily oral dosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>In vitro</I> and<I> in vivo </I>safety studies explored to date support that
<FONT STYLE="white-space:nowrap">SEP-631</FONT> has a favorable tolerability profile. In 14-day repeat oral dose non-GLP toxicology in rats and dogs, SEP-631 was generally well tolerated with wide safety margins over projected maximal exposures at
human efficacious doses. We have initiated 28-day GLP toxicology studies in rats and dogs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical Development Plan and Status of <FONT
STYLE="white-space:nowrap">SEP-631</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to develop <FONT STYLE="white-space:nowrap">SEP-631</FONT> initially
for patients with antihistamine-refractory CSU. <FONT STYLE="white-space:nowrap">SEP-631</FONT> is currently in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, and upon completion, we anticipate submitting for regulatory clearance to
initiate a Phase&nbsp;1 clinical trial. The Phase 1 clinical trial is intended to be a SAD/MAD trial in healthy volunteers to assess safety, tolerability, PK, and PD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to CSU, we are evaluating a range of other indications in which aberrant mast cell activation has been
demonstrated to be central to disease pathobiology. Mast cell activation drives multiple prevalent diseases, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
including allergic asthma, atopic dermatitis, interstitial cystitis, migraine, and prurigo nodularis, and we believe <FONT STYLE="white-space:nowrap">SEP-631</FONT> could offer a novel oral
treatment option for these patient populations. We plan to explore these indications as potential future clinical development opportunities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>TSHR Program: Oral Small Molecule TSHR NAM for Graves&#146; Disease and TED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are developing a novel, oral small molecule TSHR NAM for the treatment of Graves&#146; disease and TED. We believe our TSHR
NAM could offer a disease-modifying treatment that directly addresses the pathobiology of both diseases by blocking TSHR overactivation caused by patients&#146; autoantibodies. We are advancing several lead compounds towards selection of a
development candidate for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of Graves&#146; Disease and TED
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of TSHR </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Graves&#146; disease is one of the most prevalent autoimmune conditions affecting over 2&nbsp;million patients in the United
States and is the leading cause of hyperthyroidism. In Graves&#146; disease, the body produces autoantibodies that bind to and activate TSHR on thyroid cells (Figure&nbsp;11). These autoantibodies stimulate the thyroid gland to produce excess
thyroid hormone, resulting in hyperthyroidism. Thyroid hormones affect many body systems, so symptoms of Graves&#146; disease can be wide ranging. Common symptoms of Graves&#146; disease include anxiety and irritability, tremors, heat sensitivity,
weight loss, rapid or irregular heartbeat, and sleep disturbance. Although Graves&#146; disease may affect anyone, it is more common among women and people younger than age 40. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">TED is a related, yet distinct, vision-threatening autoimmune condition that develops in approximately 50% of Graves&#146;
disease patients. In TED, autoantibodies bind to and activate TSHR on orbital fibroblasts located behind the eyes, thereby resulting in inflammation, orbital fat expansion, and fibrosis. TED is a progressive disease and early diagnosis and treatment
is important to prevent worsening and serious eye damage, including proptosis (eye bulging), strabismus (misalignment of the eyes), and diplopia (blurred or double vision). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g72w39.jpg" ALT="LOGO" STYLE="width:5.9325in;height:3.12in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 11. </B>Overview of TSHR physiology, the role of TSHR autoantibodies in the
pathogenesis of Graves&#146; disease and TED, and our strategy to develop a TSHR NAM to reverse the effects of TSHR antibodies as a potential disease-modifying therapy for patients with Graves&#146; disease and TED. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current Treatment Options and Their Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The most common treatments for Graves&#146; disease have remained largely unchanged over the past 70 years and include
antithyroid drugs, such as methimazole and propylthiouracil, designed to lower the amount of hormone the thyroid makes or block the effects of thyroid hormone on the body, radioactive iodine therapies that aim to destroy overactive thyroid cells,
and thyroidectomy surgery to remove all or part of the thyroid. For many patients, there is a high rate of disease recurrence after treatment with antithyroid drugs, and lifelong hypothyroidism develops after ablation and thyroidectomy. In addition,
these treatment options may initially address the underlying symptoms, but they are not disease-modifying and do not stop disease progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current treatments for TED depend on disease severity and are designed to help manage symptoms and slow disease progression.
For patients with mild TED, lifestyle changes and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> remedies, such as artificial tear drops and selenium supplements, may help with dry eye relief. For
severe TED, steroids and/or eye surgery, such as orbital decompression may be considered. Historically, patients have had to live with TED until the inflammation subsides, after which they are often left with permanent and vision-impairing
consequences and may require multiple surgeries that do not completely return the patient to their <FONT STYLE="white-space:nowrap">pre-disease</FONT> state. In 2020, the FDA approved TEPEZZA (teprotumumab-trbw), an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-IGF-1R</FONT></FONT> human monoclonal antibody, for the treatment of TED based on its ability to decrease proptosis and resolve diplopia in patients. Despite reaching global sales of $2.0&nbsp;billion in 2022, TEPEZZA
requires several IV infusions over several months and has risks of serious side effects, including hearing loss and metabolic issues, such as hyperglycemia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule TSHR NAM </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there is a significant unmet need for a disease-modifying approach that directly addresses the pathobiology of both
Graves&#146; disease and TED<I>. </I>Our highly selective, oral small molecule TSHR NAM program is designed to block the activation of TSHR by autoantibodies and could lead to a universal treatment option for all Graves&#146; disease and TED
patients. Our NAMs are designed to prevent the activation of TSHR even in the presence of excess amounts of TSHR activating autoantibodies, thus potentially providing protection for patients with high serum antibody levels and for patients with
polyclonal activating antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With few innovative, <FONT STYLE="white-space:nowrap">non-surgical</FONT> or ablative
treatments, we believe that there is a significant unmet need in Graves&#146; disease. While treatments exist for TED, they are focused on the most severe patients, so an oral small molecule TSHR NAM, could provide a new option for all TED patients.
Because over-stimulation of TSHR is at the center of Graves&#146; disease and TED, we believe that if we can treat Graves&#146; disease patients early in their disease course with our oral small molecule TSHR NAM, our treatment may be able to
prevent the progression to other manifestations of the disease, such as TED or Graves&#146; dermopathy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Discovery and Preclinical
Activity of Oral TSHR NAMs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have used our Native Complex
Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to identify multiple tractable chemical series of oral small molecule TSHR NAMs.&nbsp;Molecular pharmacology studies with TSHR NAMs have demonstrated multiple compound series with high
potencies and desired drug-like properties. In cells expressing human TSHR, cAMP signaling activated by an autoantibody isolated from a Graves&#146; disease patient was significantly inhibited with several of our lead compounds. In addition, our
compounds exhibit high selectivity for inhibition of TSHR over a broad set of other GPCRs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An effective treatment for
both Graves&#146; disease and TED will require broad inhibition of patient autoantibodies, which are typically high affinity and present at high titers during active disease. Furthermore, these autoantibodies may bind to different sites on the large
extracellular domain of TSHR. We believe a TSHR NAM can have an optimized pharmacologic profile to fully block the activity of all patient autoantibodies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Experiments using a matrix of different concentrations of one of our oral
small molecule TSHR NAMs <FONT STYLE="white-space:nowrap">(SP-1351)</FONT> versus different concentrations of a Graves&#146; disease patient activating autoantibody showed strong suppression of maximal agonist effects on TSHR, even when the agonist
antibody is applied at high concentrations (Figure 12). We believe these results suggest that the antibody cannot overcome the inhibitory effects of our compound when it is bound to TSHR. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g43d06.jpg" ALT="LOGO" STYLE="width:4.59363in;height:2.49733in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 12. </B><FONT STYLE="white-space:nowrap">SP-1351</FONT> shows strong TSHR NAM in
HEK293 cells stimulated with a Graves&#146; disease patient-derived autoantibodies against TSHR. mAb&nbsp;= monoclonal antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To demonstrate that our TSHR NAM can fully inhibit multiple patient autoantibodies, we assessed the activity of <FONT
STYLE="white-space:nowrap">SP-1351</FONT> against Graves&#146; disease patient-derived polyclonal sera applied to TED patients&#146; orbital fibroblasts. Fibroblast activation by the sera is measured by quantifying hyaluronic acid production by the
cells. <FONT STYLE="white-space:nowrap">SP-1351</FONT> was able to inhibit the activity of 10 out of 10 polyclonal sera samples, each from a different Graves&#146; disease patient (Figure&nbsp;13). This result suggests broad inhibitory activity of
our TSHR NAMs against the diverse range of polyclonal autoantibodies found in Graves&#146; disease patients. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g05g90.jpg" ALT="LOGO" STYLE="width:5.69564in;height:2.12137in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 13. </B><FONT STYLE="white-space:nowrap">SP-1351</FONT> inhibits activation of
primary orbital fibroblasts by all 10 polyclonal serum samples collected from Graves&#146; disease patients. mAb&nbsp;= monoclonal antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To characterize the effects of these oral TSHR NAMs on disease manifestations <I>in vivo</I>, we developed a translational
mouse model of hyperthyroidism (Figure 14.A). Mice chronically treated with a Graves&#146; disease patient-derived TSHR-activating antibody developed multiple manifestations similar to Graves&#146; disease patients
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
including increased plasma thyroid hormone T4 levels (Figure&nbsp;14.B), increased thyroid weight (Figure&nbsp;14.C), and proptosis (Figure&nbsp;14.D). After one week of <FONT
STYLE="white-space:nowrap">SP-1351</FONT> treatment with repeat oral dosing, several of these manifestations showed signs of reversal including normalization of thyroid hormone T4 levels, reduction in thyroid weight, and reduction of proptosis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g30c65.jpg" ALT="LOGO" STYLE="width:6.005in;height:3.5675in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;14. </B>(A)<B> </B>Translational <I>in vivo</I> mouse model of Graves&#146;
disease. (B,C,D) <FONT STYLE="white-space:nowrap">SP-1351</FONT> demonstrates reversal of the hyperthyroid state and proptosis in mice chronically treated with a monoclonal TSHR autoantibody. mAb&nbsp;= monoclonal antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the same mouse model, effects on thyroid tissue were assessed. Thyroid glands of Graves&#146; disease patients are
characterized by follicular hyperplasia and/or hypertrophy, intracellular colloid droplets, follicular colloid reduction and scalloping, increased vascularity and lymphocyte infiltration, all of which manifest in our mouse disease model. After oral
treatment with <FONT STYLE="white-space:nowrap">SP-1351,</FONT> we observed significant reduction in follicular hypertrophy and colloid droplets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Next Steps </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are continuing to optimize multiple early-stage oral small molecule TSHR NAMs, with the goal of advancing lead compounds
towards selection of a development candidate for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. In our preclinical studies, we have identified multiple TSHR NAMs that demonstrated the ability to reverse hyperthyroidism and proptosis
in a novel mouse model of Graves&#146; disease and inhibit of multiple Graves&#146; disease patient TSHR autoantibodies in cell-based assays using primary human cells. We intend to pursue future clinical development of our TSHR NAM program for the
treatment of Graves&#146; disease and TED. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Incretin Programs: Oral Small Molecule Single- and Multi-Incretin Receptor Agonists for
Metabolic Disorders Including Obesity and T2D </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on unique chemical and structural insights obtained with our
Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, we believe we have an opportunity to discover and develop novel, next-generation, oral small molecules as selective single- or multi-acting <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP, glucagon receptor agonists. We are advancing several lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Overview of Obesity and T2D </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Disease Background and Role of Incretins </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obesity and diabetes are two of the most prevalent chronic diseases in the world, affecting a combined total of more than
800&nbsp;million people, and are associated with severe health complications, including cardiovascular disease and kidney failure, as well as an increased risk of death. Obesity is defined as having a BMI of greater than or equal to 30 and is
associated with more than 200 comorbidities, including diabetes, which can lead to blindness, limb amputations, and the need for dialysis. Despite increased awareness about obesity as a global epidemic and the advancement of new treatments, no
country has reported a decline in obesity prevalence across its entire population. It is predicted that 1.55&nbsp;billion people will be living with obesity globally by 2030. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">More than 400&nbsp;million people worldwide live with diabetes and approximately 90% of all diabetes cases are T2D, which is a
chronic disease involving sustained high levels of glucose in the bloodstream. Under normal conditions, insulin is produced by the pancreas, enabling glucose to enter cells to provide energy needed for normal tissue and organ function. T2D results
from either the pancreas not producing enough insulin or the body&#146;s cells not responding normally to insulin, known as insulin resistance. Uncontrolled diabetes can lead to severe health complications, such as an increased risk of heart attack,
stroke, neuropathy, kidney failure, limb amputations, and vision loss. The key risk factors for developing T2D include obesity, genetic predisposition, a sedentary lifestyle, or a history of gestational diabetes. Moreover, T2D and obesity are
considered <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> with 90% of people with T2D being overweight or obese. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Incretins (e.g., <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and glucagon) are a group of metabolic hormones that,
along with their associated receptors, play significant roles in glucose metabolism and homeostasis (Figure&nbsp;15). <FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP are secreted in the intestinal tract after eating, and subsequently activate
their respective receptors expressed on pancreatic beta cells, to stimulate insulin secretion in a glucose-dependent manner. Glucagon activates its related receptors expressed on pancreatic alpha cells, to counteract the actions of insulin by
stimulating hepatic glucose production and thereby increases blood glucose levels in a glucoregulatory role. The widespread therapeutic effects of <FONT STYLE="white-space:nowrap">GLP-1</FONT> and GIP receptor agonism in patients with diabetes are
well-documented and include slowing of gastric emptying, increased satiety, reduction of food intake, promotion of weight loss, and reduction of cardiovascular disease morbidity and mortality. Moreover, there is a complex interplay between the
actions of <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and glucagon, and recent clinical data from the triagonist injectable peptide retatrutide (in development by Eli Lilly and Company) indicate there are potential additional efficacy
benefits on weight loss and its maintenance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g78p09.jpg" ALT="LOGO" STYLE="width:4.5775in;height:3.0075in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure&nbsp;15. </B>Overview of the physiologic effects of <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP, glucagon acting through their respective receptors <FONT STYLE="white-space:nowrap">GLP-1R,</FONT> GIPR, and GCGR, and our strategy to develop oral small molecule single- and multi-incretin receptor
agonists. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Current Treatment Options and Their Limitations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Standard treatment for obesity and T2D is lifestyle change through a combination of diet, exercise, and behavior therapy, and,
in the case of T2D, metformin. According to the 2022 ADA Standards of Medical Care in Diabetes, management of obesity is an important factor in the treatment of diabetes since even a small degree of weight loss can improve blood glucose levels,
resulting in a decreased need for glucose-lowering medications. While lifestyle modifications can produce weight loss, the magnitude required for disease modification is approximately 10% to 15% of total body weight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In recent years, several injectable peptide agonists targeting incretins have been approved for the treatment of T2D, and, due
to their ability to increase feelings of fullness, decrease appetite, and effectively promote weight loss, for the treatment of obesity. Third-party clinical data with incretin receptor therapeutics have demonstrated substantial and sustained
reductions in body weight, as well as the ability to lower blood glucose and improve glycated hemoglobin (HbA1c). Global sales in 2023 for Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk), and Mounjaro and Zepbound (tirzepatide, each
marketed by Eli Lilly and Company) were $18.4&nbsp;billion and $5.3&nbsp;billion, respectively. As a class, the marketed GLP-1 and GLP-1/GIP products generated $36 billion in global sales in 2023. While the benefits of currently <FONT
STYLE="white-space:nowrap">marketed&nbsp;GLP-1&nbsp;and&nbsp;dual</FONT> <FONT STYLE="white-space:nowrap">GLP-1/GIP&nbsp;receptor</FONT> agonists are well-documented in patients with diabetes and obesity, they suffer from several limitations
including tolerability, prolonged titration schemes, and injection administration, and supply challenges. The most frequent adverse events <FONT STYLE="white-space:nowrap">with&nbsp;GLP-1&nbsp;receptor</FONT> agonists
<FONT STYLE="white-space:nowrap">are&nbsp;GI-related</FONT> issues,&nbsp;including nausea, vomiting, and diarrhea, which necessitate dose titration protocols to manage treatment and often contribute to treatment discontinuation. Finally, certain
doses of semaglutide and tirzepatide are currently on several global health authorities&#146; drug shortage lists, highlighting the need for additional scalable treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beyond currently available treatment options, we are aware of numerous injectable peptides in clinical development that are
exploring the combination of agonist activities at the <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and glucagon receptor metabolic targets. In addition, orally administered <FONT STYLE="white-space:nowrap">GLP-1&nbsp;receptor</FONT> small
molecules are being clinically evaluated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our Solution: Oral Small Molecule Single- and Multi-Incretin Receptor Agonists
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Our Program Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe there remains a significant unmet need in the treatment of diabetes, obesity and other cardiometabolic disorders to
discover and develop products that can deliver the activity of mono- or multi-acting injectable peptide agonists, like semaglutide or tirzepatide, but as oral small molecules. By exploring novel, single-acting or various multi-acting <FONT
STYLE="white-space:nowrap">GLP-1,</FONT> GIP and glucagon receptor agonists, we believe that we have the potential to discover and develop oral products that have the potential to increase patient convenience and compliance, and to improve
tolerability, ultimately expanding the treated population. Given the significant market opportunity, we are leveraging our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to discover novel scaffolds across various
product profiles to explore multiple different treatment options for patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Discovery and Preclinical Activity of Oral Incretin
Receptor Agonists </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have used our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> to
identify multiple tractable chemical series of oral small molecule incretin receptor agonists. Structural biology demonstrated that our compounds occupy novel binding sites, distinct from the known orthosteric binding sites occupied by
clinical-stage small molecules, danuglipron and orforglipron. Analysis of the respective binding sites show a high similarity of more than <FONT STYLE="white-space:nowrap">80-90%</FONT> for <FONT STYLE="white-space:nowrap">GLP-1,</FONT> GIP, and
glucagon receptors, in contrast to the modest similarity of approximately <FONT STYLE="white-space:nowrap">40-60%</FONT> at the danuglipron and orforglipron orthosteric sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our portfolio of discovery-stage incretin receptor agonists includes several potent, selective mono-GIPR agonists, dual-GIPR /
GCGR agonists, and <FONT STYLE="white-space:nowrap">triple-GLP-1R</FONT> / GIPR / GCGR agonists. Cell-based assay data for an exemplar incretin agonist compound for each of these profiles is shown in Figure 16 which demonstrates differential potency
and selectivity of these compounds in their ability to activate GIPR, GLP-1R, and GCGR-induced intracellular signaling: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mono-GIPR agonist exemplar SP-3561 demonstrated high potency (EC<SUB
STYLE="font-size:75%; vertical-align:bottom">50</SUB> = 3.1 nM) and was about 60-fold selective relative to GCGR and greater than 10,000-fold selective relative to GLP-1R. Mono-GIPR agonists may have therapeutic potential alone or in combination
with GLP-1R agonists. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dual-GIPR / GCGR agonist exemplar SP-7606 demonstrated comparable GIPR potency to SP-3561 but with
significantly improved GCGR potency (EC50 = 17 nM) and still high selectivity relative to GLP-1R. Dual-GIPR / GCGR agonists may have therapeutic potential alone or in combination with GLP-1R agonists. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Triple-GLP-1R / GIPR / GCGR agonist exemplar SP-2297 demonstrated comparable GIPR and GCGR potency to SP-7606
but with significantly improved GLP-1R potency (EC50 = 330 nM). Additional optimization efforts are underway to try to further improve GLP-1R potency. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g69v12.jpg" ALT="LOGO" STYLE="width:5.58681in;height:1.54992in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 16. </B>Cell-based assay activity of exemplar incretin receptor agonist
compounds: cAMP readout in recombinant cells overexpressing GIPR, <FONT STYLE="white-space:nowrap">GLP-1R,</FONT> or GCGR. EC<SUB STYLE="font-size:75%; vertical-align:bottom">50</SUB> = half-maximal effective concentration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Favorable physicochemical and <I>in vitro</I> drug metabolism properties of one of our selective mono-GIPR agonists, <FONT
STYLE="white-space:nowrap">SP-3561,</FONT> translated into promising PK in mice with low clearance and high oral bioavailability. Subsequent evaluation of <FONT STYLE="white-space:nowrap">SP-3561</FONT> in an oral-glucose tolerance test (OGTT) in
diet-induced obese (DIO) mice (Figure 17.A) demonstrated significant dose-dependent glucose reduction at oral doses of 10 and 30 mg/kg (Figure 17.B,C). DIO mice were fasted overnight, and 30 minutes after oral dosing of <FONT
STYLE="white-space:nowrap">SP-3561</FONT> a glucose challenge was administered, and blood glucose levels were monitored for two hours after dosing. At 30 mg/kg, <FONT STYLE="white-space:nowrap">SP-3561</FONT> demonstrated effective glucose control
comparable to retatrutide (clinically studied <FONT STYLE="white-space:nowrap">triple-GLP-1R</FONT> / GIPR / GCGR injectable peptide agonist) dosed subcutaneously (Figure 17.B,C). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g38i22.jpg" ALT="LOGO" STYLE="width:5.6225in;height:3.385in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 17. </B>(A)<B> </B>OGTT model with DIO mice. (B,C)
<FONT STYLE="white-space:nowrap">SP-3561</FONT> improves oral glucose tolerance in the DIO mouse model comparable to retatrutide. PO = oral, SC&nbsp;=&nbsp;subcutaneous. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A second selective mono-GIPR agonist, SP-2991, was studied in a 14-day
repeat dosing weight loss study in DIO mice (Figure 18). SP-2991 was evaluated at a once-daily oral dose of 30 mg/kg, alone or in combination with once-daily subcutaneous injections of the GLP-1R agonist peptide semaglutide at 10 nmol/kg. These
cohorts were compared with once-daily semaglutide subcutaneous injections at 10 nmol/kg, once-daily subcutaneous injections of the dual GIPR&nbsp;/&nbsp;GLP-1R agonist peptide tirzepatide at 10 nmol/kg, and historical vehicle controls. Body weights
of the mice were measured prior to compound dosing on day 0 and on days 1, 4, 6, 8, 10, 12, and 14 when the study was terminated. SP-2991, when dosed alone, resulted in about 7% average body weight loss relative to vehicle controls, which was
statistically significant. When added to a subcutaneous daily dose of semaglutide, SP-2991 resulted in about 33% average body weight loss, which was similar in magnitude to what was observed for tirzepatide in the same study and significantly more
weight loss relative to dosing of semaglutide alone. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g19m19.jpg" ALT="LOGO" STYLE="width:5.32636in;height:3.13812in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Figure 18. </B>Mono-GIPR agonist, SP-2991, when dosed orally once daily in combination
with subcutaneous dosing of the GLP-1R agonist peptide semaglutide, resulted in significant body weight loss in the DIO mouse model, which is comparable in magnitude to subcutaneous dosing of the dual GLP-1R/GIPR agonist peptide tirzepatide. PO =
oral, SC = subcutaneous, QD = once daily. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Next Steps </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have identified potent, selective mono-GIPR agonists, dual-GIPR / GCGR agonists, and
<FONT STYLE="white-space:nowrap">triple-GLP-1R</FONT> / GIPR / GCGR agonists. Oral small molecule mono-GIPR agonists with favorable PK properties have demonstrated the ability to achieve glucose control in a mouse model of glucose sensitivity and
demonstrated weight loss in a DIO mouse model as a single agent and additive weight loss when dosed in combination with semaglutide. We are continuing to optimize multiple early-stage oral small molecule incretin receptor agonists and plan to
continue evaluating them in a variety of metabolic models with a goal of advancing lead compounds towards selection of one or more development candidates for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a
strong emphasis on proprietary and novel products and product candidates. While we believe our product candidates, platform, knowledge, experience and scientific personnel provide us with several key competitive advantages, we face competition from
major pharmaceutical and biotechnology companies, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
academic institutions, governmental agencies and public and private research institutions, among others. Our future success will depend in part on our ability to maintain a competitive position
with our structure-based drug discovery platform. If we fail to stay at the forefront of technological change in utilizing our platform to create and develop product candidates, we may be unable to compete effectively. Our competitors may render our
approach obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and
platform. Several other companies also focus on GPCRs and have platform technologies that are distinct from our Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, including Nxera Pharma (formerly Sosei Heptares),
Structure Therapeutics, Tectonic Therapeutics, and Confo Therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, any product candidates that we
successfully develop and commercialize, including <FONT STYLE="white-space:nowrap">SEP-786</FONT> and <FONT STYLE="white-space:nowrap">SEP-631,</FONT> may compete with existing therapies and new therapies that may become available in the future that
are approved to treat the same diseases for which we may obtain approval for our product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of
product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent
protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are aware of pharmaceutical companies that have commenced clinical studies of products or have successfully commercialized products addressing areas that we are targeting. Takeda owns the rights to an injectable parathyroid hormone product (brand
name NATPARA), for the treatment of hypoparathyroidism. NATPARA was voluntarily recalled in September 2019 in the United States due to manufacturing issues and is now only available to a limited number of patients through a Special Use Program
offered by its manufacturer. In October 2022, Takeda announced manufacturing of all strengths of NATPARA will be discontinued globally by the end of 2024. Ascendis Pharma received regulatory approval for a proprietary once-daily injectable PTH
peptide, palopegteriparatide (brand name YORVIPATH), in Europe and in the United States. In March 2024, AstraZeneca acquired Amolyt Pharma, who was developing eneboparatide, a proprietary, once-daily injectable PTH peptide, for hypoparathyroidism,
currently in Phase 3 trials. In addition, we are aware of several academic groups and companies working on making longer-acting agonists of PTH1R. Other companies and groups are developing or commercializing therapies for hypoparathyroidism,
including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, and MBX Biosciences. Several companies are developing clinical-stage small molecule MRGPRX2 inhibitors, including Escient Pharmaceuticals (acquired by Incyte Pharmaceuticals
in April 2024), Evommune, and BioArdis. Further there are several other companies pursuing therapies for CSU addressing other receptors of interest, such as Genentech, Sanofi, Celldex Therapeutics, Jasper Therapeutics, Acelyrin, Allakos, Novartis,
Third Harmonic Bio, and Blueprint Medicines. For TSHR, we are aware that Byondis and Crinetics are also working on research stage compounds, but they have not yet entered clinical development. In addition several companies are working on other
mechanisms to address Graves&#146; disease, such as Immunovant, and TED, including Amgen, Viridian, Argenx, Roche, Lassen Therapeutics, Tourmaline Bio, Sling Therapeutics, and Acelyrin. There are also several currently approved injectable products
targeting incretin receptors for the treatment of obesity or T2D. These include, but are not limited to, products such as Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk) for T2D and obesity, respectively, Trulicity (dulaglutide,
marketed by Eli Lilly and Company) for T2D, and Mounjaro and Zepbound (tirzepatide, each marketed by Eli Lilly and Company) for T2D and obesity, respectively. There are also several injectable peptide products in development pursuing similar
indications with similar mechanism of actions along with combination products, including those being developed by Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, and Viking, among others. In addition, there are
oral products such as Rybelsus (semaglutide, marketed by Novo Nordisk) approved for patients with T2D and other oral products in development for treating obesity or T2D, including those being developed by AstraZeneca, Eli Lilly and Company, Pfizer,
Roche, Structure, and Terns. Based on our continuing evaluations of the competitive landscape, we may decide to reallocate resources and reprioritize our development programs if we determine that a particular product candidate or target indication
is no longer commercially viable or advantageous. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our competitors, either alone or with their collaborators, have
significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors,
including the safety and effectiveness of our products, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position.
Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any
products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may
develop, if approved, could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial opportunity could be reduced or eliminated if our
competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other
applicable regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to
compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing and additional
products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not own or operate manufacturing facilities for the production of our product candidates and currently have no immediate
plans to build our own clinical or commercial scale manufacturing capabilities. We have engaged, and expect to continue to rely on, third-party contract manufacturing organizations (CMOs) to supply our product candidates for use in our preclinical
studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we intend to rely on third-party manufacturers for later-stage development and
commercial manufacturing if our product candidates receive marketing approval. As our current or future product candidates advance through clinical development, we expect to enter into longer-term commercial supply agreements to fulfill and secure
our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the number of manufacturers is limited. In the event it is necessary or advisable to acquire supplies from an alternative
supplier, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. If we need to change manufacturers
during the clinical or development stage for product candidates or after commercialization for our product candidates, if approved, the FDA, European Medicines Agency (EMA), and other comparable foreign regulatory authorities must approve these new
manufacturers in advance, which will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay. Reliance on third-party manufacturers and CMOs may expose us to
different risks than if we were to manufacture and develop product candidates ourselves. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur
some delay in identifying and qualifying such replacements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have personnel with extensive technical, manufacturing,
analytical, and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our intellectual property is critical to our business and we strive to protect it, including by pursuing and, once obtained, by
maintaining patent protection in the United States and in selected foreign jurisdictions for our current and future product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. We
also rely on the skills, knowledge, and experience of our scientific and technical personnel, as well as that of our advisors, consultants, contractors, and collaborators. To help protect our proprietary
<FONT STYLE="white-space:nowrap">know-how</FONT> that we elect not to patent, such as our proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, processes for which patents are difficult to enforce, and any other
elements of our current or future product candidates, technology and product discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents, we
rely on confidentiality and other agreements to protect our interests. We generally require our employees, consultants, scientific advisors and contractors to enter into confidentiality agreements prohibiting the disclosure of our confidential
information and requiring disclosure and assignment to us of their ideas, developments, discoveries and inventions important to our business. In addition, we also plan to rely on regulatory protection based on orphan drug exclusivities, data
exclusivities, and market exclusivities. See the subsection section titled &#147;&#151;Government Regulation&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent positions of biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex
legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary
protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we may file in the future, nor can we ensure that any of our patents or future patents will be commercially useful in protecting
our current or future product candidates and methods of using or manufacturing the same. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even
challenged after issuance. As a result, we cannot guarantee that any of our current or future product candidates, if they obtain required regulatory approvals, will be protectable or remain protected by enforceable patents. Moreover, any patents
that we hold may be challenged, circumvented, or invalidated by third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success will also depend in
part on our ability to operate without infringing the proprietary intellectual property rights of third parties, and in part on our ability to prevent others from infringing our proprietary rights. It is uncertain whether the issuance of any
third-party patent would require us to alter our development or commercial strategies, or our future drugs or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary
rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. See &#147;Risk Factors&#151;Risks Related to Intellectual Property&#148; for a more comprehensive description of risks related to our
intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent Applications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We generally file patent applications directed to our current or future product candidates in an effort to secure our
intellectual property positions <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> these programs. For our current or future product candidates, we will, in general, initially pursue patent protection
covering compositions of matter and therapeutic methods of use. Throughout the development of our current or future product candidates, we will seek to identify additional means of obtaining patent protection that would potentially enhance
commercial success, including by protecting inventions related to additional methods of use, processes of making, formulations and dosing regimens. The intellectual property portfolios for our current product candidates as of September 25, 2024 are
summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Agonists of PTH1R </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We own five patent families directed to certain small molecule agonists of PTH1R and therapeutic methods of using them. As of
September 25, 2024, we have two pending Patent Cooperation Treaty (PCT) patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applications, nine pending foreign applications, and three pending United States provisional patent applications. Any patents that may issue from patent applications in these families (or in the
case of provisional applications, if issued from future <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire between 2043 and 2045, absent any disclaimers or potentially available patent term
extensions or adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Inhibitors of MRGPRX2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We own one patent family directed to certain small molecule inhibitors of MRGPRX2 and therapeutic methods of using them. As of
September 25, 2024, we have one pending PCT patent application and seven pending foreign applications. Any patents that may issue from patent applications in this family (or in the case of provisional applications, if issued from future <FONT
STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire in 2044, absent any disclaimers or potentially available patent term extensions or adjustments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Inhibitors of TSHR </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For our TSHR program, we own two patent families directed to certain small molecule inhibitors of TSHR and therapeutic methods
of using them. As of September 25, 2024, we have one pending PCT patent application and two pending United States provisional patent application. Any patents that may issue from patent applications in these families (or in the case of provisional
applications, if issued from future <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire between 2043 and 2045, absent any disclaimers or potentially available patent term extensions or
adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Small Molecule Agonists of Incretin Receptors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For our incretin programs, we own five patent families directed to certain small molecule single- and multi-incretin agonists,
of incretin receptors, and therapeutic methods of using them. As of September 25, 2024, we have four pending United States provisional patent applications, one pending foreign application, and one pending PCT application. Any patents that may issue
from patent applications in these families (or in the case of provisional applications, if issued from future <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications that we file) are projected to expire between 2044 and 2045, absent
any disclaimers or potentially available patent term extensions or adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent Term Extensions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may, in
certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend beyond a total
of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are
available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If one or more of our pending United States patent applications are issued as United States patents covering our current or future
products or their therapeutic use it is possible that the patents may be entitled to patent term extensions. If a therapeutic use of a drug candidate or the drug candidate itself receives FDA approval, we intend to apply for patent term extensions,
if available, to extend the term of patents that cover the approved use or drug candidate. We also intend to seek patent term extensions in any other jurisdictions where available. However, there is no guarantee that the applicable authorities,
including the FDA, will agree with our assessment of whether such extensions should be granted and even if granted, the length of such extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Trade Secrets&nbsp;&amp; <FONT STYLE="white-space:nowrap">Know-how</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to patent protection, we also rely on trade secrets, trademarks, proprietary information, confidential <FONT
STYLE="white-space:nowrap">know-how,</FONT> and continuing technological innovation to develop and maintain our competitive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
position. Our trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> includes our Native Complex Platform<SUP
STYLE="font-size:75%; vertical-align:top">TM</SUP>. However, trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We seek to protect our trade secrets, proprietary
information, and confidential <FONT STYLE="white-space:nowrap">know-how,</FONT> in part, using confidentiality agreements with any collaborators, scientific advisors, employees, and consultants and invention assignment agreements with our employees.
We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide adequate protection. These agreements may also be breached, and we may not have an
adequate remedy for any such breach. In addition, our trade secrets, proprietary information, and <FONT STYLE="white-space:nowrap">confidential&nbsp;know-how&nbsp;may</FONT> become known or be independently developed by a third party, or misused by
any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our current or future products or obtain or use information that we regard as
proprietary. Although we take steps to protect our proprietary information, third parties may independently develop substantially the same or similar proprietary information and techniques or may otherwise gain access to our proprietary information.
As a result, we may not be able to meaningfully protect our trade secrets, proprietary information, and confidential <FONT STYLE="white-space:nowrap">know-how.</FONT> For more information regarding the risks related to our intellectual property, see
the section titled &#147;Risk Factors&#151;Risks Related to Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions,
including the European Union (EU), extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,
post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with
applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review and Approval of
Drugs in the United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and
Cosmetic Act (FDCA) and its implementing regulations. The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety
of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or
partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the U.S. Department of Justice or
other governmental entities. In addition, an applicant may need to recall a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An applicant seeking approval to
market and distribute a new drug product in the United States must typically undertake the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in
compliance with the FDA&#146;s good laboratory practice (GLP) regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND which must take effect before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board (IRB) representing each clinical site before each clinical trial may
be initiated at that site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices
(GCPs) to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of an NDA and payment of user fees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product by an FDA advisory committee, where appropriate or if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which
the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices (cGMP) requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity,
strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity
of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with any post-approval requirements, including risk evaluation and mitigation strategies (REMS) and
post-approval studies required by the FDA. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before an applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical
studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient (API) and the formulated drug or drug product, as well as<I>&nbsp;in vitro</I>&nbsp;and animal studies to assess
the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term
preclinical testing, such as animal tests of reproductive adverse effects and carcinogenicity, may continue after the IND is submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The IND and IRB Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an
investigational clinical trial and a request for FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND,
applicants must submit a protocol for each clinical trial and any subsequent protocol amendments. In addition, an applicant submits the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or
literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more
proposed clinical trials and places the trial on clinical hold. The FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to
delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or
partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold)
may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that
the investigation can proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an
IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with
GCP, including review and approval by an independent ethics committee (IEC) and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in
<FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trials, as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an <FONT STYLE="white-space:nowrap">on-site</FONT>
inspection if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the foregoing IND requirements, an IRB representing each institution
participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the IRB must conduct continuing review of the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to
study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with
the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a
data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. The FDA or the
sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health
(NIH) for public dissemination on its <I>ClinicalTrials.gov</I> website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Human Clinical Trials in Support of an NDA </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical
trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be
evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1. The drug is initially introduced into healthy human subjects or, in certain indications such as
cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine maximal dosage.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2. The drug is administered to a limited patient population to identify possible AEs and safety risks,
to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3. The drug is administered to an expanded patient population, generally at geographically dispersed
clinical trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for
the labeling of the product. Post-approval studies, often referred to as Phase 4 studies, may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended
therapeutic indication. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Progress reports detailing the results of the clinical trials must be submitted
at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected
adverse reactions; findings from other studies or animal or<I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction
over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the
information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the
clinical data submitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies often complete additional animal studies and must
also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug
candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be
conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review of an NDA
by the FDA </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of required clinical testing and other requirements, the results of the
preclinical studies and clinical trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to
market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically
increased annually. Certain exceptions and waivers are available for some of these fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA conducts a preliminary
review of an NDA within 60 days of its receipt, before accepting the NDA for filing, to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for
filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins <FONT
STYLE="white-space:nowrap">an&nbsp;in-depth&nbsp;substantive</FONT> review. The FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10
months from the date of filing, and applications for &#147;priority review&#148; products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional
months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During its review of an NDA, the FDA typically will inspect the facility or facilities where the product is or will be
manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs), finished drug product manufacturing, and control testing
laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization
strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of
the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare
professionals, and elements to assure safe use (ETASU). ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of
patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not
made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Fast Track, Breakthrough Therapy, and Priority Review </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended
to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with
one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater
interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical
data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However,
the FDA&#146;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA believes that the
designation is no longer supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Second, a product may be designated as
a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies,
including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary
project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third, the
FDA may designate an NDA review for a priority review if it is for a product that treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be
illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious
outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a
marketing application from 10 months to six months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Accelerated Approval Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful
therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical endpoint that can be
measured earlier than an effect on irreversible morbidity or mortality (IMM), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic
image, physical sign, or other measure that is thought to predict clinical benefit, but is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a
therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated
that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect
is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accelerated approval pathway is most
often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accelerated approval pathway is contingent on a sponsor&#146;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4
or post-approval clinical trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022 (FDORA), the FDA is permitted to require, as appropriate, that such trials be underway prior to approval or within a
specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA
must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such
studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the <FONT
STYLE="white-space:nowrap">agency,&nbsp;pre-approval&nbsp;of</FONT> promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The FDA&#146;s Decision on an NDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the basis of the FDA&#146;s evaluation of the NDA and accompanying information, including the results of the inspection of
the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific
indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued,
the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have
been addressed to the FDA&#146;s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may
decide that the application does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA approves a product, it may
limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further
assess the drug&#146;s safety or effectiveness after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management
mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA,
including, among other things, requirements relating to recordkeeping, periodic reporting, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
product sampling and distribution, advertising and promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements. After approval, many
changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain marketed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required
to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly
regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any
third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or voluntary product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may
be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted
<FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the
distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and
regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request
marketing authorization for a new drug. A Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and
efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for
whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
or published literature, in support of its application. Section&nbsp;505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of
an Abbreviated New Drug Application (ANDA). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among
other things, to a previously approved product, known as a reference listed drug (RLD). ANDAs are termed &#147;abbreviated&#148; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety
and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through<I>&nbsp;in vitro</I>,<I>&nbsp;in vivo</I>, or other testing. The generic
version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><FONT STYLE="white-space:nowrap">Non-Patent&nbsp;Exclusivity</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any
applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a
new chemical entity (NCE). For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological
or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification,
which states the proposed generic drug will not infringe one or more of the already approved product&#146;s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following
the original product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDCA also provides for a period of three years of exclusivity for <FONT
STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and
are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication, but it
generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug
as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A drug product
can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms. This <FONT
STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection and patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <FONT
STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Hatch-Waxman Patent Certification and <FONT STYLE="white-space:nowrap">the&nbsp;30-Month&nbsp;Stay</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims
that cover the applicant&#146;s product or an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly
known as the Orange Book. Upon submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no patent information on the drug product that is the subject of the application has been submitted to the
FDA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent has expired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which such patent expires; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the
drug product for which the application is submitted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Generally, the ANDA or 505(b)(2) NDA cannot be
approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the
listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or
505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders
may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV
certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was
favorably decided in the applicant&#146;s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an
ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take
many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent
litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires seven and a half years after approval of the innovator drug,
unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent Term Restoration and Extension </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments,
which permits a patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between
the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14 years from the product&#146;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the
expiration of the patent in question and within 60 days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office (USPTO)
reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review and Approval
of Medicinal Products in the European Union </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to market any product outside of the United States, a company
must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and
distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the
product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows similar lines as in the United States. It entails satisfactory completion of preclinical studies and adequate
and well-controlled clinical trials to establish the safety and efficacy of the product for each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
proposed indication. It also requires a submission to the relevant competent authorities of a marketing authorization application (MAA) and granting of a marketing authorization by these
authorities before the product can be marketed and sold in the EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Clinical Trial Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, an applicant for authorization of a clinical trial must obtain prior approval from the national competent authority
of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the relevant independent ethics committee has issued a favorable opinion. In April
2014, the Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted in the EU. The Clinical Trials Regulation is directly applicable in all the EU Member States and repealed the Clinical Trials Directive 2001/20/EC, as of
January&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in
the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, known as the &#147;Clinical Trials Information System&#148;; a single set of documents to be prepared and submitted for the
application, as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by an elected Reference Member
State, with support of the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (the Member States concerned). Part II is assessed separately by each Member State concerned.
Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national laws of the concerned EU Member State, however
overall related timelines are defined by the Clinical Trials Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Marketing Authorization </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To obtain a marketing authorization for a product in the EU, an applicant must submit an MAA either under a centralized
procedure administered by the European Medicines Agency (EMA) or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure or mutual recognition procedure) for obtaining a marketing authorization in
multiple EU Member States. A marketing authorization may be granted only to an applicant established in the European Economic Area (EEA) (which is comprised of the EU Member States plus Norway, Iceland and Liechtenstein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid
throughout the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products,
advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of HIV, AIDS,
cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for other products containing a new active substance not yet authorized in the EU, or for products that
constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the centralized procedure, the Committee for Medicinal Products for Human Use (CHMP) established at the EMA is
responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization.
Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by
the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from a public health
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
perspective and in particular from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops,
but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific
opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP opinion, the European Commission will adopt its final decision on the MAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) (UK) has left the EU, Great Britain is no
longer covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations currently continue to be recognized in Northern Ireland). On January&nbsp;1, 2024, a new international recognition
framework was put in place by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK medicines and medical devices regulator, under which the MHRA may have regard to decisions on the approval of marketing authorizations made by the
EMA and certain other regulators when determining an application for the grant of a UK or Great Britain marketing authorization. The MHRA also has the power to have regard to marketing authorizations approved in EU Member States through
decentralized or mutual recognition procedures with a view to more quickly granting a marketing authorization in the UK or Great Britain. For additional information related to the regulatory framework in the UK, please refer to the discussion below
under the section titled &#147;<I>&#151;</I>Brexit&nbsp;and the Regulatory Framework in the United Kingdom.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
decentralized marketing authorization procedure allows an applicant to apply for simultaneous authorization in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within
the mandatory scope of the centralized procedure. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The Reference Member State prepares a draft assessment and
drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the Concerned Member States who, within 90 days of receipt, must decide whether to approve the assessment report
and related materials. If a Concerned Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose
decision is binding on all Member States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The mutual recognition procedure is based on the acceptance by the competent
authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of another EU Member State. The holder of a national marketing authorization may submit an application to the competent authority
of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Pediatric Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants have to
demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Pediatric Investigation Plan (PIP) covering all subsets of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific
waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or more of the measures included in the PIP. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product for which a marketing
authorization is being sought. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a <FONT STYLE="white-space:nowrap">six-month</FONT> extension
of the protection under a supplementary protection certificate (SPC), provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even
where the trial results are negative. In the case of orphan medicinal products, a <FONT STYLE="white-space:nowrap">two-year</FONT> extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions
and is not automatically available when data in compliance with the PIP are developed and submitted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Data and Market Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight
years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. Data exclusivity prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the
innovator&#146;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar (abbreviated) marketing authorization, for a period of eight years from the date on which the reference
product was first authorized in the EU. During an additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator&#146;s data may be referenced, but no generic
or biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">10-year</FONT> period will be extended to a maximum of 11 years if, during the first eight
years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit
in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative
medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained a marketing authorization based on an MAA with a complete
and independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Orphan Designation and Exclusivity
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regulation (EC) No 141/2000 and Regulation (EC) No.&nbsp;847/2000 provide that a product can be designated as an
orphan medicinal product by the European Commission if its sponsor can establish that: (1)&nbsp;the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2)&nbsp;either
(i)&nbsp;such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii)&nbsp;without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate
sufficient return to justify the necessary investment in its development and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method
exists, the product would be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An orphan designation provides a
number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product leads to a
<FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity being granted. During this market exclusivity period, the EMA, the European Commission or the competent authorities of the EU Member States may only grant a marketing
authorization to a &#147;similar medicinal product&#148; to the authorized orphan product for the same therapeutic indication if: (i)&nbsp;a second applicant can establish that its product, although similar to the authorized orphan product, is
safer, more effective or otherwise clinically superior; (ii)&nbsp;the marketing authorization holder for the authorized orphan product consents to a second orphan medicinal product application; or (iii)&nbsp;the marketing authorization holder for
the authorized orphan product cannot supply enough orphan medicinal product. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal
product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no
longer meets the criteria for orphan designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before submitting an application for marketing authorization.
Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Periods
of Authorization and Renewals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A marketing authorization has an initial validity of five years. The marketing
authorization may be renewed after five years on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the relevant EU Member State for a nationally authorized
product. To this end, the marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since
the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent
authorities of the relevant Member States decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period. Any authorization which is not followed by the actual placing of the medicinal product on the
EU market (for centrally-authorized products) or on the market of the authorizing EU Member State (for nationally-authorized products) within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT>
sunset clause). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Regulatory Requirements after a Marketing Authorization has been Obtained </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to
comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compliance with the EU&#146;s stringent pharmacovigilance or safety reporting rules must be ensured. These
rules can impose post-authorization studies and additional monitoring obligations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#146;s license is
mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive (EU) 2017/1572, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good
Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and APIs, including the manufacture of APIs outside of the EU with the intention to import the APIs into the EU.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The marketing and promotion of authorized products, including industry-sponsored continuing medical education
and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the EU notably under Directive 2001/83/EC, as amended, and EU Member State laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aforementioned EU rules are generally applicable in the EEA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Reform of the Regulatory Framework in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current
regulatory framework in the EU for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval.
In April 2024, the European Parliament adopted its position on the legislative proposals. Once the European Commission&#146;s legislative proposals are approved (with or without amendment), they will be adopted into EU law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Brexit and the Regulatory Framework in the United Kingdom </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The UK ceased being a Member State of the EU on January&nbsp;31, 2020, and the EU and the UK have concluded a trade and
cooperation agreement (TCA), which was provisionally applicable since January&nbsp;1, 2021 and has been formally applicable since May&nbsp;1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition
of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented previous EU
legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework continues to apply in Northern Ireland). Except in
respect of the EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore aligns in many ways with current EU medicines regulations, however it is possible that these regimes will diverge more significantly in the future now
that Great Britain&#146;s regulatory system is independent from the EU </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under
the TCA, under a new international recognition framework which was put in place by the MHRA on January&nbsp;1, 2024, the MHRA may take into account decisions on the approval of marketing authorizations from the EMA (and certain other regulators)
when considering an application for a Great Britain or UK marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;27, 2023, the UK
government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#147;Windsor Framework.&#148; This new framework fundamentally changes the
existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (i.e., Great
Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single <FONT STYLE="white-space:nowrap">UK-wide</FONT> marketing authorization will be granted by the MHRA for
all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the <FONT STYLE="white-space:nowrap">EU-UK</FONT> Joint Committee on
March&nbsp;24, 2023, so the UK government and the EU will enact legislative measures to bring it into law. On June&nbsp;9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January&nbsp;1, 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Review and Approval of Medicinal Products in Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Therapeutic Goods Administration (TGA) and the National Health and Medical Research Council (NHMRC) set the GCP
requirements for clinical research in Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance with the regulations, standards and codes set by the TGA and
NHMRC is mandatory. Under the <I>Therapeutic Goods Act 1989</I> (Cth) and the <I>Therapeutic Goods Regulations 1990</I> (Cth), it is a condition (amongst other conditions) of all clinical trials involving investigational medicinal products to comply
with the National Statement on Ethical Conduct in Research Involving Humans, published by the NHMRC (the National Statement), and the Guideline for Good Clinical Practice published by the International Council for Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH Guidelines). The ICH Guidelines have been adopted in Australia, and must be complied with across all fields of clinical research involving therapeutic goods, including those related
to pharmaceutical quality, nonclinical and clinical data requirements and trial designs. The basic requirements for preclinical data to support a first-in-human trial under ICH Guidelines are applicable in Australia. Requirements related to adverse
event reporting in Australia are generally similar to those required in other major jurisdictions (and there is alignement with the European Union&#146;s Clinical Trial Regulations: Regulation EU&nbsp;No&nbsp;536/2014), although reporting timeframes
may differ to other jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials conducted using &#147;unapproved therapeutic goods&#148; in Australia,
being those which have not yet been evaluated by the TGA for quality, safety and efficacy (and including unapproved indications of therapeutic goods which have otherwise been approved for use in Australia) must occur pursuant to either the Clinical
Trial Notification Scheme (CTN Scheme) or the Clinical Trial Approval Scheme (CTA Scheme). In each case, the trial is supervised by a Human Research Ethics Committee (HREC), an independent review committee constituted in accordance with the National
Statement that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. A HREC reviews, approves and provides continuing oversight of trial protocols (including any amendments), methods and materials
intended to be used in obtaining and documenting informed consent of the clinical trial subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The CTN Scheme broadly
involves: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the investigator or sponsor of the Australian clinical trial submitting a &#145;Notification of Intent to
Conduct a Clinical Trial&#146; form (CTN Form) to the TGA and payment of the relevant fee (for unapproved medicines, this was AUD&nbsp;429 at 1&nbsp;July 2024: <I>Therapeutic Goods Regulations</I> 1990, clause&nbsp;3, Schedule&nbsp;9,
item&nbsp;14(a)); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the TGA may request further specific information relating to the &#145;unapproved therapeutic goods&#146; that
are the subject of the clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to a HREC, of all material relating to the proposed clinical trial, including the trial protocol;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the HREC reviews the scientific validity of the trial design, the balance of risk versus harm of the
therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol. The HREC is also responsible for monitoring the conduct of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the institution or organization at which the trial will be conducted, referred to as the &#147;Approving
Authority,&#148; giving final approval for the conduct of the trial at the site, in terms no less restrictive to those advised by the HREC; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensuring that the CTN form is signed by the sponsor, the principal investigator, the chairman of the HREC and
a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial, however CTN trials cannot commence until the trial has been notified to the TGA. It is the responsibility of the sponsor to ensure
that all relevant approvals are in place before supplying the &#145;unapproved&#146; therapeutic goods in the clinical trial in Australia. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the CTA Scheme: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment, which
includes payment of the relevant fees (for unapproved medicines, this was AUD&nbsp;2,046 for a <FONT STYLE="white-space:nowrap">30-day</FONT> evaluation and AUD&nbsp;25,426 for a <FONT STYLE="white-space:nowrap">50-day</FONT> evaluation, as at
1&nbsp;July 2024: <I>Therapeutic Goods Regulations</I> 1990, clause&nbsp;3, Schedule&nbsp;9, items&nbsp;1(a) and (b) respectively). The TGA encourages all sponsors to request a <FONT STYLE="white-space:nowrap">pre-submission</FONT> meeting with the
TGA in order to clarify any questions about existing studies or the proposed data package for the CTA application, and obtain specific advice from the TGA relating to the CTA application process, including the best ways to submit the application and
dossier; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the TGA will undertake a preliminary assessment to ensure that there is sufficient data to begin evaluation.
If critical data is missing, the TGA may request further information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a sponsor must forward any comments made by the TGA Delegate to the HREC(s) at the sites where the trial will
be conducted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A sponsor cannot commence a trial under the CTA Scheme until written advice has been received from the
TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Approval for inclusion in the Australian Register of Therapeutic Goods (ARTG), is required before a therapeutic good
(including pharmaceutical product) may be marketed (or supplied, imported, exported or manufactured) in Australia. Exceptions apply to therapeutic goods/pharmaceutical products that are supplied, imported, and exported to and from Australia for the
purposes of a clinical trial, on the basis that certain conditions are met (e.g., the trial is conducted in accordance with the CTN or CTA scheme). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once a sponsor decides to register a therapeutic good/pharmaceutical product in Australia, in order to obtain registration of
the product on the ARTG, it is required that (amongst others): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sponsor submits appropriate documentation, including the outcomes of clinical trials and studies, to allow
the TGA to assess the quality, safety and efficacy of the therapeutic product/pharmaceutical product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sponsor submits evidence which demonstrates that the manufacture of the therapeutic product/pharmaceutical
product complies with the applicable GMP requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The TGA has the ultimate discretion to decide
whether to include the therapeutic product/pharmaceutical product in the ARTG. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants,
third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved,
imprisonment, and exclusion from government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act (FCA), which can be enforced
through civil &#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be
presented, claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money
to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are
deemed to &#147;cause&#148; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or
making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of
violating these statutes without actual knowledge of the statutes or specific intent to violate them in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH),
imposes requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of,
individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended
HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek
attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even when HIPAA/HITECH do not apply, according to the Federal Trade Commission (FTC), failing to take
appropriate steps to keep consumers&#146; personal information secure constitutes unfair acts or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act, 15 U.S.C. &#167; 45(a). The FTC expects a company&#146;s data security measures to be
reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable
health information is considered sensitive data that merits stronger safeguards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Reconciliation Act (collectively, the ACA) and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Department of Health and Human Services (HHS) information related to payments or other transfers of value made to physicians (defined to
include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals (i.e., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered
nurse anesthetists, and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require us to calculate and report complex pricing metrics in
an accurate and timely manner to government programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims,
consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or
services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and
marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical
sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If our operations are found to be in violation of any of such laws or any other
governmental regulations that apply, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity
oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers
performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which
third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product.
Factors payors consider in determining coverage and reimbursement are based on whether the product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors.
Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price
or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost- effectiveness of medical products
and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct
expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need
to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could
reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a third-party payor&#146;s decision to provide coverage for a product does not imply
that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage
and reimbursement can differ significantly from payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The containment of healthcare costs has become a priority
of federal, state and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting
coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs,
including price controls, restrictions on reimbursement and requirements for substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by
any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with
predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the
level of reimbursement. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the
government, such as average sales price (ASP) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the
sale of any approved products. Even if we do receive a favorable coverage determination for approved products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example,
the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their commercial products, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
has resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing
of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that
compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or <FONT
STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU Member States have the option to restrict the range of products for which their national health
insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability
of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many
countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by
many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and
regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between <FONT
STYLE="white-space:nowrap">low-priced</FONT> and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow
favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Current and Future U.S.
Healthcare Reform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, there have been a number of legislative and regulatory changes to the
healthcare system that could impact our ability to sell our products profitably. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly
affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA, among other
things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to
23.1% of the average manufacturer price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required collection of rebates for drugs paid by Medicaid managed care organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer
50&nbsp;percent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D (later increased to 70%); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposed a <FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or
importers who sell &#147;branded prescription drugs&#148; to specified federal government programs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its enactment, there have been judicial, administrative, executive,
and legislative challenges to certain aspects of the ACA as well as executive orders related to the ACA&#146;s implementation. For example, President Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In
addition, on June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. It is unclear how other healthcare reform
measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare,
review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the Inflation Reduction Act of 2022 (IRA), among other things, (i)&nbsp;directs HHS to
negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than
the negotiated &#147;maximum fair price&#148; for such drugs and biologics under the law and (ii)&nbsp;imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that
outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions took effect progressively starting in fiscal year 2023. On August&nbsp;29, 2023, HHS
announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have
a significant impact on the pharmaceutical industry. Further, on December&nbsp;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of <FONT STYLE="white-space:nowrap">march-in</FONT>
rights under the Bayh-Dole Act. On December&nbsp;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of
<FONT STYLE="white-space:nowrap">March-In</FONT> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights. While <FONT
STYLE="white-space:nowrap">march-in</FONT> rights have not previously been exercised, it is uncertain if that will continue under the new framework. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2020, FDA released its implementing regulations regarding section 804 Importation Programs under the Medicare Prescription
Drug Improvement and Modernization Act of 2003. These regulations provide guidance for states to build and submit importation plans for certain drugs from Canada. On September&nbsp;25, 2020, CMS stated drugs imported by states under this rule will
not be eligible for federal rebates under Section&nbsp;1927 of the Social Security Act and manufacturers would not report these drugs for &#147;best price&#148; or Average Manufacturer Price purposes. Since these drugs are not considered covered
outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. On January&nbsp;5, 2024, the FDA approved Florida&#146;s Section&nbsp;804 Importation Program (SIP) proposal to import certain drugs
from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also
submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, on December&nbsp;2, 2020, HHS published a regulation removing safe harbor protection for price reductions from
pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The IRA delayed implementation of this rule to
January&nbsp;1, 2032. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other legislative and regulatory changes have been proposed and adopted in
the United States since the ACA was enacted: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to
providers of 2% per fiscal year, and, due to subsequent legislative amendments to the statute, will remain in effect until 2032. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to
several types of providers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100%
of a drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, effective January&nbsp;1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise
affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The IRA also includes several other provisions that may impact our business to varying degrees, including
provisions that create a $2,000 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cap for Medicare Part D beneficiaries, and impose new manufacturer financial liability on all drugs in Medicare Part D.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Individual states have also been increasingly active in passing legislation and implementing
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and
which suppliers will be included in their prescription drug and other health care programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
state governments will pay for healthcare products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although a number of these and other proposed measures
may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new
legislative measures to control drug costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Data Protection, Privacy, and Security </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, we collect, transmit, store, use, disclose, transfer, maintain and otherwise process
sensitive information, including personal data. Accordingly, we are, or may be become, subject to numerous data protection, privacy, and security obligations, including global, federal, state, and local laws, rules, regulations, guidance, industry
standards, external and internal privacy and security policies, contractual requirements and other obligations related to data protection, privacy, and security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These data protection, privacy, and security obligations are evolving and may impose potentially conflicting obligations. Such
obligations may include, without limitation, federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., the
Federal Trade Commission Act). In addition, in the past few years, numerous U.S. states have passed, or are in the process of enacting, comprehensive privacy laws, rules, and regulations that impose certain obligations on covered businesses, and
similar laws are being considered in several other states, as well as at the federal level. While these laws exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and are examples
of the increasingly stringent and evolving regulatory frameworks related to personal data processing, as more fully discussed in the section titled &#147;Risk Factors&#148; included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, to the extent we collect personal data from individuals
outside of the United States, through clinical trials or otherwise, we are, or may become, subject to foreign data protection, privacy, and security laws, such as the European Union&#146;s General Data Protection Regulation (EU GDPR) and the EU GDPR
as incorporated into U.K. domestic law post-Brexit (UK GDPR). Such foreign data protection, privacy, and security laws impose significant and complex compliance obligations on entities that are subject to those laws, as more fully discussed in the
section titled &#147;Risk Factors&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, we had 68 full-time employees, of which 41 have M.D. or Ph.D. degrees. Within our workforce, 52
employees are engaged in research and development and 16 are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining
agreements. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our human capital resources objectives include,
as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the
granting of equity-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our corporate headquarters are located in South San Francisco, California, where we lease and occupy approximately 44,819
square feet of combined office, research and laboratory space at 250 East Grand Avenue, South San Francisco, California 94080. The current term of our lease expires in July 2032. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that our existing facilities are adequate for our current needs and for the foreseeable future. To meet the future
needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may become involved in or be subject to legal proceedings, claims and litigation arising from the
ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an
adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the name, age and position of each of our executive officers and directors as of the date of
this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Executive Officers and Employee Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey Finer, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">58</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Executive Officer, President and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liz Bhatt, M.S., M.B.A.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">57</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Operating Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jae B. Kim, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">55</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief Medical Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Samira Shaikhly</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">55</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chief People Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ran Xiao, M.B.A., CFA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim Chief Financial Officer and Vice President, Finance and Business Operations</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Uwe Klein, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior Vice President, Biological Sciences</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel Long, D.Phil.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">51</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior Vice President, Drug Discovery</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jeffrey Tong, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">49</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Chairman and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Abraham Bassan, M.S.<SUP STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">40</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Alan Ezekowitz, M.D., D.Phil.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">70</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bernard Coulie, M.D., Ph.D., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">58</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shalini Sharp, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(1)(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">49</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jake Simson, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">39</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of our compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of our nominating and corporate governance committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Member of our audit committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a biographical summary of the experience of our executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Executive Officers and Employee Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jeffrey Finer, M.D., </I></B><B><I>Ph.D</I></B><B><I>.,</I></B> has served as our President since December 2019, and as
Chief Executive Officer and as a member of our board of directors since November 2021. Since 2016, Dr.&nbsp;Finer has served as a Venture Partner at Third Rock Ventures, a healthcare venture firm, where he was involved in the founding and launching
of multiple biotech companies. Prior to joining us, Dr.&nbsp;Finer held positions as interim Chief Technology Officer at Ambys Medicines, Inc., a privately held cell and gene therapy company, from 2017 to May 2019, and at Maze Therapeutics, Inc., a
small-molecule precision medicine company, from 2016 to June 2019. Earlier in his career, Dr.&nbsp;Finer held numerous research and development leadership positions, including as Director, Drug Discovery Technologies at Cytokinetics, Inc. a
small-molecule biopharmaceutical company, from 1998 to 2007, as Vice President, Discovery at Five Prime Therapeutics, Inc. (acquired by Amgen, Inc. (Nasdaq: AMGN)), a protein therapeutics company, from January 2007 to August 2011, and as Vice
President, Molecular&nbsp;&amp; Cellular Biology and later as Vice President, Research Technology at Theravance Biopharma, Inc. (Nasdaq: TBPH), a publicly traded biopharmaceutical company focused on multiple therapeutic areas, from 2011 to 2016.
Dr.&nbsp;Finer obtained his B.S. in Chemistry and B.S. in Biology from the Massachusetts Institute of Technology and his M.D. and Ph.D. in Biochemistry from Stanford University School of Medicine. Dr.&nbsp;Finer completed residency training in
Internal Medicine at Stanford University School of Medicine, and residency training in Ophthalmology at Massachusetts Eye&nbsp;&amp; Ear Infirmary and Harvard Medical School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Finer is qualified to serve on our board of directors based on his extensive experience as a senior
executive in the pharmaceutical industry, his drug development expertise, his research work for both medical and academic institutions, his public company experience, as well as his knowledge of our company based on his role as our President and
Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Liz Bhatt, M.S., M.B.A.,</I></B> has served as our Chief Operating
Officer since June 2022. Prior to joining us, Ms.&nbsp;Bhatt held positions as Chief Business&nbsp;&amp; Strategy Officer at Applied Molecular Transport Inc. (merged with Cyclo Therapeutics, Inc.), a biopharmaceutical company, from September 2019 to
May 2022, as Chief Business Officer and later also as Chief Operating Officer of Achaogen, Inc., a publicly held commercial-stage antibiotics company which declared bankruptcy in April 2019, from September 2017 to June 2019, and in various senior
management positions at Gilead Sciences, Inc. (Nasdaq: GILD), a publicly traded biopharmaceutical company focused on treatments for viral, cancer and inflammatory disease, including Vice President, Corporate Development, from July 2006 to September
2017. Earlier in her career, Ms.&nbsp;Bhatt held numerous corporate development positions across a range of biotech and pharmaceutical companies, including at Maxygen, Inc. and Eli Lilly and Company. Ms. Bhatt previously served on the board of
directors of eFFECTOR Therapeutics, Inc. (f/k/a Locus Walk Acquisition Corporation), a then publicly traded clinical-stage biopharmaceutical company, from October 2020 to June 2024. Ms.&nbsp;Bhatt obtained her B.A. in Chemistry from Pomona College,
her M.S. in Biomedical Sciences from the University of California, San Diego and her M.B.A. from the Kellogg School of Management at Northwestern University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jae B. Kim, M.D</I></B><B></B><B><I>.</I></B><B></B><B><I></I></B>,<B><I></I></B> has served as our Chief Medical
Officer since September 2024. Prior to joining us, Dr.&nbsp;Kim served as Chief Medical Officer of Design Therapeutics, Inc. (Nasdaq: DSGN), a publicly traded biotechnology company, where he currently serves as a consultant on clinical development,
and Avidity Biosciences, Inc. (Nasdaq: RNA), a publicly traded biopharmaceutical company, from January 2022 to September 2024 and July 2020 to August 2021, respectively. From February 2016 to July 2020, Dr.&nbsp;Kim served as Clinical Research Head,
Chair of the Clinical Trial Review Board and Vice President of Clinical Development at Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a publicly traded biopharmaceutical company, where he oversaw the development of multiple clinical assets across
inborn errors of metabolism, cardiology, neurology and infectious disease. Prior to that, Dr.&nbsp;Kim served in roles of increasing responsibility at MyoKardia, Inc. (acquired by Bristol-Myers Squibb (NYSE: BMY)), a clinical-stage biopharmaceutical
company targeting therapies for cardiovascular disease, from November 2014 to January 2016, and at Amgen, Inc. (Nasdaq: AMGN), a publicly traded global biotechnology company, from December 2008 to October 2014. Dr.&nbsp;Kim is a board certified
cardiologist, was an NIH-funded Principal Investigator and served on the Faculty of Medicine at Harvard Medical School and the Brigham and Women&#146;s Hospital before joining the biotechnology industry. Dr.&nbsp;Kim received his B.A. in Biological
Sciences from Cornell University and his M.D. from Cornell University Medical College. He completed his post-doctoral fellowship in Genetics at Harvard Medical School and his clinical training in Cardiovascular Disease at the Brigham and
Women&#146;s Hospital and Massachusetts General Hospital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Samira Shaikhly</I></B> has served as our Chief People
Officer since February 2023. Prior to joining us, Ms.&nbsp;Shaikhly was the Chief People Officer at Ambys Medicines, Inc. (the IP of which was later acquired by Cytotheryx, Inc.) (Ambys Medicines), a privately held cell and gene therapy company,
from April 2022 to November 2022, where she led the People&nbsp;&amp; Culture function as the company evolved from a research-focused to a development-focused organization. Prior to Ambys Medicines, Ms.&nbsp;Shaikhly held various roles of increasing
responsibility, including Global Head of Human Resources, Corporate Functions Business Partners, at Gilead Sciences, Inc. (Nasdaq: GILD), a publicly traded biopharmaceutical company focused on treatments for viral, cancer and inflammatory disease,
from September 2006 to September 2021, where she was responsible for all general and administrative human resources functions. Earlier in her career, Ms.&nbsp;Shaikhly held human resource roles in the technology and retail sectors. Ms.&nbsp;Shaikhly
obtained her B.A. in Communication Arts from the University of San Francisco and is a certified Executive Coach from New Ventures West. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ran Xiao, M.B.A.</I></B><B>, </B><B><I>CFA</I></B><B></B>, has served as our Interim Chief Financial Officer since
October&nbsp;2024 and has served as our Vice President of Finance and Business Operations beginning March 2022. Prior to joining us, from January 2018 to March 2022, Ms.&nbsp;Xiao served as the Vice&nbsp;President of Finance and Corporate Controller
at Ambys Medicines, Inc. (the IP of which was later acquired by Cytotheryx, Inc.) (Ambys Medicines), a privately held cell and gene therapy company. Before joining Ambys Medicines, from August 2015 to December 2017, Ms.&nbsp;Xiao served as the
Corporate Controller at Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a publicly traded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical stage biopharmaceutical company, where she played a key role in the company&#146;s initial public offering. Previously, from August 2012 to December 2014, Ms.&nbsp;Xiao served in roles
of increasing responsibility at InterMune, Inc. (acquired by Roche Holding AG), a privately held biotechnology company, most recently as the Senior Director of Business Process, and was part of the team responsible for accounting operations,
financial planning, system implementation and business acquisition. Ms.&nbsp;Xiao received her B.A. in Accounting from Shanghai University of Finance and Economics and her M.B.A. from the Illinois Institute of Technology. Ms.&nbsp;Xiao holds the
Chartered Financial Analyst designation from the CFA Institute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Uwe Klein,
</I></B><B><I>Ph.D</I></B><B><I>.,</I></B> has served as our Senior Vice President, Biological Sciences since August 2021. Dr.&nbsp;Klein has over 25 years of experience in small molecule drug discovery and deep expertise in GPCR biology. Prior to
joining us, Dr.&nbsp;Klein was Vice President, Biology at MyoKardia, Inc. (acquired by Bristol-Myers Squibb (NYSE: BMY) (BMS)), a clinical-stage biopharmaceutical company targeting therapies for cardiovascular disease, from October 2019 to November
2020, and then Vice President, Biology at BMS following the acquisition, from November 2020 to March 2021. Earlier in his career, Dr.&nbsp;Klein held positions as Vice President, Biology at Numerate, Inc. (acquired by Valo Health, Inc.), a
privately-held dug discovery company applying novel machine learning algorithms to drug design, from October 2014 to September 2019, and as Senior Director, Molecular&nbsp;&amp; Cellular Biology at Theravance, from September 1998 to October 2014.
Dr.&nbsp;Klein obtained his B.S. and M.S. in Chemistry, and his Ph.D. in Biochemistry, from Goethe University Frankfurt, Germany. He also earned a certificate in Bioinformatics at the University of California, Santa Cruz, and completed his
post-doctoral fellowships in Molecular&nbsp;&amp; Cellular Biology from University of California, San Francisco and Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Daniel Long, D.</I></B><B><I>Phil</I></B><B><I>.,</I></B> has served as our Senior Vice President, Drug Discovery since
December 2021. Prior to joining us, Dr.&nbsp;Long spent over 20 years, from January 2001 to December 2021, at Theravance Biopharma, Inc. (Nasdaq: TBPH), a publicly traded biopharmaceutical company focused on chronic obstructive pulmonary disease
treatments, where he held numerous scientist positions, including as Vice President, Head of Medicinal Chemistry, Biology and Pharmacology. Dr.&nbsp;Long obtained his B.A., M.A. and D. Phil. in Chemistry from the University of Oxford and completed
an industrial post-doctoral fellowship at DuPont Pharmaceuticals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jeffrey Tong, Ph.D., </I></B>has served as a member of our board of directors since December 2019, as Chairman
of our board of directors since November 2021, and previously served as our interim Chief Executive Officer from December 2019 to November 2021. From December 2021 to October 2023, he was interim Chief Executive Officer of Marea Therapeutics, Inc.,
a privately held biotechnology company. Dr.&nbsp;Tong is currently a Partner at Third Rock Ventures, where he has worked since May 2016. Earlier in his career, Dr.&nbsp;Tong served as the Executive Chairman of the board of directors of Delinia, Inc.
(acquired by Celgene Corporation) and President and Chief Executive Officer of Nora Therapeutics, Inc., each a privately held biotechnology company. Prior to that, Dr.&nbsp;Tong was VP of Corporate and Product Development at Infinity
Pharmaceuticals, Inc., held a position at McKinsey&nbsp;&amp; Co., and was a founding researcher at the Harvard Bauer Center for Genomics Research. Dr.&nbsp;Tong has served as a member of the board of directors of Rapport Therapeutics, Inc. (Nasdaq:
RAPP), a publicly traded precision small molecule biopharmaceutical company, since December 2022, as well as on the boards of directors of numerous privately held biotechnology companies. Dr.&nbsp;Tong previously served on the board of directors of
Nurix Therapeutics, Inc. (Nasdaq: NRIX), from February 2018 to May 2022. Dr.&nbsp;Tong obtained his A.B. in Biochemical Sciences from Harvard University, his A.M. and Ph.D. in Chemistry from Harvard Graduate School of Arts and Sciences and his
M.M.S. from Harvard Medical School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Tong is qualified to serve on our board of directors based
on his significant experience building and leading successful biotechnology companies and his scientific expertise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Abraham Bassan, M.S.,</I></B> has served as a member of our board of directors since November 2021. Since April 2021,
Mr.&nbsp;Bassan has served as a Principal at Samsara, a privately held life science investment firm, where </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
he served as a Vice President from July 2017 to April 2021. Since May 2022, Mr. Bassan has served as the interim CEO, President and a Director at Link Cell Therapies Inc., a privately held
biotechnology company. From February 2021 to May 2022, Mr.&nbsp;Bassan served as President of Cargo Therapeutics, Inc. (Nasdaq: CRGX), a then privately held clinical-stage cell therapies company (Cargo Therapeutics). Prior to that, from December
2014 to July 2017, Mr.&nbsp;Bassan served as Director of Program Biology at Revolution Medicines, Inc. (Nasdaq: RVMD), a then privately held oncology company. Prior to that, from September 2012 to September 2014, Mr.&nbsp;Bassan served as the
founder and Chief Executive Officer of Aurora Medical, Inc., a privately held molecular diagnostics testing services company. From 2010 to 2012, Mr.&nbsp;Bassan served as an Associate Director of Program Management at bluebird bio, Inc. (Nasdaq:
BLUE) (bluebird bio), a then privately held biotechnology company, where he was the Project Manager for several of the company&#146;s gene therapy programs. Earlier in his career, Mr.&nbsp;Bassan was an Associate at Third Rock Ventures, where he
played a leading role in the firm&#146;s investment in bluebird bio, as well as the ideation of Blueprint Medicines Corporation (Nasdaq: BPMC), a publicly traded precision medicine oncology company. Mr.&nbsp;Bassan currently serves on the board of
directors of Cargo Therapeutics. Mr.&nbsp;Bassan previously served on the board of directors of Graphite Bio, Inc. (merged with LENZ Therapeutics, Inc. (Nasdaq: LENZ)), from June 2020 to March 2024, and on the boards of directors of numerous
privately held biotechnology companies. Mr.&nbsp;Bassan obtained his B.A. in Molecular Biology from Princeton University and his M.S. in Developmental Biology from Stanford University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Mr.&nbsp;Bassan is qualified to serve as a member of our board of directors because of his education and
experience in the life sciences and oncology fields, venture capital experience, as well as his service on the boards of directors of numerous companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Alan Ezekowitz, M.D., D.</I></B><B><I>Phil</I></B><B><I>.,</I></B> has served as a member of our board of directors
since December 2022, and previously served as our interim Chief Medical Officer from January 2022 to September 2024. Dr.&nbsp;Ezekowitz has served as an Advisory Partner at Third Rock Ventures, a leading biotech venture and company-formation fund,
since January 2023, and was previously a Venture Partner at Third Rock Ventures from December 2019 to December 2022. Previously, from November 2011 to June 2019, Dr.&nbsp;Ezekowitz served as the President and Chief Executive Officer of Abide
Therapeutics, Inc., a privately held biopharmaceutical company that he <FONT STYLE="white-space:nowrap">co-founded,</FONT> which he oversaw through its acquisition by H. Lundbeck A/S in 2019. Earlier in his career, from March 2006 to March 2011,
Dr.&nbsp;Ezekowitz was the Senior Vice President and Franchise Head at Merck Research Laboratories (Merck), a healthcare company, where he was responsible for the bone, respiratory, immunology, inflammation, dermatology, and endocrine franchises.
Prior to joining Merck, Dr.&nbsp;Ezekowitz served at the Harvard Medical School as the Charles Wilder Professor of Pediatrics from June 1995 to March 2005, as the Head of Laboratory for Development Immunology and Principal of the Cancer Center and
later as Chief of Pediatric Services at the Massachusetts General Hospital for Children from June 1995 to April 2006, and as a director of the Partners Healthcare System from 2000 to 2006. Dr.&nbsp;Ezekowitz currently serves as a member of the
boards of directors of Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a publicly traded small molecule drug discovery company, and Organon&nbsp;&amp; Co., a global healthcare company. Dr.&nbsp;Ezekowitz was honored in 2008 with the establishment of the
R. Alan B. Ezekowitz Professorship in Pediatrics at Harvard Medical School. He was the Principal Investigator of an NIH Program Project Grant that included Jules Hoffman, Charles Janeway and Fotis Kafatos who led to the discovery of the TOLL
receptors and contributed greatly to the understanding of the field of the innate immunity. Dr.&nbsp;Ezekowitz obtained his M.D. from the University of Cape Town in South Africa and his D.Phil. in Cellular and Molecular Biology from the University
of Oxford. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Dr.&nbsp;Ezekowitz is qualified to serve on our board of directors because of his considerable
qualifications, attributes and skills, including his distinguished scientific background, experience in leadership roles in the biopharmaceutical industry, venture capital experience as well as his service on the boards of directors of numerous
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Bernard Coulie, M.D., </I></B><B><I>Ph.D</I></B><B><I>., M.B.A.,</I></B> has served as a member of our
board of directors since December 2023. Dr.&nbsp;Coulie has served as the President, Chief Executive Officer and a member of the board of directors of Pliant Therapeutics, Inc. (Nasdaq: PLRX) (Pliant), a publicly traded late-stage biopharmaceutical
company, since </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
February 2016. Prior to joining Pliant, Dr.&nbsp;Coulie <FONT STYLE="white-space:nowrap">co-founded</FONT> ActoGeniX N.V. (ActoGeniX), a biopharmaceutical company, and held roles of increasing
responsibility, including as Vice President R&amp;D, Chief Medical Officer, and Chief Executive Officer, from September 2006 until February 2015, when it was acquired by Intrexon Corporation. Prior to
<FONT STYLE="white-space:nowrap">co-founding</FONT> ActoGeniX, Dr.&nbsp;Coulie held various positions with increasing responsibility in drug discovery and clinical development at Johnson&nbsp;&amp; Johnson Pharmaceutical Research and Development
Europe. Earlier in his career, Dr.&nbsp;Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic, Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr.&nbsp;Coulie is
currently serving as a director and chairman of Dualyx N.V., a privately held biotechnology company based in Belgium, and as a member of the board of directors of Charcot- Marie-Tooth Association, a <FONT STYLE="white-space:nowrap">non-profit</FONT>
patient advocacy organization dedicated to the development of new drugs to treat Charcot-Marie-Tooth disease. Dr.&nbsp;Coulie previously served as a director of SQZ Biotechnologies Company (acquired by STEMCELL Technologies Canada Acquisitions,
Inc.) from July 2021 to March 2024, Calypso Biotech B.V. (acquired by Novartis AG (NYSE: NVS)) from February 2019 to January 2024, Myoscience, Inc. (acquired by Pacira BioSciences, Inc.) from June 2016 until March 2019, Biogazelle N.V. (acquired by
CellCarta Biosciences Inc.) from July 2015 until November 2018, and ActoGeniX (acquired by Intrexon Corporation) from April 2010 until February 2015. Dr.&nbsp;Coulie is a board-certified internist and received his M.D. and Ph.D. from the University
of Leuven, Belgium and his M.B.A. from the Vlerick Business School, Leuven, Belgium. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Dr.&nbsp;Coulie is
qualified to serve on our board of directors because of his extensive experience and expertise in operations management and executive leadership at various biopharmaceutical companies, as well as his service on the boards of directors of numerous
companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Shalini Sharp, M.B.A., </I></B>has served as a member of our board of directors since January 2024.
Prior to joining us, Ms.&nbsp;Sharp served as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceuticals Inc. (Nasdaq: RARE), a publicly traded biopharmaceutical company, from May 2012 to October 2020. Previously, from August
2003 to May 2012, Ms.&nbsp;Sharp held positions of increasing responsibility at Agenus, Inc. (Nasdaq: AGEN), a publicly traded clinical-stage immune-oncology company, including as Chief Financial Officer, and also served as a member of its board of
directors from May 2012 to June 2018. Earlier in her career, Ms.&nbsp;Sharp worked at Elan Pharmaceuticals, McKinsey&nbsp;&amp; Company, and Goldman Sachs. Ms.&nbsp;Sharp currently serves on the boards of directors of Beigene, Ltd. (Nasdaq: BGNE), a
publicly traded oncology company, Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a publicly traded biopharmaceutical company, and Organon&nbsp;&amp; Co (Nasdaq: OGN), a publicly traded healthcare company. Ms.&nbsp;Sharp previously served on the board
of directors of Mirati Therapeutics, Inc. (acquired by Bristol-Myers Squibb Company), a then publicly traded commercial-stage oncology company, from March 2021 to January 2024, Sutro Biopharma, Inc. (Nasdaq: STRO), a publicly traded
biopharmaceutical company, from November 2018 to November 2023, Precision BioSciences, Inc. (Nasdaq: DTIL), a publicly traded gene editing company, from December 2018 to June 2022 and Panacea Acquisition Corp. (Nasdaq: PANA), a special purpose
acquisition company, from June 2020 until the completion of its business combination in February 2021. Ms.&nbsp;Sharp obtained her B.A. in English and American Literature and Languages from Harvard College and her M.B.A. from Harvard Business
School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe Ms.&nbsp;Sharp is qualified to serve on our board of directors because of her extensive experience and
expertise in financial management and executive leadership at various biopharmaceutical companies, as well as her service on the boards of directors of numerous companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Jake Simson, Ph.D.,</I></B> has served as a member of our board of directors since June 2023. Dr.&nbsp;Simson has served
as a Partner at RA Capital, a multi-stage life sciences investment firm, since December 2020. From July 2013 to December 2020, Dr.&nbsp;Simson served as an Associate, Analyst and then a Principal at RA Capital. Dr.&nbsp;Simson currently serves on
the boards of directors of Bicara Therapeutics Inc. (Nasdaq: BCAX), a publicly traded biopharmaceutical company, Janux Therapeutics, Inc. (Nasdaq: JANX), a publicly traded immunotherapy company, and Tyra Biosciences, Inc. (Nasdaq: TYRA), a publicly
traded precision medicine company, as well as on the boards of directors of numerous privately-held biotechnology companies. Dr.&nbsp;Simson previously served on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the board of directors of Dice Therapeutics, Inc. (Nasdaq: DICE), a publicly traded biopharmaceutical company, from December 2020 until August 2023, when it was acquired by Eli Lilly and Company.
Dr.&nbsp;Simson obtained his S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and his Ph.D. in Biomedical Engineering from Johns Hopkins University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that Dr.&nbsp;Simson is qualified to serve on our board of directors because of his significant industry experience
as an investor in the biopharmaceutical industry and educational background. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors currently consists of seven members, each of whom is a member pursuant to the board composition
provisions of our current certificate of incorporation and agreements with our stockholders, which agreements are described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; These board composition provisions
will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board
of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting board members is
identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our
business, understanding of the competitive landscape, professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their
resignation or removal. Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which became effective upon the effectiveness of
our registration statement of which this prospectus forms a part, also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes that
all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority
of our directors then in office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Staggered Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms of our amended and restated certificate of incorporation, which will become effective immediately
prior to the completion of this offering, and our amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part, our board of directors will be divided into three
staggered classes of directors and each director will be assigned to one of the three classes. At each annual meeting of the stockholders, one class of directors will be elected for a three-year term to succeed the directors of the same class whose
terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2025 for Class&nbsp;I directors, 2026 for Class&nbsp;II
directors and 2027 for Class&nbsp;III directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;I directors will be Abraham Bassan, M.S. and Alan Ezekowitz, M.D., D.Phil;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;II directors will be Jake Simson, Ph. D. and Shalini Sharp, M.B.A.; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;III directors will be Jeffrey Finer, M.D., Ph.D., Bernard Coulie, M.D., Ph.D., M.B.A., and
Jeffrey Tong, Ph.D. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation, which will become effective
immediately prior to the completion of this offering, and our amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part, provide that the number of our directors
shall be fixed from time to time by a resolution of the majority of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The division of our board of directors into three classes with staggered
three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Director
Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our common stock has been approved for listing on the Nasdaq Global Market. Under the Nasdaq listing
rules, independent directors must comprise a majority of a listed company&#146;s board of directors within one year from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a
listed company&#146;s audit, compensation and nominating and governance committees be independent within one year from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq
listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not, other
than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its
subsidiaries, other than compensation for board service; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10C-1,</FONT>
the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#146;s
ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid
by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors undertook a review of the composition of our board of directors and
its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has
determined that all members of our board of directors, except Dr. Finer, Dr. Ezekowitz, and Dr. Tong, are independent directors, including for purposes of Nasdaq and the SEC rules. In making that determination, our board of directors considered the
current and prior relationships that each director has with us and all other facts and circumstances our board of directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our capital stock by each
director, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors that are affiliated with certain of our major stockholders, and the transactions described in the section titled &#147;Certain Relationships and Related Person
Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted a policy, subject to and effective upon the effectiveness of the registration
statement of which this prospectus forms a part, that outlines a process for our securityholders to send communications to our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Board Diversity Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have adopted policies and procedures for director candidates for our nominating and corporate governance committee, which
provides that the value of diversity should be considered in determining director candidates, as well as other factors, such as a candidate&#146;s character, judgment, skills, education, expertise, and absence of conflicts of interest. Our priority
in selection of board members will be identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture
among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
standards. Our nominating and corporate governance committee and our full board of directors are committed to creating a board of directors with diversity, including diversity of expertise,
experience, background, and gender, and are committed to identifying, recruiting, and advancing candidates offering such diversity in future searches. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Board Leadership Structure and Board&#146;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Currently, the role of chairman of our board of directors is separated from the role of Chief Executive Officer. We believe
that separating these positions allows our Chief Executive Officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing the chairman to lead our board of directors in its
fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the Chief Executive Officer is required to devote to his position in the current business
environment, as well as the commitment required to serve as our chairman, particularly as our board of directors&#146; oversight responsibilities continue to grow. While our amended and restated bylaws and corporate governance guidelines do not
require that our chairman and Chief Executive Officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate
governance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Risk is inherent with every business, and how well a business manages risk can ultimately determine its
success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction, and intellectual property as more fully discussed in the section titled
&#147;Risk Factors.&#148; Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees,
has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and
functioning as designed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The role of our board of directors in overseeing the management of our risks is conducted
primarily through committees of our board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. Our full board of directors (or the appropriate board committee in the case of
risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing
the management of a particular risk or risks, the chairman of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables our board of directors and its
committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Committees of Our Board of
Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has established an audit committee, a compensation committee and a nominating and
corporate governance committee, each of which will operate pursuant to a charter that has been adopted by our board of directors and became effective upon the effectiveness of the registration statement of which this prospectus forms a part. We
believe that the composition and functioning of all of our committees will comply with the applicable requirements of Nasdaq, the Sarbanes-Oxley Act and SEC rules and regulations that will be applicable to us. We intend to comply with future
requirements to the extent they become applicable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The full text of our audit committee charter, compensation
committee charter and nominating and corporate governance committee charter is posted on our website at <I>www.septerna.com</I>. We do not incorporate the information contained on, or accessible through, our corporate website into this prospectus,
and you should not consider it a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. Our board of directors may establish other committees as it deems necessary or appropriate
from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audit committee consists of Shalini Sharp, M.B.A., Abraham Bassan, M.S., and Jeffrey Tong, Ph.D. and is chaired by Ms.
Sharp. The functions of our audit committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public
accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of
management responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and
concerns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending based upon our audit committee&#146;s review and discussions with management and our independent
registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements
as they relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing our audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related party transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and
regulations of the SEC and the Nasdaq listing rules. Our board of directors has determined that Ms. Sharp qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC regulations. In making this determination,
our board of directors considered the nature and scope of experience that Ms. Sharp has previously had with public reporting companies, including her service as Chief Financial Officer of Ultragenyx Pharmaceuticals Inc. Our board of directors has
determined that Ms. Sharp and Mr. Bassan each satisfies the relevant independence requirements for service on our audit committee set forth in the rules of the SEC and the Nasdaq listing rules. We are relying on the phase-in exemption provided under
Rule 10A-3 of the Exchange Act and the Nasdaq listing rules with respect to the composition of our audit committee. Dr. Tong is an affiliate of Third Rock Ventures and may be deemed to beneficially own in excess of 10% of our common stock, as of the
date of this prospectus, which would leave him outside the safe harbor provision of Rule 10A-3 of the Exchange Act. Dr. Tong will serve on our audit committee under the phase-in exemption referenced above. In accordance with the phase-in exemption,
a majority of the members of our audit committee will satisfy the independence standards under the Exchange Act and the Nasdaq listing rules within 90 days of the date of effectiveness of the registration statement of which this prospectus forms a
part and all members of our audit committee will satisfy the independence standards under the Exchange Act and the Nasdaq listing rules within one year from the date of listing. Both our independent registered public accounting firm and management
will periodically meet privately with our audit committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee consists of Bernard Coulie, M.D., Ph.D., M.B.A., Shalini Sharp, M.B.A., and Jake Simson, Ph.D. and
is chaired by Dr. Coulie. The functions of our compensation committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and
based on such evaluation reviewing and recommending our Chief Executive Officer&#146;s compensation to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of all employees serving at or above the level of Senior Vice
President; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence
standards identified in the applicable Nasdaq listing rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and
when required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in
the evaluation of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each member of our compensation committee is a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue
Code of 1986, as amended (Code). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our nominating and corporate governance committee consists of Abraham Bassan, M.S., Bernard Coulie, M.D., Ph.D., M.B.A., and
Alan Ezekowitz, M.D., D.Phil. and is chaired by Mr. Bassan. Our board of directors has determined that each member of our nominating and corporate governance committee, except for Dr. Ezekowitz, is independent under the Nasdaq listing rules, a
non-employee director, and free from any relationship that would interfere with the exercise of his or her independent judgment. Dr. Ezekowitz, by virtue of his former position as our interim Chief Medical Officer, is not independent under
applicable rules and regulations of the SEC and the Nasdaq listing rules. We are relying on the phase-in exemption provided under Rule 10A-3 of the Exchange Act and the Nasdaq listing rules with respect to the composition of our nominating and
corporate governance committee. Dr. Ezekowitz will serve on our nominating and corporate governance committee under the phase-in exemption referenced above. In accordance with the phase-in exemption, a majority of the members of our nominating and
corporate governance committee will satisfy the independence standards under the Exchange Act and the Nasdaq listing rules within 90 days of the date of effectiveness of the registration statement of which this prospectus forms a part and all
members of our nominating and corporate governance committee will satisfy the independence standards under the Exchange Act and the Nasdaq listing rules within one year from the date of listing. The functions of our nominating and corporate
governance committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors criteria for board and committee membership;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees
recommended by stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our board of directors the persons to be nominated for election as directors and to each of
its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to our board of directors a code of business conduct and ethics and a set of
corporate governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of our compensation committee is, or has at any time during the prior three years been, one of our officers
or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of
directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors has adopted a written code of business conduct and ethics. The code of
business conduct and ethics apply to all of our directors, officers and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions). The full
text of our code of business conduct and ethics is posted on our website at <I>www.septerna.com</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to
disclose on our website any future amendments of our code of business conduct and ethics or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar
functions, or our directors from provisions in the code of business conduct and ethics. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We
have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Compensation Recovery </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors has adopted a compensation recovery policy that is compliant with the
Nasdaq listing rules, as required by the Dodd-Frank Act. The compensation recovery policy provides that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting
requirement under securities laws, we will seek to recover any incentive-based compensation that was based upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year
period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officers would have received based on the restated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation, which will become effective
immediately prior to the completion of this offering, and our amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part, limit or eliminate the personal liability
of directors and officers for a breach of their fiduciary duty of care as a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
director or officer. The duty of care generally requires that, when acting on behalf of the corporation, a director and or officer exercise an informed business judgment based on all material
information reasonably available to him or her. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s or officer&#146;s duty of loyalty to us or our stockholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in
Section&nbsp;174 of the Delaware General Corporation Law (DGCL); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for our officers, any derivative action by or in the right of the corporation; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to
seek <FONT STYLE="white-space:nowrap">non-</FONT> monetary relief, such as injunctive relief or rescission. These provisions will not alter a director or officer&#146;s liability under other laws, such as the federal securities laws or other state
or federal laws. Our amended and restated certificate of incorporation that will become effective immediately prior to the completion of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent
permitted under Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As permitted by Delaware law, our amended and restated bylaws, which became effective upon
the effectiveness of the registration statement of which this prospectus forms a part, provide that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other
agents, in connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director
or officer, then the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer,
director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained such insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the indemnification that will be provided for in our amended and restated certificate of incorporation and
amended and restated bylaws, we have entered into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the DGCL. These indemnification
agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any
action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to
attract and retain qualified individuals to serve as directors and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This description of the
indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an
exhibit to the registration statement of which this prospectus forms a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the
Securities Act, and is, therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no pending litigation or proceeding naming any of our
directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations
and determinations regarding our future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in
this discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As an emerging growth company, we have opted to comply with the executive compensation disclosure rules
applicable to &#147;smaller reporting companies,&#148; as such term is defined in the rules promulgated under the Exchange Act. The compensation provided to our named executive officers (NEOs) for the fiscal year ended December&nbsp;31, 2023 is
detailed in the &#147;<I>2023 Summary Compensation Table</I>&#148; and accompanying footnotes and narrative that follow. Our NEOs for the fiscal year ended December&nbsp;31, 2023 consist of our Chief Executive Officer and the two most highly
compensated executive officers (other than our Chief Executive Officer) who were serving as our executive officers on December&nbsp;31, 2023. In addition, while we are required to disclose a total of three NEOs, we are voluntarily including two
additional NEOs, Drs. Long and Klein, given their roles with the Company during the fiscal year ended December&nbsp;31, 2023. Accordingly, our NEOs for the fiscal year ended December&nbsp;31, 2023 are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jeffrey Finer, M.D., Ph.D., our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Liz Bhatt, M.S., M.B.A., our Chief Operating Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Samira Shaikhly, our Chief People Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Long, D.Phil., our Senior Vice President, Drug Discovery; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Uwe Klein, Ph.D., our Senior Vice President, Biological Sciences. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, the compensation of our NEOs has consisted of a combination of base salary, cash bonuses and long-term incentive
compensation in the form of restricted stock awards and stock options. Our NEOs who are full-time employees are eligible to participate in our health and welfare benefit plans and 401(k) plan like all of our full-time employees. As we transition
from a private company to a publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2023 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information regarding compensation awarded to, earned by, and/or paid to our NEOs for services
rendered to us in all capacities during the fiscal year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal<BR>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Finer, M.D., Ph.D.<BR><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">501,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">284,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,347,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,136,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liz Bhatt, M.S., M.B.A.<BR><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">203,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">883,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samira Shaikhly,<I><BR>Chief People
Officer<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">322,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">742,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Long, D.Phil.,<BR><I>SVP, Drug Discovery</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">369,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212,090</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uwe Klein, Ph.D.,<BR><I>SVP, Biological Sciences</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">363,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">578,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported consist of (i)&nbsp;for Dr.&nbsp;Finer, Ms.&nbsp;Bhatt, Ms.&nbsp;Shaikhly,
Dr.&nbsp;Long and Dr.&nbsp;Klein, $284,310, $203,270, $132,094, $149,590 and $149,607, respectively, for discretionary annual bonuses earned for the fiscal year ended December&nbsp;31, 2023 and (ii)&nbsp;for Ms.&nbsp;Shaikhly and Dr.&nbsp;Long,
$50,000 and $62,500, respectively, for <FONT STYLE="white-space:nowrap">sign-on</FONT> bonuses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent the aggregate grant date fair value of stock options awarded to our NEOs
during the fiscal year ended December&nbsp;31, 2023, calculated in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic&nbsp;718, disregarding estimated forfeitures related to service-based
vesting. For a description of the assumptions used in determining these values, see Note&nbsp;10&#151;&#147;<I>Stock-Based Compensation</I>&#148; to our financial statements included elsewhere in this prospectus. The amount reported in this column
reflects the accounting cost for the stock options and does not correspond to the actual economic value that may be received by our NEOs upon the exercise of the stock options or any sale of the underlying shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent 401(k) matching contributions made by the Company to our NEOs.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Shaikhly commenced employment with the Company on February&nbsp;1, 2023 and her annual base salary
and annual bonus for 2023 were <FONT STYLE="white-space:nowrap">pro-rated</FONT> accordingly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Long commenced employment with the Company on October&nbsp;4, 2021 and his <FONT
STYLE="white-space:nowrap">sign-on</FONT> bonus was paid in two tranches: (i) $62,500 within 30 days of January&nbsp;1, 2022 and (ii)&nbsp;$62,500 within 30 days of January&nbsp;1, 2023, subject to his continued employment with the Company through
each such date of payment. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Narrative to the 2023 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2023 Base Salaries </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our NEOs each receive a base salary to compensate them for services rendered to us. The base salary payable to each NEO is
intended to provide a fixed component of compensation reflecting the executive&#146;s skill set, experience, role and responsibilities. Base salaries are reviewed annually, typically in connection with our annual performance review process, approved
by our board of directors or the compensation committee of our board of directors (compensation committee), and may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities,
performance, and experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From January&nbsp;1, 2023 through October&nbsp;31, 2023, the annual base salaries for
Dr.&nbsp;Finer, Ms.&nbsp;Bhatt and Dr.&nbsp;Klein were $496,375, $409,863, and $362,472, respectively. Ms.&nbsp;Shaikhly commenced employment with us on February&nbsp;1, 2023 and her annual base salary from February&nbsp;1, 2023 through
October&nbsp;31, 2023 was $350,000. Effective November&nbsp;1, 2023, the annual base salaries for Dr.&nbsp;Finer, Ms.&nbsp;Bhatt, Ms.&nbsp;Shaikhly, and Dr.&nbsp;Klein increased to $526,500, $430,200, $357,500, $369,400, respectively.
Dr.&nbsp;Long&#146;s annual base salary for the entire fiscal year ended December&nbsp;31, 2023 was $369,357. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2023 Cash Incentive
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the fiscal year ended December&nbsp;31, 2023, each of our NEOs was eligible to earn a
discretionary annual bonus based on the Company&#146;s achievement of certain corporate performance objectives, as determined by our board of directors. The 2023 target annual bonuses for Dr. Finer and Ms. Bhatt were 40% and 35%, respectively, and
30% for Ms. Shaikhly, Dr. Long and Dr. Klein, of the applicable NEO&#146;s annual base salary. The corporate performance objectives for our NEOs&#146; 2023 annual bonuses were based on the Company&#146;s achievement of certain program, platform and
finance/business development goals, which were determined to have been achieved at 135% of target. The discretionary annual bonuses received by each NEO with respect to the fiscal year ended December&nbsp;31, 2023 were $284,310, $203,270, $132,094,
$149,590 and $149,607 for Dr.&nbsp;Finer, Ms.&nbsp;Bhatt, Ms.&nbsp;Shaikhly, Dr.&nbsp;Long and Dr.&nbsp;Klein, respectively. Ms.&nbsp;Shaikhly&#146;s 2023 annual bonus was <FONT STYLE="white-space:nowrap">pro-rated</FONT> based on her commencement
of employment with the Company effective February&nbsp;1, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with Ms.&nbsp;Shaikhly&#146;s and
Dr.&nbsp;Long&#146;s commencement of employment, they were also entitled to a $50,000 and $62,500, respectively, <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus payable in 2023, subject to their continued employment with the Company through
the date of payment. For Ms.&nbsp;Shaikhly, her <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus is subject to full repayment if she (i)&nbsp;is terminated by the Company for &#147;cause,&#148; as defined in the Shaikhly Offer Letter (as
defined below) or (ii)&nbsp;resigns from the Company for any reason, in either case prior to the second anniversary of the payment of the <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Equity-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we
believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote
executive retention because they incentivize our executive officers to remain in our employment during the vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, our board of directors periodically reviews the equity incentive compensation of our executive officers and may
grant equity incentive awards to them from time to time. During the fiscal year ended December&nbsp;31, 2023, we granted option awards to our NEOs under the 2021 Plan as described in more detail in the &#147;<I>Outstanding Equity Awards at 2023
Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT></I>&#148; table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Perquisites or Personal Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Perquisites and other personal benefits are not a significant component of our executive compensation program. Accordingly, we
do not provide perquisites or personal benefits to our NEOs with an aggregate amount equal to or greater than $10,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>401(k) Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently maintain a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) retirement savings plan
(401(k) plan) for our employees, including our NEOs, who satisfy certain eligibility requirements. Our NEOs are eligible to participate in the 401(k) plan on the same terms as other full-time employees. Our 401(k) plan is intended to qualify for
favorable tax treatment under Section&nbsp;401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. Our 401(k) plan allows for discretionary matching contributions under
the plan and in 2023, we provided discretionary matching contributions equal to 50% of up to the first 8% of eligible compensation, capped at $3,000 annually per employee. We believe that providing a vehicle for
<FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our NEOs, in accordance with our
compensation policies. Other than the 401(k) plan, we do not provide any qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> retirement or deferred compensation benefits to our employees, including our NEOs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Executive Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into an offer letter with each of our NEOs in connection with his or her employment with us, which set forth
the terms and conditions of his or her employment, as applicable. The material terms of such offer letters are described below. In connection with this offering, we have adopted a new executive severance plan (Executive Severance Plan), which will
become effective upon the closing of this offering. Each of the NEOs may participate in the Executive Severance Plan. The Executive Severance Plan provides for certain payments and benefits in the event of a termination of employment, including an
involuntary employment in connection with a change in control of the Company, and will replace the severance provisions in the NEOs&#146; offer letters, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Prior Employment Arrangements in Place During the 2023 Fiscal Year </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Jeffrey Finer, M.D., Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;9, 2022, we entered into an offer letter with Dr.&nbsp;Finer effective as of September&nbsp;13, 2022, for the
position of our Chief Executive Officer (Finer Offer Letter). The Finer Offer Letter provided for Dr.&nbsp;Finer&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial target annual bonus,
each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Finer Offer Letter also provided for a one-time $100,000 sign on bonus and the
grant of an award of restricted stock. Dr.&nbsp;Finer is eligible to participate in the employee benefit plans generally available to our employees, subject to the terms of those plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Finer Offer Letter provides that in the event that Dr.&nbsp;Finer&#146;s
employment is terminated by the Company without &#147;cause&#148; or he resigns for &#147;good reason&#148; in either case outside a &#147;change of control period&#148; (each as defined in the Finer Offer Letter), subject to Dr.&nbsp;Finer&#146;s
execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, he will be entitled to receive (i)&nbsp;base salary continuation for 12 months following termination and
(ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Finer had he remained employed with the Company until the earliest of (A) 12 months following
termination, (B)&nbsp;Dr.&nbsp;Finer becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Finer&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Finer Offer Letter provides that in the event that Dr.&nbsp;Finer&#146;s employment is terminated by the
Company without &#147;cause&#148; or he resigns for &#147;good reason,&#148; in either case within a &#147;change of control period,&#148; subject to Dr.&nbsp;Finer&#146;s execution and delivery of an irrevocable separation agreement, including a
general release of claims in the Company&#146;s favor, in lieu of the payments and benefits described above, he will be entitled to receive (i)&nbsp;base salary continuation for 12 months following termination, (ii)&nbsp;the amount of his
then-current target bonus for the year of termination, (iii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Finer had he remained employed with the
Company until the earliest of (A) 12 months following termination, (B)&nbsp;Dr.&nbsp;Finer becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Finer&#146;s COBRA health
continuation period, and (iv)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Finer also entered into a standard form agreement with respect to confidential information, intellectual property
assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Liz Bhatt, M.S., M.B.A. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;20, 2022, the Company entered into an offer letter with Ms.&nbsp;Bhatt effective as of June&nbsp;15, 2022, for the
position of our Chief Operating Officer (Bhatt Offer Letter). The Bhatt Offer Letter provides for Ms.&nbsp;Bhatt&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial target annual bonus,
each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Bhatt Offer Letter also provided for a one-time $60,000 sign on bonus and the
grant of an award of restricted stock. Ms.&nbsp;Bhatt is eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Bhatt Offer Letter provides that in the event that Ms.&nbsp;Bhatt&#146;s employment is terminated by the Company without
&#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Bhatt Offer Letter), subject to Ms.&nbsp;Bhatt&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in
the Company&#146;s favor, she will be entitled to receive (i)&nbsp;base salary continuation for nine months following termination and (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to
provide health insurance to Ms.&nbsp;Bhatt had she remained employed with the Company until the earliest of (A)&nbsp;nine months following termination, (B)&nbsp;Ms.&nbsp;Bhatt becoming eligible for group medical plan benefits under any other
employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Bhatt&#146;s COBRA health continuation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, the Bhatt Offer Letter provided that in the event that Ms.&nbsp;Bhatt&#146;s employment was terminated by the Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Ms.&nbsp;Bhatt&#146;s execution and
delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, in lieu of the payments and benefits described above, she would have been entitled to receive (i)&nbsp;base salary continuation for
nine months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Ms.&nbsp;Bhatt had she remained employed with the Company until the
earliest of (A)&nbsp;nine months following termination, (B)&nbsp;Ms.&nbsp;Bhatt becoming </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Bhatt&#146;s COBRA health continuation period, and
(iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ms.&nbsp;Bhatt
also entered into a standard form agreement with respect to confidential information, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Samira Shaikhly </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On December&nbsp;22, 2022, the Company entered into an offer letter with Ms.&nbsp;Shaikhly effective as of February&nbsp;1,
2023, for the position of our Chief People Officer (Shaikhly Offer Letter). The Shaikhly Offer Letter provides for Ms.&nbsp;Shaikhly&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial
target annual bonus, each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Shaikhly Offer Letter also provided for the grant of an
award of stock options and a $50,000 <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus subject to full repayment if Ms.&nbsp;Shaikhly (i)&nbsp;is terminated by the Company for &#147;cause&#148; (as defined in the Shaikhly Offer Letter) or
(ii)&nbsp;resigns from the Company for any reason, in either case prior to the second anniversary of the payment of the <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus. Ms.&nbsp;Shaikhly is eligible to participate in the employee benefit plans
generally available to employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Shaikhly Offer Letter provides that in the
event that Ms.&nbsp;Shaikhly&#146;s employment is terminated by the Company without &#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Shaikhly Offer Letter), subject to Ms.&nbsp;Shaikhly&#146;s execution and
delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, she will be entitled to receive (i)&nbsp;base salary continuation for six months following termination and (ii)&nbsp;monthly payments
of the portion of the premiums equal to the amounts that the Company would have paid to provide health insurance to Ms.&nbsp;Shaikhly had she remained employed with the Company until the earliest of (A)&nbsp;six months following termination,
(B)&nbsp;Ms.&nbsp;Shaikhly becoming eligible for group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Shaikhly&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Shaikhly Offer Letter provides that in the event that Ms.&nbsp;Shaikhly&#146;s employment is terminated by
the Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Ms.&nbsp;Shaikhly&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s
favor, in lieu of the payments and benefits described above, she will be entitled to receive (i)&nbsp;base salary continuation for six months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that
the Company would have paid to provide health insurance to Ms.&nbsp;Shaikhly had she remained employed with the Company until the earliest of (A)&nbsp;six months following termination, (B)&nbsp;Ms.&nbsp;Shaikhly becoming eligible for group medical
plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Ms.&nbsp;Shaikhly&#146;s COBRA health continuation period, and (iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ms.&nbsp;Shaikhly also entered into a standard form agreement with respect to confidential information,
intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Daniel Long, D.Phil. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On September&nbsp;27, 2021, the Company entered into an offer letter with Dr.&nbsp;Long effective as of October&nbsp;4, 2021,
for the position of our Senior Vice President, Drug Discovery (Long Offer Letter). The Long Offer Letter provides for Dr.&nbsp;Long&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and initial
target annual bonus, each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Long Offer Letter also provided for the grant of an award
of restricted stock and a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus subject to two disbursements: (i) $62,500 which was paid within 30 days of January&nbsp;1, 2022 and (ii) $62,500 which was paid within 30 days of January&nbsp;1, 2023,
subject to Dr. Long&#146;s continuous employment with the Company through each such date. Dr.&nbsp;Long is eligible to participate in the employee benefit plans generally available to employees, subject to the terms of those plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Long Offer Letter provides that in the event that Dr.&nbsp;Long&#146;s
employment is terminated by the Company without &#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Long Offer Letter), subject to Dr.&nbsp;Long&#146;s execution and delivery of an irrevocable separation
agreement, including a general release of claims in the Company&#146;s favor, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination and (ii)&nbsp;monthly payments of the portion of the premiums equal
to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Long had he remained employed with the Company until the earliest of (A) six months following termination, (B)&nbsp;Dr.&nbsp;Long becoming eligible for group
medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Long&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Long Offer Letter provides that in the event that Dr.&nbsp;Long&#146;s employment is terminated by the
Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Dr.&nbsp;Long&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, in
lieu of the payments and benefits described above, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company
would have paid to provide health insurance to Dr.&nbsp;Long had he remained employed with the Company until the earliest of (A)&nbsp;six months following termination, (B)&nbsp;Dr.&nbsp;Long becoming eligible for group medical plan benefits under
any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Long&#146;s COBRA health continuation period, and (iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Long also entered into a standard form agreement with respect to confidential information, intellectual property
assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Uwe Klein, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On February&nbsp;17, 2021, the Company entered into an offer letter with Dr.&nbsp;Klein effective as of November&nbsp;1, 2021,
for the position of our Senior Vice President, Biological Sciences (Klein Offer Letter). The Klein Offer Letter provides for Dr.&nbsp;Klein&#146;s <FONT STYLE="white-space:nowrap">at-will</FONT> employment, and an initial annual base salary and
initial target annual bonus, each of which has subsequently been increased as described above under &#147;<I>2023 Base Salaries</I>&#148; and &#147;<I>2023 Cash Incentive Compensation</I>.&#148; The Klein Offer Letter also provides for the a
one-time $100,000 sign on bonus and, at Dr. Klein&#146;s option, either grant of an award of restricted stock or an award of stock options. Dr.&nbsp;Klein is eligible to participate in the employee benefit plans generally available to employees,
subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Klein Offer Letter provides that in the event that Dr.&nbsp;Klein&#146;s
employment is terminated by the Company without &#147;cause&#148; outside a &#147;change of control period&#148; (each as defined in the Klein Offer Letter), subject to Dr.&nbsp;Klein&#146;s execution and delivery of an irrevocable separation
agreement, including a general release of claims in the Company&#146;s favor, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination and (ii)&nbsp;monthly payments of the portion of the premiums equal
to the amounts that the Company would have paid to provide health insurance to Dr.&nbsp;Klein had he remained employed with the Company until the earliest of (A)&nbsp;six months following termination, (B)&nbsp;Dr.&nbsp;Klein becoming eligible for
group medical plan benefits under any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Klein&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Klein Offer Letter provides that in the event that Dr.&nbsp;Klein&#146;s employment is terminated by the
Company without &#147;cause&#148; within a &#147;change of control period,&#148; subject to Dr.&nbsp;Klein&#146;s execution and delivery of an irrevocable separation agreement, including a general release of claims in the Company&#146;s favor, in
lieu of the payments and benefits described above, he will be entitled to receive (i)&nbsp;base salary continuation for six months following termination, (ii)&nbsp;monthly payments of the portion of the premiums equal to the amounts that the Company
would have paid to provide health insurance to Dr.&nbsp;Klein had he remained employed with the Company until the earliest of (A)&nbsp;six months following termination, (B)&nbsp;Dr.&nbsp;Klein becoming eligible for group medical plan benefits under
any other employer&#146;s group health plan or (C)&nbsp;the end of Dr.&nbsp;Klein&#146;s COBRA health continuation period, and (iii)&nbsp;accelerated vesting of all time-based stock options and other time-based stock-based awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Klein also entered into a standard form agreement with respect to
confidential information, intellectual property assignment and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Executive Severance Plan</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has adopted an Executive Severance Plan (Severance Plan), which became effective upon the effectiveness
of the registration statement of which this prospectus forms a part, in which our NEOs, and certain other executives, will participate. The benefits provided in the Severance Plan will replace any severance for which our NEOs may be eligible under
their existing offer letters or other agreements or arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Severance Plan provides that upon a termination by
us for any reason other than for &#147;cause,&#148; as defined in the Severance Plan, death or &#147;disability,&#148; as defined in the Severance Plan, or resignation for &#147;good reason&#148;, as defined in the Severance Plan, in each case
outside of the change in control period (i.e., the period beginning three months prior to and ending one year after a &#147;change in control,&#148; as defined in the Severance Plan), an eligible participant will be entitled to receive, subject to
the execution and delivery of an effective release of claims in favor of the Company and continued compliance with all applicable restrictive covenants, (i) 12 months of &#147;base salary&#148; (i.e., the higher of the annual base salary in effect
immediately prior to the date of termination or the annual base salary in effect for the year immediately prior to the year in which the date of termination occurs) for our Chief Executive Officer, nine&nbsp;months for Tier 2 executives (which is
determined by the plan administrator and includes our Chief Operating Officer), and six months for Tier 3 executives (which is determined by the plan administrator and includes our remaining NEOs) and (ii) an amount equal to the monthly employer
contribution, based on the premiums as of the date of termination, that we would have made to provide health insurance for the NEO if he or she had remained employed by us for up to 12 months for our Chief Executive Officer, nine months for Tier 2
executives and six months for Tier 3 executives. The payments under (i) and (ii) will be paid in substantially equal installments in accordance with our payroll practice over 12 months for our Chief Executive Officer, nine months for Tier 2
executives and six months for Tier 3 executives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Severance Plan also provides that upon a (A) termination by us other
than for cause, death or disability or (B) resignation for good reason, in each case within the change in control period, an eligible participant will be entitled to receive, in lieu of the payments and benefits above and subject to the execution
and delivery of an effective release of claims in favor of the Company and continued compliance with all applicable restrictive covenants, (I) a lump sum amount equal to 18 months of the base salary and 1.5x of the &#147;target bonus&#148; (i.e.,
the higher of the target annual bonus in effect immediately prior to the date of termination or the target annual bonus in effect immediately prior to the change in control) for our Chief Executive Officer, 12 months of the base salary and 1.0x of
the target bonus for our Tier 2 executives and 9 months of the base salary and 0.75x of the target bonus for our Tier 3 executives, (II) an amount equal to the monthly employer contribution, based on the premiums as of the date of termination, that
we would have made to provide health insurance for the NEO if he or she had remained employed by us for 18 months for our Chief Executive Officer, 12 months for our Tier 2 executives and 9 months for our Tier 3 executives, and (III) for all
outstanding and unvested equity awards of the Company that are subject to time-based vesting held by the participant, full accelerated vesting of such awards; provided, that the performance conditions applicable to any outstanding and unvested
equity awards subject to performance-based vesting will be subject to the terms of the applicable award agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
payments and benefits provided under the Severance Plan in connection with a change in control may not be eligible for a federal income tax deduction by us pursuant to Section 280G of the Code. These payments and benefits may also subject an
eligible participant, including the NEOs, to an excise tax under Section 4999 of the Code. If the payments or benefits payable in connection with a change in control would be subject to the excise tax imposed under Section 4999 of the Code, then
those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Outstanding Equity Awards at Fiscal
<FONT STYLE="white-space:nowrap">2023&nbsp;Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information concerning
outstanding equity awards held by our NEOs as of December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP> </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options&nbsp;(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or<BR>Units&nbsp;of<BR>Stock&nbsp;That<BR>Have&nbsp;Not<BR>Vested&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>of Shares or<BR>Units&nbsp;of&nbsp;Stock<BR>That&nbsp;Have&nbsp;Not<BR>Vested
($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Jeffrey Finer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/13/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/2/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">348,420</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,684</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Liz Bhatt, M.S., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9/13/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/15/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,881</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">506,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,387</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81,264</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Samira Shaikhly</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/31/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151; </TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,683</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/30/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151; </TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,098</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Daniel Long, D.Phil.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/26/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/2/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,456</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">216,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,163</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Uwe Klein, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10/26/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,842</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/12/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/1/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,163</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11/11/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Each equity award is subject to the terms of the 2021 Plan (as described below). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">This amount is based on the fair market value of a share of our common stock equal to $4.65 as of
December&nbsp;31, 2023, as determined by our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares underlying the stock option award or restricted stock award, as applicable, vest in 48 equal
monthly installments over a four-year period, commencing on the vesting commencement date, subject to the applicable NEO&#146;s continued service relationship through each applicable vesting date. The award is also subject to certain acceleration of
vesting rights as set forth in the applicable NEO&#146;s Offer Letter, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares underlying the stock option award or restricted stock award, as applicable, vest as follows: 25%
of such shares vested on the first anniversary of the vesting commencement date, and the remaining 75% of the shares vest in 36 equal monthly installments over the following three years, subject to the applicable NEO&#146;s continued service
relationship through each applicable vesting date. The award is also subject to certain acceleration of vesting rights as set forth in the applicable NEO&#146;s Offer Letter, as described above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The shares underlying the restricted stock award vest as follows: 25% of such shares vested on
December&nbsp;1, 2022, and the remaining 75% of the shares vest in 36 equal monthly installments over the following three years, subject to the applicable NEO&#146;s continued service relationship through each applicable vesting date. The award is
also subject to certain acceleration of vesting rights as set forth in the applicable NEO&#146;s Offer Letter, as described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2021 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Plan was initially approved and adopted by our board of directors and stockholders on October&nbsp;26, 2021 and has
been subsequently amended from time to time thereafter to increase the number of shares reserved for issuance thereunder. Under the 2021 Plan, we have reserved for issuance an aggregate of 5,403,314 shares of our common stock for the issuance of
stock options and other equity awards. This number of shares of our common stock reserved for issuance is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. As of December&nbsp;31, 2023,
options to purchase 1,123,296 shares of our common stock and 774,225 shares of our restricted stock were outstanding under the 2021 Plan and 227,819 shares of our restricted stock were outstanding from grants made outside of the 2021 Plan. Our board
of directors has determined not to make any further awards under the 2021 Plan following the completion of this offering, but all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outstanding awards under the 2021 Plan will continue to be governed by their existing terms. The maximum number of shares that may be issued as incentive stock options under the 2021 Plan may not
exceed 42,419,145 shares. In connection with this offering, we have adopted a new incentive equity plan under which we will grant equity-based awards following this offering, as described below under &#147;<I>2024 Stock Option and Incentive
Plan</I>.&#148; This summary is not a complete description of all provisions of the 2021 Plan and is qualified in its entirety by reference to the 2021 Plan, which is filed as an exhibit to the registration statement of which this prospectus is
part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares of our common stock underlying any awards that are forfeited, cancelled, reacquired by us prior to
vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise), or held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding under the 2021 Plan will be added back to the
shares of our common stock available for issuance under the 2021 Plan (or, following the completion of this offering, the 2024 Plan (as defined below)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has acted as administrator of the 2021 Plan. The administrator has full power to, among other things,
select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the
specific terms and conditions of each award, subject to the provisions of the 2021 Plan. Persons eligible to participate in the 2021 Plan are those full or part-time officers, employees, <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors, consultants, and key persons as selected from time to time by the administrator in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021
Plan permits the granting of both options to purchase shares of our common stock intended to qualify as incentive stock options under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be
determined by the administrator but may not be less than 100% of the fair market value of our common stock on the date of grant, or in the case of an incentive stock option granted to a 10% owner, the exercise price shall not be less than 110% of
the fair market value of our common stock on the date of grant. The term of each option will be fixed by the 2021 Plan administrator and may not exceed ten years from the date of grant, or five years from the date of grant in the case of an
incentive stock option granted to a 10% owner. The 2021 Plan administrator will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Plan administrator may award restricted shares of our common stock and restricted stock units to participants subject
to such conditions and restrictions as it may determine. These conditions and restrictions may include continued employment with us through a specified vesting period and/or the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2021 Plan administrator may also grant shares of our common stock that are free from any restrictions under the 2021 Plan.
Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of certain corporate transactions and events, including a reorganization, recapitalization, reclassification,
stock dividend, stock split, reverse stock split, or other similar change to the Company&#146;s capital stock, the 2021 Plan administrator shall make appropriate adjustments to the maximum number of shares reserved for issuance under the 2021 Plan,
the number and kind of securities subject to outstanding awards under the 2021 Plan and the repurchase or exercise price of any outstanding awards under the 2021 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the effective time of a &#147;sale event&#148; (as defined in the 2021 Plan), all outstanding option awards granted under
the 2021 Plan shall terminate unless assumed, substituted, or continued by a successor entity. In the event of such termination, individuals holding options will be permitted to exercise such options within a specified period of time prior to the
sale event. In the event of a sale event, all unvested restricted stock awards and restricted stock units (other than those that become vested as a result of the sale event) will be forfeited unless assumed, substituted, or continued by a successor
entity. With respect to individuals holding restricted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stock that is forfeited upon a sale event, such restricted stock shall be repurchased by the Company at a price per share equal to the original per share purchase price paid by the holder for
such shares of our restricted stock. In addition, in connection with a sale event, we may make or provide for a cash payment to participants in exchange for the cancellation of their options (to the extent then vested and exercisable, including by
reason of acceleration in connection with such sale event) or outstanding restricted stock or restricted stock units, in an amount equal to the difference between (a)&nbsp;the per share consideration in the sale event times the number of shares
subject to such awards being cancelled and (b)&nbsp;the aggregate exercise price of such outstanding vested and exercisable stock options, as applicable, with any such cash payments in respect of restricted stock or restricted stock units to be paid
at the time of the sale event or upon the later vesting of such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may amend or discontinue
the 2021 Plan and the 2021 Plan administrator may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under any outstanding award without the
holder&#146;s consent. Certain amendments to the 2021 Plan require the approval of our stockholders. The 2021 Plan administrator may exercise its discretion to reduce the exercise price of outstanding stock options or to effect repricing through the
cancellation of outstanding stock options and grant of replacement awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No awards may be granted under the 2021 Plan
after the date that is ten years from the effective date of the 2021 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2024 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan was adopted by our board of directors on October&nbsp;1, 2024, approved by our stockholders on October&nbsp;18,
2024, and became effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part was declared effective by the SEC. The 2024 Plan replaced the 2021 Plan as our board of directors has
determined not to make additional awards under the 2021 Plan following the completion of this offering. However, the 2021 Plan will continue to govern outstanding equity awards granted thereunder. The 2024 Plan allows us to make equity-based and
cash-based incentive awards to our officers, employees, directors and consultants. The following summary describes the material terms of the 2024 Plan. This summary is not a complete description of all provisions of the 2024 Plan and is qualified in
its entirety by reference to the 2024 Plan, which is filed as an exhibit to the registration statement to which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have initially reserved 3,690,000 shares of our common stock for the issuance of awards under the 2024 Plan (Initial
Limit). The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January&nbsp;1, 2025 and each January&nbsp;1 thereafter through January&nbsp;1, 2034, by 5% of the
outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or such lesser number of shares as determined by our compensation committee (Annual Increase). The number of shares reserved under the 2024 Plan is
subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares we
issue under the 2024 Plan will be authorized but unissued shares or shares that we reacquire. The shares of our common stock underlying any awards under the 2024 Plan and the 2021 Plan that are forfeited, cancelled, held back upon exercise or
settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of our
common stock available for issuance under the 2024 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The maximum number of shares of our common stock that may be
issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on January&nbsp;1, 2025 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 3,690,000 shares of our
common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The grant date fair value of all awards made under the 2024 Plan and all
other cash compensation paid by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed $750,000; provided,
however, that such amount shall be $1,000,000 for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan is administered by our compensation committee. Our compensation committee has the full power to select, from
among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of
any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2024 Plan. Persons eligible to participate in the 2024 Plan will be those full or part-time officers, employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options
under Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the closing price of our common stock on the date of
grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing price was reported) (110% in the case of certain incentive stock options) unless the option (i)&nbsp;is granted pursuant
to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S. income tax, or (iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code.
The term of each option will be fixed by our compensation committee and may not exceed ten years from the date of grant (or five years in the case of certain incentive stock options). Our compensation committee will determine at what time or times
each option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee may award stock appreciation rights under the 2024 Plan subject
to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of our common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of
each stock appreciation right generally may not be less than 100% of the closing price of our common stock on the date of grant (or, if no closing price is reported on that date, the closing price on the immediately preceding date on which a closing
price was reported) unless the share appreciation right (i)&nbsp;is granted pursuant to a transaction described in, and in a manner consistent with Section&nbsp;424(a) of the Code, (ii)&nbsp;is granted to an individual who is not subject to U.S.
income tax, or (iii)&nbsp;complies with or is exempt from Section&nbsp;409A of the Code. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation
committee will determine at what time or times each stock appreciation right may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee
may award restricted shares of our common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals
and/or continued employment with us through a specified vesting period. Our compensation committee may also grant shares of our common stock that are free from any restrictions under the 2024 Plan. Unrestricted stock may be granted to participants
in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits
for dividends that would be paid if the recipient had held a specified number of shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
compensation committee may grant cash bonuses under the 2024 Plan to participants, subject to the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The 2024 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2024 Plan, an acquirer or
successor entity may assume, continue or substitute outstanding awards under the 2024 Plan. To the extent that awards granted under the 2024 Plan are not assumed or continued or substituted by the successor
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
entity, upon the effective time of the sale event, such awards shall terminate. In such case, except as may be otherwise provided in the relevant award agreement, all awards with time-based
vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and
nonforfeitable in connection with a sale event in the administrator&#146;s discretion or to the extent specified in the relevant award agreement. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights
will be permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii)&nbsp;we may make or provide for a payment, in cash or in kind, to participants
holding vested and exercisable options and stock appreciation rights equal to the difference between the per share consideration payable to our stockholders in the sale event and the exercise price of the options or stock appreciation rights and we
may make or provide for a payment, in cash or in kind, to participants holding other vested awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of
directors may amend or discontinue the 2024 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an
award without the holder&#146;s consent. Certain amendments to the 2024 Plan require the approval of our stockholders. The administrator of the 2024 Plan is specifically authorized to exercise its discretion to reduce the exercise price of
outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder consent. No awards may be granted under the 2024 Plan after
the date that is 10 years from the effective date of the 2024 Plan. No awards under the 2024 Plan have been made prior to the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>2024 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP was adopted by our board of directors on October&nbsp;1, 2024, approved by our stockholders on October&nbsp;18, 2024,
and became effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part was declared effective by the SEC. The ESPP is intended to have two components: a component intended to qualify
as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code (423 Component) and a component that is not intended to qualify <FONT STYLE="white-space:nowrap">(Non-423</FONT> Component). Except as otherwise
provided, the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component will be operated and administered in the same manner as the 423 Component, except where prohibited by law. The following summary describes the material terms of the ESPP. This
summary is not a complete description of all provisions of the ESPP and is qualified in its entirety by reference to the ESPP, which is filed as an exhibit to the registration statement to which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP initially reserves and authorizes the issuance of up to a total of 369,402&nbsp;shares of our common stock to
participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2026 and each January&nbsp;1 thereafter through January&nbsp;1, 2034, by the least of
(i)&nbsp;369,402&nbsp;shares of our common stock, (ii) 1% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31, or (iii)&nbsp;such lesser number of shares of our common stock as determined by the
administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All employees who are customarily employed by us or one of our designated subsidiaries for more than 20 hours per week and who
have been employed for such period as determined by the administrator, with such period not to exceed two years, are eligible to participate in the ESPP. However, any employee who owns 5% or more of the total combined voting power or value of all
classes of our stock will not be eligible to purchase shares of our common stock under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may make one or more
offerings, consisting of one or more purchase periods, each year to our employees to purchase shares under the ESPP. The administrator may, in its discretion, determiner when each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
offering will occur, including the duration of any offering; provided, that no offering will exceed 27 months in duration. Each eligible employee may elect to participate in any offering by
submitting an enrollment form at least 15 business days before the applicable offering date. Unless the administrator chooses otherwise prior to an offering date, and to the extent an offering has more than one purchase period, if the fair market
value of the our common stock on any exercise date in an offering is lower than the fair market value of our common stock on the offering date, then all participants in such offering automatically will be withdrawn from such offering immediately
after the exercise of their option on such exercise date and automatically re-enrolled in the immediately following offering as of the first day thereof and the preceding offering will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up
to 15% of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the
last business day of the offering period at a price equal to 85% of the closing price of the shares of our common stock on the first business day or the last business day of the offering period (or, if no closing price is reported on that date, the
closing price on the immediately preceding date on which a closing price was reported), whichever is lower, provided that no more than a number of shares of common stock determined by dividing $25,000 by the fair market value of our common stock on
the offering date of such offering (or such other lesser maximum number of shares as may be established by the administrator) may be purchased by any one employee during any offering period. Under applicable tax rules, an employee may purchase no
more than $25,000 worth of shares of our common stock, valued at the start of the offering period, under the ESPP for each calendar year during which any option granted to the employee is outstanding at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be
refunded. An employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares
of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I></I><B><I>Senior Executive Cash Incentive Bonus Plan</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2024, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan (Bonus Plan). The Bonus Plan
provides for cash bonus payments based upon Company and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our Company, or
corporate performance goals, as well as individual performance objectives. The following summary describes the material terms of the Bonus Plan. This summary is not a complete description of all provisions of the Bonus Plan and is qualified in its
entirety by reference to the Bonus Plan, which is filed as an exhibit to the registration statement to which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee may select corporate performance goals from among the following: developmental, publication,
clinical, or regulatory milestones; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or
after interest, taxes, depreciation, and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions, licenses, collaborations or strategic transactions; financing or other capital raising transactions;
operating income (loss); return on capital, assets, equity or investment; stockholder returns; return on sales; total stockholder return; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer
satisfaction; working capital; earnings (loss) per share of the Company&#146;s common stock; bookings, new bookings or renewals; sales or market shares; number of prescriptions or prescribing physicians; coverage decisions; leadership development,
employee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
retention and recruiting and other human resources matters; operating income and/or net annual recurring revenue; or any other performance goal selected by our compensation committee, any of
which may be (A)&nbsp;measured in absolute terms, or compared to any incremental increase, (B)&nbsp;measured in terms of growth, as compared to results of a peer group, (C)&nbsp;compared to another company or companies or to results of a peer group,
(D) measured against the market as a whole and/or as compared to applicable market indices and/or (E) measured on a pre-tax or post-tax basis (if applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each
performance period. The bonus formulas will be adopted in each performance period by our compensation committee and communicated to each executive. The corporate performance goals will be measured at the end of each performance period after our
financial reports have been published or such other appropriate time as our compensation committee determines. If the corporate performance goals and individual performance objectives are met, payments will be made as soon as practicable following
the end of each performance period, but not later than two and a half months after the end of the year in which such performance period ends. Subject to the rights contained in any written agreement between the executive officer and us, an executive
officer shall be required to be employed by us on the bonus payment date to be eligible to receive a bonus payment under the Bonus Plan. The Bonus Plan also permits our compensation committee to approve additional bonuses to executive officers in
its sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Equity Grants to Named Executive Officers Prior to this Offering</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2024, our board of directors approved option grants to certain employees of the Company, including our NEOs, with
Drs. Finer, Long and Klein and Messes. Bhatt and Shaikhly being granted options to purchase 348,419, 40,648, 40,648, 92,911 and 34,841 shares of our common stock, respectively (Executive Options). The Executive Options were granted under the 2021
Plan and have an exercise price per share equal to $6.81. Subject to and contingent upon the earlier of an Initial Public Offering (as defined in the applicable option agreements, and which includes this offering) or a Sale Event (as defined in the
2021 Plan) in which such Executive Options will be assumed, continued or substituted by the successor entity, in either case no later than September 30, 2025, the vesting commencement date for such Executive Options shall be the date of such Initial
Public Offering or Sale Event, as applicable. 1/48th of the Executive Options will vest upon each monthly anniversary of such vesting commencement date, in each case subject to the applicable optionee&#146;s continued service relationship with the
Company through such vesting date. In the event that the Company terminates an NEO&#146;s employment without Cause (as defined in the applicable NEO&#146;s offer letter with the Company) (or, for Dr. Finer only, he resigns for Good Reason (as
defined in Dr. Finer&#146;s offer letter with the Company)), within the Change in Control Period (as defined in the applicable NEO&#146;s offer letter with the Company), subject to the applicable NEO signing a fully effective release, all of the
unvested shares subject to the NEO&#146;s Executive Option will immediately vest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_14"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents the compensation awarded to, earned by, or paid to each person who served as a <FONT
STYLE="white-space:nowrap">non-employee</FONT> member of our board of directors during the fiscal year ended December&nbsp;31, 2023 for their service on our board of directors during the fiscal year ended December&nbsp;31, 2023. Other than as set
forth in the table and described more fully below, we did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the
<FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2023. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors affiliated with Samsara, RA Capital Management, and Third Rock Ventures, including
Mr.&nbsp;Bassan and Drs. Simson and Tong, did not receive cash or equity compensation from us for their service as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The compensation for the fiscal year ended December&nbsp;31, 2023
received by Dr.&nbsp;Finer, as an NEO of the Company, is presented in the &#147;<I>2023 Summary Compensation Table</I>&#148; above. Dr.&nbsp;Ezekowitz, who is affiliated with Third Rock Ventures, previously served as our interim Chief Medical
Officer during the fiscal year ended December&nbsp;31, 2023, but was not an NEO. Dr.&nbsp;Ezekowitz has been omitted from the table below since he does not receive any compensation for his services as a member of our board of directors. See the
section titled &#147;Certain Relationships and Related Person Transactions&#148; included elsewhere in this prospectus for more information regarding Dr.&nbsp;Ezekowitz&#146;s compensation for the fiscal year ended December&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2023 Director Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abraham Bassan, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Coulie, M.D., Ph.D.,
M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Tong, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2023, Dr.&nbsp;Coulie was the only director holding outstanding equity awards and
held options to purchase an aggregate of 29,034 shares of our common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported represent the aggregate grant date fair value of the stock options awarded to our
directors during the fiscal year ended December&nbsp;31, 2023, calculated in accordance with FASB ASC Topic 718, disregarding estimated forfeitures related to service-based vesting. For a description of the assumptions used in determining these
values, see Note 10&#151;&#147;<I>Stock-Based Compensation</I>&#148; to our financial statements included elsewhere in this prospectus. The amount reported in this column reflects the accounting cost for the option and does not correspond to the
actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Coulie joined our board of directors on December&nbsp;7, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Director Engagement Letters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ms.&nbsp;Shalini Sharp joined our board of directors on January&nbsp;18, 2024. We have entered into director engagement letters
with Dr.&nbsp;Coulie and Ms.&nbsp;Sharp. Pursuant to these engagement letters, each such director received an initial stock option grant for the purchase of 29,034 shares of our common stock that vests in 16 equal quarterly installments over four
years, subject to continued service through each applicable vesting date. The stock options are subject to full accelerated vesting upon a &#147;sale event&#148; (as defined in the 2021 Plan). In addition, pursuant to their respective director
engagement letter, Dr.&nbsp;Coulie and Ms.&nbsp;Sharp are each entitled to receive an annual cash retainer of $30,000, payable quarterly. Dr.&nbsp;Coulie&#146;s first payment occurred in January 2024. Each such director is eligible to receive
reimbursement for their reasonable expenses incurred in attending board of directors&#146; meetings in accordance with our generally applicable reimbursement policies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Non-Employee Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, our board of directors has adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation policy, which became effective as of the date on which the registration statement of which this prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
forms a part was declared effective by the SEC. The policy will be designed to enable us to attract and retain, on a long-term basis, highly qualified
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive cash retainers (which will be payable quarterly in arrears and prorated
for partial years of service) and equity awards as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Retainer for Board Membership:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT> chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Additional Annual Retainer for Committee Membership:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the non-employee director compensation policy provides that, upon initial
election or appointment to our board of directors, each non-employee director will be granted a one-time stock option to purchase 33,246 shares of our common stock (Director Initial Grant). The Director Initial Grant will vest in equal monthly
installments over three years following the grant date, subject to continued service through the applicable vesting date. The Director Initial Grant will expire ten years from the date of grant and have an exercise price per share equal to the fair
market value of our common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, on the date of each annual meeting of stockholders
following the completion of this offering, each non-employee director who continues as a non-employee director following such meeting will be granted an annual stock option to purchase 16,623 shares of our common stock (Director Annual Grant). The
Director Annual Grant will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting of our stockholders, subject to continued service through the applicable vesting date. If a
non-employee director joins our board of directors on a date other than the date of the annual meeting of our stockholders, then in lieu of the Director Annual Grant, such non-employee director will be granted a prorated portion of the Director
Annual Grant corresponding to such partial year of service at the next annual meeting of stockholders. The pro-rated Director Annual Grant will vest in full upon the earlier of (A) the first anniversary of the date of grant or (B) the date of the
next annual meeting of our stockholders, subject to continued service through the applicable vesting date. The Director Annual Grant (including any pro-rata portions thereof) will expire ten years from the date of grant and have an exercise price
per share equal to the fair market value of our common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Director Initial Grants and the
Director Annual Grants (including any pro-rata portions thereof) are subject to full accelerated vesting upon the sale of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director and $750,000 in any other calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will reimburse all
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by directors for their attendance at meetings of our board of directors or any committee thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Employee directors will receive no additional compensation for their service as a director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Equity Grants to Directors Prior to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In September 2024, our board of directors approved option grants to certain directors, with Mr. Bassan, Drs. Coulie, Ezekowitz,
Simson and Tong and Ms. Sharp each being granted an option to purchase 13,356 shares of our common stock (Director Options). The Director Options were granted under the 2021 Plan and have an exercise price per share equal to $6.81. Subject to and
contingent upon an Initial Public Offering (as defined in the applicable option agreements, and which includes this offering) no later than September 30, 2025, the vesting commencement date for such Director Options shall be the effective date of
such Initial Public Offering. 1/16th of the Director Options will vest in each quarterly installment following the vesting commencement date in each case subject to the applicable optionee&#146;s continued service relationship with the Company
through such vesting date. Upon a Sale Event (as defined in the 2021 Plan), all of the unvested shares subject to the Director Options will vest immediately prior to the Sale Event, subject to the applicable optionee&#146;s continued service
relationship with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following is a description of transactions or series of transactions since January&nbsp;1, 2022, to which we were or will
be a party, in which:<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets
at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than 5% or more of our outstanding capital stock,
or any immediate family member of, or person sharing the household with, any of these individuals or entities or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compensation arrangements for our named executive officers and our directors are described in the sections titled
&#147;Director Compensation&#148; and &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Private Placement of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Series A Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2021 and 2022, we issued and sold an aggregate of 75,000,000 shares of our Series A convertible preferred stock in two
closings, at a purchase price of $1.00 per share, for an aggregate purchase price of $75.0&nbsp;million. Included in this amount was $14.7&nbsp;million of the then outstanding principal and interest on convertible promissory notes issued to Third
Rock Ventures V, L.P. in 2020 and 2021, all of which converted into Series A convertible preferred stock in this financing in accordance with their terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Every 8.6103 shares of our outstanding Series A convertible preferred stock will automatically convert into approximately one
share of our common stock immediately prior to the completion of this offering. The following table summarizes purchases of our Series A convertible preferred stock as described above by related parties: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Stockholder<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A&nbsp;Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures V, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,250,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value
Fund<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Third Rock Ventures beneficially own more than 5% of our outstanding capital stock.
Dr.&nbsp;Tong and Dr.&nbsp;Ezekowitz, members of our board of directors, were designated to our board of directors by Third Rock Ventures and serve as Partner and Advisory Partner at Third Rock Ventures, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">$26,593,667 of the total purchase price was funded in cash and $14,656,333 was funded by the conversion of
Third Rock Ventures V, L.P.&#146;s convertible promissory notes (inclusive of principal and accrued interest). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Samsara beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Bassan, a member of our
board of directors, was designated to our board of directors by Samsara and is a Principal at Samsara. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i) 2,968,200 shares of our Series A convertible preferred stock purchased by Biotechnology Value
Fund II, L.P. (BVF II), (ii) 4,077,015 shares of our Series A convertible preferred stock purchased by Biotechnology Value Fund, L.P. (BVF) and (iii) 454,785 shares of our Series A convertible preferred stock purchased by Biotechnology Value Trading
Fund OS LP (BVF Trading Fund OS and, together with BVF II and BVF, Biotechnology Value Fund). Entities affiliated with Biotechnology Value Fund collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Series B Convertible Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2023 and 2024, we issued and sold an aggregate of 121,657,452 shares of our Series B convertible preferred stock at a
purchase price of $1.23297 per share for an aggregate purchase price of $150.0&nbsp;million in multiple closings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Every
8.6103 shares of our outstanding Series B convertible preferred stock will convert into approximately one share of our common stock immediately prior to the completion of this offering. The following table summarizes the shares of our Series B
convertible preferred stock issued to our related parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Stockholder<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Rock Ventures VI, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,737,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,499,999.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA
Capital<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,331,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,999,999.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,165,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,999,999.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Goldman<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,165,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,999,999.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,516,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,499,999.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,082,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,499,999.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value
Fund<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,055,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,999,999.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Additional details regarding these stockholders and their equity holdings are included in the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Entities affiliated with Third Rock Ventures beneficially own more than 5% of our outstanding capital stock.
Dr.&nbsp;Tong and Dr.&nbsp;Ezekowitz, members of our board of directors, were designated to our board of directors by Third Rock Ventures and serve as Partner and Advisory Partner at Third Rock Ventures, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i) 14,598,896 shares of our Series B convertible preferred stock purchased by RA Capital
Healthcare Fund, L.P. (RA Capital Healthcare) and (ii) 9,732,596 shares of our Series&nbsp;B convertible preferred stock purchased by RA Capital Nexus Fund III, L.P. (RA Capital Nexus and, together with RA Capital Healthcare, RA Capital).
Dr.&nbsp;Simson, a member of our board of directors, was designated to our board of directors by RA Capital and is a Partner at RA Capital. Entities affiliated with RA Capital collectively beneficially own more than 5% of our outstanding capital
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i)&nbsp;2,846,638 shares of our Series B convertible preferred stock purchased by Special
Situations 2022, L.P., (ii)&nbsp;2,233,760 shares of our Series B convertible preferred stock purchased by West Street Life Sciences&nbsp;I, LP, (iii)&nbsp;1,587,908 shares of our Series B convertible preferred stock purchased by WSLS Emp Onshore
Investments, L.P., (iv) 1,560,292 shares of our Series&nbsp;B convertible preferred stock purchased by Broad Street Principal Investments LLC, (v)&nbsp;598,990 shares of our Series&nbsp;B convertible preferred stock purchased by WSLS Emp Offshore
Investments, L.P., (vi)&nbsp;2,129,548 shares of our Series&nbsp;B convertible preferred stock purchased by WSLS Offshore Investments, SLP, and (vii) 1,208,610 shares of our Series&nbsp;B convertible preferred stock purchased by Special Situations
2022 Offshore Holdings II, L.P. (collectively, Goldman). Entities affiliated with Goldman collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Samsara beneficially owns more than 5% of our outstanding capital stock. Mr.&nbsp;Bassan, a member of our
board of directors, was designated to our board of directors by Samsara and is a Principal at Samsara. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents (i)&nbsp;1,665,002 shares of our Series&nbsp;B convertible preferred stock purchased by
BVF&nbsp;II, (ii)&nbsp;2,196,680 shares of our Series&nbsp;B convertible preferred stock purchased by BVF and (iii)&nbsp;193,566 shares of our Series&nbsp;B convertible preferred stock purchased by BVF Trading Fund OS. Entities affiliated with
Biotechnology Value Fund collectively beneficially own more than 5% of our outstanding capital stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Agreements with Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Financing Agreements with Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our Series A and B convertible preferred stock financings, we entered into an investors&#146; rights
agreement and stockholders agreement containing registration rights, information rights, voting rights, and rights of first refusal, among other things, with certain holders of our convertible preferred stock and certain holders of our common stock,
including holders of more than 5% of our capital stock and entities with which certain of our directors and officers are affiliated. Pursuant to our amended and restated investors&#146; rights agreement (as amended, the investor rights agreement),
entities affiliated with Biotechnology Value Fund and RA Capital were each granted the right to designate a board observer in a nonvoting capacity, which right will terminate upon the completion of this offering. These agreements will terminate upon
the completion of this offering, except for the registration rights granted under the investor rights agreement, as more fully described in &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Management Rights Letters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our Series A and B convertible preferred stock financings, we entered into management rights letters with
certain purchasers of our convertible preferred stock, including holders of more than 5% of our capital stock and entities with which certain of our directors or officers are affiliated, pursuant to which such entities were granted
certain&nbsp;management&nbsp;rights, including the right to consult with and advise our management on significant business issues, review our operating plans, examine our books and records and inspect our facilities. These management rights letters
will terminate upon completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Side Letter with Goldman </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with our Series B convertible preferred stock financing, we entered into a side letter agreement (Goldman side
letter) with entities affiliated with Goldman Sachs &amp; Co. LLC (Goldman), which collectively hold more than 5% of our outstanding capital stock. Pursuant to the Goldman side letter, Goldman was granted the right to designate a board observer in a
nonvoting capacity, which right will terminate upon the completion of this offering. Certain of our obligations under the Goldman side letter will remain in effect after the completion of this offering, including our obligations to defend, indemnify
and hold Goldman harmless for any damages, liabilities, losses, taxes, fines, penalties and reasonable costs and expenses arising out of third-party or governmental claims related to Goldman&#146;s status as a securityholder, subject to certain
limitations and exceptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Service Agreement with Third Rock Ventures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third Rock Ventures, a beneficial owner of more than 5% of our outstanding capital stock, has provided us with certain
consulting services, including without limitation, business, technical, financial, IT, and scientific advice related to our business pursuant to a service agreement with Third Rock Ventures, dated August&nbsp;25, 2021 (TRV service agreement).
Dr.&nbsp;Finer, our President, Chief Executive Officer and a member of our directors, is a Venture Partner at Third Rock Ventures. In addition, Dr.&nbsp;Tong, a member of our board of directors, and Dr.&nbsp;Ezekowitz, a member of our board of
directors and our former interim Chief Medical Officer, were designated to our board of directors by Third Rock Ventures and are each affiliated with Third Rock Ventures. Dr.&nbsp;Ezekowitz served as our interim Chief Medical Officer from January
2022 to September 2024 and did not receive any cash compensation from us for his service as our former interim Chief Medical Officer, as his services were provided to us through the TRV service agreement. For the fiscal years ended December&nbsp;31,
2022 and 2023, we incurred costs totaling $1.3&nbsp;million and $0.3&nbsp;million, respectively, for the services provided to us by Third Rock Ventures, which included, among other things, the services of Dr.&nbsp;Ezekowitz in his capacity as our
former interim Chief Medical Officer. For the six months ended June&nbsp;30, 2024, we incurred costs totaling $0.1&nbsp;million for the services provided to us by Third Rock Ventures, which included, among other things, the services of
Dr.&nbsp;Ezekowitz in his capacity as our former interim Chief Medical Officer. Drs. Tong and Ezekowitz did not receive any cash compensation from us for their services as members of our board of directors. Of the total fees we incurred under the
TRV service agreement in the fiscal years ended December&nbsp;31, 2022 and 2023, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
$253,500 and $239,000, respectively, were attributed to Dr.&nbsp;Ezekowitz&#146;s support in his capacity as our former interim Chief Medical Officer. Of the total fees we incurred under the TRV
service agreement during the six months ended June 30, 2024, $111,000 was attributed to Dr. Ezekowitz&#146;s support in his capacity as our former interim Chief Medical Officer. Additionally, as compensation for Dr. Ezekowitz&#146;s services as our
former interim Chief Medical Officer, we granted him options to purchase 11,613&nbsp;shares of our common stock during the year ended December 31, 2022, and 26,712&nbsp;shares of our common stock during the year ended December 31, 2023, at exercise
prices of $1.55 and $2.76 per share, respectively. During the six months ended June 30, 2024, we granted him options to purchase 23,227&nbsp;shares of our common stock at an exercise price of $2.76 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Employment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into offer letter agreements with certain of our executive officers and granted stock options to our executive
officers, as more fully described in the section titled &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Equity Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted stock options and restricted stock awards to purchase shares of our common stock to certain of our executive
officers and directors. For more information regarding the stock options granted to our executive officers and directors, see the sections titled &#147;Executive Compensation&#148; and &#147;Director Compensation&#148; included elsewhere in this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we have entered into new agreements to indemnify our directors and executive officers. These
agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any
action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of directors or an executive officer to the maximum extent allowed under Delaware law.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Policies for Approval of Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors reviews and approves transactions with directors, executive officers, and holders of 5% or more of our
voting securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction were disclosed to our board of directors prior to their consideration
of such transaction, and the transaction was not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approved the transaction. Further, when stockholders are entitled to vote on
a transaction with a related party, the material facts of the related party&#146;s relationship or interest in the transaction were disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we adopted a written related party transactions policy that provides that such transactions
must be approved by our audit committee. This policy became effective upon effectiveness of our registration statement. Pursuant to this policy, our audit committee has the primary responsibility for reviewing and approving or disapproving
&#147;related party transactions,&#148; which are transactions between us and related parties in which the aggregate amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and in which a related party
has a direct or indirect interest. For purposes of this policy, a related party will be defined as a director, executive officer, nominee for director, any security holder known by us to beneficially own more than 5% of any class of our voting
securities, and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth, as of August 31, 2024, information regarding beneficial ownership of our common stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The information in the following table is calculated based on 26,000,408&nbsp;shares (including 707,885&nbsp;shares of
unvested restricted common stock subject to repurchase or forfeiture) of our common stock deemed to be outstanding before this offering and 42,000,408&nbsp;shares of our common stock outstanding after this offering, assuming no exercise by the
underwriters of their option to purchase additional shares of our common stock. The number of shares outstanding is based on the number of shares of our common stock outstanding (including 707,885&nbsp;shares of unvested restricted common stock
subject to repurchase or forfeiture) as of August&nbsp;31, 2024, as adjusted to give effect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of
22,839,774&nbsp;shares of our common stock immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale of 16,000,000&nbsp;shares of our common stock in this offering (assuming no exercise of the
underwriters&#146; option to purchase additional shares). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each individual or entity shown on the table
has furnished information with respect to beneficial ownership. Except as otherwise indicated below, the address of each officer, director and 5% stockholder listed below is c/o Septerna, Inc., 250 East Grand Avenue, South San Francisco, California
94080. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not
necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities as well
as any shares of our common stock that the person has the right to acquire within 60 days of August 31, 2024 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person
holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or
entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Third Rock
Ventures<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,718,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA
Capital<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,825,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,208,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invus Public Equities, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund,
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Goldman<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,412,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Biotechnology Value
Fund<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,342,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Common&nbsp;Stock<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares</B><br><B>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Finer, M.D., Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">930,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liz Bhatt, M.S., M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samira Shaikhly<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Long, D.Phil.<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Uwe Klein, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Tong, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abraham Bassan, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bernard Coulie, M.D., Ph.D.,
M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alan Ezekowitz, M.D., D. Phil.<SUP STYLE="font-size:75%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shalini Sharp, M.B.A.<SUP STYLE="font-size:75%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jake Simson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All executive officers and directors as a group</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(13 persons)<SUP STYLE="font-size:75%; vertical-align:top">(16)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,516,394</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 1,054,318 shares of common stock held by Third Rock Ventures V, L.P. (TRV V),
(ii)&nbsp;4,790,773 shares of common stock issuable upon conversion of Series A convertible preferred stock held by TRV V, and (iii) 2,872,956 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Third Rock
Ventures VI, L.P. (TRV VI). The general partner of TRV V is Third Rock Ventures GP V, L.P. (TRV GP V). The general partner of TRV GP V is TRV GP V, LLC (TRV GP V LLC). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. (TRV GP VI). The
general partner of TRV GP VI is TRV GP VI, LLC (TRV GP VI LLC). Abbie Celniker, Ph.D., Robert Tepper, M.D., Reid Huber, Ph.D., Jeffrey Tong, Ph.D., Kevin Gillis, Neil Exter, and Cary Pfeffer, M.D. are the managing members of TRV GP V LLC and TRV GP
VI LLC and collectively make voting and investment decisions with respect to shares held by TRV V and TRV VI. David Kaufman is also a managing member of TRV GP VI LLC and contributes to voting decisions with respect to shares held by TRV VI. Dr.
Tong is a member of our board of directors. The principal address for the entities and individuals named in this paragraph is 201 Brookline Avenue, Suite 1401, Boston, Massachusetts 02215. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 1,695,515 shares of common stock issuable upon conversion of Series B convertible preferred
stock held by RA Capital Healthcare Fund, L.P. (RA Healthcare) and (ii) 1,130,343 shares of common stock issuable upon conversion of Series B convertible preferred stock held by RA Capital Nexus Fund III, L.P. (RA Nexus). RA Capital Management, L.P.
(RA Capital) is the investment manager for RA Healthcare and RA Nexus. The general partner of RA Capital is RA Capital Management GP, LLC (RA Capital GP), of which Peter Kolchinsky and Rajeev Shah are the managing members. RA Capital, RA Capital GP,
Peter Kolchinsky and Rajeev Shah may be deemed to have voting and investment power over the shares held of record by RA Healthcare and RA Nexus. RA Capital, RA Capital GP, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of such
shares, except to the extent of any pecuniary interest therein. The address of RA Capital is 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,219,470 shares of common stock issuable upon conversion of Series A convertible preferred
stock and 989,050 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Samsara BioCapital, L.P. (Samsara LP). Samsara BioCapital GP, LLC (Samsara LLC) is the general partner of Samsara LP and may be deemed
to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has the voting and investment power over the shares held by Samsara GP, and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara
LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. The business address of Dr. Akkaraju and each of the entities listed above is 628 Middlefield Road, Palo Alto, California 94301.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 871,050 shares of common stock issuable upon conversion of Series A convertible preferred stock
and 706,464 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Invus Public Equities, L.P. (IPE). Invus Public Equities Advisors, LLC (IPEA) controls IPE, as its general partner and accordingly, may be
deemed to beneficially own the shares held by IPE. Invus Global Management, LLC (IGM) controls IPEA, as its managing member and accordingly, may be deemed to beneficially own the shares that IPEA may be deemed to beneficially own. Siren, L.L.C.
(Siren) controls IGM, as its managing member and accordingly, may be deemed to beneficially own the shares that IGM may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren, controls Siren and accordingly, may be
deemed to beneficially own the shares that Siren may be deemed to beneficially own. The business address for IPE, IPEA, IGM, Siren and Mr. Raymond Debbane is 750 Lexington Ave, 30th Floor, New York, New York 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,412,929 shares of common stock issuable upon conversion of Series B convertible preferred
stock held by Deep Track Biotechnology Master Fund, Ltd (Deep Track Fund). Deep Track Capital, LP (Deep Track Manager) is the investment manager of Deep Track Fund. Deep Track Capital GP, LLC (Deep Track Partner) is the general partner of Deep Track
Manager and David Kroin is the managing member of Deep Track Partner. The address of each of Deep Track Fund, Deep Track Manager, Deep Track Partner and Mr. Kroin is 200 Greenwich Ave, 3rd Floor, Greenwich, Connecticut 06830. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 259,428 shares of common stock issuable upon conversion of Series B convertible preferred
stock held by West Street Life Sciences I, LP (WSLSI), (ii) 247,325 shares of common stock issuable upon conversion of Series B convertible preferred stock held by WSLS Offshore Investments, SLP (WSLSOI), (iii) 184,419 shares of common stock
issuable upon conversion of Series B convertible preferred stock held by WSLS Emp Onshore Investments, L.P. (WSLS Onshore), (iv) 69,566 shares of common stock issuable upon conversion of Series B convertible preferred stock held by WSLS Emp Offshore
Investments, L.P. (WSLS Offshore), (v) 181,212 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Broad Street Principal Investment LLC (BSPI), (vi) 330,608 shares of common stock issuable upon conversion
of Series B convertible preferred stock held by Special Situations 2022, L.P. (SSLP), and (vii) 140,367 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Special Situations 2022 Offshore Holdings II,
L.P. (SSOH). Goldman Sachs &amp; Co. LLC (Goldman Sachs), as the investment manager of WSLSI, WSLSOI, WSLS Onshore, and WSLS Offshore, may be deemed to have voting and investment power over the shares held of record by these entities. Bridge Street
Opportunity Advisors, L.L.C. (Bridge Street), as the general partner of SSLP and SSOH, may be deemed to have voting and investment power over the shares held of record by these entities. Goldman Sachs &amp; Co. LLC and Bridge Street are direct and
indirect wholly-owned subsidiaries of The Goldman Sachs Group, Inc. (GS Group). GS Group is a public entity and its common stock is publicly traded on the New York Stock Exchange. The shares were acquired in the ordinary course of the holders&#146;
investment business and not for the purpose of resale or distribution. Goldman Sachs, Bridge Street or GSGroup may be deemed to beneficially own the securities held by WSLSI, WSLSOI, WSLS Onshore, WSLS Offshore, SSLP and SSOH. Goldman Sachs, Bridge
Street and GS Group disclaim beneficial ownership of such securities except to the extent of its pecuniary interest therein. The address of GS Group, Goldman Sachs, Bridge Street, WSLSI, WSLS Onshore, WSLS Offshore, BSPI, SSLP and SSOH is 200 West
Street, New York, New York 10282. The address of WSLSOI is 12E, Rue Guillaume Kroll, 1882 Luxembourg. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 473,504 shares of common stock issuable upon conversion of Series A convertible preferred
stock and 255,122 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Biotechnology Value Fund, L.P. (BVF), (ii) 344,727 shares of common stock issuable upon conversion of Series A convertible preferred
stock and 193,372 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Biotechnology Value Fund II, L.P. (BVF II), and (iii) 52,819 shares of common stock issuable upon conversion of Series A convertible
preferred stock and 22,480 shares of common stock issuable upon conversion of Series B convertible preferred stock shares of common stock issuable upon conversion of convertible preferred stock held by Biotechnology Value Trading Fund OS LP (BVF
Trading Fund OS, together with BVF and BVF II, the BVF Entities). BVF I GP LLC (BVF GP), as general partner of BVF, may be deemed to beneficially own the shares beneficially </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
owned by BVF. BVF II GP LLC (BVF II GP), as general partner of BVF II, may be deemed to beneficially own the shares beneficially owned by BVF II. BVF GP Holdings LLC (BVF GPH), as the sole member
of BVF GP and BVF II GP, may be deemed to beneficially own the shares beneficially owned by BVF and BVF II. BVF Partners OS Ltd. (BVF Partners OS), as general partner of BVF Trading Fund OS, may be deemed to beneficially own the shares beneficially
owned by BVF Trading Fund OS. BVF Partners L.P. (BVF Partners), as sole member of BVF Partners OS and investment manager of BVF, BVF II and BVF Trading Fund OS, may be deemed to beneficially own the shares beneficially owned by the BVF Entities. BVF
Inc., as the general partner of BVF Partners, and Mark N. Lampert, as director and officer of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Entities. Each of BVF GP, BVF II GP, BVF Partners OS, BVF GPH, BVF
Partners, BVF Inc., and Mark N. Lampert disclaims beneficial ownership of securities beneficially owned by the BVF Entities. The address of each of the entities listed above is 44 Montgomery Street, Suite 4000, San Francisco, CA 94104.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 754,907 shares of common stock (including unvested restricted common stock) and (ii) 175,860
shares of common stock issuable upon the exercise of options exercisable within 60 days of August&nbsp;31, 2024 held by Dr. Finer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 174,209 shares of common stock (including unvested restricted common stock) and (ii) 34,474
shares of common stock issuable upon the exercise of options exercisable within 60 days of August&nbsp;31, 2024 held by Ms. Bhatt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 36,811 shares of common stock issuable upon the exercise of options exercisable within 60 days
of August 31, 2024 held by Ms. Shaikhly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 92,911 shares of common stock (including unvested restricted common stock) and (ii) 8,129
shares of common stock issuable upon the exercise of options exercisable within 60 days of August&nbsp;31, 2024 held by Dr. Long. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 104,525 shares of common stock (including unvested restricted common stock) held by the
Klein 2024 Revocable Trust dated February 25, 2024 (the Klein Trust) and (ii) 8,129 shares of common stock issuable upon the exercise of options exercisable within 60 days of August 31, 2024 held by Dr.&nbsp;Klein. Dr. Klein is a co-trustee of the
Klein Trust and shares voting and dispositive power with respect to the shares held by the Klein Trust with his spouse. The address of the Klein Trust is 1254 33rd Avenue, San Francisco, CA 94122. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 6,677 shares of common stock issuable upon the exercise of options exercisable within 60 days of
August 31, 2024 held by Dr. Coulie. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 17,420 shares of common stock and (ii) 33,969 shares of common stock issuable upon the
exercise of options exercisable within 60 days of August 31, 2024 held by Dr. Ezekowitz. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of 6,677 shares of common stock issuable upon the exercise of options exercisable within 60 days of
August 31, 2024 held by Ms. Sharp. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 1,202,041 shares of common stock (including unvested restricted common stock) and (ii)
314,353 shares of common stock issuable upon the exercise of options exercisable within 60 days of August&nbsp;31, 2024. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>The following description of our capital stock and certain provisions of our amended and restated certificate of
incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended
and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this
prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our authorized
capital stock will consist of 500,000,000&nbsp;shares of our common stock, par value $0.001 per share, and 10,000,000&nbsp;shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, there were 3,163,020&nbsp;shares of our common stock outstanding (including 784,550&nbsp;shares of
unvested restricted common stock subject to repurchase or forfeiture) and held of record by stockholders. This amount assumes the conversion of all outstanding shares of our convertible preferred stock into 22,839,774&nbsp;shares of our common
stock, which will occur immediately prior to the completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the
stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose,
subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in
all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Immediately prior to the completion of this offering, all outstanding shares of our convertible preferred stock will be
converted into shares of our common stock. Upon the completion of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000&nbsp;shares of preferred stock in one or more
series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund
terms, and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common
stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company
or other corporate action. Immediately after completion of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of June&nbsp;30, 2024, 1,796,272 shares of our common stock were issuable upon the exercise of outstanding stock options
under the 2021 Plan, at a weighted-average exercise price of $2.68 per share; no shares of our common stock were issuable upon exercise of outstanding stock options outside of our 2021 Plan; and 3,690,000 shares of our common stock were reserved for
future issuance under the 2024 Plan, which became effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any future automatic annual increases in the number of
shares of our common stock reserved for issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2021 Plan that expire or are repurchased, forfeited, cancelled, or withheld. For additional information
regarding terms of our equity incentive plans, see the section titled &#147;Executive Compensation&#151;Employee Benefit and Equity Compensation Plans.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of our
preferred stock, will be entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the investor rights agreement between us and the holders of our preferred stock.
The investor rights agreement includes demand registration rights, short-form registration rights, and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling
expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Beginning six months after the effective date of this registration statement, certain holders of our common stock, including
common stock issuable upon the conversion of shares of our preferred stock upon the completion of this offering, are entitled to demand registration rights. Under the terms of the investor rights agreement, upon the written request of stockholders
holding at least 25% of the securities eligible for registration then outstanding to file a registration statement with respect to at least 25% of the securities eligible for registration then outstanding, having an anticipated aggregate offering
price, net of related fees and expenses, of at least $5.0&nbsp;million, we will be required to file a registration statement within 60 days of such request covering all securities eligible for registration that our stockholders request to be
included in such registration. We are not required to effect any registration pursuant to this provision of the investor rights agreement (a)&nbsp;during the period that is estimated to be 60 days before and 180 days after the effective date of a
registration statement that we initiate, (b)&nbsp;if we have already effected two registrations pursuant to such requests for registration on Form <FONT STYLE="white-space:nowrap">S-1</FONT> or (c)&nbsp;if the initiating holders propose to register
securities that may be immediately registered on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-1</FONT> is further subject to other specified conditions and
limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Short-Form Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the investor rights agreement, if we are eligible to file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> upon the written request of stockholders holding at least 10% of the securities eligible for registration then outstanding to file a registration statement with respect to securities having an anticipated
aggregate offering price, net of related fees and expenses, of at least $1.0&nbsp;million, we will be required to file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement within 45 days of such request covering all securities
eligible for registration that our stockholders request to be included in such registration. We are not required to effect any registration pursuant to this provision of the investor rights agreement (a)&nbsp;during the period that is estimated to
be 30 days before and 90 days after the effective date of a registration statement that we initiate or (b)&nbsp;if we have already effected two registrations pursuant to such requests for registration on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> within the twelve month period immediately preceding the date of such request. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other
specified conditions and limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the investor rights agreement, if we register any of our securities either for our own account or for the account
of other security holders, the holders of our common stock, including common stock issuable upon the conversion of our preferred stock, are entitled to include their shares in the registration. Subject to certain exceptions contained in the investor
rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The investor rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify
holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The demand registration rights and short form registration rights granted under the investor rights agreement will terminate on
the earliest to occur of (a)&nbsp;the closing of certain liquidation events, (b)&nbsp;the fifth anniversary of the completion of this offering or (c)&nbsp;at such time after this offering when the holders&#146; shares may be sold without restriction
pursuant to Rule 144 under the Securities Act (Rule 144) or another similar exemption under the Securities Act within a three month period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ordinarily, other than underwriting discounts and commissions, we are generally required to pay all expenses incurred by us
related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel and reasonable fees and disbursements
of a counsel for the selling security holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Delaware Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some provisions of Delaware law, our amended and restated certificate of incorporation and amended and restated bylaws
include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate
with our board of directors rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides for the division of our board of directors into three classes
serving staggered three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the <FONT
STYLE="white-space:nowrap">holders&nbsp;of&nbsp;two-thirds&nbsp;or&nbsp;more</FONT> of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting
from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors
and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote
of the stockholders at an annual or special meeting, and that stockholders may not take any action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated bylaws or
removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws provide that only a majority of the
members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our amended and
restated bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws establish advance notice procedures with regard to stockholder proposals relating to the
nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to
the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the
preceding year. Our amended and restated bylaws specify the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special
meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any amendment of our amended and restated certificate of incorporation must first be approved by a majority of our board of
directors, and if required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class
entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated bylaws may be
amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled
to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as
a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The
existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of
its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in
one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our
board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings
and assets available for distribution to holders of shares of our common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a
change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general,
Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested
stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or
the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding, for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of
the assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, Section&nbsp;203 defines an
interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for
the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty
owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
provision of the DGCL or our amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, validity or enforceability thereof) or as to which the
DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">However, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any
duty or liability created by the Exchange Act or the rules and regulations thereunder. Consequently, this choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or
any other claim for which the federal courts have exclusive jurisdiction or the Securities Act. Moreover, Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty
or liability created by the Securities Act or the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our amended and restated
bylaws provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any
complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced
by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any
part of the documents underlying the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While the Delaware courts have determined that such choice of forum
provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those
other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, our amended and restated bylaws provide that any person or entity holding, owning or otherwise acquiring any
interest in any of our securities shall be deemed to have notice of and consented to these provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Limitations on Liability and
Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See the section titled &#147;Management&#151;Limitations on Liability and Indemnification
Agreements&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Stock Exchange Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our common stock has been approved for listing on the Nasdaq Global Market under the trading symbol &#147;SEPN.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&#146;s address is
150 Royall Street, Canton, Massachusetts 02021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of our
common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock
or impair our ability to raise equity capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the completion of this offering, based on our shares outstanding
as of June&nbsp;30, 2024, a total of 42,002,794 shares of our common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares,
all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements of
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice provisions of Rule 144, subject to
compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days
preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be
sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule 144, subject to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144, as currently in effect,
our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90 days after the date of this prospectus,
within any three-month period, such stockholders may sell a number of shares that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 420,027 shares
immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares of our common stock from us; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar
weeks preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales under Rule 144 by
our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rule 701 under the Securities Act (Rule 701) generally allows a stockholder who was issued shares under a written compensatory
plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule 144, but without being required to comply with the public information, holding period,
volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of our Company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares,
however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, all of our directors and executive officers, and the holders of substantially all of our securities have entered into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents us and them, subject among other things and subject to certain exceptions, from
selling any of our securities for a period of not less than 180 days from the date of this prospectus without the prior written consent of J.P. Morgan Securities LLC. See the section titled &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of this offering, certain holders of our securities will be entitled to various rights with respect to
registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the
registration. See the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Equity Incentive Plans
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the
Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon
filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the
<FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described above. As of the date of this prospectus, we estimate that such registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> will cover approximately
4,059,402&nbsp;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS <FONT
STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion is a summary of
material U.S. federal income tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering. This discussion is based on
the Code, Treasury Regulations promulgated thereunder, published rulings and administrative pronouncements of the U.S. Internal Revenue Service (IRS) and judicial decisions, all as in effect on the date hereof. These authorities are subject to
differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested, and do not intend to request, a ruling from the IRS with respect to the
statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our common stock pursuant
to this offering and who hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion is not a complete analysis of all potential U.S. federal
income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section&nbsp;451(b) of the Code,
and also does not address any U.S. federal <FONT STYLE="white-space:nowrap">non-income</FONT> tax consequences, such as estate or gift tax consequences, or any tax consequences arising under any state, local or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to
special rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens, or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships, S corporations, or other entities or arrangements treated as partnerships, pass-through
entities, or disregarded entities (including hybrid entities) for U.S. federal income tax purposes (and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations&#148; within the meaning of Section&nbsp;957(a) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;passive foreign investment companies&#148; within the meaning of Section&nbsp;1297(a) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, investment companies, insurance companies, brokers, dealers or traders in
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have elected to mark securities to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations (including private foundations), and
governmental organizations, or international organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of employee stock options or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquire our common stock through the exercise of warrants or conversion rights under convertible
instruments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as &#147;qualified small business stock&#148; under Section&nbsp;1202 of
the Code or &#147;Section&nbsp;1244 stock&#148; under Section&nbsp;1244 of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that elect to apply <FONT STYLE="white-space:nowrap">Section&nbsp;1400Z-2</FONT> of the Code to gains
recognized with respect to shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired our common stock in a transaction subject to the gain rollover provisions of the Code
(including Section&nbsp;1045 of the Code); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic
security or a constructive sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an
entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partner, the
activities of the partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax
consequences to them of owning and disposing of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND
IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER
ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX TREATY. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our
common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or any organization taxable as a corporation for U.S. federal income taxes that is not created
or organized under the laws of the United States, any state thereof, or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign trust or estate, the income of which is not subject to U.S. federal income tax on a net income
basis. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As described under &#147;Dividend Policy,&#148; we do not currently anticipate declaring or paying, for the foreseeable future,
any distributions on our capital stock. However, if we were to distribute cash or other property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce a
holder&#146;s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under &#147;&#151;Gain on sale or other taxable
disposition of our common stock&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding effectively connected income,
backup withholding and FATCA (as defined below), dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the
dividends or such lower rate specified by an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
applicable income tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our withholding agent with a valid IRS
Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying
such holder&#146;s qualification for the reduced rate. This certification must be provided to us or our withholding agent before the payment of the dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder holds our common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide
appropriate documentation to the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock in connection with the conduct of a trade
or business in the United States, and dividends paid on our common stock are effectively connected with such holder&#146;s U.S. trade or business (and, if required by an applicable tax treaty, are attributable to such holder&#146;s permanent
establishment or fixed base in the United States), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder generally must furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form), certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
Holder&#146;s conduct of a trade or business within the United States to the applicable withholding agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">However, any
such effectively connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United
States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively
connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but
that qualify for a reduced treaty rate, may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors
regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
conduct of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the
United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present
in the United States for a period or periods aggregating 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a
United States real property holding corporation (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
holding period for our common stock, and our common stock is not &#147;regularly traded&#148; on an established securities market within the meaning of applicable U.S. Treasury regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at
the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch
profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the second bullet point above will be subject to U.S.
federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.- source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (even though the
individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair
market value of our worldwide real property interests and our other trade or business assets. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we
will not in the future become a USRPHC. Even if we are treated as a USRPHC, gain realized by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as
(1)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder owned, directly, indirectly and constructively, no more than 5% of our common stock at all times within the shorter of (a)&nbsp;the five-year period preceding the disposition or
(b)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is &#147;regularly traded&#148; on an established securities market within the meaning of applicable U.S. Treasury regulations. There can be no assurance that our common stock
qualifies as regularly traded on an established securities market for purposes of the rules described above. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences to them if we are, or were to
become, a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding
any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder indicating the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required (because
the distributions were effectively connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty) and regardless of whether such distributions constitute dividends.
This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup withholding, currently at
a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of distributions on or the gross proceeds of a disposition of our common stock provided the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS
Form <FONT STYLE="white-space:nowrap">W-8BEN-E</FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a U.S.
person who is not an exempt recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. If any amount is withheld under the
backup withholding rules, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Withholding on Foreign
Entities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal
withholding tax of 30% on certain payments made to a &#147;foreign financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to
collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are
foreign entities with U.S. owners) or an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as
specially defined under these rules) unless such entity provides the withholding agent a certification that it does not have any &#147;substantial United States owners&#148; or provides information identifying certain direct and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain
circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock and would have applied also to payments of gross proceeds
from the sale or other disposition of our common stock. However, proposed regulations under FATCA provide for the elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other disposition of from property of a
type that can produce U.S. source dividends or interest. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA withholding does not apply to gross proceeds from sales or other dispositions of
our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prospective investors are encouraged to consult with their tax advisors regarding the possible
implications of FATCA on their investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR
REGARDING THE TAX CONSEQUENCES OF OWNING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL,
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering the shares of our common stock described in this prospectus through a number of underwriters. J.P. Morgan
Securities LLC, TD Securities (USA) LLC, Cantor Fitzgerald&nbsp;&amp; Co. and Wells Fargo Securities, LLC are acting as joint book-running managers of the offering and as representatives of the underwriters. We have entered into an underwriting
agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting
discounts and commissions set forth on the cover page of this prospectus, the number of shares of our common stock listed next to its name in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,560,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,480,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters are committed to purchase all the shares of our common stock offered by us if
they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters propose to offer the common stock directly to the public at the initial public offering
price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of $0.756 per share. After the initial offering of the shares to the public, if all of the shares of our common stock are not
sold at the initial public offering price, the underwriters may change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have an option to buy up to 2,400,000 additional shares of our common stock from us to cover sales of shares
by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30 days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to
purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of our common stock are purchased, the underwriters will offer the additional shares on the
same terms as those on which the shares are being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriting fee is equal to the public offering price per
share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is $1.26 per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the
underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Option<BR>to Purchase<BR>Additional<BR>Shares Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Full&nbsp;Option<BR>to Purchase<BR>Additional</B><br><B>Shares Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,160,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,184,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the total expenses of this offering, including registration, filing and
listing fees, printing fees and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $5.8&nbsp;million. We have agreed to reimburse the underwriters for expenses relating to the clearance of
this offering with the Financial Industry Regulatory Authority, Inc. in an amount up to $40,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on the web sites
maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account
holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have agreed that we will not, subject to certain exceptions, (i)&nbsp;offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration
statement under the Securities Act relating to, any shares of our common stock or any securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii)&nbsp;enter into any swap, hedging, or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of any shares of common stock or any such other securities, or publicly disclose the intention to undertake any of the foregoing (regardless of whether any of these
transactions are to be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC for a period of 180 days after the date of this
prospectus, other than the shares of our common stock to be sold in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions on our actions, as
described above, do not apply to certain transactions, including (i)&nbsp;the issuance of shares of our common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible
or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of restricted stock units (RSUs) (including net settlement), in each case outstanding on the date of the underwriting agreement and
described in this prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of our common stock or securities convertible into or exercisable or exchangeable for shares of
our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the closing date of this offering and
described in this prospectus, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of our common stock, or
securities convertible into, exercisable for, or which are otherwise exchangeable for, common stock, immediately following the closing date of this offering, in acquisitions or other similar strategic transactions, provided that such recipients
enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; or (iv)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted
pursuant to any plan in effect on the date of the underwriting agreement and described in this prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive officers, and substantially all of our securityholders (such persons, the <FONT
STYLE="white-space:nowrap">lock-up</FONT> parties) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each
<FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 180 days after the date of this prospectus (such period, the restricted period), may not and may not cause any of their direct or indirect affiliates to,
without the prior written consent of J.P. Morgan Securities LLC, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend,
or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our common stock (including without limitation, our common stock or such other
securities which may be deemed to be beneficially owned by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or
warrant) (collectively with the common stock, the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities), (ii) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences
of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities,
in cash or otherwise, (iii)&nbsp;make any demand for or exercise any right with respect to the registration of any the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, or (iv)&nbsp;publicly disclose the intention to do any of the
foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Such persons or entities have further acknowledged that these undertakings
preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other
derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such
transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. Such persons or entities further confirm that they have furnished
the representatives with the details of any transaction such persons or entities, or any of their respective affiliates, is a party to as of the date hereof, which transaction would have been restricted by the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements if it had been entered into by such persons or entities during the restricted period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The restrictions described in the immediately preceding paragraph and contained in the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including
(a)&nbsp;transfers or dispositions of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities: (i)&nbsp;as bona fide gifts or charitable contribution, or for bona fide estate planning purposes, (ii)&nbsp;by will or intestacy or any other
testamentary document, (iii)&nbsp;to any member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#146;s immediate family or to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or
the immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor, trustee or beneficiary of the trust or to the estate of a trustor, trustee
or beneficiary of such trust, (iv)&nbsp;to a corporation, partnership, limited liability company, investment fund, or other entity (A)&nbsp;of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and its immediate family members are the
legal and beneficial owner of all of the outstanding equity securities or similar interests, or (B)&nbsp;controlled by, or under common control or common investment management with, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the
immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (v)&nbsp;to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i)&nbsp;through (iv) above, (vi)&nbsp;in
the case of a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or common investment management with the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or its affiliates or (B)&nbsp;as part of a distribution to limited partners, members or stockholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; (vii)&nbsp;by operation of law,
(viii)&nbsp;to us from the <FONT STYLE="white-space:nowrap">lock-up</FONT> party upon death or disability, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is an employee of us, upon death, disability or termination of employment of
such employee, (ix)&nbsp;as part of a sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired (A)&nbsp;from the underwriters in this offering or (B)&nbsp;in open market transactions after the completion of this offering,
(x)&nbsp;to us in connection with the vesting, settlement or exercise of RSUs, options, warrants or other rights to purchase shares of our common stock (including &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of
exercise price and tax and remittance payments, or (xi)&nbsp;pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction approved by our board of directors and made to all stockholders involving a change in
control, provided that if such transaction is not completed, all such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities would remain subject to the restrictions in the immediately preceding paragraph; (b)&nbsp;exercise of the options,
settlement of RSUs or other equity awards, or the exercise of warrants granted pursuant to plans described in this prospectus, provided that any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities received upon such exercise, vesting or
settlement would be subject to restrictions similar to those in the immediately preceding paragraph; (c)&nbsp;the conversion of outstanding preferred stock, warrants to acquire preferred stock, or convertible securities into shares of our common
stock or warrants to acquire shares of our common stock, provided that any common stock or warrant received upon such conversion would be subject to restrictions similar to those in the immediately preceding paragraph; and (d)&nbsp;the establishment
or amendment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that (1)&nbsp;such plan does not provide for the transfer of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement shall be made voluntarily in connection with the establishment or amendment of
such trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> provided that if a filing under the Exchange Act or other public announcement is required, such announcement or filing shall include a statement to the effect that
no transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities may be made under such trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> during the restricted period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">J.P. Morgan Securities LLC, in its sole discretion, may release the
securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters described above, in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our common stock has been approved for listing on the Nasdaq Global Market under the symbol &#147;SEPN.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for,
purchasing and selling shares of our common stock in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making
short sales of common stock, which involves the sale by the underwriters of a greater number of shares of our common stock than they are required to purchase in this offering, and purchasing shares of our common stock on the open market to cover
positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to purchase additional shares referred to above, or may be &#147;naked&#148;
shorts, which are short positions in excess of that amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters may close out any covered short position
either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for
purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be
downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open
market to cover the position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have advised us that, pursuant to Regulation M of the Securities Act, they
may also engage in other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open
market in stabilizing transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding
a decline in the market price of the common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them
at any time. The underwriters may carry out these transactions on Nasdaq, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. The initial public offering price was determined
by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters considered a number of factors including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information set forth in this prospectus and otherwise available to the representatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects and the history and prospects for the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our prospects for future earnings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general condition of the securities markets at the time of this offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors deemed relevant by the underwriters and us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters can assure investors that an active trading market will develop for shares of our common
stock, or that the shares will trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time
to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees
and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions
in our debt or equity securities or loans, and may do so in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the
securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material
or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction.
Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a
solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Notice to Prospective Investors in the European Economic Area </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area (each a Relevant State), no shares have been offered or will be
offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in
another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following
exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of
the underwriters and to us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus
Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances
which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such
proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer to the public&#148; in
relation to shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Notice to Prospective Investors in the
United Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No shares have been offered or will be offered pursuant to the offering to the public in the United
Kingdom prior to the publication of a prospectus in relation to the shares which (i)&nbsp;has been approved by the Financial Conduct Authority or (ii)&nbsp;is to be treated as if it had been approved by the Financial Conduct Authority in accordance
with the transitional provisions in Article 74 (transitional provisions) of the Prospectus Amendment etc (EU Exit) Regulations 2019/1234, except that the shares may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus
Regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
UK Prospectus Regulation), subject to obtaining the prior consent of underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of the shares shall require us or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA
or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any
form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means
Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus
Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order) and/or (ii)&nbsp;who are
high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in
circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this
document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Notice to Prospective Investors in Canada </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing
Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or
damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the
purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in Switzerland</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus does not constitute an offer to the public or a solicitation to purchase or invest in any shares. No shares
have been offered or will be offered to the public in Switzerland, except that offers of shares may be made to the public in Switzerland at any time under the following exemptions under the Swiss Financial Services Act (FinSA): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any person which is a professional client as defined under the FinSA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to obtaining
the prior consent of the representatives of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss
Financial Services Ordinance, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of shares shall require the Company or any investment bank to
publish a prospectus pursuant to Article 35 FinSA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be listed or admitted to trading
on a trading venue in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither this document nor any other offering or marketing material relating to the
shares constitutes a prospectus as such term is understood pursuant to the FinSA and neither this document nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in
Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in the Dubai International Financial Centre</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document relates to an Exempt Offer in accordance with the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. This
document is intended for distribution only to persons of a type specified in the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority (DFSA) has
no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for this document. The
securities to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the
contents of this document you should consult an authorized financial advisor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to its use in the DIFC, this document is strictly private and
confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be
offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the United Arab Emirates
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab
Emirates (including the Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this
prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central
Bank of the United Arab Emirates, the Securities and Commodities Authority, Financial Services Regulatory Authority (FSRA) or the DFSA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001
(Cth) (Corporations Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission (ASIC), as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or
more of the categories of investors, available under section 708 of the Corporations Act (Exempt Investors). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares may be distributed in Australia, except where disclosure to investors is not required under Chapter
6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares, you represent and warrant to us that you are an Exempt Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As any offer of shares of our common stock under this prospectus will be made without disclosure in Australia under Chapter
6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies
to that resale. By applying for the shares of our common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate those shares of our common stock to
investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and
Exchange Act. Accordingly, none of the shares nor any interest therein may be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in
Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan,
except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the
relevant time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (SFO) of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (CO) or which do not constitute an offer to the public within the meaning of the CO. No advertisement,
invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to
be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to
&#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in
Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the
Monetary Authority of Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell
any shares or cause the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the
offer or sale, or invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289)
of Singapore, as modified or amended from time to time (SFA)) pursuant to Section&nbsp;274 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the
SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which
is: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(c)(ii) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and
Securities-based Derivatives Contracts) Regulations 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Singapore </I><I>SFA Product Classification</I> &#151; In connection with
Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of shares of our common stock, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the
shares of our common stock are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale
of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Bermuda </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Shares may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of
Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are
permitted to do so under applicable Bermuda legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Saudi Arabia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on
the Offer of Securities and Continuing Obligations Regulations as issued by the board of the Saudi Arabian Capital Market Authority (CMA) pursuant to resolution number
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3-123-2017</FONT></FONT> dated 27&nbsp;December 2017, as amended (CMA Regulations). The CMA does not make any representation as to the accuracy or completeness of this document and
expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the
information relating to the securities. If you do not understand the contents of this document, you should consult an authorised financial adviser. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in the British Virgin Islands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or
subscription by or on behalf of us. The shares may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands) (BVI Companies), but only where the offer will be made to, and received by, the relevant BVI
Company entirely outside of the British Virgin Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in China </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus will not be circulated or distributed in the PRC and the shares will not be offered or sold, and will not be
offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan),
except pursuant to any applicable laws and regulations of the PRC. Neither this prospectus nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with
applicable laws and regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Korea </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea
and the decrees and regulations thereunder (FSCMA), and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any
person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange
Transaction Law of Korea and the decrees and regulations thereunder (FETL). Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection
with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws and
regulations of Korea. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in Malaysia</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be
registered with the Securities Commission of Malaysia (Commission) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to
persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may
only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds
RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum
in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with
total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)
a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other
person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries on the business of dealing in
securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to
subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in Taiwan</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant
securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a
registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B></B><B><I>Notice to Prospective Investors in South Africa</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Due to restrictions under the securities laws of South Africa, no &#147;<I>offer to the public</I>&#148; (as such term is
defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the South African Companies Act) is being made in connection with the issue of the shares in South Africa.
Accordingly, this document does not, nor is it intended to, constitute a &#147;<I>registered prospectus</I>&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not
been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or
delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Section&#8201;96&#8201;(1)&#8201;(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the offer, transfer, sale, renunciation or delivery is to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(i) persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(ii) the South African Public Investment Corporation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(iii) persons or entities regulated by the Reserve Bank of South Africa; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(iv) authorised financial service providers under South African law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(v) financial institutions recognised as such under South African law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(vi) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised
portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:16%; font-size:10pt; font-family:Times New Roman">(vii) any combination of the person in (i)&nbsp;to (vi), or </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%" VALIGN="top" ALIGN="left">Section&#8201;96&#8201;(1)&#8201;(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is
equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Information made available in this prospectus should not be considered as &#147;<I>advice</I>&#148; as defined in the South
African Financial Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Notice to Prospective Investors in Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of our common stock
under the Israeli Securities Law, 5728&#151;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#150;1968,
including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified
investors defined in the First Addendum of the Israeli Securities Law, 5728&#151;1968, subject to certain conditions, or the &#147;Qualified Investors.&#148; The Qualified Investors shall not be taken into account in the count of the Addressed
Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require us to publish a prospectus in accordance with and subject to the Israeli Securities Law,
5728&#151;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our shares of our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35
Addressed Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Qualified Investors may have to submit written evidence that they meet the definitions set out in of
the First Addendum to the Israeli Securities Law, 5728&#151;1968. In particular, we may request, as a condition to be offered shares of our common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting
on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#151;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law,
5728&#151;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728&#151;1968 and the regulations promulgated thereunder in connection with the offer to be
issued shares of our common stock; (iv)&nbsp;that the shares of our common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728&#151;1968 (A) for its own account, (B)&nbsp;for investment purposes
only, and (C)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728&#151;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified
Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli
identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of our common stock being offered in this prospectus will be passed upon for us by Goodwin Procter
LLP, Redwood City, California. Cooley LLP, San Francisco, California, is representing the underwriters in this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_22"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial
statements at December&nbsp;31, 2022 and 2023, and for each of the two years in the period ended December&nbsp;31, 2023, as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration
statement in reliance on Ernst&nbsp;
&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_23"></A>WHERE YOU CAN
FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (File Number 333-282469) under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus, which constitutes part of the registration statement, does not
contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus
to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file
annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at <I>www.sec.gov</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx762905_24"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Statements as of and for the Years Ended December 2022 and 2023 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:42)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_3">Statements of Operations and Comprehensive (Loss) Income</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_4">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Financial Statements as of December 31, 2023 and June 30, 2024
and for the Six Months Ended June 30, 2023 and 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited Interim Condensed Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_101">Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_102">Condensed Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_103">Condensed Statements of Convertible Preferred Stock and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_104">Condensed Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin762905_105">Notes to Condensed Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Septerna,
Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying balance sheets of Septerna, Inc. (the Company) as of December&nbsp;31, 2022 and 2023, the related statements of operations and comprehensive (loss) income, convertible preferred stock and stockholders&#146; deficit and cash
flows for the years then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at
December&nbsp;31, 2022 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting.
Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Mateo, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;2, 2024, except for the eleventh paragraph to Note&nbsp;1, as to which the date is </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October 21, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_2"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In
thousands, except for share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">12,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">546</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred stock, $0.001 par value per share; 100,000,000 and 75,000,000
shares authorized at December&nbsp;31, 2022 and 2023, respectively; 75,000,000 shares issued and outstanding as of December&nbsp;31, 2022 and 2023; liquidation preference of $75,000 at December&nbsp;31, 2022 and 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.001 par value per share; no shares authorized issued or
outstanding at December 31, 2022; 121,657,452 shares authorized at December 31, 2023; 60,828,720 shares issued and outstanding as of December&nbsp;31, 2023; liquidation preference of $75,000 at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share, 150,000,000 and 260,590,689 shares authorized at
December&nbsp;31, 2022 and 2023, respectively; 3,181,829 shares and 3,168,134 shares issued and outstanding at December&nbsp;31, 2022 and 2023, respectively; 1,527,641 and 1,002,044 shares subject to repurchase as of December&nbsp;31, 2022 and 2023,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_3"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations and Comprehensive (Loss) Income </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses (income):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses (income)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) income before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income and comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share attributable to common stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net (loss) income per share attributable to
common stockholders:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,928,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,177,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:85pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_4"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,235,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,052</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A Convertible Preferred Stock, net of issuance costs of $31</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">952,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,181,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B Convertible Preferred Stock, net of issuance costs of $479</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repurchase of unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,168,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:130pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_5"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net (loss) income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repurchases of forfeited restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series A convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series B convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure for noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
asset obtained in exchange for operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment held in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral
part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_6"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of the Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Septerna, Inc. (&#147;Septerna&#148; or the &#147;Company&#148;) is a clinical-stage biotechnology company pioneering a new era of G
protein-coupled receptor (&#147;GPCR&#148;) oral small molecule drug discovery powered by its proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. The Company&#146;s industrial-scale platform aims to unlock the
full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of product candidates focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> replicates the natural
structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as the Company believes, the first time. The Company&#146;s foundational technologies enable it to isolate, purify, and reconstitute full-length, properly folded
GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. The Company then applies
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen
for, and optimize potential product candidates. Leveraging its platform, the Company has transformed GPCR oral small molecule drug discovery to an industrialized and iterative structure-based drug design approach to expand the landscape of druggable
GPCR targets with novel oral small molecule medicines for patients. The Company&#146;s Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is designed to enable it to target certain GPCRs for the first time, uncover
novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was incorporated in Delaware in December 2019, under the name GPCR NewCo, Inc. In June 2021, the Company changed its name to
Septerna, Inc. The Company is headquartered in South San Francisco, California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which assumes that the Company
will realize its assets and satisfies its liabilities in the normal course of business. The Company is subject to risks inherent in operating an early-stage biotechnology business. These risks include, but are not limited to, dependence on the
development of marketable products, the ability to attract, retain, and motivate qualified personnel, rapid technological changes and the rapidly evolving nature of the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has historically financed its operations primarily through the issuances of convertible promissory notes and convertible preferred
stock. In November 2021, the Company entered into a total of $100.0&nbsp;million of Series A convertible preferred stock financing which was divided into two tranches. The initial tranche was completed in November 2021 for net proceeds of
$44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the conversion of the then outstanding convertible promissory notes plus accrued interest. In November 2022, the Company
executed the second tranche for net cash proceeds of $30.0&nbsp;million. In June 2023, the Company entered into a total of $150.0&nbsp;million of Series B Convertible Preferred Stock financing, which was divided into two tranches of equal amounts.
The first tranche, which was the issuance of $75.0&nbsp;million of Series B Convertible Preferred Stock, was completed in July 2023 for net proceeds of $74.5&nbsp;million (see Note 8). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second tranche, which is the issuance of the remaining $75.0&nbsp;million, was completed in May 2024 for net proceeds of
$74.9&nbsp;million (see Note 8). Upon issuance of the Series B Convertible Preferred Stock, the Company also amended the Series A Preferred Stock agreement to cancel the remaining 25.0&nbsp;million unissued shares of Series A Convertible Preferred
Stock originally authorized under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded a gain totaling
$47.6&nbsp;million for the sale of an <FONT STYLE="white-space:nowrap">in-progress</FONT> research and development (&#147;IPR&amp;D&#148;) asset related to a GPCR program (see Note 4) and $0.2&nbsp;million in revenue related to research services
(see Note 5) resulting in net income of $4.2&nbsp;million. Management expects to incur net losses for the foreseeable future as it conducts research and development. To date, none of the Company&#146;s product candidates have been approved by the
U.S. Food and Drug Administration (&#147;FDA&#148;) for commercial sale and, therefore, the Company has not generated any revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the income generated during the year ended December&nbsp;31, 2023, the Company has experienced net losses from operations and
negative cash flows from operating activities and capital expenditures since inception and had an accumulated deficit of $46.6&nbsp;million as of December&nbsp;31, 2023. The Company believes its cash and cash equivalents of $88.5&nbsp;million as of
December&nbsp;31, 2023, together with (i)&nbsp;the receipt of the remaining $22.6&nbsp;million in the first half of 2024 related to the gain recognized during the year ended December&nbsp;31, 2023 and (ii)&nbsp;the net proceeds from the issuance of
its second tranche of Series B Convertible Preferred Stock of $74.9&nbsp;million received in May 2024 (see Note 8) will be sufficient to fund the Company&#146;s operations for, at least, twelve months from the date of issuance of the financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will need substantial additional funding to support its continuing operations and pursue its development
strategy. Until such time as the Company can generate significant revenue from commercial sales of its product candidates, if ever, management may seek additional funding through the issuance of preferred stock or common stock, debt financings, or
licensing arrangements or collaborations/partnerships with other companies. The amount and timing of future funding requirements will depend on many factors, including the pace and results of clinical development efforts for the Company&#146;s
product candidates and other research, development and manufacturing activities. Management may not be able to raise additional capital on terms favorable for or acceptable to the Company, or at all. Any failure to raise capital as and when needed
would compromise the Company&#146;s ability to execute on its business plan and may cause the Company to significantly delay, scale back or discontinue the research and development of some of its programs or curtail any efforts to expand its product
pipelines and will materially harm its business, financial position and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its founding, the Company has
devoted substantially all of its resources to organizing and staffing the Company, business planning, raising capital, developing its proprietary platform and structure-based drug discovery platform, identifying and discovering its product
candidates, establishing its intellectual property portfolio, conducting research and preclinical studies, including Investigational New Drug (IND)-enabling studies, initiating and conducting clinical trials, establishing arrangements with third
parties for the manufacture of its product candidates and related raw materials, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;17, 2024, the Company&#146;s board of directors approved a 1-for-8.6103 reverse stock split of its issued and outstanding shares of common stock, which was effected on October&nbsp;18, 2024. Upon the effectiveness of the reverse stock
split, (i) all shares of outstanding common stock were adjusted; (ii) the conversion ratio of the convertible preferred stock was adjusted; (iii) the number of shares of common stock for which each outstanding option to purchase common stock is
exercisable were adjusted; and (iv) the exercise price of each outstanding option to purchase common stock was adjusted. All of the outstanding common stock share numbers (including shares of common stock subject to the Company&#146;s options and as
converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted in the financial statements to reflect this reverse stock split
for all periods presented. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. The number of authorized shares has not changed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;), stated in U.S. dollars and include all adjustments necessary for the fair
presentation of the Company&#146;s financial statements as of December&nbsp;31, 2022 and 2023, and for the years then ended. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting
Standards Codification and Accounting Standards Updates (&#147;ASUs&#148;), of the Financial Accounting Standards Board (&#147;FASB&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of
Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures at the date of the financial statements and reported amounts of expenses during the reporting periods. These estimates form the basis for judgments the Company
makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information
from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are
not readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. Estimates are used in accounting for, among other things, useful lives of property and equipment, the rate used in determining
the present value of lease payments, fair value of assets and liabilities, research and development accruals, the fair value of common stock and stock options, the allocation of a revenue contract&#146;s transaction price to each distinct
performance obligation on a relative standalone selling price basis, uncertain tax positions and the valuation allowance for deferred income tax assets. Actual results may differ from these estimates and assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company
has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of
Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that
require the Company&#146;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior
rights and preferences of the convertible preferred stock senior to the Company&#146;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios.
Changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s results can also be affected by economic, political, legislative, regulatory and legal actions. Economic conditions, such as recessionary trends, inflation, interest, changes in regulatory laws and monetary exchange rates, and
government fiscal policies, can have a significant effect on operations. While the Company maintains reserves for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating
segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (&#147;CODM&#148;), in deciding how to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allocate resources to an individual segment and in assessing performance. The Company&#146;s CODM is its chief executive officer. The Company has determined it operates in one segment. As of
December&nbsp;31, 2022 and 2023, all of the Company&#146;s property and equipment was maintained in the United States. For the year ended December&nbsp;31, 2023, all of the Company&#146;s revenue was generated and incurred in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial
instruments, which potentially subject the Company to a concentration of credit risk, consist primarily of cash and cash equivalents and accounts receivable. The Company invests its cash equivalents in money market funds and limits its credit risk
by placing its cash and cash equivalents with banks and institutions that are highly creditworthy. Such deposits may be in excess of the Federal Deposit Insurance Corporation (&#147;FDIC&#148;) insured limits. The Company is exposed to credit risk
in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary focus of the Company&#146;s investment strategy is to preserve capital and meet liquidity requirements. Management believes that
the Company is not exposed to significant credit risk due to the high-credit-quality financial institutions in which those deposits are held. The Company has not experienced any losses on its cash and cash equivalents since inception. The Company
has no significant <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet concentrations of credit risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to all
of the risks inherent in an early-stage biotechnology company. These risks include, but are not limited to, limited management resources, efficacy of product candidates, intense competition, and dependence upon the availability of cash to sustain
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash
equivalents. Cash equivalents are reported at fair value. At December&nbsp;31, 2022 and 2023, the Company&#146;s cash equivalents are all held in money market funds. As of the balance sheet date, and periodically throughout the year, the Company has
maintained balances in various operating accounts in excess of the FDIC insured limits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash is comprised of cash that is
restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#146;s lease agreement (see Note 6), the Company is required to maintain a collateral account to secure a letter of credit issued to
its landlord. The collateral account is classified as restricted cash on the Company&#146;s balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash, cash
equivalents and restricted cash consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">89,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable and Other Receivables </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes a receivable when the Company has an unconditional right to payment, which is generally at the time of delivery of
assets, or at the time services are rendered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An allowance for expected credit losses over the life of the receivables is reserved for
based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is
<FONT STYLE="white-space:nowrap">re-evaluated</FONT> on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. No allowance for credit losses was recorded during the year
ended December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company&#146;s accounts receivable and other receivable related to sale
of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset balances were entirely attributed to Vertex Pharmaceuticals Incorporated (&#147;Vertex&#148;) (see Note 4 and Note 5). The Company did not have accounts receivable as of
December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment is recorded at cost, subject to adjustments for impairments, less accumulated depreciation. The Company depreciates
property and equipment using the straight-line method over the estimated useful lives of the respective assets, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lab equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Furniture and fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Office equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Computer Equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shorter of remaining lease term or estimated useful life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation or amortization begins at the time the asset is placed in service. Maintenance and repairs that
do not improve or extend the life of the respective asset are charged to expense as incurred. Upon disposal of assets, the cost and related accumulated depreciation is removed from the balance sheet and the resulting gain or loss is reflected in the
statements of operations and comprehensive (loss) income within other income, net. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived assets for impairment, primarily its property and equipment, whenever events or changes in circumstances
indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the undiscounted expected future cash flows the asset is expected to generate over
its remaining life. An impairment loss would be recognized when the estimated undiscounted future cash flows expected to result from the use of the asset or asset group and its eventual disposition are less than its carrying amount. Impairment, if
any, is measured as the amount by which the carrying amount of a long-lived asset or asset group exceeds its fair value. There were no impairments of the Company&#146;s long-lived assets for the years ended December&nbsp;31, 2022 and 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for
its leases in accordance with FASB Accounting Standards Codification (&#147;ASC&#148;) 842, <I>Leases</I> (&#147;ASC 842&#148;). The Company adopted ASC 842 on January&nbsp;1, 2021, prior to entering into the lease agreement for its office and
research and development space. At inception of a contract, the Company determines whether an arrangement is or contains a lease. For each lease, the Company determines the classification as either an operating lease or a financing lease. Lease
recognition occurs at the lease commencement date and lease liability amounts are determined based on the present value of lease payments over the lease term. The lease term may include options to extend or terminate the lease only when it is
reasonably certain that the Company will exercise that option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses its incremental borrowing rate based on the information available at lease
commencement date in determining the present value of lease payments if the Company&#146;s leases do not provide an implicit rate. The Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay
to borrow on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets represent the
Company&#146;s right to use underlying assets for the lease term and operating lease liabilities represent the Company&#146;s obligation to make lease payments under the lease.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets also include any lease payments made prior to the commencement date and exclude lease incentives received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected to apply the practical expedient of combining lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for
the real estate lease asset class. Fixed lease payments on operating leases are recognized as lease expense over the expected term of the lease on a straight-line basis. Variable lease expenses that are not considered fixed are recognized as
incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company elected the short-term lease practical expedient that allows the lessee to not record a lease
liability and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases with a term of 12 months or less. See Note 6 for additional information on the Company&#146;s leases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company records all shares of convertible preferred stock at their respective fair values on the dates of issuance, less issuance costs. In the event of a deemed liquidation event, such as a change of control of the Company, proceeds received from
the sale of such shares will be distributed in accordance with the liquidation preferences set forth in the Company&#146;s certificate of incorporation unless the holders of the convertible preferred stock have converted their shares of convertible
preferred stock into shares of common stock. Convertible preferred stock is therefore classified outside of stockholders&#146; deficit on the balance sheet as events triggering redemption are not solely within the Company&#146;s control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not adjusted the carrying values of its convertible preferred stock to the liquidation preferences because of the uncertainty
of whether or when such an event would occur. As of December&nbsp;31, 2022 and 2023, it was not probable that such a redemption would occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
generated revenue for the year ended December&nbsp;31, 2023 from service revenue for research activities performed related to an agreement with Vertex (see Note 5). The Company considers revenue to be earned when all of the following criteria are
met: (i)&nbsp;the Company has a contract with a customer that creates enforceable rights and obligations; (ii)&nbsp;promised products or services are identified; (iii)&nbsp;the transaction price, or the amount the Company expects to receive,
including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; (iv)&nbsp;and the Company has
transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract
is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. When a contract contains variable consideration and the variable consideration is constrained to the extent
that it is not probable that it will be received, it is excluded from the transaction price. A contract&#146;s transaction price is allocated to each distinct performance obligation on a relative standalone selling price basis and recognized as
revenue when, or as, control of the distinct good or service is transferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company&#146;s revenue was entirely
attributable to Vertex. The Company did not record revenue during the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale of
<FONT STYLE="white-space:nowrap">Non-Financial</FONT> Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of <FONT STYLE="white-space:nowrap">non-financial</FONT> assets
that are outside the scope of the Company&#146;s ordinary activities are accounted for under ASC <FONT STYLE="white-space:nowrap">610-20,</FONT> <I>Other Income - Gains and Losses from the Derecognition of
<FONT STYLE="white-space:nowrap">Non-financial</FONT> Assets</I> (&#147;ASC <FONT STYLE="white-space:nowrap">610-20&#148;).</FONT> Pursuant to ASC <FONT STYLE="white-space:nowrap">610-20,</FONT> the Company applies the guidance in ASC 606,
<I>Revenue from Contracts with</I> <I>Customers </I>(&#147;ASC 606&#148;)<I>,</I> to determine if a contract exists, identify the distinct <FONT STYLE="white-space:nowrap">non-financial</FONT> assets, and determine when control transfers and,
therefore, when to derecognize the <FONT STYLE="white-space:nowrap">non-financial</FONT> asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation
of the gain or loss for the <FONT STYLE="white-space:nowrap">non-financial</FONT> asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses consist primarily of employee-related costs,
including salaries, benefits and stock-based compensation for employees engaged in research and development activities, costs related to research activities, preclinical studies, production of preclinical materials, information technology-related
costs, allocated overhead costs including facility-related expenses, contract manufacturing, consulting fees, costs related to laboratory operations and fees paid to other entities that conduct certain research and development activities on the
Company&#146;s behalf. Payments made prior to the receipt of goods and services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into various agreements with outsourced contract manufacturing and development vendors. The Company estimates accrued
research and development expenses as of each balance sheet date based on facts and circumstances known at that time. The Company periodically confirms the accuracy of its estimates with internal management personnel and external service providers,
and makes adjustments, if necessary. Research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of
research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will
adjust the accrual accordingly. Payments made under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs to secure
and maintain patents covering the Company&#146;s technology and product candidates are expensed as incurred and are classified as general and administrative expenses in the statements of operations and comprehensive (loss) income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets
and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would
be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation
techniques used to measure fair value must maximize the use of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value
measurements as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the
measurement date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities,
unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or
liabilities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities
that are supported by little or no market data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous
market in which to transact and the market-based risk. The carrying values of the Company&#146;s financial instruments, which include cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued expenses, approximate
their fair values due to their relatively short maturities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to stock options and restricted stock awards granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> is recognized based on the grant-date fair value of the awards. The fair value of stock options is determined using the Black Scholes option pricing model on the date of grant. The fair value of
restricted stock awards is determined using the estimated fair value of the Company&#146;s common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair
value of the Company&#146;s common stock is determined by the Company&#146;s Board of Directors with the assistance of management and an independent third-party valuation specialist. The valuation methodologies used to determine the fair value of
the Company&#146;s common stock utilize certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair
value of the Company&#146;s common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants
Technical Practice Aid, &#147;<I>Valuation of Privately Held Company Equity Securities Issued as Compensation,&#148;</I> to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require
management judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and
preferences of the convertible preferred stock senior to the Company&#146;s common stock at the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under different scenarios. Changes to the
key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For stock-based
awards with service conditions only, the Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting term of the award
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of four years. For stock-based awards with vesting criteria subject to the achievement of performance-based conditions, in addition to service conditions, the Company recognizes stock-based
compensation expense on an accelerated basis over the vesting period when achievement of the performance criteria becomes probable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense is recorded within research and development and general and administrative expenses in the accompanying
statements of operations and comprehensive (loss) income based on the function to which the related services are provided. The Company recognizes stock-based compensation expense for the portion of awards that have vested. Forfeitures are accounted
for as they occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> Income Taxes (Topic 740): <I>Simplifying the Accounting for Income
Taxes </I>on January&nbsp;1, 2021, with no impact to the financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the asset and liability approach to
account for income taxes. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities.
Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates
expected to be in effect in the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not
be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions recognized in the financial statements by prescribing a <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any
resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related interest and penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive
(Loss) Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from
transactions and other events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company did not have any other comprehensive income or loss for the periods presented and therefore comprehensive (loss) income was
the same as the Company&#146;s net (loss) income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net (Loss) Income Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net (loss) income per share is computed by dividing the net (loss) income by the weighted-average number of common shares outstanding
during the period, without consideration of potential dilutive securities. Vested restricted stock is treated as outstanding for accounting purposes. Unvested restricted stock is not considered to be outstanding for purposes of the calculation of
basic net (loss) income per share. Diluted net (loss) income per share is computed by dividing the net (loss) income by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of
potential dilutive shares outstanding during the period. Potential dilutive securities include stock options, unvested restricted stock and convertible preferred stock. The dilutive effect of stock options and unvested restricted stock is computed
using the treasury stock method and the dilutive effect of convertible preferred stock is calculated using the <FONT STYLE="white-space:nowrap">&#147;if-converted</FONT> method.&#148; For all periods presented in a net loss position, diluted net
loss per share is the same as basic net loss per share since the effect of including potential common shares is anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net (loss) income per share attributable to common stockholders is
presented in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers all series of its convertible preferred stock to be participating securities. Under the <FONT
STYLE="white-space:nowrap">two-class</FONT> method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of its convertible preferred stock do not have a contractual obligation to share
in the Company&#146;s losses. Net income is attributed to common stockholders and participating securities based on their participation rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments &#150; Credit Losses: Measurement
of Credit Losses on Financial Instruments (Topic 326),</I> which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments,
including trade receivables and available for sale debt securities. Topic 326 is effective for annual periods beginning after December&nbsp;15, 2022, and early adoption is permitted. The Company adopted Topic 326 on January&nbsp;1, 2023, and the
adoption did not have a material impact on its financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the
Company as of the specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures</I>. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment
expenses on an interim and annual basis. The ASU is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods after December&nbsp;5, 2024, with early adoption permitted. The adoption of this standard is not expected to
have a material impact on the Company&#146;s financial statements at adoption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</I>, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve
income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years
beginning after December&nbsp;15, 2025, on a prospective basis. Early adoption and retrospective reporting are permitted. We are currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status and Smaller Reporting Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). Under the
JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this
extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as
of public company effective dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is also a smaller reporting company as defined in the Securities Exchange Act of
1934, as amended (the &#147;Exchange Act&#148;). The Company may continue to be a smaller reporting company even after it is no longer an emerging growth company. The Company may take advantage of certain of the scaled disclosures available to
smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as its voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $250.0&nbsp;million measured on the last business day of its second fiscal quarter, or its annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and its voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of its second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Balance Sheet Components </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash
Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Money market funds are highly liquid investments and are actively traded. The fair value of the Company&#146;s
money market funds are based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level&nbsp;1 of the fair value hierarchy. There were no transfers between Level&nbsp;1, 2,
or 3 for any of the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $0.6&nbsp;million and $0.8&nbsp;million for the years ended
December&nbsp;31, 2022 and 2023, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses and Other Current Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued operating expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Gain on Sale of <FONT STYLE="white-space:nowrap">Non-Financial</FONT> Asset </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vertex Asset Sale </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September
2023, the Company entered into an asset purchase agreement with Vertex under which Vertex acquired an IPR&amp;D asset related to a GPCR program, including all intellectual property, materials, and compounds associated with the program (the
&#147;Vertex Purchase Agreement&#148;). Additionally, as part of the agreement, Vertex assumed all claims, counterclaims and credits associated with the program, and the Company gave up all rights to the intellectual property. The transfer of the
IPR&amp;D asset to Vertex was completed in November 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the same time in September 2023, the Company entered into a research service
agreement with Vertex under which the Company agreed to perform certain exploratory research activities for Vertex (the &#147;Vertex Research Service Agreement&#148;) (see Note 5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the IPR&amp;D asset sale should be accounted for under the guidance at ASC
<FONT STYLE="white-space:nowrap">610-20,</FONT> as this type of transaction did not meet the definition of &#147;ordinary activities&#148; of the Company and Vertex should not be considered a &#147;customer&#148; in this transaction. However, since
both the Vertex Purchase Agreement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the Vertex Research Service Agreement were entered into at the same time with the same counterparty with a single commercial objective, the Company combined the contracts and applied the
allocation principles under ASC 606. The Company identified the performance obligations in both contracts, determined the transaction price and allocated the transaction price to the performance obligations in the contracts based on the estimated
standalone selling price for each performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded a gain on
sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million for the sale of the IPR&amp;D asset to Vertex on its statements of operations and comprehensive (loss) income. The Company received $25.0&nbsp;million in cash
at the closing of the agreement in September 2023 and recorded the remaining balance of $22.6&nbsp;million in other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset on its balance sheet as of
December&nbsp;31, 2023. As of December&nbsp;31, 2023, the sale of the IPR&amp;D asset was complete and the Company had an unconditional right to the $22.6&nbsp;million. The Company received the payment of $22.6&nbsp;million of this balance in the
first half of 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Vertex Purchase Agreement also provides for a potential milestone payment payable to the Company contingent upon
achievement of a certain research milestone. The milestone payment amount is determined based on the timing of achievement of the research milestone. The variable consideration related to this milestone payment was determined to be improbable of
receipt at this time. As a result, the milestone payment was excluded from the transaction price. After the potential milestone payment, the Company will not receive any other payments or future royalties related to this IPR&amp;D asset. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Revenue </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Vertex Research Service
Agreement</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As disclosed in Note 4, the Company entered into the Vertex Research Service Agreement in September 2023 under
which the Company agreed to perform certain exploratory research activities for Vertex. Although the Company accounted for the IPR&amp;D asset sale under the guidance at ASC <FONT STYLE="white-space:nowrap">610-20,</FONT> the research services
portion of the transaction fell under the scope of the revenue from contracts with customers guidance, ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Vertex Research
Service Agreement is for a <FONT STYLE="white-space:nowrap">two-year</FONT> term, however, Vertex has the ability to terminate the agreement with a <FONT STYLE="white-space:nowrap">30-day</FONT> notice at any time. As a result, the Company concluded
that the contract duration is 30 days, representing a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> service contract. The Company recognizes this service revenue over the performance period of the
research services as the services are provided. The Vertex Research Service Agreement also includes a provision related to additional research services, which the Company concluded met the definition of a customer option under ASC 606. The Company
will recognize revenue related to the customer option if and when it is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the
Company recorded revenue of $0.2&nbsp;million related to research activities performed in connection with the Vertex Research Service Agreement, which is also included in accounts receivable on the Company&#146;s balance sheet at December&nbsp;31,
2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Operating
Lease</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, the Company entered into an operating lease for 12,560 square feet of office and research and
development space at the Company&#146;s headquarters in South San Francisco, California, which was scheduled to expire in February 2023. In September 2022, the Company amended the lease agreement to include an additional 9,348 square feet of office
and research and development space, increasing the total leased premises to 21,908 square feet (the &#147;Original Leased Space&#148;), which was also scheduled to expire in February 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, the Company entered into another lease amendment to extend the lease term
of the Original Leased Space (the &#147;Extension of Original Leased Space&#148;) and lease an additional 22,911 square feet of office and research and development space (the &#147;Additional Leased Space&#148;). Upon completion of the construction
of the new office and research and development space in November 2023, the Additional Leased Space commenced, and the Company relocated its operations to the Additional Leased Space and vacated the Original Leased Space to allow the landlord to
renovate it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Renovation of the Original Leased Space was completed in July 2024. Upon completion of the renovation of the Original Leased
Space, the lease of the Original Leased Space commenced, resulting in the total leased premises increasing to 44,819 square feet (the &#147;Leased Space&#148;). The lease term for the Leased Space is for eight years from the commencement date of the
Original Leased Space. The amended lease also includes an option for the Company to extend the lease for an additional eight-year term (the &#147;Extension Option&#148;). As of December&nbsp;31, 2023, it is not probable that the Company will
exercise the Extension Option. As a result, the Company did not include the Extension Option in the calculation of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recorded an operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and operating lease liability for the Additional Leased Space as the lease commenced in November 2023, when the Company took control of the property. As of December&nbsp;31, 2023, the
entire balance of the operating lease liability associated with the Additional Leased Space was classified as <FONT STYLE="white-space:nowrap">non-current</FONT> as the Company received a rent abatement for four months in the first year of the lease
and, therefore, the operating lease liability will increase over the 12 month-period starting from December&nbsp;31, 2023. For the year ended December&nbsp;31, 2022, the Company did not recognize a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset or operating lease liability for the minimum rental payments associated with the Additional Leased Space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the expenses recognized and cash paid for the Leased Space (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, the Company recorded an increase of $0.6&nbsp;million in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and operating lease liability related to the Extension of Original Leased Space. In December 2023, the Company recorded a $12.6&nbsp;million <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and $12.6&nbsp;million operating lease liability associated with the Additional Leased Space. These amounts are disclosed in the supplemental information of
noncash activities on the statements of cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the remaining lease term of the Original Leased Space
was approximately 1.0 year. The incremental borrowing rate used for the calculation of the present value of lease payments over the lease term for the Extension of Original Leased Space was approximately 18.8%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the remaining lease term of the Additional Leased Space was approximately 8.5 years. The incremental borrowing
rate used for the calculation of the present value of lease payments over the lease term at the lease commencement date was approximately 12.3%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, future minimum rental payments for operating leases, including
for the Original Leased Space, were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Future<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undiscounted lease payments*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total present value of operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:17%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Related to the Original Leased Space, which was under renovation at December&nbsp;31, 2023 and commenced in July
2024. </P></TD>
<TD WIDTH="18%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and 2023, the Company did not have any finance leases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may be subject to legal proceedings, claims and litigation, as the Company
operates in an industry susceptible to patent or other legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are
expensed when incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware
law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements
with its officers and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also agreed to indemnify the investors against certain losses, claims or liabilities due to
certain statements, omissions or violations by the Company if Company securities held by the investors are included in a registration statement. The certain statements, omissions or violations that are covered by these include, but are not limited
to, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the applicable registration statement, (ii)&nbsp;any omission or alleged omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading, (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act of 1933, as amended, the Exchange Act, and certain other securities laws. The Company will reimburse the
investors for any legal or other expenses reasonably incurred by them in connection with investigating or defending such losses, claims, damages or liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable. The
Company is not currently aware of any indemnification claims. Accordingly, the Company did not record any liabilities associated with these indemnification rights and agreements as of December&nbsp;31, 2022 and 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company&#146;s convertible preferred stock consisted of the following (in thousands, except for share and per
share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Price&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, convertible preferred stock consisted of the following (in thousands, except for
share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.23297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the Company executed a Series A Convertible Preferred Stock financing arrangement that would
provide financing of up to $100.0&nbsp;million over an initial tranche and subsequent callable tranches through the issuance of up to 100.0&nbsp;million shares of Series A Convertible Preferred Stock at an issuance price of $1.00 per share. In the
initial tranche, the Company issued 45.0&nbsp;million shares of Series A Convertible Preferred Stock for net proceeds of $44.7&nbsp;million, of which $30.0&nbsp;million was received in cash, net of issuance costs, and $14.7&nbsp;million was for the
conversion of the then outstanding convertible promissory notes plus accrued interest. The Series A Convertible Preferred Stock financing arrangement represented an equity financing, per the terms of the outstanding convertible promissory notes, and
as such the unpaid principal and accrued interest outstanding of $14.7&nbsp;million was converted into approximately 14.7&nbsp;million shares of Series A Convertible Preferred Stock. Additionally, in November 2022, the Company executed the second
tranche and issued 30.0&nbsp;million shares of Series A Convertible Preferred Stock and received net cash proceeds of $30.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Convertible Preferred Stock Purchase Agreement provided that, upon the fulfillment of certain conditions, each investor would
purchase its pro rata portion of the shares to be issued in additional Series A Convertible Preferred Stock closings. Further, the Company agreed to sell, and issue said shares of Series A Convertible Preferred Stock on the same terms as the first
tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were not freestanding from the associated shares of convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023, the Company amended and restated its certificate of incorporation to, among other things, increase the authorized number of
shares of the Company&#146;s convertible preferred stock to 196.7&nbsp;million shares, of which 121.7&nbsp;million shares are designated as Series B Convertible Preferred Stock, and to establish the rights, preferences, privileges and restrictions
of the Series B Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023, the Company entered into a Series B Convertible Preferred Stock financing
arrangement in which 121,657,452 shares of Series B Convertible Preferred Stock were authorized to be issued at an issuance price of $1.23297 per share over two tranches, for total proceeds of up to $150.0&nbsp;million. In June&nbsp;2023 and
July&nbsp;2023, the Company issued an aggregate of approximately 60.8&nbsp;million shares of Series B Convertible Preferred Stock at an issuance price of $1.23297 per share for net proceeds of $74.5&nbsp;million related to the first tranche, with a
potential second tranche of additional funding for up to $75.0&nbsp;million based on approval of the Board of Directors and consent of the majority of the holders of the then-outstanding Series B Convertible Preferred Stock. The Series B Convertible
Preferred Stock Purchase Agreement provides that, upon the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fulfillment of certain conditions, each investor will purchase its pro rata portion of the shares to be issued in additional Series B Convertible Preferred Stock closings. Further, the Company
agreed to sell, and issue said shares of Series B Convertible Preferred Stock on the same terms as the first tranche in the Purchase Agreement. The Company did not separately account for tranche purchase rights described above as they were not
freestanding from the associated shares of convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the Series B Convertible Preferred Stock, the
Company also amended the Series A Convertible Preferred Stock agreement to cancel the remaining 25.0&nbsp;million unissued shares of Series A Convertible Preferred Stock originally authorized under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the
remaining approximately 60.8&nbsp;million shares of Series B Convertible Preferred Stock for net proceeds of $74.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
rights, privileges, and preferences of the Series A and Series B Convertible Preferred Stock (together, the &#147;Convertible Preferred Stock&#148;) are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible
Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of the Convertible Preferred Stock is initially convertible, at the option of the holder at any time after all
authorized shares of the Convertible Preferred Stock have been issued or if otherwise approved by the holders representing at least a majority of the then outstanding shares of the Convertible Preferred Stock, including at least one holder that,
together with its affiliates, holds only shares of Series B Convertible Preferred Stock and is a major investor, as defined in the Company&#146;s amended and restated investors&#146; rights agreement (the &#147;Required Vote&#148;), into shares of
common stock as determined by dividing the original issue price by the conversion price in effect at the time of conversion. The Series A Convertible Preferred Stock conversion price is initially $1.00, and the Series B Convertible Preferred Stock
conversion<B> </B>price is initially $1.23297. The conversion prices are subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Convertible Preferred Stock. The
conversion prices are subject to adjustment in the event the Company issues additional shares of common stock without consideration or for a consideration per share less than the conversion price in effect prior to such<B> </B>issuance, unless the
Required Vote determines that no such adjustment shall be made to the conversion price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special mandatory conversion will occur if a
convertible preferred stockholder fails to purchase their agreed upon share, as originally allocated to such holder in the purchase agreement, in additional closings of the Convertible Preferred Stock as defined in the purchase agreement, and such
failure is not cured as specified in the purchase agreement following receipt of the subsequent closing notification. Holders of Series B Convertible Preferred Stock have the option to waive the special mandatory conversion as specified in the
purchase agreement. Upon such event, each share of the Convertible Preferred Stock held by such holder will be automatically converted into that number of shares of common stock equal to 10% of the original issue price divided by the conversion
price in effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mandatory conversion of all outstanding shares of the Convertible Preferred Stock at the then
effective conversion rate will also occur automatically upon (i)&nbsp;consent of holders representing the Required Vote or (ii)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $1.849455 per share (subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm commitment underwritten public offering resulting in at least $50.0&nbsp;million in
gross proceeds to the Company, after deducting underwriting discounts and commissions, and in connection with such offering the common stock is listed for trading on the Nasdaq, the New York Stock Exchange or another exchange approved by the board
of directors, including the approval of at least a majority of the Convertible Preferred Stock directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company, other
than dividends on shares of common stock payable in shares of common stock, unless the holders of the Convertible Preferred Stock first receive, or simultaneously receive, a dividend on outstanding shares of the Convertible Preferred Stock in an
amount at least equal to the dividend payable based on the number of shares of common stock at the then conversion rate, such that the calculation should result in the highest preferred stock dividend. The board of directors has not declared any
dividends <FONT STYLE="white-space:nowrap">to-date.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Board Representation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of outstanding shares of the Convertible Preferred Stock is entitled to one vote for each share of common stock into which such
shares of preferred stock are convertible and shall vote together with the holders of common stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis, except as provided by law or by the other
provisions of the Company&#146;s certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of shares of Series A Convertible Preferred Stock, exclusively
and as a separate class, are entitled to elect three directors of the Company. The holders of shares of Series B Convertible Preferred Stock, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of
record of the shares of common stock and any other class or series of voting stock (including the Convertible Preferred Stock), as a single class, are entitled to elect the remaining directors. The size of the board shall be set and remain at seven
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protective Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time when shares of the Convertible Preferred Stock are outstanding, the Company shall first obtain the approval of the Required Vote,
voting separately as a class, with respect to the following actions: (i)&nbsp;consummation of a liquidation, dissolution or winding up of the Company, or effect any&nbsp;merger, acquisition or consolidation or any other deemed liquidation event,
(ii)&nbsp;amend, alter or repeal any provision of the Company&#146;s certificate of incorporation or bylaws, (iii)&nbsp;create, authorize, issue or obligate the Company to issue shares of any equity security or increase the authorized number of
shares of the Convertible Preferred Stock or of any additional class or series of stock unless it ranks junior to the Convertible Preferred Stock, (iv)&nbsp;reclassify, alter or amend any existing security of the Company that is pari passu with the
Convertible Preferred Stock, or is junior with the Convertible Preferred Stock , in respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such
reclassification alteration or amendment would render such other security senior to the Convertible Preferred Stock, or in the case of a previously junior security would render such security senior to or pari passu with the Convertible Preferred
Stock, (v)&nbsp;pay or declare any dividend, other than dividends on the Convertible Preferred Stock, or make any distribution on any shares of capital stock prior to the Convertible Preferred Stock, other than common stock or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options to acquire common stock repurchased from former employees or consultants in connection with the cessation of their employment/services, pursuant to the provisions of existing plans or
agreements, (vi)&nbsp;create, adopt, amend, terminate or repeal any equity or equity-linked compensation plan, (vii)&nbsp;increase or decrease the authorized number of directors constituting the Board of Directors, change the number of votes
entitled to be cast by any director or directors on any matter, or adopt any provision inconsistent with Article Sixth; (viii)&nbsp;create or hold (or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to
issue) any shares of capital stock in any subsidiary that is not a wholly-owned subsidiary of the Corporation, or sell, lease, transfer, exclusively license or otherwise dispose of any direct or indirect subsidiary capital stock or all or
substantially all of any direct or indirect subsidiary assets; or (ix)&nbsp;sell, assign, license, pledge or encumber material technology or intellectual property, or enter into or grant any royalty streams related thereto, other than licenses
granted in the ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution or winding up, or in the event of a deemed liquidation event of the
Company, the holders of shares of the Convertible Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders, or out of the consideration payable to stockholders, as
applicable, before any payment shall be made to the holders of common stock, an amount per share equal to the greater of (i)&nbsp;the original issue price, plus any dividends declared but unpaid, or (ii)&nbsp;such amount per share as would have been
payable had all shares of the Convertible Preferred Stock been converted into common stock immediately prior to such event. If, upon the occurrence of such event, the assets of the Company available for distribution to its stockholders are
insufficient to pay the holders of the Convertible Preferred Stock the full amount to which they are entitled, the holders of the Convertible Preferred Stock shall share ratably in any distribution of the assets available for distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Classification</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company has classified the Convertible Preferred Stock outside of permanent equity on the balance sheet as these shares can be redeemed upon the occurrence of certain change in control events that are outside of the Company&#146;s control, including
liquidation, sale or transfer of the Company. The Company has not adjusted the carrying values of the convertible preferred stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would
obligate the Company to pay the liquidation preferences to holders of shares of convertible preferred stock, and at the balance sheet dates these circumstances were not probable. Subsequent adjustments to the carrying values of the liquidation
preferences will be made only when it becomes probable that such a liquidation event will occur. As of December&nbsp;31, 2022 and 2023, it was not probable that such a redemption would occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2022, the Company was authorized to issue 150.0&nbsp;million shares of $0.001 par value common stock. In June 2023, the Company amended and restated its certificate of incorporation to, among other things, increase the authorized number of shares of
common stock of the Company to approximately 260.6&nbsp;million shares. As of December&nbsp;31, 2023, the Company was authorized to issue approximately 260.6&nbsp;million shares of $0.001 par value common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to dividends when and if declared by the board of directors, subject to the preferences applicable to
outstanding shares of the Convertible Preferred Stock. The board of directors has not declared any dividends and the Company has not paid any dividends. The holders of common stock are entitled to one vote per share on all matters to be voted upon
by the stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reserved the following shares of common stock, on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, for future issuance: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,613,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,710,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,129,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock outstanding under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,188,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">774,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock outstanding outside of 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,123,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for future grants under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">815,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,634,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,001,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,599,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, the Company adopted the Septerna, Inc. 2021 Stock Option and Grant Plan (the &#147;2021 Plan&#148;), which authorizes the Company to
grant incentive stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, restricted stock awards, unrestricted stock awards and restricted stock units, to officers, employees, directors, consultants, or other key persons
of the Company. The terms of the stock option and restricted stock agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2021 Plan. The exercise price of stock options shall not be
less than the estimated fair value of the underlying common stock on the date of grant. Stock option awards expire 10 years from the grant date, or as otherwise determined by the Board of Directors, or in the case of incentive stock options granted
to 10% stockholders, the term is no more than 5 years from the grant date. Additionally, the Company granted and issued restricted stock awards and allowed the recipients to purchase the unvested restricted stock awards at par value per share. The
shares issued for unvested restricted stock awards under the 2021 Plan are subject to repurchase by the Company at the original issuance price in the event of the holder&#146;s termination of its relationship with the Company. Consideration received
for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#146; deficit as the related awards vest over the requisite service period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 Plan initially authorized a total of approximately 2.4&nbsp;million shares reserved for future issuance. In June 2023, the Company
amended and restated its certificate of incorporation to, among other things, increase the shares reserved for issuance under the 2021 Plan to approximately 4.2&nbsp;million shares. Approximately 0.8&nbsp;million and 1.6&nbsp;million shares remained
available for future issuance under the 2021 Plan as of December&nbsp;31, 2022 and 2023, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes restricted stock award activity under the 2021 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date Fair<BR>Value Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,188,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(400,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">774,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to grants under the 2021 Plan, the Company has also granted restricted stock
awards outside of plan, under the terms of restricted stock purchase agreements and subscription agreements, and unvested shares are subject to repurchase by the Company upon the holder&#146;s termination of its relationship with the Company at the
original purchase price. Consideration received for shares associated with the unvested restricted stock awards is initially recorded as a liability and subsequently reclassified into stockholders&#146; deficit as the related awards vest. The
following summarizes restricted stock award activity outside of the 2021 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Grant<BR>Date Fair<BR>Value Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restricted stock awards generally include a service condition for vesting and vest over four years with a <FONT
STYLE="white-space:nowrap">one-year</FONT> cliff vesting and <FONT STYLE="white-space:nowrap">pro-rata</FONT> monthly vesting thereafter, but some awards vest over different time periods. In addition, some restricted stock awards include vesting
criteria subject to the achievement of performance-based conditions in addition to service conditions, for which the Company periodically assesses the probability that the performance criteria will be met and only recognizes stock-based compensation
expense related to these awards when achievement of the performance criteria becomes probable. The total fair value of shares vested during the year ended December&nbsp;31, 2023 was $1.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and 2023, $0.1&nbsp;million and $0.1&nbsp;million in other liabilities on the Company&#146;s balance sheets was
related to the unvested shares subject to repurchase of approximately 1.5&nbsp;million and 1.0&nbsp;million shares, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes stock option activity under the 2021 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,078,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,123,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,123,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options include a service condition for vesting and most stock options vest over four years with a <FONT
STYLE="white-space:nowrap">one-year</FONT> cliff vesting and <FONT STYLE="white-space:nowrap">pro-rata</FONT> monthly vesting thereafter. The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated
as the difference between the exercise price of the options and the estimated fair value of the Company&#146;s common stock, as determined by the Board of Directors, as of December&nbsp;31, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair value of options that vested for the year ended December&nbsp;31, 2023 was
$0.2&nbsp;million. The options granted in the year ended December&nbsp;31, 2023 had a weighted-average per share grant-date fair value of $3.01 and a total grant date fair value of $3.2&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
weighted-average assumptions used to value employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock option awards granted under the 2021 Plan during the years ended December&nbsp;31, 2022 and 2023, using the Black Scholes option
pricing model, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of the options granted, the Company uses the Black Scholes option pricing model
and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fair
Value of Common Stock &#151; </I>Given the absence of a public trading market for the Company&#146;s common stock, the Board of Directors, with input from management, determine the fair value of common stock by considering a number of objective and
subjective factors including (i)&nbsp;valuations performed by independent third parties, (ii)&nbsp;important developments in the Company&#146;s operations, (iii)&nbsp;the rights, preferences, and privileges of the Company&#146;s preferred stock
relative to those of the Company&#146;s common stock, (iv)&nbsp;actual operating results and financial performance, including the Company&#146;s levels of available capital resources, (v)&nbsp;the conditions in the capital markets, biotechnology
industry and the U.S. economy in general, (vi)&nbsp;the stock price performance and volatility of comparable public companies and (vii)&nbsp;the lack of marketability of the Company&#146;s common stock, among other factors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term &#151; </I>The expected term represents the period that the Company&#146;s stock options granted are expected to be
outstanding and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term). The Company has very limited historical information to develop
reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The Company will continue to apply this process until a sufficient amount of historical information regarding
employee exercise patterns and post-vesting employment termination behavior becomes available. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility &#151; </I>Since the
Company is not a public company and has no trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period, where available, equal
to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage and area of specialty. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free Interest Rate &#151; </I>The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of
grant for periods corresponding with the expected term of the options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend &#151; </I>The Company has never paid
dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Stock-based Compensation Expense</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense for restricted stock awards and stock options recognized in the Company&#146;s statements of operations and
comprehensive (loss) income is presented as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8194;&#8194;&#8195;1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;1,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, total unrecognized stock-based compensation expense related to unvested
restricted stock awards and unvested stock options was $5.2&nbsp;million, which is expected to be recognized over a weighted-average period of 2.9 years. As of December&nbsp;31, 2023, total unrecognized stock-based compensation expense related to
unvested restricted stock awards subject to performance conditions, which were improbable of achievement, was $0.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the provision for income taxes were as follows for the years ended December&nbsp;31, 2022 and 2023 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, the Company had no income tax expense due to operating losses
incurred. For the year ended December&nbsp;31, 2023, the Company recorded income tax expense of $0.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of
the Company&#146;s effective tax rate to the statutory U.S. federal rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. federal taxes at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State NOL reserve</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;14.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and
temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The types of temporary differences that give rise to significant portions of the
Company&#146;s deferred income tax assets and liabilities are set out below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sec 174 capitalized research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets before valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;10,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;21,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a valuation allowance for the amount of deferred tax assets that are not more
likely than not be realized. Management considered all available evidence, both positive and negative, including but not limited to the Company&#146;s historical operating results, income or loss in recent periods, cumulative losses in recent years,
forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in the total valuation allowance for the years
ended December&nbsp;31, 2022 and 2023 was an increase of $10.2&nbsp;million and $1.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2023, the Company had $14.6&nbsp;million of federal net operating loss carryforwards and $28.9&nbsp;million of state net operating loss carryforwards, available to reduce future taxable income. Of the federal net operating loss carryforwards,
$14.6&nbsp;million will carryforward indefinitely. The state net operating loss carryforwards will begin to expire in 2041, if not utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company had federal research and development tax credits carryforward of $2.0&nbsp;million and state
research and development tax credits carryforward of $1.8&nbsp;million, available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2041 if not utilized. The state research and development tax
credits have no expiration date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal Revenue Code section 382 (&#147;IRC Section&nbsp;382&#148;) places a limitation (the
&#147;Section&nbsp;382 Limitation&#148;) on the amount of taxable income that can be offset by net operating loss (&#147;NOL&#148;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation.
California has similar rules. When an ownership change occurs, IRC Section&nbsp;382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations. The annual 382 limitations may limit the full use of available tax
attributes in one year but the identified ownership changes may not result in expiration of tax attributes for use prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expiration of their respective carryforward periods. The Company performed a Section&nbsp;382 analysis through the year ended December&nbsp;31, 2023 and determined there were ownership changes in
2021 and 2023 that resulted in 382 limitations limiting the full use of carryover attributes in 2023. The ownership changes did not result in a reduction of its net operating loss or in its research and development credit carryforwards expiring
unused. Accordingly, none of the tax attributes have been reduced but limited the full use in 2023. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2023&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions based on tax positions related to current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment based on tax positions related to prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;2,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reversal of the uncertain tax benefits would not impact the Company&#146;s effective tax rate as the
Company continues to maintain a full valuation allowance against its deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties
related to uncertain tax positions in income tax expense. During the years ended December&nbsp;31, 2022 and 2023, the Company did not recognize accrued interest and penalties related to unrecognized tax benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income taxes in the U.S. federal jurisdiction, the state of California and various other U.S. states. The Company is not
currently under examination by income tax authorities in federal, state or other jurisdictions. All income tax returns will remain open for examination by the federal, state and foreign authorities for three or four years, from the date of
utilization of any NOLs or credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third Rock Ventures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2022 and 2021, the Company issued a total of approximately 41.3&nbsp;million shares of its Series A Convertible Preferred Stock to Third Rock Ventures V, L.P., a holder of more than 5% of the Company&#146;s outstanding
capital stock, during the initial and second tranche closings, for cash proceeds of approximately $26.6&nbsp;million and upon conversion of outstanding convertible promissory notes of $14.7&nbsp;million (see Note&nbsp;8). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company issued a total of approximately 12.4&nbsp;million shares of its Series B Convertible
Preferred Stock to Third Rock Ventures VI, L.P., a holder of more than 5% of the Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $15.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2021, the Company entered into a service agreement with Third Rock Ventures, LLC (&#147;TRV&#148;), a holder of more than 5% of the
Company&#146;s outstanding capital stock, (the &#147;TRV service agreement&#148;) under which TRV provides consulting services to the Company. For the years ended December&nbsp;31, 2022 and 2023, the Company recorded expense of $1.3&nbsp;million and
$0.3&nbsp;million, respectively, for such services as general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and administrative expenses in the Company&#146;s statements of operations and comprehensive (loss) income. As of December&nbsp;31, 2022 and 2023, outstanding accounts payable to TRV were
$0.1&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s interim Chief Medical Officer, and also a member of the
Company&#146;s board of directors, was designated to the Company&#146;s board of directors by TRV and is affiliated with TRV. He did not receive any cash compensation from the Company for his service as its interim Chief Medical Officer, as his
services were provided to the Company through the TRV service agreement. Of the total fees the Company incurred under the TRV service agreement for the years ended December&nbsp;31, 2022 and 2023, $0.3&nbsp;million and $0.2&nbsp;million,
respectively, were attributed to services provided as the Company&#146;s interim Chief Medical Officer. Additionally, as compensation for his services as the Company&#146;s interim Chief Medical Officer, the Company granted him options to purchase
11,613 shares of the Company&#146;s common stock during the year ended December&nbsp;31, 2022, and 26,712 shares during the year ended December&nbsp;31, 2023, at exercise prices of $1.55 and $2.76 per share, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RA Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2023, the Company issued a total of approximately 12.2&nbsp;million shares of its Series B Convertible Preferred Stock to entities affiliated with RA Capital Management, L.P., which collectively hold more than 5% of the
Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $15.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Samsara BioCapital
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company issued a total of approximately 4.3&nbsp;million shares of its Series B
Convertible Preferred Stock to Samsara BioCapital, L.P., a holder of more than 5% of the Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $5.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Net (Loss) Income Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted net (loss) income per share (in thousands, except for share and per
share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2022&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2023&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator, basic:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of earnings to participating preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income applicable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator, basic:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding used to compute net (loss) income per common share,
basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,928,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator, diluted:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of earnings to participating preferred stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income applicable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator, diluted:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used to compute net (loss) income per common share,
basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,928,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used to compute net (loss) income per common share,
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,436,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,177,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share, basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income per share, diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Potentially dilutive securities not included in the calculation of diluted net (loss) income per share because
to do so would be anti-dilutive were as follows (in common stock equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2022&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2023&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,451,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total antidilutive securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,496,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">538,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements&#151;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Employee Retirement Benefit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a 401(k) retirement savings plan (the &#147;401(k) Plan&#148;) for its employees. The 401(k) Plan allows eligible
employees to make contributions up to the maximum allowable by the Internal Revenue Service (&#147;IRS&#148;). For the year ended December&nbsp;31, 2023, the Company made matching contributions of and recorded contribution expenses of
$0.1&nbsp;million. For the year ended December&nbsp;31, 2022, the Company did not make any matching contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated all subsequent events for recognition and measurement purposes through August&nbsp;2, 2024, (except for the impact of the
reverse stock split as discussed in Note 1, as to which the date is October&nbsp;21, 2024), the date the financial statements were available for issuance. The Company has concluded that no subsequent events have occurred that require disclosure,
except as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subsequent Financings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the remaining
approximately 60.8&nbsp;million shares of Series B Convertible Preferred Stock, for net proceeds of $74.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer and
Director Equity Awards Modification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2024, the Company&#146;s board of directors modified the terms of stock option
awards for 0.8&nbsp;million shares of the Company&#146;s common stock granted during the year ended December&nbsp;31, 2023, stock option awards for 0.5&nbsp;million shares of the Company&#146;s common stock granted in 2024 and restricted stock
awards for 0.9&nbsp;million shares granted during the years ended December&nbsp;31, 2022 and 2021 to certain executive officers and members of the Company&#146;s board of directors. Under the modified terms, accelerated vesting provisions were added
associated with certain change of control events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_101"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share and per share data) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT>
asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Convertible Preferred Stock, $0.001 par value per share; 75,000,000 shares authorized at
December&nbsp;31, 2023 and June&nbsp;30, 2024; 75,000,000 shares issued and outstanding as of December&nbsp;31, 2023 and June&nbsp;30, 2024; liquidation preference of $75,000 at December&nbsp;31, 2023 and June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Convertible Preferred Stock, $0.001 par value per share; 121,657,452 shares authorized at
December&nbsp;31, 2023 and June&nbsp;30, 2024; 60,828,720 and 121,657,452 shares issued and outstanding as of December&nbsp;31, 2023 and June&nbsp;30, 2024, respectively; liquidation preference of $75,000 and $150,000 at December&nbsp;31, 2023 and
June&nbsp;30, 2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share, 260,590,689 shares authorized at December&nbsp;31, 2023
and June&nbsp;30, 2024; 3,168,134 and 3,163,020&nbsp;shares issued and outstanding at December&nbsp;31, 2023 and June&nbsp;30, 2024, respectively; 1,002,044 and 784,550&nbsp;shares subject to repurchase as of December&nbsp;31, 2023 and
June&nbsp;30,&nbsp;2024, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_102"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share and per share data) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,284,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an
integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_103"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except for share and per share data) </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Unaudited) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other<BR>Comprehensive</B><br><B>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,181,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,201</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Series B Convertible Preferred Stock, net of issuance costs of $479</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,801,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Repurchase of unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,801,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,179,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(70,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(63,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,168,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Series B Convertible Preferred Stock, net of issuance costs of $58</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Repurchase of unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,517</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net unrealized loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,163,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(77,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_104"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In
thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,769</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Amortization of premiums (discounts), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Deferred income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(767</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating lease, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,698</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(913</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Maturities of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of Series B Convertible Preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repurchases of forfeited restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">132,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited
condensed balance sheets to the total amounts reported on the unaudited condensed statements of cash flows:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">132,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Supplemental cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash paid for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Supplemental disclosure for noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Equity receivable included in prepaid expenses and other current assets related to issuance of
Series B Convertible Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance costs of Series B Convertible Preferred Stock included in accounts payable and accrued
expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unpaid deferred offering costs included in accrued expenses and other current
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Property and equipment included in accounts payable and accrued expenses and other current
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin762905_105"></A>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Condensed Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis
of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of the Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Septerna, Inc. (&#147;Septerna&#148; or the &#147;Company&#148;) is a clinical-stage biotechnology company pioneering a new era of G
protein-coupled receptor (&#147;GPCR&#148;) oral small molecule drug discovery powered by its proprietary Native Complex Platform<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>. The Company&#146;s industrial-scale platform aims to unlock the
full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of product candidates focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company was incorporated in Delaware in December 2019, under the name GPCR NewCo, Inc. In June 2021, the Company changed its name to
Septerna, Inc. The Company is headquartered in South San Francisco, California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements have been prepared assuming the Company will continue as a going concern, which
assumes that the Company will realize its assets and satisfies its liabilities in the normal course of business. The Company is subject to risks inherent in operating an early-stage biotechnology business. These risks include, but are not limited
to, dependence on the development of marketable products, the ability to attract, retain, and motivate qualified personnel, rapid technological changes and the rapidly evolving nature of the biotechnology industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has historically financed its operations primarily through the issuances of convertible promissory notes and convertible preferred
stock. In June 2023, the Company entered into a total of $150.0&nbsp;million of Series B Convertible Preferred Stock financing, which was divided into two tranches of equal amounts. The first tranche, which was the issuance of $75.0&nbsp;million of
Series B Convertible Preferred Stock, was completed in June and July 2023 for total net proceeds of $74.5&nbsp;million. In May 2024, the Company completed the issuance of the remaining $75.0&nbsp;million Series B Convertible Preferred Stock under
the second tranche for net proceeds of $74.9&nbsp;million (see Note 6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, during the fourth quarter of 2023, the Company
recorded a gain on sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset of $47.6&nbsp;million for the sale of an <FONT STYLE="white-space:nowrap">in-progress</FONT> research and development asset related to a GPCR program, resulting
in a reduction in the accumulated deficit in the fourth quarter of 2023, and net income for the year ended December&nbsp;31, 2023. The Company received the remaining balance owed of $22.6&nbsp;million related to the sale during the six months ended
June&nbsp;30, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred significant losses and negative cash flows from operations since its inception and expects
to incur losses as a result of its continued research and development activities. To date, none of the Company&#146;s product candidates have been approved by the U.S. Food and Drug Administration (&#147;FDA&#148;) for commercial sale and,
therefore, the Company has not generated any revenue from product sales. For the six&nbsp;months ended June&nbsp;30, 2023 and 2024, the Company incurred net losses of $19.8&nbsp;million and $30.6&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had an accumulated deficit of $77.2&nbsp;million as of June&nbsp;30, 2024. The Company believes its cash, cash equivalents,
marketable securities, and marketable securities, <FONT STYLE="white-space:nowrap">non-current</FONT> of $155.7&nbsp;million as of June&nbsp;30, 2024 will be sufficient to fund the Company&#146;s operations for, at least, 12 months from the date of
issuance of these unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements (continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim condensed financial statements have been prepared in accordance with generally accepted accounting
principles in the United States of America (&#147;U.S. GAAP&#148;) for interim financial information and pursuant to Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Securities Act of 1933, as amended (Securities Act), and
reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair presentation of the Company&#146;s unaudited interim condensed financial statements as of December&nbsp;31, 2023 and June&nbsp;30, 2024, and
for the six months ended June&nbsp;30, 2023 and 2024. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates
(&#147;ASUs&#148;), of the Financial Accounting Standards Board (&#147;FASB&#148;). The interim condensed financial statements are unaudited. The operating results presented in these unaudited interim condensed financial statements are not
necessarily indicative of the results that may be expected for the full year or for any other future annual or interim period. Actual results could differ materially from estimates and assumptions. As appropriate, the Company assesses estimates each
period and updates them to reflect current information, and generally reflect any changes in estimates in the period first identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These interim unaudited condensed financial statements should be read in conjunction with the Company&#146;s audited financial statements for
the year ended December&nbsp;31, 2023 and the related notes thereto included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Accounting Policies
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2024, there were no changes to the Company&#146;s significant accounting policies as
described in the Company&#146;s audited annual financial statements for the year ended December&nbsp;31, 2023 other than the policies outlined below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Equivalents and Marketable Securities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company holds marketable securities that consist of highly liquid, investment grade debt securities. The Company&#146;s cash and marketable
securities are held or issued by financial institutions that management believes are of high credit quality. Marketable securities are classified and accounted for as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale.</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> marketable securities with original maturities of
90 days or less are classified as cash equivalents. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> marketable securities with original maturities of greater than 90 days and remaining maturities of
less than 12&nbsp;months are classified as current. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> marketable securities with remaining maturities of more than 12 months for which the Company has
the intent and ability to hold the security for more than 12 months are classified as <FONT STYLE="white-space:nowrap">non-current.</FONT> The Company&#146;s marketable securities are carried at estimated fair value, which is derived from
independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported in stockholders&#146; deficit as accumulated other comprehensive loss. The amortized cost of marketable securities
is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has the ability, if necessary, to liquidate any of its cash equivalents and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities to meet its liquidity needs in the next 12 months. After consideration of the Company&#146;s objectives to preserve capital, as well as its liquidity requirements, it
may sell these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities prior to their stated maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews its portfolio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
loss or other factors. If the decline in fair value is due to credit-related factors, the Company recognizes a loss in its condensed statement of operations, whereas if the decline in fair value
is not due to credit-related factors, the Company recognizes the loss in other comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excludes the applicable
accrued interest from both the fair value and amortized cost basis of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities for purposes of identifying and measuring an impairment.
Accrued interest receivable on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities is recorded within prepaid expenses and other current assets on the interim condensed balance
sheets. The Company&#146;s accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to <FONT STYLE="white-space:nowrap">write-off</FONT> any uncollectible accrued interest receivable as a reversal of
interest income in a timely manner, which is considered to be in the period in which it is determined the accrued interest will not be collected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred Offering Costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s deferred offering costs consist of legal, accounting and other general and administrative costs directly attributable to the Company&#146;s planned initial public offering (&#147;IPO&#148;). After consummation of the planned IPO,
these costs will be classified in stockholders&#146; deficit as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital recorded as a result of the IPO. In the event the planned IPO is terminated, all deferred offering
costs will be reclassified to general and administrative expenses in the Company&#146;s condensed statements of operations and comprehensive loss. As of June&nbsp;30, 2024, $0.4&nbsp;million of deferred offering costs were included within other <FONT
STYLE="white-space:nowrap">non-current</FONT> assets in the Company&#146;s condensed balance sheet. As of December&nbsp;31, 2023, there were no deferred offering costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reverse Stock Split </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17,
2024, the Company&#146;s board of directors approved a 1-for-8.6103 reverse stock split of its issued and outstanding shares of common stock, which was effected on October&nbsp;18, 2024. Upon the effectiveness of the reverse stock split,
(i)&nbsp;all shares of outstanding common stock were adjusted; (ii)&nbsp;the conversion ratio of the convertible preferred stock was adjusted; (iii)&nbsp;the number of shares of common stock for which each outstanding option to purchase common stock
is exercisable were adjusted; and (iv)&nbsp;the exercise price of each outstanding option to purchase common stock was adjusted. All of the outstanding common stock share numbers (including shares of common stock subject to the Company&#146;s
options and as converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been retroactively adjusted in the financial statements to reflect this reverse
stock split for all periods presented. The par value per share and the authorized number of shares of common stock and preferred stock were not adjusted as a result of the reverse stock split. The number of authorized shares has not changed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Pronouncements Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the
Company as of the specified date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-07,</FONT> <I>Segment
Reporting (Topic 280): Improvements to Reportable Segment Disclosures</I>. ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment
expenses on an interim and annual basis. The ASU is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods after December&nbsp;5, 2024, with early adoption permitted. The adoption of this standard is not expected to
have a material impact on the Company&#146;s condensed financial statements at adoption date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</I>, which enhances the transparency and decision usefulness of income tax disclosures. The standard is intended to improve
income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU is effective for fiscal years
beginning after December&nbsp;15, 2025, on a prospective basis with early adoption and retrospective reporting permitted. The Company is currently evaluating the impact of ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> on its condensed
financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash is
comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. In connection with the Company&#146;s lease agreement, the Company is required to maintain a collateral account to secure a letter of
credit issued to its landlord. The collateral account is classified as restricted cash on the Company&#146;s condensed balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts
Receivable and Other Receivables </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assessed if an allowance for expected credit losses over the life of its receivables
should be reserved for based on a combination of historical experience, aging analysis, current economic trends and information on specific accounts, with related amounts recorded as a reserve against revenue recognized. The reserve is <FONT
STYLE="white-space:nowrap">re-evaluated</FONT> on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the reserve. Based on its assessment, as of December&nbsp;31, 2023 and
June&nbsp;30, 2024, the Company determined that an allowance for credit loss was not required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the
Company&#146;s accounts receivable and other receivable related to sale of <FONT STYLE="white-space:nowrap">non-financial</FONT> asset balances were entirely attributed to Vertex Pharmaceuticals Incorporated (&#147;Vertex&#148;). As of June&nbsp;30,
2024, the Company&#146;s accounts receivable was entirely attributed to Vertex. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $0.4&nbsp;million and $0.6&nbsp;million for the six months ended
June&nbsp;30, 2023 and 2024, respectively. Construction in progress as of June&nbsp;30, 2024 related to leasehold improvements for the Company&#146;s Original Leased Space which were under renovation at June&nbsp;30, 2024, and placed in service in
July 2024 upon commencement of the Company&#146;s lease of the space. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses and Other Current Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued operating expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income taxes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes service revenue associated with the Vertex Research Service Agreement over the performance period of the research
services as the services are provided in accordance with Accounting Standards Codification (&#147;ASC&#148;) Topic 606, Revenue from Contracts with Customers (&#147;ASC Topic 606&#148;). During the six months ended June&nbsp;30, 2024, the Company
recorded service revenue of approximately $0.7&nbsp;million related to research activities performed in connection with the Vertex Research Service Agreement. During the six months ended June&nbsp;30, 2023, no revenue was recorded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-Sale</FONT></FONT>
Marketable Securities and Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records marketable securities and cash equivalents at their estimated
fair values, which are based on market prices from a variety of industry standard data providers and generally represent quoted prices for similar assets in active markets or have been derived from observable market data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that
prioritizes the inputs used in measuring fair value as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1: Unadjusted quoted prices in active markets that are
accessible at the measurement date for identical, unrestricted assets or liabilities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2: Quoted prices in markets that are not
active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable
(i.e., supported by little or no market activity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value measurements of the Company&#146;s cash equivalents and marketable
securities are identified at the following levels within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$82,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">$&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities, <FONT STYLE="white-space:nowrap">non-current:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-Sale</FONT></FONT> Marketable Securities
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, the Company&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities consist of debt securities, including U.S. Treasury and agency securities, corporate debt securities and commercial paper. These
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities are carried at fair value and are included in the tables above. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company records an allowance for credit losses when unrealized losses are due to credit-related factors. At each reporting date, the Company evaluates securities with unrealized losses to
determine whether such losses, if any, are due to credit-related factors. The Company evaluates, among others, whether the Company has the intention to sell any of these
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities and whether it is not more likely than not that the Company will be required to sell any of them before recovery of the
amortized cost basis. Neither of these criteria were met in at June&nbsp;30, 2024. The credit ratings of the securities held remain of the highest quality. Moreover, the Company continues to receive payments of interest and principal as they become
due, and the Company&#146;s expectation is that those payments will continue to be received timely. Based on this evaluation, as of June&nbsp;30, 2024, the Company determined that unrealized losses of its <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities were primarily attributable to changes in interest rates and <FONT STYLE="white-space:nowrap">non-credit</FONT> related factors. As such, no allowances for credit
losses were recorded at June&nbsp;30, 2024. The Company did not hold <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities at December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest receivable as of June&nbsp;30, 2024 was $0.1&nbsp;million and is recorded as a component of prepaid expenses and other current assets
on the Company&#146;s condensed balance sheet. The Company did not have interest receivable at December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2024, all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities in an unrealized loss position had been in an unrealized loss position for less than 12 months. As of
June&nbsp;30, 2024, the Company held 36 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities which have been in an unrealized loss position for a period of less than 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, the following table summarizes the amortized cost and the unrealized gains (losses) of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities presented within marketable securities, marketable securities, <FONT STYLE="white-space:nowrap">non-current</FONT> and cash
equivalents (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Remaining</B><br><B>Contractual</B><br><B>Maturity&nbsp;(in&nbsp;years)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized&nbsp;Cost</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Gains</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized&nbsp;Losses</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Estimated&nbsp;Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; "></TR>
<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Less&nbsp;than&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Less than 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Less than 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total maturity less than 1 year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 to 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1 to 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, the following table summarizes <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities in an unrealized loss position (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less than 12 Months</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Unrealized&nbsp;Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of business, the Company may be subject to legal proceedings, claims and litigation, as the Company operates in an industry susceptible to patent or other legal claims. The Company accounts for estimated losses with respect to legal
proceedings and claims when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or
occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also agreed to indemnify the investors against certain losses, claims or liabilities due to certain statements, omissions or
violations by the Company if Company securities held by the investors are included in a registration statement. The certain statements, omissions or violations that are covered by these include, but are not limited to, (i)&nbsp;any untrue statement
or alleged untrue statement of a material fact contained in the applicable registration statement, (ii)&nbsp;any omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein
not misleading, (iii)&nbsp;any violation or alleged violation by the Company of the Securities Act of 1933, as amended, the Exchange Act, and certain other securities laws. The Company will reimburse the investors for any legal or other expenses
reasonably incurred by them in connection with investigating or defending such losses, claims, damages or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum
potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company is not currently aware of any indemnification claims. Accordingly, the Company did not record any liabilities
associated with these indemnification rights and agreements as of December&nbsp;31, 2023 and June&nbsp;30, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company&#146;s convertible preferred stock consisted of the following (in thousands, except for share and per
share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion&nbsp;Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,828,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.23297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, the Company&#146;s convertible preferred stock consisted of the following (in
thousands, except for share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion&nbsp;Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121,657,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.23297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2023 and July 2023, the Company issued 58.8&nbsp;million and 2.0&nbsp;million, respectively, shares of
Series B Convertible Preferred Stock at an issuance price of $1.23297 per share for total net proceeds of $74.5&nbsp;million under the first tranche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2024, the Company executed the second tranche of the Series B Convertible Preferred Stock financing arrangement and issued the
remaining 60.8&nbsp;million shares of Series B Convertible Preferred Stock for net proceeds of $74.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and June&nbsp;30, 2024, the Company was authorized to issue 260.6&nbsp;million shares of $0.001 par value common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reserved the following shares of common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, for
future issuance: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,710,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,710,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,129,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,129,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock outstanding under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">774,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">594,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock outstanding outside of 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,123,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,796,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for future grants under 2021 Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,634,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">966,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,599,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,387,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer and Director Equity Awards Modification </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2024, the Company&#146;s board of directors modified the terms of stock option awards for 1.3&nbsp;million shares of the Company&#146;s
common stock and restricted stock awards for 0.9&nbsp;million shares of the Company&#146;s common stock to certain executive officers and members of the Company&#146;s board of directors. Under the modified terms, accelerated vesting provisions were
added associated with certain change of control events. No incremental stock-based compensation expense was recognized as a result of the modification. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following summarizes restricted stock award activity under the 2021 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT></B><br><B>Grant&nbsp;Date&nbsp;Fair</B><br><B>Value&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">774,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(167,967</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,517</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">594,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes restricted stock award activity outside of the 2021 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Weighted-Average</FONT><BR>Grant&nbsp;Date&nbsp;Fair</B><br><B>Value&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total fair value of shares vested during the six months ended June&nbsp;30, 2024 was $0.6&nbsp;million.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes stock option activity under the 2021 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,123,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">695,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,796,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of June&nbsp;30, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,796,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair value of options that vested for the six months ended June&nbsp;30, 2024 was
$0.5&nbsp;million. The options granted in the six months ended June&nbsp;30, 2024 had a weighted-average per share grant-date fair value of $2.76 and a total grant date fair value of $1.9&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
weighted-average assumptions used to value employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock option awards granted under the 2021 Plan using the Black Scholes option pricing model, were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense for restricted stock awards and stock options recognized in the Company&#146;s condensed statements of
operations and comprehensive loss is presented as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2024&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2024, total unrecognized stock-based compensation expense related to
unvested restricted stock awards and unvested stock options was $5.9&nbsp;million, which is expected to be recognized over a weighted-average period of 2.8 years. As of June 30, 2024, total unrecognized stock-based compensation expense related to
unvested restricted stock awards subject to performance conditions, which were improbable of achievement, was $0.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Related Parties
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third Rock Ventures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2023, the Company issued a total of 12.4&nbsp;million shares of its Series&nbsp;B Convertible
Preferred Stock to Third Rock Ventures V, L.P., a holder of more than 5% of the Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $15.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2024, the Company issued a total of 12.4&nbsp;million shares of its Series&nbsp;B Convertible
Preferred Stock to Third Rock Ventures VI, L.P., a holder of more than 5% of the Company&#146;s outstanding capital stock, during the second tranche closing, for cash proceeds of $15.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2023 and 2024, under the TRV service agreement, the Company incurred fees of $0.2&nbsp;million and
$0.1&nbsp;million, respectively, which were recorded within general and administrative expenses in the Company&#146;s condensed statements of operations and comprehensive loss. As of December&nbsp;31, 2023, outstanding accounts payable to TRV was
$0.1&nbsp;million. As of June&nbsp;30, 2024, $0.1&nbsp;million of expenses related to services provided by TRV were recorded within accrued expenses and other current liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2023 and 2024, of the total fees under the TRV service agreement, $0.1&nbsp;million and
$0.1&nbsp;million, respectively, were attributed to the Company&#146;s interim Chief Medical Officer. Additionally, the Company granted its interim Chief Medical Officer options to purchase 23,227 shares during the six months ended June&nbsp;30,
2024, at exercise prices of $2.76&nbsp;per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RA Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2023, the Company issued a total of 12.2&nbsp;million shares of its Series&nbsp;B Convertible
Preferred Stock to entities affiliated with RA Capital Management, L.P. (collectively, &#147;RA Capital&#148;), which held more than 5% of the Company&#146;s outstanding capital stock, during the first tranche closing, for total cash proceeds of
$15.0&nbsp;million. During the six months ended June&nbsp;30, 2024, the Company issued a total of 12.2&nbsp;million shares of its Series B Convertible Preferred Stock to RA Capital during the second tranche closing, for total cash proceeds of
$15.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Samsara BioCapital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2023, the Company issued a total of 4.3&nbsp;million shares of its Series B Convertible Preferred
Stock to Samsara BioCapital, L.P. (&#147;Samsara BioCapital&#148;), a holder of more than 5% of the Company&#146;s outstanding capital stock, during the first tranche closing, for cash proceeds of $5.2&nbsp;million. During the six months ended
June&nbsp;30, 2024, the Company issued a total of 4.3&nbsp;million shares of its Series B Convertible Preferred Stock to Samsara BioCapital during the second tranche closing, for cash proceeds of $5.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPTERNA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Condensed Financial Statements&#151;(continued) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all periods presented, diluted net loss per share is the same as basic net loss per share since the effect of including potential common
shares is anti-dilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive were as follows (in common stock equivalent shares): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,796,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,174,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">711,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total antidilutive securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,306,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,507,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated all subsequent events for recognition and measurement purposes through October&nbsp;21, 2024 (including the impact of the
reverse stock split as discussed in Note&nbsp;1), the date the condensed financial statements were available for issuance. The Company has concluded that no subsequent events have occurred that require disclosure, except as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2024, the Company appointed a full-time Chief Medical Officer to succeed the interim Chief Medical Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2024, the Company amended the 2021 Plan to, among other things, increase the shares reserved for issuance under the 2021 Plan to
approximately 5.4&nbsp;million shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August and September 2024, the Company granted a total of 1.2&nbsp;million shares of stock
options to its employees and members of its board of directors, 0.6&nbsp;million of which include vesting criteria subject to both service conditions and achievement of performance-based conditions, related to the consummation of the Company&#146;s
IPO or a Sale Event, while the remainder include vesting criteria subject to service conditions only. 0.7&nbsp;million of the stock options granted also include accelerated vesting provisions associated with certain change of control events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>16,000,000&nbsp;Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g762905g00w02.jpg" ALT="LOGO" STYLE="width:1.93125in;height:0.453125in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>&#8195;TD Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>&#8195;&#8195;Cantor</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B>Wells&nbsp;Fargo&nbsp;Securities</B></TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">October&nbsp;24, 2024 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Through and including November&nbsp;18, 2024 (the 25th day after the date of this prospectus), all dealers that effect transactions in
these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold
allotments or subscriptions. </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g762905g00b98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g00b98.jpg
M_]C_X  02D9)1@ ! 0$!] 'T  #_[1<@4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'].
M4?         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !].4>  $  0'T
MY1X  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             \8   P&    !@!G #  , !B #D .     $
M             0             ,!@   \8                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   \8     4F=H=&QO;F<   P&
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   /&     %)G:'1L;VYG   ,!@    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !3A"24T$#      ,YP    $
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M "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  ,@ P #( -     $ .$))300B      $R34T *@    @
M!P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,    !
M  (   $Q  (    ?    <@$R  (    4    D8=I  0    !    J    -0
M  'U     0   ?4    !061O8F4@4&AO=&]S:&]P(#(U+C @*%=I;F1O=W,I
M #(P,C0Z,#@Z,#(@,#DZ-#<Z,#,       .@ 0 #     ?__  "@ @ $
M 0  # :@ P $     0   \8         !@$#  ,    !  8   $:  4    !
M   !(@$;  4    !   !*@$H  ,    !  (   (!  0    !   !,@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0$Z17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
M    D8=I  0    !    J    -0   'U     0   ?4    !061O8F4@4&AO
M=&]S:&]P(#(U+C @*%=I;F1O=W,I #(P,C0Z,#@Z,#(@,#DZ-#<Z,#,
M  .@ 0 #     ?__  "@ @ $     0  # :@ P $     0   \8
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !              !(     0   $@
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M*"@H*"@H*"@H*"@H*/_  !$( D,'- ,!(@ "$0$#$0'_Q  <  $  @(# 0
M            !08$!P(#" '_Q !9$  ! P,# 04$! D&"@D# @<!  (#! 41
M!A(A,0<305%A%")Q@3*1H;$(%1<C0E)5P=$S8G22LN$6)#8W<G.4HM+P)30U
M0U."L\+Q8W63)D1D@R=4A(7B_\0 &@$!  ,! 0$               $" P0%
M!O_$ #41 0 " @$# P$( 0,%  ,!   ! @,1(002,1-!42(%%!4R87&!\)$C
M0J$SL<'1X08D0U+_V@ , P$  A$#$0 _ /5*(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(HV_7(VVB,C&[I7<,'JIK6;3J$3.HVDD5*
M'^%$K>_)V1_2VMQN(^"D--ZD%;4.H:YIBJV' +AC?\EK.&8C<3O2L7C>I65$
M18KB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B*JS:AGM][=!<F;*9QP'#H/)7I2;^$3:(\K4J?KJ9\M
M1;Z*G/YU[\X],JP37FWQ0]XZJB+?(')/R5"U!J.EIK[27*0QLC!P.\?C("VP
M4F+=TQX5M$W^FO,RV9&W:QK3X !4[6U V*IIJ^G!;-N]XMZG!RI#3.I([U*]
ML;J=[,9:^%^X? J8N5!#<*?NI]PP<AS3@@JE)G%?<EH[HF'913MJ:6.5C@X.
M:"2#XKN50T5/BX5],#AK/M(.,JW/<UC2YQ :.I*KDIV6T4MW1N7U%U4U3#5,
M<ZGD;(UIVG'@5VK.8UY7\B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B+KFG9$/>//7 ZH.Q<1(PEX#V^Y]+GI\5JG
MM8[4VV%@M-@'>7J88+G#(IP>AQXN/@/FM&072ZVB>>X-NE5[74'?*_O#^</4
MY!X/S7=@Z&^6O=,Z8WS16=/8)KZ8$@RMX\?!0=RN5HN#O9KA"\,)P)'-X6BK
M+VQQ"TOI[U0U$M8SALE.\;9!_.!^C\LKNM>NZ>Z3=W-05%*#RPO=N#OG@+6G
M13$RI;+.FTM4TM@TG;Q<*U\TP>X-A@#^9'<D 'P'JM-:AN-1?[N^M?%' S:(
MXX(_HL:/#X]22N?:==ZZ2FHVS!\UMAC,L?H_H<GT&/AE4FFCN-= V45,;&D9
M$9?C 7GYO4M>:3SI]M]@UZ;I<,=1,;O;_B$O')+;(I*B*JDI9">'1R%A^PK9
M'9!VA:CU54UEA#Q4NI8@\5K^'AN<8<?'X]?BM':BIZZGHVNJ,.;G +3E6C0F
MJ*;1M#****H_&50![3-NV@8Z,'7@<_$JW2X+Y+ZK[,?_ ,BZO%?'%9KJ?^6\
M+E;JVU5\C:J24->TD31 X<>JR+?5WR[1MI:43F%GZ;N!\R?N6MK=VM7YHW1,
MIZV'(S'4#=GYCD+8.C.U:DU#'50^R&V5%*UKG,):YK\G'N^/V+TLM,N.NYK$
MOC:]MO?2^Z:M4MLIY?:) ^64@D-Z#"F%4*/7%$]I;*Q[G-."YF,?%6.W7.DN
M#,TLS7$=6]"/DO-R4R;[KPZ*376H9B(BR7$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%@5%6.\D8';0WCCS08-3<A*)!N+0
M#@8*@FW61M6Z-SR_?TR5PNM)4,<Z2GQW;LD9*P;=1;@Z:J=^>#AM#3]'_P"5
M*&I.U*VR6GM(;7G)BJX6S!QZ%P&UPSZ8!^:JER=5U,<D,;'N8[#FD CSX'Q_
M<MT]H5LCO]I]F) J8COIY",[7>1]#T6H?Q9J6 ,9+:WQ-8<.<YG+?7 YQPO=
MZ//7)CBLSS#DR5F+;A69K550!L[AN<XDX\3YJ4==XJI]O@I?S9,K0X>(&>GE
MURLZ\ R1,@HF.FJ'@X:P9/ASC"J=1;ZREF#9HI() X?R@V8]>>BZYX\,XY\K
M?K:]5CB+1#)BBQWCF ?2)&.?E]ZKM%[1O8QF''/T=O[EBRW"6MG[^?:7X#3@
M<''"LE)<Z9U/&QC6 M:.-H'/[^5-:UCFI-K3';/B'5/,;?)1SRQM<WO&.DB<
MT$. \"%CW>E9/J6M93;.YDD,C=I]UH=SCY96%>XY@\NF.X$]1X<]./@5*W6Q
MMLM#2UU#4NFWXW': ,.&1XI%8B^]<RF;VFL1,\0^4=IGIZ@NW 1MY(9[VX?O
MZ+KL]];8]5NK'1NDIL&)[&C!<W'AZYPL6:]5 =&1AV1EP/*[;I''4V@5,D1B
MJ&^!')''HIM&XTI"X4W:RZWRS-;889(GC&V:0YQ]2G=+=H\55.:VHB;;3$[(
M]_+2W^Y:XI6T-QI(G5 :Z9C<.][!_P">J[+=;QJ&OCMM WV>#&Z:4C(8T>7J
M<CA<UL&.(F;>[2+3.HAZS;>65M(V>"8&-[0YCF'((\\KGI^[/J:J6EF=N+1N
M:[QQY+6^C[(-/V,TM-45$D!)>P3/W8\\<<#/@KGIRF%+&^>H_EWC'7H%X%ZQ
M69B'9$[7-% VZO<VX,@W%T<F1@^!ZJ>5%A$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1=;JB%L[872QB9P);&7#<0/(+L0$6!?73
MMM50ZE<6RM&1A8>DKF;C; 97@U$;BUXSR%>*3->Y'=SI-J+OEU%NC:&1F69_
MT6A9U;4LI*62>7.U@SQXJJ6&GJ;W>3=ZOW*>/W8F>?D5;'2)W:WB%;3/B'V/
M5%=33!MRMSV-)X(!'WJV4T\=3 R:$Y8\9!71=J1E;030R#JTEI\CX%5WL[J)
M#15-)*2XP/\ =)\C_P#"M:*WI-JQJ81$S6VI6U$18-!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%\<X-:2X@ =
M25]4'JFK--31M:<%[L*U*]TZ1:=1MU7/55'1N<R,&5[3@X46_6WT=D+22<;2
M"/WJ,M6G:B[F8RRAC6NPYX/4J9&B8(V;H:E_?#H7-R%V=N"G%O+'=[<PE;3J
M&GKI.YE:8)\XVN/!/H5-+4U_I+A;)1D$8<2X]=WJK;HO40KXQ253CW[!AKC^
MEZ*F7IXBO?3PFF2=ZLMB(BY&PB(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@*L:B8^AF,^1W
M,KL=>0[R^Q6=5S6Y!HZ5GBZ;_P!KD$/<+@UU.T-=D",G[0HJBE[^O #L,Q[R
MC*^1[8X@P\.ICQZ@M_BNNCE=3OC<[)WCGT4H3M3'#%*R5C07,<,9/H5$7262
MJK9'Q !N!R?@N,U<)(Y-KLXD'0^:Q9*D"I<P' #1GXX6V'\RMO!8XZ2VRRF*
MGC%1*<N< HW75E_'5L=$8VMD=C9(1RWGDKBZM9%<8Q*1C=CXJ=EKX9FD AQQ
M]075W6B>[?++4:TK%%I2PT=N;!'0Q3.+<.DD&YSCYY\/DH:F[-HJRXRN9524
MM#U;$WE^?B?!6^CJ8F5#]Q'!^I<ZVX]SG;])IR#E6KFO7Q)-8GRI.IM#]V*.
MGHJB22-TC8WN>!EK<G+OM5HI[!8Z.TNHQ11/;M^D\;G./J2K!;YV2T^^6,$N
M .5!ULC?;@W(V;NBFV:]M1,HBD0P+!IJSPUDLDU+&^F:08F.;G!\>3U"D-1:
M7M-\B;$(FP-;@[H0&D8\/)2;C'+3@;FM&%QM\D<,4AZG) RHG+>9WLBL0J55
MHBS4M&\49EAD/&XO+L_$%66S6R"FHX*.A@9%%P.!R?,GS*P;K4,PXYX!RK!I
MTXI_:)#])ON? ^*SR9;=OU2M6L;X3% YL=0YCA[D<?N@_P#/HIZXU#"PEN J
M9).X5CMAZQNS]169'7.J(8NOOM'RRW*X6RXV"UR,E;65+AN+<QM'AGQ*L"PK
M(_O+11/\X6_<LU0D1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$0D 9) 'J@(NJ.IAE#NZE8_:<':<X/DJU9]7T-;6ST_MU$X0EQ<1*"_&>
M!M'3'BKUQVM$S$>%9M$+4B^-<'-#FD%I&01XKZJ+"QKA<*.W0MEN%5!31.<&
M!\SPP%QZ#)\5DD@#)( ]5K+M\@I*C1)J97[I:69KFL:<EP<=KAC/D<_):8:1
MDO%9]U;6[8VV+3UU-41/D@GC?&PD.<T],=5U6ZXQUV\,:\.:2#EI Z\<D>/5
M>-Z2[W&B=)%#6SQQQ,/=]W)@%A^E[N>3C[E9^SC5-\H-0VNWVNJ<Z&IF8YT,
MH+F;<X<XD\@8&>%Z%_L[MK,]S",^Y\/5R+$%RHS_ /N&+L;64SOHSQ'_ ,P7
MENC<.]%Q8]K_ *#FN^!RN2)$57UUK.CT?!22UU//,RH>6YB ]T#&2?KZ*5L=
M\H+W0-K+?.U\!YR>"/7"OZ=HKWZX1W1O231=<$S)XA)$X.8<X(^.%V*B1$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6A>UWM#OS-6U.F=.SMHHX&M[VH:??<
M2T..'?H@ ^'/"WTO+':'2OI>U*_L.0^65KPYSOT7,;C[\+O^S\=;Y)[HWJ&.
M:TUKPK7>UUKND%W=75;KE&[>V>1[G.)!QU\>N,96_>SO64VIM/.KVRE]33O[
MNHB:>6GP./(A>=;K'6OBC8&98,D>(//CGQ4?8*6K?5R,IZB6F>P@N<QY:1X>
M'JO4S88RQK3GK;7+UNS5A%0T5#6&!QVN:6X(_BNRLTO*VJ-79:LP=Y[Q;G Y
M\EI;1MYKI0Z@N-0:R1C\,E><NP>@/CE;RTQ>HS!'15D@;41@-!=QN"\[/BM@
MYHUI:+\60.HZ:X4- !65G?RRD-:P..?BI73-=64\]-;9VLPUN'-(PYO&<K[J
MNDG-P@K0SO(8L%H(RW/JNO39C?=*Z[53Q&W'+G'#03X*FXMBY_LGB^H6NM+Q
M1SF)NZ0,.T>9PJUH9T;'5<1SWSB'],<=/O675ZLML+9 R1SY&CC#>,_-1N@Y
M632U<\TS#42.(:SQQU*QK2U<=NZ&DVW:-+DB(N9J(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B J;VAU9IX(MFW)
M!R#\%<EK36M3)5W00Q@O9RSW>>/%='2UW?;++/&EET#(9;7(_& X@_8K,HK2
M]$VALT$;!C<-W/7E2JSRS$WF87I&JL.ZT$5PI'Q2-!)'NGR*U7)3S6VY-9&\
MQS"3Y>BW J!J^G/XSD[IC"YQ!Y."M^EO,3-6>6ONN]NJ/:J&&?Q>T$_%9"KN
MD[G3^PQ44LFRI9D;7<9Y\%8ESY*]MIAI2W=&Q$146$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0%6]:,)90.'_ (KA];3_  5D4-J=F^FI3Y5#?MR/WH-:5C29(6X^C%(W_G^J
MN_V9SF0>[QMS]REA!&)8P]F3+'4!I\L'^"S!1[K=2.:,%S /K:I0I,,!8R=N
M.7-B=];\?N54O%5/'?ZP0;O=+00.?!;-IZ2'\RZ20-WT[">,XVR9'WK7[XQ4
M7&:1O6:1S^GID+IZ>-S+.\H:Z1321MJ'$[FM\/CU63;[E/A\?NE^  3QX+-=
M%))0L!!P&X)_=CY*-H:1\E4'-X#9 W/EPNKB6?AT1R5T$TDQR_<"7>77A=GX
MUDJ26.86@#&25.34+X*%[GOW -<,8]"H\4;7OJVQCWVAK^/+Q34;-LNEO;8H
M!!*XMVC <HN\UDA<'TY)V^\'+M]C$M0&G &PN/U+.J:(RT\?=,]WN\G'*=L>
M1'4MXGG8&MC?O\<'A9-)<:FGC>:DDM=^CY*/HHG05C>,9>YGPX_N4E(3)&UL
M@Y>[ /S34<FW"TU3+C>J>FD8XQO+LY\2 3A6^B$C(0&DAH:WCXN*JMF@%%?Z
M-^"-E5M.?7C]ZV.VD:VGJ]AW".&-X.,<9)7'G\PUHC9&%@$A!_D7\_)=M"TL
M]F&/T6?:P_P4Y5T3?87Y;G$,OW+';"W?1.8,-?' X#YD?O6"ZYZ6<76&D!ZM
M:6_42/W*447I@8LL'Q<?]XJ44)$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$11CKS VK]D+7^U=X&=T!DX/Z7EC'*F*S;PB9B/*31?&/:_.QS78X.
M#G"^J$BH?;-9ZRZZ/E?03OC-&XU,D;7;>\:&G//F.H^"O$TT<#=TKVL'J5 7
MJ]Q/M]5%#'W@=$X$OZ=#X+3%>:7BT>RE]:F)>39;M7B2&%]7-+3%YDCD[T_2
M/&7'Q(QE84DQV3ES7.?$=S\X][/7D=<]?DNR2%KQ+&!D-B;,U@..<<GR^2ZZ
M.GGN$L#J:"29\V8W[1G<!XDXP%]/Q$.#R]/=G5956G0MHHZACG538=TCI7%Q
M!<2['RSCY*7ENM7+_P!Z6CR:,*LZ6?4?X.6]M8<U+86LD.<Y(X_<IAOT0OF,
MF^Z9GY=6YTY32/D!+WN<?4Y52[0*.2Y6B.E9,(_SG>$D9S@' ^L@_)6OP4#J
M(>ZP'CAW[E;!.KQ,(\QJ6F'Z,N3):=K!3O:8L/?O(R,>/'*NG93IZHM%?+4U
M3X7N-/W;0T9+1NSU4W['*Z9T3!O>T%IQY J2L%/44]0X.8X1D;3N;CITPN_-
MU%KTFLJUI$2L<9)!)7)?&C POJ\M8!(Z%=C:VHA([N:0#RW+K6)<9>YIGR#K
MC ^*FL;G28:P[9-1U-UNE';W&1T%,YW5O\HXMY/P' ^96N+/<:RW-8*2JGAE
MF!8XQN+7;01P<9XX6W+I005T<C:N 2@M+6$CD \$@JINT$R:>..@K'MVY:!(
MT.))]?[E[G3YL=,<4GV8VK,SMLWL/UP;Q#4T%?&.]@:":L#B0Y. XXQNPMNL
M<UXRQP</,'*UK9;?2VFWPT5#!'%%&T#W&ANXXY)]2I2&:2%V8I',/H<+Q\]X
MO>;5C3>EIK&I7=%7*2^2LP*AHD;YC@J;I*V"J;^:>,^+3P5BUBT2R$6M[;VK
MVZ?5=59ZZG]DCC>^.*<R;N\<UVW!&.,^')6QVN#FAS3D$9!6F3%?'^:"MHMX
M?41%FL(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("\V_A)PMI]:VVHHI@VKGI0V1K3@C#B&
MD_$'[%Z0ED;%$^21P:Q@+G$^ "\6:]U)+J+6E?=R?<,NV$']&-O#1]0S\UZ/
MV;29R3;VACGGZ=)!KO8[>'550'2C(+@.AZ?/A50W)\-<Z:G_ #66[2#X_%3]
MOJ*:N<T/ISO#< !IVYY'*B+U34M//G:YS2>&M.">/AYX7LV\.2OE8:*[.T]9
M:2HHBU]?4.$NZ0;O7.%AR:PO=94RS7"XU+W2$Y.=HSY#&,*MP2O/=-F<2&#:
M [G:/)6CV&@=$UX+L #<0[(/KCJD5CSKD\<-F=E?:7/;*BFM5]F,]MF<(XZA
M[LNA)Z D]6YXYZ*]=I>K+'9ZVGMU96,9/MWF!C"<9/!)' S\<KS77U<'^+P0
MG#2]I+G8 QGKE9.L+C+J+5-PK\MD#R 'L&00UH'[ERVZ2ELO?''RO&28KJ7H
MZPZFT[?:22VQ^RTTTK-K'C&''PYZY4>^WW*UU40BH)72Q'B2,$AW*\Z6@G>Z
M![W;OT2/#S^SE;Z[#M>5=;35MKO\\;HZ -$53(X]XX$G#3YX ZK+-@G!6;TY
MCX6K:+\3PML%9J"LG8R2&:-Q<#NV%H SX^"O0Z<]5CTM;35613SQR$> /*R%
MY.6_=[:=-*]OOL1$62XB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B(.$TC88G22'#6C)*K\>I1W[1/$V*(OV\NRX>&2K#+&V6)T
M<@RQPP0M;:DLLU)6]Y"QSW EP)/#@NC!2EYF+,[VF/#98(< 0<@\@HM>Z:U:
M8(C!4MWQQCC)PYH_@IV?6%$R+=&UQ<1D D!1;I[UG6B,E9A8IG!D3G.<&@#J
M5JFYF&.\;C+NR\EP=]$$J2N&H)K@X@%[6=6X''P4+J"-\<C7ANTO8#APY*ZN
MGQ33S[LLE^[PV9^.[?!3QETXP&CZ()PLZBK(*V'O:61LC.F1X+6U%%(;:V:6
MG=W>,;R.,JQ:+J&.J)!$1LD9D@>86.3IZUK,PFF69G4K<H/4-D=<,2T[PR=H
MQAW1RG$7-6TTG<-[5BT:EK":)\%3W<P,=0UQ&?#(]5L6USFIM\$KOI.8,_%:
MXUJ7B]S;> T[CSC/17G3U93_ (IIVF>,.QT+AGJNSJ([J5LY\4=MIA,(@((R
M#D+$KJZ.D;R-S_U1^]<41,SJ'1,Q',LM%"V:_1W"JDIGQ]U,WD>]D."FE-J3
M2=2BMHM&X$1%581$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!%&7VZ?BRF#F1]Y,\X8WS4 Z]WZG9[15T(CIQR06?\X6M,5K1N
M%)O$+DBP+)=:>[T8GIG>CF'JT^JSUG,36=2M$[Y@1$4)$1$!$1 6'<^Y[N$5
M R#*T,]'>"S%&WH;O86^=4S[,G]R" FI>_\ 8)*6,AK657!.3DC&/K4K24X;
M04+9!@M#!CUPHJ9SVR00,<0#[>T@>G12E%-OMMN=URUCOL4H4JL&**I(/\G1
M. /PE 54BIV0"EJ"?TPT_-I"N-\=2MM]:(-VYT #?+'?<_/*@8J2:6" ;6[6
M/8_!ZXYRNSI_R3/ZLK^4=#-$*( ^\2YY'R<1]RP*0]PZ=K0<]_$X8]<?WJ7?
M1-;0C<2) 7$^\#XD_O6!$TQU,A+3W<AA][X')6_LHS+M:]U'4.CSD,<0#SY_
MP4/0?F;E,2,AT()'U_P5NJ6NDI) S:6N81\>%5(-XK'F1F']Q&""/0I[CA,W
M%PA[D$-<QP /R4I9J>=]!3NDX;LYSXKH;AM;1.(QEVW_ '"LZE,S;7!B0["S
M("F2%?JV-;6-  ]VJ'3U_P#E2L\-.RAW^[EKFG.>?I#*BWL+[EMZ9J8^?_*I
MNXT0%LFR3PQQ4# E@_Q^4MZ"=A'U!;+$6R"K:?&@=];7N'[UK^-I-;(TXR9X
MQ]C5LF2!\M/,]A;S2RLP3CES\KEZCV:4]TJ:9CHV-SG,;_MZJ%LCV-@MCI6;
MMU) P9\"YQ /V*>:\,$9\FO433U J8;2!$Q@>RED! Y^D[C/EPN9HL-C>U]K
M@<R-L8P1M;T!R5G*.L'%"YOZLTK?]\J14)$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 7&61D4;GRO:QC>2YQP N2KO:!89]2:7JK;2SMAFD+'MW_ $7;
M7 [3Z'"M2(FT1,ZA$\1PP+UVBV*TMK>_G,CJ9@>6QEI+L],<^H6D=9]HEPN=
MX=462JK*"B# _8UOOAYZ9(Z@\8!^"IVHK'566X5-KJ-])6Q[BZ N#A)GD$'I
M@X42'&5LL-5(YM4S)W[P /(>J][I^DQX_JCEQWR6MQ*^Z+UE>8-?6=M;<*HL
MFJFQSPM.UCV$$##1QCGZUZ'K+[([+:=O=C]8\E>1[!4STEWM\E/3M=<:27='
M'M)#\9SDY\<KTI25(JZ6*<-+0]H.T]6GR*XOM#'JT3$<+XK3K3.ED?*XND>Y
MSCXDY6/(.3ZKL8<M1S<A>;'"T<2H%3;:5E6'.HX'.8"S=W8) SSX<+[#1EK!
M'!&&B,G&QG ^I6&JHYA<P]C,Q..7'R!&"NVT4<U++,92W80T#!ZXSRNV<OT[
M(A\L+9V0N;+N[OJS<,%30X 76P9/HNU<E[=T[)%B5]#%6, DSQY%9:*L3,<P
MA'PV]D56ZH;NW$8QG@>:S6-QR>JYKYD9PIFTRG: UU<JRU:>FJK?M;*'M:7N
M&=C2<%V.GUJAZ:[2*UDS:2]MC#8\N-03ASF8ZEH&/#J/,*Y=IU3W&C*^,%HD
MJ V!F[H2X_PRO/EP)F@IZ@%C902QYY!)'ACR"]7H<-,F*>Z/=C:9B7H"+7]A
MFM\E4RL#&,<&$2-(//B!X]%GVNIAO5N/<2Q2T^X@21NYSUQCP/*\[SSADD??
M/8=[06N'\GG/.0%,6+4%RM-PCAMDAE=),T-I6L!;*X@< ]0.BTOT-:UGLE$7
MG;>1M/\ C3"XM-.UH&T]>!C^]<H+.R*K9-$\X:<@8Y^M2T)<^%CI6;'EH+FY
MS@^(7->3ZEF^WQC=OQ7)$6:'![L=%4=<:RCLD4E+0R?](EF2\=( ?TB?/R"L
M5RJ?9XB1R]W#1ZK66K[)^."V>,XEA.YX/_>CR*Z^EQUM:)OX1;QPUM[74FJH
MY(I7NJ<N>Y^[+LDYSCIGQRML:/[6;A3T=+;+B7SLWEGMI+2\-/#<M\1G/KT6
MHY9)FS5$T\1A='N:QKP 0<\#"S]/V*YWAT=+9J-U6]I:Z9Y<&L9GH"XXQYX]
M%[>:F.U?]3PQK-HGA[)M+Y)*&(RAF0T#<R3>'8\<K+5=[/K1<;'I:DH;S4QU
M-9'G<^,N(P3P,NY..F58E\U?46G3OKX$1%5(B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B N/>QYQO;GRRJCJNZU,U8+5;0[O'8:YS>N?)8\FBZF9K7
M.K6QO Z,SA;UPQJ)O.MLYO.]5A>$5"@-WTY4-[][JBG.!@NR#\/)6&EU+2SS
MB-\<L0/ >[&/L46P6CFO,$9(]^$XA(! )&3X+X7 -R2 //*H.J*WOK^V*D)=
M.PAK7-/CY!1BQ^I.DWOV1M?T7&'<(F=YR_:-WQ221D8S(]K1_..%DNY(OC'M
M>,L<UP\P<KZ@(B("(B B(@(B("(B B(@(BQ[E74]MH*BMK96Q4T##)(]W0 )
M$;X@4/MRU,+#HV6EAD#:ZYYIHAGD-/#W?('[0O,=UH(::V1O9C?N;GGJ"#_<
MK/K*]3:ZU'/=:I[X:-GYJDB'5K,\'XGJ5%ZBIF168-$A.TM?[W4\X'V+Z+I,
M/HX^V?,^7#DMW6VX6? MS12/8)7'!!.>?,CT4%=J&IC?WDLG>^)<#T6=IZEC
M'>5D[OS</('F?58UWNXJ7%L+2(QQEW7'IY+IG4J1OV1D0R1D$J<LS97B0218
MA:"07#C/IZ^"QJ6>"AN$X>QVS.!MYVC.?FIUTS*^BF]BE+9<#&!D@^7/WJ?!
M*.T_;Z&Y7FHAKI]L;6'N\.VESL@ #[5]H:AEMN%9 SF)DCMISS@9"B:"5M)<
MV.FSL:2'XYRI2W4%-7T\CI*B1DK\GCGG/BHCWE$LZ6J9+122T+6&3!!R!]RY
M=G^J:.P,N N5-43MJ',R^+'NXSUS\5T0TL5C:^1\_>->W&T9:/3]ZPK%#%64
MM9'([:9'9XQD>JK:.Z-)CAOVQ7_3=SIHJC2]V,=7$<OI:CW)3Z@9Y^65M6Q5
MWXQM<%2>'.&'?$<%>+J>W,M51'6FH#C$[>W!Q@C!^*]0]BVJJ74^E"8&=U44
MDACFCSGKR'? C[BO*ZW!-*=WETXK;MJ%_1$7EN@1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%7+GK?3ELO;+37W:G@KG#.QYX'D">@
M/H5:M9MQ$;1,Q'E8T6%4W*GAC#FO$A(!&PYRL!]TG<<M:6MSP< A3&.THF\0
MG%U55-%51&.=@<T_8J_77M[80PO9&X\[FGP58GJGQN?*RL<XYX(>05M3I[3S
MO3.V6(X3=ST5%/)OIW-!Z8/ND_,*/@T34M> 71AO0ESLY^Q2>F-3>T3"EKG@
MN/#)#X^A5DFK&LR&#>1]2M;+EQ?3)6M;<PCK/IRDM[6EP$L@Z9' ^ 54[0!N
MN##L+L MP%;S>FQOQ-$0WS:<JNZKIF54\4[9G")^2US1PHZ>\SDW:3)6(KPR
M6PE^AFAH<#R1Y]2HG0HEI[N&O+Q$XN:T'IG']RQFOFAB<QL[Q'CH''I\%DV2
M</O%+[V,2;B3Q\5TS75+1\L8O,VCAL21[8V.?(X-:T9)/@J?>-7,#I(J$GW>
M-X&22NC65VDEG-+"7"GB(W$#Z;O)9>G--L+6UMS:Q\[O>:QHP /#(\USTQUI
M7OR-K6FT]M5'N%542R&>I8XN?C#G>*YT[*V2@W0RNV-.2W)6R[]9X;I2B-FQ
MLL>=GE\"J#46>YVXR1B-^"" 2"1Z8(75CS5O''$LK4FK+MFHJBWQ/:V4.!&
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MU(V,;6[.&^ XZ*/=6/CEH0!D!Q./_*5D0/B%MB,K=KVAP'/JDD(V.H<ZOCC
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MSUT3OT2=I^!5O7*UI.X$1$7$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$04V_/=8[RRY%A?$\[2?(>*MM+.RIIXYXCF.1H<#Z%8E^H1<+7/!CWB,M^*
MJ=EU";7;WT%4UPJ8^(MW3YKI[?5I$QYAEOLGGPO%33Q5,1BG8'L/4%5W4.G:
M0VN1U*!3R1C=NSU^*Q[;J8PU#(;G)ELGT7[< ?W+.UI4EEC_ #3^)7 ;ASD8
M)_<E:WQWBNR9K>LRH<EUJ:IL5/55,@AB&&D#.?0J=T':Y9KG)<:@.[J,%L6X
M=3TS]2R;E<[+IVQT_M5/%4S,C!+0!QXDDK36J^T?4-ZEEBM=8;7;@-HCIFX.
M/,NQGZL+MI2^>LQCC4?+'BL[L]"ZCN\=HMSIBYO>.!$8/B51Y,2VJ2^:@NC*
M.@&2>].2?0#/7T6B[;K.[:?=!27-[[C;VYV1RN]YF3DX<L/6&HJO65?W-)(Z
M*V4_O0T\AQSCEQ \5:G1SC^F)Y^2<G=S/A>[9VL-I[A5.LT$QC9GN^]=D2<\
M$M\/K*[=/]OMV=?J>GOENHO8GRB.1T <U[ 3C(R3G'DM:VFUFWQ22U;&N>0"
M(\>G]_V*MW)VVM>]I&=VX$.#OM71?IL<QS'*M+S$\/?@((!'0HH+0EX;?](6
MFYL()GIVE^/!XX</K!4ZO M';,Q+MCD1$4 B(@(B("(B B(@+SW^$'JZ6Y7%
MFE+3)F&+#ZQS3])_@SY<'XD>2W-KG44.EM,5MUGP3$W$3#^G(?HM^M>2+4ZK
MGKJBLN$4CY:EW>NF>.I).?K*]+[.P=UO4M[,,]]1J$A26_;;FP.>W>WJT#+0
M0?'(\_DJW>Y91,87N>XCW=W0%HZ#'ITX\E+7JLJ+6<L+W[WDASO=P-PX'B>G
MBHB@J1-6QU%6<["#C&1X_O7KQS+F\,RU/FI*0MGAD,4SL'+,AH\2.%B7JW1P
M-$U,XNC=X8Z?!6&XW">AE:YE.R2$L Z'+3CDE13*]EPJXJ=C' .>.#C@#UX]
M5;]U8^88MNI&532^I?N>.,9\E*SR06R(FGC=DLZM/!^*KM/O?(6Q[RX],?%3
ML\-1%:7^UEA&?'D\ \95A6FM=/. WESBI 6FX,+71Q.&>0X'"CZ=K^]S'DN'
MD%9;1=)9!W%1N]W&UX\.52L<+3.G1J%Y]AA;4.#IV ,X].O[EBTLT-#1Y+_S
MS@#[O/7[EA7J5SJY^]Q=@\'T69I?2E[U;<!!8Z*:9I.'2D8CC'\YW0*E\D5Y
M36FX8]GH;EJ6ZT]MMD+ZBIE.UK&]!_./D/,KUIV0]G[=!V:>.6H%37U9:^=[
M1AHP#AK?09/*Y=E79U1:%M;@'-J;I.!W]3MQ_P"5ODW[U>UXO4]5ZGTU\.NE
M-<R(B+B:"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B BXO>UGTW
M!OQ*ZWU,38G2![7!OD<H.Y%$RSOG8278'@ M:]K6KJS2ME8;9(YM;5O,4;L_
M0&.78\3_ !5\=)R6BM?=6;:C<NKM?[6F65T]DTW(R2Z<LFJ,^[3^@\W?<O/@
MHJBJG]JKY'NDG)?OD)<YYSR?-=]AM\]UK7RO(> 3+*^5W4]>I\\JPQTDLD!.
MZDR6?I#:6C/!QXKZ'!@I@C4..]YLZ;=J6YV:$,@KG=TP\1O=D?5U"VWV?Z_L
MVH(/9:FHEHKP[ ;"3[CS_-/C\"M$79E5)+%WL!>27,:(P U^#C(QZ^*@27PS
M'!<R1AZ@X+2%&:E<L:CB2D:YEZIU!<;7;WN_&-XH8WD='2 ._JJ"I;[9JUQC
MH;E!.6]<9'WA>?(X7SO8XNSO(!<<D GS*L-#8ZFDFIIH*AL3Y02."00/ORJ4
MZ?4:F2UFZFO8 3&[#Q^D%:++?)(J8-J 2P\9=^XK4.G+LZ>%A,@+APX-.=I\
MELBAV3V>6K=(QL43?>,AVAHQR5CGQ1$:LFEI]D]4U\,[-S'=5V:?N<4;ZBEG
M+'AX#F1NYY^"TU=M>T4+I(K<?:#T#SD-!]%3JNXU-36^V.K7LF/T9 XM^0QT
M5*_9G=SO2_KZ>I)*2B<USIJ< GR&%@RQ4T+'"G: /'S6B;3VB:CMT88VL%;"
MP<LJ6Y./]+JKUIG7]OU$!$[_ !.X^,#SP[_1/BN;/TF;%'/,+TO2WCRL4M06
MES*B8-A9EP<3T5=K=9449>(+D&L8[').3]2U_P!K]TJGWFGHF/D%.(P_8"0'
MN)/U]%01)*UON2X.,N:3TP5Z'388O2+7]V-YF)F(;D_*%/2NDDIZV67!]T.;
MQ_%3]J[<XJ8LBO=MG='Q^?A/('JT]?K6@Z6X2#!FYW<'G!*G.YIY&QXE/<O.
MT.+<ECO(K:W28;QS"L9+5>I+3K[3]ZA8^UW2E>YWZ$CPQX/D6G!6?47.IA.1
ML</(A>*JZ$TE1',S!P_.!QR"O1IU9/=;;35-,SNX9(@[ .3T\UYN;H)I;5)X
M;US\;EM.W7>GJV.W/;%(WZ37.Q]2SV2,D'YM[7? Y6D::MJYJR/:T .(&>BD
MHZJKHJG)W->[QR>OH0LYZ/7NGUOT;>14:TZOFA>(;E'N'ZXX</CYJZTT\=3"
MV6%P<QW0KER8[8YU+6MHMX=B(@(/0@_!9K"(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B BZWSQ,!W/;D>&>54>T#6\6DK#-7OI^^>?S<+ [Z3SG
M&?3CE6K6;S%8\HF8CF5FK+I0453!3UE;303U!(BCED#728\@3RODESIF.(#B
M['4M&0%Y%N<]RU!627F^3235DGOMY #&> :,\?!=NG.TF[Z>EE@DC974CP0(
MIR06GID.ZCX+TI^SM5WO<L/6F9XAZ9N^I+<&R1UD#9*,#+GEP.!YX7GFON,?
MX[KZR/ H))W.B:\XPS)VCZL+G!K:Y7)DHN-!2Q44[71YC)!;GCQ//55N6T/_
M !Q#'65#8[?'$9))7G#0,XP/,GC 5<G3VQ1$5CR\G[2I?J>VGLLLFJ:9S#'3
MPQM'0N><Y5-U5>IIR&2/! &&@<#"DZB*R&0MIXZA\8Z2-(R?D5%R69L]ZIIX
MHY9K= '3SM/!VLR2#Y9QCYJF3#EI'U0X<71]N2-PW)V%:.NL6AYWU,XI8:Z8
MU,<9ZO& &DCR.%8FTMSMTS&0T]5[4QQ VYVGU"TW5]I5RG<!'&RECS[K8B?=
M'AXJ9MG:GJFT0B:.KBKZ4#)AJ&YQ\'#!'1=E>ERTKQJ?T>]6:ZB&[[3IVXU,
MT=3=YRWW@\Q[MSOK\%=%K*@[0#54=#6TL<CQ41->YG5N2.0/@<JQT6KXS+LN
M%,^GY^D.0/BO.RX\MN;0Z*32O$+4BX12LEB;)&\.C<,AP/"Y-<'#+2"/1<K9
M]1$0%5+\Z:CKI'D.[J3EKO#X*UKXYK7C#VAP\B,H*I3UK&TQ;QD]5ATT[WUI
M9$>'=?(>JFKEIX3S.DII1%NY+"./DL:ILYMM#WT1,LP=EYQ^CZ!2A5=8VB*E
MMS9B[>YCN<#'5V57II'5,$+8X]Q8]KB&CH%/:OK3+8ZDDX#0'$GPY5?TS=(I
M;:R2'WV2_I>?.%U8=]K.WE&1P0TX=WD>V3<[W3TZE8EZ/>N>^-I/$>-H]5*W
MDPS/;DAI) )^:L H(YM/MEA:UN(]P /7"T[M>5=*W2!C;?(Q\I[PAQ('3.%#
MMIGFHW1.W Q#)/AG*F[+2LJJI[IB.Y9^CYE9EX;2PQ'NFL;Q@!H 4]T[-(%K
M7LJ8'NP2#@'Y%*9K9*5CI'N).2,'IE25AM1JJ%]94M=)&QWT6GZ/J5CU$4$4
MT<=,-K"X-(/. G<:1,U$65( =F,2L)/CR/[E(5-''+2R['D!K2?/*L#X:#V-
MS&Q-W?K'KGXK!MM)$[O>_<70] P'JG=)I#2T+O:)VMD!]YN"1UX5ATXR:B?,
MR%KY8I:=[7^6[(QC[5C7-L38B^&/9D?2 Z^"L-@.V@DGD86@@-C!XR/$JMIW
M&I(CG:TTDPG<UCS[@ 7RMCIZ89IFAN&[1CR\E@VB">M:_P!FY>QF['GST61'
M;KA5S"-T$D8S@N<, +CF-2VAE:?H9ZBNCJI6N;#'[P)&-Q\,*W+A!&(861-^
MBQH:/DN:JD1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!PEE9$ 9'!H+@T9\ST5)O
MG:=8K-J6&SUKI6[CMDJ<?FXB?H[O'G'7P4MKL/@L-56QU0@=3L,C>]?MC#@#
MM)X_6PO(MQD?4R/DK&SU,DA_./W.<XGD$Y/RPO0Z3I*YHFUI89,DUG3VG7UT
M-'1.J9' LQEN#]+/3"UU<JZ:OJG33GD]&CHT>06HK%J:\TUMIH9Z^K?3Q@"*
M*I.]K&@  #Q_N5DM.I*NON441;$V-QVX:#G..JPOTUJ3,,KYN[A=*63NYVN/
M3."II0"E*"</9L<??;T]0N<K+(<W/(ZJ#O=+C,S1P[W7^GJI]<7-:X$. (/F
MKTOVSM?:JQP/KX-\;1WK<QOW<;O)WQ4_0QR,I862G=(UH#CZK(9!&P88T-'D
M!A=@ '13?)W<)V-&!A=%96TU&S=53LB'\X\GY*(U5>S;(6Q4^#52#@G] >:U
M]/-)/*Z2:1TDCNKG')*K%=\L[7TO=5K"AB)$$<LQ\\;1]O/V*+GUI4NSW%-"
MP>;R7?P5416[84[Y3DNJ+K)TG:S_ $6#]ZPY;S<9<[ZV?Y.Q]RCT4ZA&Y=LE
M1-+_ "LTC_\ 2<2NM?$4H$7U!R4'P+DQ[F'+7$'T*[)*:1A?EIVMY)PNE3,3
M7R,B.KE9XAPZ8<%:[!J.F$,=-6;HG#@//+<*F(HF9F-2M%IAN*-S7L#HW!S2
M."#D%<EK"QWNIM<H#"7TY/O1$\?+R*V+;JZ"X4S9Z9X<T]1XM/D5E,::5MME
M(B*JPOF%]5%E[2K5!>7T=5%+# '&-L[N<N!(/NCD#CK]BTQXKY-]D;TC>O*\
MKZH^VW>CN$#)8)F;7G#<G&5VU58V%[>?=#L/."<!/2MW=LQR;CRRQP<A7:G?
MWE/$_P#6:#]BUU/7L+"(#N/3=X!7NQN+K12%QR>["I,3'EIBGEG(B*&PB(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(J_J2*[NE:^V.<&@#AIQYYX\<\*
MU*]TZVB9U&T[/*R"%\LA 8P9)*U[';CJ5]?,P %F7,=YG/19$MOU)=2(*R3N
MX,\GHK=9;;':Z)L$9W'JYWF5T1,8(W$[EG^>?'"BBJ[ZWBBKJ4NJJ9VUDG3#
M?53MHMTUPLTL53[K _=#O' .#GY<J0O]19K3!+<+GW;1$TO(ZDX\F^)6I]0=
MM=9*7,TY;HHF#_O:O+B?_*",?6MZ5R9X_P!*K.8BD[M*I]N%96VV^QV?.R%L
M#92\#B0G)^SHM:4E//4?R9>YSO'GHK]J374NI*04>L;?22'=^8KZ:,LDA],9
M.0J715@H*FICI2^JA:>)&9&1\/)>M@BU:16\<L+ZWN$I74$<M%%%,\-##CI@
M@_'_ )Z*,EM$3:=T]#4?G8STSGGRRL>XUAN#?=W!_@ >#\E-V:V^Q43_ &W;
M'++[W/5@QU/IUX6LPK"&H[O/)(R&=P#>A\,GUPL&_1Q"8&/: 6[C@=3RI.ML
MT9;(ZEE;(0>-O(=Z?%051(Z;BH<XN8, GTZ!9W\+U\[AZ1_!6NLE5I2YVZ1^
MX4=0'1CR:\9^\'ZUNU>>?P3-N=2#/O?F<#T]Y>AE\_U4:RR[*?E$1%SKB(B
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M[G"]U!3,M=5](/I6AK"?5GT3T^*]3INMQXJ128<V3%:TS+0C87QL#8WQR1@
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M6[A\LG'[U*&=62]]&QCG'NPY1[YQ2R_F>,\%8=WKO8H8N\^BZ9S3\MRB+O=
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M*J];,9XR6G(#@#]:Y4KW$R#<=O?. _KA<D\\M6Q-,4T'L3*MC<S29!<?#G&
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M<X$;=@W'<M$0J45$^!SSDG#MBR*=U4)^[CD.W(SGPR<*4H8N_EKHGX!.US?
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M- #H3@XZ\K$HH]MYE9^LP%)\#M@=(!+M/.%SC)J*R)N6C8P]!RLVDHWD/.,
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MYG<!@2<9:[YC[EY66D]-?U<?CWATUF,D=MGF:@ODT56R5LSVS-+1R,Y\"/\
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MW#F_:N)JN$\<;Q&<D9</%0-Q9MU7;QNR&PR$%9YJ>(N?%0]RG_\ U+0.\XI
M@XW2H,MPNT3SDF@:0?@\*Q7QW>1Z?'Z]1&[Z@JFR-]9J.XQ1\N=2!@^?*L]2
MU[OQ+OP!1N!E]?=QP@M:+K@FCGCWPO#F^B[%"1$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!'9VG'5%B7>M;;K94U;QD1,+L>:F(VB9U&Y>?]2OJ)+E)/(\Y+W>]
MGQR<J(?[Q)<<D^*R;K<'5,CL#(+BXG'4E8,;BYQ!/(7KUC4/G+\S,P^AG)(7
M7*"!QU7>3A=3W9'56A6LNKO 1[W7"Y X:3PL7/O'/19##EG/13II:NG-KCX!
M=4[CTQA9<8&WA=%4!L)\E$*5GEA^BG*-S3"W!\%!#'CU4K0\0M(4RTRQPSLC
M*^9'4(",<KBTY)4.=S#1CD+@YK2,8Z>"Y%P 7%AW%"-L9\9 (&1Z+I; X\8/
M*D2T +BT '"F++QDF(*>,MC:#X+L3P7'/'"AGYY<7,!?ST73. QV3S\5W&3@
M^!"C:F=SY-C/_E3#7'69EL#LUU*^V5D5&\?XK,[#@/ GC<MU+1_9UHZXW"J@
MN%7'W%"TAS7.ZR#KP/+U6\%YO5=O=]+V^DB\4U81$7,ZA$0D $GH$$3>91%4
MQ//2*":7Y@ #[U7G@13LR<COZ>$?"-A<?M*E+_BIADEB=QW>S'F-P)^O&%5*
M*K=-7M=DD%\LH'D<[1^]3"$_>*YT;&%A_E''/^BUCC]ZI3G_ (PJW5$LAPR-
MC,CT R?O5CK*@4YE=5-YAI97AKO,\#]ZIM!))%;)WD-Y8<9\\+IZ:/,L[NU@
MH^\?LE$H$>1G/Z3MV5%2Q%LH?&W<UK9!\S@#]ZRNX;$Z4L(&P,:1\&K'8T2U
M>PN)8TQ#&>I+BX_8NJ&:>J#W5OD,8#F-C.,>@56IVAT]02,>ZR,?( _O5EN%
M='0TSA&!X-#3SU./WJ&H7"H#YMK6E\QX ZX)_@$]QT&F9+/4;\D'NVX'JXJ0
MNSZ>*CD; "22!SQXX_>NRCI6,K&/?*,E^2SU:T\?;E85W<R0ANX,;N!'K@YQ
M]BGW'392T&9[FY#I''ZL#]R^S!DS6E@P.]F=T\LC]X4C9HHH[=$'%I=MR3YY
M.5C>SR,< &_2:0,=,O>3^X*HNVE*84UOMN_@-#Y3Z#N\_P#N4W'2]S9XG.QE
MM.Z0^GN+&BIO\1#6O:TM@=$ 3CZ1:T?8U2=QDCCH)A(,L=$V,@?SW;?WKSK3
MN9ET1Q")H:1AAA+Y&Q^STL6-WB0PD_5N"N-!#[-100@@]VP-R/'A5FI9'))6
MF%I:UD;V')SR7",8^3%;0, !52(B("(B B(@(B("+X'-+BT.!<.HSR%]0?'.
M#6ESB T#))\%KS4-T=<:P["?9X^&#S]58-97'N*9M)$[$DHR_'@W^]4I3##+
M;_; I*VS;F&,GD<CX*-7*-YC>'-/(4L8G2=1=<$K9HPYOS'DNQ0NX.9Y+K>S
M+2US<M/!!7>BF)6B57K;9+$Z00-=)$\\8ZM]%G66EEI:4QOX#G;L'P]%,X'D
MF!Y!:3FF8U)MU-:<8 X7:T;0OJ++>R9%KK5EX=7UCH(G'V:(X !^D?-7:^U)
MI+153-.'-9AI]3P/O6JE:D>[*\^PB(M&8B(@(B("(B B(@(B! 1?5\0$7U?$
M!$1 1%]0?$1?>J#XOJQ:FMA@R"[>_P#5;^]2.E[?/=JCVFJ!911GA@X$A\O4
M*)E,0N.E&?B^VEY;F><[CGP'@L^65\IR]Q*X(LUA$1 1$0$1$%&U>YQO!#I/
MS?=@ @X+/-55D+96O)>3R<'S6S;E8X*^0.E<1@DY;P>?#*Y?B"V>RL@]D9L;
MT/Z7U]5U5S5K6(9]LS+6;630-?W9#F@@<^:J]U@K'557-W[]L."TC/.>,!;O
MH- 4UUKA3P5=53L<#N+2';1Y\A:^[4^SZXZ#J*:II:RJK+-)[IG+>8G>(<.G
M/@5V]+GQS;4SRM7';6U2@I-C70OC9WK6MJ'2N+B[SV_->@NQ"_R_X+1MJ:6C
MI*5M282Y@+2XD9W$DG)\_0A:/TQ;WWF\VZC?6ROCGWO<]N&D-8TGKU7IBQZ4
MIK73V*GIJ>1])&QSI0\[CO=@[G>?E\@M.MO3M[++XHG>X7.&:.=A="]KV@XR
MTY&5S7"&*.&,,A8UC!^BT8"YKPY_1VP(B* 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0: _"K/.FFC_P#B#_Z:TM37>JBA,6_<WU6\_P *& 2C
M3'(#B^=HS\&+1UUMWL;(IV#=&2&NSX.QD=/,?<5]%T/_ $*_WW<67\\ITU#V
M6Q\]5*7.+<EHR!Z#USYJG5(E?,Z0M<T.YX\E8H[O2.@8V1KS(TC]'/ECXK-N
MHCBI1+( T$9P'>'.&].HY"Z9C?#.)TJ%/N=(W8,N)&!GQ5FL]K%,YM0]VZ3(
M:T@?1.>O/7QY4!'LDA?+&,31.R['0M\#\EFQWFMD?MB[L.=TVL')*1S!+A?:
M>9M9(Y\6QF!MQCD=,GGT73#<G-@IXRT&2"3<UQ.21Y?8I^K<]UIE%4&!_=@9
M#AS@C PJ@ .]'(Z]5',2F.86%NI'M#0Z(N:W Y>2./1<M0-BJJ<UD0V[L. /
MD2<^/FNVVV6D?&)9Y ]S3]#.!X_;PN&HRX4S61M+6@-#N?+. K?*O[(N"O;3
MVUK6.'>.R.A]WG@KOT'8GZHUK;+6 Y\<TP,QQTC'+C]65!$[P(VM+GEV&@=3
ME>J^P3LZ?I.UONEVC:+O6L'N8Y@CZ[?B>"?@ N'J<WIUW[^SHQTW+:\4;(8F
M1QM#6, :UHZ #H%R1%X+J$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1Q#6DDX Y*+&N1(M]06]0PH,,U(J'DN/N> 47=HF31.:./$%8\-5
MAO5<HWB>7#C[HZJ4*I%%4PWW>Z*0Q=R6;\>Z.?-=MA@GWU;71N#I)W.&?+S5
M[/="#& H>L(:26<$>2#+IZ*..GVN#7/Q](^:JUND,-[NS#P=S#]A5@I:TR1>
M\?>;P5#FG$UYKW@.!<QAW >B"BP/;[=*XM)<YY(Q\5)222=R,/.2TG&.I\EA
M55$^&I@8[+7!N7'&".2IN Q]Q[FT[1C!ZA>A6T=D,=<RK-).\7:O_.%L>_+G
M;,_H^("C;;6/,$NU[O>D=D^:GA$QUQNL3?=<2TY'!QA0MOH":9HA<'%Q<2?
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M/D'.D/V*W*HT+8K5349;[YB +AGJ[:&DJV1/;)&U[#EK@"%"7)$1 1$0$1$
M\ JO7N^".P25E.YT.).Z>YPYCP3GY\?:IBN95/8UM'+'$[/O.>W=QZ!>?^VI
MM5345KHG1S31F>62IRQQ;OX&3CT''Q*ZNEPQEM$3++)>:PUS%J^\T%YDOU!=
MGPW6H)=.W=N;+SP' \=,<+>ND^W#3U=9(9+]*ZAN@]R2!D+WAQ_6:0#P?5>>
MJR?V6F>YD8;&XM]G<Y@^CSG&>><+G;ZQM7<.[IH-H+@6$- V@#)^M>OGZ7'D
MC=O9S5RVJWM7ZPM=SKY9_:M@>[W0]CFX'AU"P;CJ2BI2QD3Q42/&X",Y 'J5
MKI]0YCW=['R<=/)<J9^^I+FQY!'7/T5YD8*[9S>9;4MM8VMIQ*S!:>A'BLI0
MFCFR"S-WG+2\[#CJW_G*FURWB(M,0O'AV03.A?N;T\1YJ7@F9,W+#\1Y*$7*
M-[HW;F$@JJT3I.HL.GK6O&)<-=Y^!66#D9'10O$[?41$!$10E7M<R;+&6Y^G
M(UOWG]RUXM@:\:39F$>$S3]A6OUK3PQOY$1%95]7Q$0?5\1$!$1 1$0$1$!%
M]7Q 1$0$7T+IFJ(H?Y21H/EU/U(.U/ _>HR:Z@9$,>?5W\%@3U,TW\H\D>70
M?4J[3I+SW""+(:3([R;T^M1M17339&=C#^BWA8T;'2/:R-I<\G  &25=M.:1
MQMJ+J 3U;!_Q?P4;3$(O2^FY+DYM15 QT@/SD^'IZK8T,3(8FQQ-#6-& T=
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MA[JJ4^8'"G.S^MJJ34UO;3Y+^^;AOB3GHIOLOTH_4-VFCJV.CHHF;GR #.?
M ^JW;8M%6.R50JJ*B;[4!@2R'<X?#R7#DRQ&XEZ>'#:8BRQHB+B>@(B("(B
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MKZ*^=@.J:NDU5!;=Y=351[M[!T/D?B%Q9:ZW#S>IK/;,0]1(B+E>2(B("(B
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MP1N__@,__(U;.1!K5NC;J>H@'QD_N7?%HBO(_.3T[?@2?W+8:(*1!H4\&>N
M\PR/]Y*D:?1EMCQWKIICZNP/L5F1!@4EGM])@P4<+7#](MR?K*SQQT1$!$1
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M"DHJV:6ECWL+R3M+F@9( QGSY7+4'-M<X[&2- '4'T^YR[9YAE'"PW#LYO\
M:;717>PL==K56P,G'=QATC YH(#F>.,]1]BJE?6W"*4QU=++ X#!#X2T_,$+
MU)V(59K.S"Q/)R8XG0_U7%H^P*[20QR#$D;'C^<T%>7^(7QS-;1O3H]"+<P\
M5TE;'6V\05#CM:.@ XY^"ZK]5-DI6LIB=K3R22[!YP.G'C]2]87WLZTK>WND
MK;/3MF=UE@'=./Q+<9^:K-#V':4I;JRK<*RHA8<BEFEW1D^O&3\,K:/M+',<
MQ,2IZ%MM%,TY?GTS!%!%.Y[6D N#=OC@YX^WP6U.SG2T&FM,5IKJJ"2\5[FF
M1L?O=TP X;GH3DY/R6V*C2UIE&&TK8@. (^ /DNJ'2-LC?N+9'#.=N[ ^Q89
M.MKDC4K1AF&3I*$0:?I&#I@G[2I=?(V-C8UC&AK&C  Z +ZO-M/=,RZ(C4:$
M1%5(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"AM5Z:MFJ;4^WWB#O82=S7 X<QWFT^!4RBF)FL[@F-O,&M>QJ]Z?[RIL#G76
MWMR[NP,31C_1_2^7U*%LUB;<Z)DE8]XE=N!C P6$<;3ZKURH&^:6M]SWRB%D
M%6[GOXV@$GU\UZ6'[1M$=M_\N>^"/-7GG0_9Q3W'5\4MYF;%:H 'NAD(#I'#
MHSRQXY7IEM;10PM#9X6QM&  X8 \EKRMTE<8*L/A9WF/TA[RQFV&]O/=NBG<
MP'@XP,)FBN>>Z;(I::1K398N5.]I="XR@>+1PJ?K1M!?Z84M?0P5$;';F[VY
M<#ST*[+'9;M31D/:1GP=)@?9E2\.G>\>'ULP.#G9$,?;U7/$4Q6W$K;M:-::
M4N_9[[5',VS43S.&[F-C. ?DM*WFGK:*MDI[A3S4T[#AS)&EKOM7O"EIH:6/
M9!&UC?3Q4;J#3-FU#&QEZMU/5[""UTC/>;\#U717[1GQ:.$>A[O.W8AV4NO\
ML5\U!"YMI8<PPN&#4$'J?YOWKT_&QL<;61M#6-& T#  7R&*."%D4+&QQ, :
MUK1@ #P 7-<6;-;+;<MJU[8$1%BL(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M(*KVGW(6S1M=(7;3*!$#\3S]F5Y6JJDSU#BP9YP .5Z_U/8Z745EJ+;7;A%*
M![S>K2#D$+75E[%K?1UO>U=PDGA!_DVLV%P]3DX^2UQWBL.SI\U<=9WY:(GH
MYP !&7;OU>>5C5]-'3D,W.=,/I\^Z%ZOJ^S_ $Y40[!;VPG&-\3BT_WJB:@[
M%FU$Q?;*Y@!_\=IW#YCK]05XRQ/EM7JZV\O/C\CT7TEK6 ,>23U&.BL6LM*5
M6F+DZBKY&F1O(<T</'@0H.EA:^1Y=G;X8"O'/AO68MS#G11/JGB/.QGZ3\<!
M=T]#/3N:(7"8../='1=4C&M!'(;UZJR=G]71TM\I'76/OJ)DH+V.YR.G3Q\#
MA)W!?=>4W8.RZ\7ZP/N#'PPL&2P.)W2XZXX^2U]=J6.EJN[BW].05[5M\])6
M6^*2@?&^E>WW#']'"\E]H%BJ+%J6:*IC<(V/]UY'#FYX(^2SI:;3RYL.:<EI
MBS$M5,8:?W@2X\GT]%(!Y:WU7"E=WS&B(<GA<RQS"YKA@M/0KNK$1&H>M741
MJ'QKO?Y\EW D-Z+I<T\.'@OK90&<\%67@:[>X@+L+ >3RL-DH]H 'V%93I..
M$A$3MQV#)7:QH /"Z(]SCST\ED9X2$P^DKB[WFD+XT$Y*ZGO[L]>$-N4NT,Q
MU*ZK;6R4E7'/$=KF<@]"/@HZY519D!V&'R5GT+H*]:G/?4_=Q6]KMKIY#QQU
M  Y*RO>(\N?+EK7\ST7HJ[.O6G*2LE&)2"U_J0<9^:G%&::M$5BLU/00N+Q&
M#N>1C<2<DJ37G3K?#P+:[IUX$1%"HB(@(B("(B#2GX1EPNM-'00T=PJZ6V2-
M+:H4[2,EQ]W<X=!P1A:%I:%D<LL\<0D$/+&[^9,'EWV+UAKL4]SH*VB8R6*X
MOA?%3ND81'*[P:? C/GXX7EZ:@EI97T\UME#J%S=X=EN6[@-I/J3A>[T$QZ>
MM:TX\N]HZC#JNO=.UKA!&26A[N&NZX4I05M142.,L;)0V3#@TX('D/-1U831
MT9CD@![\EYW'.'9\%\AB#+;OA+W/J'!I'0,.? >)7;:D6C5H8SRMIJF550:6
MEE +!AS2>F%-V2U&LJ>ZB:61@#O9!T'I\2NCL_T+7ZDD[FWN,-MAD(GK9&\@
MXY:P>+N?@%O^ET7::.W0TE$R2%L30T/#LN<?-V>I7D=5:N*>VL\_]EZ89MRI
M$$3((611-#6,&  N:L=7I.KCR::2.8> /NG^"AZFVUM-GOJ:5H'CMR/K"\[:
M\UF/,,1$(QU1%1$1 1$0$1$&K-01QT]QK!3N>(FR\-SX^/VY6*TELD R2'<G
M/7E=UT]ZLG<\$@3NW'/\X^"ZF-/MH=D';QP<<+T:^&$NRGW-ED:X^ZP'//1;
M0M[=E!3M\HVC[%K6U0"KKVT].6ODJ)FQ,:T9)R<+=%-IRY2 #V?NV^;W ?9U
M6'4>T-<=9GPB45HI](3'FHJ6-]&-)4G3:6H(L&0RS'^<[ ^Q<NVT8K2HBS:6
MUUM5CN::0@_I$8'UE;#IK?24V.XIXF$>(;S]:R5&UXP_,J72:2J7X-3-'$/)
MOO%3-'IFWP8,C'3N'B\\?4%-HHVTC'6'"&&*!NV&-C&^31A<T1%Q$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0>0-0VMD/:5J&GK<NQ62N&6YSO<2T\>."NJLKX:>F/=
MR.)P6>[D >0/@!Z9\#PME]N^CJZ*]LU/9Z62H@D8&UK(AES"WH_ YQCRZ86H
M)VBX,,M*'2S,()807;AZCIA?28+QEQQ:LN"\=MIB4UV27)U#VO6ASB-DLCX"
M0,;A(UV,YYZD<K=7X2437]G;7N'\G61'['#]ZU7^#SHZKN>LQ>9V.906M[B7
M.'TY2" T?#.3\O-;[[4]-R:KT76VRGE9%4$MEB+^&ES3D GPSTRO.S9*UZFL
MS/CRZ*U^B8>;-/U<7<14D46)"<[>?>!;G;P/''FJQJ.JE>7PN<<,.TM<>=P)
M!XZ#H%+BT7?3D@?<:9].8'9$@((!\#D9'GCXJ$<*[4EV@H+=%+45,[MC(VDD
MG)S\!YD]%ZEIXW[.>L<Z>G?P<'[^RZC&?HU$P_WL_O6SE4^RW2CM':.I+5+-
MWM0"99G#H'NZ@>@Z*V+YS-:+7F8=U8U B(LTB(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MK3^CZVKJ[13.[^<X#Y7;S&W]5I\!]JMZ*DY;S$QORM%8@1$6:PB(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B(.F2DIY9!)+3PO>.0YS 2/FNY$05?M-N$=OT3<W2=9HS T>KN/NR?DO
M'5>1/7.,)#MY\/->N^URS27G1-;'!(&2T_\ C#23C.T'(^HKR3;:*4UK YI
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M  KS.B?AF+YG^_P>O9Z8_*?I+]JG_9Y?^%/RGZ2_:I_V>7_A7F=$_#,7S/\
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M  KS.B?AF+YG^_P>O9Z8_*?I+]JG_9Y?^%/RH:2_:I_V>7_A7F=$_#,7S/\
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MJ@]BEF_%FC8ZF1N)J]YG/'Z/1OV<_-7Y<V6D4O-:SO2]9W&Y$1%FL(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#X_Z#O@O-/9!74ENUK!45
M]3#30"*0&25X:T$MXY*]+N&6D>:U%^1*D_;51_\ @'\5W=)EQTI>F2=;_P#K
M+)6TS$Q[-@?X8:<_;ML_VEG\5EVR^VFZ3.AMMRI*N5K=[F0RM>0,XS@'IR%K
M3\B5)^VJC_\  /XJPZ+[.F:5K:NJH[I)+-/3N@:7P@!A)!W=><8Z*E\?3Q6>
MV\[_ &3$WWS"I=N6J65#V:<H=LA:X/J' 9P[]%@]?$_$#S51T==*S0&KVMNE
M.Z)DC6LJ8R.0QV"'#U'7[%M*P=EE';=01W:LN,UPE8\R[98P Y_ZQ.>>>?BI
M;7FA*+5QII9IWTM3#EO>L8'%S?U2/C^]=5.IP4K&'S68YG]6<TM,]WN^]ILT
M=1V<W::%[7Q20-<US3D$%S<%:W[ KO245SN-#52LBDJFL=$7' <6YR/CS]A5
MOU'89-.=D]WMSJ]];%&P&)SV;2QI>WW>O(RM<=F6C:35U#=HYYGT]3 8S#*W
MG&=V01XC@)@K3[O>)GZ=^?\ !:9[XUY6?\(&[4LK;;;89625$;W2RAISLXP
M?4\_4N=WI)*+L"HX9AM>=LF/1TI</L(69I_L;I:2X,J+O<#6Q,(<(61[ X_S
MB2>/17W5VGHM1V"2UOF--&\M.]C0<;3G&%2<^*D4QTG<1.YE,4M.[3[J)^#T
M/^@;H?\ ^)']D**_"'HY/:K/6@$PECX2?(@@CZ\GZEL306D8M(4-330U;ZH3
MR"0N>P-QQC'52NH;)1:@M<M!<HR^!_.0<.:X=' ^!6?WFM>I]6.86[)G'VM1
MZ6T/8+MIB"YNU!71!L>:AHE8!"X=001POG9E0:5J-74TMFJ[T^M@WR!M3&P,
M(P022WXK)J.Q-W?.]FO8$)/ ?!EV/7!PK_H?1EOTE2R-I"^:JFQWM1(!DCR
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M2W)H'0D.CYZR6&NDJC4-:TA\8;MP2?/U476=E5!6ZEJ;K65LLL=1,^5]/W8
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MW1[(V\N<?I/=XN)\U*+@ZOJYSSJ/RML>.*1^HB(N-H(B(*AVN?YN[Q_HQ_\
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MB B(@(B("(B B(@(B("(B B(@+A%#'$7F-C6&1VYY QN/F5S1 1$0$1$!$1
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M[P,<''BK5H:.L_$YFN%%344LSR]L4$0CPWPW >*BWCE-?/"PHB+-H(B("(B
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M'ZE7+%+?ORB70MIZ#VES(Q4M+G;6QY;RWUQA?:*":E[4[;#5W5URJ&T[][W
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MD?$?458E1]&?Y;ZM_P!:S]ZO"K:.5J\P(B*J1$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MEE[MK_B%9T3<FH1MGLE!9Z%U);X1%&_Z9SESCYD^*:?LU-8K?['1&0Q;R_\
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M7,      < !$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
*1$0$1$!$1!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g762905g00w02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g00w02.jpg
M_]C_X  02D9)1@ ! 0$!0 %   #_[18&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $X< 5H  QLE1QP"   "   < E  "')R,SDS-3,S' (% "U-:6-R;W-O
M9G0@5V]R9" M(%!R;VIE8W0@2F%G=6%R("T@1%)3(%,M,2YD;V,X0DE-!"4
M     !"E;&ZR*0O_4Y\P:E[UG=6I.$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !0     $  0%
M     0 !.$))300F       .             #^    X0DE-! T       0
M  !:.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M             )$   )J    !@!G #  , !W #  ,@    $
M             0             ":@   )$                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   )$     4F=H=&QO;F<   )J
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   "1     %)G:'1L;VYG   ":@    -U<FQ415A4     0
M     &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A
M9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X
M=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI
M9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!
M;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"
M1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE
M9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG          MR
M:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\        #A"
M24T$$0       0$ .$))3004       $    !#A"24T$#      +8     $
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MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9.$))300A      !7     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #0    ! #A"24T$(@
M   !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!.P "
M    "0   +&':0 $     0   +P   #H   !0     $   %      4%D;V)E
M(%!H;W1O<VAO<" R-2XW("A7:6YD;W=S*0 R,#(T.C W.C(W(#$Q.C4V.C$R
M ')R,SDS-3,S      .@ 0 #     ?__  "@ @ $     0   FJ@ P $
M 0   )$         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0%.17AI9@
M34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    )
M    L8=I  0    !    O    .@   %      0   4     !061O8F4@4&AO
M=&]S:&]P(#(U+C<@*%=I;F1O=W,I #(P,C0Z,#<Z,C<@,3$Z-38Z,3( <G(S
M.3,U,S,      Z !  ,    !__\  * "  0    !   ":J #  0    !
MD0         & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              $@
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M*"@H*"@H*"@H*/_  !$( (@"0P,!(@ "$0$#$0'_Q  =  $!  ,!  ,!
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M9.7?;[33_I*C!=^W*'RV3?PT_7(KFLT%-5,IQ[K_ -%PLDY890:(BPRP$1$
M$1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$
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MRJVY;;7UUG?(Z!CS&3(PM.HZ"LZN0[F/Z"U/C;NH+H>79/;,4M,EPN\XCC'
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MS>#_ $PLOC<?K!;-GN,1'N7,B(O&%XX;NHK3)-9[9=(VES*>3L3R.0.UX?Q
M4X*[,JLE/D5@K;75_)5#"W?::[T\A\A48YCBURQ2[S4-SA<W>G^[E ^!(WD(
M*]!M=ZE7RGW16MCUR8JV5T]MKZ>MHWF.H@>'L<.0A4%CFZ!HW4[([_;9HY@
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MTH);;HY].\S-/7HM;K\)R:@#C56*X,:WC<(2X#RC57 BL1W:U>\DR+I1_/\
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M=C:^33?$=.B(BW46VK$WD%%1[&31$2"01$0 1$0 1$0 1$0 1$0 1$0 1$0
M1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0
(1$0 1$0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g762905g01n96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g01n96.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[23.4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 9     !  $!D     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              5%   &\@         !
M                          $             !O(   5%
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   5%     %)G:'1L
M;VYG   &\@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   %10    !29VAT;&]N9P  !O(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MRABYF@<=KG &#I]+Z(U1%&=3:X*22204I))))2DDDDE/_]'U5))))2DQ<T$
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MZ&/NSLFZZ!O%%F=971A5[&>I9N^TXV/^DN>E,"@2>'S_ .]^9=#'(FAN6_\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(
M P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @
M 3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T    9
M   !   !D     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T
M.C X.C Q(# S.C$W.C$V   #H $  P    '__P  H ( !     $   ;RH ,
M!     $   5%          8! P #     0 &   !&@ %     0   1X!&P %
M     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!-D5X
M:68  $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %
M 0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
M     0   *0   #0   !D     $   &0     4%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,C0Z,#@Z,#$@,#,Z,3<Z,38   .@ 0 #     ?__
M  "@ @ $     0  !O*@ P $     0  !44         !@$#  ,    !  8
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M&_-2,$DDLK>*.K&>A(\7'P'3ES7SMJ:6UELA#8S-VUD+#FNWDGD/IT V#1Z
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MOSVXA\%[N*KA3HZ6^>5NTYK1N\11M%Z(=G<+ELI=LOJU:L,KJX&W%8D8W<@
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"X^U\ERN/M?) <HB(
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M$7E&P1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %U/UFKLNI^LU =D1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MS6M'4N.P"\J]VK9<6U[,,KAU#'AQ'X*;"Y[HNDDL<9:))&,+CLT..VY]%W4
M(B( B(@"(B (ND4T4N_=2,?MR/"X'9=T 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %U/UFKLNI^LU =D1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!<?:^2Y7'VOD@.41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( NI^LU=EU/UFH#LB(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B +C[7R7*X^U\D!RB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( @ '0!$0!$5-[4]8C2&G>^KALF3M.[BI&>G'MN7']4 $_@
M/%6C%S:BM0W8UI_*:NT8<CITML1OO1]\R2!KMWAC@.$D> W!Z^:TR[(SGZD<
M;!^MNXJ0OP/R+;+[\\EBW8/'+8D.[W/Z[[_'P4"POCD=!8'#.SK^L/O#T7TV
MR4N1@H2S.*I+$[HR;%VQ)7DC>(R'#;< @KK%,U_N_5=Y%>+_ *I75PW]#X'R
M799&5S-"[TX39RN/KM&_'.USMO!K?>)_)8D=AHB<Z4AO!]8J9T_:IXN62Y?<
MY]Y[>".K$WCDB9UW</ GU\%C6E96XEX*[-F8R@Z\Z=QD;%!!'WLTK@2&-WVZ
M#F=SRV69+BZ^/FIORE@NJSL=*/9^;G,^SUZ<7Y*D4-=7*CK#:V'9)6L1]U*V
MS/P%PWW')H)',;]4R^N<MD8HFG$XJ$Q-$;2V63?@'U6]/#?KXKA<*C>F1M=&
MS\MA(+>MZN.H0""M+'$YS6#ZK>'=Q/JNFN\;6A92R.-J&K5FXH71&,LX7M)V
M.Q'B/W*C1]JN3CR$]V?"1QSRUA6$M2?C=&  -VAP'/EYK-Q^O8\QC)\3+;?/
M),X2-CNN<)V$?=!//Y;K%0J1<6]WQEKIW..BB81]&Y(P'E4M.XHO)DGBWY]5
M++'OU67*KX7GA)YM<.K7>!"ZHNV3,I+>C#P!WK67_P"<LR._/;^"VYV"3?\
MHUE:?/\ HV2FV]&OV>!^96H,"[NJ[J<ONVH2>\:?'<[\0\P5B0:NRE&#.X?"
MS/J16;9-BW&??(# W@8?LGKN[J.6RPVNC*KS8\2U*2BKL^C-2=H.E].R&+)Y
M>$61R->$&:4?%K 2/GLJXWMMTF7;.&5:S[YHOV_Q7SY##'%OP- )YN<>;G'S
M)ZD_%>BI'Z9"W.;N6=8N':[JC#9JT9<%>BM0WIJLCP-VO8^/C;[S#L1R<WJ/
M!0^EL=7OS7Y+G&Z&E4?:,3'<+I2W8!N_@.?,^054S%..PR-W"!*';->.1!\.
M?Q7II[,VH+(;WSX+K >&6,\)>.A^?F%VPHNG#"F8IJYLFOC;.-R6G;&DZM@9
M:]$9VLL /;"'[M WV Y ./%UV4MGL/:S6IM*X&_+:N18PR27LA;C<T3 $.D#
M2[JT;;;[GJM=MU!F7W1(S+WVF$EP<V=P/&1L=N?DLB;46:GW[_,9"3=CH_?L
M./NNZMZ]#XJCHSNG=7_LLI(O7:W7;J'2S<S!:QUNSC++HGFC,V5K:SR>#BVZ
M$;#\UHVZ 8)R>@8ILBW4ALLQMF:&&R.&Q78\M9*/(CQ^!49CZ_TEEH:'-O')
MQR@\B&-YD?/;9;4H<C3<;W6XK)XI7-FXX.;CZK7_ %A$P'X\(62N@*YW7.:'
M)57UA7+)JMT#W><$A^/-OY[_ (JS[K#RD<$^/GBMO;' YIXGN.P;Y'?TZJT7
MA=R+7*3NO-C)+]QF/IN_3R<WO\(F>+C_  "Z5FV+7?LC<V*.N-Y;+QRX>>SF
M-/UM_#P5LTIB8\93=(6GVBP>)[G\W;> )6\JF7-*)9V9*T*D-"I%6K-X8HF\
M(\SZGU/5904;DLQ1Q@'MEAC'N&[8QS>[X-'-1\>K\6YVSG6(F_?DA(:/FN8T
M+&B\:UB*S"V6O(R6)PW:]AW!^:]MT 7"Y7"$'!5H['\:[(ZSNY1S?Z+C(/9F
M$CDZ:39SMO@T ?WE3[,DW%#7I1&>_9>(:T0^T\]-_0=2? +?NAM/1Z8TW5QS
M'=Y,T%\\OC)*X[N=^)_#9<>V5<,,*U9K36=R>1$7DFP1$0!$1 $1$!4=7:$I
M:@O19"&S8QV4CVX;58@$[=-_/;XA0\79G)<M12:FU#?R\,)XF0/'"WY\S^6R
MV,BWCM56*PIF,MGIR=VBMZETI#FY\*\6'568R83,CC8"' ;;-]!R4;F]"RV-
M0S9K!YJSB;L[0V;@8'L>!L.G+R'FKLBB->I#1EI482U10Z'9U'5SM#,NS%VS
MDH'E\LLX#N^W&VVWV0 NV4T!(<W9RFGLW:P]BT=YV1M#V//GMR]?-7I%;]55
MO>_1N*_IZ=K6*C@-"T<;4R3+T\V3M9)G=VK%C;B>WR'D%#1]FUZO6=CZ>K,E
M%B#N/9N$$AIZM#M^GR6QT4+::J;=]>H/9Z;25C P.(J8/%08_'L+:\(V'$=R
M3XD^I41AM)18_5F3S\MM]FW<;P-:Y@:(F\N0\^0 ^2LR+-5)*^>NI?DXY9::
M'E:@CM5IJ\S0Z*5A8X'Q!&Q4#H73 TGBI<?'>DMP&4R,[Q@:6;]1RZ]%8T13
MDHN"T9+@G)2WH(B*A8(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( NI^LU=EU/UFH#LB(@"(B (B( B(@"(B (B( B(@"(B
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M2X;]  /-0I5'%9<//P[A:-SVQ&B+6<TAD\Q%.R/V8.=#"1N9BP<3MO@M?9F
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M$0!$1 $1$ 1$0!$1 $1$ 7'VODN5Q]KY(#E$1 $1$ 1$0!$1 $1$ 1$0!$1
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M-R0-AD>T$]T0-MA^MRZ] M:5*5:&&.Y^?]&56M&C/%+>O)_DDLYJZGHO6F;
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MB (B( B(@"(B (B( B(@"ZGZS5V74_6:@.R(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( N/M?)<KC[7R0
M'*(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M!GXDE6]36UBNA$4=)/I?L$1%B;!%TCECD<]L;VN<P\+@#OPGR*[H B(@"(B
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M7_CB\ED84J2_R27.>81$7.= 1$0!$1 $11>I\Y3TW@;N7R3BVK5C,CN'J[R
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MDIFOR$D?7;;C/%S(^7"?FM%7-0"6M.QE"<QN81Q.<T=1Y+9<.8IBEIO4^G[
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MLV/FL8^XTLN5)713,/4.W)W^>^_S6?IJK-D]6X.C1'';-Z&78?8:QP<YQ]
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M5<8_+'/2DH4E*7RYG9W-4<%1-K)3=W'OPM &[GN\F@<R5G02":&.1H< ]H<
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MC#&ZS T"Q&PC8\;.0=R\6\UI2PXE*'=[,I4<E&T^]>J-1".Q0NS8O).#KM8
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M=EU/UFH#LB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M,?"!)EK .VS/"('S=L=_(+UDU4QQ&(T31&0G@:(^\'NUJX'(<3O'X#=1&E]
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MW/Y%7U;[1-)N,=^OMV>9AL\&XJ4MRR]^WR[0B(N4Z@B(@"(B (B( B(@"(B
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MB;%7B&S6C\R?,E;853C>6KTZ.GV[S+$ZDK1T7RWOW<3,1$6!L$1$ 1$0!$1
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M=_DLOLLNB]H;&%K@[N6>SDCQX#P_N 5"E[1LO+V,9O*6HJT6H\7,:=V)\>[
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M_9@@>'/]VE.GBS>26IG4GAR6;>GS@2>ELID]1967*-WK:>:TQU8G,''9._\
M6GQ Y<AZJVKK&QD4;8XVAK&@-:T#8 #H%V43DI/)61,(N*LW=A$14+A$1 $1
M$ 1$0!$1 $1$ 1$0!=3]9J[+J?K-0'9$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MA(1$0!$1 %U/UFKLNI^LU =D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M5OUFE3+WM8W=[@T>9.RP3G1GEDT=47&<;K1GS3K#LFS>G]+Y3*RYRI*VG"9
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M?P]/5?8FF<JS,X*A>:YG%8@9*YK7 \)+02%IMD*M%_<VF12ITFLHHRJN/IU
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MO5]_=FDD?"[;]9O"1O\  JYZ [(68C(0934MJ&_<A/'#6A:1!$[P=N>;S\0
M/)>MCM5NX_366O9C3LU6[CWQ L$H?#,UYV#F2#<';Q^*GLYKR/&ZCPF+CJMG
M^DJTMCO&R#]'P,+MMO79=,]HVB<<+>150BLT7=%IBCVS9#Z'HYW):4F@T_:F
M;"+<=ECB"YW#]3??KZ+<L;VR1M>SFUP#A\"N24''4N=D1%4!$1 $1$ 74_6:
MNRZGZS4!V1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M?<#UYGFNAU4R+'S7)KV)O:L[6'TB\1_27L#JP8[A]BVX.\WVX>HWZ[\^BO\
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M$+U,3;=O-^&GF8.N-.0ZJTQ=Q%AYB[]H,<H&_=O:=VN^1 7S;=T'J^A<-2?
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M^'26G*W\AVIZA^B\2Z2MIVJX.FFV_K/UCZ]>%OS6W<)BJ>%QL-''0MBKQ#8
M=2?$D^)/FO#3&!I:<Q,5#'LX8V<W./-SW>+B?-2J\BO64^9#**^79ZU"@X7G
M4SD]?9!$1<QTA$1 $1$ (!!! (/(@JF]FV]*/,X1_7&W7AG_ %<GOM_(D?)7
M)1U?#UJ^;MY6+O!9M1LCE&_NGAZ';S6D))1E%[_/Y<SE%N2DMWE\L2*(BS-
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MU*[>\E>?V1T'J>2ACC,]J?WLW,_#XT_\AJR?I9!^O(.GP 4MI3 XW&TXK-2
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M<P'?EL/#FOHQ0M33NGZV<ER-7%XZ/+.&[YF1-$O/Q)Z\_/Q4O%+'*7]U(Q_
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M>E',GX4)/\%G*C6D[M,O&M1@L*:L6Q%5!KFD>F,S9^&/D_P79NM:KNF*SO\
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MLKIB2:+!8*"P,ADK$V\F1DV)(#?M!NQ.^P55T1K#V3M+I:JLRV@<U:EKWA)
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ML*:O-V+RH_,YO&X: S92Y#69^N>9^ ZE:*U#VJ9W)A[*9CQE<].Z.\GS>?X
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M$0!$1 $1$ 1$0!$1 $1$ 1$0!<?:^2Y7'VOD@.41$ 1$0!$1 $1$ 1$0!$1
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MS/9( S</8T$ >>^W[UYP4\5J7M!T[@<KE+&4TW#A1/2[^=S1;?Q.!<X@CB(
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M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %Q]KY+E<?:^2 Y1$0!$1
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M#<_66JPU(.,-;K+OT]C)N5.:E/-6>?=K[FP5A,R=9^7EQC7N]KBA;.YO"=N
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M_*NKIV,/UHV.>X?DX!5E03>*I47GY%H[1)+#3IOR\S:5FY6JM+K-B&(#KQO
M_>J'JWM,Q]%XI8:Q7GN.Y.L2;F" >;B.;CZ-W6#5[&,1Q<>0R-ZU)YCA9O\
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M$8 [LUIG/)/CONT*LW-1R:2Z&O0M!4W+--OI3]="8: T -  '@$1%RG4$1$
M1$0!$1 %YOL0QRLB?-&V5_U6%P!=\!XKT6C>T*TR;5N7S,-&.W0P1K1WVRRE
MLI=Q;M,#@-V; \QOL[H0KPAC=@;JM7JE1S&V[4$#G_5$D@:7?#<KFQ<K5PTV
M+$,0=]7C>&[_  W6B=.8G!:SUAKN?73A+8IS!E:*S8,?LU;AW#VC<;<MCO\
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MX$CD?D=BL:4E&2;T]#>I'%%I:F<#N-QS"^=>U[0V3QNI+N:QE*:YBKSA+)W
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M^,M%)F,-$!D8V[S0M']>T>(_6'YK0PXFN\6N:?@01_%?9*TYVP:!!;/G\-&
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M](J,:Y@\XG#D/D01^"XMMI8H8UN\OGF5IRP5,.Z7G^5Y&T$1%Y1V!$1 $1$
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M@\!B0/WKMVAC_P#FUH(_K2_P54UE"RLX\.AD=!M)$1>>9A$1 $1$ 1$0!$1
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M;R!:[;ELN.<JDKQ6G]?DU2BLSV;B\9D:^/O4H)JS'7F5;%=TG&-G'JUVP_\
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MC<=$1%B;!8.7Q-#,5C7R=2*S$?!XZ? ]0LY%*;3NB&DU9E,_FSE\'[VE,J3
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MD_HJ6+3N+JRF*$W*O$^QM]H!PZ=/Q\5UT-K;,QW-4XK5!ANW<+"; FK  2M
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M1;\"%<L=?J9*HRSC[,-FN_FV2)X<T_,+(D8V1CF2-#F.&Q:X;@A4S(]GN/\
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M[(>SKV/NLYGH=K)]ZM7=_9C[SA][R'A\5M]9T:7\Y'=]5^IJWZ;9]%DVO)=
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MRC/^^DMFJQ=FO%$1VJE)7B[]C+8BJ(UJ[[6F\^W_ /1VG_>7(UO']K YX?\
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M?VE6>[QE:N#SEDW(]&C_ !V7'M]3D]FG)\//(ZMAARFT0CT^691<3P_2E+C
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M8#P._B%;L5FJ.38#5G:7^,;N3A\EW4=KIU7AT?!ZFL:BED2*(BZBX1$0!$1
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M2QZ>U5@;>FLM-L(&67%S9B>@!X1S/AYK1T9HBZ-J(B+(D(B( B(@"(B (B(
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M$V4U7A=;T9KV?]HCL36K6[H[L;">Z>T=-AN-V\QS&_38;N10ZSM:WRXL:[[
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M+)[S9<=HUCN**#?AFN['J[R;^'7YK(PNF,GK3(Q9[7,;H*D9XJ6'W]Q@\'2
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M?=8QHW=([P:T>:U'9N9!F>Q.=U'BY<EJ').<W"X:-X:RO&T;E\A=R!V/C_\
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M ^(YD+(IW=3RQ\=*6K<9YM>QWX\P51;?GAE"5^HCE=UF7M%2QG-30;^T8<2
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M&/$.=C'=[[-N1C]&?VA]DJ=C>R1C7QN#F.&X<T[@A<O8V1CF/:'-<-B"-P5
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M]2[@<D_CR.&>("\_VL!&\,GQ+-M_4%6?.5R"XHB*I(1$0!$1 $1$ 1$0!$1
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MXX[)!Y/D(WY=/'_%;'JUX:E>.O6C;%#&T-8Q@V#0/ +U17G4<LMQ+E<(B*A
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M:@LS\33,PGA89!MNS<\E]!:GT9I[5#HGY[$UKLD0V8^1OO-'EN.>WHO2SI'
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MI&31,DB<'1O:'-<.A!Z%6I2C.&*)S?4]EJ;+7P5."MU:>AI_MVT#D<Y/6SN
M@]IMP1=Q8K!P#I(]R0YN_(N!/3?HM-8C2.HLM=]EH8:[WQ.SG3Q&)D?JYSMA
MM\-U]CHDZ-.;Q269?9?K&T[)2=&FU;I6G40.A=.QZ5TK0Q$3^,P,_2/^\\G=
MQ'H22M-0:IDQ/8_J?5$DO^6<[D)H(B.9#@XQL:/1K&DKZ#6O=.=G%6A=LMR
M;9H5LF[)8Q@<1W3GC=P<WH=G;[?%=,))7<CRW=YFG="9NM1T5KW2E>]);K,I
M.NTYI&.C<_=@$C=G 'D[T\U3[-J^_0#-'F20.I]YF7NW/]086O9S^+C^*^L\
M_HW"9[(1W<E4[RRR!]8/:XMWC>"'-.W7J5@/[-],O,Y=0]Z:BW'/=QG<P-
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MPBE.SN@LBC8;LSPM6=MO,&?-Y <S/?>9!OZ-)V_>KM##'!$V."-D<;>0:P
M?)=T5I3E/[F2Y-ZA%%ZBS^-T[CW7,O:97A'3?FYY\F@<R50N^U/VB;BMWF T
MN_\ M3L+-EOIUX1_YYJ84G)8GDN)*C?/<2^JNT*M0MOQ> @.7S(!+HXC^CA
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MQY+L->)B'_);)+F_ .ZA9<@H:P370L^[YU%<%M5<]!INNT[QW,BS]FRY=OH
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M#$WI;L<@L5)JL\9X7L>-P?5KNA"SD6<::B[QR7 JHV>01$6A8(B( B(@"(B
M(B( B(@"(B (B( NI^LU=EU/UFH#LB(@"(B (B( J'E]&VL;:GR6C)(8'RNX
MY\7,-JTY\7-V_JY#R]X;@^(5\12G8&KZVJ*C+/L><AFP60Z=S?\ =8X_J3?4
M?\C\E/1_I6!\?OL/1S>8/S5JOT*F1KN@OU8+4#NL<T8>T_(JJS=FVGQ(7X]E
M[%O)W_R?=E@;_HAW"/P4\U@YV/D4+7!I<00T<R2.2QSV?R\PW5FI T^'M6Y_
M'9>D?9MA9'!V4L9?*'Q;<R$KV'XL#@WY;)9<00^0U/C*DWLU>5^3R!Y-IXYO
MM$F_D[AW#/BXA9%+2F4U*X2ZO#:6+WW;A8)./O-NGM$@Y/'CP@ =.JN^)Q&.
MQ$'<XJA5IQ?=@B:P?D%G)=+0'6*-D4;(XF-9&P!K6M&P '0 +LB*H"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"X^U\ERN/M?) <HB( B(@"(
MB *L5-$8B'4MK.SMEN9"9_&QUE_&(!]U@\!^*LZ*T9.-[,E-K0(B*I 6M-8G
M^=':-A=.,)-3&_Y2NCP)&W=M/X_FMAY&Y%C\?9N6'!L->-TKR? -!)_<J+V/
MTY;-/)ZGO-<+>;L&9H?U;"TD,'PV_+9;4N:G4X>;+QR3D;"1$6)0(B( B(@"
M(B (B( B(@"(B (B(#$RV0K8K'6+UV01UX&%[W'R_P 55]$X^SDKTVJLS&66
MK;>"G ?^3U_#E]YW(E8DV^N-3=RT[Z<Q,N\CAS;;L#[/D6MY'U*OP&PV'147
M.=]QU2_8A@_D]>A<.W?W<0B*,U-EXL#@;V3G:7,K1E_"/M'H!^.RLW97.>$7
M.2C'5E"[9M2SLB@TQAMWY/(D,D#>K6'D&_%W[MU9M+Z>KZ1T8^I'L96Q.EGD
M^^_;F?AX#T"J'9#@;.2R%O66=:YUNVX^S->/JM/5PW\-N0]/BM@ZQE[G2F7D
MWVX:LA_U2L8YWJ,]3:)1IX=CIO1\Y\7^#![,F\.@<%ZU6N_'G_%695OLWM06
M]#85]5V[&UF1D>(<T;$'YA61:P^U'!M-^6G?B_,+4VO[$D?:C@[+7 14&PAY
M\N^D<Q;96H]5QNNV-<76$%]+V1C#Y=VX2$?FJ5=#J^FVY1M\+=[2]3;B+QI3
M"S3@G;S$L;7C;U&Z]EJ><U8(B( B(@"J.N]36</>P&+Q;879++W! SO6DM9&
M 72/V!'0#\U;EKCM-J2UM9:'U &N=5I77UK!#20QLS"T//H"!^*O32;S!%G6
M^M-06\Y9T1BL38Q.*L&MPVW/$UM[?K<&Q '7ENLC,ZYU+=U%5T[IG&T*F591
M;>R+\H\]W5#AR9[AYG\EAOT3K/ 6<W1T;D<=%B,O8=9[Z=KA/3<_ZW!L=CTY
M+(U#V?YVMF(,WI^Y4R-^7'MQV2@R;3P7& ;<9+2-BMN9?=\XD&#G.TG56&T/
M)?O8W#Q9:+)1TN,3=Y6E8[?:0<+^)O3Q7ECNU+/QYO)XO(,T_??!BYK\5C%/
MD?$QS&N(;)Q'QV\-NJCHNQS,#2MVK([%MM7LG7NR58&%D$4<8<"P;[[[\2L,
MW9K=P^?SITH*D."S="6&Q4=[@AF+'!KF #IN1R^*G]O0C,AL#VK:EDR&E69:
M+3TU;/D-8S'ND,]<N V+VN=MRWYCT*V-V::HGU-A[9R,<4>4Q]N6E;9$"&<;
M'<B-R>1&Q^:PNSKL_P -I3"XR6;%8Z/-UZS63W&1CB+@/>/$?/S54[-<M'AZ
M&H\J^-SK&:RLUFO7.X(C!X&N=Y;[;^NZY]HK4:4)3EDD:TJ4ZLE""NS;63R-
M;&573W)1&P=/$N/D J/;M9/539G1-]FQ,(+G;_:VY\_,^G19>+T_=S=D9'4+
MWAAYL@Z<OA]D>G56;,M95T_=;$QK(V5WAK6C8 <)7C5%5VR#E/FT^&]]?!=!
MZ5-TMDDHPYT^.Y=7%])CZ-KL@T[4+&@.D;QN/F2>JFE@X"/NL+19Y0L_<LY>
MCLT<%&,5N2.#:)8JLI=+*WJZ<5+>'LS?\7BL>^?+<<C^]6-K@YH<T[M(W!\U
M!:V@$N E>YO$(7ME(\P#S_+==-,V75I7XFRXDQM$E9[O[2(]/F-]ES1J.GM,
MH2TE9]NGC;Y<Z'3539HR6L;]VOJ6%$1=YPA$1 5_4@]IR>&HCH^?OWCTC&_[
M]E8%7X![5K.S)U93K-C'[3SN?R 5@7/0YTISXORR\[G17YL80X*_?GY6"B-6
M4/I#!68@-WM'>,^+>:ET.P!)Z+2K356#A+1Y&5*;IS4XZHKNA+_MN"C8]V\M
M<]T[X>'Y*Q+7>C[S*NIK$3 65+CG=T#T)#CL1^:V(N3Z96Y6@D]8Y=WX.OZC
M1Y.NVM'GW_D(B+O.$(B( B(@"(B (B("+U/>^C\':F:[:3AX&?M'D%@: I>R
M8!DCA[]AQD/PZ#\A^:C=>RNNWL=B83[TKPYVWAOR'\2KE!$V&%D48V8QH:!Z
M!<,/W=IE+=%6[7J9K.;? [.:'-+7 %I&Q!\56X2[3E\0//\ DBR_]$X_V#S]
MD_JGFK*O&Y6BN59*]A@?%(.%P*ZJD,6:U1=J^A[(J_AK4N.N?1&1>7<MZL[O
M[5OW3^L%8%-.>-7"=PB(KDA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %U/UFKLNI^LU =D1$ 1$0!$1 $1$
M 18F5R-/$T)KN2L1UZL+>)\DAV _Q/IXJE2:FU'FV\6!HU\30=SCN9-KGR2M
M\"V $%H\?>(^"E1OF#8"+7!IZG)XW:Q=WGDW&L#/]'CW_->D>?U9A=W9*I4S
M])O-\M!A@L1M\3W3BX/\]FG?XJ<*W,&PT4?@<S0SN/CNXNPV:!W(^#F.\6N:
M>;7#Q!YA2"KH B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"X^U\ERN/M?) <HB( B(@"(B (B( B(@->=K]N6W7Q>EZ)/M6:L"-_">;(6D
M%[CZ;?Q5\Q]2*A1KU*S>&&"-L;!Y #8*.DT[1DU1'GY!*Z_%![/'N[W&MW))
M \^94PM)26%17QEF\DD$1%F5"(B (B( B(@"(B (B( B(@"J&M\I:GL0:;P<
MA9E+S=Y)F_\ )8/M//J>@^*L^2FFK4+$U:!UF>.,N9"T@%[@.0YJ"T3@I\;!
M8OY9S9,WD'=[:>#N&_=C;Z ;#XJDKOFHZ*.&"=26[1=/LOP2^#Q57"XNO0H1
MAD$+>$#Q/F2?$E9R(KZ&$I.3N]0M2]KE^3-5LEC:<A;C\7&V2Z]IY22N(#(O
MEOQ'Y*]ZUSCL'AR^JSO<C9>(*D/WY7=/D.9/P53U1@V8/LS-![^]LV+4#K,Q
MZRROE;Q.651W31Z&P)4YQJ2U;27J^S=T]1L##1"#$48@-@R!C=O@T*#[3GF/
M0&=+3L36<T?/E_%69C0UH:.@&P52[6'\.A,BWQD,48^<C5:646<^S<[:(7_V
M7F1^A&G Z@O8&39L%J)F0J@<@-QM(T? C?YJ_*E]H,+Z5/%Y^NW>;$2M>\#[
M4+MFR#\.?R5Q@E98@CFA<'1R-#VN'B#S!2&7-)VE\HE6XY/K7NK,[K7NFZXR
M>!UL\LW%V[::W?Q 8&C]RO\ ._NH))#T:TN_!:QQ&I:FC^R6MEL@UTK[3GOC
MA9]:621YV ^7,^@1J\DB:#<:<G'6\5YOT+CV>VO;-%8:;<D^S,8[?S:-C^85
M@7RQIWM9U+A*[*M2OBWT8WO<V&5CRX!SB[;C#O#?;?9;_P!!:RHZNT\<E '0
M/A)99A=UB>!N1ZC;F#Y)3E&2YKO8UV_8JVSS<ZD;1;=BT(J5B^U31>4O14Z.
M?KR697<+&%CV\1\@2T#=>$G:]H6.9\3]00B1A(+>YEY$=?LK;DY<#S[E\10=
M;5F$LU\K/!?8^+%G:XX,=^B]WBY\N?+RW72SK+ 5L-C\K8R<4=#(.8VK*6N_
M2EW38;;_ )*N%\ 3ZX<UKF[. </(C=5347:-I33F4?CLUF(JMUC6O=$Z-[B
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MB (B( B(@"(B (B( N/M?)<KC[7R0'*(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( N'N:QCG/<&M:-R2=@ N52]=VYLG;JZ5QDA98O
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M>L;9@TQJ3(RL<RM=<!!N-@\,807#TW.WR5R?V1Z(??-LX.,.+N(Q":01;_\
M5AW#\MME=Z]>"M797KQ1Q01MX6QL: UH\@%I0H1HMM.]SR?JGUK]=25)0LKW
M>=SYT[,- Y;5NC--27<E0KX2G;-EL4=3^DDM>>1DW\2KQ>K1?_Q$XT=S'P'#
M2DC@&Q/&MJP0Q01B."-D<8Z-8T #Y!<&"$SB<Q1F8#A$G".(#RW78ZS;;Z_$
M\&Q\W,Q.<M#M3GQ>:;0I0VI3/6-82&<<!/)VXX>7+H5SJ' 4SV6:!S;HWNR
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M/M?)<KC[7R0'*(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M7I767? G8?D L:G.G&/;W?EF]+FTYS[._P#"9TU7O5EQF2;_ ,FL-8\_J/\
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M>^[M(L;+1$7,6"(B (B( B(@"(B (B( B(@"X^U\ERN/M?) <HB( B(@"(B
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M:#[!CJ;3W,3CU>22>?3Y@>2VPBT51I6(L$1%F2$1$ 1$0!$1 $1$ 1$0!$1
M$1$ 77^T'P79=?[0?! =D1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6/D
M;<="A8MSDB*!AD=MY ;K(6/D16=1G;?=&VJYA;(9' -X3R.Y*AZ%HVNKFJL-
M?[0-:U#EL5D,?B,<][A!$Z/B<X ]22#_  ^"FM#:JS7\Z+>E]6Q0?24,??0V
M(!LV5OKX=#Y#Q4)4T7JK3;'2:&ST-O%R.,L56<@MV/D>A^(V4KHW6N2DU/\
M0&L,3%0R[F;Q3Q_5E \/'\CLN:+::Q73\#W:\85(3Y&,912RME*/2][MOU-A
M6K=:HP.M3Q0M/0R/#?WKTAECFC$D+VR,/1S3N"OGFGE\-G]5YG):QKY&\V*8
MP5:T,3Y(HV [<]NA]/7=3?9WDXL7KFW4P$61&GK4#INZM1/:(I6@GEO\-O\
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M*!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %P?K-7*X/UFH#E$1 $1$ 1$0!$1
M %PYP8TN<0&@;DGH N52NTW>VW 8=[WLIY/(-AM<)V[R(,<\QD^3BT#X;J8J
M[L#UD[3-(QSNB=F8SPNX3(V&1T8/_6!O#^:MM>:*Q!'-7D;)#(T.8]AW#@>A
M!5<C:V&$5XF,CKM'"V%C0&!OD&]-E$]GK?HS4NI<%5_]75^XN0,'U8#,'<4;
M1X-!9N!X<14V3T(+XB(JDA$1 %B9?)TL/CYKV3LQ5:D+>)\LAV "RU!:NTIB
MM65:U7.0&Q6@F$PBXMFN</!WF/12K7S!2>S+M4&O-<YS'8^M&W"TX!)7G<")
M93Q!I)&^P:>9 VWZ;K::TIV=5H*7\H;7-:G#'!7AH5F1Q1M#6L:&Q[  =%NM
M7JI)Y=!""*F9?M1T7B,E8H9+4%2O<KNX)8G!V['>1V"M6,OULICZ]['S-GJ6
M&"6*5O1[2-P0J.+6;1)[S2LAB?+*]K(V N<YQV  \5JOLU[5G:YUWF\72K0#
M#5(^*M8V<))?>VXCN=MCU'+=87:SG)-4:B@[.\+<;6;,!-F+H>![/ .?=[_>
M=[O+R/Q43V;0XW#]NFHZ5!]>&A!CH(( '@-V&P 'F5M&"4&WJ5;-\HB+ L$1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 7!;N=_%<H@.-O4IMZE<H@.-O4IMZE<H@.-O4
MIMZE<H@.-O4IMZE<H@.-O4IMZE<H@.-O4IMZE<H@.-O4IMZE<H@.KP0PD$[K
MGB'FN40''$/-.(>:Y1 <<0\TXAYKE$!QQ#S4?G\;7S6&N8VT3W-F,QN(\/52
M*(U?(F,G%J4=4:BP4NN]&4QB1AXLY1@]VO-%)PEK/ 'E^]2&F<#G<SK./4^K
M(H:8K1F.I2C.Y;OXN*V:BR5*VKR.^?U!RQ.,$I2R;5[YZ[[*_0C4T.)U%H;4
M>3GP&-9F,+D).^]G:_A?$\]>H/\ YV4WI&IJ;(9VWEM2/-"B^/NX,8Q_$!OU
M+N77_P ^"OR*522>N16IMTIQ=XK$U9RW^U^FUS4N(JZIT#9R%'%8@9K#SS.F
MK=W+P.BW\#R/I^"ZVM,:DO:(U-+E9'S9?*EIBI-D)9"T/!V&_+?8>'DMN(HY
M%6M?(O\ \E.^-16*Z;>]VSX]]K7*TW!C(:!BPE_>-TE)D#_'@<&CG\B%2L):
MUOIC%#!_S?CRA@!CKW62[-X?L[C;P^2VTBET[YIV,J6V."<9Q4DW>SOKV-%"
MQ>GLX_0.5H9O(FWEK\;]N-V[(MQL& ^2J+\1J>]V73:<LX1T4U,PM@<V0'OP
M'[N.WAL-ENM%#I)[^@O#ZA.+;PK52ZFN%NXUOJS3V2NY[0UBM6<^.@X>TN!_
MJQLSK^!63VR8/(9W T(,7 ZQ+'=9*YH/1H!W/YJ_HIY-6:XE([;.,H227,O;
MM;?J=(VD1M!)W "[;>I7*+0XSC;U*;>I7*(#C;U*;>I7*(#C;U*;>I7*(#C;
MU*;>I7*(#C;U*;>I7*(#C;U*;>I7*(#J_<,<0X[@+L.@763^K=\%V;T" (B(
M B(@"(B (B("E:4:+6L]069QQ2Q.$;.+JT;D<OP"ELYJFAB;IIVX;3WE@>>[
MCXF['?U]%%9>E?P>H9,SBZYLUK VLQ-^L#Y@+N_744K.[IXR]):/(1N9L ?4
M[KQX5EL\)4IRPRNW=J][O=Q/9G1_43C5C'%&R5D[6LK9\#'%O%6=$YMN$KRP
M0L8[C;(.9<1OOU*Q+-F>MIO27L\\L7'(QK^!Q'$/(^:]:.)O4M&9YUV'NYK8
M=*(F^\X;CIR73)TK3]&Z?L00O>ZD62R1@>]M\%S2Y1PNU9X-RM_+AU'5'DU.
MR=UCWN_\>/63G:)8FK:9EEK320R"1FSXW%IZ^84+K&DZ:_@I76[ -A[(]@[^
MK.WUF^17CJW/'/X-\.-I6C$QS7SO>S;AV/(#S.ZD=9MEAJX*ZV&22*K*Q\@8
M-R!M_P""OM,XUW4<<XI1X\7<SV6G*@J<992;EPX*Q[YJAD6FE4=EC5Q,4>TU
MI\P;+([GR)_#Q4+#<;BM1XZ+%9N3(06)!'-$^3C#=SMO^?Y+C-3P6\]2RF6J
M69L-+!^C:6'W'<_K >._\%YY"2.SE</8QF+EK8R&PW]+W7#QDD<]NNP 65:H
MG)RADTU;-WMEIN2L;4:;45&>::=\E:^>N]ROU$GDVW[^N+&/K9">M7= UTG
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M (B( H75V BU%B#4=,^M8CD;/6LQ_6@F;]5X\]O+Q4TBE.P->B+7<;?9G8S
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 <.&[2
M/1> E</)$0'/>N]%QWSO1$0#OG>B=\[T1$ [YWHAE=Z(B =\[T3OG>B(@'?.
M]%U$SM^C?P1$!R)G>B=\[;P1$!U[]WDW\%SW[]O#\$1 #,[;H/P7(F=MX?@B
M(#D3.]$$SO1$0#OG>BZF9V_0?@B(#D3N]%QW[M_#\$1 .^=Y#\%W@D<]Y#MM
M@-T1 CW1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
>!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g762905g02n01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g02n01.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[2QL4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ &0     0 ! 9
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   &&   ">           0                         !
M  G@   &&                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   &&     !29VAT;&]N9P  ">     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !A@     4F=H
M=&QO;F<   G@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M      0    !.$))300,     "(@     0   *    !C   !X   N:   "($
M !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!8
M65H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M  $  /;6  $     TRU(4" @
M                           18W!R=    5     S9&5S8P   80   !L
M=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP
M   48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C
M:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,
M=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O
M;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M   2<U)'0B!)14,V,3DV-BTR+C$
M                                 %A96B        #S40 !     1;,
M6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M      !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@
M                9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                 &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<
MG@    %865H@      !,"58 4    %<?YVUE87,          0
M              */     G-I9R      0U)4(&-U<G8        $      4
M"@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W
M 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4
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M(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/
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MM@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7
M<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LV
MR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76
MV-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3
MXMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCN
MM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG
M^W?\!_R8_2G]NOY+_MS_;?___^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !C * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#U59YS^H;B!T]Y@D?3:-.S@?H^_P#]6>FKUCMC2X"3P!YG0*!-S(<XM<)
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M-SZ[[30 0YI#G0"2 '';.T?2?Z:LBD.$V^\G4@D[?AL^BG]%I+B[W!Q! /:
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M^=U)C*W;O9=Z58= _-=['>SZ:H=(R!9E,]-E;&V-#YI96WVD?0=L=ZGV;?\
MS#MGJV6?SOHU>G]HM=<MV"IA:'!\AI+&V0Z1]&I^UKK'M^A[TK/A]B;/A]CH
MT9&/D,+\>UES 8+JW!PD?FRU5G]3Z.RUP?EXS;:SM?NL8'-,[=CI=N;[O:@]
M$<2RX%K60[45M:UA.K=[?3'N=[6[W+.ZCD^CEV-%5(=6'6EUC*R7M)O:[_"5
MO^E7^C]OJVWU_P#<?U,A"D4[PMJN;5=2]MC''VV,(<"-0=KFHRK8[&LQJ&M;
ML CVPT1S](5?HMW[WI^Q64E%JY(C%ML^T?9 PFRS(.V&M89>7^K[-GIL]_\
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MQ_LKY;2107ZA,?R4PC3CGSA?+Z2=]JP_1__9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 2Y-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $
M  !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !
M  $   "D    T    9     !   !D     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C Y.C$P(# R.C$P.C$S   #H $  P    '__P
MH ( !     $   G@H , !     $   88          8! P #     0 &   !
M&@ %     0   1X!&P %     0   28!*  #     0 "   " 0 $     0
M 2X" @ $     0              2     $   !(     3A"24T#_0
M"           _^$!-D5X:68  $U- "H    (  <!$@ #     0 !   !&@ %
M     0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!
M,@ "    %    )"':0 $     0   *0   #0   !D     $   &0     4%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#DZ,3 @,#(Z,3 Z
M,3,   .@ 0 #     ?__  "@ @ $     0  ">"@ P $     0  !A@
M    !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,
M   !  (   (!  0    !   !+@("  0    !              !(     0
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M*"@H*"@H*"@H_\  $0@$D@=H P$B  (1 0,1 ?_$ !T  0 " P$! 0$
M       %!@$$!P,"" G_Q !C$  ! P,!! 4%" P*" 4" @L!  (#! 41!@<2
M(3$305%A<10B,H&1"!5"4I.AL=$6(S0V5%5B=)*RL\$7)C,W4V5R<X+2)$-U
M@Z+#X? E-59CPAC3\3A$E"=%A*-(XF1VM/_$ !H! 0 # 0$!
M   ! @,$!0;_Q  V$0$  @( ! 0#!P,% 0$! 0   0(#$002(3$3,D%1(F%Q
M%%*!D:'!\ 4SL14C0M'A\5,T0__:  P# 0 "$0,1 #\ _5*(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M!+79:2".L+?I:CI/-?P>/G5+4UUAK3)OI+81$5&@B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MDDS@N Q\RA=JQPZUD\@]Q^A,46G/6,E8C\#-:E>$O;!>9[==S[PV?>;6./\
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MM6WOK/I"<M\5WM]CN+[K6LJ*EL;WQ/9\'#3W#K57T]]D][MYJJ:]"-@>8R)
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MTJ:B;N0GJSZ(_P#D4MO_ ()K^JI.#:>XCI&=0!.2![=X>M:32OA^'KXHC?\
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MBK$^+J_SGO\ A[/O6-;<+:^AN5!.74+7!L\0 +7 G@>WB#CV*Q4=3%64L53
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MS?-*)V;QLCT=;RQH:7A[G$=9WSQ6SKC[TKI_<E;M@MC+/:*:@CD?*R$$![@
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MGP5HR5BT>T0(K:U]ZG_\0S]ZL.F?O<M?YK%^H%YZHLD=_MGD4T\D+>D;)OL
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M(,+"RL%0"P5E8*D81$1 L+*PI!$1$,(B("PLK"D%A9ZEA$!6%DK"E L+*PD
MB(@PL+*PI0PB(B&$1%((B(,(B(A\E862L*80(B(AA865A3"&[;O1D\0B6[T9
M/$(L+]W5C\K;1$55Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M?#M6+1>K9>(W/M5?3U;6^D8G@X\1S7$--VV/:!M6ODE_<^6FI.D+(0X@;K9
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M)^@?.K]4005E+/32M:^A=GIW/X](>O\ _'V*DV%@DVE73?DW&-H@7.Y</,X
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MB*@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M?4,CX96R1.+'M.00JVI%ATA%7K=J.-S RN;T;Q\-HR#ZNI2\=PHY!EE5"?\
M&%SS682VD7F)X2,B6/']H+PGN5' TF2IB&.H.R?8%&I&VHF]7B.A88XB'U)'
M =3>\J+N6HGR QT33&W^D/I'P'4J^2227$DDY)/,K6F/UD?4CW2R.DD<7/<<
MDGK*^41;($1$!$1 1$06+1C?MU6[JW6CZ5:%!:0A+*&64@CI'\/ ?]E3JYK^
M:4B(BH"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B A( R>00D $DX 4)<*TSN+(SB(?\2O2DVE2]XI'5[5ERYLI^7Q_
MJ48YQ)))R3UK&5C*ZJUBO9Q6O-IW)E83*^<JRK.5C*]J6FEJ7$1#@.;CR"S7
M4CZ0LWW-=O<B%'-&])Y9UOT:Y*QDK&5\Y4H?8>1WK) >"6\UZ0T%3.S?CB);
MU$G&5KM=NNX^!41,2G4P^H)I*>4/B.'#Y^XJS4%6RK@WV\'#@YO855YAAV>U
M>UNJC25(>3]K/!_AVJF2G-#3%?EGY+6L+(XC(XA87*ZQ$1!A$12,(B("(B($
MZD1!A865A0"P5E8*D85?T]HVQZ>N-776BD=#550(E<97.R"[>( )P.*L"*T6
MF(U$JS6)F)F.PL+*PH2K^GM'V33]RK*^TTCH:JKR)7F5SL@NWC@$X'%2%^L]
M%?K5/;;I"9J.;=WV!Q:3AP<.(X\P%((K3:TSS3/52*5B.6(Z(^PV>BL5LBM]
MKA,-+%DM87%QXG)XGBH^Z:0LMTOU)>:VD=)<:4L,4@E< "TY;P!P<%3Z)%IB
M=[)I68Y9CH*OV;1]DLUYK+K;J0Q5U67.ED,KG ESMXX!.!DJP+"1,QT@FL3J
M9CL@*72%EI=33Z@@I"VZS;V_+TKB#O  ^;G'4MO45BMVHK:Z@O%.*BF+@_=W
MBTAPY$$<1_U4HL*>:V][1R5U,:Z2T+':*.QVR&WVV-T5)%G<8YY?C)SS/%1^
MK-)6?5=/%%>:8R&+/12QO+'LSSP1]!R%/K"1:8GFB>I-*S7EF.BA4^R32,-O
M?2>032![@]TKYW=)PY#(Q@=P"]-H<\FF-!"*UVFGN%N@C;3305!<X,A P"<'
M)QPX]7-7E?) (((!!X$%7C):9W:=L_!K$3%(T_/<%SV:P:;FKZ:@='?GT[FL
MI'&5[8Y2TC+226[N>().<=ZNGN>K94T.D:NJJ6%C:VIZ2'/-S&M#=[P)S[%=
M3I#39J34&P6HS$[V]Y*SGV\E-@   # '(!:Y,T6K-8WU]V&+AIK>+VUT]HTH
MEXV4:4NE:^JDI)Z>1[BYXIIMQKB3Q.Z00/5A6336G;7IJB-+9J44\;B'/.\7
M.>>UQ/$J76%C.2UHU,]&]<5*SS5C4J_9M(6:S7NLN]OIWQUU6'"5YE<X$.<'
M' )P.(":ETA9M255'47>GDEEI,]$6RN9CB#QP>/$!3Z)SVWO?5/AUURZZ(#4
M6D;/J&NH:NZT[Y9Z(YA+97, X@\0.?$!9U5I*S:IC8V]4G2OC&(Y6.+'L'8"
M.KN.0IU$B]HUJ>Q-*SO<=U)T_LOTO8ZV.KIJ2:>HB<'QNJ92\,<.1 &!GQ!5
MKNMMI+M02T5RIV5%+*,/C?R/[P>];:*9O:T[F45QUK&JQT573>@M/Z;N3J^T
M4DL528S'O/G<\!IQD8)[@K2B*)M-IW,E:UI&JQI\]2PL]2PD)$1$0PL+*PI0
MW;=Z,GB$2W>C)XA%A?NZL?E;:(BJN(B("(B B(@(B("(B"LV^/WKUI54=.-V
MCKJ;RSHQR;*UP:XCLR"TGOR>M16TJWFZL%'+*Z.)\8+' 9W7!V<XZ^I35=]_
M5K_,YQ_Q,7EK&%Q--,.+ "P]Q6F*=6VF)FL[A3]*47V.TS(H9G2^>7/<1N[V
M>8QZE?P01EIR#Q!5,6[17*>D9N-#7Q]37=7@M,M)OU]46M-IYI[K)+(V*)\C
MSAK1DKF^K;(W4<\4TE2ZG>PNXAF]EIQPY]P4]=+E43T\CBT$1L<]L3/A$ D#
MQ/)<AT1KZ^W;4DE)5TK:R%['O%/3L:Q\&.PN(&.H[QRHQ_[4[]4X[6I/-7N[
M]H6)M/:7P,)Z.)X:W)Z@T+YTS&*^\WB[5 WI65#Z*#/*..,X..S+LD^KL4;8
M+I=*.A\W2MUDZ0[^]T],/#_6]RUM(WNY0V^J$6F+G,'5D[BYLU.,$R'(XR<P
MLKSN9E'=T!%6OL@NW_I*Z_+TW_W4^R&[?^D;K\O3?_=51945:^R"[?\ I*Z_
M+TW_ -U/L@NW_I*Z_+TW_P!U!945:^R"[?\ I*Z_+TW_ -U35JJIZRD$M50S
MT,F2.AF<QS@.W+'$?.@YCJC;#4::\LEN>A]0Q4-/,8O+'"-L3_.P""3R/5XK
M=BVH5K;5>*^XZ*OMM@M](ZJWZS<8V4@@;@()XG.?45I>ZB_FCK_SB']=6':_
M_-'J/\P=] 06?3=T;>]/VRZQQ.A974T=2(W')8'M#L$]>,J17 :79\^39%1:
MD&H+Q'J"FM#*VFFCJ2V*$,B#VQ",#=W  !Q&3SRMJ^ZENK=#;/MHWE$^[3B(
M7>&,^9+!( 'OW>606Y'B@[HBY;?[E4:GVO6/3]LJWMM=I@]];BZ%Y;ON<"(H
MB1SSD.QV*L:2L%7K37FT"&YZAO-/;;==MV&EHZCH\N(/$G!.   &C YH.\K2
MO=7/06FKJJ.CDKJB&,OCIHSATI')H/>N0VZUG:+M#U90WNXW%MDT])#14M'3
M5#H=]Y9ETDCFX<XY'#CUK4M=QNEBBVE:1DN=564]GHQ4T-3._,T;)(\[A>,9
MP>10=FT]75-RLE%65]!);JJ>(/DI)';SH7'FTGK47KC54>E*>T2RTCZD7"Y0
M6X!CPW<,F?/.>8&[R7)[E>KM5[-MEEBI;C44T^I!!!55K7?;1&&-<_#CR<<\
MUX;4-#LT>-(U%EN-SJ*!U]I&S4-54&;I9026/87>BXX<#Q#?.ZL(/T&BK?V0
M7;_TE=?EZ;_[JQ]D%V_])77Y>F_^Z@LJ*M?9!=O_ $E=?EZ;_P"ZGV07;_TE
M=?EZ;_[J"RHJU]D-V_\ 2-U^7IO_ +J?9!=O_25U^7IO_NH-O55*9K?TS!YT
M)WCWMZ_K5/5D=?[JYI:[2-U((P1T]-_]U<)VA:XOUBU2*"FHO>^*)K7^3U3&
M2/F!/6YI(QPP-TY6M+Q$:D7>M^_6S?F-9^M"IM0$DCI=66"1[#&]]NJG.8>;
M23"2/5R4^MH]4"(BD$1$!$1 1$0$1$!$1!"Z;^Z=0?[4D_9QJR6NC-=6L@!P
MT\7'L:.:K>F_NG4'^U)/V<:OVC(QO54I''S6@^T_4J3.J[%DC8V-C6, :UHP
M .I?2(N9(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@H^HJ?R>ZR]DGVP>OG\ZC5<=447E-#TS!F2#+O%
MO6J<NFD[A B(K@B(@(B("(B L8'8LH@+&%E$!$1 1$0$1$!$1 7M14SZNIC@
MB])YY]@ZRO%6K2%*&T\E4X><\[K?[(_ZJMK<L;$Y30LIX(X8AAC &A>B(N5(
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MC7?U4^^7..T6]]5*PO((:U@."XGEQZE[:9Z&\1P5%+3QP/K3F0M: XD$@[Q
M\[&#Q*G]96RCN5G$-9"7ETT;(]T[I#W.#1QZAQ4CIC3;+,U@\P-B;N1L9D@=
MY)YGZT\6LT^9NG)KUW^BQ1L;&QK&##6C "KVB'-%)<X,_;(;C4-<WK&7EP]H
M(*L2KUXME72W+WXL36NJ2T-JJ5SMUM4P<N/4\9.#U\BN91844-:M24%PG\E>
MY]'7XR:2J'1R^H'TAWC*F4!$1 1$04K;#I*KUMHBILM!/#3SRRQO#Y02T!KL
MGDI375BGU!HBZV6FECCGJZ8P,>_.Z#VE6%$%8IM.U$.S-FFS-&:IMI][^E .
M[O\ 0[F]VXSQ4-36"CTSL3=8]4S1R45%:GPUDD? %H:<EN>OL[\+H"UKG;Z2
MZ4,M'<J:*JI)1NR0RM#FN'804',/<VZ;J+1H1MUNCI9+K=W">1\W%[8F@,B9
MGLW6@^M6/0&D:O3FHM97"JJ(98[U<!5PM8#EC<$8=W\5<XHV11LCB8UD; &M
M:T8  Y !?2#F5ST?J6QZTNVHM#5=M<V\!AK:"X,=N=(QN!(QS2"#CF.]?-DV
M=7&.SZLJ;U<:>JU-J*,LFFCC+(86AFZQC1DG QS_ .ST]$'+;GLSK*G9YI.V
M4MQBI=0Z<;#)258871F5@ ((Y[IQA1]YT3KO5M78:K4UTL\#+3<8:MM)11/#
M)=TY<]Q)/G8& .7G%=B1 1$0$1$!$1 52UG01/JJ6L?!'(YOFM<]@<8W#D03
MR]78K:O"MI8ZRF?#*,M<.?8>U6K.IV.0UOWZV;\QK/UH5-J,OE*^BU_:8).)
M;15>'=1&]#@J3737KM B+ <'%P:X$M.#@YQXJ1E$1 1$0$1$!$6 X$N <"6^
MD >(\>Q!E$1!"Z;^Z=0?[4D_9QKJ&FJ4TUL87C#Y?/([!U?,N<Z'IC5WB]0C
MT3=I"[^R&1DKK0   ' !87GII(B(L@1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MT,PJ[G(ZYW'KJ*@9#?[#/18/!;]CM5/9[>REI@3Q+I)'<72O/%SW'K)/%;Z
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M%_K74-++6N;-4EN\8V[O X\ T>M?LU<&V\;-:NXW!VH[% 9YG-:VKIV>D['
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M$[I/+>-2[XY;UYZ3N&RB(I486%E84H;MN]&3Q");O1?XHL+]W5C\K;)#022
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M<S><X9;$X<!WE6-H#1AH '8$1<MK3/=(B(H @$8(R%5-1VAM,/*J5N[%GSV
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M("(B B(@(B("(B B(@(B("(B B(@+3N=NAN$.Y,,.'HO'-JW$4Q.NR)C?25
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MSFY&XYP;NG/5Z)7.XKM?9-G]LN^]1U--053Z20U=/#.]Y<0YF=]I<>3@3G.
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M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!"
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M(B("(B B(@(B("(B B(@(B("(B HW4M\H=-V*MN]VEZ*BI(S)([K[@!UDG
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M))WCU]ZIBF.(UECI$>GS9Y=\-S8;1$S,=_E/R_!.U6H[G6P"*>I=N-&Z,$Y
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M:-0)'06X4/3[N 3T>YO84#2V2WZ#V*SVG4$PK+=04$S*ES1N]*T[Q( ZB=[
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M:'TM>+AY===/6JKK.&9IJ5CG''+)(X^M6)$'Q#%'!"R*"-D<3 &M8P8#0.0
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MST==#T,H:3P>&Y.6GAQ[PN6TNK;-K#W0VEJS3]2^H@@ME1$]SX7Q$.\XXP\
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M-]Z7+_X%;!^%5_Z8^I8_@4T_^%5_R@^I=11/M.7[Q]JS?><N_@4T_P#A=?\
MICZEC^!/3_X77_ICZEU)$^TY?O(^TY?O.6_P):?_  JO_3'U+'\"6G_PNO\
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MB(86%E84PANV[T9/$(EN]&3Q"+"_=U8_*VT1%5<1$0$1$!$1 1$0%R6Y:?\
M?/W0;)[E:/*[3[QN;TD]-TD'2=(W R06[V,]_-=:1!HVRT6VUAPMEOHZ,/\
M2%/ V//CN@+@=/34[=07YNTG2U\U!?W5LGO<TTTE12/@)^UMB(RQC>W>Y=:_
M12(/S316"\1^Y]UG0.L=935TM=,8Z%D#BX#?'!@ \YHY CA@+KVO:?4#]E%5
M!I;IH[X*2(1",[L@P6[X:>IV[O8[U>$0?E?6%JLERT++3Z0T)?9;[B)]775U
M#+T\.'MWO/>,O>[B/-ZB3R72MJ=!<X(-G]]HK75W"*QU39:NFIHRZ8,=& 2&
M\S@CB%UY$'(-9U-3JJY;-;M06FZ10-NSGRQSTKV20M#7MWGM(\T<.96_MXMU
M;<*728H*.HJC%?:6600QE^XP/&7''(#M74$0<7]T*VNT[-9-9:=+1>(7OM?1
M#TIVS-.Z!UDAS00._N4S+I"336P>OT_21R5-:VWR=((V;SYIGY<XX'$G)^96
MC4^D(-1:@T_<:ZJE\GL\SJF.D &Y)-P#7N//S>./%6=!0=-6.IK]AE!8YXWT
MU746%M(62M+71O=#NX<#Q&">2I=DUO<[%L[CTM6:3OS]3T=+[W1PPT;WPS$-
M+&2"4#=W2,$\5W)$'!;EHVZV+0FR^S&EFJJJWW:.2JZ",O$0(D<22,X +L9Y
M*5JJFLV>;5]07>LL]SN%DU!#"YM304[IS!+'O M<UN3QWN?_ %7940<:V<RW
M:[[:]17^NL=?:[?5VJ)E*:J(M+FM> "[L<<$[IX@8RI[W0U#5W'91=J:W4L]
M74NDIRV*",O>0)F$X X\N*Z.B"A[:J.JKMD6HJ6BIIJFJDI UD,3"][CO-X
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MM/.YL<+ZN5QGJ8Q\)T;AE@SR!*Z6B#ENV)PHM6;.;M,=REI;N899#P#.E9N
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M&S45ADJ7&.FCJG$R8X!YC<U@)Z@2XC/;@=:<L3&T\\Q;3IB(M=M=2.EZ)M5
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M%]MJ+Q?JBR@$4]NDK7&& \=T@=>[G@#D+H.G;];=1VQEQLE6VKHGN<ULK6D
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M*-DN\6^6T['2@<-\$!N?7S2-R/5U'(\;KY@&'@[<;@D>.>"W&-#&AK0 T#
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MICHB8W#GL4FY*R5IWAP<#VJ>AF9,S>C<".L=8\53K.80RJAH)73VR&7<HYG
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MB4#+F.X$>I4'NB(H!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(A( ))P!UE
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$0(B(,(LK"F 6%E81
MB(@\*VIBHZ2HJJAV[#!&Z5[NQK1DGV!539732SV>JU%6MQ77^<UKOR8>4#>[
M$09ZR5Y[4YY*BU4.GJ9Q%1?JME$<<Q!G>G/R8</6MC:172671+Z.T?::ZM++
M70;O#<DD\QI']D9=_A1,-39Y_P"/WB\ZPE\YE7(:&W'XM)$<9_Q2=([PPKVM
M*QVRGLMGH[;1,#*:EB;$P 8X 8RMU0D1$0$1$!$1 1$0%7=;7.JH*"F@MY8R
MIK9N@$KVY$;=USG. ZR . [58E7]?4D=3I.XR.8\S4L3ZF!S#AS)&-):X'M_
M<2IKWZHMO714Z6!E-31019Z.)@8W)R< 8XJ4L[L32-^,WZ%'L.]&QV0=YH.1
MR.0IBUT_1Q]*3ESQP[@MKST<^./B>=:Z.#46GZBH<T0":6'S_1$CV>8?'S2!
MXE715"\4<=PML]+.S?BE;NO;VCN[^M2.A[C)<=/0>5.WJVG)IZG)XB1O#)\1
MAWK66NFV\3UTGD1%581$0$1$!$1 1$0$1$!$1 3DBYAM)U-6W6YLT1H]^_=:
ML;M=5L/"@A/,D_&(SPSGEUD((V[..U/7?O1#Y^D;#,)*R0<&U50.48[0/.!Z
MN?:%V$      <@%#:/TY0Z5T_26BVLQ# WB\CSI''BY[N\E3* B(@HFG\:=V
MC7:Q@;M!>(S=J0=3)1ADS!XX:_'Y3EY71OO!M.I)XQBCU) :>4=3:F .<QWB
MYA</\ 6SM9C?1V6CU'3,<ZKL%4VL:&CB^(YCE;X=&]Q_PA;&TRB==-$5%7;S
MOU=#N72C<SCO/A(D !_*#2WP<D=$3&XTFNI86I:+A%=K117&GQT-7 R=F.QS
M0X?2MM;PY9$1%*&%A96%,(;MN]&3Q");O1D\0BPOW=6/RMM$157$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$%.VAZW
MI]+4S8H6LJ+G,,QP[V P?'=U@=G:N,7[7-_OD)@K*XLI][/1P-Z,'N)'$CN)
M4-?:N>NO=PJJLDSRSO+\]7G$8]7):65[N'A:8ZQN-ROCM#WIZF>G>74\\T+S
MPWHWEA]H*^"XEQ<XDDG))YDKR#VXSO#VJ=MFE;[<NB\CM=2]LN"U[F[C<'KR
M<<%I;5>L]'93)$(==2V"TL[KK<ZL9\E;"(2>HOR#CQ ^E3MBV2VF*@A-Y?/4
M5A ,HCE+8P?BC SCO70+7;J2U44=);H&04T?HL9R7G<1Q-+5FM49>)BU)I#;
M1#P&3R4/>-3V:SQM?<;C!$''  )>2?!N2N"(F>D.**S;I"811]DO=NOE*:BT
MU<=3$T[I+<@@]A!XA2"3$Q.I)B8Z2*.U!>:.PVN6ON,O1P,P.'$N)Y- ZRI%
M<CV_U$HI[13[OV@R/DWOR@, >PE:X,?BY(K*/JYUJ35-UU!5S2UM7,('N.Y3
M->1&QN> P.!\2HVW4-5<ZV*CM\+YJF4[K6M&<=Y[ .LK[L%MEO-ZHK= X-DJ
M9 P./$-',GU $K]%:)T;0:3@F\E?)/4SXZ6>3&2!R  Y!>IGRTX>NHCK[.B,
M_+'1(Z;L5#I^V,H[? R,8!D<.<CNMQ/,J51%XTS,SN6$S,]9$1%"!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%^._=+-?/MB= )7M$
ME-31C#C@;Q<%,7[W/=YM5BJKG07^.IFIHC.(</C+@T$D!V>!X<$3I^K$7Y9V
M/:AOFT+2.IM"UEP,DTE%TM'5SY+HV[S06.(XD<0>WB53]HVR*]:#L3+I<KK2
M5,+IFPAD#I [)Z^/5P0?M9%^+=GVQJ^:YTS'>K==J.GIY))(A'.9-X%CL'EP
M5M]TC;*BPZ,T-:IZDRRTK'Q/D8X@/(:!E!^I45*V*.+MD^E"XESC;XLDG)Y+
M\Z;9))![HX;LD@W:NWXPXC'FQHA^P$1$!$1 1$0$1$!$1 1$0%I5L#NG9.QA
M?YNZ\#GCF"/G]JW40:D#'R5#)',,;(VD#>YN)Q\W!;:(@(B\*]TS:*H=3#,P
M82P=^."",N]SDCJ#34S@TM +W\R">H>I1T3^)))<YQR2XY)*B8)@[)WLDG))
M/'/>MR*1;\FH0DFD/ R2"#D$'!![5NPUD\;@Z1QFCZP&C>'>,<_!1$4S3R/7
MC/5GQ6Y&]9S"4ZQ\53"2QS7QN&."TW;]*T-F(= . DZV]F]W=ZUJ>9T$QD8P
MO#QA[0<$GJ(SPRI&GJHJAQCPYLF,ECQQ(^@JO8:TT7<M&6+GP4I+1-:W>I<1
MR#D,G=/<0M61DKN II-_ES;CVYY*T6$-4,#6N+B T#))ZE+V"WB"/RJ5I$\@
MP >&ZW/+QZUL4MMC86R5 $DP.?R6^ _>M]+6WT!$14!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1$"PLK" B=2*8!865A$"(B"D,Q>MKCLC,&GK>"T]73U)=G
MV,B'Z27G_P :VHV6V\'TMFII+G.WJ$[B(X?7@RE9V5--33ZBO!XBYW>HDB=V
MQ,(B9ZL,SZTV> 7#4&L+^.+*JO\ (HC^13#HC_Q](?6H67A$1 1$0$1$!$1
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MCW+/\TE)^=U/[0JF>[#^Y]-?WDOZH70/<XVFX679A2TEWHIZ*J%3.\PSLW7
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MS6.HJ/W0=!:J2]5T-L-=1Q.I628C<USFAP+>O.2OTM/-'!$Z6>1D<;1ESWN
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M\$4;=Y[W%I' =@SDD\ .:FO=6T1,=58&",CD44;172$49]\)&4M5!'FHBD<
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M;VG+(9(M/4;BVX50>>DJ93Q=$'\SG(+WCMW0<YQ>H(8Z>".&!C8XHVAC&-&
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M)7IW?EL*[;&ZIU-KNEC$@8RHBDB<"?2\W> \<M54NE!46NY5-#6-#:BG>6/
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M$M-*.'4YIZVN'4X'@0>15?U78:RGN(U+I=K1>HFAE13$[L=?"/@.['CFUW:
M#P*@/?&&W/\ LWTSTDEDJS_XY0[F'QN'!TP9S;(SX8ZPWM'$.GHO*DJ(:REA
MJ::1LL$S!)&]O)S2,@CU+U0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M94K&QL;&LC:UK&C :T8 "RB#3N5JMUT:UMSH*2L:WB!40MD \,@KTH*"DM\
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MH ^.[CR\ 5,72DEH;S7Q.<TU>X>C/80<. []T''<HVF<'4+]YN13/$K>P[Q
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MT='<Z2IDI*RF8XN$4C'$<">HC!4%:=JT%19]7Z@KJ5L6G++4^34\\9)DJ7#
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M@>WD]HX#(ZB.'CZE]N=4.$,W2$OF!A'#BX# X]O/'J6T8W&J>8FAP?3EE/\
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M9H++]1ZWDZO?5L8_PP1?6KFO':B(B B(@(B("(B B(@(B("(B B(@(B("(B
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MSX/>"NDVECHZ<.(XN.\ 0N?PTXI*JOI XO\ )ZJ1F_\ &R=_/_'CU+HX.?\
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M5=DAFI9,QN):7[I!<6G=)X]N%[U#'.D?5P1!TH!-2QF 96CD\#D7#CGK([2
MN/:%N4U(]M6)I'T<4@!B+S@ M =P]A[UVBDJ#!()8MUX(X'J([05YV7'R6F(
M>UP^6<F.)LS;J@,GBE9)B-X!WNHM/%:\-2VTZL%LCRRBKXQ/3LQE@DXA[6]G
M(.QRR3VK,T3::K:(0!2U6])$T?ZMPQOMQV9.1CAQ([%FX6KWZL,U.Q_1U<+^
MEIINN)XX\#U9X@^*QG7=T5W'2$-K[3E3<)9:RWR&&X-9B(YW6OQQ''J/5E<S
M^R'4FGI:VV25'1RAYR)0V0L+F[V6N[/;S"ZYL\N\M]L\XK@'OA>UN2.8(R">
M_FH#:WIN*IM\MSC#8I*2-QSCA(PCBTGJ(YA=?#9N2WAW[.#C>&\6GBX^\.8P
MZDO#HH8W7&;=!:=TX(!()('#GC#O%?<&J[UY.(6W"9K'!I< UO$N'/EU8S[0
MJ\6N$$>]*0SS!DCD<DC'@,\?4OMS9&2. =(#NN=@\2-TD@>.>/=E>OJ'SNY]
M)2$M_NDE*7>^,KG;N>8&?.R[@/5PZP5J53GOF^V.>[TXQON)!X9:#GOX@]F%
MY,C:7/:[=W]_&2W +G#AZ@<_2O@,;T+7X+PT-) =V'C[. ]>4'ITC!)(>):[
M#PYHXD8QD]A&2?'*P9&EA&ZYQ(#2W'8W=P3WC)'SKVAIWRU(AIXS-(_?;N1L
M.\YP\X8 ]7#Q"]305K+G+1&AJ#5N'2M@+'!Y<1Q '6/./'UH1#1DW7/Z64 ,
M( <1Q+L@X)';PZEZB,NWH&$'I&NB;@<I"P#([G9'/YBK18-$7BNJWP5$,E'2
MQN+3+4-YMQZ.[G)&2#V+H]#9*>"/3^G6L89'UD#Y9=SC,(3TKGD]_1@>M89L
MT4K,QW=7#</;+DB)Z0NM)1]'K:Q4X!Z.V6:5I[ Y[X6CYHW*Y*L:<S5:MU/6
M@[T+7P44;AR)C87/]CI"/4K.OGGUXB(@'@,E>/E=/^$0_IA1&NR1HN^$$@^1
MR\1_9*_&FR#9P[:+<+A1QW-MN-' R8O,'3;^\2,8WFXY(/W-'(R09C>UX[6G
M*Q)-%$0))6,)ZG. 7XPUYHZ_[&;S;*JUZ@E=Y7O&*>G#H<EF"6/9O$.'$=Q7
M2=3;/;CMJHM/:OIKG1V_IK:R&2"6)S\/#WEQ!!Y9/S(/T'Y73_A$7Z87U'/%
M([=CEC>[GAK@5^"*[1DU'M$;I!]7"ZI-;'0^4AA#-YY #MW.<<>2_1&R+8E<
M=#:SBO=7>:2JB9!)%T4,+F$EV..2>Y$NX-FB<\L;(PO'-H<,K[<0UI+B !Q)
M/4OQYL6)/NB6')R:FNR<\_-D7Z.VU9&RC5."1_H,G)$+E'+'*"8GM>!SW3E?
M3G!K2YQ :.9)P OS-[E&XPVBQZVKZKI?)J40S/$;"]V V0G#1Q)X*F[2MHVI
M-I4-P-NI:BDTO0M$LT43CN[N0 Z9_(DDC#/#GC*#]E1R,E!,;VO X9:<KS-5
M3@D&>+(_+"_/?N2.&E]6@$X$[,<?_;*XSL]T6=?:ZJK*VO%"\LGJ.G=%TOHO
M QC>'/>YYZD2_=L<L<N>CD8_'Q3E?:_&FT79M>MD@M]XMNH9)!-+T+9Z9KJ:
M2-^"<$!QR" ?J7Z7V.ZHJ-7Z MUTK@WRS!AG<T8#WL."X#JSSQWHA=$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!1]\LU!?*)U)=*9E1">0=P+3V@\P5((IB
M9CK"8F:SN'/&VW4^CL"S2>_EE;_^BSN GC':UW#/A\RG=.ZWLU[DZ".9U+7-
M.'TM2W<>T]G'@?4K,H;4.F+1?X\7.BCDDQALP&)&^#N:TYZV\\?BW\6F3^Y'
M7WC]X]?T0FU2YU5ELU!<[>X">GK69!]%["UP+3W'@IS2NH:+4EK;64+CSW9(
MW>E&[K!7(]I5OETW1PVN*_55;2SD.;15(WW0M;R<']0SP Q]"IVG[[6Z?N3*
MRW3;DHX.8[T)&]CAUA=%>'B^/I/5W4X*,N&.6>OI+]2HJYHS5E'J>C+X6/IZ
MI@'2P/SYO>#C#AWA6-<=JS6=2\N]+4GEM'47Q)-'%CI9&,SRWG 97VORO[L,
M_P 9]/YR0**4XS^6%"K]1"JIR<">(G^V%[+\J6CW.-5=-.45TI=2PMEJJ9E0
MR!]$0 7-#@TO#^_&<>I>7N>]77HZDJ=%7*MGFI*V"H@B$\AD--*UI]$D^CP=
MP[<%!^JO*Z?\(A_3">5T_P"$1?IA?D#6^P:Y:/TI77NJO=%50T;6ET4<#VN?
MEP;S)QUJ&V5[**W:'1W"HH;G2T3:.1L;FS1.>7$C.1@A$Z?MLS1B/I#(SH_C
M;PQ[5],>U[0YC@YIZP<A?FW:_I:?1GN?+/8JJK95RT]S:72QM+6NWC*[&">K
M*O'N7,_P50<\>5SXS_:1#K$DT41 DD8PGEO. 7VOR1[K_/V9T//A;R1W><5U
MK:CM3&S_ $Q:(*2D-5=ZRE8Z$R@B%@P 7./PC^2#GB@ZU)-%&X-DD8UQY!S@
M"LR2,C;O2/:QO++CA?S_ -52W^JOT-PU6:LW"L8VIC-22'=$7'=(;\%N0<#@
MN^^ZK).SG2@)/&K9GCS^T/1.G?\ RNG_ *>+],+V!!&0<A?D/9]L&EUEHZ@O
MT6HHZ/RMKB('41DW=UQ;Z6^,\NQ?.R?4U^T%M5ATG75LM1;WU_O=/3ND<^-K
MB=ULD8/H\=T^"#]?(B(A2]HY%+6:3N+N I[Q#$3V"8&+Z7A-+YAVDZVA(P)A
M153>_,1C/[->^U:C?5Z!NSH03/1L;7Q8Y[\#Q* .\[F/6H\5S6[0--76(@45
M]M4D!<.1D:62Q\?[)EP@OJ(B BA-8:ABTU:/+98'U#WR-ABB8<%[SG R>0X'
MBJ@[:Y;6VN=_O?6/NL()DH(F[Y;PRTE_+!!&.OGPX*]<=K1N(-NE*/N5ZMEL
M.+A7TU.[&=V20 D>'-?GV\[2KQ5LI656H(HZ*=CI9GVV,L=#P&Z"]I<X,.2.
M.#D<^>*#7W(3T,\%=&^J;<9SBY3.S*&YPTO)&=X-'#B.O(X$+JQ\%:W=6;0[
MMJ3:W!+<8:+2%30SD1&:6>JBD#< X :"6Y[2>(Q\T?IK5K]3UCJZ>G;%-5#S
M3')EK6Q]6.!SDN/;@C*XM=ZFHO<E125T4)GIXL1=&S <20=[))P<;O#O*^K1
M.ZWWVP7?[=O-E:VH>QN"]N\&Y/82"2<\\875]BB*=.[.UMP_3-U--6TS(S,U
MLT;A+$\M)#7CEGN/$'N*TJ6JGB;- <1R12;DC6G.'8!X'L((*C[1=*>ZP234
MN\&L>6X<,'N/K"DY*1]32.JJ=KGUL.&M:UV.F8/@.[>!.#U%>?KEZ2IS3?MW
M>=;2R78Q/BJC3W*GXQ38R'MZV/'6WZ.I>\4D=XAFHZI@BKJ?,-3 _BTY','K
M:1@@\\'M7C0U31T=3#Y['-RW(QD'Z"HZ\S.M.HZ>^.<?>JMZ."J=C/0O:"&G
M'/B.OE\R:Z]")Z=5/U935NG(Y;;#4=-02@R,W@,AV.1..K@N7-J:FV7(S4>)
M131ND;',3AQW1ODX(XD'((Z\K],W.@I;O22N:&5,$H\YA&<]X7&->:9;8)'S
MQ1324$E/@R2$%X<,Y8< <#S![2>Q=W"9*3NMN\HB.6>BJ>_%6^G%,WH&^^CS
M.)MPY9(2"1CN<  3\Y7FR^7#R>*YP]&+G3U?223B)I(\T;N/R># ,<N/:5\-
M;2GWJ#7O#@26./7APR'=Y?CUKY?*(Z*O=3,="]L@D.YV!V.'9Z)R/'M7?X=?
M9;<I U=='77BFAF='%<VN?*T-#6N<.(=YH^,]W#JQX+1=!53QVN2H>Z1]/(6
M#I'Y(9O</$!HY+(JWOKZ0&0""K@ :1Z._AV<=AR6CYEHE\K[686%QJ:>8-8T
M')(P6^9V\<GAR5HBL=CJW)Z".H-9''(USV/:X-)+2T\7')\'<#X=B^V4SI*^
MDJ)A'F>$,F9PXD-)/#D>./8OJ&&4U=7<8HGNMSV]'.\X:8GD#. >)QYN>' G
MN*CS#.*%\#XI3+3S[D$A8XQRNX#<:?C=8&>?#J*<T&I;39IIJ:6GI@8:FE=D
M,8<ES1O# !Y]1X\\CM5VV$007/:C0UT.=Z"CGGD:1Z+R&Q\.X[WS>*BK3IZI
MND\U1-:+C),QK8=RC!,D4CLGSMWEP]%Y\WGE=/V9VZ735?J.X75]/O62W14;
MS%D,#MSIG#QPY@.%P\9GCDFD+TKZKILN!DCU15_!J;[5EI[0QPC!_P"!7553
M95036_9[88JMI;624K:BH#A@]))Y[L]^7%6M>.U$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$' M7^Z%-@U1=K0RPB9M!4/I^D,^"_=.,XPHZA]
MTY :@"MT[*(>OH9P7^H.P/G7.ZFMI;=[H^KK+C-'!1P7Y[Y99#AK&AQXGN74
M-OFN-"7O9]64%MKK?<KL]S#2>3-WG1.#P2[> \T;N\.?'..M$KKJC:]:J#9U
M#JVR1^^--+.V#HW'HW1O/-KNPA<W;[IUSO1TZP^%3_T4C[DVU&KT?J#WSI8Z
MBV3UK.ACGC#V.>U@WG 'A\7CW* ]UM;:&W5>EFVZBI:0/94EX@B;'O8,>,X'
M%!OQ^Z=WIF,=IY@!<&G%3QXG'8KMM6VR#0FIJ6TBT&LZ6F94.D,N[@.<X8 Q
M^2IO9'I^S3[.--U$]IM\D[J1CC(^F87$]N2,Y7!_=7'&T^C/9;8OVDB(?K6C
MG\II()P-T2L:_!ZLC*Y%8-M0NNT]NDO><QL?4RTPJ.ER<L:XYQCKW?G410>Z
M,TY34-- ZUW,NBC:PD!F"0,=JY/LIKX[I[H*UU\+7-BJJZHF:UW,!T<A&?:A
MI^L]::NL^C;.^XWVJ$,0R(XP,OE=\5C>L\NX9XX7,]G>W)NL=9T]D;974T=0
M)"R4S;S@&C(R/#O4;JS8O>=7[4*FX7Z]/DT\7"2+CF1C"2>@8.30/C=_+*YG
ML2IXZ/;XRE@&[#!45D48)SAK2X#Y@$'8=J.VPZ(U;-9&6;ROHH8Y3*9MW.\"
M< 855I_=-L,S14:<<(R>.Y4>=ZL@!4OW1KVQ[:I7R'#&14CG'L XE=7VD[3M
MG-TT/>*&.NI+G53TSV001T[B[I2T[C@2W#<.P<YX80TZ)L]US9]=VAU=97R!
MT9#9Z>9N[)"X\@[F#GJ()"M*_,/N/J.L]^-15F'^0>3Q0N=\%TN\2,=I SX9
M[U^GE*LL+"RL*11+8?L0UY+;"-RQZ@>ZHI">4-;C,D0[ ]K2\=X=VA4OW1>D
M7!L6KK?&2V!HBN;!\*('S),=K23D_%/<NK:OL$&I;#46V>1\+G[KX9V>G!*T
MY8]IZB"/9D=:T=&7DZDLM9;K[3QLNU&317.E(\USL8WP#SC>,D'LR.HJ:7G'
M:+55R8ZY:32W:7Y5>YK9WUC'"6FF):[=X.;O \.XXY'D<+(AB>R&FWGEL@,D
M$F,<^!:X>+>KZ%?+ELTBM.I:[3\U;)2T=2[RFU3.8")6#.]"3\9F]P',MX]1
M4KI?9_31GI+PXS5%-F%K&'#<<2'8[PY>_CXBEZ\SY/+P>3%?DF/I+UTOH*WO
MMD%5=HWRU<\#0YH>0UK2T# QW*9L>E;59JR1D,&_O@OA,IWMP<-YH^8J5FFC
MM$#7SRD4+1NES^)C[./6#R56K==TD=U::>!]13L86[X.[Q)&2!ZE2L9<LSR]
ME[3APQ'-W6<V^DI+E%6T]/&R>3[2]S6X):<D>O(6Y6%@HYS*0(PPEQ/5P7,]
M0ZRJ+B8V4+'4L<;@_>#LN)477Z@NEPI^AJJI[HNMHX9\5K7@LEM3:65N/QUW
M%8VZ S6EH91M>Z:1\H;@L##DE4*MOU=45E3-'/)$V9V2QIX!1("^VA=N/AL>
M/<P\W-Q>3+$1/HW+=<*R@F=+23OC>[TCSSXKTK[C67%X=6SNE(Y \ /4M-H7
MJQJUFM=\VNK&+6UR[Z,L:O9C5AC5[,:JS*8J^Z%P9/+&[@9,.;WX&"MU[VQL
M<^0[K6\22M/HFR-W7M#F]A7I%3LW@YP<\CB-]Q=CPRO*S<'-[S:)Z2][AOZG
M7'BBEJ]8Z/ED9=1R!S?.G<<-/47NPW/@2%U**,Q1LC)R6-#<^'!<[$8>QS7#
M+7#!"L>E:NIDJYZ6>=\\;(6R,,IR\>=C&>L>/=VK+C,4Q6)CM'1M_3<\3:U;
M=[3MT"VMW:2,$8SQ/M7,JLU#K[<*J-S65D%;(&;PRW \W==V@MQR[>Y=#]]1
MP^TGO\Y5#4T44=Z@J*4.:*S>$S#R+FMR'#OZCV\.Q</#=+ZM'=ZG&[G%O'/6
MO5[OU/<I*001VYC)0,=(Z8=&?9YQ'J!6C0P&&'=<]TDCG%[Y",%SB<DK,;5L
MQM7=3%3'Y7DY.(R9XB+O2-JV(VKXC:MB-JB9*U>D;5LQA?$;5[L"RF716K[8
M%L,"\V-7NP+*9;UA],"]F!?+ O9H6<RUK#Z:%ZM"^6A>C0JRTB&6A>C0C0OH
MEK&ESW!K6C)). !VJDRTB$5JF]Q:?LD]?*TR2C$=/ WBZ>9QW8XQWN<0.[GU
M+&BK1]C6G:BMO<S/?.J+JZZ5+CYH>1D@'XC!YH[FJ&TQ"=9:C9J2I819+:YT
M=G81PJ'$8?5<>HC@SNR>M-9S'5M_;I.E<?>VE+*B]2MY.;S92]^_Q+NQH_*"
MSF=RZ*QRPQH=DM[K:S6%PC='-<6B&AB>,&"B:<L!'QGNR\]Q:.I7!      !
MP ' !96D1J&-IW.WRL+/4L*85$1%*&%A96%*&[;O1D\0B6[T9/$(L+]W5C\K
M;1$55Q5?:!_HENH[VP$R6BJ94D-YNC(,<@_0>X_X0K0O.I@CJ:>6"=H?%*TL
M>T]8(P0@H\M746#5UPI:81MI;DUMPAWAG?D'F2MSGARB=P^,5X7:[32T)J[A
M5B&EB/3/\P%K ,YQUG@3U\5#7^AN%3H.J@HY7MO^E)'11RN +I8 W&<=9?#_
M ,07#Y;O6UE,8I*J>>FD89VL>\EKN/$8ZQU]H7I<%CKDB?>'B_U+-;%:.^I7
MN_;2<'?L]/D-W3T\O [N<'#.1&>''CPY!5*NU'>*JKFDEN$X=*'->V)Q8WS!
MG@T=1SC'BH5X($D6X',:, D^DPNX<NO)SGQ6']*Z(N+P2TN.0.MN..>W]P7J
M5I6O:'AVR6OWE]AS&%[=[<!PX;QX;KF\<=HR1[%Y@NDCW0QI(<!O;W#>:.?A
M@+Z+ "'C>>QQ(R"#@.',#Q)4G8K16WFX.I;:QKI"S?!?P8S=(:79[",CORK3
MT[J1&^D(LN=)(QS&%I<>.\<C#SC!]>>/U+#6 O<93DN;GT>.&NXG^T0"K5)H
M2_=+44PH6/$8=YS96XW?]7@D\>.?5ZE:[)L^AIZBFJKM.RKA<#O0 $-#G8 X
M]8X<>TE4G)6/5I7%>W2(4W29!;5TS^C SD!I]+/'Z,*_Z0OA8Z&TU;#O9W(9
M&_JGN["OK44-MM@=06Z"&*:H>VHE:P>CNY&>[.&C'BJYNO9=J)T!(E=*S=(&
M2"'#CA>;FU:\_-[G"1-<41[.L7./<M-$]QQ*V=HC(',.)!![BW)]06]9IAO&
M -XYW@>WQ6M2Q1UD<E)4N?NG#V.8<.8X'TF]XY]BT;)4.?7/IY) ZLI)C#-N
MC SS!'BT@^.5Q:W$P]&)U,3"LZ#J&6Z_W-T)<RS2S/@B<?1+FN.X./<<>) 7
M0JVFBNMMGIG-#V3,<S=>.&2",'VKGU]J)Z.]U]+ UL$/3/>&  APD ))!ZB<
MG"\J"OKJ:!T5-5/C8XY' $M/:W/+YPNN>#MDK&2L]WG?ZECQ9+8KQV5?^#:>
M2TTDD-Q82\L9*Q\> P;Q#L'/$YSS4A=]FS14T)MU<[#ICTO3#ED9WACLQZ*L
M44TSJ6.G+_M+,8;CZ3UK=8Z21S7/D>7,]$D\0N[FO'>7E:Q6WRPBM.:*MMEF
ME%<8J]\C6]&^=@ :&C!X$XSQY]B^?L!L%1%5O9$]K7N<&;DA C;D$@#Q'L5D
M8'2.WI7%[L8X@<%MQT\;W;SF E93DM'7;>N*L](A'4-NML#J66W45.RH8.'1
M-&^&D>=D\_;UJ2%$Z6850A8)FX:TN WRWCGCU<^65OQ-Y]ZV8VK"V6733##1
M@M[IGNEE)B< &LQ@GOSU>I:MNZ*GOMVNLQZ2CL-&[#SS=,]N_)R^+&V,?XRI
M6YUT-JME375()B@9O$#FX\@T=Y) ]:B6VJ5M)9=.5>ZZMN4YNEW=$?-\UP>\
M?V7/W6#\D%<F;),]'H\+AK6>99]"T3J+3%'TS2*FIWJR?//I)7&1P/@78]2G
MD1<[M$1$$%KS[RKY^9R_JE?C+9)==96JX5[] TCZJKD@8*AK8!+A@)P<'EQ)
M7[3UC335FE;O34L9EGEI9&1L;S<XM. N%>Y>TAJ'3NHKU/?;/5T$,M'&QCYF
M@!SM\G XHF%2N>C=JFTZ\4IU-3.I60 L9+51MABA:2-XAK>+CP'CCF%^H])V
M.GTUIRWV>B)=!1Q")KCS=CF?6<E2R(A^.=0__F=C_P!OT_ZS%^QE^7+YH?4\
MWN@V7>*QUC[7[\P5'E0 W.C#FDNSGD,%?J-$OP=;;1>;YM,K;?IF<P7:6KJC
M%()S 0 7EWGCB. /BK9JG9OM.M6G;C77RZR2VRGA<^H8;M)+O,',;I&'>!5D
MV4:(U-;-N+;I<+)64]N;/6.-0\#<PYKPTYSUY'M7=MK%OJ[KLWU%0VZ!]15S
MT;V11,])[NP(.->X[ =!JQK@""^G!!Z^#U?MLECM=AV)ZHI;+04U#3NC$CHX
M(PP%QE;DG'6JW[EO2]\TW#J,WZUU-!Y0^#HA, "_=#\XX]X70=M-LK;SLOU!
M06NFDJJV>%HCAC])Y#VGAZ@4'*O<D_>OJ[^_9^S*XQH"IU12:WJI="QNDO6Y
M.-UL39#T6^-[@[ASW5W_ -S1IB]Z?T[J6*^6RHH9:F9AA;, "\!A!QQ[55-@
M&B=2V/:M47"\66KHZ+R:I9TTH :2Z1I ''KP4'.M4WC6>M=546G-87)D%9%4
M"%L54QL$4$CAZ3PP<R#@'CS ZU^P= :7I]':3H++2R&84[/MDQ&#+(>+G8ZL
MGJ7'_=+;-+A?:RBU#IJAEJZ[ IJJ&#&\YHR62=Y'+P([%U395<+W<-%T)U30
M5%%=X&]!,)V@&4M '28!^%].4%M1$1 B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@+YD+A&\QM#G@'=!. 3XKZ1!SW^#AEUND]SU/7R5=1.<F&'[6R,=3 >9
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MPR.)F7RSRN/ #K<]SC\_8LYEO2OK+YUC>VZ;M=%:[)3QNNU;_HMLI6 !K2
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MJ;5,)@JXP6V^VD[S:%AX;[NHS.!.3U [O:EDL]?>;G'J#5S&BI9YU!;,[T=
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M1'+5QG=JJY[=Z"B_=))^0#P^%CD:3*7I?+G52US;#IXL=>IF"1\KQF.BB/\
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M![D$TB(@(B("(B B(@(B("(B B(@(B("(B B(@(B^)YHZ>%\L\C8XF#+GN.
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M1Q=?]IY<>]6$V"T$Y-LHR?[EOU*L:]5J\OJ\[-'9++;HJ"U/HJ6DB&&QQR-
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MN!=@'@?,"FME,;K/M&U#9*:1QH8VR%K">MCVAI\<.([U8MEND[GIRX7V:Z"
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M!3OW->RNZ7V9V2[:&I:B6-S;G51=**K?<=QQY>;G!"F_>9^G]G59;=1Z@>R
M.PVIA&'-C.,1MSDG."/ X4!36+:)161VGZ8V\T&"QM4),/8PGB >>.?P2>*D
M:O9K.[03;1%7=)<6S>5%\CB8R\@ M'6!@<.]1^)'RA1[C%IF32<S+)IN[U$D
M;2[WVEAW&@@^D3G&.["L<E7/6; )GU,CI)&%L8<XY) G ''PX+:JK)KZ[Z<-
MEK8[724D,08',?Y\^Z,-:<$@#EDX"D(M'79NR6;3Y%/[Y/?O =)YG\J'>ECL
M"G9$*KJ"YU-%L;T]3TTCHVU>62%IP2T9./ JPLV4V:MTI2"D:8+J^%DGE9<Y
MP+B 3EN<8\.2WYM"3W'9O062LDCAN5(W>8\'>8'Y/ G'(@X4'-8]HE798[!,
MZWQT+ (S5-EP]S!R!(XX_P (/!(DU[L;2W7;3VSVUVBHN+JF>68QS5 !:7QC
M)#2>?Q<]N%6;M%IF33+*>T:>O<-XB:TLJW4KAOOX;Q<0X\#QQPX<,+H]WV>Q
MUFA*6Q1U;G55(XRQ5$I)#GG.\#U[IWB.[@HMM'M*FMT%IWK=211 ,-<V7,CF
MCEGGV=@)2))A":NJZRX;%[/+=62BJ;6-B<9FD.<&](T$Y[0!Q6+[H:T4VS 7
MIC)#=&PQS.F=(X[^\YH+2TG&,'AX*XZXTK=;KH:AM--5"NKX9F223U#PSI,!
MV3P'Y7 =BWKYI^NJ]FS[)!T1KS31Q#+L,WFN:3Q]139I1+/HNV7?9U57JXF>
M>[.@EF94/E<2W<!W6XS@CAU]J]=/5DU7L.O$=0\O$#)(V;QSAN00/ 95VT_8
M*VAV=OLU0(O+74LT6&NRW><' <?6%!V#1UVHMFEVLDXIQ7U._P!&&R9;QQC)
MQW)LTTM+&B;L7C9<KA);:5[Y&NFB],_;2=UO:3C&!WJH76+34FDI18].7:22
M,!WOM-%N,SD9).2,'EC'6KI-L^N%9LUH;--+!%<J2=\[1ODQNRYW G'8[GVK
MQK[+KZ^:>=:+A':J2EBC#?,?Y]06XW0<$AHR!G@$B4:6G9363UNA+;)52.DD
M;OQ[SCDEK7D#/J "MA5<V=V>KL.DZ2WW#HQ4QND<X1NW@-YY(X^!5C*A:.S"
M(B@ L+*PI!$1$,(B("PLK"D%A96$0+"R5A2"PLK"0@1$086%E84H81$1#"(B
M L+**4,(B(/GJ6%GJ6%,(%$:D'^CT+NMM=3D?IX_>I=1.I/N6C_/:?\ :!1/
M9->Z5/,K"R>96%:%6[;O1D\0B6[T9/$(L+]W3C\K;1$55T)K3[W*KQ9^N%-J
M$UI][E5XL_7"FT!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M00FG?N^^_GG_ "V*;4)IW[OOOYY_RVJ;0$1$!$1 1$0$1$!$1 1$0$1$!5^V
M??M??S6D^F96!5^V??M??S6D^F96KVG^>K2G:WT_>%@1$568B(@(B("(B"&U
M3IRCU+1Q4MP?.V&-^_B)^[D]_:I2DIXZ2EAIX&AD,3 QC1U # 7JBGFG6EIO
M,QR[Z("HTG;I]50Z@?T_E\0 : _S.#2WB/ E3Z(DVF>Y:]K:W/81$4*B(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B" UU][4_\ ?4_[9BGU :Z^]J?^^I_VS%/JT^6&D_VX
M^L_L(B*K,1$0$1$!$1 1$0$1$!$1 1$00EI^^:^_[C]0J;4):?OFOW^X_4*F
MT!$1 1$0$1$!$1 1$0$1$0(B(,(B*8!865A$"(B#"PLK"D$1$!$1$"(G4@PL
M%96"H!8*RL%2,(B(@6%E"I&$1$0PB(@+"RL*06%E81 5A9*PI0+"RL) (B(,
M%865A2AA$1$,(B("(L*01$1#Y6%GJ6$A HG4GW+1_GM/^T"EE$ZD^Y:/\]I_
MV@2>R:]TJ>96%D\RL*T*MVW>C)XA$MWHR>(187[NG'Y6VB(JKH36GWN57BS]
M<*;4)K3[W*KQ9^N%-H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@A-._=]]_//^6U3:A-._=]]_//\ EM4V@(B("(B B(@(B("(B B(@(B(
M"K]L^_:^_FM)],RL"K]L^_:^_FM)],RM7M/\]6E.UOI^\+ B(JLQ$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1! :Z^]J?\ OJ?]NQ3Z@-=?>U/_
M 'U/^V8I]6GRPTG^W'UG]A$159B(B B(@(B("(B B(@(B("(B"$M/WS7W_<?
MJ%3:A+3]\U]_W'ZA4V@(B("(B B(@(B("(B B(B!$"(,(B*8!865A$"(B#"P
MLHI&$1$!$1$"(G4@PL+*P5 +!65@J1A$1$"PLK"D$1$0PB(@+"RL*06%E81
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M,W#7CGDD8]:<QRR[LL+DFR+7#X]G,$M^LM;:;79K1 _R^?!94M:S&6#F<X!
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M%/)1DL96LWGG>]$Y.",>)"[![F^UVB"AO]VL1OTL%QJ&N=475K6F=S=[+V8
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M>S &>?$KM"^(8HX(FQPQLCC:,-:P8 \ OM 1$0$1$$!KK[VI_P"^I_VS%/J
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M9&5Z?8-?_P#UQ<_T#_G6OAQJ)F=;=$8*\L6M;6_JZ"BY]]@U_P#_ %Q<_P!
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M+6V<V.?3^T=M'5EOE#K:Z9[6G(87.'FYZ\8YJWA5FLVB?T:?9J32;UM^G?\
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M, ^L#*6KKK!2^^DII$14:/D\EA96%,(%$:D^Y:/\]I_V@4NHG4GW+1_GM/\
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M7?5>O]758J=W3-LE%LI8 T$2S,),DF<9[!SZUDYW.M>[#=5;0=95=_O%ZM]
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M'XEMW_ZNWZEP+:;8*_5NNY;7HRQ,-%;1T,D\,;88ND."\N<< XX#AGD5^ED
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MO;=NH<ZV58C],Q.Q["N#,]%N.P+]!D9&#R7$M36YMJO=32QN#HP=]F/@M/$
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M4!KH*<![V'X><@#PSS6\SJ-N:L;G2IXKX_1=35'>_,1^8$?0A-Q>,8I:?/\
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M^"NI'<I(79QXCF#XI!I)+"RL*4"(B(81$0%A96%(+"SU+"("L+)6%*!865A
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MUQ:X-QGOXK2T+L[T[HRFQ::"-U:_SIJV4;\TK^MQ<>(R>.!PXJW(@(B("(B
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M@@-=?>U/_?4_[9BGU :Z^]J?^^I_VS%/JT^6&D_VX^L_L(B*K,1$0$1$!$1
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MH;5[I%8=F>HZLEL8902QQCD-YS2UH'K(4;LJT=;[=LXT_2UUKHI*ME(TO=+
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M+2?:7C<PUHP[N)/!?H3*$GM31M"6G2M@L]8:JTV:@HZD[V98(&L=QY\1VJ0
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MH&JH3#>+PP,I*5XXT5)\%G<7 -)_ZE=50# P. 1 1$0$1$!$1 1$0$1$!$1
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M_P ]6E.UOI^\+ N&^Z.TK8;;L\JKA06BBIZU]=3[T\<0#SO2C>X]^5W)<O\
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MJ86O$<31NQ-PX'D&Y]:]-O5H=JV72NE(J&67RVX"HGJFL);301@AYWAR+@_
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M)Y745U32FEJ)*N=TQG!<'.<_>YDX [,<%$OV.V84\E!376_4UCE<2^UPU[Q
M0>;1QR&GL!04;5]S;>-=;,W:?M4%UM+K7)5VZAK)NAC<_  )+@[SF-#< @G*
MG[=:M13[6[-?:JQ6JP/\GE@K&P7%DLE7&<$$M#6D[I [?F5XU%H"PWNSVRWO
MIY*-MK ][YJ.0Q2TF  -QPY< .'7A>.EMGULL5YDO,U5<+K>71]$*VX5#I7L
M9\5@/!O(<@@N2PLK"E41$081%A2"(B#C&VVGKZK:3LY@L];'0U[WU0BJ)(NE
M;&<,XEN1GVJ%OEHO57M*T_IO:7?W5UCJ!Y51NIJ<4\-14LR1%(,G! !(X\>
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1B("(B B(@(B("(B B(@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g762905g02n07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g02n07.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X6;B:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C
M(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/F<P,FXP-SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @
M(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C<FEP=&EO;CX*
M(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @(" @(" @(" @
M9S R;C W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R.#,P-#$Q
M)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" S,"U*=6PM,C R-" Q,3HS
M,3HT,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" S,"U*=6PM,C R-" P
M,CHP,3HT,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M)
M;&QU<W1R871O<B!697)S:6]N.B @(" R-2XP+C F(WA!.T=R87!H:6,@='EP
M93H@(" @(" @(" @3&EN92!#:&%R="8C>$$[)B-X03OB@*(@,3,@8FQA8VL@
M<G5L97,@8VAA;F=E9"!T;R!O=F5R<')I;G0N)B-X03LF(WA!.^* HB Q,#$@
M8FQA8VL@=&5X="!C:&%R86-T97)S(&-H86YG960@=&\@;W9E<G!R:6YT+B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE<RU2;VUA;B8C>$$[(" @
M(" @(" @(%1I;65S+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C;VQO
M<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @
M($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I
M;&4@3F%M93H@(" @(" @(" @(" @("!G,#)N,#<N86DF(WA!.U5S97)N86UE
M.B @(" @(" @(" @(" @<G(X,S T,3$F(WA!.TQO8V%L(%1I;64Z(" @(" @
M(" @(" @(#,P+4IU;"TR,#(T(#$R.C(U.C0Q)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(#,P+4IU;"TR,#(T(# R.C4U.C0Q)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#(U+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T
M)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N
M(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E
M<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE
M<RU2;VUA;B8C>$$[(" @(" @(" @(%1I;65S+4)O;&0F(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0STV."!-/34P
M(%D],SD@2STQ,B8C>$$[(" @(" @(" @($,].#0@33TW-"!9/3 @2STP)B-X
M03L@(" @(" @(" @0STX-R!-/30Q(%D],SD@2STY)B-X03L@(" @(" @(" @
M0STW-2!-/3<V(%D],"!+/3 F(WA!.R @(" @(" @("!#/3<U($T]-S8@63TP
M($L]," R)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C R-"TP-RTS,%0Q,CHR-3HT.2LP-3HS
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C0M,#<M,S!4,3(Z,C4Z-#DK,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R-"TP-RTS,%0Q,CHR-3HT."LP
M-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O
M;VP^061O8F4@26QL=7-T<F%T;W(@,C4N," H5VEN9&]W<RD\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @
M(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I
M9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:&5I9VAT/C$T,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*
M4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!
M*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB
M,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G
M9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X
M=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X
M9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%J045!07=%4B8C>$$[04%)
M4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(
M0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)
M0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%
M,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K
M<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T
M3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V
M63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM
M6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%5
M14)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(
M=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15
M:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515
M-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q
M*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/
M:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q>% X04U3
M8E=98E126#!R-B8C>$$[-7I'<S9D.6-7>6IL:TIT4')#+U=05D53<S-P*VY8
M;%AA;4MS0C$T*V%B-B\Q:412-VYZ07%.9E%Y45<Q>F(V<D)&3C9%57=L:FAV
M228C>$$[9G$U=&MU2'!X-"]U;#1O5%1N5$-R,'9Z8G%V;5A3<D<V,4A43%=Z
M=6)3>71P3&UC6$TP<U5H35-S-59!:U5I-W%V8SEC0W Q851.4"8C>$$[85%Z
M<V]6<%DQ8W%$54%S06%6,GA65GA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X
M5FIU<V5F9DPK:V5:8DQY-V5Y36UO-F=I4U=O*T-J;5=D8F1%549G-TYY67-E
M2VUI<5-A67%Y3$9867%K=FYB+R8C>$$[04I1>E@O.$%T;EAF+TIH.%942%10
M*T]B868X04='4"]!26E-5E)/2W5X5D1V<4YI;"]&<#=Z24PR84XU;W)C;C1M
M:FI+<7I!97AC628C>$$[84Y7>#1H9&1685=A2TI/8W)R1VY4:WA#:C=Z:4)B
M2G%'94-D3V--:7EP5VY*0T=&9FU-4T-/87(X0W5X5C)+=7A6,DMU>%8R2W5X
M5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8U1"M:
M3W9F52]Z63AQ5U%U6C!A4C=-<$%S,%5-4DTQ-#!*8FDP.%5K;"8C>$$[54QQ
M>4Q'=U!W,7)11$-R379Z13AX6'5H,FUI>C)T,4AA+U=T6C V>G5424502S-U
M3&A5;55&+W,O051U3G@W649E5S-V-7$O;7!(.28C>$$[8CE/,"]U.55M=# O
M8W!S.&8Q-S!R2&1D=68Q840T:CA2-3=(8UE697 O;4YR13EP-5HQ:3)44S=Y
M.%-B5')R;&,R-G=M2T]S5'(X6B8C>$$[95-.='5P;W R=TMY2%-J6%,W33!)
M<D)'84AQ4&='2V]R1EA9<2MA+U!E<BM91R].>31E,G9'9W9O3&E/>7-85FEG
M4TYW1E9A<E4P4"8C>$$[<45T.'IM-W=A94IW,F4V,U@U3D]$;#A4:4YJ6DY0
M>D-H+TYB4SE%2C%Q.$PV85I%4C5O<&M98VI8:5!S<$PR.$UQ,'=W;59J-VTS
M2B8C>$$[8T)X4VQT.% Q2U U86594%!O,'EE1%),9UA3>'ES-7-M3G1,3%1G
M=GAH2EI9-7EU,S=&9G9W-G9&06TK6'HO4G-I1353,VED=F=5328C>$$[;FYZ
M.'AO=GI$=&]T46MU=WAU-#%K,&AE54-01WIQ4VE2>D=I<7<V1FHY3DU09W<X
M33!">35U2#0R;T=B8UA(>3(K.'944$U8-7@V5"8C>$$[<"ML>71B5S!Y83%'
M-F]D3'9O,V=K44Y8-#,V<58R+UIB9DY:-%(K1'-2;FEF9C--9SAG*V$U9DY(
M;#5.5&UT>&)3*V\X5&]P2E%L2R8C>$$[9D5H3SE$6#<X:$M.1G1J2WAB23AI
M>61I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F59969V32MR828C>$$[6BM:6&PV>FAU2EED2VM&<S$K-G9%;'5G;'5(:G)C
M;SA%<GEH*U!'4&A+;G!T.%(R=W$Y36=N:&YH:FYG:U=71U91.%5Q14UR2W=Q
M<B8C>$$[2W<R24DV2$%Q+T95;#@W9CAO6G(O=T0R>G)V+T%*35!I<5DV6B]X
M>F)4+VI$2"]X15EQ:6-69&EQ;6)E03-#,T)J53-#23!A4S!(328C>$$[235"
M6E$S5VA+06ME,D=Z5DMU;&AI;%AH2VEY2C$T<T%2.7AW3%-886PU83!457)D
M66)M,%0Y,C-/0U=-96Q,12]W1%!(26Y&:V)B<28C>$$[1&QK37-O;EEO<#4Q
M<4]L95IR6'HQ6F%D<BMQ4&8K54QQ9T5T>D1%-DUA15(R,#=&3TE:;E5B+W1D
M<44W6CA*=T]->6E+>40X5V=J=B8C>$$[569Z5CAR1%-V3&A%5C%',FQ026M-
M3#-Z33EX66PR<5)B>3$Y4U-*:T)$4DYY239R6'!K9%!,>$IC=E8Y+W8X05!Z
M8U16-%1+1D$Q-28C>$$[.7DW.'-.5#%E=S!:-V%X=DDY8FHP='EL-7!S1&,R
M84)J5DQI>6MB:50S-5).,T(K>51L1V]X,4QC5F%D1UI#2$-46FHY,U%V471.
M."8C>$$[-F569%-V27)+>3%+1V$X;51N2&)G:T]25&M246=5641Q=E5::FU*
M8W-30V1:1DQS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:28C>$$[<G-6
M9&ER<U9D:7)S5F59*V9Z<#EZ*UE':V%B96%$<$=Q47I1,C=85C-Q5G)(8WI2
M=U-8;C%9>'AT27EH3U1Z<7EB8C!B6G5Y<C!M>B8C>$$[=$Q7>71)3$\P:5=#
M,71O,6AT-$EW1E))-#%#;VEQ3F=&555!>%8U-7%8-7%E64Y-<S<R9E503&M6
M=3EP9E$R3$@V-TQ,06YQ=RMU,"8C>$$[;'I00F%3:4%2;S!D9&U7<F9A1DU6
M5#,X>'9-;6<V9#5:,6EY=G(V1S)U-VY4<G(P24I'05HK551Q3TDY,C)X5FM/
M;$U','5Z6E151R8C>$$[0TUG*WA167%I<U9D:7)S5F1I<G-654PK=W1.47-P
M<DLX:5=A,75%36,P5&1#<'E56D=*<V,Q965E62],1W K6F1*9GE493-W:79R
M0R8C>$$[5T\X<SE1;%5Y1S5S;$12<7I52R]V14PX2E!O8CER33=$;6IJ;#1G
M1W@R<G5,6&MH>$-K;3!Z>71Q=C5E=F%$,6MV6#E34V$P=4DP328C>$$[6FPK
M14<U<TAR>2]V65EX2D1V.$$S:54W-5!.;$=E>4YQ+T8O<F%*67I#:4]9+T)(
M-G9.2#-8:W)3=% X>E=V;C9'-V4V,%<T=5!R,28C>$$[=VEG07=I-$):6BM6
M9FEI1'5#=V]#1CAA6F<X4G)H-G1W05!Q2$HV;T-#05%A9S=G:DMM,3)+=7A6
M,DMU>%8R2W5X5C)+=7A6<5%31R8C>$$[3FA'44I+2&=71E%$,G%!4E5F5&E&
M96)E8G9+9C5L86YQ,FY4,G5T9E996&(P8GA,0U,V=&]K4E$P;G%-;G%T56XW
M2'<P4%0U-7--3R8C>$$[8D1'2D)J9G9O;TE:-7!5971*1S0Q4U<S;&5O.4PV
M=$A)9T-G8CAV5651:S5H5$UF-&)3=V951#5G1W)E64AV-#E7:W8T3&Q*=DLP
M3R8C>$$[;G9C>#)C='9(1$=Y4GE02%<R0F5:6%=B-G=/:"M(86U25DQ.63@V
M9FTQ3%DS14=L858V5GDQ<F5Z5W0V,FTS5EAE0T,S:VE14E-3528C>$$[:&MD
M-7!O,3E5<T=-9%%R0F=-0V]36'IP*V%K5G5,97@P;6-Q.3=+6'97,#8O9'AB
M+W!/44=14C-,:V]H=$9$3$=/5&(P54QT:%9#828C>$$[>#4K+TXV-FUV;UET
M0W5)3$)D3G5P<F-X861Q2WEY6&9,:D1B37E/<VE/=G!S4DI'+T4Q2&E-5EIH
M-6(X-RMD3'973E5T9%$X=#-5="8C>$$[;D)+5G-*<F4R87I,4FDW=4E/8G1F
M>E%X=5!2:&EL*T)U6'@W2V-#<V5M,6(X>6LP*WEH<W1/,64V=#1V36MJ6%8S
M>%9,:#="3E9(;R8C>$$[=T9B;5-#6#!:3%$Q3&AE1DM";59E5D95;3%7-C$S
M5E!Z43 V-'9R0SAN=$Q05T1$1'%$844S*VEX=UAW:&AI9W9Q8T=G;4AX>7EV
M=28C>$$[=2]#;DQ9<3DU=TMK,7HU43AV,TLX2F)D>6I45#--:4Q03VEY4UA)
M2WIE<7%U0DMJ2V%C2'%T3F=.<U9A.#=F.&]:<B]!4#)Z<G8X028C>$$[-4U0
M:7%9-EHO=T%C,C O-'=X+SA21TMO;D9867$W1EA9<3=&6%EQ>$PX>6)S851O
M<U!M2TM'4U,X,&5D2EE7:D-N-$I#2355:W%19B8C>$$[5&M5.%=P5V@T=%1B
M37)3>#1P8TA34T-R5SDS62ME+TM$6$9R2&-754YY4S%J4$UQ3$MK<T0Q:FY1
M23!N,EI5,C,W64-$:'E585!E9R8C>$$[:7=W+WE&*UE';DIR32]K<E5O,6A*
M85-/2TUH:6E81'9397EP.%AW3$E8.4YQ,#0P1U=:.4]F<4@T2&4T3TA64D=1
M-'9X-W9X,%IT-28C>$$[8FMF5')Y-#AT5'-Z0WI55#9823%36'-M3D%P2DIQ
M64@O9&XO04-E4&IM264Y>G@S36AY2UA9<3=&6%EQ-T9867$W1EA9<3=&5G)Y
M4B8C>$$[;T%864M'255624939&=.*S5X5F1I<41B5W1'6%4P,'!R*S-8535"
M>5-W37%#9&Q!3%9%5F5:2$56-EEQ<DIE5V(S56QO:SAB6&-3<B8C>$$[2DQB
M:#%-:4DY47)-;&511&-446Y&5F)&6%EQ;S-T.5I71G!,95@Q>$AA,FM#.#5R
M:60Q:FI24BLP>G-1<6HU-'%S,#=63DTQ2S,K<R8C>$$[-F1D=S-T=GE+971B
M>4I+;DIE<3AK3$-O>%8U-W$K<69M4G O;C9X,'=A<$)C-E9Q139816-%5G!B
M23!D;CEA-%-X>7E3,V%Y:FA%>28C>$$[05-*0S-.;30P531Q.4QX5F=.>"MD
M9FLV,FQU,6Y%-E$R;#@K;DYC9S(X:4Y*0VMK:S=G4GI/-G!%:TI:=E564V%J
M:4=X5FMN;F(O;"8C>$$[1$YF+T%/,F1D+SA!2F@X5E1(5% K3V)A9CA962]W
M1&E)>%9%-'$W1EA9<3=&6%EQ-T961RMS<F$K<W W2S914U<Q>D<P53!:-D9(
M2"8C>$$[1F@Y>'=X:U%B0W-D.'57,%!L-U9P=DQ564MA9$UH=F1'1$=O54%H
M8FU!12]Y3W=K03A(4&AM4FQ02$AJ-CAJ*V=O96,K62])<6574"8C>$$[>D-S
M9DY-,3!:-TLY,4-3.&LO9&=#2FI.-G)O5'E.94U43DE$-$ED<WDT-7A015EG
M8F=6*VAW375N:D-9>58Q+T@V+V<Y2C@Y>E%A9"8C>$$[<&M0;4%Y3$9C85!+
M2F]I>' V<5-F0DQB+W=$4%94468U5D0R>E=X-VY/;#-P>G!/<C9D<3EH1G%'
M;E1R8U=K=W%K:2LR>$)",T)(8R8C>$$[2$%24U%B4FU"3'-69&ER<U9D:7)S
M5F1I<G-696-E9"]Y-3@Q-G$Y:W5I-C=,1D9B4T,U63-T>$MZ97-H+V1S9VI3
M9S1B-6LT<S!29"8C>$$[:'=.5G!C:S8T6E97-TY.0S!I9E0T83-&-V-89'A+
M:65S2G!42VEU0CA8<#%65%%K.3AO;$LS36A'=7)$4$TO-69E6G13,3=5=%$P
M:28C>$$[.&@P;'(R3U9495)45&,S8S)$,C%V2S!(1#DQ8U%Y3TM4=WI!;4UC
M0W!R:U=B2#50>74O3D=B6#E:,6XY3DI:,V5O>%=I5U5T=G%6-B8C>$$[-U=Q
M=V-J3D1X93-%8VMC:&MF:'E7:UIB:W$Q1D-Q:6)Z.'1V>D]-53AL;G)S8V5O
M,V1R0F)Y,UEV8C5(:F$R83A:0W)C6E!5,W59;28C>$$[4$E#=D)L055.6$-Q
M=' O:V(X,FMU-7!,,U<T-6)/95EY>5=+86QF07-R4S-:0TIC96ER=V5N2&-1
M531#:D=+:D-J131&5$]Z.&HK9"8C>$$[4C5$.'@V2'%7<6I5.54Q:7IM=$QE
M-'5R;6%325!.0SA44S%-5EE64$U(,&Q6<45F84YD;%=5955V3$UE:#)5=DXR
M;#%'+V1,:E4U,R8C>$$[8U-C-3%H4T@T4W%1<GA626Q685)R,'%26$98;E!N
M>E@O3#,O04-T5%%6270W=61*3$,P1%$V:G=L17-M;W1'56US:$Q'2FQH:U%-
M2R8C>$$[8VU2>#A3:V1&6'-72W-),5 X;V9+*W)/6G16:W5B,C9A6#%*3'%1
M=W)).%E79%!19C T;S%:3T8P-C%)-3!P.%=W>%9&+VU.-60P8B8C>$$[55!,
M3W-8=#5B*W)D5S)N6%AO>6,S6&IX:61H<W)!2&9X1TMS:3!P475L,F%J64-#
M340V14=+;W)&6%EQ-T9867$W1EA9<3=&56PX,28C>$$[-F9C,T9H2&4R0SAT
M53!Q45AL:6\V=55"16M0>6UI3$HX>40R>3=$24$P95(R+TAU5D-E63=',3@R
M*U1'87E#>6TT:5,W,#1U3FI);R8C>$$[-6]R8C=C=G-/4$%K6DQ&3'<X;2]U
M3$-C94E5:V5I5SET-3@O3&%05$QM-&MH;&=+5S X;T%-9V4S-'1'>G%E-WAL
M1UEB8FY";6E95"8C>$$[3%9H4$9#:GI',S0K.4UF22ML3#58=4HO2W)31V%)
M<CEE<TQL:%%Y2U%S8S9K1&%S8V="*U1$2S5'.3(V27):;4=16D]X5C)+=7A6
M,B8C>$$[2W5X5C)+=7A6:&9M:C@R+TM0;'DY:G,W<#5B<5-34#%/5FU)-555
M8VEV1FIZ5VIF1#!Z37<V2$IK1FIB,W1C<V]J>EI,;VUU-EIR5B8C>$$[:$)E
M,D5Y>5)Z4E)Z1U!K<&MJ17$X;%=25DQC5SA2;5!K>'EG84Q-1S!M,40X=V1,
M<U!-8C9&8U=D,DI)-4Q'2U,Y55%M,T1A:S!K9"8C>$$[="]U,S%D,VA:5"LW
M,C9N8F9+,')B9CA!36YY-60R5G1C5TAR6&LQ-V53-F9:5U532W,X<S!+=$DS
M15-.1V=1=W(V;V1M031%2'9I<28C>$$[2F)Z>'!C16UL=V%J8C-7;EAE<EA-
M;&Y"83--641P2D=3=DM1>'1);G!U+T959%=)675T3W5+<4=G9FU&<%=S-GDK
M:W!A6&1P9$$S<28C>$$[>&TT15!'439D8T,Q=65*:&QM231Y34MC9TMJ<&EQ
M1C%F.# Y0S!M8E598C8P=31M,#)30T]2;45#>'5,;C%21S1K85I5:E5M,V9A
M628C>$$[;W@K1V=02F%Q<W-S-W!,=7IG=6M6,%,T:E-656M5;S1$<4=!6E1U
M1T9D>&ER>#-Z8F)E83E++TUV4F]K=5I,+T%%-U5.471P-5I$628C>$$[5U-P
M0DA*9D9L='A);&Q.33-"45-885I#4'16<6-+=F%-0W!49&5B=DML<$9C>3-E
M=%=&=D9:>D,R=35*8FU&1FAN27%)<$-Z04DU028C>$$[<GA/*TMQ9FYB+VQ$
M3F8X02LR9&0O=T1*:#A65$A44"M/8F%F.%E9+RM):D955&ER<U9D:7)S5F1I
M<G-69&ER<U9E6C9F-51N,'8X028C>$$[3F=S,3=.1F\Q>D1.9F%B6D-2>$,Q
M=U-05VDT06AF9TUJ4T)13VQ0035S2EIU3$)Y.5A);W)D1V%7=CA!:'(X>F)V
M5&E1=6TK6EEZ9"8C>$$[5UDR05<U:DQ.26<V9&%U>"MA1$MP*W9'2F19-T@Y
M1&HO5&LX<&9E>6)Z5EDS571L1F8R0T8Y5#!U5#8Q84E/<V=!26QH,C,O04AS
M6B8C>$$[2R]/;FAM3$5U455Y,"LO=&11<UE,-C%F,4QE-5):26TO=T%L:%AF
M=U!I34)#55)I<G-69&ER<U9D:7)S5F1I<D,O32\U4BM54$U6-28C>$$[1F0S
M36-T<3A59G!"3$UX=V]2>4Q666-'<3-X9&-Z34]U>5EX43,Y-UA,14IC,E-A
M2F]/;#9,67=79&A!<V%1>%)W;5AI;VMK5TIE2R8C>$$[;5)L0SAM.%1M4&MY
M>6UB3$U#:VTQ5#AV3D@Q3%8Y5C%A831N4SDQ5WIJ<T1):3(U83-J:D1G4&)/
M.$QY4G5233E4>5!8,D9+,&].4"8C>$$[>6TX=%%A<3)P,D5T>' Q=TI)6C=:
M3$U7,%56=E!$0S!";&EJ15!(;$Q%-5=13GE6:#(R1D966%=V>7<P9E<P=51Q
M;#=D,U9Z3D1&1"8C>$$[0F5Y0S%-.7%96FUN171Q,V]5:6M:,BM)9V1!3FA1
M67%I3DPO04,V,$A4-V4K:5=3-FML,4,X;78W;3E363)L,%I*-51->65V66DQ
M:R8C>$$[369.>5%J12M(5$953G$S-5AA2'$Q>%!D86AD6%4Q-4TT8C9X4S%8
M:6=-;$EJ1W-!:&Q10V1H*RM2,C)"<E56>%9L3VY734=N-F9A,B8C>$$[14)9
M=U=K36-%4FM9=3532E%I.&U/-T=G,TIX5C56*UE/;5,V:"MB;6=T1EI094Y9
M<'!L=WIX,F-D,%E%+U-%:&%2<%=U;T=T,2M$9"8C>$$[,&AF<'8P1TMV6&-6
M958V<"M7+VUJ5DY4,4,U:W1T3C U<FDT:6QS-S9W=F)P2F]6=%DU63=::D5,
M84]+5&@V=%=I96]F:S-X06-2:"8C>$$[5FQ(-6HV5&8S9FQN5C=I1%=R>E0T
M661/=795<S=:3$YO<&%23U0V:&YT-352569#941R=#<W-$9:1G!123!U>D)*
M66E#3W!.2VXT0B8C>$$[-%EQ:7-69&ER<U9D:7)S5F1I<G-69&EQ5F5:3DAL
M,4]W071:0D1Q5G!)='IP,7<S4DHT-CAE5E R2$)+3U U4V-T>%0T5'9Y4$Y7
M1R8C>$$[*V9.5C O569*165V=%!(<&5S-DYC:5<S:6Y98S0W-C-.6DQ19T5C
M>7=8669T0VIF6GDO1D%X;5DX-&MF6C!,:39U44=->4IR:#,K3"8C>$$[32],
M4&U'>#AW84IA-G):3W)2,T-+>F]'1$=/4V=,>'14.7!4<V-X<'=-5%)B<T]5
M6DEI435&-35O03@T858K845L;F0K=F)E6&)U-28C>$$[=D1A4D4O-DMW8U-3
M>&E0.6M-9G151R]82D=J1E)F13E8>7!S9&ER<U9D:7)S5F1I<G-696-E9"]Z
M8VLP1V$Q:',Y3&QD<&=Z>4<Y:B8C>$$[;'1V:%4P;V=:4518>#=:6DA(8EA+
M9$UZ,$1Z0D1R3G%K.&1R8S(S2T]/5VQX0SA926M&9F=:9T9E;G1K0TM:9S)X
M4%A04&9M3%0O3R8C>$$[;#EP:U5-175K861(<#DQ9'0Y6&Y,>#)T>5IX9'I3
M6$EK.4=0,$5T=6%H:W$O=T)K8C<T17!2969N1G)53V<O<$$V5C9&+UEA;6M/
M<B8C>$$[-E101DUS-# V5TM3-E-A25 V5$-15SA:+UI9339S0G140W%N3"MB
M2&U7-G5:6# K1S)J<T@Q<5!3-T5T85A.,TY*8E1A63DO1F-H228C>$$[6F]Y
M,W$X5DMG2TM+,BM"5U)Y*V8W<B]$*VM88UES:G)%;6]A6G S;41456U%-U=C
M=#E02$).13-P3CA-:UIK3D$S:#-X5DYF3#)T-B8C>$$[,60V-W%L:&9I,&4Q
M=%9J83)N=$]9<$E78U0R-V5O5#9R455J-5-+1D98-#A146-66DAI<GI4>G(U
M83%,579Z2CAU86YA,DTQ>EHR>"8C>$$[9T4Y>D-Z:45',G57:V-4;&)Y,T,K
M;#EP05E*96)F0V%9<3E,>%8R2W!,-3(O=T-533$O+T%,6C$S+WE99D95>#!Z
M+VIM,FXO04)H:B8C>$$[+W=#26I&551I<G-69&ER<U9D:7)S5F1I<G-69&ER
M>6(X*W9,5G,K:')R16-R44TQ>$-,-DY63$I,=U(P:6M91&\V0FEO2G!7=$-E
M;28C>$$[8DQS+TIC=45I,T@Q1T-/5TY3-4E4.&TY5FHP2S!G<UI,;UA/:6%X
M3WE7;#-X2T-$549!<F)Y03%P-C!957!V,4)P,7@Q=4\U8D-I4"8C>$$[=6%C
M14)H4$0O0V58:V4W-'-R,5AZ>C5,,7)52E!+;C%U5TQ6:&-M,V=K4THV=S-C
M3&M+-E!3;%5D9DAF-5IJ+T%*6$E).&1B5F)M128C>$$[9W Q<&9M:3-3,FYG
M,3)A2%0Y4S O:70Y-G)I2TIG>&]K.&)/5D)J;#=E0BM(<4UX>DAU5&%D,CEX
M8C--0U0R.'%445-$;$A,1W=D1R8C>$$[2&E'1E%C:6Q5>%8R2W5X5C)+=7A6
M0S,K:S98<4%J1B]:=UA9:5!+251X<$QX2C=R>D)P,'=G;W!&04%#9S9917!F
M8V589DPY>E!D5"8C>$$[,T]M5VLP.3E'24PR5U-#3C-M:5@W36-R1E-8554R
M5G1S5E=4959V3$4Q,SED;3!I>6QV2WAN-GDY=D4P=%EL2U(O1U8U9D%R14QV
M<R8C>$$[3VU+<D(U4CAQ3&-,8W)O=&=,:$I6=49M1G1$>D4P83A5:T1C83@Q
M6%E.,4%X5D<V:'!E;6%L16M/;S)K3C5$2$ES,&-D>$=K<7)):"8C>$$[<6IG
M3T-!>3EJ,GA61#9:-6(X=3964&-81VPV6&%71GAD;70Q3F%W4E%V2V%K,6M:
M1E5V=7A/*TMP:FER>DMY+TQV5E@X.'HK8615,"8C>$$[=E1:+U%V6"]!14QB
M>%-M4#9V0DI05U,X:U%12#%R<5)36DMT2CA046(T<3E.>%9G2#5V95903EAM
M2W@P;4QY+TXV8VQT9%-35&9'128C>$$[-$8W85=+1V8T:4$S;WEU<E4V.7AU
M35944#AX=CA2+S1:,6HY2&95+W%0-D]U=G)0,6HQ9E8O=6XU8T](=R]:-E8W
M-'%Y3%-U6#9,<R8C>$$[*U9/6&]2,7 P<G='2V]R1EA9<3=&6%EQ-T9867$W
M1EA9<3=&549R96HR97,V5&0V6&5,>71R=4UX>54V:792:#=Q845E*U1X>DU*
M0R8C>$$[439+:T=R+VQJ-5<Q1%-O<D)9;G,R:&A30T\V='IW:TM206-05C(T
M>3A307<U0V]/-&]C=6IQ<&<R9#)%-$-1;W9%53!N5V9+=C5J4B8C>$$[,VUQ
M=S-&=W-&-TQ/;#E-:GA*9&5M>%IP03=++UAQ>#9$<5149DYO331Y62M%8E=+
M8T=/56I*=WE"<G8V1FU(-7<V=$1R4&QM>C%"9"8C>$$[3&QI94=B.3-F*W)A
M>7=T1S1)6E5K=#5*=617-&UM,EE7;C S<6]N-R]W0FIM>F]H3E!Y>C@X-DQO
M=FLV>'1.6%,W<W%S+V]81'=45"8C>$$[451'4GDY25AI:F)P>3-5-5AN,'A%
M<4)"*TE(-E5X24%1*VIF;71C>F9M0F,V9F1A=6MM9TDP;C%52EIY*W1+869$
M1'A74#%!>58K228C>$$[;%)8:C<U:UI.1T)I0D5F5C<Q17AB34YB+TY(>79P
M1G%T>DUT-4Q'>D)$=W1:531K9VM6331H6'0R3UEU4%)Z:V$R*V)+,513+W=!
M>B8C>$$[4$ME;U=59#)*-6)D6DLX635O;C4P0G!8-$$V-SET.$4Y2D]*<$YR
M9$4O33-Y,7)7=2]O4WA&>3$V3V9)=$5644--16QI,61G93-Z1R8C>$$[3U13
M5&A(:4Y5:3)76FI*9&ER<U9D:7)S5F1I<G-69&ER<U9E6%<R<RMC3E<X*U!B
M,C$S4WHP:3A-3V]14G!*>E="<FQX1C9K4FQH4R8C>$$[<GAP+V5C6$A"9WEP
M549G5F5O-$9D:7%3*V1V*U5-,2\O=&Y89B]*:#A65$A44#A!:FTR;B]'1U O
M:4EX5D4T<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<6A.53!N5&16
M=$=T3E%T,'5B9&E'-$]/:DPP6E-.,5ED;4<T=WAK4GE9>F=*0VDX=3@U+VMH
M9#,X56$V1&5W;R8C>$$[;VQ-:VE8;TMV=40O04QU:%%T2C$O=T(R2U<O>74R
M6C)(5S$Y5G5&;C!K<$%#2C5'.2\Q+W)T9#5C.&]E9G1!,$EA3DES;'IA:&Y-
M:R8C>$$[3G0K:C=M0F<W5C)J=D9T,S,W.'!0-EDU33)/8W)R-R]!3D1,1$-E
M3TA$5BLT9R]F5$%.13AT;3$X+U0R,FXS=#=A-G1P-3EE2E5S628C>$$[2C5&
M8S$U;UEK=6U3:6AH.6QM*U%Z3'EA<3AD165K*V8W1VI(;4)Y;4EV:4AU+U=N
M9C5R83$U=UAY+V(R;7 S17,Q;DY-=DYP8D$R3"8C>$$[3WEQ>$%01V%66$AE
M;$]V>7EN4W=X.%9I=U(U,RMG3G5O,4IX>#1J.7E0.$%Y+SA!3G8U9W@K5DQ3
M3%1R84,V=$EI-E%V3F$S.'I"5B8C>$$[62]$-FM#<VQ&-D%D:'1K32M,1THW
M,SAW>GAA9WEI0U!U2U,O;&@U:SAW6'8U=%%Y6',O2U<O.$%8:79J-F%Q6%='
M0U)K53%534%R4B8C>$$[<C<W0W5:97%J:CA$8G!334]9>6Y4-DIZ4G5A-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&56LX.$5J>58U9TE"66I48G=H4E-P
M+R8C>$$[8U!S2S!'2W!B<#-M<EA6,"LR03AM-G=W15-!34ID26]F:$<T<G%!
M3TMO:B]!0EIR,R]5;6%Z+WE/,&8O04QY1TMU+WA:<C,O049*;28C>$$[<R\X
M04DW4B\K.&AI<G8X049M=F8Y4UIR4"])-U(O.$%V25EQ:'12."LV;' Q;DIE
M,W9L1%=9<F%+;G%397!P1%4U349'>39G5#%)-R8C>$$[67%I9CA783DO=T)3
M6G)0+T%#3S!F+W9)67$W+T%"6G(S+U5M87HO>4\P9B]!3'E'2W4O>%IR,R]!
M1DIM<R\X04DW4B\K.&AI<G8X028C>$$[1FUV9CE36G)0+TDW4B\X079)67%H
M=%$X*S9L<#%Q8G$X.&XV>D9!2&IJ3"MP<$1F1DY)<U-#:39G5'4W9UEQ:68X
M5V$Y+S%*;7,O."8C>$$[:G1(+T%/.&AI<G8X5V$Y+S%*;7,O=T1)-U(O*SAH
M:7)V.%=A.2\Q2FUS+SAJ=$@O04\X:&ER=CA783DO,4IM<R]W1$DW4B\K.&AI
M<28C>$$[1W9V4'5P5T-24UA8:R]763!M;6ET-&HV;6M.5U=:>$A'=G<V9V9T
M37=&96U+;T<R5S-T=%5/<3(O=T-83V]X86MZ4$EB>%@P65-L<"8C>$$[2SAY
M5R]31F9I-4=U5$]34D98<S%$0D%3-&=">&0V-WI!+SA!:4<R:G1T6CAG-G9D
M=U%V-FMA3F-A571';U)7<6%K<#9(1T=356538R8C>$$[=4=/459)5T9F4F11
M=61%,#E.4#!V>4IR1G1:>&QM4TE4-E-W0EDQ3S<V:7@V*RM#57I),E4T.&-9
M0V\W0FE/9S92-3 P-WHO04@S;28C>$$[;6)Y,W%-<U8K6E)*84EU:G%55B]S
M8T@O045L<W=O3U15*TQF>'DR5U5'06I82GAC5VUN2$MC:&Q9;#!R-4TX9S@U
M,U@V53 W5#E1."8C>$$[=39N<&8V56UE,G1B<35F5#-I.59,95<U-'0Y5W4W
M:5%6:G0S;V5&2S51-7)*8U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-64U1Z
M<B8C>$$[<3)J-E0U53%3+S%M2U=F4V]R9'AE=W=!;5)O6$A"=TM-;$YM-CAH
M:7)T23AY5TYZ<F0Y-65J=&)M,75D3&AI;$)N44Q(3$)).&M34R8C>$$[4DYY
M6FEV3T)X.%%"3DMI;S-X5D\X5F1I<G-64TQZ='%E:#9F;TQ0<F--:RMN5'HR
M.7,X8TE03&Y036E25DE:0T(V:%=P<FEQ>GDY-28C>$$[-#!,6#<K-G-D4&1Z
M3F%Q,&Q854):66QU6G)2<$EY0V%Q2C=74F0V2&]E:$=+<V=X5C)+=7A62E!/
M;"]O96YE5S=Q*S%Y3C5.371M9R8C>$$[;&U73V]02EHP35161$I13$IX3$5S
M1D$S8F%U2V]Z461A=&1B,&DR,5<P5C!T<G!3.%%L041C47A7=G=L;$E.2W%Y
M:V=J8T=M2V\O1B8C>$$[6%EQ-T95;#@S6"]L-U1T1T]O-BMW5WAS<&]:,$Y7
M0DYW:W%M04M&235-6D].0C X9'-65%-Z=5)D5VM6>45-66U53W%->4U11T92
M."8C>$$[56)3268Y:7A'2W$R2W5X5C)+<$PU<W9D0C!R5% X439Y<$U'9T=3
M+VAD3U)D6D)"3$%3<7%12%IO<&Y50G1T-CEQ:%9.8E,U:G5R5R8C>$$[1S5J
M<4DU,%=203)X-'5!=W(Y*TMQ=4MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5FIV
M;7)Y3&\S;5<R=F]B>6$W9V)53%0Y2#-%;'9/-"8C>$$[06=,:5%H65I0571W
M+TEF8CE0;%1A=$U65G1&.'$O;W96-R]5,C%7*W8U=%%)36M6,&)F,# T,$$T
M0T-'13=!041K5W R-FUQ<659<28C>$$[-T9867%X=GI&-4(P9EA)-W1:<FDX
M=&YV<#=3-'58:&Y:9U=S2%8T46M5+W)1>$1K9S5E;6EL=2M+<6YL>GE.;UAL
M*RMU8C-4,6LY828C>$$[-5%X56M934DT;75:<G1O-#9!9D-:-W%2=#9N;T]G
M1TMS9WA6,DMU>%9)+TTO:S=2+TUI44151W5%93%B;$$P13AK86<X;&8Y-4-#
M628C>$$[2F=41TYP63)&4&YI<4LX=6%"6658.4=T=$DP.$U,4S%$0U!M450X
M8G1),S)1<6HT;4]W04$V055X5DUS5F1I<G-64T1Z1#5),%!8<B8C>$$[<4LX
M=E1C3&57-6=A,VQI;FM#23%T3TQM2FAB<U=T;5E33'5Z4FMK8F1-5E(O;#=1
M<D113D1S9$8P.$U,3%0T5F=G.5)U5#A51DMS,R8C>$$[8VY&57=X5C)+=7A6
M:DAM-SAU9DQF;71:5'%H=D9L:W0S=%9L='(R-F=#239U:%E1<$E)1V%K<F9B
M:F%O,F%O,GA6:T9H6GA73FIB,B8C>$$[54I9=S)S4U%X;5)I-VQ9,4-J:W@S
M63!'-4]+<2M+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W9$=D](-28C>$$[;65B.5!G.#!.8C9I12MQ43-S*VM8;'%,5V%"4D)D
M>%%R1E!&2D@V,$UY8VEV-WIK<VQ35G!40W%),5!Z<#5X;C%Z4SE(,%!Z04HY
M4B8C>$$[,4)D65(W54A4-4DT<FDR:6=.;6I4*V=!-F9V1$DS16-I<E5P55EQ
M;3)T+VUF<F1J<5=J5T0R5C%(0V]P<DXP3%=3,VQU3&A*-V4Q328C>$$[9&I(
M9%(P:VHU,UAQ:V=B>'%E2D9$:7%8="M92&U7,FQD>G)55C%P:S-M2%-R8E0W
M.'!B3DA.<#DV-DQC4DQ*1W-3:&\V3UA"5&Q'0R8C>$$[;TQ%-S1Q:F90,VYZ
M>D1O4&YM1T<S=35','E&=$XY6%,T;V](861B;4A62DIL5FU1>3@S87AI5F5,
M:CAC0W5S=GHT:'5V359T;TLV3R8C>$$[<3-6>$I:;W-H=7@V8G)E0D-8:%EX
M05 V4$UI46)B:6=Q8TMO5'IL-3DX-39.<79N2S)S<C%:-TY,1V5F4F)R,#1'
M6%0W:7AT234W:28C>$$[3U5H9FDY5#%X-F9Q02]&.$]"5U@K4W1B,5,K,7DY
M=')M+V$K=$8P9E(W,D%S<TEP3F1M-T4W0F]5:G%(.4).:E=N86U+<WEX5C)+
M=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!81BMG+SA!16QZ-B8C>$$[3E P
M-3E6:"MU8T]D9G$S3U0P4%9P.$@R+U8T8W0O=%4W-'%K=FU0+T%*5C<O:4]$
M.4]C9C!V=W1F5#4K=C9F2#$R*W)E<'@O8R\S,R8C>$$[2VY0-F1S5EID:7%6
M,E V1"]4,G!F5G%F<&XP-V8Y23AU9G%E:E=8-G8Y=F)H>3E8:G@R<GDW,7A6
M3DU69&ER<U9D:7)S5F1I<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7(O+UH\
M+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-3@Y9C,W,3 M
M86%E-2TV.31B+3@S83(M9#,S86(P,S V-30T/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C4X.68S-S$P
M+6%A934M-CDT8BTX,V$R+60S,V%B,#,P-C4T-#PO>&UP34TZ1&]C=6UE;G1)
M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$
M,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD
M969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HP9#(S-3AE9BTV,F(R
M+3)A-#<M.34R92TP,#$S,C@Y,6,Y8S \+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,&0R,S4X968M
M-C)B,BTR830W+3DU,F4M,# Q,S(X.3%C.6,P/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z9F$T93!E8C M8C Q
M82TU,#1D+6(X8S$M860W,S!B,&1B-#0T/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T+3 W+3,P5#$Q.C(R
M.C0W*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R."XR("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-3@Y9C,W,3 M86%E-2TV.31B+3@S
M83(M9#,S86(P,S V-30T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(T+3 W+3,P5#$R.C(U.C0Y*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^
M4')I;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" @(" \
M:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL=7-T<F%T;W(\
M+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" @(" \>&UP5%!G
M.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/
M=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R
M96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @
M(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @
M(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXS-#$N-#<W-#DQ/"]S=$1I;3IW
M/@H@(" @(" @(" @(" \<W1$:6TZ:#XQ.#,N,3DW,C P/"]S=$1I;3IH/@H@
M(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @
M(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G
M.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<RU2;VUA;CPO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1I
M;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A8V4^4F]M86X\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q
M+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/E1)4E]?7U]?+E!&
M0CL@5$E27U]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1.86UE/E1I;65S+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4:6UE<SPO<W1&;G0Z9F]N
M=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O
M;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R
M<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET
M93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9I;&5.86UE/E1)0E]?7U]?+E!&0CL@5$E"7U]?7U\N4$9-
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @
M(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L
M="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-C@@33TU,"!9/3,Y($L]
M,3(\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT
M:6YT/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXV-RXU-S@Q,#$\+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C,Y+C V,C4P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C$R+C$P.30P,#PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/DL]
M,3 P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^1U)!63PO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)A>3XR-34\+WAM
M<$<Z9W)A>3X*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,].#0@33TW-"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#,N.3@T,SDY/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^-S,N.#(X,3 Q/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STX-R!-/30Q(%D],SD@2STY/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M.#<N,3 Y,SDY/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-#$N,#$U-C Q/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXS.2XP-C(U
M,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIB;&%C:SXX+CDX-#0P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TW-B!9
M/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT:6YT/C$P,"XP,# P,# \+WAM
M<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^-S4N,SDP-C Q/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S8N,3<Q.#DY/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M0STW-2!-/3<V(%D],"!+/3 @,CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ
M,# N,# P,# P/"]X;7!'.G1I;G0^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C<U+C,Y,#8P,3PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C<U
M+C<X,3(Y.#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$
M1B!L:6)R87)Y(#$U+C P/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  8$!08%
M! 8&!08'!P8("A *"@D)"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G
M*2HI&1\M,"TH,"4H*2C_VP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" +G
M!6@# 2(  A$! Q$!_\0 '  !  (# 0$!              <(! 4& P(!_\0
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MK4?'+&Y'->U>2HJ<%0]3PM])#04--1TK$93T\;8HVI^2UJ81/@0]P@
M
M
M
M                                !1KPA/;AU)_61?0L+RE&O"$]N'4G
M]9%]"P+"[=I_@JC_ *EG[*&48MI_@JC_ *EG[*');4]?4>BK5&WIJ;[KUJ]'
M1Q3OW6(O)9)%ZF-YKV\D"(D\):6HU?K/3VC-/Q>-7&'>EF1O*-7XQO+U(C45
MR]RH3=I&P)H[0M'9[<SQF6AIEW414;TTO%R\^6\Y5Y\LD=;/+]L\TE3U574Z
MMH+A?Z]RRU]QD5=^5RKE4;PX-1>2(==I?:1:[\W45TBJ8(M,VIT<3:Z1',Z1
M^%61>/Y*98B<,JN>>4"JJ7C9[M&ME347"ILMU9+(]TTDM*[I%WE555?Q:KUJ
M=!LIVT7[3=[IZ'4E;47"S/D2*9*I5?+3\<;S7+QX=;5ZN6%+6Z8U38]44SY]
M/W.FKHV+A_1.\YG])J\4]:$)^%3HVBJ:6SW>VTS&WRJK64*MB3#JG?:Y6Y3K
M5%:B9[%] %A&JCFHYJHK53**G6?IBVFF=1VNCII';SX861N=VJC43/S&4$1!
MM6VU,T!J=MG=8G5ZNIV3]*E7T7LE<F,;B_F]O6<=Y447\DG_ /F"?9DQ:IV<
M:4U5<TN%_M+:NL2-(DD6:1OFHJJB8:Y$ZU-/^!+9]_)V/Y3-]<*C7RHHOY)/
M_P#,$^S.EV<;>(]::PH;"W3SJ):I)%29:Q)-W=8YWL=Q,YW<<SI?P);/OY.Q
M_*9OKE;?!T8UNVJSM1.#5J,=WXF0"[  "
M
M
M
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M_0R!877  0
M
M
M                                                         I1X
M.WMV6GTU/T,A=<I1X.WMV6GTU/T,@6%UP $
M
M
M                                                          ,>
MFKJ2JEECIJJ":2+'2-CD1RLSRRB+PY*0#M/HM=;3=1W6TZ7<VETU:YO%)'OG
MZ)M1,B(K][&5=A5QC&.&>:F;X-FEZ_1VIM9V:[/@?5PQT;G+ Y7,PY)')A51
M.I>P"=HYHI'RLCD8]\2[LC6N158N$7"]BX5%]9]D-;;;FS0%]L.L+6O15%35
M)1W&!JX;60;JKER=;FXPCN:93JX$R1O;)&U[%RUR(J+VH!^@
M      4H\';V[+3Z:GZ&0NN4H\';V[+3Z:GZ&0+"ZX "
M      #7WN\45DI8ZBY3)#%),R!JKUN<N$_S5>Y%-@77Q3<3.@ $4
M
M
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M)=I^SVJJX['IVVNL$\[D;''+"QB3NZDWVJN7=F]Z$)F   (
M   %*/!V]NRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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MJWJREJZ>=Z)E6QRM<J)V\%,D\S&O+V  @
M
M
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M>@E3DO-J];53J5#8F-D
M
M                                           5(VW[2-4W/7UPL&GJ
MROI:*AE6G;#0JYLDKV^R<Y6^<O'.$Y81#A/&]I'NC5_^.I)RN6J=)[/=N%XK
MY:U'I<HFPU\+:>19*.7#7(]%W<.8Y,91%5<KW'8_AWV?>_4GR.;ZH55GQG6+
MZVWMU!-J!U$M5%E*YTRQJN^F/9\,E]2&=5[:]#7&SNH:)ZWBHJ)8HV4LE/)&
MQR](WSE<J)C'/THA,P  ! HUX0GMPZD_K(OH6%Y2C/A!*B[8=2*BY3I(D_\
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MYWG?!AI,AK9/O-G']T !X>P
M
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MWB>SK@ >'L
M
M                               0OI&LT=1[0=9LU0^VPZE6Z.=')<=U
M%6G5C>B2-S^"<.I./+JP2@R[:?6/S*^U+'CJFCQCX2-MN.QYNN9&7:S314M\
MC8D;DEX1U#4Y(Y4Y.3J7LX+U*E>:C8SKZ"I6!=.SO7.$='+&YJ_WM[ 58#;C
M7Z$GT=71++:*B^O;B@;2*Q]0DV?-5%9Q1,\\\,$QTJ2)31)-QEW$W_3CB5XV
M,;!ZJT7BFONLEA2:F<DE/01N1^'IR=(Y.'!>*(F>../4MBP@
M      !2CP=O;LM/IJ?H9"ZY2CP=O;LM/IJ?H9 L+K@ (
M                         X3:#LYM^IX9:FE;'27?&4F1,-D7L>B<_3S]
M/(KO?++<+'6NI;K2R4\R<MY.#D[6KR5/07#--JO3=OU/;'45SCRB+O1R-X/C
M=VHO^76;_%YML7V;]X_9YF%1#TIX9*B>.&!BOED<C&-3FY57"(9VH[1/8KW6
M6VJXR4\BMWL8WDZG)Z4POK.WV#V>FN.K'U=2]BNH8^EBB5>+GJN$=CL;^M4.
MSDRQ3'.3X/.DWZ)L,>F]-4=MCPLD;=Z5R?ER+Q<OP\/0B&\ /F+6FTS:?BR/
MB>&*HA?%/&R2)Z8<QZ91R=BHI">T/9"C&2W#2C7*B><^A7BO?T:_[J^I>HF\
M&7!R+X+;I+Q>D7C4JZ;.-I5;INI9:M0+++;&+T?GM59*94SRZU3JW5Y=78NQ
MVZ:TIKI3T-IL]2R>D>U*J:2-<H[/L&^KBJIZ.P[+:?LV@U*Q]?:61P7G*;SG
M.5K)D1.2\%\[EA?A("HZ6GMFH$I=34E4V&)ZLJ88U1DC>],\._O^<ZE*8N3/
MJXX^U'F'/Y=<TX_2K\?C^34'ZBJBY3@I8BV[)='7*A@K*&HKIJ:9J/8]LZ85
M/\)Q.U39BW3E(RYV-9IK>W#9V2+O/B7\[*)['DG<OIX8Z\BEK=/Q<?+[.S8J
M3>?$?))&B*NW[0]!PQ7F)E140?B)\^S:]$X/1>:*J87/I0CO6>S6Y:=C2MMT
MKZ^D9YSWL9NOBQUJB*O#O0V'@]7*TT]35TDDTL%TG1$1CY$Z*=J+E,)CV:97
MKXHOI)U7BG$T<O\ +O,1X=[AW]?!6UO*'=G.T]SY&6[4\S<+PBK7<,<L-?\
M6^'M)@C>V2-KXW->QR9:YJY14[44B3:'LO299[GIMJ)*JK)+1]3NO\7V+_-^
M#L.8V<Z^J-,3);;FQS[9OJCD5,/@<J\53M3M;_[7Q-8M&ZMB+37M980'E2U$
M-731U%-(V6"1J.8]BY1R+UH>IB90
M
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MP0                *4>#M[=EI]-3]#(77*4>#M[=EI]-3]#(%A=< !
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MX@(_V/:KFU!:)J2X/5]=1;J+(O.1B\E7O3&%]7:2 89C4Z9HG<;  10
M
M
M     4]VK:%U)JS:SJN;3UIFK889XF2/:YK6H[H6+C+E3*X.:_ QM _DW/\
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M[LKZU4[$UKSN6S2-0  \O0
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M/5E;/)45,M/F261RN<]R.5%557T'8R,;)&YDC4<QR*US53**G8<Y9:*V;/\
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M#*RIN&RK3]57U$U34R1R*^69ZO>[\:].*KQ7@@,?P?O:?TW_ %4GTKP!(0
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MRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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MX\%+;[3Y9H /#V
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MRT^FI^AD NN  @
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M5(B,E15XO;U/]?7W^D[8\3&IT]Q.XV  B@
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MF-]*:!L6]CEG=1,\U^$SP /"NHZ:X4LE+7TT-33281\4S$>QV%SQ1>"\4/<
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M4_0R!877  0
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M>EIG=_-S/UJGK,MOM5VQ5^S.DR@ Q,H
M
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M+R@  $                "E'@[>W9:?34_0R%URE'@[>W9:?34_0R!877
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M+UZ96ENJ  'EZ
M                                  >=1/%3023U,L<,,:*Y\DCD:UJ)
MUJJ\D.0BVI:(DK/%6:GMG2YQE9<,_P :^;\X'9@P(KQ;I;A!0PUL$E5/ ZIC
MC8[>5T2*B*],=67(AG@   !H;QK'3UFJXJ6Y7FBAJY9&Q,I^D1TJN<N$3<3*
M\U[#?                       &LO-_L]CZ+[LW6AM_2YZ/QJ=L6_C&<;R
MIG&4^$UOW_Z0_E38_E\7U@.E!J;7J:Q765([7>K962+^13U3)'? BJ;8
M  ^)XF3P20RIO1R-5CDSC**F%/&V4-/;+;24%#'T5)2Q,@A9E5W6-1$:F5XK
MP1.9D@   ,.\6NDO-NEH;E#TU+*K5>S>5N=UR.3BG'FB*9@
M       "E'@[>W9:?34_0R%URE'@[>W9:?34_0R!877  0
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M5R+#!(_Q:K8_\C"XSZ47YLF6/M5U\88ONV_*5D0 8F4
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MW0]+AKW*JXX.3&>SK/WPGKCJ/3]DHZZTZCK*6DJJGQ9]+ UL:M\Q5RDB)O\
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MJU+16FAC6&K9#-;WIF.KB=G>1&JO![4XHY/7DGZ![)(8WQ+F-S45J]W4!]@
M(                %*/!V]NRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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M;VR,:^-R.8Y$5KD7**G:6]=2E)W#] !X>P
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MPY?0BIW8 V/A4U'2;,9(Z:5KUCN,+*AK795B*USD1R=7-B\>U#<[/=&Z(O\
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ME#:+;;W;U!;Z.E=VPPM9^I#-/*EF6>FBE=%)"KVHY8Y41'-[EPJIGUGJ$
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MWD^')N@@  !2CP=O;LM/IJ?H9"ZY2CP=O;LM/IJ?H9 L+K@ (
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M$3[$]73UR26.XRNEDB9TE-(Y<KNIS8J]>."IW9["6#7M&ITV*SU1L !%
M
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M(7<*4>#M[=EI]-3]#(!=< !
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MVR1M?&Y',<B*US5RBIVH8,OG;/B\:?0 ,;(
M
M                                   IKM6U1?-);;M17"P5T]&]9HVN
MW>,<F(F>:YJ\'<^OM)6V;>$':;TD5#JV-EIKUPU*A,K3R+WJO%GKRG>;"QS:
M=O&T?:%I34D5).ZIJH*B&"IQ^,_$,:NXOYR83EQX\#@=I7@ZU5)TM=H>9U7
MF7+03N1)&_T'\G>A<+WJ%=!MEV:62WT=#JW2;&4+HZN!9XZ5V(9HWR-:CFHG
M!%RK>7!44L$4(L6H=265ZZ6J:BJ@H)ZF%E105#5_%N;*UW!KN+%RU.6,E]P
M "   '/7W1.F;]4^,WBQ6ZKJ5YS20IOKZ7<U.A &JL6G+-8(W,LEJHJ!'<'>
M+PM8KO2J)E?6;4 #4:@TS9=0MB2]6VFK'0KF)\C?/C7^:Y.*>I3ZT_IVSZ>A
MDBLENIJ)LJ[TBQ,PZ1>USN;E]*FU       *4>#M[=EI]-3]#(77*4>#M[=E
MI]-3]#(%A=< !
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M^#)7[5=,<_9MM9<'Q!*R>&.:%R/CD:CVN3DJ*F44^S$R@
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MLIYEPRLHZA*B-WS)\&<]P$R P[-<Z*\VRFN-KJ8ZFBJ&;\4K%X.3_+T=1F
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M)U;IEM/=JE]NJZ>GJ(EDCI)7OD1%>B91%8F43/$N,   0
M *4>#M[=EI]-3]#(77*4>#M[=EI]-3]#(%A=< !
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M:CF.:N4<B\45#U>-3MYQSN-2^P >'L
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MIM.P>(VUK5X2U35229>]<)N>M%ZC:>"EJW[JZ1J+!529J[4_,2*O%8'KE/\
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M+S7&43BJ>FP[:+4Z0NS-":RH&T&)>BAF6)(W1R.7@DF.#D=PP_O3*JG% LT
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M]NRT^FI^AD+KE*/!V]NRT^FI^AD"PNN  @
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M]'PRL21CDY*U4RBGJ8F4
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M                "E'@[>W9:?34_0R%URE'@[>W9:?34_0R!877  0
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MCXP\8Y[:EE  QL@
M
M         .#VC[*].Z^F@J+LVHIZV%NXVII7HUZLY[KLHJ*G%>K)L*/9]8*7
M02Z0\6?+9U8K7)([+W.5V]O[WYV]Q14Y<"MVVO6.J]3;1+GI^PON7B=!(L$=
M'0(_>D5O!SW(SB[CGGP1,=^>'^]W:%[U:I^(G_<%3;'X/FG=-U_W9O\ J*>:
MRTTC7K3OIMU5RY$:UST5<HJJB<&IG/46(1,)A."%"66;5]+6T$U\M]]BHFU4
M6\^KAE2-%WTQE7)@OL"0 !   ")]KNTZX6"N^X&C+7+=]1+&DDK8X7S-IF+R
M56MXJY>>.2)A5YDL&JL5AH[*^X2TJ/?45]2^IJ)Y517R.<O!%5$3S6IAJ)U(
MGI50JC;]O>O++>59?DBJFQOQ-1U-*D#VIUHBM1%:OISZ"UVE+]2:GT[07FW*
MJTM9$DC4=S:O)6KWHJ*B^@KYX8E#11RZ<KF,8VX2I-$]R)Q?&W=5,^A7+CTJ
M2IL#MD]DV2V2*X(L4CXWU*M?PW&O>Y[<]GFJB^L*CS;EMDONE-;NLVG%I.BI
MZ>-9UFAWUZ1V78Y\MU6?"< SPA->2/:QBVYSG+A$2DXJOPFQL&WAECNE]D?I
MZ*XLN-QEJUF=4;C]U<-8W&ZO!&M:A,VS7:UI;7%4VA@A6WW54RVFJ6M_&8XK
MN.3@['9P7N D*R)6I9Z'[K.8ZX= SQA6-W6])NIO83J3.3- " ,:HKZ.FDW*
MFKIXGXSNR2(U<>A5//[KVWWPH_CF_O S2E'@[>W9:?34_0R%RONO;??"C^.;
M^\IKX.J__P!Z[3Z:GZ&0+"ZX "
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MHGY/77'S=V#\8YKVHYBHYJIE%1<HJ'Z>7H
M
M                         !".KKS8=ENU::_SU4;X[] D=;11IO3P.;[&
M9J<MQ=W"HJHN>*9Y)L?*%T+_ *^X?)5_>11>=G-TVA[<-84517LH?%I.F665
MBO58EPD:-;E,^;CK0WGDNR?RM9_Y<OVH5U&HMO.D+C;5H;=33W&IJ98XVP55
M/NQ+EZ<7+GJY^E$)P*O5W@X7&S,AN%MO;+G44\T;_%?%>B5[4>F<.WU3*)E?
M46A   (   8]PK::W4,]973,@I8&+)+*]<-8U$RJJ9!4G;GM<JM0W=MKTZG_
M #)13(]SGQ;S:R1J\%<U4PK$5.#53"\UZL!(-ETE4;5M:MUGJBGD@TW3X9:;
M?*F'5$:+E)'IU-5>..O@G).,TROHJUU7;'OBD>D*)/ CN+8W[R)E$XHB[KL>
MA2F?X<-HB,W6W9K41,)BAAX?[!*>S>OU:[8YJK5E$Z:OU5<*G>C>^-'O6./=
M9EK,87=3I,-1,<.74%=M=MA.@J^)S8[3)12*G"2FJ'HJ>IRJWYBO&U;9M<ME
MEYM]SMM:^HH'3(ZEJL;LD4K?.1KL<,\,HJ<\+P0ZW9[X0MXME:M%KF&2OIU7
M'C$438YXE[VIA')\"^GD25J.)VV'[D4-);JZDTO353:VKK:V%85J-U%1(HFK
MQ5%WER[@B=X$JVFI=66NCJ9&[KYH62*WL56HN/G,H_&M1K4:U$1J)A$3J/T(
MKWMWV2ZEUKK9ETLC:-:5*2.%>FFW';R.<J\,=Z$=>3OKG\RV?*O^$N2 NU-O
M)WUS^9;/E7_":SP<8U;MFL;5YL\8S\1(7<*4>#M[=EI]-3]#(!=< !
M
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M9Z,<4]"DR%;MCL4DFT"W+&BX8DCG+V)N.3]:H61,&2-2SXYW  #&R
M                                             XK:3KB/2E,R"F8R
M>YSMWHV.7S6-Y;SO\DZ^)!ESU=?[E,Z2JNU6N5SN1R*QB>AK<(>ZTFW=XM>(
M[+4 K+I[7^H+-.QS:^6K@1?.AJ7+(U4[$5>*>I2P&D-1TFI[.RNH\M7.[+$J
MY=&_K1?\E%J34K>+-T #P]@    #&6X4;55'5=.BIP5%D3]X;7T;E1&U=.JK
MU)(G[RN7A::<M%OMUEN=OMU+25DU3)'-)!$C%E16[V78YKE.:\>)V&S+9;HR
M\[-K!57*PT\U54TC))9M][7N<O%5RBH!,R+E,IQ0%6=HU->=A^IK96Z2NM7)
M8J[>5*"JD62-'-5-YBHO4J.3#O9)QX]MD],7B'4&G;;=Z5JMAK:=D[6KS;O)
MG"]Z<O4!G5-1#2Q=)4S1PQ[R-WI'(U,JJ(B97K551$[U/4KSX5NH*R2EI;!:
MDE<VE:VY7"2/_LF;^Y%E>KSG9_PJ2QLGU4W6.A+9=E<BU2LZ*J1.J9O!WHS[
M+T*@'7&,MPHT7"U=.BI_WK?WF25Y\)S1-M=;K#/8;32P7:KN"4F:>)L:S;[7
M*B.PG%<M3"KV@6$CD9*Q'QO:]B\G-7**?17GP2M7+4VROTK62?C:15J:5'+Q
MZ-R^>U/0Y47^^O86& _'N:QJN>Y&M1,JJKA$0QONC1>[*;XUO[R,O"$NM2_3
MU+I:T._YROCG-<J?]G31IORN7NPB)WHJD/\ @IZ<M-\U%>IKQ04]=XI3Q]"R
MHC21C5<Y<NW5X9\WYP+82UE-$Y$EJ86*J91'/1.':?'W1HO=E-\:W]YP&W/3
M-FN&SF^UE3;:1U;24:O@J.B:DD>YQ1$=C*)W<B)?!AT3IW4]BOE1?[5!72Q5
M#(XW2Y\UN[GAA0JT,<C)&[T;VO;VM7*'T5[VN;-8M$6&?56SRMKK-/1.:Z>G
MAJ'JQ[%<B93*JO!53*+E%3/#M[W81KV?7FCW5%Q:Q+G12^+U#F)A)."*UZ)U
M91>*=J*$2.  !Y4M3!5Q=+2SQ3Q;RMWXWHY,HN%3*=:*BH1)X15!=F;/;O<V
M:AK:>.G<S=HZ5J11O8Z1&;KUXO<N'?G(G#V)L/!H]IVR_P!.H^F>!*!K[K>K
M7:$:MUN5%1([V/C,[8\^C>5#6Z^O=38M-3U%MA2HND[V4M%"O)\\CMUF>Y,[
MR]R*1W^ *S72)U7JN[W:YWR=-ZHJTF1J;_\ ,:K5PU.I%^;D!+]#6TM?3MJ*
M&IAJ8'<I(9$>U?6G ]RHC*:[;#=K-#205TE39:YS%<B\&S0N=NKO-Y;[5SQ3
MNZE5"W8             !4W;'M(O=AVPULEJCHJ>IMF[3QU#8EWY8G,:Y8Y/
M.PYN5RG#*83"H:GRB=<?G6OY+_Q$EZDOFR^Q[2KU#J>E2ZW2NJ8UFGEHVRPT
M2)&UJ,557NRJM1>>.HE--G6C%3AI:R_(X_W!56ZG;;K'43J:UUE32PTU141)
M(M-#N/<F^BXWLKA.'47..#U!LHTG<[?T-'9[?;:ILC)(JJEIFM>Q6N1W5C*+
MC&.\[P   @       #R=3PNEZ5T,:R)^6K4S\)Z@       I1X.WMV6GTU/T
M,A=<I1X.WMV6GTU/T,@6%UP $
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M(Y#^Q+5[$B33UPD1KD574CW+SRN59Z<Y5/7W$P&*^]]V6FM=@ 'EZ
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M<I1X.WMV6GTU/T,@6%UP $
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M^LG32UOGM=@HJ6MG=4UC6;U1,Y<K)*Y=Y[O0KE7"=280V@
M(UVO;5K;L\A93L@2MO50WI(Z9KMU&MY;\B]2<."<UQU<R ZCPBM;25*R1I:X
MH\\(FTRJWX5<J_.2WI[0^FM;:[UE<]4,^Z%SIKDZE92/F<UL,+&-2-VZU45<
MIGGPX=N3MDV5:&1N[]Z]MQ_5\0KAMD6W.FUA<(K+J.DAH;I-PADB5>AG=^;A
M<JUW8BJN>W.$6;B#MKFS/1EATA6WZUTK+-=:!$GI)H97)ORHJ*UFZJX7*]B9
M)MI7ODIHGR-W7N8BN3L7'% CT                   I1X.WMV6GTU/T,A=
M<I1X.WMV6GTU/T,@6%UP $
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M!(O*5B)['^DB?"B'NT=4=4/%9Z9Z92@ #&R
M
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M+3Z:GZ&0+"ZX "
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MW*F;O))RZ9G+/I3AGTH2&8IC4ZEEB=QN  $4
M
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M34_0R%GOPMZ$_E-0_"[]Q6#P='-7;59U1>#EJ,=_XF0+"[  "
M
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MX3*_ 34:6?%Z-^B9VL3L !A4
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MGC">G\3(A=LI1X.WMV6GTU/T,@5=< !
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M-J>CMZ5\?0J[?G<E-'YL:>RZO5Z50GDU<^"V">FT]UB=@ ,*@
M                                                        QKE7
M4ULM]175\S(*2GC6665_)K43*J<13[3$J:9M;2Z1U5-;'IO1U<=$U4>WJ<C-
M_?5J\\XY 2 #2:6U79M4TTDMDK63K$N[-$J*R6%W8]CL.;ZT-V
M          I1X.WMV6GTU/T,A=<I1X.WMV6GTU/T,@6%UP $
M
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ME$7"IGJ4^?SVM>\WM\7N-?  !A4
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M.WMV6GTU/T,A=<I1X.WMV6GTU/T,@6%UP $
M
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MA?R5<?GEAREMM_A&E_K6?K+I'(]I8:8YKT1KRV,%IMO8 #EM@
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MM/IJ?H9"ZY2CP=O;LM/IJ?H9 L+K@ (
M
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M9^LND4OML<CKC2M8URN65B)A.O)= YGM68F:_K_PZO&^( #D-D
M                                                        'A'1
MTT4[IHJ>%DSO9/:Q$<OI4]P                       4H\';V[+3Z:GZ&
M0NN4H\';V[+3Z:GZ&0+"ZX "
M
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MI&\_AX+ZSI3F7WU3$OI<4UM2+5\2  \,@
M
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M%^Y[U\G9]<>4AHOW/>OD[/K@TF@$+^4AHOW/>OD[/KCRD-%^Y[U\G9]<&DT
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M!Q>SC:/9=H#:];''6Q^);G2^,QM9[/>QC#E_-4[0
M
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M '2R96SP-?8:L]-+_P#=+)@D  0
M                                                  I1X.WMV6GT
MU/T,A=<PZ>UV^GF26GH:6*5.3V0M:Y/6B 9@
M       !$GA1^U-5_I4'[1+9Y5--!51+%4PQS1JN=R1J.3X% @GP/OXG7S]/
M3Z-I/9X4E'34;',I*>&!KERJ1,1J*OJ/<
M     "IOA?\ \>;/_9J?2R%CMF7M<Z6_LNF^B:;JKMU%6/1]71T\[T3".EB:
MY43LXH9$;&11MCC:UC&HC6M:F$1$ZD0#Z
M     *4;/O\ K$TW]L3_ +3RZYAQVNWQU"3QT-*V=%WND;"U'9[<XR!F
M                            $>>$)[3VI/ZN+Z9A(9\3PQ5$3HJB-DL3
MO9,>U'(OI10*W^!K[#5GII?_ +I9,QZ2AI*/>\3I8(-_&]T4:,SCMP9
M
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M624K)=*.]VFEN5LG;/1U4:212-ZT7]2]2IU*!F@
M        .9VAZSMNAM.R7:ZJ]Z;R1PP1^SFD7.&IV<E55ZD0Y'1FH]>:WTY]
MWK:W3]II)U?XG3U,,M0^1&JK<O>CVHU,HJ<&KVX E0$/;+ML4FHM43Z6U/;H
M[=?HGR1M6%RK%(]F=YN%RK5X*J<51<?#,(
M     /R1[8XW/D<UC&HJN<Y<(B)UJH'Z"+*[;#2W"_+8M!6J?4MS3._)&](J
M:-$X*Y9%SE$[<87J53N-,IJ-6RR:F?:FN<B='!0,D7HUZ]Y[U\[JY-3U@;L
M                               !51$RO!$*^7O;O55&U"WV'3$=%-9G
MUD-'+4RL<YTJND1KW,5'(B)QPBX7.,]8%@P
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MNH]/54SY+/<I>A2)ZYZ&9WL7-[,KA%3OSU%Q   "
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M^2FI-RHID<N>C1RJCFIW91%QVJO:!8H !
M 0)J/PC::RZ@N=K=IN:9U%4R4RR)6(W?W'*W.-SAG!N+5MLBN^SK4VI8+.^E
M?:MR-D3YDD1[WX1JJJ(F$153/=D&G1:VKJC4M];HFRS/C:YB37JKC7"T].O*
M)%ZI).7<W*E4Z2FAHMND=+2QMBIX-1I%'&U,(QK:G"(G<B(3CH':SH#3-E6*
MHNU75W6KD6IN%8M')F>=WLEY>Q3DB=2(0"M\H?PM.OW2.^YJWM:[?W%ST73[
M^<<\[O4%A?H&LTQ?:'4MBI;O:9'R4-2BK&Y[%:JHCE:O!>*<44V80
M
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MY417*Y<KZ54V@ 0
M
M
M
M
M
M                . U!M.H*+4WWMV&@J[_?TSOTU(K6LAQSZ21RX;CAVXZ\
M =^".KMM!O.GJ9:S4^BKA2VUO&2IHJJ.KZ).U[4W51.\R=!;3+;KBX7R*P4T
M\M-;8HGMF=YKIW/1_FHU<8QN8RJ\<]76'> B'4^W.WZ6N"4-_P!,:@HJE6[[
M6R,A5'-Y914D5%3@O)3VTUMJI]3LG?8-):EKF0JB2.BBB5K57DBKTF,]P$L
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M;4WZJ5KY,]#31)O2RX_-;V=ZX3O(HC\)RRK5[LFG[BVFS_I$E8K\?T>7S@6
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MN7*Y%7ANJO8=L
M
M
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MRXL,5Y\#G^ ]2_I,/[+BPP)  $
M
M
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MI?TF']EQ88$@ "
M
M
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M\<D9(KG0=%N;J*F/9+GF2
M
(       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g762905g05g90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g05g90.jpg
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M(^'_V@ , P$  A$#$0 _ .J41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$&AU7K"QZ3;2NU!7"D%27"'\$^3?+<9]JT^
M$*/>S%H7^G#\SG^PH?V2GY7I/]JJ^JQ5(@Z+]F+0O].'YG/]A/9BT+_3A^9S
M_87.B(<W1?LQ:%_IP_,Y_L++M&U'1]WN=-;[?>.EK*E_1Q1FFF;O.YXRY@'5
MX5S2MOH?O@:5](M^H]!UFB(@AVU#7#=!66FNL]MFKJ1]0()3%(&F+()#CD<1
MP(\N/"I;33QU5-%/3O$D,K ]CQR<TC(/[EH]?Z>CU5HZ[667=S50%L;C^;(.
M+'?(X J(=CI?Y+OLZ@H:S(N%GD=;YV.]L SVF1^R0W^J4$@VFZYIM"6:FK)Z
M22NGJJAM-!31.#72.()X<^6/[PI9 Y[X(W2LZ.0M!<S.=TXXC/6J7O+?OX[(
M2WV_\9:M*0=M3=;34.P0/+G<_@<LVY:PU7J_6ETT]L^?14%%:'".MNM5'TGX
M7B-QC>(Y@CEU'B.&0MY1&HUM##M,IM'&BD,T]$:T5.^-T#+AN[N,_F\\]:B-
MMU=JK2&L[5I[:!+17"BN[C'0W2ECZ(B7@-Q[>7$D#@.L<3QQ&=HU=>*+LC;4
M--4D%5=JBSB"!L[B(V9=+E[\<<- )P@Z"48U=JJ33]XT]0QVFJKFW:J%,Z:'
M.[3#>:-]_ \.ZSU<BJRU)J7:)LWJ[9<]5W&UWJQ5=2VFG;!!T3H"[)[D@ \@
M<$YY8.,J6[4=7733NJM"4%L?"VGO%Q%-5!\>\2S?C' ]1P\H+'15EM*UO>:7
M5%LT?HJGII=05T9GDGJ<F*EBX]T0.O@3\@X'(6FN5YVC:"K;=6:BJ:34UDJ9
MVP5 HZ3<GIR?SFAHXC@>><XQPR"@G!UM"-I@T=VE)TQHNW>V=\;N,XW=W']^
M5+E39.>RE81_07_45D7G6.J=4ZXN6F-GSJ*B@M6&U]UJF=(&R'/<,;RSD$<1
MQ+3RQQ"W$50TFK=6:*U=:;-K^>BN=LN\G0TMTIH^B='+P :]O+B2/WYR<$*W
MD&OU!>K?I^T5%SO%4REHH&[SY'_W #F2>H#B55<&V.\W@.J=*;/KS<[8"=VJ
M>_HA)C]$;K@?D)6!MP!U'M0T)HZH<[[FS2&LJ8P<"4 G@?ZK'C^L5>$$,=/#
M'#!&R.*-H:QC!AK0.0 Z@@@.@-J=JU7<Y;/54E79;_$"76^M;NN=CB=T]>!Q
MP0#UXPK!5(=D];6T-HL^L+<!!>;56QM;.T8+F') )Z\. _>?"MIM5VBWC3E1
MHB2P4L=4V]=)O4KAQE<6Q]&T._-[J3B4%MJ)[3=9Q:$TU]V)Z-]8SIV0]$QX
M8>ZSQR0? JZU=<MK&D+-)J:X7*QUU'3EKZFVPT^!&TN [EV XXR..?WK][(6
MZQ7S8=;KK3M+(JV:EJ&M/-H<TNP?)E!=T;M^-K\8W@"OI5CKO5]VTEK/1P>^
M$Z9NCA25.]'W4<IX-=O=0[H'^J5N=L6KI=&:&J[E1[CKC(]E/2,<W>#I7'P=
M> '''B035%K]/"O%BM_W9>Q]R,##4EC=UO2$=T / #D+8("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(L&ZWBVVB(276
MX4E%&>3JB9L8/[R$&<BC5+K[2-5-T5/J>ROD/ -%;'D^3BI'%(R6-LD3VO8X
M9#FG((\J#Z1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZ%V_!/$[<EA=X6N^0<#D<!X%'M/;(-/VF]4]UJZJ[WJMICFG==:KIA">HM
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MHM-7>JIK"&3P4<TL;NV9CNN:PD'!?X0I5L;[UFE_,(_H03%$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 15KMEUS=]&FR,LD-!*^N=,'FK8]P:&!I&-US?TBJ
MZ]FC6?\ Z73OS>;_ -U;*+5=<<Z8:+F)M6I^&N>4NCT7.'LT:S_]+IWYO-_[
MJ>S1K/\ ]+IWYO-_[JR^GN>37]=8_EZNCT7.'LT:S_\ 2Z=^;S?^ZMKI':YJ
MBYZLLUMN-+9!2UM2('F"&5KP"TG()D(ZO HFQ<ICG,,J,79KF*::ONOI$1:E
MD1%1FW#4NHJG5<&F]%5\])4T-NGN=:^ \2&M):SR\/\ \P@O-%&-F6IF:NT/
M:;P"#--$&S@?FRM[EX_>"1XB%(ZF>&F@?-4RQPPL&7/D<&M:/&3R0>B+7TM[
MM572R5-)<Z&>GC.'RQU#',:? 2#@+/#FEH<""TC((/#"#]1:VFO]GJJPTE+=
MK?-5#@88ZACG_P (.5G5$\5/$Z6HE9%$WF][@T#JXDH/1%KZZ^6F@ECCKKI0
MTTDH!8V:H8PO'B!/%>MS:^>TU;:6H;!)) \1SYX1DM.'9\7-!EHHYL]H[A0:
M4I*>\7EEZK6%^_6L=D29>2!GQ# ^1;!FH+,^M[39=[<ZKSN] *EA?GP;N<H-
MFBBVTW4C]*:)NMVIC3FL@A+H(YSP>[('+()YYP%[;.[TZ_:-LU=45,,]=-1P
MRU/1D<'N:"<@<N.>""1HOQ[FL8YSW!K6C)).  L"KO=JHJ:.HK+G0T\$IPR2
M6=C&O\A)P4&P18LUQHH:'MV:LIXZ/ =T[I6B/!Z][.%^V^OH[E3B>W5=/5P$
MXZ2"02-SY0<(,E%%=J6IAI+0EWNX<!/%"64^>N5W<L_O(/D!5<[#]3:AIM55
MFE];5\]7655#!<J.2<\0',!>SY,_O8Y!>"*"[<;I76;9=>Z^U54E+6PMBZ.:
M,X<W,K <?(2%L-*ZCH6:4TXZ\W:DCKZJWT\I%14-8^5SHVDG!.3DH)4B @@$
M'(*("+3ZOU%1:4T[5WJZ]*:.EW>DZ)N\[NG!HP,CK<%L:"JCKJ&FJX-[HIXV
MRLWA@[KAD9_>@]T15!4W^[Z:V_T]KN5PJ)M/7ZF/:D4KLLAF Y-\>\TC'_W
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M6HK;-7OKJ]LC96S2-=&!)('G #01Q:.L\%.40:+66E+1K&S/ME^I1/3D[['
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M()#;J1M#114S9JB=L8P)*B0R2.XYXN/$K)1$!$1 1$0$1$!$1 1$0$1$!$1
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M]7X_VCO(@BVR?O9:5]&4_JVJ5**[)^]EI7T93^K:I4@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M\N>X=>'%X!__ !1+&U]14NB=LFB;Y98(Z2.\S.M]=%"T,9+DM <0.&>[!\K
MKP5+[>!VWKG9C;XNZG?=>F(',-:^/)^G]RNA$(AK76\.E[_IBURT4E0^^5)I
MF2->&B(@L&2,<?;_ -RVVLKZS3.E[E>I8'5#**(RF)KMTNX\L]2J_;N]L>T/
M92YY :+J[B?VX%,-N+VLV3:G+B .U2/E+@ B4:VR7AFH.QXK;O'"Z!E=3TM0
M(W.R6!TL9QGK4;['ISM+ZLK--3.(I;M;*6\4>\>;C&WI /E)^2-9>L?_  FT
MOHVA]9$L763':?TYLKUS "/N7#2TM86CB:>2( Y\G=#RO03+;_6SRZ7H=-6]
M^*_45;'0LQS;'O O=Y,8!\3E'NQ8IF45MU=2PYZ*"[.B;GGAHP/H6XH'-U;M
MZJ:MI$EMTK1"&(CBTU,P))']7(\K0M;V,WXK6WIJ1!G6F?[S]O%=96=Q:M3T
M_;\+![5E4W._C]H-<3XRU6XJ7VQY9M>V6O@_'FKD:['/<WH\_P!Q<KH1 B(@
M*K-MLNS@"ACVA;IJ]TNIQ").G#,\>+.(;GP\,YPK37,^L+79[]V3S[?K!S3;
M'4L;8(Y)3&V1W1 M;O @\7%W7Q/#K0ALZG7>QZ71+]*1.JZ>S.<U[HH::0.<
MYK@[)<0222T D\<*U]EE^L5^TG')I.EDI;12R.I(8WL#/:@$D#)X=US/$\<J
M@]$:&T3/7:]T]JKH:2MM=4\TE9)4NC>R#B X NW78P#Q!]LK,[%NYLN&S 1,
MIH8'457)3O=$P-Z8[K'!YQS=AP!/^ZB5O(B(@1$0$1$!$1 1$0$1$&FUK[S;
M]YA/ZMRT^QOO6:7\PC^A;C6OO-OWF$_JW+3[&^]9I?S"/Z$$Q1$0$1$!$1 5
M.]DK[BZ<](GU$JN)4[V2ON+ISTB?42K.UGC=IQ&E7M/HI%$1=IY5AWCW)K/B
MG?05VM1?D<'Q;?H7%-X]R:SXIWT%=K47Y'!\6WZ%SL9FAW.%9*MWLB(J;J"(
MB B(@(B("(B B(@(B("(B#QK*JGHJ9]16SQ4].SV\LKPQK>..)/ <5JOONTW
M\(;/\]C^TMQ/#%41.BJ(V2Q.]LQ[0X'R@J$Z\M%MCDTUT=OHV[UY@:[=A:,C
M=?P/#D@E-MO=JNDKHK9<Z&LD:W><RGJ&2$#ED@$\%L%C4MOHJ1Y?24E/ \C!
M=%$UI(\' +)0$1$!$1 1$0$1$!$1 1$0$1$!$1!H;[K'3M@K&TEZO5#0U+F"
M013RAKBTD@'!ZL@_N6M=M,T5NG_^46GE_P"H:J6[(0?_ -36^BX/63*NL#P!
M=+#\/^=;BOXN7/\ TT5WOAGER=&;-=H.DJ#9_IRDK=1VR"I@M\$<L3YVAS'!
M@!!'A4MMFO=*W2NAHK=J"VU-7,=V.**<.<\XS@#Y%R-@> *1;-0/9)TMY[_E
MO65[AORJ)K^+I_K_ /I3?^*>7)UXB(N6WB(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B HMI#WQZU]*1?R=.I2HMI#WQZU]*1?R=.@E*(B B(@(B("(B B(@(B
M("(B B(@J[:[54]'JK1TU9/%!$!6 OE>&M'<,ZRM7]\5D_IBV_.F?ZJVZ^W4
M5P#!7T=-5!F2T3Q-?NYYXR."P_O:L7]"VSYK'_HHF.;379BN>?-6'WQ63^F+
M;\Z9_JGWQ63^F+;\Z9_JK/\ O:L7]"VSYK'_ *)][5B_H6V?-8_]%'PL/IH\
MU8??%9/Z8MOSIG^JP9KM;J[4VD8J*X4E1*+O&XLAF:\XZ.7C@'EQ"MW[VK%_
M0ML^:Q_Z+UI[#:*:=DU-:J"&9ARU\=.QKFGQ$#@D4LJ;$4SSYMBB(LF] ]L&
MB[AKNR45HH[A%148J6S59<TETC6\FC'E)X]8"F])3Q4E+#3T[!'#"P1L8.36
M@8 _<O5$$ VQ: DUW:+?'0UD=#<Z"I$]/4O:3NC'=#AQYAI\K0M#KVQ6_4.K
M+'2P:B^XNT:BI!-#-#"XMF9QWAQ !;D/P,YP3D$*W5$==[/K)K1U--<VU$%?
M2_B*VDEZ*:,<\ \<C/A'#J04AMXTUJ&FT:RMUIJL76M[89#04-- V&/>)[IY
M ]L[=!'+AGQJX]:;/Z;6&D+9;ZJ>6BN- R.2EK(O;P2M:!GQC@,C(Y#P+"L.
MR"PVV]4]VN%9=[Y74Q#H'W2JZ81$<B!@<?+E6.@IVOT5M,OMN=9;YK"ULM,C
M>CGGI*8BHFCZVG@ ,CG@_O4DU+LZIZG9-/HFP2,HX3'&R.68%W%LK9'.=CF2
M0?E*GR(,#3U ZUV"V6^1[9'TE-% Y[>3BQ@:2/W*#Z V>5>F=*:GM-1703R7
M:>>:.1C2!&)&!H!SX,*QT05C:-E4/L/LT1>ZMLKFN>]M5 W&X\R.>UP!\&<$
M=8RM;%I+:K%:Q9FZOLYH!'T K'4SC5"/&/!C..O.?'UJX$00*BV:6^AV65.B
MZ2HD;%/"]KZIS<N=*XYWR/*!P\ QGK7[LFTWJC2ULDMFI+Q1W&A@CCBH&P1[
MKHF-SD..Z">&[SSC"GB(,*^43KC9;A0L>&/J:>2$./(%S2,G]ZT.RS2\^C-#
M6ZQ551'4S4IE+I8P0UV](Y_ ']K"E:((+LXT34Z4ONKZ^IJX:AE[KW5D;8VD
M&,%SW8.>9[L<O OB31-:-K4^L8:NGZ)UN-&RG<UV]O\ 4XGP<%/400'9#H.?
M1-!=77.MCK[M<ZLU-14QM(#O ./C+C_64ZJ8(ZFFE@G8)(96%CV'DYI&"#\B
M]$04M;-D%VH-G.I]("\4LE'<*ADU$]S'9@ >TN#O#D,;RZ\KVH=![0]/VF.R
M:9U=0"T!@:U]7 73TV1W0C(!R,YQG&/$KC1!%=FVB:+0VG_N?22R5-1+(9ZJ
MJD]O/*>;CX!X!])R5*D1!CW"AI+E1R4EQI8*NEDQOPSQB1CL'(RTY!X@%>T4
M;(8F10L;'&QH:UC1@- Y #J"^D0%!-J&SFEUO'1U4-;-:[Y0'>I*^ =TSCG!
M&02,\1@@@_+F=H@IH:6VQ&+M-VM[2*;&[VP*8=-N_P#+Y_+\JFFS/0='H:V5
M,453-77&MDZ:MKIO;SOX^7 XGK/,\>*F*((!LIT)5:*FU$^KK(:D72M-4SHV
MD;@R>!SU\5/T1 1$01K:3IR;5FB;I8Z:>.GFK&-:V60$M;A[7<<>1;#2=K?9
M-+VBURR-EDHJ2*F<]HP'%C TD?N6U1!4E7LXU'I[4MRN^S:]T=##<G]+56ZO
MB+H=_).\T@$CB3PP,9YXX#.T;LYN,6KOOLUQ>&7B_,88Z9D,>Y!2M.1W(ZS@
MGJ',GB>*LU$%9:TV<W*?6#=7:(N\=IOSHQ#4,GCWX*EH '=8R1P#1R/(<B,K
M"I=G.HM1:BM]UVDWJCKJ>W/Z6FMM!$6P;_4YY(!/+E@^7&0;:1 4%IM$U,.U
M^KUB:N$TLU *,4^Z=\'N>.>6.Y4Z1 4<VC:>^^G0]YLPQTM53D1$\A(.Z9G^
ML I&B"!;#;V;SLWM39LMK;>W[GU4;O;,DB[G!\>Z&GY5*=56Q]ZTS=K7%(V*
M2MI):=KW#(:7L+03^]8EFTM16?4=WN]ODGB===U]33 CH3(W_P P#&0XCGQP
M5OT$9V::<FTEHBUV.IGCJ)J-KVNEC!#79>YW#/E47U7L^O,>L9=5Z"N]/;+K
M4QB*LIZJ,N@J0,8)P"0> ZO'D<<V<B"M-&[/[LS5YU9KJ[072]1Q&&DBIHRV
M"E:<@[N<$G!(Y=9Y]5EHB"B.R5MOW8U1LXMO3R4QJZV:$31^VC+G0@.'C'-9
M-\V:[0=4VR:TZIUE12VMC"8VT]/N.GD [@RX:. ."1D\O#Q%EZHT=;-27BPW
M*XNJ!46:<U%,(GAK2XEI[H8.1W \"D:)5Y?- 55QV-0Z+96P,JF4M/3FH+3N
M$QN82<<^.[_>MG==&-NFRW[TJN9A?]SHZ03 =R)&-&Z_'/ <T%3!$0@^R#0S
M]"::EH:NJ96U]34.J*BH:#W9. !QX\ !\I*\]E&AZG13+^*NKAJ?NC7.JV=$
MTC<!ZCGK4\7X\%S' .+21@.'5XT%0-A.KNR&-3'W5MTI1]$Y_-IJ9 >Y\H#C
MY"Q7 M%HW2]#I2UR4= Z:9TTSZBHJ)W!TL\KSDO>0!D\ARZEO4!$1 4"VC:-
MTK<[C:]2ZDJ&6^>U31R-JG2MC;(UK]X1OWN!&0?'Q*GJYOVE6\[0NR I=(W>
MOFI;/1TP>R.,@&1QCWW;N>&\<XS@\&H0S==:,T%M,N=?J2UZMAH7TW11W"8,
MWH<GN6$EQ;@G &<D<!\MO[/=)VW1FF*>TV9SI*<$RNF>073/=C+SCAU#EU *
MB-#:(MM91;7-+BLFHK=35409,7 E@B=*YI>2.(RT9Y?(ISV*MUJ[ELR?%6/=
M(VAK9*:%SCG$>XQX'R%Y^3")7$B(B!$1 1$0$1$!$1 1$0:;6OO-OWF$_JW+
M3[&^]9I?S"/Z%N-:^\V_>83^K<M/L;[UFE_,(_H03%$1 1$0$1$!4[V2ON+I
MSTB?42JXE3O9*^XNG/2)]1*L[6>-VG$:5>T^BD41%VGE6'>/<FL^*=]!7:U%
M^1P?%M^A<4WCW)K/BG?05VM1?D<'Q;?H7.QF:'<X5DJW>R(BINH(B("(B B(
M@(B("(B B(@(B\:V8TU%43@;QBC<\ ]> 3_@@]E%-?\ XS3'IJG^J]5%!M\O
MDT$<K=/VT->T. -4_K_JK7WW;!>KLZVE]EMT?:58RL&*EYWBT.&[[7_>5F,'
M>F.<4L/F4^;IA%SU[/%]^#]L^=/^RK,V2:UJM;V>X5=;10T<M+5FFW(9"\.&
MXQV<D#]+^Y87,/<M1SKCDF*Z:NDIRB(M+(1$0$1$!$1 1$0$1$!$1 1$0<S=
MD'WS6^BX/63*NU8G9!]\UOHN#UDRKM>DX?\ CT]_52O9Y%(=FW?)TMY[_EO4
M>4AV;=\G2WGO^6];,9H5;,;6>'7B(B\NOB(B B(@(B("(B B(@(B("(B M3J
M#[N[L'WO"V%V3TO;QD'@QN[GRYSXEMD05ZV\ZX.IGV7H=-=.VC;6=)O3[NZ7
MEF/#G(4SL?W5[2_[]%"*O>/Y&7[F[U>VXYYK1QM'LJSNZ_N+&/\ _N]2M 1$
M0$1$!$1 1%@WH7,T?_<CJ)M7O#C5M<6;O7[4@YY(,Y% J^Z:UH[Q:[>[[W'/
MKS*&O$<^&;C-XY[KK4HL(O@$_P!WWVUQ[GHNTFO'ASO;Q/BQCQH-JB(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("BVD/?'K7TI%_)TZE*BVD
M/?'K7TI%_)TZ"4HB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@*IMLNR0ZUK::]6.O%MO],T,$CB
M0R4 DMRYO%KAG@X9\'@QL=M6B]0ZRHK7%IF[1VV2FD>Z5SYY(M\$  =P#GD>
M:JCV#=H_PPI_GU3]E$PU]%L(VAU-35PU][IJ>EK7A]9(:R23IR">Z<T#NSQ/
MMO"NC= :3HM%:7I;+;G.?'%ETDKQATLAXN<?].H !4%[!NT?X84_SZI^RKJV
M0Z8O&D])NMVHK@RX5IJ'R],R5\@W2&X&7@'J/[T$U1$1 B(@(B("+3ZJU+:=
M+6F6XWVMCI:9@.-X]U(?T6MYN/B"J38KM9O&O=H=VM]5%3PVB.DEJ::-L>)&
M@2QM:'.SQ[EYSXT%YHH+M@V@P;/=--K>@;4U]2_HJ6!QP'.QDN=_N@>#P@=>
M54#-M&T#3YMEUU?IZF%AN!#HS'$8W%IX]R=XX..(#AQ'[T'3*+&M==3W.VTM
M?12"2EJ8FS1/'YS7#(/[BLE!IM:^\V_>83^K<M/L;[UFE_,(_H6XUK[S;]YA
M/ZMRT^QOO6:7\PC^A!,41$!$1 1$0%3O9*^XNG/2)]1*KB5.]DK[BZ<](GU$
MJSM9XW:<1I5[3Z*11$7:>58=X]R:SXIWT%=K47Y'!\6WZ%Q3>/<FL^*=]!7:
MU%^1P?%M^A<[&9H=SA62K=[(B*FZ@B(@(B("+7WB]6NRQQR7BY4= R0EK'5,
MS8@XCJ&\1E:S[_-)?"BQ_/HOM()&BPK1=K=>:=U1:*^EKH&NW'24TK9&AV <
M$M)XX(X>-9J B(@(B("Q+S[D5WQ#_JE9:Q+S[D5WQ#_JE!Q);/<VE^*9]"R5
MC6SW-I?BF?0LE>NMY(V<ZKK(KZ[&/WM:@]*?Y$2H57UV,?O:U!Z4_P B)<_B
MFE&_M+=A\TKC1$7!6Q$1 1$0$1$!$1 1$0$1$!$1!S-V0??-;Z+@]9,J[5B=
MD'WS6^BX/63*NUZ3A_X]/?U4KV>12'9MWR=+>>_Y;U'E(=FW?)TMY[_EO6S&
M:%6S&UGAUXB(O+KXB(@(B("(B B(@(B("(B B(@(B((JSOI3^AH_7O4J459W
MTI_0T?KWJ5("(B B(@(B("(B"+:C]^^D/VJOU*E*BVH_?OI#]JK]2I2@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(JNVZ:NO6E:>R?<&IBIW
MU<TC)'20B3@UH(P"LJ*9KJBF.LHF>4<Y6BHMI#WQZU]*1?R=.J"]EG7']+4O
MS%BPJ':/K"AJ[A44]UIQ+73">8FC8<N$;8QCP=RQJM_X_$?Q_P#L-?SJ/-UF
MBY5GVO:XAB=(;K2N#<<.TF#/%=5#DJ]ZQ79GE7#.FJ*OO B(M3(1$0$1$!$1
M 1$0$1$!$1!$-H6O[=H9MO-RI*ZI-:Y[8VTK&.(W "<[SF_I!0_V?+!_0M__
M .5#_P"ZM3V3WX[2?[=5]5BI==/!X*B_;^.J9ZM%R[-$\H7][/E@_H6__P#*
MA_\ =3V?+!_0M_\ ^5#_ .ZJ!16_\5:\Y:_J*O)?WL^6#^A;_P#\J'_W5GZ>
MVT6.]WV@M4%KO$$]9+T,;YHXPP.P3QQ(3U>!<Y+?;/.^+I;S]OU'K3?X=;MV
MYKB9^S*B]-540Z_1$7'64?V@7R;3>C+O>:6*.6>B@,K&29W7$=1QQ576'76U
MB_6BENEKT?99J*I9OQ2&I#=X9QR,F1R4[VU]ZG5'F;OI5=[+-L6BK#L^L=KN
METDAK:6#<E8*65VZ<D\PW!1+<VC:K?;7JJW6':-IMEGDN+@RFJX)M^)SB< '
MB1S(&=[AD9&#E7"N;]<:DI]L6KM,671M-53TE!5BIJZ]\18V-N1G&>(X \\9
M. %9>T6'6EXU':[)IF:2T666,R5UWC#7/:>.(V@G(/ <>'MAQX'(6*HIM*UI
M3:%T_'<ZJEEJC-4,IHHHR&Y>X$C)/(8:>.#Y%4NTB@U+LMMU-J"V:[NESW)V
M,FH+G*)!*TGC@$^+!P,\<Y&%Z]E!15%;IBQWEESJHZ26I@B% ,=&'N;([I?#
MO '""V=HESU#:; *C2-ICNMRZ9K#3R' W"#EW,<L#KZU)VY(&>:I/;)-?M![
M)HS1ZEN-5<?NBP&ND(;*6.:[N.'5P"WNU_5]VME38-,Z5?%%?KY(6-J9 "*>
M,8R_!Z^/@/!IZ\(A9Z*D]0Z1U?I.Q5-_LVO[I<KA0QFHGI:XA\$[6C+FM82=
MW@#CZ1S7KM$U[67'8'!JJPU$MOJZAT.71.XQNZ3<>T'P9!'D07.O&MJ64=%4
M54V]T<$;I';HR<-!)Q^Y4[]Y>N-1V-M^J==7"W7:HA%3!04@+*:'(WFQN /=
M<, DY^7K:2O5WVB[#JNHJ[I/07.F,T4]53- ,W1MS@CD-YK@#CQH+#V=ZKAU
MKI>"^4U-)2P3R2,9'(X%V&O+03CADXSCJ\)4E5)=BY9JR+15'=GWFLEHIFS1
M,MK@.AB<)?;CKSW)_B*NU!45[VD:DO&JKC8-FUBI[@^VOZ.LKZQ^["Q^2"T#
M(Y$$<^.#PP,K JMI.MM%5-+)M'TY1"S3R"(U]L>2(B?TFESL^3AXL\EK31:R
MV3ZJO];8["=1Z;NU2:LM@)Z:%Q)., $\,D<B" .1RME'M@T/K&%^GM9VZKMG
M3.:)(+BPB+>#@1E[3EO$#B0 B5TP2QSPQS0O:^*1H>QS3D.!&00OM5QM9U9)
MH71]MI-,P1.N-;)';[;&>Z9&,8#N/, 8 SUD96BFV>ZRI[8ZX4VT>Z2ZB:SI
M.B>X&D>_GN;AX 9X9Q\B(7(BIN+:'6ZDV!7C4-,\T-YI(GPS.AX=',TMXM\&
M0X''5G"P]FUBUOJJET]JRZZRJZ6FQ$[[FPM.Y-"S )><X+G[I<20?;?N"\$5
M6[&K[<[OJ;:#!<ZV:IAH;LZ&F9([(B9OR#=;XN _<OC6%]NE)MWT9:*:NFCM
ME72ROGIFN[B0ALF"1\@_<@M5%1NJKMJZX;<:O2NGKT^@HZBWL>^1S=\4S>!=
M(QOZ9X-!_P![Y5J-4NUMLTU?8J*UZGJK]%J OI8H[J2\139:T.YG !>T\,<B
M"@Z)1<_;2+5K'9W9XM64^N;E=)H9XVU5)4MQ!('''<LS@#/#&.1X$85]4%0*
MRAIZEH+6S1MD /4",H/=8K[C1,N+*!]93MKGLZ1E,96B1S./=!N<D<#Q\2TN
MO-9VS1%J@N%Y95/@FF$#131;[MXM<[B,CAAI5"7+:SIZ?;9:M3,BN7W.IK6Z
MD>TT_P"$WRZ0\&YY=T..4'3ZUVHYZ^EL-PJ+/#%/<(8'R012@ELCP,AIP0>.
M,?*M+H#7EIUS3UDUE96,92N:R3MF+HSEP)&.)SR4K00O9#K7[^]&07:6**&L
M;*^"HBBSNL>T\,9X\6EI^5;O6=^ATSI6Z7FHP64<#I0TG&^[DUORNP/E55;.
MV?>3MOU-I5W<6Z\L^Z= WJWN)<UO_P"8_P#]863M_FEO]RTMH*A>1+>*L3U1
M;S93L/$GQ>V=_41*>[,KW=-2:+MUXO=-3TM36M,K8H X 1D]P>)/$CC\H4H5
M/Z]OMXJ=9VK9WHFKCM&*435E<&ASJ>$##6,!Y' 'C[IO$<5J]74&J=E]L;J6
MV:ON%_H::1@KZ"YOZ3?8YP;ECN;3DCEX<\<$$A.=J6M*S2$VFF45-3SBZ7%E
M')TV]W#7$<6X(X^53M4+V1=T?7Z>T#=;*T2R5%PBJ:1K^3BY@<P']X61K'1^
MM[)IFNU,W:#<IKQ10FKEIFM#:5P:,N:UF<8 !QD<<<AE!:FN:^]6S3-75:8M
MS+E=F%G0TSS@/R\!W6.323SZEM;7+43VRDEKHA#5OA8Z:(<F/+07-^0Y"J36
M>M;I6=CJW5%#4/H;I-#3N,L!W2U_3-8_=\ /=?(5GZ^UU<=,[,=/U%NQ4:@N
M\=/34SI!O?A'Q@N>1UG_ !(06JH)M6UI6:.CT^ZAIJ><W&XQT<G39[EKLY(P
M1Q44KMGFN:*RRW2CV@7BJU'%&9NUB0:65X&>C##PX\@2,>(+3[7JZZ7'2&SF
MJU!0&WW5]YA%13G'<O&1D8)X'&<=642OY%5>U?55Z.JK)HC2-3'176Z,,T]<
M]H=VM -[BT'K.Z[]PQSR-%JNPZLV?V274MEUO<KRZBQ+5T-S=TD<T>>ZW>/<
MXY\...OPD+Q1:O2UY@U%IVVW>D!;#6P,F:TG);D<6GQ@Y'R+:("(B B(@(B(
M"(B B(@(B("(B B(@*AMK^I-5:@VA4^S_1%4:"00B6KJ6R&-W$;W%XXM:&XY
M<23A7RJ$VRZ5U59=?4^O]"POJZ@1".JIXX^D=P;NYW.;FEN 0.((SXP(1?0=
MIU8W3NTZQVNZS3WZAJ:9C:CMEX),;WN=N./$$AN..,YXJW=@>LJO6N@8ZRZ$
M/N%+.ZDGD QTA:&N#L>$AXSXP5SO8=2[11<M3LL=@J8Z_44V_4NCHI-Z$]UG
M<)X,'=GB[./"%T?L/T5/H;0L-NKRTW"HE=55(8<ACW #=!Z\-:T>7*)3]$1$
M"(B B(@KS7>RJU:WU=07B^U,[Z6DIQ"**/N1(0]SLN=SQW6,#!X<U3_8YP14
MVW75L%/&V.&*GJV,8T8#6BJC  \6%U&N8.Q\[_VLOB:S^:C1+X[,&9\FH=-4
MI)Z)M/(\#QN> ?JA3KLHZ:(;)( UH @K(-P8Y=RYO#Y"H_V7NGZFHM]DOU-$
MY\-(7T]0YHSN!Q!83X!D$9\)'A4<VT[5+3K;9_9;/9>GEN<\T4M3#T3AT3FM
M(W ?SB7.X8SR073V/L[ZC8_IQ\IRX121CR-E>T?W ++JMJ^AZ6IEIZC4=&R:
M)YC>TA^6N!P1R\(6=LLL4NF]GUBM52W=J(*8&5OZ+W$N</D+B%MGZ>LTCW/?
M:+<Y[CDN-,PDGPG@B$"U5M6T15Z7O%-3:CHY)YJ.:.-@#\N<6. '+PE;_8WW
MK-+^81_0O76.GK-'I&^/CM%N8]M#.6N;3,!!$;N(X+RV-]ZS2_F$?T()BB(@
M(B("(B J=[)7W%TYZ1/J)5<2IWLE?<73GI$^HE6=K/&[3B-*O:?12*(B[3RK
M#O'N36?%.^@KM:B_(X/BV_0N*;Q[DUGQ3OH*[6HOR.#XMOT+G8S-#N<*R5;O
M9$14W4$1$!:S4M]H--V6HNMWE=%10;H>]K"\C><&C@,D\2%LU7FW_O4WCXRF
M_F(U-,<YB!C2;9]#2@"6IJW@<MZW3'_I4>?M1T8==0W$/J.T6VU].7?<Z7\8
M96. QNYY \51Z+M?XJC^2K]1/DZ2CVSZ'B;B.JJV#GAMNF'_ $J>V*[4E]M%
M)<[;(9*.J8)(GEI:2WR'B%Q@NJ=B_>LTUYHWZ2J6,PD8?ERGGS;;5SX^::(B
M*BVB(B L2\^Y%=\0_P"J5EK$O/N17?$/^J4'$EL]S:7XIGT+)6-;/<VE^*9]
M"R5ZZWDC9SJNLBOKL8_>UJ#TI_D1*A5?78Q^]K4'I3_(B7/XII1O[2W8?-*X
MT1%P5L1$0$1$!$1 1$0$1$!$1 1$0<S=D'WS6^BX/63*NU8G9!]\UOHN#UDR
MKM>DX?\ CT]_52O9Y%(=FW?)TMY[_EO4>4AV;=\G2WGO^6];,9H5;,;6>'7B
M(B\NOB(B B(@(B("(B B(@(B("(B B^)I8X(R^:1D;!S<]P _>L?[IT'_KJ7
M_FM_U0:!G?2G]#1^O>I4H6RXT7LGS/[<I]S[CL&]TK<9Z=_#FI3]TZ#_ -=2
M_P#-;_J@RT7XQ[9&-?&X.8X9#FG((7Z@(B("(B!R7YOM_2;^]1C:F2-FNJR#
M@_<NI]4Y<?LH:8L;F%G+P*UAL+5B.?PSRY-==R*.KKW4;V_?OI'NA[:KZ_\
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M=5);WW"IF>UD%'2W&1TDN3Q( =R Z_(.M7O?[':]06]U#>Z&GKJ5QST<S-X
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MK9C:SPZ\1$7EU\1$0$1$!$1 1$0$1$!$1 1$05IV130[9?6M< 6FJI00>O\
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M5*]GD4AV;=\G2WGO^6]1Y2'9MWR=+>>_Y;ULQFA5LQM9X=>(B+RZ^(B("(B
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M>LTUYHWZ2N5EU3L7[UFFO-&_25Q^+?IW]EG#^*:(B+C+(B(@+$O/N17?$/\
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M CIW8W96,SC). X>7N@.M+50:RV/76Y4MEL$VI=)5<YJ(64SCTT!/#& ">0
M/ @X!R.(7MJ;5&M]HMHJ-.V31%?9H*T=%4UUTS&UD9/=8!:/[LGGPZT2\.R
MU<R\Z%T@RW&K-LU#4,DF9 W,SXF[I,8'6[+AP\+0OJJU1HRHTVZQG9IJ9E 8
M^C:&V=H<WAC>#M[.]U[W/*D6O-F%14;.+!;--SC[L:=='/1R2=STKVCNAX 2
M>(ZL@#EQ6/+M.U@^UNHH=G-]9J$LZ,/,1[4:_EO])RW<\<?)GK0173E1=G]C
M'J:COE/602T DIX!51.8\P]PYO!W' +B/(,=2F^Q'0^GZ?0.G+G+:Z2>Z2Q,
MK#62QATH>>+<./$ #  '@7S<]/ZI]@J[VV^U4UXU'4T[G%C '%I)&(VX'=8
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M(1$7I%)+MCG?6T[Y:CU#UU>N4-CG?6T[Y:CU#UU>O.<1UY[+MG((B*BVB(B
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M*5CSG>&\2'$9ZCPXGPE="*D=N.TB^6[4%%H[0T3GWRJ:'22L8'O9O9W6,!X
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M.>^3<O1$7KGK3B,C*%KHB+GLA<B[3>^7JGSQOJ8UUTN1=IO?+U3YXWU,:O\
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MLLQ$10"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=FATL'ISN]$1%06VWV-^]>N]*UOKW*=*"[&_>O7>E:WU[E.EMATJ>@J\V_\
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MVATE%45%1IV%D$,;I)'=N1'#0"2<;W@782U6K03I6\@ DFBF  _8<MOUU_\
MDQ^51Y.<M$1;0ZK25IELVEJ2JM_:[6PS.K&,+VM[G)!<".2WG:6U+X&T7S^/
M[:LW8<QT>RC339&EKA3<01@CNG*<K3%ZN/%LY0YY[2VI? VB^?Q_;6QT<_:9
MIR6ZR?>+35+KA.V=W_>D3 S=C:S XG/M<_*KU18U7*JHY3(J_P"^O:;_ +.J
M7^V(D^^O:;_LZI?[8B5H(L!3>I[KM+ONG+I:7Z IH6UU+)3&47:)Q8'M+<XZ
M\953MV8[2 T#[VX>'_\ FQ?;77B+;:OW+//X)Y<V-5,5=8<CLV7[1W#)T]3-
M\M;%]I?7L6;1_P"@*3Y[%]I=;(MWUU_^3'Y5'DY3V:TNO)K#41V+3U%5T]-6
M30R/DJVL(E#LN;@NY#>YJ5_<S:C\$[;_ &@S[2F?8_1OCTU?A(QS";[5D!PQ
MD9;Q5G+3\ZOS;.4.?ON9M1^"=M_M!GVEDZ:I-IMFU!4W5VCJ">2:E;2]&+G&
MP ->79SD^%7PBBJY55'*9%9??+M.^ -O_MB-/OEVG? &W_VQ&K-1:Q67WR[3
MO@#;_P"V(U4^I= ;1[WJ2YW8Z:I(75THE,0KXG!F&-;C.1GVO]ZZE19V[E5J
M?BHGE*)B*HY2Y)]BS:/_ $!2?/8OM)[%FT?^@*3Y[%]I=;(K'UU_^3#Y5'DY
M M>GM<:>UW04)L=(^[55)*Z&!U6S=='EI<=X' (W>2GWW,VH_!.V_P!H,^TI
MGJ&-Y[(#2<@8XL%KJ078X#GUJSEJG$7*IYS+.*8B.4.?ON9M1^"=M_M!GVEC
M5]AVG5L,4<NE+>UK)X9^YN$>3T<C9 /;=>[CY5T4BQF]7,<IE/)6?WR;3O@%
M;_[8C_T3[Y-IOP"M_P#;#/\ 168BUBL_ODVF_ *W_P!L,_T58ZVT5M'U1J>J
MO+],T=,Z>..,Q"X1O W!C.<CFNFD6=NY5;J^*B>4HF(F.4N2O8LVC?T#1_/8
M_M)[%FT;^@:/Y[']I=:HK'UU_P#DP^51Y./#IC6^F=7:>9566D[?K))64<7;
M3"V1P9W62#PP'9XJP_N9M1^"EM^?L^TIEM-C>[:?LQ<UCG-;55>\0,@?@V\U
M9RU58BY5/.99Q3$1RAS_ /<S:C\%+;\_9]I85YT[M.NEJJZ&32]N8RIB=$7-
MKV9 (QGVRZ-11\ZN?%/*%81ZBVG,C:S[P[<=T 9^Z[%]??)M/^ 5N_M=BLU%
MJ%9??)M/^ 5N_M=BA>TJS[2M;QVULND:&C[2D>\%MRC?O[S<8YC"Z!194U33
M,51U@F.?V<E>Q9M&_H&C^>Q_:3V+-HW] T?SV/[2ZU16?KK_ /)K^51Y.,]7
MZ"UM8=.UMRO%II8:" -,LC*ICR,N ' ')XD*RJ>W[39X(Y8]+VPLD:'-/;[>
M1&1UJ?\ 9!,?)LAU"R-KGN+(L!HR3^&8IQ9ABT4(//H&?5"UU8F[7/.J644Q
M3'V47]RMJ'P6M?S]O^J?<K:A\%K7\_;_ *J_T6/SJ_-/*%,Z-?M+TU88[:S1
MMNJ V6:7I#=&-R9)'2$8X\M['R+;NU#M3WCNZ(M('@-T:59Z+4EYTKI7TT3J
MA@CF+ 7L!R&NQQ&>OBO1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1!&=;ZXL6B8*6;454^GCJG.9$61.DR0 3
M[4''-4+V0>T_2VL=$T]NL%=+/5LK63%KJ=[!NACP3EP YN"OC76A;'K>"DAU
M#!+,RE<Y\0CE='@N !Y<^2B'L :"_H^K^=O_ -42U6B=MNA[7HZQT%;<YV55
M+0PP2M%)(0'M8 1D#!XA6AH[55JUA:#<[#.^>C$CHM]T;F'>&,C#@#UA03V
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M3@YKP>L$(/=$1 1$0$1$!$1 1$Y("+0TNL]-55T^YM-?[7+7[VZ(&53"\N\
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MI*&^4VO=-W"KD- UN_"TY-*!^>P=;#^</&2<@G$9TM40;>=H< U.^2FI+=;
M[M*"3=$D@< ]S? "7 GKX 9X95YZ)VG:4UI&V*V7"-E6\8-%5 1R^0 \'?U2
M52VU[9U<=GU];K?9^7P4L3^DFAB&>U2>9 ZXCUCJSX.1+7[7-F=3LNJZ/5NB
M:VIBHX9FM<USLOIWGEQ_.8>1!\.#G*Z.V>ZB&K-%VF]A@C=5P[SV#DUX):\#
MQ;P*Y_%^UUMTTX;10T=GHK=',P5U0V;!R.+<L)+@WKX Y(Y\"NA]%Z>I]*Z6
MMMDHWNDBHX@S?<,%[LDN=CJRXDX\:#=(B(@1$0$1$$%VYNB9LFU,9WEK>UL
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MW^*GC9'$R*&-C&-PUK>E8  !R "IW2VU>FT/L6M%KLNY5:EJ3.0S&\VF!E>
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M*WI:B1K^(<1NL!;^<TY>"/&%9.L]46W2&GZB\7F4LIHL -8,OD<>36CK)_\
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MH.8W'FUX .'<,C@3GF&AU'>])6+9@VP[/[O55^H[M-'VU4P1O9//G.\UY(R
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MP;Q#71N+CW3>+20<G!\2#%LNI=I.SIU7H:EHI)JJ23%$3$93'D\70GD6N\?
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M$1 1$0:;5^F;9JVQ5%IO4 EII1P(X.C=U/:>IP_^.16+H'1UKT18([59HR&
M[\LS^+YGXXN<?DY<@I&B B(@(B("(B"C]OFR$:DBEU#IF(,OL0WIH6<.VP.L
M?_<'5X>7/"J#9BV+:+M'HJ?:/>:B9U-$(J>GJ#CIW,X"(G\WPGK<<\<E=GJC
M=MVQA^HZYE^T@(Z:]&1O;$6]T;9N/XP'J>.9\('AYDPN^&*."%D4+&QQ1M#6
M,8,!H'  #J"^UK-,4==;]/T%)=Z[[H5\,+6356[N]*X=>/\ 'KYK9H@1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!%CUM=2T(A-9410=-*V&+I'AN_([D
MT9YD^!8]_O%#8+/572[5#:>BIF;\DCNKJ  ZR3@ =9*"N.R%T-=]7:=IZBP5
ME0*NVN,S:%KL-G\8_P#N#'#RD<RJ8I=9W':E]ZFA=25,M(\5KF5M4#NNJ&M;
MW (/Y^0X<>&2TXRIU4]DD&5 J(=(UK[(9-P5;Y]USODW2W/BWOE6NVBZ/MFT
MBS??[LTD=]U(G;]72QC<D>]O'.![64<#P]MS''F2PMJ.R"KT$ZGU7L]J*P,H
M2))HR[>EAQ_YC3CNF_I ^/F,XF%BNNG]O>B'VN\-CI-1T;-[+!W43^72QYYL
M)QEOR'J*SM@NU=NLJ7[AW_#-04\9[HC JF#F['4X=8^4=8$[TGH#3NE+I<KA
M9+>R"JKG[SW<^C'6QGZ+<\<#Z   P=C^B9]!Z29:ZNY25T[I#*[B>BB)_-C!
MX@=?C))X*;HB($1$'X]S6,<]YPUHR3X J.'9(:<;J:HHI:&K^Y+';D=PC[HO
M/6XQ\"&^#B3XE>2X\U1I>S:3V[/MFH:)DNF[K)O,R2SHHYCP<UPXMW'Y'D!\
M*)AU;IO4EFU+1"KL-RIJZ'K,3\EOB<WFT^(@+G#:U17G9CM>9KBUP&>VULF^
MXGVF\YN)(GGJSQ(/CZ\%1+:KI2FV8ZMI6:.U)5ON$G==KQ$B>G!]J'/9P.>H
M8!QU*7:?VRZBI*INF-H^F9+L)RV%T3Z7<J'Y. #&1NR9ZN \J#.VI;9K%K30
M,EAL=!737:YNBC$,D0_!.#VG@03O'(P,>'Y%H+9;[OL6VM66D@J34V^[B%DL
M0/MV/=NEKA^DQV2".?RD*P-?Z=J-&1T5?LPT#";E4C>DK!'T\E(?T6QDG!/(
MN' <0O79GLXO]SU6S6^TR;I;JS!I*(XQ#CVKB!P&.8:.OB>*"\$1$0(B("(B
M B(@(B(/A\L;#A\C&GP%P"_.V(?UT?\ $%%-4;-=)ZINAN-^M(JZPL$?2=L2
ML[D9P,-<!UE:CV$MGWP>'SRH^V@L+MB']='_ !!.V(?UT?\ $%7OL);/O@\/
MGE1]M/82V??!X?/*C[:"PNV(?UT?\03MB']='_$%7OL);/O@\/GE1]M/82V?
M?!X?/*C[:"PNV(?UT?\ $$[8A_71_P 05>^PEL^^#P^>5'VT]A+9]\'A\\J/
MMH+"[8A_71_Q!.V(?UT?\05>^PEL^^#P^>5'VT]A+9]\'A\\J/MH+"[8A_71
M_P 03MB']='_ !!5[["6S[X/#YY4?;3V$MGWP>'SRH^V@L+MB']='_$$[8A_
M71_Q!5[["6S[X/#YY4?;3V$MGWP>'SRH^V@L+MB']='_ !!.V(?UT?\ $%7O
ML);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\03MB']='_$%7OL);/O@\/GE
M1]M/82V??!X?/*C[:"PNV(?UT?\ $$[8A_71_P 05>^PEL^^#P^>5'VT]A+9
M]\'A\\J/MH+"[8A_71_Q!.V(?UT?\05>^PEL^^#P^>5'VT]A+9]\'A\\J/MH
M+"[8A_71_P 03MB']='_ !!5[["6S[X/#YY4?;3V$MGWP>'SRH^V@L+MB']=
M'_$$[8A_71_Q!5[["6S[X/#YY4?;3V$MGWP>'SRH^V@L+MB']='_ !!.V(?U
MT?\ $%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\03MB']='_$%7OL)
M;/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\ $$[8A_71_P 05>^PEL^^#P^>
M5'VT]A+9]\'A\\J/MH+"[8A_71_Q!.V(?UT?\05>^PEL^^#P^>5'VT]A+9]\
M'A\\J/MH+"[8A_71_P 03MB']='_ !!5[["6S[X/#YY4?;3V$MGWP>'SRH^V
M@L+MB']='_$$[8A_71_Q!5[["6S[X/#YY4?;3V$MGWP>'SRH^V@L+MB']='_
M !!.V(?UT?\ $%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\03MB']=
M'_$%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\ $$[8A_71_P 05>^P
MEL^^#P^>5'VT]A+9]\'A\\J/MH+"[8A_71_Q!.V(?UT?\05>^PEL^^#P^>5'
MVT]A+9]\'A\\J/MH+"[8A_71_P 03MB']='_ !!5[["6S[X/#YY4?;3V$MGW
MP>'SRH^V@L+MB']='_$$[8A_71_Q!5[["6S[X/#YY4?;3V$MGWP>'SRH^V@L
M+MB']='_ !!.V(?UT?\ $%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?
M\03MB']='_$%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\ $$[8A_71
M_P 05>^PEL^^#P^>5'VT]A+9]\'A\\J/MH+"[8A_71_Q!.V(?UT?\05>^PEL
M^^#P^>5'VT]A+9]\'A\\J/MH+"[8A_71_P 03MB']='_ !!5[["6S[X/#YY4
M?;3V$MGWP>'SRH^V@L+MB']='_$$[8A_71_Q!5[["6S[X/#YY4?;3V$MGWP>
M'SRH^V@L+MB']='_ !!.V(?UT?\ $%7OL);/O@\/GE1]M/82V??!X?/*C[:"
MPNV(?UT?\03MB']='_$%7OL);/O@\/GE1]M/82V??!X?/*C[:"PNV(?UT?\
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M(.04'ZB^998XF%\KVL:.MQP$CD9*P.B>U[3UM.0@^D0G R>2^(IHI@3#(R0
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M1!R%^H"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M#E(6#>'RKU1$&#7V>V7&1LEPMU'52-X-=/ UY'D)"S(XV11M9&UK&-&&M:,
M#P +Z1!AW"U6^Y;OW1H*2KW?:]/"V3'DR"O:DI*>B@$-'!%3PCDR)@8T?(%[
M(@(B(/"NHJ6O@,%=305,).3'-&'MSY"OEMOHVTT=.VDIQ3Q^TB$;=UOD&,!9
M*(/*6F@FC;'+#&^-O)KF@@?(ON-C8V-9&UK6-& UHP %](@UHL%G%5VR+3;^
MV<[W2]K,W\^'.,K9(B# KK-;*^9LU=;:*IE;R?- U[A\I"SF-:QC6,:&M:,
M 8 "_4084]HMM16-JY[?1RU;<;LSX6N>,<L.(RO=U+3NG$SH(C,.4A8-[]Z]
MD08U=04=PBZ*OI:>JB!SN31AX_<0E!;J*W1F.WT=/2QDY+8(FL!^0!9*(/F6
M-DT;HY6-DC<,.:X9!'C"P[?:+;;GN?;[?1TKW<'.@@:PGRX"SD0%5O9'6"Z:
MCV?1T-CHI:VK%;'(8H\9W0U^3Q\H5I(@@VS/3;(=FVG;?J.U0.JZ6#==#51-
M>8W;Q\.<*<,8V-C6,:&L:,!H&  OU$&%+:+;-6MK);?1OK&XQ.Z%ID'];&5[
MFEIS/TY@B,WZS<&]X.?->R(,2X6N@N6Y]T:&EJ]SBSIX6R;ODR."]'T5*^..
M-]-"Z.,88TQ@AH\0ZE[H@      #@ %KX;':H:OMN&V4,=5G/3,IV!^?#O8R
MM@B#YEC9+&62L:]AYM<,@_(OR&&*!FY!&R-G/=8T ?W+[1!XQ4M/%*Z6*")D
MCN;VL )\I7C<+5;[B6&X4%)5&/VAGA:_=\F1P68B#\C8V-C61M#6-& UHP %
M^HB##^Y5O[?[>[0I.W?_ %'0MZ3^+&5[QTT$<SI8X(FRN]L]K ''RE>J(,>N
MH:2OAZ&OI8*F+.=R:,/;GR%*&AI*"'H:"E@IH<YW(8PQO[@LA$'C)2T\DS99
M((G2MQA[F N&.7%>KVM>TM> YKA@@C((7ZB#S@IX:=I;3PQQ G)#&AN?W+\J
M*:"H#140Q2AO+?8'8_>O5$ # P.2QJ^@H[A"(J^DIZJ('.Y-&'C/D(62B#PH
MJ*EH(!#0TT--"#D,AC#&_N"^JJGAJX'P54,<T+QAT<C0YKO*"O5$&)!;:&GI
M>U:>BIHJ;.>B9$UK,^'= PLF.-D3 R-K6,;P#6C "^D00;;?::Z][+KY;K33
M255;.V(1PQ^V=B9CCCY 2M1L,TK-;]E]':M4VEC9V5$KS3U<;7XRXD'!R.2M
M!$'Q!#%3PLAIXV11,&&L8T-:T>(!?-5305<#H:N&*>%WMHY&!S3Y05ZH@Q;?
M;:&W1N9;J.FI&..2V")L8/R +VGIX:AH;40QRM!R ]H=C]Z]$00;:EJ#4FF;
M512Z/T_]V)'O,4D38WNZ(;O<G#.KJ_<JWV#Z U =:7'6VMJ5]-6S;Y@BE #S
M)(>Z?N_F@#+0#X?%QZ!1 6!76:V5\S9JZVT53*WD^:!KW#Y2%GH@_&,;&QK&
M-#6-& T#  7E!2T].YQ@@BB+N98P-S^Y>R(,>NH:2OAZ&NI8*F+.=R:,/;^X
MK]HJ*EH(!#0TT%-"#G<AC#&_N"]T0>,]+3U!::B"*4MY%[ ['[UZ2QLEC,<K
M&O8>;7#(/R+Z1!\0PQ0,W((V1LY[K&@#^Y8M/:+;35;JNGM]'%5.SO31PM:\
M^5P&5FH@\8J6GAE=)%!$R1WMG-8 3Y2D-+3P/<Z""*-SN98P G]R]D0%C5]O
MH[A$(KA24]5&#D,GC:\#Y"%DH@QJ"WT=OB,=OI*>EC)R601M8#\@"]IHHYXG
M131LDC<,.8\9!'C"^T085OM%MMKGNMUOHZ1S_;&"%L9/EP%D5%-!4 "HACE
MY![0['[UZH@_&M#6AK0 T#  Y!8<]HMM16-JZBWT<M4W&[,^%KGC'@<1E9J(
M/%U+3NG$SH(C,.4A8-[]Z]D1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
I$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g762905g10t06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g10t06.jpg
M_]C_X  02D9)1@ ! 0$"KP*O  #_[2/L4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0(5[
MAR@        *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! "KW#E  $  0*O
M<.4  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!$0      !     "
M   "0    D      .$))300>       $     #A"24T$&@     #00    8
M            #I0  !      !@!G #$ , !T #  -@    $
M             0             0    #I0                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P  #I0     4F=H=&QO;F<  !
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   Z4     %)G:'1L;VYG   0      -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !SA"24T$#      9LP    $
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MX$'JE)!T(-#?_(IT2*U_E^"TL#UEY;:?VE2QS&MN(./80QH#6W@SL=L=:_\
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MJWNOOL:V@N+2VRVR_>[U2YWJV>IZEB2D/_.CZM?^6V%_[$U?^E$O^<_U:_\
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M7/J]&PMAQEP (;I],M<\;_\ 1[?Y:JTT959JIJ>*&O+]@VD1)_2N>Q[J]_\
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M)*?_V0 X0DE-!"$      %<    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  ,@ P #( -     $ .$))300B      $R34T *@    @ !P$2  ,    !
M  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (
M   ?    <@$R  (    4    D8=I  0    !    J    -0   *O     0
M J\    !061O8F4@4&AO=&]S:&]P(#(U+C,@*%=I;F1O=W,I #(P,C0Z,#@Z
M,#$@,30Z,3@Z,C,       .@ 0 #     ?__  "@ @ $     0  $ "@ P $
M     0  #I0         !@$#  ,    !  8   $:  4    !   !(@$;  4
M   !   !*@$H  ,    !  (   (!  0    !   !,@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0$Z17AI
M9@  34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4    !
M    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4    D8=I  0
M   !    J    -0   *O     0   J\    !061O8F4@4&AO=&]S:&]P(#(U
M+C,@*%=I;F1O=W,I #(P,C0Z,#@Z,#$@,30Z,3@Z,C,       .@ 0 #
M ?__  "@ @ $     0  $ "@ P $     0  #I0         !@$#  ,    !
M  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !  (   (!  0
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M*"@H*"@H*/_  !$(!ET&^P,!(@ "$0$#$0'_Q  =  $  @(# 0$
M    !@<%" $"! ,)_\0 :Q   0,# 00#" D." D*! 0'  $" P0%$08'$B$Q
M$T%1"!0B87&!D=$5&#)4DY2AL=(6%R,W0E)35G)UDK*SP3,V56)S=(+A)#1#
M@X2BH\+B)28G-41%8\/3\$9DA94H.&6DM./Q5T=FI?_$ !H! 0 # 0$!
M           ! @,$!0;_Q  Y$0$  @( ! ,&!0,$ @(# 0   0(#$002(3$3
M05$4(C)A<9$%0H&AP3-2L14CT?#A\4-3)&*"DO_:  P# 0 "$0,1 #\ VI
M
M
M
M
M
M  !Y+Q<(+5:JNX5;D;!31.E>OB1,FJ,VV'6KZR2:.[[D2O5S8>]XE:C<\&^Y
MSCJYG1@X6^??+Y*7R13NVY!C-,W>&_Z?H+K38Z.JA;)A%SNJO-OE1<IYC)F$
MQ,3J5XZ@ (
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MHY8W;S7)Y2UL=J];1I$3$O2 "B0
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MS\:'M,IC725@ $
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M                                                          $
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M,>6D[ !Q-
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M3Q&5.&8U.I:@ (
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M[%3J/J       #Y05,%1TG>\T<O1N5C]QR.W7)S1<<E\0'U
M
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M=XWMDC:^-S7L<B*US5RBIVH!V
M
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M5A  Y5P
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M%9F;TM]?L>DPN< '*T
M
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M<UKL;R(N.U#DFV>-3%:ZWW_]$5]9  <ZX
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MU1,Z2P$7^K&G^K_ZE5HYTJ.]^^$J,IN*F,X[24"U)KK?F1.P %4@
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M9D  0                      &1D !D9  9&0 &1E  &1E.T !E.T93M
M93M&4[0 &4[4&4[0 &4[1D !D 8C4]Z;8J&&KDCZ2-TS8WHB\41<\4]!D:*K
M@KJ6.HI9&RPR)EKFKS(=M=7&F(L+_P!H;\SB Z+U;/IZIZ.7,MOD=]DCZVK]
M\WQFD4W7<*3?5M2O4'QHJJ"NI8JFDD;+!(F\U[>2H?8S7           (5M5
MUC4Z-LU)64=+#4R3S]$K955$1-U5SP\A-2HNZ47&E;7_ %W_ '''1PE(OFK6
MW92\ZK,PZ1:\V@N5%712JW^BE3]YF]*;2N_KTRS:CM4UEN4G")LJKNR+U)Q1
M%15ZNWM+#B3$;$\2%7]T%;HWZ5I[K'X%;0U#-R5.:(Y>7IPIMCMBS6C'-(C?
MG&U9BU8WM:0(5>=;PV39_07VH9TM35P1+##G^$D<W./)S52/TMMVF7.D]DI+
MU26Z=R;\=!T**F.I'+A<>?)C7AYF-VF(CMU6F_HM4$-V<:MFU#35M)=X&TE[
MMTG154*<$\3D3L7"D8=J74NN;]6T.C:B*VVFB=N25[V;RR.\6?(N$3JYKQ01
MPU^:8GIKO/D<\:6R"L;#>]3Z;U72V35\C:ZAKG='2W!D>$W\<&KA.OEA?F,-
M7:SUE7ZVOFFK RE>YDKFQ3/9NK3L3FY5Y+S3FBEHX2TSJ)C6M[\M'B0N<%95
M.I[[HG1K4U0L%POLTZQ43(E5>E3AQ=A$Y*O4G'*(>6.U;3*BA6Z.OE-!5JWI
M&V[H6[N/O57&,_\ O)$<-YS:(CRGU.?Y+7!$-G6KG:FLU0^N@[UN="]8JN%$
M7P7)UHB\>.%X>)2+4MTUGKFKJ9;#.RQ62)ZLBFEBS)-CKX_NPG5Q*QP]MS%I
MUKN<\:Z+8!4]AU%J33>OZ+3&JZN&XTUP8KJ>L1FZY%PN$X>-,87M3B9#7FI;
MZ_5E'I;2ZP4]7/#TTE5*B+N-X\D7L1.Q5+>RVYHK$QK6]^6CGC6UD J>MJ-=
MZ+JJ2JK:OZI+5(]&5#(J?$D2+UIA,^?EVDIVCZN?IF@IHK?3I5WBNDZ*D@PJ
MY7AE51.>,IYU0B>'MS1%9B=G/TZI>"JG6S:9!0K=?9RDEJVMZ1;;T"*UR<]S
M*)S_ />24:/UM27W2$]ZG8M,ZC1Z5D7X)S$R['BQA4\I%\$UCFK,3]$Q;?=+
M2#7'6E72[4[=I9E' ZDJ8.E=.KEWVKNO7")R^X3TD7LEPU[KMDUTM-PI[):T
M>K:9KHD<LF%QQX*J]BKRSG"$>LM5>9]NUECU+#''<J>)T+G1^YD1(I%1Z>7)
MTX^%B.;GF)F(GIZ*3D[:;! %?[1M37BDO5JT[IE(67.X-<_IYL*D;4SRSPSP
M7MY''CQSDMRPTM.HVL %37'ZX.D4AN,EP9J*A1R=\4S*?#VMZU;A,^?TI@EN
MO-8QZ8T]#6,@=/6U:MCI:947+GJF>*)QPG7YDZR\\/.XBDQ._1$7]>B6 JN*
MU[3*BB]DW7RD@JU3?;;EA;N_DJN.?_O)(]":NEU-IZMEG@2EN]$KH:F#'!LB
M(N%PO4O[E%\$UCFB8G7?2(OOR3$%#:9U3M"UG1S06:>DBDHWYFJG-:S>S[EN
M,*G4O)"4734^HK7K#1=DJJBGZ2LA9[((V-';[\X547JY+R-+<'>L\NXVB,D3
M&UH@PVM+A46K2=WKZ-S6U--3/EC5R91'(BXX=9$;=JF[S[%I=123Q+=DIY9$
MD2-$;ELCFIX/+DB&-,-KUYH]=+3:(G2QP4_8[IK_ %S:X*NW3T=FHD9N]/NY
M=4/3@Y43"X3*+_>>;3FM=87R.HT[000.O=)*YE1<9,)&QB+C.[CW6>'+S&WL
M=NO6.G?KV5\2%T@J:S:@U'IC7M#I_55PBN<%R8BQ3,9NK&Y55$ZDX*J8QXT4
MMDQRXIQS'7<2M6VP &2P
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M7CI?_(4Q-EIKQ1[?[4S4%Q@KZ]U*]9'P,W&M18I,-QA.S/G,O-_^9.#^J_\
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MU%\3MXSSTI./FC6X]$UF8G2=@ X6H
M                        "M-L4F]+:X<\DD>J>7=3]RD3A3=B:GB)-M?:
MJ7*WO7W*Q.3SH[^\C4:Y8U4["%X[.QR<' ')P#@#D'"'('9%5.2J,JO,X0
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MUD:F29;.-15UMNL-!$R2II*A^ZL+>*M7[Y.SQF5Z;ZPO2VNB[P 8M@
M  J'NE?XJVO^N_[CBWB(;3-%_5K:::C2N[R=!-TJ/Z+I$7@J8QE.TZ.%O7'F
MK:W:%+Q,UF(2Z/W#?(A4_=!W:-;'1V"G^RW"NG8Y(F\5W47AZ5PB><\L6R.^
MMPU=<5R,3AAJ2?\ J$DT;LPMFG[DETK*JHNMU1<MGJ.3%[43CQ\:JOF-L<8<
M-O$Y^;7EJ59YK1K6D(VVVRIMFB]'4V^YK*)$@DE;R:]&-PO^JXSC-GNL9&LD
MCVCUKXW)O(J1NPJ+UIX99.H;+1:@M,]NN<724\J<<<'-5.3FKU*A7$.S_65N
M@2W6C62LM2)NM22-=]C>Q.>/,J>8OCXCFQQ7FB)C?>-[W^DHFFIWK;SZ%TXR
MWZGU(D>J'7F].HW1U#.B5%1R^Y5SU5<JBIC!Z^YTDC32=QIEPE3%7.61O6B*
MQB(J^=KO03#0VCZ#2-O?#1N?/53+O5%5)[N5W[D\7SF OVSVL9>JB[Z-O#K/
M6U/\/$K=Z*1<YSCJX^)?%@BV:F7FI-N^M3KT^B8K,:E)]0ZGM]DN5IH*Q)'U
M-RG2&%D:(NZJJB;SLJF$RJ<>)7^SM$^O3K;//'#])#/Z1V?R4%[]GM2W.2\7
MI$Q&]R89#U>"G;Q7L1,\NL]NGM%OL^NKWJ#OY)8[DW'0=%A8URB^ZSQY=A2+
M8L=;5K.]Q]YVG5IU,H/W0J3LNVDYHJE:1K99$2I1,]"[>C7>\W/S&2=L\UBJ
MHYNT2O5/Z-R?[Y/]5Z=M^I[1);KI&KHG+O->U<.C=U.:O;Q*^;L_UG!3):Z;
M6:I9T;T:9C5)&L[$Z^7\XTQ9XG'6D6BLQZQO^)1-=6F=;<;.J*ETY=-5U[M1
M^SM5# DE6C8U1V\W>=[I55%7@J<SSV.;7.T&D?<J.^4]@M+WN9%'!$CY%PN,
MJO/SY3R$_P!(Z.M>F+');*.-963HO?$LGNIE5,+GQ8ZB&TVSO4]BDFIM):K2
MBM4LBR)%- CW1Y[,HJ+PZ^ C-2]K3N-]-3,?QK^#EF-(;<+#46+;#I*GN%_J
M[U6.>R622HSF--Y41$XKP7"K@L#7NG+!J_4<= VZ24&IJ6'?8^%%SN<TSRSC
M.>"HJ9/A%LFC@O-KO++U537BGJ&U%345+-_OE45,IC*;B8143GA%,SKG0C-0
M5M/=;9726R]TZ8CJ8TRCD3DCD_?V*O,FW$4F]9B_6(UO7G]/1'+.IZ(->&Z^
MV=T3KB^^4]YM,3FM?'4*JNPJX3W7%.?4Y3S[57U%XU5H>OHJY]LCKX&K#4\^
M@<Y47/5QPYI(V;.K]>YX6:XU(ZX6Z%^^E+3MW$D7^<N$^95[%3F3+5>D;9J2
MQ-M=5'T,<2)WN^)$1851,)N^+'#'83[12EZS.IGKN8CU_P G),Q*%+L\UBBJ
MJ[1J_=Z\PN3_ ,PPNG;'34&A=>MM.H%O4LL3NG<V!6(U[6N5<*JKO*J*O%.P
MS+] ZTD@6V2ZT<MH5.C5>C7I59V=O+^<3[2NFK=IFRLMELAQ!Q61S^+I7*F%
M<[M5<%;\1RUUS1/;M&NWKT3%=SVTP&Q2>*?9O:4B<BK%TD;T3[EW2.7"^947
MSD1ODS).Z0LC6*BNCIMQV.I>BE7YE0RM1LUNUJN%1+HG44EJI*EV])3/9O-9
M^3^[AGQG.G=DZV?5]#?W7V:KGA5SYFS0Y65[FN:J[V]P]UX_*3%\-;7R<WQ1
M.HU/FC5M1779:!7^T6S:>U3=[?9:RXOHM0HQTM(^)JJY&\57/5CP57&47AP+
M (AKS1$&J%IJNGJI+?=Z1<P5D2<43.<+Q1<9\? X^'M%;[F=?-I:-P@=UMVO
MM V^6XT^H8;K:Z9$5\53E7;N<<G95$\CLGAVN7&2^V_0-YIYUH&5+E?TW-*=
MZK&N]_9PJ_V22?6]U/>592ZOU4ZKM37(YU/3LW5EQU*N$Q\I-[WI.TW?3;+'
M44Z,H8VM;"D:X6%6IAJM7M1/[SM]HI2];3J9\YB/+7[RSY)F)A!UV>:Q545N
MT6N5/Z%R?[XV7V."U7?5$D6HUO-8K$95_85:C7^$J*KE5=Y>8CT%K.F@2VTF
MM'-M*)N-S&O2M9V)U\OYQ-=)Z2H-,6%]MMROWI459:A_%\CU3&\OJ*9,VJ37
MGB=^D:^_1,5Z]D"[F["V"]+]UW[Q_00XV@-5NVW1TCN$:QM:B^/??ZT)=LUT
M6[1=%74RUZ5C:F;I47HNCW>&,<UR=]H.BXM64]*^.J?0W*C=OT]4Q,JWDJHJ
M93L3CU"<]/:;7WTGIO\ 0Y)Y->;[;49V4^SV_OD7".I7QIY7>"GRJ02SI_\
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M?),5B.H #%8
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M]:TOUD?0QQ0VQ51LZ2JJO7>PF6XX=:\S7P;Q$SZ1M7FA,P 9+
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M+.4:]$1>'B5%0K?A[TKS3_Z^J8O$SI)P 8+
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MW2$FHZJ.KA26%5W>7%,%XM$N7)@OC[QT?< $L@
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MZ*L6II&HO0NJVHSL^Z_<J%P&?&5BN:T0G'.ZP  YEP
M                        #X5_^(U/]&[YE/N *MV>Z)Z96W.]PJC$7,-.
M],;W\YR=G8A:0!:UIM.Y16L5  52     *QU=I:Y5.JJJ]:&OM/2WA(VQU=*
MYS7;W+&4PN,HB<%0PTVM]4Z<J:6+:#8::>WNF:C:N)J>"Y.*.3BK55.>."\#
M.:KTA?:'5,NIM$3P-K*AB-JJ6;@V7'7V<<)V>4QTNE-6ZYJZ1-<+2V^U4S^D
M[UI5RZ5WC7*X\N>M<'ITM2:QSS$UU_\ U'RAC,3N==_V8O:A)>';8+ ED[V=
M5=Z(M)WU_!;RK)E?+RQX\&6?'M=<KFO=8EC<F%X)C!*-H>BTU+24DU!4=Y7:
MWKOTDZ<$3EX*XZN"<>KTD8FAVHW&F6U5"6VEB>G1R5\;DWE;UJF%Y^1$%,E;
MTK$<O3I._P"#4Q,L-8;/<+%LNUS2W"JH9T7>D1E+)OI$]6^$B]G)O G6Q)J)
MLRLV$YI*J_"O.B:"9;=F]RT[9Y&NJJN-V_/-PZ21<95<<N"8,MLVLM7I[1EN
MM=QZ+OJG1Z.Z)V\WB]SDPOD4SSYJY,=M3UFW\=TTK,3'T073B+[8._*[@O>O
M#R8C/;W1KVMT%$U5\)U;'N_HO/1K72%]9JZ+5&CYZ=*]8^BF@G7#7HB8\^4Q
MV<C ZET/K;6EM?)J"MH8)X>-+1PKB/*\U<O'CCES-:6I.3'EFT1$1'UZ*ZF(
MFNGUVQ9^M!9/+39^#4L9S6LT,K41$:ENPB>+HB-:_P!(W._;/;=9Z/O?OZGZ
M%7[[U1F6MPN%P2Y:&9VF%H%W.^%H^@Y^#O;F[S[,G/>]9QUC?G*]8G<_17W<
MWM1-#UCL<5KWY7_-QF/M'_YC+KCK@X_ L);L@TO<-)::GH+JZ!TSZITS>A<K
MDW5:U.M$X^"IY+?H^YP;7*W4KUI_8Z:/=:B/7I,]&UO+':G::SEIXN6=])B=
M?LKRSRUA893[&M?W1LO?J9W:5%I=[MZ).7^T+@(/M#T;4WJKHKS8:IM'?J'A
M%([W,C<YW7>E?2J*<_#7K6TQ:=;B87O$S'1+;O)1PVNKDNB1+0LB<Z?I6[S=
MQ$XY3K0KW5FJ[7:(-.P:;L=/=*VI9O6QB,1K8FKPRG#*>1,<N:'@K++M"U9$
MEKU!+0VVUN5$J)*?"OE1%ZD15Y^9#)ZQT%5]%8*S2,L<5?9&HR&.9?!D;XU[
M>?I4UQTQX[1%[;_7IVZ;5F9GM#&7*/:A<[;5NKJBR6:D;"]ST8W?56X551<[
MV.'7P/'L<1?K+7U%^^J<?!-,M56O7^KJ22@ODEOL=N>U6S=ZY?+,GWO-41%Z
M^)D-G>CKE8-#W>QW%U.Z6>2;H7Q/545KF(U%7*<.**:VR5C%-9F-[CI'_>J(
MB9G:#:065.YYORP9W^EDY?>Y9O?)DLK8_'!'LYLO>V-U8W.=CK?O+O?+D\NR
M[2-78M#3V2_M@>Z:27?2)^\US'HB<\)XR/4>GM<Z*=-1Z5?1W.T/>KHHZE<.
MBSYT^1?,1EM7-STBT1[VX])*Q-=3KR3VOEL3M44D,R4RW](7.A7=^RI'A<\>
MSGP4K[83_P!1:K1O/OM_#^RI(-"Z-N-)=ZS46J*IE3?:IBL:R/W$#>Q/D3Q(
M-D>D[GI6EN\5W6F<M54)+&L+U=E,+G.43Q&<S2F.](MOM_GKKY)C<VB=,-W-
M_P#%:ZHONDKUS^@P^&T)S5VW:+:B^$UC55/[;SF/2.L='WNXR:*=0U5MKG[_
M $52["QKQZN'+.,HO%,<!!L_U-/K&QZDNUPIZJMCF1]4Q%W61,3DV-,<>"N[
M.)OS8_%MFYHU,3]>RNIY>73XZ]B;/MRTJR1$5J,C=A>U'O5/E1#/;?\ 'UO9
M<^^8OG4^VJ=(W.X;2;#?Z-:=:.C:C9D>]4=C+N28X\'&2VJ:<K=4Z5=;K:^%
MM0LS)$65RHW"9SQ1%[3&,E>?%.^W?[K:G5F0T:QL6A+*UJ(C4MT*X3^C15('
MW.>/82];O+OM,?HEC6"@GH=+V^WU"L6H@I&0/5JY;O-8C>'BX$7V1:1N.DK=
M<8+H^G>Z>=)&="Y5X8QQRB&<7KX>2-]9F/\ ,IU.ZIZ #D:
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MG!$0Y B(CLB^2U_BD !*@
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MK<M5*U>;5<B81?'NHWSY)L.0,LEYR6F\^:U8U&@ %$@
M
M
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M
M
M
M
M                                              (UM+X: U#_ %*7
M]522D8VG_:^U!_5'_,:8?ZE?K"MOAE$MA]\M5%L\I(:RY4=/,R:7>9+,UBIX
M:JG!5[%0]6U;5>F9]$76C6Z4%542Q;L,44K9';^>"X3.,+QR139'LZTYJ/1D
M=PN]&^:J?-(W?29S<(BX3@BX,9<=-T>S37U%5UM$RNT_.JI&^5B.6)?FWF\_
M&GC/3G'BMQ%IB9YHG>O7Z,8M,4CT69L=AGM.S.A===Z%K6R3HDB85D2N5R9\
MW'SF$AUIK#55142:)M-(VU0O5C:FMRG2JG9Q3T<?*6)=[M14.GJFZ3JDU!'
MLR[B(Y'LQR3MS^\K*R7O7.H;4R?1]ILUHM#GN2!TO-41RHJHB<.>>HY\?^Y-
MLLUCK/GVA>>FJQ+*:(UU>JC5\FF-76^"EN.XKX7PY1KT1,\E5<HJ(JHJ+U$!
MO5?J9NVZ&=MLIENS$5M-2I)ECX]Q^%5V>>[E>KB9*U4=[I-NUA;J6X05U>ZE
MD>KH6[K6-6.7#<83L5?.92[?_F/M.?>_#X&0Z:Q7'>9K$=:3/R4F9F/U6U:9
M:J>VTTMPIVTM8^-%EA:_?1CL<41>L]0!Y$]9=  "
M
M
M
M
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M&M/%94KFVFD2\.A=<$C:D[H?<*_'%4\1[0#GF=SM< !
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MKA4NB>-:9/I 7.#R6>X07:TT5QHU<M-5PLGB5R87=<U%3*>13U@
M
M
M
M
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M?Z9G[-@&Y^S=G1[/=,-[+93?LFDB,#L^_B'IO\VTW[)IG@
M
M
M
M                                                         '#F
MHYJM<B*U4PJ+UH<@"-NT'I1RJJZ<M.5[*5B?N.$T%I1.6G;5\6;ZB2@OXE_6
M4<L>C'VNR6JT[WL7;:*C5R858(&QJJ>-43B9  K,S/64@ (
M     U6N7=,WZDN-53ML5K>R&5\:.5\B*J(JIV^(#:DZRIF)Z?S5-3_;17[\
M7[7\))ZP[NH;ZYCFKI^V<4Q_"2>L!W(_#:3J!/\ Y!_[:,VR-2>X_D67:%?'
MKA%=;G.QY98S;8         :']T+]N/4O]+'^R8;X&AW=#?;CU+_ $L?[)@&
MZ>S_ /B)IS\VTW[)IGC!:!_B+IS\VTW[)IG0
M
M
M
M
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M W4T%_$;3OYNIOV33.F#T%_$?3OYNIOV33.
M
M
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M35;OXSO1/RJHKDPO%,=7#BA8(
M                                              U?NG<Q7&KN%54Q
MZEI$2:5TB-=2NX955Q[HV@ &JB=RS=/QFHOBS_6=D[EJY_C/1_%7?2/GMEVL
MZCOVKY],:$EK(:>GE6G5U$B]/4RM54=A6\4:BHJ(B<\97Q0^:AVPZ7B6ZS.U
M/!%%]D?(L[Y6HB<<O;E4QV[R8 OG8CL=K-G-^N%PJKO!7-J:;H$9'"K%1=Y'
M9RJ^(N0JK8'M1^N#9YZ:YMCBOM"B=.C$PV9B\$D:G5QX*G4N.W"6J
M  -#NZ&^W'J3^EC_ &3#?$T.[H;[<>I/Z6/]DP#=70?\2-._FZG_ &33.&#T
M)_$C3WYNI_V;3.
M
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M/VMP,J-F&JHY$14]C9W<>UK%5/E1"(=RU,^79)1M>JJD=3,QN>S>S^\"VP
M
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MV3#?$T/[H;[<>I/Z6/\ 9, W5T)_$G3WYNI_V;3-F$T+_$G3WYNI_P!FTS8
M
M
M     ,5?[_06&.%]Q=.ULJJC>BIWR\4[=Q%QYS*GGK*VDHFM6LJ8*='>Y661
M&9\F0(Q]<;3_ -_</_MU1] ^5/M-TS4QH^GJ:R5BY1',H)W)P7"\489]VH[(
MSW5YMK?+5,3]Y%ME=[M<>AZ%)KE1,<LDZX=.Q%XS/\8T,[9=86F\US:2@?5N
MG5%=B2CEC3"=JN:B$A/%2W:W5<R14EPI)Y5151D4S7.5$Y\$4]H
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MZ2,X]%$B+A%\:IE<+UJSM+JIH(J6FBIZ=B1PQ,1C&)R:U$PB)Y@/H
M
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M^S:9LP>A/XD:>_-U/^S:9P
M
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MKJYR.J:A&^'+CEE>>/$9(
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M[<>I/Z:/]DP#=70G\2-/?FZG_9-,X8/0?\1]._FZG_9-,X
M                                   ,9?)KO#'$MEHJ2K>JKOI45+H4
M:G5C#'9^0R8 B??VM/Y#LO\ ]R?_ .D8[3FI=77ZS4ESI;#:(Z:I9TC$DN+]
M[&53CB+Q$](?L@^UK8,]5/C_ %E RMGJ=0RU>[=[=;J:FW57?IZMTKL]286-
M/G,V
M                "/ZRU;;-)4,-1=72*LS]R**)$5\BHF5PBJG!$Y^8F(FT
MZA6UHK'-;LSTO\$_R*0?8A]K2U?E3?M7F*^O/8G-7%!<^76QGTR.;.-I5KTY
MI&DMEPI*YT\+Y5586,5N'2.<G-R=2H:^!D]'/[=P_P#?"\@0O2FTBR:ENZ6V
MD2IIZMT;I&,J&M;TB-YHW#ERJ(N?(30SM6:SJ6^/)7)7FI.X  57
M
M
M               +R4"@=>[6]GVG=25EN;I6GNU7!(K:B>.EA1O29\)-YR95
M47FO:1Q=ONBT]QL_A_0@3_=(YL=V=VG4^T+5%FUDE0ZJHE>Y&-E6-7N214<[
MM7J7SEUIW/FS]/\ NZJ7RU<GK \NQ3:58=::AKZ*S:8BL]1#2],^9B1Y>U'M
M3=\%J+S<B^8N,A.A=F&F-$W.>OT]230U,T*P/<^=S\L5R+C"KVM0FP
M   T.[H;[<>I?Z:/]DPWQ-#NZ&^W'J7^FC_9, W5T'_$?3OYNI_V33.&#T)_
M$C3OYNI_V33.
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M;_Q7JOCC?HG"]U/0_BM4_'&_0 V1!K:O=4475I6H^.M^@<>VHI.K2D_QY/H
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MX<'(B[CG+V^#(W]%#8$
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M5X;W-?,G%2X^YIIW4^QJQ;Z8619Y/,LS\?)@"#=UQNJ_1C6_PRU<F[V_Y/\
M?@V'3EQYFOVUN'ZL-ONB]-QHCX+<WONIX\D5V^Y%[/!C;^DAL"
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M&^F@?XC:<_-U-^R:9TCNSB5)MGVF9&\G6RF7_9-)$
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M?(B%F!$PF$X(91FMR33U=$\)CG+7+KK$:  9.H
M
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M+8                                                   %<S[;-
M03R0S7]C)(W*QS5IY>"HN%^Y L94RF%.$8U%RC41?$A6WU\]GGXPL^+R_1";
M<MGGXPL^+R_1 LH$3TAM$TMJ^NEH].W5E94Q1K,^-(GM5&(J)GPD1.:IZ26
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M;0-T=G$+:?9_IF)BJK6VVF1%7^B:2(P6@?XBZ<_-M-^R:9T
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M>;FM\)WE<O%?.ID@99,U\GQ2Z\'"8>'C_;KK_( #)T
M
M
M
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M>Z#^W%J7^F9^S:!NIH#^(NG/S;3?LFF>,#H#^(NG/S;3_LFF>
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M^>K@YJ)@D  0
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M*YSAO'ARY 5G?-L^LTUS>M/Z:TS27-;?-(Q$9'*]ZL:[&\J([R'/UT-KG_\
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MFX7'9S*C[F6^5#;=?-'7*3?J[!5.CC55YQJYR*GD1S5\SD3J NP
M                                    .'(CFJU>2I@Y &F.EM0UNPS:
M9>:&XV^2IHI,QN9G==)%O*L<K%7@O#]Z<%0^&S/:Q2:+OVKKFEMGJ7W9ROIF
M;R-1B[[W)OKV>$G+L-CJBY[.-I[GVNMEM]PJX7.C2"H18:B-4]TC%7#NK[E<
M'CH=@F@*2L;4):9IMU=Y(YJF1S/1GBGER!67<JZ<KKIJJ[ZUN+%2%4DCB>J8
MZ6:1V7N3Q(F4_M>)3: ^%#1TU!214M#!%3TT349'%$U&M8B=2(G!#[@
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MOC=[J-W6BF7.2U9K.I0  @
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M98(Y,\%5TF&_ZL:@;$@
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MX5OK.>_Z3WU3_")ZP/0#X)6TJ\JF#X1#[-<CFHYJHYJ\45%RB@<@
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M3Q-C;Z$1#U@ 5O'I:ON&VI=25-##1VVW4:T]/*F[TE7(].+G8XX:BX3)9
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M>AFNU##5R4,G34ZRHJI&_AX2)RSP3F90
M                   '#\[CMWW6. &LNO=IFG=F]\KK5L[L%ODO"2.2LN$R
M*_=D555S$7.\Y47GQ1$7AA3OLSVS:IN&FM;72\OIJV6TTL4]-$L*1M17.5JH
MN[A53EUYX$=[F.FMU3M,NZZB;$^],8]].E1C/2[_ -D5$7[K^\D7<^T5!+JO
M:?2W6.%]N5RLG;+[CH^DESGL3 %M[(-I-#M$LDD\47>MRI51M52[V=U5SAS5
MZVKA?)A4\:STU+[FE8H]ME]BL#GK9N@J$9O*O&%)6]&J^/W/I4VT
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MBCFHBHIJW@EV@=85&G*UL50Y\UL>OV2+.=S^<WU=9UY/P_4;I.Y2O7O>%/\
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MZ*&8A1&Q,1J(B(B(B(8Q#)P_P3?(2.P
M
M                                                          &E
MM[=M@2\5W>WU:) L[^C1B5&[N[RXQXL 6)MBV$7"Y:AJ-0:)EB;+4/6:>D?)
MT;DD7BKHW<N*\<+CCZ"L+;L4VCSU,T"6V2D9,N)9):MK6/\ RL.55]"GSWML
MW;K?_P#<!5VS+S^K?S)4 ;-[%=F-/LZLT[9)F55WK-U:F=J8:B)R8S/'"97C
MU^A$L8UX[FQNO4U7<UUI]47>/>2]%[)K+N=)TC.6_P!>-[EU9-AP
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M0M!='/1:UB=!6-1,8F:B;RXZLY1WD<!,P
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MGACZDW)%QC^R]/0AL%3?XO%^2GS&N>S[-9W5.JIX$58X6SH]4ZL;C/G V0
M                                           1S:'<;[:M)UM7I2WL
MN%VCW>BIWM5R.17(CEPBHJX3*XR:I:YU?M$KM9:8JK_8^\[K1R[UNI^\WL29
MZN;PPJJKN*-3@IM[J#4%IT[1I5WRX4U#3JN$?,]&[R]B)S7S%67NBM>U#7NE
MKUI?4=MGAL,J35%/EW2.1)&NRB8Z]W&0,GLDU9KZ_P!VJX=9Z9CM=%'#OQSI
M#)"JORB;N'N7/#*\.6"TS":CU59=-244=[KXZ5]8_HX&N1561W#EA/&GI,V
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MO00(J*N&\W*O+"=64ZR6:>M%+8;'06J@;NTM'"V%G:J(F,KXUYKXU R
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MU>['6S5-QMT,-/4Q(G2238F9CBB;B(O!>&<JF,%JGB<9:+9=U0  Y
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M9-WRX5<<E/:     \U'<*.MDGCHZNGG?3OZ.9L4B.6-WWKD3DOB4#T@
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MU?I.>EF14WUA<K'(G;T;T_>73H+6=BUO;9+AI^;?1CD9-'(S<EC7J1R?,O%
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M'-<F45.2H<D#V%7E]]V5:?JYG.=,R%:=ZN7*JL;E9GSHU%\Y/
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MYT[(G.1/=.QX2^=<KYS-@
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M*IX@+!!'=%:G9J.BJ$GIGT-UHI.@KJ&1<N@DYIQZVJG%'<E0D0
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MKP5,IQ0]8 \MIMU):+;3T%M@93T=.Q(XHF)A&HAZ@
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MS57_  'WGV2U*9Z&MHG_ )42M^;)X)=E5T:JJUM"_P#)>J?.A'C\+YXI^_\
MY/#O_<[5^VJ>2CE916AM/4.3#)9)ND1B]N[A,^3*%::AN*W2M;4255;63*Q$
MDGJW)O/=U[K$\%C>QJ$HGML6E;AJ&&]4=.^I6VPI1QNP]N\^1Z*]/&B-^0@I
MZ7!5Q6CQ,==,,LVCW9G;(V"CKKG<&6ZVO<DU4N[N[^ZUV$SQ^4LO9AH"UW2&
MHJ[M)+-44=3)2ST2MW$CD8O%%7.7)A47ACF530U4U#6055,]630O21CDZE1<
MH6=%'<-4:JK*_3+WQQ5M%3U%6QDNXULZ;\;L\>QC?04X_)DQUW3M)ABMIZKN
MIH*>AIV04T<4$#$PUC$1K43R'$E;2Q_PE3"WRO1"J$T)J67^%J8O[<ZK^X^L
M>S6ZO_AJVD;Y%<O[CP][=>EC2W^TQ?PEQI4_SB'DEUA88\[URA7'WN5^8A\.
MRYW^6N3?[$:^L]T.S"A3^%KJAWY*(A QVO\ 4]NU%!:--VVJ<YMXN$5+5*UK
MFKWNF7R(B_SD;N^15+.ABC@ACBA8V.*-J-8QJ81J)P1$0K'5NSR.WVR&[:<2
M>:\6JH9701/?PFW%\*/EUM5R)X\$^TU?*+45FIKG;)>DIYFYPONF.ZV.3J<B
M\%0D9,K7:-6)I;6>GM1T\2.6J26W5C$=N],S=WXU7QM5JX_*+**[K64NMMH=
M-!&C*FT:=;(ZI=[J.6JD3=;'V+N-WE7L5R($.GUTZ?\ DY_PJ>HX7:G3_P G
M/^%3U$O^I:Q_R72_H'5=)V)?^[*;]$CJGHB/UU*?^3G_  J>HY3:I3==O?\
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MK_HA-$;2V>XUBQ?+,_Z -+E!3?U)[4F>YU53.\LB_0./J<VLM]SJ.B=Y9/\
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M%YHIG"OVP1:6VITT=&G1T.IX95DA:F&MJH41V^B<DWF*N>U6HI8!69V  (
M          #A[MQCG85<)G"<U Y!A?J@9UV^O3^PWZ0^J!GO"N_0;](#- PR
M7]G\GU_Z#?I&9:N6HO+*9
M                   CVMM7VO1ULCJ[JZ5[YI$AIZ:G9OS3O7DUC<\5(E5;
M4+C9XHZW5&BKM:K.YR-=6=-'-T65PBR,;Q:GI LX'SIIXJJGBJ*>1LD,K4>Q
M[5RCFJF45#Z(J*JHBIE.8
M                       "IE%3M!PY<-54XX0#5391;+'H3:UJ6QZY9;XF
M[BK15%P:S<<W>RUR.?P17-7Y%3F7TV[[/D;X-?I7'BEI_6:E6C3>IMLNM[U4
M,JH$K&*LLCJN1R-B9O*C6-PB\$Y(GB)9[635G\K63X27_P!,#9[3]?IJKJ)6
MZ>JK1-.UF7I121N<C<]>[U9,Z4CL$V2WK9[J"Y5MWK;?40U-*D+4IG/54=OH
MO'>:G#"%W         475[ 7RUE1-3ZOJX8Y9'2)'WFU=W><JJF=[QE [0Y[
MKH_6=RL++BM4VC>UK9G0M:KD5J+RX]IOD:)=T-]N/47]+'^S::QGRQVM/W1J
M%R:>V)UE[T_;+H_5T\+JRFCG6-*)B[BN:BXSO)GF7+L\TLW1VEJ:S,JWUG1.
M>]T[V(Q7*YRN7@G+F?79[_$/3GYNI_V;3/E;9+WZ6M,IU$=@ %   %;;8=&S
M7RG@NMNC?-64C=R2GCQO319RJ-S]TG%43KS@B%FT5HZ\1_X+JA\50W^$I:G<
MBFB7K1T;L*BE\&*NFG+)=I4ENEGMU9*B81]13,D=CRJF3IQ\5DI7DB>BLTK/
M684G>M(Z2MRNIZ6_55VNKDQ#;[<C)II'=BHW.ZG:YV$0LW97I*32UC=W\J+<
MJM4DG:U<MBQR8B]>,KE>M57JP2:U6>VVECF6JWT=$QWNDIX6QHOEPB'N(R<3
MDR5Y;3T(I6.L0  YU@  "(7#0=(MTGN=AN%=8;A4.WIWT+F]'.O:^)Z*Q5\>
M$7QDO $+?HNXUS.BO>L+U64R\'PP)%2M>G8KHVH_'D<A)[+::"R6V&@M-+'2
MT<289'&F$3M5>U5ZU7BI[0      #!ZFTM;-1=[/KF2QU=*JNIJNFE=%/ J\
MU:]O'S+E%ZT,X (9]2=_ST?U=WCO;&$3O:FZ3'Y?1_+@RFFM)6S3\T]33)/4
MW&H1$GKJN59IY43DBN7DGB3">(SX                   "*770=IK+K)=*
M*2MM%TE1$DJK;.L+I?RV\6O\KD4\Z[/+?6RQOU)<;IJ!(W(]D-PG3H4<G)>B
M8C6+_:129@#K&QD<;61M:QC4PUK4PB)V(AV
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MTRC45$3*^8#:H&L&OH[GIK:ELVL27NOJ5B92QSR],]J5"]\*BJYN\O-.''/
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MEU+H;:##H/7E:ZY4]<W>MER>Y555XX:JKQ5%PJ8555%PG%%0"^
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M?FZG_9M,^
M
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M$G6+HW5,#HT?ATBKA51,\T RG==_:RH_SG%^SD+)V9QI'L\TTQJ81+=!^HA
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M:(=T-]N+4?\ 2Q_LV ;H[/\ ^(FG/S=3_LVF>,#H#^(NG?S=3_LVF>
M
M
M                      %Y* O)< 8;=XJ<HTX6AN:JO^$T?P+OI#O"Y^^Z
M3X!WT@#DPU3,,]PWR(85;==%_P"V4N/Z!?I&::BHU$7BJ(!R
M                                                           #
MPWZCGN%DKZ.CJI*2IG@?'%41KAT3E:J(Y/&B\36O3.U+5VS):RR:[LMTNRMF
M5T=7).Y7(G8USD5'M7&4X\,FT1UDC9(F)&-<G8Y,@:K:GNFIMO=UM5KM=CJ;
M38*6;I)JB95<WCPWU7"(JHF]AJ9YKYMH[=1PV^WTM%2MW:>FB;#&WL:U,(GH
M0^[6HUJ(U$1$ZD0Y
M   7@B@=0&J6RN_VK66T=;%J'1.F4[X=,Y9HJ/HY$<U'.XY5<\ER7_'LST3&
MY%;I6S93MI6+\Z&G&HJ?6[=:7"YQP:@;7LJ)-RI9'*CT3*HF'(G+'#AU'NAU
M/M:B:FY6ZJ5/YS)7?.B@;P4-%2V^E934%-#34[$PR*%B,:WR(G!#[FO7<W7W
M75TU1<X=82W:2A91[T??D*L:DF^WDJHG'&]\IL*         -#^Z&^W'J/\
MI8_V3#? T/[H;[<>I/Z6/]DP#=/0/\1M._FZG_9M,Z8+0/\ $;3OYNI_V;3.
M@
M
M
M
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M,Z8+0/\ $;3OYNI_V33.@
M
M
M
M
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M/XBZ<_-U/^R:9XP.@/XBZ<_-M-^R:9X
M
M
M
M
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M5[1[G<Z2KM=/1)20ME1T4JNWLNQCB@%O@
M
M
M  PF<XX@      &OG=D+_P U=/\ ]=?^HI9>P[[4VE_ZFWYU//MAV;MVCVVW
M4<ES=;VTDSI=Y(.EWLIC'NDP2;1=A9IC2ULLL<[JAE%"D*2N;NJ_'7CJ QFT
M+9]9->T]'#?VU"LI'.=%T,NXJ*Y$1<\./)"#+W.&AE3@ES3_ $G_ (2Y@!2J
M]S;HGJDNJ?Z0GT35S:;8J736O+U9K>Z1U+23]'&LBY=C"+Q7SGZ&FA&WA/\
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M#]8J_N,_XR:B_JD?ZX&UH
M
M
M   &BNW.UW";:QJ66&AJI(W5.4<R%RHO@IUHAO4,)V(!A-#,='HK3['M5KVV
M^G:J*F%14C:9L                               T!NUHN3]IM8]+?6*
MQUW>J.Z%V,=,O'.#?X83L                              !CM2(JZ=N
MB-15<M+*B(G-5W%-'-C]GN,6U+3#YJ"KC8VOB<YSX7(B(CNM<&^@
M                      !"]M$<DVRS4T<,;Y)'T;FM:Q%557AR1": #3+N
M8+974VUJBDJ:*IAC2FGRZ2)S4]QVJAN:,
M    J;NH*>>JV4545-#)-(M5"N[&U7+C>[$*T[CZ@JZ34>H75=+/ BTD:(LL
M:MRN_P",VD
M
M                                                      ?&MJH*
M*DGJJN5D-- Q9))'KA&-1,JJ^)$0H>[]TO:H;A-'9M/5]QH85P^J61(N&>:-
MW5X>54\QGNZIO$MLV6RT\#U8ZX5,=,Y4Y[G%ZIY]U$\YW[F:RT<.QZC>ZGC>
MMR?,^HWFHO2)ON8B+VINM3AY0)QL_P!;6?75C;<[',JM1=V:"3A)"_[UR?,O
M)22FI?<W5;['MIO5B@<J4=1WQ#N9ZXGJK5\N$5/.;:
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MU/O6HYJ?^U-U-B7VJ-+?U)@$V
M
M
M    !1?=?4KY=GMOJ&\60W!N]_:8]$)5W.,K)=CFG]S'@),Q?*DSR7:WTW2:
MNTM<+)7\(JJ/=1Z)E8WIQ:]/(J(OR&N%IM.V#9U0UVFK#;4K:"HD<L-5"QLJ
M1JO!7,7*;N<)P>G#F!CMA<:U?=&7*HA\*..6NE5R<L*KFI^LAMX5%W/^RV70
MEOJ;A>U8^_5S4:]K';R01\]S/6JKQ54X<$QVK;H
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MIT;6/2-J2N7>5<.<G/JZP)^
M
M
M
M
M
M
M
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M5!)'25[&.BKVR)NM5SE;X3>I$5.*YY<2Q@
M
M
M
M
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MH@&Q(
M
M
M
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MY?(Y#9O5.E;)JRE@I]04$5=!"_I(VO<Y$:[&,\%3J A'<RMW=C]H7[Z2=?\
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M@MS95IGZD= V>T/:B5$4*/J/Z5WA/X]>%54\B(!*P
M
M
M                                     =)Y8X(GRSR,CB8F7/>N$1/&
MI$:G:;HZFJ.ADOU*K\X56;SVIYT14+5I:_PQM$S$=TQ!X;/>+=>:;OBTUM/6
M0\E="]'8\O8>XB8F.DI  0
M
M      (MK[0=BUU1TU/J"GDD2G>KXGQ2*Q[%7GQ3J7">@D5OI64-!34D3I'1
MP1MB:Z1V\Y4:F$RO6O#F?<      $/NVSFP7?6M+JBYQ5%3<:5&)"R255B9N
MY5JHSQ*JKY>),
M
M
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MB61K=UR)P553GGM4#<H
M
M
M
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M;L:T_CKZ=?\ ;R%F
M
M
M
M                                                           !
M1=MVI:@J=O\ +HYR47L.VIDB3$2])AL2N]UGM3L+T-3]/*CNZ\J%3W]4)_L'
MFV    "JKOL3LUSVA)JV:Y7!M7WU'5] W<Z/>8J*B<LX7=0M4    *5[K?[5
M\'YQB_4D+J*5[K?[5T/YQB_4D D'<W_:9T[Y)_V\A916O<W_ &F=._DS_MY"
MR@
M
M
M
M                                        :67G4.UZ&ZUB0RZJ;"DS
M]Q$IY%3=WEQCP>6#=,U=N&JMM.C:ZJ[ZMM1<;<R1RL=+2I4,1F5PJOC\+EVJ
M! ?JFVQ+RJ-5_%I/HG9NH]LB\IM6+_HTGT2QK%W3LL3TAU-IM6N1</DHY5:J
M?YM_TBQ]/[=]"7A&-?='VZ9W^3K859CRN3+4](%%;$K'JM^VBTWC4%JNZ*^2
M:2>JJ:9[455B>F7.5.M50W&/!:KM;KK"V>UU]+6PN3A)3RMD3THJGO
M   %*]UO]JZ'\XQ?J2%U%*]UM]JZ+\XQ?JR A(.YP^TSIW\F;]O(645MW.'V
MF=.?DS?MY"R0
M
M
M
M                                                  =.FB_",_20
M[FEM\V,;2I;O72T]KE?#).][%;7Q(BM5RJG!7@;>7FS6.]Q]'>+?;ZYG941,
MDQY,IP*[ONP;0%TWG4]'+;I%^ZI*A43/Y+MY/0B&N_UEMI^?^IZCX_#_ .H=
MV[%-J&/^JI__ +A#_P"H!=6AMA/U'Z^ME\M=_2JHZ9SUD@ECW7JCF.;A%:N%
MYIU(7J:J[&=E^O\ 3^T>SW.]V^6&VP.?TSG5L;TPL;D3P4>JKQ5.HVJ
M    %+=UM]JV+\X1?JR%TE+=UM]JV+\X1?JR A(.YP^TSIS\F;]O(625MW./
MVF=.?DS?MY"R0
M
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MYTTS*BGBGB7,<C4>U>U%3*'T
M                                           !UD54C>K4RY$7">,#
M7G;AMTJ[#>I]/:-2%:N!=RIK7M23<?UL8U>"JG6JYXY3' JJ+:]M2I'=]RW*
ML=#G>7IJ&/HU3]#@GD)7W+-)0W?:)?:^^,CFO$;%GA;,G%'N>O2/1%^Z3Y,J
M;8N1'-5KD147@J+U@5-L*VNLV@Q5%OND$5)?:5G2.;$J]'/'G"N:BJJHJ*J9
M3*\T5.Q+:-3&045F[K.G@TPV-E,M6UKXH/<,5\/V5J(G4BJY<=2^0VS
M    %+=UM]JV/\X1?JO+I*6[K;[5L?YPB_5>"$@[G'[3.G/R9OV\A9)6W<X_
M:9TY^3-^WD+)
M
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MKR1S5]SGCA414R!LJ^:-DC6/D8U[O<M5<*OD0UYV)?;ZVA[O/[+CX9#([.=
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M
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MI*6[K;[5L?YPB_5>$PD'<X?:9TY^3-^WD+)*V[G#[3.G?R9OV\A9(0
M
M
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M;88U5R00)]TJJGNG97R97M)X
M                                              5,M5.T!RX:J\\
M:F[(+#8],;6]1Z=US2V^21&JE&^X1M<QR;V\CD5W!%<Q47Y#8-MCT$J9;;-,
M*GB@@]1J&EIU7MDUS=ZFF:V>KC57/2:5&-@CWE1K$SU)G&$,^G<Z:ZQ_W6G^
ME+]$#:JU6K2E-<(I;30V.*L;GHWTT439$X+G"M3/+)(C638_L6U7I7:):;S=
MEMZT5*LBR=%.KG>%&YJ83=3K5#9L         4MW6WVK8OSA%^J\NDI7NM_M
M71?G"+]5X(2#N;_M,Z=_)F_;R%E%:]S?]IG3OY,W[>0LH
M
M
M
M
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MLHK7N;_M,:=_)G_;R%E
M
M
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MTO.L+KI7:E06J^21S:<OB;E#/T:-=33IA%C<J<T5<<5X^$G8I98
M                        +R7', #2/9[L]J=IVMM2176Z+0UE/*^:=5BZ
M1SWK(J.3FF,*6:WN6J'[K4U3YJ5OTBL-8[176K:[>-0:!_P!LCG0R*J(]E2N
M<.D5JIA$<J(N.WCUF29W1>ND3"K;'>-:7_B N'9[L"H=&ZOH+[#?*FJDI%>K
M8G0M:CMYCF\5S_.+K-9-D.VO5>JMH=HLUU2@2BJG2))T=.K7<(W.3"YX<40V
M;         %*]UO]JZ'\XQ?J2%U%*]UO]JZ'\XQ?J2 AG^YN^TQIWR3_ +>0
MLLK/N;/M,Z>_S_[>0LP
M
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M)]#:ABD1%8^WSHN?Z-Q5_<BS/DV:UC'JJMBN,C6>)%9&OSJH%W
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M -O(6:5CW-*YV,V'RS_MWEG
M
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M_*G_ &SRT"J^YBB='L=M"N=O))).Y$^]3I7)CY/E+4
M
M
M               8&$[  &$[
M !4145%3*+U'FM]OH[; Z&W4E/20N<KU9!&C&JY>:X3K4](
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MWD++
M
M
M
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M"0=S=]IG3WDG_;R%EE:=S=]IG3WDG_;R%E@
M
M
M       ?'ONG3_+Q?IH.^Z;WQ#^FAAY**FZ1Z][Q<U^X0X[QI5YT\/Z" 9I*
MF!>4T7Z:'T:Y'-16JBHO6A@?8^C7_LT/Z"&8H(VQ4D;(VHUJ)P1$PB<2!]P
M2    &GUGVHW_3>U>YSU]PKJO3\=QEAJ8'O=(R.-9'(BHB\E3'#R8 W!!\Z6
MHBJZ:*HII&R02L1['M7*.:J914*+[I'4=YL>H]&PV:Z5=#'4OE2=L$BM21$=
M&B91.?-?2!? !U<]C%1'N:U5Y97&0.P!QO)O8RF>P#D X8]KTRQS7)VHN0.0
M JHG-0    ZMEC>Y6L>USDYHBY5#Q:@E?3V&Y31N5KXZ:1[7(N%14:JHH'O!
M4W<SWFYWW0-35WJOJ:^I2ND8DE1(KU1J,9A$5>KBOI+9  '#7->F6.1R=J+D
M#D ZR/9&W>D<UJ=KEP!V 1<IE.*!51%1%5$5>0  X:]KE5&N153J10.0%5$3
M*KA BHJ914P  145."Y  #(  $7VD:TH-"Z9GN]Q19%1>C@@:N'32+R:GSJO
M4B*!* :XV>DVN[2V)=77I-,6>9-ZGCB56*YO4J(WPE3QN5,]2'SU#;=K6S6F
M]F8-1NU':X/#J8Y<OW&IS56N\+=\;5X ;) C6SK5U'K;2='>J%-SI4W)HLY6
M*5/=-7YT[45%)+R $3VHZS@T)I&IO$T/?$R.2*G@SCI)'<DSV<U7Q(2MCVO3
M+'-<GB7)Y;E;*&YQ1Q7*CIZN.-Z2,;-&CT:Y.3D1>L#7YU=MWGH?J@C6BCI5
M9TZ6U(HM[<QG&ZJ*[EU;V\6ML@URW7VDFW)\"4U;#*M-51)R;(B(N6]>%1R+
MZ4ZC[[1M;T.CK5EZ]\7>I3HZ"@C\*2>5>#4PG5GFO[R$:.IY]CNR^2X7>WU5
MQNE?6=\U5/1MWG1OD3W/D:C>*]JJ!9MYU+;+/>+1;*^5[*RZR.BI6MC<Y'N:
MB*N51,)S3F9DU.UIMEAN^NM'W9M@N-/'9Y97NIY51'S;Z-3P>'-,%V[-]J=+
MKBY344%CNU!)'&LJR5$:='C*)C>SSX\L 6( <(YJN5J*F\G-,\0.0   3CR.
M'.1J9<J(G+BH'("KCF   147.%Y  ,IE4RF4Z@ !U8]C\[CFNQSPN<'8
M                                   #J U1VI[*-3:<U;/JG9ZM544L
M\CJA.\7+T].YRJKD1$XN8N5QC/!<*G6M9VRY:_9JBMK[<R]-OU:UT4\D5,[I
M7HN,IA&\.2<L8P36ZLVI;+;S755$VOCM+ZA\K=W%12N:KE7BWBC57S*3'1_=
M-QOZ.'5MG6-V41U30KEOE5CESZ%4#)]SSLEN5DNS]5ZP8YES<UW>U/([>>Q7
M^ZD>OWRHJHB9ZUSQ-@2.Z/UMI[5],LVG[G#5*B9?%G=D9^4Q>*$B
M %*=UQ]J^#\XQ?J2%UE*]UO]J^'\XQ?J2 AGNYL^TSI__/\ [>0LPK'N:E_Z
M&K#XEG_;/+.
M
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M?"+Z@,L#$^R%;[WI_A5^B$N%;[VI_A5^B-ITRP,6E=6K_P!G@^$7U'/?M7^
MB_37U$;1IDP8I:^J3G##^DOJ.$N%4O\ DH?2I(RP,5W]5?@X?2H[^JOP</I4
M#*@Q7?U5]Y#Z5.>_JK[R'Y0,H#%]^U7WL/RCOVJ^]A^4#* Q??M5]Y#\H[^J
M?O(?E R@,7W]4_@X?2H[^J?P4/Z2@90^57 VJI98'/E8V1JM5T3U8Y,]:.3B
MB^,\/?M5^"A_27U!:VKZHH/TE]0&)^HN'JOFHT_^IR>LBS+'5+M*ELOU1ZA2
MWMM3:M&I7NW^D696\UZL)R+ 955KEX0P?IKZBM:/4S)-ME2Q5B5W>7L:QS5\
M%7M=TB\?+EOE0UQX[9-Z\HV3:*]TS;HUB>ZO^HW>6X.3YD)/$Q(HF1HKG(U$
M:BN7*KCM5>9CGUE:WE3PKY7JG[CYK7U_52T_PSOHF6T]67(Y<M)05];-4NNM
M[@=*N59!7O8QOD;R0]?LA</>=-\.[Z 2X7!?^QTWP[OH TAVKM*^QM!2S4E^
MU"CY*^EIW;UP>Y-R2=C'>?#E,W]0L/\ +^I/_N"^HP>U;44MML-(M5! DO?U
M//'&R95<[HI6R+]SRPW'G0F<%SJ*FFBJ*6&!\,K4>QZ2KAS53*+R-)I:*Q>>
MTHBW73O8;,RS12LCK;A5](Y'*ZLJ%E5,=29Y(90Q'?\ 7^]:?X9?HG'LA7^]
M:;X9WT3-+OJ*]Q6*C94STE?5-?(D>Y14[IWIP5<JC>*)PY^0CZ;1K?GC9M2I
M_P#29E^9#/-KZ]?^S4WPSOHGCO\ J&:RV6JN-5# D<+,HB2*JN=R1$X=:X)K
M'-.H[H[=V+I]I=GJ4>M-;[_,D;W1/6.TSNW'MX*U?!X*G8>ZV:WH;C7PTD-M
MOS))7;J.FM<T;&^-SG-1$3RD)V+ZFFK%O=*^.)]945;[@J.D5J>'A'(U,+P1
M4_UBS'5M8W_LT'PR_1-,V*<5YI*M;1:-PR8,5W_6^]Z?X5WT1W]6=<-.G]M?
M49+,J#%=_5?X.#TJ._JO[R#Y0,J#%=_5?WD'RG/?U5]Y!Z5 R@,7W]5?@X?2
MH[^JOP4/Z2@90&+[^JOP4/Z2^H=_57X*'])0,H#%]^U7X.'])1W]5?@H?TE
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MIKZAW]5_@H/TE RH,7WY6?@X/2IS'5UBR-:Z*#"KC*.4#)@
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MKS2?)-+<T;=43@,'(0S6<8.4  Y0[Q?PC?*?,[1_PC?*@&4
M     &%DZ=9'XI)U3>7CX/'Y3I_A*?\ 8IU_1]9G0!@%=4HG^(5'^KZS,4&]
MWI'OL<QW'+7<TXGW
M
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MC&.)/>^M<JO@V[3N/'53?0,,VVZW;JYU^6BL+I74*4/1)52HW=Z3?WL[G//
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M*=4.T?NV^4#*@ D
M
M                                     !51$555$1.M2E^Z%VA7?2$F
MF6:;KX(EJYI.^/ 9)EK=S"<<X3PEY 70#I'-')_!R,?^2Y%.X
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M8TQ(GE R8
M
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MRHI962PO1'->QV45.U%.\?ND\IX\.ED
M
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M;<J?T#209" 8!-#Z73E8K?\  H>ZT6"T6::26U6VDI)9&[KWPQ(Q7)V*J&1
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MT(GAIY3QN*G';)-L<])=--Q75F0 !SK@
M
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MJ>X3Q6K1%3<:-JIT=2ZL2G63@F? >S*<<IY@):"OJ_6^KJ"*.2KV=3,9)+'
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M)R_1.._XD_R-=\1F^@ NE!3W2BDI*UBO@?C>:CE;R7*<4XD?70%@=_V>9/\
M2)/62'O^)?\ (5WQ*;Z)RE;'^ K?B<OT1T2KZSZ+M$VJM04LD=2Z"G[WZ)O?
M,B;N]'E>OK4D,6@K#'*R1M//O,<CDS4R*F4\6\?+3EQIW:RU3NMJ79=3)X-/
M([E%QY-)-W[%^!K?B<WT0/2JG&3S+6Q_@:WXG-]$X[]C_ UOQ.;Z)*'I!Y>_
M8_P-9\3F^B<]^Q_@JSXI+]$#TY!Y>_8_P59\4E^B._8_P59\4E^B!ZD4AVOW
MNM6H=):D?GO*@JGP5CD_R<4S=S?7L:CMU54E'?D?X*L^*2_1.E5/1UE)-2UE
M-4RT\S%CDC?1RJCFJF%1?![ )*UR.:CFJBM5,HJ=9R5A21:@TE3NCTPZ6]VB
M-/L-LKX98YH&_>QS[JY3L:]O!.&\>:W:KU7K6T=-04C-,T,JN9WST<E=4KA5
M1=QK6(QO%%3*JJIV ?/:7!4:OUI;K+9I(O\ D>)]55S.RK8Y'HC61Y3[I4WE
M\2&+33NL+;GO661Z)R[WJU^9V"<:7MELTW;%I*"*Y/5[UEFGFI9WR32+S>]R
MLXJIE>_HOP5;\2F^@!55XU1K/3]GK*JI95JR")SU=)3L>B83FKD3Y2U=G5F9
M8]'6RE:N_,^))YY%YR2O\)[E\:JJGDO#*2[VBMM]3!5N@JH7PO3O27DY%1?N
M?&>?97?75MD]AKFY67RT(E-4Q2(K7/:G!DJ(O'=<U$7RY0";$.VOV^.X;.;[
MO)B:FIW5<#TYLEB\-KD\[28D"VP77&FY=.V]O?-[OC5HZ:F8OA;KN$DB]C6M
MRJJO#D!FK1,^KL]!4R<7S4\<CE\;FHJ_.>DIZADU?I:F9%)#<XJ>%J-1)8UJ
M(D:G),^%NIY%0SMLVDJJ-2X4+96_=24K^/Z#E_WB-ITL0A^UJOHZ?0-[IZBK
MIHJB6E=T<<DK6N>O4B(J\3SU6J7:JN%/I_1M2ZGK)HUFK:V2)<T,**B<&JF'
M/<JX3J3BI)K+L\TU:XW*MLAKZJ3C+5U[4J)I5ZU5[\KYDPGB)0R-'-!5T44U
M)-'-$J(B/C<CFKYT/INX17.5$:G%57J(W>-GM-3O=<=%/98;RSPD2!,4U1C[
MB:)/!5%[41%3GU%>,OVI->R34:44E.VFD6"KI8VOZ&&5BX<DCD15?Q3@B<.7
M#K($QU/KZEH6R06C<J94X.J%7[$Q?$OW2^3@0.OTMJC74$KIF(V*5JHVIN"N
M8C?''&B;W#J7P?.3W3&E;3:)&5-PCK*^O9[ERV^9(XOR&;N$\JY4ESKG!CA%
M7?$9_H 5G)JG:5IAE);[G:;3<:=C$8MV1\NZJ(GNI$:BJU>'%<8SUF,LFL=6
M6>WOBT_;K!J)U1622.BMM5)(^-[W*Y=[P41K4[55"WVW*%/\E6X_J,WT")[*
MJ^FAL-R8R&J3-TJW>!1RKSE7FJ-Y^)>)(\FE;5K:76B:BU7%9$WX.]V012/<
MZDBRJJC.&%<Y<9557@F"Q<^'YSQ.N,:KPBK?B<WT3AEQC5[42&MXKUT<J?[H
M&>
M
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MTW9(78Y.3YE3@I)C3GN:J^MTYMBDL4RJC:I)J.HCSPWXT<Y%\J*Q4_M*;C
M#Y5<3IZ2>*.5T+Y&.8V1J95BJF$<F>M.8&JO=&;5*B]7.HTCIR1R4$,G0U<D
M?.HE1<+&G\U%X>-?%SG?<_;'VZ78R_ZFB8Z^/3[! Y4<E*U>O\M?DY=ICI.Y
MAM;Y5D^J:X[ZKO*YT+%55[<Y/4WN<8$7/U97KS(B?O OLQ=TT[9;M4-GNMGM
MU;.UNXDE13,D<C>S+D5<<5X>,[Z;M:62PV^V)43524D+8>FF7+Y-U,97QF1
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MZZNBI66:^PND7'23T3F,;XU<J\$)(
M
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M&/T7<79QK;4B>1T'_IDLH8'4M'! ^>6H=&Q&++,J*]^$YNPB)E?(?<
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MK^C;^NT$,W8;):[)1MAM%NI**-417-IXFQ[R]JX3B9(ZQ_P;?(AV
M
M
M                            #6W7W=(U%LU!76[35HI:B"DE="M352.5
M)5:N%5K6XPF47'%<IQX$7]L[JK^1[+^A+],#;H&N.RC;QJ#6&O;78KA;;7#3
M5:R(^2%LB/3=C<[AERIS;V&QP         I3NM_M80?G"+]20NLI3NM_M7P_
MG"+]1X3#.=S6]&[%[$KEX-Z?/PSS);*Z=+G3UVK:UB.N-VGDW'KQZ.F8]6Q,
M;V)A,KVJIBNYL8DFQ:S,=R<M0GIF>938Y,M'8:K3=8YK;E9*F2"2/DJQJY71
MO3Q*U4X^)0A/C!:WT[!J?3E7;ILME<W?IY6KAT,K>+'HO4J+@SIB=5WRETYI
MZNNM<]&Q4\:N1.M[N36IVJJX1$\8$8T/M!MEPTQ;Y+O71PW-K.BJF.:Y,2L5
M6NZN64521MU78G<KK2^=^"O=(;*H9--4,]UK+A3W*H9WQ41,5FZQ[U5RMPK5
M7AG',R;ME%-GP+O5(G\Z-J^HA/1WU/6P:TU)0Z5M]7TEJZ%:VZO@?C?B1VZR
M'*=3G9SXF^,L&DIH*.FBIZ2&.&")J-9'&W=:U$ZD1"K=)V1-$;4WT<M0^HI[
MY;T2GF>F%26%RJYGZ+LIY%+7)0^59305E++35<+)J>5JLDCD;O-<B\T5"D9+
MEJ32&HJ[1EF?--0Q,2LM[HZ=T\S*=ZJG19XHB-<BHBKU8XEYD$M4O?\ MDO4
MM,B.@M]JAHYI$ZIGR.DW?,W"^<"*4FA-1WZ=M1>I4IT547?K)%GE3R,1=UOI
M)?0[,K#'"YMQ9-<GO8K'+4/\'"\%PUN$3YR;@:3M7%IK;KL_8EJO5+5W'3</
M@45SI8W3201_<QSQM17>"G!'HB\$3)[TVJ:5F9(EOJZRXSLX=[T=!/)(J]F-
MS@OEP3@AVD/XZZV3.42IIL>+[ T(>2T6RYZHU#27_4U"MOHK>KG6RVR.1TB/
M<F%GFQPWL<&MX[N5ZR0W/2=AN3MZMM-'))^$2-&O_23"F; $%J]F-FE:Y*>H
MKZ?/)J3=(U/,]%^<\FP>CCHM%5$6&I6)<JMM6B<%25LJMPJ=2[K6_(6*5U<>
M^= ZGN-XBI*BKTQ=WI/7-IV*]]!.B86;<3BYCD1-[&516Y\0%B@Q]IO=KN]$
MVLM=QI*NE<F4DBE1R>?CP7Q$0U1K=*VHET[HA4N5^F3HGSP+O06]%X++(].&
M4YHW.55, =MC4:16*]10?XDR]US:7'+HNF7&/%G>)Z8G2=BIM-:=H+1196*E
MCW=]W.1R\7/7QJY55?*98        "/:FTC;K_/!5RNJ*.YTZ8@KJ.3HIHT[
M,];?YJY0B$4>LY-:RZ=FU9&VD;0]]I4QV^-)W)O[FZJKX*+XT0M A<7';%4>
M*QM_;J$PRFF-(VO3LM34TK)9[C4KFHKJIZRSR^5R\D\280D  0$)U?:KE;;Y
M%JO3<"U57'$E/7T"+A:N!%54W,_Y1JJJIVY5"; "*V?:#IFY1+FZP4-2S^%I
M*]W>T\2]CF/POG3*>,Q]ZV@03O=;M%0_5!>'^"U:;PJ:!?OI9D\%$3GA%55Y
M'JVD6RBK*:SOJJ2GED2ZT;4<^-'+A96Y3*]2IE,$LIJ>&EB;%30QPQ-Y,C:C
M43S(!AM%6%=/6)E+//WS72R/J*NHQCIIGKESO)R1/$B&=  &!U)I&R:B<R2Z
M4+7U,:8CJ8G+%-'^3(U4<GI/9?8+K44T;;)74U%.C\O?44RSHYN%X(B.;A<X
MX\3!.MFM5]SJ6TI_]*=_ZH$8T!HNT7&HO,]Z[\O$E!=9J6G2XU+YV1LC5N[X
M#EW<IVJF2U6M:QJ-8B-:B81$3"(A7VG])ZMLC;@E/J:V2=^U<E;)TEK=P>_&
M]C$J<.!G;?0:K970OK[[;)J5KLR116US'/3L1RRKCRX"4E  0
M                8/6&FZ;4UI[TGDDIYXGI-3542XDIY6^Y>U?W=:90S@ K
MMNJ-3Z6II&ZOL<USI*=JN6ZVG=<CF)]T^%51S5PF55,H?9-3:FU)3,32MB?;
MJ:=J.;<[LYK4:U4]TR%JJYRXXIG"$FUHF='WU/\ Y"?]FXZZ'_B;8OZC#^H@
M#2.G:;35K=34[WSSS2.GJJJ7^$J)G>Z>[R]G4G S0 '661D3%?*]K&)S<Y<(
M>?V1HO?E-\*WUBYVZBNM$^CN=)!5TK\;T,[$>UV%RF47QF ^MWH[\6+/\49Z
M@/#INXT*:\UAFMIO"6D5/LK>.(L=I+4N5"JX2MIE7LZ5OK(\FSC1J*JII>SY
M7G_@K/4=X]GNCXWM>S3-H1S5RB]ZLX+Z E*  $                     "
M-WF'5C[A(ZSUEFCHE1-QE3!(Z1%QQRJ.QS\1'=3Z?US?K'66N:YZ?CAJ6[CG
MMII=Y$RB\/"\18P AB4NO6L:UMQT[P1$RM++Q_UC.:<COL<4WU15%OGD54Z+
MO.)[$1.O.\JY,N
M
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MK7#*RLN]9<WO<BH^I1B;GB3=1#+
M   ,-?-,VR]SLFN,=2Z1C=Q%BJYH4QG/)CD1>9F0!$9=G.FY8G1RTU<^-R;K
MFNN52J*G8OV0XCV<Z;BC;'%35T<;$PUK+E4HB)V(B2$O &%LFF+79:AT]O95
M-D<W<7I:R:5,>1[E3SF:
M
M
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MW2<\>0S5AU#!>I98X*.Y4_1M1RNJJ1\+5\2*Y.*@U+,@ (
M
M
M
M
M           !U :V7;N9IJ^YUE6FIF-6HF?+NK2*N-YRKCW7C,?+W+E<C5Z+
M4],J]6]2N3_>,A<>Z?6BN%52_4FC^@E='O>R&,[JJF?X/Q'F=W4[U3P=(M1?
M'</_ .6!@]A.BV6/;;4VN^5JP7BSJZ2")B994M5BHJHJ\?<O:Y$YXSV&W!I[
MLPO=TV@=T52ZBBH^]_"66=L:JYL,38>CXN\?!/*IN$         *5[K;[5T/
MYPB_4D+J*5[K?[5T/YQB_4D!#.]S5]IFP?Y_]N\LTK+N:OM,V#RS_MWEF@
M
M
M
M
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M-@\L_P"WD+-*R[FO[3-@_P _^WD+-
M
M
M
M
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M
M
M
M
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MJ*6[K7[5T7YPB_5>"&>[FW[3.GO)/^WD++*T[F[[3.GO)/\ MY"RP
M
M
M
M
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M:M>%7V2HL)Q_AV^LZ-OUG<F6W6WJG:E0SU@9(&.]G;0G_>M!\89ZSCV?L_\
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M@>@
M
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MI_\ $]'\6?ZRJKCH"JH=J3-%OKXWU#JF.F2J1B[OAHU47=SGAO&_IJ5J/_\
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MLLU3_4)/F*N[C?\ BMJ#^N,_4 C2]RY=.K4U'YZ9WK.OM7+M^,M#\7?ZS:H
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M(V)&QK&IAK41$3Q'(
M
M
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M&9D<;$RYSE8J(B(G-2E^Y1TW>K"[4;KW:JZWI-T/1]\PNCW\;^<93CS0V#
M
M
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MBOA?V+XNQ>L"5@
M
M                                                       #B1[8
MV.?(Y&L:BJYRKA$3M-?[KMKU/?;I71[,],MN5MM[L3U4['/63CA%:UKDPBX7
M'-53CA"\[]1.N-CN-#&_<?4TTD+7?>JYJHB_*:@:!VA56S;1FL--R1NI=0I5
M-2E5T>=R1? D5<\/!1J*F>:J!L+KO0+=I>AZ)M^IH;;J)L#9&21^'WO*J9<Q
M5ZVYX*GHY%-[(-5UFRC6-=I#6\704M5*U4J,Y2-Z\&OWNN-R=?5Z3ZW_ &>:
M^L6EH-8V_5]?6U[84K*F!LS\L14WEW<JJ/1$7BBHG7A%);:;=0[>]ED-7=&Q
M4VI:)SJ=*N-N-V1.*93[QR*BJG4N< 9;;CLA@UM2^S.GDB@U#$U%RBHUE6U.
M2.7J=V.\R\,*ECZ$MMTM&DK907ZO2X7*"%&2U"-QO+U)X\)A-Y>*XRO,\>S'
M359I/1E!:+C<I+C40-\*1WN6?S&<,[J=6>/D3")*0*KVI[9*#1-U99J&W3W>
M]N:CW4\3MUL:+Q3*X5554XX1.781G2VWC3FKY);!K.T):V5?V%>F>DL#\\,/
M5416>7&/&A&Y;O'LX[I*[W#5,:^Q]U:[H:M6[R1,>K51R>)-W=7'(\>WUFG-
M?ZKT[2:$EIKAJ*L>Z.>2E7+',PFZLCDZTPJYZDSGJ Q6LM'7;8OKJW:FLS5K
M=/QU#GTZN55Z-')AT3^Q5:JHCNO"+SX%_P T6F-L^S]'(B24TR+N.5/LU',B
M?(Y/0J=J*5]W/M]DU)9[WL^UM VKEMB+$D<_%5B:[=5B^-CD3"\^*=A*]EVR
M6306KKM745ZG?9JA-V"A[?'(J\U;Q1%3S]@'EV![/-3:"DO$%YND$MKDDQ34
ML2JY%5%_A<K[C*<-WKZ^29L/6VJ;=H[3E5>;P]R4T&$1K$R^1R\$:U.U5,TZ
M:)DK(G2,;*]%5C%<B*Y$YX3KQE/25'W3NEKKJ;0<*V6.2HEH*A*B2FC3+I&;
MJHN$ZU3.<>4"'>V)O5)64=?=M'R4VFJMV(9LOZ1S<\7-<J(UR]>.'EZST[<-
MD\>IJ%NLM#,;WY+"E1/3PICON-S<H]B)]WA>*?=>7G#=9[1:_7FCK+HFFTM-
M27*L?#'&^5<,56+NHL:83AP5%5>29/9=+_M4V0^P;K]54];8(T93,A8QCHU:
MUN$C5R-1R.W4X+GCCKX@6%W/>T>BU5IV'2UY;&R[T4'0=%(U-VIA:F."+UHG
M!R>?MQB*W8A<[)M3MM[T'7,MUK=+TLZ.=E:9,^$Q&_=M<G!$ZNOAQ,KJ39)0
MZMOECUGH^X.LLU4Z.LG?$F-YKDWND8G4_"\>I>OKS=;$Z.)J.>KMUN%>[&5Q
MUKU =BC]N>UF[Z!UE9*.@I8I+>^'OBI;(WC.BN5NZUWW*HB9SVJA<M-<Z"JG
M=!35M--,WW4<<K7.3S(I1/=6VN!\^C;K4Q))#'6K33-7DK'*CL+^BH$YKZ33
M&VW9\CH7Y8]%6*56ITU',B=:?.G)4\RE&;/KQ<]ANT2LL^K856UUZ,;)41HK
MFJUJKN3,7K:F514YIQX93!\=2NN6P?:$E1IJLBJ;1<&](VCE?O;T>?<O3FBH
MON7?WH6/H&V3[9]EU0[7,M+45"5$G>%73HB3TZ]>\B<$X_<];<9ZE D^V#9C
M;=I-DCN%KD@BO+8D?25J+X$S%XHUZIS:J+P7JSY4)+LHLEYT]H:W6W4E=WY<
M(6JBNSO=&W[EF]]UA.&3X;(M&UNA])LM-PN\ER>V1SF<,,A:J\&LSQQU\>M>
M'CFH      /%>[I262T5ESN4J14=)$Z65Z]343J[5[$/:0S;-9*K46S'4%LM
MZ*ZKE@1\;&\WJQZ/W4\:[N/.!6-NVNZ_U-7PUFDM&12Z?DJ.@9)4;RN?QXJK
MT<B-\N%1%X94DNV_9)%KBB]D[2D5+J2!G@N3@VH1/N'+V]CO,O#E3>FMI-=-
MLQTYH?3=2ZWZ@GN"T+YT3=W87O54<CON55TB)E./@KVF5UKI;7FR3O?4ELU/
M5W6AC<U*GI7O5&JN.#V.<J*U5X9Y^0D9WN<MH"6IZZ"U2Q:&OIYGLI'2INY<
MJY6)W\[.<=O+LSE-J>Q&>OU-1:AT#-';+B^I:ZI:CMQC%SGIV8Y*G-6ISYIQ
MSG[:MT#;]LNE+/JVQR1VR^3Q,<Z1<[C\+AS7XXY:J+AW/ACLQ=%EHY+?::2C
MGJYJV6")L;JB;&_*J)[I<)C) ^M!'/#14\=7.E14,C:V29&;G2.1.+MWJRO'
M!46T;;I1::O\UDL5HGOEQI\I4=&_<9$J<VY1'*JIU\,)V\RY#5O9?J.EV8;5
M-4VC6K4IG5\V\RX2-54QO.<U57[UR.SGM3CX@D]EVH:/VO43]*ZLMS[95U2X
M@Z21',Z3[E8Y,(K7]B*F%Y<<X6O+0RZ[!-J#'WB-]99:J-8.^6-STD&45%;G
MDYJHF6^M%.^UNQVC7^U&"GV9)!4UCZ5]17S4ZX@5[<JCLIPWEX(JIP55;UY+
M%V1UE+M=V8UNGM8L=45]M>D#IG?PK45%W)$5>3DPK5[<<>:@2S:1H6Q[6M)P
M5MOG@[]Z+I*"X,XIA>.X['-JKS3FB^=%].P[2VH=):.9;M47&.JD1V8(&>$E
M,S[S?^Z\G).I5/GL4V>UVSZU7"CK;PZNCGG5\,+4Q'$WM3/'>7KZN'G+$2:)
M9G0I(Q96M1SF(Y-Y$7DJIV<% AVU+:';=GUE95UT;ZFLG<K*6DC7#I7=?'J:
MG#*\>:%9:>V]72'5%';-<Z9=9Z:O5J02X>US$<N&N<C_ '3>U4QCL4[=TG9+
MS3ZCTUK*V42W*CM#DZ:FW5<C%1^\CE3L7DJ]6$(/KW4-XVT:FL=BL5@EMEPH
M&OJ7.K'X<S*-7*\.#>#<=N\@&7[H+8]);UJ]4:/A5M&_PZ^AB3W''*R,3[W*
M(JMZN:<.5F;(==VC:9H]UJND4+KC% D-;12)X,K<8WVIUM7Y%\RK75OV@;0-
M [0J"T[2JB.LM=P<D?2)&Q&(U51.D8YK4Y*J91>KJY*36IV)PTFU"WZFTU<'
M6FC:]9:JFA3CO=D?#"-=UHO+CCQ!BM(;&KSH[:Q[)Z;NS:73.[OO8]=]\C55
M<P*WKQA,/7EP7BJ%\G#W-8Q7/<C6HF555PB'FHKE0USWMHJVFJ',]TD4K7JW
MRX4"A=8;<;AI3;%6VBXTS7:=IE9"^-C$Z5,L1W2HO7[KERQXR8;3M!6;:WI:
MEN=EJH$N*1[]#7MXM>WGT;\<=W/G:OG1:\VQZ6H;CW0E@@ND2K07NDZ*16KA
M=]&O:CD7M3['Z"")JK4VQ.]WW2]#6TU93R,58E5=Y(7.;X,J)]R]$QEJ\%X>
M4"7]S_KB;0U\J]":RC=1(ZH7H9)>'13+A%:Y?O7<%1W+/B7*3?;/L874U<R_
MZ1DCH-0->UTOA*QDV%]WE/<O3MZ_*=+CL^7:SLQLESO4]'#JM:9KV7"E1%8]
MJJJHV3'/AC..3LXX91;5T79ZFP:7MMKKKA+<:BEB2-]3+S>OJ3DF>.$ ]=@I
MJRBLM#372L[]KHH6LFJ=W=Z5Z)Q=@]X      !'-H.L+?H?3,]YNN^^-CDCC
MBCQO2R+R:F?(J^)$4K;0.T':+J34EM6KTC34NG*[,C9W;[71P_?;ZNPJ\4PF
MZF]U<.)].ZOL=7==G,591(]Z6VJ;431M_!JU6J[S*J>95(/)KBZ;5*S26D=+
MW26S-DHDDN<T>6.21B+O-;C"JB(W*(BHB[R9Y 9G;]L:?<'U6J-(Q[M:C5DK
M*)B8Z;'-[$3[KM3KY\^<BV!;1Z/66GF6"[I$R\T</0OA>U-VIB1,;R(O7C@Y
M//R7A6]UEUGL-U;03UUXJ;QINKDW7+*]SFR-^Z3=<J[CT3BF%X^DL756QJFO
M>LK3JK2=Q6RNDD;452P)A79X])'U(Y>2HO#CGM10Q<>Q*Y:>VI4%ZT/<VVZS
MN<LD['JKG0IGC$C?NVNZLKP\R9OFHFCIX))IWMCBC:KWO<N$:U$RJJ=T3"(F
M57QJ1O:5:JN]Z"OUMMJXK*FD?'%QQE<<O/R\X%/Z@[I.""NG^I_3=1<;9 [<
M?622K$CE\2(UV$7JRN?$9":X:1[H+3,M!$KK=J&D;TL*3(BR0KUJBI[N-5X+
MYEPBX,'W.VO]-6;1]5I?5$M+:ZRFFEZ1*M-UL[7+Q1RKPWDXMPO4B%372BGI
MM4ZAUALU;/#8+-5L='4MX)'O\,-1>;,Y3"_<JF>8$YV/ZHJMDFMKEI;6L704
M]9*U752Y5&/Y-DRO-BIU]7I++VY;(8-<TS;SISH(;^QJ>%G=CJV=6\J<G(G)
MWF7J5/37Z?M6V[9=;+I41QTMUE@58:EB96&5%5KFKVL5R+P)ALNTO6:/T=1V
M>X726Y3PY7I'>YC1>3&=>ZG5GY$X('NT);;M:-*6Z@U#<DN5RAC1LM2C<;W8
MF>;L)PWEXKC*D2VK[5:?1572VBV4$EWU%5HBPT<2KAJ*N$5V,KQQP1$XXZBR
M(IHI5>D4C'JQVX[=<B[KNQ>Q36K:337S0FW:/6S;3/>+75HUC$B:KE8JQI&K
M$7"[KN&4[<KXP)/L_P!K'U:7VIT5KS3K*"X5+7L2%[';DF&JY6/8[BU=U%5%
MZ_%P*OUOHN[[%M:T&I;&CJRPQU&_$K^/1YX+%)Y4541W7XE/9)5:KVL[3EU'
MH>@99:JRP-@Z:J<BJUV7^ZRU45R[SDQA<(A)=G>L]15VM:W9SM7ABKDK&NC3
MIHV-5'(W>1,M1$<UR)E%YYQA0+0W=,;9]GZ.5O2TLZ+A5PDU),B?(Y/0J=J*
M1O8)LZU+H*X7R&ZW*)]G>_=IJ=GA=*J8^S?S.'!4YKU\D5?9LPV2RZ#UE=JZ
M@O,ZV2H8B0T7:O\ XF4X[O4J<5SQ\=IU55!21+)53Q0QI]U(]&IZ5 ^O4:Y:
M4[H":/7USM>KHHX+4^K?#3RL:B+28=NHC^UO#BO-/)RV'I*JGK(4EHYXIXEX
M;\3T<GI0U8K]GUNOVVK7>GZU.@GJ(%KJ"=%5.BD56NSCK1=Y45.P"8;>MD*:
MAAEU/HYC$N:QJZJ@B7A6,QG>9CAOXZOND\?/W]SQM'H]1V&GTE>6,BN]#!WN
MR-Z>#4PL3')?ND1,*GBSVXI.R;4]8:+H9]'T=?2/=2UB10U3W)(D*-<J.8CE
MX*Q5QSY)G'BO#5NQA-0WZS:FLUPBL=X5S)KA)2(KF.?C*R1?SLYY\%3BO'.0
MQM5L1N5GVHV^^Z$N$5KM?2)+4,<JJL29\)C6X\)KDZE5,>@OPZQ-5D3&N>Z1
MS41%>[&7>-<<#L      "!;7-I%'L]M=,]]*^NN5:Y64E*Q<;RIC+G+U(F4Y
M(JJJIY4GIKKW4]/66G46CM701.GIJ"9&/:J>"U[7I(W/Y6%3^R!--F.I]?ZA
MO551ZTTO26^V=!O]*C7,7PN3<.<[>RF<IPQU]A5&VC936Z+NJZNT:S-KAF;4
M2TS4SWJ]%SG'7'GT9[#+R7*[[;]=W&AT]J*ILVFK?3L>SHT<U\CE3FYJ*BKX
M2JG%<(B)UJ>71]^U/LVVDT^B]:UCKI9KHYL+'3.65JI(NZU[5=QPJ\'-7AS
MMC0>JK!M=T5/!6TT4CU8D5PH).;'+]TWKPJIEKDXICM0BNRW9)?=![2JZJH;
MLWZEW1KB-RY?4(N=UCF\D<Q<+O=?#'-43(V#8NS3>U%FH=/766@LZL<Z2BCX
MN5RK_!Y7*+&O/CQ3'#J5+A \=XN5)9[55W&XS-AHZ6-TLLCON6HF5_\ Z% 7
M#NF6QU#IJ#255-:4?N-J9JCHU=YD:J(OBRI9>WNSU]\V5WNDM6\ZH:QLRQMY
MR-8Y'.;Z$SYB ;(MI&B*W9?!I[5$M!0+1T_>]12U2(C)VIGPV]JKS5.>]GQ
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M
M
M                                            "FMNFQN+6R+>+$L=
M/?XV;KFNX,JD3DCEZG)U+YEZL7* -4Z+4NURGTP_1"Z5JI9NA[S96OIGY9$J
M;N-_/1KA.".R77L/T))H'13*"L>Q]PJ)%J*E6+EK7*B(C47KPB)Q\I8(   #
M :RT=8]8V]M'J&@CJHV+F-V5:^->UKDXH4WJJ?36P6XTDE@TC45E17QNS6RS
MJJ,PN-QKE1<+UJB8X8YFP9PYC7IA[4<G/BF0*%[G[3-XKM7W[7]^H5MJ73?[
MVIE16JJ/<CE=A>.."(BKSYE]@ :P]U7<+A2:^TN^R5-4VX4U(^HC;!G,?AJN
M\F/$Q<^)I8^Q#:W2:[HFV^Y+'3:B@9X<:<&U")S>S][>KR&>NVSZ&X;5+1K-
M:UZ.H:9U.ZE<Q%:_*/1JHO5[M<\^HJ7;=LBJK37OUGH!'P30.[XJ*6#*.8Y%
MRLD6/2K?1V 9ONBM-Z@@O-AUMI:)]3-:%3I((V*]6^%O(_=3BK5XH[Q$,O6I
M=8[<J.AT[1Z;;;Z)D[9:RM<CEC8J93.\J83FJ[J95?26YL(VE_7 L,D==$Z.
M\4*-;4JUF(Y,YP]J\D5<<4ZO(6>!X+!;(K+8[=:Z=RNAHJ>.G8YW-48U&HJ^
M@H_NB-37*NU38] 6BL6@9<W1]]SYW55'OW6MSV<%54Z^"%_D0UAL\L6K+]9K
MM=XI'U-L?O1HQVZV1,Y1K^&51%X\,>@#7':SLPFV2PVG4NE[S5OW*AL3G28:
M]DF%<BHK41%:NZJ*B_+DMO;%15FN=A--7T,"R5SH*:YMCC3C[E%>C4\CG</$
M>?NM^&R^!,X_Y1B_4D(Q=MJ]1:M$:2TMHIJ5VJ9Z"E8Y8V)(V#,;?!QR5Z]G
M)$Y@=]D>R.MU%4QZKVFK+5S2QHE/0U/-6XPUTB=7#DWSJ6?LKV86[9VZZ.M]
M;553JYZ*J2JB-C:W.ZU$3FO'G\Q+=-+<UL- M_2G;=5A;WRE/GHT?CCC)D@
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M=S:J.3F]>&4Y(GCQFZ@.E/$V"".&/.Y&U&-WE55PB8XJO%3N
M
M
M                                                'BM%IM]GIW4]
MJHJ>CA<]9',A8C45RKE57'6>T    *\V]:4GU?LXKZ*AC?+7T[FU5/&SG(]N
M4W?.USO/@P^PO9+3:'M\=SNK6SZCG9X;^:4S53BQOC[5\R<.=M@
M                  /C6TE/74DU+60QSTTS%9)'(F6O:O!45#K;Z*FMU'%2
M4%/%34L3=V.*)J-:U.Q$0]     5+W2&B;AK+2=OCLD#JBXTU8U6L1<)N/16
MN5<]2>"N>Q%+: %>['MF5OV?69$1&5%ZJ&IWU5XY_P QG8U/EYKU(EA
M                     #QW6UT-WI%I;I205E,KFO6*9B/;E%RBX7QGL '#
M6HQJ-8B-:B81$3"(AR    % ;<]DMRUIM&LM9:E6.EJH%AK:AR9;3HQ<H[QJ
MY'81.U"XM%:5M>CK!!:;+#T<$?%[UXNE?UO<O6JF=
M         >&X6BWW&IHZBOHJ>IGHWK)3OEC1RQ.[6YY*>X    !KEK[8G6ZK
MVSU%8CGT^GZJ..IJ:GAE'XW71L3M7=1>Q-[S&QH Q^G[+0:?M%-;+13,IJ*G
M;NLC;\JJO6J\U4R
M
M
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M;$MJVL=8:O\ 8R_V>FCH5@?(L\-/)$L:IC&5<Y45%Y8\9?8
M
M
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MZFIE/'Q-3+#>;OJ';-I^Z:@?(ZNJ;E2R>&W=1&+(W=1J=3<<@-[@
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M/;8;G=M52Z0US21TU\8]\<<S&[B.>Q%5S'MSC/!<*G!>SMO4
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MI;W0QNAZ15CEA<N5BD;[IN>OJ5%[%3D!)MQOWK?0$:B<D3T'(
M
M
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M)SX&M>TIJ,[J:U,8B-8VLMZ-1$X(F(S;4U*VE+GNJ[=GDE=;T^2,#;4
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M*BF[)H]>]$T-%MNMNDM.RSU3(JBGBFFD5'.<_@^1W!."(F>'5NJ;P@
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M*9SEY(K4<YB>)%7/]H"]0
M
M
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MW:$JY;I55C[K?9D5%JI&[J1HONMU,JN5ZW*N5\7$M$
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M.!^\R!C'NQV[K'+NM7Q\2_M(:;MVD]/TMGLT2QTE.F$WERY[EXJYR]:JO$S
M
M
M
M
M
M
M                                                           #
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g762905g14g14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g14g14.jpg
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MQ  : 0$! 0 # 0               0(#! 4&_\0 +A$!  (" 0,# @4$ P$
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M>Q8JG),ORK%U7+ER9Y([QF8!
M
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MKV*K7)S*A1? V1>K\5+R<53^N0(IP !
M
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M_J4WKE#7A30 #(
M
M                                             #YPW?Z5K?MW^TI0
MG V^=XK^I3>N4GN[_2M;]N_VE*$X&WSO%?U*;URAKPIH !D
M                               T]BS3)U!=9J.R4,53% Y6.GF<N3U3
M8NJB<G3GM.75ISW36$)=-P@T)U[KO^RZ#RO]Y^=>Z[Y_1=!Y7^\[']/W?0ZH
M;\!H3KW7?]ET'E?[S(L$:76WB\06Z\44=*ZH<C(IHG*K=9=R.1=V>[/,SEP=
MV,=4P7#;( .HH
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MWWJ&QUDKGV^K75B1RY\5)R9="[LN=47G*#/,Y&B=&?3+438 #@4
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MSAT]^TK$  /&;
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MBSP2Q(NQ%>Q6Y^4])?P6C^W[ERW1!ISD15X^PM5.34JLO6T]O7S9WON],_\
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M.V
M                                        #YPW?Z5K?MW^TI0G V^=
MXK^I3>N4GN[_ $K6_;O]I2A.!M\[Q7]2F]<H:\*:  9  !Q+E;*&YQ)%<J.G
MJHTW-FC1Z)X,]QU]!A+#]!,DU)9J".5%S1Z0M547H5=QW8-1GE$5$@ #(
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M4L<BMY$1<W*O1EGGT'4W\+#/JSF9M8E6X /";
M
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M1MU?-S.+43$LD !T&@
M                                                        ?.&[
M_2M;]N_VE*$X&WSO%?U*;URD]W?Z5K?MW^TI0G V^=XK^I3>N4->%-  ,@
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M>T=XSI<76KC$U(KA"F513HNY?UF_NK]VXZ',XGM3UX?I^RQ-LL !Y[0
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M9)%GQG7Z2>$%ARXTE,^FIZ:5&0Q(N;F0-UG/5R\ZHKL_"B;>6MP@
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MO^.Q4WGCIE^^0*IL !D
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MH
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M>N4*IH !D
MP?2I@N/%-G6:F:C;K2M587=T3>L:^'DYE\*F< WKV9:\HRQ[B+7L=&]S)&JU
M[5R<U4R5%YC;&@_&CZ*N9A^XR_\ !SJO4KG+_P N1?T? [U^$Y.G7!W$3?C%
M;HOR4BHVL:W]%VY'^/<O3ESFG6N5KD<U51R+FBIO0^@CHY>G]_XEQ]I6F#"M
M%.+6XHP\U*AZ?A*D1(ZA%7:_9L?X_6BF:GS^S"=>4XY=X<@ #
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M&WSO%?U*;URD]W?Z5K?MW^TI0G V^=XK^I3>N4->%-  ,@
M                                      #T5])!7T4])5QI)3SL6.1B
M\K53)25,=X9GPKB":AES= OY2GE7].-57+QIN7I*R,*TL847$^&W)21M=<J5
M>-@SWN3])F?2GWHAW>%R/9SJ>TI,6G_ ^(Y\,8AIKA"KEB1=2>-/_,C7>GAY
M4Z40J^BJH*ZDAJJ25LM/,U'L>U<T<B\I&3FJURM<BHY%R5%WH;MT"8L1T3L-
MUCNW;K2TCN=-[F>M4\9W?4-'5C[F/>/LSC+<P /%;
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MP-OG>*_J4WKE#7A30 #(
M             &-WG'.&[/.Z"ONT#9FKDZ.-%D<U>94:BY>,PC3AC.HM;(['
M:YG15$[.,J)6+DYK%S1&HO(JY+GT9<YH<]+B\#W<>O.:AF99=I,2RU&()+EA
MVNCJ:6M59)(T:YKHI/TMBHBY+GGY3&[37SVJY4U=1O5D]/(DC%3G3D\"[CB
M]C##IQZ)^65A8;O%/?K)27*C5.+G8CE;GFK'<K5Z478=D:$T"8GZBNDMBJI,
MH*M=>#/]&5$VIXT3RHG.;[/G.3I]G9./AN)L !P*
M                                    GFV:+J72G=KUB3$]\K.-6OGI
M8Z.E5J+3,BD<QK'*Y%R7),\LDWY\IGN@RRTV&[1B6T43Y7TM%>YXF/F<BO5J
M1Q;55$1/N,(TNZ*,1,Q!58GT<UM3!4U:Z]724]0L#U?RO8J*B+GO5%7?GEGG
MDFEY\,Z3JEU123VS%4C:B19)FO9,L<CUR17.7Y*JN2;5YD"MPWS&]&_A*V),
M-3LFCDB;;;@^%<V3*KG;,TV.U,V[>=,N0H<G;0'H7N5BO<.(\5L93U$"+U+1
MHY'N:Y4RUWJFQ,D5<DV[5S7+(HD 8?IA1RZ+\3I'K*]:&1&ZN_/+D,P/">&*
MHA=%41,EB=L<Q[4<U?"BA$+QZ+-(+V->W#USR<F:9JB+Y%7-#]ZU.D+O>N/G
MM^(NHU%B_3]A7#MYJ+9'#77&>G<K)9*5K.+1R;VHYSDS5.A,@MIRZU.D+O>N
M/GM^(V7P;<+W[#.E"J9B*VU-%)/:)71K,FQZ)-#GDNY<LT\J&2]DUAW]B7;R
MQ_$=EHGTM18ZTAW*@2A='3)3+-0R3-;QL*=HDD:JW]%RY.\6W/9D&Z  $
M             ?.&[_2M;]N_VE*$X&WSO%?U*;URD]W?Z5K?MW^TI0G V^=X
MK^I3>N4->%-  ,@
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M4ORIZSMX<U^3*B;O&B>5$.OS]/N:^N.\?9<9;] !X+8
M                                    ]-;*Z"BJ)F(BNCC<],]V:(JD
ME]DKB[]G63^3)_N%:U4/5%+-#K:O&,5F>6>6:9&$6C1)@J@ME+2R8?M]5)#&
MUCYYH=9\CD3:Y57/:J[0- ]DKB[]G63^3)_N#LE<7?LZR?R9/]PW-C&RZ*,'
M4[)<0VFR4JR)G'%U/KR/\#&HJJG3N&!;#HTQM9Y;G8\+T#J6.=U.JS4B,57(
MC57).;)R!6M]'.F'$>.=)6&K7<V4--1I/+*YM+&YJR*D$F2.57+LVYY<^13A
MK;#.%,$UM\HKIAF@I[9=+-4NZH@9"L4K=:-[%CD8N62+K(Y';475V*J*;)"
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M^TI0G V^=XK^I3>N4GN[_2M;]N_VE*$X&WSO%?U*;URAKPIH !D
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M38*EZ)'-G/39K^FGRFIX43/Q+SF\CR.3I]G9.+438 #@4
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M $K6_;O]I2A.!M\[Q7]2F]<I/=W^E:W[=_M*4)P-OG>*_J4WKE#7A30 #(
M                                                        !/.G
MC#R6W$<=T@;E!<457HB;&RMR1?*F2^',H8QG2/A],283K*-K=:I8G'4^6_C&
MHN2>/:GC.SQ-WM;8F>R3%PEVS7":TW6DKZ9?RU-*V5N>Y<ESR7H7<5Y9;E!=
M[52W"D=K05$:2-YTSY%Z4W$<.16N5KD5%1<E1>0WEP?,0\;1U=BJ).WA7CZ=
MJ_J*O;HG@7)?\2GI>HZ>O#KCQ]F<9;A !XC8
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MP-OG>*_J4WKE#7A30 #(
M                     F33'84LF,ZAT+5;35J=4LYD55761/\ %GY4.AP5
M>W8>Q/07)-K(I,I$YV+L=]RKXS?.FRP?AC"$E5$Q755O7CVY)M5FYZ>3;_A)
MK/H.)LC?IK+]I8GXE:,,K)X62PN1\;VHYKDW*B[44\S7F@^_.N^$4I9W(L]N
M<D'2L>6;%]:?X389X>W7.O.<)\-P  XP
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M_P M/A-I\&RWXIO&.+ABS$3ZY\'4:TJ5%5FBS.5S51K<_P!%$:J[-B+D!2@
M"    &-Z0,6TN#,-S72JB?42:R0T]-'\N>5WR6)Y%7P(N\#) 2+B/33I.MMP
M945]'^"*>5=:*FGMZM8Y.;-Z:R^)?(;WT+:1XM(=@FFFA9376C<UE5"Q55NW
M/5>W/;DN2[%W*B^$%-A@U7IKTI+@CJ.U6:"*JQ!7(BQLESU(6JNJCG(F]57-
M$3H55Z>GQYB_%VBYUEN%[N5/B"V5KUAJHDI&T[X7HB+^3<U=NS6RUL]W3L#=
M@.'9;G2WJTTERMTJ2TE5$V6)_.U4S\2]!S    ^<-W^E:W[=_M*4)P-OG>*_
MJ4WKE)[N_P!*UOV[_:4H3@;?.\5_4IO7*&O"F@ &0
M                                         !^/:U[',>B*UR9*B\J$
MCXSL<N'<25UME1=6-^<3OUHUVM7R??F5R:CX0=A2>U4=ZA8JRTSN(F5.YNSR
M5? [9_B._P"G[>C9TSVEF8:\T28B7#^+J?C7ZM%694\^>Y,U[5WB7+Q*I3Y%
M95^CF^_C#A"@K7JG5"-XJ;+]=NQ5\>Q?&<WJ6KMLC]C&62@ \IH
M                                         $V8RL&/-,%UN$MLJ8*#
M"M+4R4M+'/.YC9UC<K'2*UJ*KEUD7:N[<G*9[P<K'/AS"E[L];)%+44=XFBD
M?$JJQRI'%NS1%R\1@VD"Y8ZT17RX5-@2.LPG75#ZJ-D\*R1TTCW*Y[%5%16=
MLJJFW)<^?,UG3:;\744=U;;GT-(^XU;ZR62.#6<U[FM:NKK*J(F34WHH5O2I
MQ!#@K3G;L.VR1&VB]PHZ>B:O:4U0Y7:KV)^AK9)FU-BYYFYR1M &$+[BS2!3
MXMO/5+Z*EE6H?65&>=1+EDU&JN_)<E54V(B9<Q7(  QG25B1^$<$76]PQ-FG
MIHTXJ-VYSW.1K<^C-R*H1DRHCD5'(BHNQ47E.KPY8;?ARW+06B#B*3C9)DB1
M=C5>Y7*B<R9KL3D, T 8RQ%C"QW.;%%,C)::H2.*9(>*21%3-6Y<[=GE0V5;
MKA1W.E;4VVKIZNF<JHDM/(DC%5%R5,T54V*!R0#P6:-LS(72,25[5<UBN36<
MB9(JHG,FLF?A3G \P     X=7;*.KKJ.LJ8&RU%&KG0.=FO%JY,E<B;L\MF>
M],UYU.8 -;\(FGHI]$=\?7,8Y86QOA<J;6R<8U&JG3M5/ JF \$"Q5%-:+Y>
MYVN9!6/CIX,TRUDCUE<Y.C-R)X44[W2-%5:4\4QX.L\CH[!:YDEO-<W<LB9Y
M0L7E<F:Y\R[_ ).W:]LI[98:6W6:A2*EB;&L=+3HNU6L3-<N?G5>GI"H\TH7
M!]VX0%2KUS;%<X*5B+N1&.:W+RHJ^,V]PO\ ^PUG_B2?TI#36/Z-]OX0-;',
MBMUKS'.F?ZKWM>B^1QN7A?\ ]A;/_$D_I2 =MP5;E)7:+DIY7*O4-9+ S/D:
MNJ_UO4SO&6.\.X,=2-Q)<.HUJD<L/Y&236U<M;Y+5R^4F_G-><$RB?3:-*FH
M>F255PDD9TM1K&Y^5J^0P_AD_.<)_4JO7$!L_KY:/?V__P#J3_ .OEH]_;__
M .I/\!$ !3D7&1LUPJI(US8^5SFKSHJJ4-P-E3JS%:<O%TR_?(3B49P-_I'%
M/V5/ZY LJ=  9
M               X5[MT5VM%;;ZC+BZF)T2KEGEFF_Q;SF@L34W C2Y44UNN
M%31U3=6>GD=&].E%R-FZ +^^DOL]EE=_P]8U9(T7DD:G)X6HOD0_-/\ 8EI+
M_3W>)J<36L1C\N21J9?>W+R*:UM5=-;+E2UU,[5FIY&RL7I1<SZ+XY6C]X_E
MQ]I62#A62XPW>T4=PIE_(U,39&IS9IN\*;CFGSLQ,34N0 !
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M:U.9$52AN!LB=68K7EXNF3[Y"?+O]*UOV[_:4H3@;?.\5_4IO7*&O"F@ &0
M
M  &,Z1K F(\)5M&QJ.J6IQU.J\DC=J>5,T\9*2HJ*J*F2H6F3!I>L+K'C.K5
MC$;2UB]4PY;DUE[9/$[/Q9'J^F[?F=<_NSE#8/![ORSV^ML<RYNIEX^'ZCE[
M9/$N2_XC;Q)&![X[#V**"XYN2*.35F1O+&NQR>3;X40K9CD>U',5%:J9HJ<J
M'#ZAJZ-G5':3&7Z #H-
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MT',Q;C'$GXZXR>YM+3TSJ>VQ<6D;5UU36>UO-DF6:[\]^P#>H "
M       /G#=_I6M^W?[2E"<#;YWBOZE-ZY2>[O\ 2M;]N_VE*$X&WSO%?U*;
MURAKPIH !D
M              -=:<;!^%L)K70L1:FW.67/EXM?EIZE_P )L4]=3!'4T\L$
M[$?%*U6/:NYS53)4.35LG7G&<>!%Y2VA7$"7G!\5-*]75=O_ "$F>]6_H+Y-
MG^%30&+;.^PXCN%M>CD2"548J_I,7:U?&BH9)H;Q%^ L70PRNRI*_*GDSY'*
MO:.\NSP*I[G+UQNTWC^\,1\2ID 'S[8
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M1W@^AJDJ*7#-I9,U<VNZF:NJO.F:;/$92B(B9)L0
M/G#=_I6M^W?[2E"<#;YWBOZE-ZY2>[O]*UOV[_:4H3@;?.\5_4IO7*&O"F@
M&0
M        :?X06'N.H*2^T[$UX%XBH5.5BKVJ^)<T_P 1HQ%5%14545-J*A8M
M\ML-XL]9;ZE,XJF)8UZ,]R^%%R7Q$A7&CFM]?4T=4W5G@D=&].947)3W/3MO
M5A.$^&,H51H[OJ8APC05KG:TZ,XJ?GXQNQ5\>_QF1F@] &(.H[Q4V6=^458G
M&0Y\DC4VIXV^RAOP\OE:O:VSCX:B;  ==0
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M_&N?.;#T,X<QW>\0TF(](597MI:#6=14=7VCG2N:K==8]FJB-<[>F>WF"M^
M (                ^<-W^E:W[=_M*4)P-OG>*_J4WKE)[N_P!*UOV[_:4H
M3@;?.\5_4IO7*&O"F@ &0
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M:-;E353EBHKY3)VKU1%5&RIR+DB\R_6WA&V                  !\X;O\
M2M;]N_VE*$X&WSO%?U*;URD]W?Z5K?MW^TI0G V^=XK^I3>N4->%-  ,@
M
M     "=-.F'UMF*?PC"S*EN+=?-$V)(FQR>/8OC4P6PW2HLMXI+C1KE-3R(]
M.9>=%Z%3-/&4[I*L'XQ80KJ2-B/JHV\=3\^NW;DGA3-/&2HJ*BJBIDJ'O\+;
M&W5TY>/AB?B5D6>X0W6UTE?3*O$U,396Y[T14SR7I.62YA[2-?[!:(K;;YH.
MIXG*YG&1ZRHBKGEGGNSS\IF6&---2E0R+$='$Z!RY+/3(K7-Z5:JKGXLO&>?
ML]/VXW./S"]4-X@]-%505M)%4TDK9:>5J/8]JYHY%Y3W'0[-
M                               U3AZY8^H+E?I66:FO&'_PI5)31K5)
M#5-8DKL]76[5S<\\D547IRR,JM>/['5U;:&NEFL]S=L2CND:T\CE_=5W:O\
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M &E*$X&WSO%?U*;URD]W?Z5K?MW^TI0G V^=XK^I3>N4->%-  ,@
M
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M58 6Z7!^&+7A&QPVJR4Z0TT>U57:^1W*]R\JK_\ &X[H (
M  ^<-W^E:W[=_M*4)P-OG>*_J4WKE)[N_P!*UOV[_:4H3@;?.\5_4IO7*&O"
MF@ &0
M              ,7Q[@RAQ?;VQ5"K!5Q9K!4-3-69\BIRM7F,H!K#/+">K&?
MD2EC/!-VPDZ)UQ;$^GE<K8YXG9M<J<B\J+ESF,M5$<BJFLB+M3G*XQGA^'$V
M'JJVSJC7/36BDR^1(GR5_P!%Z%4DVNI)J&LGI:J-8YX7K&]B[T5%R4][A\GW
M\9ZN\,3%*QP/7VZXX5MT]FB;#1\6C6PI_P"6J;%:O2BY[>7?RG>$]Z#<5_@F
M\NL]9(J4=<Y.+55V,FW)YV[PY%"'C\K3.G9,>&HFP '74
M                       <>XO=%;ZJ2-<GLB<YJ\RHBFF-"U%CC%5C@O\
MB7%]PAH9U5:>FIXH6ND:BY:SG*Q<D5478B9\N8&F-)E'C*_XVQ-#0P8@N5JA
MN<S6,B;--"Q6O7)$1,VIE]QU$-KTF01I'!1XPCC;L1K&5*(GB0N>EI8:2-T=
M-$V-CGOD<C4RS<YRN<OA555?&>X+:/M$$&+(=+N%OQJCOK(N-GXK\(I*C=;B
M)/DZ^S/+F+!/14P4TLM,ZI9&Z2*37A5^]K]5R9MZ=57)X%4]X0
M   #QD>R.-SY'-8QJ9N<Y<D1.=5/(XUPH*2Y4RT]PI8*JG54<L<S$>U51<T7
M)=@&KL=:>,*X;XR"W2.O=>W9Q=(Y.*:O[TF[S=8VG;ZCJNAIJC5U>.C;)JYY
MY9IGD17PC[=1VS2I<(;=2PTL+H89%CA8C&ZRL3-<DV)F6;8?H.W?W:/V4"L>
MTD:0+1@*UQU-T62:IG56TU)#MDF5-^7,B9IFO3RKL,=N6E.KPQ6VMN.\.K9Z
M*Y9I#505:5*1.3+-LJ(UJMRS3/+/QY*:(TT7B2^:>6T[W*ZGHJJGHHF\R(YJ
MN_S.<;0X8#47!%F=EVR7%$1?_I/]P*;VBD9-$R2)[7QO1'-<U<T<B[E13R-6
M<&F]R7G170LG>KY;?*^C5R[]5N3F^1KFIXC9M35TU+J]4U$,.MNXQZ-S\&81
M[@</\+6[_KZ3^<WWC\+6[_KZ3^<WW@?.V[_2M;]N_P!I2A.!M\[Q7]2F]<I/
M5V5%NE8J+FBS/]I2A>!M\[Q7]2F]<@:\*:  9
M                                                 #2NGK"?_+Q%
M0Q<T=8C4\37KZE\1NH]%?20U]#44E4Q'T\\;HY&\[53)3FT;ITYQG"3%HT8Y
MS'(YBJUR+FBIO12H-%F+6XIP\UT[D_"-+E'4I^LO(_P+ZT4GS&^&Y\+X@J+?
M/K.B3MX)53+C(UW+X>1>E%/S!6(ZC"]_@N%.KG1HNK-$BY))&N]/]4Z40]OD
MZ8Y.N\>_AF)I6P.+:Z^FNEOIZVAE26FG8CV/3E3WG*/GYBOB6P $
M                           <6Z_1=9]B_P!E24<&<(*KPQA>VV6/#]/4
M,HHDB25U2K5?ERY:NPJZZ_1=9]B_V5)VT<:",+XGP19[S5U]V;45D'&2-AEC
M1B.S5%1,V*O)SA8</LGZ[O8IO3'?".R?KN]BF],=\)F'8U80_:-\_G1?[8[&
MK"'[1OG\Z+_;!\.@P7IFN&/](^%K4^V4]OI65,L[]259'/5*>5$3-43)-J_<
M4<:2L>A6VX*QSAF]6*LN%0UE5)'/'4:KM5KH)<G(K6IEDJ(FWG\N[0@
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MJ=S1TR??("5-@ ,@
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MU14-0:*\):1L"4"6Q]1A^Y6A'*YD,E1*Q\2JN:ZCN+78J[<E1=O-M-R@ G2
M                 !X30QSQK'-&R1B[VO:BHOB4\P!P_P %V_\ Z&E_DM]Q
M[J>DIJ9RK3T\,2KL56,1N?D/< /&1C)(W,D:U[')DYKDS14YE0X%LL-HM4LD
MMKM5!122?+?3T[(U=X5:B9G8@      ^<-W^E:W[=_M*4)P-OG>*_J4WKE)[
MN_TK6_;O]I2A.!M\[Q7]2F]<H:\*:  9
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M=T<%WC3\K BY:Z)^FW/DZ.3[UZ7,X<ZIZ\.WV6)9J #SV@
M                                                    ?.&[_2M;
M]N_VE*$X&WSO%?U*;URD]W?Z5K?MW^TI0G V^=XK^I3>N4->%-  ,@
M
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M*I@7]*-V>2\RIO1>A3G'E3$Q-2T  @
M                               /G#=_I6M^W?[2E"<#;YWBOZE-ZY2>
M[O\ 2M;]N_VE*$X&WSO%?U*;URAKPIH !D
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M^365**L<\;?T7IORZ%S1?&=/E<.='YHFX:B;9( #I*
M                                      ^<-W^E:W[=_M*4)P-OG>*_
MJ4WKE)[N_P!*UOV[_:4H3@;?.\5_4IO7*&O"F@ &0
M
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ME<ZF<Y=ZHW+5_P JHGB,V/G]F$X93C/AR  ,
M              ^<-W^E:W[=_M*4)P-OG>*_J4WKE)[N_P!*UOV[_:4H3@;?
M.\5_4IO7*&O"F@ &0
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M_P"5$7QF<!$1$1$3)$!\_LSG/*<I\N0 !@
M           'SAN_TK6_;O\ :4H3@;?.\5_4IO7*3W=_I6M^W?[2E"<#;YWB
MOZE-ZY0UX4T  R
M
M                                       ZZ_WNVX>MDMPO5;#1T<?R
MI)5R3/D1$WJO0FTQVTZ3,,W&XTM#U54T=35HCJ5*ZEDIDJ47<L;GM1'9[,N?
M,#,P    'SAN_P!*UOV[_:4H3@;?.\5_4IO7*3W=_I6M^W?[2E"<#;YWBOZE
M-ZY0UX4T  R
M
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MX,>]\U9YK/A!2[ 0GUX,>]\U9YK/A'7@Q[WS5GFL^$%+L  0
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M][J>F5'^X9_:Z"FM=MI:"@CXJDI8FPPQZRNU6-3)$S7-5V(F\+;D@ (
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M"^/Q51X?Q-6R7"CKG\3#-.N<L,B_)[;>Y%79MW9ITYEI4X "
M                TIIITGXJPE;HI;9AQ:*EJ'K"ROK9&2+K9*N21L<N2Y(J
MIK+R;CL.#1B"ZXEP7<Z^^UTU;5K<GM1\J_);Q<:ZK4W(F:KL39M VV#$]*.,
MH,#8/J[Q*Q)9D5(J:%5R225V>JB]&Q57H135F$H\28MT6W/&=9BF\07E6U$]
M'%2S\53QI%GDQ8D3)R*K51<\]BIXPW^#5.@#27+CRRU--=D8EZM^KQKF)JI,
MQ=ST3D7-%1439NY\DVL                          -!Z>]+-SL6((<+8
M8GCHZMR,6JK7M1RQZ^YK478FQ455Z4RR WX#3.DNP7W"&!9[]8L87Z6YVY&2
M3=5U"2Q3M5R([\FJ9-WYIES9;=YD^A+'4F/<&I7UD3(KA32K35*1IDUSD1%1
MR)R(J.39SY@9^                                ##])FD"TX LR5ES
M59:F7-M-21KD^9R>IJ;,UY.E<D,5P5!C7'E+%>\27::P6>H3C*6VVQ$CE>Q=
MSGRJBN1%3D3+/?L VT#C6ZCCH*1E-"^=[&;G3S/F>OA<]55?*<D
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M8&=$DB1TU.WC:FH<B:]1)SY<JKL1&^! ,U 1<T1=WA 0
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MEG!)OE9<,&W*W5;WR0VZH:E.YRYZK'IGJ)T(J*O^(#>8 "
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M29&:V_429^7W?<;("
M   =-B6JN\%)-'9+6VMJ'Q+J.DJ&Q,:_:B9YYKER[$.Y $MZ--$6.<&8VME]
M=06^I92N>CXDK$:KFN8YBY+EOR=GXBD*RJNGX GJ**W,_"NH[BJ6:9$:K]R:
MSTV9<NP[0 2+?=">DF^WBKNES=0S5M4]7R2+5IMYD39L1$V(G(B'OPGH$Q?3
M8HM%1=V47X/@JXI9]6IUEU&N15R3+;L0K,!;  $
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MF(Q5<N:HFW)-G)M,OT68&I, X7CM=-+U1.]ZS5-0K<N-D5$38G(B(B(B>\S
M                                 :'TIZ'[E/C*#&.!70)<F3LJIJ.5
MVHCY6JBZ[5W;<MJ+ERKGM/?I!P;BC2O<K%#=+7^+=IH$<^H=-4QSRR.=JYHQ
M&*J;$;L553?NY#>( X=FMM+9[326VWQI%24L388F<S6IDGC.8
M
M
M
M
M
M
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M.FBFP]28FN,]L6JI4U)]17*V345S55&IGO5/ !48
M
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MJ@_]@(5T  @
M                                                    '7XB_L_<
M_P"ZR^PIV!^/:U[',>U'-<F2HJ9HJ 3SH,TD38?PK0VK'%'76^W(F5NNL].]
M('QJN:,<_+),L]B[LN;+;L+'VDG"5+A6X1QW6@NM150/@AHJ.9L[YW.:J(W5
M:JY)MVJIL)88E@XE8V+#JZO%JU-7+FRYCAT5EM=#,LU#;:*FE7>^&!C'>5$
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MN$7336^HBJ86UE#'QD3D<U7)Q:*B*FQ<EV!86(  @
M
M                                                   !X311SQ.C
MGC9)&[>U[45%\2@ <5EHMS'M>RWT;7-7-%2%J*B^0YH    #AW>U6^\T3J2[
M45-6TKMJQ5$:/;GSY+R]( &(IHDP2URK'8TB1=JMBJ9F-\U'HGW&0X=PO8\.
M,>VQ6JCH5?L>^&-$>_ZSMZ^-0 .Y       !X311SQ.CFC9)&[>UZ(J+X44X
MK+1;6/:YEOHVN:N:*D+45%\@ '-
*         '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g762905g15a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g15a01.jpg
M_]C_X  02D9)1@ ! 0$!0P%#  #_[1LD4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0]
M0Y         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !0]0Y  $  0%#
MU#D  0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -!    !@             $&@  !V$    & &< ,0 U &$
M,  Q     0                         !              =A   $&@
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $&@
M  !29VAT;&]N9P  !V$    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,     !$(     0   *    !9   !X   IN   !#L !@  ?_8_^T
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M0,YS"6N%1(+3!'S"X+"KS[CZI^TWXXW-=Z=Q:[='M^F_\W=N7>?6C_Q/Y_\
MQ+EYY@8U>7U'&QK9V7VMK>6F##C'MY5C#\A\VASAK+#<Z;76O%_A.@_%R 6[
M*\XDD:'):9 (=;ZFUWL_1"S\Y,,>T.#7U]0WD.=M%[8(;&^/?[&-W?3>]6NM
M=&^KO2,*S-?]KOJK>QGLLK$[@[5N^MOT-G^9^D5VSZI]!JZ<S/>[+:Q[&/\
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M3!$]VKS3J_2,OI.3]GRQN:Z33<![+&_R?W;/])3_ -\5C 11C>I:'.QD)0R
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MDEM5CZP3R0QSF;C_ %MJM=$_Y:P/_#%?Y5++Y)?W2H&W_]+C,K^EY'_'6_\
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MO]6[+;64MZ?TH=/Z:#8S?</>6!WYK/9<U]OY_K>I[T#%^JN=TCKK<SIN38W
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ME))))*?_V3A"24T$(0      5P    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  (  R #  ,@ Q     0 X0DE-!"(      3)-30 J    "  ' 1(  P
M  $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$
M @   !\   !R 3(  @   !0   "1AVD !     $   "H    U    40    !
M   !1     %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-#HP
M.#HP,B P.3HS,3HR,        Z !  ,    !__\  * "  0    !   '8: #
M  0    !   $&@         & 0,  P    $ !@   1H !0    $   $B 1L
M!0    $   $J 2@  P    $  @   @$ !     $   $R @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 3I%
M>&EF  !-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0
M  $   !J 2@  P    $  @   3$  @   !\   !R 3(  @   !0   "1AVD
M!     $   "H    U    40    !   !1     %!9&]B92!0:&]T;W-H;W @
M,C(N," H5VEN9&]W<RD ,C R-#HP.#HP,B P.3HS,3HR,        Z !  ,
M   !__\  * "  0    !   '8: #  0    !   $&@         & 0,  P
M  $ !@   1H !0    $   $B 1L !0    $   $J 2@  P    $  @   @$
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M 0$  @,!                 0,"! 4&_\0 .A$!  ("  0#!@4#! $$ P$
M  $" Q$$$B$Q$Q11!3(S05)A%2)Q@:%"L<$C4]'PD31#<N$D1/%B_]H # ,!
M  (1 Q$ /P#U2
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MHO>JI](T>S)0^]53Z1I2P'E<?H?BG$_5_$+I]F2B]ZJGTC1[,E#[U5/I&E+
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M4=8
M
M
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MF$^([]3VFPT%!!+9KVMPJ'/1KXEB5NZW"\<^?"?"8Q>)UKYK9PVCFB>FNZ-
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M\K&I/Q2'<=-)^*0[C0=X
M
M
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MFI'8;%"FXCUSA$X>957X#<4":6O%\EL?>N^FB571Q5B-PKE3/'EPY<%RIC;
M[A"V2YV][D29^[,S/-R)P7XN'QFR?=MH4E]JJ"GHZ5(XW.5DTD*I&YN>'A9X
MK@B\VYYKOM]],\$4\*M];FTSO4;_ &^R)V/2T-MVIQ6:OC;54B*Y6]*W@]NX
MKD54_P#.*&]U;-I#2M_6FDT^RLEE1KY$RB,A:OBMZUQQZO.8-@K;I6;7:)M]
M2!*Z!KXG)#[5/P;E[?*:;;-^?=5^ZB^J9Q$VO$6GY*9FN+!:^./ZNFX[=&SV
MP:7MUG90U]JA2GCJ'*QT;?:YQE%1.HK0NC;G^;EF_>_]A2Y9P\S..-M;VA2M
M,\Q6-=GH&UVAE\V3V^@DJFTC9:=F9G-WD;AV>64^DT>G]FE+;;U15C-1P3N@
ME:](T@1%?CJSOK]!W77_ $-IOW$?UBL="_GA9_XEGTE%*VFMIB==9;V;)CK?
M'%J;G4==S"6;=?SKI/X5OUG&YVI6VS:<ELM73V>E=$DSNEA:U&)*F.2KA?H-
M-MT_.RD_A6_6<;[;]_D+3^]?]!-?_;C]498C?$6UUB8_ND.N;M0T.BJ.KJ[1
M#6TTB1[E,]^&LRWAA<+R\QYYE<CY7N:U&-<Y51J=2=A>>T*CJ;ELVM;+?!)4
MNW8'[L35<N-SGPZN)1;VJQ[FN14<U<*B]2F?"Q'+*CVI:TY(WVU#@ &TY@
M      7EI#VD?F0HTO+2'M8_,AH\;VJ[GL7O?]O\K&I/Q2'<=-)^)0[C0=X
M
M
M
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M[_M_E8U)^*0[CII/Q2'<:#O
M
M
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M:7EI#VD?F0T>-[5=WV+WO^W^5C4GXI#N.FD_%)YCN-!W@
M
M
M
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M))&Y'HB*N7*KDX95>I#LT'<K36[.:NQ5ETIJ&I?TC56=Z,3PERBIE>)4(,O
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M)^*0[C0=X
M
M
M                          0;;-^8]3^]C^L>>CT+MF_,>I_>1_6//1T^
M#^'^[S/M?X\?I_R  VG+  $  "0 =0
M                "                    $  "0    @   "\M(>UC\R%
M&EY:0]K'YD-'C>U7<]B][_M_E8U)^*0[CII/Q2'<:#O
M
M
M
M"#;9OS'J?WL?UCST>A=LWYCU/[R/ZQYZ.GP?PWF?:_QX_2/\@ -IRP    $
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M2/S(4:7EI#VD?F0T>-[5=SV+WO\ M_E8U)^)0[CII/Q2'<:#O
M
M
M
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MC4GXI#N.FD_%(=QH.\
M
M
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MV_.3I?PR;J)[94Z^Q#C-I*P1^.^N7GN*Y6;V$7D9M!=4JIHH]Q$WVJJ*B]:
M;,  #$N_Y*K/W+_H4RS$N_Y*K/W+_H4FO=AD]R5";1?S3JOVF?60K.W<D+,V
MB_FI5?M,^LA65NY(=6G=Y.WNMHWD<G"<CDO:@.H     0  7EI#VD?F0HTO+
M2/M8_,AH\;VJ[GL7O?\ ;_*QJ3\4AW'32?BD.XT'>
M
M
M                                                          $&
MVS?F/4_O(_K'GH]"[9OS'J?WD?UCST=/@_A_N\S[7^/'Z1_D !M.6
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MI#N-!W@
M
M
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M2\M(>TC\R&CQO]+N>Q>]_P!O\K&I/Q2'<=-)^*0[C0=X
M
M
M
M 0;;-^8]3^\C^L>>CT+MF_,>I_>1_6//1T^#^'^[S/M?X\?I_P @ -IRP
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M\BHO6ABO9=530-:U48C55R)EIVLB6/AG+3MDC;*C<\D5'<#[ ^6-PG#D?0
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M2'M(_,AH\;_2[GL7O?\ ;_*QJ3\4AW'32?BD.XT'>
M
M
M                                                          $&
MVS?F/4_O8_K'GH]"[9OS'J?WD?UCST=/@_A_N\S[7^/^T?Y  ;3E@
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MXI#N.FD_%(=QH.\
M
M
M                                (-MF_,>I_>Q_6//1Z%VS?F/4_O8_
MK'GHZ?!_#_=YGVO\>/T_Y  ;3E@       !)] _YZJ_=I])&"3Z!_P ]5?NT
M^DQOV94[KOT!^3ZG][_1"4$7T!^3ZG][_1"4'(R^_+UW!? J  K;0
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MT7\U*K]IGUD*SMW)"S-HOYJ57[3/K(5G;N2'5IW>3M[K9IR.3AO(Y+VH
M    %Y:0]K'YD*-+RTA[2/S(:/&_TNY[%[W_ &_RL:D_%(=QTTGXI#N-!W@
M
M
M
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MK'YD*-+RTA[2/S(:/&]H=SV+WO\ M_E8U)^*0[CII/Q2'<:#O
M
M
M
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M2'M(_,A1I>6D/:1^9#1XW^EW/8O>_P"W^5C4GXI/,=QTTGXI#N-!W@
M
M
M
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M!%W(_,AH\;VJ[GL7O?\ ;_*Q:3\2AW'32?BD.XT'>
M
M
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MK:N!S4ZG)Q:OPF[CS4R=I<7/P67![T=/5@  M:H     !      !  "  $
M'+6JYR-:F57@B(<Q1NED1D;5<Y>"(A-M.:?Z%S9)4WIE^)I5ERQBC<MKA.$O
MQ-M5[?.77IJP)&K99VHZ5>2*GM2U--T*L1JJAC6.S\E<TF=#2MA8G Y5[S>=
MR]5APTP4Y*0R8&[L:(?8!@N
M
M
M                                         =0 &!7T3)XW(K47*%-;
M0=#OIY):ZUQ^#[:2%J?.GV%Z&'6TK96+P0LQY)QSN&OQ'#4XBG+=Y-7R@M/:
M%H=?PE=:XD;(F721-3VWE3RE6N:K7*CD5%3FBG5QY8R1N'E>)X:_#WY;?^7
M +&N          ( <M:KW(UJ*JKU(2.S:;DF<V2K3#>IB<_A*[Y*XXW9L8.&
MR<1;5(:6AH*BM=B"-53K<O)"7V72[&*CYF]+)Y4X)\!*;39,,:UD:-:G)$0F
M%LLJ-1,M0Y^7B;7Z1TAZ'AO9F+#^:W64<MEB5<>!A/,2F@LK6(F6F[IJ-D2<
MD,IJ(G(UG28L%$R-J<$,IK4:G!#D #5:EN7<VW.<U?PTG@,\_:;4KG5EP6MN
MCV-7\%!EC?/UK_YV%F*G-9J<;G\'%,QWEI557.55XJJ\5+#TI:$M]&DLK?\
MU,J97/Z*=A&-(6[U[<4ED:BPP8<[/)5ZD)]6U4-%2R5-4](X8TRYR]1;GO\
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MI*=L3$X(<NUYO.Y>IQ8J8:\E(Z/FCI6Q,1$0RP#%8
M
M
M
M      ,6KIFRQJF"I]?Z%2=9:VW-W:A$RZ-$X/\ [EQ&/4TS96KP,Z7FD[A3
MGP4SUY+P\E/8YCG->U6N:N%1>:*<%R;0-#MKE?64#495I[9$X))_<I^H@DIY
MGQ3L5DC%PK53BAU<66,L;AY7BN$OPUM6[?*76 "UJ@     9-!1RULZ1PM\Z
M]2&79[1-<';W%L7C8Y^8L2PV)D3&LBCPWZ36S<1%.E>[I<%[.MG_ #WZ5_NU
M-@T[' J+N[\B\W*A/+19<[JJWYC9VBS-8B*K22T],R)J<#FVM-IW+TF/'3%7
MEI&H8E#;F1-3@;%C$:F$0^N0,5@   ,.[72AM%(ZIN=7#2P-3*OE<B?%VE-Z
MSV\T5+O0:8I5JY4X>N)_!8GF3FI;CPWR>[#&;17NN6[57K.W5$Z>V8Q53S]1
M52JKE557*KQ4KO1^K+]K#5,D]YKY98((W/; SP(FJJX3P4Y]?/)9-'$L]5#$
MGZ;D0VZX?!Z2X?M#)XF2*1\O\K#TG1^M+-%E,/E_".^'^QDWZUP7JSU=NJU<
MD-0S<<K%PJ=:*GE1<*9L;$CC:QO)J(B'T:%IW.W;QTC'2*Q\D.TIHZILTD:5
MUXFN-/3KO4\;XT;N+C"*JYXKCS$J]94OKA*CUM#TZ?\ N;B;WQ\SO!#-YS]4
MS22VN_6>\PTJ-HWM6.:5C<>'GAO+YC0Z8N,FJ*BWVF@=N5#W8;+$GA,3FKO@
M/1FMZRS4>GJI=1)3NHGM5G1S,1Z/=U(B+S4KKU/+M.TUJFI**GIH+RZ1[W^#
M^$?'G*8=V)V%D8KS2;Q'2$;C>F]H]C&C(J-(JNVK73[V^^IJ)%=*]WE4T^V?
M2MKLNSJJKK!;64E70-3HI*9%8YK%7PLJG-,=I;QUU4$-332P5,;)()&JU['I
ME'(O-%,>:>VTO(>C=1T[:)>D1'/<W@Y785J]I>^SS0NG9M*)45EH@J)KDBR3
MR5"=(Z1%5<<5Y=13>E=#V9VN;0UR.DAJ+C4=)3H[$;8VJW<:J=G%WG/5<;&1
M1MCC:C&-1&M:U,(B)U&(B=MV<Z6M5)60VRSTM.M2QS'/W-Y4RG5DB^SC3FK]
M+U[[74.I)K0C\MJ4>N=WLW<<RUC2:MU%3:;H(*FK]K-.V!J]2*N>?Q$S,SW&
M[!TTE5#50LD@D:]KF[R84[B   '74PMJ*>6%Z9:]JM7X2IZF%U/42POYL<K?
MB+<*ZUC3]!>I')RD1'FQP]NLPY?M3'ND7]&#9Z]M/6,B<]J.<F4:J\5+%ME2
MDL*<3SAM;A>VU4=;"YS)8)L(]JX5$5.WSX-?HK:C>[.C(ZB1*^G3ANS+X:>9
MWVFU/ 6R5\2D_LNX+-S88W\NCU:"O]*;3[+>E9$^;UI4K_[<ZXROD7D3R.9L
MB9130OCMCG5HTW8G;L !@D/ES&N3"H?0 U-?;&3,=EJ+DK#66@F3=)4VY$BG
MYJS'@O\ L4N4QJFE;*U<H9TO:D[JIS8*9J\MXV\GU-/+33/BG8Z.1JX5')@Z
MB_=8:.IKM [>9N3(G@2(G%/[%*7RS5=FJW05;%1,^"]$X.0Z>'/7)T^;S/%\
M#?AIWWKZM: @+VB   $  '=24\E5.V*)N7+\Q]4%'+63I'"W/:O4A8FG;$RG
M:UK&Y<OMG8XJ:^;/&.-1W;_!<#;B9W/2KJTY8FT[$1J;SU]L[',L2QVA&HU5
M3YCLLEH1K456DIIH&Q,Q@Y=K3:=R]1CI7'6*UC40XIJ=L34PAW@$,P
M
M
M
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M(B': 0R
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M?)W??./\0FLO$M7R=WWRH0/!IZ'-*W_\0FL_U=J^3N^^/\0FL_$M7R=WWRH
M/!IZ)YI6_P#XA-9^):OD[OOC_$)K+Q+5\G=]\J #P:>B.:5O_P"(36?B6KY.
M[[X_Q":S\2U?)W??*@ \&GH<TK?_ ,0FL_U=J^3N^^/\0FLO$M7R=WWRH /!
MIZ'-*W_\0FLO$M7R=WWQ_B$UGXEJ^3N^^5 !X-/0YI6__B$UGXEJ^3N^^/\
M$)K/Q+5\G=]\J #P:>AS2M__ !":S\2U?)W??'^(36?B6KY.[[Y4 '@T]#FE
M;_\ B$UGXEJ^3N^^/\0FL_$M7R=WWRH /!IZ&Y6__B$UGXEJ^3N^^/\ $)K/
MQ+5\G=]\J #P:>AS2M__ !":S\2U?)W??'^(36?B6KY.[[Y4 '@T]#FE;_\
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MFDJ&RL3"GF\V&V&W)9L1.XW#( !4EPYJ.3"G5ZV9G.$.X <-:C4PAR
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M]Q%@ 6@":VG0R5^AZG4/=#HUA9([UOT.<[G^[>Z_,0HPK>MYF(^0  S
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M"$^I9O==/W7L4LK5MU BO@9N(BM5SUSQYJ:/3NKKOJ/U0%DI;M4,EAH*BI9
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M:ANM?4]OOMWIX%N+*=)DD8W&'H_&4[,]AIO5;?DG2G[<_P!6,V5'_P#"K/\
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MPH&>62>9\LSW/D>N\YSERJJ<U51+55$D]1(Z2:1=YSG+E54ZCO</@KAKJ.Z
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M+"BYZ-K48U5\J)C)TV'4EVL+GK:JQ\"/]LW@YJ_ O TX'AUB.7702.]ZUO\
M>J5::OKW.@7VS&-:Q'>?=1,FKLUWKK-6)56RH?!,B8RWDJ=BIR4P (QUB.6(
MZ"72[1=3RS12ON7A1KEJ)$Q$SY4QA?A(_>;I5WFX2UUPD22IDQO.1J-SA,)P
M3AU&"!7'2O6L: W]BU??+'#T-MKY(X>J-R(]J>9%S@T )M6+1JT;$@OFL;[?
M(.@N->]\/7&UJ,:OG1$3)I:6IFI*AD]+*^*9BY:]BX5%.D"M*UC41T$P]DC5
M'0=%W2\'&,]$S>^/&3045ZKZ.\,NL50Y:]CE<DLB(]<JBHN<\^"FN!$8J5WJ
M(&[N&J+K<+U3W:JJ&OKJ=$;'(D;41$155.")CK4ZM0ZAN6H:F*>[3I-+$W<:
MJ,:S"9SU(AJ03%*QJ8CL)50[0-24-$REI[D[H6)NMWV-<J)YU3)CU6L[[56>
M2V5-:LM)(JJY'L:KERY7+X6,\U[2.@Q\*F]\L#>T>J[O26&6S4]2UMOE1S71
M]&U55'<^.,G-@U;>K#$Z*V5SHHE7.XYJ/;GS*BFA!,XZ3N)CN)9%M#U-'4RS
MI<G.?(B(J/C:YJ(G8BIA/@,&S:MO%F?6.MU2R):MV]+^":N5X]J<.:\C0@CP
MJ:URP/I[E>]SW+ESEROG/D L$JM^O]24%&REI[B[H6)NMWXVN5$\ZIDZ*G6E
M]JK5-;JJN6>EFRKTD8USERN?;*F2. K\*F]\L#?1:LO$5@=965+4MSFJQ8^B
M;G"KE>.,G5IW4UTTZZ9UIJ&PK,B(_,;79QYT4TP)\.FIC7<9;+C51W):^*9T
M=6LBR](SP5WE7*KP)%4;1-33QLCDN2[K51?!C:F<=N$XD2 MCI;O V^HM17+
M4,\4MVG2:2)JM8J,:W"+YD-5&]8WM>U<.:J*B^4^0916*QJ.PW6H=3774+*9
MEUJ&S-I\]'B-K<9QGDG'DAV7C5EXN]LAM]?4MDI8MW<8D36XPF$XHF30@QC'
M2-:CL-]:M67BU6F6VT-2V.CE5RO8L379RF%XJF30@$Q6(W,1W DR:ZU EH2V
M)78I$CZ+=Z-N]NXQ[;&?G(R!:E;>]&P-_J#5MXO]'%2W2I;-#$_?8U(FMPN%
M3FB=BJ: ":Q,Q,QV&UT_?[CI^J?46JHZ&1[=QV6HY%3S+P,6ZW"INE?-6UTG
M25$JY>[")GX$,0#EC?-KJ-I8K]<[%,Z2U5<D"N]LB<6N\Z+P4V5WUUJ&[4KJ
M:LN+UA=P<V-C6;R=B[J)DC((G'29YICJ  ,P        +TTG[2/S(467II3V
MD?F0Y?M+^G]R%C4GXI *3\4@.6E1/JN?R!8?XI_U#S$>G/5<_D"P_P 4_P"H
M>8SI\-\.%-NX "]B              !]1M5[VM;Q<Y41 +1T_L2U!=+)#=*R
MLMMJIIFHYGKV56JK5Y+P1<9\IJMH&RN^Z+M\5PK)*6KM[W(WUQ2O5S45>6<H
MB\>TLNX:!M^G](6^3:AK"Z+3*J+';X'*K&NQ[5,HJJJ)UHB$NVB=S*CU/N]9
MF2K;/6S%INGRK]U.2KGCDU?&MS1UW&V>NBD=/['[_?\ 1T.H+7-23,F<C64V
M7)(N7HU5Y;J(F<KQY(IM*G8+J-MKGJZ*OM5?)"B[]/33*Y^4YMY8SY,EE:0J
M9J3U,==/32.CF91S[KVKA4XJG T'J1YY7UNH6/D>YBLC>J*N4SE>/G$Y+ZM;
M?:2(A1VFM.W+4=\BM-JIW2UDBKX/)&HG-7+U(A:UNV(7^SWZUU"5]JK)J>JA
MFEIH)EZ5C$>BJ["HF26>I]I8&;2MH$C(F))#*L<:HGM6K*_*)Y/!;\145%>;
ME[,L=9ZZF]=NNZ1J[*Y5JR[N[YL<,&<WM:TQ'R1K4+!]5S^6]/?P\OUFE"0M
M1\K&O7=:KD15[$+[]5S^6]/?P\OUFE#TL#ZFIB@BQTDCD8W*X3*KCF3@^'!;
MN]@ZGKZK9[LMMS]$VN*I5&1HKFQJY$16Y6143BN5^DA6FMMEHOFG[C;-I,+(
MY7YCQ%3.<UZ+G.4X[JHIJ:75FT+9';*&EU-;Z:LM+\QP1RS-<YN..$>Q5Q\*
M*3'2=XT7MD9645;IQ*2Y1P[[W8:JMSP562-PN47M1#7Y8K&[1N/6&6T$]3CI
M&WW75M9=Y7T530T;Y(H*6?C*J\%;(C53&$1>OK/G;MH6HFV@/N,5TMKNZ];#
M2QTR2*LL2JUC$5[<<$X9\QW["+0E@VZ7:U-E65M)3U$2/5,;R(YF#2;0O_B2
M7_YK1?1$6;GQ9F)^2/DV/^'/4WKI8NZ-KZ-&([I=Y^[G*^#[7.>'SFBTOL:O
M&HGWEM'<K:SN74NI9%<YZH]R(BY:J-7AQ+%]5C>J^C33]!1U4T$$J32R)&]6
M[ZHK4;G'9E?C,WU*:N?HS4"JJN<ZL7BO%57HVD>)?P^>9-1O2@= Z2J]::A9
M9Z">""=T;I$?-G=PWS(J]9]ZLT9<=.ZQ?IM[HZRX(L:-];Y5'J]J*B)E$7K)
MCZF7_5*#^&E_H63'305'JKJE9VHY8J1LD>>IR0-POSJ66R36\Q\HC:(CH@-+
ML U$^*#UY<[/154R99333+TBKV)A%RI&:;9O=:37])IN].I:*21=])IWXBD8
MG'@Y.W&/.;C;U=;A3[6:BH942QRT:L=3JB^TPJJBH1:[:LONJM06R;4-8^ID
MBF8C$<Q&HU%<F<(B(33GF-S/<Z+]V^:"BN.G;$EMK+5:Z:T0SJD$KNCZ5%2/
MA&B)Q7P>/G0I.?9G<X=G$6LG5E&M!(U') BNZ5,O5G9CFG:69ZK?_*Z-_9JO
MHA,VXHJ^I/I,=43?^NI3CM:M*]>\IF.LJCV:;-KEK^.YOME91TR4'1[_ *X5
MWA;^]C&$7Q%.O0&SNXZUO-QMMOJZ2"6B3+W3J[==X2IPPB]A;'J1/\IJ[_\
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M>,]G M>G<NB]E4=?;8XTN%2C%=*J9XN7G\"&!LFU-<+W<ZNTWJ9:ZFFB<_\
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MLOQ'F\W>L]2UVK=05-WNBLZ>941&,3#6-3@C4\R&D+L5.2L0QF=R  L0
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MOAPIMW  7L0                    @
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M53Z>I;NO;\2IVH=+'DB\.KPO%USQKM/HZ@$X@L;8
M
M                7II3VD?F0HLO32?M(_,AR_:7]/[D+&I/Q2 4GXI <M*B
M?5<_D"P?Q3_J'F(].^JY_(%A_BG_ %#S$=/AOAPIMW  7L0
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M5M?745+4,DJJ)S6U$:9S&KF[S47SIQ-"9FW67?I2N..6L:AF@ AF
M&+<;?3W"G6*I9E.IR<VKVH90)B==D6K%HU/96-\L\UJJ-U_APN]I(B<%\GG(
MS?K1%=J16.PV9O&.3L7["Z[A1Q5U(^"=,M<G/L7M*SNE!+;JQ\$R<E\%W4Y.
MU#=P9IG]7!XKA[<+>,F/M_92LT4E-/)!.U6R,7"HIPA-=;6=:F#U]3-S-$GA
MHGZ3>WX"#QNRAU\=XO7;K<-GC/3FCO\ -]@ S;
M &PL-+'676"GG15C>JYPN.I5(F=1MC>T4K-I^37@L+O5MGB2_P X[U;9XDO\
MY3YBC1_$L/W5Z"PN]6V>)+_..]2V>)+_ #CS%#\2P_=7H+"32ML\27^<=ZML
M\27^<>8H?B6'[J]!87>K;/$E_G'>K;/$E_G'F*'XEA^ZO06%WJVSQ)?YU'>I
M;/$E_G'F*'XEA^ZO06%WJVSQ)?YQWJVSQ)?YQYBA^)8?NKT%A=ZML\27^=1W
MJ6SQ)?YQYBA^)8?NKT%A=ZML\27^<=ZML\27^<>8H?B6'[J]!87>I;/$E_G'
M>K;/$E_G'F*'XEA^ZO06%WJVSQ)?YU'>K;/$E_G'F*'XEA^ZO06%WJVSQ)?Y
MU'>I;/$E_G'F*'XEA^ZO06%WJVSQ)?YU'>K;/$E_G4>8H?B6'[J]!87>K;/$
ME_G4=ZEL\27^<>8H?B6'[J]!87>K;/$E_G'>K;/$E_G'F*'XEA^ZO06%WJ6S
MQ)?YQWJ6SQ)?YQYBA^)8?NKT%A=ZML\27^<=ZML\27^<>8H?B6'[J]!87>K;
M/$E_G'>K;/$E_G'F*'XEA^ZO02?5EGH[90134S7H]TJ,7>=GAA?L(NU<EM+1
M>-PV\.:N:O/7LY !DM                   +TTG[2/S(467II3VD?F0Y?M
M+^G]R%C4OXI *3\4@.6E1'JN?R!8?XI_U#S&>G/5<_D"P_Q3_J'F,Z?#?#A3
M;N  O8@                  $ZV+_GJS]Q)]!!2=;%_SU9^XD^@B>RGB/A6
M_1ZHT)3PU$E8D\4<NZC,;[47',EO<VB]QT_HT(OL]_&UWF9_4F1S,TSSR<!2
MLX*S,>O]V+W-HO<=/Z-!W-HO<=/Z-#*!5N6WX=?1B]S:+W'3^C0=S:+W'3^C
M0R@-R>'7T8O<VB]QT_HT'<VB]QT_HT,H#<GAU]&+W-HO<=/Z-!W-HO<=/Z-#
M* W)X=?1B]S:+W'3^C0=S:+W'3^C0R@-R>'7T8O<VB]R4_HT'<VB]QT_HT,H
M#<GAU]&+W-HO<=/Z-!W-HO<=/Z-#*<N&JO'AV&%1W2EJJ=TS)6M:Q51R/7"M
M5.TF.:>L')3TAK:^2E@J704UH94O8B*]61M1&Y,FV-M=QI^E@I($PNZYKHT1
M6KV*AKM.W*"2Z7!7R*L\\VZU$3@C43@9#VNMNH4E:UO05RHS"+C#D3F7377Y
M?FKB*]]0VO<VB]QT_HT'<VB]QT_HT,E7(BHBJF5Y)VG)1N5GAU]&+W-HO<=/
MZ-!W-HO<=/Z-#* W)X=?1B]S:+W'3^C0=S:+W'3^C0R@-R>'7T8O<VB]QT_H
MT'<VB]QT_HT,H#<GAU]&+W-HO<=/Z-!W-HO<=/Z-#* W)X=?1B]S:+W'3^C0
M=S:+W'3^C0R@-R>'7T8O<VB]QT_HT'<VB]QT_HT,H#<GAU]&+W-HO<=/Z-#!
MO=!21VBL>RE@:YL3E14C1%3@;@P+]^1:[]T[Z":S.X89:5Y+=/D\W[;UQH63
M^(C_ *GGZ%<H>@-N'YBR?Q$?]3S]!R.I1S_9_P +]W><A.0+&\ (
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M5%JX_M.^@U38+A5QTM!>[;4U,F=R**I8]SL)G@B+E>"&7+/HC<-R #%(
M &FU3;.Z%N<L:)T\7A,\O:AN036>6=PPR8XR5FENTJ>5$5%14RG)44JO4-"M
MLO,T*)B)_P"$C_97[.1=NJJ%**[2;B8CE\-ODSS*\V@T236R.K8GAT[N/[*\
M_P"AV.&R=?U</A+3P^?P[?/I_P (2U<H<G7"[+3L-]W@
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M5NGRE0^TEV[9J?\ B$^JX@T"Y0F^TW\BTW\2GU7$'I_:GH.'^&H]G? C]7>
M"UO                   %Z:4]I'YD*++TTG[2/S(<OVE_3^Y"QJ3\4@%)^
M*0'+2HGU7/Y L/\ %/\ J'F(].^JY_(%A_BG_4/,1T^&^'"FW< !>Q
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M,63^(C_J>?H.1Z!VX?F+)_$1_P!3S] =2CF^S_A?NR$ 0%C>
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M=E^C];ZAKHTX)TBJGP\3J;R.WO<;=JEN:L6]7( #(
MVVE/R_2>=WU5-2;;2GY?I/.[ZJF-_=E5G^%;])7GL_\ \[5?NT^DFY"-G_\
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M(#EI41ZKG\@6#^*?]0\QGIWU7/Y L/\ %/\ J'F(Z?#?#A3;N  O8@
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M8IU<D3T<K>:=A XZ^29_2M@5*>-/"PF$4W&E*CUS<:F1D:MBW."XY\2$I2
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MU**F4?.B+Y<+_P#P($[LM4ZLM\<SUWE7/'&,\3-,:VIBBBPF.'(R2$@
M".ZUU?;M)6]M3<7.?)(JI%"S&\]4_IY?*86S_75'K&DJ988'TDE.]&N9(]%S
MGDJ+\!;&&\T\371CS1O27@ J9      :K57Y!J_V4^E#:FJU5^0:O]E/I0RI
M[T*L_P *WZ2H7:;^1:;^(3ZKB#TWM2<;3?R+3?Q*?5<0:G]J>AX?X;5]G? _
M=D  M;P                  !>FD_:1^9"BR]-)^TC\R'+]I?T_N0L:E_%(
M!2?BD!RTJ)]5S^0+#_%/^H>8CT[ZKG\@6#^*?]0\Q'3X;X<*;=P %[$
M              G6Q?\ /5G[B3Z""DZV+_GJS]Q)]!$]E/$?"M^CU9L]_&5W
MF9_4F9#-GOXRN\S/ZDS.7F]^4^S_ (%?W_N  J;H   <F6JB]:8  @=0[UM>
MDDZY%W7+V\-WZ6M^,ZJ=Z1UU1 [VDR+E/_/(X[=32MIJU^]'ES9<MQV+Q_H:
M^IK-VM@5&M3>1$5V.W*?82AV4ZN?;YX5YL<UWPIC/SHIQ*Y9**G<W/@9:BX\
M_P#5$.B&M?ZYJ4\%J<>28_\ .9T-JY%HG_A.._C*>7"I](&WJE=Z_AD:WBO#
M/P*1;:#52T-EN\C%5J/@<Q%7EEVZGVFVDJGN6G5'KC+57B0[:M4[U@?&]ZHQ
M\D3%3/P_T+<$;R5C[L;SJLJKNWK>.W,9.Y_KC"(F[R7@=U#$]+2U]#%'TFZN
M\KTXKYE.C43W-I&0I3>!E$;*KM[/PG?;'NAM6]6/:V!$\'#L./21\VE\FEBJ
MMZ:%^YOSM<N6XX.3/ RKS&BPI4S-Z*I<J<-[.4_H85LA?-7IT&%PN45W9Y1>
MY6/KW)$JN8F.O/$C?3<IB.O1D2-8ZU*C)UEDRCMU?T3T?IF25=/1R/3>WZ>)
M>/-51AYUG9T="KD@2-5;C.<E^:?J',LT3=["LAC1,_LG-]I=JKN'GNW3W+):
M4<JKS>J(J8SEKDQ\YWU[GK+1(N$<G#'PM^PTZU4K;:F)$5ZJ[*KY$<9E35N2
M>%J+\.,]:');#.695NZIU[JY_D:G]3Y2=627![5XM8YWPX<8=/6.6XO14:F&
MKX76OM3B.KC=#5+N> ]%1RMYKGA_4)9S'M[E31LX-1ZL^!,?82?22[U#QYHU
MJ?-DA7KF);<B(][$>YW%4RO-2<Z58U+>KFKE%=P^#@$-R "$@     8%_P#R
M+7?NG?09Y@7_ /(M=^Z=]!E7O"O+\.WZ/-VW#\Q9/XB/^IY^AY'H';A^8LG\
M1'_4\_0<CJ4<WV?\+]V0@"<@6-X                    X ]3:8J?7FG;9
M/G*R4\:JOEW4S\Y9^@I=ZV3QYXLES\"HGV*47L=N?=#2$<+E_"4<BPKVXYHO
MSJGP%O:$JTBN$M.Y<),W@GE3C]&34SUW67'X6?"XGEG]$["KA%5>H'S(BNC<
MUJX545$7L-!Z!1VL]I=3='UEBHVLHHJJ*5B2JBK(K414PG4BK\Q6NBV4TFDY
MF5<%0KDF=&V5BJB-SV?V-Y?[-4QW2[4-P8Q]TA1Z0RP3)X2+RX=644BMCK;E
M1VJEII.CDMS9'+-N-Q)$B+A55?ZFU6(B.CA9<E[VF+3UABWS9ZV2@GJ;.Z:I
MEC<C=U'\7)V[JIR-OLWMJT-NND]Q8C4RD4:.3+V.;QX)YS>3I=:&:=((4<^6
M-KH7+CPF^-S3DB\3"LEJN4E6^2AFA8ZD<LC9)$5$J7NPJH[/#ER+(M,5Y88>
M+::329Z.^OFJKTE++"]64JS-]<)+&K7/DSP;QZN!D798:1BW&NA;)"UZ(L4G
MM^?M6)V<!#='U=QK+?<HH*.X4TK4;$Z1-W+EX/\ +CF:ON+,NI(9+E6J^&9K
MNC8]-]9&Y5,M1."+U^8Q5Q&N[$K(]*-M5;7+41LJZI5D@9"BHZG=O91<)\1F
M0WBKI;-5W.EZ)ZU2MZ-[U1S6/PB+\.30:[L-#0RT;[0W<B>BQO1'>W=Q5/CQ
MR[3NM^FI%TXZ..NFD8L/KE(&\&,D5?:X7KP1UWI9/+-=RFS((/65*MUJ8UFA
M;TCI$>KFN=A<M1.7')VW**B?:%J*F+\#X*)25#4>]7+XKN:>0B>EH+C34<MD
MJXFHZ?$L+9D5TC\JB81>2(G%24U])-5UE*YTT,4E'NNQ(F62-QA<IGGUF2KI
M$M78+I/375MK?1QU4]*J34\CG\F*O)SO(>@=/:@M,=!1425;$J$:C%8N<H[K
M^<\_R24]+JB*7>FDJ*IFZQ8Z=$;(F>34[."$NL<$]^N,= Q]-;YU553+';ZJ
MU454XX7*_P!"N]8F.K:X?+;';5(WM?(.JDC=#311R2+(]C4:KUYN5.L[36=M
M\RO2.)[W<FHKE^ J*1RO>YR\W+E2R=45:4MFG7.'2)T;?.O]LE:&WP\=)EQ?
M:E]VK3T=UM3>K?-@LFSMQ$WS%=Z?9TE3O8YJ65;6[L*>8UK3NTRZN"G)CK7T
MAF  Q6@  @6T_9M0ZW9#4=.ZCNE.W<BG:F45N<[KD\^<+U94@4FQ_6=; VBN
M6L>DMR<.B665Z(GD:O OH%].)R4CEB6$TB>J&Z>V?VZQZ'J].4\CWLJV/Z>=
MR)O/>Y,;V/@3AY"+;-=G.IM&W9&I?J22R.D<^:F9&N]*NZJ-XJWAQPO!>HML
M$>/?4Q/S3R0K/9'L\K]%5URGKZREJ&U28:D.]E..>.40[=K>S9=;/HJRBK6T
M=QI6JQKGHJM>W.<+CBF%S\98X'CWY_$WU.2-<JDM0[*M7:EM4<=_U5#65,"H
MD#%8K8FIUJJHU%5W+CCX28W'9Y3WC9W0:;NDS4J*2-J1U$29W)$3&41>HG@)
MGB+SK[(BD*1J-ENM:^UP6.Y:N@?8XE1&QMC7?W47AGP45<=BNP3+4NSFEN>S
MR#2]%4.@;3JU\4STWE5Z9RKO/E2> 3Q%YU]B*1"LM%Z!OE!IVNL&I;S!66>6
MF6G@@@9A8LKG.5:BKS7GDT-@V5ZNL+*FWVG5T5+9ZEV949%F3':F4\%<=CD+
MK \Q?K]_L<D*MV4;,ZS1&HKK635L%12U,:Q0M;O;Z)OHJ*[*(F<)U=9D;+-G
MU?H^^7FNK:NEGCKO:-AWLM\)5XY1"R@1;/>V]_-,4B$ VF[.H]7R4E?15CK?
M>*/\3.B91<+E$7'%,+Q14-10:,VA35]*^[ZXW::'JI(\.<GE3=1%7RNR6L!7
M/>*\I-(F=N&INM1%57*B8RO-3D I9      ==0Q'PO:O)45%.PX<F6J!44K5
M9*]J\T54+!T5+TED8WK8Y6D,U!3K3W>I9C"*[>3X>)O= U:-DJ*5R\78>U/I
M_H;F7\U-N!P4^%Q/+/WA,P :;OA7^@_]2=HG\32?_CM+ *_T'_J1M$_B:3_\
M=IG7M;_OSA$H7ZHK\OZ>_AJCZT959:GJBOR_I[^&J/K1E5G>X#X$-3+[TNG3
M_P"28/,OTJ2_9Q_J3IG]_+_T7D/T_P#DF#S+]*DOV<?ZDZ9_?R_]%Y1E]RWZ
M//X/_61_\EA^J+_)5C_BG?4*4+K]47^2K'_%.^H4H6^SO@O0YO>6[ZG^Z6^A
MM]]96UU+3O=5,5&S2M8JIN>52V&Z@LSW(UEVM[G*N$1*EF57XSQ[14L$]97.
MFA9(J/:B*Y,]1E^LJ6*6!\<$;7)-'A4;Q3PT-7B.%B^2UMM3\2KCOX/+]GLH
M'Q!^)9^RA]G*=8  &-<Y>AM]3(OZ,:_050JY55ZRP=:U?K>T]$U?"F=NX\G7
M_0K>MG2FI)YW<$C8KOB0W.'KT_5P_:=^;)%(^7^53ZEFZ?4]<Y%RB/W4^!#X
MCY&$R5:FKFG=SD>K_C4SF<CN:U$0[..O)2*^D.0 &0
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M+)_$1_U//T!Z!VX?F+)_$1_U//T'(ZM7-]G_  OW9" ("QO
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MS\YN6_T\>G Q1/%<3S3V[_M"3Z6I\JBX)_3-W8T0CFFZ7<8BX)0B81$-)Z
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M/@.OPN/\T1Z.%PU9XGB>>>W?_AJJ)F&F<G(Z*=N&G>=&7>  0
M        &VTI^7Z3SN^JIJ3;:4_+])YW?54QO[LJL_PK?I*\]G_^=JOW:?23
M<A&S_P#SE5^[3Z2;GGLWORU_9WP(_< !4W@ ^)I60Q/DE<C&-3*N5<(B ?8*
M@BVFU\%TF6H9#-1J_#6(W=5K<]OVEL4-5%6T<-3 Y'12M1S53L4LOBM3NJQ9
MJ9?==LDC(V[TCVM;VN7!$J76L-=JEEKMU.^I@1%1\[.2+V^;RF=K6T+?[:VW
MPU<=/,DB2>$O%41%3E\)]Z.TY!IZVI"UL;JEW&69OZ?9S^@QC41U9]9GHT^T
MS1"ZNIJ=]-4MIJRGWFHYR<'M7FU>SD1RDV9O=H2'3TCWQU,4ZU"52KP5ZKQX
M=F$0M"YUC*"W5-7*J(R"-TBY\B&GT/?I]0VEU74TS8%1^XFZY51WE\A=3B,E
M:Q$=H8S2LRT>R;0LNCJ2XR5U2R>OKI4=(L:88UK<[J)\:K\)/00^PZFJZS6-
MRL]='#&R%%6'=145<+UY7CP5"JUK9)FTLHU7HE=5-ZWII9MQS]QJNW6)E5\B
M$?TEJZDU!TD2-];UC'*BPO7BJ=J$E*^U;HBHK;W'7V-S*21?"E=OJW+L\TQR
M(KJ>DD[CLL$'73,6*GBC<N7-8C57S(:74NI(K'+3LDA=*LO%<+C=3M%:S:=0
MSB)GLWP,"S7:DN],L]%)O-1<.3DK5\IGD3$Q.I0  @?$\,51$Z*HC9+&[@K'
MM1R+\"D"U=LLL-XHJAU#2,H:]45621<&[WE;RP6 "S'EOCG=)TB:Q/=XEN-%
M/;JZ>CJV+'/"]6/:O4J&.7SMWT.^J;WPVJ%7RL3%6QB<VIR?_1?@*&/3\-GC
M/2+PTKUY9T  O8@  ] >IYU*M5;*BQU,BK)3?A(,K^@O-$\R_27$>0=G-Y=8
M]96RK1V[&LJ1RY7AN.7"Y^//P'KY%RF4/.^T</AY>:.TMO#;==!JM5?D&K\R
M?2AM35:J_(-7^RGTH:-/>@S_  K?I*A-IGY%IOXE/JN(/3^U)QM,_(U-_$)]
M5Q!Z;VIZ'A_AM7V=\"&0 "UO                   %Z:3]I'YD*++TTI[2
M/S(<OVE_3^Y"QJ7\4@%)^*0'+2HGU7/Y L'\4_ZAYB/3OJN?R!8/XI_U#S$=
M/AOAPIMW  7L0                  "=;%_SU9^XD^@@I.MB_YZL_<2?01/
M93Q'PK?H]6[/?QE=YF?U)D0W9[^-KOV6?U)D<O-[\LO9_P "O[_W  5-P
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MQ$?]3S]!R/0.W#\Q9/XB/^IY^@.I1S?9_P +]V0@"<@6-X
M       .HL[8SJMM%4K8Z^14AG?FF<O)KUYM\R_3YRL0USF/1\;E:]JY1R<T
M4B8VKS8HRTFLO7M+/)2SLFA<K9&+E%0LNQ72.Z422-PDK>$C.Q?L/.^S+64>
MH;>VDK)$2Z0-P]%_]Q/&3^I8MIN,UMJDF@7R.:O)R=AJY<?-'W<KAL]N$R36
M_;Y_\K+N5#!<J"HHZMB/@G8K'M[44T>D]$V?3#Y)+="YT\G!997;SD3L1>I#
M;VFYT]R@WX'>$GMF+S:9QHSN.CO5Y;ZO'5I-2:<IK\ZF=4RS1N@5=U8UQE%Y
MH9MLM-#;(F1T5-%%NIC>1J;R^=>:F<!N>R8I6)YM=1>"<31:FU-06*U/JY9H
MY'JJ-BC:Y%5[EX(GF[5[,FGVN7::T:5WX9.B9/,R&9^%54C=[;&.2^4\ZVZX
MPNU9'*C%FIJ??_!S*[>EWEQO(F.2)A,&=*<W5K<1Q/A?EB.NDBVE2T=\NK;M
M4)):[C0[OKJ1B*U)FKQ;N-ZU\I#[A8UEOE-5,J:A]'6OW$<N))6JK<IEW)25
MZN@66Q3QT,?2OJ)(T=&Y-]6X7VS%ZN'#'(Q+;IZYTLM E)3P1N:B/2*6==Y_
M:[_8J]A?%==(<J<TWCFF6+W,GMEIJ:6T5KJNHIT5[:>:)%<U>UJF?I"6)8HZ
MQ*2>GZ:!&U3Y$QAR+QW4YJAU0U=V6[03U5/3Q-1CJ9C]Y<HKU^<L>S;(J&JA
MI+M3W2J6KD:O3-G3>C>O7A$PJ8ZB)M%>K/'AOEW5IJ?1^H(KC3UU/2U$]NG5
M)Z9J-3I8DSG=D1RIC*87X2^Z5TCJ:)T[$9*K45[47*(O6AS3Q]%!'&KE<K&H
MW>7KPG,YD>V-CGR.1K6IE57J->UIMW=?%AKAWRN7N:QCG/5$:U,JJ]2%<ZFO
M+KE5*R)52EC7P4\9>TS-3:A6LWJ:B<J4_P"D[DK_ .Q&'N1K55R\$-G#CY?S
M6<KCN+\6?"Q]O[NJJFZ*)5;Q>[@U/*9NEK:JO1ST555<JJF)1TSJN?><G#J0
ML"P6](F-7!3EOSS]F_P7#>!3KWGNV]M@2*-.!G'#&[K<(<E3<  !@:A_(%S_
M (:7ZJGEC9+M(BT'#=(Y;:^M]>/C<BMF1F[N[WD7/MCULO%.)U]!#^JC_E0V
M,6:M*S2T;B6%JS,[B7E?7NL*K:E5V^BLNG71U$;EXL7I'N5V.;D1,)PZR0;9
M:"\6>CTK2U[JN>PTM-%#5+3N5$<YN$<BKYDX9/138HVKEK&HOD3!RYK7IAS4
M<G8J9+(XN*S7EKTACX>][EX\UNRR5-MM];I.PU]%:X9.CFK*GCTLBIE&IQ7D
MC7?'U%W;0]13V[2]GD33<%]L<T$:SRN\)&)A,\$3P>')Q:?11[N[T;-WLQP/
MK=:K=W=3=[,<"+<5%N7<=ON1CUOJ\C7]VGKU6TB;-[3>:>[.D15:B^"WR-PJ
MKSQQX$[VU:/O=5:].7IU,ZX55%2MIZ^-B;R\/"WL)S3*N1?@+\;%&U<MC8B]
MJ(?:IE,+R)GC)W$Q'8\/OMYOHM2[/ZZ6DI:#9]455?(J-E@C;Q:O^W"JKOA1
M"0;:](526;3UVT[;71,M*9?1L\)T355'<DSG"HN<9YEVMBC:N6QL1>U$/M4R
MF%Y&/F=6BU8[>L[3R=-2\\:ZVH+K#0%7;;39ZY)71M=73O:G1PM:Y'+A4[51
M$XXYEA[ /],[?^W)]8L%(HT142-B(O/AS/IK4:F&HB)V(AC?-6:<E:ZZ[3%9
MB=S*N_5 ?Z8W']Y%]="J= ;98=*:5IK0ZRR5+X=[\*E0C47*YY;JGIIS4<F'
M(BIV*A\=!#^JC_E0G'GK6GAVKOKON36=[B7G335HOVTS:'3:DNU ^CM,#FO1
M7(J-5&+EK6YYKGFID[2D1WJA]-HJ(J*^CX+^\4]"M1&IAJ(B=B'"QL5R.5C5
M<G6J<3+S7YMZZ:U"/#Z(7MFL]7?-G=TI+=$Z:J3<E9$U,N?NO151$[<9*HT#
MM"=;] R:1CLUPJKU&V:&*.-B;J(]7+EW6F%<O4>C3Y2*-'91C47M1##'FBM.
M2T;Z[3-=SN)><_4_VQUVT[K:UJNX^J@;!GL5S7H<[-=;2;-XJ_36I+37.JFS
M*Z!L#4<KW+U<53*+U*F3T-4TK9:2>&-SH%E8K>DB7=<W*<T5.LJ*FL^U6R3S
MPT=;;;U3JN(YJY<O:G;G@N?.JE\9JY>;FUJ==-_Y8<LUUI$]DU55UNW.YU5R
MIW4M7,D\CX'<X\\4:OE1,(>D"KMEFS^YV6_7+4>IJB*6[5JN560^U;O+ER]G
MP(6B4\5>M[_E^4,L<3$=0 &LL  !7FWF[):]G=:U%Q)6.;2L\N]Q=_\ :CBE
M]E>HVJSN-6/\-.-.J]:=;3?^J7U VKO%!9('Y;1M669$\=R)A%\S?K%+Q224
M\S)H'K'*Q4<US>:*AV.&P_Z/7Y]7,XNL9IFKTY;JN6AJV3PKAS5Y=J=A9EIK
MXKE1LGB7R.;XJ]A0^BM2PW^WMWU:VNB1$FC[5\9/(I-+)=9K75;\:[T3N#V+
MR<GVFMFQ;_5H\)Q,\-?DOV6@#%MU?!<($EIGHY.M.M/.91H3&N[T%;1:-P
M)         #XGFC@B=),]&,:F5503.NLD\K((7RRN1K&)E54K6_W9]TJW.RJ
M0,7$;?)VF9J6_.N+U@IE5M*WX%>O:OD(G=[E3VJADJ:IVZQO).MR]B&[@PS'
M7YN%QO%3FMX6/M_=I];WU+3;^BA7_P!7.BHQ/%3K<5E1QJOA.XJO%3MN-;/>
M+C)5U*KER^"WJ:WJ1#O@CW4.SCIX==?-T^$X>.'QZGO/=VL3"'(!DV0
M                -MI3\OTGG=]534FVTI^7Z3SN^JIC?W959_A6_25Y[/\
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MH]6[/?QM=YF?]Q,B&[/?QE=YF?\ <3(Y>;WY9>S_ (%?W_N  J;@
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MVX?F+)_$1_U//T!Z!VX?F+)_$1_U//T!U*.;[/\ A?NR$ 0%C>   0
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M'6Q88Q=9[NEPG!5P?FMUM_9S3Q;J&2B8.$3!R9MT
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M/$?"M^CU;L]_&5WF9_4F1#=GOXRN\S/ZDR.7F]^67L_X%?W_ +@ *FX
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M!$]E/$?"M^CU;L]_&5WF9_4F1#=GOXRN\S/ZDR.7F]^67L_X%?W_ +@ *FX
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M095[PKR^Y;]'F[;A^8LG\1'_ %//T!Z!VX?F+)_$1_U//T'(ZE7-]G_"_=D
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M)QIS5=IU$R1]IJDG;'C>PU6X^-#7OAR4ZVALTSX[]*RWH"+E. *EH
M           !6.V;:%%IFW26RWO1]WJ8\<%_$-7])?+V&WVGZ]I-'VE_1O9+
M=945((.>%\9W8B'D^YU]3=*^>MKYG35,SE>^1Z\54Z'!\+XD\]^S3XGB.3\E
M>[&>YSWN<]RN<Y<JJ\U4^3D'8<Z)<  ,HEP#DX"8EP#D!DX.,'((3$OG=-KI
M6U+=+W308S&CM^3]E/\ S!K"U]E=EZ&B]>2L_"U"\,]3>HU^)R1BQS/S78:\
M]M+(TW:6N5%5OS$_H;:QD:<#6Z<I-R-JX).U,-1#@.BZ&TC&]2':V)K>2'V
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M:F$1#M 3N=:  $                      :K57Y!J_V4^E#:FJU5^0:O\
M93Z4,J>]"K/\*WZ2H3:9^1:;^(3ZKB#TWM2<;3?R-3?Q"?5<0BF]J>AP?#:O
ML[X$?J[P 6MX                   O32GM(_,A19>FD_:1^9#E^TOZ?W(6
M-2?BD I?Q2 Y:5$^JY_(%A_BG_4/,1Z<]5S^0+#_ !3_ *AYC.GPWPX4V[@
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MD_%(#EI41ZKG\@6'^*?]0\QGIWU7/Y L/\4_ZAYB.GPWPX4V[@ +V(
M                          @          (              !
M                        3/0.C);_ #)45.8Z%CN*];U[$.O0>C:C4%4V
M:H:Z.WL7+G8XO\B?:>C=.6*.""*&GB;'$Q$1K43@B&KGS\OY:]V=:[<Z:L<<
M,,4,$361,1$:UJ81$+!M-N;$Q.!Q:+:V)B90W;&HUN$.>M&M1J80Y
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M7R%%W"BGM]7)35<:QRL7"HIW>&XBN:/NAC  V0
M
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M_P Q["TOOROR3_F/,8_4Y95$"W?86E]^5^2?\Q["TOOROR3_ )CS&/U.251
MMWV%I??E?DG_ #'L+2^_"_)/^8\QC]3EE40+=]A:7WY7Y)_S'L+2^_*_)/\
MF/,8_4Y95$"W?86E]^5^2?\ ,Y]A:7WY7Y)_S'F,?J<DJA)=H+2$^H:M)9D<
MR@C=X3_'7L0F=/L7>V>-TMV61B.17,]:XWDSQ3._P+=L&GXZ6*."G@;%"Q,-
M:U,(A5EXF-:HRBGJZ].V1D,44,$:,B8B-:B=2%AVFVMB8F4.+3;4B:BJTWC&
MHU,(:"P8U&IA#D                    .'\6*AX\O[.COEQ;V5$GUE/8;O
M:J>1M8,Z/5%U;C&*A_TG0X#O9R/:WNUEICC!]'!TG$B7&#@Y[1@EE$OG .0$
MQ+Y[3@^L )?&#C!]X.,$I?!Q@^\' 'S@XP?1Q@)?.#@^\'"$CXP#ZP<8 ^<'
M&#Z..LD?.#@^@2E\ ^L' 3#@X.0$OG!P?6#C!*7S@X/O!P!\8.#[.,!+X.,'
MW@X)'R<'T<8 X!R231^FI;Q4MEF:K:-B\57]->Q##)DKCK-K+<=;9+<M31VF
MI+Q4I+.US:-B\5Y;Z]B%Z6&U<(VM;AK41$1.I#JL%G1C61QQHUC41$1$X(A8
M-IMZ1,;P1#@\1Q%LUMSV=O!AC#77S=MJHDB8F4-JB83"'#41J80Y-=>
M             #KEB21JHI7NT#1L=YIUDBPRKC3P']2^12QCKFB21JHJ&=+V
MI;FKW'DNOHYZ"KDIJJ-8YHUPJ*8Y?>O=&17MK'L<V"=B_C4CWE5.SFA7E1L_
MFB54]>Y__1_Y'8Q\=CFN[SJ4(."8]X\WNO\ _:_N.\>;W6OHO[F?G</U?Q(A
MP)CWCS>ZE]%_<=X\WNM?1?W'G</U?Q(AP)CWCS>ZE]%_<=X\WNI?1?W'G</U
M?Q(AP)CWCS>ZU]%_<=X\WNM?1?W'G</U?Q(AP)CWCS>ZE]%_<=X\WNI?1?W'
MG</U?Q(AP)CWCS>ZE]%_<=X\WNI?1?W'G</U?Q(AP)CWCS>ZU]%_<=X\WNM?
M1?W'G</U?Q(AP)CWCS>ZE]%_<=X\WNM?1?W'G</U?Q(AP)CWCS>ZE]%_<=X\
MWNM?1?W'G</U?Q(AP)CWCS>ZE]%_<=X\WNM?1?W'G</U?Q(AP)CWCR^ZU]%_
M<=X\WNI?1?W'G</U?Q(AP)CWCS>ZU]%_<=X\WNI?1?W'G</U?Q(AP)CWCS>Z
MU]%_<=X\WNI?1?W'G</U?Q(AP)CWCS>ZE]%_<=X\WNI?1?W'G</U?Q(AP)CW
MCS>ZE]%_<=X\WNM?1?W'G</U?Q(AP)CWCS>ZE]%_<=X\WNI?1?W'G</U?Q(A
MP)CWCS>ZU]%_<=X\WNI?1?W'G</U?Q(AP)CWCS>Z_P#]K^X[QYO=:^B_N/.X
M?J_B1#@3'O'F]UKZ+^X[QYO=2^B_N/.X?J_B1#@3'O'F]U+Z+^X[QYO=2^B_
MN/.X?J_B1#@3'O'F]UKZ+^X[QYO=2^B_N/.X?J_B1#@3'O'F]U+Z+^X[QYO=
M:^B_N/.X?J_B1#@3'O'F]UKZ+^X[QY?=:^B_N/.X?J_B1#@3'O'F]U+Z+^X[
MQYO=2^B_N/.X?J_B1#@3'O'F]U+Z+^X[QYO=:^B_N/.X?J_B1#@3'O'F]U+Z
M+^X[QYO=:^B_N/.X?J_B1#@3'O'F]UKZ+^X[QYO=2^B_N/.X?J_B1#@3'O'F
M]U+Z+^X[QYO=2^B_N/.X?J_B1#@3'O'F]UKZ+^X[QYO=2^B_N/.X?J_B1#@3
M'O'F]U+Z+^X[QYO=2^B_N/.X?J_B1#@3'O'E]UKZ+^X[QYO=2^B_N/.X?J_B
M1#@3'O'F]UKZ+^X[QYO=2^B_N/.X?J_B1#@3'O'F]UKZ+^X[QYO=:^B_N/.X
M?J_B1#B]-*>TC\R%>MT-*JX]=KZ+^Y9^FZ-T2,14Y<#0XW/3+R\D[TE.:3\4
M@.:9,1(#0'V]J.;A375%M9(JJJ&S &D[C1K^B@[C1]B&[ &D[C1^*@[C1^*A
MNP!I.XT?8@[C1^*;L :3N-'XJ#N-'XINP!I.XT?BH.XT?BH;L :3N-'XJ#N-
M'V(;L :3N-'XJ#N-'XJ&[ &D[C1]B#N-'V(;L :3N-'XJ?$.XT?BH;L :3N-
M'XJ#N-'V(;L :3N-'XJ#N-'V(;L :3N-'V(.XT?BH;L :3N-'XH[C1]B&[ &
MD2S1^*@[C1^*ANP!I.XT?BH.XT?BH;L :3N-'XJ#N-'XJ?$;L :3N-'V(.XT
M?BI\1NP!I.XT?BH.XT?BH;L :3N-'V(.XT?BH;L :3N-'XJ#N-'V(;L :3N-
M'XJ#N-'XJ&[ &D[C1]B#N-'XJ&[ &D[C1]B#N-'XJ&[ &D[C1]B#N-'V(;L
M:3N-'XJ#N-'XJ&[ &D[BQ^+\P[C1^*ANP!I.XT?BH.XT?8ANP!I.XT?BH.XT
M?BH;L :3N-'XJ#N-'XJ&[ &D[C1^*GQ#N-'XJ&[ &D[C1^*@[C1^*ANP!I.X
MT?BH.XT?8ANP!I.XT?8@[C1]B?$;L :1+-&GZ*&736YD:\&FP '#&HU,(<@
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MEFC1?:I\1ETM V+DAG@ B83"
M
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M8(B(F$ ,68
M
M
M
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M16YD34X)P,Z.%C$X(AV%*]PQB-3"(<@
M
M
M
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MR0Y(9/AD36)P0^P
M
M
M
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M*GHX5Y,5ZJ_'E3J)Y9[HYHGLD8/ECT<A]$)
M
M
M
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MBMV$150VL4*,0PWONSB-=B!JM;Q.T A(
M
M
M
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M+3>4]*R-."&0UJ-3@AR0D1$1.
M
M
M
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M."'T
M
M
M
M                                           =4L#9$7*&FN%H9*U4
MW45.PWP5$7F!4]\T7!*]SX4="_KW4X?$85)IME.N&1JJ^,O,MZ6F9(BY0QDM
MT:.SNH3S3K2-1O:&VNQ<LM)106ID:)X)M(J=D:<$0[N1"77%"UB)A#L
M
M
M
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MBK^BASN/P8\/+R1K>UV&TVWM/$7*< ==.N8T.PYJ\
M
M
M                                                          59
MZH+\WK=_%?\ 8XHHO7U0/YO6W^*_['%%'H/9_P "&GF]X !O*@  !U ( " $
M  "0    $ @ )  $ <'()    @   $#@Y" D    !   D       $ $ )
M  0  ) X.>H                 $     "_='KX$7[*%!%^:/\ :1?LH<CV
MIVK^_P#AL</\UC4GXI#N.FD_%(=QR&R
M
M
M                                                *L]4#^;UN_BO
M^QQ11>OJ@?S>MW\5_P!CBBCT'L_X$-/-[P #>5 0      (  $@    ( '!R
M2       "  !(    $     "  0$@            ('!R 2
M@<'(!(           7YH_P!I%^RA09?FC_:1?LH<CVIVK^[8X?YK&I/Q2'<=
M-)^*0[CD-D
M
M
M                           59ZH'\WK=_%?]CBBB]?5 _F];OXK_ +'%
M%'H/9_P(:>;W@ &\J          A 'HV72]B30CZE+/0>N.YJR=)T#=[>Z+.
M<XYY/.1ZEF_T[D_^5+_T3G>T+37DU/S7X8WMY: !TE "R=D>B*?4#IKC=&J^
MAA=N-CY)([KSY$X?&3RKU#H>WWCN++14N^U>C=(E.Q8V+V*[GDT\G%Q6\TK6
M9F.ZVN/<;F=//0+=VKZ I**@=>K$Q(H686>%O%N%Y.;\W#RFHV0:5MM\JJBJ
MN[XWQ0*C64[GHBO5>M4YX,HXJDXO%^2/#GFY5<@]"7#4NB+1=^Y,M!3K(U=U
M[V4S',8O8JKQ,+:EHNT2::J;O;*:.GJ(&I+F),-D:JHG+ER7)57C?S1%JS&^
MS*<72=2H@$NV:Z4[Z;TL<RJVB@1'S*G-4ZD3SEOZBJM':.IH*6MM].JO3#8F
M0->_=\9<]7PEF7BHQW\.L;EC7'N-S/1#MAMEMEUHKHZY4%+5N9(Q&+-$C]U,
M=62%;3:2GH=<76FHH(X*>-S-V.-J-:W,;5X(GE4OO0]'8VTU1<=-[K::M5'.
M8U>#7)U8ZE\A1>UK_4*\?M1_]-IK<-EG)Q-I^6NW_AG>NJ0B)N]':<JM37F.
MAI?!;[:65>4;>M32%Z[ :"..Q5U=A%EFFZ/..*(U.7SFWQ6:<..;1W5XZ\UM
M)%1V+2NB;8R2I;2Q*B8=45&'/>OD^Q#LM][TAJESJ*FDHJMRI^)DA5JN\R.1
M,_ 4]MFN<U=K6I@>_,%(C8HV]2<,N^'*D*HZF6CJHJFFD='-$Y'L>U<*BH:>
M/@IR4\2UIYI6SEY9U$=%A[5= ML#EN=I;BV/<C71JJJL3E_[2MR=ZDVFW6^V
MN>@GIJ2*"9-UVZU57X,F3L@TK;K[5555>)(GPP*C64ZOPKW+QRJ<\)_YR-G'
M>^'#O/\ )7,1:VJJ[!Z$N6I=$66Z=RIK?3J]BHQ[V4S',8O8JKQ,3:EHNT2Z
M;J;M;J>.FJ*=B2;T28:]OE3D85XV.:(M68WV93BZ3J5# L+8Q9K=>KU6PW2D
MCJ8V0[S6OSP7).KYI_1VDJY]UN=.S<D1&P4C6[R91.*HBKQ7SEF3BZTOX>IF
M6-<<S&U!@]+VVATKK.PK+24%.M.Y58N[$V.2-W8N.2\4*#U'8);5JF>SQ;TK
MTE2.+AQ=O<OI)P<5&69K,:F"V/EC;2&XT9!%4ZLL\%1&R6&2KB8]CTRCD5R9
M14+WL>CM/Z2L:U-SAIYI8V;T]1.U')GK1$7J,"QS:-U=>*::UP>M+C0S-F8B
M1MC5Z-7/)%PJ?.46XZ+1;EK.O5E&+6MRU6VJPVFUZ8IIK=;:2EE=5-:KX8D:
MJINNX91/(:W9,FE.]ZH[X^Y'KOUPN[Z\W-_=W6XQO<<9R23;Y^:-+_%M^JXT
M^QK3%FO.FJFHNEOAJ9FU+F(Y^<HFZWAS\I12_P#^)N\SW^7=G,?ZG15^JO6O
M?+=.YW1>L_7,G0]#C<W-Y<;N.&,&J)#?+2DVNZZTVV)&-=7/@A8G)J;ZHB%X
M46F],Z+L737&&F?N(G23U#$<Y[NQ$7Z#<R<37#6L:W,JZTFTRIS9514UPUG2
M4]=3Q5$#FNS'*U'-7AV*3+;A9+9:K7;'VVWTM(]\SD<L,2,5R8Z\$JTC/I/4
M=W9<K' E+<*7.6;B1JYJ\/:HJHJ&E]4)^2+3^_?]5#5\:<G%5[Q]O_*SEB,<
MJ/!=.RO1]C[B,N]U?3U4[VK)T;W(K86IGFG;PZS=VG5&B;O=$M=/;X&R/=T;
M'/I6(UZ]6%3B;%^-U:8K69UW5QBZ=9>>RPME>A8-3NFK+C,J45.]&+"S@YZX
MSSZD,[;/I"AL:TEQM<:00U#UCDB3DCL914\_'XBTM +85M"][?0[G@]/T2+[
M?'7DKXCB]X8OCWU_AE3'^;4O/^T*CI[?K*Z4M%$V&GBD1K&-3"(FZA'2Z=KJ
MZ4]875(?6W?'OQ[V$=OYWFY\GM3+V=Z M=#8XKO?XV2SO9TV)O:1,QGEYN)G
M3BZTPQ:T3Z?JB<<S:8A1:!#T/:+IHG5=5-:X*"G21,HU'P-CZ1$ZVJG$J[:E
MH]FEKK$ZD<KJ"J171(O-BIS;\Z%F+BHO?P[1,2QMCU&XG:$@OG0NB;-9M-LO
M%[BCJ)G1=.]TB;S8VXSA$,FS:HT1?:]+=%;H(Y)%W&+-2L:CU\BH5SQO6>2L
MS$?-E&+UEY]!8>UW2MOL-;!56F2-L%0JM=3H]%6-R=:)SPI7AMXLD9:Q>JNU
M9K.I  A8Q   !P<@  0   %^:/\ :1?LH4&7YH_VD7[*')]J=J_O_AL</\UC
M4GXI#N.FD_$H=QR&R
M
M
M                                  *L]4%^;UN_BO\ L<447KZH+\WK
M=_%?]CBBCT'L_P"!#3S>\  WE0 "  !(   #@Y 'J6;_ $ZD_P#E2_\ 1/+1
MZNHJ5:[1D%(C]Q9[>V+>QG=WH\9Q\)R_:4ZY)^Z_!\WE$%P>PG-[^Q_)5^\8
MMUV/2T%MJJM;TQZ01.DW?6RIG"9QG>-F.-P3.HM_=AX5_1/]D+&1[/K:YN$W
M^D<Y4[=]R?0B$'FTYLW?,]\FHZE7N<JN59V\_P"0VNPS4D$MI?9*B1K*F!RO
MA1RXWV+Q5$\R_2:Z[[':F>_22T%;3QVV617[KT7?C15SNHB)A?C0T(UCS7B]
MIKOK^J[O6-1M*KMJG2S]*5EL@O5/)FD?#'OJJJJ[JHW/#GR*MV<:#J-4])52
M5#J6@C=N*]J9<]W8A(=HNC-+::LJRLGJ&5[TW88DDWE>O6JHJ<$)1L,N--4:
M26CC<U*FGE=OLSQ5%XH[^GP&46\'!-\.^L_-&N:^K,*736S[3,F+K4-J*EJY
M5M1,KW9\K6X3XT)=K*6#O N4D*(VG=1+T:(F,-5.'#XB!W+9-55>IYZR:Y0I
M;GR=*YSL])SXIC&/AS\!/-8PQU&@;G'1N1\24B[BM\)%1J?V*,DUFU)B\VGY
M_9G7>IZ:0WU/D;$L]UD3\8Z9J+Y$PI =L$CWZ]N.^JKNHQJ9ZDW4-OL4U-36
M:Z3T%<](X:U6[LB\FO3.,^<F.TC9O-J2Z-N=JJ8(IWM1LS)E5&NQP1R*B+QQ
MU&US1AXJULG2)A7KFQZA@>I[ED6@NT2JJQI(Q43J1<$!VM?ZA7C]J/\ Z;2[
MMGFFJ?2EODM_KJ.>OD_#3*WAPY)A.PI':U_J%>/VH_\ IM'#7B_%7M7MK_@O
M&L<1*(E_;!)V/TI4PM=E\=2JN3LRB8^@H%";;*]6LTQ>'LK%7N?58;(J)G<7
MJ=CZ3:XS%.3%,5[J\5N6W5T;6J9]+KRYH]%1)'-E:JIS16HO B#6JYR-:BJJ
MKA$/2FKM(VK75)35D55NRM9B*IA5'(YJ\<*G6AI=*[):.TW**MN%<ZM?"Y'Q
ML2/<;E.2KQ7."C%QV.N*(MWCY,[8IFW3LJ>\Z*O]GA=-6V^1(&IO.E9X343R
MX-OLYT'4ZJ26I?4NI*&)VXLC4RY[N>$3X>9.MLFLZ6&V36.@E26KFPDZL7*1
MMZT7RKV&=L*N--/I)U$Q[4J::9RR,SQ5'+E'>;J^ B_$YO+^),:G_'J12O/I
MAR:8V?Z:EQ=JAM14M7*MJ)E<N?*UN$^,E^L9H.\&XRPHC:=:/+$1,8:J<.'Q
M$"O.R:LK]455;)<H6VZ:597.=GI415RJ8QCX<_ 3W6,+*S0=SAHGM?&M*YK'
M,7**B?\ \#3R36;4GGFT_/[+:[U/32K?4_\ YP7#^'_[D/G;\]RZCH6JO@MI
M^"=G%3Z]3_\ G!</X=/K'QM]_.6B_A_ZJ;G_ .[^RK_VDB]3VJ]Q[LF>"3LX
M?_2:F\QQR[=J)LJ(K4FC=Q[4;E/G1#:^I[_)%W_?L^JI$=I-<ZV;4UKF)EU-
M)#*B=N[A<&%:S;B<D1Z?\)F=4B4^V[R/9I")C%5&/J&H['F4IW0,\M/K*SN@
M<K7.JHV+CK17(BH>@+U14&OM(;E+4HD<Z))'(G'<>G4J?,J$0T1LU=IRZMNM
M_K:5S:=<Q-C5<;W4Y55$^(PX;/3'@MCMWZ]$WI,VB89VWS\T:7^+;]5PV!?F
ME5_Q;OJM&WS\T:7^+;]5PV!?FC5_Q;OJM*__ -+]V7_NHAIQC7[=IT>G!*VJ
M7X4:]4^<WGJA9)$I+/&CEZ-SY'*G4JHB?:0BX79;'M6KKCC+8+C*YR)UM5RH
MJ?$JER:PL%%K[3E,^BJV(J+TM/.G%.*<45/B^(ORSX>7'DMVTQK'-6U84YL>
MEDCUY0I'GPT<UWFP3SU0?Y(M/[]_U4,G9WL^=I6Y=T;U64[JE?P4#(G+NY7R
MJB97R8,?U0:XM-H7G^'?]5")RUR<76:=O_Z16:XYVT>A]EK[E;8Z^]5DM-3R
MMWVPQ<'*WM55X(2FST.SZR7:E@HW05%SZ1K(W.>Z5R/SP7Q47/6A)K+)3:BT
M/#%13HUD](D"N9SC7=W53'D4@>E-F$EAO45UOERI4IZ23I(T8JIO*G)7*N,<
M<<.)5.:<G/XMYC7RA,5Y=<L-EM_5.]:A3K6L1?\ [''5ZG[\@W+]^GT'=M^B
M<_2M%(U%5K*M-['5EKC"]3[4QK;;I3;R)*V5K\9XJF%XDQ_Z*?U_R?\ NH#M
M#1';3+BUW):EB+\32_M4TUNETQ54]UJ74MN6-K))6+NJUN4QQPOD*HVHZ(N$
M-QN^IFU%.M*CV2MC3._^BG'ACASYE@V*NH-=Z(=3OD3>FAZ&H8B^%&].O'G1
M%&>T6QX[UGI'2?MV*1J;1/S0ZRVS9Y9[I35])J*;IX';S=^9%3X<,/G;+J&Q
MWO35-';+C3U%3%4M?NLSG=W7(OTH?%AV-R1W-SKW60RT+<[K8%<CW]F>'@_.
M1;:?8K!IZOIZ2S2RRU/%T\;G[S6)U)GM7_SF78XQ7S1,7FTPQGFBL]-+ V>[
M0[566>"VWJ2.FJ8F)#^$3P)4QC_Q%-W5Z TE>6+-34D4;G)PEHI=U$\J(B[O
MS&CTSI32&I=+JZVT\;*F2+=>]7*Z2&3'8J]IK--;+[_:;[!4)=Z>*EB?G>B<
MY7.3/+=5,)GSJ46\.+6FEII/HSC>HW&T8VE:!FTNR.LIZE]502/W,O\ ;1NX
MX1>U.',@)>^W:]4D5@CM+9&OK)Y6O5B+Q8QN5ROPX3XRB#H\'DODQ1:_=1DB
M(MJ '!R;:L           OS1_M(OV4*#+\T?[2+]E#D>U.U?W;'#_-8U)^*0
M[CII/Q2'<<AL@
M
M
M                             "K/5!?F];OXK_L<447KZH'\WK=_%?\
M8XHH]![/^!#3R^\  WE0@"          22#7.I8(8XHKQ4-CC:C&M3'!$X(G
M(C8,;4K;WHVF)F.R3]_^J/?JI_\ M^PZZC7&I*F"2">[U#XI&JUS5QQ1>:<B
M. P\''],?^$\T^KZAEDAD;)"]T<C5RCFKA4\RDBCUSJ:.+HV7FJ1B)CFB_T(
MV#*U*V]Z-HB9CLR*^MJ:^H=/6SR3S.YOD=E3FW7"KMM2D]!4RT\R?I1NPIC
MRU&M&V]N&K[_ '&G=!676IDA=P5N]A%^(^J/6.H*.ACHZ:Z3QTK&[C8TQA&]
MG(T ,/"IK7+">:?4Z_*;^CUEJ&CIFT]/=ZID+4PC=[.$^$T ,K4K;WHVB)F.
MS<46I[U15L]737*H94SHB22;V5<B+G'$P+C75-SK9:NOF=/4R85\CN;L)A/F
M1#& BE8G<0;D !DALK1?;I:,]S*^HID7FUCN'Q<C.K-::BK(715%XJG,7@J(
M[=^@CX,)QTF=S$;3S2.57*KG*JN5<JJ]9DVZOJ[=4I44%1+3S)R?&["F,#*8
MB8U*&]N&K[_<*9T%9=JF2%R85N]C*? *'5U^H:!M%27.>.D:BM2),*B(N<IQ
M3RFB.##PJ:UJ&7-/JV5HO=QLU1)/:ZN2FED3#G,QQ0^;S>;A>9VSW2JDJ96-
MW6N?C*(8 ,N6N^;75&Y[-M9=1W>R121VJNEIF2*CGHS'%4\YAW.XU=TK'U5P
MG=/4/PCGNYJ8H$4K$\T1U-SK38VB^W2SN<ZV5T]-GFC'<%^#D=UQU->;D^-U
M?<JB98W(YB.=P14Z\<C4 CDKO>NIN6YO&I[S>:9M/=+A-4PM=OHQ^,(O%,\O
M*IQ9M3WFS4SJ>UW":FA<[?5C,85>6>7D-.!X=-<NNAS3W=M94S5E5-4U4BR3
MS.5[WKS<Y5RJFPL^HKO9FN;;+A/3L=S:UW#XE-4"9K$QJ8Z&VYJ=47NJK8:N
MHN=1)/"[>C<KO:KVHG(^+UJ.[WN*..ZUTM4R-5<Q'XX*:D$1CK'6(-RV-GOE
MSLSG.M==-3*[GN.X+\'([;IJ.\756K<+C43[BHJ(YW#//DG U(')7?-KJ;GL
MWERU;?;G0OHZ^Y33TK\;T;L87"Y3J[4-;;;C66RI2HM]3+3S)^G&["F*!%*Q
M&HCH;EO+GJV^W2E?35]TJ)H'>V8Y41%\^#6VZX5EMGZ:@J9:>5/THW*F?/VF
M*!%*Q&HCH;F>J13ZWU)/"L4MXJE8J85$<B</.A'I'ND>Y\CG.>Y<JY5RJG )
MK2M?=C1N9[LJVW&LMD_34%3+3R^-&Y4SY^TW;]=ZF>Q6.O-5NXQS3["- B<=
M;3N8V1,QV=E3/+4S/FJ)7RRN7+GO<JJOPG6 90@ !(    "  !(   7YH_VD
M7[*%!H7YH_VD7[*'(]J=J_NV.'^:QJ3\4AW'32?BD.XY#9
M
M
M
M   %6>J!_-ZW?Q7_ &.**+U]4#^;UN_BO^QQ11Z#V?\  AIYO>  ;RH !
MD    ! (#@Y)       "$  "0!P<@ @ '!R @!  0.#D   "0       @ (
M0  )     0  )           !U    0  )  ( .#D "_-'^TB_90H,OS1_M(
MOV4.1[4[5_=L</\ -8U)^)0[CII/Q2'<<AL@
M
M
M                                                    "K/5!?F]
M;OXK_L<447YMVHZJML- RCIYJAS:G*MB8KE1-UW'@4>^U7!G!]#5M\\+D_H=
M_@+1&&-RU,L3S,- 9/K"L]R5'HU^P>L*SW)4>C4W.>OJJU+&!D^L*SW+4>C7
M[!ZPK/<E1Z-?L'/7U-2Q@9*6^L]R5'HU^P>L*SW)4>C7[!SU]34L8&3ZPK/<
ML_HU^P>L*SW)4>C4<]?4U+&"&3W/K/<E1Z-?L'<^L]R5'HU^P<]?4U+&!D^L
M*SW)4>C=]@[GUGN2H]&OV#GKZFI8P,GN?6>Y*CT:_8.Y]9[DJ/1K]@YZ^IJ6
M,#)]85GN2H]&OV#UA6>Y*CT:_8.>OJ:EC R4H*SW+4>C7[!ZPK/<E1Z-?L'/
M7U-2Q@9*6^L]R5'HU^P>L*SW)4>C4<]?4U+&!D]SZSW)4>C7[!W/K/<E1Z-?
ML'/7U-2Q@9/K"LQ_E*CT:_8.Y]9[DJ/1K]@YZ^IJ6,#)]85GN2H]&OV#N?6>
MY*CT:_8.>OJ:EC R4H*SW)4>C7[!W/K/<E1Z-?L'/7U-2Q@9/K"L]R5'HU'K
M"L]R5'HU^P<]?4U+&!D]SZSW)4>C7[!ZPK/<E1Z-1SU]34L8&3W/K/<E1Z-?
ML"4%9[DJ/1K]@YZ^IJ6,#)[GUGN2H]&OV#N?6>Y*CT:_8.>OJ:EC R>Y]9[D
MJ/1K]@[GUGN2H]&OV#GKZFI8P,E*"L]R5'HU'K"L]R5'HU^P<]?4U+&"&3W/
MK/<E1Z-?L'K"L]R5'HU^P<]?4U+&!D^L*SW)4>C7[!ZPK/<E1Z-?L'/7U-2Q
M@9/K"L]RU'HU^P>L*SW)4>C7[!SU]34L8&3ZPK/<E1Z-?L'K"L]R5'HU^P<]
M?4U+&!D^L*SW+4>C7[!ZPK/<E1Z-?L'/7U-2Q@9/K"L]R5'HU^P=SZSW)4>C
M7[!SU]34L8&3W/K/<E1Z-?L'K"L]R5'HU^P<]?4U+&!D]SZSW)4>C7[!W/K/
M<M1Z-?L'/7U-2Q@9/<^L]R5'HU^P=SZSW)4>C7[!SU]34L8&3ZPK/<E1Z-?L
M'K"L]RU'HU^P<]?4U+&!D^L*SW)4>C4=SZSW)4>C7[!SU]34L9 9/<^L]R5'
MHU'K"L]R5'HU^P<]?4U+&!D^L*SW)4>C7[!ZPK/<E1Z-?L'/7U-2QB_-'^TB
M_90HQ+?6=5)4>C7["]M(QJUD>4XX0Y7M.T3%=3ZMC!'=8=)^*0[CII?Q2'<<
MEL
M
M
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M;@^@
C                                            _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g762905g19m19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g19m19.jpg
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M59OE3/6!+0>6V7"DNM!#6VVIBJJ29,QS1.1S7IG'!4[T4]0
M
M
M
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M5=C^F\_U4G[UY8)7^P#WH--_H7_O7E@!
M
M
M
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M
M
M
M
M                      T"VM^^=JK]93_74W]- MK?OG:J_64_UU"8;>[
M/>@TW^A?^]>6 5_L ]Z#3?Z%_P"]>6 $
M
M
M
M                                                      :!;6_?
M.U5^LI_KJ;^F@6UOWSM5?K*?ZZA,-O=@'O0:;_0O_>O+ *_V >]!IO\ 0O\
MWKRP @
M
M
M
M                           #0+:W[YVJOUE/]=3?TT"VM^^=JK]93_74
M)AM[L ]Z#3?Z%_[UY8!7^P#WH--_H7_O7E@!
M
M
M
M                                                          &@
M6UOWSM5?K*?ZZF_IH%M;]\[57ZRG^NH3#;W8![T&F_T+_P!Z\L K_8![T&F_
MT+_WKRP @
M
M
M
M                              #0+:W[YVJOUE/]=3?TT"VM^^=JK]93
M_74)AM[L ]Z#3?Z%_P"]>6 5_L ]Z#3?Z%_[UY8 0
M
M
M
M
M  !H%M;]\[57ZRG^NIOZ:!;6_?.U5^LI_KJ$PV]V >]!IO\ 0O\ WKRP"O\
M8![T&F_T+_WKRP @
M
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M@.NFB2"FBA1SG)&Q&(YW-<)C*G80D
M             ^*Y$5$5415Y)V@?0   /B*BJJ(J*J<T[ /H
M                                                           !
MH%M;]\[57ZRG^NIOZ:!;6_?.U5^LI_KJ$PV]V >]!IO]"_\ >O+ *_V >]!I
MO]"_]Z\L (                                 "%Z_UE]@6I1T"-?<'
MMWE5W%(DZE5.M>Q )H#6^NO-RKY5DJZZHE<O'C(N$\R<D/=8]67>SS-=!5R2
MQ(O&&9RO8J>GEZ"=AL$#%:9OE-?[6RLIO)7.[)&J\6.ZT,J0
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MZ\$!IK+<ZG'B]NK)$7K;"Y4^@]55I:]4E#)65-NFBIXTR]SL)A,XY9R-AA0
M2.^BJI:*KAJ:=RMFB>CVKV*A:#-JM/CR[7,B]TJ+_ J^AI9:VLAIJ9JOFE>C
M&IVJI-W;+KNGN:NA7^\]/\H&>;M4H/OK?5)YG-4[6[4K4ONJ.N3S(Q?\Q&';
M,;VG*:A7_P QW\IU.V:WY.24CO-+_P B.0F+=I]D7G3U[?\ RV?S':W:78EY
MI6-\\2>L@CMG6H4Y4\#O-,TZG;/]1IRH6KYIF>L<A8C=HVGUYS5#?/"IVMVA
M:<7G6O;YX'^HK%VA-2-YVQWHEC7_ #'4[1>H6\[7-Z%:O\1M MANO=..Y7%$
M\\,B?Y3M;K;3KN5TB]+')_ IYVDK\WG:JKT,R=3M,WQO.T5WH@<O\!L+K;J^
MP.Y76F]*JAVMU18G<KM1>F5$**=8+PWW5JKT_P#IW^HZG6BY-]U;ZQ//"[U#
M83_:9K!)6MMEFJF/A>W>GFA=G>S]XBI\_P 7:5D<Y8WPR*R5CF/3FUR85/0<
M"0+>V4ZEFN$4MKKY%DF@9OQ/<N5<SDJ+VXX>A>XJ$EVRM'KK.DW,[J,DW_-N
MK_' %Y @&T:AVB55RI7:$NMIHJ%(<3,JV9>Z3>7BBJQW#&.SK,93VW:RFDZN
M*:^6%;\M2QT$R1>0V'"[R+Y&,YW<>2O#/'BF,4K2!5>E;;M;AN,KM0WRPST:
MT\J,:R+BDJM7HUX1MX(["KQY9/1X/FJ[OK'1-3<=05#:BK9720(]L;8TW48Q
M43#41.;E LP                               $.VM:S9H71E5=DC;+5
MJY(*6)W)TKLXSW(B*J^8\FF]"P5=FIZK6,D]WO51&DE1+/,]&QN<F59&Q%1K
M&IRX(B]9$_"NMU15;/*2LIV*^.@KXYID1,HC%:YN5]+FIZ2X+;60W"WTU93.
M1\%1$V6-R<E:Y,HOQ*!5E%>ZS0NU*BTE75E16Z>O46_;I*F19)*67*HL6^O%
MS55$1,Y5-YO'F8>LL]/5>$.ZRRSU[;4ZT^-K2Q5TT;.DWL91&N3'FY';M<IG
MWG;;LWMU$F]44<CJZ?=^\B;(UV5[/N3D\ZGL7_YI$_4/^<)9':!I>ZZ?LM3?
MM"WFYTU90,6HDH:FJDJJ>I8WBYN[(KL+A%QA4[.O*2O9KJR'6NCJ"]PQI$^9
MJMFB1<]'(U<.3S9XIW*AZ==72FLVC;U7USVM@AI)%7>7W2JU41OG551/207P
M8K54VS972OJVN8M;4254;7<%1BX:U?3NY\RA"R[K<Z*TTGC-RJHJ:#>1B/D=
MC+EY-3M5>I$XE/SUUMN'A%::GM-8^H1U#4].QTKUZ.3=?PW'+Y"X5.&$X8,M
M7UZU_A%VZV5R_P"BV^SOJJ2-W)9WNPYZ)UKN93NPIU:D@B9X2.D9F,:V62UU
M"/<B<781^,_&H%AWC4]FLTRPW*X0PS(SI'1\7.:S\)R)E4;WKP/93W6WU-K2
MYT];326Y6++XRV5%CW4YNWLXPF%*T\'BO=>+)J6YUW&ZU-YF\:WO=-PUFZS\
MUJ<$3JXD3LNGZFNKMK&C;96-H+=XU3RT;G<(X9I';^XG<Y4:W"?$!=%!JNR5
M]=%1TMQB=5S(KHX7(K7R-1%57-1415;A.:<#$:>;I*DU1J>Z6JYT\EQF2)]S
M=XUOLA1J*C<\<-Y+_P B):>UE7NUC9K%M)L/V.OS'2?8^X0+O4]4JL5KD1>K
M*+RSSQG'!#CL\HZ;VVMJ=-XO#XNJT?VK<3=^YN7ERY\0)S5;0-)TMNAKZC4%
MO9232.BBEZ5%21S5P[=[41>M.!GW7"C;;OL@ZJ@2AZ/IO&%D1(]S&=[>Y8QQ
MR4IL2M-!-L(N,DU'!))/'6,D<YB*KFHKL)E>I.SMXF,=17&Y>#!IZ2B59DHY
M&5-1"KD3IH(YGY9QX+]ZN/R0E<[-9Z<65(I+S1P2*Q)&I4OZ'?8O)S=_&\G>
MF4,]%(R:)DL+VR1O:CFO:N4<B\E1>M"IM=TC==:ET,ZS44\K:&M\;K):BE=&
MR&#@KHW[[4\IV$3=Y\./#B6S&QD<;8XVM8QJ(UK6IA$1.2(@0Y
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MD>6JY\BIE&(G6OIPGI F:[5:GJM</[5?4<5VJUG5;:?]HIVILIEZ[NS]@O\
M,<TV4.Z[PWT4_P#[B.0\R[5*[JMU-_C<<%VIW'JH*3XW>L]J;*.V[_\ \?\
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MB3?;YG+Q3T'=:](V>V:FN6H**F<RZ7%J-J)5E<J/1,?>JN$]RG) AG@
M                                                TQNO_P S[/\
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M003-EN]7XPC5ST,2*UJ^=>>/B+(!.XXPQ,AB9%"QK(V(C6M:F$1$ZD.0!
M           /)<[9172#H;A31U$?4CTXIYEYIZ".>UWI[I=[Q:7'X'3.QZ_G
M)< /);+;1VRGZ"WTT<$7-48F,]ZKU^D]8              !C[[:*6]VZ2CK
M6*L;N*.3W3'=2IWE17G9W>J*9WB<;:V#/!T;D:['>U?X9+M %$V_05_JY4:Z
MC2F9UOF>B(GH3*_,6OI#3%+INC<R)W2U,F%EF5,*[N1.I#/@G<  0
M    C&T&^5EALS*BWQ-?(^5&*]S<HQ,+QQZ,%17_ %/77Z-C;BVG>Z-?(>V/
M=<G=GL[C8-S6O:K7HCFKS14RBG5XI3?[O#_@0F!K*=U).M-4QS)''(K%RC9&
M[S57O3K-D_$Z;_=X?\"'WQ2F_P!WA_P(-T;*LTKKR]5U]HJ2>.&>&9Z,<UD>
MZK47[Y,=G,MDZXX(8G9CBC8O:UJ(=A"0
M   'E6W4*JJK1TRJO_A-]1\^QE#_ +E3?LF^H]8 \GV-H?\ <J;]DWU')EOH
MV/1S*2G:Y%RBI&U%3YCT@   !5'@U6&Z:>T#54E[H9Z&I=<)9$BF;NN5NZQN
M<=F6KYRURG/!5JJBKV<5;ZJ>69Z7.9$=(Y7+Q9&J\5[U5?2H%Q@
M
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M76054*_?1/1<=RIS1>Y3W'+,;=5E$Q,;P  )
M
M                                    "KO!TU!/J/0E35U-)0TKV7":
M-&4<"0L5,-=G=3AG+EX]R%HE7^#HZPNT)4KI=EP91?9";>2N<U9-_#?P>&-W
M=^<"T      'CBNE#-<I+?#5PR5L3-^2%CT<YC<HF7(G+GUF,OFHDH;U;[+0
M4[:N[UK'RLB=)T;(XF>ZD>["JB95$3"*JJOG5 SX,)I?4$5\;7Q+$M-7V^H6
MFJZ97;W1O1,HJ+PRUR*BHN$RB\D7*'1<]1O9J-EAM-+'67-*=:N9)9NBCABS
MNMWG(UR[SEY(B=2JN.L)$"/6;5E!<=.5=W<CZ=E$Z6*LA?Q?!+$JH]BXYJF.
M&.>4[3QZ6U'J&[7-8+KH^ILU(D:O2IFK8I,KPPW=;QRN?F4"6@
M
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M%@,>V1C7L<CF.3*.1<HJ'':EJ3M:%MBS4RQO2=WT &+8
M
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MZ-:J,SG=:UJ(UJ9XKA,KPRJX3 98
M
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MYBWM,ZRL6I&)]BJ^)\V,K _R)4_NKQ7SIE#DO@O3K"UP:W#G_#//P2  &IU
M
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M3,6"DWMQ5PUV]Y2JN<.1.SAPPG! M
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M/7RMIXJE$W5IIE]RV3J5KE3".X87"+G.4"2
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MZ,MD]-3U$E3)/)TDDKTW<X3"(B=2>LE(.6^:]XVM*UQ:/#AMVJ5VD !J=(
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ME7M?NIO+\>20F(T?:$L&E;1:=Y'+14L<#G)]\YK415]*Y4RX0
M                                        :!;6_?.U5^LI_KJ;^F@6
MUOWSM5?K*?ZZA,-O=@'O0:;_ $+_ -Z\L K_ & >]!IO]"_]Z\L (
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MZ++IO)5I;;M>SUK&IJ>&EIXX*:)D,$;4:R-C=UK43DB(AV '$N>@
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MJ*>1T;V]BHN#S%K3!2M9B.DO*Y=;ER7K:W6K91NV;2[G(UK;BKE7"(D"<?\
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MJBL?#&U*")_1139XS/3*/5/R47@B]:HO5C.2(F-F=9BT;P  A(
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MN\]D+V-W4SC*JY>7F15[C):>N/V7L-MN71]%XY315'1[V]N;[4=C/7C('O
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MJ_\ V'<S;M2+[NQ3IYJA%_RF%?L,NZ>XNM OG1Z?P.E^PZ_I[FX6M?.^1/\
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M*K^FW\8W<*G'//AS+E&2L5Z&GR6O'I1W1_Q^@ #6Z0
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MI_KJ;^F@6UOWSM5?K*?ZZA,-O=@'O0:;_0O_ 'KRP"O]@'O0:;_0O_>O+ "
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MOR/H\W+8!CFO8U['(YKDRBHN45.TRK;=X;B/#LN@R^3R=.Z>Z?KP?0 2X
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MPV!^^##_ &>7Z#8^Z?ZLK/T+_JJ:X; _?!A_L\OT'7@_T[JK6_\ 48?;\FS
M .1:@             5'X2']&[5_:U^HXMPJ/PD/Z-VK^UK]1QNT_P#J0X]?
M_P!/=E]@7O?1?VF7Z4+%*ZV!>]]%_:9?I0L4C-_J69Z/_0I[(  :G2
M                                        Y@            Y  ".V
M2Q26"ZU:6S<6T5TKJA].JX6FF=Q<YG:QR\5;PPN53.<)(5:BIA414[#Z  5$
M5,*B*G>  (]36-]7J5E^NZ,6HIHW0T-.U=YM.UWNWJO7(["(N."(F$SQ59"
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M>KBJ\C+               T"VM^^=JK]93_74W]- MK?OG:J_64_UU"8;>[
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M-1S'L7*.1>2HIU5MN\!Q+AN7A^3L7YQ/2?'^7, &2N
M ,;>+%:KTD:7:WTU7T>=Q98T<K<\\*9($Q,QSA$UBT;3"->P/2WP#0?LD'L#
MTM\ T'[)"2@R[=O%K\AC_+'N1KV!Z6^ :#]DAD[-8K594D2TV^FI.DQOK%&C
M5=CEE3) B;VGE,IKBI6=XK$  ,6P        .$\K8())9,[D;5<["9X(F3F
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MCA<1TO+IHNG2C@\;5JU/1MZ7=Y;^...[)W '(M8Y
M
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MW(YKVJ]5145.:!,-P]@'O0:;_0O_ 'KRP"O]@''9!IO']2_]Z\L (
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MM1[)&+E'(IUUMN\3Q/A>7A^3LVYUGI/C_+N !DK
M
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MVM^^=JK]93_74)B6W?@^^\_IO]%)^]>6$5_L ]Z#3?Z%_P"]>6 &(
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MU+W&^MMWE>*\*R</R;3SI/2?[3ZWJ !DJ0
M
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M_30+:W[YVJOUE/\ 74)AM[L ]Z#3?Z%_[UY8!7^P#WH--_H7_O7E@!
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M&VD[QS>)X]I<6EU?D\,;1M  #)3
M
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M+U_(=R7S<%[B=FV)WZ/":C39=-?R>:NT@ ):
M
M                                                       <96J^
M)[$>YBN14WF\V]Z9ZRG;1==0VO;E)IG4&HJV>TU%*M5;4=%"WIE3"[CU1B9P
MC9$X8Y)VER%3^$-9ZG[ 6_5=H3%VTY4MJV*B>ZBRF^B]W!JKW([M F>T>KJ*
M#1MRJ:&LJ*2N8S%,Z!&*Y\SEW8V8<BHJ.>YJ<NL]VG:6KM5B@COEU?7UC6(Z
M>JF1C$WL)G"-1$1N>77WD7I+Q3:YO6FW4#M^V4],V\SIG/VQR*R"->]%Z1RI
MVQM,7<ZRJOVUJY69:"W7"EM-!#+'2U\[HXU?(JJZ7=2-Z.5$W6IE.&5QS4"=
MZF66HTS<)+;<)*65*=[XZFGW'*BHU53&\CDQP[/B(SL3N\]?LML-=>*YT]74
M))O35$F72.Z5Z(F5Y\L8,1IS1MWTQ7ZOJU?;J2P7&D?)%:Z25\C:>9&HBN;E
MC41%\I51$3FB=1"]-:0L]U\&[[)7*F6IKH+;52T\LCU5:=6/D<G1IR;Q3*]O
M7D"\-8VJ>\Z=JZ&DN]39YI$:J5M.N'Q(CD5>M."HF%XIS,I3-Z*EB:Z99=QB
M(LKE3+\)[I>KCS*)VAJMW\%^@N=?)++6QT5(Y)%D<F\Y7QM57)G#E5,\\\U)
M+>Z]+EKW1.E*Q<VJ6WNKYX%]S5/:W#&.3K:F%=N\EX9Y 6@R6.K@>M+4-<BH
MK4DB<CMU?G3*=Y6VQNXW.LONO*:ZW.JN"4-U6GA?4*F6L3*(B(U$:G+J1#/V
M[0U):M>RZCM=4M%!44J4T]NAC:R&5Z+E)%QUHG=Z>96VF;S-I^AVT76D1%J:
M6Y3/BRF41^'(U53N544"]%J(4G2!9HTF5,I'O)O*GFYG:4O6:$KM4: H8Z&W
M6.FN,T4-7#>O'9'572+NN657)"CE5W'/E=?<A;=CCK(;-0Q72:.>O9 QM1+'
M[F21&HCG)W*N5 C]SO<MRU@W2]JE6)T$"5=QJ6>ZBC5<,B;V/?Q7/4U%QQ5%
M3!WJ^U-RVH0:*I[K-:*2"W^.22Q*WIZIV]A(VN>BX1$RY53REPO>8O8G,^MU
MSM/K9\K.MW2GRO-&1K(UJ?$9O:;LYM6O)(YHZR2WZ@MZ)T-;3KY<><JU')PR
MF<JG%%3CA>8'I;0ZALVL;'"E\J;AI^I=*R6.JC8LT<B1.<U-]K4WFKA5XIE%
M1.*G@O&K+E?MH$NCM*3LHTHHDFNES6-)'0HN,1Q-7R=]<IQ5%1./#@1G26L=
M7Z.U?;-);1F1UM/<']#07:+BKW<D1R]?%43BB.3**N47)U;!]Z':GM2@K>%<
MZN21J.YJSI9N*=V',^- E8MPT[>J2W3R:?U)<'W)K%6-MQZ.:&5V.".3=16^
M=JICL7D8NHNUWL^AK1JF9\\[J>A@DNU')QWV;J=(]J?>R-55=PX*B*B\<*EA
M&,U1 RITU=X)4S'+22L<G<K%10A[:*J@KJ."KI)&RT\\;98Y&\G-<F45/.BG
M<5KX.-;-6[(;(LZJYT/2PM5>MK9'(WXDPGH+*
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M8;>[ />@TW^A?^]>6 5_L ]Z#3?Z%_[UY8 0
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MQ>Y3UFQY:U9K/9M&T@ "
M
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MUQCG].$].MMG]TU!0:?N%NKZ>UZLLB(D%0Q7/A>F$16NRU%PN,\EQE4XY+,
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M=]<MBSP56IR1RHN,\\<.0&'V;Z<]B>B+/955'2TT*=*YO)9'*KGX[MY5)(
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MV >]!IO]"_\ >O+ *_V >]!IO]"_]Z\L (
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M#+XK<%3C2SJB.5?R5Y.]''N,ZWB7F^(\"U&BWM$=JGC']X[OV3$ &2E
M
M
M
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M5=Q5RUD]O@DE<[FYRQHJJO>O,SY\8QL;&L8U&L:F$:B81$[#Z$
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MX?@C+%^USVZ;>/K]2>@ S><
M
M                   .NGGBJ8NDIY&2Q[RMWF+E,HJHJ>A45 .P
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M6_?.U5^LI_KJ$PV]V >]!IO]"_\ >O+ *_V >]!IO]"_]Z\L (
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M+Y[K.%:K1<\M>7C'./KVLV #)7
M
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MCMC*NM;Q\:K<2O1>U$5-UOH1 )Q05<%?105='*V:FG8DD<C>3FJF45#O "
M            - MK?OG:J_64_P!=3?TT"VM^^=JK]93_ %U"8;>[ />@TW^A
M?^]>6 5_L ]Z#3?Z%_[UY8 0
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M;<I  $
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MW*[SV-PV215YJWJ3M\I55<;H=NSRSR6#0]BM4Z8GI:2-DJ=C\9=\ZJ2
M     #%:JLD&H]/UMHJWN93U;.CD5O/=RBJB>?&#G8+#:M/43:2R6^FH:=/O
M86(W>[U7FJ]Z\3)'BO=SIK+::JY5[U924L:R2N1,[K4YJ![0=%%5TU?2QU-#
M415%/(F\R6)Z.:Y.U%3@IW@                #0+:W[YVJOUE/]=3?TT"V
MM^^=JK]93_74)AM[L ]Z#3?Z%_[UY8!7^P#WH--_H7_O7E@!
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MY(QY)B9F-^7U  "7
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M8W(YKVJ]<*BIS0)AN%L ]Z#3?Z%_[UY8!7^P#CL@TWC^I?\ O7E@!
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MF@>V2*1J.:]JY1R+R5%+S2ZFNHKO'7OAX?B?#,G#\O9MSK/2?'^7, '2K0
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M"]IMX3$Q^]82\ &:A
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MI/WKRPBO]@'O0:;_ $+_ -Z\L ,0
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M]?[KL+\QGTXIE#<\%DQ7Q3V<E9B?7R  &L
M
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M[V*VUE4F$Z6:G:YRXY(JJG'TF;@ACIX60P1LBB8B-8QC4:UJ)R1$3DAS
M#0+:W[YVJOUE/]=3?TT"VM^^=JK]93_74)AM[L ]Z#3?Z%_[UY8!7^P#WH--
M_H7_ +UY8 0
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MESQQA<ODR=[%Z_-S\YV:77TS>C?E93\4X!ET>^3%Z5/C'M^::  L'GP
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MMYG$UKOSWKTCOVZK8HI73T<$TD3H7R1M>Z-W-BJF51?,=P!N> GG(  @
M
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MTW^A?^]>6 5_L ]Z#3?Z%_[UY8 0
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M]"_]Z\L (
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M57O5553W%I7?:.UU>6R=CMSY/\._+?P  9,
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M $
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M$<WEQ14PN<A,#C'&R)JMC8UC5578:F$RJY5?C.2*BIE%R@
M           *F4PO(Q4&F['!6>-P6:VQU>=[IF4K$?GMWD3)E0!Q2-B2K*C&
M](K4:K\<51.K/9Q4Y                        T"VM^^=JK]93_74W]-
MMK?OG:J_64_UU"8;>[ />@TW^A?^]>6 5_L ]Z#3?Z%_[UY8 0
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MUWV=U.FWMC].OJZ^[Y;K&!PAECFB;)"]LD;DRUS%RBIW*<RP>?F-@
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M4G@L%LBLMCM]KIN,-%3QT[%7K1C4;GYCW@
M                         - MK?OG:J_64_UU-_30+:W[YVJOUE/]=0F&
MWNP#WH--_H7_ +UY8!7^P#WH--_H7_O7E@!
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MYBR2*Y&KVX[26EEIXS16?+3$SZGG-?;26O'F<3$;<]_'X@ -[@
M                           &.U*CETY=48BJY:27")SSN*5QX+R*FR2A
MRBX6HGQG\\LN^5$E)9+A40+B6&GDD8N,X5&JJ?003P>[W<+_ +,Z*MNU1XQ5
M=-,Q9%:C<HCUQP1$3K L@
M                   >.2V4SKG'<6L6.L:SHW2,7'2,XX:_\)$555,\ESC&
M5S[     'CCMM,VYON#FK)5N;T;9'KGHV<,M8G)J*J(JXY\,YPF/8
M                                                :!;6_?.U5^LI
M_KJ;^F@6UOWSM5?K*?ZZA,-O=@'O0:;_ $+_ -Z\L K_ & >]!IO]"_]Z\L
M(
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M-TLF\F(W(W"/WU7=PO6OGS:$2N6-JR(B/PF\B=2A#D
M
M                          :!;6_?.U5^LI_KJ;^F@6UOWSM5?K*?ZZA,
M-O=@'O0:;_0O_>O+ *_V >]!IO\ 0O\ WKRP @
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MRN1W!%RG%>TSUAO[[M>;W0.M5?1MMLK8FU%1'NQU.45=Z->M$Q\Z=H&<
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M--X_J7_O7E@!
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MENY_Q<6_.2RGJ(:F))*:6.:->3XW(Y%]*%E3+3)SI.[S6;2YM/.V6DU]L.P
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M'+Z=W/I)@5KX.5MFMNR2S)4-5LE1TE3NKU->]5;\;<+Z2R@@
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M7EA%?[ />@TW^A?^]>6 $
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MD?!"Q%RUJJY6Y7DS@F57*3L <*>&.G@CA@8V.&-J,8QJ81K43"(B=AS
M        <9HF30OBE8U\;VJUS7)E'(O!44Y #Q6>TV^S424EHHJ>BI4<KDBI
MXT8W*\UPA[0 ,-=M+6"\5;:J[62VUM2W")+44S)'83DF53)EXHV11MCB8UD;
M$1K6M3"(B=2(<@    T"VM^^=JK]93_74W]- MK?OG:J_64_UU"8;>[ />@T
MW^A?^]>6 5_L ]Z#3?Z%_P"]>6 $
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MBH=A,;W:JVFU3<K32WV1C%ZE<USU=C_$TMX
M                          !H%M;]\[57ZRG^NIOZ:!;6_?.U5^LI_KJ$
MPV]V >]!IO\ 0O\ WKRP"O\ 8![T&F_T+_WKRP @
M
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MX&VN?)7I:4;*DK-B%L?GQ.[5D79TK&R?1NF"K-B%R9GQ*[T<O9TL;H_HWB^
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M'V"\8GJ**>WI5-Z=ZR/CD:_=7REXX5...WE@F!SWK-9Y]Z0 &
M                #PV:TT-EHUI+73LIZ=9))MQG+>>Y7.7XU7Z#P:NTA8M7
M4<=-J*VQ5L4:JZ-7*K7,5>>ZYJHJ>A3.@".VG1.G[1I^:R6NW-I;;-GI8XI7
MM=)E,+O/1=YW#AQ7EP.--HBP4M@ELE-1216F3.]2MJID8J+G*8WN"+E<IR7K
M)( (Q-H/3D]@CL<U ]]HC7+:1U3*L:<<IPWN2*F43DBGJN>D+'==/LLESH&U
M=L9C<BGD>]68Y;KU7>143@F%X)P,Z (]I/1>G])4<]-IZVQT3)_NKF/<Z1_G
M>JJ[AU<>'4<[#I&RV&MJZNTTCZ>HJW*^H=XQ([IG<?*>CG*CEXKQ7CQ,\ (2
MW95HEM^2\MT_2I7H_I47>?T>_G.]T>=S.>XFP $*K[/)8=<RZHH(7RTEP@;3
M72&)JN>BL^YSHU.+L)EKD3CA45,X4]]TT3IV^7*GNMPHWU59$J/@G6JES%QR
MBLP[R>/'A@DP X0QMAB9&Q7JUJ817N5R^E5RJ^DQ]^L-KO\ 3,@O%%%4LC=O
MQJ[*.C=^$QR8<U>]%13)@"-T^B;'%6054T%573T[MZ!U?63521+VM25[D1>]
M$R9'4%QEH*)R4-.ZJN,J*VF@3DY_:Y?O6)E%5R\D[55$7)@".Z TS'I/34%N
M27IZE7.GJJC&.FF>N7O^/@G<B$B
M                    :!;6_?.U5^LI_KJ;^F@6UOWSM5?K*?ZZA,-O=@'O
M0:;_ $+_ -Z\L K_ & >]!IO]"_]Z\L (
M
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M>!CJM72N:])OW]-S'H-3>L7KBM,3W[2EX/C7(YJ.:J*U4RBIR4^FMR@
M  ,9J*R4]]H&TM5+4PM;(DK9*:58WM<F<+E/.==OL%/23PSSU%975$**D4E7
M+TBQY3"JB<$1<<,XSWF7!EV[1'9WY# 5^EX*J].ND=PN=)4N:C'I3U&ZQR)R
MRU45#)VRVTUMB>RF8[>D=OR2/<KWR.[7.7BJ_P#]#V 3>TQM,CQ5-NCJ;C2U
M<SWN2F1RQQ?>H]>&_P!ZHF43LRI\O=JI;U:YZ"O8KZ>9,+A<*BHN45%ZE1<*
M>X$1:8VF.X8:UV"*CNDUSGJ9ZVX21-I^FFW45L:+G=1&HB)E>*]JF9 $VFW.
M0 !
M                                             !H%M;]\[57ZRG^N
MIOZ:!;6_?.U5^LI_KJ$PV]V >]!IO]"_]Z\L K_8![T&F_T+_P!Z\L (
M
M
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MW=3"+WX/4 <_L5\S,\Y  $
M
M                      !H%M;]\[57ZRG^NIOZ:!;6_?.U5^LI_KJ$PV]V
M >]!IO\ 0O\ WKRP"O\ 8![T&F_T+_WKRP @
M
M
M
M                                                         #0+
M:W[YVJOUE/\ 74W]- MK?OG:J_64_P!=0F&WNP#WH--_H7_O7E@%?[ />@TW
M^A?^]>6 $
M
M
M
M                               :!;6_?.U5^LI_KJ;^F@6UOWSM5?K*
M?ZZA,-O=@'O0:;_0O_>O+ *_V >]!IO]"_\ >O+ "
M
M
M
M
M   - MK?OG:J_64_UU-_30+:W[YVJOUE/]=0F&WNP#WH--_H7_O7E@%?[ />
M@TW^A?\ O7E@!
M
M
M
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M9-S.<9PO#.%^(R@
M
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MBF<Y,M2:-6*J=V4/M#;JVOW_ !"CJ:G<QO\ 0Q.?NYY9PG#DI>_AA_TGT_\
MV-_US)^!I[K5_FI/_6"6O_L=O?P/<ODK_4/8[>_@>Y?)7^H_14!&[\ZO8[>_
M@>Y?)7^H>QV]_ ]R^2O]1^BH!N_.KV.WOX'N7R5_J.JJLUTI('35=MK8(6\Y
M)('-:G5Q54/T:*R\)/WG;Y^=!^^8#=I/3P2U,S(:>)\LKUPUC&JYSE[D0R'L
M=O?P/<ODK_4278;[[.F?[5_E4WP"=WYU>QV]_ ]R^2O]0]CM[^![E\E?ZC]%
M0$;OSJ]CM[^![E\E?ZA[';W\#W+Y*_U'Z*@&[\ZO8[>_@>Y?)7^HQCD5KE:Y
M%147"HO4?I0?G'>O]<U_]HD^LH3$NV*P7B6-DD5IN#XWHCFN;3/5'(O)47!R
M]CM[^![E\E?ZC?39S[WVF?U93?NFDA"-WYU>QV]_ ]R^2O\ 4/8[>_@>Y?)7
M^H_14 W?G5[';W\#W+Y*_P!0]CM[^![E\E?ZC]%0#=^;M91U-#*D5;334\JI
MO(R5BL7';A?,=M%:Z^O8Y]#0U52QJX<Z&%ST1>Q<(6]X6OOFTOZLB_>2E@^!
MY_12_P#]M;]1 EK1[';W\#W+Y*_U#V.WOX'N7R5_J/T5 1N_.KV.WOX'N7R5
M_J'L=O?P/<ODK_4?HJ ;OSJ]CM[^![E\E?ZCIK+1<J*'I:VWUE/%G=WY87,3
M/9E4/T;*:\+#WKH_UA#]5X-VH-+33U<[8:2"6>9V<,B8KG+Z$/=[';W\#W+Y
M*_U$\\&CWX;/^CG_ '+S=D)W?G5[';W\#W+Y*_U#V.WOX'N7R5_J/T5 1N_.
MKV.WOX'N7R5_J'L=O?P/<ODK_4?HJ ;OSJ=IZ]-:JNM%Q1$XJJTS^'S&+/T>
MN_\ JFM_0/\ JJ?G"$PRB:>O3D14L]Q5%XHJ4S_4/8[>_@>Y?)7^H_0RU?ZL
MH_T+/JH>D(W?G5[';W\#W+Y*_P!0]CM[^![E\E?ZC]%0#=^=7L=O?P/<ODK_
M %#V.WOX'N7R5_J/T5 -WYMU5-/23NAJX)8)FXS'*Q6N3/'DIZ:.T7*MAZ6B
MM]9419QOQ0N>W/9E$+"\);WXKU^93_N6%[>"C[UKO[?-]# EJ;[';W\#W+Y*
M_P!0]CM[^![E\E?ZC]%0$;OSJ]CM[^![E\E?ZA[';W\#W+Y*_P!1^BH!N_.K
MV.WOX'N7R5_J//6VJX4,;9*Z@JZ:-R[J.FA<Q%7LRJ'Z.E$>%_\ T%L_ZR3]
MU(#=JI1TE36S=%1T\U1+C.Y$Q7NQVX0]OL=O?P/<ODK_ %%G>"E[Z?\ ]#-]
M+3<<&[\ZO8[>_@>Y?)7^H>QV]_ ]R^2O]1^BH!N_.KV.WOX'N7R5_J'L=O?P
M/<ODK_4?HJ ;OSHDL%XBC=)):;@QC45SG.IGHB(G-57!CD155$1,JO)$/T,U
MY_0?47ZNJ/W3C\^K=_U^F_2M^D)A[/8[>_@>Y?)7^H>QV]_ ]R^2O]1^BH"-
MWYU>QV]_ ]R^2O\ 4/8[>_@>Y?)7^H_14 W?G5[';W\#W+Y*_P!0]CM[^![E
M\E?ZC]%0#=^;51!-33/AJ8I(9F+AS)&JUR>=%/726:YUD#9J2VUL\+LX?% Y
MS5QWHA+]O7ONZE_3M_=M-F?!F]Y^T_I9_P!ZX):>>QV]_ ]R^2O]0]CM[^![
ME\E?ZC]%0$;OSJ]CM[^![E\E?ZA[';W\#W+Y*_U'Z*@&[\ZO8[>_@>Y?)7^H
M\M=;JV@W/'J.IIM_.[TT3F;V.>,IQ/T?-:/#)^Z:4\U3_P"F"):[4-!65[G-
MH:2HJ7-3+DAC5ZHG?A#U^QV]_ ]R^2O]1=W@=_TDU#_9(_KFTX-WYU>QV]_
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M9^?2_1*;(&M_@:_]6U9^?2_1*;( D  0
M
M                        '174=-<*26EKZ>&III4W7Q3,1[')V*B\%.\
M1FTZ!TK::R.JM]AH8:B)56)_1[W1JO6S.=WT8), !&[WH32]\KUK;K8J&IJU
MPCI71X<_'X6/=>G)GZ2F@HZ:*GI(8X*>)NZR*)J-:U.Q$3@B':    &@6UOW
MSM5?K*?ZZF_I$KALVT=<:ZHK*[3M!/53O6265[,J]RKE54)AC-@'O0:;_0O_
M 'KRP#R6BV4=GMT%!:Z:.FHX45(X8TPUJ*JKP]*J>L(     &J_AA_TGT_\
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M==5-8D:2S,RJ-155$^-5^,]FG--V?35/-!8;=3T$,KM^1D+<(YV,94)98 !
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ME00H[P-?^K:L_/I?HE-D#"Z;TK8],MJ$L%LIJ!*C=65(6XW]W.,^;*_&9H
M
M
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M*&9J*Y<JN)XTXKV@;6@
M
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M7YRB_DX](2LT !
M
M
M
M
M
M
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M=E>"81<KP0"1@@+-K6E4IHYZJ>NHHIFHZG=5T,T25*+R6-7-P[FG)2?
M
M
M
M
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M7YSO/:Q$5?C0#(  (
M
M
M
M                         #@L,:JJK&Q57K5J', <$AB3E&S_  H<P !P
MBABAWNAB9'O+EVZU$RO:IS '6V")DKI611ME=P<]&HBKYU*3HMME13;3K]8-
M0T$5);J198Z7<8]:B61BX8F..\LB<41$3FG%2\#S/H*-]8VK?24[JMB8;,L:
M*]$[$=C(&&T%:)K1I]OCS&MN5;+)75N[_72NWG)_=RC4[FH2!\;'N8KV-<K%
MWFJJ9W5PJ93LX*J>E3D /+!;:&GJ7U-/14T50_W4K(FM<[SJB94]0
M
M
B                                          '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g762905g30c65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g30c65.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[2!X4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "
M.$))300E       0FHFM72AMNB$"R,NI9P4_VSA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!Y            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 9
M   !  $!D     $  3A"24T$)@      #@             _@   .$))30/R
M       *  #_______\  #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              63   )8@         !                          $
M            "6(   63                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   63     %)G:'1L;VYG   )8@    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   %
MDP    !29VAT;&]N9P  "6(    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M.H8V772Q@P+K@:PX$$!K-OO<[V_I%B?5;^C=:_\ 37;^0J?U3YZA_P"FN_\
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M#N%(OJO]7<7"J&?T_-R"S),N;8RMH=6Q[_2K>RRAMS';';+7L=^D_G*UOYQ
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MP,,57;F;<)KO7JR_9LN9[&6_S_H6NO8.9F[:K<NK$Z,&A^=((L>&.#GT.O\
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MJ?CS!G=:WG\W<AMP[!?2X.QC9ZC"\>M7(&X'][<Y( VJ]*?_V3A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %^34T *@    @ # $   ,    !#K,   $!  ,    !"/0
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @   &0
M     0   9     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP.3HQ," P,CHQ.#HS,      $D   !P    0P,C(QH $  P    '__P
MH ( !     $   EBH , !     $   63          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0              2     $   !(     3A"24T#_0
M"           _^$!AD5X:68  $U- "H    (  P!   #     0ZS   ! 0 #
M     0CT   ! @ #     P   )X!!@ #     0 "   !$@ #     0 !   !
M%0 #     0 #   !&@ %     0   *0!&P %     0   *P!*  #     0 "
M   !,0 "    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @
M"  (   !D     $   &0     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,C0Z,#DZ,3 @,#(Z,3@Z,S      !)    <    $,#(R,: !  ,
M   !__\  * "  0    !   )8J #  0    !   %DP         & 0,  P
M  $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$
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M"@,!(@ "$0$#$0'_Q  =  $   <! 0               @,$!08'" $)_\0
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M593T@8:J>*$//*WM'AO,? 903T0(@(BE5%3#31=I431Q1Y YGN &3TW*":B
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MX5>^.<M?J;5&G=%6(4\M27FY5,=0XB/EC]Z'XR<'?]2L_%:Q<1[CIEM;<XK
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MU[WB7E!+6C :0!MLJ_A7)=]&\6+MIS4K*6)VH&&Y0"D<3")!S%P;D#<@'(]
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M7#JSZBU!27N>6NI+G3-#!-1SF,O:#D-=XA7*Q:3H+-J"]WBE=.:N[/8^H#W
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M)?,AII_9UN:3N8).H&>N,#\Y6/W :CUEQGN-STD^V"+3<8HHI*\.=&9' EY
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M]TTL$^E;=/K.FU._MO;.GIC2L(?YG(23NWQ\XJ_HBFU$1$!$1 1$0$1$!$1
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M&U+T7RDU_I6LK11TU_M\E23@,$HW/[%=[S>+?9*+V7=:N*EIN9K.TD.!S$X
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M>:K^*/G72")[6GLIW<W_ $(ZA^\U7^8?.GT(ZA^\U7\4?.ND$3VM/93NYO\
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M>:K^*/G72")[6GLIW<W_ $(ZA^\U7^8?.GT(:A^\U7\4?.ND$3VM/93NYO\
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M<"XM(^$!7BIX=:GU%)!2ZTU.RKL\#PXT]+#V9J".A>?_ /:M\NN'GEEK4_\
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M*]$111$1 1$0$1$!$1 1$06RNLE'776CKZMG:RT@<(FN]ZTG[+'BKFB("(B
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M@*H1%SO/FHB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MLG'VJBNF$1IR ?%$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M',?-3/Y'.9T)QG;\ZV-HFPR::XO"VR/[1C(GNCDQCF81D9]/<L.XC?5W?/\
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M!$1 1$0$1$!4UQ_F%5^*=^PJI5-<?YA5?BG?L*3J.-;/_1-'^*;^Q5:I+/\
MT51_BFJK6LOWJ01$601$0$1$!$0("(B B(@(B("(B B(@+8W C UE+DX'L5_
M[0M<KUKBTY:X@^(.%9=#:&F+?4UO$+4SK7?!:[E'4R=G&6!PG',>N=B,X].Z
MS^TS7N2UW%G$*DM<=OCCQVK'9[3QR.@'AT.5S@USFO#VN<'@Y#@=P?'*GU%;
M5U+ VJJZB=H.0V20N'ZRLR:FCK=MI\.Y:34&@;UI6&H;!6.D>^G$FW,PD%OK
MW&"JSA]INHT&;G?=42PTT;83#&QC^8NWR3\.!@+3+'.8\.8YS7C<.:<$*;4U
M=35<OLJIGGY?>]K(78]651M_A8YUZTMJV"'E%753/>V,G&.9HQ\&=EA^AJBI
MT;Q"IJ:Y 1DN%-4-:[('/C!SZ#A8?3U$U,\OIII87D8YHWEIQ\"R?0[M-NK9
M*W5M;5-GAE9)$UH+Q+C<\V 3U [U9UVGHV+Q3-+I;1U3;[>>62[U;Y'@_:N/
M,_X-P/A4CAC0MN7"B[44DS8!//(P2/. TD-QGX5@7$O5+-4WULU*US:&G9V<
M <,$CO=CNRKCI[5-MH>&MULE0Z45U2]Y8 PEN#RXW^!9]*UZQE_#W3]5H.AO
M5WU&^"!O9!L;6/YN;&3GX3@ */AS=ZBZZ'KJ"R3P0WN"625C)F@M=SO+AL>[
M<C/<M*S553/&R.>HFE8SWK7R%P;Z@5!#))#()(9'QR#HYCBTCX0JC<VIJC5%
MLT34U&HKM0TTT^8O84=.QQD!VQS#OZGT+2KO>'U*=45,]2\.J9Y9G@8#I'EQ
MQ\*E)ZC;O%8@\,])X(Z0_P $J5K['N.Z9&1D21?N/6J"YQ;@N<0.@)SA"YQ:
M&ESBT= 3LG79.3;^IJ=]9P=TQ2P;S324\;!Z2<!7G56IJ30-ILMCAM\5>1!Y
M['NP&\N/..QW))*T0'OP!SNP.@R=EXYSG'+G$GQ)RK1OG1&L:+68N%BJ;;#0
MQOIRX,C=EKP3@]PW&05;^%5L]A:>UC:KA*V'LYWT\DKC@ =GCF]6-UI9KBTY
M:2#X@X7O._!\]V#UW.Z@W+PUT=6:1NM=>K]-30T,%.YD<C9.82 D'G] P/UK
M4EZK!<;Q75K00VHF=( ? G;]2DOJJA\#8)*B9T#?>QND):/4.BDH-L\-'PW[
MA[>]+-F9%<7N>^(/. X.P0?SMP5;/<ZBL^F+C<=7U+Z2>/(IHJ>1KN<@'8Y&
M^3CX%KN-[HWM?&YS'M.0YIP1ZBIE355%46FJJ)IRWH97EV/5E*1MR"E^CWA9
M;J"V3PB[6YS2^![N7):",?""""HK;1'A[P\O O<D0N5RYFQ4['<QW;R@?!DD
MGHM/03202"2"62*0='L<6D?"%[//-42=I4S2S/QCFD<7''K*=_B3EIM2CP.
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M B(@+DWRM/KH:1_%M_BA=9+DWRM/KH:1_%M_BA!UBSWC?4O5XSWC?4O4!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MYN=/;"B^[*;]*WYU[[847W93?I6_.NBO;?3^/J;H_P!#'\RA-ZT\!GZ&Z/\
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MYU]L*+[LI?TK?G3VPHONRF_2M^==%27G3S/^[=&?_1C^9>/O6GVC/T-T9_\
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M97]DU6F_;"B^[*;]*WYT]L*+[LIOTK?G6Z&:_P!-.Z:3IOT4?S*>S6^FW?\
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MD#/3'I78:QK16B-/Z-HW0:=MT-*) .TD S))CIS.ZGJLE3TT?$1$0$1$!$1
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M.W.54,:QS<'*Q6EN;0!E^0/$J]4E>R0>:\*P71H8P$-'7Q43"1L"J85&6>:
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M<@J\VG2M-;7M? UIF;]F[<*_P4S6/YB"7=22IHVKJ9@:T;;J8Y^Q"DM<1O\
ML48',<J]%CP-<YV_15#.6,*%NRAD<,+EE5B&24%P'<J>67F<0S;'>HRUSGNY
MAYJQ_45\IK<PQ0'FF;U"YVNF./FZ+K55[**,OE<"K'6:RAADY8W-(QT6!WB\
MNJBYTTQ8/M05C\ESC#O-:"1WE<WIQX+.+CK:60R",'E*L%3J:<AP8XQ@]X/5
M8W)<6O!:&$9[U+8_G(R#C*L;\FF<Z*N+S7>>\N)!.ZV53S<P8\C<K3^A^:34
M38^C>5;CEIL1P<GANJX9\EUA:'0'TJ.E=],(/0*11 MC(*FTW\L[(1SL5$AY
MG+S&ZF%OFY4#=T1Y WD)WRICMVKSH4SG(00Q]"H9^@ [^JG,;YIRI1;SL*@E
M,'TOUJ$'ERIX&P 4F<802)!C?Q4I\1<WIG?*G'<!5,;>5A(\%19I&D..=@J>
M3S0['>KH^,/<XD*FG@!: .J@M-+3\KB[!ZKVL<&''BKH8C&PD=%::SZ8[SO%
M6"T5F.U:_&XV5-5R"1HW  VW554@'F 6/WNK9'2RMSR@-)SXE6+.;&*Z?EO$
M@:"6M=MA7Z@=*]IE]XT^/<L&IZ][)<RD%SCD%9);*AU0!SRD#/3N6JOE90VM
M!/*6$MZ94]@(:"P^;G.%1T[6$<O."JJ,G./L>B2L54Y+FG/54%7'AA!PJT;'
M;=>R1<[3L,^E;E8K&G,< 7,.6YZ#J%*:YNY:#S*JKH'1SET9Y/$>*IR6R#?S
M"NL938JDN\V0;>)4FKI.T:2T!P/<CN@&<CQ4<,K@<XVZ%6#$+A25%.9I&$M\
MTY([QA=:<7ZT4' 5E0[/FPT?ZW,7/U1#%40/P!GE.WP+?7'B=]'P DDA:PO;
M%2 <PR!YS%D<YVV[UM2/9$W_ $:DS[Z0X+AZ LWLUWII6@4SB]@V[0]"5H45
M,]34]K53R2O'>3L/@6>:7KI 6-<0_P &G8*P;OMTX?'M^M7*-RQ*P5)<T E9
M2QVS<()X=L5X#ONI?-U1H+]CWK-72:'@Y9C*C[,@8/K7D8#,@)+(&1DD[KE:
MW)S>O<&MP785FKKW#3->TN&1MU5BU7J1E(UP!QL>BU5==4OFD=V9)W7.\WHQ
MX?K6PKEJ%\A<V-^!XY5ADN<I>0Z8?G6OY;W4O<<NP/0I0K)7/YN=RSY*[8S'
MT9TZ9SI"[MCCUJ&OK@V#E:\GFV6)QW%T;.IRHZ:=\[G<Q..Y--:D7^GFD;<:
M<R@AK<8]*W+:ZP>Q87. QR!:LT[+[*JHZ>IC#@,8?A;7H*:)M+&#C88"..:I
M8 906GJ%51DOYN["IFPELG,.G15<;>2(D]Y5C@.A+N4] [P5(R=K:\Q;$M"K
MY7  ,;W#*MK*3%:9M\E!5RLQ+S$8'52JIAE$9:>A[E5SCFV]"E B.)N/%![,
MYQE8.@PIA;R#)4LM,E0WP 4R20 X<B)':@C/IPI,L@YP#TRJ@,:YIQURJ6H9
MC/CG*(CBD$;Y&$@'&R0'+7 ] ,JGD87U44C>AV*J#YID""@J@9&-'I4^'9F/
M0HG1[!0MZ.(15'5[ []-U2W+>!@'V053-YY</0I%V;BCC+>K581:&-'9&$[A
M6F^2AD38QLYJOX+&9D.#D+%-0/(#WD'=5N/+;5-F P=U>6N\P+7ULK1'4O()
M ST684E9'(UI+T6Q=&C(4#@0O&3L(P'+USPX9&ZL<[%)5LYFG&Q5GJ&LDRR9
MH&.A"OC@7 X"M59'ASL#+>_T+>+"W%\E*X-G!?&[HX=RJF2=.4Y9CJJ5LQB!
MCD\^(]#X*!S#3NS"XF$[N"ZR(N36\[>:,>=WJ"2=K1Y^01WJ1!79=D#E]![U
M4R-@K8O,<!(1G"(SW@/6]OQ"@C<1S>QY<?F72ZY-\GN.>'BY R0YC]BS;_ N
MLD01$0$1$!$1!S7Y6>G[Q'=;!K&SQR21VUHBD,;"[L2'ES7D#['?&?4J.@\J
MV)MN:VOTQ(^N#0'.AJ0(W.[S@C('HW6]^(NL;)HO3\M?J)^:9Y[-D#6A[YW'
M[%K3U7*=SXOZ(GNAJ(^%MJ>T.R'/D:TG?J6AF%)?07?AC+?N*W'"'6%52>Q;
M?0ELKWL![.-K1AD8<??./?\ #T4WA!+>>(GE R:JKH0VGH.T+Y(V$1M#6F-C
M 3WG.?SK;_!CBII76$/M19Z!MEK8H^?VOY&M8YO?R%N [T[ K9ULME#:Z?L+
M;1T])"3GLX(PQN?' 6NB=58B(HHB(@(B("(B B(@(B("Y-\K3ZZ&D?Q;?XH7
M62Y-\K3ZZ&D?Q;?XH0=8L]XWU+U>,]XWU+U 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$**G%;2FM=1
M"IA]EM8)##SCG#3T..N-D'+FK;[0,\JEGT:R-]J*(-CI14;Q1$Q@M<0=L<Q.
M_BNCKA?].,M<LM==+5[ +#SE\["QS<;CKOLL)XQ\&[7Q%,58*@V^\Q-Y&U36
M<P>W[5[<C/KZK3,'DLZB-2V.HU#;6T8=[YK'N<!Z&D 9^%2=-'Q5WD\:FI*'
M7NN8Z.7LM&-;+6@/![.%@>>4@=V6D[>@*/R5Y(JOBKK*KM;2VUR,>Z+#<  R
MY;MW;+:5BX-6W3W#N\:=L]26U]U@,53<969<[(Q[W.P&3ME7+A!H"R\.Z"IM
M5OK65EUEQ-5R.($CAT;YN3RM6I>?]$;$1$441$0$1$!$1 5DUQ]1E]_P,W[C
ME>U9-<?49??\#-^XY!H/R)?Z&U/^/A_=<NEUS1Y$O]#:G_'P_NN72Z B(@(B
M("(B B(@(B("(B B(@LEX=J/V4!9H[0:;E&35OD#R?\ RC&%0\VMOZO3?QY_
MF64H@P+3M[UC?*&6J@IM/Q-CJ)J8M?),23&\L)Z="6Y5T#M:YWCTYCT23_,I
M/"WZGJS\J5O_ /T/67H/&<Q8WG #L;@=,KU$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$&D+]&'7NX;?_ +0_]XJD[!C1NKK>@/;>OVW]D/\
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MKGRF-*ZTU8+;0Z5II*JV&-QJHNUC:TO#O-.'$;^D+45%P^XX4%![!HG76"C
MY1#'<VAK1X <^P2=-%7_ %%I2WV/RF=/4>AH^S(FBJ*NGB)+:<9!?Z@6[X]*
MZT[EQ!9^%?&*S5L]9:J2LI*NH&)9XJZ,/D&<[NYLG=;/X,Z?XLT&OZ*HUI47
M-]E;'*)1/7-E9S%AY<M#CWX2=-)\72"(B*(B("(B B(@(B("(B N3?*T^NAI
M'\6W^*%UDN3?*T^NAI'\6W^*$'6+/>-]2]7C/>-]2]0$1$!$1 1$0$1$!$1
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M@:"T<S@LLM5 ]L?.=VCQ5-1VXRSM#'' 64LI^R+(XMR[&0N-,JK[+&Z)O:N
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M&7W_  ,W[CD&@_(E_H;4_P"/A_=<NEUS1Y$O]#:G_'P_NN72Z B(@(B("(B
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M5!,]Y&7.&3W*00XGUKS+B[).5ZTDC!SGN7*UJ!'*J>4X!\5,D>XG'+D^"EU
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M-OO^!F_<*#0?D2_T-J?\?#^ZY=+KFCR)?Z&U/^/A_=<NET!$1 1$0$1$!$1
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M0).'#H%34-#)53MEJG9;G93XJ":ID&6EWK[ED='1-8P!_<B;*9@C &!L%,:
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M=5_%<J)5M_\ JHU!^4ZK^*Y42_3^'_"P^4_LQ>HB(NJ"(O4'BWSY-7U(W?\
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M!1-<@B)4+=R4=N%$T (/1T1WO4/1>9R"@DX\TX5.[=5?1I5+XJB0\N!V&5
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M<"-E/:!A! T!I.5"_#L#"B?CO7G?E2CUS>4^:O']%'W*!_10>-4?<H(^IRO
M[SB BO7'JH,J)R@QNH(VC;.%ZX!>] H3DJ"$MPC1NHQTW14,+Q>@%#T0>$[(
MU> '*BZ902W]ZD#J?!3)"I*J(G-4)&RGN:"T%2G#""FGV!RJ8#.<*IJ% V,B
M,^D(JC?$3YP4&"YIR#D*K#<LPH0P-#LA)11<HW[UXYH<T$]0JCDR3A27@@KI
M$>%G:1D8*M<L1:\@^*O,8QN>BI*MC7O\WJ$5:W09:X =5)BIW"3&/.(QGT*^
M-C/8'+<*0YHYQ@>?CIXHB@,+7CE<SWI_.O6T[Z=_;PGG@Z.'>%<1%SL)>.5P
M_6I3&]BX2 9:=BQ78@DIHGAH&[7CFSX*2^EW.-\JXQ\G*6#H[<^A1OA,9 8.
M9OB@L%13D1OR#T*Z.O _]A:<?^##_P *T/419BDYAW%;ZO>VB(?Q4/\ DK.E
M9]6#9QE27G=3'*65S:0.V4.<J)QV4&<!9V:>\Q *\!RH.;* ]<(J9@*($ ';
M=0,WSE1-W*#T.&.FZB:,''<5"YH(QE3F@-: -R@ER-:S._0*F<"6@C.<J;.7
M23",;-QDE18#789N @ES,Y,8\%!S;8'AU4,G.Y[BX[9V4 <&N$33GO)03Q[X
M9&_<H99FL:_/3O437<L;L^^[E25#CV :P<SG'SE L["2QTN[M\>@*HW=(,[]
M4:UL$<;&G?KE&D!CI3L,\H"(DS$M;+R]9 6#YTI&,911PD><!RD^)"]K,L$(
M;XY4V4<K7.(Q@904[7<K7EO4^:J5H/,T#H[F)_,HV]8FG;FW*@+_ *7,6C=X
MY1Z,[(KRV$NMX>>KR1^M>EFTH!W4^*'V.QL#1EK #ZU YW:2N,8P,8*04[>6
M&-[CUY>JG0#S(P=CRD@J35-:(PQYP7;)!S$!K#D#;*HCIB9!,QW7E4+"\4O(
M2, J*4EKW,8,'&"5.?%R1CU(*=L;3%(X[85OC+FN')T)5R<]OL=P[RK>U_TD
M$= 4'M2P8>UA])5-<V]I31U#!N!RE5C3S"1Q'0*A$HEA=%XGHK%6U[,MY>@Z
MKR6+GIA@><"IU5&6OY3X**G;EA00=GVE*8W'(QU6-B$LJ'PG(ZX63!P;EA^R
MZ*TUL3FO$F-V]58BW,83N_WS#W*=)"USN<#8J>(<C('53XH=@#T5BJ".%N^R
MG-B"J9(PT;+UC.FRJ2*;V,,;A0&(#H"KFY@Y0I,C1ND%N<-UZ1EF ITD62<*
M!K"#NMQBUFW UA;Q"@S]SR_L722YTX)-_P#T@0G_ .'D_8NBUJ,B(BH(B("(
MB#ESRLXWT.O-(7JMI34VB%@9(PCS7.$A<6^&2W]B\UCQ$TM>.,W#V^4%T@;:
MZ2!_LA[_ #>PSG#7#N*Z-U7INUZJLTUKOM(RJHI<$L=L01T((W!](6CZOR5M
M-R51?37VZPPDY[-S8WD#PS@).0PF_:@M_$+RDM-U.DXGOAI9X>TJ6LQVH8[+
MG^H#;)77JY]T1+H7A;Q(;HNV6VY5%_JNSB?<IBQV0\!P'4<HW'0?G700Z)Z'
MJ(B("(B B(@(B("(B B(@+DWRM/KH:1_%M_BA=9+DWRM/KH:1_%M_BA!UBSW
MC?4O5XSWC?4O4!$1 1$0$1$!$1 1$0$1$''%_P#JHU!^4ZK^*Y4:K+_]5&H/
MRG5?Q7*C7Z?P_P"%A\I_9B]7B(BZH(B("WSY-7U(W?\ *<G\.-:&6^?)J^I&
M[_E.3^'&OG_:7X4^?^6L6VT1%\-H1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!<Y>4GQ9U/HK4=):=.3T]-%-2B9TKH6R/R21MS9 Z>"Z-6':XX:Z6UO*
MV;4-L%14L9V;)VR.8]K? $%0CD?3M'K?BG./9>MJ6,2.P8:RY]F[X(6_,ML:
M9\EFU0%DFHKY45QZNCIH^R;\8DE4&M?)LL%!#)46K53K<!N&7%S2T?\ F !_
M4M156H=4<.*X06/6]-6L!QBBJ#.P8\6O;@*CL[0_#;2NB7OET[:F4]0]O(^=
MSW22.'AS.)V]2R]<[^3GQBU'KC44]EU RBE;#3&85$<99(X@@8(!Y>_N 71"
M B(@(B("(B B(@*R:X^HV^_X&;]PJ]JR:X^HR^_X&;]QR#0?D2_T-J?\?#^Z
MY=+KFCR)?Z&U/^/A_=<NET!$1 1$0$1$!$1 1$0$1$&EO*8_F.F/\;)_"<M*
M+=?E,?S'3'^-D_A.6E%]S[-_"OS_ ,,9"(O5]!'B(B KUH/ZX&E_R@S]CE95
M>M"?7 TO^4&?L*X>*_!S^2QUTB(OS38N:_*'^N/2_DP?Q"NE%S5Y0_UQZ7\F
M#^(5V\-^+'C^T/X;/_O6-;HB+Z[\D(B("(B#8OD]_7,D_)DO\2-=,+F?R>_K
MF2?DR7^(Q=,+Y/B?Q*_5_9O\-C_WK1$1<'N$1$!$1 1$0$1$!$1 1$0:DNK<
M76OP=S._]I5(UI#?3XJ\W2S7.2YU<D=#,YCIGD. V(R<%4S;)=2=Z&?'J7"R
MMQ:^4-'BH9GE[.6,X]:NSK%=![V@G_,I9L-UWS;YSZ@I)5E6=N6-QG'CZ5.8
M"W8="KC'IZZY//0SGPV4UECNC'?S"<CU*ZIM:2U02N+6<HZ*[OL=UZB@G_,I
M#[!=G'^CY_S)JFU!"T ;*H V5<RPW0#>@G_,O38[J.E!/^9-4Y+3*[J$9TRK
M@ZP78G/M?/\ F4;+!=0-Z"?\RFJ;4 Z*!W5746&Z ?S&?\R\]H;IG/L&?\RF
MJ;6S.&$]ZE,]\KL^PW7&!03_ )D;I^Z C_H$_P"935-K<X84&5=9+#=>Z@G/
MP*7[0W;']'S_ )DU3:@RO%<18;M]P3_F40L-TSO03_F4U3:W#HO"[JKI[0W3
M'\PG_,H6V"Z;YH)_S*^6FUOZ8\%#C=7.2PW7 Y:"<_ @L-T^X)_S*ZIN+:.J
MADV*NHL-TS_,)_S*"6PW8G:@G/P*:IM9W#.REEF%>/:"[?>^H_,HAI^ZX_H^
M?\RNJ;6S&&A29#YVZO)L-VR![7SX]2ESZ>NI][;Z@_ FJ;6.1A>%$&>9A7=N
MG;N/_=]1^91'3UV VM]1GU)JFUB$?*"H)&9&%?/H>O!V]K:C\REG3=YY]K;4
M8]224VL<49P<JEF;@NSW+*(M-7@.R;=4#X%356F+R9#R6RI</0T*ZIMCK),1
MD%JA:P$$CKE7X:7OI)!M=3C'VH4KZ%KZUNUJJLY^U"U)3:T,&&X=DJ341Y=S
M-(!]*R)NEKYV>3:ZGF\.4*G.EK\3YUHJS_Y1\ZNA9HP7-P3D^*.:.;/V/17D
M:6OP(+;35?%'SJ<-)7HMY?:RIQUZ!-&XQQC#Y\?1W5JFT[W##7G'<K^S2=Y/
M-S6NJ#QT=RCYU(J=(WWDYX[75%_>.4;IHVM%4P&*0M=D8.5N^^_43%^+A_R6
MJ8-+W_V.[-IJ1D$%I:,K;MZI)Y=)LIX8G.G#(AR#KMC*LZ5FM>.[\J42KH^Q
MW3NH9_S+P6*YX_F,WYERU6EJ=T4J0$C *O+[%<^Z@G_,J>:QW;<-MM0?@35-
MK2-A@%38P2"JR/3UV)\ZWU ^!1^T-X:[ M]01ZDU3:E:-EZ-B<*NCL=VYM[?
M.!ZE$+'=>8_] GQZDU3:WL]\HB[E)P-U7>T5UW_Z!/\ F7CK#=2W^85&?4FJ
M;6YF0'9/G.*2/$+.4'<JY06&YM!+J"<GTA>QZ?N1>2^@G]&R:IM9Y'B*$O?X
M*FH8BZ-TSC@N=T5ZJ=/768!AH)^7/@H_:&ZAS0+?/R@8Z*:IN+7( 92,^: J
M<9,Q:T$^.%=WZ?NSCGVNJ/S*.&PW>.-SFV^?F/=A357DL=?)V9:T[/.S3Z%4
M<IEJ&,;[R-F2/$J)VGK[4WAKI[74BF8W;S1N5<6V*[1\\C;=4%Q/3'<FJ<F/
MULYEK88V'NW5;4Y$9;UR,*91::O/LV226V5#0!EI+1U5P?8;N9&GV!.6XWV3
M5.3')<AA<?L&;+R !K8,[@CF=ZE>Y-/7=\1_ZLJ<DX(Y1T4MNFKRTN_ZNJ"
MT-&W<FJFU%(]K7[G<_L4F-K& EN=CG"N$NG;X^JC/M94<@&,X"JI-/7=Q\VV
MS@#T=59*NV.UL?:U%.WTY*C@'*ZH9W Y:5>X]-W=I>]UNJ"X=!RJ2W3E[PX&
MV5.",^]":IN+57>9-'RG)*FSO<UO(1G97+Z&KPZH8XVVIPT=2T*:_3UY>]SC
M;9QCILKJIR8XY_+!.\@8C;E4-(TO9RY\UQS_ )K(JS3-]>RJ8RUU)#F8&&C=
M4\>E;ZT-Q:JK<#[$;*:J[BAIG P2;9/0JUMA#:DGFQ@[!911Z6OD3:EAM=2
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M1 1$0$1$!$1 1$0$1$!$1 7/'E!Q\2;CK*CMN@W7AM ZE#I32.,4?.7'K)L
M<=V5T.B@XXM7DX:XOLIJ-272GHWNW<Z>4U$A_,?\UL33WDN::I&L=>KK<+A*
M.HB#86'X-S^M=!HJ,4T;P\TOHY[I=/VB"EJ',Y'3^^D<WP+BLK1$!$1 1$0$
M1$!$1 5DUQ]1M]_P,W[A5[5DUQ]1E]_P,W[A0:#\B7^AM3_CX?W7+I=<T>1+
M_0VI_P ?#^ZY=+H"(B B(@(B("(B B(@(B(-+>4Q_,=,?XV3^$Y:46Z_*8_F
M.F/\;)_"<M*+[GV;^%?G_ABB]7B]7T$>(B("O6@_K@:7_*#/V.5E5ZT)]<#2
M_P"4&?L*X>*_!S^2QUTB(OS38N:O*'^N/2_DQO\ $*Z57-7E#_7'I?R8/XA7
M;PWXL>/[0_AL_P#O6-;HB+Z[\D(B("(B#8OD]_7,D_)DO\1BZ87,_D]_7,D_
M)DO\1BZ87R?$_B5^K^S?X;'_ +UHB(N#W"(B B(@(B("(B B(@*742]C!))C
M/(TNQXX&5,5-<?YA5?BG?L*#3,/'N.6-LC-,U!:\9&:MG3\RB]W=OX,5'RMG
MS+1]L_H^F_%C]BJ5]Z?9_!UT<YE6Y_=W;^#%1\L9\R>[NW\&*CY8SYEIA%?=
M_![+NMS^[NW\&*CY8SYD]W=OX,5'RQGS+3")[OX/8W6Y_=W;^#%1\L9\R>[N
MW\&*CY8SYEIE$]W\'L;K<WN[M_!BH^6,^9/=W;^#%1\K9\RTPB>[^#V-UN?W
M=V_@Q4?+&?,GN[M_!BH^5L^9:97B>[^#V-UN?W=V_@Q4?+&?,GN[M_!BH^5L
M^9:87J>[^#V-UN;W=V_@Q4?+&?,GN[M_!BH^5L^9:81/=_![&ZW/[N[?P8J/
ME;/F3W=V_@Q4?+&?,M,(GN_@]C=;G]W=OX,5'RMGS)[N[?P8J/EC/F6F%ZGN
M_@]C=;F]W=OX,5'RMGS)[N[?P8J/E;/F6F$3W?P>QNMS^[NW\&*CY6SYD]W=
MOX,5'RMGS+3")[OX/8W6Y_=W;^#%1\L9\R>[NW\&*CY6SYEIA$]W\'L;K<_N
M[M_!BH^6,^9/=W;^#%1\K9\RTPB>[^#V-UN?W=V_@Q4?*V?,O?=W;^#%1\K9
M\RTNO4]W\'L;K<WN[M_!BH^5L^9/=W;^#%1\K9\RTPB>[^#V-UN?W=V_@Q4?
M+&?,GN[M_!BH^5L^9:81/=_![&ZW/[N[?P8J/EC/F3W=V_@Q4?+&?,M,KQ/=
M_![&ZW/[N[?P8J/EC/F3W=V_@Q4?+&?,M,(GN_@]C=;G]W=OX,5'RQGS)[N[
M?P8J/EC/F6F$3W?P>QNMS^[NW\&*CY8SYD]W=OX,5'RMGS+3")[OX/8W6Y_=
MW;^#%1\L9\R>[NW\&*CY8SYEIA$]W\'L;K<_N[M_!BH^5L^9>CCPT?\ =BH^
M6,^9:71/=_![&ZW1[N[?P8J/EC/F7GN[M_!BH^6,^9:81/=_![&ZW/[N[?P8
MJ/EC/F3W=V_@Q4?+&?,M,+U/=_![&ZW-[N[?P8J/E;/F3W=V_@Q4?*V?,M,(
MGN_@]C=;G]W=OX,5'RMGS)[N[?P8J/EC/F6F$3W?P>QNMS^[NW\&*CY8SYD]
MW=OX,5'RMGS+3")[OX/8W6Z/=W;^#%1\L9\R>[NW\&*CY8SYEI=$]W\'L;K<
M_N[M_!BH^5L^9/=W;^#%1\K9\RTPB>[^#V-UN?W=V_@Q4?*V?,GN[M_!BH^5
ML^9:81/=_![&ZW/[N[?P8J/E;/F3W=V_@Q4?*V?,M,(GN_@]C=;G]W=OX,5'
MRQGS)[N[?P8J/EC/F6F$3W?P>QNMS^[NW\&*CY8SYD]W=OX,5'RQGS+3")[O
MX/8W6Y_=W;^#%1\K9\R]]W=OX,5'RMGS+2Z)[OX/8W6Z/=W;^#%1\K9\R\]W
M=OX,5'RMGS+3")[OX/8W6Y_=W;^#%1\K9\R>[NW\&*CY6SYEIA$]W\'L;K<_
MN[M_!BH^6,^9/=W;^#%1\K9\RTPB>[^#V-UN?W=V_@Q4?*V?,GN[M_!BH^6,
M^9:81/=_![&ZW/[N[?P8J/E;/F3W=V_@Q4?*V?,M,(GN_@]C=;G]W=OX,5'R
MMGS)[N[?P8J/EC/F6F$3W?P>QNMS^[NW\&*CY8SYD]W=OX,5'RQGS+3")[OX
M/8W6Y_=W;^#%1\K9\R>[NW\&*CY8SYEIA$]W\'L;K<_N[M_!BH^6,^9/=W;^
M#%1\L9\RTPO4]W\'L;K<WN[M_!BH^6,^9/=W;^#%1\L9\RTPB>[^#V-UT-H7
MBNS5.I8+0;)-1NFC>\2NJ&O Y1G& %LY<Q\$OKFVW\1/^Z%TXOE>,X6/"XGE
MQZ-01$7E41$0$16O4.H+3IRC95WZX4U!3/>(VRSO#6EQ!.,^. 4%T185[JVA
M/PLM'R@+#.*7':S:<LM/5:4KK5>ZI\W(^!L^2UN/?;(-T(L T+Q2TYJ2V6@2
MWFV1WJMB874,<X+FR$;L ZY6?IH$1$!$1 1$0$1$!$1 1$0%R;Y6GUT-(_BV
M_P 4+K)<F^5I]=#2/XMO\4(.L6>\;ZEZO&>\;ZEZ@(B("(B B(@(B("(B B(
M@XXO_P!5&H/RG5?Q7*B5;?\ ZJ-0?E.J_BN5$OTWA_PL?E/[,7J(B+L@B(@+
M?/DU?4C=_P IR?PXUH9;Y\FKZD;O^4Y/X<:^?]I?A3Y_Y:Q;;1$7PVA$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0.Y<_\?M<:_P!-:KI*31L4KZ%],)'E
ME&)AS\Q[\'T+H!>(.)[CQOXK6SL_;&04O:>\[:@:SF]61NIK^,O%V.D]E2,D
M;38SVIMH#<>O"R?5VH*&D\JADNM'CVIH@V*F[<9CA)C!:_'3',3OX[KI"HU3
MIR*@=45%[M0I0TDN-3&6D?GW3TV>NFE/)SXB:XUKJ&I.H7MGLS:=W+*RG:QO
M:@C;F'?@G9=$!<K\!KU%5<?]3LTL"W35:V:4QL!;'YKARO [LDG'H*ZG;T3T
MAZUZB(@(B("(B B(@*R:X^HV^_X&;]PJ]JR:X^HV^_X&;]PH-!^1+_0VI_Q\
M/[KETNN:/(E_H;4_X^']URZ70$1$!$5IOUIJ;H(?8UXK[;R9S[%Y//\ 7S-*
M"[(L2^A*X_AC?O\ ^Q_]-6&RVR\5^I]0VV35MZ;#;70")S1#S.[2/F/-]+\4
M&RT6)?0E<?PQOW_]C_Z:R*U4DE%0QT\U9/6R,ZSS\O.[U\H _4@JT1$!$1!I
M;RF/YCIC_&R?PG+2BW7Y3'\QTS_C9/X3EI1?<^S?PK\_\,9"(B^@@B(@*]:#
M^N!I?\H,_8Y657K0?UP-+_E!G['+AXK\'/Y59U==(B+\TV+FKRA_KCTOY,'\
M0KI5<U^4/]<>E_)@_B%=O#?BQX_M#^&S_P"]8ULB(OKOR0B(@(B(-B^3W]<R
M3\F2_P 1BZ87,_D]_7,D_)DO\1BZ87R?$_B5^K^S?X;'_O6B(BX/<(B("(B
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M''(T4LAPX#<9PKQ_M!\.?OW)\DE_TK!-*^3=I>\:;MEQGN%R;+54[)7-:YN
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M[CC;P&5FM1O;@%J^Z:UT&+M?#":OV3)%])9R-Y1C&V3XE;(6EO)'.>$S3_\
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M%M_\/$IC+YIQXR-.0X\?8\2GO:?E^O\ H\E<S^RJ?^OB^.%[[*I_Z^+XX73
MO>FR<#3T/R>-1"\:<.?_ &?@V_\ AXT][X_E^O\ H\E<R^RJ?^OB^.$]E4_]
M?%\<+IH7C3A_[O0?)XT-YTV/^[\'R>-/>^/Y?K_H\E<R^RJ?^OB^.$]E4_\
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M<S^3W]<R3\F2_P 2-=,+Y/B?Q*_5_9O\-C_WK1$1<'N$1$!$1 1$0$1$!$1
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M B(@(B("Y-\K3ZZ&D?Q;?XH762Y-\K3ZZ&D?Q;?XH0=8L]XWU+U>,]XWU+U
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MPOFB9C-1Q27NUL\[GIVXGC;_ &H_L_6W\RWCH[5-AU-;&3:;KZ>I@8T#LXW
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M<%IQSFE6P.QYX'/XJ:YI[,;;JGC+Q4=?-*K'.R<(XH(F9418/%3(AA>.Z%!
M%$T9!RO&C=>OV!P@A<1ONJ:7<$!36L)W*B[+**IHVX:1G*D.B()PJ_L^4%2-
MR2.Y! PGEW"\8X.)&.B]>"!LH8\-!)QE!)D8"_E/BO*EK(X2]QP1T7DQ)?EN
MVZHKBY]1&V-F=CN4%IJBZ5Q)&0%1"3V-'+V6[W*_.I^2+E.,D;JUU @IF.DD
M(R.XE(L8_P"QI7&1\Q'G#(!7C9F4E$XG!=X97L\4E7523O>YC,>:U6&?E93U
M41F^FD9!)5C<C(;95AKFSL9S-[P.]9933-J&/<QS6QO'3T^"UQIBH>QL43Y
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M=EK&CJJRS5Y?$70U$9+7-(_."%F=#(^6O=4V*;V#=8W<\E&3RLF<.O)\RO\
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M;! 27$X"AIVR54[886EQ=CHML:,TK%04[:N8ATN<X*D:N4D7'AWIMEIIV35
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MG_'P_NN72Z M?<>OK9W'\;!_%:M@K7W'KZV=Q_&P?Q6H.>3U/K7B]/4^M>!
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MV=UJ,6JZ.,9W*]>,=%XS?.ZC \5ISE2STW4]HRS"@D;S8PIK!RMP@F1#;*]
MP20D71>N.$1ZTG*]F][YO5>-W1WI1$@DYWZH!D%1N;OE0M*(AAZ.&5'T(RO
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M "/ALE?)$XMD9 ]S7#J"&E<?T6J-02T5/))?KH7OC:YQ]DNZD+K[4GU/7/\
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MC*]CPY@([T&&E;KC593R#O4Z1@F80/UJDB52TG'79(RRC@TSDU_"W&W82;_
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MV_HT]RG0OX+VW]&LV1!A/N4Z%_!>V_HU<+'H'2UAN+*^SV*BHZQ@+6RQ,PX
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M$6H^)W&^T:+U'0V6GIGW2M?*UM6R!PS TG&!XO\ [/SH+OQ^U'=M+\-+A<K
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MM>?O%;OE+_\ 2GN[7G[Q6[Y2_P#TK4:)]VX?9?>OB.\_1MSW=KS]X[=\I?\
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ML4T+HVLUA755+15,%-)3QB1QG!WWQC9;.H^'NI='&JKM#W:GJFRLPZ&H8,R
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M=IKI'0T[;C*P125(C':.:.@+NN%7(FA$1%$1$!%2R5]+'<(J%]3"VLE8Z2.
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MGY]_SK%:_553PJX\ZLN5SMQK)*L2F#.V0_=C@?#;!]&5<?* M$^@>*%IUW8
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M1C\ZNM\DZ,F\F_1NN-'7>\4%\F9'IZ%Q;'$[+A+)W21>#<=?'X%OU.B("(B
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MTV*M=V@[1PEA."WJKG3O[6G;@G.,D*@EYF.<UPRUVYSW*HAH)N5H$YQGHK@
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M;331TU%3M#(XHQ@ ?/Z57(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MRGN&Y5--4<F1""X]_H4N-_*3VFYQOE<;6I-]%0Z;S,Q-:1G=1>R&@#MBUO@
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M2M/GA")\C"Z,^@*WQ[EW-MA7N,!T6W@K;4-#24@M5P:.0JU4[\->,J]5["Z
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MY.%78=<TU=1:GJ8[/$2\N@S#4GP9S XP>\_J72#1RM WV\5ZB B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M<T^)Z!=##HB**(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MRN::UWF/\.4KJ^]C/#VF_$0?\*Y+SB-_]T_L76MWWX?4WXB#_A6J->/BYLY
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M$1$!$1 1$0$1$!$1 1$0$1$!$1 )PM \>.-3+'01TFB+O;9KDV8-J7M<)'1
M=P&"T],$YV6=^4#7UUNX37^>UN<V?LA&YS>K6..''\Q*U]Y*MFTK<^'=1FBI
M*NZNE?'7]LP/=@GS1O\ 8\N.BG4Z)@N-H\H?AM+;VR1V_4M$1+V3SD1R#;F'
M>8W9QGN^#?7>FKWQ@X:L?IV"QU5?2L<6TX=3.GC8?&-X'O?0=E;>,6G9>$_%
M&EK]$2R4[9(?9L<3?/[ 9(<TCO9MW]Q72O!GB31<1=.^R8FM@N=-AE93#HQQ
M^R;XM.#A7XP81P,X:WV#4M9KK7[^:^U8/8P.]]%G&7.[@<# :.@6^$"("(B
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M SN#8QU5324#2 0W!'595-AR/%5,9SU7LD88-E+:<*HGYV1AYCZ%"W<;J-F
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M6V7&Y44515VU[GTSWMSR.(QGYO I.5E/2Q=:=[)8FR1Y+'@.;D8V*F(!CHB
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C$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g762905g35e11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g35e11.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( Q<%1P,!(@ "$0$#$0'_Q  =  $
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M##LMP,'/H/-61TU/;ZK3UMGLK8V6R2GC=3-C;NM;&6C= '5@8X(-DB(B!$1
M1$0$1$!$1 1$0$1$!$1!I]9?<A??F,_[MRJ;X*WWU8_F4W\*MEK+[D+[\QG_
M ';E4WP5OOJQ_,IOX43"Y2(B($1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 5,O">BK*?:Y53U37&"2"!]+O#+2P, (']\/^E7
M$N-?2VZ!LU;,V&)TL<(<[K>]X8P>ES@/2N1VL;/:#:!8/%*DB"X09?250&3&
MX]1[6GAD>GJ1,-OH/55OUCIFDNUKD:8Y&@219\J&0#RF.':/K&#UK V?Z,@T
ME5ZEEIVQM9=+BZJC:S\",M&&]V'%_#L(52-(:BO^R'7L]/5,D8(91%7T9=Y$
MS.T=^#EKN_L)"O#2U$5520U,+PZ&5@D8[M:1D'Z$%5/"ZOOC>KK798WYCH*8
MRO ZI)#R_P +6GTJ=]E=NI]&[*K-'<)(Z5D-**FIDE<&ACG^6[>)[-['H559
M6G:7MQ>PETE/<KENY!X^+L/_ $V*>MI^QBWW.P9L]3>/'FS1-8R6LEJ6.#I&
MM=D/)P "3D<L<>""08*6WZUHM-WZ6![&TTYKZ/> WG-+7M83V AS7X[0.Q?6
MTR^^YO05]NH=NR04SA$?_P!X[R6?\S@N@HJ:*CHX*6G:&0P1MC8T=36C 'T!
M05X7=^\4TI:K)&_$E=4&:0 _]G&.1\[G-/\ =1#A_!'L7CNL[E>)&YCMU-N,
M)ZI)#@?\K7_2L#PK;I2W#:3#34I:^2AHV03.;^.7.?N^@.'TKN-A.@;\_9Y'
M<+5JNJL8NCW2/BBHXI26@EC7;SO*!(!/ ]:[31VPW3EBNXNURGJ[Y<Q)THEK
M2"T/SG?W>MV>.7$HET^R"AK+;LSTY27,/;5QTC=YK^; 22UI[PT@8[EUZB#5
M^WS3NF=25]FGH+E534<G1R2P"/<+L D#+@>!X<N8*S]G>V:TZZU$+1:K7<XI
M>B=,Z68,W&-;CGAQ/,@>E$-9X16TN71UHBM%EEW+W7L)Z0<Z>+B-\?VB<@>8
MGJ"YKP;O<G8J)M;<[[;7ZKNQSN25#3)$PG@S)/QG'B1G/$#J4:ZIBFV@^$-4
M6^4N=#+<_$\#\&"([KL?W6./G*[CPN+3:K=2Z9DH:.FI:MSIH\PQAF8VAN <
M=A/#SE$K-+G=1:DTYHVCJ*JZUE'0"1QE=&W'23//,A@XN<<#J6-LFKJFY;-M
M.5=>]SZF2BCWWN.2[ P''O( /I4<[<]D-CK-+72^V.C;0W:CC?5/Z(D,G:W+
MGAS>6<9((ZT0YO9CH>]ZEVN5&N[E;9K1:/&I*N"*=NY)*79#0&\^L$GD>K.>
M%E57_P $?4=?<K->;/7323T]O=$^F<\Y+&OW@6 ]F69 [RI[K*B*DI)ZFH<&
M0PL=(]QZF@9)^@(E4OPD:M^J-L%#8: !TM.R&A;CKED=O?QM'H*M?::"&UVN
MCH*4;L%+"R",?V6@ ?4%4W833RZVVXU=_JVES('S7%^>0<XX8WT%P(_15O$)
M%%'A-7W[#[+JNGC?NSW.5E(W'/=SO/\ 1NM(]*E=5<\*>X37S7FGM+4)WY(F
MM\D=<LS@T ^AK?\ $B(27X,=A^P^RZEJ9&;L]SE?5NSSW<[K/1AH/]Y1#X0-
M5+K/;3;]-T3B6TYAH6XX@22'>>[T!P!_15HJ>.CTQIB.//1T%KI ">R.-G/Z
M&JK_ (.E'-J[;#<M2US=[Q82UCB>($LI+6CZ'/(_11,+501TMJMD<8='3T=)
M"&@N(:UC&C'$GD  N,K-JM@AMM5<Z2&YW"T4K^CGKZ2E+H&'(!\HD;P&1Q;D
M<5#7A(:RN&H-7T^A+'(X4[98XIVL./&)WD;K3_9;D<.W/8%(VUBEHM#[ :RT
M4FZV-E/'11]1D>YPWG><^6X^E!).F[];-2VB&YV2K95T4OQ9&Y&".8(/$$=A
M7.Z@VG:;LU]CLGC$]?>I'B,45!$9I [L/X(/<3D*+/!=AND6S'5510AW223/
M%$T\C,V$<1Z2P>A<WX)UK%7KN^7*X[SJVBI\ 2_'$DCL.<<\<X:0?TB@F^7:
MSI6BN-1;[Y4U%EKX TOI[A"6.P1D$%N\TCS%==8KO07VV0W&T5+*JBFST<S
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MX'F"@[-$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 185WNUOLU(:J[5U-14XX=)42B-N>S)/-<XW:9H\N&;Y QA.!)(
MQ[(_\9:&_6@[!%XT573UU-'4451%44\@RR6)X>UP[B.!7L@(B("(B B(@(B(
M"(B B+P@K*:HFGA@J(99H"!*QCPYT9/(. Y>E![HBQQ6TIKC1"I@-8&=(8.D
M'2!F<;V[SQGK09"(B B\35TPK&TAJ(15.89&PEXWRT<W!O/'$<>]>R B(@(O
MB>5D$$DTIW8XVE[CV #)4%;*=MESUIM'DLT]MIHK7.R1U.8P[I(@P9!><X.0
M,<AQ(03Q@9RB(@(  ,#@$1 1$0$1$!:Z^WRUV"B=67JOIJ&F'X<\@;D]@[3W
M!?-_I+G6THAM%SCMKW$[\YIA,\#'X )#0>\AWF5&-K$%THM>W:@O5VJ+M4TL
MNX*F8G+FD!PX9\G@1P'!$PORQ[9&->PY:X9![0CG-8TN>0UH&22< !>-N_W"
MF_X3?V*OGA8ZUJJ*&ATM;IW1"JC-36EAP71Y(8SS$AQ([@B$NLVDZ-?<?$6Z
MEMAJ-[< Z8;I/9O_ !<^E=:"" 0<@]:A.]Z=H&^"\RF;31CH[3%7 AHR)<-D
M<_SDD^@K7>"CK2INUIKM.7*9TTEN:V6E<\Y=T)."SS-.,=SL=01*=ZRJIZ*E
MEJ:R>*GIXF[SY97AK6CM)/ +G+/M"TE>+@*&VZ@M\]6XX9&)<%Y[&Y^-Z,JN
M_A,ZOJ;UKB'2E-,]MMHG1MF8P\)9G8.3V[H( '4<J0/"@LE%3;+:!])3QPFV
MU43*<QMP8V%KF[H[!\4^<!!.**+O!UUG4:OT&T7*4S7*W2^*S2..72-P"QY[
MR#C/66DJ440(B(-/K+[D+[\QG_=N53?!6^^K'\RF_A5LM9?<A??F,_[MRJ;X
M*WWU8_F4W\*)A<I$1$"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@+$O$[Z6T5U1",R10/>T=X:2%EK\>UKV.8\!
MS7#!!ZP@YK9A3QTVSO33(CD.M\,KG?C.>P/<[TN<3Z5TRXC9M4&U,J='USMV
MMM!(IM[_ +>C)/12-[<#R#V%O>%VZ N-VA 0W/1U9'PJ([RR%I',LDBD:\>;
M''T+LEP]3,-3[0Z.GI3TEMTXYT]3*.+75CV%C(QVEC'.<>PN:@[A$1 1$0$1
M$!::MJ[Y'52-I+31S0 ^1(^M+"X=XW#CZ5N45;1,])V7QWBD[S6)]N_\IAH/
M'M2?D2A_\0/_ $UB6N^WZY4;:FFLE'T1>]@WJ\@Y:XM/_9]K2NGGFB@C,D\C
M(XQS<]P:!Z2N=V?5,$VG6,AFBD>V>H):UX) ,[R#]!"Q36W;BO:GI/EZO4VZ
MY,<XK7[N-XF(_P 7C$_ZO4]O'M2?D2A_\0/_ $UO8RXQM,C0UY W@#D ^?K7
MTBRUK,=9W:V3)6_2L1[-_P"<R(B*S$(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(H;NVTJ]Q7.JBAAIH(XY',$;XR7#!QQ.>:"9%HM9WXV"T":G@\:N%3*V
MEHJ;..FG?P:,]0'%Q/4 2HM]\V__ /PGZK_S63HO45=JS:=;&78PEENH*FJA
M;&S=^V.=%'GT-<X?WE.P[G3^BZ>"I;==1/;>=0/&754[<LA_L0,/"-H[N)ZR
M5UCV->PL>T.:1@@C((7ZB@<->M+36*66^:&C;35C3TE3;&>33U[>L;O)DG8\
M=? Y!75:?N]+?K+1W2WO+J:JC$C,C!&>8(ZB#D$=H*SU XU=<]+ZBU/9[68/
M$H+G))&U[-[=Z1K97 <>6\]W#O03PBA#WS;_ /\ PGZK_P UOM$:\NUVU#3T
M%;#!)%,""Z)A:68!.>?+@IV$HHB* 7X]C7L<Q[0YCA@@C(([%^H@K9M5TY;-
M$[6=,7R6D9[EZ^81U5,?Z&.0<"2WD!AP=CEY+E9&)K&1L9$UK8V@!H:, #JP
MN,VQZ4&L=G]SMT; ZL8WQBE[>E9D@#SC+?[RXK9]M$GK=B0J(G=)J*D+;1'&
M[XSZAQ#(2?.'-)_1=V(EM]!:3LU?KG4>IX*&)M)#5"CH(P/M8?$ )9FMY9,F
M0".6Z3UJ1KM=[=9Z<3W:X4E#"3@25,S8VD]F7$+PTK9H=/:=M]IIR7,I(6QE
MYYO=^$X]Y.2?.HQT+<+IJ35&L;M':K7<9*:Y26V UM:Z)U/#&  UC1"\ .)+
MB<C)\P1"5(*BW7VV.=25,%=0S M,E/,',<.L;S3_ *J&_!_%%8[OM+9))#24
M%)=BP.ED#61L:Z0#+B>S'-;[9WH:_P"FMH=\NQ%JHM.W-F\;;25#Y.BE\G#A
MF-@Y[_+'!V.I<SL?T];;YK/:2;Q3,K88;T\LIIQO0[Q?)Y18>#B.HG....:)
M3?:KG07>D%5:JVFK:8DM$M/*V1F1U9:2,K0LT_IJ/:&^]AT(U/+2]&6>,>68
MA@%W1Y_1&<*/=D-+#8]LFT.QVV,06QO03QT[/B,) /DCJ^.?J[%XV"V4=J\*
M"Y16^!D$4EFZ5S6<BXEF3YSA$)IN%?26VE=4W&J@I*=OQI9Y!&P><DX7C:;Q
M;;S Z:T7"DKH6G#GTTS9 #V$M)PHVTS6-U5MKU2+D!+!IV**GH('\6QN?GI)
M<?C9&,]APNAH= 0T&TVJU?0U\D#:NGZ&HH(XP&2.P 'DY[@>7/CE!PM@MM+:
M_"AN45%'T<<EFZ5PWB[+B69.2<\<*9[C<**V4KJFY5=/1TS>!EJ)&QL'I) 4
M24G_ .U-6_\ <0_S,7O;;C<=0;6]5]#;K?<6V)L%+2Q5M6Z$0;[2Y[V@1/!<
MXC!=P(  ZT2E"TW:W7BG-1::^DKH <&2FF;(T'LRTE%&5CT+J.V[67ZHHXK-
M:[35PF.NH::JDDZ5VZ</ Z)HSO;I_P 7:B(2I6T[:NCJ*=Y(;-&Z,D=0((_U
M53K?M:NNSF8V"?25FCN5L8**2I;&8I)6LX!SB.><!V>1SE6W7+ZOT!IC5[V2
M:@M,-5.P;K9@71R =F\T@D=QX(*L0[;KG#M#J=6LM5&:F>@% :<O=N!H>UV]
MGGGR5TA\)N^XX6&V ][Y/YKN(-@-B&OJB::W,.E30AL4(JY>D%3O-\H\<XW=
M[K]"Z5NPC9\/_P"B2'SUDWM(GDAZ7PFM1F-PCLMI:\C@X](<'S;RL#LAJ)*O
M9KIVHG=O334C9'N[7$DDKG9=@^S]\;FMLTL9(P'-JYLCO&7$+LM!6:73VC[5
M:)R'24<(A)!SG!X'Z$&^1$1 B(@*BNWO[[NI?^.W]VU7J5%=O?WW=2_\=O[M
MJ)A>.W?[A3?\)O[%2_PF*A\^U^[,<3NPQ01M[AT37?M<5="W?[A3?\)O[%4+
MPK+3)0[2Q7%IZ&X4D<C7=1<S+"/H:T^E"$ZZA;N^#E*#S&G6?N0H%\%6H?#M
M59&PG=FHIF.\PW7?M:%.^HI-[P;Y'C!WM/1?7"U0WX(UI?5:ZN-R+3T-%1%F
M]_;D< !]#7H1T1_K"=];M@N\CSY3[W(T9Z@)B /H 5FO"F^]/4?.X?VE5WVI
MVQ]BVV72.1NZV2Y-K&$C@6R.$F1_B(]"L-X5!QLIE';60CZW(.!\#>H>*_5%
M/D]&Z*"3'>"\?ZJSBKMX'=I?':M179[2(YYHJ:,]NX"YW^=JL2A+A:W:YH:A
MK*BDJM0P1U$$CHI&&*0[KFG!'!O:"O#WYM ?G)3_ *F7V5%^H?!OKKK?KG<6
M:BIHVU=3+4!AIG$M#WEV,[W>L#X,%P_.:E]5=[2'))NI]KVA:O35VIJ;4,#Y
MYJ26.-@BD\IQ8X ?%[2H(\%8@;5HL]='-_HM]=_!MK[;::VN=J.ED;30/F+!
M2N!=NM)QG>[EH/!7&=JT)[*.8_4$%RT1$0(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B+Y>]C 2]S6@<R3A!I=
M4:9I-0,IY))9Z2X4KB^EKJ9P;- X\\'!!:>MI!!ZPM0R37EM'1/IK%?(V\&S
M]/)12.[W,W'MSYB!W+?U6HK-2%PJ+I1,<WFWIFEP] .5HZG:-IV%V&5,T_#.
M8X78\W'"#QEM^L[Z##<ZZ@L%"[A(VV/=/4O'8)7M:UGG#">PA=/8K/0V*V0V
M^U4[8*6+.&@DDD\2XD\22>))XE<34;5K:USA!05<C0.!<6MS]96OJ=K+R6^*
MVIH'7TDV?V!3L)510Q-M3O+G.Z*FH6-/Q<M<2/\ F6!5;1]13AHCJ(8".N*%
MO'_%E-A.R* 3K75$Y#1<9B1QPR)@_8U?#[]JNN>R-M9<W/\ P6PAS2?\.,IL
M+ HJ_2LUA4LZ*9M^D8XCR7B4CZU]^YS5G]4N/^,_S39"?ES.L+_54,]':+#!
M'4W^OWC"R7/1P1M^--+CCNMR!CFXD =T3#2&J:@ESJ"J<1PR^0 _65SPM=YH
M*2Z7=TLU.^GN+K;(V-V'1AL<;AEP/$%SG>G':L.HR]S2;[;[-W0:6-7GC#-N
MSOTE-U%L\M,CVU6IM_4=R/%\]Q D8#V1P_$8WL &>TE:S3FA=.76P15$]K@@
MK1-4!E92#Q>=F)GAN)&8=P  ''' *&/LU=/RE6_KW?S7Q%=;C$S<BKZMC,D[
MK9G 9)R>OM7*GBM>U%NS\\GIX^BV2,<T[R.<Q/3RW]?K3S;+C<],7NELNHJI
M]PM]:XQVZZ2- DZ3!/03XX%Q .Z\8WL$$9Y]LJNT,5XOT%>(Z^I=XE2RUN_*
M\O:QT;2YAP3C.\&_^@K*V2L^R-FH*W ;XS3QS8'5O-!_U71TNH](K-MMH>>X
MGP_ZOR1BF_:G;?IT9J(BV7-$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!8D]
MLH:B4R3T5++(>;GQ-<3Z2%EH@P?L-;/R;1?J&_R7):WHH=/5MHU5;Z.-D-L>
M^*O9!$ 322@![\ <=QS6/QV!R[M?CFAS2UP#FD8((R"$'Q3S15,$<]/(R6&1
MH>Q[#EKFGB"#UA>BXANE;MIV5[]$5]/'0O<7&T7!KG4[">?1/;Y40S^#AS>/
M !>OV5UQ(.B9I>T0RGATTEW<Z,=^!#O'S<$'1:@O%'8+/4W*Y2='30-WCCB7
M'D&M'6XG  ZR5SV@].B*QNK+]04YN]RGDKZILD8>8G2'(CR1^"W=;_=7U;-)
MU=5=(+MJ^X,N=;3NWZ:EACZ.DI7?C-822]_]MQ)'4 NO08/V&MGY-HOU#?Y+
MVI:&DI'%U+2P0N(P3'&&D_0LA$!$1 1$0%"^F-F51:MMUWN8:]NG"&W*",?T
M;JIP>W&.66;TI'8'-4T(@*![I9]9;-=?WB]Z2M#K]I^]2]/4449\N.0DDX X
MCB78(!&#@\@IX1!P^DJ_4MWEDONH[3)9Z:&%T=+:V2]++(207228P,^2 UN.
M&79YA<OL:H+S9M2:UJ+S8[A1PW>O=64SW-:X;N9'8.ZXX."/2I@1!#^AJ"\4
MNVG5EZK;'<*>UW6...GG>UN,L#1EP#L@'!*^:6BO#=OU3J)UAN(LTEO%"VHW
M6_&\D[Q;O9W<@CDIB1!"&M=/:IT=M-FUMHRW&\4=PC$=PM['8?D #('/CNM(
M(!P<Y&"NWTC7ZFU-<(+E?+,[3UMI070T<DW23U$A!;O/P!NL:"[#2,DG/4%W
M"((=IJ.\,V^U.HW6&Y"S26\4+:C=;\;R3O;N]G=R".2P]<:?U;H_:14:UT/0
M_9:DN,;67"W@^42 !D#GU @C)!SPP5-R(.!T?<=4ZJKX*^^V1^G+72[SF4KY
M]^:ID+2W+N W6-#B<$9)P>I%WR("(B")=NNUGW!006ZTQ15%\JF=(.DXL@CR
M1O.'620<#N)/8:QW+:EK>X5!FGU/<V.)SNP3&%H\S68"L.^Y:3MFW+5CM;^)
MQ5<D5(;;/7,!B;%T0WPTG@T[V>)[\=:D>'4^BY(_M-[T\6?V:J''[42J]H#;
MSJ>PU\++]4OO-K) D9-CIF#K+7\R>YV0>[FK?VJX4UUME+<*"42TE3$V:)X_
M":X9!7!ZPO\ LR-IJ1?:S3M5#N',;'12RNX?@AN79["%[; 6O;LDL'2!X!;,
MZ,/^,(S,\LS_ '=U!("(B($1$&'=9ZVG@#K=1,K)2<%CIA$ .W."JPZVV*:[
MU3JNYWN:*T0/K9C)T3:MSMP8P!G<X\ .*M4B#0Z1EOGV.IZ?4%NIJ:>*%K'2
M05/2MD< !D#=!&>:TFU[9[2[0M.BCDD%/<*9QDI*DC(8X\VN_LGAGS ]2[E$
M$%3V/:+5[-(]!OL-%$1$RC==S<&&(P-(QB,#?SN@-Y*0]E6@Z+9_IH6VED\8
MJI7=+55);@ROQC@.IH' #^979(@BG;CLI&O:>GN%JFBI;]2-W&/DX,F9G.XX
MCD0<D'O.>[2ZXT_K[:19+9I^Z6:DL5-%,R:MKGUK)Q*6M(\AC./63@]PRIP1
M!I=&:;H=):;HK-:VD4],W&\[XTCCQ<YW>3Q6Z1$!$1!I]9?<A??F,_[MRJ;X
M*WWU8_F4W\*MEK+[D+[\QG_=N53?!6^^K'\RF_A1,+E(B(@1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 18=TK)**G;)%15-8XNW>CI]
MW>'?Y1'#^:U?N@J_S<N_T1?]14MDBL[2S4P7O&]=OC'[N@1<R_5<C*R*E?8+
ML*B5CGL9B+):W&3\?JWA]*]O=!5_FY=_HB_ZBKWU/F)7G1Y8ZQ'QC]W0(L"T
MW"6N$IFMU71;F,>,;GE9[-UQ_P#16!>M766T->*JNC=,WAT,1WWY[,#EZ<+)
M6>U&\,%ZS2>S+?+SGFBIXC)42LBC;S<]P:!Z2H>O>U"YU+GLM<,5'"?BO<-^
M3Z^'U+GX:#4>K*ETNY55CAC+Y#NL;GLS@#S!6V52S<]H.GZ O:*IU5(TX+:=
MF]GS..&_6N0N.U>J=*\6ZWPLCY-=.XN=Y\ @>A+7LIJ9&;USN$<#L\&0LW^'
MG./V+K[3L^L%OXNIG5;_ ,:I=O?4,#ZDY"+JC6VI;A-B.ME:<<&4[ /V#*\(
M-.ZEOLSIG4=9._KDJ#N_6\CM4^TE'34<8CI*>&!@X!L; T?4O=-T(2I-F%]F
M&9GT=/W/D)/_ "@CZUNJ'9/Y.:ZZ>5CXL,7(^<GC]"E-$W2X*EV6V6//3SUD
MQ/:\-Q] 6QI]GNG(9-_Q)TG#E)*XC]JZQ% TM/I6Q4[-V.TT>,Y\N(//TG*S
M8K3;H9&R14%(Q[3D.;"T$>8X6:B  !R "(B B(@*.Q00,U7J?3-Q\BEU T7*
MB>?PI QL<K1_::61OQV.[BI$6FU3IZEU%0,@J)):>HAD$U+5P'=EIY1R>P_4
M0>!!(*B8BT;2M2\TM%JSM,*S7.AFMMPJ:*J;NSP/,;AW@\_,L5=WM+L6HH*E
MMPOE-23-:UL+[C2'=;.>37/B/%CL#!P2WEC')<SIJT5]YND<%LHFULK,2/B?
M+T3"T$9WG8.!QZ@3V!>6RZ:U,W=1[GU+2<1QYM'&JM.T1'/VQU_H[ZAMK['L
MQEI86C[/:I(HJ9GX0$@(SYFL+GDJ8J"ECHJ&GI8<]%!&V)F>QHP/V+G-,Z8J
M*>Y.O>HJJ.NO;HS%'T3"R"CC/..%IXC.!EQXG Y#@NJ7IL6.,5(I'@^9ZO4V
MU6:V:_69$1%D:XB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@C/;-LII-H5)#403MHKU3-+(
M:AS<M>W.=Q^..,YP1RR>:K7<MB&OJ&I=$+&:EH/"6GGC<UW?Q((]("O B)W5
M-V?^#M>Z^MBJ-8.9;;>TASZ>.0232CLRW+6COR3W*UE#204%%!24<38::"-L
M44;1@-:!@ >A>R(@1$0$1$!$1 1$0$1$!$1 1$0$1$&GUE]R%]^8S_NW*IO@
MK??5C^93?PJV6LON0OOS&?\ =N53?!6^^K'\RF_A1,+E(B(@1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1:V_VJ2[T;((KI<+:6O#^E
MH7L:\\"-TES7#''LZ@N7KM*&@I7U%;KK5$,+!ESWU, '[E!NJ_[N+/\ ,ZK_
M #0K]U-JVV:> ;62.DJ2,M@B&7$=IZ@/.H/U-=*@W2,674NHI6L8Y@JJB:/I
M,'&0S$8W0<#GQX#DOO36S"]:@F;55=WNL%(]V7SS2MWWCKW069)[SP6/'UM[
M?Y0V,_W,?_I__JS;ZBUS>+_*::CWZ6FD\D00$E[_ #D<3YAA9%BV:W:X1QS5
MKHZ&)Q!W9,F3';N]7F)"D'1.A+=I*2IDI*NNK99L#I*US'NC SP:6L;C.>/F
M"ZQ9=VNYG3^B++9XP6TS:J?KFJ&AYSW#D/0NF' <$10"+\<X-:7.(#0,DD\
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MM.4^N?W3)[\L'Y%E]8'LJ1].W&2[6:EKY:5U*9V[[8G.WB&GD2<#F./I5=M
MV!VHM24U(X$TS#TLY[&#F/3P'I5F6-#&AK0 T#  Y +I\/RYLT3?)/)YGC^E
MT>CFN'3UVMUGG,\O#K+]1$72><$1$!$1 6%>;K0V6VSW"ZU4=+1PC+Y9#P'4
M!WDG@ .)6:H:VV7%S=HVS2V51Q;);CT\C7?%?(US&LSYM[_F0=U3Z]LSKE1T
M-8VOMLU:<4KJ^DD@9.?Q6N<,;W]DX/<NK4<^$)00UVR>]OE $M(&5,+^MCVO
M'$=A()'I6_V87:>^[/M/W*L<75,](PRN/X3P,%WI(SZ4'3.<&-+G$-:!DDG
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M.\.X@JT^R[4\^K-(4UPKZ9U)<HWNIJR!S2TQS,.'#!XC/ X/+.$'6(B("(B
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MR<_;9#DC(X<  .'#(X<%T]';J*B<YU'1TU.YWQC%$UF?/@+*1 B(@(B("(B
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MY"^_,9_W;E4WP5OOJQ_,IOX5;+67W(7WYC/^[<JF^"M]]6/YE-_"B87*1$1
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B H>VR:O$A-BMLH+0<U3V'
M()ZF9[N9] [5U>U#5WN<M0IZ-[?LG5 B/_\ =MZW_P"@[_,HNV::0=JBY23U
MCG-M],X.D..,KL_$S].3_-<W69[6MZ/AZSU]3TG!]!BQXYXAJ^5*](\Y^>C>
M[)-$^.RLO5VA/BL9S3Q/;PE/XQ_LCJ[3YN,U+YAC9#$R*%C61L :UK1@- Y
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M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4->$D/\
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MVY:L=K;Q2*KEBI#;:BM9O1MC$0#PTG@T[V>/G4C0ZOT7(S[5?]/;G9XW"/\
M5$JN: V[ZHL%?$R^54EYM9($L<^#*T=9:_GGN=D>;FKA6FX4UVME)<*"42TE
M5$V:)X_":X9"X/5^I]F;K34B^5VGZV$L.8HW1S2.X?@AN3GO"]M@37LV2V#I
M&O:"V9T8?S$9F>69_NEJ"0$1$0(B("(B B(@(B("(B B(@(B(-/K+[D+[\QG
M_=N53?!6^^K'\RF_A5LM9?<A??F,_P"[<JF^"M]]6/YE-_"B87*1$1 B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B+$NU?#:[94UU4<0T\9D=CF<=0[SR43,1&\
MK5K-IBM>LHNVXZA ;!8J9_$XFJ<?\K?]?H6NV):>\;NDUWJ8\PTHW8<CG(>O
MT#]H7"7*LJ=0W^>JD:73U4N0P<<9X!H\PP%8_1]G%BT]24)W>E:W>E(ZWGB?
MY>A<G2T]*S3J+=(Z/5\2R_5FCIH,?WK1O;W_ +]/9#<HB+KO)"(B B(@(B("
M(B B(@(B("(B B(@(> R>2+SJ?\ =I?T#^Q$Q&\L7[+VW\HT?Z]O\USNT*Z4
M$NDJUD5=2O>718:V5I)^VL[U54\RBQ=X]UA^BM,62N3O9Y3$]/+WKF?9>V_E
M&C_7M_FO2"Y4,\HC@K*:60\FLE:XGT JEZVNEKY4:<OE-=*..*2>#>W6R@EI
MWFEO'!!ZT[Q@R?1.(I,TR;SX<O'XKBK\>]K&DO<&@<22<*L%?M3U;7@1LKQ!
MO'@*>)K2>[/$K!I]+ZPU/+TYH;C5N))$M2XM';P<\@*>WY-.OT9O2.UJ<M:1
M\^>RR-QUAIVW%[:R]4#'LSO,$S7.']T9*YVMVNZ3ISB.KJ*GAG[3 [Z/*PHO
MMVQC4M3O&J=148'(22[Q/^$%=';]A0\DW&]Y\GBV"#D?TB>(]";VGP3Z!P?#
M_>YYM/J_I$_JV5=MQM$;\45LK9VXYR.;'Q^DK3W#;I.X$6ZRQL\GXT\Q=@^8
M </2NCH=BNG8'DU-1<*D=372-:!] 6WH]E6D:9Y=]C739&,2S/<!Z,IM9'?<
M#Q=,=K?']X17-MJU*]F&06V,YYMB<?VN7":DO=7J&\37*X]'XS,&AW1MW6^2
MT-'#S!6JI]'Z<I]SH;%;06# )IVD_21DJN^V2F@I-H5RAI88X(6MBPR-H:T?
M:V]05;1,1SEU^"ZW1Y]1---A[$[3S]\<G%(B*CU#]C^.WSA789\4>94GC^.W
MSA789\4>99,?B\7]+O\ R?\ W?R?J(BRO&"(B B(@(B("(B B(@(B("(B B(
M@(B("(B N?KM%Z<KZN2IJ[/223R'>>_=P7'M..M= BM6UJ_=G8<O[W^E?R'2
M?0?YKCMJNSZVQZ5EK-/VV*"II7B601 Y?'@AP]' ^@J64(R,'B%EQZC)2T6W
MF4;*5HI]UEL>I;C4R5>GZAE#*\[SJ>0$Q$]Q'%OFP1YEQD>QK4KIMQTEO8S/
MQS,XC_+E=NFMPVC??93:4;QL=)(UD;2][B&M:T9))Z@K)Z2V;V2ET[0Q7BUT
M]1<.CWIWOR3O'CCGU9QZ%YZ"V7V_3=0RNK9?'[BWBQQ;B.(]K1UGO/T!2&N?
MK-9V_LXYY+1#E_>_TK^0Z3Z#_-9]GTM8[-4FHMELIJ><C=Z1C?* [ 3R6Y1:
M$Y;S&TS*VPB(J B(@YN;06D9I7RS:7L<DCW%SGNH(B7$\22=WFM_24\-'314
MU)#'!3PL$<<4;0UK&@8  '  #J7JB"/-F['7C5>K]43-.Y-5"V41</\ L(.!
M<WN<\N/H70;0=3^X_2]5>1;JBX]"YK>@@X$[QQDG!P!VX71H@P[-7?9.T45=
MT$M/XS R;H9AA\>\T'=<.T9PN(HF.OVV:NJWM)HM.4+:6$D<#4S^4]P/<P-:
M?.I#1 1$0$1$!$1 1$0$7G4S,IJ>6>4XCB87N('4!DJO^D/"(?>]<T=JJ;+'
M!;*ZH;302MD)E87.W6%W4<DC(&,9Z\<0[K;)LJHMH5'#/%,**]4S2V&H+<M>
MWGN/'/&>1'+)Y\E6RY;#=?452Z)EE%4P' EIZB,M=]+@1Z0%.&US;75Z$U<Z
MS4]F@K&"!DW2OG+#Y6>& #V+B_A/W#\V:3UIWLHF-V#L_P#!UO5;715&L7QV
MZ@80YU-%())I.[+<M:._)/<K4T5+!0T<%)21-AIH&-CCC:,!K0, #T!5AF\)
MZZ&)PATY1,D(\ESJAS@#YL#/TJ>ME5=47/9W8*ZNE=-55%*V21[CDN<>)0=4
MB(B!$1 1$0$1$!$1 1$0$1$!$1!I]9?<A??F,_[MRJ;X*WWU8_F4W\*MEK+[
MD+[\QG_=N53?!6^^K'\RF_A1,+E(B(@1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 44[<K\(J.GLD#O+F(FGQU-!\D>D\?0%*DLC8HWR2.#6,!<YQY #K57[_7S:
MDU355+ Y[ZJ;=B;U[N<-'T87/XCEFN.,=>MN3T'T>TM<F>=1D^[CC?W^'[NS
MV+:<%=<7W6I;F"D<.C!'!TG5]'/Z%-ZU.E+-'8;#2T$>-YC<R.'X3SS/_KJP
MMLMO!BC#CBD>#DZW56U>>V:WC/Y>'Y"(BRM41$0$1$!$1 1$0$1$!$1 1$0$
M1<YJW6=FTM!O7.I!G/Q::+#I7>C/ =YP$Z,F+#?-:*8XWF?)T:Y[5NK++IVD
ME%TKHV3%AW8&G>E=D'&&CCZ3P4(ZJVNWR[3.BL__ +,I2<-$?E2N\[NKT?25
MK]/;.=2:F?+6UC)*2$Y>^HK=[??Y@?*)[S@=ZIV]^CTF#Z/QAK&77Y(I'EX_
M/LW<)UHB+"]^+J]E=MI+MKJV45Q@;/2R&0OC<3AV(W$9QW@+E%V^Q;[Y-H_^
M;^Z>ICJT^(6FNERVK.TQ6?TE96AL]MH&,90T%)3M9\41Q-;CZ LY$6P^36M:
MT[VG<1$141$0%\NC8XY<QI/:0OI$'QT,7R;/\(3H8ODV?X0OM$3O+XZ&+Y-G
M^$+[1$1N(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B(/QS0YI:X M(P0>M1S8=C&C['JEM^H
M:.?QF.3I887R[T,+^UK<9X=62<*1U'.U+7U\T,TUD>E#=+, -ZLBK-TQGL>S
M<):,]>2/,>"#3:IV<Z8UKM0N)U!7NDK64,+H:&GGW'MC!(=(\8SC+F@<5]_!
MZT+_ %>X>M'^2AJFVX]#M/J]7_8#>Z>VBW^*^-_%P]KM_?W/[.,8Z^:ZWX40
M_-/_ /B'_P#+1/-U=RV$;.Z40Q5,M72253^A@<^MP7/() ;O#!/#DI+T#99M
M.Z.M-HJ7M?+10"%SF\G8ZU6S7'A!^Z?2UPLXTQ%#XW&8^FDJ^DZ,]3@W<'E#
MF#G@0%839+<*VZ;-].UMT<]U9+2-+WO^,_' ./>0 ?2@ZU$1$"(B B(@(B("
M(B B(@(B("(B#3ZR^Y"^_,9_W;E4WP5OOJQ_,IOX5;+67W(7WYC/^[<JF^"M
M]]6/YE-_"B87*1$1 B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B"/MLNH/L7I\6^G
M?BIK\L..;8A\;Z> ])7#;&K";EJ'Q^5N::B\O)ZWGXH_U]"U&T>[NOVL:IT)
MWXHG>+0 <<AI(R/.<GTJ<]#6)FGM.TU'N@3D=),>UYY_1R]"Y6'_ (G4VR3T
MKT>JU<_5O#*:>/OY.<^SYVCXM\B(NJ\J(B("(B B(@(B("(B B(@(B("QKC7
MTMMHY*JX5$5/31C+I)';H"T.M]:VO25+O5TG25CVET-*SX[^\_BC/6?1E5[O
ME_U%M#O,=.&23$N^TT< .Y'U9_FX_4%6UMG:X;P;+K/[6\]G''C/\OWZ.VU[
MMBFF?)1:4S%$,M=6O;Y3OT >0[SQ\RY71^SN^ZOE-=4.=34<CMY]74Y+I,\R
MT<W><X'>I,T)LBH+2Z*MOSVU]:W#FP@8BB=S_O\ IX=RE,# P.2K%9GG9T,W
M%]/H*=QPVO/QM/SS_3RARFD- V/2X$E%3F:LQQJ9\.?Z.IOH743M+X9&MYEI
M 7VBR1&SS>;/DSW[S+:9GUJQG9'J[)_V&#UEG\T]Z/5W]1@]99_-6<14[N'?
M_BG6>5?A/[JQ^]'J[^HP>LL_FNGV:;.M1V+6EON-RI(HZ6'I-]S9FN(S&X#@
M#VD*=42*1#%F^DFKS8[8K17:T3'2?'WB(BN\^(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+G[?K&R7#4539*6M8^N@'$?
M@O/6UIZR.L?R.(UVO;3>BZ>QZ<F^V<65-6P_%[6,/;VGT!0A33RTU1'/3R/B
MFC<'L>PX+2.1!6YBTLVKO;DY&IXI&*\4QQOMU_HNRBC;93M'BU+"RVW9[(KR
MQO \FU '6.QW:/2.Z25JWI-)VETL.:F:D7I/(1$5641$0$1$!:K4NH;5IFW>
M/WVMCHJ3?$8DDR07'.!P&>H_0MJM#J/2MLU)64,E\@96TM'O/CI)6[T1D.!O
MN'X1 R #P\H]V Y_WXM _G+2_JY/979VFXTEWMM/7VZ83T=0P212 $![3R/'
MBHLVPZ4TY1:390V?3MF@N]XJH;=221T48<QTCO*<"!D88''/4I5M=##;+;24
M%(W<IZ6)D,;>QK0 !] 09*Y9FO\ 33Z@1MN68C+T JN@D\6,F<;HGW>CSGA\
M;FN4\)74=1I[9G4,HI'1U%QF;1![3@M:X.<_'G:TC^\NFK=+4@V63::Z%@IV
MVPTP;CDX,X.\^\-[/:@ZY:R^WZUV&".6[UL-*V5VY&UQR^1WXK&CBX]P!48;
M)-H(CV&/OM[D=,^S-DIY'$^5*68Z,9[2',;GM6JV8:AL37^[+7]]MS-274GQ
M:&:48H:?)#&-;^!O#CD\P1WY";+77Q7*E\8IV5+(\XQ44\D#O\+P#COPLM?%
M/-%401S4\C)89&AS'L<'-<#R((YA?: B(@(B("^9HHYHGQ3,;)$]I:YCAD.!
MY@CK"^D00%6>#O::G7U5,75$6F:BF=*R.GE:Q\%1OM\CB#EA:7D=F,=F=I\&
M[1?]9O7K$?\ TU\[=-LDVB;A%9;!3T\]U+!+/+."YD+3\4  C+CSYX QSSPB
M ^$/KG/]+;1__B_^:)YIIH?![T-0U44\_P!D:EC7#[74U(W''/ '=:"<GJRI
M>@BC@ACA@8V.*-H8QC1@- X  =05)=2;;-7ZALU1;+A-1"FGQO&.G#7C!!!!
MSP.0.(XJV>RFXUUWV=:?KKL7.K9Z5KI'NYOZ@X]Y !]*#JD1$0(B("(B L"_
MW:EL5DKKK<'%M)1PNFD+1DX:,X ZR>0':5GJ'O".OMO@M5DT[=:YU%17>L::
MV9@+G,IHR'/P "<D[H' H,;X2.C/ZK>O5V?]1=1L]VLV+7=WFMUDI+FV6&$S
M223Q-:QK00.8<>))[%%>G=ENR'44S8;/JVX5$[OBPFKBCD=YFNB!/T*8MFVS
M:R;/F5PLCZN5]86F22J>U[L-S@#=:W XE$MKK75]FT9:#<;]5"&(G=C8T;TD
MKOQ6MZS]0Z\+D9=KM';1;Y]36"\V2V7 @4U;4L8YAR,C?#'%S.''!"@#P@+_
M "ZBVO/H'/+J*W2QT43,\ <CI#YRXD>9H4U>%5 Q^RHDM'VFMA<WN^,WAZ"@
ME^":.H@CF@D9+#(T/8]ARUS3Q!!',+[4(^"?J.6ZZ(K+352%\EJG#8R3Q$3P
M2T>AP?Z,*;D0(B(-/K+[D+[\QG_=N53?!6^^K'\RF_A5LM9?<A??F,_[MRJ;
MX*WWU8_F4W\*)A<I$1$"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+E]I5[-BTG5S1.
MW:F;[1">L.=S/H&3Z%U"@K;5?Q<;Y':X/Z&@R'G\:1V,_0,#SY6IK<W<X9GQ
MGE#J\%T?I>KK68^S'.?9'[SR86R"Q?9;4[:J9F]34.)G9Y%_X(^GCZ%8)<EL
MOL9L>E*=DS-RJJ?M\H(X@GD#YACTY76IHL/<X8CQGG)QG6>EZNUHGE'*/9'[
M]1$1;;E"(B B(@(B("(B B(@(B("CS:7M*I=+;U!0,;579S,XSY$&>1=VGKW
M?V+#VI;3*:R4\]LL<S9KN[+'R,P6TW;GM=W=77V&--FF@:O6-8^ON$CX[6R3
M[;*3E\[N9:T_M/>J3;PAZ3AO"L=<?IFOY8XZ1Y_/AY^QKM,::ONO[U+4.?)*
MPR#QJLE/!F3QQVG')H^I6-TCI.U:5H13VN##S_23OP9)/.>SN'!;.U6RBM-&
MVDME+%2T[>(9&W SVGM/>LM36NS4XGQC)K9[%/LXXZ1^_P \A$16<81$0$1$
M!$1 1$0$1$!$1 1%R]TUY8;7<)J*LFK6U$)W7AEOJ)&YQG@YK"#Z"@ZA%QOO
MEZ9^7N'_ (75?]-><&U'2M1&)(*RMEC)(WF6VI<,@X(R(^H@CT(.V1<;[Y>F
M?E[A_P"%U7_377PR-FACECSN/:'-R"#@]QXA!]HB("(B B(@(B("(B B(@(B
M("(B B(@(B("(B JUZGH]HKK_7E[;Z_,KMUU*9#%NY.-W=X8PK*(LN++W<]-
MVKJ=-Z1$1VIC;R57\2VA?):G_P#KKYDH=H'1NWX=3%F..>FQA6J19O2I_##3
M^JH_'*D1!!(/-%/6U[9F*T37S3T.*H9?4TK!_2]KVC\;M'7Y^<%TE+/5U4=-
M2POEJ)'!C(V#+G'L 6[CRUR5WAQ-1IKZ>_8M[O6_:%E2^LA;0-E=5%XZ(0YW
M][/#=QQSYEUWB6T+Y+4__P!=3+LJV=PZ6IFUUQ:R6\RMXGF( ?P6]_:?0.'.
M0UK9-5&^U8W=33\+M--[VF)GPA5?Q+:%\EJ?_P"NNQV4TNN8]74[KD+NRVAK
MO&/'B_<+<'& [KSCE^S*G=%AMJ>U$QV8;6/AL8[Q;MSR$1%K.F(B((LK=7[2
MHJR>.FV<QS0,D<V.3[*1#?:"<.QGAD8*DBSSU53::.>XTHI*V2%CYJ</#^B>
M0"YN\.!P<C*RT01W5_\ O#MII(!Y5'IFA-0_L\:J/):#YHP2/.I$7*Z$TY56
M1]]K+I+#-<KM<)*N1\1):V/@V./) /DM ])*]]H-KO=XTM546F+J+5<WEI94
MG(P <D9 )&1UA!&OA:44L^SZ@K(FES*.X,?)W-<Q[<_26CTJ6[I71-TW65[7
MCH!2/G#O[.X3GZ%B5&GV7;1HL6I)!7]-2-@JY0-WI7AHR\=AWAO#L*Y0Z.U/
M+I)ND9[Q0_8<1"E=7LC?XV^F'#H]T^0';ODE^3P_!R@@VAMU73^"G<9VM<(J
MJ[-G=PYQ!S&9\V^U6*TQIRRU^S*V6HT-,ZVU=NB#V,C #MZ,9?R^-DYSSSQ6
MW]S%I]RGN;\4;]A_%O%>@_L8QS[>O///%<SIS3FJM-V'[ 6ZY6VHH808Z.NJ
M6OZ>GC/)KHP-V0MY [S>0X(ES'@M35HT==[=5R.E@MUSDIX'GD!AI+1W9.?[
MRF9:/1>F:'26GZ>TVW?=''E[Y9#E\LCCESW'M)_DMXB!$1 1$0$1$$&UFGM)
M3;8-<W'78I'LBIJ2HIFUC\,$1BW7N SY6',QU\^]:'5M!H*EAMFM],6>VW?3
M$$AH;M30PD;@<06RAKL%KVG XXR' =ZD+;5LI@VATU-44M2RBO-*TLCF>TED
MC"<[C\<1@\01RR>!RO/9'LJ9I'1UVL]_F@N+[JX^,LC!Z(,W=T-&0"3Q)S@=
M79E$HNVGW;9?16&U731E+:)[M%5QS-I6P9;)'QWV3,<. QV\<XPK'Z6NU+?=
M.6VZ6\;M+5P,EC9^("/B^CEZ%66_>#7?H[V]ECN-!-:WORR2I>YDD;>QP#2"
M1VCGV!64T38(M+Z4MEE@E,S*.$1](1C?=S<<=622<(-TB(B!$1 1$0%!^V38
M[>]?ZH-T@O-%!3Q0-@@IY6/\D#)))':XGJ[%."YF\:]TO9;['9KK>Z2EN3P"
M(I"0!GEO.QNMSWD(*?:XV1:MT; ^LKJ-E301\75=$\R,9WN& YOG(QWJ9?!@
MVD5]\?4:8OM0^JGIX>GI*B0Y>6 @.8X]>,@@\\9[ K .$<T):X-DB>W!!XAP
M/[0J[[%]'1T.W+5]9;&;MEM;Y::(M^*)'N!Z,?H@.'=P1*$=4[\NUZ[=+G?=
M?)0[N_V@JSGA3?>GJ/G</[2H'VYV233FV6IJ'M+::MJ(Z^)_($.<"_Z'AWU*
M=/"I>!LJ>-X>76P@<>?QC_H@X#P."_[*ZG _H^@@)\^\_'^JL^H(\$:P24.D
M+G>)V%AN50UD61\:.,$;P[MYSA_=4[H2@N]>$;:+5>*^WR6*OD?25$E.Y[96
M .+'%N1]"POA.6;\W[C^M8NJNFP31ERN5775+;CT]5,^>3=J<#><XDX&.TK&
M^#OH?\2Y^M?_ )J')R%\\)"T7&R7"A98:]CZFGDA#C*S#2YI&3]*X/P5SC:M
M".VCF'U!2WJ+8%HN@T_<ZRG;<>FIZ665F]4Y&\UA(SP[0HE\%< [5HCV4<Q^
MH(+E(B(@1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&NU%=H+'9JJX5)\B%F0/QG<@WT
MG"@+9];I-2:X@?59D:)'5=0X]>#GCYW$#TKK=NUZ+I:.S0O\EH\8F [>(:/V
MGTA;W8G910Z<?<968GKGY:2.(C;P ])R?H7*S?\ $:JN+PKSEZK1?_C^%WU,
M_>R<H_/^L_!(B(BZKRHB(@(B("(B B(@(B(.3VH:AK-,:5DN-N;"ZH;*Q@$K
M2YN"3G@"%#OOTZG^2MGZEWM*2MO7WOY?G$7[2JTK%>9B7N/H]P_3:C23?+2)
MG>>ON29[].I_DK9^I=[2\:S;'J>II98!XC 9&EO211$/;GK!+C@J.45.U+O1
MPC11.\8H^"0=E.A?=A73U=QF<VW4SP)-UWERO/'=SU#M/T=HLE04=/;Z.*EH
MH604T3=UD;!@-"BGP</N?NWSIO\ D"EU9:1M#P_TAU67+J[8K3]FO2/<(B*[
M@B(B B(@(B("(B B(@(B("(B B+3:MU'1:8L\EPN#CN@[L<;?C2.ZFA36LVG
M:.HW*XW9!]PL'SVN_P#RR90SJ#:GJ2Z3O--5?8ZGSY,5.,$#O>>)/T>9:?3^
MM]06%C8[=<9&T[7N?T+P'L)<XN=P/:22<=9*Z$<-RS&\S"O:6P1<)LUV@T^K
M8W4M3&VFNL3=YT8/DR-ZW-S]8_:N[6CDQVQV[-HYK"(BH"(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("T=!I2S4&H*J]4M%&RX5 PYXY ]9:.HGK/7
M].=XBF)F.BLTK;:9CH(B*%A$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 51+A
MX1&LZ>OJ88XK1N1RN8W-.[. 2/QU;M1K8]B^CJ2WQMN=GIZ^O=E\]1(Y_EO)
M).!G '%! WPCM:_)6?U9WMI\([6OR5G]6=[:L1[T6@_S9HOI?_-/>BT'^;-%
M]+_YHGDKK+X1>MWQN:UMIC)& ]M,[([QEQ"LKL?FDJ-F6FYIWE\LE(U[W'F2
M>)*P9MCN@I8G,.FZ5H<,98][2/,0Y=#H6U1632-KME-4LJH:2$1,F8<AX!/%
M!O41$0(B("(B HCVI[$+9KB\OO$%QFMMRE:ULKA&)8Y-T8!+<@@X ' ]7)2X
MB")-%[*]0Z?HA;Y=H-T?:QP%-34[8RT=C7O+RP?HX4E6"RV_3]LCM]IIFT]*
MPD[H))<X\W.)XN<>LGB5L40<CM(T!9]?6AM'=VOCFA)=3U46.DA<>>.T'AD'
M]N"N4N.R>Z:CI[;;]9ZNENEFM[@Z.F@HVT[Y2!@&1X<23C(X#/$]?%2RB#'M
MU%36VAIZ*@@9!2P,$<43!AK&C@ %D(B B(@T^LON0OOS&?\ =N53?!6^^K'\
MRF_A5LM9?<A??F,_[MRJ;X*WWU8_F4W\*)A<I$1$"(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B L.\7"&U6NJKJ@_:H&%Y[^P>DX"S%%FW&^=#0T]GA=Y<Q$TN/Q1D-'I.3
MZ L>7)&.DWGP9]+I[:G-7#7K:=D72.KM5:E.Z#+6ULN .H9_8 /H 5G+=21T
M%!34D Q%!&V-OF PHBV%6,2U=7>IF\(?M$/Z1&7'T# _O%3*M'AV.>S.:W6S
MN?2'45[RNCQ?=QQM[_Z1_,1$72><$1$!$1 1$0$1$!$1!'>WK[W\OSB+]I5:
M597;V0-G\O'G4Q?M*K4L-^KZ)]%_^2G_ -4_R$1%1Z-/O@X?<_=OG3?\@4NJ
M(O!P^Y^[?.F_Y I=6>G1\NXY_P _E]O\H$1%9R1$1 1$0$1$!$1 1$0$1$!$
M1 5=]O=UEJ]8-M^\>@H86@-ZM]XWB?H+1Z%8A5HVV.I)==U$]%50U EBC,G1
M.#MQX&[NDCKPT?2M_AT1.7>?)6W1P2(B[RC9::NDMEOM#<8'$/IY6O..MOX0
M](R/2KA Y (Y%4\T[;);S?*&WP-+GU$K6<.H9XGT#)]"N&!@ #D%Q^)[=JOF
MO41$7*6$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%R.U"NO5JTQ)<M/
M3-9+2N#YFNC#]Z/D2,]G ^;*OCIV[16/%$SM&[KD58_?>U=_7*?U=G\D]][5
MW]<I_5V?R6]]5YO./GW,/?U6<15D&UW5Q.!60$_-F?R5AM*"Y^Y^B=?9!)<G
ML#YL,#0TGCNX'8."P9])?!$3>8YKTR1?HVJ(BU601$0$1$!$7XXAK2YQ :!D
MD]2#]1<3;]:U&I*^H@T9;XZZAIGF.:Z5,IBIB\<VQX:72$=HP.]=E3]+T$?C
M&YTVZ-_H\[N>O&>I!Z(BC_;!M(I]GUI@D93MK;E4O BIBXM 9GRGN(Y#J':3
MYT$@(M9?[W2V*QSW2OZ0PQ-!W(F[SY'$@-8T=;G.( ':5%-[VM:LT\UERU!L
M^JJ2P.> 9A5-?+&">!<T#R3W'''AE!-*+!L5VH[[9Z.Z6R42T=5&)8GXQD'M
M'4>HCM6<@(B("(B B(@J_P"$1M U3IS:(Z@L=ZJ:.C%)$_HHPW&\=[)XCN49
M>^]KS\YJWZ&?R5KM0W30-AU;65.HZZW1WFHAB:YM6T.+(V[V[N^3P!R<]JQ_
M=]LP_*EB_5#V42JM+M:UW+&YCM35X:X8.Z6M/T@9"M[L9<7;+-,.<27&B823
MUJ-=KNK-FUPTE426NOM[KY2XFMSZ*'$C9@>'$-QNGK!X8[\*4=E&H/=/L]LE
MV=#'#)/"6R,C;NM#V.+'8'4"6DX[T'6(B(@1$0$1$!$1 1$0$1$!$1 1$0:?
M67W(7WYC/^[<JF^"M]]6/YE-_"K9:R^Y"^_,9_W;E4WP5OOJQ_,IOX43"Y2(
MB($1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$'E65,-'2RU%3(V.&)I<]SN0 58-4W66]WZJ
MK)"XF60[K>>!U-] P%+.VN]BEME/:XSY<YZ63]$'R1Z3_E4?[*K,;QJ^F=(S
M>IZ3_:)21PR/BC_%CZ"N9Q"\W[.GKUM\_/L>F^C^*N&,FOR1RI'+V_/+WINT
M-9_L'I:@HG-Q,UF_+^F[B?HSCT+>HBZ-*Q2L5CI#SN7+;->V2W69W$1%9C$1
M$!$1 1$0$1$!?$\L<$,DT[VQQ1M+GO<<!H'$DE?:A7;UK(L:-.6V;#G /K',
M/(=4?^I]'>HF=HW;O#]%?79XPT]\^4>;C=INLZG6EZ90VYCW6Z&7<IHF ETS
MCPWR.T]0Z@>\J8-FV@Z*PZ=B9=**FGN4_P!LG=+&U^X>I@)Z@.SKRN9V%Z(%
M+3LU'<XQXQ*W_8V._ 8>!>>\]7=YU,2K6/&78XQKZ8JQH-)RI3K/G/SU];7?
M8*T_DN@]79_)/L%:?R70>KL_DMBBOL\]WV3\4_%X4E'2T;'-HZ:&G:XY(B8&
M GT+W1$4F9F=Y$1$0(B("(B B(@(B("(B B+3:FU-:M-4K9[O5-A#\]&P N>
M\CL _P#T*:UFT[1 W*XO5^TBQZ<=+ 936U[.!IX#G=/8YW)OUGN42ZUVI7;4
M!=26L/M]"XXW8W?;9.S><.7F'UK(T;LENMVD%1?B^W49&]@X,S_1^#YSQ[ET
M*:.N..WJ)V]2N_DU&H]<:DUC5^)P&9D$KL,HJ0'RNXXXN]/#N6^TML;N=<PS
M7V=MNC+3NQLP^0G'#/4!Z<^93)IK2UGTW#N6FBCB>6[KICY4CQWN/'T<ENU%
M]=V8[."-H-O-5S46SC4=EJ'M^Q\M; #Y,U(TR CM('$>D+76W1FH[C,(J:S5
MV2<;TD1C:/.YV K:(K1Q/)$;3$;G91_LPV>1:48ZMKWLGNTC=W>;\6%O6&]I
M/6?1YY 1%H9,ELENU;JM'(1$5 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%
MS-PUYIBWUDM+5WFF9/$[=>T;SMT]8) (RNF4)7?8A-47.IGHKS&R"60O:V6(
MES<G."0>/G6QIZ8KS/>VV4O-H^[#O_?)TC^6Z?\ P/\ Y+XGVAZ.GADAFO-,
M^*1I8]KF/(<#P(/!1O[Q5=^6Z;]2[^:>\57?ENF_4N_FMON='_F3\^YC[63R
M1;J&FHZ2]5D-LJ6U5"V0]!*W/E,/$<^L#@>\+7*3-6;(KC8+%4W-M?#6-IP'
M/C9&6NW<\3Z.?FRHT +B  23P "[.'+3)7>D[[-:U9K/-U.S1MH;JNFJM0U<
M5-0TOV[$@)Z1X^*W@#U\?1WJPGODZ1_+=/\ X'_R46T&Q"YU%%!-/=*>GED8
M'.B,3B6$CXI.>87O[Q5=^6Z;]2[^:YNHG2Y[;VOT^?)FIWE(VB$E^^3I'\MT
M_P#@?_);"R:PL%[J_%;5=*>HJ,%PC&6N('/ (&?0HD]XJN_+=-^I=_-=#H39
M))I[4=-=:RZ,J/%\F..*,MRX@CB2>7'DM7)ATD5F:WG?Y]3)%LF_.$L(B+GL
MPB(@*&_"8U'64&G+9IVTND;6W^H\7)B!+S$,!S0!QRXN:.\9'6ME6[.-5SUD
M\T6TR\01R2.>V)M."& G(:/+ZN2YG;;:ZBR5^S2^U]3)6TUFK(H*ZK>W!/E1
MGI'#CC.X[TD(EOY]8OV:6*U4U;HZNHM,0AE,*QM1%))&?QI(VDX).23O<SV\
M%*5#5P5]%3UE'*V:FGC;+%(TY#VN&01YPN/VU^+2;)]3>-%AA-&2PGD7Y!9C
M^]NX7YLS:-+;*+ -15$5%XO2,,SZEXC$6\<AKB>1&\!CM1#J-07>EL5HJ;C7
M.<(86YW6#+GN)PUC1UN<2 !UDA01MVL]53[+Y[Q>VM^SMRN%.^=H.13Q@/W(
M&GL:"<GK<7'K4G;1-,7C53K%5:;U%#;!0R.J6N=3-J62N+0&/ /D\ 78/'XV
M1R4/[>;#K:W:&;/J764-XH?&XFBF;;HH#OD.P[>:,\./#O1,+(/I(*J*E-1&
MV3H7-ECWOP7@'!]&5S6URJIJ79MJ(UC!(V:C?3QQXR7RO&XQH'6=XM7MI*&[
M6#3E3+K34,%S?&XS&K-.RF;%$&CR2&\.&''/>M1;ZRAU5=*:^76KIH;52.Z2
MV4<TK6N<[EXS*TG@<9W&GXH.3Q.&D-ELFT_4:8V>6.TUO^]00[TK<YW7O<7E
MOH+L>A=:L"TW>@O#:E]LJHZJ.GE,#Y(CO,WP 2 [D<;PSCKX<P5GH"(B B(@
M(B(*U[:=FFHM=[4*V:QPP"GIJ.!KY:B3<;O'>X#@23P7'?!TUO\ C6GUD^RK
M+Z\VBZ<T.(FWZM+*B8;T=/"PR2.;VX'(<.9PN#=X2.C <"EO3AV^+Q_]1$HP
MM?@V:KGJHVW"OM5+3Y\M[)'R. [F[H!/I"M'I.PT>F-.4%FMH=XK1Q]&TNYN
M.<EQ[R23Z5%$GA)Z/;&XQT-Z>\#@WH8QD^?I%)V@+U/J+1EHN]4QC)ZR 3.:
MSD,]00;]$1$"(B B(@(B("(B B(@(B("(B#3ZR^Y"^_,9_W;E4WP5OOJQ_,I
MOX5;+67W(7WYC/\ NW*IO@K??5C^93?PHF%RD1$0(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M+YFD9#$^65P;&QI<YQY #F5]+@=K>H&4%G-LA<1558\K'X,>>/TXQ]*"(=:W
MJ2^7NHJY"</=Y#?Q6#@T?1]:F'8S:?L?I)M3(W$U<\S$XX[@X-'U$^E0E8K;
M+?;]2T$&=ZHD#<_BMYD^@ E6CI8(Z6EAIX&AL43!&QHZ@!@!<K2?V^HOG\(Y
M1\_/5ZGBO_ Z#%H8^]/.WS[?T>J(BZKRPB(@(B("(B B(@(BQKG7TMKH)ZVO
MF;#30M+GO<> '\^Y$UK-IVCJY;:IJT:4TV^2![?LC4YBIFGC@];\=@'UD*%M
MENBYM97F6MN+WFVP2;U1(XDNF>>.YGOYD]A[U@7NX7+:-KAK:<.+JB3HJ:)Q
MX0QC//T9)/G5D])V&FTW8:6V4?%D3?*?C!D>?C./G*QQ]J?4]=EM]1Z*,5)_
MMLG7U1_3I'KWEMHV-C8UD;0UC0 &@8 '8OU$61Y 1$0$1$!$1 1$0$1$!$1
M1$0%^/>V-CGO<&L:,EQ.  M/JC4MLTU0FINM0(\_$B;Q?(>QK?\ 7DJ^ZVUU
M=M:5C**ECD@HG.#8Z.(EQE.>!=CXQ[N0^M;6GTM\W/I'FB9V2!K?:_343YZ+
M3D;:J<#=\;<?M;7?V1^%Y^ \ZC/3^FK_ *\NTU0"]^^[>FK)\A@X\>/6>/Q1
M]2D'06R!L9%9JP-D.,LHV/.!^FX?L'TJ8**DIZ&ECIJ."."GC&&1QM#6M'<
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M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!>-;4Q4=)-4U#MV&%A>\]@
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MN;(XF045),W,4#1Q<XMY.<YQ/$]0""(Z7PGX'5X;5:8D91$XWXZP.D [=TM
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MUEN%S<V>-5FK6=NS'KZO1:30VX7H\F6(F;VY<HYQ'GMO[_@LHUH:T-: &@8
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M*T#G@SO?&\^B1O'^T.Q<:NWT=#>655ZN-+037:T5D71W6E8X=+(>.)(L_&D
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MHVG[4[M;[2Z!ENL4<$(-3*6,:Z2,2$@ $DG//')H4R[(M&2:%T7!9ZBK;55
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MO $@9)QC(&<[;:"=2-TM4G13:=UZRWHA/C&[GRL;W#..W@@Z-0VW_P#:F?\
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M7>KJ64CX !/3N=E[7]0:/PL]6/\ 0J#]<ZPN>O;Q3P0P/93A^Y2T<9+BYQ/
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M'3][(R3]9(^I;FSDIL6/65U+1,WZRI@IV=LL@:/K4!S:@U-> \-JZ^9I/%L
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MGM711'=UZ^)'-'^CMDEJL\C:F[O%SJA@M:]F[$P_H_A>GAW*26M#6AK0 T<
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MULF*6Y?;J;)X-G:.(_O-'TM':LU<,S2;J[\]EM$1%A6$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$'S(7"-QC:'/ ):TG&3V95=ZSPF/$ZN>EJM(S1SP/='(QU<,M<#@@_:
M^T*Q2KMM'V/4]_VSTSW5#Z*V7B"2HE?$T%W3Q@!S6YX N!:[C_:0AX?"AA_-
M63UX?]-/A0P_FK)Z\/\ IK<CP9M,8XWB]9_2B]A?OP9M,?EB]?XHO81/)H*K
MPH":>04FEMV<@ACI*W+0>HD!@SYLA3/LBJ)*K9KIVHG.]+-2MD>>TDDG]JC"
ML\&2PN@D%'?+I'-NG<,HC>T'JR T$CTJ4-DE-)1[-]/TLV.E@I1$_':TD']B
M#K41$0(B("(B B(@(B(*$:JB=%M@NT<WQA?)<YZ_MYXJS7A3?>HJ/G</[2H?
M\)+2\^G=I$>H(XG?8VY/9,) .#9FXWVGO. [OR>PJ4_"GKZ9VRFGW)6N\;K(
M3#@YWQNN=D=V/VA$N+\#B)YN>J)1GHVPP-/G+GD?L*L\HB\&32<^G-!.K*^)
MT59=914;CAAS8@,,!\_E._O!2ZB%4-3^$#K"V:ENU!30V@P4M7+!&7T[R=UK
MRT9\OG@+6?"/UK\A9O5G^VK2S:/TS/-)-/IVS22R.+WO?0Q%SG$Y))+>)7Q[
MB=*_FS9/4(O91*K%5X0&L+K2S6^HCL[(:MA@>X4[QNM>"TGX_85LM VV/1-Z
M9=K3(^2L;$Z(F;#F$.QG@,=G:K!:HT=I:#35WE;INS,,=),X.90Q!PPQQR#N
M\"JY:;ECO<\5#82:J<1[S8(<EP:.[GP6MJ-3.#;:LSNZ?#N'5UO:WR13;S\4
MJ>^A?ODZ']4[VEP =6LLEON?CTA=<'3R3-;)@LE$SPX$ \.HC//*V'N0U)^1
M[A^K*YR?<IJF6*;=CGC<62-=P(<#@@^E<S5:J<].SW<Q+U'!^#QI<TY*YHM&
MW.(_W9?C]9_6ZC]8?YIX_6?UNH_6'^:QAQ'!"<#)Y+D[R]/V*^3:;M5-IV[W
M.2ND!MXA?"QTI)?,96AH SQ XD^A=T=I]^)^+1#_ .4?:484P;5U4,%.!+42
MO#(V-XN<XG  [\KHO<AJ3\CW#]65UM+JIP4[/=S+S'&.#QJLW>6S17ERB?\
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M$6'3SA9;A!77B.1@+GS"4D9X^2/)^I1W>KE)<GPNG?&71,Z-HCB;& W).,-
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M6+SS_N9%=U"94\^#CK7Y:S^LO]A/@XZU^6L_K+_85PT0W4\^#CK7Y:S^LO\
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M$!$1 1$0$1$!$1!I]9?<A??F,_[MRJ;X*WWU8_F4W\*M_>*(7*T5U"9.C%5
M^'?QG=WFD9QU\U%.RW8C'H/5+;TR_/KB(7P]":01_&QQSOGL[$2F%$1$"(B
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M[A^IQ5]$)$1$0(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=Z2MJN1V9:\MNO[!]D;:UT,T3NCJ*9YRZ%^,\^L'J/7YP0NN1 B(@(B("(B
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M>X%=>JP::\'F^VW7M'55%PH_L-1U3:AL['GI9&M=O ;N.#C@ \<#O5GT!$1
M105J_:C'=MK.F-+:>J=^BAN,9KJB)WDS/!_HP1S:.OM/FXSJ@(B("(2 "2<
M=:@JOVH,U)MNTUIW3]27VBDJ)#431N\FIE$3^ [6-^@GCU H)QJ)XJ:GEGJ)
M&10Q-+WR/.&M:!DDGJ "YC2FT/2VJ[A/0V"[PU57""YT6XYA+1P);O ;P\V5
MLM9V3W2:4NUFZ<P&MIWPB4#.Z2.!QUC/,=BA'8ML3OND]<Q7N^U5&V&C;(V)
ME-(7F9SFEN3D##<$GMSC@@L.B(@(B("(L:YLK)*&5EMF@@JR &23QF1C>/$E
MH<TGAGK"#TJZF"CII*BKGB@@C&\^25X:UH[23P"U^F]16G4M)-56*MCK::&8
MP/EC!W=\ $@$CCP(XC@JJ>$Q:[_:+U;A>=2U-XIJR-TD<;V"%D3FD @1M.[U
MCCS[>TRKX)/WM*S_ +RE_=QHG9-:(N7VBZMBTAI]U6(C57&=W04-(WBZHF/)
MH'8.9/9Z$0]Z_6FGZ#5%)IVJN4;;S5 &*F#'.)SG&2!AO(\R%T*HYLINM9>]
MMUCN5SG=/655=TDLCNLD'Z!U =05XT2+1ZAU;8-.30Q7V[TE!),TNC;/)NEP
M' D+>*K/AB?=%IWYK)_G1$+"6O6^FKJ)3;;U1U0BC=*\Q/WMUK>9]"P#M0T0
MTD.U1:P1P(,P63LM@CI]F^F(X6-8S[&T[L-&.)C!)]))*IUMVA9#M;U,R)H:
MTU =@#'$L:3]9*)A>J":.H@CFA>'Q2-#V.;R<",@A?:U>E/N7L_S.'_(%M$0
M(B("(B OB>5D$,DTKMV.-I>YW8 ,DK[1!R-1M*T;32NBJ-26Z*5O-CY=TCT%
M9^G]9:<U#5OI;'>J*NJ&,Z1T<,H<X-R!G'9DCZ5$?A#:2;JK6-@HJ6,"X36V
MM?&YHXO?$&O8T^<DC^\J][,-3R:.UU:[L2X0Q2]'4M[8G>2\8[AQ'> B=E_U
MCW"MIK=13UE=/'3TL##)++(<-8T<R2O:*1DT3)(G!\;P'-<#D$'D0HSVRO??
M)[+HJF<X&Z2&IKBT\64D/E.SV;S@T#THAO/?1T1^=%J_7A;6BU=8:ZAGK:.Z
M4\U) T/DF826M!. <^=?SZHV-?6PL<,M=(T$=V5_2"&-D,3(HF-9&QH:UK1@
M- Y !$N1?M.T5&\LDU-;&N' @S $+L 00".15-O"IBCCVJ/=&QK3)10N>0/C
M'RAD^@#Z%<>'^B9^B$0^D1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 7-[2KM+8M W^Y4[BV>GHY#$X?@O((:?02
M"ND7/;0[/)?]#7VU0#,]522,B':_&6_6 @H7I>E9<-36FDFXLJ*R&)^>L.>
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M&#Q+6N));DC'($XX'FH4VQT=3;]I-\IJZOEN-5'(SI:J5H:Z5QC:2<#@!QP
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MAD_[[I7_ (=3^V-=AX)/WM*S_O*7]W&N/\,G_?=*_P##J?VQKL/!)^]I6?\
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M64TVZ=R9AD+P [EGJ(ZBK46':&RYV^>_5E!46?34<0#):^/=GJ)3Q\AC2?)
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MV.'>#P*(@TON)TK^;-D]0B]E= !@8')$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
/1$0$1$!$1 1$0$1$'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g762905g38i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g38i22.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[1\(4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !D     $  0&0
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             %2@  ",D          0
M                   !              C)   %2@
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   %2@    !29VAT;&]N9P
M",D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !4H     4F=H=&QO;F<   C)     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !@ * # 2(  A$! Q$!_]T !  *_\0!/P
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M8Z1=U#*R7/?E7.IH]ME5N**0YQW-]EL_X)[?TFQ'ZS;DU>D:'WL,/GT*#?\
MN?3:#_VWO_[XJV!TOZP4=1JOR^I?:,=C'BQFP-W3&UFWZ/\ PGK?39L]+_#6
M*QURCJ%E3+L3/;T^J@/=D/<T.!; ASB[Z'I[7I:7T2+/0^32%O5VBNHY.6Y[
MPVP6#$K@-VNLV6MW?SCMS:_W_4J5_HUN7:VYV4^YY! :+Z!1 C78UI=ZGN65
M9@]?J]7U.OL9Z#!9;-;1M8=VVQ_[K/T=BT>C=/ZQBY.19U#-^UUV!HK;MCW
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MY1-2%4?\)M=?ZI?U;ZD8V=D,8RQ^6&EK)VPQUM;?IESOHM1/\6?\YU/X8_\
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M4,1]V&[;8QN-=+?S'>IOR6,_G6O_ )M[U<>WK-5;[;<S&#*PYQ(QK##1[O\
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M6/12Y[JJVL-AEY:(F$5)3__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      $N34T *@
M  @ !P$2  ,    !  $   $:  4    !    8@$;  4    !    :@$H  ,
M   !  (   $Q  (    >    <@$R  (    4    D(=I  0    !    I
M -    &0     0   9     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C R-#HP.#HP,2 P,SHS-CHU,P   Z !  ,    !__\  * "  0    !
M   (R: #  0    !   %2@         & 0,  P    $ !@   1H !0    $
M  $> 1L !0    $   $F 2@  P    $  @   @$ !     $   $N @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 39%>&EF  !-30 J    "  ' 1(  P    $  0   1H !0    $   !B
M 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0
M  "0AVD !     $   "D    T    9     !   !D     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T.C X.C Q(# S.C,V.C4S   #H $
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MABZ=[F[J)'*UJO3_ (7?)-NT5%3*<4-.)PQCF)KVE6EN;N  YEP
M
M
M
M
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MB@EMM4Q%W8)'*Y)$7@["M3JRG/L+7RX\N'EB-3'8BLQ;:W@ <+0
M
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MA5ERKTIIND;E=W'5V*4WKRETQI2U.N6D]>7&34<#FN8Q]9TR3+GBBM1N$]/
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M<]=(VO4 &"P
M
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MU=VN^VC4EXNUGK+8RIH(^ABJ&*BM8BM1J*N,95$SCO+O G+O?3K)H !DD
M
M
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M(T=[%%7EE4X\#+FO^A;=J;U\-5-]6Z3IX%IGUSTI>%1'NHJ,:F?)5$X9])L
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M8PI.
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M.\EEMH:>VT45+11-B@C3#6I_\XJ0%MH:>VT<=+11)%#&F$1.OO5>M5[3T@
M
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M/GR<F>*+W*>O2.I:34EN2HIEW)F\)857RF+\W>3J=;1N-Z9P $)
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M1[<]%I6VFLM%PI(JB.>EJ4XIECE1S7?;-7CQ[B_Q>G+H@ !1(
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MQ>+?M7IUM7N-@-(ZEI-26Y)Z949.U$2:!5\IB_-WF-Z<O6&M+\W26= !FT
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M^Q5MSJ;I2ND>Z>IF21TZN;N^6JIG@BKC&.98A2\Q.HCZ$  ,T@
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M$1.T1&G( $@     $)VP_65-^7C^438A.V'ZRIOR\?RBU/-"MO+*B  =3E
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MQ.W"X53V.)RQCQS:7D\-BG+DB(;*VB%]/::*&9<R1PL8[SHU$4]8!\L^G
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MVG8.$$L<\+)8'MDB>U'->U<HY%Y*BG,S2
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M5]KHZQJ82HA9*B=F\U%_B>H\MJI$H;91TC5RVGA9$B_BM1/X'J.:5@ $
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ME*;1FEZ6S4DKIDBRZ25R861Z\W8ZO,2,Y[:W.EX  5
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M;!$D<?!J<D(KOZEN7_B[#YS/I\1,%U!$P?0
M           83.<)GED                                     5$7&
M41<<0                   (1M0UB_3-!!#0=&ZY5*KN(],HQB<W*GN(G_L
M&W#\/?B<D8L<=93<$%V9:OFU!!-2W-8_'HO+:YB;J/9VX[44G1,QI;BN&R<+
MEG%D[P  AS@,5JF]0:?L=5<:E45(F^0SV[UX-;Z5P5QH7:/<*^]M@O2T_BU2
MNZQ6,W>C<J\$SGEU$Q&W=P_P[/Q.*V;''2O_ +HMP $.$ .,CVQQN?(Y&L:F
M55>2(!R!2T^U2X2ZC>^B;"MH9)NMC5B[TC,\79ZE5.*%QT55%6TD-33N1\,K
M$>U4ZT4G73;NXOX=GX.M;98\W_M2[@ 0X1$1%541,KS4          %1%145
M,HO!4-2]JNFG:8UE60,:J456Y:FF7N<N7-]"K[BH;:$.VI:.9K#3CZ>/=9<:
M=5EI9%]MCV*K[5W)3IX7/X.2+?1S<5A\;'-?JU?TY>JG3U[I;I1)O2P+Y4:\
MI&+P<U?.GQFT-GN5'>K5!7T$C9J2I9E,]_-KD[>I4-4:FGFI*F6GJXG0U$3E
M9)&].+')U*2;9]K.ITC7O16.GM<[LU%.B\6K[=G^+M3K/2XWAO&KXN/N\[@>
M)\&9Q9.RV;I:K7L[LUXO]AM:RUK^2.<KFQ(Y>KK:Q%XK@U^N];77.HJ*ZIJ%
MGKZA=YTS^OS=B8Y(;86>Z4-ZMT=9;*F.JI96\TZO\+DZE[E(%JS9-;KE))4V
M*9+74N7*Q;F] Y?Q4XM]!Q<+GIBM/B1U]7=Q6"^2L>'/3OKU:].=&R%K&M=#
M-&N^UK_MEZ^/7DR%-.]CX*FEE?%*Q4DBD8N',=U*A+;ILTU52*K%M*5L7MZ>
M5KT=W[J\4/)0[/M4.1(J?3]3&U%_\QS6-3TJIZ=>(P_6T:EYM\&:>U9YH61I
M6_T^OJ6*GK9&T.K*-BK'.QODSLZ^'6G'BWJ7BA(Z32M?4S-2]U%)XFU<NAI-
M_,V.IRNY-[DXF"V;;-JFQ76&\7JIC6KB:Y(J:!<HQ7)A5<[KX=2$YU/?Z#35
MIDN%SDW6-X1QI[.5_4UJ=O[#Q,T4Y]8^L/9PS;D_U.[YJ.^6[2]F=77%R14\
M:;D44:>5(['!C$_^(AK=JO4=?JB[.KKDJ-1ODP0-7R(6=B=J]JC5FHZ_5-W=
M7W%=U$RV"G:N60-[$[UX97K,[LRT!5:TK^DDWZ>RPKB:I3G(OM&=_:O4>G@P
M4X6GBY>[S,^>_%7\+%V?-F.@JK6EP6217P66!^*B=."R+_NV=_:O5DVEM5NI
M;5;X*&WP,@I8&HR.-J<$1!:[?2VJWP45O@93TL#49'&Q,(B(>H\WB.(MGMS6
M>C@P5P5Y:@ ,&X     QFI+!;=26J6VWJE954<F%5CLHJ*G)45.*+WH0RT;&
MM)6ZNBJG05E8L+D=#'5U+Y(XU3EAO+W<EC M%[1&HD$3"83D "H
M
M
M
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M #!N
M
M
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M=I$1'8 !"0
M
M
M
M            !@       8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      .'31?[
MQGZR";^A?^*IIGL\T[=M<WVJM]+>IJ1\3%EWI'O<BIG&."G1AP1DB;3.HA6U
MM=&YK9&.7#7M5>Y3D:K:UV<:JT+9EO<6I))HX7M1_12R1O;E>"IQX\2\-BVI
MJS5>@Z6ON?&L9(^"23&.DW5]E[BIZ4&3!%:<];;@BVYU*<@ YU@
M
M
M               ^.<UC5<Y4:U.:JN Y4:U7.5$1$RJJ:O:CU%J':SKF2Q:=
MJWTUHC<Y&HCE8Q8VKQD?CBN>I#;#AG+,]=1'=6UM-G(JNGF<K8JB%[DZFO15
M.XUAU5L9OFD+/+>[)?)*F:E3I96Q-="]&IQ5S515SCL+:V'ZHNVI-+.^B"FJ
M&5U*_<Z>2)6).Q4RCDX<5ZE\V>LODP1%.>EMPB+==3"Q  <RX
M
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M*R:"5J/9)&[>:YJ\E14YH=H
M
M                  >"_P#2>H=PZ'^E\7DW?/NJ:[>"BK/HEOJ.QTBTC-W/
M/V?'^!LNYJ.:K7(BHJ85%ZS6+5&E-2;+=:OU!I6F?56M[W.:C&*]K&N5<QR-
M3CA.I?,=G#3%J7Q[ZSV9VZ3$MF:N>&EI9IZI[8Z>)BOD>[DUJ)E57NP=5MKJ
M.X4S9[=4PU$#N3XG(Y/B-9-5;4]6:VM;K%;;&^G\93<F\78][Y$ZV]R+UEP;
M#]#3:+TQ(VXX]4ZQ_2S-1<I&F,-9GK[?.I3)P_A4W>>OHF+;GHL4 ',N
M
M     /CW(QCG+R1,E>T.U:VU;Z61EIO#;;/5)1>/NA;T+)E?N(U5WL^RX91%
M0L&9%="]J<U:J(53#I.\LV7VFTK1_P"WP7:.IDB21O"-*I9%=G./8\0,_P"N
M10NNCH8K5=I;8RJ\3?=&1-=3ME1=U47RM[".\G.[C).2C[MI._R:CFFL]@FM
M5W=6;_JO0US8Z26/>RKI85=ESMWR53'%>.2\$SA,\5
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M#?7.$1.;@-Q0
M
M     !Q;&QBJK&-:J]B8.0
M    QVHDNJV:J^A]:1+IN_4/&L]%O?XL<3(@"J]W;)[?1W^M\PW=LGM]'?ZW
MS%J "J]W;)[?1W^M\PW=LGM]'?ZWS%J "J]W;)[?1W^M\PW=LGM]'?ZWS%J
M"J]W;)[?1W^M\PW=LGM]'?ZWS%J "J]W;)[?1W^M\PW=LGM]'?ZWS%J "J]W
M;)[?1W^M\PW=LGM]'?ZWS%J "J]W;)[?1W^M\PW=LGM]'?ZWS%J "J]W;)[?
M1W^M\PW=LGM]'?ZWS%J "J]W;)[?1W^M\PW=LGM]&_ZWS%J''I&=(L>^W?1,
M[N>./,!5N[MD]OH[_6^8;NV3V^CO];YB4ZDU[9M/W"2CJ_')I8(TFJ5I:=TK
M::-5PCI%3V*+[I(DKJ5;=X^D\:T71=-TR+Y.YC.]GLQQ K3=VR>WT=_K?,-W
M;)[?1W^M\Q*-.Z^LM^ND=!2>.133QNFI75-.Z)E5&G-\2K[).7NH>&T;4+'=
M[K%0T%/=I723.@;.E$_H5<BJU5W^6,HO$#"[NV3V^CO];YAN[9/;Z._UOF+4
M %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[
MNV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V
M^CO];YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V^C?]
M;YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN
M[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;
MZ._UOF+4 %5[NV3V^CO];YAN[9/;Z._UOF+4 %5[NV3V^CO];YAN[9/;Z._U
MOF+4 %5[NV3V^CO];YB3:'36R3U7T:NLBP[J=!ZG;^=[/'>WNHEP
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MY<YW>JJJF;  &K=W_ODM_*4__2M-I#5N[_WR6_E*?_I6@;2
M
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MGL6JN5:WVJ*O4F$.JVZ%TU;+NESH;130UC7*YCT;PC5>:L;R:JY7BB)S DH
M
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M_P"E:!M(
M
M               #XYR,:KG+AJ)E5-5] Z?T3K"74^J-H%5%"ZNN\R4B2UKH
M$Z-%3BB(Y,^R3W#:"YQ,FMU5%+-T#)(W,=+E$W$5,9X\"K=';#-!6^U.9+1Q
MW[I'*J554])%1/:MW<(B 2+9SH+2&F7RW31\:JE7$D:S)5/F:]N<\,JJ%7Z#
MT_0;9=6:HU)JULU9:Z.J6@M]$LCF1L:U$57>2J<>/QJ>S9C2?0+MZOVC+3-(
MZP55&E=%3O=O= _@N$[$XJGFP>[P2E:S1%[IE7ZM!>)VR-ZT7#< >73=*FR_
M;A2:6M4L_P!#>H*5T\5-+(KTIYF;WL57DB[N/27R49M2:M1X1&S:"'C+''+*
MY.QJ;WS*7F!0VL($VE;<TTA<)YDTW9*-*JJIHWJU*F5<8153CA-]/<4\&T'3
M5#L>O^FM3Z+;-144U:VBN-'TKGQ2QO7&]ARKA4X_$9C0#4IO"8U]%+E)9J2*
M9B+UMPP[_"N>B[/Z&G3C-47&&.-O:[('3MKKZC4VM=):"HZJ6"WW-5JK@Z%V
MZ]\*<FYZD5,_$8S:QLSM&@=)R:NT$V:T7:SN9,JQS/<V:/>1KFN1RJB\\^@]
M-U8ZA\(W1+JMNXDMH6%BKUO1,*A.MOLK(=CVJ7R)EOBN,=ZO:B 0_;1K:KK-
MGNE:2QROIZK5TD,#9HUPZ.-^ZK\?K(GNG7K#8;IRUZ(JZS3K*JCU!;J=:F*O
MCJ'](^1C5<N]QQQ5")7^-U'8M@$U6BMCCJ&(]5ZMY(MTV+U9(R'2UYDD5$8R
MCF<Y5[$8X# ;&]52:RV=VB\5./&Y&+'/CV[55JKZ<9])-"H?!4B?'L>M[WIP
MEJ)WM\V^J?P4P.TO9%K/4NL[A=;-J>.AH9U;T<"RRINX:B+P;P OP&K?K"[0
M_P -(O?Y_G/-X/#[S0;;+G9+I=9ZWQ.EFCDWYGN8YR.8F41R@;6@       &
M,U+9XK_9*NV5$]33Q5#-Q9::58Y&]Z.3D9, 5'ZQ5H_"35?_ #-X]8JT?A+J
MO_F;RW !4?K%6C\)=5_\S>/6*M'X2ZK_ .9O+< %1^L5:/PDU7_S-X]8JT?A
M+JO_ )F\MP 5'ZQ5H_"35?\ S-X]8JT?A+JO_F;RW !4?K%6C\)-5_\ ,WCU
MBK1^$NJ_^9O+;5S4YN1,=Y] J/UBK1^$FJ_^9O'K%6C\)=5_\S>6O555/21]
M)53Q0QY1-Z1Z-3*\DRICM3Z@H=.6SQVY.?N.D;#&R-BO?+([@UC6IQ55 KGU
MBK1^$NJ_^9O'K%6C\)-5_P#,WD]TMJFCU#)64\4-325]&Y&STE4S<D8BIEKL
M=:*G6G \.HM>6VRW"HHUIZZMEI(TFK/$X5D2EC7.'/7S(JX3*X3. (AZQ5H_
M"75?_,WCUBK1^$NJ_P#F;R87?7ELHGTD5%%5W6HJ:?QQD-!$LKDAX8>O4B+G
MAUKU'"JV@V9E!:ZBA\9N,MS:Y]+34D2ND>C?9*J?:[O)<XX\ (EZQ5H_"75?
M_,WCUBK1^$NJ_P#F;R=6W65EKM-2WWQMM/0P[R3K4)T;H7M]DQS5XHY%X8/;
MI6_4>I[!27BV*]:.J:KHE>W=54153./0!7'K%6C\)-5_\S>/6*M'X2:K_P"9
MO+< %1^L5:/PEU7_ ,S>/6*M'X2ZK_YF\MP 5'ZQ5H_"35?_ #-X]8JT?A+J
MO_F;RW !4?K%6C\)=5_\S>/6*M'X2ZK_ .9O+< %1^L5:/PDU7_S-X]8JT?A
M+JO_ )F\MP 5'ZQ5H_"75?\ S-X]8JT?A+JO_F;RW !4?K%6C\)=5_\ ,WCU
MBK1^$FJ_^9O+< %1^L5:/PEU7_S-X]8JT?A+JO\ YF\MP 5'ZQ5H_"75?_,W
MCUBK1^$FJ_\ F;RW !4?K%6C\)=5_P#,WCUBK1^$NJ_^9O+< $'T+LWH='W.
M:MI+M>ZU\L71*RNK'2L1,HN41>OAS)P
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MIK^L7S](/^0PS8
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MH\=I?NF'WQ!X[2_=,/OB =X.CQVE^Z8??$.4=1!*[=BFC>[L:Y%4#M
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M\_XH;H&G\-^OVW+:I8YJ2WK16RV/:]58JO; U'(YSG/PF7*J(B(;@
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M>6W2U<L"NKJ9E/)G",9+TG#MSA#U
M
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M>I]47:T6=5GCM\,<KJMJ_4Y%>YR89VHF[S3A[A+@*L]830'WKJ/A<GSCUA-
M?>NH^%R?.6F *L]830'WKJ/A<GSCUA- ?>NH^%R?.6F *L]830'WKJ/A<GSC
MUA- ?>NH^%R?.6F *L]830'WKJ/A<GSCUA- ?>NH^%R?.6F *L]830'WKJ/A
M<GSCUA- ?>NH^%R?.6F *L]830'WKJ/A<GSCUA- ?>NH^%R?.6F *L]830'W
MKJ/A<GSF9TELHTGI2\1W2R4,T-8QKFM>ZH>],*F%X*N"=
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M20U8C>Z-[7QN5KVKE'-7"H7ELLU%/?+1-#7/62KI'(UTB\WM7.%7OX*!-0
M                  '1</ZA4_DG?L4\>EOK9M/YI%\A#V7#^H5/Y)W[%/'I
M;ZV;3^:1?(0#)@
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M*N>]3L]6;7]\J+W]OS@>\'BCNUNED:R.OI'O<N$:V9JJJ^;)[0
M
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MR\7.PJIZ3+;&]BZ:)OM7?KS715UUE5Z1)"U4CA1RJKERO%57. +D
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MHWHJIYT-9ZB:6HF?-42/EE>N7/>N55?.>BSW*IM-?%644CHY8USP7@Y.Q>U
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M\R':4G6^B0 $
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MGOX.4_Z[OG+) $ MFQW0MLN%/746GZ>.IIWI)&_><NZY.2\5)^
M
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M\45%RBA+Z
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MVDV/;#5ZQKYM(7#H;(Y6] SQN-F/)3/!4SS O@U=V.?WG-5_DZCY;#G]#?A
M??;_ /?1?,87P=(;I#MZNL=[D1]S92SI5NWD=O/WF9XISX@;<@     !A]6:
MAH]+V:2YW)E4^GC<UJMIH'2ORJX3R6_M S *M]?'2WW)?_\ EDIUS[>-(T\3
MI:B&^11-YODMLC43SJH%K JU-N6EE1%2DOZHO7ZF2#U\=+?<E_\ ^5R_,!:0
M.BWU<=?0T]7 CTBGC;(Q)&*UV%3*91>*+W'>
M
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M] &<
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MSUU])_=M3\#E_E G8/#9+K1WNUP7"VR]+2SIO,>K5;GCCDO%#W
M
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M):FM^J+3'76Z5,+PDB<J;\3NMJH1Q7"6P_F[PIP^2+UU]6; !Q.@
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M>*?&!9(/);;E1W.G2>@J8JB)?MF.R>L
M                                                    :N['/[SF
MJ_R=1\MAM$:N['/[SFJ_R=1\M@&T0  %9[=_[#M'Y^WY#BS"L]N_]A6C\^;\
MAP%197M&5[0 @RO:,KV@ ,KVC*]J@ ,KVGUJKO)QZSX?6\T\X%[;'_L?6S_,
M_>.)D0W8_P#8^MG^9^\<3()
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M[')E'-7**@'(
M *J(BJJX1  *<M^T34FL-I#K;HNWP+IBU5*17*OGX=+A<.:S/?G&,JN,\"S]
M4Q7.;3UPCL$D45U?$J4SY5PUK^I5X*!E 4YLQVB:@;JQVBMI%%'2W]6=)2U,
M28CJFHBYY<,X15RG/CP3!<8                   #5W8Y_><U7^3J/EL-H
MC5W8Y_><U7^3J/EL VB   K/;Q_85H_/V_(<685GMX_L*T?GS?D. J( !
M   'UO-#X?6\T O;8_\ 8^MG^9^\<3(ANQ_['UL_S/EN)D$@
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MT^U=Z"=V'55HO;42BJV=-C*Q/\EZ>A>?H S@
M                  '36,=)1SL9[)T;FIY\*=P IWP7YX(M%W*TN<U+I07.
MI95QK[)%61<*OH_87$5%K_9+55^I)-3:%OLFG[]-_6%;QBGQUN1.OAQYY,#)
MIC;C5-6EEU=:H(EX+41L1'>=,,R@'JVJ3P7';SLWMUOW77.DDEJ*ES.;8<91
MJ_JN]TO$K?99LKI-%U-3=;A6S7C456GU:NGYHG6C$ZD7KZRR
M        &KNQS^\YJO\ )U'RV&T1J[L<_O.:K_)U'RV ;1   5GMW_L*T?G[
M?D.+,*SV[_V':/S]OR' 5$  @     #ZWFA\/K?9)YP+VV/_ &/K9_F?+<3(
MANQ_['UL_P SY;B9!(
M                !6.DOLZ:X_,Z3]A9Q6.D?LZ:X_,Z3Y(%G
M               #P7Z6W0V6NDO:P);&PN6IZ?"Q]'CCO9ZL&JT.UO9_H[44
M]5HK1,<KLJUM9+-T2XZ]QJHJM3W"S/"WK*JGV9,AIE<D%35QLG5/:IQ1%[E5
M$)!LCT)I"ET'9YZ.U6^N=54L<LM5-$V9TCU;EW%R+CCE,)R P&Q;6.A=6ZGN
M5RMMN2WZMK<R3-J%WWO:B(B]&[EC")E$P76:J;8+):=&[:M(U6D8XZ.NJ)&2
M34L"X:U5?N[R-^UWD5R8Y<#:L                   .E])3R/5SX(G.7FJ
ML154UJNL;$\*OH48U(?&Z9.CQY/]31>1LV:SW7^]E_\ YE-_T:&E)GK[(ELB
MVCIF.1S:>%KDY*C$3!W@&>TA%=I-Z]1M,SK%)N550J0Q8Y\>:^A,DEJJB*EI
MI:BHD;'#$U7O>Y<(U$YJI3-MGEVC:V:^IWFVN%%>V)>&(D7@GG<JHOF7N)UT
MVK-NNF:V.Z5Z!CM07"/ZO,W<I&N3V$?6_P [OV)WD4\)C7E1#%3Z'TUOS7FY
MN2.I;$OE-C<F&QIWOSZ$3O+5VAZKH="Z/K+O5(W=@9N00)PZ21>#&)Z<>9"F
M?!NTC57^]7':/J=BRU-;*]:+?XIE7+OO1%ZDPC6]R*)G92O+"U=CN@Z?0&CX
M+<W=?73+TU9,B>SD5.7F1,(GF)/?+HZU4K9FV^OKU<[=Z.BC1[T[U153@9$\
M=TAK9H$;;JJ*EESE7R0](BIV8R@B-RLK?:=J>>Y;/M0T46F=11/GHI&(^:F8
MUC55.;EW^"$F;K21&I_^%-3_  1G\YB=HJ7>WZ,NDEQO=(Z!\2Q]&VBW5D5W
M!&HN_P %4SMOCOM?1055)?Z*2"9B/8Y*#FB_\9KX4<L6W_G]D;^S/6RK6NH(
M:E::HI5D;O=#4-1LC.YR(JX7TGI.FB9/'2QLJYF33HGER,9N(Y>U$RN/=.XQ
M2   >"^6:W7VWR4-XHH*RDD3#HYF(Y/.F>2]Y[P!K5J_87>M+7!]^V5W2HCE
M8[I%H72;KL(N=U'9P]/\+O=-;*^JK9*ZI?5RSMJ72N65JN5N'Y7>3'5QSP/T
MFD_HW>93\W]1_7%=OSR;]XXF!X6R2-SNR2(O<]4+@\&W2='K&Z:CH[C-.Q8J
M2)\,C'9W'*]R9PO!4[BG"\_!)OMLLVL+O#=:Z&DDKZ:**F25VZDCT<Y5:B\L
MX4F+36=PI>E;UFMHW"QY='ZZT*]\VF:Y]?0,5%Z)G'/GB5?V&8T_MHB9/XKJ
MNVRT,S<HZ2)JJB+WL7BGQEPHJ*B*BY13#:ATO9M00[EVH(9U3D_&Z]OF<G$V
M\:M_F1_-Q_A+XO\ ;WU]IZQ^\/59[S;KS3I/:JV"JCPBKT;T54SVIS3TGO*3
MO&R"XVF=:W1EWECD;Y20R/5CN''".3@OF5#HHMI>J=*U$=)K2TR2Q9W>FW=Q
MZIVHJ>2X>#%NN.=_Y(XRV/IQ%>7[]X7F"+:6UY8-2-8VAK6,J7)GQ:;R)$]'
M7Z"4F$UFLZEVTO7)'-6=P  A8          'ENO]EUGY%_R5,?HGZSK%^8P?
MNVF0NO\ 9=9^1?\ )4\&B?K.L7YC!^[::1\N?='U9D*B*BHJ910#-*+WW0.F
M[TCUJ[7 R5RY66!.C?GSH0"OV,5-!4/J=+7Z>E?]JV3+7=R;[53]A<X.C'Q6
M7'TBW12<=9[PHUM]VDZ/W676@6Z4;$XOW>EX9]NWBGI0SMBVU66J>L5XI:BW
M291,XZ1OIPF4]PM54RF%Y&!OVC[#?6*ESME/(_\ WC6[CT_XDPIKX^')\VFO
MO'[*\EJ^6?ZO9:+[:KPQ'6NX4M5E,XCD153SIS0R14%VV*4['K/IV[U-%.BY
M:V155$\SDPY/C,9TFU'22-:YJW:CC]JB3<./7A'C\-CR?*O_ "GH<]H\T+R!
M4-BVV44CT@U!;9Z&;*(YT7EM1>O*+A4^,L2Q:JLE]8BVJY4\[NN-'8>GG:O$
MQR<-EQ>:JU;UMVEF@ 8+@       .BLHZ:MA6&L@BGB7[61J.3XR!WW9?05*
MK+9YWT4W/=7RF9[NM"PP!4+;GK/1Z[MPA=74+<*KG9D:B?CIQ3TDKT_M%LUT
M1K*F1:&H7ANRKY*^9W+W29.:CFJUR(K5YHO6174&@K+>-^1(?%*EW_FP</=;
MR E,;V2,1\;FO8O)6KE%.14<NFM6Z4>LMBK'UE-Q^ILX\.]B\/<,E9-J$72)
M3W^C?2RIAJR1HJIGM5J\4^,"R@>2VW*BN<"36^JBJ(^V-V<>?L/6
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MZWFA\/K?9(!>VQ_['UL_S/EN)D0W8_\ 8^MG^9^\<3()
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MIV1X7MRTF:QK>_\ /[&VL]/?-I6Q&:&EOD'JUIAKMQCT57L1N<KN/]DQ>Y_
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MIZ,EI6._VN^TZ36FN@J6=:,=Y2>=.:&=\5J=X=&'B<6;R3U]/JR8 ,VX
M \MU_LNL_(O^2IX-$_6=8OS&#]VT]]U_LNL_(O\ DJ>#1/UG6+\Q@_=M-(^7
M/NCZLR #-(       #$WO3EGOC-V[6ZFJD[7LXIZ4XE?7W8K::AZS62LJ+?-
MG+6JN^Q/-UI[I:X-L?$9,7DLK:E;=X48MIVFZ0<CJ&K]5J1B<6([I&\O:NPY
M/0>VU;:GT\C:?4UEGIY4X/?"BIA>W<=Q^,N8\=SM5!=8.AN5'3U4?M9HT=CS
M9-_Q5+_-I$_>.BGAS'EEB+#K?3U\;_X?=(%?CC'(O1N3T.P2-%14RBY3N*QO
M^QC3]PWWV]\]OE5<X8N_'R]JOHY*1M=)[0](OW[!<W7&DCY1;^>'Y-R_L4>!
M@R?+OJ?2?W.>T>:/Z+R!2M%M>NUHE;3:PL$L3\JBRL:L2KYFNX+Z%)U8]I.E
M[PY&07-D$JI["I3HE\W'@OH4SOPF6G68W'VZK1DK/U3 'QCVR,1S'(YJ\E1<
MHI].9<     #%WK3]LO4:MN-)'*[&$?C#V^93* "K+GLWKK=.M7I>X2->U<M
MC>[==Z')P7TG51Z\OEAG2EU1;WR(BX61&[KU\R^Q4M@Z:NEIZR%8:N".:)>;
M)&HY/C Q%@U7:+XU$HJMJ3*F5AD\EZ>A>?H,Z5[?MF%OJ56:T3/H9LJNZOE,
MSW=:&#;<-9Z.5&UL3J^A:GLG*LC41/\ $G%OI MX$+T_M&LUSW8ZIZT,Z]4J
M^2OF=R]TF4;V2,1\;FO8O)S5RB@<@       82J^O*W_ )E/\N,S9A*KZ\K?
M^93_ "XS-@                   .,C&R1N8],M<BHJ=QR.$TB10R2*BJC&
MJY43N K6385L]DD>]]@8KGJKE7II.*KZ3&WK9#LHL=&^KO%MHZ.G8F5?-5/:
MGRN)$9-K>L-?W.HM.S^FM5IC8]8W5-?5L694SC+6+Q]Q%(MM1V6U]CH;->-6
MZCJK]<JRYPTKV29Z-C'9543*JO5U8Y@6/LZV@Z%I]5T>E-G-C?T%4YW35D,2
MLC;NM5<JKO*=RQQX%WF+T_I^T:?I$I[);:2AA5$RV")&9\^.9E /'>:26NM-
M92TU3)23S1.8R>-<.C<J<')YBB=([4+OL_H)=.[1[/>JFY4LCDIZVFB6=M4S
M*X\K//\ @O4;! "DMDUCO.H=IEYVCWVWR6J"J@2EH*.7A(L:83?>G4N&I[JF
M%L=SJ=B6K-14-WM%?5:8NM4M;25M'$LO1O5$RQR)RY?$;#@"C]"P7+:'M69K
MNNME3;;);*9U+;8ZIN[),KLY?N]28<I-:C7TD&UBGT8^TRI'/3+4,KU?AKL-
MRK43'''#K)V8"33$$VM(=1U-5/+/34SJ:FIU5$CAWU3?<G6JNPU./8!5^T&"
MXZ!VLQZ^H;547*S5U&E%<HZ5N]+$J>Q>C>SR6^XIB;W=JG;9JC3]NLMIKZ73
M-LJVUM=6UD71=(K>*,:B\^STFPH I[;A8;M2WW3.M].4+J^HL<CFU-'%[.6!
MV%7=[<85/2A&-<Z\K-K-F;H[1MCND+[@]C:^JK8%CCIHD=O.3.>>40V( %1[
M8= U55H*Q-TQ#TURTQ)#44<7)9$CW45OG5&HOH(WJ/:_6:JTQ/IW3FF+RW4]
MPB6DEBF@5D=/O)NO<KUZDRN/C-@ !%MEVE?H+T+:K$LJ2R4L:](].2O<JN=C
MNRI*0 !J[L<_O.:K_)U'RV&T1J[L<_O.:K_)U'RV ;1   5GMX_L*T?G[?D.
M+,*SV[_V%:/S]OR' 5$  @     #ZWFA\/K>: 7ML?\ L?6S_,^6XF1#=C_V
M/K9_F?O'$R"0
M     -/-;?7OJ/\ 2$WRE-PS3S6WU[ZC_2$WRE/1^%_.GV_9AG\K#  ^@<8
M    $NV0?91T_P#C3?NG$1)=L@^RCI_\:;]TXYN,^1;V:8?/#:X 'R[O
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M.L3FHL3D5?&6<."GBTC<KO'I6S,BLCI(VT<*-?XRQ-Y-Q,+@E=T_LRL_(O\
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M                   !J[L<_O.:K_)U'RV&T1J[L<_O.:K_ "=1\M@&T0
M%9[>/[#M'Y^WY#BS"L]N_P#8=H_/V_(<!40 "      /K?9)YSX?6\T O;8_
M]CZV?YG[QQ,B&['_ +'UL_S/WCB9!(
M        \E3<Z"FE6.IK:6&1$SNR2M:ON*IU>K=J^^=#\(9\X$6UAHBZW^\+
M646L[Q:(>C:Q*6E:S<14YKQ3.5,'ZUM__P#U*U'^K&6+ZMVK[YT/PAGSCU;M
M7WSH?A#/G HYVF-2)M0CTMZX6H.@=;'5W3X9O;R/:W=QV84EGK6W_P#_ %*U
M'^K&=#[G0?3#03^/4O0>H$C>DZ9N[GIF<,YYEF>K=J^^=#\(9\X$3TEH:[V*
M\QUM9K:\W6!K51U+4M9N.RG-<)G@3PQ_JW:OOG0_"&?./5NU??.A^$,^<#(
M\45VMTTC8X;A222.7#6MF:JJO<F3V@   -/-;?7OJ/\ 2$WRE-PS3S6WU[ZC
M_2$WRE/1^%_.GV89_*PP /H'&     !+MD'V4=/_ (TW[IQ$27;(/LHZ?_&F
M_=..;C/D6]FF'SPVN !\N[P                 Z*ZKIZ"CFJZV:."FA:KY
M)9%PUJ)UJH&/U3J2U:6M+KE?JMM)1-<UBR*U7<57")P0AOKX[/?PBB]YD_E/
M-M O6SS7&G7V:ZZLM\=,^1DBNAJV([+5RA6/K8['?PV3X='\P&/U[K^S7/;1
MI6[;/Y'25;7-IZN>*-8VU".?C<5%1-[@J\5[NPVP*,V=Z6V2:<U#35=GO5%7
MW;>W*99JQ)%:Y>'DMY9[\%Y@        5)M]V=7[:'!:J6TW&GIJ&E>Z26";
M.)'KA$=P[$SCSE7^$-LQTAHK0U!56=CZ>Z+4LA;O3*Y9VX57*J+V8SE#8?:#
MK&VZ'TW/=[L]=QOD11-]E-(J*J,;WK@UZT;I2][:M3-U9KJ7Q;3T;MVFI-['
M2M1?8L3J9G.7<U5, >C:=JBZTO@U:2@JIYDJ[M#''-(YR[[XFMWN*\^*(W/;
MDQ.K]D]CMG@_V_4-/')ZM=!#5S3J]</;)Q5F[R1$1R8\Q+/#%H6IH_3DE*QK
M::GJ'Q(UB8:U%8F$1$ZO),KM KX4\%BBD9(QS9K92PM5%YN5K4QY\HON 8%^
MOZ]?!3\?2ID]5%>EJ6='>4B])C.>W<X$>TMLELEQ\'ZOU#-')ZMK3RUD,V^J
M(QK.*-W>6%1J^Z>!;74-\$A*A6.W%N_C7+[3?W,^Z6CH.Y4\?@LU<RR-W8;7
M50N55Y.W7-Q[JH!W^"9J"HNVSN6@JI%D6V3K%&YRY5(W>4U/,F51/,6]77>V
MV^5L5?<*.FE<W>1DTS6*J<LX5>7 HGP-*62/25\J'(J1RU3&M7'/=9Q_:2O:
M[L8IMH^H*2Z5%ZGH'4]*E,D<<#9$<B/<[.55/;?$!A-N=U2%]'=K#J9&QJG0
MU$--7HB(OVKD1'=?%%]!3RW=7*ZY.N&:[IVKXVLWU3>1BHGEYSG'#GR,[J_8
ML_0")70S.NM"]$:ZH?$C5A7L5J91$7AQ(\D,7B"IT4>.E3AN)[53U,..?"K;
MI+PN.IR99M&^L?W6#L=J+?3UERU-<*^GFGI&.;3PNF1TLLKDXN1,Y7@N,]Z]
MAC=;ZPGTYIFL92O5^IM2JK(U8GEQ0J[#GIWO55:WS&#M,U-:K54UE8D4-$CD
M>YR1-WN'#@[&>/+&<*IF=BMJCU/JBY;2-8(REM%ND1M#'([,;7)G=8W/-(T5
MJ)VN7M.3B8GQ9KW>GP>*,6**PM[8!L^30FCFOKF[MYN"-FK%7[3&=V/_ (45
M<]ZJ=&T':BVDD=:M*;M7<'+N.G8F^UB]C43V3OB0CVI-97K:!<EL>DH)H:!5
MQ))R<]J\%<]4]BS/N_$6#H#9Y;M*Q)/(C:NZ.3RJAS>#,]3$ZD[^9K7%3!'-
MFZS](_=T[WV1?0FR^22K]6=9N=4UCW)(E,]V_P >V1?MEY<.HMUC6L8UC&HU
MK4PB(F$1#Z#FRYK99W9,1H !D        /CV-D8YDC4<QR85JIE%0KK5>R>T
M75ZU-H<MJKD7*.A3ZGG\5,87O14+&!ICRWQSNDZ%))?]::$_V?4E&MVM&-WI
M\JY4;R]GU>9WNF8TW%LSO],Z6GM]OAE8Q7R0SIN/:B<UXKQ3O0M.2-DK',E8
MU[')A6N3*+Z"AMN-CL%EDI)+93^+7*J<YSV1+B/<3FN[U*JJG+O.O'X?$VY;
M1JWK'[([._9;1Z/U%>;W1RV&C:YTRU-,BM7^BPC<<^[/_$6U9-*V.QU#Y[1;
M*>DF>W<<^-.*IV&JVGKO4V&\4URH51*B!V41>3D5%147NPI;%%MEN4$,3[MI
M]5A>UKFS1.<U'-ZW(BIA?=-.)X&W-O%'1$3ZKK!6ULVQZ;JW(VI;64CEPF9(
MT5J>E%4E-LUIIRYN1M'>*-\B\F.D1KO<7B<5L&2GFK*VT@!QCD9(U%C>UR*F
M<M7)R,0  %8;2]BNF=;))4="ELNJHJI54K$1'N7_ 'C<8?\ M[RHH+OM)V'R
MMI[M3NONF&)Y+\N=&Q,\,/XK&O\ A7AQ-K#KJ((JF!\-3%'-"],.9(U'-<G8
MJ+S A6SK:CIK7<"):ZQ(:]&HLE%4>1(U53CC/LD[T)R43M%\'VWW&9]UT/4>
MHEV:O2,A:JMA<[.>"IQ8OFX=Q%K)M@UALXN*67:=:ZFMIVKNQUC41)%1.MKN
M#9$[\HH&SX,'I+5EDU;;TK-/W""LB3@]&.\J->QS>:+YS. ")ZHV?:>U$CWU
M=$V&I<G]/3X8_P ZXX+Z26 FMIK.XE2^.N2.6\;A151LZU=I"=]3HVYOJ8$7
M?6%';CG8[6*NZX^Q;5Z]E'46C5M%4VZK?&YGCM.U62,=U.W%[.Y2]#&WJQ6R
M]TZPW6A@JF*F$WV<4\R\T]!O&:+?,C?^7%/!6Q_(MK[3UC_IJK)K/4KD>QU^
MKWL7+5^K+A4%OU5J;--14-XN"95L,,3)5QV-:B>XA*]K^SVGTJRFN%H69;?,
M[HWL>N]T;^*IQ[%PO,C>AK5J&2L9>M/6M:U:"3.5:CF[V.6%7BN.SN.^+4M3
MFC3PK4STR^':9W]MST;0Z6HJJW:?H::X5,M56,C19I97;SG/7BO'LRN$[C*%
M*KM7U-:7*S4&E'M7M1'Q\>:<T5.1E[?MNT_.K4JZ6OIE7.55C7(GN*>?.#)W
MT^@IQN"(BO-KWW'^5I@B=NVB:5KT9T5ZI8WNY,F=T:\L]9)::LIJIC7TU1%*
MQR(J*QZ.147ER,IK->\.JF2E_+.W> "JX                  /CFHYJM<B
M*U4PJ+UD3OFSK3%Y5SJBV10RKG,E-]2=E>OAS):"],EJ3NLZ1,1/=2];L>N-
MJG?4Z0O\T#UY,D56.Y];F\_</(W4^T;1ZM9>[:ZY4;,9DW=_A^4;R]*%YA41
M45%1%1>I3ICC;6Z98BW^?ZL_"B/+.E7V';18*Y6QW.*>W2KP57)TC$7SIQ3T
MH6%:[Q;KK$DEMKJ:J8O7%(COV&+ONBM/7MJI<+53N?G/21MZ-^?QFX4KZZ;%
M4AD=/IN]3TDR<6LESA%_';Q3W%)UPV3M,UG^L&\E?NN,%&-N.TW1ZHE93NN]
M&S&7;O3)C\9$WD\ZF:L6VNV3O;!?:"HH)\X<YGU1B+W\E3W"+<%DUNFK1]DQ
MEKVGHMD&(LNI;->T5;5<Z6I5.;6/3>3SIS,N<EJS6=3#2)WV  0.FLI*>M@=
M!5PQS0NYLD:CD4@E^V86^J<LUIG?0SYWMWV3/0G-/=+! %1-N.L]'N1M="^X
M4*+[)RK(F/QTXM])[ZS:M3NM&]14CVW%W#<DXL;WYZ_,6<J(J*BHBHO4I16U
MJACHM4IT$$<,,L#7HD;$:BKE<KPZP,3-J^^2W!M:ZX2I.UKF-5N$1&JN51$[
M.">XA9.@->I=5;07=6LKE5&QO:U<2^CJ4I@E&S%DC];6[HL^2KW/POVNZN?X
M!#8$ !(                =%P_J%3^2=^Q3O.BX?U"I_)._8H&L>PC:II/1
M.FKC;M0W!]/5OKY948V%S_)7"(N43N4LGZ879U]^)?@LGS&"\&2QVZMT9<WW
M2U4=1*ERE1'5%,USL<.MR9P6_P#0KI_[Q6KX''\P$2TOMGT5J>^TMHL]SDFK
MZE52-BT[VHN$55XJF.2*6*8RDT_9J.H9/26BWP3L]C)%3,:YOF5$RADP
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MU6TQNF[!;].VUE%:H&Q1I[)W-SUZW.7K4RH!SS,VG<I  0
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M6O154[RJ=';"=+:3U)17NV5%T?5TBN6-)IT<SBU6KE-U.I2U@
M        &KNQS^\YJO\ )U'RV&T1J[L<_O.:K_)U'RV ;1   5GMX_L.T?G[
M?D.+,*SV\?V%:/S]OR' 5$  @     #ZWV2'P^MYH!>VQ_['UL_S/WCB9$-V
M/_8^MG^9\MQ,@D      1O6U+JBJI:=-'W*WT$[7JLSJRF69'-QP1,*F"(>I
M&US\*=._\M=_,!:8*'UQ=]J>DH;5)5:@L,Z7"NCH6(RW*FZY^?*7RN7 DOJ1
MM<_"G3O_ "UW\P%I@K&FM.U=M3$M1J?3SH4>BO:EM<BJW/%/9=A9R<N/,
M                     #5#:[]DN_?CQ_(0B)+MKOV2[]^/'\AI$3U\'RX?
M(<=_N+^X #9R@    #*:4^NNQ_GT/RT-R33;2GUU6/\ /H?EH;DGF\9YX]GT
M?P?Y-O?](  <CU@T\UM]>^H_TA-\I3<,T\UM]>^H_P!(3?*4]'X7\Z?9AG\K
M#  ^@<8     $NV0?91T_P#C3?NG$1)=L@^RCI_\:;]TXYN,^1;V:8?/#:X
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M64L\DL:-5$8JN8N,+Q3T@;=@  5GMW_L*T?G[?D.+,*SV\?V%:/S]OR' 5$
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MG_QIOW3B(DNV0?91T_\ C3?NG'-QGR+>S3#YX;7  ^7=X
M  8/7,5SGT?=XK"Y[;J^G>E,K';KDDQPPJ\@,X#3B^4NVJPVFIN=WNMPI:&G
M;ORRR5C,(GN\^K!TZ9;MJU);8[A::V]/HI$S'+),V-)$[6YYIW@;F@T_T/==
MIB;4+58;_>KA25"2MFDI:Z;<Z>)%X[G##N"+R[%-P
M &MUT_O1._2-+_T)=MVM>I:BODEMNI:>BI5QN0.MK95;_P 2O3/N&OEQHKNG
MA!OI7W>)UU]4*;_;O%$1O]3RGU+>QP3"<^\#:<$7M]HU3#6PR5NJ::IIFNS)
M"EK;&KT[-Y)%QYR4
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MFHY?3@"+;'-+3Z.V=6>S5JM6KA8KYMWDCW.5RIWXSCT$S  &KVQU<^$YJO\
M)U'RV&T)J[L<_O.:K_)U'RV ;1   5GMX_L*T?G[?D.+,*SV\?V%:/SYOR'
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MLBVOH1]P %4@
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M;1&KNQS^\YJO\G4?+8!M$  !6>W?^PK1^?M^0XLPK/;Q_85H_/V_(<!40 "
M     /K?9(?#ZWV2 7ML?^Q];/\ ,^6XF1#=C_V/K9_F?+<3()  !K5X9_\
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M88 'T#C      EVR#[*.G_QIOW3B(DNV0?91T_\ C3?NG'-QGR+>S3#YX;7
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MKRWL ;F@
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M2G_Z5IM(:MW?^^2W\I3_ /2M VD
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M^HHDF&QW[*FE?S]G[%)'Z!@ @
M        -7=CG]YS5?Y.H^6PVB-7=CG]YS5?Y.H^6P#:(  "L]O']A6C\_;\
MAQ9A6>WC^PK1^?M^0X"H@ $      ?6^R3SGP^MYIYP+VV/_ &/K9_F?+<3(
MANQ_['UL_P S]XXF02  #6KPS_ZMI7\I4?L8:PFSWAG_ -6TI^4J/V,-828
M       'Q_L'>8_1'9K]C[3?Z.@_=H?G<_V#O,?HCLU^Q]IO]'0?NT D8 (
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M_P#I6FTAJW=_[Y+?RE/_ -*T#:0
M
M   U*VZ[--8W_:7<[E9K#45=#*V-&2L>Q$7#<+S<BFVH T,]9O:#^"]7[Y%_
M,279CLJUO:MH6GJ^XZ=J8*.FK&22RNDC5&M3/'@XW.
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MF        !\?[!WF/T1V:_8^TW^CH/W:'YW/]@[S'Z([-?L?:;_1T'[M )&
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M                   !JW=_[Y+?RE/_ -*TVD-6[O\ WR6_E*?_ *5H&T@
M
M
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M=W_ODM_*4_\ TK0-I
M
M                                            -7=CG]YS5?Y.H^6P
MVB-7MCG]YS5?Y.H^6P#:$  "L]O']A6C\^;\AQ9A6>WC^PK1^?M^0X"H@ $
M     ?6\T/A];S0"]MC_ -CZV?YGRW$R(;L?^Q];/\S]XXF02  #6KPS_P"K
M:5_*5'[&&L)L[X9_]6TI^4J/V,-8B8        'Q_L'>8_1'9K]C[3?Z.@_=
MH?G<_P!@[S'Z([-?L?:;_1T'[M )& " -<_"'^R'0?HIO[YYL8:Y^$/]D.@_
M13?WSSKX'Y]43V5P #Z)F     !US_T?I3]IV'7/_1^E/VF>7R6]DPW5B_HV
M^9#D<8OZ-OF0Y'RS0  &J&UW[)=^_'C^0TB)+MKOV2[]^/'\A"(GKX/EP^0X
M[_<7]P &SE     &4TI]=5C_ #Z'Y:&Y)IMI3ZZK'^?0_+0W)/-XSSQ[/H_@
M_P FWO\ I  #D>L&GFMOKWU'^D)OE*;AFGFMOKWU'^D)OE*>C\+^=/M^S#B/
M*PP /H'&     !+MD'V4=/\ XTW[IQ$27;(/LHZ?_&F_=..;C/D6]FF'SPVN
M !\N[P                                    !77A ZCJ=,;+;M64$C
MHJV964T,C>;%>["K^KO%":<V/VNZ;";AJJ:2H6]]#+60NZ3ZFC&<=U6XXY1%
MX]Y;GA8P/EV2RR,15;#6P2/QU)E4ROI5#QZ"K86>"U52N>W=BM55$[*\G;KD
MQ[JH!Z?!3U)4WS9RM'6RK+):YE@8]RY58U\IJ+YD7'H+CEJ(8G(V66-BJF<.
M<B&OO@9T[V:4OLSDPR2J8UJ]N&<?VDBVT[&)]HVI**ZPWJ*@2GI$I5C?3K)O
M8>YV<[R>V^("W?':7[IA]\0U>NTT:^&(V1)&='TE/Y6\F/ZJWK.SZ5BL_"NG
M^ N_G*RJMF,M/M=302W2-TJNC;XYT"[OE1))[#>[\<P-ZO':7[IA]\0>.TOW
M3#[XAK%]*Q6?A73_  %W\X^E8K/PKI_@+OYP-G?':7[IA]\0>.TOW3#[XAK%
M]*Q6?A73_ 7?SCZ5BL_"NG^ N_G V=\=I?NF'WQ!X[2_=,/OB&L7TK%9^%=/
M\!=_./I6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5GX5T_P%W\X^E8
MK/PKI_@*_P X&SOCM+]TP^^(/':7[IA]\0TOVL;$I]GFF([S-?(J]KZEE-T3
M:98URY'+G.\OM3+Z(\'>IU3I2V7N/4<%,RMB25(74BN5G%4QG?3/(#;GQVE^
MZ8??$'CM+]TP^^(:Q?2L5GX5T_P%W\X^E8K/PKI_@+OYP-G?':7[IA]\0>.T
MOW3#[XAK%]*Q6?A73_ 7?SCZ5BL_"NG^ N_G V=\=I?NF'WQ!X[2_=,/OB&L
M7TK%9^%=/\!=_./I6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5GX5T
M_P !=_./I6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:*;(=F,NT:X72E@ND
M=O6A:CE<^!9-_+E3VR8Y%G?2L5GX5T_P%W\X&SOCM+]TP^^(/':7[IA]\0UB
M^E8K/PKI_@+OYQ]*Q6?A73_ 7?S@;.^.TOW3#[X@\=I?NF'WQ#6+Z5BL_"NG
M^ N_G'TK%9^%=/\  5_G V=\=I?NF'WQ!X[2_=,/OB&L7TK%9^%=/\!=_./I
M6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5GX5T_P !=_.5AM/V9R:#
MU3:;+-<XZUUPC;(DK8%C2/,FYRWESV@;V>.TOW3#[X@\=I?NF'WQ#6)/!8JU
M3/T5T_P%?YQ]*Q6?A73_  %W\X&SOCM+]TP^^(/':7[IA]\0UB^E8K/PKI_@
M+OYQ]*Q6?A73_ 7?S@;.^.TOW3#[X@\=I?NF'WQ#6+Z5BL_"NG^ N_G'TK%9
M^%=/\!=_.!L[X[2_=,/OB#QVE^Z8??$-8OI6*S\*Z?X"[^<?2L5GX5T_P%W\
MX&SOCM+]TP^^(/':7[IA]\0U VA^#_4Z-T;<[_+J"&K91-:Y86TBL5^7HWGO
MKCV78>79AL*J->:4BOD-^AHFR2OCZ%U*LBINKC.=Y -R?':7[IA]\0>.TOW3
M#[XAK%]*Q6?A73_ 7?SCZ5>L_"NG^ N_G V=\=I?NF'WQ!X[2_=,/OB&L7TK
M%9^%=/\  7?SCZ5BL_"NG^ N_G V=\=I?NF'WQ!X[2_=,/OB&L7TK%9^%=/\
M!=_./I6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5GX5T_P%W\X^E8K
M/PKI_@+OYP-G?':7[IA]\0>.TOW3#[XAHC9MFLESVL5>AVW...6GDEC\<6!5
M1VXW>]AO=?G+1^E8K/PKI_@+OYP-G?':7[IA]\0>.TOW3#[XAK%]*Q6?A73_
M  %W\X^E8K/PKI_@+OYP-G?':7[IA]\0>.TOW3#[XAK%]*Q6?A73_ 7?SCZ5
MBL_"NG^ N_G V=\=I?NF'WQ!X[2_=,/OB&L7TK%9^%=/\!=_./I6*S\*Z?X"
M[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5GX5T_P%W\Y76V/91-LT@M4L]VCN/C
M[Y&(C(%BW-Q$7/%RYSD#>+QVE^Z8??$'CM+]TP^^(:LVSP8JNNMU+5MU13L2
M>)DJ-6B5<;R(N/9]YZ?I6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5
MGX5T_P !=_./I6*S\*Z?X"[^<#9WQVE^Z8??$'CM+]TP^^(:Q?2L5GX5T_P%
MW\X^E8K/PKI_@+OYP-G?':7[IA]\0>.TOW3#[XAK%]*Q6?A73_ 7?SCZ5BL_
M"NG^ N_G V=\=I?NF'WQ!X[2_=,/OB&J6H?!JJK-8+G=':F@F;14TM2L:42H
MKT8U78SO\,X(EL?V/S;2+/6U\%XBMZ4TR1*Q].LF]EN<Y1R ;M>.TOW3#[X@
M\=I?NF'WQ#6+Z5BL_"NG^ N_G'TK%9^%=/\  7?S@;.^.TOW3#[X@\=I?NF'
MWQ#6+Z5BL_"NG^ N_G'TK%9^%=/\!=_.!L[X[2_=,/OB#QVE^Z8??$-8OI6*
MS\*Z?X"[^<?2L5GX5T_P%W\X&SOCM+]TP^^(/':7[IA]\0UB^E8K/PKI_@+O
MYQ]*Q6?A73_ 7?S@;/,JJ=[D:R>)SEY(CT55.XTGL6D'Z&\(6P6&6L;6O@JH
M)%F;'T:+OMSC&5Y><W8
M     !J]L<_O.:K_ "=1\MAM":N['/[SFJ_R=1\M@&T0  %9[>/["M'Y^WY#
MBS"L]O']A6C\^;\AP%1  (      ^M]DA\/K?9(!>VQ_['UL_P SY;B9$-V/
M_8^MG^9\MQ,@D  &M/AG_P!6TK^4J/V,-8C9[PS_ .K:5_*5'[&&L*$P
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M3_XTW[IQS<9\BWLTP^>&UP /EW>
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MM,LB-WMS?8K<XZ\9R1#8[LXCV;6>MH(KF^XI4S)+OOA2+=PW&,(JY)^
M       U5US_ 'N[9^6H_P!V;5%?7;939KGM(I]:35=>VY0NC<V)CF]$JL;A
M,INY^,L$                                              &KNQS^
M\YJO\G4?+8;1&KNQS^\YJO\ )U'RV ;1   5GMW_ +"M'Y\WY#BS"L]O']A6
MC\_;\AP%1  (      ^MYH?#ZWF@%[;'_L?6S_,^6XF1#=C_ -CZV?YG[QQ,
M@D  &M7AG_U;2GY2H_8PUA-GO#/_ *MI3\I4?L8:PDP        /C_8.\Q^B
M.S7['VF_T=!^[0_.Y_L'>8_1'9K]C[3?Z.@_=H!(P 0!KGX0_P!D.@_13?WS
MS8PUS\(?[(=!^BF_OGG7P/SZHGLK@ 'T3,     #KG_H_2G[3L.N?^C]*?M,
M\ODM[)ANK%_1M\R'(XQ?T;?,AR/EF@  -4-KOV2[]^/'^[0B)+MKOV2[]^/'
M\AI$3U\'RX?(<=_N+^X #9R@    #*:4^NJQ_GT/RT-R33;2GUUV/\^A^6AN
M2>;QGGCV?1_!_DV]_P!(  <CU@T\UM]>^H_TA-\I3<,T\UM]>^H_TA-\I3T?
MA?SI]OV89_*PP /H'&     !+MD'V4=/_C3?NG$1)=L@^RCI_P#&F_=..;C/
MD6]FF'SPVN !\N[P                                          ?'
M.1C5<Y4:U$RJJN$1"#2[7-"17=;:_4U E4CMQ>*[B+V=)C=^,POA+WZHL>RN
MX)13/AJ*U[*5'L7"HUR^7A>]N4])3]KV4V&H\'*74TD+UOJTTE<VHWW<$:YV
M&;N<8PG8!ME&]LC&OC<U[')E'-7**AR*;\%._P ]YV9+35<KI9;95/IFN<[*
M]'A'-1?-O*GF1"Y                    \%\O-ML5ODKKS74]%2,YRSO1J
M>;CS7N([IG:=HW4U?XC9;_25%7]K$[>C<[\5'(F]Z,F VQ[+9]HU;9W/OCJ.
M@H79?1]#O)+ER;SMY%3"[J83AP-?=L]BTK;M46.W;*7.DO3)'13,HYG2JR9'
M(C..55'YSG'I W)N5?26RBEK+C4PTM)$F])-,]&M:G>JD4T_M2T7J"YI;K3J
M&DGK%7=;&N\Q7KV-5R(CO1DI?PMKW7LH-,:=DF<U:AB5%4C5PCWIY*93K3*J
MN/,8C;YLRLNA-(:?NVFV2TU?!*V.:9)'*Z5V[E'\5X.1R9X8Y@;9@C6S2\OU
M#H&P765V_-4T<;I'=K\8=\:*24                 8G4NI+/IFA\<O]QIJ
M"G5<(Z9^-Y>Q$YJO<AEC4+6]52Z^\(2LMVIJ]*;3=I<]K^DFW&,CB1-_"]2N
M<O/F!LKI'7^EM7221:=O5-63,3+HDRQ^.W=<B*J=^#WZHU19-*T*5>H;E3T$
M"KAJRNXO7L:U.*^A"B]*[/\ 1]TVDT5\V8:NHJ2*@:DDE# JS/<N51WLG(NX
MJ*B+S3)'-<PMVB>$U2Z=NLDCK52/6#HD<J)NL8LCT3')7+P54 V,TCKG36KT
MD^AR\4U<^-,OC:JM>U.U6N1%QWX)(:A:[ME'LGV[6"HTTCZ.W3K"Y\+7JJ(Q
M7(V1N57*HO/CUFWJ<4                  $5VJWBJL.SO4%RM[E;5T])(Z
M)Z?:.QA'>CF!W7;76EK17^)7/4-LIJO.%BDJ&HYJ]Z9X>DD%-/%501STTK)H
M9$WF2,<CFN3M14YFJ&Q/9+8]?:"N=[OU15R726IEB9,DR_4E:B>4Y/ME55SQ
M,OX)^JZJF;J33U;4.GI:&/QNFWG91N%5'HWL:N$7'4!L!J'5VG]./8R^WF@H
M)'^Q9/,UKE[\<\&1M=RHKM1LJ[75T]93/]C+!(CVKZ4-3-D>EJ7;)KW55XU=
M+4U$$2HYL;95:J*]SMQ$5.36M;C"&7\'6LJ-)[8+]HMU1))0/Z5(V.7ATC%1
M4=CJ56<\ ;3@                $:VCZ@JM,:-N5WM]&E;5T[,Q0+GRW*N$
M3@BJ!RU=KC3ND'4K=1W2*B?5+B%KFN>K_0U%7'>2%TC&Q+(YR-C1N\KE7"(G
M:IH=M1AUA/=K3>M>*]E;<O*@IGINK!&UR)C<Y,RO5SZU-Q-I6G[IJC0=79K'
M7QV^JJV-8Z9^<;F4WF\./%.'I \-;MAT#17!:*HU-1).CMU=S>>Q%[WHBM^,
MFM#6TM?1QU=%40U%+(F\R:)Z.8Y.U%3@:^R;#-,::V4W.HU2D<E[IZ::9]?%
M,]&L<F58C47"8]BF%3B5_H#4]VLG@[:O=%-.QCJZ*DHWHY4Z)9$;TF[\?+K4
M#9&JVMZ$I;LMMGU-0MJT=N*B*Y6(O+"O1-U/=)M!-'40QS02,DBD:CF/8N4<
MB\E1>M#5#26R>QW/8!7Z@J8'.OCH):N&IWW)N-9Q1N[G"HJ-7/#K+#\$F_U%
MUV>SV^JD=(MLGZ.)7+E4C<F\C?,G%$ N\
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M<3(UJT)X0FE]/Z7H[;5T%XDGAWMY8XHU:N7*O#+T[3/-\)[2"\[9?4_R8_\
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MF$0[                 !I6_2='?/"4N=BORR,HY[C+(YJ.W5E:J;S6HO\
MB13=0J#;%L9CUI=8;]9+BZU7^)&HLN%5LN[[%<IA6N3'!R 4_M<TU0;+MJ^F
M*O1+9*5TR-E2G217[J[^XJ(KESAR+C"JO$]]I:EN\+YZU2HQ)ZJ9S55>:R0K
MNI[JX)MH+8770ZJI]1:^OTEZK*946&%RN>F\GL5>]V55$YHB8XF>VR;'FZWN
M5+?+-<5M=^IFHU)=U5;(C5RWBBHK7(O)R 5;X32.NFV32]LIL.GQ"Q$3M?*F
M/V&UR<$0HS9EL1K+3JUNJ-:WIUXNL7&)JY?AZ<$>Y[N+E1$X)PP7F
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M)QX<B_M!:4H=%Z7H[);-YT-.BJZ1^-Z1ZKESE[U4"0
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MP="6@"(MV:Z,:JXTS:^/_H(%V:Z,545=,VO*?^@A+@!$EV;:,5%1=,VK'Y!
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MB(B)A$X(
M
M
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ME]/,[P
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M01_BI^P#F
M                                        !0E3?-0['M8RKJ6KJ[UH
MJ[3J]E=(JNDHI'=3N[AR1<8XIQX 6#M2UX_2,-OH;30+==1W1ZQ4%$U<;RIS
M>Y>IJ9X\O.5Q>MHNTK05705>N+59*RV5LJ0I3V^3%0QR]3$WE5^/,J<N*9.6
MW"Z3:<UIH[:3;H$NUFIZ>2G?T+LM1'HNZY'<41%W^"]V.LRFS*SQZCF]<O7-
MQHJN=[%DH:=)4=3VR+GYM_")E>:+W@7+15+:NEBG:R2/?:CMR1NZ]N4SAR=2
M]QW%.^#E55ESBUC=I*BLJ;96W9SJ&6I<YRO8B856JOVO)/07$      =-;51
M45'-55"JV&%BO>J-5RHB<^"<5,'H76=EUM9_5&P5231-=N21N3=?$[L<U>*&
M9N5;2VZ@J*RX31P4D#%?+)(N&M:G-5-5);I=J+5LVO-E.EKU#8I'JM;$L>*>
MN8BY5[6)Q1.?%$X<^U +$U9"_:5M;K]'W.MFI=,V.FCJ:F"&3<=5R/1%1'+[
M1$7_ .9(58-/4,.T]];LEJ*ZVZ>M+56[5Z/=+32JU,K&QG-ZXY\5[>KCV[0;
M?/M"MGK@;,9ZE:^:G\2O-LIWJVH<SAEBXZ^&.7%,*G89*T;48&Z0CTGLZT->
M::\OC6!E/+3XB@5>#GO?S=VY5$SU@7?H;55OUEIZ&\6=TBTDKG,3I&[KLM7'
M%/C])GR(;)M)+HG0EMLLLC9:F)N_4/;[%9'<78[B7@==1/%3023U$C8X8VJY
M[W+A&HG-54HZ7:/KW7%PJ?6KLM'ZATSUC]4[CE&U#D]HBJG#EV]^"5>$A/5T
M^QK43Z!7->L;&O<U<*C%D:COF\RJ2#9.R@CV;:;2TI&E'XA$K=SDJ[J9].<Y
M X[-*G5]58Y':^HZ&DN3958QE(N4<Q/ME\I4X]Q+0N<+CGU%7;#]97G4TVJZ
M'4CX9*ZU7%T#7PMW6[F.")YE1>*\>(%H@        \5KNUONK:AULK:>K;3R
MN@E6%Z.W)&\VKCDJ&"DUK1^N-#H^&&1]<M&^MFDY-C:BM1J=ZKO>C $/U]KN
M\7*]W+1FS^TRW&ZQ0?[96I4)!'1J[DB.5.+L*A']E>OK]I2Y4VC-JT,E)5OP
MVWW&=^^V=/:.D1515[%SUX7OX:9O<&S3;+J:T:F5*>AU#,VMHKC)Y+%7&-QS
MEY)G*>?SF?\ ";BM-;LW?'520+<WSQ);41461TJO:F&=:\%XXZ@+>1<IE.0*
M7V*:IOEMOU3L\UKOR76BITGHZM5ST\'#@JKQRB*GQYY<;H          XRR,
MBC?)*YK(V(KG.<N$1$YJIYK5<J*[4,5;:ZJ&KI)>+)H7H]KN.."H!ZRC-;:R
MU/KYE[L&S&US/IJ23H)[TVK2G1)&KE61JN,\L+QY*619]84M\UE?]-TD,J.M
M,3$GG=P17OX[K4[$14X]I56PJ_4^AK]?-G^IG-HJ]*]]113S*C&53'\MU5QQ
M\G*=N<=0$AV2;1Z^6N^@_:%3NMNJJ9J)&Z;@VL;[9J\E=RY+QZBWRC/"9H*"
M\)I6@M]1'#JR>Y1QT4L:_5(XUSO.7=XHU%W5R2'8CK>Z7Q+GIO5D+HM361R1
MU#L<)F?:O\_[>"]8%I         '1<*VFMU%/65\\=/2P,62661VZUC4XJJJ
M!WG"HFCIX))IGHR*-JO>Y>341,JIQI*F&LIHJFDE9-!*U'LD8[+7(O)44AE'
M?H-H>FM7T%I1\*0OJ+4V5ZXWW]'C>3L3+OB K#5FJ]=;3;?(_9I:*JDM-%5;
MT-S\=; ZK5B\FM=C+<]2]WF)WLBVE_14V6RZCI_4O5U"F[4T4B*Q9$3_ ,QB
M+U=J=7F([X.6K:.BL::#O*);M169[X70389T[=]5WF9YKQX^A>LP>WJUK>]J
M&F8-%5<=/K%D,LKY8'8=&QC5<WI%3EE>"9[>P#8H$!V+ZZDUSI9\UP@\6O%!
M*M)71<L2M1,N1.I%[/.3X
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M_BI^P#F
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M%<B9QD]P%>;%-(7#2^GZVIU Z-U]N]4ZNK$CY1N=CR$\W\2PP
M
M                             $-VJZ%CV@:92SS5\E U)FR]*R-)%X=6
M%5"9 "F]EFPRFT#JQM\BOT]<]L#X.B?3-C3RL<<HY>PN0       '36P)54<
M].KMU)8W,WL9QE,9.X :YT/@NT=)64\[=553NAD9(C?$VIG=5%Q[+N-BV-W&
M-;G.$P?0
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M8J:DB9#3Q-1C(V)AK43DB(!PMM!2VRAAH[?3Q4U+"U&1Q1-1K6HG4B(>D
M<9'MCC<^1R-8U%<Y5Y(B=8'(ZJRJ@HJ66IJYHX*>)JODDD<C6M1.:JJ\CC'6
M4\E"E;',Q]*L?2I*U<M5F,Y3NP47#J:KVM[19+38[G2OT/2TK9*VGDBXUF\J
MM5CD5-Y,+RXIC"*!;&I;/:-H&C)Z"2H2>V7")'1ST\G#M:]JHO'"X7')2G-*
M7^KT3='[-MJK6UUEJFK#;+G4)F*:-5PD;U7N5$SGR5X=BG7!+=M@5^2"I6>X
M[.ZZ7R)$3?DH7JO)>7=W*G+CS]>VC4>E-HU)IK3%EJV76NK[E"Y%I<[U/#RD
M>J_:^2O)?X =#]([0]F=;6T.S=6773EP55IX:AZ*Z@D7[;RN:)[B]:9+>T1I
M6"QP+7U=+0_1'6Q,]4JRFBW$GD1.*HG4F>S&>9Z=!V&HTSI>BM-7<Y[G)3(K
M4J)D1'*W*X3AU(F$,^ /CG(UJN<J(U$RJKR0^E*ZKONHMHU_OND-&1T$%EHF
M^+W*XUJ.7?>O..-&KGT]R@71&]DL;7QN:]CDRUS5RBIVHIB-22,M-KKKM2V=
MUQKX(G/9#3QHLTKD3@U%YE':)O\ ?]C-THM+;09&5&G*IVY;[G#ES(5]H[.%
M1O+@J<,]G+8B*1DT3)(G-?&]$<US5RBHO)4 H1_A#35U*RALFB[U+J63R$I)
M(U1C'_C(F53T(2_8KH>YZ?9=+_JV=M3JB]R)+4N;RA9S;&G5PRO+AR3J+-1K
M4<KD:F\O-<<5/H       *FV@;3+W1ZFFTYH'3SKY=:2)LU8]Z[L4*+R;S3+
ME1/C0#LVXZGNM%4Z;TKIVK?;[EJ&JZ%:YJ(JT\2*B.5J>V\I,<N1&=2["*JD
MCCOFD=2W3Z+*-$?'45DRR=.J?:JY>+<IGM3J5#PW6YLVTV%K+6QUDVAZ;G\8
MBI9EQAZ+Q1%7FBJB<^2HF>!D:/P@66NB6WZLTS>J?4\2;BTT$".9,_M:N>"+
MZ0,)6:D]=?1SNCC]3-I&EI/&HH%7=?(^-4W]SKP[=5%;U+@OC15VGO\ I*U7
M*NHIJ.IJJ=KY:>9NZYCE3BF.SL[C6;46D+K8='IM.KD6UZP==_'DA8O.*5[4
M2)S>[CZ%5%-J[74/JK925$S.CEEA9(YGM55$54 ](          %0[5;M>KU
MM L6S^PW&6TQ5M.ZMKJZ!V)6Q-5R;C.Q55.>3RZLVL:B=J"Y4.S_ $NZ^4EH
M?N7"J>JHW>3V3&85%54PO;RY$=OMPFVF45IU]LU=T6KK JQ5%NGPCU8N=Z-4
M7@O-53CQ15ZP/3J?9'<]$3NUAL\O%=+=:1%EJJ6K>LOCK$]DBNYJJIG@N>["
MG3=]4PZXL-IVB:-B<S4^G7HMPMS5S*^!W])&N.+D7&6KCMY*>Y_A TU3;9+8
MS2][75<C%A2@Z#R.E5,>RSG=SW9P1)-&5VRZNV>7ZDEZ"_7.L;172D:_+94E
M=O*U$_PHNZO>B*!M!22^,TD$SHGQ+(QK^CD3#FY3.%3M0[@G(          ?
M'.1K5<Y41J)E57J*'N6VK4D\]9==,:/EN.CZ*1T<M<Y5:^3=7#G,3/+/<OH
M]NIJF[;0]K%=HZCO%79K'9:9D]:M(]6353W\F[R<4:G C^H="7?8U42ZOT-7
M5%=:F<;G;:ARJKX\Y5^]UXX\53*9Z^)VWJHJ[A>+?M9V6L]46.B\7NUL=PD<
MU.:;OMD1>I>I%3*9.>H]M3-9Z>JM-Z1T[>)-17&)U*Z&I@1L=/O)NN5SL]60
M.=5>8KAJ:P;3M P3UL=4]ELO5N@;F54=[%7-3.'-7=X]F#8#"+A53OX]1K?8
M]-2[*]K^C;=8JE7P7VEZ*Y4B+O-WF-XRIGDF4S[O4;(@
M
M
M
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M]S6,<]ZHUK4RJKR1"AIJS5FU^NN%1IF_SZ7TC02/ABJXL]+6R-YORBIAG+K
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MIP9G#E3O5,(9O97I.^_1#<M:ZX6-M^N$2004D:Y;1P(N=SSKPSYN\"T
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M,<_'%43L,@!7.SG9[56>[U&I=77+U9U34LZ-9]W$=-'_ +N-.I.\L8
M
M
M
M                  *OVA;%=.ZNN$MWA?56J_.=O^/4LJY<Y$X;S5RG4G+"
MD5AN.U;9JN[>*6+6.GH__P Q3<*F)O8J<%7W%\Y?0 U?U=M$T]<=6::VA:7J
M71UMOD2CO%#4-5DR4[UQG=Z]W>=Q15ZC9REGBJJ:*HIWI)#*Q'L<G)S53**1
M+5^S/26K:EE3>K-3R537(Y9XVHR1^%SARI[)%[%)92T\-)314]+$R*")B,CC
M8F&M:B81$3L [0     B^TVT5%\T1=:*BN2VNH6+I&5>51(U;Y655.*)PXJG
M$D=94PT=)/55,C8X(6.DD>Y<(UJ)E57T(4BFT;:)JR.HN>SS3-M73T3W-BJK
MC-NNJD:JHKFHKFX;P_\ <##;%-J]\UIJ6EL&H*ZVQ4[:&2-Z=&Y)+@_*HCV+
MP1,(G+KX\.QK^UR[,MGEET/:;M*V/45S=3RULR(B4T+G-WT14Y)A>:YZSE;H
M+?MTTD]\%M=IS5%C?N4U92M^HL>BYW6O1.+<JJ[J+E%X^?%7#65?J>VT^S[:
M!HNNN.I&5+8'24[D9Y/):AK\*B+C*Y]BJ 9O:UI33E1:=";/+*C5KDJV)')#
MATD-,B+TLBKWY1>]2X] V"LTUIFFMEQN]3=ZB+.:B?&<=34PG)$QSRO>8G9S
MLQTYH))I++3ROK)FHV2JJGI),K?:[V$PG<G83< 8W4EEHM16.MM-T8Z2CJXU
MBD:QZM7"]BH9(IJ]:KU;KC5EUL&SJ:EMMNM+^AK;O4,WU=+[2-O=A<KQ] $?
MTO?KKL4U%#I36$SZO1]4Y?4RZ*F5I\_:/[$YY3CC.4X<LYJ=Z;.MJ5#JFD5/
MH9U,YM+<]SBV.?\ \N;S+E$54[R+:BNVH+!4-TOMH@IKOI2YKT<5XBCW70R=
M2JO4J>9%3GE4R=--1W'3'2[,=9,J+KI2]-6*S76-BR.A7FQ,)G&ZJ-7NY\N0
M3[:ULWJKG70ZOT+,E#J^C\MKFJB,JVHGL'(O!5X83/!<\2R["^XRV:C?>XH(
M;DZ)JU$<#E<QK\<415,/LTMMZL^C+=;M2SPU%PI6K#TL:JN_&U<,557[;=1,
MDG      !56VW4%WBN&F=)Z?K?4VKU!5+"^N1$5T4;4RY&YY*O:?-4[;;/:;
MM44%GM=TO[Z1^Y5RV^%7QP*G-%=C"JG'W#&:WIZ3;)L]I;]HBJ>R\VNHZ>DR
MF[(R5OLHG9Y91<IZ /)=]D&H=-TOJGL^U==WW>!-]U/7S))'4XXJW&,(J]_N
MIS);L?VEQZVIJFWW.G6WZFMR[E;1N3'%%PKF\>6>KJ.6Q_:92:XMKJ6M1*'4
ME']3K:"3+7(Y."N:B\<9SPYIR7OA^WFW-TOJ[2FNK(O179UPCH*F)G!:N-_4
MN.>$;CTIV 7C4P155/)!4QLEAD:K7L>F4<B\T5"!;.=F=-H._7NIL]PJ4M%>
MK7Q6URYC@=QRJ*O%>I$[N>2P6KEJ*          !#+9M&LE;KZYZ0?(ZFNU'
MN[C9N#:C+4<NXO6J9Y<^L"';5+C=M2;1K/L^M%SEM-)44SJVX54.$E?&BKAC
M%ZO8K[IBK[LZU?H"+U9V;ZAN%R2#RZBUW*1)4G8G%4;P3CW<%[%,]MSTO=75
M%IUOI)BOOUA57.A:F5J8%]DSOX;W#O4ENS77MIUY8HZVVRM95L1$JJ-R_5*=
M_6BHO'&>2]8'5LMV@6W:!8EK*%'05L"]'5T<G!\#^SO1>I?XDDOMHH;]:*JV
M7:G94T52Q8Y(W=:?P7O*;U/00Z-\(/2]RL:-B34B/I:^E8F$?A,]+A.]$SYE
M[2\P(1LJT%] %LKK=#=:JMHI*ATE-#-C%.Q5X-3AS[5)N          *2O<M
MTVF[3;UI:FO559].V%C$J?$U1D]3,_JWESAJ87D7:1JW:+M=OUO<]54W3MN5
MPA9!,W?Q'AO6C<<UPG%0*@T_75.R+:A)8+UJ9]7I6KH'5K9*^3+Z=R.W4RO/
M*JBIA.:+R+PT[J"U:CH$K;'7P5M*JXWXG9PO8J<T7SD4EV4:;K]6W74%^I_5
MFIK58D<5<B2,IVM:B;K$7O15[LE>VFQTV@_"/H+9I1>BMEYH9)JRB8OD0*W>
MW5QU)E$QV94"YM8Z7M>K[#46B]TZ34LR<^3F.ZG-7J5#P;,M*2Z,TI!9IKI4
M7+H7N5DDV/(:J\&IW)_%25                                     !
MB[[?[;8X4DN52V+/L6(BN<[S(@&4!#J':/IZKJ&PK/- KEPCIHE1J^E,X]),
M&.:]B.8Y'-<F45%RBH!]    X3L66"2-LCHG/:K4>W&6JJ<TSUH!S!2^P76%
M^KK_ *HTKK.N?67FV3J^.1[&M58N#?M43KPO+[8N:1[8XW/>N&-1555ZD0#D
M"GMBVI[_ *TUCJ^[55?*NF:>H6EMU+N,1G!?991-Y>#4YK]LI<"N:CD:KDWE
MY)GB!]!C=35$M)IN[5-,]8YX:262-Z)G=<C%5%X]Z$$\'?4ETU-LSI[IJ"M=
M5UKJF>-TSVM;Y+7X1,-1$Y 6: BHJ91<H0[2MKU=2:QU%5Z@N]-5V"H<BVRE
MC3RZ=-Y>#O(3JQUJ!,0?'.1J9<J(G:JGW.6Y10 *B\''55ZU39M0S:@KWULM
M-<GP1.<QK=QB(F$\E$+<<YK<;SD3/:H'T
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M5)3:)O.I:>SLEHZ.[);:?,JITZ<E?RX<0+G!TT,_C-%3SJW=66-K\=F4R=P
M   "@+!MNU9J1*M^G=!27&&FF6&22&HX-<G4N>["@7^"CZK;5?=.]'4:WT#<
M[7;GO1GC,3VR(S*\U3)<%KO-!<[)!=Z.I8^W30I.R95PFYC.5SR R *1J]M-
MUO\ <ZJBV8Z5J+\RF7=?62N2*%5[LJGQJA\@VS7S3E;2P;3M(U%EIZER,96T
M[DEB:O\ BPJ\/,JKW 7>#IHJJ"MI(:JDE;+3S,22.1JY1S53**AW
M                              'DNUQI+3;JBON51'34=.Q9))9'8:U$
M*.FVF[0M4I/==GVEV.T["Y6Q2U:?5*O'-S4RG#/#AGEV\#';7KF^Z[6;5IO:
M"LULT0KTDIUB7R*Z3ACI7)Q:W*JF.KTY+8V@:TLFS;2#:J9(VM:Q(J&CA3C*
M['DM:B=76J]@$=L&K$VN;)M0PT=.^@NZT\M'/3*[*LFW.&%YX7../'F53H"[
MW_7MBM>S.@<FGZ>UQ.BO51OHDTK&O5O1QMX*BK]MW\^_IV4;4;?L[MMQDO\
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M[4_4G1MCD=>Z&)TOC]-(^6GC16X<BNZ14SQW>7-2[P
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M,L5'K:IUK(V1MU6F6&25\F6-C1$XHG5A&]7>5TVQ;=45-[56FU[?J'__ "+
MM6L[37ZHJ-&U,JR7VFI4DJHWQ8C>F&[V[GV2+O9Y<@*7VP:NM&UFX6#26B94
MK:IM:VIDK'-6)D34:J+A7X55X]782/PL;E'1Z&M%LGD5(ZZNC;)CBNXS#G*B
M=>.' [O"4TK8*/9O5WRDI*6VW>W/B=1U-,Q(9%<KT;N9;C/!57'<92AU1INN
MTWH"+:'2T\UYNE/#+2K54R/1)EW>*.5,-55W5]P#!)MMJ;+0TLD^S^_PZ<BC
M;&RXR,5J*Q$PCMU6\$PG:9';IK.DN&P:NNNFZM)J:YK'31S,545J.?Y2*G-%
MX*BHI;ETAHY;7517)D3J!8G),V5$W.CPN<]V,FFEGHZRK\&G5SX4<^AH[VR>
M#/)&)NH['I<@%L:;VI:>T-I>V6"PV>Z7KQ"G8VMGMU.KXV2[J*_>>B85<YRI
M,]DS]%W^ONNKM(;[+A<%W+A$YRM<Q^<^4SDBY1>/7Q,ML<H;92;,=.MM$4+:
M>:BBD>K&I]4>K4WE<O6N<\RM=G<,-N\)W6E#8D8RUOHVRU$47L&S>0J\$X(N
M\Y_NJ!G-<[+':BOUXU!JN\U-=;::-[[=:6JK88L,]D[M7.5X8\_4<?!-7.R.
MG5>:U<W[4+1U/];ET_-I/DJ5=X)GV(J?\[F_:@%R$7J=$66;7,&L)V2NN]/"
ML+'NDRQK<*G!J\EPJ\4[5)01CZ-K(_7#M'NED2\=!TW1OCPQS<(O!5YKA>7<
MH%*[;-<V3:/3V[1FCI&W*YU-8QRU#FK$RG1J\51ST3*\^1D/"*IWSQ[-])3R
MN?3UE?%'487^DW$:S_[E,_X0FD-.LV972Z,M]'0W"W1MEI*FGC;$]CT<B(U%
M;C.<XP5QK.XUT^B]C.K+VLBNIJQC:F63FJ;S=URJO:UF<@;0S45/-;WT4D+'
M4KX^B6-6IN[N,8QV8*2\$^JDBLNJ;&YSEBMET>V+>7.&NZO_ *<^DO&2:..G
M=,]R)$UN^KNK&,Y*,\%"!T]LU=>DST5PNS^C7'-K>.?_ *P+KO-0^DM%=4PX
MZ6&!\C<IE,HU53]A0&A-;;3MIE@_\"]3+:RF<Z.JN<D?]+)G*,C9E<8:K<KQ
M+ZU)];MU_-9?D*53X)+439,U43BZNG5?=0"-:?VF[0_5NXZ$J;90UFK8I-R"
MM7R861HF722(B\>&%3&,YQ@]=1J_:%L[UE8J;7%5;[K9KS4)3I+"S<6%RJB+
MCLQO<E1<G;I-$^FKU.N$RE$WY+3EX5']/H']+I_]H&9VD;0-13ZWAT/LYIZ:
M6\]$D]963IEE*Q>K'+.%:N>/-$QDB>M]9;4MF=E>^^.MMU@J-UM/<8XOZ"3.
M5:]N4RBIE$Y<3)[.7LH_"8UW35V&U=33LD@5_!7LQ&O#//ACW#-^%544\6R*
MMBG<Q)9JB%L357BYR/15QYD15 DFL-5R6C8]5Z@J)&-JW6Q)&JGDHLSV<,=G
ME*4_M-L#M-^"W9:"5N[/XS3S39YJ][G/7/NDDVE.6\Z?V9:.CROJM-335"(N
M/J$3&JY%[ES\1D/"Q:C-DBM:B(C:ZG1$]*@>[7NTI^F[9:;!I>F;==85\$;:
M:D:BN2%%1$Z23').O"JG+L.W5NN+SL[V<TM=JAU)<]45DB0P4M/'T<:RN3.Z
MB(JJY&]:]?=DJJGM-WV,:FL&L+M6+>K?>&-ANM0Z/+X'NZVN7CA$5,<LX5.P
ME7A$U4*W_9A?'2MEL3;DV1\J<8\.5CD=GEC=10/0R;;5:[=]$5:ZTUR-:DLU
ME:S=<C.M&JB\'8[U)1L US<]>Z:N=RNZ0H^*O?#"V-F[B-&M5$7CQ7CS+)J)
MH8J22:9[4@:Q7N<J\-W'$I/P2I(Y='Z@D@PD+[Q,YF/:JUJI\0%Y&MG@IW^S
MV:R:HCN]UH*&22Z*YC:FH9&KDW43*(Y4RALF:I^#?L\TMK2U:DJ=36F.OGI[
MDL43W2/;NM5J+CR7)UJH%I;:MH.D8]G-[I/5>W7"IK:9\$%-3S-F<]Z\$7#5
M7&%PN5["J]3SW;27@L6"TS.?#77:HZ/HW*J*D+U>_=7LRF[P[%4O.R;(-!66
MK956_3%"V=B[S72[TNZO:B/54(EX5M@GN>S6*MH8]Z6TU3:E41.4>%1R\.SA
MZ,@63H'3]'I?2-LM5OB;'%#"W>PB9<]4RYR]JJN3OUA8Z34>F;E:KC"V6GJ8
M7,PY$7==A<.3O1<*B]QT:"U#1ZHTE;+M;I$?%-"W>3/%KTX.:O8J+D]&KKW2
M:=TU<;K<9F0T]-"YZJY<97'!J=ZKA$3O J7P4+M42Z3N]@JY%D=9:UT$>5RJ
M-55X>;*+@O$H[P4+341Z5O%_JXUC6]5KIHT5,*K454SYLJN"\0
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MC+8%RQ'XXX,H            \,MFMDM>E=+;J)]:G*H= U9$_P"+&3W
M
M           !PFBCFC6.9C9&+S:Y,HIS &/HK);**9):2@IXI43".:Q$5#(
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MM+[J1]&D/U98_:JN[R_XBY=(:<M^D]/4=FL\:LI*9FZU7+ESUZW.7K5>:F8
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M)%$Y?\6&IP\R9+P '10TD%!1P4E'$V&F@8D<<;4PC6HF$1#O
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MA;2_!9/YRPMBVQJMV?:@JKI6:A\>26!8$@BB<QBY5%WG9<N53'#S@7,
M                              !QED9%&^21R-8Q%<YRKA$1.:@<@1WZ
M.-+_ (06SX2WYSU6_5%BN,W14%XH*B7EN1SM5?<R!F         %5$YJ
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MWFX4U%"O!'3R(W/FR>&P:STWJ"=8;+>Z&MF3CN12HKO< SX
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M/'W/Q)+[A<[J3+3R)$J]F]C_ -BS898YHF2PO;)&]$<US5RCD7DJ*!S
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MNZ<*VFI&,E;G.ZO/=]'(S-+I^STE>ZMI;91Q5;N<K(6H[W<&3
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MBVOJO55+7VK4,38-16E_15+6IA)$RJ;V.W*<<<.SF66
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M5EYW7-IKA<5=%GDJ(KE7'ZV"_
M      !ATTS9DU,NH4MU/ZLK#T"U6XF^K.S/Q9[.!F
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MNUZUSJ6!T%PO#O\ 9X7HJ.BB5<\EY(N&HG<G>7(
M              %=^$!9+EJ'9==+;9*22LKI)(',AC5$5R-E:J\U1.2*:E^M
M!M!_!2O_ %H_YC?@ :#^M!M!_!2O_6C_ )C;;8)9;C8-F=MM]YI)*.MC=(KX
M9%15;ERJG)50L(    ,9JAKGZ9N[&-5SW4<R(B)E57<4R8 ISP4:*JH-EJPU
MU--33>/S.W)F*QV%1O'"F=VZ: CUWHZ6.G:B7FA1T]#)G"[_ #5G_$B8[EPI
M8P H/3;+GM4V+7+2M^IJBBU%0QI$CZF)T;97-ST;E54XYQAV._M/+I#;3)HN
MQ4]@VA6"\T]WH6="U]/3](V9J<&KG//'6F4-ACXK47FB*!5FR34>M-77NZW:
M\T26O2R\*"EGB1)W]ZKSPB8SGK7AR*^V;ZABV?;8M96?4%!<&S7ZYQ^)RQ0[
MT:HKW8<JY3#?+3BF394^*U%7*HF0-5=GNHX=C>IM1T6N;%<)*NKJEF@N%/ D
MJO:O)$7*<%Y\.U<GW:A?M0ZYO^DK[!IFX46F;;<6="^:+ZM*Y7M5SU8F51B-
M:GQFU*M1>:(OG/H% >$-/+9M>Z!U7+1U51:+?(]:A\$>\K<N:J<.U4SS[#R7
MRXKK#;=LPU):**N6URTSU626!6]'A9DP_FB+GOZS8I414PJ90(B(F$X(!"-M
M6G:O56S*^VJVMWZV6%'PLSC?<UR.W?.N,%7Z&VULL^E;=IJJTQ?)=44%.VC;
M214_D2.8FZU=Y5X(N$SP[38<^83.<)GM H?P;+;>J#4FMG:BI'4];-4,DD5&
MJD:N7*JC5ZT3..!@=AFHHM#:YU%I*_T%PBN-UNRK3/;#F)457(BJ[/!.2YX\
MS9<^83.<)GM UUV1:3J+S%M;M%RIZBDANE6^..22-6Y172X<W*<4XIR.&@]I
MM3LNLL>D-?6*Z)5T"K'2U%'#TK)V*N6\<IV]75CKR;'!41>:(H&N>SF;4-[\
M(&6_WZSU-OIZNVN6F9(Q?J</VC7+R1W-53O.%)5W38?KS4,E=:JRX:.O-0M4
MRII6;[X7JJJJ*G#EO*BHO/"87F;'A414PO$"AUVK:DU[J"VV_9C:ZJEHFR;U
M;<+E3(C$9UIC*X]"Y5<=62^$SA,\5"(B<D1/, !1E305B^%C25J4D_B:6M6K
M/T:]'GHUX;W+)>8 K[;GHVIUGH2II;9N^JM*]M5297&\]BYW?2F43O4@%#M^
M=06*.UW'3%Y^B^&-(5I6T_U)\B)A'9SG"KQY&P!\W4SG"9[0*O\ !\T=<M,:
M6K:S43=V]WFJ=6U,:JBK'G@UJXZ^:^DLFXHJV^J1$556)R(B>93T "E?!7H:
MN@TE>F5U+/3/=<7N:V:-6*J83BF3KU105;_"ETI6LI9W4<=JD8^=(U5C5^J\
M%=R12[@!2.E*"KC\)?4]6^EG;2OHVHV98U1CEPW@CN1U^$[05E=4:$6BI9ZA
M(KKOR=%&K]Q/)XKCDA>0 BNU.&2?9QJ.*"-\DKZ&1K6,3*N7')$*-;H2]7C8
M9H^OM%-(W4&GYW5D-+(BL=(F^BJW"]?DHN.&?2;. "B6^$-3);DI'Z8OBZG1
MNXM$E-Y'28]MG.[GNS@\.D-#WNS;'M<7+4,#OHAOL<T[Z=B;SF-QP;A.M5RN
M$[4-@]U,YPF>T^@:Q66V7*ZZ*V4Z3=1U4<<M6M9<-^)S4CCA=O(CE5,)E47@
MO87+MLII:G93J:GI87RROHWM9'&U555QR1$)P *>M.@X=9>#[9K!<HEIZM*1
MKX7O;NN@F15PN.KK1>Y5(K9:*];1ME%XT/J.FJ*34]E5K:>>>-S63]&OD+OJ
MF%XM5JJG:BFQ9&=I-ENE^T=7T6G[E-;+LJ))35$3U8J/:N4:JIU+C"^<"I]/
M[6M466ST]@O.@[S4ZBI8TIVO@8G0RN:FZURNSPSPRJ<#R>#.ZY/U_KM]^1C;
MHYS'5+6+EK7JY55J>;EZ#*T6N-K-MMT5GJMG;JZ[1L2)MP2K3H)%1,(]W5E>
M:^4GH)-L/T'<=*45UN6I9V3:@O$_C%3N+EL2=3$7KXY7T@6<J(J*BIE%X*:Y
M1LO^Q'6M]JH+-4WC1MXF\91U*F])3O5554QU8RJ<>"HB<38T 43==OE/>[?/
M0:'TY>[A>9V+'&V:EW(V*O#+EWB3;)MFRZ?V4U&G+^K9)[HV22M8U<HQTC4:
MK47M1$3CVEGHU$Y(B>8^@:W:3U!J'8>^IT]JBS5MRTLR5SZ&X43.D5C5557/
M%.W.%PJ+G&4/5JS:Y<MH%KFT]LRL%UDJJUO125E5"D386K[+"Y5$7'6O;VFP
MZHBIQ"(B<D1/,!#]DVBXM!Z*HK,QS7U")TM3(WD^5V-Y4[N&$[D)@
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M/LG+S5R]ZKE5\YF
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M)4VVQ4%/.G%'LB3*$C
M
M
M
M
M
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MB)R
M
M
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MZ,M%FWD<ZDIVL>Y.MW-?C520
M
M
M
M                                               $1U3LUT?JJJ\9
MOVGZ.JJ>N;"QO=YW-5%7TF3TOI2Q:5I5I].VJEM\3O9="S#G>=R\5]*@ 9L
M #$:DTU9=347BE_ME+7P<T;,Q%5O>B\T]  &$TSLOT7IBM2LLFG:*FJFKELJ
MHZ1S5_PJ]5QZ"9
M
=                                  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g762905g43d06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g43d06.jpg
M_]C_X  02D9)1@ ! 0 #YP/G  #_X8/[:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX
M;7!'26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @
M(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C
M(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B"B @(" @(" @(" @
M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @
M(" @(" @(#QD8SIF;W)M870^87!P;&EC871I;VXO<&]S='-C<FEP=#PO9&,Z
M9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B/F1S<#(Q,6$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @
M(&1S<#(Q,6$N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(X,S U
M-3 F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#,P+4IU;"TR,#(T(#$Q
M.C,T.C0Q)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#,P+4IU;"TR,#(T
M(# R.C T.C0Q)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!
M.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#(U+C N,"8C>$$[1W)A<&AI8R!T
M>7!E.B @(" @(" @("!,:6YE($-H87)T)B-X03LF(WA!.^* HB S,R!B;&%C
M:R!R=6QE<R!C:&%N9V5D('1O(&]V97)P<FEN="XF(WA!.R8C>$$[XH"B(#$Q
M-2!B;&%C:R!T97AT(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!O=F5R<')I;G0N
M)B-X03LF(WA!.R @(" @("#B@*(@,SD@<&%T:"!O8FIE8W1S(&AA=F4@=&]T
M86P@:6YK(&-O=F5R86=E(&]V97(@,C@P+B8C>$$[*BHJ1DE8($%.1"!215)5
M3B!04D5&3$E'2%0@4T-225!4*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @(%1I;65S+4)O;&1)=&%L:6,F(WA!.R @(" @(" @("!4:6UE<RU2;VUA
M;B8C>$$[(" @(" @(" @(%1I;65S+4)O;&0F(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!D<W R,3%A+F%I)B-X
M03M5<V5R;F%M93H@(" @(" @(" @(" @(')R.#,P-34P)B-X03M,;V-A;"!4
M:6UE.B @(" @(" @(" @(" S,"U*=6PM,C R-" Q,3HT,SHQ-"8C>$$[15-4
M(%1I;64Z(" @(" @(" @(" @(" S,"U*=6PM,C R-" P,CHQ,SHQ-"8C>$$[
M4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!6
M97)S:6]N.B @(" R-2XP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @
M3&EN92!#:&%R="8C>$$[)B-X03L@(" @(" @XH"B(#(T('!A=&@@;V)J96-T
M<R!H879E('1O=&%L(&EN:R!C;W9E<F%G92!O=F5R(#(X,"XF(WA!.RHJ*D9)
M6"!!3D0@4D5254X@4%)%1DQ)1TA4(%-#4DE05"HJ*B8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R @(" @(" @("!4:6UE<RU";VQD271A;&EC)B-X03L@(" @(" @(" @
M5&EM97,M4F]M86XF(WA!.R @(" @(" @("!4:6UE<RU";VQD)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U
M;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF
M(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9'-P
M,C$Q82YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C@S,#4U,"8C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,S M2G5L+3(P,C0@,3$Z-#8Z
M,CDF(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,S M2G5L+3(P,C0@,#(Z
M,38Z,CDF(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,C4N,"XP)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($QI;F4@0VAA<G0F(WA!.R8C>$$[(" @(" @(.* HB R-"!P
M871H(&]B:F5C=',@:&%V92!T;W1A;"!I;FL@8V]V97)A9V4@;W9E<B R.# N
M)B-X03LJ*BI&25@@04Y$(%)%4E5.(%!2149,24=(5"!30U))4%0J*BHF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97,M0F]L9$ET86QI8R8C>$$[
M(" @(" @(" @(%1I;65S+5)O;6%N)B-X03L@(" @(" @(" @5&EM97,M0F]L
M9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @
M(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @
M(" @(" @(&1S<#(Q,6$N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M<G(X,S U-3 F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#,P+4IU;"TR
M,#(T(#$Q.C0Y.C0X)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#,P+4IU
M;"TR,#(T(# R.C$Y.C0X)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R
M+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#(U+C N,"8C>$$[1W)A
M<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T)B-X03LF(WA!.RHJ*E1H
M92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@
M;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE<RU";VQD271A;&EC)B-X
M03L@(" @(" @(" @5&EM97,M4F]M86XF(WA!.R @(" @(" @("!4:6UE<RU"
M;VQD)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S0S9# V+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M(')R.#,P-34P)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" S,"U*=6PM
M,C R-" Q,CHQ-SHS-R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" S,"U*
M=6PM,C R-" P,CHT-SHS-R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" R-2XP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @3&EN92!#:&%R="8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @5&EM97,M0F]L9$ET86QI8R8C
M>$$[(" @(" @(" @(%1I;65S+5)O;6%N)B-X03L@(" @(" @(" @5&EM97,M
M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#/3D@33TQ,# @63TV-2!+/3$F(WA!.R @(" @(" @("!#/3<U
M($T]-S8@63TP($L],"8C>$$[(" @(" @(" @($,].#<@33TT,2!9/3,Y($L]
M.28C>$$[(" @(" @(" @($,].#0@33TW-"!9/3 @2STP)B-X03L@(" @(" @
M(" @0STY,"!-/3@P(%D],S @2STT,"8C>$$[(" @(" @(" @($,]-C<@33TU
M,"!9/3,Y($L],3(F(WA!.R @(" @(" @("!+/38P)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]D8SID97-C<FEP=&EO;CX*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R-"TP-RTS,%0Q,CHQ-SHT-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C0M,#<M,S!4,3(Z,3<Z-#4K
M,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A
M=&4^,C R-"TP-RTS,%0Q,CHQ-SHT-"LP-3HS,#PO>&UP.D-R96%T941A=&4^
M"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@
M,C4N," H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T
M:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$T,#PO>&UP
M1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA
M=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-5
M1VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C
M>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G
M445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!
M=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%
M2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M+SA!04519T%J045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"
M05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!
M04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"
M04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C
M>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I8
M5T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP
M-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53
M355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$
M9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X
M<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD
M;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C
M>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!
M=T1!44%#15%-4D%$.$$V9#4X:',T9GI',&TS93(P-VYE=B8C>$$[6DXK:V(R
M9%8Q165T94Y&3$9P-FUE2U=V1&E#54AW1&-C;4Y!5F5I-G(U9W-D1W5.27,W
M;U1/*W)827-B5U961$0Q=E1A465O,5)3<28C>$$[>'-C0W-E5#@R=$-B6')B
M45=S8C),5F)M.$YI3%=95S!,<5)(1$XV>$5K-D9K359Y:CA5-5-5<CA&9'-6
M6G9I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<GEJ.'AT4C!#2#AZ
M=DQ.=&17:R8C>$$[8C9M.&QG66)L.5-.;R]&-S%K4E5T;&IK.69I,5=)3$M$
M<TXK>%8V0G(S;'$R,7$V,&DT;G5:-$1O,31,*S-317AH6&Q73C1G2D]A4R8C
M>$$[17)W;%E556IR9U9*8D0X<S=+,W55;75T63%(53!3-D8Y-D8T8E)K3G=S
M>7IP2BLV=&]N5FQK5'%R06MF0V%R44)65"]!1$DX<RM7-28C>$$[.4Y/<U0V
M5EIY-G1(9&%E<V5O=F)X3F-Q0F5W<E)::79-8D5J<FER3F-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<R8C>$$[5F1I<G-69&ER<U9D:7)S
M5F5&6% U;&5B8C-78F933DPQ;WI8*V\V<$0Y4E=Z5WA-13)L>7).9$(T2DHT
M;4M/24532C%K<7ES43(O228C>$$[3&A6:W0O-3(X=S(O;'I1.4IU<C$W2'IH
M9#9P86%49%AC;'(V155Z:'=B=6$S4S5J06QI.4I70WE);U5S5G Q04E62B]-
M;C5G*UIV<B8C>$$[*W5F;UA8235,2EAT1'!-8U)T1$Q/4#-Z6&-/;G4Y=DER
M,T-!4DLP37EU971'6&M!0W%C5V9N6%=:=DLO;DA6<E!6;'9H0F9N4B],8R8C
M>$$[<%<S8FI04TLQ4U4K:VE,2GIU-6EW0D)"54-M>'=+:$Y.+TYI+W0O3D]R
M851)2F18:6@Q1TMX=&5::6=A3TM*,'1,:5%'3T922S1M5R8C>$$[96%12&EQ
M4G%.>%595E9R<C@P.5HQ:CAU3E(Q,U1R56%(9#-$43(O;#)E4U9*;FYL;%)*
M6$EJ;6E287A!=7!7:D)I<#1N;V-64UA4+R8C>$$[04UW+T\R=7)R9'AB-FED
M3T9T0F\R;C9F6E)X5WIY:E5D5&M14$Q+2DDU1'E53E5P<W%G,$DU2S)+<'IQ
M6&U0>6IQ4&XQ6713;#%R5"8C>$$[9&-S<C(P<UE,4WHK=DI:,TEJ=E@K<DYC
M8UEK9UI'6G52-7-6-$XX3$4Q=TLY5WA6,DMS8R]-2"]!2E)I5"]M3# O.$$V
M:C1-5EI(:28C>$$[<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E%M<#9666%N06M&.48V<U5C<R8C
M>$$[8SA9-4UH5U=*9SAB:&M+:T9704DS-C1Q<3,Q;&)8,6QC5U8P;G%7=#%'
M.$TX9%-/56-I;%=7<6M%5D(W67%G.4,X=6%,;TYN2EHV5"8C>$$[8D,R=#5:
M1VYL5&LW;'!(041->E-&;4I)541R:7%)=F1,<V(R5S)L=6\O5F%Z:T4Q=4-Z
M0E9K2%)Y9TE6:79B:T14=&ER1R]-;FLW428C>$$[.5,X-&%,<F0U9G)B6'1P
M>$9V87-L<7I41T-1>7 V56LP8E1X,&0O,VYO<T]1;T=X5F8U,S!N5F(W5F9+
M:RMN,G-K-C9F<7DS3B]+:R8C>$$[:V%,2&$O5C5O,C5+.&E&+S-J;V%+0V1V
M=E9E6&%.*U9N-6\R,35Z=7)J:U!8:$U-=G)O9E-N:G5.36MN=F503&(Q,',W
M9U58-&IY;R8C>$$[=TA.<TMV4B]Z270O36IA85I93#9Z:C!K6%=N*W!A4U=C
M<C-"4#$R2&-8075K44-T4#DP;BM/0E=A-'$W1EA9<3=&6%EQ-T9867$W1B8C
M>$$[6%EQ-T9867%L1W K84Y)<TPV1%0U3&U%6# U25=*-4%G44)#+TM2<4AG
M0T9O2SE49TIP;$="4$EC;4UA+W=#93E46%%P-VU'3S$P-28C>$$[6E9F-FYC
M4UAA3E!+14I5;3-G0TAK,W=M;%1K;UDU6E!P1&)'26A)8U<O;#EQ5S9&-3,Q
M-CE.>DYO679.53!P<$97,FYU<DUY>6-G:28C>$$[:#$U>'E7<U%!87983%1P
M2E%.4TE(=DLU36M:04=Q4&MK+VQJ6$PV-#%Q4U!Y.$Y1=4Y9=$EP-#EB:75*
M;UHT=6)3<'AA0T=E-VI50B8C>$$[4W)!;%1T5VYF26Y38TE"2D$K9C9M574Q
M235U3$@V5'=N<$5$=C9I:69J84EU2E!-:#@P2TI99%-8>E),36PQ8C)W;G1L
M=%1:>'A,1R8C>$$[>"MR:3=-9&5A='1Y,S8Q<G1G+TLR3TQI2'8S+T%&3F<W
M4G%0:%9'<4\Q0R]N.5@R=&5B>#5M=7 W9'1D,'I5;CE32U<S<T=T1$A#<R8C
M>$$[9'A)5C1Y4VDP=6)G;$8W.'%:26%-5'8Q4E!Z+T%&3710,FA,1'1!05=D
M.6=F.3%B,3(S:F%/,VEJ63AM4D96:C1K0VU59V)/1DTR4R8C>$$[5E1#>&1I
M<G-69&EQ5'IX*UIU5#%M:6%-;S1I1G)'16-31VY!=5HR9%-V5W1..%92=&=U
M<DM8*W9Y45-$8C O46ID2V1A.'5B=FER028C>$$[+W=!=V1..#9187DY,V]#
M,VPY6F%P6FU+-W1)8GEA15<X.6LS,6Q(:#1T4TDS8V%.8FMP5#1I<#,K2W%Q
M5%,K879Z4T=P-EAQ0C R5"8C>$$[-#=A5T,W=%EB4%5N=$A75R]S-#!K.4XO
M4VMH;6EG:VUF:S0S0TY4-%=$07%O>BMA4'I)=2],;6U2=G!..7 Y>$<R:U-3
M<$)B86DY=R8C>$$[>71.03$R>&U-:VI"54AQ>%-25$)N22M/=$181E=E*U%T
M93@R87AB6&MV;4Q413!X,&M8-G1#:51O>7%1955C:&Y60DEY168S:V15628C
M>$$[2&)V9U9G6D9U=FXV5DY:,4]'>F<P>2MK=3=3,W5R,59-<&UU:$EK9'1B
M<$I&9$1K<7%F5&1':60P57%'-595<3EK4F=Y:&A7:D%%5B8C>$$[0D(S.%%D
M>&=6=D973V9M1"]W06]X2B]Z1C9F+T%.4CA'2W-J>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+<U(X.65D8E11,&5Z3C1T<"8C>$$[97HR<VHR;DM.;DQZ2#19
M55)L<7%%<W)B<W1-:DM91&QA6%)Z>D=O:2LO>4AE>%!Z9C5B:# O>2LR:#9F
M<'8X06E,>DYD0F)Y*VUC328C>$$[>%)E4E0Q9G1!,#5-4D=H2G)2;6%P0G)K
M869446MB>4A:=$AA3U1(2SA0;T$U9G0W>64O-6)B2C5P;&QP9FQ(>6A:4&$R
M26@X>C9H828C>$$[>'!$0C9F<C--;#(P44IJ;U=5.$DR-FIK<4M01$I3,VQW
M9RMG9DMN6#9R57EK5$]2=6-V=$M).',V3"M9.#)K=W@K6DYC1G)/0S-.3"8C
M>$$[2TM&<F=Q4U-"2D\T:VHO-$-0<#-R9VY+1BMK3TIG>#5U2#%Y,SAV>"MH
M1U=F-5HK5G)7-'5,;%9U;G5B='5D,4XY8G5)>DLR-3530R8C>$$[1C1L63<Y
M>&M4;6M25$]/;&=#5'9:.'EP4"M5+VMD.5=J,4YR2GI.2$=9:$=:<%-H-T)Z
M5G58241B-U908D0T.'%P0C!E37HT-C-16"8C>$$[;68X04PK-RMS-E9C*U5&
M<SE,;G1B<%I,=5(T=51'4'A",S)'.58R<C1J1$1+3BM,9&IM,#AR0G@Q1VIV
M<WIW5G!V,7EH>DA9<3=&6"8C>$$[67$W1E=)95DO=T$Q9DHR9RMM3&DU835A
M4FU1<F%H6D-P4VQE5E=7;EA+>FQ(5&0R,FLW1C%'92M%5C<Y:RLP9GI$;RMS
M4C@Y3W5K;B8C>$$[25989$9)3$E(1E)Y1U-J35,U3T1N,'5416%M2U%0;DQZ
M0G$K:#9E;#5P*VY186=/87AY2E!D3F$O2$Q):U558V9'1S1,>5-34T%+2R8C
M>$$[064O5$I/3VXK2W5X5C)+<T(X,RMD<B]3=E!/:F%.0EI7:G@S4G1!.3-C
M4C-J>D%85C P1')#,$9V3$-H5E5R5U=60G8W2$978S-F,28C>$$[=C9P3CE4
M.5 V,S9B9E8O5W(V9G%54$1N>"M,:GDV,'A6-7AA*V5F4&$O;T4S8TYL3&$S
M*W!3,G0O<4YP87E.171U3'!,4S-:63)U+R8C>$$[5FHY9"M81U5H,496<798
M0W%C9FU0-6<P>4A41'!C:E1F6$AU=%!:471V3S!D4')S3&8S<6]9:'-0-7-6
M6G!G5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%9B3$Q(1$4X<W)"230Q3'4U
M-D)61E-4:7)Z3W@P8E$O354R<2MC4$TQ=4IB1S U+U4P8W-V<'!#3U5J9D-6
M*W=&5DMF>B8C>$$[<2]J:TEW.%-69D(R,&16:S!U25)G94=5+U9,,V9W:C5E
M<C1H:U=M,S%P-68X=EA8;6)Z1$M,834Q0G9R;#97<5=13TM15WEJ-U)-8R8C
M>$$[9$9#:CEQ<#<U;#505DE2:GE',S=84S5-:UE237!'9VE02T9O,3-&+VEA
M.5I:9%(Q5TY8:31S2%,S=%-/561V17=*2'9)4CEP=F]Y=B8C>$$[26$Y239-
M34ES8UHU;C=",TUK>71V56]R=3!M:V%/2V%/4U)F=$EJ0FE+94E".3A*:5%Q
M<F=6,DMU>%8R2W5X5C)+=7A63$YB.',V1"8C>$$[<G%22G$Y;$AE<D%365)+
M0V5*86QA54DV,'E-;V<X,THP*W-Y-$Q/3U)J9F-M35558TU34E)+1FIJ54EI
M:F]&555!>5%$:GEK4V)+6"8C>$$[6$AL9GDW4'%0-E1K,#8S+T%%;#9K57)8
M<7AQ:WIT04M297!)=$=C2BMY1TI!,CA-54IN:7)S5F1I<GER>F)F87IC9FU4
M;U4P1FIQ:R8C>$$[3FQ:>E%16$5O5VM%66MU,VA%;SE/*VA1<&-C84XV='4U
M-%4T:FQT:%8V<F=607)O3VA,4&%Z<G Q<4HW0E!3<UI21$=(9VI.4&=I8B8C
M>$$[:E9&,D=Y-'%L6#5G+W=$2TU39CAX96XO05!59D)I<DDX5F1I<G-69&ER
M<U9D:7)S5F1I<G-6670K675P>5=U9R]624%(=611:U<S:B8C>$$[:E!29WA(
M=TAR=$EX5TPO6EI'4F]7-4=L=RM*:T54>38K-&)N-T=/96)V2S$Y2E U4SAU
M-F9-5VEH17-M<$EA2#$T;U1%.&MJ,4YF:28C>$$[:THK;#AZ=$59-#132B]"
M66%N36-U47HW>BM".$4O.$%.5VU7;FUJ5C=F>3-D<#9M;#(P9C$O5D%+9VQM
M-5)7<U%98G)Y4$]1,#,K028C>$$[9&IL14I'231H>F-(3FI'43A"*VYM9C!F
M<BM$2G)7,7-T3W-O-V$S:E,R<S=:06MC83!615)2<TUR2DI,:U)I04M(2EI.
M<3)L43)J6"8C>$$[:S$W0DAA2CEU-&561FI7=FDU4$594D-23E9U='904$MC
M,VQN4R]-1W5A<G!K1V]A:613;')!8F$Q;6UH:FI)1$]I4W%04RM+5W K,28C
M>$$[.6M,;7=Z:6-O4FI)9U8U=&-A0DMP8V5E4$]8*TY98F$S,'EF.4%/;G%0
M03EV1W0S.$-G36DX<&Q8-&Y+:U9O84AO85E"<'-F:#)4-B8C>$$[=F9T.7EM
M575,>5ID1C5K=41C4E)85VI8;&EK<"]V-VE85'=I:GA)4S9D+RM"535I2$-+
M,FM$+W!V,4TK3'E4<T5%5DA42U=4<U9D:28C>$$[<G-69&ER1%!-,VQF>C5F
M=V]U;65:+W%Z0U%S4C9+>&9"43!8;$A5=#E/6F5,3FE(3TM'4C966F%V8DY)
M9%$Q3#8K1T$Y365I:U!#;"8C>$$[82]92G)82TIY:651<$Q&=GI&,'9Z='$X
M8U9N<'-+<G!%9'=K='=B4S1I3C-C;TE8<$<X1C-#='-)>&-E;5A5>71Z44A9
M9$UR5D18;B8C>$$[;#=8.55M.'%83C=P:&@Q8E)*66I-+SA!;V-M;4)6:VI7
M-6M32FUA6DAA3TUT8G-I8VM.05-0:7A6-D9I<G-694(K8R\X3C9H*V-M:28C
M>$$[,RML>&],:3,Q0S!T9%1D=$]U05AU64QZ,#)B-GA*6GEP.%!&5E8P:U=V
M.$%.44$T5F4K6499,V%F;4XU3W5K9V5/+UI&=5I$1F)M828C>$$[,W5)3UI%
M:U58365R1VXW<WE835-#5#="6F=!831Q,RM94#A!>6I%;B]-6' O=T0Q2'=9
M<7E01EA9<3=&6%EQ-T9867$W1EA9<3=&6"8C>$$[;75R96%R2V(X,&)$>3=,
M6BMT3DAD0U-+-SE9:TEG=%$O1#!Q54@W,$)T:C%82W!(8T(R,FPP36IP.&UC
M1VA%5C@K9C)F97EF4UI%=28C>$$[+TUU=#9V27=&=EEH3DYG:T]W06A8,7)L
M=FQZ:T-N+U5Z36YT0TUE+V8Y5'%&+VMY3U=B5#4Y86Y"1GAR8WAV47)D56=)
M0U<P92]H0R8C>$$[<6MJ*UEN25I/9&1Z5F@S2$8O3S,O5CEJ9FY(55E9.4]/
M;$QA+W!'*S%D6DQA,C K=$$T6F%34$DS-T5A2V%S,SA336YG9V(T<F]2-B8C
M>$$[=&MJ,%-4.'8O=T%R.4<X=C9D1CED=&AD-F]J1C-N;C1U:74Q3C19*U1Q
M;7=!-69A4'EO374Q5W-L33=';W-967A%339Z0V)(67%X6"8C>$$[>GHU1W,O
M3DQA5S X8V).<#EW<WA,<WDX-'%J,4E44E<K1U1I3BLQ37ET3G%4:G5U;UE4
M9TI-<4=W07!4,D=9<DXR2W5X5C)+=7A6:28C>$$[2&U4.'IT0C!'1TM393$Q
M0U%Y>G)B:&9Q5GI#2VLO159E94]*2&]"<T9*2C=E3UA1=T=89#@S17DV,D5/
M66QZ<C94*W!K3VUA,5HV:R8C>$$[,&DR.&0P:&I!3&978E,V=%%A,2MY8FE/
M3&PP+UIY=5531RM'55,U6#A14CDT634U,B]-3S P3U-(5&1-.4Q5=DU%.#9W
M=' X8VM44R8C>$$[,C9'1C=H<'!O;6QH3E!3:5EO<&1E6F]!8VDR36TP9E5)
M9%,P:7@Q1T8O56AV8F5+-&IK-$=0:W-Q0G=E1$9I=%%E:$\R2V]V1EA9<28C
M>$$[.&DO36(V>B]!37)9.'0X64AE0W5N97!C4FTT<D=F<GHP<6]V8F$S26)O
M87=3<T)V+TM-2W978FE.<&)E5TI31EHP6E%Z3'I516EL4R8C>$$[<'!Y2'1G
M5C5T0BM2=6Q2*VEF<FEW:7$O5S=E,&=-1G-55S9S-W-R8GA'5U0P3U5U;F=N
M-&U(>'911&%I<6,O;5!O=G$V6611*W8S:R8C>$$[9D<V,#AF5D5L<&)N+U19
M4E5X,#8W,38T5EIP9U8R2W5X5C)+=7A6,DMU>%8R2W%D>F-25S%V3&-43GAI
M:%)P2D<X1E562BLT67%W<B8C>$$[>5IC0WDP1%=F3F5O2U5A-V5A-61444U)
M<F-U94%0.$%X;$UN1#))=UEO;55T=7!P>DY6-EEW>"]Z4EHY.'0O=312.$5L
M.'IA=&8V1B8C>$$[-6,P3'DQ2F)Z>5AN;5)I;7!4>%)S>DDQ,4M*3'9I45%7
M:U!Q<V]8<E1E=5IT0U5Z26-O.'9H>61.<3@S1'=W;RMS,2MT-E!Q8VDR928C
M>$$[;%A%>5-F5F\W4T8U07EH94MR16A.2T5%8U%";4Y!6$E$=F-W-T)*+TM.
M;E!D97(U:W9W>'9D5%5#,%-505!"66<Q:&IO04%R4"]E4R8C>$$[52]A3E R
M4FQU95%(;TA)9F5I4&5Y5$UD:S=&6%EQ-T9867$W1EA9<3=&6%EQ<VQH:&Q#
M:59&:T-S2%5-06%-<'%R0W9C2&]C5G!F:28C>$$[<4$Q,E!11S!Y5CEF5S%/
M;'<P:VYA+T5:=# T.4=C>2]!2V5*>%9Z-C5O3G9(66,Y471963E32TIP;DMA
M3E9U0S1"4EE+;CDU>4)&028C>$$[;&-64BM+=7A6-#4K6E,R42].>GDR,&AG
M135/;4)F5B]23'DP1V]38V944S=*=GAU5%9R6E(X.71L6'-E2W5X5FIN-6<O
M=T1+35-F."8C>$$[>&5N+T%0569":7)).%9D:7)S5F1I<G-69&ER<U9D:7)&
M+WI%=G T=$-85#=893DQ5V%/>G0Q;U=(-WAH6&M"*WEF<W0X.&I),$A),"8C
M>$$[=4U4>4%(-F5:.7<S4#),3F(P*T=(5#E#.'%7;R]C6$TP555O-F8V2EI+
M2G!3869Z;$91+S8R6D=N2$-$3"MA4'1/>EAM>6Y*37E03R8C>$$[4G17=%E)
M3EDX,UAL-TQ'<W1P;S!9<TQB:V]91S5L<$QC<TMJ.6QF5%0O9W9F26YA3F0W
M:4%C57EF-74S-B\P2E@K6CEI,VU#,%1Y=B8C>$$[8G-Q5'9&3'%.>D]26#!9
M8F13<V5W23-L;%E,+T%+;V9W>DHP8W5!.%HY,WI:-4)E>DQT23!Y,C!R4S=8
M5&)A=F]7:U-X25<S66A25"8C>$$[:W@X5#%/67,U;55I5#%:9U5I.&=L46=V
M-T,T;&%+0S5I;&Q3<&5.2%9M1DYJ54$Q-S1A2W5A+W-6=5!Q>EA%475+9V5I
M6%AN56EO*R8C>$$[1W1E;4Y+<C1&9&ER<U9D:7)S5F1I<D(O3F8U5U=V;5-+
M0DPW5C<V8C!*,6Q54VU"9T5,1#%65&I%:$):3F@Q1F%60GI.=S9W-"M54B8C
M>$$[*U!I,7IX.%1*.4@P6CE-5C O4T8Q95)K2W%2,TII2WAH83 T0T]/2VU9
M,E1*>&1!1UE&2EHU;S!,5G18=#=Q>FU7>G8Y36U-4G0W1B8C>$$[,G5,1V%*
M-'E'.54S:TQ4.&ER<GE13$-L1"LQ=&QA57,O=T%*95I,:'9,,&PY3$,R<#9+
M63!K,39+-6Y795='3U)$36I7,W!#3B]R8R8C>$$[8V1*07HP56UO<GA'2W,S
M>%8R2W9.9D]T,V)7+S5K84UP,4]'>6UN5WA2;TI):$IC5$PY95!#3WI0<DEF
M:DQ&6GHV5&-).39I=498<"8C>$$[4DY"6$%R>&944C5Q=E!-,6Y*6C-'=FY4
M2717.68V:'%51W%7=V$R2G0T;EDS5EE9>49+4&-#1U905$MS55560D=&5V%F
M;5!F87=M;28C>$$[1S)I,'HQ8D$S5VYL<B\Q,%=H*W5W;6YP16-J=G1I<DY-
M0W5X5C)+=7A6,DMU>%8R2W5X5F=/9WIA4G(O04IW9W8T9%1&-2MJ-U5Z<B8C
M>$$[62]V:C9%<SE%4#A!94UW,E5B.4XV2$E70U$U;FAZ>%DU5T-,4$1F=3-)
M*W=F9V]'.&Y-6&Y05B].<3,U:VDP,$A3.5 P:V)T8S-,228C>$$[:4UI1&U+
M9G8R5F1L,TDY<S).,6I%2S-/.2]J>61F:WE#271M5VI7.6XU93!/1S-V<G5.
M6C%6-VDK=4I(0RMP3DEX;&YL,V]A1C)9+R8C>$$[3$U59WE/=UA(2&AJ6#0X
M,$8U67-:9%%S-S-7-W9N1%!R<D-21BM(;6QI<6Q,84DX9S%+;U1),V-->'DS
M3DQH26E0-&9V-G!I3W)*:R8C>$$[57%G57-8239S,4MN-V="*T=9>%IT-'%W
M1%%F>F$X;%A(;4AZ3G!T>'%6=%EF;S(W4E9U3'5E3T=/64-*26Y-8D]60C13
M>$UP*V<Y."8C>$$[=6QI;%%,2&E#26TO3E0X=G8P>F%H3F)G;5 Q968K-45K
M=E8T868S870Q;V-(:%-R:VUW,V5F;D8U1W0W;7ET:W5P3&E7+VYJ=%E"2"8C
M>$$[1WE$,4I70W)Y86(P9T)V,7A'1U,R>EEB:71+93)62F1I<G-69&ER<U9E
M8BMD=GIQ<R]+8U9S*V\V1'%52#%I-5=&1VY7,U)7:E9H-B8C>$$[>G@X6FY:
M:7%'<6=G0W1+:UID1$1X8VEX37%::#5F.$%-5#9Y<G8X06]U.7-)9W%V1DQD
M<D-%;%8K:&I-57,Q9'0X<FQ';5-'.'DK628C>$$[<G%'>C%#>CAT3F$V:C5M
M<S!J:V93,FQJ85=/3GE#6DI)9E9H8C="<6],<GE.0GE(6$EQ>#),.'I,=6$K
M,#!7<V-D>EE4=V%-.#!N<"8C>$$[4$9,33)T5%-W8S1K36HK:W-":#532S--
M:F1A-U9+<C!01EA9<3@K.'<R4#5J6$AM+U1P>DY&0C5B='(R06]D3V=7839-
M4FM(25A%:R8C>$$[>DLX85!25FLY1D0X0EEK,$9#<3E">%8R2W-C+TU(+VQ'
M2E K6794+T%0<5!G>%9K94MU>%8R2W5X5C)+=7A6,DMP2#5J,3ER37@V6B8C
M>$$[<#E*=&1V4GAT24]O:D)Q1%!,<V%);$-F96Q",W=%.4=Y3TTX4$5F<"]4
M*U!X>5DY2#57,%AY4&)Y,T=I4G9.-6LQ:%5S-%=L:V1X3"8C>$$[3E0K.5I#
M5U95:D%,=C1+2U9Y>D)H0FQ:-41M,UIT8E!*05%0,'@U2E8U6#AV6%8Q-7ES
M-S)#.6UU4$MU:GAT1EE"-'E9<FDW5E-S<R8C>$$[-C!"46AP6&0O5DIR>3)'
M,41M4FQY5T19.5)D4$=%<#5U2R]13UAV5&)Z<C5B,&YZ9#5O,&Y3-4EV54]K
M3CEB,4]C9EI70G@X1G,S*R8C>$$[5DUY9RMY9VYV:SE0;&QI9UIF>G1H*W8T
M3U9/26M1>G=!055(5$U&<UEL-7DX*S)7:TIC869P.7).<F5U<$-:;3!Y>EEQ
M,%5D4#=Y-"8C>$$[;4<P0RM&9FE0-TE/5U%X,W9Y0T-72&9L;&]M<V5C4$PW
M6%AN93<Q2U-32U9O5&\U;F5#,5I/2W-S:F5K=VML<EAO-S!R6#1C<WEY128C
M>$$[5#951&9M>G9Y+S5/,&)33&U:<F)23D]S-#)C4$)*8DEV<4QX5D9!4#=P
M1'553%8U9&9V>7%5>65Q445$96513D=M+TUI>C@R3DYD1"8C>$$[5E5T-4%G
M178W;TI%16E%65%J-T1#5FE2-&UU15I$=S!T8C)M4&UR>48U5#@Q=&%T<CEJ
M.61.;'E.<E=A84U)6'!Y2454;TMN:4XX128C>$$[8VAJ>55I,"]647%H4E=I
M9T%62DHR.%-D>FM%=#1Q-T9867$W1E5.9F%P<&QG14XY9'<R9VMQ27I026MF
M2VY7;DEI=$LT449T14DV3R8C>$$[:75J0FM907%W3E%19'=14F=63&9-<#AU
M>#9.8UA8;4M/,V938DY48S-"=30Q;&E14FEV4&EW8F-D<4-V:&EQ0FYU4$IM
M;C9N<%5:="8C>$$[258Q2R]A5CE,.4-Z85=7<VQ$3DQ71TYJ17 U:C%*1S1R
M=CA!16-66D1I<G-6945A5#5V=61++TUI+VAT9%@P4&YQ971.63,Q;DIE-B8C
M>$$[:$IF3W8V4DU+0F):-&UT,&QJ:5!P9TEW5VY5-UE693<T1EDO-6@X.&%&
M;T8O83)/;T\T;75L5U-Q2T-S551834YO<VMH2D9&33DQ1R8C>$$[=3%4,5!1
M2$961#AW-VTR6'DV.$Q3;TIJ9#9F4TUS3U@K.3!"-F1C5EI0:7)S5F5B868X
M06YD;RMO>7I,8E=,=WA20E-S;#=01&)L=28C>$$[5F1G2WE#;TDS1F-I4E X
M06UU>'DV4$1J1RMA0DYK96UZ=5!L.#!D+WET5W<O=T(Y5W8X03!N42\P>')*
M+TXK,7@K1%0O=T-Q9C=%<R8C>$$[2#@W-C$U2#$S6$QB561:8C!T4W0T-%DY
M2%-#5DIO=E574U-2>DTV<E%,4VQ"9SA#8W).5CA1-75N-U)';DA"0U%-2D@Q
M96XT9F-N,R8C>$$[;E X04TS52\P0DMD2T9L2&566&DP9#8X:V="4'AC5E-/
M259P-'94-6UM6%E"8W972T1Q3F-)>'@S:&QX>G9R1W1V;6QF;6)Z-2ML+R8C
M>$$[3'IA6F,V=F%W:3AI5T]E1S)H:TE5;6A94&-85#AI0C1R1B]S<VA,0D]8
M=3EZ;C94=$1$<'I'9D-4:TAF3&$O9U!V5E!),G%E5W9+2R8C>$$[6#%H<$UF
M.$%I1%4R;$-1,W1K,%ET:D<P56)G4&134#93+T=7-45(=%-M=WEZ2'!Z5RMW
M864P93!P86I*>'E";$MV9U!D>6]6.&5Q4R8C>$$[9FPY<3A8;6IZ1')K=FUN
M5U1$85=B1TXT6F)H479",TIE,U=:,G%K4F]/45-N2VQ+,$)",D=F84E%439N
M1UHU0U)-8TUF9GHY-TMR<B8C>$$[.#9.2U!M6B]+5V=T<#%T8DI#1$)R<SDP
M<U9N0V=503!I2TER;&5I27(P3S(Y2S!O1VU!2$9-;2LW.7)K.%A125!74'I:
M.'%E5%<P<B8C>$$[5#E$=F]T9"MV6$Q0<F0W0T1D4T5L9FIU1$I'-F]Z;"M)
M0T1O;TDR;TUI65-Y16LW9'I+=T4U.#)Z+VTY-6DP4V5(>7I9>&5856UO<28C
M>$$[5%AS-$8K>4XQ6E)$>FIT.78X<&XX3U!82S1C04\K-E1B2G9**VM7;FQR
M>7)B<F515RMN6$MX0UA6-6A*>E8W:6XW,F%3-&LK2BM48B8C>$$[.&Y05&)+
M-7ES<$=Y3E1Z9#558U945W)"9T]P1GI#9C%.:V5%<EE9:C54+TYJ5#E7,38X
M<TQW:7ET-%5K94LU=4HT4D<S0C!12U!G:B8C>$$[<51Y3$0T=6XS-4]73V=X
M13=,2C(Q-WE+8G-4='%/;&TW1DM3;6$S.5-T3G9I-6-U9WE.1FQ94S-Z1"MA
M9FQ(4DI)56MU1&4K=4=93B8C>$$[6D=/8TQX249(26-5<EAB0TE%;TUW1U=1
M>7),0VMQ,31Y2T=7=E=J0W516DPX5F1I<G-69&ER0B]/4#56,E!M25<O1%5,
M;3%-1%--,R8C>$$[<7EZ,V=0<54K>7,X<$5D3U W3U1J3VU%;U=Y8E).0G1D
M270P:6AL=4I323!J6G W:65:9F=&2V]K<VMI>"]*85I%;3)11DI(-34X9R8C
M>$$[5&5B3D]V<D=B6#<V>G1R=4UR2&%2>#)B,C9-65AI<7EV05I853@K6D)L
M<4=!2T9#05%%<G!V2DXS9"]O;&11=F],;V%24$900F0O528C>$$[>$AE+S90
M2TI),5=D2E%I0FQ12DQ32VIQ5#EM=4MS<WA6,DMV3FXX=65E+SA8=')M;UA6
M:EHV4W5O26QT<#EL2TQB,31'=4932U,Y.28C>$$[4T-4,35U1S9O2%@T=&Q.
M8TMV4V-#<V8X=RM2=$(Q+U5,5RLQ0DI$3F)+<U)#34%S:U-834XR<V-G25!W
M:64Q:F)A:#9I=$-C5E-Z."8C>$$[>F1,.'9R;TUU<C-L<&%,8W<S3VYK-FA.
M2$=*1558<TDO=E=&44M(>'A63V8X8F544"MR+T%+9"\P;'=F.#$T<3<O1S-K
M>B]Q+W=#;B8C>$$[9CE*8T@O3F5+=DM94$MV:W4Y1G9(9&%T<$=K>#(Q<VMB
M;3-V-')J,35X.755:FY&=W(T8C5D2$M2=GHY-T1H5B]W1$%0-6(O05!5,R8C
M>$$[5T@O22M(+W%V:R]Z2C=H.&@K<&5"2TY7+TPS>7@Y8VDO4FYN2%(P=&Y!
M16=M=6\P8W95;'5+:#5!,W<K*T$U-S5H0F=E.40K8G9Y-"8C>$$[.&QF;S%0
M,$YR96Q8,3(P=T5S5%A.<D(K-S1S4S-.<'0O:4,W6DUA<5A,:VE51S5F>30X
M:VYY>#9G,7935')H:$)A,2MS5V](<59&5B8C>$$[.5@Q=5!4=FED6$ER-&5Z
M=DM0-6-E4GIP>FY83EDP;7IU;&Q94E%I-G0U;#E,:7!$9G4U=W8R:3-A=4$V
M;5$U3$A(,V]F>40U2CAU5R8C>$$[97%8<VUQ,V5H,G-,<"LU:W5:9$YV=WIC
M*WE03$IW3D\K0V5C;G%S64AQ:G8X2V%$1"M94V%N8F%Z;T5D:VI)>5A58VQH
M2'A!9T-%:28C>$$[,59U4#)T=F9R:V9&,G!E13-A8RMC=$,P+UAR-GEU0C4Q
M,&%28E-0,#$Y4U=#2&E!,5%&5TIM5VU2:DU"36]7;79N0F\Y83!P8D](>B8C
M>$$[-W!B3TI6:V\X,79B:6EH:#EU1FUB=C!Y35I!9$5Y0DLV,E-W8GEQ3D-V
M9E!U;2MK.$115$MK;'1)2TU45VMJ>4LU-CDX94E89$HT9"8C>$$[<5(S:W4Q
M+TQV>7A9>C)O.'@V8F9E=DPV=G%45#)W2R]#1F]0:E!H:DM6<D=.2G1A86XK
M5F1T8U-Z5RMO-D]S>C=3:UA6=65T1#!,;28C>$$[;E%:1WEM;4TS96AE44QJ
M>G5V;6-E83E.4E9K:6LO4C1L='5(-W%.639C=E8O830Q*WIK*U!A;5!"=F%E
M-G=0>6DQ;#1N,4<K,'%:;R8C>$$[45)'4F524C!$57(O04AC:3$V9#AI2D5-
M:D5&3S0O3V9K;4].63 Q-U1G:4%+;RMT=V)!8D0Y=DEP8B]X=#5-+S9V.$%P
M,R]36$(O>B8C>$$[6&EQ85=6.5I8,7-L,5I8160Q87E6.4]E1C%K:F%H2VYI
M>6MG,$EP:7%T:7)S5F1I<G-69&ER<U9D:7)S5F53*V)V3#%V2"M:*VHS9"8C
M>$$[>70O<7-K='IA,TYH1&-#-G5B5TIX8T9:4D%)=E1T-V-7-E5N6G!35TY!
M0G1517$Y87=+-T95;3@S5U9P9C9/3$<U=31R4F)I-71"1R8C>$$[.#552SAI
M6$UC<7A!358U3DIW-'%09D956$AB84I,3DY$1D9B4$YB:TQ01W%X;&]Y>6AL
M1&=B<E930TLY<U969C!:<'8O3$I$+W=!:28C>$$[,2]P:7)V,%IP=CA!>7E1
M+SAI,2]P:7)V,%IP=B],2D0O=T%I,2]P:7%3-C5O=6@S1W)A1WIY5VQT3'!T
M>DQQ1%=Z<D=(;6E&;F-7>B8C>$$[04%K2&EH=5$U86A',DMP;%E,-60Q1S!J
M=DY01G!E5VMT9E-U3&-24WAT43!01C!Q<&]25$954BMJ3DXO-5I)9BM282\P
M>%8S-DTP,R8C>$$[+VQK:"]W0U)A+S!X5C,V33 S+VQK:"\U1G(O5$95:75R
M1'DS865:2G15=7)M>&=3,W-69W5,85@P:TU996)K<W(X:4])62]#2VI&528C
M>$$[.%A4=$Q:47DR<T1+=W%#23!)25 P67$S*VI.3B]W0U=32"]K5W8X051&
M6&9O>E1F*U=32"]K5W8Y359D*VI.3B]W0U=32"]K5W8X028C>$$[5$95:S W
M4R],.7 U:3%73C4W2U,Y,4M32S1J,"MK66UJ4TLS:FE0=U8U14AH>7)4=FEQ
M9"]O>E1F*U=32"]K5W8Y359D*VI.3B\U6B8C>$$[268X06M7=CE-5F0K:DY.
M+S5:268K4F$O,'A6,S9-,#,O;&MH+W=#4F$O,'A63"]+.6IA8519=&]Y6%55
M.7IB4WI44WA2:T)K5S9N:R8C>$$[;E%.1T-3=7HP2&I41E4U>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6:"]N1'EX-6TQ;#=B,&)I>6UT-UA69$XQ0S%G
M;%-3,VMI:28C>$$[<W!L;6Y6<&Q.>C9R4VQ0:'!'9UAV6$96;C5F951D9CAU
M-FHU:75D6'8W8E5',6DU9W59-7)E1U-";5I,9$EP6&MJ95-92U=D96ES4B8C
M>$$[,S)R>%96;65+=7A6,DMS2#%0>7 U<W5F3G1L<E5J85IQ149L8F%P8GAX
M4TQ,86QK=E)$.5AG;%=L,DI&47=N;DI55D1B4C=F17%M,R8C>$$[:TQ1.50P
M8E%0<6UP>%=S5CE*8U0S3G=,2C5*26UK=5I$3DDO2U))5#A5:G-E25%"4E)2
M,')I<DES5F1I<6QD<&1087I*85-P1&1.1R8C>$$[=W0U<$5-<4I)465$3D='
M:DQG2&-R>49F15EQ.'@X-&9L9C5O,2]72C<T,U9I<G9:-E9'6FPY5T@Q-VY4
M<G@W;5)N:$-3*VUK:7EC5B8C>$$[+V5/4GA(6$98;V9L,U-M,&IY+W!M:W1-
M8FAT3W1)3%%Z=#EQ47=2<DAZ4'4S1W5+<&AI<G-68V$P3D11.6ED>%A&6&YE
M:B]L-35M="8C>$$[=GI"2&UR5713=&)K=5@K=&96;W!,94]59E9L9VI0,58R
M=4%K<6-D-6A.57 X3DM9<3E%>%8R2W5X5D,V<$9Q8S%H3$AP9'I&6C-Z8R8C
M>$$[9E)U3&E&<FU.84U#,TM*6DE#,59Q0CA9;V0O8D973"M19DHO;41Y-V4V
M<3$O<5,S;'!F4WE4;V=,<WHS170Q4$LP-V-X*S=0;U-1>"8C>$$[8T99:C1+
M.3A66FQI<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9C
M4T%+;EE$1EAM;'0K9"MH>&%D<D8Y<59V228C>$$[1C R*T5%361O1FQA4S%M
M9V$U='!J5C%51C0T,T)"8C=9-&9A,GA61W0K8R]L;C8P;&]T;F9V9'EZ>#)K
M54AP>$MZ5%-4<F)&4&IL5B8C>$$[5C14>4MJ8VE015989D=L4W94=GHV,$,U
M3GIC1S)U;7,U2&=85&=)631J*RMT65IW:S!R>FU0:WI82$9E;F=/4C9M;%1/
M-B]/2%-.3R8C>$$[.'1A1G)/<6%F9' K;71.3W$K;&(K:DM);UEL:&%9<U=K
M:G%&1G=P1D)Y23=6,G=+<S$S.#1.37-.3W1,*TLR9$EX<6MU;F%R1&-L1B8C
M>$$[:V=I=&)G5W0Q2W9",U8O5&MD1#A,2#1A;G-C5E9V2VXU;%!Q5W S,FHV
M:F(K;'%#6&5R4F%D4$5G1G9.0G!D>#9*<BLY:VM%;$=5="8C>$$[54%(.6Y&
M56<P5#@W<$E%3"M:;V\R16UK-F)Q:T-A9$-Y=E<V<V)M*W4K6')4379#1TLQ
M*TAF:V9!:S1Q>49F>E!T9%AS9&58>3="2B8C>$$[.68P;7AU8G5+-'4T,4YO
M6&=L;6=62#E+55-!=$IB4#A*-'1X*TQU2W%P4F]F-6\K6719,6)1.5!3,'0W
M3G)Q,#%&9%DY5TM6;6DQ4"8C>$$[5%!45V%'2F95:B]D<3AO3E17;TY+9S<T
M<7IR>69Q.7IR6&Q,4DY9=6Q23')5<D,Q=DHP:4)%66MN:%=29V=9<U%O3&)6
M2GA63CA69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5E5R>C9P.55N*W4K;CE4.4YV<E!R8V93.4QI928C
M>$$[9E!L.%!(:C%R=%1&6&UF-6HO.$%+;U!2='8P<#E4*W1E<&(O04\X2#%$
M-GHV6#%E6#9V-G9R9C=O-%8Y3W4Q95!(0W))3%@O04I68B8C>$$[.5%T=E<O
M4F93>B\S=BMR+T%&;C%E22MQ*W8V,S=Z,78U969X5G=+,7!N+TMM*V%F;W8X
M07<W>G%N1#9T.5)R>6]N<# T9#9E;G@O,B8C>$$[4'1I<7!E9CAQ;"]2=&HY
M8R]12#9-*W)3+V\S,79Q9F]F5DMR-C-O8W9G.4MV2&YX*TAP6$96=R\U5E(Y
M53%#;C9"*W X6E P<E0V;B8C>$$[-EA(,6@V=C%J.6UN<E4U8R]W0G)R=FEQ
M33!F+T%!1GIN+U%8-DTY8C!N.68Y2"]6+U4Y3W9X,3E(-'%C<58Y.%934'DS
M+WEQ<B]$="8C>$$[:G@O4C-O9E4W2&@K:V9Q;C%R-G(V3&9O+W=#<U8K3"LT
M-65L>BM,:EAV>7A62E!),R]+<78P;')N,4QL>#E+-"]3,S$O=T-Q+U9F5"8C
M>$$[*W,O=F97-&9$6#%/;G)F1E-T4#)S2W-Z=E X04$O,6U,,"\P9BMM4%1U
M=C!D-D@Q6#8W,% Q;C9T>C-R6#=F878R<T-O-WEH*VEF."8C>$$[2C9**VAU
M9C9)*V]7=C9..5-V4#9T-DLK:GER=GDT57)I<6)9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<2\O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" @(" \>&UP34TZ26YS=&%N
M8V5)1#YX;7 N:6ED.CAE8C8P,SEB+6,Y,#(M.#8T-RTX,V0R+30T,3<S9F8T
M96%C.#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#HX96(V,#,Y8BUC.3 R+3@V-#<M.#-D,BTT-#$W,V9F
M-&5A8S@\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$
M,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$
M/GAM<"YI:60Z,&9E-C$P8S M,F5B,RUC,30W+6(R93,M.3<X.# S-C8U9#$Y
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.C!F938Q,&,P+3)E8C,M8S$T-RUB,F4S+3DW.#@P,S8V
M-60Q.3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y
M,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD
M:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.CEF-C5A864Q+64T9&4M,V8T-RUB9&-E+6(R.3@T.6(Y,6$S
M,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C R-"TP-RTS,%0Q,3HS-#HQ-2LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@,C4N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.CAE8C8P,SEB+6,Y,#(M.#8T-RTX,V0R+30T,3<S9F8T96%C.#PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R
M-"TP-RTS,%0Q,CHQ-SHT-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T
M;W(@,C4N," H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/&EL;'5S
M=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R
M='5P4')O9FEL93X*(" @(" @(" @/&EL;'5S=')A=&]R.D-R96%T;W)3=6)4
M;V]L/D%D;V)E($EL;'5S=')A=&]R/"]I;&QU<W1R871O<CI#<F5A=&]R4W5B
M5&]O;#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R
M=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6
M:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ
M/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM
M.G<^,C<N.3<X-3$V/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XQ
M-2XT,# V-S4\+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!I
M8V%S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ
M93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"
M86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM
M97,M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%M:6QY/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N
M=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E
M(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N
M=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL
M94YA;64^5$E"7U]?7U\N4$9".R!424)?7U]?7RY01DT\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97,M0F]L9$ET86QI8SPO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/E1I;65S/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9"!)=&%L:6,\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/E1)0DE?7U]?+E!&0CL@5$E"25]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL
M94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1I;65S+5)O;6%N/"]S=$9N=#IF
M;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^
M5&EM97,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y2;VUA;CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14
M>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP
M,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$E27U]?7U\N
M4$9".R!425)?7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*(" @
M(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA=&5.
M86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/DUA
M9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL;W<\
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U<$YA
M;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X;7!'
M.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S
M/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^
M5VAI=&4\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y";&%C:SPO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STY($T],3 P(%D]-C4@2STQ/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^."XY.#0T,# \+WAM
M<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G
M96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXV-2XR,S0S.3D\+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ
M+C$W,3DP,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-S4@33TW-B!9/3 @2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'
M.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M-S4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^-S8N,3<Q.#DY/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STX-R!-/30Q(%D]
M,SD@2STY/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT:6YT/C$P,"XP,# P,# \+WAM
M<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^.#<N,3 Y,SDY/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-#$N-# V,S Q/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXS.2XP-C(U,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXY+C,W-3 P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,].#0@33TW-"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT:6YT/C$P
M,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F-Y86X^.#,N-3DS-SDX/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S,N
M.#(X,3 Q/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STY,"!-/3@P(%D],S @2STT,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I;G0^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@Y+CDY.3DY
M.#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C@P+C P,# P,3PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,S N,# P,# Q/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^-# N,# P,# Q/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STV-R!-/34P(%D],SD@2STQ
M,CPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I
M;G0^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C8W+C$X-S4P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C4P+C,Y,#8P,3PO>&UP1SIM86=E
M;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^
M,S@N-C<Q.#DY/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,3(N,3 Y-# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^2STV
M,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N,# P,# P/"]X;7!'.G1I
M;G0^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT
M83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^-C N,# P,# R/"]X;7!'.F)L86-K/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \+WAM<$<Z0V]L;W)A
M;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U<$YA;64^
M"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XQ/"]X;7!'.F=R
M;W5P5'EP93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z0V]L;W)A;G1S/@H@
M(" @(" @(" @(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3 @2STQ,# \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O;&]R86YT
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$U+C P/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A
M8VME="!E;F0](G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)"A0.#PP0
M%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_VP!# 0<'
M!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"C_P  1" +M!6(# 2(  A$! Q$!_\0 '0 !  ,!
M 0$! 0$           8'" 4$ P(!"?_$ &<0  $# P$$ P<-# <$" 0!#0$
M @,$!1$&!Q(A,1-!40@4(F%Q@9$6%Q@R559TDI6ALM'2%2,V-T)25'63E+&S
M,U-B<H*BP20UT^$T0V-SM,+B\%>$I,,F.&6#XV2C)41&9G:&U/_$ !L! 0$
M P$! 0             ! @,$!08'_\0 .Q$!  (! @,$!@D#! (#      $"
M P01$B$Q!1-!410B,F&!\ 85(U)QD:&QT4+!X18D4_$S8B4TDO_:  P# 0 "
M$0,1 #\ U2HOK[7=CT-;!5WRI+7OST--&-Z68C\UO9XS@#M4BK)9(*2>6"!U
M1*QA<R%A ,A X-!. ,\N*ANF]"4IKG7_ %5!!<M2U.'ODF DCI!U10@\&M;R
MWN9.3UH*1O>WK6MYE<-)V 4E+GP'BG?4RGQY]KYL>=<>+:EM@IG]+/!721\]
MV6T -](8#\ZU\ &@!H  Z@B*SSHSNB?]KCHM>6DV]SCN]]T['!K?&Z-V7 >,
M$^17_05E-<*.&KH9XZBEF:'QRQ.#FO!ZP0OS<*"CN-.ZGN%+3U4#QAT<\8>T
M^4'@HEI_2TNC]1"/3L;CIFOWC/1;_@T,P&1)'D^T=C!:.1+2.&41-D1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1NJ+9=M1Z@;5Q,K(V4=.VF,?2SD_>]XY/6,XY<.)PM#("(B(X&T(AN@=2EQ
M ME3Q/\ W3EE/N6"!M7@R>='-CT!:?UCHB'5<=1!<+W>X:&<!KZ2EG9'$0!C
M'M"2#S()(41LVP73-DN4-PM-RO\ 25L))CFBJF!S<C!_(ZP2,(JUJF>*EIY9
MZF5D4$32]\CSAK6@9))Z@LT:GVNZ1U+K '43;C4Z;MDF]1T<$#7,JY1_UTN\
MX>"/R68Z\GGA7EJ315-J/2HL-VNEVEIB\/DF;,QDLP!)#7D,P6\1PQU!0'V.
M&BOZ^\_O#/L(D.9?.Z'M%;;WT&DJ"Y&\56*>E?41,9'&]QW0XX<<XSG&.*F6
MMMKFGM"WJDLM[-=/5NA8^66&)KFL!R 7<1Q."< %<VQ; M(6:\T-SII+H^>C
MF9/&V6=I87-((R P9&0N_M%V6:<UY-%4W>.HAKHF=&VII7ACRW)(:<@@CB>8
M14ILUYM>H+0ROM=93UEOE:?OC#EN.L$=1[054&P#2\-'K'6M_MC RQS53Z2W
M%OM9&"0EQ9VM!#0#Y>Q=C3FP72=ED>73W:NB?[>"HJMV)_\ >:P-WO(>"M2E
MIX:2FBIZ2&."GB:&,CC:&M8T<@ . "(^J_$T4<\3HYHV21NYM> 0?,5^T0>+
M[D6WW/H_V#?J3[D6WW/H_P!@WZE[408_[K"F@IMHE"RFACA8;;&2V-H:,])+
MQX+5>DOP5LWP*'Z#5EGNN?QD4'ZLC_F2K4VDOP5LWP*'Z#45U41$01$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%!-8
M[4K#IJ\168-K+I?)" V@M\72R GD#Q !Z\9SUX4QNU0^CM594Q-WY(87R-;V
MD-) ^98][G?4=%3[6G7#4E2WOBOBE8RIF/#IWN:<DGED;PS_ &L(L-&5&U"B
MM,+)]66.^6"F>0T5%53"2+)Y NB+B#XB N_H?5MOUG:9;G9VS]Y-J'P1R2LW
M>EW<>&T<]TYZ\'AR7KU=9H=0:8NEIJ&-?'5T[X@#U.(.Z?*#@^9<38_IZ?2V
MSJS6JNBZ*LBC<^=F0=U[G%Q&1P.,XX=B(YNJ=KNG]+5II;[2WFD>7.;&^2A<
M&2[IP2QQX.'+B.T+SVO;1IRZTU146NBO]9!3_P!-)3VY\C8_[Q&<*H>Z_O+:
MC4EDL["#WG3OJ'X_.D=@#T1@^=6SW-MD^XVRFVO>W=FN#WUK_(XX;_D:T^=%
M2#1FTG2NL)C3V.ZQR58&332M=%)@<\!P&]YLJ8+!%XK74^UZNJ]/> YMZ>ZD
MZ+A_UQW<8ZCV=A6]T!<R^Z@M%@ACEO=SHZ!DF=PU$K6;^.>Z">/,<ETU\Z@P
MLC=-/N!D;2XN</:CK_@B*SO&W;0ENRV&YS7"4<.CHZ=[L^1SL-^=6; \R0QR
M.8Z,N:'%CN;<]1\:P]H.C9K?;=2N9 UE+57-]<^-K<-;$UQE+<=0P,>=;D14
M+V@;3--Z%#&7JJ>^L>W>924[=^4CM(R T>,D9ZE'M%;==)ZHNT5M;WY;JN9P
M9"*QC0R1QY-#FN(!/CPIQI[2]OLPJ9 P55?5R.DJJVH:'2S.)ZSC@T#@&C@
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M:@FD;OQ6]CZU^>T#=;_F<T^9;60E1VR78/!I:Z07K4E9%7W* [\$,(/0Q/\
MSB3@N(ZN QSXJV#JK3P.#?K3GX9']:]]VAJ*BU5L-%(V.JDA>R)[\X:\M(:3
MCJSA9=]C)J#W=M7Q9/J0:BMURH;E&^2W5M-5QL.ZYT$K9 #V$@E0O;M??N!L
MMOM0QV[/41=Z1=N](=TX\C2X^9?K8OH670&DY+75U$-352U+ZB22$$-.0UH'
M'CR:%5?=A7S=@L-AC?Q<Y];*WQ#+&?QD]"(Y7<?V/I[[>[Y(WP:6!M+&3^<\
MY=CR!@^,M2JK.YHL?W'V5T,SV[LUQD?6/\A.ZW_*UI\ZGEYU+9++5TU+=[M1
M4514G$,<\S6.?QQP!/;PRBJ]VRT^THVNNGTG<*%EN8TN=!2QN;6%F..''()_
MN[I[,JG^Y9U+2T6MY+5745/)57)KS#7.;F9CPTN+-X_DN /GPM<D@-)<0 .)
M)60-@5B=>]M51<Z",BU6V:>I+P/! =O-C;Y3O9QV-*#3VOM+1:RTS462IK:F
MCIZAS3(^GW=YP:<[IR#PR!Z%EO:GL*N>C[9-=[56"Z6N$;TWWO<EA;^<1Q#F
MCK(Y=F.*U<-363[O&R?=:B^ZX&>].F;TG+/M<YSCCCGA?74TU)3Z<NLMQ+11
M,I973;W+<W3G/F1%-]RQKBMOUHK[#=IWU$]M:Q]/*\Y<83PW2>O=(&/$['4K
MV)P,GDLV=Q_I^HC^[FH)F.932M;1P$CVY!WGD>(8:/3V*X]K]\]3NS:_W!K]
MV44QAB/7OR> TCR%V?,BLFLSM'VZ \9*>XW3/_R[#_PV+<0&!@<EDON1['W[
MK2XW>1N8[=2[C#V22' _RM?Z5K1"19_[K^\=!IJR6=CL.JZEU0\#\V-N!GSO
M^9: 66=LY]5_="V/3[?#@IC3TTC1RP3TDA^*[YD(:!V9V?[@Z L%M+=V2"CC
MZ0?]HX;S_P#,2LT]U!=);]M1I+'1_?#10QT[6#KFE.\?F<P>9:Y>]L4;GO(:
MQ@R3U !8WV4L=KK;\+K4#>A%5-<WY_):TDL'F<6!"&@]?ZII-D^S:BCIV,EJ
MXH645#">3WM;C>=X@!D^8=:AG<^:=EU3%5Z[UF3=+C52NBHS4@/;$QIPYS&G
M@/"R!@< TXYJN^ZFU%%?=3V06^<S6QE"9(7AI#7N,TC'.;GF/O8P>1QD<%H_
M1<=+I'99:C5$14]!;&3SN["&;[SZ=Y!G"MOC]*]TK5.T]BGI);E%2ST\7!DC
M7[K9 6CA[8N(["IGW5.O;E:ZBCTO::B2E944_?-7+&=USVESFM8#U#P23VY
M[57^Q"QUFN]KSKY4QDTM+5.N=5)U!Y<7,;GM+L>8%3_NG;=IV\W^RT<=Q$.K
M9#'2LCP.BZ)[_!,SB?  +B0>)X\L8(#LNT18])=SQ<S<:&F?7S6QT\\\D8+^
M^'M\ !QXC=<YH&.SQE5MW->FI-5W:K?5W2[4]-:#!-"RGGW8W.+R=UP(/ [O
M(8ZU:FMM&;0-=6:AL-SJ;#:[7$6.J9J:669]06C@0TM;@=>[GGCCP4_V<Z(M
MF@[ VV6H/>7.Z2>HD]O,_M/8.H#J])(2E<O5-WCL.F[I=IL;E%323X/66M)
M\YP/.NHJRVZS]^6FQZ6B?B74%SAI7@'B(&N#Y'>;#?2B*JVJ:>DH.YTTO+4
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MYZE?:H:@V!T^F=2Z?O&G[A5UCZ2X125$53N "('PG C'$<.''*OE$$1$!$1
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MF_H,_P 5R>IYOZ#/\5RF'KW7CW,M_I?]:>O=>/<RW^E_UK+ZNR_=AE]9ZO\
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M/G4UW&_FCT+GVB[TETEKXZ!QD91SFGDD \ R  N#3UXS@]AR.HHCHHB("(B
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M?"9*IS@V($8!:UK3GF>L<AS7=1!46Q?9YJ39T*VFFJK174-9(R1^Z^1DD9'
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M/K5>;6MH6IK5M;NTENN(IY;?*^F@D9!&'"(X.XX[OAMSQP[.#Q"XOKX;0??
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M .95"4C)=9ZYWIW8CGE+WGJ9$WJ]  \I5@?/4U4-,[-8Z#<#;E?7=))Q\)L
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M'=S(9I0_&96\@6]H ZNKB>M6ZKJ;3-^'PAAV;CK7%Q[[S;J(B+G>@(B("(B
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M!YC!QXUI!$$1$!$1 5 =U3>9ZQNG]&VP[U7<JALTC >)&]N1M/B+B3_A"O\
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MH<R2-P<UP/(@CF%]$1PM<ZBATKI6XWB=N^::/,<?]9(3AC!Y7$!4OZZ>U?\
M^'COW*H^TNEW1%WU+3WG3T=AT_57*AMT@N,SC2R2P/E!(8UV[CVO%W/K'8O!
MH[ND*.IKF46K[4ZVN+MPU,#B]C#_ &F'PFCR$^1%6ALNNFI[Y9)KEJ^@9;*B
M67<AHFQ.88V-X;SMXEV7'/F [5,E\Z:>*IIXYZ:1DL,K0]DC#EKFD9!!ZPOH
MB"(B B(@(B("(B B(@(B("+YU$T5-3RSU$C8H8FE[WO. UH&22>S"AVD-J&E
M-77B:V6.Y&6LC!<&/B='TC1S+"1Q_B@IW:?=]:;)=67&ML$C9--7>H=5M;-#
MTD4<S^+VD\"TDY(P0"#V@J,^R2UEC_H=D\O02?\ $5[ZIVL:"M]=76._UX=+
M"XQ5%/)122LSV'P2"J^=?]@;JKIS1TF_G.!0U 9\7=W?F17*V=7[6NU_5-O=
M>7LATS;*EE94"GAZ.*21AWF,R<EQSCAG ''L6G%4ULVPZ-=76.PZ.#9W5=7'
M2B&.F=3QP,<>+N+0/,.U6RB"(B B(@(B("(B B(@(B("(B#(G=<_C(H/U9'_
M #)5J;27X*V;X%#]!JRSW7/XR*#]61_S)5J;27X*V;X%#]!J*ZJ(B((B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@+F:ENC+-8ZRND.#$P[G#.7G@T>DA=-5EMINKHZ>CM4>,2_
M?Y/(.#1Z<^@((IL^$+;O6WRZ/)I[;"^JD<>)<_J\_,^7"C6R^WOU3M)BJJL/
MD9'(ZNF).>(.6Y/]XM77UC-)8-FE!;@YC:B\S=\S-YNZ%H!:/%D[I]/C4VV
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M+ S3>E*"WAN)@P23\<YE=Q=\_#R!2%3-DX[S)HL'<8HK/7K(B(M3K$1$!$1
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M9X&N.>CR2U[1XLAIQVD]JT0J"[E:P5+8=0:IJX711W24,I@X8WF!SG.=Y,D
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MI>2ST,=KM-'00\8Z:%D33VAHQE>M:,V3O+S?S6!?.JGCI::6HG=NQ1,+WN[
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M3>JJ"ZZEOM'+2TU2QU/#&TL,TH.6-)=RX@>",YY+1B B(B"(B B(@(B("(B
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M.<GSKJ(BYIG>=Y>G6L5B*P(B**(B("(HKM$UA3:0LIG>!+6S9930Y]L[M/\
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MZ?ME3WLZ.-KGEV[QEPUH)+G$%@P,\ K<NFV>V:=,$=QTGJ>W6SA%%434 BC
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MB^1Q''R!@])06'#K77,^S:37D8L[*5H=.VTFG>2:<.W2XR[^=[ )Y8QZ%/\
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M,_K+_P"Q,I H1M6O#;!;K3=',+S3UI<UO:XP2AH\F2%MPUFUXB&-IVC=7G=
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M("(B B(@(B("(B B(@SQK_:-9-G6U6NJK##)7559&V.\TC2&1=(T> ]K^.)
M#APP0<]1ROE[*"D]ZT_[Z/L+P6;91;M1;8]:4>KIZJ)S9C74D43PPU$4KW'?
MR0<AN6@XZSXE._8[:'_-N?[U_P"E%Y(S9]OT^J]5:>LULLYMS:JOB9/+),V8
MNCSQ:!NC&>''FM#*F/63TSIJ^6"[V:MEI*FFN,+MVLJ 6S#/M&^#[<]2N=$$
M1$!$1 1$0$1$!$1 1$0$1$&1.ZY_&10?JR/^9*M3:2_!6S? H?H-66>ZY_&1
M0?JR/^9*M3:2_!6S? H?H-1751$1!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5%[1:J2[ZYEI62[T<;
MV4T?8T\-[_,2KINU:RW6RJK)3AD$;GGQX')9JDK6P07"NJ=Y\IC>(SVROX Y
M[1ESO\*;[<VW!AMGRUQ5ZVG9XXZ4ZOVA4]O@F+Z9\PIHI,<H(Q@'']UN?*5J
MMC0QH:T - P .I43W.=FZ6X7*\2Q99"P4\+R.&\[B['C  ^,KW6%(Y;O<^D6
M:O?5TM/9QQ$?'_K81$/ <5F^>47W0]X;+<+=:(SGH&&HE_O.X-'H!/G5E[+[
M0;+HBV4TK V=[.GEX8.\\[W'Q@$#S*C+BY^NMJ;F0D&*IJA&PCJA9PWOBM)6
MG!P& O1U7V>&F+XRD"\UQEJ8*1\E#2BJG!&[$9!'GCQ\(@KTKEZHNK+'IVXW
M*0M_V:%SVAQP'.QX+?.<#SKSXC>=DM,169F6=]KUZK=0ZQ912TXADI *9M.R
M42#I"<G! '$Y \RL;9UI2Z:.@DD]3\-7<I<A]2:YHPW/!K1N\!RSVGS*!;%K
M0_46NW7*N=TC:,FKD+N._*3X/SY=YEI-=F>_!$8X>1H</?6MJ;3SF>73^'+M
M-9=*B=[;C:F448;EKVU0ER<\L #'E741%QSS>Q6-HYSN(B**C&I-=6+3=>*.
M\5,L$[F"1H$#W M.1D$#'4526V#746J:RGI+5(\VJG&_ES=WI)#GPL'C@ X&
M?&K$[H"T4M5I2.Y2/9'5T<H;&3SD:\X+!X^1\Q6=5[?9VGQS6,L=8<N:]M^%
M>NS76>D-+:7IZ&2X/-9(>EJ"VFD.9#U#AQP !YE<<3Q)$QX#@' . <,$9[0L
MR[%M,_=_5D=14,WJ&WXGDR.#GY\!OI&?(TK3BX^T*4IDVK.\^+;AF9KS$1%P
M-HB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(JVU)M=M%DO55;N\ZRIDIGF.1[-T-WAS R<
M\%S/7RM/N37_ !F?6NFNCSVC>*L)R5CQ6G<IIZ>WU,U)!WS41QN>R'>W>D(&
M0W.#C*IL[=2"0=/X(YCOO_T+H^OE:?<FO^,SZU3.KJ^ANFH:VNM5/+3TU0_I
M>BDQEKC[;EU9R?.N[1Z+>9C/1JR9?NRM7U]O_P"W_P#ZO_T*<[-]:5&LXJR<
MVKO*E@(8)#-O[[SQ( W1R&/2%EE7)HW:I8]-:=H[9!:JYQB;F1X+!OO/%SN?
M;\V%MU6AI6GV-.?XL<>69GUI7LBJ/U\K3[DU_P 9GUIZ^5I]RJ_XS/K7F^A9
M_NMW>T\UN(N;IR\TNH++2W.@+^]ZAI+0\8<""00?&""%TES3$UG:6R.8B(H"
M(B"O]K]PKI;=;]+V&=T%YO\ -WNR9I.8(&^%++PX\&\/\2KKUAM4_P#Q%K?B
MR_\ $7;VO;)=0ZSU2+W:]104IAA;#30.:]G1@<3X;2>)<2<X[!U*N(M8[2MD
M=XIZ?5O?%RM+W8 J).F9(WKZ.;F'8ZCYPBM&;.]+^I'3$%LDK)*ZJWG2U%7)
MG>FD)]L<DG@ T#CR 4E7.TW>J/45BHKM;).DHZN,21D\".T'L(.0?&%T41"]
MK-ZJK9ICO&SD_=N\2MMU" <%KW\'/\0:W>=GJP%5OK#:J_\ B+6_%E_XBE6V
MC9?>]>76@K+;?H:&.AB+88'QN&'DY<_?:>9&Z.74JGJ+UM2V/UT#KW/-<K.7
M[N9I3402#\T//A1G'(''D*+#0>R[1DFB[#+25ERENEPGE,L]9+G>?U-;Q).
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MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M=.'3.DJ6CE_Z5+]_GX8P]P'@^8 #S+U:I_WEIG]9?_8F4@4?U3_O+3/ZR_\
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M!$1 1$04EK"DV6:7U-<)-;.IJR[W6H-46RPOE= P@  AN0!P)R>)RII3[,-
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M$(HV[D?>\KWCP> QO-' \3YU.;!KNT6K9[/1MKHX[N^>KZ&GE!C>[I*B0M<
MX#/@N#N"J6_S8BC@;Q<\Y('8DSM&[M[.TLZO4TP^$SS_  \4\V V W'4-5?*
MEI,5$-V,]1E>#GT-S\8+0*BNS'3[=.:/HJ4@BHF:*B?>&#TC@,CS# \RE2QK
M&T-_;&KC5:JUJ^S'*/PCYW%7>UW7,FEZ.&BMA;]TZII<'D9Z%G+>QUDGEY"K
M$6=-OD,S-<-DDST<E*PQGJP"X$>G/I7;HL=<F6(L\J4 N%PK+C.Z:OJIZF5Q
MR72O+C\ZFFRC7$FF+D*.JW76JJD'2\.,;C@;X/9P&1V* K^M!<X-:"23@ =:
M]Z^*MZ328Y,6TQQ&1R7,U-=X;%8:ZY5!:&4\1> ?RG?DM\YP/.O1:(Y(;311
M3YZ9D#&OS^<&C/SJG>Z)U"X=Y6"![=TXJ:C'/K#&_P 3CR+YO%CX[\+5JLW<
M8INBVQ^T2:FU^;A7-;+%3.=63EPX.D).[_F.?\)6EE -B>GG631L4U1"(ZNO
M=WP\\SN$> #YN./[14_66HOQ7Y=(:>S\/=88WZSSD1$6AW"(N=J.ZPV2QUMQ
MJ7-:RGB+QO' <[\EOG.!YU8B;3M!T4WW0VHNEK*2PTTIW(1T]2T'@7'V@/D&
M3_B"G^R#3@T]H^G,K2*RM J9MX8(R/!;YA\Y*I?9W:9];[0#57%O2P"5U96'
M.!SR&^0NP,=F>Q:>7I:R8PXZZ>OXRT8O6F;R*/ZI_P!Y:9_67_V)E]Z^R3U5
M7),R^76F:_&(H71!C>&.&6$_.O!4Z1=4R4[Y]07I[Z>3I8B7Q>"[=+<_T?8X
MCSKBI%8G>9;9W\DH11[U.5/OEO?QX?\ AKN4L1@IHHG323.8T-,DF-YWC. !
MGS+7:(CI.ZQ+ZHB+%1$1 1$0$1$!$1!%M6_A+HS]8R_^$G4I46U;^$NC/UC+
M_P"$G4I64](2/$1$6*B(B HMLP_ Z#X35_\ B95*5%MF'X'0?":O_P 3*LH]
MF4\4I1$6*B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(OA7UE-;Z*>LKIXZ>E@:7R2R.W6L:.9)47
M]<W1/OIM'[RU!+T7,T_?K;J&DEJK+5,JZ5DABZ:/.XYP )W3U@9QD=>1U+IH
M"+SW"MI;=1RU=?40TU+$W>DEF>&-:.TD\ HQ!M*TE*^$?==L<<SMV*>:"6*&
M0]C97-##YB@EZ(TAP!:00>((ZT0$1$!$1 1$0$1$!$1 1$0$1$&?MMVS+4/J
M@FU=L_GJHZR=H[\IZ28Q2EP&-]F",Y &6\\\1G)5&W*\[1*ISJ"XUVJ7N/@N
MIY7SY/B+>M6YM6VS:I@UQ5V?1;-REM\W02.;3"9T\H]L#D' !R,#!X9SQX:*
MLE145=FH*FN@-/5S4\<DT)_ZMY:"YOF.0BLT; MCMV]4-)J35-))0TM&\34U
M-.,2RR#VKBWFT \>/$D#J6I% ;]J2ITMM&LU%7U1GLVHBZ"%KP ZDJ&!H :1
MS8_> P<D.XYP<*?(@B(@(B(/%>;51WFA-'<HNFI2]DCHR2 XL<' '',9 R.1
MZU[2!C!'!%7FU"]W*JQI#2&'Z@N,?WZ;.&4%.>#I7GJ)Y-'/K'(9#/&RNP-O
MFWV22RQXM-ON,U9OL'@LB:]VX/.=T#R^)7+W4&J'6#25KIH!&^HJZ^.7HY!E
MKV0D/(< 02-[H\^52[1FE;#LLT;4;CPV*&,U%=6R#PY2T<2?$.IH^<DDR6OM
M5JOM/"^YVVDK8]W>8*JG:\M#L'DX''4BLTV3NFKQ%.T7NQT%1!GPC2N?$\#M
M\(N!\G!:*T1JRU:SL,5ULDQD@<=U['C#XGCFUPZCQ'IR%"]:;#M(:@HY>\:!
MEGKR#T<]&-UH/5O1^U(\@!\:KWN6*.Y6/6NL+#6<&TK6MF .6B5CRT$>4;WF
M0:47CN]SHK-;IJ^Z5,=+10@&2:0X:W) &?.0O8HYM&TV[5VC+G8HZEM*ZL:Q
MHF<S?#=U[7<LC/M<<T1SO75T-[Z+;^T3UU=#>^BV_M%2_L7ZOWTP?N1^VGL7
MZOWTP?N1^VB\D,[IB_VK46NZ.KL=?!74S+>R)TD+L@.$DA(\N"/2M=:2_!6S
M? H?H-6']J^A)-GVHH+5+7LKG2TS:GI&Q=&!ESFXQD_F_.MP:2_!6S? H?H-
M0EU41$01$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$'&UC>76'3M77PQ">I&[%3PDXZ29[@R-OD+G-SXLKRZ4TK3V
M9KJRL<*^_5 WJNXRC,CW=;6_F,'(-' #Q\5XMJCVTNF8+E(?O%MN%)6S#_LV
M3-+O0,GS*71O;+&V2-P>QP#FN:<@@\B$'EN]KH;Q0R4=UHX*RED&'13,#FGT
M]?C5(VC9PVW[88[=),^6T0P"Y4O2.WG%C7AO1$GB=UY;Q_-(SQ5]*&OGCKMK
M=/%!(TNM=HEZ< \0Z>6,L:?-"3YQVJ3&[HTVIR::TVQ3M,Q,?"4R1$5<XJL[
MH-E!ZF:.2=K>_P 5&[3G/A;N"7^;@//A6FLZ;:[P^^ZUCME&.D;18IV!O'?E
M<1O?/AOF79H:3;-$^7-)1>R:-O\ >Z)M9:K;)44SGE@>'M:,CGS(]*M'9OLI
MFM]PANFI#&9(2'PTC#O .')SSRX=@S_HK,TG:6V+3EOMK0T&"%K7EO(OYN/G
M))766S/K[WWK7E!$/A<*R"WT-165<@CIX&&21YZF@9*S%IJDFV@[2M^N)=%/
M,:B?/5$W\GQ<-UOG5B=T%J?O6W06"DE(FJ<2U(']6"=UN?&1GS>-='8+IH6O
M3;KM4-'?5QXLR.+8@> \YX^3"U8_LL<W\9Z/*U'^ZU-<,=*\Y6<UH8T-8 UH
M& !R 7]1%R/6$1$!4AW0FIV/[WT[3.!<QS:BI(/(X.ZP^8[WQ5;^H;K!8[)6
MW.JR8::,O('-QZ@/&3@>=9PT5;:G7^T-U3</#B,O?=42,MW 1AGD/!OD\B]#
M08XB9S7Z5_=IRS_3'BM_8IIO[AZ2945,'1UU>>FD)]L&?D ]G#C_ (E8"
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M/!]/:-^HRURYMI]F.31GG)7%,XHWEG_4^H*_4EWEN%SEWY7<&M'!L;>IK1U
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MXN\B]O1Q.#',6ZRX-1VABQQ/#.\OJT@C@NC:KS=;;'44UHJIX>_0(Y&P^VD
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MF@X^=>I:FP1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M(7*L?/"TC'WL!K0?.6N\V%<J_%/#'3P1PT\;(H8VAC&,&&M:.  '4%^T!$1
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MC$8.YN[@Y8YGLX*8;!=H[]>Z=F9<MQMZH"UE1N# E:?:R =6<$$=H\8"^=E
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MV@P</!6-O>[.BZ"LU77QT-NB#JESO"SP:QOYSCU +5V@M(V_25J%-1ELM5(
M:BH(\*1W^C1U!8BM-3WM5M+CX#O!=]:O[8]JW16E:"IJ+Q=HXKQ.XL<WH)'&
M*,<FY#2.)&3@]G8KJ,<VQ<6_PV9Z;38\.2;1'7]&AD5<56VS0D$1>V\/F/YD
M=-+D^EH'SJ$WWNB:,/DCL=L>YN,-FJCCCGGN-\7C7!3!>_2'H3>(7Z2 ,DX5
M7;8]3::FTW6VBHJV5-P.'11T_AF.0'@2>0ZP1G."50NH=I5SU 'MN=SJ9('D
M.,#1NQY'+P1P7$9=K8ZW5CY)ZEE6&XIXF0@A[CUN=GP0.?(Y\2]##HZ8IB][
M\X\FBV6;<HAQKQ5F2M C=PA. 1V]95X[#-$4FJZ9]ZN['/H87B..#.!*\<79
MZ\#AY<^)9\5F;)-JD^@:*Y4DE$ZOI:@B6*+I=P1R8P3G!X$8SY L\N7)PVX.
MLI6M=XW;#ABCAB9%"QL<;!NM:T8 '8 OTLR5O=(7A\C30V*WPLQQ$TKY"3Y1
MN_P7&K>Z!UC4- A9:Z7!SF*G<21V'><5YWHUY;^\JUHOR][8VETCFM:!DEQP
M L<2[0]I&J'B*DKKG-O-<!';Z?<R.O\ HVY..WJ7AO>CM=NMOW2U#37(4;2,
MRULQ<6EV ,M)+NP<E8TVWM63O/*$@[HO6D6I=51V^VU#)[7;6[K9(GAS)97<
M7.!' @<&^8]JKC3%ZJM.W^ANU <5%)*)&@\G#K:?$1D'RKWLTL7-R;K0M/88
MJG_2)?F#3+I8]Y]SHXCDC=?%49X'&>$1''GYUUUX:UX6J9F9W3#46V36NIWB
MCH9N\&2^"(;:QPD><_G9+\_W2%^]-;&-8ZG>VMN+1;XIG!SIJ]Y,K@>9W.+B
M?[V,JR^YI;34,5RM<KK?45C/]HBJ(:>1LFX<!S7.?&W@#ND#)YGL5YKFOF[N
M>&D;-E:\7.951H_87I>Q]%-<FR7BK:TAQJ !"3VB/C\Y*M.G@BIH(X:>-D4,
M8#6,8T!K0.H +Z(N:U[6ZRV1$1T<ZNL5IKYS/76N@J9B #)-3L>X@<N)&5\/
M4KI_W"M7[G']2["*;RNSC^I73_N%:OW./ZEUXV-CC:R-K6,: UK6C  '4 OZ
MB;S((B* BX>M[S+I_3%;<Z>..66#<PR3.Z<O#>./*JG]>>[>YM!Z7_6LJTFW
M1C-HCJO1%1?KSW;W-H/2_P"M?:GVTU[2[OFT4L@ZNCE<S'IRLN[LG>57<BHG
MUYKS[G6_T/\ M)Z\UY]SK?Z'_:3N['>0O99TVU_A[4_]S%]%=7UYKS[G6_T/
M^TH/JN_SZDO$EQJXHHI7M:TMBSN\!CK)6>.DUG>6%[1,<G'1$6YK:TTQ^#=I
M^"1?0"Z2H&W[7;O14%-2QT% YD$;8FEP?DAHQQ\+Q+T>O->?<ZW^A_VES=W9
MO[R%[(J)]>:\^YUO]#_M)Z\UY]SK?Z'_ &D[NQWD+V143Z\UY]SK?Z'_ &D]
M>:\^YUO]#_M)W=CO(7LBHGUYKS[G6_T/^TGKS7GW.M_H?]I.[L=Y"]D5$^O-
M>?<ZW^A_VD]>:\^YUO\ 0_[2=W8[R'KVEZYU!9=85E#;:X14L;8RUG0L=C+
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M71AE@:.R*5Q$@\G+QE%3NIV)6K3&I-,7G2_W1DDI[G#WQ%(\2-$63E_  C!
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M-\G.^VO!6TM)1S=%;ZUU;#C/2.A,1SV8)*U9JZ?A^SZ_A)%[>+].KICR(;Y
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M[MK^+)]2>QDO_N[:_BR?4@T1ZO=(>^NP?*,/VD]7ND/?78/E&'[2SO[&2_\
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MG_[MO\%CONJ?QK2_ H?_ #+8E!_T*G_[MO\ !%?9$1$$1$!$1 1$0$1$!$1
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MOFL7=TK^..^?W*?^0Q7^-L^C]-6>U4-75U%3/%2PQR]Z0F1L;@P9:79 R.L
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MP2#%S!.0?],A6@B"K[9L>@MFH:F^T6K=31W:I!$U09H7F0''!P=$01P'#'#
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,$0$1$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g762905g46d29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g46d29.jpg
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M*"@H*"@H*"@H*"@H*"@H*"C_P  1" 4J!VP# 2(  A$! Q$!_\0 '0 !  ,
M P$! 0            4&!P(#! @!"?_$ &80  $#!  # P8&# P$ P0!%0$
M @,$!081!Q(A$S%!"!0B46%Q%18R@9&3%S535%5S=)*AL;+1(S0V-SA"4G)U
M@K/2,V*BP20EPAA#5H.4PR:CX?#Q8],G2(65M"A$9%=VAL3C_\0 &@$! 0$!
M 0$!              $" P0%!O_$ #<1  (" 0,# @0% P4!  ,! 0 ! A$#
M$B$Q$T%1!&$4<8&1(E*AP? RL=$C,T+A\045-&*")/_:  P# 0 "$0,1 #\
MSA$1?MSXH1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MTDOC7NMU%3<[N1Y9IQ/0['L:Y9_4NC=42N@860EY+&D[Y6[Z#?N6QX5_];W
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M2RJUO=%ZX_T%6.(%?5FFG\U,4.INS/)\@#Y7=WA9DM$S7BO=LKL+[564-##
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M&S<'LQNN4W*M:;/1VVRT\7H>;Q%H[0N&F\W<>F^X!5#%=_\ M(W#8U_#U/\
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M>T+@XM_R@'Z%1Z#CMD=/2B*II+=52@:$SF.:3[2&N ^C2HF89;=\MKFU-YJ
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M+*RTV^HEJ(J8,!DEULN+0XCIZMJM*Q<<D4^S(TXNCVWBZUUYKGUETJ9*FJ>
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M!GF]5'([LVO.W03-WR[/J(/7V$^(5:XR7ZSW#AA04M!=;?4U39("Z&&I8]X
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MZJ9SV@_U6]S1\PT/F7TAQSN\6/X)604@;%4W67L?1Z$['IN/^5NOG"^65W]
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MU*,^SVW3?UH\^91M-!$1>TXA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MD_O.\?H&_':HZ+C\/CU:JW_G;@WU)55EFQ[+JFQXS>[/2TT)%U:&2SN)YFM
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MR-GO=#<FPLG?2S-F;&\D-<6G8WKVJ/11I-4PG18[YE=1><T&15E/$9>VBE[
M$\FF<NF^O1Y?TKIS3)*G*\AJ+M61LBDE:UHCC)+6AK0.F_=OYU!(L1Q0BTTN
M%7T*Y-\EFFRZH?@D&+,IH8Z9E0:A\S2>>0[)T?#74?FA>G!,ZK<3CJZ44U/<
M+75_\>CJ!MCCK6QZCKH>A!5011X8.+BUL]RJ<D[LTVW<6JBT5W/8[#;+?0<I
MW2PM(YWGN<]PT7:&]#H.JK6%YE5XK77&MIJ>*HJJR%T)DE)VSF.RX:\=@*KH
MLKTV))JN>2]27-DKC5^KL<O,%SM<H94Q$_*&VO![VN'B"KR>*S*>::NM.*V>
MAO,P//6M;S$$]Y:W0T3[_?M9BBN3!CR.Y(D9RCLF3UCRR[6?)Q?H*@RW!SG.
ME=+Z0EYOE!WL/[M=RM-=Q-A,[ZVTXK9[?=Y"7&MY.T<UQ[W-!  =[>JSA$E@
MQS=M!9))4F6K.LTJ\Q-M?<((HYJ.'L>T823)W=3OQV#]*ELLXDOR?'VT5RL=
MN-P;&V,7$-W(UH<">78Z;UUT?$K/T3X?&M*KC@O4EOOR6;+,NJ<BM=DM\M-#
M3T]I@["(1DGFZ-&SOQ]$*3QOB)46ZQMLEXME%>[2P\T4-4/2B/\ RNZZ[SX>
M*HR(\&-QT5L37).[+SD7$6LN%F=9K/;Z.QVA_P#Q(*-NC+_>=X_0-^.U&6_+
MJB@PBXXU!30B&NF$LM1L\_3E]$>&O1_256418,:6E+O?U#G)N[)C$;X_&\AI
M+M%3QU,E,7.;'(2&DEI&^GJWM*K(:^7*9K_#*8*]]2:EKF?U'$[T-^'AU\%#
MHMO'%O4UOP34ZHTRHXH4ER>VION'6:X7(  U)!;SZ[N9NCOZ54LRRNXY9<F5
M5R,;&Q,[.&"%O+'$SU-'_=0"+$/3X\;N*-2R2DJ;)W"K]'C5_@NLE"RND@#C
M%&]_*UKR-!QZ'>NO3UJ*N%9/<*^HK*N0R5%1(Z61Y\7$[*\Z+IH2EJ[F;=4%
M(X_>:ZP76&XVJ<P541Z.'4$>((\0?4HY%6DU3(G6Z-4DXM4E9(*F[878ZRXC
MOJ7, )/K.VD_I54S?.+OE\T7PB^.*DA_X-+ .6-GMUXG7B?FTJLBXP]-BQO5
M%;FWDE)4V6K$<SJ,9L]YH:2C@D=<X^S=,\GFC'*X#E_.)5?ME?56NO@K;?,^
M"J@<'QR-[VE>5%T6.*;=<\F=3V]C4W<6V7"-AR7$[-=JE@Y1.]@:X_2'?HT%
M#99Q*N=\M1M-%24=HM!^52T3.4/'J)]7L "HJ+E'TN*+M1-O+-JK+5BV9U&.
MX_>K724<#S<V&-\[R>=@Y2WT?SBJJB+K&$8MM<LPY-JF3N$Y%)BN007:"FBJ
M9H6N:QDI( +@6[Z>PE1UYN$MUNU;<*@ 354SYG@=P+B3H>SJO&BNB.K7W%NJ
M"LN"YA7X?<9:BA9%/#.SLYZ>8;9*WV^WOZ^TJM(DX1G%QDK03<7:-$DXEBCE
M[7&<;M-EG<X&2:)G/(1O9:'$#E!\=!0F29G67K,8,C%/#35D+HGM8W;F\T9Z
M'K[@JLBYQ]/CB[2W-/))[67G.,^CRSS:2>P6^FK&2MDFJ8QN28-&N4G6PWYS
MW!1.>9759C>FW&LAB@<V%L+8XB2UK02?'VDJN(K#!"%:5P1SE+DT2U\3I/@>
MEMN2V.WWZ&D'+3R5(U(P>K>CON'_ 'VHC-,ZN64104CXJ>AM=/\ \&AI6\L;
M?43ZS^CU!5)%F/I\<9:DMRO))JFRS7'+JBMPFVXR*:&*DHI3-VC2>:1QYN_P
M_KG]"_,#RV?#KI45]'2PU$\L#H&F4G3 2#L:\>@5:1;Z,-+C6S)K=V6'"<JK
M,2R!MVHXXYY.5S)&2[T]KN_KW@]!U7YFN009'=&U=+:*.U-#-.BIF@![B22Y
MQT-D[_0J^B=*.O76Y-3K3V.R!XCFC>Y@>UK@XM/<[1[E8L_R^JS.\15]9!%3
MF*$0-CB)+0 2=]?[RK*+3A%R4GRA;2H+OH:N>@K(*NCE=#40O$D<C3U:X'8*
MZ$5:O8AIDO%*"N?'57O$K-<+JP "K>WEYM=Q<W1W]*J^2Y)>,WO5.ZXR-<]S
MA#3P1CECCYCK31]'7O5;7HM]9-;ZZGK*5P944\C98W%H=IS3L'1Z'J%QCZ?'
MCW@M_P"?8V\DI;-FW\4LSDQ;)Z2QP4M+<+/!;HH:BAJ6\T;SLD'V$ -T50LE
MXBU-QLSK-9K;1V.TR'<L%(.LO]YVAL?-U\=JJWZ\5U^NL]QNL_;UDVN=_*&[
MT !T  '0!1ZYX?20A&.I6U_<U/*VW7!;,!S:KQ">L$5-!6T-:P1U%+/\EX&]
M?K(\1HJ9BXH34%QIY;%8K9:J*-_:24].W1J"-Z#WC1(!ZZ&NY9TBZ2]/CFW*
M2W9E9))4F6^S9S5VW.:K*#203U<[I'B-Y(:PO]7CT'11EER>XV?)_AVBD:*T
MRND=S#;7\Q/,"/$':@T6^C#?;E5]":WY-(K^)T#ZA]=;<4LU'>'DN-:6=HYK
MSWO:T@ .]IVH+.<VK<PAM0N,$3)J&(Q&5A.Y=\NW.WX[;OIZU5$6(>GQP:DE
MNBO))JFS0+QQ)?>,3AM%SL=NGJH(!3PUSF[?&W0&V@@Z.@.H(4+D&75-XQBR
MV-U-#!2VP'E+"29"1\IV_'O^E5E%8X,<>%[AY)/EEUQ3B!566SOLUPH*2\65
MSN84M6/D'>_1/AUZ]QZ]VEZ+UQ)JI[/-:<?M=%8;=/\ \9E(/3E![PY_3I\V
M_#>E0D4?I\;EJK?^=N!U)55EFL.75%EQ:\V6FIH2VZ -EG)/.UH&M#P\3]*B
M\;NKK)?:&YL@9.^DE$K8WDAI<.[>O;U4:BZ=..^W/)G4]O8E<HO4^0W^MNM6
MUK)JI_.6M)TWH  -^H **1%J,5%4N"-WNPB(J B(@"(B +]!(((.B%^(@-9Q
MGCA?+711TUSI(+FV,<K97O,<A'_,1L'WZVNV_P#'6]5U))!:Z"GMSGC7;<YE
M>W^[L  _,5D*+R? X-6K3N=>MDJK)*R7FLL]\IKM2/W602]J'2>ES'QYO7O9
MW[UH69\8:G)\9J;1+9J>#S@-$DHF+M<K@[H-#74#Q*RM%UG@QY)*<ENN#$<D
MHII/DUNT\;;A!98Z"\6BDNCHVAHEE?R\VNXN;H@GV]%U1\;+T^"NIZVWT-13
M5(+&Q:+&Q,+>4L&CU'O64HN?P6#G2;ZT_)JW!"SY),ZMNN*7.@ADA>(9Z2KY
MBV5I&P2&@^W1Z'H5>HLAXB7?*;?;)[$;;0PUD;JNIBC?R21L>"[4CNG*0#W=
M3O2P3'<ANN.5QJ[+6R4LY'*XMT0X>HM/0_.%<9>,V920F,5U.QQ&N=M,SF_2
M-?H7G]1Z7)/(Y)1?SY7^3>/+&,:;:)_RFJN*7)+52L<#+!3%SP/#F=TW^:HW
M%N,UVM-JCMUTH:>[4\30QCI7%C^4=P)T0=>T;6:W&NJKE6RU=?/)45,IYGR2
M.VYQ7F7>'I(=&.+(KHP\LM;E':S0L]XJ7;+*#X.;!#;[:2"^&$EQ?KN#G>H>
MH +/41=\>*&*.F"I&)2<G;"(BZ&0B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"T_A?]H*C\I=^RU9@M/X7_:"H_*7?LM7F
M]5_MG3%_49@B(O2<PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M 8/K)/\ <GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\
MP?62?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]
MV.G#P4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K
M)/\ <GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/]R?8NPS\ P?62
M?[E<T3XC+^=_=CIP\%,^Q=AGX!@^LD_W)]B[#/P#!]9)_N5S1/B,OYW]V.G#
MP4S[%V&?@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/\
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M@&#ZR3_<GV+L,_ ,'UDG^Y7-$^(R_G?W8Z</!3/L789^ 8/K)/\ <GV+L,_
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MQZZ WU/L"L2*//D>SD_N50BN$$1%R-!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RI
MJ?R=OZU+J(@_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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ML)]H\1T/7V>"E,'H::VX=9*2@:UM-%1Q!G*.A]$'?O)Z_.LFIHVVSRKI8[>
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MPS+<%XQY;B<SA#;;BWX4H>;HUHZEP'N!</\ Y2[^!43LHS'+\_J6DLJZ@T-
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MG +W=+,UQ#:P.Y.T .B6MY3OZ5)8[<\@XBV'([+E>,5.-PSTO8Q3/+G%Y>'
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MR>3]4J<;/YV^%?Y<[_4B3B)_2.X??D\GZI4APOD_W!MJ(B\I0B(@"(B (B(
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M@>\>?CG2UE!Y.^/T5SIS3UM*ZCIYHN=KN5S(W-/5I(/=OH5]!*B\9<*JL\Q
M6>AJH*645+)^TF!+=-#AKI[UTAE_$D]DF0IUNN_%>RV2GLL&,T-WF9$V.FNX
MJVM86:]%SV$@\P&M]1\_>;/PFP2?#,?N<MVJ6UE^NDCJFNG;W%W730?$#;CO
MUN*O])$8*6&)Q!,;&M)'CH:7.5O/$]@Z%S2%AY+5)44^5^ -7F]CQ:LN.,6J
MGOUHGJWQRT)G$,L4K6M]-I/0@@@$=?D^"TG$\0R?)>(%/F?$"GIZ#S",LMUK
MAD$G9D[])Q&QOJ3W[)UW  *R\&,(JL"Q2>TUU7!52R5;Z@/A!  <UHUU\?15
M\73)EN3T_<AEEQQ.\S>4%;,GCI ;)#;C!)4=JSH_ED&N7?-_6'77BK3Q.PZG
MSG$*NS5$G8R/(E@FUOLY6_).O5U(/L)5J1<M;M/P4Q2TWKBWC]KBLL^(T=XJ
M8&"&"Y-K6M8]HZ!SP2"?^DE3_"# ;CCM7=\ARJJCJLEO#N:<Q=60LWOD!\>N
MMZZ#0 [MG3$5>2TTE5@Q[R@<#O>2&T7;#XN>\THEI9 V5D9=!(P@^DX@=-D=
M_P#7*O\ P[QQF*87:+*P-YZ: "4C^M(?2>?G<2K$BCR-Q4? ,4N&(Y=@><73
M(>'])3W:U79W:UEKEE$3FR;)+FDD#O)(_O$:/0KIN%FX@\2KS;&9!0#%,=HY
MA/)'%5\\\Y'@"T^K8&P -D]3I;BBUU7S6_D&;\8,#KLEBM-VQFHCI<DLLO:T
MCY.C9!L$L)]X&M].\'OV*W>*SBIE]CJ;#+C%'8A/$Z*KKS5MDYVZZMC:#T+N
M[J3W]X[UMB*1R-*JN@4'@7CMSQ;AS06J^4XIJZ*25SXQ(U^@YY(ZM)'<?6KU
M4P1U-/+!.P20RL+'L/<YI&B/H78BS*3DW(&$V"Q9[PIJ:ZWXU:8<GQB>8S4\
M9J&PS0$^!W[AO0(.M]-D+WV+#LJS'/K=E?$&GIK;2VOTJ"U0R"0M?O8<X@D=
M^CO>R6CH %LZ+;S/FM_(,LK,3O,GE!4.3LI ;)%;C ZH[5G1_*\:Y=\WB.NE
MJ:(L2DY5?8'ENM!3W2V5=OK6<]+50O@E;ZVN!!'T%8KC5#Q&X84\UCM=BI\I
ML+9'/HIF5+89(@X[Y7 ^WKK7>3U6Z(K&>E5R@91PVPV_S9K7YQG0IX;O41>;
MTM# [F;31].\C8WH:Z$]Y)[^C@7B%[Q;"[]07RC%-5U5=--"P2L?S,=&QH.V
MD@=0>]:NBKRMVOYL#(.%.&7VP\&;U8;K1""ZU(JA%")F.YN>,-;Z0) V?658
M^!N/W+%^&]MM5\IQ35\+YB^,2-?H.D<X=6DCN(\5?$261RN^X,LBQ*\M\H*7
M)S2#X$=;NP%1VK/E\H&N7?-X=^ERQ3$[S0<<\LR*JI RSU](R*GG[5AYW 1;
M'*#S#Y#N\>"U%$ZC_2@8O<\4RW!<ZNN1X%14]WMEX=VE;;))1$]LFR2YI.AW
MEQ'?\HC7<5U?%O,>(^6V:X9M:X+#C]HE\XBH!.)9*B38/I$>'0=^NFP!UVMM
M17JOQOY!AD^.9E@7$R_Y#C%EAR&U7MQDEA\X;%+$XNYM;=ZB3W C1'=I1_$_
M%^)'$G'R^KME%:H:1[9*:T,J6R2SO)Y2]\A(8.5I<0/?T[E]!HJLS33K<49!
MQ;Q*_P"3XEAU/;;=SUM%503U<)FC;V0$>G=2[1T>G0E:^B+FY-I($5EEG^'\
M;N-J\YEI754+HVSQ$AT;O!PUZCKIXK),:N'%3#;3%8I\2@R!E*.RIJ^*N:SF
M9X<V^IU[0TZ^E;@BL9TJ:M R[A#A5YM5\O\ E66FGBO=Y<-TM,=L@9O>B>XG
MN[B>[O)*KN#8_G.#<0[S!1V6EKL<O%R$\E9V[0Z&(O<=@%P.P'=1H]W1;FBU
MU7O?<&"V*PYQPPRK('V#'HLCLEVG[=CF5+898SMQ /-ZN8@]"#T.QU"\'$K#
M^).=16Z[UEOHJ9]#4---98:EI<UIZND?*XAI=MK1H>!\.N_HE%5F:>JE9*,V
MXP8:[+(+/56JX0VS*;=+YQ;W3/ YCT)8=;\0T[ .B/455[])Q9OF-U]MO%!9
MK'1"F?YY<8IA(^2,-/,&-#CHD;'77?WA7;BK@!S2GME30W%]LO=JF,]%5M;S
M!KCHD$>K;6G?AKQ52N6&<4\CH9+1D&5V>GM4P[.HDHH#VLK/$?);W^.B%J$E
MI5M;>0>?R?;'3W_@146FXM=YI7S5$;B.\ D#F'M!&Q[0N&,LXF\.: V"#'J;
M*+5 XBBJHJIL+V-))#7 ]=>S73NV1I:[B6/T6+8[0V:UM<VDI&<C2X[<XDDE
MQ]I))/O4LLRRVWM:93*.&^*9749G6YCG=0VFJY8^QIK73S%T<+>[;M$@Z&]=
M3U))ZK5T1<Y2<G;!DO$;![_!FU+G. NIWWB.+L:NBG=RMJF :[SH;UH:)'R0
M0=CK#9*WB=Q$MQL$V.TN,6R<AM;5RU39G.8#LM:&]='U:Z]VP-K<T6UE:K;@
M499Q+P*IEX,#$L3IC4RP"!D3'2-87AKP7.)<0-GJ?G5^QBBEH\5M-#6,Y)X:
M**&5H(/*X, (V.G>%*HL.;:I@P#"+/GW"F:Z6BU8S#D=GJ:DST]1%5LA>"0!
MZ7-U[@W8UW[T2NK+<,XB9+E&-93=**C+Z&MC<VTTT[/_  T+7AY<7N< YQ(T
M=>H?-]"(NG6=ZJ5DHR[-\4O-SXQX9?:*D$EKMS'MJ9NU8WD)YM>B3L]X[@5J
M*(N;DVDO!3,^+6*Y)7W6RY)A54/A:U..Z*:4MBJ&'P[P-]2.NM@]XT%6<HJ^
M)V<V*HQQV&TEEAK (ZFMJ*ULC6MV">5HZ^'AS?\ =;DBW'+26W ,7XJ\-[G4
M\(+#BN+P&OJ+?40EW-(R/F:UD@<_TB!U<[NWXK6+W32U./5]+ WFGEI9(V-V
M!MQ80!OWJ019<VTDP9[P'QRZ8KP[I;7?:84U<R:5[HQ(U^@YVQU:2/TJ.Q+$
MKS;^.F69%5T@99Z^E;%3S]JP\[AV73E!YA\AW>/!:FBO4=M^08'C5BSGA;?[
M[%8\=BR2R7*H[>*1E4V&1AV=!W-U[CH]-=-@]Z\?$/#N)&:SVB^UUOHH7T%4
MPT]E@J6%T;-\SI'R.(:7$M:-#P]77?T0BUUG>JE8HR[B=BEYOO$+ +K;*/M:
M*UU1EK'F5C3$TOC/<3L]&GNWW+]S+%+Q<N-.'W^CI!):K?"]E3-VK!R$\^O1
M)YC\H=P*U!%E9&J 1$7,!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M?D$'^FU8?PYLMKO7'GB)%>+=1U\4;W.8RIA;(&GM -@.!T5(0B[OL4TQG%_
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M$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\I" ET1$ 1$0!$1 $1$ 1$0!$1 $1$
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MZ4/[+9\1S.'S$MVMCLMTH[U:J6Y6R=M115+!)%(WN<#^H^SP5EC<=V#V(B+
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M=ZU;E&JV8"(B@"(B (OR1XCC<]QTUH)/N58X=YI0YU:*JYVJ&:.DBJGTS#,
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M0L#.T;T.B  -$'U @@CJI.ARR\2\?[CC#ZEILT-N%0R'LV[#],Z\VM_UCXJ
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MQ7 /'OAL"-]7'_J*GO*7I*BKX1W0TP<[L9(9I /%@>-_1L'YEA548US_ )!
M8Y'Q9S&U1Y%%D=OL<%2.VH[=YHU[71GY/.X@D CQZG77HN_A+GF57_BA?+%E
M#(:46^B].DB8WE;,U\;2\.ULAVR0-D>DM*X>5U-<L%L%50O:Z!]#"!RGY)#
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M7USZZOHY::ODZR5%')V;I#ZW#1:3[=;7=@G";%<*J_/+51R35X!#:JJ?VCV
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M="6C8/4:[NN]]""J\<=2ONO/[@GL<XQV6YWVFLUTMUWL-QJ2&P1W*G[,2D]
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MJZ*HIBXM$T;HRX>&P1O]*[D6-3I+P"H<.,&IL*Q)]@95/KH'R2/<^1@82'@
MC0/L5>X=\)Y<&R U-MRBXRV;;R+7(W^#VX:V2':)'3KR^"U!%KJ2WWY 6<YQ
MPKI+_?V9#9;K68_D+6\KJRDZB0:UZ;=C9UH=XV._:T9%(R<7:!E5GX/MDO\
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M&WM74KV;IGD=3&!O7LWH?,O-#!<5*4DKX]SHYTZ2LU)%E'"C+JZ[6_*<EO\
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ME51P//HQG4>^7Z7_ $*3QTDNZ5@UA%E/&G*KI%7V3#L0J'0Y#=YFN=,SOIH
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MKO1RC)*NJLUE=HT-DB=RE[/!\QUOKWZ\?8.AU1<)1TNBA$19 1$0!$1 $1$
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M=?0OW"KZ,FQ6UWH4_FPK81-V//S\F_#>AOZ% \</YI\G_)#^L+,.&=9Q+ON
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MND[*28\SV\SG>KT">N^\ *G\></L>.TUGL]MN5UN%_N-4T 5M:Z8LCZC9;T
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MM_Z6M5>X>O9'Y26>-N!#:Z2G;YN'][H_X,]/\H9]"V6QVRGLMFH;71<WFU'
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M]4NFI;?,QD9%(6L<UK7 AK=@@#T0.[N7OL5KI[)9:&UT7-YK1P,IX^<[<6M
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M-^QRT7]]$^\T,=6ZBE[:G[0G^#?TZ]#[!WJ615.N $1% $1$ 1$0!$1 $1$
M5<S#",>S T9R.W-K?-"XP[D>SEYM;^21O?*._P!2L:*IM.T#SV^BIK=10T=!
M!'3TL+0R.*)H:UC1X !>A$4 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'BO?VHK
M/Q3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0'J1$0!%6>)M946_AY
MDE7132054%!-)%+&=.8X-)!!\"L:\FK-[[79#56C*+C55OG]&*RA?4R%YTQ[
MFN#=^OK^85TCC<HN2[ ^BUFULX-X[1YF[))Y[A75(G=4P05,H=# ]SB[;0&@
M]">@)Z=.]:)55$5+2S5%0\,AA89'O/<UH&R?H"^9.$><Y+D/&BE-PN5=\$7$
M553!1/E/9B/4@8 WNZ%NOF6L49-2<70/J!5FV85;+=G%TRJ!]2;E<81#,USP
M8PT!@'*-;!] >/K5DD>R-CGR.:QC1LN<= +HI+A15CG-HZRGJ"WO$4K7Z]^B
MN2;7 /2BJ'$ZRWV^62FI\9O@LM6RI;(^?G<SGC#7 LVWUD@_,K:7-8&A[@">
M@V>\I6U@Y+R7BWPW:T5UNJB\4]9 ^GD+#IP:]I:='UZ*YR5U)%4MIY*J!E0[
MY,3I ''W#>UQNM7YC;*NJ]'<,3I ''0) )U^A%8(["\:HL1QRDLEK=.^CIN?
MD,S@Y_I/+CL@#Q<?!3:SS@;EU?F>&NNMYDA\[DJY6B.)H:UC!K30._0]9V5?
M:JKIZ2/M*NHB@C_M2O#1])5FFI-/D'<BZJ:I@JHA)2S131G^O&\.'TA52^V6
M^U7$"QW.AO@IK+31N;56_M'#SAQYM'0Z'O'?ZE$KY!<$7YSMY^3F'-K>M]5T
M0UU)/.^""J@DF9\J-D@+F^\ ["@/0B+S/N%''5"FDJZ=M0>Z)TC0\_-O: ]*
M(NBKK:6C#35U,$ >=-[60-V?9M =ZB,ML-/DV/5MGK)JB"&J: 9:=P;(PAP<
M"TD'KL!9QE%^ND'E&8C:*>X5#+54V]\DM*V0B.1W+4:)'<3Z+?H"UY;<7"F"
MF<..'-EP*&J^"C45%75$&>KJGATCP.X;   ZGP]^U<U^.(:TEQ  ZDGP7GI+
MA1UCG-I*NGG<WY0BD#B/?HK+;D[8/2B+S&X48JO-C5TXJ?N7:-Y_HWM0'I1#
MT&RNB:LI8&,?/4PQM>[E:7O #CZAOO* [T7'G9S\O,WF[];ZK]>YK&\SW!H]
M9.D!^HN+I&-:'.>T-/B3T73/74E/-'%454$4LGR&/D#2[W ]Z ]"+JJ:B&EB
M,M3-'#$.]\C@T#YRN4,T<\39()&21N&VO8X$'W$(#FB+\<0UI+B !U)/@@/U
M%YZ2NI*PO%)503EGRNRD#M>_17H)T-GN0%9S_"K9G%KIJ"\OJ6005#:EAIWA
MKN8!P&]@]/2*LP&AI>2"YT%1.8(*ZEEF'?&R5KG?0#M5+C?<:RT\+;]76RIE
MI:R&.,QS1.+7-W*P'1]Q*VDY-1!>$5<X;5=17</\;JZR9\]3/;H))99#MSW&
M,$DGQ)*FI;A1PU#:>:KIXYW?)C=(T./N&]K+5.@>E%$9?15UQQFY4EHKO,*^
M:$MAJN8M[)W]K8ZA<,0I*VUXO;J6]7 5]=#$&SU9<2)7;[]GJE;6":1 00""
M"#W$+\:]KB0US26]X![E ?J+K?/"R-\CY8VQL^4XN #?>?!?E+4P5<0EI9XI
MXCT#XWAP^D(#M1>>&NI)YWP0U4$D[/EQLD!<WW@'87H0!$7FJ+A1TTS(:BKI
MXI7_ "6/D:USO<"4!Z41>>KKZ2C+15U5/ 7?)$L@;OW;* ]"+\:0YH+2"#U!
M'BOSM&>EZ;?1^5U[O>@.2+STE;2U@<:2I@GY3IW92!VC[=+.^.6;7'#[5:/@
M9T#:BOK6TSY)&\QC8022T=V^GCM:C%R>E TQ%P[6/DY^T9R=W-S#2X>=4_G7
MFW;Q><:YNRYQSZ]>N_2R#N1=5340TL1EJ9HX8AWOD<&@?.5^TU1#51"6FFCF
MB/<^-P<#\X0'8BR//[Y=*+CA@MLI*^IAM]7&\ST['D,E(YM<P\>X+7%J4=*3
M\@(B\T=PHY:EU/'5T[ZAO?$V1I</FWM9!Z47X][6#;W-:/63I?J (N(>TO+
MYO,.\;ZKJJZREHV!]94PP-)T#*\,!^E =Z+C&]DC&OC<U['#8<T[!"&1@<07
MM! V03W#UH#DBZJ6I@JXNTI9XIH]ZYHWAPW[PH[+;W#C>-7.\U+2^*B@=,6
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M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$1 $1$
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MQQ[^7TG$^[W$35GKH^(?E$TUZLFY['CU(8758!Y)'D/ Y3[Y#KUAI*D.%_\
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M'0;]G@!LJ7X;76CP+BWG-IRN:.@ENM2*NDJZ@\C)6%[W <YZ=0_W;:1WKO\
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MU'C-D%UL^:\-Z2UUTU-37"Z=C51QG0F9VD Y7>S3G?2M96)<?OYP>$W^,?\
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MY%<+%PZBN&/7&2EJ'5L4?;0.&RTM?L;^8*K7&CFXM\7KW9+E6U,6*X\ Q]+
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M6WV^&"US->V2F;OE<'C3A\X3J12I+P4Q?$?Z(]7^15G^O(M%X%?S2XS^3?\
MJ<K%38O9:;&W6""W0LLSFN8:4;Y"UQ)<._?4DE>ZT6VCL]M@H+93LIZ.!O+%
M$SN:._04GD4DUY=@QK _Z3N>?D+/U0+]X+L$G%KBNQWR75C0?SY5K5'CEIH[
M_67NEH8H[K5L$<]2-\TC1KH?S6_0EJQVTVFY7"X6ZABIZVX/#ZJ5F]RNV3L_
M.3]*KR)IKV2(8OY/-XH\-?D.$9'50T%SI;@Z:+SAPC$S"UK?1)Z'Y =[0[HK
ME=.)?;\2;)BV)LH[L)N9]RG8\N;31@CJ'-.M@!VP?$M'BK1E>#XWEA8[(;13
M5DK!RME.V2 >KG:0=>S:[<4P^P8G#)%CUJIZ$2:YW,!+WZ[MN.W'YRDIPDW)
MK<& XG;[-Q"XE9:>)=>]U50U)BH[=-4F!C8PYP/+H@G6F] ?'9WM1''-N#VF
M6QV?"Z2@;40U;9JR>E_A.0=S6.DV22>IUOP7T-E'#C$LHKO/+Y9*>IJR #,"
MZ-[M=W,6$;^==@X>8D+&+.+!0BV]H)C"&:YG@$!Q/>3HD;)\5T6>*:>_R["C
M.^/O\X/";_&/_JM.MM41=,:L]UJ;747&@BJ)[9():-[]DPN!:=CKW[:WO]2E
MUPE*XI>"F)^5C_(6S_XM%_IR+:A_P_F49D6.VG)*2*EOE#%6T\4@F8R3>FO
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ME$TV17C<5DO5$*5U41Z$3P&C1/AHL83[';\"M=Q7$;#BE/)#CUKIZ%LFN=S
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M21R-#FO:>\$'O"Y=17';@I@^"X/PK9A]!?+O4T-PJ)(&S5536UQZ2$;<"SF
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M\V0<.^*%JI1NHJJN5D0[MOY26CYR OHR@HX+?0T]'11-AIJ>-L44;>YC6C0
M]P"\&/XY:,>;5-LM!%1BJD[:81[]-_K.T62K]P9GY/V;6A^!TECN=;!07>T\
M]//353Q$[0<=$!VM].A]1!VH+)+E3\0N/6*TN.R-K:#']U-55Q'FC#N8.T'#
MH>K6#8\2?4M1R;AMB.35IK+U8J:>K=\J9I=$]_\ >+".;YU,8WC=GQJB-)8;
M=34,!.W"%FB\^MQ[W'VDK74BFY+ED,:Q>X4W#[COEE#D$K:.BR$MJZ.JF/+&
MYW,YW*7'H.KWCKXM]H73Y4N9VB?#HK#;JZGK*ZHJ&32-@>)!%&W?5Q'<22T
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M(&N=])&U[D0   :'0!$1 $1$ 1$0'&1C)&%DC6O8>\.&P5^L:UC0UC0UH&@
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M3S>]??M-]6@)=%$>;WK[]IOJT\WO7W[3?5H"711'F]Z^_:;ZM/-[U]^TWU:
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M-[U]^TWU: ET41YO>OOVF^K7?3Q7%K")ZF%SM]"UFNB D$1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)
M=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'BO?V
MHK/Q3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0'J1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0$1!_*FI_)V_K4NHB#^5-3^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 41??XW:ORD*741??XW:ORD("71$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!XKW]J*S\4[]2YV
MK[5T?XEG[(7"]_:BL_%._4N=J^U='^)9^R$!ZD1$ 15'BZYS.&&4N82UPM\Q
M!!T1Z)43Y/3W2<'L=<]Q<XLFV2=D_P /(MZ/PZ@:(B*(R+)K)C<+);]=*2@8
M_P"1V\@:7^X=Y^992O9 ET4+C>56+)62.L%VI*_L^KVPR N;[V]X^<*1N-?2
M6RCDJ[C504E+&-OEGD#&-]Y/1*:= ]**G4G%#":NK%-!DUM,SCR@.EY03[''
M0_2KB"" 000>XA'%KE (JK4\1</IKI\'3Y);&5@=R%AG&FN]1=W ^PE9WP=F
M=+QHXF R.?&)F\HYM@#G=W+:QNFWV!MR(O#>;O;K)1.K+Q74U%2M.C+/(&-W
MZMGO/L7/D'N15K'\[Q?(:OS6S7VAJZGPA9)I[O<TZ)^92UYO-MLE/'47BNIJ
M*"201,?/(&!SR"0T$^/0_0JXM.J![T5?AS3&Y\@=8X;W0ONS7%AIA*.;F'>W
MVD>KO7YD6;8UCDPAOE[H:.<C?922CGUZ^4==?,KI?% L**%QS*K%DK'NL-VH
MZ_L^KVPR N:/:WO'SA9?E<CQY4V&1A[A&;7*2W?0^A4^"L8-MI]@;4B+Q7B[
M6^RT+JR[UM/14K3HRSR!C=^K9\?8L<@]J*L6+/\ %+]6"DM%_H*FJ<=-A$O*
M]W]T'1/S*8NUXMUH%.;I74](*B40P]M(&]H\]S1OO/L5<6G30/>BJU=Q#Q&@
MNAMM9D5MBK6NY'1NF'HN]3CW ^PE>S(LPQ[&V0NOEXHZ+MAS1MDD',\>L =2
M/:KIEX!.HO#9;O;KY0,K;/6T];2/.A+ \/;OQ'3N/L4?D>8X[C;FLOMYHJ*1
MPVV.64<Y'KY>_7S*4VZ!/(H+&\OQ_)2]MAO%'7/8-NCBD!>T>LM[]>W2S+-)
M'CRG,&C#W!CK?*2T'H?1J/!:C!MM,&U(L5K)'_\ M4T,?.[L_@<GEWT[G^"V
MI)1TU[@(H^LO5LHKE36^LKZ:"NJ6N=#!)(&OD#022T'OT 5#4?$/$*VZBVTN
M1VV6M<[D;&V8>D[U ]Q/L!65%OA M**MW_.L7QZM;1WJ^T-)5'1[)\GI 'N)
M [OG4]15=/7TD5513Q5%-*WFCEB>'->/6".A1IK<'<BKN19OC..3B"^7NAHZ
M@C?9/DV_7K+1U 4C8KY:[]1^=V6X4U=3[T9() \ ^HZ[C["FEU= D46*VF1Y
M\JF]1E[NS%G:0W?3NB\%K%^OMJQ^C\ZO=QI:"G)T'SR!@<?4-]Y]@6I0JEY!
M)(H#&\SQS)9'QV*\T5;,P;=%')Z8'KY3UU[=*<GEC@A?+/(R.)@+GO>X!K0.
M\DGN"RTULP<T51I^)>%U%P%%#DUK=4%W*!VX#2?4'=Q^E3U[O5LL5&*N\U]-
M0TI>&"6HD#&EQ!(&SX]#]"KBULT"01 0X @[!Z@J'I;W;+U;;A)9[A35K( ^
M*1T$@>&/ ^2==Q4H$PBQSR4Y'R\,)'2O<]WPA*-N.S\EBO\ D.=8QCM4*:]7
MVAI*GH3"^3;QOUM&R/G6I0:DXK<%D1>*S7:WWJA;66BMIZVE=T$L$@>W?JV/
M'V+VK' "+HKZRFM]))55]1#34T0V^69X8QH]9)Z!5RT\1<0N]P;0V[(K=/5N
M/*R,2@%Y]3=_*/N546]T@6I%U5=3!1TTE15S104\8YGRRN#6M'K)/0*HLXI8
M.^J%.W*+9VA.MF73?SOD_I11;X0+FB\\]=2P4#ZZ:HB91LC,SIR\<@8!LNWW
M:UUVH&YY]BELHJ6KKL@MT5/5-YX'=L'=JW>N9H&R1L$;11;X!9D4=8KY:[_1
M"KLM?35U-O7:02!X!]1UW'V%=&1Y/9,:@9+?KI24#'_([:0 O]P[S\R4[H$P
MB^?_ "@<DMM]L.)U>/W2"L@^%VM<^GEWH\IZ. ZCW%:#Q7LEGO$F.F]9 VS&
MFKA+3@N:WSA_3T.I&UTZ=5?<%_1>:Y5]);**6KN-5#2TL0V^:9X8UH]I*SC.
M\YQO(>'65P6&^4=751VZ9W9Q2Z?H-/4 ]2/:%B,7(&H(J!P#>Y_"+&W/<7.,
M+]DG9/\ "O4G=N)&'6FL=2W#([=%4,/*Z,2\Y:?4>7>C[U7!ZG%;T"V(HZV7
MVU76V.N-MN-+54+02Z>&4.8W0V=D=VAZUCN(<3::MXRY)%<LDI?@%D#(;:#,
MUL+G$LWR^#G$[Z]2D<;E?L#<T7BO%VM]EH75EWK:>BI6]#+/(&-WZMGQ]BB,
M>SK%\BJC2V6^T-74]3V+)-/.O4T]3\RSI;5T"R(BKO$'(:?&<2N5?-74]'4"
MGE%*Z9P ?/V;BQH![R2.[Q1*W2!8D66>3YF,60X51P7*]1UN1%T\U1$^4&8-
M[5VB6^ T6Z\-$*XY%G&,XY/V%[OE#25&M]B^4%X'K+1U'T+4H-2<06)%#XYE
M%CR2)\EANM)7B/Y8AD#G,]X[Q\ZY5V2V2@K:BCK;M14]53P&IEBDF:US(O[9
M!/0>U9TNZ!+(H;&\HLF2T\TUANE+71PD"4POV6;[MCO&]'Z%&#B/AQN?P>,E
MM9JN;DY>W&N;U<WR=_.KI?% MB+P6V\VVYU5;36^OIJFHHGB.ICBD#G0N.^C
M@.X]#]!7CR3++#C36&_7:CH2\;8V:0!SAZPWO/T*4[H$VBB<=R6RY)3OFL-S
MI*^-AT_L) XL]X[Q\ZRCBMQ#;;>)>(6JCO\ !3VV.KW=F,E:.33FZ$A[P-;Z
M=Q\5J.-R= VU%&&_V@607@W.C;:BWG%69FB(C>M\V]=ZA[1Q&Q"[UK:.W9%;
MIJEQY61]KREY]3=ZV?<LZ6^P+6B(H B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@(B#^5-3^3M_6I=1$'\J:G\G;^M2Z (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( HB^_QNU?E(4NHB^_QNU?E(0$N
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(#Q7O[4
M5GXIWZESM7VKH_Q+/V0N%[^U%9^*=^I<[5]JZ/\ $L_9" ^)N*N0Y6SBE=C5
M5UPIJVFK',I8XY'-[.,._@^0#P+='IW[WXK[0Q:6NGQJTRWAG)<GTD3JENM:
ME+!S#7AUVO5-04<]5%4S4E/)4Q?\.5\8+V>XD;"]*[9,JFDDJHA4.,'\UV5?
MX?-^R5$^3O\ S.8Y_<F_UY%+<8/YKLJ_P^;]DK'N$?&G%,6X>6>S75U>*VE;
M().S@YF^E*]PT=^IP5C%RQ5%=P?2"^3,0S#"KMF^09)Q,G%34NG[*WTD].^>
M**$$Z]$ MZ#0 /M/>=K;L,XQ8ME]_AL]G=7&LF:YS>U@Y6Z:TD]=^H+-,/KZ
M#A#EU]Q_-:+DLM=4FJMUQ-/VK-=VCH$]W*#KN(]1VM8HN.I-;@KG$+,<'M]_
ML>3<,Y6TMVI:D-JJ>GI7T\<\)&SL%H;X:.N_F]BV/B]C5HOM78;IE>104&-T
M+^TDH9O1;5//4>ES#KK0T 3K>N]5R[<2(,BR>U6/A;;*"Y2/D#JVLJ*$]A#'
MW?\ *>G4[]@ V2HKC?YK0\9<7N&:4TM1AK*?D Y"^)LOI[YFCOZ]F2/$#QUI
M;IMI</?Y@\?$[(>$-?B-QH+%1T,EU; XTK[?;C&YD@&P2_E;Z/3KU/3:]-QR
MROM?DIVFJAJ)!6U;?@]LV_2:SM)&]#_<C+?G4CGN>8M687=[%PXH8[A7UE(]
MCVV^B,<<$.CSO>>4  -WKVZ7AL>,RYMY+%OMULU)<*9TD\,>_E2,GD)9[RUQ
MU[PJJ45J\]P:!A_";$J'#*2WUUCH:R>6G::FIFB#I7O+?2(?\IO7NT1I4?R>
M[(,<XG\0+0V1\D=(8XXW/.W%G,XLW[>4A3>*<<\9AQ:"/)9ZFWWRCB$-31/I
MWE[Y&C1Y=#74CN)&O'UJ%\GVXU=WXH9_<+A2R4=15=E+YO(-.C:7.+6GVAO*
ML5-1GJ_FX-_6 ,ML7$KC[>Z;( :FR8Y$&04;B>1TAT"7#QV>8GUZ:#T6_K K
MW52\*N-%RR.Y4L\F+9!&&RU,+"[S>7I\K7M!.O$.Z;((7/#WKFM@3'&_AU8H
ML(K;W8;=36B[VAHJH)Z&,0'32"0>76^G4'O! 50XT7^HR+R>L2O$[M5<];"Z
M1PZ;D;',USAZMEI*F^*G%*U99C<V+8$9[U=[L!!J&![6Q,)',27 >'3U#9)(
MTHOCQ83C' /%K,]S7RT=9 R1S>XO[*4N(]G,2NV.UI4N;!J.%\+\:QN*VUE+
M;HW7JFCV:^1SG2/D<TA[CUT=[/NWT5 M=KX<8)7W9^>7ZU7_ ""JJ'2S355-
MVSXP?ZO9CGY3O9]?4>I;5>&5<F.US+8[EKW4KQ3NWK4G(>4_3I?-_!&^X!CE
MEK8,WIZ>ER>*J>:A]PI'2R$>'*>4ZUUV.AWU6,;E)-MM@Z[/>,7F\H+&*SA]
M"^DH*EKH:EL<!ABD<6OWRM.NFN7P V >]7C+/Z56%_X5+^Q5*H77*&9%QVP:
M[4U!446/A_FE!//%V0J3UYGM!_J\TC0/_N M^6?TJL+_ ,*E_8JETES_ /Y8
M-M6"^43%+29?B=[O-JJ+MB-%S^=4T8VT2$GJX=W=RZWT/*1XK>EF'%#.KO@^
M46:HK*)DV&5#3'63QPE\L4G4=3O6NK3K773@O/A;4MBE'K7\)>(\%%36:MI,
M9N\4S7Q21TK:67?]G?1CCO6NI((Z*1\JN.88EC$4<[O./A-C6S#T7<W9N =T
M[COJJSQBO7#;*; ZGQ&AAK\JJI&-I3043XI-\PYN?T1S=-C1V=D>]2O'*CK;
M=PSX=T=U>9*^GJZ:*=Q/-MXB(/7QZ^/BO1%5*+W^3(6W,^%F)6WA9>8*:STH
MJ:.WRSLK3&#.9&,+N8R=_4CJ-ZZ]RAO)^P:QWCA[1WO(J""[U]9SQA]<T3=E
M%&XQLC8';#0 WP]:U'B/_-[E'^%U7^D]5;R;_P"9RP?_ #_]>1<M<NFW?<%3
MX#4T=CXH\1+!;^9EL@F:^&$DD1Z<X #?L.OF"_8K1P_PO([W7\0L@M=\OE;.
M92*JF[1T#3U#>R'/H^WU  :3A>)3QLXHBF($YZ1D]P=S'7Z53^"]WPO&Q>H.
M)%/#!E3:Q[I);E2F9Q;H?)/*='FYB?7L=_AT:;;?LN.0=55>\1J.-F%5W#J$
MTD<M4*>K=#3F"*3F<&^BT@?U7$'H/!7_ #7^E!@O^'R_LU"I6;99!DG%7A]<
M;;0STV,TM?'!35DL)B9.\R,+RP'7H@<GZ5=<U_I08+_A\O[-0J^WR8/RL_I6
MT/\ @Y_4];:L2K/Z5M#_ (.?U/6VKSY?^/R*CY]X^6EM]XN8%:Y)9(H:MKX9
M71NY7&,O], ^UO,/G7L\H' <9M'"RJK[/9J.@J[?)"8IJ>,,>0Z1K"'.'5W1
MV^N^H7IXJ?S]<-O>_P#65/\ E*_S-WW^]3_Z[%UC)IP2_FY#JP+AIC-=@5!/
M>[73W.Y76E955=;5-[2=\DK0XD//5NMZ&B.Y4G@5?ZBP<%\RJ6O,AL]14.I@
M_J >S:0/=S=?G*VOA]_(/&_\-IO])JQ;@!9VY!PRSNT.>&>>UD\ >?ZI=$ #
M\QT5%*U+5Y0)G@+@-GN.'19-DM#3WB\W=\D\DM=&)N5O.0  [8V=;)[^NO!1
MM_ME/PQXWXK48VWS2U9&\TE51,.HN;F:W8'@ 7L('@0? Z7+A-Q'M^"V+XG<
M0.VL]RM;WLC?+"]S)HRXN!!:#ZSH]Q&M%<(ZY_%SC!8;E9::<8MCCC*:V6,L
M$TNP[3=^LM9T[] D^ 6_Q:Y.7]/Z>P)2T_TK;U_@[?U0JB5>58K=^,^15W$F
MI<^WVJ1U';:)\+Y8B6N+2XM:"/ZI.CWEWL5[M/\ 2MO7^#M_5"H0SP<*.+.0
M5&34#I<8R&3SB&N$':MADV7%I&O N<"!UURE(_K2!6.*N4\/):6AO/#N:.W9
M/05#)(C243Z=LC/$.'*&GP/7O&QXJY<8[S49>.'..03/IJ/)#%55G9G1,9Y"
M&^T#F<=>L-7HRSBE;;E4T%GX6VZCO5[J91S.?0GL8H_'FV&GU=>X#?5>SCI8
M[K2G$<PME(*RJQV5KZN"F80'1[:26MZD-!:1XZ#M^!1.G&U7/(+7>N$N(5^+
MSV>FL=!2$Q%D-5'".VC?KH_G^4X[UO9Z^*S3CI8JW&N =HM%RN7PG/27"*,5
M!C+"6<LO*W1)[AH;]0"M=XX]8E\7):BRU4]5=Y8RVGH13O$G:D::'=.7H=;T
M3[-JM\2+-F%\\GNGER/M*N^Q5#*Z>)L+6O9%Z30TM:!U <''ITZ^I9QZTUKX
MON#?J7^+1?W!^I8=Y-7\F,U_Q.;]@*5H./&+SX[2FC\\JK])$UC+7%3O,CIM
M:Y>;7+K?CON\/!0WDPQU$6(9A'6MY*IEQE;*WU/$8YA].UE0E&$M2\ \'!6]
MRXYY.N07:GUYQ2S5#XMC8#^1@:3\Y"KW"G(N%UKL'G>92Q7+):U[Y:R2MH7U
M/*2XZ ):1W=21U))5GX$V+XR^3]?+,'ACZR>HB8X]S7\C.4GV; 7'A;G^/XI
M86XMQ"I&VB\VHNBYJBD+Q,S9+2"UI\.GJ( ()VNS_P"27-]@0^"9-CMMX[4<
M'#^I><=O<1CJJ7LWQLCF <06M<!XAONYG!?3BQW!<TJ\TXBR?%:STD>&T<9$
MM?-2%DDDFCKLSL:V2.A&] DZV MB7GS<H(PGBO$<SXT8OA-9)(++' :ZJB8X
MM[5VGG1U[& >SF*N&;\(<9O^-/M]LME!:*UFC35E-3M8^-P/CRZ+@?43[>]5
M;C#35F)\2\>XB4]'-5VRFB-)<6PMVZ-AYASZ]6GGV;: =;7IS/C?9)\>DIL%
MJY[CDE:T14<,-*\NC>[^L0YNCKU==G7@NB4VHZ/XP2/$;"Q<\/QZDRW+HZ:V
M6M['7&65G9BOY= ;<7^B=!W]K9=OP5/S'(."\F.5EKH:.W351A<R V^W.$K7
MZ/*1)RCQT?E=?':CN,=/=J67AS6<0A+<+/!HW;L6 ,$Q<"X.#=#Y.@-=_*[7
M>K7=^(.%LL%5:N'%##<;W6T[X*:EMM 8^4N:1S//* &C>S_]Q5BFDN7\N 1G
M"^KFJO)?O;9Y'/["DKH6<QWIH:X@>[J5Z/)YX?8_7\/:*]7RVTUTKJWG =6,
M$PBC8\L:QH=L >B3Z^JC.$,K'^3/E4;7#GBCKFO'B#V6_P!1"T+R=/YG<>_N
MS?ZSTR-Q4J\@I?#2W4^+>45E=AL[3!:9:!M0*<$EK7?P3AKW<[]>PKIX86:A
MXC\1LQR;)Z=EPBH:KS.AIJ@<\4; 7:VT]#H =.[;G'O4C8?Z5V1_X2S]F%1F
M/7>+@YQ&R2@R:.:'';W/YW15[8R]C#MQY3KK_6T?$<H.M':KMW7-($=Y1&"6
MBPUV.7NQ4<5 VHN$=/4P4[>2)SOE,<&CH#H.'3UJS^4Q_P ;!/\ &&_K:J9Q
MRX@T.8R6"EQML]5:*2Y1.GKS$YD;ICODC;S $GEYR?F5S\IC_C8)_C#?UM5C
MJN&KW!YN)\'QVXX8WAM>]YL=+3FNJ86N+1*_3CHZ]C6CV<SM*7XR\,L;EX>W
M6KM-HH[;7VVF?40S4D0B):QI+FNY0.8%H(Z^M1_%ZGK,/XF6'B)34<U7:X83
M1W%D(VZ-IY@'_0_W;: >]=?$[C!8+S@UUMF(S3W6XUM'*U[(X'M%/#RGM'O+
M@-:9S=V^JQ'4]+AP";X7VZHN_D]6RWT=Q-LFJ:.6,5@9S&(&5^SK8\-]=C6]
MJM66HX-8788K5<JJR7>NC;JHJ31^=/F?XD$-< /4 >BZ/-KK5^272161LKYS
M!N5D6^=T0G<7@:]G?[-KMX<YSPJL.&6QS8J2"ZQ0,;/&:$R5+Y@/2]+E/-MV
M]===1W*T_P 3WY[ C_)\J;7/Q1S2AQ^*6/&ZJF$T5+.P@:YFCJT^'IN ]A"[
M^'F+V*;C[FU#+9Z!]'1Q,?30.@:60NW'U:-:!ZGN7'@O<JJOX^975W6AFMM3
M7T/;Q4LXY7MCYHN0$>ODY3]*XTV46W O*&S"?)73TU/<(8Q3RB(N#MB,CN\.
MA&_6"M2O5)+P@1N=Y+CUTXZUD'$"JD;CEDC[.EI.S>]DLVFD\S6@^)<?;RM'
M<O-Q5R3A=<\>-3AKX;=DE$]DM%+14+Z8N(<-@D- [MD$]Q 5FRO_ /)KQGK<
MGN]N?5XK?8A'-.V+M/-I?1ZD>]N_:''6R-+W9EQ;QZ6BAH.'-%37O(:M[60Q
MMH'<C!OJ7 AI/3IH=W>=:57_ !<4_P!@:CPZO<F18-8[M4:[>JI6/EUT!?K3
MB/G!7GXI6RAN> WT7&D@JA3T4\\(F8'=G(V)_*]N^YPWWJ;L$=7%9:%ES93,
MKA"WMVTS>6)LFO2#1L]-[7ES2FEK<.OU+3L+YIZ">)C6C9<YT;@ /G*\B?XK
M13-O)GLEO9PPMUUIJ*DBN\PJ(G5HA!D([5V@3WD#3>F_ *%LUNX9X#-<FYM?
M+3?[_/4.DGJ*JF[=[=_U>0<_*=[)\>J\G K+J:JX756'6B::++8*.M?#&YA:
M.<EQ:0[NWM[>G?T*B.".0\/,=QN:#+X*:DR:&HD\Y?7T;I)#UZ<IY21H=".A
MV"O2XRN3=\]B'7B]WQJ;RBK!4X!"^DM=9!)%4,;"88Y'<DA):T_U>C#W ;:I
M;-L<ILJ\IJGM=Q+W6]] R2IB:\M[5C&EP82/ N#=^Y>&3)1D/E"X;>(Z"HH;
M&YCJ2WR5$?9^< -DV]K3W ND 'S*U2?TL(O\)_\ 25IVG?\ _(//QRM]!@N!
MML^&T<=K?D-<RGG,)(VSE.^\] =-&AX$^M7N@X1X938TRSR6*BG;V?(^J?$.
MW>[75_:?*!WUZ'07@\H'$:[*L(:ZS,=)=+;4-K((V_*DT"'-'MT=CUEH'BH>
MW<?L?EM+&U=#<VY$ (W6N.F<7NF[N5I[M;]?7V+DM<H+3SW!"^3;1''KUQ*H
MIY7S"W54<1D=U<]L9G&_G 5(X;Y=@U;=KSDO$V=M9>ZNI/805%*^HBABT-:'
M*6^.AON#?:KKY,TE5<[UQ)?>(3%65-9&:J+^P]SI^=OS$D*.X<7FW<)[C=<1
MX@4@@I_.75%#<7TQDCE80!W@$ZZ ]-Z)(.EU?]4O.W (+(LPPRU<0\;R#AI.
M*>1TX@N5+#3O@BDB<0/DD!O=ON\0T]X5LXRV&TNXSX UUMHRVXU#C6 PMU4>
MFT>GT]+IZU)_9";E6=6JS\-;50UMO8[GN5PJ*(B.-FQ\GY)! !UOO) "\WE"
M5;+%Q"X>9!7,E^#*.H?VTC&<W+IS#].MG7CHJ)O4EWI_,'[Y1%F=;Z#$)J2S
MNJ<2M54Y]=;Z1O*P-VTC;6]PUSC?<.;VJ,K:_@]Q#LS;;2.H<9N)<TPS.HVT
MTD9!&QS#T';&QHN\=JW9MQ.KK=;L:RG'J9MPPNKD<VOE$#NVC <6[&R-#H[O
M'>W6QL*E\6,IX6Y-B]6+12P5^1U+>6C\THGQS]J3T+G<HV!X@[VIC4J2:?S7
M[@^A;13.H[514SZE]6Z&%D9J'_*ETT#G.O$ZW\Z]:J?":VW&T<.;!07KF\_A
MI@)&O.RS9):P^UK2&_,K8O))4VBA$10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0$1!_*FI_)V_K4NHB#^5-3^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M91SF>CMU'!,>^2*!K7'YP-KW(E@(B( B(@"(B (B( B(@"(B (B( B(@"(B
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M!_R!43-87>X$[/S+'> S68WFG$BPTSY/@FW5 EAC<[FY "\'Y^4-&_'E"\O
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M06#?*=<O>#ZUTEB45?\ X0L-LL]NI.+E]O8R:*6LEH0R6SF1NZ9@$7\*1S;
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M*H]#G.>X-#%0W2DD=2P 1L974YT&CN#9!K8^<K1>%^=X]E%W,;K+26R_NYI
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M/D,KF![G;<0 3MQ)[@%RCGBO3O%W;LTX/J*9*+ O*7@?#><?KM;88WQ[]K7
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M6'\@9_K/6L>4]_-#<OQ\'^H%;LJX?XQE=P@KL@M;:RJ@8(XY#-(SE:"3K37
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M>6FH:9A@C8(0SJ]VW/(&]-  )<>O?M>N*_'K:_P0^ILUQQF5\.ZZS/ YZFD
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MGDXLWA].SLH)*"<PQ_V6]M$0/F'ZEPOMSI+!Y5,UPNTPIJ.&L:Z25X.FM=
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M:I-HH41??XW:ORD*741??XW:ORD+ )=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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ML'-)*[^RUOB?T#Q6?_9R@I6Q55ZP_);;9Y2 ROFIO0T>XGNZ>XGYU(XY25I
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M:;\ U!%4^&?QL^+TGQ\[#X6\X=R]CR<O9:;R_)Z;WS*V*-4Z 1$4 1$0!$1
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MFF,7(W%D4K8*B&XQ,>_E=XA^NF]:V-'KWD;"L/E"W".[8SP_N, +8:RXP5#
M>\->SF&_F*\V06#B;Q3-';,FMM%CF/QS-EFY)0^20CV!SB2 3H'0WW[TK+QN
MP^XW2S8A08U;WU$-MKXBYC'-'9Q,;R@]2.X +:DM4=3W!#\4X67KR@L"LUQ
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MXDGIOY1&NXJMIK3?*0//Y5MNI7V''+BYC!6Q7)D#'ZZECFN)'NVT%=_E,?\
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M\_/DU94?B]E;L9Q=[:-Q^%:XFGI6M^4">]X'L!^DA7>1[8XW/D<&L:"7.)T
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M6"]<+>+>.6:+(+A=L?OA,?85TG.Z-V];![@02T[ &P2"/%2GDR_+SK_&'?\
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M'L.PM51;6225)@XPQ1P1,BA8V.)C0UK&#0:!W #P"I&;<*L3S&J-7=K<65Q
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M!J+=;92YK&5+!VKW!Q;RM:">8DM.M>K?15:/CO:F".JK\<R2AL\I 9<)J/\
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MD5_BQJIO.(2V"EAN#>PFJ*@/F>X]2WET"T= ?F"W#$G2K^?(%Z\H[[=<.O\
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M_P 8=^U(HXJ,9)>P-M1$7F*$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!<99&Q1/DD.F,:7.)\ %R57XGW'X+P"^U(=
MRN\V=$T^IS_0'Z7+6..N2BNY).DV47A)Q&N^4Y=54%U,(I74[YJ<,CY3L/
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M .Z'V;]BJ5EX>YAEU*ZZYUEEZM-9,\F.VVV81,IV[.@=;!/Z=:V24Z=-ZG5
MVQ%C'"&\WN@XE9+@]TO,E\H;= VH@K9^LC=\GH%VR3TD\2>K?F7BS:\5F2\9
M9<,K,EJL;LU-2LD8ZEE$,E;*X-/*'G^\1KK\@]-]UZ3U5?N#=$6.4&.9E@V=
M6:.S72[9'BU<[LZR.OE$CZ0; Y^8Z]>^@ZZ(UW+\S#([_F/$*7!\,N!M=+0Q
M]I=;G&-O9W>@P^!Z@=-'>^H .W3M[/8&R(L&SG&[_P +K+\:L>RV]W)E')&:
MVBND_;1SL<X-.O5U(]O7>^G6Y<5\VJ[-PD?DE@;J>KB@=#(YO-V+9=>F1W;
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M>9X'+*.;KI:XBO4=M^08)8;=EW!Z[72CM-@GR3$JR<U$ I'?PU.X]-%NB3T
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MD[6G:U^F\VVGJ/'JT+OZ;)''D4Y=C&2+E%I%&XJTD=EDP"KC(9#;;A%3<W<
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MM=V[_9%ACTOZ')$1>0ZA$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M9:+*R1M(Q[I/X5_,XN<=DDK,LB:?N"=64^4Y=?@WA/71-=ROKYXJ5OYW.?\
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MO++'P8J[M75EMEHJ>R^<6J.*,\\7*QQ_A-@ ]S>X^M>WX_7O_P!G?XX\]/\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M_P#D<^(?PM_4Y//O-O\ \-VN^SY_F^5[?8FN*?/>P3O"L <-,4T-?^54Q_\
ML35F7!F.27/.+T<!U*^N+6'U.+Y]+8L6M/P#C5IM';=OYA2Q4O:\G+S\C WF
MULZWK>ME5S!,#^*F395=_A+SOX=J14=EV'9]AZ3W:WS'F^7WZ'<N:DOQ>_\
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M1<K+43-ADEM?/VD)/L/?T!\.NM;"O'$_/J3!\?AK3 ^MK:QXAHJ2,Z,SS^D
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M( B(@"(B (B( B(@"(B (B( HB^_QNU?E(4NHB^_QNU?E(0$NB(@"(B (B(
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M$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'BO?VHK/Q
M3OU+G:OM71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0'J1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$
M1!_*FI_)V_K4NHB#^5-3^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 41??XW:ORD*741??XW:ORD("71$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!XKW]J*S\4[]2YVK[5T
M?XEG[(7"]_:BL_%._4N=J^U='^)9^R$!ZD1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RIJ?R=O
MZU+J(@_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 %$7W^-VK\I"EU$7W^-VK\I" ET1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 >*]_:BL_%._4N=J^U='^)9^R%PO?
MVHK/Q3OU+G:OM71_B6?LA >I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 1$'\J:G\G;^M2ZB(/Y4U
M/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MQT.@7[B&2VW++'#=[+(^2BE<YK7/86';3H]#[0KI=7V!,HB* (B( B(@"(B
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M[RO)CL_%7/K:V_T5[M^-6VHV^CI!2MF<]F^CG%S2='U^/?H#2\V:T\U1Y*-
M*<$]G;Z*1X']D.9OZ._YEJG#"KIJ[AWC4]$YI@^#X6#E\"U@:X>\$$?,NLG2
M<JWLA4.&6>7J?*Z_"\[@@BR&D9VL513C4=5'T.P/7H[Z:Z;Z @JHS9MQ!OW$
M/*\0Q:HI&2P5&X:N>-H;1P,)#M^B>8N+F ;![CT\1[[P]EP\K&Q"@(<;?;'-
MJRWKRDLF[_K(_I"[.#X'V<>)IUU$K1O_ #E:J*N5=D_U!IO#^FR2DQN*+-*V
MFK;P)'\\M.T-:6;TWN WTZ]P[UX.,-]K\:X<7J[VB5L5=3-C,3W,#P-RL:>A
MZ'H2KDLZ\H?^9S(_[D/^O&N$/Q35^2E3L-3Q5SNP4EYM=YMN/T<D+>PC?3MD
MDJ2!HR/VTAH<X$@#P\/$V#@EG%XR1]^LF5Q0MOEDG$,TD0Y6R@EPWH=-@L/4
M:!!'16CA4 .&>*:&O_*Z8_\ V)JS'A9')-Q:XLQ0G4CW\K#ZG%T@"Z.I*2KC
M_)#OILOS3B7?[G3X!64EEQVWR]BZY30B5\[O^4$$>W730(V>H"[*;,<PP#+[
M79N(=3276T75_94UU@B$3HW[ T\  :V1OIW'>SHA?ODFSP_8^N%"-,K*6XR=
MO&>CAMK-$C_*1_E*\WE6R,J;+C%JIR'7.JNC70,'RB TM.O\SV+=+J=.M@6&
MIR^]67CI!CMWJ626"[4O/0 Q-:8Y0.H+@-GJQPT?[;5)<<,QJL-PIU1:7-%X
MJYV4M&"T/](G9/*>_P!$'YR%!>4E9ZAV*V_)K;]L\>JF53'@=>0N =]#@P^X
M%03KE#Q2XSXR*3^$LECH6724=X[:0->UI]H)CZ?\KEF,5*I]ES]/\@M.?YU=
M\-QS';7%%'=<UNS601M+0UG:Z:'O(&NG,X #I[^A417V[C#9;9)>?C+:[K/
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M^0PZ)+B.F]> ]94)!@&?W2%LN3<1ZJEYAS206V!L0;ZP)!R_3I9B]M3I7_.
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M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( HB^_P ;M7Y2%+J(OO\
M&[5^4A 2Z(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@/%>_M16?BG?J7.U?:NC_$L_9"X7O[45GXIWZESM7VKH_Q+/V0@/4B(@"R
MW,.#=NNU\??<=NE;C5[D)=)44)]&0GO):"#L^.B-^(*U)%J,G%V@8N[@G<;S
M+&W-L[O%ZH6.#O-&M,3'$>O;G#]&_:M;LMJH;):Z>W6JFCI:*G;R1Q1C0:/^
MY\23U*]J*RR2ELP?+O";")\DNV87.SWZML5YH[K)%'4TXYVNC<YQ+7LV.8;
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M-WO/K))VO?@^/LQ7%+;9(ZAU2RCC[,2N;REW4G>MG7>IQ%')M4P?CVM>TM>
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MG:G3)HR=\A/@0>H/M.^_8S*XXSQMR2RLQF[L:VV>BR2:6> <[6GISO:2YPZ
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M]<6WOVH&K(OQ@(8T./,X#J=:V5^KS%"(B (B( B(@"(B (B( B(@"(B (B(
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M<OI.T-CH=#2MJIO$A^5T..4L7#RAIY[@V9K"V5S V.$-/]MP'?RA6RB$S:.
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M8?XJ:N#.-F44LEMJ*.RX]33@LEJ8I07\I[]$/>1T]0!]H7IR04I7:KYD1Y^
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M*DR.D-0YW*T2!\;7'U!S@ ?I65&3X0+PBX32QPPOEFD9'$QI<Y[CIK0.\D^
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MYK_1MHA*Z /V272- +FANMDC8WH>*]>)YMCF6B3XO7:GK7QCF?&W;7M'K+7
M'7MTFB25T"Q(B+("(B (H6U959+K=:BV6ZXPSUT <9(6@[;RN#3WC70D*:6I
M1<74E1$T^ BA;OE5DL]Q@H+E<88*V< QPD$N=LZ'</$J:1Q:2;7(33(K*['3
MY)CU;:*MSF0U+ TO;WM((<T_,0"J!0XKQ$MENBM-OR6V"WPM$44KX#VK&#H
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M !NU?E(4NHB^_P ;M7Y2$!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M)\2>JUCBW#N]^P(SR9ZFG.;YY!:J>IH[4^2.:"DG;RNB',_0+=G1T0/F"\W
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M'S\X%0_F: ?ZVMZ]JCVNGW0*UA6?</:''*;&<RQ;X)JH81!5&HH \/<!HO)
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MJ_B]EUSC:UM):X111-:/18&Z8-?-$[Z5W\"Z87J:^9?< )+A65;HHW.ZF-@
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M;G=753F$OKI><L#=]&^KO4E5;2LIW</\WM^;T=?46V"KIS15+J66.I:UK@X
M'8Y7'IU_05PS#.K;C%YLUIGIZNLN=VD[.GIZ1K7. V!S.YG#3=GO]A]16=<)
M:NGQGB%Q5H:Z5L%)3U N/,[H&1DO<3]#FK]X30RY3D=]XHWR)S8-/@M,+_\
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M@$1%@'7%3PQ/<^*&-CW?*<UH!/O78B( NOL(NV[;LH^UUKGY1S:]Z[$0!$1
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M^HE3B+$\\IQ<9=W98P47:"(BXFPB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M]KR#GUZM]Z[EB<M5>Q0B(L (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B("(@_E34_D[?UJ741!_*FI_)V_K4N@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B *(OO\;M7Y2%
M+J(OO\;M7Y2$!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J7.U?:NC_$L_9" ]
M2(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=OZU+H B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"B+[_ !NU?E(4NHB^_P ;
MM7Y2$!+HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB \5[^U%9^*=^I<[5]JZ/\2S]D+A>_M16?BG?J7.U?:NC_$L_9" ]2(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B B(/Y4U/Y.W]:EU$0?RIJ?R=OZU+H B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"B+[_&[5^4A2ZB+[_&[5^4A 2Z(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/%>_M16?
MBG?J7.U?:NC_ !+/V0N%[^U%9^*=^I<[5]JZ/\2S]D(#U(B( B(@"(B (B(
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M"(^#KE^&'?4-_>GP=<OPP[ZAO[U+H@(CX.N7X8=]0W]Z?!UR_##OJ&_O4NB
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MWJ61 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M=) N*$@=Y5)PKBCBN85IHK1<'-K]%PI:B,Q2. [];Z'W E93Q<XC6V#B[B\
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M*@IVVUD?9&$Q@M>-:)</ZQ/B3WK(."L7Q;XO9WB5"7"TQZK(8M[$1);T'S2
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M4;DE[I,>LU1=+B9!2P<O.6-YCU<&CI[R%YL0R>W99;)*^T&4T[)3">U9RGF
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MM726;'CP2QJ>MOY[?<RH2E-2TU1:51>*UQR>EHZ"CPZF?+5UCWLDD9'S&)H
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M=")A%*V1C>4.83T(+0-C?K[]JE57$_/,<J*2/B+C5/<Z>)_\&;E0"-V_$QR
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MM=2YQV-:]15V\K;^0UE_Q:/_ $I5TA%*<6ER"_V_,:FBPRNO^<VDX[YJ]P=
M9Q.7-Z<I!:!LN)T!ZPJ52<3LYO%'\+X_P[EGL9!=&^:L:R:9G]IK>_K[ [V;
M7E\KB69O#^V11NY89;FQLA\#J.0@'V;Z_,O?33\98*:*&GM6'LAC8&,:U\F@
MT#0 ]+NTL1C'3JI;@NW#G.+;G5E?6V]LD$\#^RJJ2;I) _U'V>H^_P 00*76
M<6+Q>;_76WASBSK[%0/Y*BMEJ!##S#P:3T/=T.^OJUU4-A>*YAC]QS_(+S';
MH'W*WS2]E02EP%2 7 AO>.]Q[^\J=\EJ&"/A-2OA#>UEJIG3$=Y=S:&_\H:H
MXPC<EN"@U>5S9/Q[P?X0M-39[I0\\%51SGFY':>X%KOZS2""#_\ ?/TRL1XE
MT\#/*%X>3L#14RQR-DUWEK>;EW^<Y;<LY6FHUX*BF<3,]I\)I*%K:&:Y76XR
M]A14,)TZ5W3>SHZ'4#N)V0J7<>*>8XQ%'7YK@;J2S.>&OJ*6L9*Z'9T.9HW^
MDM5AXQ8%4YA'9ZVRW1EMOUJF,M'+)\AQ.CHZV0=M:0='QZ=51+KF/$K$Z"4<
M0,3M]^L;-=O40!I! (])P&P!O1ZL"UCC%I4DW_."%^XL9I;[#P^IK^;537VA
MJ9(3%#,0&.:]I<U_5KO#V>*D\ZSRVX5BD%VN$;WOG#64U)#KGE>1L-'J \3X
M>_0.:<?[Q07_ (#6VZ6=O)05-3 Z)G*&\@T\<NAT&B".G3HOSB7J?BUPHIZX
M T :'L#ODF7;?^X8K'&FE?O^@)D<4<OM=.RZY7@%10X^[1?40U DEIVG^L^/
MOUZ]AO\ V5EX><0G9?@5PR0VUM*:5TS1 )N?G[-@=OFY1K>_4KI=HH)[5615
M@:ZF?"]LH=W%A:=[^98AY/>OL#W[7=VE9KZIJS^&46ZK@'LL?&>^97:X3AN%
MS7"X@.-6'5(;!3'F(:WM' <SBT!VNFM^*L?#7B=)DU_KL<O]FELF0T;.T=3O
M?S->WIL@Z'7J#KKL'8)49Y+$,<7">G>QH#I:N9[R/$[#=_0 HRI 9Y6%)R@#
MGM)YO;Z#OW!:E&%RBEP"UV_+X9^+F0XY36"F%?0T J//VO DJ/1C(C/H[ ],
M#Y1^2%CM!D>5#C[<KFW"S-?#;PPVLUS-PLY8QV@DUKNUT_YE>L5_I49?_A3/
MV:=<+/\ TL+Y_A+?V85J-1O;L"TRYA$WBY9,<JL?IFW"KMOG3JXO!E@]&0F,
M>CLCT2-\P[ST79Q$XF1XS>*.P6:U3WS)*MO-'10NY0QO73GNT==Q.M=P)) 5
M5OG]*['O\'=^S.NKAP!4^4?GT]8-U4,#60\W>(_0'3Y@WZ5G1'E^+!)1<5[Y
M8+O04O$?%#9*.N?V<5=#4MFB8[U/UO7MZ[\=*Q\1^(T.)5UOM-!;:B\Y!<!N
MFH8'<I+=D<SG:.AT/@>X]VE8\NI+!5VH-RQEO?;62M=_X\M$0?U#?E=-]2/G
M6>9[F=OM6<VZW8KBU/?\R=3@Q3,#6=A"6G0,FMZY23K8&CW]5F*C-[1_P#PW
M?BGFV+1,K\OP'S:SEP:^>FK&R.BV=#>MCZ=;/BKKG.?08]PY^-MOIA<:9[(9
M(HS)V7.V0@ [T=='>I9;Q6J>)U?P\O4N1T6/VFSMC:9X8GNDG>.=N@#MS>_7
MJ7/-R3Y)ELW]ZT?^HU;Z<7I==ZV!83Q4RN\TQK\+P2HN-H8.M7/.(^V(^5V;
M#HN&]@$;WZAW*RX)Q'9FN'7.Z6BUR_"] 'LDMDDH#C*&DM:'D=SCTV0-=>G1
M6'A_#'3X+CL4+0V-MNIP /Q;5EOD]@-SSBHQH 8V[#0'A_"U"Q47&5+@%3X+
MW[(XN*&9.I\6=,^ON4?PDWSMK?@[<LF_#^$US.[M?)]J^G%A_ O^=;BO_B(_
MU9UN"F=W+[!%#XF\1J?#'T-!2T$UVOUP.J6@@.G.ZZYG'1T-]!T.^OJ)52NG
M%S)\5H9*C-\'EH(I&.-+-!5-DC=)HEL;RW?)O6M_H[]>>CU/Y6%=Y^ 33VH>
M9\WAZ#-Z_.D_2KQQQBIYN$^3"K#2QM(7MYO!X(+/GYM+248N,6KL%+XPWTY/
MY.4EZ=3BF-:VFE[$/Y^3<S>F]#?T*>R#-G8#P?QZ\LH!7DTU)!V1E[/Y46][
MT?5ZE1LL_HD4'Y/2_P"LU>GCK_1WQWW4/^B5M13J/:V#>Z67MZ:*77+SL#M>
MK8VJ7PNSQV<1WMS[>VB^#:PTG2;M.TU_6^2->[JK?:SNVTA'4=BS]2^?^"T\
ML>!<4JBB),S:BJ?$6]_-V3B"%QA%.,OH4M53Q8N]\O==;N'&+OOL5$_DGKI9
MQ##S>II/0]W0[&_5KJIKA[Q*=D-^K,<R&T2V+)*5G:.I9'\[96].K':&^\'7
MJZ@GKJ-\E^&"+A'0/@#1)+/.^8CO+N<MZ_Y0U7.\06"*_MK7LMOQI%*\4CI"
MSSDL =\@'TB.KN[VK4]*;@EP0IE]XK5M3DU7C_#_ !V7(:^C/+53F8101.!T
M1S'H>H(ZD=0=;79B_%2J=E,&-9U8)<>N]3_%GF420SGP <.FSW#1(WTV#T4-
MY)<4)X>W"I;IU7-<I.W>?E$AC- GYR?G*Z/*Q:R+&L<K(.ERANC13N'R@"QQ
M.O\ ,UGZ%K3'7TZ^H+MQ'XAG%[E;;+:+3->LBN(+J>CC>& -&_2<[1T.A^@[
M(TJQ-Q8R+&:VB;Q$PYUJMU7*(FUU-5-F9&3_ &@-^_O!T#H%2/%; +O?,AM.
M38A=X;;DMOB,3!-\B1GI'7<?[3AU!!!ZZ5/NF?YMBT,3.*6&4=RL[96@UE.U
MK@T]P=K;F[[] \J0C&25*_[@UWB!FMKPC'W76ZN<]KG"."&+J^=Y&PUOT;)\
M L_EXF9Y1T!O-QX<2QV,-[1_)6 SQQ_VBS6^@Z]6CVZ59X\UM5=\UX:/L IJ
MB.HU4T+*K8AD>YS"WF]A 9T]JM[JKC0YI:ZUX@6D:(+Y-'_J2,$HINM_(-%Q
M'([=E=@I;Q9Y3)25 Z<PTYCAT+7#P(*F%EGD_8A>\.L5UH[YYH&5%7YQ VFE
M[1K=M =[ODA:FN,TE)I<%,(IN.EUO$=12XUAU1<+Q!42,D@BE=(R.%N@)'$-
M'5Q) 'L[^NE;\CXHLQO$[+6W>SU+<@NS!YO98G%TO.? G6QWCPWLZT>JJ?DJ
MP1MH,OJ T=J^Z%CG>):T; _ZC]*A>)3[]-Y2-K&/0T,]RI[<'4<=>2(M<LA<
M>A'7JXCVCV+T.$'-QK@A::OBCF./0LN68X#+1V-S@'U%+5-E? #XN:/^_*M,
MFR>T0XJ[)'5C#9Q3^<]N.XLUTT._?AKOWT67WN/C#=K/76^NMF(FEJH'PR_P
MDGR7-(/>[U%4_.;%?,1\FAEFNSHC*RX-#NQDYV]BYY>.O][2STXRKB[[ N5O
MXJYC>Z=UWQ_A[456.M)Y97U3632M!ZN8SQ]P#O5M0G "\07_ (LYY=:1DL<%
M6R.5K)6Z>W;NXCU@]%MV*PP4^,VB&C#13,I(FQ<O=RA@U^A9+PGIX*7COQ)C
MI T1;C?IO=S./,[_ *B44HN,DE7_ *"[</,[=EU^RNW.MXI!8ZOS42";G[;T
MI&\VN4<O_#[NO>G$+/'8C?\ %+:VWBK%\K/-3(9N3L?2C;S:Y3S?+[NG<J5Y
M/Q_^OKBH/'X6'^I.N/E .'Q_X5-V.;X6WK_YL"FB/4T]O^@7OB9Q!H,%H:4S
MT\U?<JU_9T=#!\N9W3WZ&R!W$[(T"J96\5,PQV&*Y9E@4E%8WO:U]13U;97P
M G0+F_OY?5WKR90!4^51BT-:-P0VUTD#7=W/RS'?OV/T!;)?8+=4V>LBO;:=
MUL,9-0*@@1\@ZDN)Z #6]J?A@E:NP?/?E0W^LN=@L0HK:)<?FGAK*:Z-G&IG
MNCDU'R:V/1.]K0<IS>XVSA?77[+<.AAGAJ61?!=14LE:]I<T!_,&D=Y/37@J
MCY2[+;'PQQIEB\U^#&W2-L'FA:8N41R_)Y>FM[[E:O*=_F@N?XZ#_5:MJFH*
MNX+3=\TM6-X%2Y%=F^:TCZ>)[*>+1<7/:"V-@Z;/T= 3T 5$CXFY[44'PS2<
M.)7V0M[1O-6 3NC[^8,US=W7HTJM\8PV>S\(*.K^UL\T J ?DGT81U_RN?\
M25]%@   #0"PU&$4VKL%6P7-[9FF,F\6@O CVV:GDZ/B>!LM=^C1\0LXL'&R
M\97;F,Q+#)[A=ALU$?G($%.W>F\TC@ 7'1.NGO*\O!QK:;B?Q5I*'0H&S%W*
MWY+7\\G0?2X?,O?Y),,<?#2KD:T"22Y2<SO$Z9& M.$8*3J^/U!.</.*-1?<
MIJ,7RBQ2V/((HS(V)TG.R4#J='7?KJ.\$ ]5IZP_*@&^55B): "ZUOW[?1J%
MN"YY$E37=%1GW$G+*7'\JPVWU-DIKC)=:SL(ZB5P#J4\\8YF[:>OI ]"/DKH
MXE<4J?!,DM%NK;=)44U=#)*Z:)_IM+=\K&LUZ1<=#O'>JUQZ_G&X5_XH?]2%
M=7%N&.?COPV9*T.:'.=H^MK]C]("Z0A%J-^&0[KOQ9S*Q4[;O?>'D]+8"X!T
MGG0,L;2= N&O1]S@.O3:UZQ76EOEFHKI;WE])5Q-FC<1H\I&^H\#ZU7.,;0[
MA9E(< 1YA*>OK VO#P#)=PAQHG[@X?\ V1RQ)1<-25;E+^B(N("(B *"S3%Z
M#+;));KB" 3SQ2M^5$\=SA]/=XA3J+49.#4H\HC2:IGSY#P[XB8K)+%C%T;+
M2/=O4,XC!]I8_H#[M^]?M+PARO(K@VJS"[AC>XETIGEUZA_5 ^?YE]!(O;_^
M1R\I*_-;G'X>'T*5EV(/J.&4V,V'7,V.*.'MWZV&O:XDG7?T/@LNL_#GB19J
M5U-:;I%20.>9#'#6%H+B -ZUW]!]"^AD7/%ZS)CBXJG;O<U+#&3LQ;'\6XFT
M]\M\USOAEH8ZB-\[//'.YHPX%PUKKTVO1Q%X>7N_\0J2\T'FOF<0AYNTEY7>
M@[9Z:6PHK\;-3UI).JX)T8U3"(B\9V"(B R3*, O-RXLT&14WFWP=#/32.YI
M-/U&1S=->Q:)F%OGNV*W:WTG+YQ54TD4?.=#F+2!LJ71=Y>HG+3?_'@PL:5^
MYFW!3#+IA]'=8KQV'-4R1N9V+^;H =[Z#UKU\7<$^.5HB?1=FR[4I_@7O.@]
MI/I,<?5XCV^\J_(J_4Y'EZW<G3CHT=C-L+Q_*K9P^NM@N3X!4BGDCM\\4YVW
MF:=-)UL:=H@^WV+R\!'7,T-_BNU;-6OIZWS<2/F=*W;1Z7*3X=RTNY4<5PM]
M31U!>(9XW1/+'%K@"-=".XKSV"S4%@M<5OM-.V"EC[FCJ23WDD]23ZUN7J-4
M)IK>3(L=-5V)!4#BAPWI<SCCJ8)FTEVA;R-F+=MD;_9>/U$=V_%7]%PQ998I
M:X.F;E%25,^?8L1XKVZG%OHKE(ZD:.5KHZUNFCV%VG >Y2>&<%ZN.[0W7*[D
M)9HY!-V,#B]SW [!>\^WU?2MO1>J7_T,K344E?A')>GBGON9/QIP*\YA<+9-
M9_-N2GB>Q_;2<IV2"-="I3B7B%SR+ ;99[=V'GE/)"Y_:/Y6Z;&YIT=>LA:(
MBY1]5.*@E_QX-O%%W[E8X9V2KQW"K?:[CV?G4'/S]F[F;U>YPT?<0K.B+A.;
MG)R?+-Q6E4C*.-6!WC,*^V36?S;DIXWL?VTG+U)!&NA]2TVU0/IK71T\NNTB
MA9&[74;#0"O4BZ3S2G".-\(RH)2<EW,.R/A7>Z+.!>\+DI88A(*AC)).3LW[
M])NM=6GU>HD+W<>F7^.S6N[4=;);XX&%E3%!5.872/+=-;K7-K3OF6QJ&O.-
M6N\W.WUUR@,\M"2Z%KG'D#CKTBWN)&NFUZ(>LDYQEDWTG-X534>Y)4 >VAIF
MR[[01M#M]^]=5W2,;)&YDC0YC@6N:1L$>HK]1>*SN89D?!ZZVR\NNF"7 4_4
MN;"Z4QOBWX->.\>PZ^=1M9@G$[(P*6^7'EI=]1-5@L/M+6;W\X7T*B]L?_H9
M4E:3:[M;G!^GCV*3PQX?TV$4E3RU3ZNMJ@WMI".5H#=Z#6_.>I5<XF<*'7VZ
M&]8Y4LH[HXATC'DM;(X=SPX=6N_7[/'647&/JLL<G5O=FWBBXZ:V/GJLP3B=
M?866^\7'=""-]O5AS#KQ(;LN^<+6^'6&4F%V0T=._MZF5P?45!&NT=X #P \
M![_6K4BUF]7DRQT;)>%L2&&,'?<S+BCPLARNI^$[7.RCNV@'EX/9S:[MZZ@C
MU]52SBO%IL'F#;G,:8#E[05S>[^]\M?0*+6/UV2$5!I-+BU=$E@BW?!CO#K@
M])9;O3WB_P!P$]; _M8X8">4/];G'J?=H>\KEQ@X>7O*\HHJ^T^:^;Q4K8G=
MK+RGF#WN[M>IP6P(I\;EZG5;W+T8:=)Q+ Z,L> YI&B"-@A8=)PNR#'\\%XP
M]])YE'+VL<<LI:0T_*C/3N[Q[M>*W-%SP^HGAO3P^34\:G5]C\826-+F\KB.
MHWO17ZB+@;"(B B(/Y4U/Y.W]:]]PA=/;ZF&/7/)$YC=^L@A>"#^5-3^3M_6
MI= 8KY/?#2]X--?_ (Q-I#'71Q,8(9>??*7\V^@_M!53A[P*O=AXFT5UN!HG
M66BJ7S1EDI=(X#F[/T==^^4KZ51=NO.V_(HP_,N&-_NW'"VY72>:?!5//2R/
MYY=2:CUS:;KV>M2G'/A/)G3J2ZV2ICI;[2,[,&0EK)F D@%PZM<"3H^WYQKB
M*+-)--=@?,UVP7C'F5+26;)J^DAMD#VN,SI8_2([G'LQS.(\-ZZ_2MCJ\#B^
MQ548=35<CR^C= VIG)<72'TN=WLYO#P'0*[(DLTI5VH'SIP;P/B7AF14]'-)
M308T:DS5;&S1O;+Z/+MO3G\&^KN"\M;PISS#N(-9?>'LM+/!4OD+1)(UI:Q[
MMECVOT" ==0? 'HOI5%KXB5W2W)1\PYGP:XAY)74=\N=UM]=>7_\6(N[..G:
MT@L:P@:/>[?0=?7O:O'E </+_G]-CQL[*1DM()3.V:;E#2\,T ='?R2MF13K
MRM/P*/F^Y</N+%BM+\<QB]LK,=E:6-!DC9)"QWRF%SAS =3\D_,-Z6@\#.&
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MP'J&MYCW^KIOUZ6W(I'*TJ\ RKB?PO?>>&%LQK&'Q0RVJ2.6G$YT).5KFG9
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M2!C:V;T7#?<2S73UZVKKE&26W&K*^YW.;EIQH,#!MTCCW-:/$E)>GR1:37/
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MWR\O-IO+WDN+0![2%.G*ZH&@(L7KN-U?:>RK+[@5\M]CD<&MK)#Z0![B6%H
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M<H/,.LDG>/!:NNN1JHI> 5/B+GEHP6TBJNCS)4R[;34<766=WJ \!W;/A[]
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MN+/#&X48#:^6M-.\M[W1]I&-'V:>_P"DKJK*6&I\K*D=.P/["V]JS8WIPC<
M?TJ6Q7$,GR;B!2YEQ!@IJ 6]A9;K7#().S)WZ;B"1OKOOV3KN  /O=B5Y/E
MLR<4K?@46_L.W[5N^?E(UR[YOT+:DDM-\)@@O*VJ)X\!ME-"2(ZFY,;)UT'
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MR_U6Z_[C6]'9UI1I2:DG6P)GB-DV-8WF5E%'CDU_S-L'+114Q/-%%IP&W=?
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MJMO(^;EY61LZ>BT?,/5W=W?N[(BSDR2R/5(1BHJD$1%@T$1$ 1$0!$1 $1$
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M>U6,7)T@7A%1^)F=NPJ?'XVV\5OPK6"D),W9]ELCTODG??W=%>$<6DF B(H
MB(@"(B (J/G^=NQ/(\1M3;>*H7ZL\T,IFY.P].-O-KE/-_Q-ZV.Y7A5Q:2?D
M!$10!$1 $1$ 14?%<[=?>(.2XR;>(!9PTBH[;F[7>OZO*-=_K*O"KBX[,!91
MDW#B_4N:5N4\/K[!;:^O:&UE+5Q<\,I&NN]'7<#W=^^O72U=%8R<> 8]2\,\
MER/(+=<^)=_I:^GMT@EI[?0Q<D1?O>W$@;[AX'?=L!;"B)*;ER B(L@(B( B
M(@"(B (B( B(@"(H3-[Z<9Q.Z7H4XJ310&;L2_DY]>&]'7T*I6Z0)M%!X-?S
ME&)6N].IQ3&MA$O8A_/R=2-;T-]WJ4XC5.F B(H B(@"(B (B( BHU?GKJ7B
MS;L+^#@YM72&J\\[;1;H//+R<O7Y'?OQ5Y5<6N0$5.XKYH[ \3=>FT(KB)V0
M]B9>S^5OKO1]7J5KH9_.J*GJ.7E[6-K^7>];&])I=6#N1$4 1$0!$1 $1$ 1
M$0!$5<XBY*</PRY7YM**LT;6.[ R<G/S/:WY6CKY6^Y5)MT@6-%%XI=C?L8M
M-W,/8&OI(JGL@[FY.=@=R[T-ZWWZ4HHU6P"(J-PFSUV?6VYU;K<*#S*L=2\H
MF[3GTT'FWRC7?W*J+:;\ O*(J/79VZEXL6["_@\.;5T9JO.^VT6Z#SR\G+U^
M1W[\447+@%X1$4 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M 1$'\J:G\G;^M2ZB(/Y4U/Y.W]:ET 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!1%]_C=J_*0I=1%]_C=J_*0@)=$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'BO?VHK/Q3OU+G:OM
M71_B6?LA<+W]J*S\4[]2YVK[5T?XEG[(0&,Y9Y1%IL.6U%HAM%16TU),8*BJ
M9,&D.!T[D81Z6B".I&_TK9[974]SMU+744G:4M3$V:)_=S-<-@_05AN7^3I2
M7S+ZJZT=[=1T59,9YZ<P<[FN<=NY'; T23WCIOQ6XVFWT]JM=';Z)I934L+(
M(FD[(:T #] 7;)TZ6CDAZE\S8;D[^"F1W^SYA:JQU%7U9J*>Y0,#NT'71ZD<
MPUUZ'8.^B^DJ^9]-0U,\,)GDBC<]L0.B\@$AN_;W*E<,LVMW$W&:FHEH(8G1
M3&&>AF<)N7Q:3L#8(]G@?4IC=1=JT4\,N7X!Q/LE38/AN%S:UH887GL)M[!'
M('CJX$#NVI#)6NX=\(ZYN/RO<ZTTA\V?4ZD/1W3F[@>]5KBOPEPVHQ6[W."@
M@M%;2T\E0RHI?X)H<UI(#F#T2"1KNWUZ*!MMWN%Z\E.X55V?)+4-I)86RR';
MI&,DY6DGQZ#6_8MJ,6DX\7P0]&-WWBIGV.4MVQ^HM%FHQ$&M?4Q\TE9*T:>X
M#E<&LY@0.[N\5Y\.XCY[FU//8+106^BR&@D>RXW&H![&)H.F\K!O^$)#AKJ/
M1WX]-'X(M#>%&,!HT/,VGZ252/)Y ^.'% ZZ_#!&_P#YDRU:_%LM@=V'9CF%
MDXGT^%9]+15SJZ STE;3,#-Z#CUT ->@X=VP0.\*2S?,<HK,[;AN!TM+%61P
M"HJ[C6L)CA:='31W'Y3>NCU=K70E0F??TFL#_(G_ /U=>B^YGE^4\1;GB6!3
M4-LAM;-U=PJH^T<7= 0UI!'>==W@3L)I3:E2X^@(S+<BXG\-8*>\Y!<+3?[*
MZ9L4[(H!$]F]]VFMUW=#UZ]X7H\J6ICK.'6/U,))BFN<,C-^HQ2$?K54X[8M
MD5HP-U=E6<U5VDDJ8XHZ)L(@A<X[.R ?2T 3W!3GE"?S-X;^4TG^@]:BE<9+
MSV!*^4I_'L _QAOZV+;5B7E*?Q[ /\8;^MBVU<)_T1^I3.^.V6W/#,(;=;*Z
M)M3YW'"3(SG'*0[?3Y@JG77/BW=K#)E%IEM%KMW8FJ@M;X^TFDA YAS.+2.8
MCKH$?,O9Y5_\UK?R^']3UISVAF)N:T::*'0'J_@UI-1@G7<AD.+YQGW$VS12
MXA%;+&RF:(ZRNJ@9!)/WEL3=.TW1:3L?UM;Z=9OA'FV0UV67W#LV93/O-L8)
M6U%.WE;*S;>\=W]=A! '0]1T7G\E, <*FZ'?73$_]*C\6_I4Y=K\%L_9IUN2
MC<HUP#U7#.<MS/,;G8.&S:&CHK6[LZNZUC><<^R-,&B.\$#H=ZWT"Z9,VS/A
MYD%MI.(SZ"YV.X2=BRZ4D?9F%_\ SC0'M(UW;()T0NGR57,AM.5T$_2YP71Q
MJ&GY6BT ;_S->O3Y64T X<4E,_3JJ>X1]@P=7$AK]D#W'7SA*74Z=; X<>_Y
MQ.$W^+__ %6G5FXL9_68U5VNPXU1,N&3W9VJ:*3Y$;=ZYW=1[?$#H23TZT_C
M-')#F/!J.<[F9<6->3_:$E-O]*B>*ENN%;Y1EB@H[R^R3U-O#*6N$8DY7?PN
MV@$CJ>H_S!(134;\/^X+%>*CB[B5LDOU?<+)?*2F;VM5010\CFQCJXL<&@G0
MWU_05=SQ&M'V,CFHYS0=AVG9;'/VF^7LO?S^COY^Y4R[</<RBM=9)<^*E2V@
M;"\U#I*%O*(]'FWZ?=K:I.8V"GL_DU2TUBO;+Y;V7)LYJHHRQO*7<I;K9[GZ
M^E%&,Z^?8%OL=5Q=R^U1WZ@N%EL='4-[6DH98.=SV?U2YQ:XC8UUW[=!2>+\
M2KK=L"S"6XT4=!E&.PS"=@;N)SVL<6N )];""-GN[^JT7$)X*G%;--1EIII*
M.%T?+W<O(-*H9CEUGON)\0+1:ZATU=:[?41U3!$X-8[LWCY6M'J#W'P*QJU.
MM()7A!D%=E'#JSWF[.C=6U39#(8V\K?1E>T:'N:%"6;,;M5<>+[BDSX3:*2W
MMJ8FB/3P\B$]7>(]-RY^3F]KN#F/<I!Y1,#[#V\BJN*3QS^5;EIB<'!EJ;&2
M/[0%."/F/1-*U3]K_N#MX7?S_<2/[L?ZPO3<\WRS,<RN>/<-Q14E':G=G6W6
MK;SCM-D<K!HCO!'<=Z)Z#O\ -PN_G^XD?W8_UA4+@GC&1WA^3P6C,I[!5TM>
M6U5,RF$A>[J \DN'B'#YEUTJW)]D@:%'F>8X%DMKMW$:2@N5GN<G8PW2D9V9
MBD]3VZ U\W=U!.B%M"^=N(W#NO=;:.#.N*G_ (.2H!IVU5" #*&GJ-/]1/TK
MZ'B:6Q,:]W,X  N]9]:XY5&DT4J7%3,3A&)372&C?6U;GMAIX0#HO=OJ[7<T
M $_H\521;N--50-N OMAI:A[>T%N\W&F^/(7%IZ^'?KVJQ<:<]J<'L=%\%4L
M=3=[E/YM2ME^0T^+CU&^\#6QWJ#APOB7=(@_(>(3;>PC;X;;2-'*/$!_HGY^
MJL%4;=?4A-<&<]J\WQ>MGNE+'376WSNIJAL8(8X@;#@"3KQ!&^\+/N'6<<2>
M(UOF@L\ULMPI)#YS=)H.8$GY,;&:(V!LDGUCNZ;]/DK<OP/F79S/GC\^]&5Y
MV9!RGTB?6>]2GDFS0/X<UD41;VT=QE,K1W]6LT3\WZEN24-5+P#UXGF^36//
MX<-XB"DGGK6%]ON5*WD;-W^BX=!X$=PT=#KL%>'/.(F66SBS\5,;I*6M=54C
M/-8Y6Z#)7=3(]PZ\K6AQTNKC<15\7.&%%1GFKHZPSO#>]L?:1G9]FF/^@KL,
MT$7E6AL[FA\MGY(=^+];Z>WE#D2C_578'#)+[Q,X=T\-\R&LM>06,2-;614\
M'9/@#CK;2 .F^@)WU(V/%3W&3B!58[P\M&1XS-$YE;50@/DC#^:%\;W]Q[CZ
M(4MQVJ(*;A-DKJIS0U]-V;0?%[G -U\^EC7$Z">F\E["XZH$2><0.T>_E=',
M6_\ 20F-*>EM=Z!H^$UW$Z\9#07F["V46*U@,IHB 9H8BTEFSK?,?1WU\3T'
M<HNFS7->(U[N4/#M]!:K#02F%USJX^T=._\ Y001[=:[B-GKI:W=()),:JX*
M0:E=2/9$&^#N0@:_0LM\E&>G?PRD@B(%1!72B=OB'$-()^;7T+*:<7.EL#\M
M.<Y7B&:6['.)+:*JIKH[DHKK2-Y&E^P.5PT!WD ]!K8/4*:XF9I?Z+)[5B>%
M4,,MZN##*ZJJFGL:=@WUZ=YTTGV=.AVJOY4;FSQX;;Z<@W.>Z P-'RM=&G_J
M<U2N=YODU=Q&CP7!/,Z6N9 )ZNOJV\PB! =IK>H[BWP.RX=VMJJ*E4J\_+Y@
MB,MN'%K!+3)?[A>++>K=3N::FG;3\A:TN V--:=;(Z[WU[E?[WQ$H+3PQAS*
M:%YAGIHY8:;FTY\D@'*S?O/4^H$K*^+>)970</+O<LLS^IKF1L8!0P4[8(I7
M%[0&NT?2'7>M>"C>*$4K_)FP>1H<Z"*2F=,!_9[*0 GYR!\X6E",]/S[ N-L
M=QDO]ICOE/<;';&SL[:"UO@V7,/4!SBTD$C_ )O'KI==;G$V:\"LPDN5%YC=
MZ"&2EK(0#R\X\6[\.\:\""MJH9H:FB@GI7-=3R1M?&YO<6D;!'S+,.(>76;)
MN&F>TUFJ73RVR%]/4_P;FM:_9'1Q&G?)/<3^E<XRU/\ I[H%+X7R\2[_ ,/[
M1'B<]JL=IHX>PBGJV]I+5.:3S. Y7 -WL=WAXJ[<',[O5]NU]QK+Z>"*_6=P
MYY(!ILK=ZWKZ#L="'#H%-<#FAO";& T:'F@/_452>'W])7/_ ,D9_P#45J34
MM:KC_(-O67<2,^O%-E5%AN#4D%3D52SM99JC_A4L?7J?;H;Z]PUT)("U%?-%
MRLUVN?E+9'26W(9<?KIZ1CX*AL(D,S!'%M@!(]1/^0K&&*;;?9%+3?;UQ.X>
M4K+WD55:LBLC'M%9'3Q=E+"TG7,TAHZ;(&SOV@=ZG^+F?5-EX84>3XM-$[SJ
M6 Q/DCY@8W@GN/CW*MY=P]R6+'*]V3<5)FV8Q\M29Z$<G*2!H^GZR%"\6+;3
MVCR:[/0T-S9=:6*IC[*L8SE;*TND((&SK6]=_@NJ49./S(6457%S)[<V^V.>
MS6:AF9VU);IF<\TD9&V\[BT@$C7B._P5DX-9_-FF*U=7=Z=E+<K=,Z"K;&"&
MD@;Y@.I'B->L%7BR-#;-0-:- 4\8 _RA8=P!N4-GMO$NY57,:>BKY:B0-[^5
M@>XZ^8+GM.+VX![[-D?$CB*^MK\5FMV.6.&9T$#JR R3S:\2""/$> UW==$K
MTX=FN7VCB9!A.?>8UDM9 Z:DKJ1O+S:#CU&@->@X=P((\0H[$[AQ,XF6YU[M
M]^M^-66:1[((HJ832EK3HDEP]>QO8ZCN"KL5GJ[%Y2.)4=SR*KOU=YLZ26>H
MZ=GMDVF-;L\HT-Z_YETTK>+KC^;@]/%:YW2U>4999\?H65UV?;!#30O.FE[^
MV;S.]@V2>[H.\*=R.\<5,"HFW^]U5GOMIC<WSREIXNS="TG6VNY0=>&SOVC2
M[+Y-!#Y5=A[=S6E]H+(R[^V1-KY];5]XQ5%/2\+LH?5N:(W4$L8YO%[@6M'Y
MQ"CE_2J[ H/E%W6EOG ^FNE \OI:R>GFC)[]$$Z/M'<5<,ZSF# \ H*]T!JJ
MV>.*"DI@==I(6>/L&MGYAXK'<J@FI_)+L#*D$/,['@'^RZ61S?\ I(4OY1D,
MSZ3AK**HT5,V8,?5<O,('$1<KR/'0#C\Q54$ZB^+8+(RFXTR6_X6^$K"R<M[
M46<P>'?R%^M\WA\KYU9,'XF4F0X#<L@JZ5]+56EDGG](.I8^-I<>7?@0.F_'
M8\%"#AUGI&QQ3K2/R!O^]>'A-8L?Q^WYM55>74E_H:L@7-YA[)L1_A _G]([
MYN8]WJ67IE%_L@=.,W+BIG=F9D5GO%BL]OJ'/--1N@[4EK7%OIN+21U'A] 5
MSX2Y3D%_I[I19=:'4%UMD_8OF9$YL-0-D<S">AT6G>B1U!\5GMLX572CI&W7
MA+GE1!;*G<L-/.7.A=U]8V#W:ZLWT5FX09SD5RRF]XAFL%/\,VN,2^<4X ;(
MW;1U Z;]-I! '0]PTDTFGIK^S0-:6,5&69IFV;7^R8+5VVT4%CD$%1554?:2
M22;<#II!&MM=X>'?UTMG6'WGA[:,NRJ[WSAWE\UIOL4O)7"D<2SM>N]Z(()(
M.^I&P>BYXM.]E)G$,BSJU9W#C&;4D-RI:F$RP7:@@<&-(!.I-#0^21W#J1W@
MK]XAY[??CG383@5+337R2+MJFJJ>L=*PC?4>O6CL[[P "2JY:LKSW \XL&/9
MU4T=YMUXE\WIZN(:D:>8-WO0/0N;L$'H>A7?@I%+Y3>;Q5IU43T;70%W]9FH
MCH?-KZ"NNE6Y-+CZ$/V]9+Q%X;S4-PR^IMV06">9L-0ZD@[.6 GN(T!OQUO>
M]:Z;!5DXE9Q>Z.^67&L(HH:F\75G;"JJ6GL8(^OI'7>= GV =QVKGE^36K$K
M,ZZ7VH,%&U[8RX,+SS..AH#J5FV:\0,@NF;T&'</O-(*N>E;5S5]8PZB8YO,
M--(Z>B0>H)V0-#JLQ_&[T_X!&Y96\6\(M$M_K;S9+S04W*ZHIFTW(6M) V--
M:2.OKW[%-<6;U'D?D[7"\01F)E;24\W9D[+"98]MWXZ.PJGQ4Q'+:+A]>;EE
MG$"HK(HH@/,J>G;!%*XN #7$$;&SW:7KO']$6/\ ((/]=BVDGIEMSV!9QF'Q
M(X#8W=HZ1]94FVTD,$(!TY[HAHN([F@ D^[7BH]MOXT5E VX"^6&CG>SM!;O
M-QIOCR%Q:='P[_G75=L]J,%X*X2^V4L=5=KA0TM-2LD^0T]BW;CU&_ :V.]>
MN'#.)ETB#\@X@LM['#;X;;2-!9[ _P!$_/U64JW=<]P3G!/.ZO.,?K'W>ECI
MKM;Z@TU2V($,<==' $G7B"-^'M6+<#:K-*R"^V7"?,:*/SYU357.K;SB/8#6
ML8W1!<>4GN/S>-R\E#E\WS$1SOJ(_A!O+,\[=(-.](GQ)[UZ_)3F@=C620L<
MWSAEV>]X\>4L:&GW>B[Z"M.H:Z7@'LQ[-LKQC/*'%.(WF54RYC5!=*5O(U[^
M[E<- =^AW @D=X.UY;Y_2LQ[_"'_ +,RZO*((J<PX;T%*>:XNN7:,#?E-;SQ
MC?NV/T%=M\_I68]_A#_V9E$E6KRF"7S_ #R^29G#A. 4U-+?#&)JNKJNL5(P
M@'J/7HM.^OR@-$GI#7O(N(_#=D%VRRHMN0X^9&QU3J6+LI:?F.@1H :WTZ[W
MW=-[53I;'>;KY0>:4=KR67'K@Y@E;(V$2&:+3"&C9'@6GYO8K'FW#W((\:K/
MC;Q4E;97<K9_.*$<AVX<H.G[^5I51A&DZ_<&XV^L@N%!35M'()*:HC;-$\=S
MF.&P?H(7>J]P[H(;7@]DHJ6O;<:>&E8V*K8WE$K->BX#9Z:UXJPKRM4RA$10
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$1!_*FI_)V_K4NHB#^5-3
M^3M_6I= $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 41??XW:ORD*741??XW:ORD("71$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MCAB:&,8T:#6@:  ]6EV(BY@(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B("(@_E34_D[?UJ741!_*FI_)V_K4N@"(B (B( B(@"(B (B( B(@"(B
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MNY-,82=<H)[S[NGM5"QC.<LI<LJL*S&GM[;]-2OFME?3AP@G<&N(YAZMM/4
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!$0?RIJ?R=OZU+J(@
M_E34_D[?UJ70!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MVQ?@[8;->X;Q75=SOES@(,,USG[7LB.XM&AU'AO>N\+24164G+=@(B+("(B
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MPTNFFK*6J<X4U3#,6_*$;P[7OTLT4[T4#A]^DOU/<Y)8&PFDN$U& UV^81D
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M)U=C-#:J2TEQ$$MS,ADJ #KF#6:Y0=>*L,;FF^R(Y)%]15K$;_6W&KN%LO=
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MQ2%LL<H)/:!_?S;)ZGUKIAP6VMN%%<*FJN59<*.0215-54E[@ ".77<&G?4
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M:[NY(^I@JOLU_>_-?N'C>]?S8@*NT6ZHXOVN2>AII)'6EU07.C!)D9(P-?\
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MA:;!4S55''-+73-Y)*JIF=-*YOJYG'H/<K O/EG%I1CPC<4U;?<(B+D;"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@*WQ)_D!D7
MY#+^R57,?L>756,VUL>604U+)21<HCMK3(QA8- .+N_7BK[=:"GNEMJJ"L:7
MTU3&Z*1H)!+2-'J.Y=E%3145'!2TX+88(VQ,!.]-:-#K[@N\,VC'I7-^$_[F
M'"Y6SPXO8Z7'+%26JAYS!3M(YGG;G$DDN/M))*K'!W[1WC_&*K]H*]J.L=FH
MK)3SP6Z-S(YIWU#PYQ=M[CMQZJ+)<9*7+H:=U78SJWV.IO'$?-C37NXVOLI:
M4$4;FCM-P^.P>[7Z5V4]FJ+/Q8Q]E3>*^Z&2BJ2'5;FDLUKH- +0J"S4=!=+
ME<*:-S:JX.8ZH<7$AQ8WE;H>'1*BST=1>Z2[2QN-;2QOBB?S$ -=W].X]R[/
MU.]=JK]*_N8Z?]_W*QQ,C9&S%NS8UG-D-(X\HULESMD^U>'BQ!/4WG#(:2J=
M1SON#@R=K \QGD[P#T/SJ[7>T4EV%&*UCG^:5+*N+3B-2,WRGIW]_<N-TLM%
M<ZNWU-9&YTU!+VT!#B.5VM;.N]8QYE#2WVO]34H-W]#,,SMMSMU?;H<RO]==
M,3JY6Q3F...G[.3>VB7E;UC)'@1KZ-Z]&UK(VMC #  &@=P"\MYME)>;946^
MXPB:DJ&\DC#TV/?X'QVNRVT<=OH*>C@,AA@8(V=HXN=RCH-D]2LY,O4@D^5]
MO_2QAI;,VO5CCFN]=(>&<5<7SO=YT:V%O;;<?3T3L;[]'UJW8)1MHK1+&W'F
MV &<N\U;,V3F]%OI[;TZZUK_ )58T2>=SCI?]W_D*"3O_!F_$""OJ.(^(1VF
MLCHJPP5?+-)#VH:.5N_1V-["D68==KC<J"IRG(!<::AF%3#204C8&&5OR7..
MR3KU*SU=FHZJ\T-TFC<:RB;(R%P<0&AXT[IW'N4@J\[48QCV7A>7W(L:MMF5
MT\<%WNU_FLF+4EV:^K?#47"[5# T/: "QC>1SN1OAW*M4,#+CPPP>CJ7<\$M
M_;3N#7'79F25I:#WZT=>Y:A/@EFEKJJH K8HZMYEJ::&KDCAF<>\N8#H[\?6
MO13X;9J>AHJ."G>RFHJT5\$8D.F2@DC7LV3T[EZ%ZF$5M?;^S7G_  <^E)\E
M;S"@LEOK[#:*"P-KJETLM33VR%S(:9Q#0'22[&N@[NG>HJP4;F\5*JEN%HM=
MO9561SI:*D>)(W@2M ,@Y6@N[_#N6@Y%C5OOSZ66L$\=52DF"IIIG12Q[Z'3
MF^!7GM&'VBU71MRI(IC<!&Z)]1+.^1\H=HGG+B=]P]RQ'U$5"G=T_P"<_L:>
M-ZK,MCM]*> ML$<,<3ZJJA;-)&T-<_\ \20"2.I('<K;D]DMEDR;"IK/0T]%
M+Y\:=SH(PPOC,;MAVOE=WBIVEP.QTMOJ*"&*H%%-.RH[ U#RV-S'<PY 3Z(W
MUT.]35RM%)<JF@GJV.=)0S=O 0XCE?HC9]?0E67J4Y;-U<OU1%B=?;]#-KG=
M),*KLOME.#SU[6U]K8/&69PB>T>YY:[7J7Y7XK0T^3\/K#61,J*2GHZGM8W#
M;97!K'$N'B"_TM*<N%NGR?B!:YZFT5%+0V)\K_.:@ ><2'08(]$[:".;9]05
MMJK/1U5XH;I,QQK*)LC(7!Q  > '=.X]P5>90KRT[^=4O\_4*&J_'_=E'L]G
MMM9Q+O='745,^FM5'31VZE?&#''&\$O<UAZ;YNF]*MY%%%;J#B;:K8 RU0P4
M\S(6?(AE>-O#1X;T#I:??\6MM[JX:NH%1!70M+&55).Z&4-/>WF:>H]A77#A
MUEAQ^LLT=,X4=82ZH)D<9)7'J7.>3LGIZU(>IBFFV^VWR:W_ $_4/&^%[E8I
MJ2FN_$J"FO,,=1!1V6*6D@F:',YG.T]X:>A/0!=^!6^BM?$'-J6V,9%3M%&[
MLF=&QN+'D@#P&SO7AM66]XM;;P*1U0V>*HI!RP5--,Z*6,:T0'-.]'U%?N.8
MM:\>FJYK7#(R6K#.W?)*Z0R%N].)<3U]([*Q+-%P:M[JJ[<V50:=E9XQP.J:
M/&8(YY*=\M\IF":+Y<9(>.8;\0H[.<1KJ3#KU4299?*ED5)(\PRO862 -/0Z
M;W%:%>+-1WCS+SZ-S_,ZEE7#IQ;J1N]'IW]YZ+NNM!3W2VU5!6-+Z:IC,4C0
M2"6D:/4=RF/U&A12[<EECMMF:QT\-UR3![9=F-FMK+-YU%!(-QRSAK1U!Z.T
MW9TO374E-9N(TU+9HHZ:"MLTTM93PM#6;:=,DY1T!ZD;5ONF*VJYVVBHJF%X
M;1!HI98Y',EAT- M>#L= />ORRXI:[0*QU.R:6HJV\D]343.EED;K6BYQWKV
M!;Z\:[\57;GG^=R=-F9VVQ6VEX$U%RBHX?A&:V2<]46[D<">[F[]  #7L7MR
MS%K136+"6T]%%%+-<J6"::-O+)*R1CNT#G#J>;QV5HC<;MK<8^+XB?\ !G8F
M#L^<[Y/5S=Z[:^QT-?!;H:F-SF4$\=1  \CE>P$-)]?>5?B_Q7;Y;^G8G2VK
MV*)>*."P<187V"C@I'R6.I<8Z>,,;(YA!9MHZ$[TNK'L<L%;PD%;6TU--45%
M$^JJ*Y[09A-HES^?O!:[?CX+0YK/1S7NGNTD;C6P0N@C?S'08X@D:[O!0,W#
MRP2RR_P54RDED[62ACJI&TSW;WLQ@Z[_  [E%ZA.*3;3VW^5E>-VREVZG&1W
MCAT;_&*HOM4TLC)AL2D!G*7 ]_@[KXKV5T8Q[)LX%@A92ZL;:IL4#0UHE'.
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M[?6\KG[#CL:8W8)ZZ2/ITX^^W]G_ (#R4_Y[&U*N4V2ON6/R7.QVV:M<VH=
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M')4TM/4QQ00&5P9'N)NW  _*UKKX:5=I;%35?!N3(JV6IJ+W30O?3U;YW\\
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MT\GB 1M3'BBLVA[K_J^PE)Z+1Z[EFM[LM/Y[?\3EI;8QP$U1!71SF($ZYBP
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M)W^.U8:ZCIZ^EDIJV&.>GD&GQR#;7#>]$>*I^(QLBXD9O'$QK(VQV]K6M&@
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MGO4/E+)J$XWB]%4UE\M\U35=O##4-9*]L0!%.YY<.C>;J"=Z 6(^G3EIO?\
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MY[03Z.P==%EX%V>_/';[E61^#2D618+@UOO/#B&MF,S[S74+XA5/F>>0;]
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M2AP\H19KI:#<KB;;6RMF; 7M(IR).T/)Z/<3W[VK#362GI\CK;RR24U-7#'
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M#2UL+FB5K>4-(=L<K@0!L$*THHLLT[L:%P06-XW!99ZNK?55-?<:OE[>KJ7
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KR2NFN;XWRM>1RM+&\HY>GJ]>U*HI++.7+"BEP$1%S-!$1 $1$ 1$0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g762905g59y26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g59y26.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
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MXQ  9<8O[:O.'&+^VKSC$ !EQB_MJ\X<8O[:O.,0 &7&+^VKSAQB_MJ\XQ
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M\XQ  9:U?:5YP&( "N@ #ZQ^G
M                                              "Y\#?_ $E43^-?
M_+6*8+9P42XT#A I$F<^U'CMK6:W75DE*?W:BVF>PMICCQ"O2DEL_P!#=/\
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MNP  '0R
M                        !DU]*C^(AB,FOI4?Q$(^A)=&6   ?*/S(
M
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M:I,?BM\5'=>6MMO&-*349D7D(1![T? :L[   4@
M
M   5T  ?6/TX
M                                           &3:U-N)6V9I6DR41E
MT&0ZF_PJ4ZJLQE7+:4.I38Y82]QNDC/^$TGYLF0Y4 XU*,*ML2Z&HS<>A9+\
MNZ9>%71,EM-L-M(XMEAL\DA.<[^D_"*V #<(1A%1BM$1MMW8  &R
M
M                     9-?2H_B(8C)KZ5'\1"/H271E@  'RC\R
M
M                                   !N[.KQVW76:DF.4@VTJ3Q9KTY
MR1EOP8@UJ<=3K$Z>;?%G)>6]HSG3J,SQGIWB$ SA5\7<WF2P9=].H  &C
M
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MGU[OO!S56;]RI]>[[PNP!S-;S?NQEPV*3S56;]RI]>[[P<U5F_<J?7N^\+L
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M]<Y[P<V]J?=*?7.>\+< 9L_)CE:'@O9%1YM[4^Z4^N<]X.;>U/NE/KG/>%N
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M'N,-!:$J+)^$^VQT9P(J*<;C%J?2P  X&@
M        #!3K:#PM:$GU&> !F _$+2LLH42B\!Y!:TH+*U)27A/  _0
M                                8K6E!96I*?&> 4M"3(E*21GN(SW@
M#(!^*,DD9J,B(NDQ^&X@D:C6G3UYV #(!@EUM1X2X@SZB,AF
M #$UI)1)-224>XL[1D  #'6G7HU)U=6=H$M*E&DE)-1;R(]I #(
M              'XM:4%E:B2769X 'Z P2ZVH\)<0H_ >1DI24EE1D1=9F /
MT (R41&DR,CZ2              &)K02R0:DZSVDG.T9
M         _%&22,U&1$728Q)YHSP3B#/P*( 9@!F1$9F9$1=)C\2I*RRDR47
M61Y 'Z            #'C$:]&M.O[.=H R
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M-75.N$JG(<:4F7QK&A3BE),NUP>$I+"<%U$.J@&;*UA9   <R@
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MEU%I]+L%,2 9F9FM&"U-YQDTEC/A&Q;8;?\ VL9!NH)7%1R<3DLX5R9)$?\
MB)EPZ^@NRWTOABI4N?0(LFE52$=:V1W7DHT9UJ;P9DK/SD]720WU[7]3[3JU
M&IDF++ESJJYQ;#48DF9'J2DC5DRP1FK_  ,5/]I.@+GV6S681&F=17RD)4G>
M39F1*QXCTJ_\)BJ\',Y7";PQE<KS2B@T: T2$J+8EY2<8]-3IE_"0BA&4<?;
M7^"W?0^A0 !YC0          !PC]K,S*WJ!@\?Z6O_@%>_:;3*7<UIHI_&G+
M.+^Z)K.K7K+&,=.18?VM/]7J!_O:_P#@&'"Y_P!+W!I^HU_S4CVTG91?YG-]
MR7.O9%[?L^5R8M22J4>.EF8@MF%DI/;8ZE%M\Y= K=QF?_PJT4\GGC4?\Y8U
M/#90)E@UVJ2*.G30+D94VZT1=JAS.HT^#!EJ3X#470-M<?\ U5*+^JC_ )RQ
M5%)1<>C8)UJ\!=&K=DTJJLU6IQ:E,AMR"5K2IM"U)(_FZ2/&?#D6+]G2ZJI4
MHU9MVOOKD3J.Z2$NN*U*-&32:3,]IZ33O/H/P#96)P@VG1^#BA(GU^GH?C4]
MI+K"724XE1(+*=!;<^ 4G@!IM3JK=]7% _T-VI\8U!<<V$3JC6K.X]B34C;@
M^GJ&).4HRQ_8JLFK'T,I1)2:E&1)(LF9] Y+/X=:$S,E)@4NL5&GQ5:7Y\9D
MC:3X<F>[PGC(U)6KPJ,0:JJMW)#GPU4Z4CD["U&M:U,K)&/W2=NHRZ11N"UZ
MH\V]31&O*D4BFMJ=Y7#DQ$N.&2DX,]NU6HMA8ZL$,PI1LVW<-L[U6^$.C4RQ
MF[K:-Z=2W#02>3D6LS4K3C"C+!D>PR%2G</%"C-QY+5)K3].<TDN8A@B;0LR
MR:",SPI1;CQU'C(H%5IL:F?LVSFX%735H;E30XT^EA;)$6I!&G2O;L42MOA%
MPN^.TC]EJ,E"$D14V$X1$7]HUMF9^<S\XJIP7776PNSH%R7_ $*@6E&N*6^M
MV!*2@XR6DY6\:BR1$1XZ,F><8%6H_#72I5:A4ZJT:L4=4U1)CNRV2)"S,\%T
MYP9F6TB,MHIU6O!=L<#%C,1Z? E2:@WH0Y/;)QI@DGM49'T]L7F,5WA915&K
MDM'L]=D6NS%2"7Q$9E#;<9)K1@RT[]76>/FBPHQ>C]0Y,L7"Y5XU"X?[:J4]
M2RBQH:%KT)-2C[9XB(B+>9G@A>[8X8:/6+D;H<VG5.CSGS(HY3VB03F=Q;\D
M9]'0?6*)PLSH--_:&M.955(1":CLJ6M?S4?O'<*/P$>#SX!^<.]0@UR_K&B6
M_)8EU-$CMEQEDO22G$&C)EXE'X"VBX%)137;J+VN;"49_P#Q7PRSLY(?_P##
MK&YX.SM[GCO'L9V7[+D3G*N4<7Q'TJ<\7I[;?C?T#32O^MA#_P!T/_\ AUC'
M@I_Z?;__ (7O^<D1K\/_ /E!=3>L<.U"EQ'U4^D5J7,:6:3BM,$I>DBVN&9*
M,B3T9W^ 6[@_O^CWM1Y-0IQNQRBGID-2")*FMF<F9&98,B/;X#',_P!E%I!0
M[I=TEQARFT&K&W!$H\?XF-#P70WY%'X88=.2HWUH6VTA&\S_ 'Y$1>/<).G#
M\27:P39T!OASH#U2?;C4ZKOTMA>AZI-Q]3+?^T>W))\)[? +9P=WU3K[@S9=
M*8E,M17N)5QY)(U'C.2P9[-HY9P'WC:U'X)I<2KSHC$AE;QR(SID2WR5NTIW
MKR6$[.H2_P!DO_56N8V%RXO^ A)TXI2LN@3.Z  #S&P           .-_M5&
M9<',/!X_^9M?\MT=D'&_VJ_^CF'_ -YM?\MT=:'_ /8B2Z%.JW!!0('!F5R,
MUJ?%GIIR)I<:ZCBU.&V2M!$22/:>PMN=I;PD5VHUW]EZ>]577'GX\MN.EYP\
MJ<0EULR,SZ<9QGP#?VOP"VU4J%2:A-GUA:I$5I];9/().5()1D7:9QMZQO.'
M"D0:#P'SJ;28Z8\*.IA+;:=N/WR3,S,]IF9[3,QWS$Y*-[NYBVAH+3X8J3;E
MD4",[2JO+CQHK3$B8RQ^Y0YI+*24HRR9#IU>OZA46SH]S29"UTZ2E)QR;3E;
MIJ+))(CQMV'G.,8/(Y_5V&D?LLH0A"22=,8<P1?VC<2HS\^T:"7=ZK6X![.2
MU3H4V1-UMH.:T3C31$I65&1[SVECRC+IQGJEWL6]BY4OANI+]5A0ZK1:Q243
M5$F._*9(D*R9$1[\XVEM+.\;V]^$NG6Q66:,U J-7K#B.,Y) :UJ2GH,_-G!
M$>P<.X9$U9N7;)U^[8=;E./<8F-$90AN,G*>V(T[3(^@S(MPN7"?1Z74^%!*
M[?NU5!O F4I6VZAQMMPB3VN'=A$9IP6"SG&X7*A=/\Q=G0K"X2:7=]1ETQ$6
M=3:M%3K<AS6]"\;",RV]&2R1X/:-/</#/1J96I=-I]-JE8<A9Y4[":)2&L;]
MN=N.D]WA%4X-+LN>-PDR+3N)^FU60XPI1SXJ4FI!I1J3E:2+46PBPHLD9D*=
MP*]FXK=P1H-U4RWY3+VJ6U/CH6M>G)&K*N@CR1ET9\(9,4VWZ#$SZ1LZZ*9=
MU$;JE%>-R.HS0I*BPMM9;TJ+H/:7G'Y>U9ET&VI=0IM-=JDQO2EJ(UG4XI2B
M26XC/9G.[H'._P!G*F0H-,KK],KK57C29"#/BHKC"6G"(]184721IW;L$.P#
MA-*,[+H:6J/F:R7;B?\ VBZ>]>!(157(SBS90>4L(-E9I06-V"\)[]NW(^F1
MPB1_UL(O^YG_ /PZAW<;KN[3]"1[@  <#0                  4CAMV<%=
MQX[W+_C2..<&O!!0+GX.XE=J-5GPI;Q/&M:74$TWH<4DC,C3G&$D9[?,.Q\-
MO_15<?\ NY?\:1R'@IX&J'=MBTVL5*?5&WI!NZVF'$$@M+BDEC*#Z"'JI2PT
M[WMJ8:U/'@NKE1F\$O")2YDIR7$I\)?)G5&9X)2'"-)&?1VI&1=&3$S@JX4J
M?:7!M"B+IE4J+L=;JY*XK.6XZ5.&9:UGLR9;1TBX+3I-G<$%STZAQS:9. ^M
MQ:U:EN*XLRU*/I/9XA6^!]AHOV>*CA"?WT><;FSYQX46WR$1>0:<HR3=M+BS
M1T&'?U!E6.J["DJ;I*4&I9K3A:5$>G0:?M9P6.G)= I".'JCI-A^;0:[$ICZ
MM+<UQ@M"O#OV^0S,4VP;F*U?V>9E0Y Q/6JI+9;9D)U-:E$G:HNDBP?EP--P
MI/5B7P:TB=6;JILAF4II<:C0(Z$(:3I,\Y+;VI;,8P1G@2-&.)I[AR9WR^.$
M*D6E#I[LA,F=(J/_ -)&AHUN/%LVEM+9M+S[,C4VMPL4VL7$S0JC2JK1*H^6
M66J@SH)SP%TD9X/&2P?6*1PC4^@5*B6$B9<+E"N!$)@X,CBEFVHC2CYRRP2<
M*(CU9V9W#74NY;PL_A H-(N"ITNXVI[B&$.-&EUUM"EDG.O!+(]N<'DCV^,9
MC2BX^HOJ=.O?A3I-L5I%&:ASZM5S22E18+>LT$99[;;OQMP6=G4-KP?WY2;W
MBR%TSCV),51)D1)"=+K1GG&2R>S8>WP#AE-15XO#Q=C,6NPJ'47EN&V]-82X
M3K9J2I*4ZMA'ITGXB%MX'J>R?"A<%33=42L5!3*FYK46&MI&K6GMR5\P]J>C
M?DSZPE2BH^M@F[G6;Q9JTBV:BS;CC356<:-$=QU6E*#,\&K.#VD63+9OP/GF
M\^"]JT.#A=R52L347<VXA7&)D92MQ3F-*3QJ,].3SGH/H'T?7ZO$H5&F52I.
M<7$BMFXXK>>"Z"ZS,]A%UF/FF#7:?PH7:JJW[7(=+M^"YB+2UODE3G3M_P -
M2MY[BQT*&):KI_=!*Q] <&E1G5:PJ%.JN3FOQ4+<498-?4H_&6#\HLHAT>9!
MGTR/)I+S+T!:/W*V3(T&DMFS'1LP)@\\NK-H  "                   /E
M2S['IM]<*M[Q*O)ELM1I<AU!QUI29F;ZBVY(QL[=BN<'G#M3[>MZKR)U,F:4
MR&5K)6G42MBB+9J3@E9P1X/QYU=GV+ OKA5O>)4Y4R,W'ER'4G&4E)F9OJ+!
MY(]@[=87!/;=ESSGTY$F3/TFE+\M9*-LCWZ2(B(L]>,CW5*BC=-]NAS2.50K
MFB6M^T)=\V:U*D:V%,LQXK9N./.&;)DE)=>",_(.K<'W"?2KRJ<NEM1)M.JD
M9)K5&EH)*C21D1XP>\LEDCP>T4&Q6D.?M.W8I:24IN,XI!F7S3RR62\AF7E&
M=/TL_M55A1$>"A$HR+I_<-F,3C&6G=(J;18ZSPV4F)5)T.E4>KUA$%1IDR(C
M1&TC&<[<[MA[3P6S8++0N$6@5BRY-SM/N,TZ+J*03R,+:46.U,BSDSRG&#/.
M2')+:NJL7E#N&?"KE%LZCQUGQK3,5LWW$Z3P:C5C;C9J+IR1$(/ \W1G^ Z[
M&;FD.QJ6Y-)+KS2%+4V>EO2K"2,_G8Z =**73I8*1>RX=*:AIJ9+MNX8]'=4
M243UQBXL\].<X/R&9BZW9?E"MFVH];G23=B2DI.,E@M2W]19+26SHVY/!#Y_
M<^4MH6>W5K>O2F5FV4:#;B2L&K&HB)/$N$>#(^@C(RP)/##5IM=I?!K<$EM%
M/8?2:E*-O6TPYK1E6D]Z3).HB/>1!DQ<E;H,3.KVIPO4BN5R/2)M.J5&FRBS
M&*<T24O9W$1YWGT;,'UCI(^<;PI\FK7);+5P\(5)E3D/)=@%$@&HS,U)P6IO
M.,F18SU&/HX<:L8JS18LXE?/!VW5;DJ]?X1KD1'M]):(#;+_ !?$]1&2DXS@
MLX+)F9^ 2?V8IE6DVI46Y[C[]+8DDBGO/9RI.#U$6?[);/$9F0V\Z\[,NVL5
M:U;GC\F['.F:DU-:66W5),TZD&2MNP\EG&2/(JO[.,YY5PW=3:;(>D6O%>,X
M1N*-1((UJ))),^M)9/Q$.KQ.FU+M8G<[N  /*;
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M)8\!_P!!EP-_Z;!N"O*V]EJJ^ZVKK:0>A!>328Q*,4GZ6*FVSH0  XFP
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M0A9YU-*+:1)WX,L%TBJFK]/[W)B9VPC(R(R/)'N,@ B(B(B+!%T /.=
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MGR"V@&.5K7%D:15J455THN-4%)UI"-"9.M>23I-.-.=.XS+<%+M2B4NNSZS
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M:5"HE+CTZEL%'A1TZ6FB4:M)9,]YF9[S,30 9ZE
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M'.O9/X@C^K<]T,N>S&);EW 4CG7LG\01_5N>Z'.O9/X@C^K<]T,N>S&);EW
M4CG7LG\01_5N>Z'.O9/X@C^K<]T,N>S&);EW 4CG7LG\01_5N>Z'.O9/X@C^
MK<]T,N>S&);EW 4CG7LG\01_5N>Z'.O9/X@C^K<]T,N>S&);EW 4CG7LG\01
M_5N>Z'.O9/X@C^K<]T,N>S&);EW 4CG7LG\01_5N>Z'.O9/X@C^K<]T,N>S&
M);EW 4CG7LG\01_5N>Z'.O9/X@C^K<]T,N>S&);EW 4CG7LG\01_5N>Z'.O9
M/X@C^K<]T,N>S&);EP?A19$AA]^,PZ_',S9<6V2E-F>P])GM+/@!F'&8D/R&
M([+;\@R-YQ"")3AD6"U&6T\%NR*?SKV3^((_JW/=#G7LG\01_5N>Z&7/9C%'
M<N$:'&BK?7&CLLK?7QCJFT$DW%?:5C>?A,0/DU0^.DO=AJ;QLDL/KY,C+I9R
M>K9MV]8KW.O9/X@C^K<]T.=>R?Q!']6Y[HN"ILQBCN6_D47E;<KDS'*6T<4A
M[BRUI1]DE;R+P")4+?H]2EMRJA2H$J2W@D.O1TK4G&[!F616^=>R?Q!']6Y[
MH<Z]D_B"/ZMSW0P379C%'<MM2IL*IQ3BU*''EQC,CXI]LEIR6X\&/*)1:7$Y
M-R2FPF3BZN(-MA*>*U;%:<%LSTXWBK\Z]D_B"/ZMSW0YU[)_$$?U;GNA@GTL
MQBCN6<Z'2E3),M5,A'*DMFT^\;"=;J#WI4>,F1X+88D*@Q%0>1*BL'#T$WQ!
MMEQ>DMR=.['@%0YU[)_$$?U;GNASKV3^((_JW/=#!/9C%'<L])HM+HZ5II-.
MAPB7M64=E+>KQX+:),6'&B<=R2.RQQSANN<6@DZUGO4K&\SZS%/YU[)_$$?U
M;GNASKV3^((_JW/=#!-]F,4=RWQH,2*PMF-%899<4I2VVVR2E1GO,R+>9](A
M4ZW*)3):I5.I%/BR59RZS'0A6W?M(LBN\Z]D_B"/ZMSW0YU[)_$$?U;GNA@J
M;,8H[EW 4CG7LG\01_5N>Z'.O9/X@C^K<]T3+GLQB6Y=P%(YU[)_$$?U;GNA
MSKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%
M(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_J
MW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?
MU;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB
M6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3
M^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[
M)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#
M+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GN
MASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P
M%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_
MJW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$
M?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQ
MB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV
M3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU
M[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=
M#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;G
MNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=
MP%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((
M_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$
M$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GL
MQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASK
MV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(Y
MU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/
M=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;
MGNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y
M=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^(
M(_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_
M$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+G
MLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNAS
MKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(
MYU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW
M/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U
M;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6
MY=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^
M((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)
M_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+
MGLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNA
MSKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%
M(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_J
MW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?
MU;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB
M6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3
M^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[
M)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#
M+GLQB6Y=P%(YU[)_$$?U;GNASKV3^((_JW/=#+GLQB6Y=P%(YU[)_$$?U;GN
M@&7/9C$MS2<Q5F]SG^T_ .8JS>YS_:?@.I -9U3<8(['+>8JS>YS_:?@',59
MO<Y_M/P'4@#.J;C!'8Y;S%6;W.?[3\ YBK-[G/\ :?@.I &=4W&".QRWF*LW
MN<_VGX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_:?@.I &=4W&
M".QRWF*LWN<_VGX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_:?
M@.I &=4W&".QRWF*LWN<_P!I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,59O<Y_M/P
M#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,
M59O<Y_M/P#F*LWN<_P!I^ ZD 9U3<8(['+>8JS>YS_:?@',59O<Y_M/P'4@#
M.J;C!'8Y;S%6;W.?[3\ YBK-[G/]I^ ZD 9U3<8(['+>8JS>YS_:?@',59O<
MY_M/P'4@#.J;C!'8Y;S%6;W.?[3\ YBK-[G/]I^ ZD 9U3<8(['+>8JS>YS_
M &GX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_:?@.I &=4W&".
MQRWF*LWN<_VGX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_ &GX
M#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,59O<Y_M/P#F
M*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,59
MO<Y_M/P#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/\ :?@',59O<Y_M/P'4@#.J
M;C!'8Y;S%6;W.?[3\ YBK-[G/]I^ ZD 9U3<8(['+>8JS>YS_:?@(R.!&T#J
M#C)MSM"4$HO](Z?,.MB"W]</?I%_,,ZIN3!'8YWS%6;W.?[3\ YBK-[G/]I^
M ZD 9U3<N".QRWF*LWN<_P!I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,59O<Y_M/P
M#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,
M59O<Y_M/P#F*LWN<_P!I^ ZD 9U3<8(['+>8JS>YS_:?@',59O<Y_M/P'4@#
M.J;C!'8Y;S%6;W.?[3\ YBK-[G/]I^ ZD 9U3<8(['+>8JS>YS_:?@',59O<
MY_M/P'4@#.J;C!'8Y;S%6;W.?[3\ YBK-[G/]I^ ZD 9U3<8(['+>8JS>YS_
M &GX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_:?@.I &=4W&".
MQRWF*LWN<_VGX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_ &GX
M#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,59O<Y_M/P#F
M*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,ZIN,$=CEO,59
MO<Y_M/P#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/\ :?@',59O<Y_M/P'4@#.J
M;C!'8Y;S%6;W.?[3\ YBK-[G/]I^ ZD 9U3<8(['+>8JS>YS_:?@',59O<Y_
MM/P'4@#.J;C!'8Y;S%6;W.?[3\ YBK-[G/\ :?@.I &=4W&".QRWF*LWN<_V
MGX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_:?@.I &=4W&".QR
MWF*LWN<_VGX!S%6;W.?[3\!U( SJFXP1V.6\Q5F]SG^T_ .8JS>YS_:?@.I
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M=CEO,59O<Y_M/P#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_
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M_ .8JS>YS_:?@.I &=4W&".QR2=P(V@SQ&AN=V[J4'F1T'Y!)YBK-[G/]I^
MZ)5?[K^NG^HG!G5-R8(['+>8JS>YS_:?@',59O<Y_M/P'4@#.J;EP1V.6\Q5
MF]SG^T_ .8JS>YS_ &GX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG^T_ =2 ,Z
MIN,$=CEO,59O<Y_M/P#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/]I^ <Q5F]SG
M^T_ =2 ,ZIN,$=CEO,59O<Y_M/P#F*LWN<_VGX#J0!G5-Q@CL<MYBK-[G/\
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MI^ #J0!G5-Q@CL  !R-
M                                                06_KA[](OYB<
M(+?UP]^D7\P0)P
M                                                     B5;ZN?\
M7]1+$2K?5S_B_J"!)9^A1_"0R&+/T*/X2&0
M                 @TCZ%[]90G"#2/H7OUE "<
M                      "#5?[K^NG^HG"#5?[K^NG^HG
M                            "'6/JU[R?S(3!#K'U:]Y/YD"!+;^8GQ$
M/T?C?S$^(A^@                                         "#2/H7_
M -90G"#2/H7_ -90 G
M      *=>G"+0K3D)BSUO/S#22C8CI)2DD>XU&9D1>?(N(X'>S-4LOA.E7.Y
M22JE.D=LE:TF:4921&6K!Z%%C89] ]7"4HU9M2VT72_H<ZLG%71?K5X5K=N&
MH-P6SDPY3IZ6TR4$1+/H(C(S+/CP-O>U[4NSBAG5D2E<JU\7Q""5\W&<Y,OM
M$.8_*"Q[_KE/<JJ)U&JC9DEMQ"D)0XK)&DC61'M(]QF1;QZ_M,'@K=/PO_\
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M*(MGC2M/HCL \O$4U3G9=.J^YUIRQ1NP  .!L
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M-J=I&6.K&1H+-_ZT5R_H.?\ "V-*E:^+:XQ'?P'#JOPB7===ZS[>X-V(C;$
MU)>FR")1&:3TF>W)$G.PBP9GO\4VP^$:X(U\'9O"#%8:J3A?Z/*8(B2X>,D1
MXV&1D1X,L;2P9=6<F5KC$CL@#B%P<(%VW'PAS+5X/4PV$P-12)<E)*(S2>%&
M>2,B22C))$1&9GM\4>#PBWK&X4:):EPQX$=2U);DJ91J2^1ZC)Q!GN(RP6.L
MCW;BN3*PQ([N Y+:5]ULN&"KV?<BHYLI2M4%:&M"E$6%ISMVY;,S\9#)N^:U
M5>&]=KT=<<J-!1JF+-K4K*4Y5@\[.V4E/G&<J7Q<MSK   YE
M                                        (E6^KG_%_42Q$JWU<_XO
MZ@@26?H4?PD,ABS]"C^$AD
M    (-(^A>_64)P@TCZ%[]90 G
M          @U7^Z_KI_J)P@U7^Z_KI_J)P
M                AUCZM>\G\R$P0ZQ]6O>3^9 @2V_F)\1#]'XW\Q/B(?H
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M:)6,:C(MJC\)GD_*.<IVI*/?_A4M;FS  'F-@
M                            $2K?5S_B_J)8B5;ZN?\ %_4$"2S]"C^$
MAD.>JX5Z PHV5LU#4V>@\-)QDMGVA^<[EO=QJ/JD^\.W+U/$\?U#AE_[HZ&
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M$&D?0O\ ZR@!.
M  'XI1)2:E&1)(LF9]! #] 5ZU;L@W)(G-06WT\E,NV<21$XDS41*3MW=J+"
M-2@X/#):D34E=   9*     0H4\Y4V='Y+):**I*2==1I0[DLY0?21;A-%::
MZA.X 0FJI%=J[U-;6:I3+1.N$1;$$9[,GUG_ $$T&FNHO<  "
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M#;##1+==PYH-22(_FYR>3/<1BI-]!<MX 0"
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M/H7_ -90G"#2/H7_ -90 G
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MW&3P.@"K\']*J=%I3L"J(C80XI:'F7#4;IJ49F:B,BQT"T#AQ$L51ZG2FK1
M  XFP
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MC+DK?8MBV@ #B:
M  ")5OJY_P 7]1+$2K?5S_B_J"!)9^A1_"0R&+/T*/X2&0
M                            @TCZ%[]90G"#2/H7OUE "<
M                                 "#5?[K^NG^HG"#5?[K^NG^HG
M                                       "'6/JU[R?S(3!#K'U:]Y/
MYD"!+;^8GQ$/T?C?S$^(A^@
M    "#2/H7_UE"<(-(^A?_64 )P
M                  *]*LNWY4Q<E^F-*=<5K7A2B2I76:2/2?F%A :C.4?]
M78CBGU/QM"6T)0VDDH21$E*2P1%U$/T &2@
M                                                       !!;^N
M'OTB_F)P@M_7#WZ1?S! G   #1?)"A'=*KC53FU5I223RE:E*,L)TEA)GI(\
M%C)%D3JY1X%=IRX%6CIDQ%J2I32E&1&:3(RS@RZ2(Q/ 6[%@  (#REQVI<1Z
M-(3K8>0IMQ.3+*3+!EDMNXQY4JGQ:53H\"GLI8B1T$VTVDS,DI+<6W:)0
M          -%:UH4*UBD]@:<W$5)42G5DI2U+QNRI1F>-I[,X&] 6[Z   "
M
M      ")5OJY_P 7]1+$2K?5S_B_J"!)9^A1_"0R&+/T*/X2&0
M                                @TCZ%[]90G"#2/H7OUE "<
M                                     "#5?[K^NG^HG"#5?[K^NG^H
MG                                          "'6/JU[R?S(3!#K'U
M:]Y/YD"!+;^8GQ$/T?C?S$^(A^@
M        "#2/H7_UE"<(-(^A?_64 )P
M
M                                                  (+?UP]^D7\
MQ.$%OZX>_2+^8($X
M                                                       1*M]7
M/^+^HEB)5OJY_P 7]00)+/T*/X2&0Q9^A1_"0R
M                    $&D?0O?K*$X0:1]"]^LH 3@
M                          0:K_=?UT_U$X0:K_=?UT_U$X
M                                0ZQ]6O>3^9"8(=8^K7O)_,@0);?S
M$^(A^C\;^8GQ$/T                                          0:1
M]"_^LH3A!I'T+_ZR@!.
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M
M                                 !!;^N'OTB_F)P@M_7#WZ1?S! G
M
M                                      ")5OJY_P 7]1+$2K?5S_B_
MJ"!)9^A1_"0R&+/T*/X2&0
M    @TCZ%[]90G"#2/H7OUE "<
M         "#5?[K^NG^HG"#5?[K^NG^HG
M               "'6/JU[R?S(3!#K'U:]Y/YD"!+;^8GQ$/T?C?S$^(A^@
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MU<_XOZB6(E6^KG_%_4$"2S]"C^$AD,6?H4?PD,@
M                    !!I'T+WZRA.$&D?0O?K* $X
M                          $&J_W7]=/]1.$&J_W7]=/]1.
M                                $.L?5KWD_F0F"'6/JU[R?S($"6W\
MQ/B(?H_&_F)\1#]                                          $&D
M?0O_ *RA.$&D?0O_ *R@!.
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MW]</?I%_,$#@W[1/_2;8_P#$C_G$'"/':E?M+VNU(0EQLVXYFE19(\*<,O\
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M[L^@O_(.<"U_O=GT%_Y!E3\6.:H>:]T6@!5^<"U_O=GT%_Y!S@6O][L^@O\
MR#*GXL<U0\U[HM "K\X%K_>[/H+_ ,@YP+7^]V?07_D&5/Q8YJAYKW1: %7Y
MP+7^]V?07_D'.!:_WNSZ"_\ (,J?BQS5#S7NBT *OS@6O][L^@O_ "#G M?[
MW9]!?^094_%CFJ'FO=%H 5?G M?[W9]!?^0<X%K_ 'NSZ"_\@RI^+'-4/->Z
M+0(-(^A>_64-+S@6O][L^@O_ "$2FWW;333I.59I)FXI1=HO=Y@RI^+)S5#S
M7NBY@*OS@6O][L^@O_(.<"U_O=GT%_Y!E3\67FJ'FO=%H 5?G M?[W9]!?\
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MBINZ   P=@              (-5_NOZZ?ZB<(-5_NOZZ?ZB<
M                              (=8^K7O)_,A,$.L?5KWD_F0($MOYB?
M$0_1^-_,3XB'Z                                          (-(^A
M?_64)P@TCZ%_]90 G
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MKS;S>33J;42BR6\LD /4 'YJ3JTY+5C.,[< #]
M    06_KA[](OYB<(+?UP]^D7\P0)P"!7:O!H5*D5*K241H;"=2W%='41%O,
MSW$1;Q1SX3)IPSJ:+*KYT0DZSEFE!+T?;)K5JTXVYZAI0<NA+G1P&@DW?18]
MGG<ZIA*H_%$\3J2,S41G@B(M^K.S'6*L_P )DV'$[)5.RJ]$HN-2I9\6I3:/
MM+;(]22Z3!0DQ='2 %8NB]*?0K48KZ4N3HDA328Z8^-3W&&6G&<=!Y%F,R2D
MU*,B(BR?@$LUJ4_0&AL>YF+NH#=7AQWF(SKBT-D[C*B2HTZMG09D8WP-6=F
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M:K_=?UT_U$X0:K_=?UT_U$X
M     0ZQ]6O>3^9"8(=8^K7O)_,@0);?S$^(A^C\;^8GQ$/T
M                              0:1]"_^LH3A!I'T+_ZR@!.
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M DL_0H_A(9#%GZ%'\)#(
M  0:1]"]^LH3A!I'T+WZR@!.                  ,
M        "#5?[K^NG^HG"#5?[K^NG^HG
M              "'6/JU[R?S(3!#K'U:]Y/YD"!+;^8GQ$/T?C?S$^(A^@
M                                       "#2/H7_UE"<(-(^A?_64
M)P                                                      -?<%
M,[+TE^%RAZ,IPBTO,GA2#(\D9>8:1-LU&=+AKN&LIG1HCA/-L-1B:);A;E+/
M)YQU"U@.D:LHJR,N";NP  .9H
M                                          ""W]</?I%_,3A!;^N'
MOTB_F"!.
M                                               $2K?5S_B_J)8B
M5;ZN?\7]00)+/T*/X2&0Q9^A1_"0R
M           $&D?0O?K*$X0:1]"]^LH 3@
M                 0:K_=?UT_U$X0:K_=?UT_U$X
M                       0ZQ]6O>3^9"8(=8^K7O)_,@0);?S$^(A^C\;^
M8GQ$/T                                          0:1]"_\ K*$X
M0:1]"_\ K* $X
M
M                                $%OZX>_2+^8G""W]</?I%_,$"<
M
M                                     (E6^KG_ !?U$L1*M]7/^+^H
M($EGZ%'\)#(8L_0H_A(9
M  "#2/H7OUE"<(-(^A>_64 )P
M        (-5_NOZZ?ZB<(-5_NOZZ?ZB<
M              (=8^K7O)_,A,$.L?5KWD_F0($MOYB?$0_1^-_,3XB'Z
M                                       (-(^A?_64)P@TCZ%_]90
MG                                               "#R.1W\YZ)!R
M.1W\YZ)"<  @\CD=_.>B0<CD=_.>B0G  (/(Y'?SGHD'(Y'?SGHD)P "#R.1
MW\YZ)!R.1W\YZ)"<  @\CD=_.>B0<CD=_.>B0G  (/(Y'?SGHD'(Y'?SGHD)
MP "#R.1W\YZ)!R.1W\YZ)"<  @\CD=_.>B0<CD=_.>B0G  (/(Y'?SGHD'(Y
M'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<  @\CD=_.>B0<CD=_.>B0G  (/(Y'?
MSGHD'(Y'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<  @\CD=_.>B0<CD=_.>B0G
M (/(Y'?SGHD'(Y'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<  @\CD=_.>B0<CD=
M_.>B0G  (/(Y'?SGHD'(Y'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<  @\CD=_.
M>B0<CD=_.>B0G  (/(Y'?SGHD'(Y'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<
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MGHD'(Y'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<  @\CD=_.>B0<CD=_.>B0G
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M.>B0<CD=_.>B0G  (/(Y'?SGHD'(Y'?SGHD)P "#R.1W\YZ)!R.1W\YZ)"<
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M1R._G/1(3@ $'D<COYST2 3@
M                                                         !!;
M^N'OTB_F)P@M_7#WZ1?S! G
M
M  ")5OJY_P 7]1+$2K?5S_B_J"!)9^A1_"0R&+/T*/X2&0
M                            @TCZ%[]90G"#2/H7OUE "<
M                                 "#5?[K^NG^HG"#5?[K^NG^HG
M                                       "'6/JU[R?S(3!#K'U:]Y/
MYD"!+;^8GQ$/T?C?S$^(A^@
M    "#2/H7_UE"<(-(^A?_64 )P
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M\'U+8JB7&WR):DH<^<E!J,TD?5LZ!SK\/&%/&KK6UF:A4<I87\%R  'B.P
M
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M)@-3ZE5G="6UN&DD%J))'LZS,_,894M%N+HZ$ %NV[P',H
M                                         $2K?5S_ (OZB6(E6^KG
M_%_4$"2S]"C^$AD,6?H4?PD,@
M      !!I'T+WZRA.$&D?0O?K* $X
M            $&J_W7]=/]1.$&J_W7]=/]1.
M                  $.L?5KWD_F0F"'6/JU[R?S($"6W\Q/B(?H_&_F)\1#
M]                                          $&D?0O_K*$X0:1]"_
M^LH 3@                                               '/.'O\
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M-*&&5T9@ #SG0
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M#=D*L6TB@REMN5"0X;\E;>U.HR(B21])$1%Y<C&-*F_7H6VI>@ !YC8
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MB4DRR1D>2,A^CR'UP               @TCZ%[]90G"#2/H7OUE "<
M                                     "#5?[K^NG^HG"#5?[K^NG^H
MG                                          "'6/JU[R?S(3!#K'U
M:]Y/YD"!+;^8GQ$/T?C?S$^(A^@
M        "#2/H7_UE"<(-(^A?_64 )P
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MM)EI2XC41'D]XDG7GBNNJ0SXLJ=3H*7W3QVW&&9GOZM)#HZ,E)QV,J::3+*
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MM1]1=9C.%HMT>@#PA38LYM3D*2S(0E1H4II9+(C+H,RZ1[B-6ZE
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M>%G'=)>D_#C<(=$G/O5&O29%6ITFEL/$TRAA19BFA/[Q+JOM9,CQT$%F+F_
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M> AM@ ?/;<G=GZ&$(PBHQ5D@  (:            @TCZ%[]90G"#2/H7OUE
M"<                                           "#5?[K^NG^HG"#5
M?[K^NG^HG                                          "'6/JU[R?
MS(3!#K'U:]Y/YD"!+;^8GQ$/T?C?S$^(A^@
M                "#2/H7_UE"<(-(^A?_64 )P
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M-8+]K(DP(,6GL<3 C,QFLZM#2"26>O!>(2  >5N^K.P  $
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MB5;ZN?\ %_4<$;)+/T*/X2&0Q9^A1_"0R
M               $&D?0O?K*$X0:1]"]^LH 3@
M                     0:K_=?UT_U$X0:K_=?UT_U$X
M                           0ZQ]6O>3^9"8(=8^K7O)_,@0);?S$^(A^
MC\;^8GQ$/T                                          0:1]"_\
MK*$X0:1]"_\ K* $X
M
M                                    $%OZX>_2+^8G""W]</?I%_,$
M"<
M                                         (E6^KG_ !?U$L1*M]7/
M^+^H($EGZ%'\)#(8L_0H_A(9
M      "#2/H7OUE"<(-(^A>_64 )P
M            (-5_NOZZ?ZB<(-5_NOZZ?ZB<
M                  (=8^K7O)_,A,$.L?5KWD_F0($MOYB?$0_1^-_,3XB'
MZ                                          (-(^A?_64)P@TCZ%_
M]90 G
M
M                         @M_7#WZ1?S$X06_KA[](OY@@3@
M
M                             !$JWU<_XOZB6(E6^KG_ !?U! DL_0H_
MA(9#%GZ%'\)#(                                          0:1]"
M]^LH3A!I'T+WZR@!.
M!!JO]U_73_43A!JO]U_73_43@
M      !#K'U:]Y/YD)@AUCZM>\G\R! EM_,3XB'Z/QOYB?$0_0
M                               !!I'T+_ZRA.$&D?0O_K* $X
M                                         0>QK?=I'IAV-;[M(],3
M@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTCTQ.  0>QK?=I'IAV-;[M
M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTCTQ.  0>QK?=I'IAV
M-;[M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTCTQ.  0>QK?=I
M'IAV-;[M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTCTQ.  0>Q
MK?=I'IAV-;[M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTCTQ.
M 0>QK?=I'IAV-;[M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTC
MTQ.  0>QK?=I'IAV-;[M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>F'8U
MONTCTQ.  0>QK?=I'IAV-;[M(],3@ $'L:WW:1Z8=C6^[2/3$X !![&M]VD>
MF'8UONTCTQ.  0>QK?=I'IAV-;[M(],3@ $'L:WW:1Z8BHA(.I.-<8]@FR/.
MK;O&X$%OZX>_2+^8J(.QK?=I'IAV-;[M(],3@$*0>QK?=I'IAV-;[M(],3@
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MUONTCTP[&M]VD>F)P "#V-;[M(],.QK?=I'IB<  @]C6^[2/3#L:WW:1Z8G
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MWW:1Z8=C6^[2/3$X !![&M]VD>F'8UONTCTQ.  0>QK?=I'IAV-;[M(],3@
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M>F G
M                                      ""W]</?I%_,3A!;^N'OTB_
MF"!.
M                                           $2K?5S_B_J)8B5;ZN
M?\7]00)+/T*/X2&0Q9^A1_"0R
M       $&D?0O?K*$X0:1]"]^LH 3@
M             0:K_=?UT_U$X0:K_=?UT_U$X
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M6DO&OMB+J+H'>AYN)HJC/#':_JO1G2G-S5V  !YSH
M       $%OZX>_2+^8G""W]</?I%_,$"< ^<OVFY=41=U"BTF;+84[$4>AEY
M2"6K6?01[QO/EP[_ /#5V3Y2OLCR?L;QFL]?&:N+SG?JT=MD=LEN*DNYG$=Q
M ?./[,TNJJO.N1*M-EOJ:A)/0\\I9),UIZ#/?M'2+AX9K/H=7=ITB7(??95H
M>5&9-:&U$>#(SZ<>#(DJ,E+"M0I:7.C .<\(_"1!H_!SV>H4UMYR=^Z@/);U
MI-S:9ZBZ,$2MA])8,A"X%^$*%6K'<<JU1<74*6TIZHR)!:4I)2UF1YW&6"W%
MNW"94L.(MU>QU,!RM'#S9*I9,G(G):-6DI"HI\7X]^K_  %?_:2K#L=BSI5-
MJ#K,9]]:S<8>-*7$8;,C,R/:6#%C1DY*+TN1R5KG= '-X/#39<RMIIK=0=0:
MUZ$2'&32RL\XV*/<6>DR(A;+NNNCVE32G5Z8F.RH]*$X-2W%=24EM,8<))V:
M+=&\ <_M'A=M.Z*FBGP9CS$QP\--RF^+XP^I)Y,L^#.14>$"?,9_:+LZ(S+D
M-Q7(K9K92X9(4?&/[33G![B\PTJ4KV>@N=N <JI"X!\/-70BX*@[/*/VU+4R
MHF&RXMOMB7JP9XP?S?[1C:W=PNVG:]473ITMY^8V>'6XK7&<6?4H\D6?!G(9
M;O9:BYT !I;2NBDW92BJ%"EE(CZM"MAI4A7V5)/:1[14_P!H.5(A\%E4>B/N
ML/)<8PXTLTJ++J>DAF,&Y86+Z7.C /G:SN"VM5^SJ=6XE\U>+,EL$ZELU+-*
M5;=FHEYQLWBS<!MYU6L1Z];ET/*<JM(-23D'M6I!&:5$?6:5%OZ<D.DJ5DVG
M>Q%([& Y+P*5.C4VRZU/3<TRIT^/(-;TN>TIHVL(3VI$:E&9;MW2>,"2QPZV
M8[)0VI^>TRM6E,ER*HFC\N__  &72E=I*]BW1U$!I+ENNC6W1"JU7G-M0E8X
MM:>W-TS+)$@B^=DMNSHVBOV;PKVM=E3*G4Z4\S-41FVS):XLW"+;VIY,CV;<
M9R,J$FKI:"Z+V IM\<)-N69):BUB2ZJ8XG6F/';XQ>GH,^@MW28];%X0[?O4
MWT422X<A@M3C#S9H62=VK&XRSU&&"5L5M!=%M <RJ7#?9T&<]&*1,E)95H<?
MC1S6TD]WSLEDO"6SJ%TI]T4:?;?9^-4&3I'%FXJ0H]))(M^<[2,NK>*X26K0
MNC<@.9TWAOLJ=5$0DS9#)+7H1(?8-#2C\>\O&9$+3>MZT2S83,FNRC;X\S2R
MTVDUK=,M^"+JR6W=M+K!TY)V:%T6,!1+0X5;8NFK%3(+\B/4%$9H8ELFV:\%
MD\'M+.-N,Y%[&91<79E3N  !
M      1*M]7/^+^HEB)5OJY_Q?U! DL_0H_A(9#%GZ%'\)#(
M                              0:1]"]^LH3A!I'T+WZR@!.
M                                   !!JO]U_73_43A!JO]U_73_43@
M                                         !#K'U:]Y/YD)@AUCZM>
M\G\R! EM_,3XB'Z/QOYB?$0_0
M      !!I'T+_P"LH3A!I'T+_P"LH 3@
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M'0!RJRC)K":BFNH  '(H
M!$JWU<_XOZB6(E6^KG_%_4$"2S]"C^$AD*.?";;;)FTY(?):.U5^X5O+8'.E
M;'?,CU"AUR:GBSR\[PZ_]U[EX 4?G2MCOF1ZA0<Z5L=\R/4*#(J>+'/</_\
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M+33YI[.W5^Z6?@5T>(_.8M7A)PU6J,\)_EJ5?\,_PR^/<OP 1Y+);2 >4^J
M              $&D?0O?K*$X0:1]"]^LH 3@
M                    0:K_ '7]=/\ 43A!JO\ =?UT_P!1.
M                               $.L?5KWD_F0F"'6/JU[R?S($"6W\Q
M/B(?H_&_F)\1#]                                          $&D?
M0O\ ZRA.$&D?0O\ ZR@!.
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M<#PX^PQ*]C9 *V=V1U7DW;T=A;KN@U.O$HM+9DDSQX3W>D+($H2C:_<*2?0
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MXIS2DM6\MF3$VW:N3%MOU:N5ZFRH2WG'6IC1I;90UJPE.K<>,8STF+A9+EF
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MR_%Q&GI^YJ;5H:+>I+<%N5(DDG;K>7G'@27]DO -N #YS;D[L_1P@H148]$
M !#0           $&D?0O?K*$X0:1]"]^LH 3@
M                     0:K_=?UT_U$X0:K_=?UT_U$X
M                           0ZQ]6O>3^9"8(=8^K7O)_,@0);?S$^(A^
MC\;^8GQ$/T                                          0:1]"_\
MK*$X0:1]"_\ K* $X
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M#C:(\>8W)>2K.5I1G"2\HT<U"E7C/F6[5(3-0::0S/C36U:#+&4+(RQMQU;
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MJWU<_P"+^HYR:;T-+H26?H4?PD,ABS]"C^$AD,%
M                    (-(^A>_64)P@TCZ%[]90 G
M                          @U7^Z_KI_J)P@U7^Z_KI_J)P
M                                AUCZM>\G\R$P0ZQ]6O>3^9 @2V_F
M)\1#]'XW\Q/B(?H                                          @TC
MZ%_]90G"#2/H7_UE "<
M              -55;=I%5?)ZHTZ-(>(L:UH+5CJSTC:@+&3B[ID:3ZGG&CL
MQ6$,1FD,LH+"4-I)*4EX"(>@ (4                              UE6
MH%*JZT+J=/CR7$%A*UHRHBZL[\#9@*I.+NB-)]3QA1(\&,B/#8;881L2VVDD
MI+R$/8 $;OU*                                         06_KA[]
M(OYB<(+?UP]^D7\P0)P
M                                                          B5
M;ZN?\7]1+$2K?5S_ (OZ@@26?H4?PD,ABS]"C^$AD
M                       (-(^A>_64)P@TCZ%[]90 G
M                             @U7^Z_KI_J)P@U7^Z_KI_J)P
M                                   AUCZM>\G\R$P0ZQ]6O>3^9 @2
MV_F)\1#]'XW\Q/B(?H
M@TCZ%_\ 64)P@TCZ%_\ 64 )P
M
M                                            (+?UP]^D7\Q.$%OZ
MX>_2+^8($X
M                                                 1*M]7/^+^HE
MB)5OJY_Q?U! DL_0H_A(9#%GZ%'\)#(
M             0:1]"]^LH3A!I'T+WZR@!.
M                  !!JO\ =?UT_P!1.$&J_P!U_73_ %$X
M                              0ZQ]6O>3^9"8(=8^K7O)_,@0);?S$^
M(A^C\;^8GQ$/T                                          0:1]"
M_P#K*$X0:1]"_P#K* $X
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MN:C+&>4[?Y"W@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
M?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^ ?(K\P5[VKX"V@&.0PHJ7R*_,%>]J^
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MTN();:DJ0>TE)/)&*%9]J6[*M.ER)E-B+><C(4XM6\SQM,]HBV,_%I%Q76Q
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M#GLNJ=8E.FZ;.@LDLC/:1&>S O YSAAMKU-1E<  #!H
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MW;/\!9:[4Z?*IM%F%/E-QI,UGB'(IXXU1YPA?^R>W)> =)4)1EA9E5$U=%E
M4'Y1]C+^K\>1RZ61MQ^3Q(Z%.G\S*C2G<71D]@W3M?IU6MBJR&I$J.VPVM$C
M2DVWXYD6W8>Y74(Z$E;9V^2JHG<L@"@5FYG*=,M2/#[(OQ'D$XXHF36N0CB^
MU+/2KI,B%CK%SPJ9):B*:ERISB.,*+%9-QPD]9ET%XP=&:M9=0JBU-X TE/N
M>G3J;.F-*=24%*E267&S0ZU@C,R-)^ C&K+A!HZF7'T-3UQ6VR<5(3'/B\&9
M$99ZR-1$8RJ-1Z)%QQ7<MX#7UFKQ*33#GRE*-C*23Q9:C6:C(B(BZ=XV!;2(
M\8&+.URW #F]L49RX'Z](F5FM-&Q57XZ$,3#0DD),C(L;?M&)] <F4>^GJ"J
MI2:C!7#Y4DY*];C"M6,&KJ/^I>7O*@E=)ZHPJE[.Q>0%5>OJEH4\IIFH2(;*
MC2[,8C*6P@RW]MX.LAXW+43<K%HN0)2CBRI*C,VEF274Z,EG&\AA49WLU8KJ
M+L7 !KZ/5XM5.844UDN(^J.ZA:<&E9?T\(UDF\Z1&A*F/..IBIF'!XW1L-PB
M,S,NM.P]HRJ<F[)%Q+K<L8"OTZ[(,RH,PG&)T)Y\C-CE;!M$\1?9,_Y'M&=7
MNB%3I_(4LS)LTDZUL0V3=4A/6KH(7*G>UACC:]S>@-&U=%,=H,FK-N.'&C9)
MY!H,G&U%O2:3VD8A(OFE*4TM3<YN$ZHD(G+CF3!J/9C5X]F=P*C-]$,<=RT@
M*7<=RR(%[4> VU-5%4AU3R&F#5QQZ>UTGTD6=N-W2-G2IL)NJW$OETI7)UH5
M(3(5^Z8[3/:=18VF*Z,E'%NK_-B*:;L6$!SF\;WC2+4GG 34XJG4$4:6IA3:
M'#U%\Q?B(]^!:Y]?AT:G0535.N/R$I2TRT@W'758VZ4EO%=":2TU852+-V T
MU$N.'5I+T5#<F+-:22UQI31MN$D_[1%TEX2&5X.N,6I6765J;=1$=4E:#P:3
M)!X,CZ#&,#Q*+T+B5KHVX"A6[:R:A;]-FR*Y7B>D1FW5Z9RB(E*21GC9X1(X
M/ZC(-^OP)<]4Z)37R2U,=41F:3(S,E*Z=.-_A'25%)-Q=[&5/I==2Z@*H5]T
MH_WO$U J?JT<O.,KD^<X^=U9Z<#;UNO0:-&9>EN*6;ZB0RVRDUK=,^A)%O&'
M2FFDT:4XO6YM &DHMRPJI*>BDW*AS&4<8J/+:-I>C[19WD(!WW2NV=2S4%P$
MJT*G(C*-@CSCYW5GIP&3-NUACCUN6H!I:W<U-HR(2YKJN+EYXE3:=9*P6>CK
MR6.O(\Z5=$.?.5"4Q-AS-!N(8EL&VIQ);S3U_P Q,J=L5M!B5[7-\ I5E7,]
M4ZG76YJ):&FI"C:4\SH0RVDB[51]"NG![1)^7M)QQW$U#L?JT<OY*KB-^,ZN
MK/3@;=":>&Q%4BU>Y; &DKMSTVB<CY:XLREI4IDVDZ]>DB/!8Z3R6.O(FT6I
M-U:GMRV69#*%F9:)#>A98/!Y+R#FX24<36AK$F[$X  9*
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M),;:;E1VG6VEI<;2M.22HMQEX2$D8K5LSY^34(8   .!T
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M^G9UX%@&90<'9E34E=   9*
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M6;L5C6@MI;#/._9_B-E;CKUU7?&N2-%.)38T=;"5+6DW'U&9[#))G@BST_\
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M\F8SD.U[JQ<SM8O@  X'0
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M1%@N1L_\!#:#\0E*$DE!$E)%@B(L$1#]'GD[MLZ)65@  (4
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M,R(B_P#?@G6/39=-:K936>*.15'Y#7;$>IM6,*V'TX\8L@#,JK:PVT*H).X
M '(V
%  !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g762905g69v12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g69v12.jpg
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M!0$! 0    $" Q$2(3$$%$%1$Q4R4E.!D? %(C-A<;'!T2,T0J'A<D1B_]H
M# ,!  (1 Q$ /P"U(                                       (]T^
M?-E<?K(?Q&E4RUFGSYLKC]9#^(TJF?H_PG]"?Y_P^=VOV_D  ^H\P
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M=%MBFV"[W-'5K=S^%JUUFKY49DC?M/+E[9CQ6X.<S^W-UIAM:-](5]!-./\
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M(T/3BRUS5XZ3R<[4FDZE>X 'XU]@
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M99$G:)(L<NGJJK&D\FRNB1L$,VHC];-/A9-3<F6:;^P=H[3$88MCFLQKI/\
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MJF6LT^?-E<?K(?Q&E4S]'^$_H3_/^'SNU^W\@ 'U'F
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M<3W1;C<VP;4K$8YT4>IK(G(J]*Y;L_(AIP/1TXN/7/S.*=</@  V@
M           !8/N8/YIOOU\?\*E?"P?<P?S3??KX_P"%3P?B7^WM\OZN_9OU
M(==IU^:Z\^>#\9A4XMCIU^:Z\^>#\9A4XX_A'Z,_S_:&NU^W\@ 'U7F
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MMBB_U>)+L^Y7)L"53VHU[HH]1'9;D54Z<MWV(:D U6L5C4=$F=\Y  4
M   "?>Y>_5,1?60?N>0$3[W+WZIB+ZR#]SSP?B7^VM\OZNW9OU(=UIK^;&^?
MV(_Q6E2"V^FOYL;Y_8C_ !6E2#C^$?HS_/\ :'3M?MQ_#K+7I OELPK+AZED
MITMLL<L3FNB17:LF>MO_ ,RG)@'TJTK29FL=7FFTSU=5<\>WNY86AP]520+;
MH61L:UL2([)F6KO^PTV';S5X?O--=+<YC:JG5RL5[=9-[5:N[S*IK@2,5*Q-
M8CE)-IF=[=<S$=?BC']FN-V=&ZIVJGCSC9JIDDB9;OM)DTY8NN^$KK8*BS5"
M,X6.=)8GMUF2(BLRS3R=*;]Y7"&62":.6%[HY8W(YCVKDK53>BHO29EVO5SO
M"Q+=KC5UJQ9HQ:B9TFKGRY9KNY$//D[)6^2EN7#$3R=:Y9BLQXRZ;%^DS$6*
M:):*NGA@HW*BOAIF:B/RY-95557S9Y&#@S'%XP@RK997P-2J5JR<)&C_ (N>
M67:IS .\8,<4X(K&O)SX[;XM\V;0W6MH+JVY4-0^GK6/61LL:Y*BKR_9OY"0
M6Z;L6)2\$O>]9,LN&6!=;SY:VK[",0,F#'D]NL25O:O269>+I6WBX35USJ9*
MFKE7-\CUWKY/(GD0PP#I$1$:AGJR+?755NK(JN@J):>IB7-DD;E:YJ^<D6BT
MVXLIH$CE=053D3+A)H,G?^*HGL(R!SR8,>7VZ[:K>U?9EUN*-(F)<20N@N%P
M<VD=RT\#4C8OD7+>J>=5,#!^++GA*MGJK.^)LLT?!/X1FNFKFB_Z&A C#CBO
M!%8T<=M[WS25QUXO_;47JZ?F:C%6DG$&)[2ZW762F=3.>UZI'"C5S3DWG& S
M7LN&L[BL;6<MYC4RZRX:0+Y7X4CP[424ZVUD<<2-2)$=JLRU=_\ E0Y, Z4I
M6G*L:9FTSU  ;0.JQ'CV]XAL5-:+E) ZCIW,<Q&1(UV;6JU-_F53E08M2MIB
M9CHL6F.4-YA#%%RPG<9*ZSNB;/)$L+ED9K)JJJ+R>=J&'B&\5=_O%3<[@K'5
M50J*]6-U4W(B<GF1#7@<%8MQZYG%.M>#IL'8XO>$65++-.QL50J*^.5FNW-.
M=$YE-1?KK/>[M4W&L9"VIJ':\G!,U&J[G7+I7G, ",=(M-XCG)Q3,:\'4X'Q
MI5X0BNB4%-!)+71)$LLF>M&B9[VY+Y<_L0Y8 12M9FT1SDF9F-!M\-8EN^&J
MQ:FRULE,]VY[4R5CT^DU=RFH!;5BT:M&X2)F.<)173CBM8=34MJ/RRX3@%S_
M (LO8<1B7%-YQ+.DMZN$U3JKFQB_!8SS-3<G8:4'/'V?%CG=*Q$MVR6MRF76
MV32!?+-AN:QT,E.E!*V1KD=$BNR>F3M_VF/@S&MWPAM?>5\+=JU>$X2-'_%S
MRR^\IS0+.'',3$UZ]4X[<N?1]Z^JEKJZIJZA46:HD=*]43)-9RJJ^U3X '2(
MURAEUELT@7RVX5DP]324Z6V2.2)S71(KM5^>MO\ M4Y, S6E:3,UC6UFTSU=
ML[2;B*3#JV2IEIJFA6'9U2:%'.5F629KTINW\NXXD 4QTQ[X8ULFTVZNION-
M*N[81M6'74T$%';U1S71YZTCD14S=FN7])5^TY8 4I6D:K!,S/4.SPMI,Q-A
MNF92T=:V>D8F3(*EG"-:G0B\J)Y$7(XP"^.N2-7C<%;36=PDFYZ:,6UL"QQ3
M4E'FF2NIX?A=KE7+["/*RJJ*VIDJ*R>6>HD7-\DKE<YR^55/B#./#CQ>Q&EM
M>UNLNAPEC*^84E>ZS5KHXGKF^%Z:\;UZ5:O/Y4R4ZNOTUXLJJ9T4;Z&E<J9<
M)#!\+[-953V$9@E^SXKVXK5B96,EJQJ)?2IJ)JJHDGJ97S3R.5SY'N5SG*O*
MJJO*;K"N+KWA:9S[+7/A8]<WQ*B.C?YVKNS\O*:$'2U*VCAM&X9B9B=PE"73
MABM\.HUMMC=E\HV!=;VN5/8<'B#$%UQ#5[3>:Z:KE3XNNOP6IT-:FY/L0U8.
M>/L^+'.Z5B%MDM;E,NLH](%\H\)/PY#)3I;'1OB5JQ(KM5ZJJ[_\RG)@&ZTK
M3?#&MI-IGJ[:ITFXBJ\.NLM;+35-$Z%('<+"CGJU.15=TIDF_ES0XD 4QTQ^
MQ&B;3;JO< #\6^R                                     (]T^?-E<
M?K(?Q&E4RUFGSYLKC]9#^(TJF?H_PG]"?Y_P^=VOV_D  ^H\P
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M>HF38]==VMGGR([FYS%NU7[S&.(G6ON?DL8H]'-M\T!@ ^@X
M            !8/N8/YIOOU\?\*E?"P?<P?S3??KX_X5/!^)?[>WR_J[]F_4
MAUVG7YKKSYX/QF%3BV.G7YKKSYX/QF%3CC^$?HS_ #_:&NU^W\@ 'U7F
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M&^FJT8BI&SA5W9YYIR/YN<Q?M5X[17'$3J8^_HL8H]'-IGFKV #Z#@
M                  $^]R]^J8B^L@_<\@(GWN7OU3$7UD'[GG@_$O\ ;6^7
M]7;LWZD.ZTU_-C?/[$?XK2I!;?37\V-\_L1_BM*D''\(_1G^?[0Z=K]N/X
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M=)4HQ%2)-?G7/-.1>9>4Q?M5XSUI$3J8^_HM<4>CFTSS5S !]!P
M                 !>X 'XA]H
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M<G*Y43>B<QU]!EKEIDCGJ-3_ )8XZS2:SRY[1Z #Z#@
M       %@^Y@_FF^_7Q_PJ5\+!]S!_--]^OC_A4\'XE_M[?+^KOV;]2'7:=?
MFNO/G@_&85.+8Z=?FNO/G@_&85../X1^C/\ /]H:[7[?R  ?5>8
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MUUIZB")7=.K&],_8?/$T&E=KEM=!-35E/(U&]\(&QPO7/ESS=\%?*B>8Q^Z
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MWTU_-C?/[$?XK2I!Q_"/T9_G^T.G:_;C^  'U7E
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MD]T>M,GP_OZ'=:^\J[WGN?@ZL] [\AWGN?@ZL] [\BT7'%@+QDIO12>Z..+
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MO\T-U^M@_%:4N-=C]CYI?J  ];
M                                       6?[CW^9,2?WB'^%Q6 L_W
M'O\ ,F)/[Q#_  N//VK].6J=7;=TE\SU[_MT_P".PI475[I+YGKW_;I_QV%*
MC'8_8G^5OU  >M@
M                           +-]QY_-F)_KH/X7E9"S?<>?S9B?ZZ#^%Y
MY^T_IRU3J[;NEOFANOUL'XK2EQ='NEOFANOUL'XK2EQCL?L3_*WZ@ /6P
M
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M@Z3'V#;G@>\QVR].IG5,D#:A%IWJYNJKG-3>J)OS:IS9N)B8W"  *
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M/<JIE\)#@0;X(XN+Q-\M  -H           6?[CW^9,2?WB'^%Q6 L_W'O\
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M_4 !ZV
M                   L_P!Q[_,F)/[Q#_"XK 6?[CW^9,2?WB'^%QY^U?IR
MU3J[;NDOF>O?]NG_ !V%*BZO=)?,]>_[=/\ CL*5&.Q^Q/\ *WZ@ /6P
M
M        %F^X\_FS$_UT'\+RLA9ON//YLQ/]=!_"\\_:?TY:IU=MW2WS0W7Z
MV#\5I2XNCW2WS0W7ZV#\5I2XQV/V)_E;]0 'K8
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MOE_*#T<*<<3F/O%NH]+%[PXG,?>+=1Z6+WBX_P"D#?ZLOW_]A^D#?ZLOW_\
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MA3?5M_<!]*GY%3",VI^14PBP@
M                                       !E4?Q7><Q3*H_BN\X(>ZC
MY%QA&;4?(N,(0
M                            &31\CC&,FCY' A[J?D5,,S*GY%3#$
M
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MB*Y53V$O8-Q)28JL,%SH4<QCU5KXW?&C>G*U?_SD5!?#:D;E8M$MV #DH
M     =I;OU"F^K;^XXL[2W?J%-]6W]P'TJ?D5,(S:GY%3"+"
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MPI9[I4LC9/64L<[VQYZJ*YJ*J)FJKD;@DQJ=*  @
M    &51_%=YS%,JC^*[S@A[J/D7&$9M1\BXPA
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M.E:Z8XQE7VNLH:.FHHJ5]3"Z-KTD5$D8UJ.57*G(_F0F,MZ32=21.P &%
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M1B2FQ5AVFN=-DUSDU9HL\UCD3XS?]4\BH9RZC''!TDKUYM\ #R.@
M=I;OU"F^K;^XXL[2W?J%-]6W]P'TJ?D5,(S:GY%3"+"
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MWYN,,?X=!_ AU!R^BWYN,,?X=!_ AU!Y;^U+4=  &5
M      #*H_BN\YBF51_%=YP0]U'R+C",VH^1<80@
M       /Q[4>QS7)FUR9*B\Z'Z?*JE=#332LC=*YC%<D;>5ZHG(GE4#E;E46
M31KAQ9+?9ZA*22H_5K=#KN=(Y.7)5Y,F?N(VT97*/'>F"OQ1420T#Z*F6FIK
M:]__ #"MRR5[DZ$UG9]"JB<V:R9HWQO18YLTU?10OIGPS+#+3R.17L5-Z*N7
M2G^O01QI(2!NGS!*V1&I=G.3;N"Y5BS_ *67/J<)R\V7D/12.=JSU9GS3F1)
MW1%O_P#T>RW^*MI*>JLM6D\452_52=55JZK>EV;$7+HS)7?/%'(V.26-LC_B
MM<Y$5?,A"NEU(9-,>!(K[JK8E1RHDGR:S:R\N>[EX+//F,8?;V6Z-5C;3$E^
MP9);*:PUUOFNT>S.JJ]$931M?N<J/_I;L]^2=/-D2_HWLL>'\#6:V154=6V&
M!%X>)<V2*Y5<JM7G;FY<O)D96-(;;+A.[,O:1=[=F>LW"99(B(N]/*G-Y<CA
M>YI?5OT7T^V*Y8VU,K:?6_9YIR>36US5IBV/\L:YD=4DW>5\%IK98G:LD<#W
M-=T*C55%(,T;U6/M(V&VR+B9;114TCHGU<<"/GJI,];FU4:UJ.:FY>GEYIPO
MW\QW'^[2?PJ1OW,OS7Q?WN;]Z$I.J3/\$]6)@"_8EL>DRIP3BJY)=XWTZU%)
M6.8C7JB)GO\ (J([<N>2IRY'/XRLC,1:=[M:),O^;L;HVJO]%^IFU?L<B+]A
MO;G_ -S]I_PEW[I3PG_=$O\ A?\ ]AUB=3Q1Y)^SH= 5Z?=='E+356:5MKD=
M03-=RIJ?%_\ %43[%(QTC_\ J>721B%WPZ.TPP6BC7E3629BR*GVY_8\W%RO
MB:,-(V-6OR927:@6Y4:+R+4;TR^URO\ 8?:[6)UA[F*MBG1=LJHHJRH5>57R
M3,=O\J)JI]A:QPVXH\=?^GAI)^B[YN,,?X;3_AH=.<QHN^;C#'^&T_X:'3GE
MM[4M1T  94                        ,FCY'&,9-'R.!#W4_(J89F5/R*
MF&(                             !I+KA:T72_6V\UU,LEQM^>S2<(Y$
M9_E1<EY>=#1:8,64.%\'5R5+FR5M="^FI:9-[I'.16YY=5,\U[.54/II/QU!
M@JU0K'"M9=ZQW!45&W>LC^3-<M^29IR;U543S<_@#1Y6S7=N+-($Z5^(7Y.A
MIUWQ4:<R(G)K)Y-R>5=YVK'*+7Z,_M#=:$\/U>&]'5LHKBU65;]:>2->6/7=
MFC5\J)EGY<SNC\<J-:KG*B-1,U5>8YS'5-<;U@RZ4F&*J%EPJ(^"BEX3)J9J
MFM\),\EU=8YS/';<^*](<+,[C3QWL[%U\&X?FSE7^A752<C?*UO_ .?&3+X]
MS4F5NQ4B<G?9_P"Y#"POAW2MAFRT]JM"89BI($7)%UE<Y57-7.7+>JJ:'N?6
MXOV^X+;W6U+0ES7ODDF?"*[+X7!^3(],Q'!:(F-<F8ZK'D/Z6L5XDLND/#-M
MPW*U^WPO9LTB)P;Y'*K6N<N6>355';EYB8"&M(_S\:/_ .P_][CCAUQ<_*5G
MHP\96;2%A.Q5&)8\</N$]*B2U%&ZE1L2MS3/53-45$\R;NA3?X[O7Z1]S_6W
M=8TC=5T$<CF)R-=KMUD3R9YG1Z7OFRQ+_<G_ +C@)/\ M83_  ]/Q3I6>*(M
M/FD\G/8-_P#2F)]'5[;\"AOUL;;JE>;A$R1JK_\ Y_=4DO3K=9J+ TEMH<UN
M%ZF9;8&IRKPB_"_\<T^U#D+Y9'W?N;K-/3(NVVREBKX7-Y4U/C9?Y5<OV(?7
M#MZ;I*TDX:JF9.H;';&UT[4Y$JY$1-7[-RI_94U,<4\<^&_^NA'DQM&EJAL?
M=!W^UTV7!4EDAA:O3JLI4S^WE^TG<AG"_P#W0XO_ ,*9_#2DS'+-.YC^(6H
M#BT                          #E  10          <'BS17AW$=7)5OC
MFHJR1=9\E*Y&H]>ES514S\J9*:6W:#<.T\R/K*NX5;4_^FKVL:OGR3/L5"5@
M=8S7B-1*<,,&U6FAM-O;0VREBI:5J9(R-,OM7I7RJ<U@C1U:<'7&HK;945\L
ML\7!.2H>QR(F:+NU6IOW'9@Q%[1N-]33BXM'-HCQJN)VU-?MZRK-P:O9P6:M
M5.35SRW])V@ M:;=2(T\3Q-G@DB>JHV1JM54Y<E3(Y+ VCZU8,JJJ>UU%=*^
MH8C'I4/8Y$1%SW:K4.P BTQ$Q'B::[$5EH\06:IMER8KZ:=N2ZNYS5Y4<U>9
M47>:/ V [?@R2J6UUMQECJ$37BJ)&.9FG(Y,F(J+RH=:!%YB.'?(UX@ ,J
M      ':6[]0IOJV_N.+.TMWZA3?5M_<!]*GY%3",VI^14PBP@
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MR62@M=(^1]/1PL@C=*J*Y6M3)%541$SW=!G@$GFH "
M       95'\5WG,4RJ/XKO."'NH^1<81FU'R+C"$
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MJS8WO,-RNU==89H84A8RFE8UB(BJN>3F*N>;NGH.<_X?,,^%L0^LQ?\ Q$Q
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MX945SV99?"R1$]AIM'F +1@.GK8K,^JEVM[7R/J7M<[X**B-35:FY,U[5.N
MXIYQYFG,T&"[=18\N6+8IJM;E7TZ4TL;G-X)&HD:9M35SS_DF\JKRK]G3 $F
M9GJH "                           .4 !%
M             .TMWZA3?5M_<<6=I;OU"F^K;^X#Z5/R*F$9M3\BIA%A
M
M           #*H_BN\YBF51_%=YP0]U'R+C",VH^1<80@
M
M,FCY'&,9-'R.!#W4_(J89F5/R*F&(
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MWLWT_8-F^G[#QM#^AHVA_0T#WLWT_8-F^G[#QM#^AHVA_0T#C@ 10
M                           #M+=^H4WU;?W'%G:6[]0IOJV_N ^E3\BI
MA&;4_(J8180
M                          RJ/XKO.8IE4?Q7><$/=1\BXPC-J/D7&$(
M
M              #)H^1QC&31\C@0]U/R*F&9E3\BIAB
M
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M]+4<5;73I9:UM144]*YK4:D::Z,YL]RM]A8<N3'..=21.P '-0
M              RJ/XKO.8IE4?Q7><$/=1\BXPC-J/D7&$(
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M>Y&L1<T7DW+_ )B8Z3>W#!,Z3X#!L4TE19+?-,Y7RR4\;WN7G56HJJ9QA0
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MMWZA3?5M_<<6=I;OU"F^K;^X#Z5/R*F$9M3\BIA%A
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MI735?>RKBDD=O5^HCVHJ]*JB)FO22#C/_H^^_P!PG_#<13HW_P"VBX_W*O\
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M_IVU?W2+^!#8FNPU_P!.VK^Z1?P(;$\D]72  $
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MKE[3:@;D:Q]@M;[\R]NHHENK(^";4Y?#1F_=[5-F -[  $
M           RJ/XKO.8IE4?Q7><$/=1\BXPC-J/D7&$(
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M$,<,+49%&U&-:G(B(F2(>P"                              Y0 $4
M                                 [2W?J%-]6W]QQ9VEN_4*;ZMO[@/
MI4_(J81FU/R*F$6$
M                               ,JC^*[SF*95'\5WG!#W4?(N,(S:CY
M%QA"
M                    R:/D<8QDT?(X$/=3\BIAF94_(J88@
M
M      'S[Q4G6E^\GY#O%2=:7[R?D<[M$W[:3[RC:)OVTGWE(KHN\5)UI?O)
M^0[Q4G6E^\GY'.[1-^VD^\HVB;]M)]Y0.B[Q4G6E^\GY#O%2=:7[R?D<[M$W
M[:3[RC:)OVTGWE Z+O%2=:7[R?D.\5)UI?O)^1SNT3?MI/O*-HF_;2?>4#HN
M\5)UI?O)^0[Q4G6E^\GY'.[1-^VD^\HVB;]M)]Y0.B[Q4G6E^\GY#O%2=:7[
MR?D<[M$W[:3[RC:)OVTGWE Z+O%2=:7[R?D.\5)UI?O)^1SNT3?MI/O*-HF_
M;2?>4#HN\5)UI?O)^0[Q4G6E^\GY'.[1-^VD^\HVB;]M)]Y0.B[Q4G6E^\GY
M#O%2=:7[R?D<[M$W[:3[RC:)OVTGWE Z+O%2=:7[R?D.\5)UI?O)^1SNT3?M
MI/O*-HF_;2?>4#HN\5)UI?O)^0[Q4G6E^\GY'.[1-^VD^\HVB;]M)]Y0.B[Q
M4G6E^\GY#O%2=:7[R?D<[M$W[:3[RC:)OVTGWE Z+O%2=:7[R?D.\5)UI?O)
M^1SNT3?MI/O*-HF_;2?>4#HN\5)UI?O)^0[Q4G6E^\GY'.[1-^VD^\HVB;]M
M)]Y0.B[Q4G6E^\GY&RAC2*)D;<]5B(U,_(<7M$W[:3[RG86]56AIU5555C;F
MJ^8#[/:CFY+R'SV>/H7M/VH54B547)3$X1_7=V@96SQ]"]HV>/H7M,7A']=W
M:.$?UW=I496SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=V
MCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.
M$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1
M_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']
M=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW
M=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V
M@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!
ME;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5
ML\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96S
MQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'
MT+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0
MO:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]
MHV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC
M9X^A>TQ>$?UW=HX1_7=V@96SQ]"]I[C8UB+J\YA<(_KN[3)I7*YKM957SD5]
M7M1S51>0^>SQ]"]I^SJJ1.5%R4Q.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']
M=W:5&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7
M=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W
M:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H
M&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@9
M6SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;
M/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\
M?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]
M"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+
MVC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:
M-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV
M>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X
M^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ
M%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7
MM,7A']=W:.$?UW=H&5L\?0O:>XV-9GJ\YA<(_KN[3(I7*Y':RJOG(K[/:CFY
M+R'SV>/H7M/VH54B547)3$X1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=I49
M6SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;
M/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\
M?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]
M"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+
MVC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:
M-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV
M>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X
M^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ
M%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7
MM,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>T
MQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H&5L\?0O:-GCZ%[3%
MX1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?UW=HX1_7=V@96SQ]"]HV>/H7M,7A
M']=W:.$?UW=H&5L\?0O:-GCZ%[3%X1_7=VCA']=W:!E;/'T+VC9X^A>TQ>$?
MUW=HX1_7=V@96SQ]"]HV>/H7M,7A']=W:.$?UW=H')  B@
M                    ':6[]0IOJV_N.+.TMWZA3?5M_<!]*GY%3",VI^14
MPBP@
M                  !E4?Q7><Q3*H_BN\X(>ZCY%QA&;4?(N,(0
M
M       &31\CC&,FCY' A[J?D5,,S*GY%3#$
M                                                      Y0 $4
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MT8KVH]?Z*KO/94ZEK9[]IMLF))%79+C>'1TF?/%$K6-7L7M12V(R8^#2Q.P
M')0                  #*H_BN\YBF51_%=YP0]U'R+C",VH^1<80@
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M'-*\,LFE[1T^.)[F,G=K.1JJC?AMY5)C.&2=Q69^^;4>( #BT
M        95'\5WG,4RJ/XKO."'NH^1<81FU'R+C"$
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M?8AM-!4;XM%-@9*QS'I')FUR9*G\J\S>8FDZ\_[$=7>  \[8
M              .4 !%        %1%5%5$S3G
M    [2W?J%-]6W]QQ9VEN_4*;ZMO[@/I4_(J81FU/R*F$6$
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M! /S),\\DSZ3]  _%1%3)414\I^@
M   !DT?(XQC)H^1P(>ZGY%3#,RI^14PQ
M  /Q41>5$7SGZ  /Q$1$R1,D\A^@ ?F29JN29KSGZ
M                      .4 !%
M  .TMWZA3?5M_<<6=I;OU"F^K;^X#Z5/R*F$9M3\BIA%A
M
M#*H_BN\YBF51_%=YP0]U'R+C",VH^1<80@
M                                                 ,FCY'&,9-'R
M.!#W4_(J89F5/R*F&(
M                                   !R@ (H
M               !VEN_4*;ZMO[@ /K+\13X %A
M                                                      #[0<C@
M 0]2_)J8X @
M                          /K!R. !#U+\13X "
M
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g762905g72w39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g72w39.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[1W"4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ &0     0 ! 9
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   $X   "44          0                         !
M  E%   $X                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   $X     !29VAT;&]N9P  "44    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !.      4F=H
M=&QO;F<   E%     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MB#$=MR+BNZBY_P"M,K8R/S"9G2.[O]?\]6DSB&@N/ $E)2Z2&UA(EY.X]@2
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !+DU- "H    (  <!$@ #
M 0 !   !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M    '@   '(!,@ "    %    )"':0 $     0   *0   #0   !D     $
M  &0     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#DZ
M,3 @,#(Z,38Z-#    .@ 0 #     ?__  "@ @ $     0  "46@ P $
M 0  !.          !@$#  ,    !  8   $:  4    !   !'@$;  4    !
M   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0$V17AI9@
M34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4    !
M:@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0    !
M    I    -    &0     0   9     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C R-#HP.3HQ," P,CHQ-CHT,    Z !  ,    !__\  * "
M  0    !   )1: #  0    !   $X          & 0,  P    $ !@   1H
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M6N,=%5T-?42/CZSB@CRT#.,9[]EKXZ9;.7%HM=T+AS:&#(]F5TR.!C8HV/\
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M%$*Y4J*L/RS/R@J*L/RS/R@@F41%"XB(@(B("(B B(@(B("(B B(@(B("(B
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M!,HB*%Q$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 4%J"LGFJ(K/;)#'6U#>.28?_ "\.<%_F3L!WG/85
M*W"LAH*&HJZIW#! PR//@!E1NEZ*:*FEKJ]N+C7.ZV7/VC?M8QW #'MR>U6K
MQ]Z6E.(ZY2-MH8+=0PTE)&&0Q-X6C]Y[R>TK)1%7NI,[YD1$1 B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B# U!3-K;%<*5\D<;9H'Q\
M<GQ6Y:1D^"^?NC;4S-*WR=U6#+3O889.J(=N#LX'M&Q]ZR>D37]=K>_NTCI&
MGF?3ME,<SQLZ=S3@^3 >9[5M71_T426^HBK=2OIYG,!Q1L'&S/87..,^6%Z-
M*1AQ3YL]_3U=.&U:TGJ]4P>E2AD+12VZHE)(!#GANWASR?!="@DZV&.0-+0]
MH=@C!&5A4=DM=&XNI+=20N/:R)H/ZE(+AO-9^&-,\EJ3\$:$1%1D(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@UJ]1.L=>^^4;2:9^!<
M(6CFP<IA^,T<^\>2V.*1DL;9(W!['#+7 Y!'>JN:'-+7 %I&"#R*U[3F;5<*
MFQ2$F*,>D49)S]A)W;YM=MY$*_Q1\X:_'7YQ^G[?[V;$B(J,A$1 1$0$1$!$
M1 1$0?/FK.D+6=/TM5NGM/&&IXW=13T[V#A:2S/&3X;GV+ N^LND/HWU#02:
MNJ8KA;JHY+1@M+01Q!I&"'#/:KM'_P#%2[\M_P#T"L[ZK?\ DO3WYV;]D+UJ
MQ3KICZ8U,,_29;9TS=)%1I:WVVDL$;)KM= '0N>,AC#MQ8[220 M/U%=>DSH
M\I**^7FYTUUH9'M;44Q8,19^UR,>(R.U0OU1%%+'6Z-N4O6LHC11P.ECYL<#
MQ;'OP<^Q>]6:?T506B":Y:_NUQIZG#F00S-J'$<\EO%MCQ48L=*TKQO>]\;_
M /A,SMT7I*Z4VV/H^M=YLK(W5EW:#3"3<1CARYQ':6[#'>M(-XZ6-/:6?J6X
MSPU5!)%Q/@E#2^!KOBOP,8QD'M\5'=-M@CI.B_151:342VNF:Y@?.SA?B4!S
M2X=G(K;-<=*.F;AT1U%/25C9+A64C:=M'CUV.(P>(=@&#OY**4BM:]%=[GGZ
MIVF>B76-\O'1A<[S6Q/NMTIYI6PPQM#72X:"UNWB5J[W]+-=9*W4-7=(;,(@
M^1EMDC#'.:W)P <XY;9.ZA^C_4=?I?ZGZ\7&T[5;;@8V2<((CXN <6#W96'1
MVS3MPZ/Y]1:LUG5W&Z2P/>*+TW#FRX/"S@SD[X[ /8IC'%;VG4:WKMM&V^:5
MUGJS7_1M--IXTM-J.DJVPS/.S)&8SQ 'D2"/<5R?HBIM:SW2^C1E13Q532ST
MPRD 'UG8QGQXETKZDS^;M_\ [XS]@+6>@C45KTEJ_5M/J.LCM[I7AK73>J.)
MCW\0\]U:/N>;2E8XT>S<.D36>H[#KK1UIBJXV,JFPBL:& A[B\-=OW<UDZJU
MO?-+=,=MMMQJ(CINXM;P Q@< (X?C=X>/<5J_33/%5=+6AZBFD;)!*8'L>TY
M#FF5I!"VWZI73IN>B67:F:!5VJ02\0^-U9.'8\B6GV+*M:?<BT?%$I]V3T[Z
MYN.E:2TT.GY(Q=;A-AN6\1#!@<O$D#WJ*Z1=?ZAL[]/Z4LO4RZHKH8_29W-V
M8]PQ@#D"3DY[ %IN@*JHZ4>EBV72X19I;121.D:[<<;0<'VR$GV+QT[V\4_3
M%;:NY5,]%;JQD(]+B.'1AOJN(/AD'VJ^/#2MJXK1S$3,_BC?JGKYJ37_ $8W
M"W56I[A!>[15/X),-X2T]K0>8.-\[@KO5+41U5+%40.#XI6!['#M!&05\SZT
MT]HBW,IH;KKJ\77K3Q,CIWMJN'N)'%@?K7T?8J2.WV2@HX#(88(&1,,GQB T
M 9\5S^)BO368[_AI,.==(MRU[6:H@L6CZ%U%0EK72W61F6Y(R<$[ #NW)*U>
MUZUU9HSI$M^GM6W&EN]%7<($[  YG$2 1CE@C<%16I;Y6ZNZ6[AIV^:CFT[8
MZ)[V1L;)U0D+< 9=D9+LDC.<#DM0U#1:?MW2I8Z32]=+<*>*6$3U#YNM#Y2_
M)X7=P&.7;E=6+#'3T6B.WM_VB9;QTD__ !'Z7_\ VW[;EXUS_P#$Y8_.F_45
M[Z2O_B/TQ_\ MOVW+QKG_P")RQ^=-^HIC_X__P R)SI$U]J.NU\S1>ANJAJA
M@35+AD\7#Q'!.S6@<SONHN36>MNCK5MNH-;5$-TM=<0!.T8(&<$M('-I()!&
MX4:*V#2?U2M;57QXIJ2I+BV>39@:^,<+B3V9!&53ZH6]V_5&H],6K3]5#<*B
M.0ASJ=PD;Q2.:&M!',[9]RBF.NZTZ?NS&YG]SYMOZ9-?W>U:AM.F]-S4])/7
M!KGULW)H<<-P3L!S)._8O=F/2?I[4=%#<##J:RU! EJ(N%AB![0201CGR(*\
M]*4>A+E<K;I_5\\U%>(H&-AK6M+6-!&/6?\ %(R.WEX+F]XJ[CT9ZNM<.F-7
M/O=+/@OIA+UC0"X#@<T$C<;@C!5<=(M2*UCG7K'?^XR/JAX-41WRG?>IH'VE
M]9+\%M81EH]7XW;W<UU+0U3K"P6F[W/7U3326RFI&S0"$@N :"3R\,!:Q]52
MUXMFEZC@=U<=3)QX["6M('S%;7?+[:=:]&EYM^G+A#5U_P &<9IXSF1N&\B/
M,843:;X:1J->ORY/5IFG+OTD](\-=>;'<J:SV^&0QP0!FTA&^,D'/,9)VRMI
MZ'ND*OU-2WBV7Z*.*^6MI+BT8$@&1N.PAPP?,+DW1/9K)>-.U3[CK.ML5132
M.+Z=M4(F%FV'M!(SW'Q"WKH4MVE_A;4-;INY76OJ&4I9,^KA#&GB).0[.Y..
MU6STI%;1KMVX_P"R&M:7Z1^DC4TM?;K#3T];5-=UCIS&UHA9DC&20W<]^^WF
MIS7^L]:Z7M&D(JZ>*FNM49/36M8UP=AX#>6WQ3V*U]2O_M6K/RH?UO3ZJ#^5
MM)_E/_;:IF*?:/+Z8U^QZ;;9TT](==I7X.M-@BCDO-Q&6N>.+JVD\(P.UQ.0
M.["TZ\7CI4T+'1W:\S172CE>&RT^ \,)WX3PC+3@$9&0K?U0;'VOI'TE>ZAC
MC0,$67 =L<O$X>>""M]UQTP:<L5I@JK?+3WN:=PQ3P3@<#<9+GG!X>S;"I2O
M32D4IU;[_P#WT&^6*XQW>ST=PA8^..IB;*&/&'-SV%<AZ5]?ZET]TC6^T:?$
M$T<\$?!321YZR1[G-&3G//'N77;!7/N5EHJZ6E?1OJ(FR&G><F/(Y%<-Z3__
M (A=*^5-^VY8>&K$Y)BT>DIGLQ+UKGI#Z/K[22ZM]'K:.J!<(&EO 0,<0:X;
MM(R.]>]2:LZ4-,T]'J.[BD;;:E[1Z(UH+&<0)#7#F,@<\K,^JO\ ]GTU^7/_
M .1;-]43_14/[Q3_ *BNJDUF,<S6/O;B4>[,U]TELL71];;[;86OJKM&TTD<
MNX82W+B['/'Z\+1:RMZ5K7IF/54]R@DI>$5#Z(L:>",[@EN.6,; Y&5#])E'
M/+T*='U;&PN@IH^&4@;-XFCAS[6X6_ZLU[IVHZ()Q!<Z62JJK>*=E*V0&42%
M@&"W.1@]JK6D4K'37>YF)^HSQTHPNZ)W:M;3QBK!ZCT7B/#U^<8SW?;>2T:R
M7/I6NE@FU-%/!/;GL?(*.0- ECP>(M:-\<\;YV4%'8ZS_P!FV2HX'<'PGZ=C
M'^Z^3SY9W70M"=(>FZ+HFI(ZNY015=%1&G?2N<!*YX! X6]N=MU,TKCB9QUW
MSKW&L_4VU+X+)K2JBP)(V,E;G< ADA"W3H%U;=M6V6[SWR9DTM/4L9&6L#<
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MEFO]-=../CHH^KDII6@$ @$@M._CL@Z?;KU;[C7W"BHJJ.:JH'B.IC:=XW$
M@'V%2"Y?T7?TD=)?_B$/_1:NH("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MLB(N1R"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M^O@\<=^7K5_AN"L<\NT_PYQ?@_+^EC_2G\.<7X/2_I8_TKBJ\E7^R8O;]2?
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M=?,_U,.D[A<=15>N[C+&89!-'$&N!=)*]WKN('Q0-Q@[[KZ81 B(@(B("(B
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M'%KFG// 6T_5+766\:&T1=)XNJEJF&9T?<3'E$NZ=']TH(]":>9)74K7MM\
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M#'->+>Z""0\+9FO;(PGNRTG!\UV2KK+O1],M_P#@:BI;@'T=.)Z66H;"][>
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M"]2:>U-;;K"<.II@YPSC+3LX'V$KG\7X>,^*:^OHK%M2^XD7F)[98F2,(+7
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M1$!$6)=JUMOH9*APXB,!K?NG$X 2(WPB9B(W++1:/-5R39DGG>^0[Y#BT#P
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M(@(B("(B H75];6VRSFX6]O6^BR-EFAX<F6+.'@=Q /%_P ..U32HYH<TM<
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M[G%;W<;RWJP_.7#O(QR4"=-,.Y/1PH&U:HDKND*_Z;=2L9%;*>&9LX>2Z0O
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M!S' .:X<B#VKTM6T4]UMDK--U!/66\\=*YQR9*9V[#_PGB9_PA;2@(B("(B
MB(@(B("(B B(@(B("(B"CW-8TN>X-:!DDG ",<U[0YA#FD9!!R"%'ZDM<5ZL
M%PMLXS'50.B(\PM6Z$KE)<>CBU,J3FJH6FAF_+B/ ?U!!O2(B B(@(B("(B
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MPDH-B1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!:3TV 'HLU'D9_BV?\
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MSNX=SBH6XUU5<JIU16S.FG< .(CL[@ LW3-GI[S(YT]THZ6"-_"]KY0)".W
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M^3=Y(0B-'?S<HO)W[14PH?1W\W*+R=^T5,*UOBE?)\<_B(B*J@B(@(B("(B
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MBNX?MB.S*&V]._</U+RJG<E41"BH55"@HJP_+,_*"HJP_+,_*""91$4+B(B
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M++76.Y4=._JYJBFDB8_N<YI ^<KY9BAN%-<&6BJM<S;O3PN@C@]'>!)*[+2
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M*]*#T+5&MT?9YGNXI#2QM>?Q@,.^<%3B B(@(B(@5%5$%$144BJHB(">:H2
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MWTXEM]$"Z1[VY9QXPUH["0=\=BT^CT1=*JNH:2HJ8&U-7*(V00DN=CFYQ/(
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M/$T,;MPOYG;M[E:*3(V-8%1=Z2GE?'(]V6?&(:2!X96N5=TJ&F&.IK>K9,2
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M&C$1JVN:>' <T>MEW[^?L6S:PT9+QU%?;7$/X>-T36\37G.<M[CX?2N<@$P
MB3[&<9..0+MO+&Y7I^&C'>GO*U9F(TV>/5MV$A^S \6&DD')'%@=O=G_ +*K
M#K*ZQF)[3$[& /4)V.>0SY?J6M\#A*0)' X<1D\O6[_#F5YX2(WEKWY;G;EO
MD'&/>5OY./V6ZI;)-K"\S2O(J61AX;D0L YG&/WA1DEVKZF,>DUT[V$X=ZY
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M6^RQM>R'9D0>00P!HV)&"=^X+Z-6A="6FCIS0E()V%E96_QN<.&"TN PT^0
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MUU8;#9>-X_Q47GRZ]H?0_P &\!.*LYK]Y[?@YY-7:JJ8W2T6G!##$"Z1E74
M2R_BQAH(SXDKU:+I3W:B%32%X;Q%CXY!A\;QS:X=A"Z"N=ZFI!:==4E5 .""
M\1NAF:.1F8"YK_,M!'L7GQJ>'MSN&8XJM*\B< <G;%6G%>J0%T^>QHRK1#.9
M9SE:<KA5MRM"LK3E;(2>>.'XYW[AN59CJX9'<(<6D\@X85X93I[(7G"N$+SA
M3"JU)&V2-S)&->P\VN (/L*P-.S.TOJ>BI:5Q%ENSW1&GSEM/. 2"SN:[E@;
M9"D\*(N#/3=3Z;ML.\WI8K),?:1QC.3YG91;4Q.UL<S%HTZJB(N5W"(B B(@
M(B("(B J2?)N\E54D^3=Y(0B-'?S<HO)W[14PH?1W\W*+R=^T5,*UOBE?)\<
M_B(B*J@B(@(B("(B B(@(B("(B O,CVQ1NDD<&,:"YSG'  ',E>EH6L+K'J*
M4Z=M/63,$[6W*=HQ'%&UV71EW:YV,8&>>ZF(VB9TR+AKN&IIYXM-4=9<JIV6
M0S,A/HX=RXC(=N$'F1E8]BLL5L:9I7NJKG,W^,5DI+GR'F0">3<\@,!2^&Q1
M-BB:&1M :U@V#0.0"PJFKZMY8P D<R5>OR899])9F50G ))V6!3UA<_AE(P>
M1PKM7(UL#QD9(V"MIG$;A;FKCQ8B X1VGM6)/4OEV<=AV!6"[Q22.1D?&YI#
M3VJT0FM9EX>Y8[W*KWK'>[FM(AU8L;R\\UD6IQZV48V+<D^U78Z!KHFND>X.
M<,X;V*_%&R&/@C&!\Y4[=M8U&GI[@&DDX &2H*-K;]JRR6V<9H'R/GEB=RD$
M8R [O'$1MX+-O$A; U@/QW;CO"@Z"YP6G5EJKJE_#%315#Y,;DM+0 !XEV %
M68XX6R5_\4Z^7ZO?2-:Q:]22N9P]35#KF- QP]A'O69T;:EI[-55%+7NZNEJ
M#Q]9]R\#&_@0M=UEJQ^I;A',Z$000M+8F9R<'F2>_90(G\5T1BFU.FSLK3KQ
M12[Z7MESHKG$Z2WU450QIPXQNS@^/<LQ?.6F-0S6&ZLK( 'MQPR1DX#V_3W+
MOM@NU->[5!7T9/52CD>;2-B#X@KBS89Q_@\W/X><4[CLD$1%BYVG:V:UVI](
M![0X>E3;$9_W+E-]3%_4Q?X H76G\Z-'_P!ZF_Z+E/*8%OJ8OZF+_ $ZB'^I
MB_P!8-QNT5(\PQM=-4XR6-V#.XN/9Y;GP40ZZW%TG&)H68Y1"/+#X$GUO:IB
MLRK-XCNGZI]%21A]5Z/$TG +V@9/AWK -XMH./1Y,?=>C>J/W_,M?@G-6Z2K
ME:14/>X/XN;<''#X#&.2O#FKQ3W9SEYX3M7<Z"!S6L@%0YS0\=4QN #R))Y9
M6.V\TX^4MKVC\0,>?=LM>H<B>LC=]I(.'\D@$?K66IBD(G).^&QNK;>VA;5E
ML9B<>$ 1#B+ON<8SGP6,+S;R=Z.=H[S3M_<2M?B?UDKV$^K"][V^;SC]3?G5
MY1%$SDF&PQ7&U/(!EIHW'DV5H8?G 6?U$7]3%_@"T][FMC<Z3X@&79WV5RVW
M2KBH((J<1,B8W8O:7$[G8;[-'(=NRB:>R:Y-]VV=3%_4Q?X G4Q?U,7^ *#A
MOM0W_:::.1O_ -@X/N<?WJ6H:ZGK6N--)Q%OQFD$.;Y@JLQ,=UXM$]E[J8OZ
MF+_ $ZF+^IB_P!7$4++?4Q?U,7^ +5]16J@A?!'#2L8)R\OP3PX&,AK>0SGN
M\EMBP[I1-KJ4QD\$K3Q1O^Y=]!Y'P4QPBT;AJ;8HXVAL<<;&@8 :T# 5JJ@Z
MV(!@:'M(<W(V/@5?(<USF2 "1NS@.6?#P5"0T$GDNF&,1KA@LIG\;7S-CC8P
M\6QR2?<I"DG,0<Z.)I<X@Y=MC'+"L-!E.7;,'(=ZLU;W&41-<6MX>(XV+NS'
MDG=,?=0%TH(9:"NTU/ R!Q<;E9ZD-]2$Y]>)QV.,N=W^K)X+G,&)8W"3BCE8
M2U\4A.8R-N%P[VNR"NI5=M-:/XD]L-93$34\QW#)N0SW@M+FD=SO)0--#;Y+
MG3Z@J:4PVXR.IKC!(0135&0&N=CF,EK2<X^*[EDK7P^;R)F)[2;ZD%;+177)
MT3Z:FDZHR<#I,?8QDD.R>X$+;J?H]X*C%3<BYA;G+(\$N P<Y/+?*E;MJJV6
M;K*2E9U[N D,AQU;7'O/CSV6F2ZMO<SV/],ZLL'".K8 /:NB<N7)S7B%HK#<
MF:=L-KMD;ZN.%TE*YO'-([=SA@;C/(CL63)?[#05X,+X Z2/#I*>,$8'($A<
MM>]\TKY97N?(\\3G$Y)/>O30J3BFWQ3M9L]XU5654\L=!*Z"C#PZ/#0'[=Y\
M]\**JZZKKYNMK*B25^.').,#NP%B,"OL:K16*]AZB:KM*SK&]4-I T['GLC&
MJ6L]1%2NG=/$Z0/BX6!O/BSGGV!4O[HB>FT6]D3;&3">5DI^QQC#=NTG)6P6
MFMJ+;4&:D?@N $C< \;0>0SR/BL*)I+G...)SBXXY9*S(6*MN8Y:9;^;>;3Z
MMJIKG:I6%[^N@E<27_8B.(]^V0O4EWH^$"CH))7 ?&G=P#]Y*U^)JS(6K#RX
M9Q6&3+-/6RL?4"..-ARR&,; ]Y/;VK*A:K,35F0M4=NR8C2]"U9D05F)JRHP
MJ3*878VK(C"\1MV5NZ5\%JM\M75<18S :UHRZ1Y.&L:.TDD >:I,I1VIG25I
M@L-*]S)K@UW7O:<&*F&TC@>QQR&M\23V+4=+:;M\]3572FJ+IZ"X>C6\/N$S
MR(&D!SLEVP<YNP&W"UI[5(54-3423VR5V+K=6MFN\D9VI:7<,@:1R<02T$?C
MN[ELD;&1QMCC:UD;&AK6M& T#8 **QN=B-^ Z;^T7+]-E^E/@.F_M%R_39?I
M4HHVLD-7(*:,_8W.X7$?;=_L"T0\_ =-_:+E^FR_2GP'3?VBY?ILOTJ4_4B)
M1?P'3?VBY?ILOTI\!TW]HN7Z;+]*E$01?P'3'E4W+]-E^E0<VGJ>>9[Y:^]M
MDSPN$=TG8W(VV =@+<%%U;>&LE[G!KOFP?U*8B)4OVX0'UL4GWQU!_\ EZC_
M %*CM-4@+6BOU$][SPL8V[U!<X]P'%_^BFW/X0/5<Y[CPM8WFX]@"V2SVST-
MIFGX7UCQASAN&#[EOAX]JK;4>C.D6M/=K5!T?4HC+JZZ7\R.WZMEXJ,1^&>+
M<K*^L&U?V_47_P"9J?\ 6MM19-VI?6#:O[?J+_\ ,U/^M/K!M7]OU%_^9J?]
M:VU$&I?6#:O[?J+_ /,U/^M/K!M7]OU%_P#F:G_6MM1!J7U@VK^WZB__ #-3
M_K7B;H\LT\3XIZN_R1/&',?>*AS7#N(+]UN"(-2&@+4!@5^H<?\ C-3_ *U&
M7S2%MI(XHJ>X:@])F/JYO-2>%HYN^/X@>96_D@ EQP ,D]RTVLK!//4USL]5
MC[&/_MMY>_G[0K5C<J7MTPQ;)HJ@JZ1\L]PU"<RN:S%XJ!ZHV^[[\J0^L&U?
MV_47_P"9J?\ 6MAL],:2V4\#_CM;EWY1.3\Y68JK1V:E]8-J_M^HO_S-3_K3
MZP;5_;]1?_F:G_6MM1$M2Z/*0VS5FJ;=%5UU120BE?&VKJGSEA<U^<%Y)[ M
M_6DZ2_I!U?\ FZ/]AZW90"(B B(@@;#_ "[?_P ]'^P%/*!L/\NW_P#/1_L!
M3RM;NTR?%]/T$1%5F(B("(B B(@(B("(B B(@+4]:9I;SI:X-P!'</1Y'?B2
MQO;^UPK;%J_2=&YVB;E+$,RTP94L\#&\._4"@VA%XIY&S01RL(+7M#@1W%>T
M!$1$"(M=UQ?&V6SO;%Q27&J!AHX(QETDA!QCN YDGN4Q&T3.D!J^[1ZEG^MV
MT"2>$5#1<:E@(BC8TY=&7=KCC&!WJ: ;%$V*)H9&T<+&-& T=@ 4=IZA%HL5
M#0-#0Z&)HD(^V?CUG>.3E9%5*YD+G-^,KZ93?AXJ:KJGEC "1S)[%;IZPE_#
M*1@]O+"P2[.23DKP2M-,8W,IBID:V%^7#):<#/-0Y=LO!*SZ.*,P->YH+CVG
MS36FD4VPG,D$76%IX.]8SGJ3N51U<7 -R\8\@H9O%([AC!<X]@5Z\NFF)1[E
MD4]&V2$22.(XN0'<JPT).349'<T']:R9)HH0 YS6 #8$]BG?LZJUUV4AA9 T
MA@W/,GF5C72;JJ.1W%PD[9SCS6%6W!TAX8"6L';VE:;KZYNAM;&.F]=\@#FD
M[\.#\V<*]*3:T0Z:TUS9D7*[TT4E'/32LEEIJJ*8-:[L:[)^;98NH]55VH*H
M25TC>K83U431AK ?UGQ*T-MQ:?MED4E1)5U#(*6-\T[R&MCC&7./<NV/#16=
MM*]$6Z_5/"H'>K]%<9:.JBJ:64QSQ.XF/'85T.GZ*(WZ8;UD\K+ZYG'DO'5-
M=]P1CEX]ZY==+3=[2^5MQM]3!U?QG%F6CQXAMA9TM3)N(E-?$4ON(E] Z"U'
M]<=G,LP:VKA=P3!O(GL<.[*V5?*EFU!5VBM95V^H=%,T]G)P[B.T+K6E.EJC
MKIV4]]A;1R/=PMFBR8_^+)R/G7+F\):LS-8X<&;P\Q/53LZBJ)Y)V+B<@J*J
MHI%%1>EY01VH*,7"RW*B(SZ33218\7-("^()XGP3/BE&)(W%CAW$'!7W>_D#
MW+Y)Z;=/&PZ[K71L(I*X^E0G\KXP]CL_,O8_A&6(M;'/JRRQQMH!7DKT>U>3
MR7M690[-T TLMXLNKM/RM(I[C1DQ/=R#P"TG_F;[ERS46G+EIZHZFYP.B=G&
MX(W\00OH?ZF^YVQEBEINLCCK'!OQC@N R"!Y']:C/JF;G;)J&&GB?')6L'"7
M-.<9((;GOYE>97)-?%6Q]/$^O]G+]HM..N3<?%K7]]?6._\ NWSD52.22&5D
ML,CXY8W!S'L.'-<-P0>PJI7EL;Y.(,8YV!D\(SA=$N[>N9=Y?::GIHLEFJO0
M/1[S20F.KKW/X&2-R0UN #G/QN6V_8L&G?1=#%JN;I+?)4:PG>8::HE:#%%&
M1LYI]_9D\N2V3HOU!4='FC;?+JBC,-!<O7A<US1('#( +21S: 5I/3G>I]74
M-'?Z"!KK09S2->QW$YCFC(#@.1/$?<N/IB9FFON>D[]?;]G!3+D\R-S/5N=Q
MKB(YY[?ASOER.YW"KN5?45M?4RSU=0XOEE>[=Q/_ 'R6 5D3Q21$"6-[">7$
MTC*QRM=:X>C$Q/,+9V!7VUT+6HV;HNL%,\<,DD'I+QXR$O\ WA?(V@-/2ZHU
MC:K1",B>8&4_<QM]9Y]P*^[&1L@ACAA;PQ1M#&#N:!@#W+SO&W[57A14551>
M>*(40H**L/RS/R@J*L/RS/RA^M!,HB*%Q$1 1$0$1$!$1 1$0$1$!$1 6J:V
MT93:D#*ACQ37*)O"R;AX@YOW+QVC<]NRVM%:MII/57NK>E;UFMHW$N.1Z,O]
M-+U8M\<@S@/94-X3[\'YEL=GT)+*0^^3M$/]E@/QO![^T>  \UT!%T7\9FO'
M3,N'%_#/#8[=<5Y^;Q#%'!$R*%C8XV#A:QHP .X!>T1<KT!:!KRH;4ZNT_01
M[OI>LK9<?:MX2QN?,E;A?[I#9;+6W*H!=%31.D+1S=@; >)Y+G-CIJG$URNK
MNLNM=A\SNQC?M8V^ 'SY5Z1ZL\D^B6)5^@>.*1IYG<+%)2*3JI6O[!S\EIIC
MM*%8E;4=2P!N.-W+P66HNZ ]<T]A;A*HMV8#R7.+G')/,JTX*Z5;*VAA*3M\
MADIAQ'):>'*OD**HZCT=YSDL=SQV>*DV2QO&6R,/M593$\/%1,RFIY9Y=HXF
M.>[R RLSHOM/5687NL''=+LUM1*]PWC8=V1M[F@'EXK68XZG6P%!:XIHK+(?
MXW<)&E@D8#O'%VNR0 7;8W75X8F0PLBB:&QL:&M:.0 V 662WHZ<-/67M$18
MN@1$0$1$!$1 1$0%23Y-WDJJDGR;O)"$1H[^;E%Y._:*F%#Z/_FY1>3OVBIA
M6M\4KY/CG\1$154$1$!$1 1$0$1$!$1 16:ZJAH:.>JJGB."!AD>X\@T#)6B
M-N-_U"T5<%:;';)!F")D+9*B5G8YY=LS(W &3NIB-HFT0V36-]99+4XL:^6O
MJ,PTM/&,ODD(.,> YD]F%!Z<HO@FPT-#ZO611#K7#[>0[N<>\DYW5FBLXAK_
M $^MK:NXUS6&..:I</L;3S#6@ #/?S4HKQ$1#&;3,\+55(YD+G-^-WJ*+LDD
MG)4K4,ZV%S0=^84,3A:59S'*I*\$H2K3G*T0O6B5I8H^I8\M:7$9R=U8NE1P
M,ZH<WC)/<%ZM_&*<\0.,^J#W*&GF?(]SGGUC\W@D1RZJ8U6M?*XMC:7%9,%"
M,<51SS\4';VJELXFQRO<,,.,$]N,K#JKG(YQZ@\#.\C<J_/:'73',\0DYJF*
M+(?(T$=F=_<H>KKY)7_8RZ-@Y '<^:AJZO,4I:T<;SNXDKS1&IO5=26NWDPU
M=4XATN,B&,?&>/$9&/$J==,;ET32,59O9$ZSO9IV,@BJ,S//V0A^7-'=X96F
MBM!^V^=?1UXZ-+!<=,"S,@-/P.ZQE4PYE$GW9<?C9\?W!<]_@ G#V\.J#PY]
M;-'OCP]=='A_$88KJTZEA7Q?O#FS:O) :22=@!N2>X+H5RZ-[S0Z;%T#Q/.&
MA\E'&PE[&GN/:1VC"Z7I7HTTYIXP3Q4?I5?$!_&:AQ>2[[H-)X6GR"W18Y?&
M1N/+[*V\7/\ Q?(8JP"07;CL6V:(U[6::EZH 5%O>[BDA)W'>6GL*[=?]&6*
M]T51!4VZFCDF'R\48;(UW8X.&_TKA&ONC"]Z9A%7;'27BBW+S%%B2+':6C.1
MXCW+?'FQ9_N6X:?::9(U9W32VMK+J,<%'4MCJO[/*>%Y\AV^Q;*OBO25PK;A
MJ*WTUF$CZ]TS>KZOF,'<[<@!G*^TVYX1GGC=<?B_#Q@M&I[N/)6L3]V6H:S_
M )T:/_O4W_1<O=5?>&=S**%DS&'#I'O(:3VAN!OY\E'])I?\+Z5$;RPNJI@7
M-YXZEV<'L\UC- :T-: &C8 =BPI7?,N;)?IXA8I)NNZ_C:YLPE=U@=S))SGQ
MR.U7U9G8X.$T(S*T8+?NV_<^?=X^:\5%=%#1>DGB>PD!K6CUG.)P&^>=O!:P
MPGGE4#JJT]C*@?\ .!^]H^98]5=Z>GG=&X2/;'@2R,&6Q>??WG&<#FH^:Y5>
M&NF9 UA>!PLR3$<^J0X\]\ [#F5;?%+'+4N9 Z2*65TH/$UO!Q;ELF2.$@G!
MY[*8CG4JS.XW7E)UM6*)T\S&B5TK8A&T.P'.)+1OW;\^Y6K9<9S6-IZYT3S*
M"8I(V< X@,EA&3V D'PPLFW:<JJ^S1Y>T.BB;'&2XM#\'B#FG'VIX0"1@X/8
MK]OTA7&LBDKZE@BC)<.  '."-@,]A(R3C?DJQ:NI:>7>9C2S%-%34;ZFH>&,
MPTN)[\9P!VG+L =JQH[SQ5,4;J25D4LC8VR.<,Y/++>8]^1W*4U;9IVGK:&+
MCA$C9FM&<-(&"'<\#&"#V'GWJ%MMNK*RKA<(F<,3Q(T-<7^L.1><8:T<^TE*
MS7IW,HO6W5J(9]7_ !F=M*#Z@]:4CN[EF;<@ !W!8+9H**B=4RN=PO=L<9<[
M/( =I//'CX)0W..KG=#U4T,G#QM$F/7;G!Q@G<;9'B%,1ZDSZ,Y5B=P5U,]K
MQ'*UW%UA. QGVQ<?N>SS(5N:1L,9>_D-@,XR5:@C=(.LFWXCGA(Y]Q([AV#V
M\SM$\\)KQRVZFNU#4R]7#4-XS\5KP6%WED#/L6<M*>UKVEKP' ]A4UI^ND>]
MU'4.+W,9QQ/<<ES0<$'O(R-^T%9VIIM3)U<)M6ZA_5P2.[<8"N+"N;\-8P=N
MY58C<M$344S)P"26O')P_5XA8%53B%K.)Y>YYQG& !CL'?\ NRI5>)HFS1EC
MQD=XY@]X6L2B81(7B6*.4 2L:\#ED<E>GA?3Y,GK,^[ Y>?<K9( R>79CM\E
MIMEJ86RUK0(8FA@.YX1C [UK&JK>8J[X0AIVS0F,-JJ3&6U#1D<0'(R-!V'-
MPRT;X6STX/ 7O^._<^ [ KJ(F-QIQFJH?@]K*BFXY;#.[AI*HC9I_JW=N <A
MI/=P\QO5K5T&\VY]%#6RT5**RW58(K+9P\0)/.6)OW7:6;<1WR'#?3+E:?@J
MACN%'4FXV"0995M]9U/V%LG>T$8X^8.SAVK?%F_XV6K.HU+&:%=8%Y8,@'8@
M[Y[U>8%OM=[C:LAC5;C:LB-JK(]QM65&U6XVK*B:J2+D3%FPLV5F%JS(FK.9
M2O1-69"U6(6K,B:J2+T+5G0M5B%JS86K*9%V)JR8FJW&U4N%?2VND](K9.",
MN#& #+I'GDQC1NYQQL!NJ3*6345$%%2RU-9,R"GB;Q/D><!H6IUM?4.JJ6Y5
M%(YUPD+FV:V2>J6@C#JB8?:^J=\_%&WQG*,K+Y63:P-%=K:Z6:.FCJK=:&NS
MZ[G.'6U!Y#A '/+6DC&786P6ZC]#DFK+G5,J+G48ZZH=ZH '*-@/Q6#L';S.
MZI$;%VSV_P! IW]9*:BLG>9:FI</6FD/;X-')H[&@!9RQ7UT0^3#I#V%HP/>
ML.::688D=AGW#>7M/:M8JB;1"_5U7'F.!WJ\G/'ZA]*6R(;S8VQP,\NW_OP6
M*UAD>R)FQ<<>0[3[E,,:UC UHPUHP IGCA6O/*J(BA<1$0%AUT#WO8^)O$0"
MUPR!Y%9B(B8VL6N(TLXJ)0'2XQC[D'GCQ\5L;2'-#FG+3N"H-9EOGX7=4\^J
M>7@56T;Y(X2*(BS2(B("(B B*/O%Q%#"UL8#ZJ3:-AY>+CX#]> AV8.HJWB_
MB$+OC#,[@?BM[&^;NWP\U'44 JKC3T^/4!ZY^VW"T\O:<#WJRQI&2YQ>]QXG
MO=S<X\R5-Z8I\4\M6X$&H.& ]C&Y /M.3[0M)^[5A$]=MII$7B8.,$HC.'EC
MN$]QP<+-N]HM;M%[?%!&RZ/XFEH_C/W)[0_NQ]U[\+8QN 0001D$=JF8TB)B
M>S7-)?T@ZO\ S='^P];LM)TE_2#K#\W1_L/6[*J1$1 1$00-A_EV_P#YZ/\
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M\;@Z-KF\B%AW,CJF@_&)R%B,EDCSP/(![%B7"MAI(75%?4,BC'V\CN?@.\^
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M%X[.\=X6U=:TSM$]V+5RDGJFG&V7GP[E:ICU<S0W9KO5(_45XR7.<X\RXE5
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M9:*J+K735-86Q.?&TN+MLGR\>>/%9=]L-)130S4G"*B9^&&2)K^K#1DD$[G
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M128RWC:6A_EX^"GIE'5#.166LE>.)[RPGDUO9]*Q7UTK)W4\</7S,P7$'A:
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MU!4UE6[AIZ>-TKSW #)00VL;]':Z1U)!"^KN=5&[J::-P!X>1>]WVD8[7'V
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MQD]@[?F45T[V>E;+37VE9U4TTG438VXSPDM<?';'N4=HC4<]:[ADVK:8!PE
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M*T^P CYOG5R9SO20R-V"6>L1S:,_O7B0\-PIR[D0Y@\R,_N*4N']8\':1[G
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MMQDC +)WU+?LK?$Y^..WOV*Z_P#!%M^]]'_DM^A4DM5KC8Y\E!1-8T9)="T
M#OY*)S3/HFOAXKZN5U>I]/NHZAK;_:2XQN  JF;[>:W"+6NEY>!L>H;2YS@
M&MJF$YQRQE8MWOUDBXHK3:J.KD&W6F)K8AY'&7>SWK4J@>DSB:I9 Y[3E@9"
MUC6>0 Y^/-3%+7Y[$Y*XN.\MDO.J9)^*"TYBB.QJG##C^0T\ORC[ M;:T-XL
M9)<>)SB<EQ[23VE55"[#V, +I'[,8T9<\^ &Y6]:12')?);)/*J=F>Q3=OTO
M<*H!]2YE#%V!PXY3_P /(>TE3])I:UP>M-"^JD^ZG>7#_#\7YE6V:L=FE?#V
MGOPT+K8\X#VN/<T\1]P5^."IE&8J*N>.]M,_'ZETV"G@IQBG@AA'=&P-_4KW
M$>TGWK*<\^D-8\+7UERM\-0SY2BKF^=,_P"A>Z:CK*MX92T-5(\_=1NC:/-S
M@ %U$./W1]ZH23S)*>?9/V6ONBM/VAEIHRTN$E3(>*:7&.(]@'<T=@]O:I1$
M6,SOET1&HU!V+%GJ8;;!)+52MBHV#B,KSAL8\3W>*RUY>QLC',D:',<,%I&0
M0D#48=0Z'AJ&S1W^S M/$QGIK.!A[PW. 5G_ %\:4_"6S?IC/I4W06VW/#HI
M;?1F1F^>H;ZS>P\EE_ UL^]U'_D-^A"&L_7QI3\);-^F,^E/KXTI^$MF_3&?
M2MF^!K9][J/_ "&_0GP-;/O=1_Y#?H4):S]?&E/PELWZ8SZ4^OC2GX2V;],9
M]*V;X&MGWNH_\AOT)\#6S[W4?^0WZ$&F]']QH[IK;5U5;:N"KIG-I&B6!X>T
MD-?D9"Z K-+24U('"EIX80[F(V!N?<KR B(@(B((&P_R[?\ \]'^P%/*!L/\
MNW_\]'^P%/*UN[3)\7T_01$568A&0BH[B RW<CL0>'\;!Q \0',86-%]GK#,
M!]B:"QI^Z.=S\RRV.#V!PY$+$ICPPR1.V<QQ;M\WS*4,:[DOI9&C=[G-:T#M
M/$,+*K3P-CDSAS)&X]IP?F*P[IZM%)(#A\6'L/<0=OH]JMWJ1U0124X<Z7_>
M'DV-IV.3WXS@*81+Q:QQ,=(0&LFF=*UC=^$$_OY^U7*IQAU#02GE*U\&#Y<6
M?/U<*]#P0E@8W$;1@ =@6!K"H-/:F5$8!='*QT;NQKL\\]G:/:H@]'FUG,M9
M(\<3G5DA<WN((:![@%AZI:^34%A;ASXF3.D  V:X#F?)O$1XK/HZ?T2!L?&7
MR9XI)#S>\\W'S*MW5YFNMN@CP7PAU1++W-QPAOF2?F*1W/1FF5M);ZBJ:PR/
MB8YQ;Y#.%K%V%%;M.QW2\.GN4K6L>6.E+VRSO(X&,9\7XQ&-M@MAN#Y(]/UK
MZ=H?*V-Q#?8H35%HFK-#0.M9;,^A?#5PM<<"9L>#CS(!QXX5J*WWZ(/3M)-0
MV:""J#6U'$^21K3D-+WEW#GMQG&5)8(QQ @'O"LVNLAKZ>EK8@[J)PV1H<,$
M ]A4S6@&FDR,XW"UVPB&H:9WFOSG?*FYRA_?@!H;\RFEK]=(;%=YKBYKG6NM
M#15%HSZ/*-A*1]R1@$]F%/L<U[&O8YKV. <US3D$'D0>Y2JQ=%.ZB\7VCQAL
M=67M'XLC&O\ U\2USIH8VGGI:N1O#'+0SP.?V.(W#?/<J;I'FEUN2S855 V0
M^+HY"T_\KPMKO-JHKS;Y:*Y0-FIW]AYM/8YI["%GOIM$MHCKI-7QHWXH\EWG
MH8H9*/1[I)Z=T+ZJH=*USA@R,P UWEL<97)ND#3LFFM05=N<>)HWC<-@YI&0
M?:"%]":<K::ZV*CJ[:0^F,36^I_NR!@M..1"[,MMUB8]7G8,?3>8GO#U<[M;
MK4V)UTKH*1LSN",S.X>(_P#?;R7AU[M#(S(Z\6P1@9XO2V8Q[UH_2_8+G?I;
M;\%6Z6I]&9(9)&X^V(PT9.YV)]JYOIK3)J[G41W2GD@92$"6%[2QY<>33V@*
ME:5FNYEI;):+=,0F^E76%+J"H@H;4_K*"F<7F8Y'6R8QD ]@'OW6/T;AO#<'
M#''E@]FZVR*AI(HNKCI*=L?+A$8Q^I>K)8(&W*4VR$125  > <, &^<=G-6Z
MXZ>F$1CMU]<RW723W.MCFN^*R0AOZU>U%2T\UNFFF:ULD3?4D[?+Q\EF6ZD9
M14D<##D-W<[O/:5IEWN,E?5.)<1"TX8S.P'?YK&'0Q*(O;>[,Z'/7"MB#<<]
MW8/S979[^US31.CA=-'35#97QL&26C(R!VD;'"YST;6A]SU"+E(T"CMSW,8#
MOUDV-SY-!'M*Z5<[A1P2LCJ*JGA=V=9(&D^65EDGEMBCCE<COM%/.R/,\#G[
M,,\#X@X]P+@!GP5FSAK*NYQ0N)B;4$M'8'$ N ]I^<JW74S:RDFII\\$@P>T
M@]A'B#NL73-2YGIMOKRUM;'(Y[WM&!(UQR'M]^X["J>C3U7;IEAII6N$4G6&
M(2<N$/:1@GN)X?;A9EHDCDM$0A'5EC0Q[3L0X;$$=ARJF)DS712M#XGCA<TC
M8@J/LK2Z:E]8YG@<Z0G[<L?PM=YXV*>AZLBY$-B88WEM8#_%^'=V>1V[N_L6
M=2QMA:R,;M8,9/;X^]8MM:V>:IG8X/+I7,9)S!C;L #W9RLL#!(4)>KB>&!L
MC6\4C' L .,G.,?.5<I&=7%&PD$L:!GO5JK_ )/DYY&.'SSLLANSME(]0[R2
MN\0WW*XTY"M0':1SN?$<^"NLY* 1$0%155%(HH^_7BBL-IJ;E=)A#2P-XG./
M,]P [2>P+*K:N"AHYJJLF9!30L,DDCSAK6CF25P]OIW3-JC)Z^ET5;9/BG+3
M4/'E]L<_\(\2H(96@K36](FK':UU+ Z.V4[^&V4;]VG!R#OS .^>UWDNU*W2
MT\-)314]+$R&")H9'&P8:UHY !7$@$14[$0*AY*JH4%%155%(*BJJ* 7E>CR
M7E *HJE4045%54041$*"BK#\LS\H?K5%6'Y9GY0_6@F41%"XB(@*C@'-(/(J
MJ(+4#CAS'_&9C?O'85BTP/4.(^(7N+<]V2KU0#&6R@]H:X=X)PK=+DT?@"0#
MW@$X/N4H8M6<STL;MF&0N=X\() _[[E8H(C+&*V0<<\S \N^X:=PT=P"\W$>
MD7"DI'9$?K2O(."[8@-\N_W=JS*R5M#;II9 &LC87''8T#ECV81"WQEIXFG!
M"C+^TMU#8IHQQ/>]\;F]S>!QXO#"D*5[9A$\M(:]@?PGF,C."HNZ5)&J:-H
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M8ULP+=3-:]DG!$UA<QP<,@ '<+)7.[1:QJW^<&C?_$G?]%ZV=:QJW^<&C?\
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MR!QSEL3<]A<\ 'V<TM,TTM##-5$"20F0;8X6DY:/,#"QM:N?)34D#0]PGF#
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MA=^T5F4A(IP6[ DD>62HS28$MEH87;M#7/([_6.%*U;RQOV, R.<&L:>1/\
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M#KR2PY:ZE#O^?;]96-J"NEHA1U@:V402G+'\G98X#]ZQW3R"DIJGAJ*>2-G
M9W0YC+>7K?BG .?G6%<O2*E[352-<V/)8QC.%H)V).YR<>Y=-:=5E=\-CTW'
MP6VF>\CY,2;<AQ>MPCP .!Y+4:"_LL^J+K\(ATM.^9PZR-N2PC<;=V#[U;9=
M+E;*1\--6-BIV \/61AQC'@3V>><*U8M-/N0DJ*U\\$'%ZH<W[),3N7Y=V?K
M5XQQ3<Y.R-^RSK_6++E3QTEL?4,HQGK78+'3$[!@'/'Z\KUH2\"GM,5NN0ZE
MT3N"G//B:3D XY$9PH35]D-DO-M8)3-!.XOB<1@[;.!\L@Y\5(Z3;$Z^0B8
MX:XLS]WV?O46Z=1%.S#+.YY;M,,96#,>:D)AS4;4[ JE4XN5(*]S9&Q2GB:?
M5!/,*,OS)*":2]4!'7QL J(3\6HC'?W.'8?#"]L:9JIC1R!XCY!9-<UM13S0
MR?%D:6GVC"OIZ$8NNNDE&]LD;)&'+'M#FGP(R%Z4/I.K-39XX)3_ !JCQ33-
M[>)HP#Y$8(4PLWG:TD[.PXDD[#L%C:VIF5>D;O%(-A3ND![G-]8'WA7K=5MC
M:(9-AG9WTJQKADS]'WAM-\IZ.[_"-W?-E8SOJ;UUTH3H_N3WV"CDESP@&-V_
M, [%;JYK7MPX!S3WC(7+>CVX1NHGT)< YGV2,?=-//'E^]=/HP131!W/A5\L
M:G:F&=QIK.MK9!5VV>)K0)&QF5F/M7#?;SY+DE*\MD#@,D D#O..2[)6CKY*
MALA.'\33CF =ERK4=JEL4_K'CIW F*3&,X[#XK;'VU+')S;<(ND<7-ZQSN)\
MGK.=WE2<-54-I'4PJ:@4G,P"0\!_X<X6%24[FPQM(W 6:R(AKB!R&5ZD5KTQ
M$PVB'1M-Z2M\M@AJJXRRSU$0EXFR%K6 C(#0.[;?O4!%0-CU VURS.,0J1$Z
M4'#BTMXAY$[-6_6&,0:3M#(]V"GC)WSS&?UE:+*P46HIG53G21T]:))7=I:<
M.!]G$/8%YF.]IFW/HO,<-GN=IH8K?+)3TT--)"WC8^%H:=OM3CF#RW[U+4D$
M-!>GQ1L,3:FG8X-<[/$YI(//M ('DE[A:VVU7"TN:87G;??!P?WJ_<XXJJQL
M?*1*! V1DC3]M@>LTCEGO'>L8F9X6[,>OZJ"[41ZT12GB:X\? >KP3^UCWJ1
M=$*6*6H@EF9)(1LUP(D<XX!.0=^6_<H6RT4'I5P<Z(22ME;'Q2>N0W@!QDY[
M25(0O<864,.S):IQ83R8R,@G'AG8>:K/L?-GQV^6GA%0VH=-4,)<\.  DVW&
M>8\%><Z6>G8XQ<$+BTG+LEPYX&.2NUKG_!=48CAY:0WS*NT#O2*>&0 -B:,-
M9XC;?YU1+-!R 1R5H'@D<T#B!WV[%;+S&!"W9Q)#2>P=ZO1-X0=R2>9/:H2]
MA$10ESCIADEBGTY)3YZQL\Y! R1]A=D@=I RH2UU4@JXZ>:=]33U+7!CY'<3
M@0,_&[6D ^U;/TD" WK28J9'11^E3>NTX(/4NQCO\E%V^UVN.MZQ\CX(G>JZ
M0P.C&#S /$0S/> ,K6EHB)89*3-HF);'176*GL]!U[G2U+X01&P9<[LR>X'O
M*M.OU03]CHHV?G)23\P6E7E\PN,[9W5$5/G#6P\36EP)!:7-WV  #>7O6=81
M4"GEZ_KA#Q_81/GC QOG.^,\LJ8QQK<HG+.]0VVCOC9)FQ5<'4<1X6R!_$PG
MN.P(]JF5H]4.*G>P N<_#&M',N/(#QRMW&<#B.78W/>52T::8[3:.5416:JI
MAI(NLJ96QLS@%QYGN'>?!5:+R*"DOYX_L%$]T0YF1X8X^3=_G(4;4W)]S?(^
M.:1M&'EC(VG@.1L>(C<G.=N05HK,J3>(AM+JJG8[A?4P-=]RZ1H/NRE34P4S
M ZIFCB:>1>[&?+O6G"&( CJH\=W"%9IY"^KGC>2[T9K61\1SPL.2,?J]@4]"
MOF_)MS+Q;G' K(A^5EH]Y&%FM>QT?6->TQXSQ!P(QWY6G$DC!Y*VR9Q@EH <
M0=>9','(M#6^KY<1S[$FA7+ONV\5U&3@5E*3W"9OTJ^PAPRPAP[P<K2NK81C
MJV?X0C8FM/V(.C/_ -IQ9^HA3Y:/-^3;YZ.EJ'<512P2N[WQAQ^<*HIH6TTD
M$,<<,<C2TB-H:-P1V*!MU^X:-K)&RU<S21Q @>KG;B/?CYL%9T-^I'G$S9J?
M'-TK?5'_ ! D>_"IJ6G5#4ZRVMJ.%DCWP5=-F(O:-_(@\VG /ZBKU!2MHJ<Q
MM>Z0EQ>][N;G'_O"V:YVYM>UM5121B8MV=G+)6]@)'S'L4*ZGJF/+7455Q#[
MEG$/81LM:WW'+"V.8GA+Z8F)IYJ4G(@(X/!CN0]F#[,*NHJ1TD3*J%I=)#D/
M:T9+HSSV[2.8]O>KUCH7T<,CY^'KYB"X YX0.3<]O;[U)++?.X;Q&ZZEH[YX
M8XC(^:-L8&>(N&%C"2HK!]A#J:G/^]>W[(\?BM/Q?,^Y36HJ>%E= QE/"R-S
M#(2V,#C>#VGMQSQXY[%A^:VB=N>T=,Z1]1+%::<=3$Z665^ .+UI'8R2YQ[A
MVJQ0U\E34BFKF1,>X<<,D)(W',#.X<!OD=F5EW.B-9"P,>(YHG\;'$9'<0?
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MVH,TS*E\4L=.9&@%S,  <6'$]Q)4)=]:V"AME1'<;O115;'!CX(Y0\O <"<
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M-2(C;+#>=Z7+I#U<Y>!AC]_;VK$;OZI +3L0>1"V)[&O:6O:'-/85'5U#''
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M.*3K7,:X\PT'  [E?A)@J.>8IG<ON7?0<%5%PMQ.V$D%C07@?2LIIPU8M/\
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M*VS:ZO5.*NI:YE0XL>)7 EAW8<_DD*%LT$-5=J."IDZJ&25K7OY<(RNZ=/\
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MO,\I6FA$$+6#?',]Y49K&K90Z5NT[S_\L]C1WN<, >\J86L])-+Z5HNXG.#
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MT8V!:[(\=UZ6N6::.*Z2-IRSJ'Q_9N 9#7# 9C':<D8'=X+9)(NI.*N,/J2
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M12RME@D&6O:=BKJX'L)VWN+Z2,NY@86M])]P91:2J("X==7'T:-F=R#\8^0
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MN R5=^O;2_X06W_."V^>"&=H;/%'(!N ]H/ZU9^#J+^QTW^4WZ$&K?7MI?\
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MKW'2P1',<,;3WAHRKR)M&H$1$2(B("(B B(@(B("(B B(@(B((&P_P NW_\
M/1_L!3R@;#_+M_\ ST?[ 4\K6[M,GQ?3]!$159BH=R%5>7?&:@\R%> X!KN]
M7)!ME8-5(\2,AB<ULD@)#G;X YG';S"E# KHQ44]9-*\CJ,MB#?M2 #Q>?ZE
M<IXVPU%5%'\F"UX;GD7#)]G_ *K,IX&,8(MRW?)=OQ$\\J&>R2@K@P.) X&
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MMCN!RMZLUTH[S;8*^VS-FI9AEKQMY@CL([E6:S"];1;LS41%581$0$1$!$1
M1$0$1$!$1 7,OJ@-(W;66D**@L444E3%7Q3N$C^ <#0[)S[0NFH@YKTY:3NN
MK-(4%!98XY*F&M@F<'OX1PM.YRL;I,T;>+[JKH]KK=%$^GL]8):LNDP6M]3<
M#M^*5U-$'S?TO:4^&^G*UV:TU3HH[]2LDO,$8V=%"_(<[NSP@>P+H6O=&W*Z
M=(O1_<[5!"+99I)#4>N&\#2T!H [>2WV*R6V*^3WB.CB;=)HA#)4X]=S!R;G
MNV4B@Y7TH:2OTFM=/ZRTG!35M;;&OAGHIY.KZZ-WW+L$ \_>H2T:$U/=KGK7
M5&H*>EH;G>;>:"DM\<W&(V\(P7/P-\M7;T0?/9Z-=5VFP='EVL]/2S7_ $W&
MZ.HHI)<-E8[F&NQC.Y]_@I_16F=8S],\^LM44-#14M1:S3,@IY^L,)XF8:3@
M9/JDD\MUV5$'+^EO1][N.HM-:KTJVFJ+I9)'?Q2H?P-FC<"" [!P=_G5BEL6
MN-9V[4\&LY*2U6NXTAIJ.VP$2NB>1\H]^ 3OC;MWY+JZ(/FRP=%E[936RQUN
MB--9I7M;4WB>=TK9XP>;8L#UL=ZVZHT!?':WZ1+C'#!Z'>+:RFHSUF"YX8T8
M(QL-EV5$'$G:,U'1=&&E+/-IVRWYE# 65UOJW\+\YV,4F#@]_)2G0;HR^:9K
M;_5W*%MLM=>]CJ.SMJG5 IL9XCQ'EG/(+K*("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B\/EC8</D8T^)PO/I$/]='_B"&G+^EK1=^KM5:>UCHUU*^\V@/
MC?35+N%L\3LY:#@X.[A[?!1=ITIK#5_25:=4:UHZ*TT%G832T4$W6O?(>TG
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M^D/^E>#=+C]\J[](?]*QW<E;*F*Q[*3$,@W6Y??*N_2'_2O!NMR^^5=^D/\
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M>ZC6AK0UH :-@!V*J(J-1$1 1$0$1$&NW_1UIO59Z9.R>GKN'@])I9G1/([
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M40\E1 *HA1!14551!1"BH4!5A^69^4/UJBK#\LS\H?K03*(BA<1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MC?OJ_P#1I?\ 2OEX<U["?RO#[S_O]E9\9?VA]/?PKZ.^^C_T:3_2J_PK:/\
MOH_]&D_TKYB"]M3^5X?>?]_LI/CLGM'^_P!WTU_"IH_[Z/\ T:3_ $JHZ4](
M'_ZH_P#1I/\ 2OF<+T$_E>'WG_?[*_;\GM'^_P!WTM_"EI'[Z/\ T:3Z$_A1
MTC]]'_HTGT+YM"JU/Y7A]Y_+_"L_Q#+[1_O]WTE_"AI+[YO_ $:3Z$_A.TE]
M\W_HTGT+YP"]!/Y7A]Y_+_"D_P 2R^T?[_=]&_PFZ3^^;_T>3Z$'29I3[YO_
M $>3Z%\Z!>@G\KP^\_E_A3^9YO:/S_R^BOX2M*'_ .I/_1Y/H0=).E?OD_\
M1Y/H7SR%4*?Y7A]Y_+_"L_Q7-[1^?^7T+_"1I8__ %)_Z/)]"K_"-I8__4G_
M */)]"^? O83^58?>?R_PI/\7S>T?G_E] ?PBZ7^^3OT>3Z%7^$/3!_^HO\
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MJ\1QR[EHEZFM-3=[%)9*^[75GI3!+659>6<60>!H( !QN<!;U3@_P[5&QQZ
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M;3-14FH(XK>*&AMUSH(X6LJ*&H #B\#&6N((^;L4+I#1M<+S=:ZMHJ>T4-9
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M-?45)@&(C(_)9Y'LY!9U9JN_U]":*LO%;-2D8,3Y-B/'M*PGP=IB.8[:GO\
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MDN4%3*R*<CUFC@ P/\1]ZZXYH<TM/(C"A])Z<HM,6Q]#;G3.A=*Z4F5W$<D
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M?OM.FF]'%NK+?/JHUM/)"*F\SSPEX^/&0W#AX'"W)$6=[=<]4IB-"(BJ"(B
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MTM.=_18S_P"=V 3W<AXSZO/$=,+VF*QT1_<1$5&8B(@(B("(B B(@(B("(B
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,-+PVY(B(D1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g762905g73h34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g73h34.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[2I.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ &0     0 ! 9
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   %70  "3@          0                         !
M  DX   %70                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   %70    !29VAT;&]N9P  "3@    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !5T     4F=H
M=&QO;F<   DX     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M      0    !.$))300,     " !     0   *    !=   !X   KF   !_E
M !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!8
M65H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M  $  /;6  $     TRU(4" @
M                           18W!R=    5     S9&5S8P   80   !L
M=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP
M   48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9
M TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C
M:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,
M=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O
M;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M   2<U)'0B!)14,V,3DV-BTR+C$
M                                 %A96B        #S40 !     1;,
M6%E:(                     !865H@        ;Z(  #CU   #D%A96B
M      !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@
M                9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                 &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O
M;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<
MG@    %865H@      !,"58 4    %<?YVUE87,          0
M              */     G-I9R      0U)4(&-U<G8        $      4
M"@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W
M 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4
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M(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/
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MM@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7
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M^W?\!_R8_2G]NOY+_MS_;?___^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" != * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M=Q\1^5$<!X_A_M4(;N$DQ([?^9)R'__9 #A"24T$(0      50    $!
M#P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      $N
M34T *@    @ !P$2  ,    !  $   $:  4    !    8@$;  4    !
M:@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0    !
M    I    -    &0     0   9     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C R-#HP.3HQ," P,CHQ,CHS,P   Z !  ,    !__\  * "
M  0    !   ).* #  0    !   %70         & 0,  P    $ !@   1H
M!0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !     $   $N
M @( !     $              $@    !    2     $X0DE- _T       @
M         /_A 39%>&EF  !-30 J    "  ' 1(  P    $  0   1H !0
M  $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(
M @   !0   "0AVD !     $   "D    T    9     !   !D     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T.C Y.C$P(# R.C$R.C,S
M   #H $  P    '__P  H ( !     $   DXH , !     $   5=
M  8! P #     0 &   !&@ %     0   1X!&P %     0   28!*  #
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M*"@H*"@H*/_  !$(! 8&Z@,!(@ "$0$#$0'_Q  =  $  @(# 0$
M     04&!P(#! @)_\0 9A   0,# 00$!P@-" <& P0+ 0 " P0%$08'$B$Q
M$T%18106(G&!D=$5,D)259.ATA<C-#945G)TDI2QLL$()#-38H*BLS=#5W-U
ME>$8-3A$8_ E9<(G161V@\/Q)J.T*$:$Q-/_Q  ; 0$! 0$! 0$!
M     0(#! 4&!__$ #81 0 " 0($ P<"!P$! 0 #   ! A$#$@0A,5$306$4
M(C)2<9'P@:$%%3-"L<'1X?$C-%."_]H # ,!  (1 Q$ /P#ZI1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$1!$1 RF5"*B<J,HH03O)O*$03O*-[N1<4'+>[E&_W*%"#EO\
M<F_W+B@5PCEO]R;_ '+BH*8,N?2=RCI.Y<$*8,N?2=R=(>Q=:)A79TG<G2'L
M76B83+GTO<G2GL76BN(,NSI>[Z4Z8]BZBB8@R[.F/8G3'XJZD3$&7;TQ^*HZ
M<_%^E=74H3$&7=TY^+]*=.?B_2NE0F(,N_P@_%'K4>$'XH]:Z5"N(,N_P@_%
M'K3PD_%'K70H3$&7H\)/Q1ZU'A)^*/6NA0F(3,O1X4?BCUJ/"C\4>M><HFV#
M,O1X4?B#UIX4?B#UKSJ$VP9EZ/"S\0>M/"S\0>M>9%=L&9>GPL_$'K3PP_$'
MK7E1-L&9>GPQWQ!ZU'ACOB#UKRHFV#,O5X:[X@]:>''X@]:\:*[8,R]?AQ^(
M/6GAQ_JQZUXRB;8,R]GASOZL>M1X>[^K'K7C4=2;(,R]GN@[^K'K3W0=_5CU
MKQ*%=D)F7M]T7?U8]:>Z+OZL>M>%0FR#=+W^Z+OZL>M/=)W]6/6O B;(-TK.
M*X1NX/!8>WF%[&N#@"T@@]86/KNI:EU._AQ8>;5+:?98MW7:*&.#V!S3EI&0
MI7%L1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1!"E$1!$1!"(BH*%*A$$1$(0BE<444*5':J@$1
M$!0I4((12H00B(BB(BJ(1 B""B%$$(B(@>2XJ3R16%0H4J$!0I4*H*%*A 4*
M5" 5"%%04*5"(A$1!"(BHXHB(.)1"B""B%%1"CJ4J.I$0H4J%8$*%*A$$1$$
M*%*@JBRM,F6OC/5Q"L%46L_SKT%6ZX7C$NE>C7>TW65PTM=[2VD$;Z61I?/&
MYN2\ XP#U<%GEMK8+C04]91R"2GG8)&.'6"%K;:;30UFO=*TU5&V2"7>8]CN
M1!*G9_5SZ4U-5Z0NDA=!(XS6^5_PFG/#TX]8/:L-+O0.HKA>K[J:EKG1NAH:
MGHX QFZ0W>>.)Z_>A5FH]7WJX:GET]HV")T\ _G%5,,M8>O'5@9 SV]2Z]D_
MWTZV_/?_ *I%T[%P)+GJ>H=QE-46Y//&241U7&^:XT?T59?_  .YVLN#970M
MW3'DX[!Q[.86:Z@OQCT+67NTO:3X(:B!SQD<LC(7/:!$R;1-\9(T.;X)([![
M0TD?2%@]FD=)L J2\Y+:2=H\P>Y%38J[:)>[33W&AJ[5X/."6=)'AW D<1CN
M5AIO65YIM41:>UA1PPU4XS3SP^]?SY\>O!Y=?4JC0FT.QV32E!;ZY]2*B!I#
MPR%SAQ<3S]*X4M9/K[:-:KE;Z.:&TVKB9Y&XWCDGZ2!PZN.546^T+6]=IC5M
MK@:8S;'L#ZEI9EQ;O8)![AQ6QXI&2QMDC<',< YKAR(*U/M$MT-VVF6:@J1F
M*HI7QD]F<X([P>*X:9UE)IS1%VH+L1[JV5W01L<>,H<?(/T^H!15E>==U8VE
M6^QVQ\7@39FP5)<S)<\YR >K'#TK9:T%0V66SZCT(^MR;A7U#JNI<[WV\X@@
M'S9]9*VEM0O?N'HROG:XMFF;X/$1S#G \1YADH,+M6TBY5.L8^E$0TY/5NI&
M.Z/!!#>!WL\\X/F<MOK4=XT:ZFV.04\;"+C1XKL@<=\G+O\ "?H"V%HN\-ON
MF+?< 1TDD0Z4#J>!AP]>4&/[/=2W&]Z@U-25[HG0T-1T< 8S=(;O.&">OWH6
M=+5>R'[[M;?G?_UR+:B M4NO^L;MJ^^6RPU% R.AE( GC^#G X\<E;66E[+J
M6VZ:VD:LGN\SXHYI2QF[&79(<2>2"TN=_P!=Z6B%=>Z:WUUN:X"4P#!8"<?M
M[NM9!K;54U)H!E]L4C Z;HG1ND9O8:XCF.U8QKG:#;+]I^HM%@BJ:ZLK,1@-
MA<-T9!)XCCR^E=VN+;-:=C%)056.GA$#9,<@[>&1Z"JC9-DJ9*RST-3-CI9H
M&2.P,#):"5BFIM1W"W[0=/6BF=$**L:3,',RX\7#@>KD%CEIVF5-':Z.F;I6
MZ2B&%D8D:#AV !D>3UJJ=J*34FT_3-3+;*FW&)W1B.HYN]\<C@$5FE_U/<=/
M:ZH*:Y&(V"X#HXY S#HY.7$^<CT'N6:5U7!0T4]752".GA89'O/(- R2J37N
MGF:DTW54> *EHZ2G?UMD'+T'D>XK4[[_ ';5EHM&CVMDBKA*8JV7K#&' SYA
MS[VCM4&=:,U9<;A9[QJ*]!D-GB+O!HFQX=NMYG.>/9Y\JIM=TU]JN!UQM,E!
M;*!Q/0LD;O%X[<X/KX+/*S3U)+I66PP#H:5T'0M+?@]_KXK75FO.IM 4@MMX
MLLE?;(21%44ISNMSZ>'<<%!>Z/U?=1J6336K8(HKB&;T,T7!LH_ZCECL/)>J
MKU)<8MJ]'86/B]SI:4R.:6>5O8><[W]T+U:7U3IS5-<V6D;$+K$SWDT8$K1U
MX)YCS%8Y</\ 3Y;?S$_N2(+K:%K&HL=116JRTS:N\UO]&QW$,&< D=>3G'F.
M5253MI=LHW7&6>WUC6#??2LC!<!S(X 9]!7&3[;M\BZ3CT='Y.>KR7>TK:B#
M']"ZF@U78F5\+.BE:XQS19SN/'\,$$>=4^S'4EQU!)?FW)T3A25?1Q;C-W#>
M/ ]O)4>Q$=%7:H@9PC;5Y '(<2/X+GL/_I]5?GW\7(-HK7>KM8W:34OBWI&G
MCEN#6AT\\@RV+AGS< 1DGMPMB+5FR\"37VKIW\9-_=R>>-X^P(.%SNNOM)PM
MN%V=0W.WM(Z81-P6#..8 QY^*V#07ZBK-.1WMLF[1.@,[G'X  X@]XP1Z%.J
MHVRZ8N['@%KJ24$'\@K56GYW_8$KAO'@Z9@\QD/M06=OO^M=8NEJM.MI+9:V
MN+8Y)VY<_'H/'S#"[[?K"_Z>U!2VG6T4#H:MP9#6PC ))P.XC)&> (RLCV<N
M92;.[7(&$M93F0M8,D\23@=JQJY;0]/7$TWNM8*V0,D#HC4TPPQW:,]:HMKQ
MJ>XV'7]+1W-T1L5P:&4[PS#HY. .3YS]([%F5RK8+;03UE6\1T\#"][CU *B
MU[IZ/5.EY:9@'A#1TU,3PP\ X'F.<>E:N-_NFMZ"S:4#98ZDO(KY2.;6$XSZ
M "?[0"@V+LUO-XU#2UUSN@CCH99=VCA:S#FM&<DGKY@>@K,EY[?1P6^AIZ.D
M8(X(&"-C1U # 7H0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$01$00B(J"A2H1!$1"$*%*A%%"Y+CUJP
M@B(@=2A2H00L1V@ZKGT^VAH[93MJ;K7OZ.!CO>CB!D^DC"RY8/M)TU<+K+;+
MK8WM]T[:\O9&XXZ09!&">' CTY7?AXI.I'B='+6W12=G555/V2;?2NKY*FW5
M08-]](Q@)QS(Y#/H*RK26IXM2:9?<Z=@CFC#VRQ\PR1HSCO'(^E8S2;3):"1
MM/JNR5=OF'!TS&$L)[0/82LOMLUJJ-/U%1813>!RL>[,#0T%VZ<Y';YUWUHM
M%??I$<^4QT<M*8S[EL^D]6O=,WK7^H[::ZW5%MZ /,?VQ@:<C&>KO63Z>9KD
M76$WR:VNM_'I!$/*Y<,<%@>S?6<E@TZ:-ECN%>#,Z3I:<9;Q X<N?!;!TKK2
M2_70T;[#<:$=&Z3IIV^3PQPY#M7;B:7K-HBD;?T<M"U;1&;SG]51J[4&HF:Z
MI[#IZ6EC,M.)&],P$9PXG)\S5U5M9M%M--)6U#+96P0@ODBC''=',]1Y=B\&
MK+K2V3;'0W"X/<REBHP'N#2XC+7@<!WE6]WVH6$VVH9;G3U=6]CF1Q"%S<N(
MP,D]7%79:(I%-.)B8C/+_9NB9MNO,3$]WL%_O&I=)4=PTB*>&L=+NU$=1@A@
M .0/3@^98M<M0:]MUXH;7536\5=;_0AL;2T\<<3U+*MDMHJ;5I1GAT;HIZF0
MS=&X8+6GEGLR...]5.N_]*&D/-_]16=.:1JVTXK$Q&5O%ITXO,S$\EWI0:S]
MU?\ ]Y'T!H-P\(<;V]U<EC-OOVM;[=KQ#99[>V&BJ718EC P-YP;U'/!JVJW
MWP\ZTGI34[].WW4[66FMN/3UKB33#.YA[^? \\K.A_\ KOM%8S&.6.75K5CP
M]M9M..;+J"/:'X;!X946DTV^.E  SNYXXX*=I.H;O:+G8J*Q201R7"1\>96!
MPWLM#?,/*7;9->R72[4M"=.72E$[MWII&^2S@3D\.2I-K]3'1:DT?53YZ&"=
MTK\#)W6O83@>A73I:=:*WI$<IY?I*7M$:4S2T^3VRG:33L=+O6JJW./1,:,O
M[AP'[5?Z U0S5-MDE?#X/5P2=%/$#P!Y@CN_B"J>IVK:?BC<^ 5D\HXMCZ$M
MWCV9*X['[56TM-<;E<H74\EPGZ1D3A@AO'B1S'$GU*:E)\*;:E8K/+'EE=.T
M>)$4MF//S>79]KRHN]]K+5>'1=*Y[C2N8W=S@G+#Z!D>E9#M%O-78=*5-?;G
M,;4L>QK2]N\!DG/!:JL-@FN>G[U<[;EMUM=P,\+F^^<!Q+?1C(_ZK)]8W^+4
M>R.2M9AL_2QLGCZV2 G/H/,>==M30IXU9K'+,1,?G=RT]:WA3%IYXS#9%IJ'
MU5KHZB7'22PL>[' 9(!*P+:/K.YV>\1T-B;&XP0>$U1<P/X9X#N '[5FUAD9
M%IR@DE<&QLI6.<3U ,!*P;9Q1>,<FIK[7LRRZ/?2Q-=QW8R#GZ"T>A>;1K6L
MVU+QF(_V[ZLVM%:5GG+/K+7QW2T45?#C<J8FR<.HD<1Z#D+U]:P'9'4R4U-=
M=/5)(GM50X-!YECG'CYL_M6?=:XZVGX=YJZZ5]](EKZZZEOUWU)6672,=/$*
M([E35SC(:[)'#GPR".1*\M9J+56D)X)=4BEK[5*\1NGIV@.C/H XXSP(XX2X
M6R_Z3U/<KS8:1MRM]>\RU$ ]^TY)P!SX$G!&>:L*#7MAO#A07RC?0RN(!@KH
M]Z,N\Y'#SD!>W;&(V4BU<<^__7ES.9W6F+?LL=4NU5)54S]*R4/@3H07F;&2
MXD\1GJQA8=2W_7=3?JFSQ2V_PVG;O2 QM#<=Q]*VR &@!H  & !RPM<V#_3!
M?O\ <_57/A[Q-;1-8Y1V:U:S%HQ:><]UW;:G4M%I^\U6H74;JF"%TM-T(!'!
MI)WL=^%C>G[EKV^VJ*X455:Q!(2!TC UV0<'AA9WJC[V+Q^9R_N%:ZV?ZXLM
MDTK2T%?)4"HC<]S@R$N'%Q(XK6EF]+7K2)G,>7HE\5O%;6F(QW7-JU7>K;J&
MELVKZ6!CJLAL%5![UQ)P,]6,\.HC*S[@,[Q  YD]2U555[]?:OLIM5+,RV6R
M7I9*F1N,^4'$?X0 .?%99M-N_N3I&M>PXFJOYM'CGEP.2/0"LZNENM6L1BT]
M8;TM3%;3,YB.DL7L&O[A7:LA94MC;8ZJ=]/"[H\%I \GRNOCNY_*69:L\8>A
MIO%AU*V3>=T_A&.6!NXSZ5B6I=*NHMEU)%"W=KK:6U9+1Q+B?+]0=_A6=:>N
M;;Q8Z*X-QF>)KW@?!?\ "'KRKK;(QJ:<1B.7_/NFENYTO/.>;7-3?M<T]^I[
M/++;_#9V[[ (VEN./,^A9CI%NJ373#4SJ)U+T?VL08WM_([.K&50WS_3#9/]
MP/V.6PXO?M4U[Q%*XK$9C/0T:S-IS:>4]VK-/WW6VHHZN:V3VT0P3&(B6,-(
M//AP[%?VEFN1<J8W2>UNH=\=,(P-XLZ\<.:PK9_JE]AH[E VSUUP$M49-^G'
M!O5@\#Q6<V#6;[O=(J(V"Y4@D!/33#R6X'7P"[:]+5FT5I&/T<M&U;1&ZTY_
M5.M=45%HJ:2UV>E%7>:P;T<;N+6MR1D]IX'U953.-H5#3.K7U-NK P;[Z5C!
MG Y@<!GT%1%]LVY3%_'H:+R,]7VL<O65D>I=44^GYZ>*HHZVH=,PO::>/>#<
M''$]JYQ&S;2E8F9C/-TSNW6M:8B)P\-KU'4ZDTE5U=B:R"[P-PZ%XWP'CC@9
MY[P!QE>O0^H&ZCL,=4[=;5QN,50P#&Z\=8'81Q]:Z=$WFSW9]Q-DM[J&2-[7
M5 ,887N.<$XZ^!]:QN]R'0VM#=88G.LUS81/$P<&R#C@=^0#YB5/#BTVTXC$
M]8_Y_P 7?-8K>9S'G_U>:OU!6TMWMEDL/1NN=6\.>Y[=X11]I'H)\P65@$
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MD;IR_P!0R.2.@GE>:=K^L!A!(^@9[EE$>SW2S)ND%HAWLYP7N(]65DT<$4<
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M/41U#8(GU#CX?3.Z&I:>!WAR=Z1CTY64JOM]HH+?65-50TD<%14G,KV9&_\
MP7/Q8G3FEOT_VWX>+[Z_JP78G]Q:@_/S^PK%-J-GGTY55YHABSW@A[F8X1RM
M.]CNZR.XGL6YK7::&U-G;;:6.G;-(99 S/E./6INEMH[M1NI;E31U%.X@EC^
M61R*]%>+BNO.ICE/DXSPV=**9YPP;7-V-MV8T<,)/A-=#%31AO/!:"X^H8]*
M\UKT-J>AH(8*75+J2-K0>ACC.&$\2.?%9[5V6VUG@?A5%%+X&08 [.(\=GJ"
M]YYE8CB=E-M(\YF<X:G0W6S9J*"CN&C-H-LJ[M</#FW4&GEJ"W=SQ:./F\E;
M= P[#NWBO#=;307>*..YTL=2R)XD8'Y\EW:,+VGB>*QK:OBXF>OG_IK2T_#S
M$=&"6376Y?;C:=4]!;JF&4B"3BUCVY/,GT$'KRJO:S=]/U]BZ&&:EKKF][1"
M8"'O;VY(ZL<,=:SR]6&UWIK1=*&&I+>#7.!#AZ1Q7EM.DK#::@3V^V01S#D\
MY>1YLDX76FKHUM&I$3$QY1T<[:>I-9I,Q,?N]>G8:BGL-OAK234L@8V3//..
MM838/],%^_W/U5L=>&&U4,-RFN$5+&VMF;NR3#.\X+E35BN_/G#I;3SMQY.C
M5/WL7C\SE_<*QS9/34\FA:)TM/!(XOE!+XP2?*/:%F<\4<\,D,S ^*1I8]IY
M.!X$+IMM!2VRC926^!D%,S.[&W.!DY/-2NIC3FGGG)-,WBWHU]8''1FNI[)*
MXMM-U=TM(7'R8W9.&^?X/Z*Z=>Q5&J-<4-@H)A":&,SR2$9#''!R1V@;H]*V
M%<K507,TYN%+'4&G?OQ%^<L=VC'F'J2GM=#37&IKX*6-E;4C$TPSO/'?Z@N\
M<1$6\3'O8_?O]G.="9KLS[N?V[,*ETAJF:-\<NL97QO!:YKHW$$'TKCLHEEM
M\MZTW6.!FH)RZ,_&:>!QW< ?[RV$O&RUT++F^XLI8VU[V;CIQG>+>SL6?:)M
M2:7\^T1U7P(K:+58/?/],-D_W _8Y;$B]^U>*6V4,MRBN$M+&ZMB;NQS'.\T
M=B]@)!R.:YZEXO%8CRC#IITFLVF?.6K=DU[MUKMMVBN%PIZ21]87M;+)NEPQ
MC(6=P:GLU5-'!#>:.661P:QC9LEQ/(#O7E?HS3;GN<ZS4Q<XDDY=S]:YTNDK
M!25,5136FFCGB<'L>-[+7#D>)7;5OHZEIOSS/T<M.FKIUBO+'ZL3U7-XM;2Z
M"_U3'FVU4/03/:,[CMTMQY^#3ZUE57K*Q45"ZK]U:65K1O".&0.>_N [5<5E
M-!64[X*R&.>%_OF2-R"J*#1.FX)Q-':(-\'(WG.< ?,3A3Q-.]8\2)S'+EV7
M9>DSLQB>:DV3TL[J>\7BHC,;;I4=)$#UM!<2?-EWT+OVP@'0\Q(!(J(L=W-9
MHT!K0&@!H&  , !>6Y4%)<Z1U+<*=E13N(<8WYP2.1X*1K9UO%F/-?"QI>'#
MA90&V.V!H :*6+  X#R O4HC8V.-D<8#6,:&M:.0 X *5QF<SEUB,1@1$4$*
M%*@JCU6O[J'F*N%3VO[J'F*N%QU.KI7H(B+FT(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(B"(B
M"$1%04*5"(*%*(0+BI4(HH4J.U6$$1$!1UJ5""$*(@A$1%$1%41U(B!!!1"B
M"$1$0/)<5RZEQ5@%"E0BBA2H504*5" H4J$$%$**@H4J$1"(B"$1%1Q1$0<2
MB(@@HA140H4J.I!"A2H5A$*%*A$$1$$*%*A4>JU_=0\Q5PJBU_=0\Q5NN.IU
M=*]!$1<VA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$01$00B(J"A2H1!0I1"$(BA%%"E0J@B!$
M!0I4((0HB"$1$41$51"(B""B%$!0B(@>2XKD>2XJP0*%*A%%"E0J@%"E0@*%
M*A *XN<UC'.>0UK0223@ #K7(JHU:,Z2OH/+P"?_ "W+58S,0DSB,O=15M+7
M1&6AJ8:B('=+XGAP![."[)YHZ>%\L\C(HF#+GO. T=I*^9M@.IS8]4"W53BR
MW73[7O'@UDP&6N]/O?2%F'\HS4[F4U/IJB)<^5OA%8&\<,!RQI]()/F"]5N$
MM&K&GW<8U8FFYN.*MI9:,U<53"^E ),S7@L ',YY<%X_&&S8_P"]Z#Y]OM6J
M]& ?]G"YC QT%7^^50[(-FEBU;I26XW4U@J&U3X0(9 UNZ&M(X8/'RBG@4B+
M3:>DX7?/*(CJ^@:>>&IB$M-+'-$>3XW!P]87&KJ8*.G=/5SQ00-]])*X-:/2
M5H#2E/+H3;5%8+962SVVJD$4D9/-KFDC> X;S3UKMUPVHU[MC&FIJJ2*UT;]
MP-:>0# Z1P'+>)R ?,K[-[W7EC.?0\7ETY]&Y[=J>PW*HZ"WWF@J9SRCCF!<
M?0K2>6.")\L\C(XF#+WO. T=I*U!J[8E;G6=TFE#4QW2+!8R>8%DO'B,X&Z>
MO/<K2[4]]I=AMZI=5AIN,-,Z/>Z02%\8<W=+B.9YCT+$Z6G.-ENLX]5BUHSN
MAG7N_9OE:@_6&^U>ZGGBJ81+3RQS1'D^-P<#Z0M";)]FEAU3I,7*Z&M%09Y(
M_M,H:W#<8X8/:N&DZ>?0NVUFG;=623VVH>V*1CC[YKX]X;P'#>:<<?:NEN'K
MFU:VYPS&I.(F8ZMZ5-WMM+,Z&IN-'#,WWS))FM</.,KE1W.@K9#'1UU+42 9
MW8I6N/J!6@[OI^CU-_* N%JN/2"FGD>7F([KO)BWA@X[0NW:MLXMFC;%37JP
MUE;!4,J61;LDH).02'-( ((PD</3-:S;G,=CQ)Q,XY0WQ6W"CH0PUM73TX?[
MWI9 S>\V5Z <C(((/(CK6M+C9)-I>R:USU36>[1@$\$I&,R EI![G >O!6#:
M7VJ3V+0-PM-<R07RA'@]#T@/!IR/*[#'@\^? =2S7AYO$[>L3B6IU(K//HWU
M%7T<M6^DBJZ=]4S.]"V0%[<<\CGP75=+O;;4QKKI<*6C:_WIGD#=[S+7NPW2
M+K3:Y-172-TEVN;2]H?[]L1.>?:\X)[L+&]+;.+IJN_W.[;0X:VGWC]KC$@#
MGD]0/'#6CAA/"I%IB;<H_?Z)NMB,1S;JH*ZDN-/T]OJH*J#..DA>'#/H7H6@
M-&TQTCMQ]P[-5236^9[H9F%V?)W"[#L<"6GK6_EC6T_#F,3F)YK2VZ!$1<FD
M*"B%4>NU_=7H*MU3VO[J'F*N%QU.KI7H(B+FT(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B BA2B"(
MB""B%%04*5"(*%*A"!0I4(HH4J%4$1$ *"I4((1$00B(BB(BJ(1$0040H@A$
M1$#R7$+DN*L H4J%5%"E0B"A2H0%"E0@%5.K?O2OOYA/_EN5J5X[S2.N%FN-
M$Q[6/J::2!KG<FES2 3W<5JDXF)9GG#YMTAI>34.R"[3T+'.N=NN7A$ 8/*>
M.C9O-'7RXCO:O?;;)<*_0NM=8:D;)[HU,0A@Z5A8X#>;ON /('@T>8K;&R31
MU7HJPUE#7U-/42SU/3AT . -QK<<>O@KO6]GEU#I.Z6FGECBFJXMQLDF=UIW
M@>../4O=;BO?F(Z9Z^CC&E[N?/#66C/_  XW/_<5?[Y6&;.M*ZKNVD*JX:;U
M!-10132-%''*]AD>&M)(QPR00/0MO6'1%9;ME=7I:6KIWUDT<[!,T.Z,%[B1
MWKV[*]*5.C=,/MM;405$SJE\^_"#N@$-&./7Y*>T16+[9YS)X<S,9[-9?R=[
M=;KE>+E=Z^>>>_TKLALQSNM>"#)D\7.Y@YY<.U+0]M#_ "DK@VI(8999&LSP
MR7Q@M]:S"/9W76S:9XRV&NI8**:0OJJ60.RX/ST@;@8[QV%=^TO9G!JVJCN5
M!5F@O$8#>E();(![W..((ZB%J=:DZDS,\K1CZ)%)BL1CG$JS;)I6=]-<]3MU
M'74+*:G:!2,):QS@<  APXDGL5!I2>JJ?Y/.IY:V>>=YDE#7RO+SNCH^ )ZL
MY7HEV3ZKO3X8=3ZJ;-01G.ZQ[Y'>@$ 9[RMB7324#MGU7IBS%E-&^FZ")TF2
M,YSO.QQ)..)6?$K6M:;L\X_2%VS,S.,-,;,M,ZQN^FO"-.:D]S:$3/9T'2O;
MY0QDX 6PMG^S!U@OKK[?;F;G=AO;AP=UCB,%Q<>+CC([LJ_V8Z6J-(:8]S*R
MHAJ)NG?*7P@[N#C X^998L:W$VM:T5GE*Z>G$1&>KYQU';+A>-N]QH;/7NM]
M=)*\LJ6D@LQ'D\1QX@$*NU-9+C2:ZMEDUY?*RIMTKV%M7TCG-W7<"1O<L'@3
MU+;M+H.M@VM2ZM-92FC>7N$ #ND\J,L[,<SVKV[4]#MUM9J>&&6*GN%+)OPS
M2 [NZ>#F'''!X'SA=HXFL6K&>6,?26/"G$_5DDKK?INQN=)NTEMH(>(')C!P
MQY_VDKY7OLERU+7WG64%M:RWQ5;'2>0"QI)\D.^,>6\>_CS6Z]5Z*U3J#1]H
ML<UYM[33C^=RD/\ M[FDAG5R#<9SUA9C8],VZT:6988HA+1="8IM\<9BX8>Y
MW>?HX=BYZ6K70B;=9G_'_K=Z3?ETAU:&U'3:ITU27*E#6.<T1S0C_52#@6X[
M.L=V%A>U;:0ZR2FQZ;^WWN3#7R,&_P!!GX('6\]G5E=NA]GMYTA>;LZW7>E-
MHK(WL9$YKC(P\>C?RQO-SZ5B%+L4U)2U;:N"_P! RK:XN$S3)O!QYG..?%73
MKHQ>9FW+R2TWVXB.;--D^SR73C7WJ^;TU]JFEQWLGP<.XN!/6\YXGT+8RU3I
M[0.LZ"^V^KKM6BHI()VR30B:5W2,!XMP1CB.'%;6/,XY+CKSFV=V6Z<HQC"$
M1%Q:0H*E0J/5:_NH>8JX5/:_NH>8JX7'4ZNE>@B(N;0B(@(B("(B B(@(B("
M(B B(@(B("(B J^XWBCH'MCFD+IW>]AB:7R'^Z..._DO+7UM365K[=:7B-\>
M/":HC(A!Y-:.MY'JZ^I>RUVJEMK'"FC)D?Q?,\[TDA[7./$K6(CJWMB(S9XV
M7&[5 )I[1T3?@NJ9PW/]UN2N0DOV.-/;OG'^Q7")GT-\=H4_27[^HM_SC_8G
M27[^HM_SC_8KA$W>AO\ 2%/TE^_J+?\ ./\ 8G27[^HM_P X_P!BN$3=Z&_T
MA3])?OZBW_./]B=)?OZBW_./]BN$3=Z&_P!(4_27[^HM_P X_P!B=)?OZBW_
M #C_ &*X1-WH;_2%/TE^_J+?\X_V)TE^_J+?\X_V*X1-WH;_ $A3])?OZBW_
M #C_ &)TE^_J+?\ ./\ 8KA$W>AO](4_27[^HMWSC_8G27[^HM_SC_8KA$W>
MAO\ 2%/TE^_J+?\ ./\ 8G27[^HM_P X_P!BN$3=Z&_TA3])?OZBW_./]B=)
M?OZBW_./]BN$3=Z&_P!(4_27[^HM_P X_P!B=)?OZBW_ #C_ &*X1-WH;_2%
M/TE^_J+?\X_V)TE^_J+?\X_V*X1-WH;_ $A3&2_ <*>W'_\ 2/\ 8H=<[E3D
M>%V=[F?"DIIA)C^Z<']JND3,=C?'G#PVR[45R:[P28.>WWT;@6O;YVGB%[E6
MW6S4UP+93O05C/Z.IA.[(ST]8[CP71:;C4-JS;+N&MKFC>CE:,,J6#X3>PCK
M;U9':F(GG"S6)C-5RB(LN8B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("(O+=*^"V44E55.(C9@8:,N<2<!H'62>&$B,K$3,XAWS2QP1.EFD
M9'&T9<YYP .\JC.I!4DBRV^JN(!P9&CHXO0]V,^C*ZZ6T3W:5M;J( M!WH;?
MG,<0ZM_J>_S\!U=JR)K0UH:T - P .06^4>K?NUZ\Y_91FHU')QCH;="/BR3
MN<?6 HZ74WX/:OG'^Q7R*;O0WQVA0]+J;\&M7SC_ &)TNIOP:U?./]BOD3=Z
M&_TA0=+J;\&M7SC_ &*>EU-^#6KYQ_L5\B;O0W^D*'I=3?@UJ^<?[$Z74WX-
M:OG'^Q7R)N]#?Z0H>EU-^#6KYQ_L3I=3?@UJ^<?[%?(F[T-_I"AZ74WX-:OG
M'^Q.EU-^#6KYQ_L5\B;O0W^D*'I=3?@]J^<?[$Z74WX-:OG'^Q7R)N]#?Z0H
M>EU-^#6KYQ_L3I=3?@UJ^<?[%?(F[T-_I"AZ74WX-:OG'^Q.EU-^#6KYQ_L5
M\B;O0W^D*'I=3?@UJ^<?[$Z74WX-:OG'^Q7R)N]#?Z0H>EU-^#6KYQ_L3I=3
M?@UJ^<?[%?(F[T-_I"AZ74WX-:OG'^Q.EU-^#6KYQ_L5\B;O0W^D*'I=3?@]
MJ^<?[$Z74WX-:OG'^Q7R)N]#?Z0H>EU-^#6KYQ_L3I=3?@UJ^<?[%?(F[T-_
MI"AZ74WX-:OG'^Q.EU-^#6KYQ_L5\B;O0W^D*'I=3?@UJ^<?[$Z74WX-:OG'
M^Q7R)N]#?Z0H>EU-^#VKYQ_L3I=3?@UJ^<?[%?(F[T-_I"AZ74WX-:OG'^Q.
MEU-^#6KYQ_L5\B;O0W^D*'I=3?@]J^<?[%'2ZF_!K5\X_P!BOT3=Z&_TA0]+
MJ;\&M7SC_8G2ZF_!K5\X_P!BOD3=Z&_TA0]+J;\&M7SC_8G2ZF_!K5\X_P!B
MOD3=Z&_TA0=+J;\&M7SC_8IZ74WX/:OG'^Q7R)N]#?Z0H>EU-^#6KYQ_L3I=
M3?@UJ^<?[%?(F[T/$](4/2ZF_!K5\X_V)TNIOP:U?./]BOD3=Z&_TA0]+J;\
M&M7SC_8G2ZF_!K5\X_V*^1-WH;_2%#TNIOP:U?./]B=+J;\&M7SC_8KY$W>A
MO](439]1L.7T5MD'Q63N:3Z2%P.HWTG&]6RKH6<NE;]NC])9Q [R L@0C(P>
M2;H\X-]9ZU=5+40U4+9J:6.:)W)\;@X'TA=JQZLLDM#,^NTYN05'.2D)W8*C
MMR/@N_M#TY5G9KG#=:/IX0YCFN+)8GC#XGCFUPZB$F/.$M6,;J]'N1$66!$1
M 1$0$1$!$1 1$0$1$!$1 1$1!$1!"(BH*%*A$%"E$(0B*$44*5"J"(B H4]J
MCK0%"E0@A%*A%$1201U*HXIVK7VUC7U1H@6SP:@BJS5O<'=)(6[H'9@=ZG:C
MKZHT956**GH8JH7%S@\OD+=P LY8']KZ%VKH7MC$=>GZ,3>(SGR9^47%CMYC
M78QO %<ER;0B(HAU*%)Y*,'&2"J"XK%]I>J)=(:5DNT%,RID;,R(1O<6CRB>
M.1YE[]%WE^H=+6V[20M@?5Q=(8VNW@TY(X'T+>RVW?Y=$W1G"Y4+E@XSU+BL
MJ*%(!QG!PH0%"D(.)P@@J%@&@M?3ZHU7?K1+014\=N<X,D;(7%^)"WB,=V5G
MX!/(96[TFDXLS$Q/.!0I4+*H1/,AX<T$(B$8X%4<44J#PSG@@XHBG!QG!P@X
ME%6:JNCK)IJZ71D39GT<#IA&XX#B.HE5NSK4DNJ])T]WGIF4TDDDD9C8XN W
M3C.2MQ2=N[R3,9PR5<>I8;;+YJ:?:'66NLLW1:>CW^BKNC<-[#06G>S@Y/!9
MEU):LUZD3E"(G/@%('%0IQQ(1$0B(@A05*A4>NU_=0\Q5NJ>U_=0\Q5PN.IU
M=*]!$1<VA$1 1$0$1$!$1 1$0$1$!$1 1$0%7WRLDI*$^#C>JIG"& ?VW' )
M[AS/<"K!5%4!4:FHH^/\U@?.1U9<=UOT!RM>K5(Y\WLM5#';J&.GC.\1ESWG
MF]Y.7./>3DKUHBD\TF<SF1$1$$18_6:QL=)5OIIJW+V.W7ED;G-8>PN PK%9
MMT9M:*\[3AD"+A!-'40LE@>V2)X#FO:<@@]87-1H1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0%6WZWFOHOM)W*R ]+3R#FUXY>@\B.PE62*Q..:UF:SF'BLM
M<+C;(*G&Z]PQ(SXCP<.;Z""%[52V8&"]WFE:,1;[*A@[WCRO\32?2KI+1B5O
M$1/(1$49$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!8_3,]V-0
M254@S16YQB@:>3YL>5)Z =T=^\KFX5+:.@J:I_O(8W2'S $_P7BTO2FCL%%$
MXY>8]]Y[7.\H_22M1RB9=*^[69_1:(B++F(BZ*>LIJF66.GJ899(CB1K'AQ8
M>P@<D,.]%U553!21&6JFBAB' OD>&CUE<XWMD8U\;FO8X9#FG((0PY(B\U5<
M*.DG@@JJJ&&:<[L3'O +SV =:8RL1,]'I1>:>X4=/5PTL]5#'4S?T<3G@.?Y
MAUKINUXM]H;$ZYU<5,)7;C#(<;Q[ KB96*S/*(>]$:0YH(.0>(**,B+S-N%&
MZN-$VJ@-8&[QA#QO@=N.:]*868F.HB(B"(B B(@(O,+A1FO-"*J'PP-W^@WQ
MOX[<<UZ4PLQ,=1$1$$1$!$1 1$0$1$!$1 1$0$1$!$1 1>:*X4DM;+1Q5,+Z
MN(;TD+7@O:.TCTCUKIGO%O@ND-MFJXF5\PWHX"?*<./+U'U*XEK;/9[T1>5E
MQHWU[Z%E5 :QC=YT >-\#M(Y]84PD1,]'J1$1!$1 1$0$1$!$1 1$0%C]U;[
MD7B"ZQ>335#FTU:.HY.(WX[0XX)[#W!9 O'>*85EIK*8_P"MA>P=Q(."M5G$
MMTG$\^CV(O!I^H=56.@GD.9'PL+ORL<?I7O4F,<F9C$X$1%$$1$!$1 1$0$1
M$!$1 1$0$1$04*400B(J"A2H1!0I4(0E<5R7%%%"E0J@B(@+0.LM37>_[5*G
M3'C =.VRE.XV0'=,CMT'B>LG)P,@86_EI+7%PV?:BU?5VG55'5VNYTYZ/P]P
MZ,28Y<1G(QQ!(Y+U<)C=,S&>7V<]7IU9#H&TZVL>HG4URND%ZTV]IW:E\F9&
M'&01PSSX$9(XY6"5%^UI>-JM_P!.6*\F"-\TL;72@%M/&TYRWAD''#TJNV<S
MNLFV&GM&D+K47.Q2DB8G.X6;A))ZO)(&'<.Q7.A/_$7J/_>5/\%Z]FR;6F(G
MW<]/].43F(B.ZI]WM?Z0U?-I9US;<*RN#(J>28[S6N?C=D:2,C''(/#Z%ZKO
M<]:[,]46R6]WHW6AK#]L;DECAG#A@C((SD$+WZ^_\0^F_/3_ +2NS^4^>.G?
M]Z_^"U68M:E9K'O1SY)SB)G/26<[41K"KBH:/1NY3T\Y/A=:7M:8FD@#&>0P
M221Q6K=5W'4.S6OMU73:O]W&R.(J*61^]RP2",G /'B,%6&VFY2SZ]LEEOE?
M4V_2[X8WRNA! ?G.\XXYX( Z\<\+!]J\.BZ.GH:316:B5F\ZJJ]YSL\!NMR>
M&>9X*<-I\JUM'*?3_,FI;K,>3._Y2DS:BFTQ.S(9(7/&>P@%=O\ *2_[QT9^
M5+^V)>+^4(?_ (-H[_=C]UJ]O\I/_O'1GY4O[8DT>4Z7_P#I+]+?HWC!_01_
MDC]BT/K'46KI-LM7I[3ET=")@R*&.0 QQYA#G.Y=7$K?$']!'^2/V+0\G_BF
M9^5__J%>7A(C-YF,XB775SB/JJKM>->;/-4PVZINPNKKA'B#I"7,<YQ+6D9&
M00[!QRY+NU;4;0-G=3;[U<[X+A#4R;LL.<Q[V-XQD$#&0#@M[%9;>/\ 25HK
M\J/_ #VJW_E0_>7;?^(#_+>O52T6G3S6/>Z\G.8Q%N?18;8]?5.GM,VUUB(9
M770!T<A <8H\ D@'AGB!ZUB%_L.OM)Z;&I7:IGGJ( V6II2XN# X@8X\'8SQ
MX#N7#;C;:AVC]'W>&-SX*6".*0@9#<M!!/8#C"N]I.T[3MVV;UE-;JSI:^X0
MMC%-N.#HR2"[>.,<./G6=.LUK2*1G,SE;3F9W3]'EVA:C.J]@M-=GQB.>2JB
M9,P<A(USFNQW'&?2O9'JV31VP:Q5U(UKJZ:(4]/O#+6N+G$N([@#Z<+&[O;:
MBU_R;*2.LC=%--6MJ-QW AKGDMSYQ@^E=NK;74W#^3SIFHI(W2> ELTH;Q(8
M2]I..XD+44IB*^6],VS,^>':;-K5NCO&P:QF-QZ#P[P/?&[N8WL8Y;V.K&.I
M9+0[4)7[(I-1S11NNL+O!"S'D.F/!KL=A'$A:_M]'LQ;HVGN-?67!UR$+1-1
M13G?,N.( QC&>O.,*]N-AHJ_8963:6MMPIX'50K>BJW;\CV,R"X8ZL<O,K>M
M9Q%X\^V/T(F8^'LZ++8MH6I-,^,T.IIFU$S3+!2AY;TC02.0&Z,X.!A9-;-5
MZDJ=D>HJR\05-!>K?%NQU+HNC,@.,. /#>'$' [%X=G^U+3MFV;T5/65+FW*
MAA='X+N.S(021@XQ@Y'F5C2:@O.T'9-JBHJK7'2O="]E*(BX],&C>=@'S8':
MN=XMGWZQ$1,>GG^ZUQCE//"[V'7:NO>A*:KNU5)55)J96&23&2T.X#@L9V7:
MEO-TVJZCMUPN$U10P,E,4+\;K")6@8X=A57L2V@Z?T_HYUNO=9X)44T[Y0'1
MN=TC7'/# Y]6%X=@E:+CM4O]8UAC%13RRACN8!E:1E+:4U\69CEY$7SMQ+V[
M$'!NTO6KG'#0Z0D]@Z9R6^Z:BVFZINT=#?GV.QT#MU@A.'.R2&]A).Z2>. N
M&Q1G2[1]<1@@;_2MSV9F<%B&D+'INGU3>[/KV:IH)87D0/$AC:<..<G!Y@@@
M\L+M-8F]Y\XB/+/[,Q,XB/)L/9[J>]V?:%/HO4M>+DUP/@U5S.]N[XX]8+<\
M^16V[@]T=OJWL.Z]D+W-/80TD%:4V<TFB*C:'%'IBCO%3-1;\K:Z24& >21D
M@@'KP.];ING_ '77?F\G[I7CXB(B\8C'*'73SME\^[/JK7>MX;C14NHGTU)
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M&-C8UD;0UC0&M:T8  Z@%R4*S:;=9(B(Z,:J-!:5J*LU,NG[>Z8G)/1  GO
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MF.D8U^.6\,X4AC [>#6AV,9 ZER1!PDABD(,D;'$?&&5S  &!P"(@(B("(B
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MW!IW5=FU0:I]BK!4M@<!)Y#F;N>(Y@*BN.U#2-!6/I9KL'R,=NN,,3GM!_*
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M< 8.#C^"W/*P21/C=G#@6G'>M9V31NJ+!%56NT7*@9;*AY/3OC)E8",</[6
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M^56ZJ*?[ZZ[\S@_?E6H\VZ=)6Z(BRP(>11'>]/F0:\V17ZY7J*[FZU9J.AF
M82T-W1QX< KOQ_TS[H>!>ZT'3;VYGCN[W9O<EK?9ZZ9FC=9NI=X3#.[N\^15
MMH&BL$NS2M?61TCG[LO3N?C>:0.'>.&,+V:FG7=,S^SZ>MH:>^UIZ9B,1]&7
MWG4]-6:+O5RT_6MD?2POW96M]X\#L(6'Z;I]=7^RT]RI=20QPS;VZV2)N\,.
M(XX;W*NT9_HCU3S][)S_ "%W:(TK)<],T=6W4]=0"3>_F\4H:UF'$<!WXSZ5
M8K6D3'KYQEJ-.FC6T<N4XS,9\FS=)TEWHK68K_71UU9TCB)6-W1N]0Y!=M_U
M!:[! R6[UD=,UYPP.XEQ[@.*C3%![F6B*E-PEN!83F>5V\X\>65A6M+A!4ZW
MI+;;+)2W"^P1B1L]6\M9$WGP'7U%>>M=]YR\=*1JZLYZ>G+_ .,OT_JNRZ@D
M?':JZ.:5@RZ/!:X#MP>I=%9K;3U'-715-SACEHG!LS2#EI)Q@<.)\RUO0>'1
M[9K9[I.H16NC(E%""& =&_ .?A<OH7LTA04M?M:U*:R".?H'O?&'C(:2[!/J
M76=&L9GRQEWMPNG7,S,XQG]VQ]/:EM.H62.M%8RH,>-]H!#FYY9!7ANVN=.V
MJX.HJZYQ1U#" ]H!=N$]I')87:::*V[<JVGH(VPPNI"XQLX-R6L)X>?BNG8O
M1V^NCODMTB@FKO""'=, 2&$9//\ M94G2K$3;RQ'[I/#:=8F\YQB)]>:[V<W
MVNNVK]40U%<ZIHH9 :8<-UK2]X&Z1U8 6>UU93T%))4ULS(*>,9?(\X "U9L
M=931:PU9'0$&C8YK8<<1N"23&.["R;:K<[;06*"&Z6X7(U,X9#3N<6M+P#Q)
M[!GZ5-2D3J[8]/\ #.OI1;B-E8[?X>RVZ^TU<:UE+2W2,S/.&!S2T./8"1A4
M^J+S<:7:=IZWT]6^.BG8#+" ,/XNY\,]06#[2(KQ#9;;[K4MHHHVR@004>3(
MW@>9Y8_CA9)JDD[5])$G),+<^MZW&G6.<><2[5T*5F+5YQ,6]>BTL=YN,^UJ
M\VV:K>^@BI]Z. @;K3B/B.&>L^M7=WUUIVTUKZ2MN<;*AGOV-!=N^? X+#[0
M9&[9-2F$9E%&XL'?NQ86/[-6WB6SW!ULM]IK&R3$5+ZV0B3.!D?D]?G)2=.L
M\Y[06T*6]Z>D17TZMQR7VV,LKKN:R(VYK=\SM.6XY=2KZ?6NGJBLI*6"Z0/J
M*K=Z)C<Y=GEYO2M<4%MJ;7LPU3#-44DT#GM?&VFF$@8<C>!(Y=2RK9EI^UC2
M%LN(H('W!S72].YH+]_>=@Y]2Q;3I6)F9\W*^AI4K:TS,\\1]LKJY:ZTY;;@
MZBK+I#'4-.ZX8)#3V$@8"L;/J"UWBIJZ>VUD=1+2$"8-SY.<XX]?(\EK/8S2
MVJJMUX?=64TE9TY#_",$AF!GGU;V\J_0!;!!KXVEQZ)E.[P8MY[HZ7=QZ,+5
MM&L9B.L8:OPM(W1&<UQ].;8]=M TS0UKZ6HNL0F8[=?N@N#3V$@85M<+];+?
M:!=*JLC;0'=Q,/*:<G QA:@T-!=I]%S1T-NLL]!-OB>6JEW9.OWW9CJ7.MH:
MJV[&JNFJ:FFJ&,K6F%T$HD:&[S>&1WY..]6="F<9\\-6X33W16)\XC\[-BS[
M0=,0U+('W:'?< <@$@9Y9.."RB*1DL;)(G!['@.:X'((/6M87.QVUFQMLS*.
M%L[:&.H$@:-[I" 2[/>LGV6/=)H&SE[BXB-S03V![@!ZERO2L5W5[X>?5T:1
M3?3/*<<V5(B+B\JFIOOLKOS6+]YRN534WWV5WYK%^\Y7*U9N_6/I"'-#FEK@
M"T\"#UK7]QIAH?4<%RH/(L=RF$%93CWD,CO>RM'4.>?.M@J@U_0MN&C+S3N&
M2:9[F]S@"0?H6M.<3B>DMZ%L6VSTGE*_156DZQUPTU;*MYR^6G8YQ[\<5:K$
MQB<.5HVS,2(B*((B("(B B(@(B("(B B(@(B("(B B+$M5:EJ8J]EBTY$RJO
MDK=XEW]'3,^.\_L"U6LVG$-TI-YQ"UU%J2V:?A:^Y5(8]_\ 1PM&])(>QK1Q
M*QYMVU;?>-HML%HHW>]GKSF5P[0P<O2K'3&CZ6U3&OKY'7&\R<9:R?B0>L,'
MP0LH6LUKTYNF[3T^58S/>?\ G_6%#1MTJ_*NVJ[G*3S93AL+?1@94_8\HOA7
M:]N/;X:]9HB>+;RE/:-3RG#76H]"45'8+E4LN-W>Z*G>\-?6/<TD-)P1UA;"
MI_Z"/\D?L55K'[T[Q^:2_NE6M/\ T$?Y(_8EK3:L9+ZEKTB;3GG/^G-$1<W%
M#VA[',<,M<,$*B&D;&  *$8'_JO]JOD5BTQT:K>U>DX47BC9/P$?.O\ :GBC
M9/P$?.O]JO45WV[M>+?YI47BC9/P$?.O]J>*-D_ 1\Z_VJ]1-]NYXM_FE1>*
M-D_ 1\Z_VIXHV3\!'SK_ &J]1-]NYXM_FE1>*-D_ 1\Z_P!J>*-D_ 1\Z_VJ
M]1-]NYXM_FE1>*-D_ 1\Z_VIXHV3\!'SK_:KU$WV[GBW^:5%XHV3\!'SK_:G
MBC9/P$?.O]JO43?;N>+?YI47BC9/P$?.O]J>*-D_ 1\Z_P!JO43?;N>+?YI4
M7BC9/P$?.O\ :GBC9/P$?.O]JO43?;N>+?YI47BC9/P$?.O]J>*-D_ 1\Z_V
MJ]1-]NYXM_FE1>*-D_ 1\Z_VIXHV3\!'SK_:KU$WV[GBW^:5%XHV3\!'SK_:
MGBC9/P$?.O\ :KU$WV[GBW^:5%XHV3\!'SK_ &IXHV3\!'SK_:KU$WV[GBW^
M:5%XHV3\!'SK_:GBC9/P$?.O]JO43?;N>+?YI47BC9/P$?.O]J>*-D_ 1\Z_
MVJ]1-]NYXM_FE1>*-D_ 1\Z_VIXHV3\!'SK_ &J]1-]NYXM_FE1>*-D_ 1\Z
M_P!J>*-D_ 1\Z_VJ]1-]NYXM_FE1>*-D_ 1\Z_VIXHV3\!'SK_:KU$WV[GBW
M^:5%XHV3\!'SK_:GBC9/P$?.O]JO43?;N>+?YI47BC9/P$?.O]JL+7:J*UMD
M;00=$)#EWE%V3Z2O:B3:9ZRDZEIC$R(B++ BTC>-KMQCO=5%04],VDA>Z)K9
M6DN.#C).>T+E'M8NL@C^T43=WB_R7>5]/!>GV34QG#TUX6]NC=B\-YNU'9J(
MU5PF$40.!UEQ[ .LKLM-7X?;*2KW"SIXFR;IZLC.%@^V"W5-3;*:K@:Y\-,3
MTK1\$'X6/H]*XTK%K;9<]*D6O%;,CTWJVTZ@EDAH)W"H8,F*1NZ[':.T+G?]
M*VF^MD-=2M,SQCIF<'CLX^U?-K*^IME?%64,SH:F%V\Q[?V>8]86QMGFUJLN
M.HH+1J"*#%4>C@GA:6X?U-<,GGVKUWX2]??TW;5T9TIW4E<Z=V4Q6G5E/=)*
M[IJ>E<7PQEF'%Q! WNKAD\EL]%@>U+5-;8X::EM9:RHJ&N<Z4C.XT8'#O7GW
M7U[1$SS<8WZ]L>;.I9&0Q.DE>UD;1ESG'  5+1:NT_7&84EYH)3""Z3=F'D@
M=97SSJ+4=]O%&ZDN5RFFIB071X #L=N!Q6#5] ' ^2O9I<!%H]ZW-VGA9B.<
MOL#3VK+#J.2>.QW6EKI(,=(V)^2WOQV=ZNU\M?R>M,W"?7C+O3YCH:!KFSOS
MC?+VD!G?V^A?4J\O%:-=&^RLY>68F)Q(G4B'DO.C7MET31W&WMK)+A=8WS/D
M<615;VL!WW<@.07N^QW0?*EZ_7G^U7FD/O?IO._]]RN%UMJWB9C+TWXC4BTQ
M%F%_8[H/E2]?KS_:GV.Z#Y4O7Z\_VK-$4\6_=CVC5^9A?V.Z#Y4O7Z\_VI]C
MN@^5+U^O/]JS1$\6_=?:=7YF%_8[H/E2]?KS_:GV.Z#Y4O7Z\_VK-$3Q;]T]
MIU?F87]CN@^5+U^O/]J?8[H/E2]?KS_:LT1/%OW7VG5^9A?V.Z#Y4O7Z\_VI
M]CN@^5+U^O/]JS1$\6_<]IU?F87]CN@^5+U^O/\ :GV.Z#Y4O7Z\_P!JS1$\
M6_=/:-7YF%?8[H/E2]?KS_:I^QW0?*EZ_7G^U9HB>+?N>T:OS,*^QW0?*EZ_
M7G^U/L=T'RI>OUY_M6:HGBW[GM.K\S"OL=T'RI>OUY_M3['=!\J7K]>?[5FJ
M)XM^Y[3J_,PK['E!\IWK]>?[4^Q_3-XPWJ^1N[16./[5FB*^+?N>TZOS,*\5
M;_2#-LU=6$CDRKA9(WUXRN)N6LK3QK[51W> <Y*%Y9)C\AW ^A9NH3Q.\93Q
MYGXHB?T_XQJQZUL]UJ/!3*^CKQP-+5MZ.0'T\#Z%DBJ[]8+9?:?H;K1QSCX+
MB,.:>T'F%BKXK_HH=)3OFOMA;[Z)YS4P#M:?A#NYIMK;X>JQ2FI\$XGM/^I_
MZSY0O#9+O17NWQUEMG;- _K'-I[".H]R]RQ,3'*7&8FLXD4=JE0D,B(B H4J
M$$(41!"(B*)U(BJ(0)VH$$%$*((1$1 \EQ7(\EQ5!0I4(HH4J%04*5"(*%)(
M ))  XDGJ6-7;46"Z*W8/;,1^Z/XK=*3><0Q:\4C,KRLK*>C9O5,K69Y#K/F
M"H:O4^"11P</C2^P+'))'RR%\CG/D<>+B<DKNCI7$;TA#&_2O77AZU^+F\UM
M:UOA=]1>:^;._4N:.Q@#?V+QYFE).]*\][B5W])31>\;ON[5UOK9#[T-:%VB
M,=(<IG/67$4\Y^ [UKDQE7$<QNF;^2\^U=9J9C_K'*!4S#_6$^=:Q*<EA3WV
MX4S@)'](T?!E;_'FKVW:@I:HB.?^;RGEO'R2>X^U8NRMWANU# YO:%QJ:=HC
MZ6 [T9YCL7*VE6W6,.E=2U>DY;"*A8A8+VZE<VFJW%U,>#7GB8_^BR_M7CU-
M.:3B7JI>+QF'%$18;040HJ(4=2E0@A"BA6$0H4A$1"(B"%!4J%1ZK7]U#S%7
M"I[7]U#S%7"XZG5TKT$1%S:$1$!$1 1$0$1$!$1 1$0$1$!$1 52T&/5<A(P
MV>C:&GM+'NS^^%;*GU#FFDHKF 2VDD(E ZHGX:X^8<''N!6J]FZ<YQW7"(TA
MP!:00>((198$ZD1!C=FTO2:9H+B+)$^6:IR_HZB3>:YV. Y< M0P^+,3*IUW
MT]<J.\-<[<HH]]T+G?!X8X#/5R[%]!+B8V$Y+&D]I"[4UIKG/GZO5I<5-)F;
M9F9]<-=[,],RNT)5T=ZBEA9<2XNC]Z\,(QZ">:[_ +$VF^VO_6#[%GZ*3K7S
M,Q.,LSQ6INFU9QE4:7T]1::M[Z.V]-T+I#*>E?OG)QU^A5^I]$VO4%9%65!J
M*:MC&!/32;CB.K/:LG18B]HG=GFYQJWBV^)YL2M6S^RVN[4ERIA5>%TP.'OF
M+ND)!!<_/,X/T!6-JTM;K9?J^\4W3>&5O&7>DRWGG@.I7B*SJ6GK);6U+=94
M;=+V]NJGZA'3>Z#X^B/E^1C 'O?, J:Z[-;%<+G+79JZ:28YE93S%C7]O#JS
MUK-42-2T=)6NOJ5G,6]&/Z:TC:M.5E946J.6-U2&M<QS\M:&YP&CJYE>K4VG
MK?J.W^!W2(OC#M]KFG=<QW+(/I5LBF^V=V>;,ZEYMOSS8([9=8I:?HZJ6XU#
MP1B62I)<T#X([!W*_KM+VZLOUON\PF\+H6AD6[)AN!GF.OF5>(K.I>>LM3KZ
MD];*2CTS;Z34U7?8>F\.J6=')E^68\GD/[H5-<MF]EK*Z>IBDK:,S_TL=+.8
MV/\ .%FB)&I:.<25UM2LYB6/1:/L\.FI[%3T[H:&8?;.C=A[CPXEW;P"L[);
M*>S6JGM]%O\ @\#=UF^[>/,GB?2O<BDVF>4RS.I:T8F?5HFM%A%\KW:PT_74
M%7ODM%$7NBG'FP.?=P64[&[3/&^^7*:C=24=;(&T\$C<88"X\CU8<!Z"MEN8
MQWOFM/G"Y 8'!=;:^ZNW#TZG%S>DTB.OK_A@U7LPL4\\[HI*^F@G=O2T\%06
MQN_N]G<KBKT?9ZC30L+8'06X.#@V%VZ[(.<Y[<K(47.=2\^;C.OJ3C-IY*JH
ML-%/IOW#>)? >@%/P?Y6Z  ./;P7=8K5362TT]NHM_P> $,WW;SN))XGSE>]
M%G=.,.<WM,8F>741%UU,\=-3RSS.#8HFE[G'J &2HRJJ B35%U(!^U0PQD]Y
MWG?Q"N53Z7CD=0R5U0,3UTAJ"#\%AX,'H:&JX6K=6]3XL"JM6.+=+W=PYBDE
M_=*M54ZO^]6\?FDO[I2O6#3^*'GT"T-T99@.7@S/V*^5%H3[SK-^:L_8KU+_
M !2NK\=OJ(B++F(B("(B B(@(B("(B B(@(B("(B#'];7YUAL_24T?37"I>*
M>DA^/*[EZ!S*C1>G&V"W.Z>3PBYU+NEJZEWOI'GO[!R 512M]W]I=9-+Y='8
MHA%$.HSR %SO. ,>E9PNEO=KMC]7>\^'2*1Y\Y_T(B+FX"(B"GUC]Z=X_-)?
MW2K6G_H(_P D?L55K'[T[Q^:2_NE6M/_ $$?Y(_8M?VMS\$?7_CFB(LL"U^=
M1ZEO=YO-/I>"UQT]JG--)X8]QDFD R<!OO6\0 3GK6P%J*_5FCJV_7-][GJM
M+WZFE,8J&S.A=4,'O9&X\EX/>">U=]"L3,\L_O\ LDL\LNI6S6BWSWV VFMJ
MIS2"FG/OI@2,-/6#ND@]BM*FZ4D%<V@=41BN?"Z>.$GRG,;P)QV9PM/U%RN5
M5H[3%XO3YIZ.WW]LAK7Q;KWTC=]K9G- X#B/VJZ;?K;?]KE!+9ZIE93PV:H8
MZ:($LWB]IP'<B<=G:NL\/SF?K^R;EIHO:5:;G9K6Z\W*AIKK5CC"U^ UQ<0
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MUTY274VVIO%)'6!XC=&Z0>2X\FD\@>XKT7[4]FL)B;=KA!3OE!+&..7. YG
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M(;7I>H?3U=%1NNM2&\=]H.ZV(_E'/J60::T-I^W04%4RRTT5?'$PESF[Q:_
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MU!8IKO6U57[.)Z^R45;!)T[8*A[91&^CD;,P%I[<\N'4Y*:%[3$=R9AM%U-
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MC9\1OJ3HV?$;ZER1!QZ-GQ6^I<@,<D1 1$0$1$!5.K_O5O'YI+^Z5;*IU?\
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MN,1,JL41% 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4-:&C#0 .P*40$1$!$1
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M,>?R,XQW+VZ7&QF;:G>)Z=N3$T[,(U+I;4ESI-"7/3U##42VVD:YS9I P!W
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M]CF.]7RDQ,):LUZB(BC(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("Q^^O]TKC36:([
MS,MJ*PM/O(VNRUI_*<W&.P%=UTO9;4.H+1&VLN9X%H/D0_VI'=7FYGZ5Z;);
M&VRG>'2&>JF=TM1.X8,CSS..H=@Z@MQ&WG+K6-D;IZ^7_5BB(L.0B(@(B("(
MB B(@(B("(B B(@A2B(@B(@A$14%"E0B"A2H0@0<T1O,(K"]D?WIO_/:C_,*
MS)8;LD^]-_Y[4?YA69+KJ_'+MQ/]6WU$1%S<!0I4((0HB"$1$46MM4:4U#1:
MXJ-7:(J:&2MJ:9E-6T%=D,E:W&Z6N'O3PZ^U;)6O-1:.U!!JVKU)HN]PTE77
M1LCK*.NB,L$NX &N&"-TX'THD.G2FK(+CKJ&VZITPZR:O\%=X/*\ME;-"#EP
MCD'5S.#WK!]":;KM8Z4U!<[GJ>^1U-+<*QE"(:DM9 6'()&/*R<<^H+/M-:,
MO<FL:;5&M+M2UMPHX'T]'344!BAA#_?.XDEQ()'I7OV?Z/GTOIFZVN>KCJ'U
ME74U#9&,(#1+R!'<F%:QM5GO&I=DTNM;AJB\,U!#333T[H)MR&/H2YH&YC!W
MMS))YDK*M0WYEWV<:8K[SJ*6Q17 1R5+:)A=450W3F./=!(R>)P.2R#3FBZB
MT[*9-)25D4E0ZEJ:?PAK"&@REY!QSX;WT*FJ=G5TI;?I"ILERI&WW3L!IV&I
MA+X)FN:0[(SEIX\"I@8]H:\"W;5K9:+'+?Q8[G22R207=KQB2,9#X]_RNXJB
ME_T3[8?^+57[ZV);-$ZAFVB6K5NH[S25$U+!+ :2FA<R.-KAP#"223DDDGGP
M70_9I5NT=K>R^Z,'2W^LFJ8I.C.(@]V0'#/%,&6PK)_W);OS:+]P+UKJH(#2
MV^FIW.#C#$R,N QG=:!GZ%VK<(*%*A 4*5"J"A2H0>6XT%/<:5U/5Q[[#Q!Y
M%I[0>HK +SI:MH"Y\ -53#CO,'E-\[?8MDJ.7)==+6MI].CG?2K?JTQCC@\^
MQ0MM5UIH:[)J:6)[C\/&'>L*EJ-&T#LF&2>/NWMX?2O;7BZ3UY/-/#VCHU^B
MS-VC&#.*N3'>P(S2,+??SRN\P 73VG3[L>!?LPW"D-<6N(:X@#)(&<+.H=.4
M47^J+S_ZCLKWQ4;(F[L;&L;V-&%B>*CRAN.'GSEJJ6M:,B%N^?C'DO*7/D=O
M2$DK:%;IRWUA)EIFM>?AQ^2?H514:);DFEJW-'4V1F?I"U7B*3UY,SH6CHPM
M@7>P*^DTE<H\[C891_9?C]J\[K'<8O?T4W]T9_8NL:E)Z2YS2T>2O8%Z(PNW
MP*I9[^FG;YXS[$$;V\V.'G!5S$LX2T+N8N#1W'U+M;GL/J4E7-J[&J&1R.][
M%(?,TKT1T=4_WM+,?[A6)F%Q+I<NMRLV6>X2\H W\MP"]$6F9G\:BI8P=C!O
M+'B4CK+4:=I\F.2N:T')61:-HY1)-6RL+(W,W(L\W<>)\W!6E%8:"E<'=%TT
M@^%+Q^CDK1<=77BT;:N^GH[9S*$1%Y7="@\E*A4>NU_=0\Q5NJ>U_=0\Q5PN
M.IU=*]!$1<VA$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%K
M._,\7=L]@N$&&4^H8)*"J Y&2(%\;CW\2%LQ:WVR>15Z)G;_ $D=]IPT_E'!
M0;(1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%4ZO^]6\?FDO[I5LJG5_WJWC
M\TE_=*U7XH;T_BAT:$^\ZS?FK/V*]5%H3[SK-^:L_8KU+_%)J_';ZB(BRP(B
M("(B B(@(B("(B B(@(B("ZZG[FE_(/[%V+KJ?N:7\@_L2%AB>R7[QZ/_>S_
M .<]9@L/V2_>/1_[V?\ SGK,%TU?CGZNO$?U;?61$1<W$1$0$1$'16T=/74[
MH*R%DT3N;7C(50RRUM#@6BZ2,A;RIZIO3,'<'$[P]:OD5BTPU6\UY0HQ-J-G
M!U):I.]L[V_06E/"-1?)]M_6G_45XBN[T:WQVA1^$:B^3[;^M/\ J)X1J+Y/
MMOZV_P"HKQ$W>AOCY8_/U4?A&HOD^V_K;_J)X1J+Y/MOZT_ZBO$3=Z&^/EC]
M_P#JC\(U%\GVW]:?]1/"-1?)]M_6G_45XB;O0WQVC\_51^$:B^3[;^M/^HGA
M&HOD^V_K3_J*\1-WHF^.T?O_ -4?A&HOD^V_K3_J)X1J+Y/MOZT_ZBO$3=Z&
M^.T*/PC47R?;?UI_U$\(U%\GVW]:?]17B)N]%WQ\L?O_ -4?A&HOD^V_K3_J
M)X1J+Y/MOZT_ZBO$3=Z&^/EC\_51^$:B^3[;^M/^HGA&HOD^V_K3_J*\1-WH
M;X[1^?JH_"-1?)]M_6W_ %$\(U%\GVW]:?\ 45XB;O0WQ\L?GZJ/PC47R?;?
MUM_U$\(U%\GVW];?]17B)N]#?'RQ^?JH_"-1?)]M_6W_ %$\(U%\GVW]:?\
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M1$!$1 6M]L_OM'?\>I?WELA:WVS^^T=_QZE_>0;(1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0%4ZO^]6\?FDO[I5LJG5_P!ZMX_-)?W2M5^*&]/XH=&A/O.L
MWYJS]BO51:$^\ZS?FK/V*]2_Q2:OQV^HB(LL"(B B(@(B("(B B(@(B("(B
MNNI^YI?R#^Q=BZZG[FE_(/[$A88GLE^\>C_WL_\ G/68+#]DOWCT?^]G_P Y
MZS!=-7XY^KKQ']6WUD1$7-Q$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M:6*2XVV!T#8F[]8PROD:R,<&1N;*.#@-X')&.)XK?VA:RIK]'VFIKG"2I?
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M2_A\VC-YP]=.%F8S:7U@=IFCQ_\ ?E/^B[V*/LFZ/^7:?]%WL7R:5P/6N_\
M+M/O+?LM>[ZT^R=H[Y=I_P!%WL3[)^COEVG_ $7>Q?)!7 ]:O\NT^\I[-7N^
MN?LH:-^7:?\ 1=[$^RCHWY>I_P!%_L7R&5UGDK_+=/O*>SU[OK_[*6C/EZF_
M1?[$^RGHSY>I_P!%_L7QZ>2XI_+=/O+,Z$=WV']E31?R_3_HO]BC[*NB_E^G
M_1?[%\=E<4_ENGWEGPH?8WV5=%?+]-^B_P!BC[*VB?E^F_0?[%\<%<4_ENGW
MEB=.'V3]E?1/R_3?H/\ 8H^RQHG\8*;]!_L7QL5Q*?RW3[RSMA]E_99T1^,%
M-^@_V*/LLZ(_&"F_0?[%\9%0G\MT^\LX?9WV6M#_ (PTWZ#_ &)]EK0_XPTW
MZ#_8OB\KBI_+M/O*/M'[+>AOQAIOT'^Q/LN:&_&&F_0?[%\6+BG\NT^\LY?;
MM#M0T76S"*#4-%ODX&^2P>MP 66TM3!5PMEI9HYHG#(?&X.!](7YYE7NDM7W
MS2=6V>Q5\L !RZ$DNB?^4SD?VKG?^'1CW)^YN?>B+7VR7:90Z]H',+6TMX@&
M9Z7>SD?'8>MO'T+8*^9>DTG;;JT(B+((B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("A2B((B=2"$1%04*5"((BA"!!S4J!S16%[)/O3?^>U'^85
MF2PW9)]Z;_SVH_S"LR775^.7;B?ZMOJ!$0+FX"A2H00B(@A$1%$1%40B(@@H
MA1!"(B('DN*Y'DN*L H4J$44*5"J"A2H0%"E0@CJ125"H*%*A$0B(@A$14<4
M1$'%$*((*JM36&WZELL]KN\/2TDW'@<.8X<G-/4X9X%6I14:?H-A5LCK*?W0
MO=SKK=2@MAI'EK0&D[Q:2.HDDD#"VY#%'!#'#"QL<4;0QC&C :T#  '8 N:A
M:FTVZRF$*%**0.*A2H1!$1!"CJ4J%1ZK7]U#S%7"J+7]U#S%6ZXZG5TKT$1%
MS:$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6M]M'OM'?\
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M/2=+3VD4DW5)2SR0EO>-UP"#K;5;0*(CPBVV"Z1@\74]3) _'<US2,^E0-H
MH@?&/3M\M#&CRIWTXFA']^,N^D*6Z'KZ(AUEUA?J<-R1%4O94QD]AWV[V/2H
M$NOK2,ST]FO\ X8IW.I)SWX<2P^L(,CL6H[-?HNDLUSI*UHX'H9 XCSCF%:K
M5%TKM%7>LB;J^QU%ANIP(YJJ(PN:[GY-1&=W@?[2N:>TZFM4+9]+ZABO=!C(
MI;J0]Q;U!D[ /-Y0//F@SY%AUMU[1^&1T&HZ.IL%R?P;%68,4GY$K<L/FR#W
M+,6D.:"T@@\B$!$1 1$0$1$01$00B(J"A2H1!0I1"$(.:E0WFBL+V2?>F_\
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M>6V:DTO$:BT71][M\0WI**YO FW1SW)_X.'I"S"OKJ>@IS-52!C!V]?F6O\
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M[&=W>>\9QZ5C^W/4ULMVDV:3MDD<D[Q'&Z.-V]X/%&1@./:=T#'<5=[(C_\
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M2STE?[K>&B>HZ#<Z#HRWR2[/,]BQP^K75U-]YY^4)+617$KD5Q*^FPA?2_\
M)SN%\I= 2,M5CCKX#6RDRNK&Q$'#>&""OFA?8'\FF@DHME]-)*"/"IY*AN?B
MD@#]B\/'S_\ E^K564>[.J_Q4A_YDSZJ>[.J_P 5(?\ F3/JK+$7Q6V)^[.J
M_P 5(?\ F3/JI[LZK_%2'_F3/JK+$08G[LZK_%2'_F3/JI[LZK_%2'_F3/JK
M+%A]_P!55$MRDL6DH&5UY Q/,\_S>A!ZY7#X7,A@XG'' XH*W4&N[OI^%DEU
MT]!$Z3(AA9<6OEF=\6-@;EQ\RI-25VM;M3&JN=$RQ:<$8=)"RXL@J7?[R4C$
M8[F\>]>UIHM-7=\<#)M5:\J6@R.=C[2#R+O@P1<N7$_VBKJ@T9-<JN.XZXJF
M76K:=Z*B8"*.G/<SX9_M/SY@@Q/2M[N\EGJJ;9[HJEI& C^?U$^[!,[XX=NA
MTQ[^1[5+-+ZBKIA4:LLLFH)N9BGN;(Z5I_LP ;OZ1)6X&-:QH:QH:T#  & %
M*##J2X:DI*=D%+HZE@@8,-CBN$;6M'< W"[W:GN=(W>NNE[E$SK=2N94X]#3
MO?0LJ1!2V;5-GN\W04=8P58&74TP,4S?.QV#]"NE5WS3]KO</1W.CCE(][(/
M)D8>UKQAS3YBL>?47?1WEUTLUXT\/?3EN:JD']H#^D8.MWOAGD>:#-4752U$
M-7315%+*R:"5H>R1ARUS3Q!![%VH"(B B(@ZZFGAJH'P5,4<T,@W7QR-#FN'
M80>:PVHV?TU'*ZITC7U.GZK.1'3>52N/]J ^3ZL'B5FR(-=W&^5E!2/H-H]B
MAJ;6_P EUPI8C/3.[Y(R"Z/SG([TH;-76JE;<=G=VBN-J?Y?N74S])"\=D,N
M28_-Q;YEL-S0YI:X @\P>M87<=%/H*N2Y:*JA:*YQWY*7&:2I/8^/X)/QF8/
MG066F=745ZGDH9F2V^\PC,UOJANRM[V]3V_VFY"R-:YDJ;7JZH99=5T,EFU/
M3_;('-DW7[P_UE/,/?MY</-D+UT>H;EI6JCMVM7MFH7D,I[XUH9&\GDR=HX1
MOZ@1Y)X<CP09VB @@$'(/(A$!$1$%"E0@(B*@H4J$04(B$"#FI4#FBL+V1_>
MF_\ /:C_ #"LR[5ANR3[TW_GM1_F%9DNNK\<NW$_U;?41$7-P%"E0@A"B((1
M$0$1%1"(B""B%$$(B@G RB.+W8X#F5H#;;M>=12U.G=*3CP@9CK*YAXQGD61
MGXW/+NKJXK)=O^T!VE+ VVVR7<O5Q;Y+P>,$62'/\YQNCTGJ7R8PY.2<D]97
MIX?1W3NMT2]L1B'I#G/>Y[W%SW'><YQR23S)/:N^->:->AG +ZM'EL]#%VM6
MWMF&Q_QDM N%QGZ*-^-T<>'#.,#';Q.5CNU'0$NBZQFZ_I*:4X:?XC^*[Z>I
M3?LSS[/#;4S[V)Q/2?+_ +^S!PNR+FNL+LCYKZ%.CR7ZO7$K>R7.LL]?%6VV
MH?3U,?)[3S'8>T=RJJ=CI)&L8,N<0T#M)6T;9LDO-78Q<&N );O-CY.<.X+G
MJWI6/_TF(B>Y6TQ/NQ,SZ<VU]G.MZ?5M YL@9!<X .FA!X._MM[N[J68+Y*M
M=;6Z<OD552O,=53/R".3AU@]Q'!?4&E[U3ZAL5+<J7@V9OE,ZV/'!S3YBOSW
M'<)[/;=7X9_9]KA.(C7KSZK50I4+Q/2A$1!"=2(J.*(B#BB%$$$ \'#(/ CM
M"^?+CHBY:>U7%'-#6U.GA7"KII*;.[&\N!WGX!(W1D=^."^@R@)'(D>9=]#6
MG1F9B,Y<]73\2,-0;.]+W&HOEON%=2ST5MM9DZ%DLCR:EQ<XM.Z[D!ODYPMN
M]2Y'CSR5QZE-;5G5MNDT].-.,0U+_*&TI57VS6NYT,#JE]KD?TT#1DNB?@DC
M''@6C..H]RUOI^LAN1NTXG-,Z2;PZ&WQ3&-L;X\>5TAX#+21@<3A?4*KO<*T
M>%^%>Y-O\(SGI/!F9SV\N:[\/Q,:==MHRYZVE-^DX89L>LTM)3W:\3T;:$71
M[70TS00&1C)R >HEW#S+8*E0N&KJ3J7F\^;I2D4K%8$1%S:0H4J%1ZK7]U#S
M%7"I[7]U#S%7"XZG5TKT$1%S:$1$!$1 1$0$1$!$1 1$0$1$&/;1!G0FH >7
M@,W[I6#[-]!:5NFB+16W*TT\U7-#O22.>X%QR>/ K.-HGWB:@_,9?W2M=;/M
MFMHO6CK7<:JLNT<U1%O.;#5%C <D<!C@O7I3C2GGCG_IZ*3C3ZXYMAT-LT]H
MBT5]70T\-!1 =+.YA+LXX#F2L4;M/N$M$ZZ4^D+G)96^4:G?:'%GQ@WLQQ7E
MVCZ8@TULDO-':YJR:)\T<TAJ)3(X#?8#Q[. X+/[)/1>*%#,'Q>YXHF$GAN"
M,,&?1A9Q6*[Y][,X3W8C=//F\AUK9AI!NI#4'W.+<C#?*WLXW,?&SP5=:]<5
M5974D-1I:\TE/4O#&U,K6%K<\BX Y 6/:IK-*5.S ,L](Z2W5=9X/21THZ$F
MI+C@Y(X<0>*R71U)K2GF@;J6NMM12-C(<V*,]+O=679P?4DTK6LS,=^I-:Q6
M9_RP^\66W7W;E+27>DCJJ;W.:_<?G&1G!X+KVJZ+T]IS33KQ8XA:;E32-,,D
M$A!><\L$^GT+CJ6QC4&VN6B=6U=$/<]C^EI9-Q_#/#/8JS4&E:32^N+([4E3
M67;3]4[HV25DQ<(9LC&_U8[NS/8O12>=?>\NG=VK/.O/RZ+7;'435NAM)5-6
MW=GEK('O&,<2PY6Y&>]'F6J_Y00 L-A P![IQXQ^2Y;49[T>9>;4YZ=?U<+_
M  5_5*(B\[B(B(-(W'^4#045PJJ5U@K'F"5\1<*B, EKB,_0L1UMMCH]2FRF
M.T5-/[G7"*N=OS,.^&'.Z,<B5]%/L%G>]SGVF@<YQR2:=A)/;R7'Q=LOR1;_
M -69[$&G?^T7;_Q=K?UB/VK8FS#7<&O;76UM-0RT3:6H\'+)'M>7'=:[/#\I
M7WB[9?DBW_JS/8O90T-)01N90TL%,QQWG-AC# 3VG"#T(B("(A..: BZWSQM
MYO'HXKH?7,'O6EWT*X'K15DE?*?>M:WZ5Y9:F9_.1WH.%8K(NWR,8,O>T><K
MRR7*F9G#RX_V0J1W$Y/$]ZX%:B@LY;SSZ*$^=Q7BENM4_P!ZYK/R0O*Y=96X
MK"$TTLO]+*]WG*Z".>%V%=9ZUJ!P*ZRNPKK*L#A@DX',\ESV4B.2GU'?9B&F
MMN4C0]YP&Q0@1-'</(<?2N(.ZX.^*<KLV3Q13Z3NEJJXV2"EN573RQGCD.D,
M@SYVO!7/4Z0?127BRZ;U%M!C-;*V:G=N/#8SY$L@.=QQ[.7G69ZGTM;:^EDJ
M#FCJ86;S*F+@6;HX''7C"Z;CH6UR6WH;9'X#4QG?AG9Q+7CEGM' <%UW:2\'
M3[[;5,B=62P]#X2#NL>['4.TC/!=)U-VW;.,<GFK74O$TUXS'E_SOR8)J.\5
M=3!1&KJ>G+X@YD@9N@CER[>''SJFCFR.)7O@:Z2E-@KYA0 2=/1RS@.8]N.+
M0_D,GCP..I8^)2TN:2,@X."O9I1&,/?MS79V61F .2 X=AY'N6-Z6)ALO@CB
M2:.>6FR3GR6O.[_A(646.TSW<R/$@@IHSATKAG)[&CK*\FE++;ZJW5U5[H3,
M$]PJ',^U@Y:UVX#SZ]PI:]:VA::?-X)'<URIJ22JR6^3&WF\\O\ JK]UGMM.
M=Z2>:I(Y X:/3A>2NJV[NY&&LC;P:UO !:\3/PO9IZ<JR>E@8" 7./:2O!+&
M&GR5ZII<DY*"CJI&[S:>7=[2W ^E:B<=76:X>!00O7X,(Y!X4YK6=;6N!<>[
MAR7O-?32,Z)U!2F(<@UNZX?WN:U-NR1E1$*\T[:(WN;65[08AQCB/PSVGN[N
MM<(J2B,@D!D:!Q$;_*'K7N?5\/?=W!8M;,8AK$X7M1='$GREYQ=7M^$L=GJ\
M \5X7UY&>*Q&FS6C([RZW7V$1W:$ND:,,J(\"1GF/6.XK!+C:;C8]^6F>VKH
M,_TK!EO]YO-I^A>Z2O/:N,5VGIG])!(YIY'!YCV+=:VK&/)[=";4^&6=[']>
MRFNBM==,YU+*X1LZ0Y,+SRP?BGEW+>:^5J+P"OK63TH907'/)G"*4]7#X)SU
MC@OI32M>^Y:?HJF4$3.C#9 >I[>#OI!7@XK3BMLP\?\ $]*)QK1&)GE/_?U6
MJZZG[FE_(/[%S<W>:6G(!&."U-J+5E_T9>9+?<&LN5ME:74TDGD2%G+!<.!<
M.OAV=JX:>G-YQ#YVCHSJSBO5E6R7[QZ/_>S_ .<]9@M!Z<US=Z2TT5@T_1PF
MK?*]K)93O9<][G#R>K&>9[%N^RTD]%;XH:NJDJZGG),_X3CSP.H=@737TYK:
M9GS=>+T;:=YM;SF7M1$7!Y!$1 1$0$1$!$1 1%2W?55CM#S'<+I20S<^AZ0&
M0^9HXGU(+I%B/CNVI)%HL-]KB';H=X(8&'OWI-W@NBIU+J:.3 TS1P,[:J[1
ML/J *#-5B.MWR72NMVF*=[F,N&]+7/8>+*5F-YO=OD[GF+NQ>3QIOO71:=!^
M+[L\?\M46GKW?JG5E[N4=@I*R4]%0D07-GVML8+L-W@,@F0G/#Z$&TJ:"*FI
MXH*=C8X8FAC&-& UH&  NQ8B[6KJ3(N^G;[1X.-]E-X0SUQDJRM6KK#=)>AH
M[K2NJ/ZA[]R0?W'8/T(+Q$1 1$0$1$!:*_E!Z7?'5PZBI6%T4H$-5CX+@/(=
MYL#'J6]5TUM)!74DU+5Q,FIYFEDD;QD.!Y@KKHZLZ5]T.FEJ3IVW/BDKK<MH
M;0-E%RLDTE588Y;A;#QW&C>FB[B/A#O"U?)Y#W,D!8]O M<,$><%?>T]2NI&
M:R^I6];QFJ1-*V(QMED;&>;0\@'T<ET'K7,E<"NHF.>6(.$4LC [F&/+<^I=
M4<LD3RZ*1['8QEKB#]"%<3UJX8<97ND>7R.<]QYN<<D^E&5,\<99'-*QAYM:
M\@<>[*XE<"KAF8<"O;[LW/H.A]T:SHOB=,['[5XCR7!,1/5B8A!ZSUGBN;:F
M=D9C9/*V,_!:\@>K*X%<%<.<H7%<BN*,2YRU$TK0V6:61HY![R0/05UQR/B?
MO1/?&[EO,<6GUA05Q*F'.7;X74AY>*F</<,%PD=DCSY71(]TCW.D<Y[CS<XY
M)]*%<5,,2YQ3S09Z&:6///<>6Y]2,JJB,N,=1.TN.7;LCAD]IX\5UE<4Q#$N
M_P /K/PNI^>=[5TS5,\P FGED X@/>78]97!<"IB&4%<2I<0.9"R'2&B[]JV
MJ;#9+?+*PGRJAX+8F#M+SP] XJ6M%8S,LO'I+3]9JC4%'9[:PNGJ78+L<&-'
M%SCV !?>%CME/9K-16RB;NTU)"V&,=S1CUK#]E&S:WZ"MKMQPJKM./YQ5EN,
MCXC1U-_:>*SU?#XOB/&MBO2'2(P(B+R*(BP;45SK-2WB;3&G)WT\,.!=;E&>
M,#3_ *F,_P!:X'G\$#CQ(01>+Q7ZHN%18]*5!IJ2 [EPO#1D1'KBASP=)Q&7
M<0T9Z^"K+>\U,<FF-G3&T=MIG&.OO)&]NO\ A",G^DE/6\Y )Z^2Y4T+=0L&
MF])9MVD:'[55UU,=UT[@?*AA=YSY4@SQR.>2MA6R@I;70045OIXZ:D@:&1Q1
MMW6M Z@$'ATSIVWZ<H33VV(ASSOS3/.])._K>]QXDG_]BMT1 1$0$1$!",C!
MY(B#"Q'XEWJ/HN&F[E,&.8>5%4/. 1V1O) QR:['45FB\EWM\%UM=7053=Z"
MIB=$\=Q&,CO'-56AJZ>ILO@M>2;A;Y74507')<6'#7_WV[K_ .\@R!$1 1$0
M$1$!$1!5:DT_;M1T'@EU@Z5C7;\;VDM?$\<GL<.+7#M6(^Z-5I\BQZ]++C9J
ML]#3W:1@W7YY15 Y-=V.]Z>'(K8:\]PHJ:XT4U'7P1U%+,W<DBD:'-<.P@H,
M#$E5LZEC:]TU9HQY#6R$E\ELSP /6Z'E@\2WCDX6P8)HZB%DT#VR12-#FO:<
MAP/(@K7U/+-H6ICM-YD?6:2JW=#2U<YWC1EW 03$\V'(#7'S'J4Q%VSJN:US
MW/T95R8C<3GW,D<>1/\ 4DDX/)G <CP#8:* 01D'(/+"E$$1$$(B*@H4J$04
M*5"$"-YHC>:*PO9']Z;_ ,]J/\PK,EANR3[TW_GM1_F%9DNNK\<NW$_U;?41
M$ZES<!0I4((0J5""$1$41$51'4B(@@HA1!"Z:B1D;'/E>&1,:7O<>30.)/J7
M<M=;>;R;-LQO,K';LE6T43#_ +S(/T IC/(A\H;0=32ZOU?<;Q*3N3/W86GX
M$3>#0/1Q\Y*X6?2]YNE&ZJH*"26G SOY#<^;*Q_&6D#AP7UUL:UMIFFT/%#-
M-%3O8P"5I;G(W0,'S<>!7U:1MIRC./*'BXG5FDQ&8B)\YZ?ZZOE=T4D$TD,[
M'1RQG=<QPP05V,&]P ))X  9)6V=J^@JFMOL5\TQ/17*TW)P9"Z"5N6N&?)(
MZP.61RP 5V: TS0Z+J:[46N@ULML:'TEO(\J:1W!KL$<<$X ZCQZEWWQMW5Y
ML5U(F8I>8BW9MS1^H:?0FBK-2:OG937&J9TK:88+F-P.?_OF<=2U-MLU[3:L
MJH:>WC-/ >!/_OF3^Q:]U1?Z[5%]JKK=7[]1.[@W.6QMR<,;W!5S> 73A]"*
MV\6WQ2X:M>44K/N1TC_UV!>FCIIZEV*>&24CJ8TE>8<E]"_R>WV"*T2R5;Z9
ME>QP<UTQ  [2,]?\,+WZNMX.G-\9>*U=UXKG&>[$M(;.I*>FCONLJMMEM,9#
MVLD/VZ7N#>K]O<MH,VPZ?BMSQ113GHAN1"3 W@.1/'(6(;;;#6WAXU%::PW2
MV1%S9(XW[_@V,<0T=7 Y/F6H(N0/!>.NC7C*[]6<^G3'H]%K6TN6E[OKRG,?
MG.%I=:TW"YU%41CI'$\L=?-;'V%7TTE[J+1._P#F]:W>CSU2MZAYQGU!:L8K
M&S5S[9=:.NB]_32ME'?@YPO3Q&E&KIS1CAY\&8QY/K90C7MD:U[#EC@' ]QX
MHORL='WI0B(JB$1%1Q1$0<41$$%%J_:AK^Z6J[QV+2T$;ZX-;)55<K-]E,TG
MLY# XESN 6-:=VIWRTZG@M^KI**ML]95/I:>NA+&R1D.#=Y[6$C=XCGA=9TK
MQ7=AF+UF<9;T4+D002",$+BN;2$7(-<>0/'B%Q2!Q4*4590B(@A05*A4>JU_
M=0\Q5PJ>U_=0\Q5PN.IU=*]!$1<VA$1 1$0$1$!$1 1$0$1$!$1!X[S;XKM:
M:RWU!<V&JB="\L." X8X+ITW9X+!9*2UTCGN@IF;C7/.7'CGCZU9(KNG&WR7
M,XPZ*ZD@KJ.:EK(FS4\S2Q['#(<"M>'9';P'4\5ZO,=K<[)H6U!Z/'9VX6RD
M6J:EJ?#*UO:O26/5VC;+5Z7CT^^EW+=$!T36.(<QPSAP//>R2<]ZIJ79_41S
M0>$ZKOE32PO#VP/E !P<@$@9(6=(K&K>.65B]H\U"W2]&-8.U&))O#33^#[F
M?(W>W':N[5FGJ'4]EEMMS:XPO(<'-.',<.3AWJX19WVS$YZ)NG,2Q:_:*HKY
M9+9;:^IJWLH)&2LEWQOO+00-XXX\UE(&!A$2;3,8E)M,\I$1%E!$) !). %B
M5PUD)JJ:ATO1NO%;$=V61KMRF@/:^4\#CL;DH,MY+'+KK6PVVI-+)7MJ*[D*
M2E:9IB>6-UN3ZU@M34S7VHDIZVKK=3U+3A]NLY\&H&?ERDC>QV;Q_)5]:-*W
MT4@@\,M^G:,\J>S0 R =CI7@C/>&H/<[55YJ6YMVEZJ%G'$MSF93-\^!O.^A
M4%;K2ZQ1XK;_ *-MC\X+14/J'#]U9)%L^L#GMEN-/-=:D'/35\[IB3YB=WU!
M7U%9[;0QB.CH*6!@Y!D31_!!KB'5[I6Y.O[9G_T;2YX_>7";6DD) CU]8G'L
MJ;>Z+Z=Y;7:UK1AH '<%Q?%'(,21L</[0R@U[0:KOU5(QM%/I.[,(R?!;@Z)
MY]!:X?2O:[5L],,WK3]XHF 9=.R,5$+>_>820/.%D%RTQ8[G]WVFBG.,9?"W
M/K50=!T=( =/W&YV5PQAM+4%T9QVLDWAZL(/3:;U;+U$Y]IKZ>K:WWPB>"6^
M=O,>D+UN6'7S35U=()KO:+?J*./WE11GP.N8?C Y#7'S$>9>:SW6O;,^"T7%
MUV?%QDM=W'@]>WN8\@->!W@]?E+46&;%=;E7VB^T5TEEIXS+3UT/]-1U+.CF
MC]'PA_:;D=ZL'+<#K*X%<RN!6D=;EUE=A7651P*ZSUKL*ZSUJC@>M=9785UE
M6!P/6O%8:T:>UP7S'<ME_#8WO/)E:QN&Y[ ^-H'Y3<=:]IZUX+U#2U%IJX;A
M$)J1[,/CSC>X\,'J(."#U$*6KNC V95U,=+ Z65P#1])[%I3:OK!MP,5LH)7
M%L;^DFD8[ R.301V9.2JBMU/<K=0O&HYJBLB:SHJ6X@9#6\L3-'$/Y>6!NGN
M6$2U#:EYEBD;*QQR',.\#ZEWX;0B+9MUA]'@]*MHW3U7HO-3+9(;7+T;Z:&0
MR1DM\IF<Y /9Q*Z!-AI\RK(W$#D5YJF[00R&",FIJB.$$/E.])Y-'>5[.57H
MG3K5M'4EP?I[25!36_'NA.QL=,T_"J)!O;Q[F\23U +&Z)S+504]#3.)B@8&
M GF>T^DY/I5A74M4)VW&[R127%\(CC9%GHJ6,@'<9GB2<#><>9'# 5#4/RXK
MRZ5=WO2UP^G[NZ5@ZO<X'+BNVCH:NX-,D3-V <YI.#!Z>OT*XTKIV#P)ETNH
M$C'C>@@SP(^,[M[AZUZ;W7F3AD!C>#6C@ .X+6[GBJVU(SBJED--;1BG:)I^
MN:0<OR6\AY^:J:FJFJ'DRRO=YRE5-OO."O.NU:^<LS*>I0TX**,+;F]$<N.M
M<G3<%Y04+N"F&LHFD)7BDSQ7H=Q74\+4-5EXY >*Z 2'*SAHY:D.; POD'$,
M',CN[3W*ND;CT+43EZ*6>:K:^ B2(D-/(CX)7T=L9NYK])Q,FDWI8G;KN[(R
M/7Q6@Z:%M3$^!WPQ@'L/4?6N[36J*_3<CFTTLL+VDL<6 $$ \G-//BN&OISJ
MTQ'6'74THXG3G3F<3Y/K98CM0T^+[IB<Q-!K*0&> ]9Q[YOI QZEA>D=K9J)
M6QW<0NAY.E8TL<SO(/,>99E7;2M)TCG1RW>*9X.'-IF/GQY]P%?+FMM&W-\3
M4T-7@]2)M^C#MAM@$DE3?:AF0W,%-GM^&[S\ /6MPK!M.Z[T5%!%06ZYPTC-
MX[D=1&^#)<XDX+P.LE9HRHA>P/CD:]A&0YIR#Z0IJ7\2TRY\1K3K:DW=J+H=
M4L'(.*Z7UV/>Q^LK&)<'M15;Z^7J#!Z%YY*VH/\ K"/,%=LB\4%S6\W ><K&
MWSRNSO2O/I7F?QSGCYUJ*(R9];3,]_/&/2O/)=Z-G*0N_)&5CA5?=KE36RG;
M)5.?F1VY%%&TODF?U-8T<2?H'60KLB.JLK=?H<XCAE<?, L>?KF:X2RT^F+8
M;I.PEKYQ)NTL+NL22XQD=C0XK&+A'+55+*6_P3553,-^'35!("7-ZG54O( <
M\9#>7OBLIH='5%RIXFZJGB-&P8CM%!F.D8WJ#OA2$=^&]RQ,QY#&:RX5%YGE
MIJVZ7"^S@XEMNGF]%3P'L?49!/Z0\RMK/I6]MC+:.FL>F83G#J:'PRI/7Y3W
M@#/K6P:.E@HJ:.GI(8X((QNMCC:&M [@%W+(Q Z%@JVGW:O-ZN+B<G>JW0M_
M1BW0O1#H#2\3@[W&II7#X4^]*?6XE9.B"F&E-/!N[[A6K'YI'[%AFD-&Z?N%
M1J,U5JIRZ&ZS11F,&,L: W &Z1@<5LQ8GL__ *;5'_&9_P!C$'!N@Z.E&;/=
M+S;G;V]]KK7RM_1D+A]"J[KI6^NAW*GW%U-#UMN%,*:8<?@R,!&?0%L-$&H(
M:N2PRQQPW"Z:8?G=92WD>$T4SOBMF)):../?#S++J;6;J#HX]647N:'X#*^)
M_2T4A/+$G-N?[0'G*RVHABJ(7Q5$;)8GC#F/&01WA8?4Z,DMO22:0JF4+7YZ
M2W5 ,E%+DY/D<V'O:<<>109E&]LC&OC<U['#(<TY!"Y+4]GEJK1<74EBA-HN
M0!?)IZMDS35 X9?32C@TGL!QSRT<UG^F]14E]CF;$V2GK:=VY4T<XW987=A'
M6.QPR#U%!<HB("(B JFZ:;LMUXW&U450[XSX6D^OFK9%8F8YPL3,=&*?8ZTE
M\@T?Z)]JC['.D?D"C_1/M66(M^+?YI7?;NQ/['&D/D"B_1/M4?8WTA\@47J/
MM66HGBW^:?N;K=V)?8WTA\@47Z)]JC[&VC_Q?HO4?:LN1/%O\T_<W3W8C]C7
M1_XOT7J/M4?8TT=^+]%ZC[5EZ)XM_FG[INGNQ#[&>C?Q>HO4?:H^QGHW\7J+
MU'VK,$3Q;_-/W,RP_P"QEHW\7J+U'VJ/L8Z,_%VB]1]JS%$\6_S3]S,L.^QC
MHS\7:+U'VJ/L8:+_ !=HO4?:LR1/%U/FG[IEAOV+]%_B[0^H^U/L7:*_%RA]
M1]JS)$\74^:?N,,^Q;HK\7*'U.]J?8MT5^+E%ZG>U9FB>+J?-/W&%_8LT3^+
ME#ZG>U/L6:)_%RA]3O:LT1/%U/FG[C$Z+9QH^BE$E/IRW!X.071;_P"]E913
MT\--$(J:*.*-O ,C:&@>@+L19M>UNL@B(L@B*MU)>J73]DJ[I<'$4].W>(:,
MN<2<!H'622 /.@I-<7NKBEI=/V CW=N8(9(>(I(1P?.[S#WHZW8':L==0B0M
MT)I6:6&"G DO=R:[[8-_B6!W/II,DD_!'H77')<;#;C5S1LEUWJF0,AB/$4K
M0,AN?ZN%KBX]ISVA9UI*P0:<LL5%"XRRDF6HJ'^_GF<<OD=WDD^;D@]]KM]+
M:K?!0V^!E/2P-#(XV# :%ZD1 1$0$1$!$1 1$0%B]L:*/:%>8<\*ZDAJ@WO8
M3&X^HL64+&)^&TVA[[149^>@09.B(@(B("(B B(@(B(//<:*FN5#/1UT+)Z6
M=ACDC>,AS3P(6#6D^X->=&ZC K++6,=':ZFH&\)6==-(3S< ?)ZW-!ZPM@JI
MU38:74=FFM];OL#L/BFC.'PR#BV1AZG \0@QG2U5/I:^,TG=9GRT<P+[/5R.
MR7L R:=Y/-[<$CM;W@K/%KJECEUIIROT]J"04FIK7(W>GB&Z6R#RHJF+^RX8
M_P 35>Z%U%+>;>^"Z1M@O-%(:6MB;[T3- R6_P!EP\II[#W%$90B(@A$14%"
ME0B"A2H0@1O-$;S16%[)/O3?^>U'^85F2PW9']Z;_P ]J/\ ,*S+M775^.7;
MB?ZMOJ(B+FX"A2H00B(4$(B(HB(JB$0(@@HA1!!Y+1?\K*I='H>STX/":XAQ
M\S8W^U;T/(K1/\K2!S]%V2<>]BN.Z?[T;OJK5/B@A\O-7?'D9P2,\\'&5T-7
M=&OJ4<;-T?R;[_;;3?9XKI(&@C,0=Q#2< N ZL8XX[5LG;-JW24\5OCN#!<Z
M1LF9F0'RI&X/DM.1R.'9SU+Y6:"1P)#NHCA@K<>V9D=XTOHK54#&M%51^"2[
MK<>6TD_M#EJ8KXE;3UZ/).C:=V)Y3,3TY\L>?Z.?A6R"L(Q;[]0$]8<7 ?XB
MLTV=Z%V?7NLDFLUQJZTM&3!4- +0.>.'>%\ZL5Q8+Y<+'4&:VSF)QP3V9[?.
MN]="V/=O,2QKWW1B:Q+8NW;1]!IBXTLEN;N1U R!CSY'?C'TK6E'4S4Y/02R
M1YY[KL96X-+7=NU+3-5I:_2QMOU/FHMM4[AO8YM/:>)'F/<M0U5)/05T])61
M.BJ('F.1CN;7 X(7MX34F8G3U/BC]_5X=;0BL1:OPS^WHR_9QJ>[V&_,-ND,
MS*DAM13RDN9,WO[^P]ZVY6;'&7"&HK7/IZ2NG)D\&A:1$PGX(.>'J6I-F.G;
MI?;^UUJ#8V4HZ2:HEX,C'5D]O<MWMVQ6F.W/,T9=71Y86QN!C<X<,@YY+S<7
M.I&IGAH][S_UEO3V8QQ$S%?+KU\^GZ8AH*YT$ELN,]).")(G%I!YC!QQ[^"Z
MF\00O5?;D^[WBIKI/?3/+B<8SDDY^E>5O!>[GCFY:>=L9ZOJO24YJ=+VF9W-
MU,S/JPK55&CH3!I2T1.]\VF9GU95NOR5OBMCO+]#7X8^B$1%%0B(J.**OU%=
M8K'8KA=*EKGPT<+I7-;S=CD/2<+YYJ==:XK&Q7>EO4U/(]K'MM,5(',RYYW0
M>&=QS0<$DDX/+@MTT[:GPLVM%>KZ4**@T+?)M0Z8I*^LIC2UIS%40XQN2-.#
MCN/ CN*OU)B:SB5B8GG#2NU#2;QJVHN-0Z=MHN,?\XFBD+ PMXEK^!SG' '@
M2>I8?;=,T^MKS3145#42/<\25-<6&'P9C7-:UC@,M?AC>&,$D^=?3)Y$=1YC
MM08#<-  [ ,!>OVN=FV8YPX1H1%]T2E[MYSCRRJV_P!:ZVV&Y5T;-^2FII)6
MM[2&G'HRK!<)8V2Q21RM#XWM+'-/)S2,$'T+R5Q$\W>><<GS#7SU$AENUWN%
MSAK9H]]E69"6QDG/21,8<EC0 "?@DXPMX;)K_5ZGV?VNZ7+C62=)%*_&.D+'
MEN]CO ]:JZW9C'/<7S4]^N%/2/<TN@#(WD!K=T,:XC@W'#!'' SG"S>T6VDL
M]LIK=;86P4=,SHXHV\FC_P#;D^E>GB=6NI,35RT:32,6>I0I1>9T0B(@A0I4
M%4>JU_=0\Q5PJ>U_=0\Q5PN.IU=*]!$1<VA$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$%'57&ICUM;[<U[?!)J"HG>W=XE[)(@TY\SW<.]7BQBM_TE6C_A=7_FP+
M)T!$1 1$0%X+W=Z*R6]];<IVPP-(&3Q+G'DUH'%SCU <5UZBO=)8;<ZKK"]V
M7".*&,;TD\A][&P=;CU!:_E-SK-01F>*"LU6YF_#3..]26:(\ ]_QI",\<9)
M.!AO%!RU#<ZNZOA9?&5=+3U&31Z?HS_.ZT=3IW _:V=K> ''>)Y*WMFD*FXT
ML+-1F*EML8Q#8Z [E/&WXLCACI?-P;SX'FK[36FZ:R,DE,CZRYU'E5-=/QDF
M=_\ 2WL:, =05X@Z:.EIZ*FCIJ."*"GC&ZR.)H:UH[ !R7<B("(B B(@(B("
MJ[]8+9?8&QW.E9*YAS'*/)DB/:QXXM/F*M$0:SU%8:V@AC]U8ZB^6JGR8:^'
MR;E;Q\9KAQD';C!P#D.44%]DH*:&6Z5<-?9926T]ZA&&@Y]Y4-']&X<B_@,@
MY#2MFK#[]IF:FJ*BYZ:CA%1-]V6Z7[GKFXX@C!#7_P!H#C\+*L3@>DK@5B5K
MN$-GHS4TCIW::;(8IH9P>GM$O6R0<3T7'M);D8\GEEI]!\RZUG*.MRZRNQRZ
MRM#@5UE=A76>M4<"NLKL*ZRK X'K59J $VJ7'4YOIXJS/6JR]/'11L/('I".
MT#@/I_8MTZF,\F)79VXT1M/O&[OG[5A-98K9/,Z0T<<4I.2^ F)Q\Y;A9A<3
MO%RHYAY17MK6)CF]NG&(4?B[; #TK:F5HXD35+W-]65+&00QNCHZ>*GAZF1,
M#0>\XYE=]=49)B8> ]\>T]B\[?>GS+=:1'.(>[2TL>]+8=]=O4M([XU/&?\
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M$0$1$!$1 1$0$1<9'MCC<]YPUH+B>P!!@U[(U!M&MMK)!M]BC]TZKLZ=WDP
M^8=([T!<MF8-XDNVK9\E]UF,=)D<8Z2/R6#^\X/?_>"Q%U54RZ#O5WA+H[KK
M&Y&BI'C.61N<882.L8C:7^E;>M=#!;+=34-(P,IZ>-L4;0.0 P$'I1$0$1$!
M%@VUC5]3I.UT;J%C#4U<I8))&Y:P 9/#MY8]*U[1[6KZ2.D-'(,8XQ$<>W@5
MZ*<->]=T='?3T+:D9AOM%K_9EK"NU#55E-7B-YB8V1LD;=W&3C!6?3,,D3V!
MQ:7-(WAS'>N5Z32=LN>IISIVVV8A<=HUAH:]U+)+,\-.ZZ6./+&GS]?H66TT
M\533QST[VR0R-#V/:<AP/(KYIU-;:FTULM'6QEDT?J<.HCM"\]GV@7_3-,*>
MWU$<E*UV]T,[-\#N!Y@>9>SV/?6)TYYO7J\+6*Q-)?42*AT+J.'5>F*.[0,Z
M,R@MDCSG<>TD.'K'JPKY>&U9K,UGK#PBQB?_ $FT/_"*C_.@63K&)_\ 2;0?
M\(J/\Z!09.B(@(B("(B B(@(B("(B L)VF0OH&6K5-,TNFL<^_,!\*ED(9/Z
MF^7_ '%FR\]PI(J^@J:.I:'05$3HI&GK:X$$>HHC!M6-CMVJ[1>Z=S317=@M
MU06\=Z0^73O^B1O]\*R@G?3RB2(X</I[ECUIHZJ][++E8>/NU9'RT<)=Q/2P
M.)IW\?C-$9SWE6-IN$5VM-)<(/Z.IB;*!V9'$>@Y"ZTG,8&;T=2RKA$D?F([
M"N]8C15;Z2??9Q:??-[0LIIYF5$+98CEKEFU<#M4*5"R@H1$($',(C>:*PO9
M']Z;_P ]J/\ ,*S)8;LD^]-_Y[4?YA69+KJ_'+MQ/]6WU$1%S<!0I4((12H0
M0B(BB(G4JB$1$$%$*((4.&00I1$:-_E(Z"?>K6W4EKB+[A0,#*B-HXRP9/$#
MK+2?5E?,$:_0Z1N03S[1VKYBVV[))+5/47_2].Z2V/)DJJ6-O&F.<ES0.;.X
M>]QV+U<-J[?<LS>N8S#2T:]M+/- '"&:2,.YAKB,KQ1<1P7IC7U*/+>(F,2[
MV\22>)/$E=S,9&\"6YXX[%TM7:U>JCS7?6VSZ]Z;H-&P31S4\4[&$OX>63U8
M[>&%\S:FJA6:BN%2)#*Z69SW/)SO.)XGUJJCJ)F1F-DTC8SS:'$ ^A(N:Z\/
MP]=.UKQ.9L^?:;1%:3TK&.7^9]>7^7U%_)^Z.?1(II9&SQQ2![8GC/1DY)(]
M.55?R@+1;J>@IZN%D<56\\6M&-X#X6/H6F=*ZINFG9"ZVU#HP>H$C_V.Y>NZ
MWN[ZKN$;:ETU542$-CB;E[G'L'L7GC@[4XF=:+<NSI.K-]*-&:YF)Z_KGZY\
MNSPVVDGKZV"DI(W2U$SQ&Q@ZR5]1Z(T]%IG3U-0,PZ8#?GD'PY#S] Y#N"QS
M9;H%NFH/#[F&ON\K<8&"*=I'%H/QCUGT+8*^9Q_%QK6\.GPQ^[ZW"Z'AQNMU
MD4*5"\#U/F?^47625.NF4CR3%24S P=A>-X_P]2J8[##I;1U%JF.MIJJYUAZ
M.EA:0?!2<YD(ZW  @=0)SU!9E_*%L+V7VCO#6$PU40A>[' /9R!\X_85KJQ:
M6=>8*V1EPH*,TS0[%7,(]_)ZB5^AX>E+</2<XCS_ #ZOD:VI>NK:%A5&[5^F
MH-8T5QDIZZ@F%-5D3D.E>,;DP&>+B#AWY.>U89J$W2NKW7"^&IDJJL"3IIVD
M&08P".T8QR6P[WI*HI]+V:W4-=:IG2E]?,16,87N>&M:T!Q&=T \OC%6FK+O
MJ'1U7IFEO/@]PBIJ1I=3R[LL4F'$@X(\DAI:,]RS%(Z4YS.?LL:WG/YZ/3_)
M;K)(ZJ_VW)Z!T;*D#JW@=T_01ZE] +4^PFC?627_ %1)1Q4;;C-T4,,3<,#6
MX+BWNSP\X*VPOD<3$1JS$/HZ4S:D3+B5+!EP!Y94(N#J^4=2OI*K7NIJ_4$D
MQF@J974T ;ELKV/(9&X]31@9[LKG<Y+E?+<Z.FJ*!CKG1&LKH)(V1[AB<6Y8
M\CAO^^QGMZEMC7^@*R:_&_Z<:Q]1)DU,#FM))(PY[0[@20>7:L8K=.:GNEUN
M%-;;-NT513MI&SU]*R)T<0:T9WNH\.K*^U6VCJ5B8F(Y>;YMO$K:8F,KS^3M
M2W*T6N_6>YQ.C\%JF2-87!P87Q@D @D<< ^E;;6/Z#TO3Z2T^RW4[^FD<\RS
MS$8,DA &<=0   \RR \E\K5F)O,UZ/H4SMC/5@FU#2$^H*>DKK4&&Z41)8QV
M,2MSG''AD$<,\#DK6=S-13WRFBAL%75FF87QR1TSJ>7PAPXO(;Y) <>SD!Q7
MT,N72/W<;[L=F5WT>+MIUVS&8<-3AXO.Z)Q+7&RS2=SM@-WU.YKKLZG;2PL
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ME/2U0K&U+/"';K7MW-W&>U4NX.>%P<U6-/'FL.VSU3;=>J&K>-YE/.U[@.L
M\<>A6]79[6^XUE=67BF=:Y'OF8('YG>7$D,W.HY../8L?<U=3FCB<<5J:YG,
M2[1W97:KF^ITO045'4VRGKJ)SVOCKFLW7L<20YKG \1G!"BCNL;=9V]]9=*:
MI@I:66+IF1"&)A+'>0W',9QQZ\K#GM'6NEPYA3PHY^O^W2*1.5S45,+M!4M(
MV5AJ1<G2&+/E!I:?*QV+QW)G06:F9C!ED+CY@/:57QC,C?.KR_Q;VGZ*<?ZN
M8Q'S.&1](5QB8=8]V6,GDN!7-W)<.I=76'!P7OLEXGM-3EN9*9Y'2PGDX=H[
MUY6,WEWLH\Q2R$9;&PN*DXF,2WB)CFVC9[C'/!'-1R9A?Q&[PQW$=1"R+33V
MP:CJ8QP;4,WFCOX'^#EH_3UYFM-9O#+Z>0CI(_XCO6UJ2XL;=*&KB=O1"-I:
MX<G#)S^TCT+PZVEM>6^EC->[8SUT.7>_K7G=UKQ0^6ZG*@ON)[]IJBD ,4E8
MZI?GL@87@^AQ85?N6+Z@E:V^F4GC;[+6U0\[]UO_ -!5GH+_ &;QO.G'ULW]
M-<:NHK2<YRU\KBST;FX%E"HM$F&'2EEIF2L+HZ.)A&>.0P95ZN8(B("(B B*
MOO=Q-OI Z-@EJ9'!D,1.-]Q_@!D^A.IT6"Q+:K?Z[3.AKE=+5$)*R)H#"YN\
M&9.-\CK YKRMU)<*:ICZ8LJMXG,+6!AQUD'/#'>M<;2]0:D-JN,51-T=/6 Q
M=$QK71B(\" <9R!CCWKOHZ6;Q$L1>+3$0QG0.V'4ELJ9?=M[[Q32 X9(X,>Q
MW:'8Y=RVSL=U127?W7@+705L]9+6B%QR-QYS@'KQUKYXMU&&@<%LC9_2&CH[
MQ>72F)M+3.@CW??.EE!:W'F7TN+T=+;-HC$O?;0K73FT^3?\%RH9ZI]-!64\
ME0S.]&V0%PQW+UK1UDMPIA9[I%4.8X5,?2G'O6[^#QZ^_MRMXKY-J[7@I?=
MB(L-B(B B(@QS:+3>$:-N3VDB6D8VMC(Y[\+A*W'I8%XM(U'2:KU%N;PIZN*
MDKXP>7EQEIQ\V%DUVA\)M5;!C/2PO9ZVD+ ]$2/9>M+ASLBHTV6O[WQ/A'_Z
MQR#8R(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("P>]9J-K>G8S@QT-
MMJZEW<7N8P'Z"LX6OI)7?99U XGR*?3T&.XNEF)_="#U;'FF32E36N=O&NNE
M=4@]H-0\-^AH6;K$=D</0[-[ ,>_I^E/G>2[_P"I9<@(B("(B B(@(B("(B
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M)6)Z2EG;+<+=-]JGC;PB<>1X\1W<BJ[3-530W%]+/+$RI>"^)KG %_(' [0
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M"%$VO=2>X[Z(W&1]*VE;B0#RWDX'ON> 3CT+IX,LQ69?3(KJRNW*NIJYNG>
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M>#IHS&P]6>!^D!?,XJTVO,=G*T\VRX1&;-6@C>)C>' ]NZ<?P5=18EBI]Y^
M]K<N/F&2K*D8V.V5DTN2PQN) ^* 3P530->:*F8\8D+&@CLSR'[%XJ]9=+=(
M=MUJX*+6#)B]D71V_I*ESB  !)AI<?-O<>Q8&+W:JE\EPHJJGK8J>]54[XF.
M\KHY'>0_'8<9"L=JMK=<[H;=%-T=3<+:V*-[SAA>R7> /<=TCSD+ ;-LWU'1
M1UU55P,I:B.G<((3(USIB>S!(&.K/6I7K"VC,69)9]>4E#J"J?54SYVS-XU$
M9WG@N(W&-:>K&3ZE=0[3;'X/72RQ5,9:7/8-P.,K!AH=SP,G@,]BTVUTM/4/
M+X3]I+6.W3DX:"['I[?/A>7>!HV0.CD .Z&[HR<YWRX>C@ OK^R:;5;8C#Z.
MLVJ;7<'T<-LN#8[A*.$9_I&%K=YS7 ]>.U9'-=:A\S*:6J#7EID:UI#7. ."
M?,.'K7RI%5%U:RIIY'12LR]KV'#HW/?PW>UV,\0NRNNM56U%14UE8^6HB+MQ
M[GD[FZ-UN>TYY#O)7&W!1,\I:B[ZNH;_ #/IP8C%4,:XMZ3>SOX/'EV<O0K^
MDN%+5%K89F%[F[V[GBOD"SZGOEBM8MUKJW0Q.D:SHW $,<0'O.3G!/+ _:MR
M:?V@6:\U=%2P/FI:B2/I-V5NXUN.0WL\,\<=J\VKPDUYPU%LMRHL7M5ZZ(2L
M\JIC:X %C@=T]8SGBKV*XTDKV,9.S?>,@+QS68:5VNJKP/1UYE#@U_@LC(R?
MCN!:T>EQ 5+HVGZ'5-PIBUN+7;J.A:1U'=<YP_<7JUTYE76:?LSR0VKK6U,O
M9T=.1*<]Q<U@]*Y[/0^IMU==YFXENE;+4-..)A#NCB__ (;&GTK(RE$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!8/?_YMM8TM,78964-92D=I;N/'
M_P!2SA8/M,Q0UFE+T0T"ANL43W'X+)_M)/\ C""=D!=%IFMH9!NNH;K74X;V
M-\(>YOT."S=8/H[^9;0M;6_!#)9*:OCR>?21[KL?WHSZUG" B(@(B("(B B+
MC)(R)A?(]K&#FYQP @Y+$]3Q345WBN>0^FD:RG<,\8SO''H<78\X"]-UU5!3
M5'04,8JWM&7O:\!C>[/')\RPJLJ9[S3OFJY7O=.TN:S?(;&#R: .SMYKM33G
MK+S:FO6.4<Y915T,-=$78;Y;>(<,AP[PJ"2"2US!LY>*-X\F21V\&/\ BEQZ
MCU9Z^"]MGO#9+7"V/+IHAT<N]\%PX'([<KVVVO?.PLK61L>20 #D$=ZD;JM>
M[=TTM:8*<L:P$DY!SP5)45,%7K:C@N+(9HGVNHC=&_'(RQ=7H7OK:?W*GD<6
M$4#W;[7M&1"3S:1U-ZP>7$\N"^?[QIO4TNLZ@Q4U2^LEJC+#5M]Y@NRUX?R
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M] \Q"01SM\@'RCCECO&<+?9BBK*!U.P-,3AN.:YN1CK"U72Z"N7AA;+54\0
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M+B.P-.3DAPQFSY,C@<A6$<9'97FD=CDNR1R\LKEJ(5U2O)XY55;*HTDM5$&
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M4=2H]5K^ZAYBKA4]K^ZAYBKA<=3JZ5Z"(BYM"(B B(@(B("(B B(@(B("(B
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M+C<(X*>DJ)FUV&[@8068.,^8=7:%] Q:2T_1W 3Q66D#W/9)TY!)B(. !DX
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M:T].VI.VK+45=IZYB\6:EKQ&8C,P$L)SNGK&>OBK%)C')F8FLXD5/JBVON5
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M+,[EO/>>+CYU:HBP"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M" []LM\HP6'JJ)1\<CWK?@@]IX?%XSB_&GPZ=/\ +]#_  _@O!CQ-3XO\?\
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M,XYG/$?2%O.'?,,?2\)-QN]Y\<5\;BJ1&+1U<]&9B9I/2.CFH4J%Y'84*5"
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M*VE?C-8?^6N^NGN5M*_&:P_\M=]=;!1!K[W*VE?C-8O^6N^NGN5M*_&:P_\
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M^E5%;[\JMH*R2BJHZB$C?8<X/)PZP>XKTUM0V20EF0#Q [%G9BTS!$\L.EW
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MGM-;'#$T,8Q@: UHX  97SBY<"GL&BS.A1]*?9^L/R;</\/M4?9_L/R;</\
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MS)*I:R>$R.;!Y<8. \\-[O 607?PNZXIXY8*2A:<B",E[G$=;R/?'Z O=8-
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M630TF"ZLKCF5Y P.T^<E>F]ZPTSJ33E)%?;=7MO-%3.A@DA=]KW]W ).1PR
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M.&>/9P7/4T-.8O;SB9:BT\G3LRVB5KM:WV.X1WJMIZZL:RFA+7/%&"]PPX?
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MQXE;5?Q[I_FS]5/$G:K^/=/\V?JH-SK'K4WW3U!6W)^'04A-)2]@/#I7>?>
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MA/(=U@E<,M:2> )QP0>JFU9JS3^HK3;];T%MFH;K+X/#7VS? AEZFR,<3P/
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MY=,OJJAMI>YW\SAJ>FDWA.WD7DYW2[(Y(/H2*Z53M7S4YN%I-I;0MJ&PA_\
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MKY?/\<;M$V#3[[O;M.:CTQ%5P,H[G1$15327>1)N@8>[MP[)XKZ 0$1$!$1
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MD9!'H7DOEZMMAHVU=XK(J.F=(V$22G +W'#1YR@\]%IBS44]-/2V^*.:FI?
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MUF/=M.W/:>7W4&IM'5U@HX*Q\]/5T4QP)H"< GEG/4>HA8^U;"=_H2QGE4-
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M3HSYG C^*^#;O026N[5M!.TMEI9GPN![6N(_@OOI?/?\HO9[-)4/U79XC("
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M)70NB<YF>#V.' X(ZCP75L:JJD66ZV:MJ):F2RW&>ACFE=O/=$UQ,>\>LAI
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M0T@D'!P>2E:HOE/1:?V@Z5U)8*AS:;4-4:2N9'(3#4!T3G,DQRW@6#CV+:Z
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MV0/)]S*BK(K9(0[&\.&[OXX[HSYU9:BUS>_&NR632]LI*IUUMSJQDM5*8Q"
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MTW2:KL,ULK9)80YS9(IX3B2&1IRV1IZB#Q7&VV!TFGH;;JJ:"_R,)+YJBF:
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ML";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*401NCL";H[ I1!&Z.P)NCL"E$$;H[
MFZ.P*401NCL";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*401NCL";H[ I1!&Z.P)N
MCL"E$$;H[ FZ.P*401NCL";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*401NCL";H[
M I1!&Z.P)NCL"E$$;H[ FZ.P*401NCL";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*
M401NCL";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*401NCL";H[ I1!&Z.P)NCL"E$
M$;H[ FZ.P*401NCL";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*401NCL";H[ I1!&
MZ.P)NCL"E$$;H[ FZ.P*401NCL";H[ I1!&Z.P)NCL"E$$;H[ FZ.P*401NC
ML";H[ I1!&Z.P)NCL"E$# '4$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!"E$1!$1!"(45!0I4(@B*$(2H10BBC
MM4J%801$" H4J$!040H(1$11$15$(B((*(400B(B'4N*Y'DN*L"5Q7)<444*
M5"J"A2H0%"E0@%0I*A4%"E0B(1$00B(J.*(B#B41$$%$**B%'4I4("A$5A'%
M$4(@B(@A0>2Y,:7G# 7'L"L:.AW2'S8)ZF]B3:(6(R[;= 88<N&'/XGN7J1%
MYYG,Y=8Y"(B@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B F$1 PF$1 PF!V(B!@=B8'
M8B(&!V)@=B(@8'8HW1V!$0-T=@3='8$1 W1V!-UO8$1 W6]@3=;V!$0-QO8$
MW&]@1$#<;V!-QO8$1!&XWL";C?BA$0-QOQ0G1M^*$1 W&_%"=&SXH1$R'1L^
M*$Z-GQ0B)D.C9\4)T;/BA$3(=$SXH4=$SXH1$R'1,^*$Z)GQ0B)D.BC^*$Z*
M/X@1%<F#H8_B!.AC^($1,F#H8_B!.AC^($1,R81T,?Q&IT,?Q&HB9DP=!%\1
MJ=!%\1J(F9,'01?$:G01?$:B)F0\'B_JVJ/!XOZMOJ1$S)@\'B_JV^I/!XOZ
MMOJ1$S)@\'A_JV^I/!H?ZMOJ1$S)@\&A_JV^I/!H?ZMOJ1$S)AV-:UHPT #N
(4HB@(B(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g762905g76a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g76a01.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $5!;0# 2(
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M>I40M"^0 !0              ?KFJWQD5-V>\_
M      '0O!W[I63[C!_;0YZ'0O!W[I63[C!_;0\/YGB.G#>6NZO_ (F4_P#I
ML7ZY#3)N;NK_ .)E/_IL7ZY#3)Z>!_;C.7D !U9       SU/@S$]1!'/3X=
MO$L,C4>R1E'(K7-5,T5%1-Z*A+9/(P("HJ*J*BHJ;E13/LP5BB2)LK,.7ET;
MFZR/2BD5%3GSU>(6R>1@  4                     'J/N/_W<Q#][C_02
MSNF?X1W+_/@_N(1/N/\ ]W,0_>X_T$L[IG^$=R_SX/[B'S,O^1_N.T_@\8
M^FX@           %S;;?672K;2VVDGJZER*K8H(U>]<DS7)$W\1!; D7^!L5
M_P#LS>_R,O\ Y2QNF'KU:8]I=+1<**//+7J*9\:=JH3FE_9IBP :  _4:JM5
MR(NJFY5 _              G6@S^+&&OO*_H<04G6@S^+&&OO*_H<8XG\+_A
M<?+W0<\<6?O3>?OLWZW'0XYXXL_>F\_?9OUN/%^%YKIQ&+ !]!R
M  !E;3AR]WBG=/:;1<*Z!CM1TE-3/D:CLD7)5:B[\E3=UEV_!&*F,5S\-7IK
M4WJJT,N[_P )GFGN:1\'U+&^&5T<S'1R-7)S7)DJ+S*A\F@
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M>[K/4TCY^$;!V2,:]$5$U4RW(B.7=Q$7/3AS:_J\L77Z  ;0
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M+W/=YJKO*^>KAHJRG=,_>Z1&QNR55Y5R5$SY<C'5XDQF?;57EF]/(0 /8Y@
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M['=X&-945L4D,^29:^SU=5R]>3U3/F1#S\=>'GSXS)FS5T  Z(
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M6-BM1-3//-RM1?:0GN9\3V6T83Q!'>[S0451/5:[6U50R-STV:;T1RIGO/.
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M.Z9_A'<O\^#^XA$^X_\ W<Q#][C_ $$L[IG^$=R_SX/[B'S,O^1_N.T_@\8
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M (7'R]T'/'%G[TWG[[-^MQT..>.+/WIO/WV;];CQ?A>:Z<1BP ?0<@
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MMDR;'TYZ0(\>XICEH&O;:J)BPTVNF3GYKFYZIR9Y)NYD0UP =<<9C.6,V[
M:
M                           .A>#OW2LGW&#^VAST.A>#OW2LGW&#^VAX
M?S/$=.&\M=U?_$RG_P!-B_7(:9-S=U?_ !,I_P#38OUR&F3T\#^W&<O( #JR
M                                  #U'W'_ .[F(?O<?Z"6=TS_  CN
M7^?!_<0B?<?_ +N8A^]Q_H)9W3/\([E_GP?W$/F9?\C_ '':?P>,  ?3<0
M                                "=:#/XL8:^\K^AQ!2=:#/XL8:^\K
M^AQCB?PO^%Q\O=!SQQ9^]-Y^^S?K<=#CGCBS]Z;S]]F_6X\7X7FNG$8L 'T'
M(                                   ]Z:(?X887_T^']*'@L]Z:(?X
M887_ -/A_2AX_P S^,=.'Y:)[K_]YK!]S?\ K- F_NZ__>:P?<W_ *S0)U_'
M_MQG+R  [L@                                     #H+P?#OD=O\
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M.G\N<>H[HN[!J.Z+NPZ.>!]#X#P/H? >M^IT_ESCU'=%W8-1W1=V'1SP/H?
M>!]#X#UOU.G\N<>H[HN[!J.Z+NPZ.>!]#X#P/H? >M^IT_ESCU'=%W8-1W1=
MV'1SP/H? >!]#X#UOU.G\N<>H[HN[!J.Z+NPZ.>!]#X#P/H? >M^IT_ESCU'
M=%W8#HYX'T/@!ZWZG3^4( !X74
M                                      )Q2_LL/\B?T(.3BE_98?Y$
M_H!0JOK/842M5?6>PHE0                                     75'
MXKO6?53]2I\T?BN]9]5/U*D59@ J
M   %2#ZUOK*94@^M;ZP+TQ[O&7UF0,>[QE]9(/P %
M                "_A^J;ZBP+^'ZIOJ!%"K\9OJ+<N*OQF^HMQ
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M%[<LRZP;C>PXPBE=8:Y)I(?K87M5DC.M6KR=:;B<F6N;78VD@ ,J
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MF$NP &5        "_A^J;ZBP+^'ZIOJ!%"K\9OJ+<N*OQF^HMQ
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MR[:L^4ENU6Q_\24OWFH_L//01Y]L?_$E+]YJ/[#ST$<_R/./^(N'[:'[IO\
M:</?R3_U82"RV71D^RT+ZQ]BX0ZGC676KFH[6U4SS37W+F1_NF_VG#W\D_\
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M_5N8 'E;        "I!]:WUE,J0?6M]8%Z8]WC+ZS(&/=XR^LD'X "@
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M;OYW,5J?%4,/H$IWT^B>P-D3)7,DD1.ITKU3X*AR\\+_ &O[3\ ')H
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MRH;OANWX?IZ6NCJ[=1(Z266-$B?DY$^BY'*J\?,@XF-Z>M=I27NVP #R-@
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M->7E-?L !E0            !=4?BN]9]5/U*GS1^*[UGU4_4J15F "H
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MH
M             3BE_98?Y$_H0<G%+^RP_P B?T H57UGL*)6JOK/842H
M                                 +JC\5WK/JI^I4^:/Q7>L^JGZE2*
MLP 5                                   "I!]:WUE,J0?6M]8%Z8]W
MC+ZS(&/=XR^LD'X "@                                  !?P_5-]1
M8%_#]4WU BA5^,WU%N7%7XS?46X@
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M3,]_X?L9.U!W_A^QD[4 PW *OR>7\*C@%7Y/+^%3,]_X?L9.U!W_ (?L9.U
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MA+.9P%#8R=%05^$LYG "$@ B@
M                                    !.*7]EA_D3^A!R<4O[+#_(G]
M *%5]9["B5JKZSV%$J                                     "ZH_%
M=ZSZJ?J5/FC\5WK/JI^I4BK, %0
M  J0?6M]93*D'UK?6!>F/=XR^LR!CW>,OK)!^  H
M               7\/U3?46!?P_5-]0(H5?C-]1;EQ5^,WU%N(
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M=265(P 84           J0?6M]93*D'UK?6!>F/=XR^LR!CW>,OK)!^  H
M          0K2?CM,#T=M?';)+G55]1L(J:.34<Y<N3Z*YKFK4RRY2XXW*ZB
M>$U!IW_:UB?_ -UV(.R7_P!$VS:ZF2LMM)4S4[Z:6:%DCX'^-&JHBJU=R;TS
MRXC66%Q\DNUR#\<N355$SR3B-/KI:Q.BJG^R_$"Y=4O_ *(QPN7@MTW"#2\&
MFJY_X@M]HKL"W*BJZV1K(V3S.8]45V6LC5C151-_8IN@9898>278 #"@
M      %_#]4WU%@7\/U3?4"*%7XS?46Y<5?C-]1;B               ^)9&
M0Q/EE>UD;&JYSG+DB(G&JFIX=*UYOL]5)@C!M5>+93/5CJN2H2%)%3HHJ?\
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M4[^BGF'0YC"VX/N=PJ+JRH='/"V-FP8CES1V>_-4/3UP_8*G_*=_13SIW/\
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MN9E#RUL !           %U1^*[UGU4_4J?-'XKO6?53]2I%68 *@
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MN7T>;/+).I/24V^6ULH8+;;J6AI&(RGIHFPQMYFM3)/Z%R9SRYKLDT  PH
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MP7*2EPA+;Z-%DN%V>VAIXF\;E<OTO9JYI[4)%A2SLL&'+?:XU14IH48YR?\
M,[C<OM557VBIL%%58AI;S4[26JI(G1P-<[Z$>MQN1.DO%GS&5+<OZ9C#7?8
M#"@             3BE_98?Y$_H0<G%+^RP_R)_0"A5?6>PHE:J^L]A1*@
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M(U^LF7L1":X!P5:\%6I]':TDDDF=M*BIF7.29W.J\W,GS523 UEQ,LIJI)(
M PH          !4@^M;ZRF5(/K6^L"],>[QE]9D#'N\9?62#\ !0
M   A6D'1Y08OGI*Y*JIMEYH_V>OI5R>U,\T14Y41=Z;T5.?C)J"XY7&[B::H
M31+6W:LIG8WQ=7WZBIG(]E'LD@C<J<KLG+G\%ZS:L4;(HV1Q,:R-B(UK6IDB
M(G$B(?0+EG<O))H(?B7 \-]QK8<0SULC%M.]E,D:*UZYYYJN>[D["8 DRN/>
M  "*             !?P_5-]18%_#]4WU BA5^,WU%N7%7XS?46X@
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M:  0             $4 !%
M                                  "<4O[+#_(G]"#DXI?V6'^1/Z 4
M*KZSV%$K57UGL*)4                                     %U1^*[U
MGU4_4J?-'XKO6?53]2I%68 *@                                  !
M4@^M;ZRF5(/K6^L"],>[QE]9D#'N\9?62#\ !0
M             OX?JF^HL"_A^J;Z@10J_&;ZBW+BK\9OJ+<0
M                            10 $4
M                                             )Q2_LL/\B?T  I5
M#<Y./D*6SZP"H;/K&SZP &SZQL^L !L^L;/K  ;/K&SZP &SZQL^L !L^L;/
MK  ;/K&SZP &SZQL^L !L^L;/K  ;/K&SZP &SZQL^L !L^L;/K  ;/K&SZP
M &SZQL^L "XIFZK7;^4^ITSC5 "*M=GUC9]8!4-GUC9]8 #9]8V?6  V?6-G
MU@ -GUC9]8 #9]8V?6  V?6-GU@ -GUC9]8 #9]8V?6  V?6-GU@ -GUC9]8
M #9]8V?6  V?6-GU@ -GUC9]8 #9]9]PLRD:N8 %V63F?27?R@$@_-GUC9]8
M!0V?6-GU@ -GUC9]8 #9]8V?6  V?6-GU@ -GUC9]8 #9]8V?6  V?6-GU@
M-GUC9]8 #9]8V?6  V?6-GU@ -GUC9]8 #9]8V?6  V?6-GU@ -GUEY$F4;4
MZ@ 11J6ZSDW\A1V?6 (&SZQL^L !L^L;/K  ;/K&SZP &SZQL^L !L^L;/K
M ;/K&SZP &SZQL^L !L^L;/K  ;/K&SZP &SZQL^L !L^L;/K  ;/K&SZP &
3SZQL^L !L^L;/K  ;/K  '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g762905g78p09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g78p09.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[2S&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             $LP  !R<          0
M       !              <G   $LP                     !
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M;&]N9P  !+,     4F=H=&QO;F<   <G     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    !.$))300,     "*8     0   *
M  !I   !X   Q.   ")\ !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(               $  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
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M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MV8QMM(Q[Z7AP!G7:=WMM=[G5N_D+?Q1C/<#>&Y%GYE( L=_597^;_+=[*_\
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MN6G7].S^M_WUB5OT1_6;_P!4U'JGJPW9+/I,;8/%AVG_ #'^W_P5+&NK>QK
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MV/:[8_\ ,1,;IF35<Q]V=9DUM!!J?74&DQ#7#TZV.KV_\&HI)@JA2\50IT0
M  ! &@ 4+G ,+>[O:T>)*HH^)_.'X?Q12__9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 2Y-30 J    "  ' 1(  P    $  0   1H !0    $   !B 1L !0    $
M  !J 2@  P    $  @   3$  @   !X   !R 3(  @   !0   "0AVD !
M  $   "D    T    9     !   !D     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C Y.C$P(# R.C(P.C X   #H $  P    '__P
MH ( !     $   <GH , !     $   2S          8! P #     0 &   !
M&@ %     0   1X!&P %     0   28!*  #     0 "   " 0 $     0
M 2X" @ $     0              2     $   !(     3A"24T#_0
M"           _^$!-D5X:68  $U- "H    (  <!$@ #     0 !   !&@ %
M     0   &(!&P %     0   &H!*  #     0 "   !,0 "    '@   '(!
M,@ "    %    )"':0 $     0   *0   #0   !D     $   &0     4%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,#DZ,3 @,#(Z,C Z
M,#@   .@ 0 #     ?__  "@ @ $     0  !R>@ P $     0  !+,
M    !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,
M   !  (   (!  0    !   !+@("  0    !              !(     0
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M*"@H*"@H*"@H_\  $0@#A@5= P$B  (1 0,1 ?_$ !P  0 " @,!
M       %!@0' 0(#"/_$ &,0  $# P$$! 8,"@<#"@0#"0$  @,$!1$&!Q(A
M,1-!46$4(C9Q<X$5%C(S-5)RD:&QLM$((T)48G23E+/!%R0T4X*2TD-D\"4F
M-T158W6BPN$8.%;Q182CM,/3)RA7=H.D_\0 &P$! 0$! 0$! 0
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MQ@#M/63VDGB3VK(1%*)G/&1$1&"(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B#"N]MI[K1NIZD'&=YDC3A\;QR<T]1':L2P5T[W36ZYD>R-+C><!
M@3,/N9&CL/(]A!4PH#4X\!DI+U'P=2/#)\#W<+CAP]1+7>I77C^%TI^+\$_;
MY3Z(BAS$1$!$1 1$0$1$!$1 1$0$1$$+J6MG8VGMUN=NU]<XL8_F86#W<N/T
M<C'>0I"U4%/;*"*DI&;L48X9XDD\22>LD\25%6-OAM]NUR=AS&/\"@/Q6L]W
MCSO^R%/J[<(VNE_PQL$1%#F(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M B(@(B("(B B(@(B("(B B(@A-:.<W35:UA(=*&PY'Z;PW^:F8VAD;6-&&M
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MBU-9M97RM=35$;9:&YU'315+2>+<8&#YN]!OE%2-0[1:*TW.GM5);;C=KQ)
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M42L;ATI:, N/7@(-"6MEUI-L.NZ./5E-IRKJ)HZJ/PJCBD\)AW  6N>1P'+
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MP#A@\BMJ*-L-AM>GZ0TMEH*>B@)R6PL#<GM/:I) 1$0$1$!$1 1$0$1$!$1
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MJ44>TVU2:<O5/:]5BW=$]E?"XTM; ".&\/R@0.2P=!P5LVWVXSW*ZP7>L;9
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M19J_'C7^N)[1'&/_ $J<1-W9OF3Z1']D)[#5W_;U?_DC_P!*>PU=_P!O5_\
MDC_TJ;1-TL\RW_1"$]AJ[_MZO_R1_P"E>-/IR>GEGDAO=<U\[M^0[L?C.QC/
MN>P!6%$WRWS;?]$(3V&KO^WJ_P#R1_Z4]AJ[_MZO_P D?^E3:)NEGF6_Z(0G
ML-7?]O5_^2/_ $H;-7X\6_UP/?'&?_2IM$W2>9;_ *(5YPO]L'2&2*\0#W3
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MM>QS7@.:X8(/(A:EU[IAMNLLU%X9!):)2 V.;WZEX^*YISXS [ QC(!/'@K
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MF;;Z%JEE$Z1\FK;Z%JEE5NJ5ZG5(B(I0(B("(B H*]6[BZ:+W)/$#J/:IU"
M001D'J6Q.&3&5(-$3G 6++1.A>YS1XCSEP[#VJ^-IX6G+8V@^9>590Q5$)9N
MM:[J("N+HG3C"AEA"F=)P[]PDD<PD,9P=U D_<LR.P.=-^/>T1 \=WF?N4]#
M%'#&&1,:Q@Y #"VU^&$UT\3EW1$7)V$1$!$1 1$0%&W^Q6V_T8I;O21U,(=O
M-#N;3V@]2DEJK;]>+A;+7:H;?5S4S:F5XE,3BUS@T @9'$!=="DWO%:SB7#Q
M.I72TIO>,PL']%VD?^R6?YW?>O2#9GI.&9DK;1$YS#O .<7#/>">*T?HFFU%
MJFOK*:EO-S::>E?/O>%28WA[AO/K/U%0$>I;]2O$T=XN398SD!U0\X(ZB"<+
MZ,>%U9F:QJ<8^7R/WW0K$7G1X3\/J>_:8M%]=$^Z44<[XANL>>! [,CJ45_1
MQI?_ +,9_G=]ZU]M<OMS9>Z"G@KIZ>#P)DQ;!(8\O<3DG'/D%!6JGOUPTU=K
MNRZW(1T)9@>$O\<<2\\^H8^E>6FE?;$[L/V.CX?4\J+^9B)_5NFU:)T_:JZ.
MLHK=&RHC]P\DNW3VC/6K&OG/1%^NS-56T&Y5DC))@Q[))G/:YIX$$$KZ,7'7
MI:D_BG+S^+T;Z5HB]LB(3@$K0[9[CJ;1M\UQ6ZJN%H?'-.+;#3S='!"V)Q8T
M.9RD+G-//M7%Y&^$41I"LKKAI6T5EVAZ"X3TD4E1'C=W7EH+ACJX]2ER<#)Y
M("+7-7MCTQ!)4N9'=:FWTTG137&GHG24L;NO,@X<,JPZ@UO8['9J*Y5-7T\-
M<6BC92MZ62J+L8$;1Q=S')!9455TIKNTZDN-3;J=E;17.G8)'T5? 8)MP_E!
MIYCEQ':M25.I[V-C.T2X"ZU8KJ.[214\_2'?B8)(QNM/4.)^=!M'66AWWJ^T
M5_LUWJ+/?*2(P-GC8)(Y8R<[LC#C>&2<<1S771^AI+1J&KU#?+O->;[40BG$
M[XQ$R&('):Q@SC) SQZE;;6]TELI'R.+GNA87$\R<#BJ)<-K^FZ2MN=)%#=J
MVJMLKXJN*CHG2F'<YO=CDWOZT&Q$6N*K;+I2.E954CKA<:7HFRS34-(Z9E,T
M\NE(]R>X\59;OK2Q6O3,%^J*UK[=4-8:=T0WW3EWN6L:.+B>Q!8D5/TUM"M%
M\O(M/@]RMMQ=&9HH+E2F!TK!S+,^ZPL:];3[);+G6T+*:[7!U"<5<M!1NGCI
MSC.'N'(@<QU(+RBJEUU_I^W:?M]X\+=54UQ+6T;*5AEEJ7'\EC!Q)[>Q=M)Z
MYM.I;A4V^G96T5SIF"22BKX#!,&'\H-/-O+B.T(+2B(@(B("(B B(@(B("(B
M B(@P[U\#U_H)/LE<6/X&H/0,^R%S>O@>O\ 02?9*XL?P-0>@9]D*O:OV?=F
MKK)[V[S%=EUD][=YBI1"*TCY.4/R/YE2ZB-(>3E#\C^94NJMU2O4ZY^1$12@
M1$0%\:?A 7&XU^TR[TE=4R/IJ1[&4\.?$8S<!X#EDY)ROLM?,7X3>G74VKJ6
M\Q1GH:Z 1R.QPZ5F1]G'S+V^ F/-Q+GJVV5W-$B'N5FV?ZGKM&ZCIKG0RO;$
M'M;4Q#E+%D;S2.W'(]2CA3'L766 B)_#\DK[4Z<6B8EXH\769Q#[^C>)(VO:
M<M< 1YBNRP;$[?LE [.<P,.?\(6<OS,QB</HP(B+ 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!%@W>\6^STYGN=9#31CKD< 3YAS/J54.JKS?28])V=X@)QX?7@QQC
MY+.#G*ZTFW%TII6O&8Y=UVGFBIXG2SR,CC:,N<XX "I]7KVDGG=2Z;HZF]U;
M3@^#MQ$P_I/.!\V5UI]""NE;4:LN51>)@<B%QW*=O<&#^:M])2T]' V"DACA
MA:,-9&T- ]06_@K]5_PJ?_:?[1_O_"DSV?5-\@E??;I';*3<)\$MW%QX<G2$
M9^96'0YSHZR_JD7V0I:J_LLWR#]2B=#>1UE_5(_LA)MNJ6U)OI_?_:;1$7-P
M$1$!$1 1$0$1$!1VI/)ZZ?JLOV"I%1VI/)ZZ?JLOV"MKSA5.J'K9/@:@_5X_
MLA9BP[)\#4'ZO']D+,2>9;G(B(L2(B("(B B(@AM7_ CO3P?QF*94-J_X$=Z
M>#^,Q3*KVKGHCYG]!$12AJJU1.=IW:S X<77"L('<ZEC(_FKSH.85&B-/3#E
M);Z=WSQM59LD .N=H%ID #*J"FJFCM$D<D;C\\84GLCJ/"-G-C&,&FA-(1V&
M%QB_]""WHB("(L&YWBW6O<]D:V"F+_<B1X!/F"1&1G(J)<MH+8ZZ2.UT K::
M-VX9^G#!(1SW.!R._D5'UNT&LK!(;120Q08+ ^I)#R\<#P'N<.R..<XSR72-
M*TLS"]NO=L;</ 75].*OET1>-[/8JQKVLA-WL-,V2,R-GD<X;PR/Q9PW':>.
M/,M6MJZ"*U/\*DC:U@(EC>X%_2=>1S+B>.?,N*6ICI*.DN\,M(^HAB+GOG\8
MR.< '$G.=_O[RNL:..*+3F&RKY%*RU5-7;&9D93O>P-XG?#3CAU\5'V9D%/;
M:5M%@TY8'M(/N\\22>LDY4Q;KA#'0QN:XO)\=I9Q!!X@@J$KHH+7.*VC;)':
MI"6U$+07,IY"<B0-')IX@XX9(/:IK,QPERM$3QA4MI.EG0^$7:@@8;;, ^0,
MX&%YX$EOQ2<<N1RIO2VD=-7+2],R"-HG=&'.J(C^-:_'$^HYX'@K3%6PNH.A
M,3*B*1I!R0YCVGZP05 BAI]-U N=DH]VAFD8RLI6OP(3G#96Y_)XD$=X[%UM
MK7OIQIVGER<-/P^GIZMM6D=7/_Q4:VU5VFZF1TI)IVOPRLB/ =F\.;3]"S-9
MRN?8;?5SP[SY&_C7-X%[<CAZ_P":V3T%/<-]QRQY&)&\""._M6G-?40MU0*:
M@CDIZ%T<>YS,;G!QWMW)X'&[GU+-.=TQ$NDUV\N3W\.MIL#8S/"YABZ,1@X.
M_C&Z!U'/6O2Z3T=M91SU+XHI6/;XS!S&,.) YC!/'MPM<L:'5(,8\5TKP!^C
MRD^GDN*;=#?&;OL= =X;O-H)W3ZQU>M?1_=8SS==S8-7?[8*^D J@_<<[>>Q
MI<&Y:0&^<_R7:TW2@N-PJIHG-SNM9&90 7M&<N&>_AVK77'P>3>=O$11%SM[
M.'D\'CS#F>O"[N W92S&^VH'1Q]6\>''N=DGUI^ZUQS-R^R7^V4$]>&S-< 6
MXBC:2'/(P<=0!./6"HJ3538[1X&R!S*IL;:=TCW L;O# =VD?S55:Q@,;=T.
MAWGQ-+O]HP X8?\ %G'F7/C24\!!,CG0.BWB.;R.3NSKY]:JOAJ1S-TLYEUN
M/AC9GU+VU(;T#7</Q9#>0'(M/ K&K:NJKJCIJN1[Z@98UP(WHWM:3@=6Z1]:
MX;%O"-T<CHP]V8PYOC-?C!![00#D?2N=QKWL?%-NB5Y=$0.(?QS_ (2 >!7>
M*5CC$)>30Q\,D,6Z!*&R1#\DD<7;IZN7+J6->XG2V:Y$Q.!DC>6$G#FN=@%I
M'7](*SI)PW>, :!+'TC"&XWWY^O'5UKM2P.K[Q;*>)O215U?2PY!Y?C!O @]
MP*G5G&G:?HV.;Z.U$SI-?:!IQS@%5.?,(-S_ -2OJHM5_6-M5NC!X45CEE([
M#),UH^PY7I?G'H$/(HAY%!":(\E+9Z$?6IM0FB/).V>A'UJ;56ZI7J]=OD1$
M4H$1$!$1 1$0$1$!$1 72?WB3Y)7==)_>)/DE((1FD?)FV^A:I91.D?)FV^A
M:I95;JE>IU2(B*4"(B B(@(B("(B B(@(B("(B B(@(B("TU^$?_ &.P^EE^
MR%N54C:GHJ;6-NHV4E4RGJ:60O;TC26N!&"#CBO1X6\4U8M;D\OC=.VKH6I3
MFTGLXO%?;ZFZ04-08(W4%14.W&C>+V1G<.2.K).%4;A4RUDD]34%IFF.^\M:
M&@D\S@<EMNV;(M1VZ::6GN5LWI8)*=V\QY\5XP[UX6-#L0O#I&,GNE"R$D!S
MF,<7 =W>OK5\1H1:;;H? MX/Q-J5IMG@Z[7O*2A_\.A^MR\=.7VXTFC;U%3U
M&Y#3N@$;-QI;A[G[^<CCO=>5?]H&SRIO]PI:NW5D43HX&T[V3-)!#22""/.5
M 4^R^_P4%71QW"W=#5%ADRQV?$)(P>KF5X:ZFG-(B9?T/1UM&="M+3&8PH^C
M/*NTXY>$,^M?3ZU'I?9;<+??:.LKJ^F,%.\2%L37;SB.0X\EMQ</$WK>8VR\
MO[0U::MXV3EP_P!P[S+1&RNW:3U-LG90ZCEII#;JVK>\.F,;Z9QF>X.X$8."
M""M\$9:0M6;/]EULBTM3TNLK#;JNXT]14%DDC&R$QNE<]O'S.Y%>9\]B[.J>
M^:UV9V]TNH[G;Y(JF5L%= QG255.TXC<[>:>8XY5CHM)7>T6B^"35%UO4U31
M210QU8C C?NG!;NM'%7>"*."%D,$;8XHVAK&,& T#D .H+N@TULFU+IFV["Z
M)MWJJ6.GHJ>2&NII"-\/WG;S2WF2<_2J[J>5C=1[+;EI^1NGK/+13Q43ZV#?
M93/>T;K7-)X%PX Y6XJ[06E*Z[&YUFGK9-7EP<9WT[2XD=9X<2IB[VFWWFWR
M4-UHJ>LHWC#H9F!S3ZB@U3:Z&6JVMV>6[ZPH;C>*&DFQ34='N$Q/W<[[FD@<
M0, JBU)__D/M0_\ &I?XD2^A=.Z8LFFXY66&U4=O;*09.@C#2_'+)YE<NTQ9
M'6RMMSK51FAK9#+40=$-R5Y()<X=9R!\R#,L_P $T7H&?9"UEL3CC]L.TEP:
MW>=?) XXXD<5M=C&QL:QC0UC1@ <@%AV^U4%NEJY*"D@IY*N4S3NC8&F5YYN
M=VE!JS8%30-V:7UK8HPU]QK@X <",XX^I5'1^I9[3LKV>6RDCM[*FYU$D45?
M<6;\-&6$D.Q\8\F]Z^@;9:;?:Z22EMU'!34TCW2/CB8&M<YW%Q([2L.72MAE
ML+;)+:*)UI;RI#$.C''/ (-+7"2HCVV:'I;AJD7ZMC,[I&LACC93!S1@#<Y[
MV.LGD%+QT;:*ZZDN6SK6E#2AU2^2X6RY1 Q-G  <<D![<@#M"V9:]&Z<M1I3
M;;)04SJ5SGP.CA ,;G<'$'M. O.]Z%TM?*_PV[V"W5E60 9I8 7''+)Z_6@U
M>+I9]=:2T9=+A7C2=_Z>5UKEA8.BZ5HP_ (W2UPY J>T9J6\P;27:8U!46F\
M3&A=41W*ACW)&-#FC<E'(9SD86PKE8+1<[4VV7"VTE1;V@-;3R1 L:!RP.K'
M<O+3NE['IMDK;#:J.WB7'2=!$&E^.63S*"81$0$1$!$1 1$0$1$!$1 1$08=
MZ^!Z_P!!)]DKBQ_ U!Z!GV0N;U\#U_H)/LE<6/X&H/0,^R%7M7[/NS5UD][=
MYBNRZR>]N\Q4HA%:0\G*'Y'\RI=1&D?)RA^1_,J756ZI7J=<_(B(I0(B("JV
MTK2L>K]*U-O.ZVJ:1+32._(D'+YQD>M6E%5;328M'.$VK%XFL^KXCFM\E--+
M!4Q.BGB<8Y(W#!:X<""L6HIP&D$<.M?2NUW9[[-1OO%EB'LG&W\;".'A#1V?
MI#CY^2^=*YKF/D8]I:]A+7-<,%I',$+]'X;7KKUS'-^7UM#4\/J[;<O27U%L
M:U-!J+1=(WI&^'4313U$>>(+>3L=A&./G5Z7P_IG4]QTG?(KG:9 V5GBOC=[
MB5G6UP[/J7V!H;5=OUC8(;G;'\#XLL3O=0OQQ:?OZU\GQOA)T;;HY2_1^'U-
M](SS6!$1>!W$5:VC:MIM$Z2K;U5QNE,0#(H6\Y)''#6]PSS/9E: M.LMLVN8
M9[MIF*&&W,<0QL4<36$CFUID.7$(/J1%H/8[MHN5WU2S2FM::.&Z/<Z.*9C-
MPF1H)+)&YX' ."."XO&TO4M-M^I-+PU4 LSZN*!T1@!<6N;D^-SR@WZB+YUV
MV;2M86#:7%8-,U4$<4M/"8XWP->72/<X<W>8(/HI%\Q7O7&V?1M.RZ:DHJ1U
MN:\,>7Q1EF2< $L=D9Y96]-F6L:?7.D*2]4\1@>\NCFA)ST<C3AP[QD9'<4%
MI1%IK;!MLHM*F:T:<Z.OOW%CSC>BIG<O&Q[IW/Q1ZT&Y46D_P<-?Z@UK)?V:
MBJ8:CP3H3$60B/&]O9Y<^06[$!%!ZAU5:;" VOJ0:AWO=/$-^1Y[ T*!Z?5F
MIO[+&W3UL=_M90'U+V]S>(;Z^*N-.9C,\(=:Z-IC=/".\K'J#4EJL$0?<ZR.
M)Q]S$#F1_F;S*KOLKJC4G"RT?L+0._ZW7-S,X=K8^KUE2VG]&VFRRFH9$^JK
MW>ZJZIW22.]9Y>I6-;NK7E&?^[*WZ=.F,SWG_7^U4M&AK;25 K+DZ6[7'F:B
MM=OX/Z+3P;ZE:P T -  '4$13:TVYN=[VO.;2(B*4/*J_LLWR#]2B=#>1UE_
M5(_LA2U5_99OD'ZE$Z&\CK+^J1_9"N.F72/Y<_,?JFT1%#F(B("(B B(@(B(
M"CM2>3UT_59?L%2*CM2>3UT_59?L%;7G"J=4/6R? U!^KQ_9"S%AV3X&H/U>
M/[(68D\RW.1$18D1$0$1$!$1!#:O^!'>G@_C,4RH;5_P([T\'\9BF57M7/1'
MS/Z"(BE"BW+%MVPV>H PV\6V6C>?TH7=(T?,]_S+G9GBAK]66,YS0W22=F?B
M5'XX8[LN</4FUECZ.UVO4,#<RV2OAJ7D<^@<X1S?_IN<?4H_4%TBTIM"@NXC
M?-0WZ@,!$0&7U$)#HAD\LL?)W<$B,\!L:>:*GA?+/(R*)@RY[W  #O)59U!K
M*CH:.!]L=#<9ZASFQB.4;@W<;Q<X9QC(X8XDA4/5VJ'WDT$5?3"EI6R%WO@=
M&Z3'BAWTXSPSA5"^W.&W5U/)3-BEJ0UPFC:>)CZLXY'(X+TZ>A-IQZIFR]77
M6UWKY(:2/=MHW7/=) [?,N"!@$CQ<9R>L]2K=37.==Y'W6M;-42Q!T<T[FM<
M& [NX.7#/'UE4JMU155M1')0%M*YC"8-[QM\GW0=PZL8PHBJJYKC-))6R2/>
M\%\;^&]'N<"W X<#GN.5[=/PD_#G-EKDU/2T%341TT'3PR/)B<QX:POQQ'F)
M'#',Y6!1:MGIZ<[U/%,9GO<USG%@C>3G<=Z^'J5;8'20SQ-W<R1,EW >&\22
M[=[N'J*]"V29E0&L/XTB1I=PR.'BGL/#"]5?#TQQ3NES4.%;4,GE+C+4.<V8
M$;IR 7>IP(X=R\0.FBII)'9,\>\\@=;1O!X[".OM7ON@Q3FHC<(W'I@X\".X
M]A&.KJ7!$9;+O1[A8UM0XM/)Y!)Q\WKRNT0QL[9]J*G?:+7;)&3>$[I:7G&Y
MDDN;CN(/J6P;=(Z.KCW#C>."#R([UHW3[&PTDT]/O13L>V5OZ#N8QZUN"VUT
M-RHHZJG=ECN!!&"UPY@KXVM2(M,0YQ.)=32R62JBH7,#J":1S:25I]ZYN$+Q
MU8X[IZ^7!9\,4%0):>L --/&Z.1I. YIZL]7G60V!MUM\]!5@NB(!#P<.8X'
M+7 ]H(!'F4/;:A[VRTM42*^D(BJ6GK..#QW.'C#SKC''A+I/#\4,JUU)M%W?
M;+G.9I7Q;]+/@ SQYX@CX[<<<<Q@]:][S9J:Y4$D3F&>DEYL' M["#S!6'J"
MR'4&FIH8@/9&G=TE'+O;I8\8.,]XR%*:4K&5UFBGC?OAV,YYAV!O!PZB#U*<
MXX^JHC/#T:1UIIH6&[-=##,VCFD!A<3O$.W?&:[L'UJMTXB9)&8W/'C.C;UA
MPY_,#GCZE]#:TLT-SME3X2TO8&%[2/=,> <.';YE\Z4Y+98Y&Y##(Y@!' ,Q
MEW'J\89'G7UO!Z_F5Q/.$XQ.'>!\98Q[8>!B<X!O5'G(!\_9U<48Z.6!XE:P
M,$#72/;PQP);CS#/%9+;;6TC8:JHI)8(7EQ<XCAXQ\5N//Q7N;!7TE+'55=,
MUL 8\R@.!(#SG!'4U>GS*]S"/D>UD%01&[?+&RN8[B ?OX9/FRNTLKC'4=$1
MACF$F/F0<%SN_(Y+FCCF@$,LK)61R19+GM.'$'Q0#UG'!23=,7*&@CJ)&1,(
MA+7L:[QV[QSD]6!SQU).I6O.3")DE+HIY@_$D#C*P8R-W'#U$=?4NA)BB>&/
M&:;C&2.8(XM/;SQE6FHTNV@I&U4E2)XHV,%0S=P.B'NMWK/#)XJPW-E)7V[P
M:GCCJB\ P10M#B<'/B@=6 <]V5QMXFL8QQ5M:[IX'SL%#$X./21LA+N&>(P,
M]W+*ONC=+-9M$TY Z?IW"6:Y2 -W0WH@&@CCQ&](/F4A)3PWIU/043FOGEE9
MT!A WHL.!+QV!H!/'LPK3H&ECMNI-7WFOJ8YJ.TQ-H8ZD-W1A@,DYQVAV ?D
MKQ>)\3-J[>2ZUXIO2)]DMI&LKGP+*,P6J)WR(Q*\?YI5>U2]C])-#H:DJZUA
M;6W*22OGSSWI7EP^9NZ/4KHOG.@AY%$/(H(31'DG;/0CZU-J$T1Y)VST(^M3
M:JW5*]7KM\B(BE B(@(B("(B B(@(B("Z3^\2?)*[KI/[Q)\DI!",TCY,VWT
M+5+*)TCY,VWT+5+*K<Y7J=4B(BE B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@P[U\#U_H)/LE<6/X&H/0,^R%S>?@>N]!)]DKBQ_ U!Z!GV0J]J_9]V:NLGO
M;O,5V763WMWF*E$(K2'DY0_(_F5+J(TCY.4/R/YE2ZJW5*]3KGY$1%*!$1 1
M$0%J3;SHF"X6.:_V^!K+A2#?G+ !TT0''/:1S![,K;:\JRGCJZ2>FG:'13,=
M&\'K!&#]:ZZ&K.C>+PYZNG&K2:R^#*F,D\%9-EVLJK1&I8ZMA<^@F(9609X/
M9\8?I-R2/FZU'U-$8I9(7<XW%ASW$C^2Q74G<OUM].NI6:VY2^)H^-BD8?<U
MMKJ>Y4%/6T4K9J:=@DC>WDYI'!9"T-^#AJB5DD^F:U[C&&F>C)/!O'QV?3D>
MM;Y7Y3Q.A.AJ327VM'5KK4W5:2_"R+OZ/Z(#W)K6Y_RN65LRJKS0?@ZVFHTG
M10UEW;#(8H7^Y<[IGYSQ''UJZ[5-',UQHRLL_2B"H=B6GE(R&2-.1GN/(]Q6
M@]-_TP;.Z*6Q6RR.K*-KG&(MA$[&$G)+' @X).<%<'5(Z0VE:GGVN6RQ:EL%
MBI*^6IZ*I='3_CV$QEP(?O'CC'SJ)U#_ /-=0_\ B,/V K5L=V6ZB?K@ZUUX
M_<K&N=+'"X@R/E<W=WWXX- !( \W8H':;HW6S-L-5J335GGG,4T<]-.&M<S>
M#<<03Q1KZC7R)^$7524.W*EJX(3/-!3TLK(AGQW![B&\.U6;VQ[>.JU-)[Z.
M,?\ J7;:YH74]\VOVN[4%JFGHQ%2=),PC=:YCR79X]2$(?7.N-H&T2R.TY'H
M:MHH:E[3(X02Y=NN#@-YP#6C(&25>K*;GL2V04+Y;3)=[I4UI-13TY.(C)O.
MY@'. T#/:5O$(0",$91C0%GV_7BONM'22:$KXF3RMC+]Z3Q03C/&/J5YO6SK
M3=J.J=34E WV5JJ2>3?=Q$3S&[><P?DEV>)6Q=UHY-'S*.U-3RU>F[M34[=^
M::DEC8WM<6$ ?.@^>?P-/?-4_(IO_6OHJ^4,MRMDU)3UL]#))C$\! >WCDXS
MVC@M*?@NZ.OVE7:A.H+=+1"H$#8NDQXV[OYQCSA;Y2)QQ;$XG,('3ND[3829
M*.GWZIWNZJ8[\KSWN*GD1;-IM.9;:UKSFTY$1%B1$1 1$0>55_99OD'ZE$:&
M\CK+^J1_9"EZK^RS?(/U*)T-Y'67]4C^R%<=,ND?RY^8_5-HB*',1$0$1$!$
M1 1$0%':D\GKI^JR_8*D5':D\GKI^JR_8*VO.%4ZH>MD^!J#]7C^R%F+#LGP
M-0?J\?V0LQ)YEN<B(BQ(B(@(B("(B"&U?\".]/!_&8IE0VK_ ($=Z>#^,Q3*
MKVKGHCYG]!$12AAWFWPW6TUMOJ1F"JA? \=SFD'ZUJA]-67W90^CW#)J+2E0
M0V(^ZEDIB0S/I(\>?>6XU0;I_P UMI%-<^5KU&&4-3V,JVC\2[_$W?:>\-0:
M,O&K*>[44<=- Z.E<X.D<]P<0,9;P'5QYJO!HII2&.P(GQLR3^0X\G=H'459
M-I.FG:6UE5T$43O8ZIC?44;F#BR-Y\=G?NOR<=C@>I04HW8VR3PL$H<V'@[+
M2TD#YN/(K]!X::SIQ-7GMG+JYLC:ASA&7[LO2C')PQCAWCLZURV+H)1B4#<!
M+<CFS.7 ^OD5P^3=:V0#$4$CF. _) X D=@[%Y;A,3&N+A(T"FE:3DG/'(/T
M^;@N['J711/=T<3,,>S=ZL&0X)'8,+B21T4KNEW]UDAE<1_=XP".X=87K0TD
M]UJ(HX(632#I&2$<&D 8!/8,_-U*>M&EC++-#=WO:60MCW&.]\!YN#NSJ*YW
MU:TYRV(RK>\Z"4=*"1&YSW$'.0XX#O-U8]:S*.S5KXO"8J-YI6ND:XC'&/J
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MISFM&7$ =I.%RM4:\BH]1ZY]BH;147RLM]*U\U/45?04=,)#XKSCQG/('4"
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MWF[ZGNNHA<M6U%))!2U#H@V*%Y;AKBW''&!PY8R@V[(]D4;I)'!K&@N<XG
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MK:Y@SXP!]S*,#CCCCY_H5%Z7J?/VMY:2^ZITUK>:"_1Z<GHGT-6ZCZ6&HHI
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MX,I*F=HD8]QY!VYDL)X>ZPJU9+!;K)L3KI==4M55F[.-==A QSY-Z1XP0!Q
M8-WS8)4#2ZFFT[>=-4ND=<#5E#754=.ZU3;D\T<1YO$C?&;NCCXW8@OEBNEB
MM^N=H-6Z2NAFH(Z>:X25$N] UG1N<#&WJP <KSH-JG3-HZVKTQ>J2Q5CPR"Y
M.8'M.\<-+F-R]H/:0H.SOHFZ_P!L7LI2RUE#X/1BHIX6&1\D9@?O-#1Q)(RJ
MC4:BI])6"BJ]G>N3=J<R1QP:<JPVHE>'.P6-_+81W\L(/I-%PPES&EPW21DC
ML7* B(@(B("(B B(@P[S\#UWH)/LE<6/X&H/0,^R%S>?@>N]!)]DKBQ_ U!Z
M!GV0J]J_9]V:NLGO;O,5V763WMWF*E$(K2/DY0_(_F5+J(TCY.4/R/YE2ZJW
M5*]3KGY$1%*!$1 1$0%J7\).XB#1=+0-/XVMJV\/T& N)^?=^=;:6C?PD(72
MUU@Y[@CF^?+5UT*[KQ#T>%KNU8A\\30GBOI+\&34+:O3=78JA_\ 6:"3I(P>
MN%_+'F<'?.%HR2ASU*0TI<JO3%_I;K0'\; [QF=4C#[IA\X^G!7KU-*;1A]'
M6\/-ZS#[*11^G[M37RS4ERHG;T%0P/''BT];3W@Y!\RD%\^8QP?'F)B<2T-^
M%Y1RS:1LU2QA,5/6$2.ZF[S<#Z5E:3I=.;0=@UHLMPO!HXJ6&-M28I6LDB?$
M3P.]U'&?,MP7VT4-^M-3;+M3,J:*H;N21O&0>_N(/$'M6DJ_\&33L]6^2FO-
MT@A<>$9$;\#LR6Y^=&-8[$;=2,V^T<6G9YZNUTCZAS)Y#Q=$(G-WG=7%Q'SA
M3%E_^;67_P 2G_@N7T#LZV<V'0=-*RS0R/J9AB6JG(=*\=F<# [@HBDV1VBF
MVENUHVNKS7.G?/T!+>BWG-+3U9Q@]J-:%VX4#[I^$,ZW13NIY*R2BIVS-YQE
MS6C>'FRKS#^#=+4U43KUJ^NJJ=A]R&9=ZBXD#YEL'4&R.T7O:)3ZOJ*ZNCK8
M98)1"PMZ,F+&[G(SU#/%;(1B-TW9*#3EDI+5:81#14S R-N<GSD]9/:LEMOH
MVULE8VFA%5( 'R[@WB!RXK)1&Q,QR$1$8(B("(B B(@(B("(B#RJO[+-\@_4
MHG0WD=9?U2/[(4M5?V6;Y!^I1.AO(ZR_JD?V0JCIETC^7/S'ZIM$12YB(B B
M(@(B("(B H[4GD]=/U67[!4BH[4GD]=/U67[!6UYPJG5#ULGP-0?J\?V0LQ8
M=D^!J#]7C^R%F)/,MSD1$6)$1$!.:(@KM[T78[P_I:BC$52/<U%.XQ2-/;EO
M\U$^Q&K+%\#72*[TC>5-<1NR =C9&CZU>$5QJ6B,3QAUKK6B,3QCZM<WG6L,
MM#X!>Z&JM%>9H7!M0W,;@)&DEKQD<@3Q6PX)HZB)LL$C9(W#(<TY!4+K6&*>
MP21SQLD8Z: %KQD$&5@*AY]"B@E?4:2N519YB=[H&G?IWGO8?Y*_P6CLZ3Y=
MZQ[>?UCT^_\ E=45';JN[V-PCU=:'B ''LA0@R1'O<T9<U6NU76@NU,)[;5P
MU,1_*C<#CS]BBU)KQ<KZ5J1F>7?T9J(BAS$1$!$1 1$0$1$!$6)5W.@HVDU=
M=2P <S+*UN/G*#+15RHUUI2 $RZELXQU"LC)^@K&_I(T;_\ 4MK_ &X06Q%7
MJ?6^EJ@#HM269V>0\-C!^8E3%+<*.K -)5T\X/(QR-=GYB@R41$!$1 1$0$1
M$!$1 1$0$/(HAY%!":(\D[9Z$?6IM0FB/).V>A'UJ;56ZI7J]=OD1$4H$1$!
M$1 1$0$1$!$1 72?WB3Y)7==)_>)/DE((1FD?)FV^A:I91.D?)FV^A:I95;J
ME>IU2(B*4"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@TKKG2%\GU175-'
M0/J:>=_2,?&YOS')YJ/FTUJ.2S4M +'5 PS22[^\S!W@!CGW+?2+QSX*DS,Y
MYO#;P%)F9S/%J/9EI6\4&I6UMQHG4L$43AF1PRXG P "MN(B[Z.E&E7;5Z-#
M1C1KMJ+!J+/;*FI%14V^DEJ!RD?"USOG(6<BZNSSF@BGB,4T3)(CS8]H(/J*
MK&TS3]QU-I&HLEHJH:/PQS8JB1X/" GQPW'61P"M:(,:V4,%MM]-14;!'3T\
M;8XVCJ & O.2T6Z2M%9)04CJL<IG0M+QZ\96:B#SJ:>&JA=#4Q1S1.X%DC0Y
MI]17E04%);X>BH*6"FBSG=AC#!]"R40:JJ+)KRU72N%##8=0TLU0Z:CJKHXL
MGI XYW.#?&:#RQQ5GV8:3ETEIV2FKJAE3<JNHEK*R6,8899'%S@T'J&<*W(@
MPJ:T6ZEJGU5-04L52_W4K(6M<?6!E9(@A$YG$4?3ENZ9-T;V.S//"]$0>?00
M^$=/T4?3[N[TFZ-['9GGA8U3:;=553:FIH*2:H;REDA:YP]9"S40><T$4X:)
MHHY UP<T/:#@CD1GK51VC:3JM7RV"D,\++-35S:NOB?G>G#.+&#'#!).<]RN
M2(."T%NZ0"W&,+#H[1;J*=\U'04E/*_W3XH6M<?6 LU$'FR"*.621D3&R28W
MW!H!=CED]:Q8;/;8*QU7#;Z2.J=SE;"T//KQE9R("(B B(@(B("(B B(@P[U
M\#U_H)/LE<6/X&H/0,^R%S>?@>N]!)]DKBQ_ U!Z!GV0J]J_9]V:NLGO;O,5
MV763WMWF*E$(K2/DY0_(_F5+J(TAY.4/R/YE2ZJW5*]3KGY$1%*!$1 1$0%0
M]L=@?>=-,J*:/?J*!YFP!DEF#O ?0?4KXBJEII:+0Z:6I.G>+QZ/D8T[2W(P
M0O!],.Q;ZU/LOI*^H?4V><4<CSET+AF,GK(ZQ]2C;/LC:*AK[U7"2%IR8J<$
M;X["3QQYE]&/$TQF7W(\=H37=E*["H9HM%9DR(7U$CH0>S/$_P";*V&O*DIH
M:2FBIZ:-L<$30QC&\F@<@O5?.O;=:;/AZM_,O-NXB(I<Q$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$'E5?V6;Y!^I1.AO(ZR_JD?V0I:J_LLWR#]2B=#>1UE_5(_
MLA7'3+I'\N?F/U3:(BAS$1$!$1 1$0$1$!1VI/)ZZ?JLOV"I%1VI/)ZZ?JLO
MV"MKSA5.J'K9/@:@_5X_LA9BP[)\#4'ZO']D+,2>9;G(B(L2(B("(B B(@AM
M7_ CO3P?QF*94-J_X$=Z>#^,Q3*KVKGHCYG]'#FAS2UP!!X$'K53NNA:&6I=
M6V2:6S7'^^I#NM=\IGN2K:B5M->134M3C65%&HK[IL[FJZ UE$/_ ,2H&Y '
M:^/\GU*VV>[4-XHVU5LJHJF%WY4;LX[CV%9I (((R#U%5&[Z'I)JQUQL<\MG
MNA.3-3>XD/8]AX$*LUMSX2Z9T]3J_#/Y?V_U_9;D5&BU9<M/R-@UK1".'.&W
M.D:70N^4.;3ZL*YT=5!6T[*BDF9-"\9:]AR"%-J35%]*U.,\N_H]D1%+F(JM
MJ;6M#9ZQMLI(IKI?9!F*WT@#G^=Y/BL;WN(Z\941[6+]J<&76MR\$H#Q%IMD
MA8PCLEE]TX]1#2!S02=ZV@V*VUCZ&"6:ZW-O!U%;(_")F_* X-]9"P/#=>7S
M^Q6^W:<I3REK)#4SX]&W#0?.XJQV2W6VST;:33]NA@IV_P!TT-;ZSS)^=2/0
MS2>_3;H^+&,#Y^:"E/T'45S=[5&KKU79YLIYO 8L_)BP?I7O2;/]%0.#Q9*6
MKD^/4-=4N/G+\JX1TL+#D,!/:[B?I7L !R00%-8;#2_V73]''\BC8W^2R_ +
M=CX)AQ^KL4HB"O5.GM/59_K6GJ*3O?1,=_)1%3L]T7.2]EHAH)3P$E(Y]*X>
M8L(5X0@'F,H*$S0]QH&YTOK&[TC>0BK'"NC [/QG$?.N?9;6]B^%K-1WZD;S
MJ+7(8Y_V+^!]3E=GTL+CG<W7=K3@_0NO1SQ^]2AX^+(/YA!7]/:[L5[JA11U
M+J.Y]=!7,Z"H'^!W$^<9'!6A0-_L]GO]+X+J&VQ2L/!KI!R/:UXXM/K"KQLF
MI]*#?TO7>S5K;_\ AEQD_&1MYXAFYD]@?D<>:"_HJYI;6-LU!+)2Q=-1W6$?
MC[?5LZ.>+SCD1WM)"L: B(@(B("(B AY%$/(H(31'DG;/0CZU-J$T1Y)VST(
M^M3:JW5*]7KM\B(BE B(@(B("(B B(@(B("Z3^\2?)*[KI/[Q)\DI!",TCY,
MVWT+5+*)TCY,VWT+5+*K<Y7J=4B(BE B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@P[S\#UWH)/LE<6/X&H/0,^R%S>?@>N]!)]DKBQ_ U!Z!GV0J]J_9]V:N
MLGO;O,5V763WMWF*E$(K2/DY0_(_F5+J(TAY.4/R/YE2ZJW5*]3KGY$1%*!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'E5?V6;Y!^I1
M.AO(ZR_JD?V0I:J_LLWR#]2B=#>1UE_5(_LA7'3+I'\N?F/U3:(BAS$1$!$1
M 1$0$1$!1VI/)ZZ?JLOV"I%1VI/)ZZ?JLOV"MKSA5.J'K9/@:@_5X_LA9BP[
M)\#4'ZO']D+,2>9;G(B(L2(B("(B B(@AM7_  ([T\'\9BF5#:O^!'>G@_C,
M4RJ]JYZ(^9_01$4H$1$'66-DL;F2L:]CA@M<,@JE5FC)[54/KM%U?L?,3O/H
M7\::8]F[^2>\*[KQK:J"AHYZJLE9#30L,DDCSAK&@9))[%5;S7DNFI:G)5K/
MK6,U7L=J6F=9KF!RF/XJ7M+).1'=E1DMZN^MYGTNDY'VZPM=NRWLM\>;'-M.
MT_Q#D<\ K'BHY]IE5%6W"*2DTC _?I('#<FKSRZ1YYMCYX:#XP()[%WCIK[I
M2)WL.Z:\:>8<>#\!40C_ +L_E-'_ -E6*WY<)=-M-7IX3V]/M/\ O^ZSZ=L=
MKTS2NH[)2YF>=^>5QWI)7];Y7GB7'O4NVE,A#JIW2NY[OY \P^]1^E[W:[W0
MF6T3-<&'$D9X21N['CF#YU,J)B8G$N-JS6<3S!PY(B+&"(B B(@(B("(B 0"
M"" 0>HK&-.Z+QJ1P;_W;O<G[EDH@K.I-.6O5#(VU\<E)<X/&IZN!W1U$![8Y
M!U=W+M4/0ZCN>EJV&V:W+9:25_1TM\C;NQ/Z@V<?[-_Z7N23U*]3PLF9NR#E
MR(X$>8K!K8(:FEEH+Q#'4TE0.C/2-!8\'\EPY902+7![0YA#FD9!!R"%RM<,
MFJMFL[8JN2:LT9(\,BF<2^2UDGD\GBZ'GXQ/BX Y+8T;VR,:^-P<QPR' Y!'
M:@Y1$0$1$!#R*(>100FB/).V>A'UJ;4)HCR3MGH1]:FU5NJ5ZO7;Y$1%*!$1
M 1$0$1$!$1 1$0%TG]XD^25W72?WB3Y)2"$9I'R9MOH6J643I'R:MOH6J656
MYRO4ZI$1%*!$6BML^HM256JY;?HVX5%*W3MO-UKQ"3B<[V6PNQ^BUQX]J#>J
M*%TWJ"DO&D:"_B5C*2HI&U+GN< U@W<NR>[CGS+6FIMLUDKM*W=UK9>J:)\$
MD=-=7TCHZ9TF"!NRYX<> .!Q0;E1:6H[C!4Z%V5U-\O=WIZNIDI]QU,XGPJ4
M@>+*<\6GKY\U;M0[4]/V+4-98JAMPJ+O3MC<*6EIC*^7?&1N 'C@<^6,H+VB
MJNA]>6?6)K(K;X53UM&[=J**MBZ*>+/(EF>1[5 5VV73=/45@IZ:\U]%1O,=
M37T5$9::(CGEX/5UD90;)15F\ZYL-ITM3:@GJ^FMU5N"F-.WI'3N>/%:QHYN
M..2PM+[1;1?[W[#FFN=KNIB,T=+<Z8P/E8.;F<2'(+FBH5]VIV.UW6MM\-)=
M[I+0_P!L?;:0SLICV/<",'ARXE6S3E[M^HK-2W6SU#:BBJ&[S'M^8@CJ(/ A
M!(HM$Z_VD&U;9M/4K(K^*&D;/'5T\%*\MJ26'=+&CWP XX]6%<JRZVVY:]T-
M4NK[S155=35$M-;RPQQRM#,NZ9I/!P!X#CQ0;$14&\[5;);;K7T$-%>;FZWG
M=K)K=1F:*G/6'.!YCK SC"DKGM!T[0:2I=1NK3/;:LAE-T#=]\[R2 QC>9=D
M'AW%!;$5-TQM$M%^O#K2::Y6NZ"/IF4MRIN@DE8.;F#)W@,=2EM(ZHM^JJ&I
MJ[493%!424K^E9NG?8[=../+(03B*MV'6MFO5ON]=3SNAI+74/IJF2H;N!KF
M $GGRX\U7*+;%IVIGH^DI;S24%9((J>XU5$8Z60DX&'D\CU$@(-CH@((!!R#
MUA$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M8=Z^!Z_T$GV2N+'\#4'H&?9"YO7P/7^@D^R5Q8_@:@] S[(5>U?L^[-763WM
MWF*[+K)[V[S%2B$5I'R<H?D?S*EU$:1\G*'Y'\RI=5;JE>IUS\B(BE B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#RJO[+-\@_4HG0WD
M=9?U2/[(4M5?V6;Y!^I1.AO(ZR_JD?V0KCIETC^7/S'ZIM$10YB(B B(@(B(
M"(B H[4GD]=/U67[!4BH[4GD]=/U67[!6UYPJG5#ULGP-0?J\?V0LQ8=D^!J
M#]7C^R%F)/,MSD1$6)$1$!$1 1$00VK_ ($=Z>#^,Q3*AM7_  ([T\'\9BF5
M7M7/1'S/Z"(BE B(@$AH))  XDE:XB#MI-WZ63>;HVWS88SE[)S-/NC_ -TT
M@8^,<YX+*UK4U&I;TS1MJF?#$Y@GNU7$<&&#JB:>I[SCS-R>L*UPTT,,$-LM
M\3(*.G8V,MC& Q@& P>H?,@]0/"_Q<8W:-GBG=X;^.&!W+-    & .I<,:&-
M#6@!H& !U+E!5M1:/@KZL7.U3/MEZ8/$J8>3^Y[>3A]*Q+5JZHH*V.U:R@;0
MUSCNPU3/[/4^8_DGN*NB@=:U5EI;)+[8HV2T<GBB,QEY<<=0'(]_4NM;;OPV
MC/\ EZ-.^_%+QGMW^W^G746IZ6QW2TTM5@1UTCF&3/!G#@?,3@>M6!?*UWK_
M  Z5L<4E2ZA@!931U$F^^-A.<;WG^9;SV4ZG]GK%X/529N%$!')D\7MQXK_7
M@Y[PNFKX?96)AZ/$^"G2TXO'W79$1>9\\1$0$1$!$1 1$0%P]C9&.8\ M(P0
M5RB# >QK&NI*QK9:28;C=\9!!X;CNU4FVR2[/+S!::I[G:1K7[E!4/.313'C
MT#S\0X.Z3R)QV+8<L;98W,D:'-<,$%1-RMM+>+;566\Q-J*:=FZ0X>[;V_*!
M^H%!,(J3H*Z5E%6U6D]03.DN5 T/I:F3G6TO$-D[WC!#N_!ZU=D!$1 0\BB'
MD4$)HCR3MGH1]:FU":(\E+9Z$?6IM5;JE>KUV^1$12@1$0$1$!$1 1$0$1$!
M=)_>)/DE=UTG]XD^24@A&:1\F;;Z%JEE$Z1\FK;Z%JEE5N<KU.J1$12ACW*M
MAMUOJ:VJ>&04\;I'N/4 ,E?.^S*JUW+27S4-OT?1W&+4U2ZJ,U37")W0'(8P
M-Z@ 3\Z^A[G04MTH)Z&X0,J*2=NY)$\9:X=A7:AI*>@HX*2BA9!30,$<<48P
MUC0,  =B#YMT[-=Z79;M*T-7TG@EUMD$M3!2L?TF*>;>?NM</= 9QZU<+EJ+
M33OP<7.%72&D=:Q V(.!/28QN[O/.\ML"R6P7M]X%# +F^'P=U3N^.Z/.=TG
MLX!0,&S/1D%QEKH=-6QE3('!SA",>,,' Y D$\1VH-0UOD#L/_7:3Z@IZT7*
MU4'X3^IVW*:&&IGME.RF?*< G#2YH)ZR,?,MKNTQ974EKI76RE-/:W-?11EG
M"!S?<EO9A47^CP7;:GJNXZCME+66&X4=-' )<.S(P<3CFTCCQ00;98[QM]U)
M)IQ[91#ILTU5+"<M-0798,C@2!N_,O78K>K'1["VQU=530&B@FCKXY'!KFR#
M.\' \<K:6F=,V;2]$ZDT_;::@@>[?>V%F-]W:3S)\ZB;ILWT?=+JZY7#3MNG
MK7NWWR.B'CN[7#DX^=!I[2-IM-;L4TG3Z@O$M@J'W62JLU5N\62=*\Q\P1@@
MYP<>=6NS:GU%8]I-CTWJ:KL^H&7&.0T]=2Q!E3!NM)\<#ANG'5VK:5UL=KNU
MJ-LN5OI:JWX#?!Y8PY@ Y8'5A1NF=#Z:TQ4R5%ALU'15$C=QTT;/'+>S>/''
M<@TALB9J2"CU124VJK7::FENU2^MIZRE:]^\3GI"XGBT@?0ME;![?2T.E:U]
MOO<5YIJFOFF$T,#HHVO+O':T$<M[/+@K#J'0&E=15XKKU8J&KJ\!IE?'XS@.
M0<1S'G5@H*.FM]'#24,$5/2PM#(XHFAK6-'( #D@U/M'J(:#;CL]JZV1D%+T
M=5&99#NM#C&[ S\R]]8315&W79E+!(R2)]-<2U[#D.'1#D5L346GK1J.B;27
MZVTMPIFNWVQU$8>&N[1GD>)7G2:7LE)+:Y::UTL4EKC?%1.:S!IVN&'!O8"$
M&IZ:V/H[OJ:Z;,=:6^%LM9)+<;9<H@Z)DX)W^) >T$@]W85X/NUCVA[,],5E
M]K6:5N+K@[V/FIF_BA4L+AEN006D9YXX]:V;?=G>DK[<75]VL%!4UC\;\KH\
M.?\ *Q[KUJ4KM-V6NLC;-66JBFM30&MI'0MZ-H'+#<8&.Y!K.RZDU%:-I%FT
MSJ:JL]^]D89G4U?21!E1 &M).^!P ..8738'>+?;;-JFAN-9!2U5#=ZIU1',
M\,+&E[B#QZL!;#TSHC3>F)Y)[#9J.CGD&ZZ5C/'([-X\<=R\;UL^TG>[N+I=
MK!055?P)FDB!+\<M[XW+KR@^?K:]]ZV";39[/O3,FO$DS=T<71[T1/#S<58M
M2Q5MVV90MO&T"R1:<K(861[EO&^/<[@:&Y=O @<@M[6FQVRSQ5,5KH:>EBJ9
M#-,R)@ >\C!)'F 4%0;-=&T%U;<:/3EMBK&/Z1CVPC#'=K1R!\P06"P0^#6.
MW0=,9^BIHV=*007X:!O8/+/-9R(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B##O/P/7>@D^R5Q8_@:@] S[(7-Z^!Z_T$GV2
MN+'\#4'H&?9"KVK]GW9JZR>]N\Q79=9/>W>8J40BM(^3E#\C^94NHC2/DY0_
M(_F5+JK=4KU.N?D1$4H$1$!$1!X5M7!0TSZBKE;%"P<7..%2Z_:9;*>0M@I*
MJ=H."[ :/5DJ+UY6R5USDA)/04Q+&M_2ZRM>7)NZ2OC>(_:%XU-FGRAX/$^(
MO3H;RTOJZUZC+V44CV5#!ET$H ?CM''B%8%\XZ!=-[>K/X,2'F8@X^+NNWL]
MV%]'+Z/AM6=6F;+\%XBVO29MSB1$1>A[!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1!Y57]EF^0?J43H;R.LOZI']D*6JO[+-\@_4HG0WD=9?U2/[(5QTRZ1_
M+GYC]4VB(H<Q$1 1$0$1$!$1 4=J3R>NGZK+]@J14=J3R>NGZK+]@K:\X53J
MAZV3X&H/U>/[(68L.R? U!^KQ_9"S$GF6YR(B+$B(B B(@(B((;5_P ".]/!
M_&8IE0VK_@1WIX/XS%,JO:N>B/F?T$1%*!0FLK_%IK3U5<98S-(T!D$#?=3R
MNX,C;WDX"FU0:D>VK::RE=XUKTRUL\C>J2LD&8_\C-X^=X026BK+-IO3Y-<]
MM3?;A*:BLF_O9G=7R6M :.YJL]+"((@W.\X\7./Y1ZRO*#\?5/F/N(_$C[^T
M_P O4LI 1$0%UDC9(PMD8U[3S#AD+LB"OW/1FGKD#X3:J;>/Y<;>C=\[<*+L
M^S^CL5[AN-FK*FGW<MDA>>D;(T\P2>*NB*XU+1&,NL:^I$;=W 4)-JBUQ3.C
MZ621K20Z6.-SXVD<\N'#@O'6-RDIZ9E!2'=J:QKQTG]U&.#G#O\ &&.\K7-X
MUC9M,R>"S0S5,\;0!!!@",=622!G'4MIIS9QB+WMLI&9;DAECGA9+"]LD3P'
M->TY#@>1!7=:QV3Z]LUW,UJ9))2USIGR04TPQO,/'#2.!QQX+9RFU9K.)5-;
M5X6C$B(BE@B(@(B("(B O&KA,L8+#NRL.\QW85[(@I6O;;/7VREO]F;NWVS.
M-1 WKD;_ +6 _*:"//@JR:<N]/?K'172B.8*J)LC0>;<\VGO!R#WA>Q_J]:"
M/>Y^![G#[Q]2I>EA[6=>W73KO$MUS#KI;F]37;P\(8/\3@X#](]B"_HB("'D
M40\B@A-$>2EL]"/K4VH31'DG;/0CZU-JK=4KU>NWR(B*4"(B B(@(B("(B B
M(@+I/[Q)\DKNND_O$GR2D$(S2/DS;?0M4LHG2/DS;?0M4LJMU2O4ZI$1%*!$
M1 1$0$1$!$1 1=0]ASAS>'/CR6*^YT+'[CJN$.[-\+<3+)F(9B+7^JK_ "7"
MH%+;)'^#M!WW,X;Y\_8L6TNK;<\2P5)#SSC=ES3W'_V77RIQF9<?/C=B(;*1
M1.G;O[*T\ADC$=1$[=D:#D><=REERF)B<2[5F+1F!$18T1$0$1$!$1!3]0;1
M+)8[G)05)J99XP-_H8]X-/83D<5'?TM:?QGH;CCMZ ?ZEJK:)PUM>?3GZ@IN
MYT5G;LRM[8ZR%US9,^7>XX>_ +XP<8R 6C_"O=&A2(C.>+[$>#T8K29S.6TM
M+ZZL^I*Y]'0FH94-87ALT>[O <\<3VJTKY]V.>7=-Z&7Z@OH)>?7TXT[8AXO
M&:-='4VUY8>-;4PT5'/553Q'!!&Z21YY-:T9)^8*@?TU:!_^H(/\KON5IUWY
M$ZA_\/J/X;EI_9?M&T_:MGUBHJRR7>>>"F:Q\D5M,C'')Y.ZUQ>1O"SW*DO%
MKIKC;IA-1U+!)%(.3FGD5F+7FK[K=YZ2S36>ZT.F[!40=-4UM6QO3QY +6,C
M=XH/'CGDH#0>KKSJ&Z:ITO2:CH[A44=/'-0WN*G;Q#B00]@\4D''((-G:=OU
MNU#23U-IGZ>&&=],]V",2-]T./G2S7^W7BLN=+;Y^EGML_@]2W!&X_&<=_!:
M<V"VO4TEKNDU-J"&*A;<JR.2G-(UQ?-C'2;W,#>(..Y>>Q^U:G.M]8$:AB$=
M->&BX-\$;_6W;@R1\3APX(-]HM=Z#U?6>&:NM.K*B/PZPSNE,VZ&!]([+XWX
M'#@T8*S=D-YO&I-,2WR]O:(J^IDEH8 P-Z*G!W6 XYDX)X]J"[HM<:]KKY#?
M"Q^J+=I>PQPAS*@M9+45$G'(W7\ T<.7'BH+2FU.I]H>L+E<I::Z5&G7OCCJ
MJ=NXRM&"8W8ZL\,XX(-R*%=J>UMU:S39F=[+.I_"A'N''1Y(SO<NHK7/1[4J
M?3U-J*GNU'<ZYX;-)8VTK&1%COR62<';P!SQ/4IPZEN VR4UFEW(K<ZR"L?$
MZ-I>V3?<#XW/@!RSA!L11>G+_;M144M5:*@3P13/IW.P1A[3APXK6.F;EKG7
M+;C?[/>J*UVN*JEAH*%U*)&SMC<6YE<?&&\1^2>&5D_@SNE?H.O=4QB.<W6J
M,C&G(:[>&0/6@VRBU3M/U=<;=K>SZ>CO,6F[;5TSIWW62%LA?('$")N]XH/
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MU+IVDN4. Z1N[*P'.Y(/=-^=>WP-OP;4?L_4C$Z?KS3:(B]KZ0B(@(B("(B
MB(@(B("(B B(@(B("(B B(@\JK^RS?(/U*)T-Y'67]4C^R%+57]EF^0?J43H
M;R.LOZI']D*XZ9=(_ES\Q^J;1$4.8B(@(B("(B B(@*.U)Y/73]5E^P5(J.U
M)Y/73]5E^P5M><*IU0];)\#4'ZO']D+,6'9/@:@_5X_LA9B3S+<Y$1%B1$1
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M6W;0U'%'N0TT%3)F=Q\;A)O>(!UCM*K7K$<W7]I:<QB8[MZ(B+PO (B("(B
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M$S@T[F26\_R0W&!U<EV_=^&4[FQJC:#72U#I;=0TSZ($B-LKR'S#MR.#<]7
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M2RPSW5TLXW9(Z8F"7/N=TG(/:#O!=O!Z^R<3R5:N)X-3TSGN>R)[W-<0\/\
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MPTN Y D<U&[2*R>V:$FHZ)Q;=+LX6^F(YB:;(S_A!<?4O#J:FZ,+B,.NQ_\
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M27_2FVW8\N_9,(H?VR6__>_W27_2GMDM_P#O?[I+_I3;;L>7?LF$4/[9+?\
M[W^Z2_Z4]LEO_P![_=)?]*;;=CR[]DPBA_;);_\ >_W27_2GMDM_^]_NDO\
MI3;;L>7?LF$4/[9+?_O?[I+_ *4]LEO_ -[_ '27_2FVW8\N_9,(H?VR6_\
MWO\ =)?]*>V2W_[W^Z2_Z4VV['EW[)A%#^V2W_[W^Z2_Z4]LEO\ ][_=)?\
M2FVW8\N_9,(H?VR6_P#WO]TE_P!*>V2W_P"]_NDO^E-MNQY=^R810_MDM_\
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M/U+HR\6:)XCEK*=T;''D'<QGUA:(H;+:VV"FM51LWN]3JQK&T\L3Y9&TKW#
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M6GA;&/H"SU'V6]VN^0.FLUQI*Z)IPY]/*V0 ]^#P4@@(B("(B B(@(B("(B
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MJ^=57=-8Q.,RJDVM2,6Q,S*?V97>MN=JK:>ZR":KM]2:<RX]V!R)[3P/'S*
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M.>P+ZL>T/8YC@"UPP0>L+05JV=[0MGU;<J;9]7VNILU;)TH97-(=$XC&>?,
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M:STSX^EJK=')'553&?DD[V&9',A!E4=XK8MN&HZ6>IE=0TUAAJ!3[V6-?O\
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M?@>N]!)]DKBQ_ U!Z!GV0N;S\#UWH)/LE<6/X&H/0,^R%7M7[/NS41%*!$1
M1$0$1$!<+E<("X*Y7!6LAPO"JK*:D:#5U,, /(RR!N?G7K([<C>X N(!..U?
M-6C+7_2CJJY2:ENTL;V>/%3APRX$GQ6 \@T <AUKKI:<7B;3.(AZ='1C4BUK
M3B(?2-/40U,?24TT4S/C1O#A\X7JM+6C0>I=%ZUI9=-3/J[)(]HG;)(&^(3X
MP<WED<P1Q5_U%KZQ:>OL5JNLTL-1)$)=_H\QM:=[&7?X3]"6T^/X)RR^CQQI
MSN6I<+7]EVO:5NUQ;21SU%,7$ALM3&&1D_*WCCUKR;MCTFZYFCZ>J #]SP@Q
M#HN>,YSG'?A9Y-^S/W?5Y;9;$11]ZO-!9;5)<KC4,BHV $OSG>SR [250Z?;
M5IB6H9&^*YPQ/=NB:2 ;GG.'9PLKIVM&8A--&]XS6,MCU%1#31&2IFCAC' O
MD<&CYRNDE92QTPJ)*F!E.<8E=( PYY<<X6N]NT\55LT$].]LL$M1 ]CVG(<T
MY((53U@/_P"GNP#JZ2+ZWKI31W1$YYSAWT_#[ZUG/.<-YQO9+&U\;VO8X9:Y
MIR".T%=E7-F_D!IW]1B^RFJ]9VC2U50T]W?,QU83T;F1[S6@$ EQSP'%<]LY
MVPX>7,VFM>*Q+A:^I]L&E)[H*)LU4T%^YX0Z("+/;G.0._"[7/:YI6WW62@?
M/53OC=N/E@B#XVG/'CG)'> 57E7[.G[OJ\MLK^N%BLN5&^UMN3:F+P Q=/TY
M=XFYC.]GL6OI]M6EHJHQ-9<I6 XZ5D#=WU9=GZ%E:6MRA--*]^F,MDO<UC7.
M>X-:T9))P .TKSIZB"IBZ2FFBFCSC>C>'#/G"KUXNU%>]GMZK[94-GI9+?/A
MS>H]&<@CJ([%5/P><-T14Y( %4XYY < M\O\,VGT7&E_#F\^DX;07"UW<=L.
MEZ.LD@9X=5MC.'34\0='YP2X9'>KEIZ]T&H+8ROM,XFIW'=/##FNZVN'4>(X
M++:=JQF83;2O2,VA(KA4&_[6=,V:OEHWOJZN6)Q8]U-&US 1S&\7#..Y6+2V
MJ[3J>ADJ;34%PB]\BD;NR,\[>SO2=.T1F8X-MHWK&Z8X)M%7M(:OM6K&5;K.
MZH(I2T2=-'N>ZSC'$YY%<5&L+3!JV/3<CIQ<Y-W= BRSQF[P\;/9W+-ELXPS
MR[9FN.,)OPFG\(\'\(A\(QGHND&_CY.<KTZUI>7_ .91A\W_ .RE;#UAK:RZ
M3,;+I+*^HE;O,IZ=H?(1R!(R, ]_-=+:4Q,1'',9=;:,Q-8KQS&5D*X*J6D]
MH5BU/6NHJ)]13UH!(AJF!CGXYAN"<GNYJVE1:LUG$N=J6I.+1APA1"I2R+?[
M^[Y/\U(*/M_O[OD_S4@IESOS$1%B10E;+TM0\@^*W@%*5LO14[B/='@%!A72
M/5TI'J(NS&N>[=8TN/8 LR"W2.XRN#!V#B54SA<S$,%9,%'-+QW=QO:[[E*0
MTL4/N&#/:>)7LIFR)OV8<-OB9Q?^,/?R^99@  P  $11E$S,B(B,$1$!$1!#
M:O\ @1WIX/XS%,J&U?\  CO3P?QF*95>U<]$?,_H(B*4"(B B(@(B((76%C9
M?[#4T1.Y/CI()1SCE;Q:X>L!8N@KX^\V4-K!N7.C<::LC/-LC>&?,<9]:LBH
M6H/^:NLZ6^Q^+;;HYM)7@<FR?[.0_2"5UI^*-G]G?3_B5G3]><?Z^Z^HO.HG
MBIX'S5$L<4+!ETCW!K6CM)/)4RHVF61\SH;%%7Z@F:=TBTP=.P'L,F0P?.N3
M@NZ*B"Z:]NN? ;#:[/ [E)<*MTLH[^C8W'JWEY5-FU<V/IKOK^"A@_*%-;H8
MVCS/D+B@V BT_5LTW [-TVLUSG=8;>(H@?4Q8HJ-G^<#:?<M[M]GW_>@W4BU
M#1Q6"=V;5M:KM[J#[M#,/F?E3\%FUHV/IK9KFDN$1]PVJML9:1\N,A!?T5$]
MFM<VH_\ *FFZ&Z4[>!FM=81(>T]'(T?,'+WH=I6GY*AE/=7U5BJGG#8KO":8
MN/8'$[I]1071%Q&]LC&OC<US' %KFG(([0N4!$1 1$0$1$!$1 0\BB'D4$)H
MCR3MGH1]:FU":(\D[9Z$?6IM5;JE>KUV^1$12@1$0$1$!$1 1$0$1$!=)_>)
M/DE=UTG]XD^24@A&:1\F;;Z%JEE$Z1\F;;Z%JEE5N<KU.J1$12@1$0$1$!$1
M 1$0%K+:I$X7>CE_)=!N^L./WK9JINU"C,UFAJF#)IY1O']%W#Z\+II3BSEK
M1FDM90@F6,#F7#'SK?D (AC!Y[H6E-,49K]04$ Y=*'N^2WQC]2W<KUIXQ#G
MX:.$R(B+@](B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B##O7P/7^@D^R5Q8_@:@] S[(7-Y^!Z[T$GV2N+'\
M#4'H&?9"KVK]GW9J(BE B(@(B("(B N%RN$!<%<KARUD.DCVQ,=)(X-8T$N<
M>0"U'>=F>G-65=3=-+7<4]3OETG@[P^+I#QSPXM)[BMN2Q,FB?%*T.C>TM<T
M\B#P*TC)LRU5I6[5%1H6Z-\&F/O;WAA#<G#79X.QG@>"[:$XSBV)>OPTXSBV
MV?R1<UZU?LPOU#27FO;<;7.>#7.WPY@(#MTGQFN&?,LO:=1P7';=8:6K8)*>
M:& /:?RAO/.%(6K9GJ&^WZGN>O+DV:.!P<(&NW][!SN]C6G'''-3VJ=%W2Y[
M4[-?Z;H/8^F9&V0N?AP+2\G Z^87HWTBV<\<2]?FZ=;YS&<3F8Y9]%2_")M%
M!2SZ?FI:6*"29TD,AC:&[S1NX! [,GYU*;:+#;*+9E0OI*.&&2FDA9&]C0"
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MUBV/Q91.QV>5V@M?4Q<3!'1F1HZ@YT<@/T-"]-&5,M-L*U$^ D.<]["1U!P
M/T$K8.E]!C3VA+M9X)V37"X02-EF(W6[[F%K0.O='\RO/9]HF:TZ(K[%?NC>
MVL<\/$+LX:X8X'MZTMJUG,_6&WUZ3NF.\?DHFS*[7NVZ1%/:M&&Z4M0]YDJ>
MD $QSC!![ ,>I96SBT7_ $Y9]:R5UMJ+=324+Y8&R$$![6OQC!Y@'GW!9EKT
MCK[2M/56S3==0U%NE<7,EE(:Z,GF0#[D\.]7#06D:JR6FMAOMTGNE37#=F$D
MCG,8W!&ZW>)X\3D]?!-2]>,Q,<35U:Q%IB8XS]<_^*A^#Q;J22P7*ME@CEJ9
M)Q$Y[VAQW0,XX]N5:M.Z,L5@U#<Z^T5DHJIH9&24?2L+(P<'@T#>X$#F>&54
M*?0FL=)U]:-&7"GDH*EV=V9P:6CJR#PR,XR.:L.S/0,^G*VKN]ZJFU=WJFEC
ML<0QI(+LD\W$CGV+-28G=:+<_1.M:)FUXOPGT5G\&SWC47RH/_6O.\__ #&4
M?RH/X2]&Z"U;I;4-94:*J*=U%4D^+*]K=UN20US3SW<\"%DV+9[J&EV@4%^N
MM;!6X>)ZF;?P[>QC= ZP. "N;5W6OGG#K:U)O;5W1QAAR#/X2D8[Q_\ LI4+
M+7U[=M5WJZ6TF\5=-/*R&GW@-UK1NAPSV#ZUL!^C+B[:^W4^_3^QP&<;WC^\
M[F,>=8^L-#77VULU/I"JBAN7.6"7@UYY$YY8(X$'L61J5S$?_7#*ZM,Q&?;C
M[JIJ:BU;?M5VF]0:1J+?54LC"]['M._AP()X]0R/,MZ2XWW;IR,\%K2TZ6U=
M=-24]UU7=_!H*9S7LHZ&4AK\'., X ../,E;*=Q7'5MG$=GGU[1.*QCAV=4*
M(5Q>=D6_W]WR?YJ04?;_ ']WR?YJ04RYWYB(BQ*.KF2U,X9$W+6<R> RNT-M
M:.,SMX]@X!9Z+<JW3C$.L<;8VX8T-'<NR(L2(B("(B B(@(B("(B"&U?\".]
M/!_&8IE0VK_@1WIX/XS%,JO:N>B/F?T$1%*!$1 1$0$1534^L8[=6MM-EI'7
MC4$@RVBA=@1-^/*_E&WS\3U(+%<[A26NAFK+C414U+$W>?+([#6A:^O%XN6O
MK?46[2]G8ZSSC<?=+F'1Q/';"P'?<1U$AH\ZQ[E;K?:IJ>\;2+BV\WDNWJ*V
M11E\4;\\&P0<2]P/Y9R>1X*4;1:JU8T&OGETM9S[BEI'@UL@ZM^4<(QC\EH)
M[^"V)QQAL3-9S"DT TU'OG:%4W"ZWVEG=3Q6Z;>F'B^YZ*%@P1@^Z<#Q/$JZ
MTMQU?<(61Z<T[0V&@'BM?=79DW>UL,1P.'47#O"PZFST6@-1VFX6R$0VBI'@
M-6"2XM<XES9'./$DG@25LISFM&7. '+)*N\>Z/5UUHC,7CE/_2HXT/<KB"=2
M:NN]8'#QJ>D+*2(>;<&_\[E[4FS#1]/*9398:B8\WU3WSD_YR5<T7-Q1='IV
MS43-VDM-!"WL93M'\EE^Q]%C'@=/CT3?N62B")K=-6.N;NU=GM\P_3IVG^2@
M:G9=I"68S16AM)/U24<TD#AYMPA71$%&]IEYMA#M.:ON<3&X#:6X,95Q8[,D
M!_KWEC5UTU)24SX=7Z4I;S0.X/EM!$F!VF&4AWS$K82(-36"U6"ODFFV9:CF
MLU=&[,M!Q=$7<>$E/*,MZ_<[OT*<9K2XZ>>(=?6UM'"3NMNM#F2D<?TA[N/U
MC'>I_4NDK-J+<?<:1OA<7&&KB_%SPGM9(.(/)5Z1NJ=*,<V1K]5V+&'!P KH
M6]9/Y,PQU8#N7-!>J6HAJZ>.>EE9-!(-YDC';S7#M!7JM76FV4[XI+ULIN4,
M +B:BS2@MIGN_*#H^#H).7''G!SE6S2FKJ6^2RT53!+;+W3_ -HMU3PD;^DP
M\I&<_&;P\R"RHB("(B B(@(>11#R*"$T1Y)VST(^M3:A-$>2=L]"/K4VJMU2
MO5Z[?(B(I0(B("(B B(@(B("(B ND_O$GR2NZZ3^\2?)*00C-(^3-M]"U2RB
M=(^3-M]"U2RJW.5ZG5(B(I0(B("(B B(@(B("\:VEBK:26FJ&[T4K=UP7LB"
MMZ5TK#8IIIC,ZHF?XK7$8W6_>>M61$6S,S.996L5C$"(BQHB(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B##O7
MP/7^@D^R5Q8_@:@] S[(7-Y^!Z[T$GV2N+'\#4'H&?9"KVK]GW9J(BE B(@(
MB("(J+8M8W6X:]N%CJ+*Z"@IW2-95^-XP:>!XC'%56LVS,>BZTFT3,>B])VH
MN.U2ARNI7*X*UD.$55VC:N;HRQQ7!U(:HR3B$,#MW&0XYS_A4Y8K@+M9*"XM
MC,;:N!DX83DMWF@X^E;MF(W>CI.G:*Q?T9J(BQ N%RJ/KW5]TT[=K72VVS.N
M$55[Y(-[Q/& ZAW]:JM9M.(72DWG;5=UPN3S*X4H<(B+6NJ%$/)!PB+A(:%<
M*F;1=<LT=+;&/HGU1K7.&0\-W0TM^?W2LU\K);?9JVLIH#4301&1D0YO(ZN"
MK;.(GNOR[8B>[,15K9_J"NU)9)*VYVTVZ9LYB$1WO&  .]QX]?T*R]2R8FLX
MEEJS6=LN N%RN%C'"X7*X0<%$1&PX77K795#:%K-FCV6QSZ-U5X;(]@P_=W=
MW=_U*JUFTXA=*S>=M>:V%<%<,=OQL>.&\T.QYQE<E8QPA1"@R+?[^[Y/\U(*
M/M_O[OD_S4@IESOS$1%B1$1 1$0$1$!$1 1$0$1$!$1!#:O^!'>G@_C,4RH;
M5_P([T\'\9BF57M7/1'S/Z"(BE B(@(BHVJ;Q6WN\/TKIB8Q3AH-SKVC/@43
MOR6]1E< <=G,]2!?M0W&]W6?3NC)&LJH3NU]T<T/BH@?R6CD^7C[GD,<>Q1M
M/)!8)YM,Z!I!77YQ#ZZXU+B]D+CQ+ZB3B7/QC#.S'(+@E^\-$[/OZI#1X;<[
MGC>\&#N):TGW<[LDY.0.)/' 5YTY8Z#3MKCM]J@Z*G82XY)<Y[CS<YQXDGM*
M",TQI"EM%0^X5LS[I?9O?KC4C+_DL'*-GZ+<!69$0:\VB:JL9I:_3]YAKXI)
M(_%<(,CM:]ISQ&1S[E1Z36=ROMUTM;YWED,$\#9L'^T2!P\9W=P'#M6WM7Z8
MHM3VTTU8"R5OC0SM]U&[[NY:-H;)6V#7UHHKC&&2BLB+7#W,C=[W33V+VZ&R
M:S'K#ZWA/)MIS'NC/_[#Z/1$7B?)$7G-40PE@FECC+SAH<X#)[EZ("(B B(@
M(B(*GJ/1T=96F[V&I-GU T8%7$W+9A\69G*0>?B.HJORNIM65<=IU)3FPZUH
MFF2CJH'<78YR4[^'2,X>,P]7 CK6S%#:IT[1:CMXIZT.9+&[I*>IB.[+3R#D
M]AZB#CN/(Y""%TOJ:MAN@TYJYC(+TUI-/5,\6&X,'Y4?8\ C>9U9X9"N:UL6
M^SF]H[70W+O&.FM]QA\3PG=Y31'\F5N1O-[3P!"EM&Z@KF7*73.J2T7ZG9TD
M4[&XCKH.0E;V.')S>HC/(H+FB(@(B("'D40\B@A-$>2=L]"/K4VH31'DG;/0
MCZU-JK=4KU>NWR(B*4"(B B(@(B("(B B(@+I/[Q)\DKNND_O$GR2D$(S2/D
MS;?0M4LHG2/DS;?0M4LJMU2O4ZI$1%*!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1!AWGX'KO02?9*XL?P-0>@9]D+F\_ ]=Z"3[)7%C^!J#T#/LA5[5^S[LU
M$12@1$0%I74^J]07[:-4Z7LMTALE/3$MZ=_NI" ">?/GP [%NI:9U=!H'5>K
MJNCKJFHM-]@=T<E0_P#$M>6\!Q=P)QC!X9"[Z&,SF'J\+C=,S&>';./LL6AO
M;S;K^^W:C;%<K26DLN+7M#@<9'#.2#RQCUJ,T?JF\5VU^^V>JJR^W4[I1%%N
M@;NZ1CBJEH*Z7&P[5(-/6Z^R7NT3.+'NW]]F-PNR.)P6D<<'"D= _P#3WJ;Y
M<_UA=K4QNF<<GHMI8WS,1TYY,:/6&M+EM!O=ALM3'(3-+%%TK0&T[&NQOCO
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M.>%@ZNH9JG8%I6>%I<RFE+I,#W+29!D]V<?.KS;=I=@MV@J6K%5'+604[8_
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M1J4F(W3R>:NKIS%=TXVS_?CE5IHY(_P<(NESX]4'LS\4S'_W6R=EK6C9K:
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MM0Z>4. R' @9[<<N"AZ2MGHI724[RQQ&Z3SX*4TW125\5=%P; ]H:7=CQQ!
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M 1$0$1$!$1!#:O\ @1WIX/XS%,J&U?\  CO3P?QF*95>U<]$?,_H(B*4"(B
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MQ[+FVJ*"9LM9674!@AW3G\4&O)<[(X'&%O-$!$1 1$0$1$!$1 1$0$1$!$1
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M/_V3/7XSO\([5854\(B'2W"L1]Q$12YJS0:2@H]?W35+:J5T]?21TCH"T;K
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<J>%WQFL&?GYHB3:9YRR=2T\)EGHB*4"(B#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g762905g98o86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g98o86.jpg
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M=8*2PN'P\1<E)C0U4V.S1%6B)SA4A(63TD5DE*3#_\0 &@$!  ,! 0$
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M=;\N6\D+VLVR+L\[5J>JTX/9F!L==#&T\1DN(<T?S26GCR.%OOY5D@EL6FI
M" ^:1PSZM:M)MM#=^V?M)_.<](ZGM3',;,\9+(86_P"##O%QY^9)P MX_*Q
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M-V/#/X %9<^$G%O5Q\^EL+^+7MU]$1><W$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MOE)BGC#FGW6>!"["BUG-KB^GKYVIV_B[F+;K;0VR$Q6VBIJ2(G)9!$V-I/P
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M*Q=DE]NE0TOBI*J:8M'5V(H\ ?$\*%TO>^T#M2K:\VZ]0V:WTY:'B$;=N[.
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M .1-_P#P7T@BC3T?_E^I^\_V<OTUV?WBW=F%\TW75U+/7USY#','O<QH<Q@
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MV46I-+-DH^ZG9%54S9'.CGC.>H)//'WYZA-&W6GN:QI<]P:T<DDX 5,<T4C
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M+;<+1K2CU7;;?)<J;N/9:VFB;NDVYR'-'CX?3URK-;JBYW^HI*'1]CJZ1[I
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MBWA^87GIN#NHZ_0_!1I.W0D1%"1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!1.KZF2CTI>JJ$D2PT4TC"/
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MS=!*R1OFQP(667'EA^::6EE]+B(BHD1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MR_@>)Y6P6R6&KBP,QU.3W>TY#L>'HN[LPLU8XMUNUE[6:B%S8]14398R<=_
M,'_570]*:IT]J6K]FME475.-W=/C+3@?%<"K8()Z=CVN<U[G;7M<W[)\U<[.
M+N_3VM*>7#7;B83GUX!7!U'0\=EN$U6_'S7U7UK2T,,3=SRUK1XGA9'YQMU/
M[KIVD_S1E<QK;U72.+W/+CQM / ^2QHZFNJZH/<6[<^(Z!<6/1>/Q5>\V_3K
ML%ZMTCMC*E@=Y.X_%9['M>T%C@X'Q!7&'2S02;G<$GEPY'Q4O;;W5T#FO!S&
M_P#5/0^JC/I/'X:F<WW=211-IN\5= V1A]"/(^2E6N#AD+BLLNJVEWY>HB*$
MB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B N?ZSTA
M=#J*+5&CZB*"\L9W<\$W\75,\CZX 'R'((70$4RZ19MS5VJ>T![/9X]$1,J^
MG?/K&F+/GC(X_P!)2'9WI.Z6FYW6^:BK(9KM<]O>1P-PR,#H,^)Z#Y>*WI$V
M:%POLKN6I+50WF:U6=MXMDEQE88F3B*6*4!N7<\%I!;]/KW1:YH72[=*6ZMI
M&59JA4U;ZO<6;-NX-&WJ?V>OJDNH6>4+HC3]VEU/<-5:HBBIJ^IB%/3T<;P\
M4\0P>7#@DX'3U\\"YV36*XV*AOD=UIO9WU-REJ(AO:[<PAN#[I..AX/*WE$V
M:<WN=EOVF-9U^H-,T,=THKFUOME#WHB>UX_7:3P?$_,\>(M?FC4.M-3VJOU#
M;66:SVN3OXJ5TPEEFD&""<< 9 ^_SR.FHG<:<TUE;=0T':+1:EL-I;=8A1>R
M20]^V(M.YQSD_$>?BKM]LE]LFLY=4Z7HXZ]M;"V*OM[Y1&XD 8<UQXSP/OZY
MXZ,B=QISJ%VLM3:@MTM31RZ;LU(_O)F"I#Y:H_LG;^KX<^9Z\8S66*XCM@?>
MS3?]6&V>SB;>W^,W XVYST\<86\(FS31] V.XVK5&LJNOINZIZ^L;+3/WM=W
MC07\X!)'4=<*FML5RD[8;?>V4V;7%;3 ^;>WA^7G&W.[Q'.,+>D39H1$4)$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0%B7"V4-QC+*^CIZAN,?I(P[\5EHIEL\P
M:-<.RO2]42^GI)J";J):29S"WX Y'W+#.B=2VI@&G=7U1:.D=<QLH^N/W+HJ
M+:=3R3Q;O]_/_*G9BYM^>NT6U,_A^GZ&Z1,',M')M>?]'/)] %D4_:G;(?=O
MUNNEH>#@^T4SB!\P/W+H*MSP0U#-D\4<K/V7M#A]ZGZO'E^;#_;Q_<[;/50]
MKU=I^ZL:Z@O%%*3^J90UWS:<$?1?+O;E:6VOM#K>Y_B:H-J&'J/>'/W@KZ5N
M_9]I>ZY-19Z:.3_S*<=R[/G[N,GXY7%^VKLX98+5'=+9/555.PADHJ7[W1 G
M@@X'&5U]%EQ8\GX;9O[_ -V?+,K/+2;!+'':W0U8<]S?>B(]5A7FLD,P+L.(
M:/TCN"S'AA>4-0UM.S+VR_HP,8Y;Z?%7*^WUE>PO:-X=M:'9QM^?FO8RFHY=
MH"XD2U#WQAVQSLY<<GYA83HQN=AV1X'S"V6*QRRL?&W^.$G=YS[V<>?DLV@M
M&U[((X&/E#"V0R<[<'J%7''[I[M-+VEAR%N=@=&+0XL(GE+P7-&1QZGP*P+E
M;^]J!%[K9&O$9+6[6\^/Q4+WT]OJ9&1R.&';7 'AV"ILTC?<V+5-7#"R+N86
MQ2O:0YK22!Z$^)6PZ*$CK+%+*"=Y)#L>JYY<[B^MD8'#$;<[<=>?-=#TE*UM
MDHPR0ENT@ ^>2J6[\)DTB-9W^22.2U1$=T#^E=CKZ+2J5AIG.?']O.<X4MJ(
M[KW6'C._P6,RF<]C-CVN+B3MSTPK3BPEF6O*\Y<IC<-^*IBJ?=&X%KB#DYRL
MVAN$[&XC=P&X?T.0K1(?[IA@C& -VW)R%GT%LDF,SBR)H:T/R1S\E:;C/VS@
M'/BC>X2AI #"\9;GR6!ITT=MUA2SUU+!-3N?[T;QN:,^GHIAM.VGHV][-@DM
MD:0_/(XQ]%J=V>TUT[HW9 >2#\^JKR88\F.LIM;#/+"_ANF\]LKF5%\IKC3Q
MAC9(A"_'0.:3C'R_!:-2Q;I=SXQ( .6DXRMIU-=Z.X6"&)]3&^I8QKN"<[L<
MA0-GIN^_2 C+1G#O'X)PXS''L^RN5OM9[D-B?[GOY!P[T7D FEJ ^!KV$G!V
M\#X!;=[)13-!&Z.0D%YD;D9^(7E+1QM<QC7,CR\D2'[/'D%?:LE8K&5<5J9W
MK!&V,[FO/.?/*U":<BO,\9 >U^\8\P<K;KFZH@CFCR)P]I#0'\#U 6E/807'
MS5<O2V'M]!V>[TUQT]27":6)C2P!Y+@ '#J/JK/]W%@H7/:ZXQ[AP0P%WX!<
M(IS43[:6)\CFDY$8<<9^"MU=/)3R.9*TM<WJT^:Y<^"9XV5?#\.6W>V=HFFI
MFGO*\C^E$_\ L5RBU78[A5&GH+C&]SAC:X%ORY7SP[ID=,= 5(6:%\DWZ,AK
M@-V?/Z+/BZ3'&^+5\\]S=?3.F[@ZEK.[W>Z[@^7HND6NL[QHY7S5#K1ENI8)
M3&YSH6XDC/4D>(*ZWV>:LH-0TO?4$I):</C=PYA]0N+KN#+#+NUX:<.4LL=/
M!R$5JFD#V#"NK@;B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(N;W&\7_
M %1K.X6'3-?':J"V!HJZWNA*]SW?JM!X\Q\CST"S=//U79M4?FN]SNO-HFA,
MD=R$ C,+AGW7XX\/O'JITC;>T7+++<-4=H,U;7VF\-L5BAF=#3=W3MEEG(_6
M.[H.?#X>&5):0U!>:+5U1I/5<L555=S[31UL; SOX_$.:. >#]#UZJ>TVZ"B
MTCLPOEPO3]2"Y5'?"DN<M/#[C6[8QT' Y^:\H+Y<)>U^Y622HS;(;8*AD.QO
M#]T8SG&?UCXJ-&V\(N1V*Y:PU5J/4=LI;PVWV^@KI&>U"G8^0-W$-B:.!^J2
M2>>BF=,WN]6?6QTKJ>K9<!40&HH:X1B-SP,Y:X#C/!^GCGB>TVV#2VJ&7^Z7
MZB92N@-JJ?9B\OW=YRX9QCC[*V-<L[/*Z&V7GM*KJHD04U>^9Y'7:WO"?P55
M@;K/6EO%[9J!EBI)R74E)#2ME]P$@%[G<\X_Y=$L1*ZBBT'1^L:HTVH:+5(B
M;<[ "^HDA&&S1[20\#P.!]XZ**TX-:ZPMPO\6H(K-!.7.HZ)E*V5NP$@;W'G
MG'KY\=%':G;<-,ZH9?;W?[<VE=";3.V$O+]W>YW<@8X^SZ]5L:Y1V)R5DNH]
M</ND;(J\U<7?LC^R'_I,X],KJZ6:I+N"+BNC[AKS6M#42T5\@H(:*H?'WKH&
MN=.[.=I ;@- (^OCX;#67C4&J-6W"Q:;N#+90VH-965YA$DDDA_5:T\#H?H?
M0*>U'<Z2BYQ0W>_:4U?;;)J6X,NUONNYE+6]R(I(Y!^JX#@@Y ^?Q2[7F_:D
MUK6Z=TQ71VNCMK&FLKC$)7E[NC&@\?\ (\^<=J=NCHM$T^=667545KO$[[W9
MZB(O9<! (W0/'ZK\<8./O'JHFV7+4FOJ^XSV2[MLEAI)S3PR1P-EEJ'#JXYZ
M#D'YXYY31MU%%H&D[]>*#5\^D]43Q5E08/::.NCC$9F9G!#FC@'@_0]5!6"X
MZPU5J#45MIKPVWV^@KI&>U"G8^3&XAL31P. "23ST4]IMUQ1%MU#0W&^W.TT
MCI'5-N#._);AH+LX /B>/ARM1T[>KY:M8R:3U'6LK7U%.9Z"X-B#'. SEKFC
MC(P3\O'*USL\M=Z':=J=KM0%SZ66 UCO8V#VP8.!C/N>(XSU3M1MVA%S"FNN
MH]<WVZ1:?NC++8[=,:?VAL EEJ)!UQGH/W$=?#)L-\OMAUI!IC5-5'<8JZ-T
ME#7MC$;G%N<L>T<>!^[KGAVIVZ,BY!'==8ZCUCJ6QV>ZQ4--0U&[VE\+7.C9
MR&QM&.<G)R?V?KU.S0UE/:J2*YU(JJUD;1-,UH:'OQR0!CA19HEVS$1%"1$1
M 1$0$1$!$1 14&:,'!D:#\56"",@@A 1/!8D]:UF=@+S]R#+10SKT8W?I(>/
M0K-H[E3U3<Q.Y'4'J$&8BQYJIK/=;[S_ "4=4U=2W)#\? ()E%K++[- _%1A
M[/,#!"F8+C#+$)&N!:1E!FID>848^H?/G:[:WP 455N>W):]P/H4&T(M2H[Y
M)!*(ZEQ=&3@./4*9DN.YH;&>3XH)&26./[;VCXE1=\IZ*\VJJH*AT<D4\9C<
MTGS5N7:69)R5"5W&2TX(\0IEU=Q#YEU/9)=+7ZIMM<UX:,F"4='MSP5?H*VG
MQOD:6T^P%S&N/+NF<+K/:!9FZHM+H'[1<(/>IY3P3_-)7SQ5QRT]1+#4-+9H
MR6N:? A?1=+U,Y\//N.+DXNV^&UPW2C8T[IGAO>N(:T^]TX^*D*=AF$#VQ/E
M+VE[@';3MSP25J%BH6UM4ULIV0,;O>['3_@K=XG-GIZ5D7\8 1N#MON@]"NB
MUGI"7(=U'5O<PN8V0>_D_1:C4R"65SMH;GG"V*]SFKJJB.E+F0#WG1EWVG>)
M"@Y*?+<Q@XXQD*++4XW3!D/ X\>JV;2%ZCIA['6'$).6/\&DJ"EII&1[BTAA
M)&?569H3%'$[>T[QG \.<+/\M7U,XDKA*V2X3R-Y:YYQSU"R*,0331AS'18!
MY:>I47$[,8*R*>=T)!:5O+M2S3>@ZW,93[(8I<, =&0<YQR3Z95IQBAD=-)
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M,C/ZQ\@M,=V*W4843B  \G/P4M14CI-CSWK&!WO/ Y!\,*>M-I@<'Q!D9G+
MZ-V[(SY+-KQ)2.$37-DD<]KV2.P TCKE)X\*WSY1KY9/9JVF#Y74^S@O Y/B
M5J$QR]V,*>OER>ZHFC#P&O WM8<C/BM;<1N\U&56PB0M&#4!N6AQ(VEW3/JM
MMH)G1RFH[AI=G#SORWZ>"T)CB"<$A2=+<YX(8P&,QGAQ;R?0J,<IZIECYVVZ
MHP*2:1U+''([WVX=R.?):QJ&(^T"8O:Y[VAQ#.@\E1+<I:B9HG V9^RQNT%9
M4Q+,@4\8$H^R?>+0%?6XKO51%D&+U1_XUOXKM]1(/S)5 GC8N)V@#\]T>/\
MS6_BNW4C&34;XY1N:X $%>)_$/S1V<7I.W9Y_N(M[/%PA:?]5;?20]PQXW9+
ME 5=&RKLM-$XEC8W,>-OH.BV$/!!((('DO/:O*%CHJ<->,')*@[6<:SNV.AC
M9^ 4Y#,V6,/;G!\U&6ZD;%>[C5!Q+I=HQCIA!'65KJF\72=@R#4@$^6 MAF.
M;A!Z E1>F:62E_.'>XS)4%PQY*:WC< 2-WAYH(777.GI#Y2,/WK%U=+NL]M@
M_6FFCX] %EZKIGUUOC@C<!F9I.?(+%U%3ODN-DCC8YS&2') Z8QU^B":I26T
M$SCQG<0LBWG;21CTRJG8<TM<,@\$(S#&AK1@#@(-?LSL:SO/K&TK$M1$NI;I
M(T#'?-8,>F5EV.&7\_7FKD:6L<1&PGQ \ON5G0L;7TM94/&7.J78)] /[4&P
MSG=<8!Y#*CM<8.FZCT<P_P#U!2AB!J!-DY#=N%"ZWD L$K#U>]@'^L$%K5SC
M_<G&X'DM8W'GG"EK .ZM;6_L- ^@4!JMSG4-HHO_ #)8\_(8_>MCBB=!1/9U
M=@]$%ZU<4N?VB2H6V.(UU=L^,#/]E3-$"RFC:1@XY"@Z$_\ ;FY'_P#MF?[*
M"/#^]UJ7?LQY/U6VW)V[N6?M/6J6XBHU9<I6X(:]L8Q\>?P6SU+MU?3M\LN0
M1^OG?]FJ@?SF_BO-6OQI=[<]8A^ 5.NL.TY49\"TCZK&UED:8800/=8S'QQ_
M8@E-&'%B@_HC\%*VP_PFJ/AN"C=.L[BWMC_9P/N"D+1_%R/_ &GDH%DYO=S=
MZ@*1H_>NDA]%&6,%M?<B[KN4K;>:Z0^0 4"<;T7J#HB)$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5JI;NB</,$*ZJ7_9*#6:R*1UMFA<T
MY+#M'P6);06L:'M(>6#@]5.UHQ(P^N%#U,\9G;)&X.VDL=CP04EC&2/<T8<[
MJ?-8%RMT%=-33R[N\IW%S,'K\5=K9'1U<!W'8[+2%[43M@IY9GYV1M+SCR R
MI0B66V.JFBK'/<):=CHPT="#_P U*T,N^D83U Q]%KM==)*:T/K*%P+.]8\Y
M'5A_X"EK>\-GEC:<L<-S?@@SXI65$)(&6G@@J/%+3FHFI'1-]F?&!W8X&%<H
M7;))XOV79"P*6O-1?JRG<T-=!AH(/4$9R@SZ+NZ:HDIV8:SC8WT60*@^UF$C
MC;D%:IIR>3V=O?/+I8)G1$N//!_WK8J@[*R!_GEJ"JZN'=,.>0[A8ERN$3:Y
ME*UQ]H8T2CCC"CM92F*6UR D 3$'X'"LW\=UJ&W3^$L3HS\1R/Q0;#5RF2@;
M(#SP[A>W&HCBMTDLKPUFT<GU*L4_Z2V.;Y J/U"XR:5J#XAK?N<$%Z[W#V2@
MHFEF]M0X,)S]GC.5FT$ADI)&N.2,A:Y?LR:4M\_C&8WD_+'[U-V5^Z%Y\\%!
MFV]^:1GIPL*V5K9YKEW0]Z%Y;SYC*OV]VT2L_9>5#:9.+K>VGIWW[W(&FJV6
MK9#-,[=(YQ#CC&2IL';<S_.8M8TL.Z?)">L52YJV.=V*R!WGD(%_JG4MHJ9F
M@.+6]"HC451(+5;98GN:TRL+L>(*S=3G=8JP?S/WJ+O'OZ.@?XQB-WWX2#C?
M:S('ZL>/V8F#\5KE#<)*4!L8&'\$'GH>OHI;7LAJ]656T%Q]UH \\!7;=9Z:
M.ECEF;*^I$F'MVX:T>(]2OI.#'7%C^T<6=\UGT%?WLKIW,A<9/= <2T#CJK@
MLS*J:6*6:!I:WO&O<,$[AT'GA2+*.FDD(I7.= &EV7#:-_HH]U73,]F=4MD+
MFO()/F/ >BU_-%&GW:V"DIV2-E9(''!#3R"H^'[)'JIN]S4Y[T,(8XG=M/@>
M<_N4)#^LHDFUIO38=,SQLCK&2U @>YF&<$[O3A;$Q[(@PN?'.#'AK=Q'=D\+
M1:<EA[T#[&#E;!3WTRRETM+!G;L=[N,GSQYK36U+M)5%2^"<1LCC+F'.^-V7
M.R%'.N89"Z5C8V3Q'!:\9+B?%39A#**.)D44K7@/,C>'#T'JL&KH:>:CJY:B
MCF8]Q+HYAT] 5&T7PTJH>][G%PP'$NQZJUN.S;X=<+)KZ66DG[J8%K@,X\P>
M5B'&#DK*ML?2]!R"3YJ>M;G2T4L(8T[7!V[/(4!#Q'D<GR4A0U A?L(!W>/B
M%MA?#/.>4]=XI:>+,09(YP#][ 1M"@*IU0]C&23;G'JWIM6V%L1>XQ0RRT\@
M:&M:>-W]A6N7RE-).]CHNYYR&..3CXJ+YBL18D=W4C2UASCGQ'P6,[KT5Q[F
M[3QSGJK8Y*RK;&,J"GWL!+L'(X/"DA;6Q9CD([\G(P\8QZ'HJK9^E:Z)K6O!
M&<'J<>2DFQQ[6R]RS8XX+2[Q^"UF,8[M17YLG!=[FUH&27D#']JOYD;%SL#G
M,VC !.%GLB8U[2ULOO9&7D *-N=0R)CHX6X<WC</'SRK>H,.SN[S4%(?_5"[
M'#.*>@DE(R&@<+C.G<_GVDSUWY77*LXL\OKC\5X/\0N\X[>*:C=;I7/I['2R
MP8Q(^,<C]4C*FK<_<V;GJ5JUT'_9"C/[(B/W+8K2<PO/F5P-67;7?P;'D2K-
MOGCDK:UC7 O80'#RZI;S^B>/)Y4+IV0NO]X/@2W]Z#-MMQ%3+(8@6AM06'/B
MI*1W_6,7]$K6-.\554SRJ25L<SOX;"?0H+EP<-T#20,O5JY544-;1QO=B20N
MVCSPHC5TSF&@#3@]^TJC4KL7JT._I_N0;!W[I+<YY/O;>H613.S3QDGG:%'Q
MG_JQP_FE9$$F*1GHU MIS#*?-Q5JTRQQPQQQ!N'EQRWIE1NFZN2:EN.]Q(9,
M\,]!A8NC'DT=/DYP7E!L[9W&L='QM#<_-8MW@BJG4T4S=S.\#L9\B%ZQW_63
M_P"@L>Y5L=/<:)LF?TCM@QX$]$'EVH?;+O;GE^UL#N\(QUPIA\K61E[G>Z/%
M0-SKG0WREIPT%LD+R3Y<%9KW'\U#X#\4$F'9&1T/*@+-3S"\7>MF&&R89&<]
M0!_R4PUV*<'R;^Y8U$<4+W>>2@BM#LS#7SO;S)4$@D>7_-;)W;3.)<G<!A1]
MMG8(H61;2Q[2[+?BLB.9SJN5A/NM P@B=>3!MB='^M(]K0L?5SS)^;+>!_&2
M,S\N%)W*FBK:RFBG;N8PB0#U"LUU$:K4%%.7@-I@7%N.I\$$C1.VT4KNF22%
M)6L;:6/X96+M:YA8>&D8X62W$=,0WP& B7MD(]LN#R>.\4K:1N<^3]IY*B+7
M3OIK?,9.7R.+^/)3EHC+::(GRRH0E!T1$1(B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("'H41!"7%Q;5!N?=(R/BM=F;W5?71>#L2-_X^:V
M6\-Q)$[UPH"]#NZNFG'ZX,;D0Q[E[]&UXZMPY>5&)Z&5H_PD9'U"N8[RD+#Y
M$+$H),TP:>K26E2-7T^PUFGJVC=RYK7-'R.0I'3%5WU+1O<<NV=V?EQ^X+"T
MT[V>[W"'P$[OH<JFRCV.ZU=)GW8YMS!_-*#9G'N[BT^$C<?-0+7=SKF?P$L3
M3]P4U7N(;')XM<%!7;]%JBEE'Z\1'T041?P:^W* ]'O$S1\>JV.O=FG:\=6D
M%:[?AW.H:.8?9FC,9^(/^\*?>0^B/JQ!#:X.^UT\H_5E!357O45OJ1_@I6DG
MX_\ )>:G_2:;SXM+?Q55X'?Z5DQU:T.^A02]L=FF/EE1]S][3]PC_9:?QRKU
MADWV]A\P#]P5JOYMUT;_ #''[B@Q)1W^B-O4B%I^A!69IF3O+>QWFQOX+'LV
M)=-=V>G=$?<K>CW_ /5P:?#(^\H)FG.VLG;Y\J)L!Q?+T/.0'\5),=_#Y/Z*
MB+*=NH+L/-P*"BT^YJ&XQ^'?AX^>5.UA]^ ^3U PG;JJJQXAA*FJQW,7],(+
M>HCFR5G^+*PGM[W1KF^5/GZ<_N67??>L]8/_ $RL.FDSI5_D*=P^XH/GVNJ=
M^H*B7G=WA#3ZCC/W+9*2:22F<\U+8@QQ/OCW7/6G2OS<I'D!WZ0G!. >5L]@
MNM.UK6OCWRF0ES2"6M&/#U7U./C&1Y^4\[0]3-7BH =)ACB2&]!XJ,J9ZA[M
MKY';8LXYY"W>IBI:Q^YU-L#F$EQ.0\^!'DH"Y6*2-S'Q1N,3V@M#G>\3Y*F>
M/RMC=>VL/?WC?,=.F.%>@'!QT7M1 ^*1[)&EKVG!!Z@K)@C9^;S(<]YWF!\$
MX\?*;?"F-A?D#.>O"G:+3]5-"VH)8UA][EP)QYX33CHX&RS;RR=N S+=P.5L
M,(DI=@D8V/W202,Y!ZY^"UNYZ9R[6*8/HJH2MJ&2-: />;C(]!Z*U<*^H;0R
M-$L;XWY]P-_B\E6KI711[\2Q2O+A[S1AOT4#=;E*3+3Q/887$$[!U^O*BZGL
MDVQ;L]IDC#96RX8 7#/7RY6%W#G0/DQ[C>"J"[=SU689-M!W8(_2.&1X\*GY
MFGY?$6HV^X!XJ2I+7/,T2[=L8'VB,)8XV/K8Q(X,:#R2%MD+A36UXB.\"0C9
MMR'CJM;-1GORM4+ZBWV]]/$Z-['>]D_X,^*UG4\DAK6"=XD);@/;T*D:Z[&2
MH>YD;=SAC@<?1:W5S22SD3N=NQU_<J9743C/+%R3NRT#'3E>\KS@YZ_- L6S
M(@ED9C83C*F8IZK896T(=&1CC) /FK5FIV[A(1$XAP.U^?>'B%,TE&972MIV
M=V,Y<WO,<>06V,NO;"V6^D()ZIU4R.3<QS3G:X8 ^O@LFM+>[:TR,=L82=K?
M$^"D7T#27.[EP:P\ESAN(QX**N[W,C&Q@CC>, <9(]5:>)Y&-IENZ^0G]G)7
M5JO_ ,'?_2;^*YAH]FZ[D^3?WKI]6/\ JD>KVKP.NN^5V\?IMMW;MTJQG[+&
M#\%,V=V:)I\_[%$W\@6!P_H@*1LQQ;X\^2XVC*H3CO1_/*A=+\W2[O\ Y[1]
MY4K0G+'GS<5$Z5Z7&3]J<_=_S04V+_Q:N;Y3DJ=J'?PF ^I6OV YO->?#?E3
MDSLU4(\LE!%:H_25]LC\Y1^*\U2[%SM1\G._<O;N=^H;4SP&7?3*L:H=FXV_
MT<4&PCBWX_F+UCL4&?YBMR.VT1_H*W*_9:WGRC)^Y!&Z0.+362']:5Y^X*C1
M7-&/YI=^*KTZWNM.$_M[G?54:*XH'G^<4$ZT_P#6+OZ"@]0$R7ZUQCPF!^F%
M,,=FO>?)JAJO]+J^C;X1M+ON*"J]OQJ:BY_P#OWJ;G]VW ?S0M=NYWZII1Y1
MD?BMAK#BD</@$%^63;1N/DQ0E@J7R6:X.>XD!\FW/@%(W!^RV2'R8H6P^YI6
M>3Q?O/[D&5I$_P "IO1A_%3,+OX=/\ H32'_ (?&?)N/O4M ?X9/\ @MSUT<
M-Z@B?DNE!:W'@5;GN)BU ZG# 1[/OW9\5$5;C+J^D:/U,N_'^Q55;LZIG/E3
M@?>@V=\[O96R-.''"D7._0 >>%$/XI&-]6K,N$FRC..N/]R"<:0V%F2 !CE3
M%-T&%K4.3:Z<'J<+8Z'HH&6B(B1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M.D&\M<8@X!Q;U"E)K?%2RF.H;(T##CO<!P1PML;DQNMK[[BTO='3N?L?TW^
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MM:/,DI9J$N[5]%HD_:QI&*8QBXR/P<;F4[RW\%L]BU!:[]1.J[161U4+/M;
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M70=,_P![=J_R2+^H$6=MK222))$10D1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M8L5&QG@%D!C0.BJ1!28VGP0,:.@52("8'DB(& $1$!$1 185WN=-:Z5T]4_
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MM4;^0T+/@M3&C[(5FSUC98VD$$'E3K""T$+D=Z K[4U[#AH6MU=A)<<-70R
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M5_VI'GJX_=\@%-(FR30B(H2(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B N8]HUZ%14.
MI8G'NH#SCHYRZ/7S&GH:B8#)8PN'R"^>[]4/EEW.=DN))73TV'==N'K>6X8]
ML^6%4S<EO7/*Q'X>2<<KTXP50)"!T7?IX^-VH ZC'U6A7ZF?;+J7Q@MBD.YI
M'WA;\22<YY6/6TL-;3NAJ&AS3]1\%KQ9W"[:\>?9EOX:Y154=3"QX$60??\
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M X<^:KI28UD@GQQE,JPQW!,A'7@JXUWJ"/--(N.E9Z*D@;56T]<JCA$18<"
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MIE6E8D@ (W9R>@5&TY.#P.JS7L.=SL<+QC2(SD8)\E.VDS\,4 ],*] S+^G
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MQNU>04/:[[5."(FOIILXZM ;D_\ TE=ATEV?VG2]WGN-NFK7SS1NC<V9[2T
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M)C87M>6-+V]'$<A5(B"F2-DC=LC6N;UPX95OV2F-3[1[/#[1T[W8-WUZJ\B
ML?V&D]I]H]E@[_KWG=C=]>JR$0%:@IH( X00QQAW+@QH&?CA7406*>BI:9[G
MTU-!"YWVC'&&D_'"NQQLC!$;&L!.2&C'*J1 6.:*E-3[0:6#VC_S>[&[Z]5D
M(@I$; \O#&AY&"[')2.-D;=L;&L;Y-& JD04MC8U[GM8T/=U<!R5ZYH<TM<
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M$E<BKGL<3AP+CR5T/M.DSJ>O,O#1@<^6%S!Y#I''U7;QS6+RN?+\5>84W;(
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M$A9UEMX(&6K;*2B:QO1<7MW>F-:Z$1-'"F ,#"\:T-& O4!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MZ!CHB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M!$1 1$0$1$!$1 1$0$1$!$1 1$0>.^R58<B(A2U9$?1$05(B(D1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
C1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g762905g99m62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g762905g99m62.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_[20Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q >0
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ &0     0 ! 9
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              0.   )3P         !
M                  $             "4\   0.
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   0.     %)G:'1L;VYG   )
M3P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $#@    !29VAT;&]N9P  "4\    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     $X0DE-! P     &;,
M   !    H    $8   '@  "#0   &9< &  !_]C_X@Q824-#7U!23T9)3$4
M 0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&
M5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M                                                         !%C
M<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!
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M0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M
M    6%E:(        /-1  $    !%LQ865H@                     %A9
M6B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M    )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC
M:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                              !D97-C
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U
M<B!S<&%C92 M('-21T(                             9&5S8P
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$                                  '9I97<
M !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M5Q_G;65A<P         !                         H\    "<VEG(
M  !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L
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M.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9
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M(NQW?UJW.=5_PWIH69UAWV;$RL"REU64"\>JVP[FAOJ^W[,VST]C0[U/4:B
MJ^C4=T/J+F@$8OL#0T!V2/HC8QWMO;L]-K*MO\[_ ,96G_8>:W=4RC']*UH]
M0NOR3[AV:W=_F/:]*KK^78&0_$)M)97'VB"^6[07>A[&[2BX75.JYS7'$^QV
M[(WD^O6-=W'J4_R4=5.IB?;?1_716+I_P.XMC_KGN1U5POVE#OMXH!TV>@7G
M7\_=ZH_S5:35.'UMC'=;Z/+!O><JL7 .]1@-#W$4O:[94Y^SZ;F6+'^KF35B
M?8\JY[WO;T?'#L:NM[[2#<YC;16QCOSG?I=CO^%_F_TBV>LO:WKG2&-)]:T9
M362Y^T12YV\T,_1V_P!O_K:R.A9-/3;,-^9790:ND8[7!VX1NN])M9Q[6?:?
M5;:__2_]924ZSW!_U8ZDX @.'4" X%I_G,KEK]KFKQ1GT&_ ?D7M;WM?]6.I
M/;,.'4")!!_G<K\UT.7BE?T&_ ?D5OD_T_\ !_[I9/H^D_XI?Z'U/_CZ_P#S
MV%WRX'_%+_0^I_\ 'U_^>UWR@S?SDO-='8*2224:5)*+[*V"7N:T<2X@=MW?
M^2G!! (,@Z@A)3__TO55%UC&SN<!',F%) OQO5C:\UP=T ""?%_[R2F;[Z6-
MW.>T#XJOC8V <R[J%!#\B]K:[7AQ=I7+0S;.VO:[Z:H8'0:L/'-&(!54;K'D
M0207/=O?^D<[^2M7&QJ\=IV@;W?2=W/FB:LT=%)E4PL/!Z=4^G&BNMUCK'-+
MB8<\[G1O/M_J*VJV1A^M$/+&MX8 "V3RZ-/<@I*_(HK +G@3H!R?D GKMJM;
MNJ>VQIX<T@C\%1/3; X 6#;/T@W4:>$JYCX]>/7L8T-G5T=RDI*DDDDI$_&Q
M[+J[[*F/NID56N:"]F[Z?IO/N9O_ #MJJY5?2NGW6]9R *;"UE-M\NU:7AE+
M'ULEKOTMGM]BOIB >=4E/,7YV)^QNHU#-:'O^W;<<;27;K,G9MTWN]2?9^^O
M)&X^2&L!HN!(  -3]3$Q]#R7T&N>R/K%19U!M;*LY@Z?;<[(%>/O98VNO(9]
M+WV>GO8WT7T_3M]"K\]2XLQQW0NZ_!!%O,_XM[F8>'U 960<%S[F%@M:&EP#
M(+F^LWW+1RNMY=KK9ZL['KKMM:QU;*V^QKW,J>Y]E=C'?HF,?O6\SZT8!J;<
MZG*8Q[MC)H>XF XN<UE(M>YC/3]ZJW_6CI?4,._'P[,AEUU%EF*YE#B^UK&M
M>ZS!;:&U9+OTFQC-W\XF3EQ2,NZ0*:?3^MY#<NJB_J>['<+"]]E; 00 ZO\
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MI)?*J22G_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-!"(      7Y-30 J    "  , 0   P
M  $.S@   0$  P    $&B@   0(  P    ,   "> 08  P    $  @   1(
M P    $  0   14  P    $  P   1H !0    $   "D 1L !0    $   "L
M 2@  P    $  @   3$  @   !X   "T 3(  @   !0   #2AVD !     $
M  #H   !(  (  @ "    9     !   !D     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#(T.C Y.C$P(# R.C$T.C$Y      20   '
M!# R,C&@ 0 #     ?__  "@ @ $     0  "4^@ P $     0  ! X
M    !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H  ,
M   !  (   (!  0    !   !?@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0&&17AI9@  34T *@    @
M# $   ,    !#LX   $!  ,    !!HH   $"  ,    #    G@$&  ,    !
M  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !    I $;  4
M   !    K $H  ,    !  (   $Q  (    >    M $R  (    4    TH=I
M  0    !    Z    2  "  (  @   &0     0   9     !061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP.3HQ," P,CHQ-#HQ.0     $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   E/H , !     $
M  0.          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
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M*"@H*"@H*"@H_\  $0@#"P;[ P$B  (1 0,1 ?_$ !T  0 " @,! 0
M       &!P4( @,$ 0G_Q !A$  ! P0 ! (%!0D+"04& 0T  0(#! 4&$0<2
M(3$300@B46%Q%!4R@9$7-D)6=)2ALM$6&",T4E5R<Y.QLR0S-51B=9+!TC<X
M0U.")66#HL+A\"9$8\,G9':$HZ2TX_'_Q  : 0$! 0$! 0$
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M=
M
M                       ,3E.046,62HNMU=(VC@USK&Q7.ZKI.B&6*Y](
M'_LKO/\ \/\ 70WQX]64E2O#]WC"O]8KOS5Q(L0XEXOEE9\CM%P5:Q45R031
MNC<Y$[JFTTOU*4?PIN'#2GQ1L>90T+[MXS]K+3/D=R=.7JB*GM/#\BM5_P",
MMH^YI3OCH(7Q2ROCC<QD:M<JO<B+I436D]Z]CWY>S<>[CJS7KZ.,Y+K;;! ?
M$V?3YKN
M
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M6=,N?#DXKC9JSPS,+,MK#3L #QNH
M                              '&21D;=O<C4]X'('3'4PR=&2-53N
M
M              5UZ0/_ &5WC_X?ZZ%BF SK&HLMQJKLU1424T51R[EC1%<F
MEWV4WQY3'*6HI/@O@F&Y!A+*[(:6&2N6HD8KG5;XUY4UKHCD3]!&.*E#:<"S
M.URX!7/BJ$:DDL$-0LG(Y'>JBKM5T[KZJ^SWD]_>XVC>_GZOW_5,,UB7 K';
M#=H+A/4UEQE@>CXXYN5L:.3JBJB)M53XZ/H7VCCF=SZ[9\G&876M+2MTLDU#
M32S)RR21-<Y/8JIM3TC2 ^8[P
M
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MO=^J;?!STT4J,2%JL;I7NTNN^^W;J:G%;-^NS:[SRU%QHJ>KBI9ZRFBJ9?\
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MQ&N:OVD&1!UQRI)U8J*GM13L
M
M
M
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MS3IS<DY<^J30 #;D
M
M
M
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MWF4H;93434\%GK_RW=5/:B!'Q$TON/H
M
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MI[_3/G6MND*).CW[8G*Y=<J:Z%NGGYL9CR93'PUA;<=T !R:
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M1$72;/;176DK'*V&3UOY+NBJ3JG@Z;.[W )W!4
M
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MRJXSIF@ &%
M!7O&^XU-KQ.DJ*.JDI7_ #E2M=(QW+ZBRIM%7V:/=;.)V)7&\QVFEO$;ZR1W
MAQ\T;VLE=VTQZIRN7X*87TA88ZC"*6"9J.CDN=*QS5\T65$5#P\?*2GI,'L2
MTT$<2TMVHT@5C43PT1532>SH=,)+)+\_^F;=?V1WC/D%]LG%"BJ;57S,H+;;
M8Z^JI4<O)*SQUC>NO-=.3["W,QO\5GPJXWF)R.1E*KX-=>=[DU&B?%RM3ZR
MY';X;OQZ6W52(L-5B\D3T7V+,J$>QNNJ<AH<.P>L=NHME?(RYMWM4CHU:K.9
M/8Y>7XZ4UKJQD3>K;_OAW<-KI?F\.^(?SS<JB>YT"3(V1S]K$](E73?9I?[C
MVX#@M=D6&VF[U>:Y1'/5P)(]D50SE1=KVVU5//CGWN<9ORJL_4>>7"N%R7SA
M?;*VWY)?Z&XU%(CXT96N\%CMKTY/Y/UF[9-WQX_9)/$_-*N&=SNU!G.1XC=;
MN^\TEOBCJ*>KE1/%C1VT5CU1$15Z(>2VU&0\3KM=I:&]5-BQ2CG=2P.HVM\>
MK>U=.<KG(NF[3IHY\")+8ZRWNT-MS;9DM+*L%T8YZODE?I427F7JK5ZZZK^D
MY\!;A3VNV73$KA(RGO-KKIN>&5>5TC'O5S7M1?I(J+W3W>TQ>UOSG^[5V+:,
MLPB\6J2UW6Y9-8ZF=(*NEJT8Z:%%1?X5KD1O1-)W]IX,\IKA?>-5LQ^&_72U
MT,EI6H=\BD1JJ]'OZ]45/_\ AB^*+LCQ"CCKJ?B!55%345D<<5N6*-'.8YW7
M2)U5$3W'HSJSS7WCW9Z.GNM?:I%LBN^4T3T9(FGOZ;5.RFL?_M^?[%^3YG=M
MOG#"T0Y%:\MNMRCAJ8V5%%<G,>R9CEZHU4:BHID,[AK\@XN6&QP7NZ6JAJ;2
M^I?\BD1CN9'+K>T5/<9FFX3TLMQI*K(L@OM_;22)+#3W"='Q->G95:B=2.\0
M[%%D7'3'[?45=;1QNM$K_%HIEBD33W=.9/(8Y2WZ]_V-/F=8Q>,%QBLR*TYO
M>I:B@1LO@W![)(IDYD16*B-3JO9"2YC3WZ_X-9\@QFHFI+Y30QU[:9KM1U&V
M(YT+FKT7?D5]FN'4V#9':+K>Y;CD&(R3,CJ&5]2Z3Y%)OU9%\G-VJ=%3R]Y<
M.99=;L3Q-UXE<V6)6(E)%$O6H>J>HQFO;_<9RMU+.ZR=T#N?$Z3*<>M-LPCU
M<EO**US7)_$&M54D>_V:TJ)\4,_DULR6ALV/8[B]35N2>1(J^\2*U\L$;417
M/];\)W5$Z+HK>ST5[X8WBCS?((HWTM\58[S%%$B?(7/=MBIKR3347WJON+GS
M',;=C-A9<I7?*G3Z;1T\"\SZM[OHM9KOO:=1E-:Z?]I/J@=TANO#S)\8;39#
M<+M07BN;05%)<'-D<BN_\5BHB*FO/RZEPHG0K3#,8N-TR!F7YP^-;IRJE!;6
M.18[>Q?[Y%1$VOQ+,3L8SOS\D4]P\S2.T8?EMWR:OEDBI+Y50Q(]>9[D141D
M;$\UWT1/>9C *#(K]=WY7E$]114\S?\ V?9XW\K(8U[/E1.[U3KK>DW]E9X+
MPW;FM'E]567.IC6GN]8RVQ1KRLIJCG1RS+[57U$^"%I<(\PJ+S2U=AR%/ R>
MSKX%7&[HLK47396^U%1$55]_O0WE)-V>4CJX5W&LK<HSR*KJI9XJ:YI'"V1V
MTC;X;>C?8A9!5O!_[[N(O^]D_P -I:1SR_Z:GJ  RH             !4WW
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M&KE;V?&II#Z 5D
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M(#=WLTPMBQJW6.NNM7;XY&S7*?Y14*Z17(Y^M=$7MT0S0!
M           /));J:2::5\2*^5O(Y5\T/6 2Z8U]DH7-8WPM<B:16KI53W^T
M]\,,<+.6)C6-]B)HY@DDGA;;?( "H
M
M        <)FJZ)[4[JBH<P!4/";AY>\5M&3TUT6C62XM5(/!E5R=6N3UNB:[
MH93@;A5UPK&*VWWI:99YI_$;X$BN37*B=U1/864#KES99;E]?\,S&14'"KAI
M<;%39729(E+)2WA>5K8)%<O(O/O>T37TD,%CF#\2<2DJ[%C]?;ELE3(KDK)>
MKHD7HKD;K:.TG;JFR_ :_$9;MOK_ (.B*CX0<-[GB4F2P7>6":EN")'%)&]5
M>YJ<R*KD5.BJCO>1O%,"XC8C77&TV"KML=HK9.9:R3UE8G;F1FM\VO+JG0V
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MJOEV0ND$GM&4FKW_ /9T0[  X-@
M
M   !$,@X@6JQW6:WU<-8Z:)&JY8V(K>J;3S+);X2V3REX(!]U:Q_ZO7_ -FW
M_J)!BF5T.3)4K01U#/DZM1WBM1-[WK6E7V%N-GE)E+X9\ &6@
M
M
M
M
M                                       #7_BM]_5P_H1?J(; &O\
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M2]['T '-H
M
M
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MDB;"B(]47:*OFO4R/S-;OG:*Y_(X?G"*+P&5'+Z[8_Y*+["^\[:_/]33W/\
MH.^!K=@]A?D7!/,:6G3_ "N&[35-.Y.[9(^5R:]_14^LV27JFC'VBS6ZST\L
M%KHX:6*6197LC;I'.7NJ^\QCETRK9O2H^&UU7/[W<<NE:[P*"U1V^'::1)W,
M5TZI]:HGV$?Q[_NMY'__ #7^*I?=HLEML]"^CM=%#2TKW.>Z*)NFJKNZZ]YU
M18W9X;+-:(K?3MMDW-XE,C?4=S+M=I[U-WDGI$D0O&L#QJ^\-[7!7V:A5U11
M,YIFPM;(BJWZ2.1-[,+P@O=;C>0UO#O)9$?54O\ "6RH5$;\I@ZZ^*HC=_:G
MD6]24T-)314]-&V*")J,8QJ:1J)V1#Q5]AM=?<J6X5E#!-74O6"=S?7C^"D]
MYO<OBDQU(J/#;E3<-.(&2V+(Y$I+;=ZM:^W5LOJQ.5R[<Q7+T14VB?4>CBG;
MN%SZ:Y7V]NMD]TJ(55CV5*ODD>C>5FFM=U[)Y>1;%XLUOO5&ZENU'!64[N\<
MS$<GQ]Q'K1PSPZT5B55!C]$R=J[:]S5?KX(Y5T69R][O9K7A2U\IIJ;T4Z"*
MJA?$]9X%Y9&\JZ69%1=+[4+?L_#7#'6^BF=C-J=(L+'*JT[5VJM3J2R[VB@O
M%"ZCNE+%54JJCEBD;MNT7:+KW*>R-C8XVL8B(QJ(B(GDB#+EME_/9,>Z.Y;2
M4]!@5ZIJ*"*GIHZ&9&1Q,1K6IR+V1"#\(,/QZ\\)K+\YV:@J'3TVI)'P-YU]
M_-K>_>6Q4P155/+!4,;)#*U6/8Y-HY%[HITVNWTEJH8J*W01T]+$G*R*---:
MGN,3+4L72G.'U;4<.<\FP2\2<]HK56:RU+TTJ[7_ #2KYKUU\4]YW\0;C5<0
M<N3 K#.^.VTZMFO=9&O1&IU2%%]JKK?_ -E+4N]AM=XDII+I0P5,E,_Q(72-
MVL;O:B^0L]CMEF\?YKHH:7QWK)*L;=*]WM5?,UUS?59W36NT4VZ)>#6>Q.@1
MR8-?9$8]NU5M%/V1>O9J]/JW[#/\6.)#K16T>.8_64-/=ZYG.ZNJI6MAHXE3
MZ:[[N7NB%E7BTT-YH)**ZTL572OTKHI6[:NEVAAJW L7KI625ECH9Y&1MB:Y
M\>U1C4TU/@B=!,Y;+D:UX17ADW"L=18*#)+?=+]7OW4UCZEKYZEZ^7=5UTZ(
M6@1FAP'%:"LAJZ*PT$%3"[FCD9'I6K[4),9RLMVLFE2\'FM?G'%!KD16NNK$
M5%ZHOJN*MXQ6VJX?T]VL%/$]^+7V:.IHM+TI9VO:Y[/@J(O3X>PV>M]HH+=5
M5M10TL4$]:]):A[$TLKD\U]YQO5EMU\I$I;O1PUE.CD>D<K>9$<G9?B:QY-9
M;]#7947%_P ;+,@Q' Z&H="M2B5U:]B;\.-B;:NOBB]_<=V6\(KU=<;K*.?-
MKI7M;&KHJ:>-O(Y[4VU%UVZ^PM:&QVV*[NND='"VXNC2%:A&^OR)V;OV&1'O
M+)K%.GYM;<CR9V3>C6V6I<JW"CJH*2J:[NCV2M3:_%-*2;B=</W#Y;C^9,1W
MR>HM\M!5(U-HYR,5T.__ %+HLYV'X^ZEK*9;32?)ZN5)IX^3U9'HNT<J>T]]
MULUONU&VDN='#54S7->D<K=HBM[+]1KWDWX_VG2H+-[/)9^"N,I5?QZLN\%=
M4N5.JR2N<]=_#FU]1L6SZ#?@>"Z66W76EBIKE20U,$3VR,9(W:-<WLJ? R")
MI-&,L^J:)-  ,-
M
M
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M6D<J>6BPL(R2FRS&:*\T;'1QU#?6C?\ 2C>BZ<U?@J*2X6$NV< !A0
M
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M1!'-'ODD:CV[]BIM#F?&<O(WDURZZ:[:/H
M
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M\E$EGMLE:E9)04KJM.TRQ-5Z?7K9[D1$32#+DZII)CH !S:
M
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MF[[Y$[DD/C41K4:U$1$32(GD?0
M
M                                     \-):*"DN%374U+%'5U.O%D:
MFE=H]P       T                -
M
M                          =%PJXJ"AJ*NH54A@C=(]43:Z1-KT*E_?&\
M/O\ 7JW\U<!<(*>_?&\/O]>K?S5P_?&\/O\ 7JW\U<!<(*>_?&\/O]>K?S5P
M_?&\/O\ 7JW\U<!<(*>_?&\/O]>K?S5P_?&\/O\ 7JW\U<!<(*>_?&\/O]>K
M?S5P_?&\/O\ 7JW\U<!<(*>_?&\/O]>K?S5P_?&\/O\ 7JW\U<!<(*>_?&\/
MO]>K?S5P_?&\/O\ 7JW\U<!<(*>_?&\/O]>K?S5P_?&\/O\ 7JW\U<!<(*>_
M?&\/O]>K?S5P_?&\/O\ 7JW\U<!<(*>_?&\/O]>K?S5P_?&\/O\ 7JW\U<!<
M(*>_?&\/O]>K?S5P_?&\/O\ 7JW\U<!<(*>_?&\/O]>K?S5P_?&\/O\ 7JW\
MU<!<(*>_?&\/O]>K?S5Q*^'W$[&\]JZRGQR>>66E8V27Q(E8B(JZ36_@!-@
M
M
M *5XDY%>:#,*VFH;G4P4[&1JV-CD1$VWJ744!Q7^_FO_ *$7ZITXYNN?)=1C
MOW7Y%_/5;_Q)^PLC@Y=[C=6W7YSK9JKPUCY/$7?+M%WHILM;@3]&\_THO[E.
MF<G2Y\=MR6L #SO0
M
M'74SPTM/)/4RLB@C:KGR/=IK43NJJO8["!\<K-<[_P +[Y;[(CG5LD2*D;5T
MLC47:M3XH@&,3CQP]6XI1I?F\W-R>)X$GA[_ *6M:]Y9E/-%401S4\C)89&H
MYCV+MKD7LJ+YH:/NO'#[[B+;(VU+^[;G1BN\#^$\;G^ES_R==-?H-J^"-HN5
MCX8V*@O?,VMCA]9CUVL:*NT:OP3H!. 0B_<5<,L-VJ+9=KY3TU;3JC9(G(NV
MJJ;_ +E/!]VWA]^,E+]COV 6,#!8CEUDRZDGJ<=KXZV"%Z1R/9O2.UO74SH
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MHDKM(;1FL'HJ_P#:=Q ^/_ZUP&SX
M
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M]BO1.5/M)K3S15$+)H)&21/3F:]B[1R>U%+JSR.8 (
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MN$7B.OI9J=ZW!R(DK%:JZ8U%[^\OD(B)V30
M     -<?1HLERM?$OB ^OHIX(^=&(][51JKXCETB^?3J;'#2(JZ3N
M
M                                          *NDVH
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M20U*SHQ/$\17-VO-W\]'G@QNJRS@#8J>DJ88JBGE=,QLTG(V1&N>G+M>W?\
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MW$,;M^*6"EM%HC5E+ B]7+MSW*NU<Y?-549Y2[UZI(S0 .38
M                                      !C,I^]F[_D<WZCC)F,RG[V
M;O\ D<WZC@*)]"K[S+]^6M_4-B37;T*OO-OWY:W]0V)               ('
MQ'XJXWP_JJ2FOTE0M14M5[(X(^=4:G3:]4T0[]\Q@G_O3\W3_J NT%)?OF,$
M_P#>GYNG_4/WS&"?^]/S=/\ J NT%)_OE\$_]Z?FZ?\ 4?/WS&"?^]/S=/\
MJ NT%)?OF,$_]Z?FZ?\ 4/WS&"?^]/S=/^H"[04FSTE\#<Y$5;FB*NMK3IT_
M^8N2VUL%RM]-6T<GB4U1&V6)^M<S7)M%^P#T
M
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M<./6B"]S7B&VTC+I,G+)5I&GB.36NKN_D90
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M"_BG9_S9I,P!#$X68*BHJ8G9]IU_BS28Q1LBB9'$UK(V(C6M:FD1$[(AR
M
M
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M  9:
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MC6STS?I8=^42_P#T&R=)_%8?Z#?[@.T
M
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M1^$J:_\ #VOK(G1NMIT5=6!&]LD;7QN1S'(CFN1=HJ+Y@<@
M
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M!O\ <:V>F;]+#ORB7_Z#9.D_BL/]!O\ <!V@
M
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M-UGP >9L
M
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M>CXJ.>J<^!BIVTW]I8L<;8VHUB(UJ(B(B=D1#EGE+-1J3NY  YM
M       !PG<K(9'M3;FM540YFNO$WC/FN,YQ=+19\:AK*&F>UL<SJ>5RN16H
MO=%UW4",2^D-Q 9+(UN*4RHURHB_)YO;\2/9=EW$;B_3T>/+CJT].Z=LB^#3
MO:BJG1%<YW9$VI(/WPG$3\3X/S6?]I]9Z0G$17(BXA3HBKU7Y+/^T#:2Q4;[
M?9J&CED622"%D3GK^$J)K9[3IH973T<$LC>5[XVN<GL54.X"I?2@LT=XX5U2
M/K8*1]-,RHC69Z,;(Y$5.3:^:[77O,%PYXB<*(\0M<,K[1;JB*!K)8*BG3G:
MY$Z[=I>;KUWLM7/L3MN:8[+:+TZ9M&][9'+$]&N16^]44UGO6)\";/<)**IR
M&Y/FC7E?X+UD:U?Z2,U]@%_XMF?#^[WJ&CQNOM$US>CEC93Q(UZHB*JZ77L1
M2=E*\'>&O#ZEN=-E6$7.IKGP(YC5=,CD;S-5%1S>5%1=+YEU #6/BS0RYSZ1
MMFQ2XW&6BM5/3MFC1JHFWZ5Z\N^G,ND3ZC9M51.ZHGQ*?XY<)'9Q54=ZL-P9
M;LBHVHUDKE5K9&HNVIM.J*B[TOO E7%;!+?G&&K:KE5S4L5.J3QS,5/5<UJH
MBNWW3J5_Z(=XK:[";G;JR=]1%;JQ8H)'+O3%1%Y4]V]K]9 I.%G&2]-6VWC)
M-6Z3U)'2U_.U6^]&]5-@^%.#4/#_ !.*T4$JSR*Y9:B=4TLLBZVNO).B(B 3
M$@W&O$YLSX=72U4:(M:K4FIT5=<TC>J)]?5/K)R -.\=XLSXYPJJ\"N&.UR7
MV..2DA3P]-5'JO5R=]IM>R+OH7;Z,^)7#$N&T4%XB=!65<[JIT+N\;51$:BI
MY+I.Q:3J>%TJ2NAC61.SU:F_M.T#HDHZ:1ZODIX7/7NYS$55,7D]#2-QJ[JV
ME@14I)M*D:?R'&;,9E/WLW?\CF_4<!1/H5?>;??RUOZAL2:[>A5]YE^_+6_J
M&Q(        &J?IG_P"G\7_JG_K(5&O=?B6YZ9_^G\7_ *I_ZZ%1KW7XGUOX
M;\.7V<>7S'P 'TG(            !  >05A\H_B#?Z9^@7#[[Q,=_P!WT_\
MAM/S]RC^(-_IH?H%P^^\3'?]WT_^&T^)[?\ UG?B^%GP >)T
M
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MU%2VRG5->,U';=4+_2Z(GN0V5&6'3)27N  PH     !4VF@ /G*GUGW0
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MKU7,415_]Y3_ +"[>!^)Y#B&-5=%EES^<:R2J65DOCOETSE:FMNZ]T7H!8H
M    8S*?O9N_Y'-^HXR9C,I^]F[_ )'-^HX"B?0J^\R_?EK?U#8DUV]"K[S+
M]^6M_4-B0        -4_30_T_B_]4_\ 70J->Z_$MOTS_P#3^+_U3_UD*D7N
MOQ/K?PWX<OLX\OF/@ /I.(    "@ "     *#R  P^4?Q!O],_0+A]]XF._[
MOI_\-I^?V3_Q!O\ 30_0'A]]XF._[OI_\-I\3V_^L[\7PL^ #Q.@
M
M                                                      !U5%-%
M4,Y)F(]OO.T 8I;!0NDYWMD>OL<Y50R%/3PT[>6&-K$]R':":BW*TT "H'14
M5$<#'.E>UK4]J]SMD5&M57+I$ZJI6M?6ON^1NY'N=! BJC=]/8<\\^G3KQ<5
MY-_*,Q63K6U:S.15;^!_LH<57>MHG0XPZ1J[=U7R.:=3K(YOB;3\%0<N9?Y2
MG'S ^.:CD5'(BHO=%/I\VNSZG8 ?-'T $1/>=K'JB:.H(N@.3^JG"1J/:J*B
M>X^]P!Y4@5W=$4]#&-8W34T<NWF?-H/30YM/JG6W?4^K[T4#[W3N=4R>PY_@
M=$UKNJ]CSR3,UM570'#F<U?5[K[CU1\\[FQ1,YI%\CC0T556/1*=BM8O>54Z
M$IM5KCH4WM7S*FE>J$1VVJC2CI^5>LCNKU]Y[!KKOS  I_BO6,PWB'CN82.\
M.DEIYK;4KY+ZCGLW_P"I/T%P&%R[%[5EMI^;;[3)4TG.V1&\RM5')V5%3KYJ
M:QNKW% 4JOP&W8)F%:JHZLIZQU<[7TGS,61F_P#U*96\6F2V^C+6U%6W5=<U
M^<9U\U=+)SIOZE0N;(\1LV16.&T7:D2:@A5BQQHY6\O+VTJ>[H=U\QRVWO'W
MV6XP<]N<UK%B:Y6^JWLFT^"&[R2_W_1F16N>/9'EG"E\CVL8DSMN<ND3^!]I
MWW=K'^DE8'::[5FE5J^SJ_L3G*<+L646FGMU[HFU%-3JBP^LK71JB:Z.3JG0
M4.&V:BN]NN<-.]*V@I/D4$CI7+RQ=>B[7KW[J29S]_U-?X0?B8B?=CX:_P!.
MJ_N86T8>ZXW;;I>[7=JV!7UUM5ZTST>J<G-K?3S[)W,P9N6\9/DNN^U,<(ZJ
M'%<\S'$[FYM-/4USKC1>(NO'C?O>E\]:3])->)^;T^%8S+7;CGN$BI%24JKU
MFD7LFDZZ/9F>#V',8HFWRB266'_-3QN5DL?]%Z=4,1CO"C%['=H[FR"JKJZ+
M7A35]0Z=8M=E;S=E-;QR[T[Q$;M7.H^-V'7;)(64457:'P,5SMLAJ%5RJWF7
MSTNOK/9Z05735-!CMGI7LEO%5=8'TT;%V]$:].9W3LFO,LK),=M62VY:"^4,
M-92JO,C)&[Y5]J+W1?>AA\7X=8SC-<M;:K:UM;KE2HF>Z61J>QKG*JHGP$SG
M:WT32(8G$G[X7+7/3<C+73-W\4;O^XXYD]D7I!X2Z1S6,^15'5RZ3>G%C4F-
MVVER2MOT$"MN=9$V&:3G54<UO9-=D/'F6#V#,&4Z7ZA2=U.JK%(UZL>S?DCD
MZZ$SFY^1<=[0=KX6<><F?4L62!MAA61K4VKF[=M$3SZ$<QK'ZWYC?=^%^;K2
M6=7R2+;;HQ'1Q*CEVU?-J;_07+1XQ;*2_P EZ@A<EQDIF4CI%>J[C9]%-?\
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MD:H[?TMDGL&.6VPR7!]L@6)U=.M3.JN5W-(O=>O8RY+GOP2*G]))/_R.M/\
MOBF_O4R_&>S9'D&-P6S&60/9-.BUK)9?#YX4Z\J.]BKI%]Q*<HQNVY/10TEY
MA6:"&9M0QJ/5NGM[+T^)E]$F6I)\EUW:V<1I,Z@3$*:YV.QT<5/<8FT$=+.J
MMYTZ-8[KT:;!8Y)=);+2OO\ !3P7-6_P\=.[F8U=KV7X:.G(,<MM_?;WW2%9
M5H:AM3!IZMY9$[+T[F8+EGU36DDU0 &&@
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M[[Q,=_W?3_X;3XGM_P#6=^+X6? !XG0
M
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M_<IQBLE;#MM%DK%H:IJ=EG9KPW_'6T+1,V:DH  B@
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M ".;]1QDS&93][-W_(YOU' 43Z%7WFW[\M;^H;$FNWH5?>;?ORUOZAL2
M    !JEZ9_\ I_%_ZI_ZR%2+W7XEM^F?_I_&/ZI_ZZ%2+W7XGUOX;\.7V<>7
MS'P 'TG$  4  0       % !Y 8C*/X@W^FA^@/#[[Q,=_W?3_X;3\_LG_B#
M?Z9^@/#[[Q,=_P!WT_\ AM/B>W_UG?B^%GP >)T
M
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M4:J_W*EE@M]GC6BMS9F:65[E19)D3V=-(OF6&9M[2+Z@ ,J
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MELH;52LIK91T]) Q-)'#&C$3ZD/6      #&93][-W_(YOU'&3,9E/WLW?\
M(YOU' 43Z%7WFW[\M;^H;$FNWH5?>;?ORUOZAL2        !JEZ9_P#I_%_Z
MI_ZZ%2+W7XEN>F?_ *?Q?^J?^NA4:]U^)];^&_#E]G'E\Q\ !])Q  %  $
M   4  0 'D%8C)_X@W^FA^@/#[[Q,=_W?3_X;3\_<H_B#?Z9^@7#[[Q,=_W?
M3_X;3XGM_P#6=^+X6? !XG0
M
M                                               "H !PD8V1-/:C
MD(A<::=MQJF4\;E2-J/W[O<3($LVUCEI#J6XUU"C/X!RPR:5K7]M>[WDJHYG
M3Q(]\;XU7\%QW<J>Q#Z3'&SU,LI?$  :9
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MV_\ K._%\+/@ \3H
M
M
M
M           <9GI'$]ZIM&M553VG(*B*BHJ;1>BH!K]PSO?">XY!?*JVS-ME
M9>F+355NKE2-KU55YN3KKKOLBG*C]&+%VW]M>MSK9[:DGB-HM)RJF]\O.G77
MZ3YQ?X7<*X(9*RY5\6-U;MNW32;YU]JQ==_4B%$8MG648GD:6[ K]6WFW<Z)
M'$^F<K)$W_Y:[5/BF@-]88V0Q,CB:C(V(C6M3LB)Y'(ZJ-\DE)"^=O+*YC5>
MWV+KJAV@0KC#=K#:,&K),MHI:RS3.;3SQQHBNTY?I)U3MWZ+L@..XSPTSKAM
M#B5CNS9Z>"1U1#N1$J:=ZJJ[Y5ZKWU[-%Q9!9K;?K7+07NDAJZ&3J^*9-M77
MF:I<7<#X98Y423V/+)+3<VKS-I(%6I1J^Q.7JWZW 7#PJX%6/ ;TZ[I65%SN
M#6JV&29J-2)%32JB)YZ\U+=-4?1DX@9M=\OI[-<*FIN5A\-_///$KEBY6JK=
M2>6U1.B[-K@!KUQSR?*K[Q!H.'6$5+J*>:%)JFH:_D547:_23JUJ(FUUWV;"
ME \=<%RB+-*'/>'RK)=::)(IZ=NN96IO2HB_214545/@!!\0PW*Z&OXB8M27
MM]3?8**G>RI6HD:FU<CU1KEZHOELMST;,XN.98;4,OK_ !+G;:A::25>\B:1
M45??W3ZBA;?DG%6HRR_UUMQR>"\7F%E-/(VD>U(T:B(BL5RZ1>G==FP_H_X!
M58#AKX+JYKKK6S+4U*-=S(Q51$1N_/6NOO4"S3$9+C-GR>DCIK_;X*Z"-_B,
M9*FT1VE3?Z5,N *%XU\$Z"XXK!#@6/T%/<TJ6N>]J\B^'I=IM??HL[AAB=)B
M6)4%'3T$%'6/@C6L2+\.9&HCE5?/KLE@ &,RG[V;O^1S?J.,F8S*?O9N_P"1
MS?J. HGT*OO,OWY:W]0V)-=O0J^\R_?EK?U#8D        #5+TT/]/XO_5/_
M %T*D7NOQ+;],_\ T_C']4_]="I%[K\3ZW\-^'+[./+YCX #Z3B
M    H/( ##Y1_$&_TT/T"X??>)CO^[Z?_#:?G]D_\0;_ $T/T!X??>)CO^[Z
M?_#:?$]O_K._%\+/@ \3H
M
M                                      ^.<C&JYRHC43:JOD5Q1<4Z
M)UXJ*>L@5E#XBMAJ6+O;>VW)[//H68V^$N4GE9 .BAK*>NIF5%'-'-"]-M>Q
M=HIWD4      #X][8V*Y[D:U$VJJND0#Z"O,HXG4-O>L%GC2OF1?6DWJ-.O7
M2^:_H)O9KC!=K735U*Y'13L1Z>[VHOO1>A;C9W292]H]@ (H
M
M        8V2[VZ6MFMD-QI%N2-5/DZ3-\1.F_H[W[S)&L-A_[Y-S_H/_ ,!
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MCF_4<9,QF4_>S=_R.;]1P%$^A5]YM^_+6_J&Q)KMZ%7WFW[\M;^H;$@
M   :I^F?_I_&/ZI_ZR%1KW7XEM^F?_I_&/ZI_P"LA4B]U^)];^&_#E]G'E\Q
M\ !])R     0    !0  !Y >0&'RC^(-_IH?H%P^^\3'?]WT_P#AM/S]RC^(
M-_IH?H%P^^\3'?\ =]/_ (;3XGM_]9WXOA9\ 'B=
M
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MD<U==]+LY                                  %5$[G%CVO3;514]J
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MA9\ 'B=
M
M                     *CXRY%XDT=DI7^K&J25*HO==>JW_G]A8F6WJ*P6
M*IKI%17M;RQ-_E/7HB?::WU51)55,U14.5\TKU>]WM55VIUX\=W;ER9:FG4>
MJUT,USN-/14K5=-.]&-]WM7X(G4\Q;O!K'?!IY+W5,_A)?4IT7R9YN^O_D=<
MKTS;EACU72?V"UPV:T4M!3(B,A8B*O\ *=YJOQ7J9  \KU      <98V31/C
ME:CXWIRN:J=%0Y #6_,["_';]-1Z7Y.[^$@<OFQ572?%.Q@B_N)N._/M@?)
MW==2(LD/^TGX3?K1/M*!^**B^\].&6X\V>/34OX9Y%\Q7]K*A^J&K_@Y-KT:
M[\%W_+ZR_C5+2*FE+XX5Y&MZL?R:I?NMHM1OWW>S7JN_0J?48Y,?5OBR]$U
M!Q=@    !J_E5;5V7CM><A94S?([9744=5$CE5/!EC1KEU[M)]I?N?9 S&\+
MNEW3JL,.XM?A/=T;KZU0JUEC9DO$?BW:'Z1:JBIXV._DO\/U5^I='EL][DSR
MT\/\;G<JSME?475GL;3*YJ([XNY%^P]%QF4GT_9C>K:[_1FHZNU7',Z"Y5$D
MU332T[972.5=/Y7J[O[R9W'C#B]%73T\:U]9%3.5E154E,Z6&%4[\STZ=/\
MD0.S25$4O')]'S?*&N<K%;WWR2'KX5P9W'P\M#<<9B+K5)!S-\9TW.[:KS>)
MI-<V][+G)E;E?I^R^.RWVY+9W8[\_)<:?YH\/Q?E7/ZG+V[_ !Z?$A2<:L72
M2-TT=U@HI'(UM=+1N; N^R\WL(#8)K5C'":_,R/YNR&WSW;DAH;>]ZQI*Y47
MP]N1NM.15,GQ'J,\J.&M\6\V['+/9VTBHZ%9'RS<O336Z]5'=D3WF.B2]S=J
MU<HS.RXW:J>ON55N*J5$IF0M\1]0JIM$8U._0QV)\2+%DET6V0+5T5SY%D;2
M5T"PR/:GFU%[D!N5G2[XYPSDM-]I;7E5+0QR6]E2U7LG3PF<Z*FE]B=?B=D-
M^O5NSW'8^)>-VUU7+(ZGM]VH9%7D>J+M%:J[TJ;[IYCW<[SU3JOE9U@RRWWR
M]7JUT23I4VF5L51SLTWF7>N5=]>RBDRNWU667+'8DF^7V^!E1,JM]3E=VTN^
MJ]2!<(U1.)_$UJ_2^6Q+KW:<<,9FCE]('.?#>CN2V0-=I>RHB;0S<)N_DNV:
MM/&#&[M/1Q6^.Y5#ZA_AN\.E5R0.YE:B2*G1N];3W*>S)>*&/V*[/MCOEE?7
M1)N:&@@6=84_V]=O@1_T:J=D/"QLL#$2::KJ'N7^4Y'JB;^I$(7P23-WV.ZU
M./-QQTLUQF6L=7K+\H\7:;1W*FM>SZS73CN_0W=+TQ3)K7E-L;7V2I;/!OE=
MY.8Y.[7-[HIEYI&0Q/EE>UD;$5SG.72(B=U52HN$MNN-%Q%S":Y5]D=4U#87
M55#;'2*D,ODY4<U-;3>^J]5,WZ04E1%PDR!U(KD>L;$<K>_(LC4=^C9BX?S2
M3U67;J=QHQ-*ER-?7R4+7^&ZXLI7+3(N]?3]GO)#E.<VC&[9;[G7+-);*V1L
M;*J!J/C9S=6N<N^C53S*^M=)G:X)3TM+'A7S ZA1J;=/RK"K.Z]/9W/1@]':
MJ'@1/391<**X62.*='STSG*SP^9=-8KD1=HO1.G<WEAC&9;4[RC-+7CTML@J
M%FJ:JY2I'34]*U))']-\VM_1]Y6\_$.6/CH^AEBO+K;#2I2LI64ZZ\59%19=
M>;.WK*1ST?>5N7QIE25GSNMN3YD6LUKY'S+T;K\/OOSULG,/_>3J?]Q1_KN-
M3"8Y6>>U-VQE[MQ:QVV72XVV5E?-7T,J124]/3K(]?5VKT1%^BG3:^\]V1<2
M+#85I8JI:N:NJ8DFCHJ>!TD_(OFK$[?61;A73QKQ9XFU'*BS)4P1H[75&JQ5
M5/T)]AQN%]J9N)=[IL!QFBJKY31QQ7*Y5DRQLUI%:Q$WM=)KM[#'3CN3Z;7=
M[I=B7$2QY0ZLAMRU,==2,5\M%40K'-KVHU>YE</R>@RNSI<K7XJ0^(^)S)6\
MKV.:JHJ*GEV*CQY;U^^(I?W2R6M;BMF<KFVY'<C&\SM(Y7=5=W^K1]DO3>&6
M39_2.;RTE73+>;>U>RRKZKV)\7N3["Y<<]/ELEJS:#.[)617R?QW0T5GE6&I
MJID1L7,B=>5=]>^B.)QJQ9)(W31W6"BD<C6UTM&YL"[[+S>PCR4EIP;@72Q9
M3;/G.2MD;+/2[TM14R.YD15Z:UT^P\O$:HSRHX;WM;S;L<L]G;2*CH5D?+-R
M_@M;KU4=V1/>)A-F[5J91F=FQJUTU?<JG<54J)3,A;XCYU5-HC&IWZ&/Q3B1
M8LDNBVRG6KH[GRJ]M)70+#(]J>;47N0&XV=+OCW#22TWVEMF54M#');V5+5>
MR=/#9SHJ:7V)U.<-^O5MSW'8^)6-VUU7+(ZGM]VH)%7D>J+M%:J[TOO3S'NY
MWGJG5N;3G*.)5AQ^Z.MDORRNN+&HZ2FH(%F?&B]N;78YV+B-8[]9;G7VM:J9
M]N8KJFC\%4J&=^GA]U5=*0NV7VY5V59&G#7&+<BLJO!N-RKIE8DTS=IT:B[5
M$ZGDX8?.2<<<R2^2T#[C\WPK-\A1R1(OJ]$YNJJB=U),)8MM.#&:OO\ 8\EI
MKVMVFF?+4U#JE\2\C(N5$Y&N[(Y$_!0F&!7K';#PKM]RBN$\=BABVVHKU1)%
M3?G[U7LB$5X*_P#9?EWY;6_J(0BG1LG#[A%!6Z^:)+BB5*.^BJ\R<J+[NYNX
MS*ZGT3>OU6]:^,&,5M?3TTRU] VI=R4]16TSHHIE7MRN7IU,WE6>6/%KG245
M[J'4[JF%\S)%;ZB(WR5?:O9$3N8;CO#0OX3W[Y8V+DCI^:GYOP9$^AR^\@LD
M+Z_/^$B7>-)9EM\CWI(F_61BJB_W&,<<<NZ[L6%B_%''LAO;;1"M91W"1O-#
M#6P+"LR=]MWWZ(3HJ7C)&UN=<-ID1$E2Z*WG\]*C=H6T9RDU,HL\Z  84
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MG8H[]\]A/^KW;^P3_J+'X;9[:N(-GGN5D94LIX9E@<D[$:O,B(ODJ].J 2T
M    ,9E/WLW?\CF_4<9,QF4_>S=_R.;]1P%$^A5]YE^_+6_J&Q)KMZ%7WFW[
M\M;^H;$@        :I>F?_I_&/ZI_P"NA4B]U^);?IG_ .G\7_JG_KH5(O=?
MB?6_AOPY?9QY?,?  ?2<0         !0   !Y 8?*/X@W^FA^@7#[[Q,=_W?
M3_X;3\_LH_B#?Z:'Z \/OO$QW_=]/_AM/B>W_P!9WXOA9\ 'B=
M
M
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M@ \3H
M
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M*FN:SQ*NO/UF&>G'Q]-M;OE;: (#BT
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M/;_ZSOQ?"SX /$Z
M
M                       !X[Q<(;5;*FNJG(D4#%>OO]B?%5Z$2SC*Z[%K
MW1R+$VIME1'IT?9[7HO=J_#712$<2LTAR"&DI+6Z1*-$\6;G;RJK_)JI[O\
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MTE18N$V$TL$RU;K93N\)BM8LKMKM41=>U>A.CB]C7II[4<GL5-EZK>U32KN
M^.);[?>L@EH74,M^K'U4=.]JH^*#F<K&JB]MH[>O>2G,<#LF5S055?%-!<*=
M.6&MI970S,3V<S5VJ>Y25(B)V!;E;=DB)8=P_LF+54U92-J*JY3-1LE;63.F
MF5J>7,[LGP):J;14]H!+;?*R:0:+AG98L+N6,-?5?-U?.M1*OB>OS*Y'=%]F
MVH26Y62FN&-3V297_))J9:5RM=IW)R\O?VZ,H!;;Y$1NO#^RW7"Z+&:UDSZ&
MB;&D#TD5LC',337(Y/,^57#VR5^*4=ANS:BO@I%YH:B>9RSL=M5VDGTM]=?
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M>S6HF_M VUL=<ERL]#7(FDJ(62Z]FTV>T\MIHF6ZUTE%$NV4\38D7W(FCU
M    '"26.-6I)(QBN734<NMK[C7GC[CF2X_GMMXC8;3R54M/$D57#&Q7JB-V
MFU:G56JU51?9H]/I=TMS;9\;NUO@DGIK?6+).UFU1%5$Y5=KRZ*GUE173CO<
MZWB5;<E2CJ(:6EA2.2VLJ'>'*J<W7_YO9Y 2FO\ 22RJ]T3[79,6;!=)VK$V
M6)SYG-5>FVLY>_Q+?]''!JW"L(?\]-Y+K<9EJIXU[Q[1$1J^_IM?B57'Z47A
MOYV8?&U_\ILNE_N+IX+\0G<1L=J[F^W_ "!8*E:?P^?FWIJ+O](%@$.XJX2N
M?8PMD==9K;"Z5LDCXHT>KT3?JJBJG3:HOU$Q &MK/16HXV\L>7W!K>^FTS43
M]8N/A9A+,!Q5MEBN$MP:DSYO&E9RN];736U]A+P ,9E/WLW?\CF_4<9,QF4_
M>S=_R.;]1P%$^A5]YE^_+6_J&Q)KMZ%7WFW[\M;^H;$@        :I^F?_I_
M%_ZI_P"NA4:]U^);?IG_ .G\8_JG_KH5(O=?B?6_AOPY?9QY?,?  ?2<0
M %       !  >05A\H_B#?Z9^@7#[[Q,=_W?3_X;3\_<G_B#?Z:'Z!</OO$Q
MW_=]/_AM/B>W_P!9WXOA9\ 'B=
M        JWC1EM[PFX8S=:.9BV"6K2FN,3HD541R]'([NGG]@%I B/%'+68C
MP_NE]B>Q9(X?\F54VCI')IGQZZ4@EWS_ ">Q8/BM"Z."X9WD&O!C<Q&1QHOK
M<SD37T45$ NDA7%7.DP*ST%>ZA6M^55C*3D23DY>;?7>E]A7UYI>+>'VR;(I
MLEMU^CIF^-5VU:=&-Y$^EX:HB+T3:]_(Q'I!Y13Y+P;Q;(;=&KXJBXP3)$O=
M'(UVV?':: V+B=SQL?K7,B+HP.>7ZLQS')[E;;147BIC>QJ4E/OG<BKI5Z(O
M;N5)?X.+])C<N4MR"VTSJ>'Y0MECIT<Q(T3?*KE3:NU[S*9/Q-NDG &FS.S^
M%27*7PD<BLYVM<LB,>B(OEWT!;]MJ'U5OIJB6%T$DL39'1.[L54VK5]Z=CT%
M1<0N(EXM5JQ2T8W!#597D$3%C=*G\'$BM;S/5/BOPZ*8*^KQ9P&CCO\ 67NE
MR>B9(U*RWQTR-<UKEUN/2(JZ77[ +"N&?-H^*UMPM:!7NK*1:KY5XFD;KFZ<
MNO\ 9]OF3@H.XU3:[TH,2JV,?&V>RK(C9&\KFHJ2+I4\E,A7Y/F7$#+KQ9\!
MKZ6RV:T2>!4W*:+GDEE[*UB+M-)I?("[ 4K8LKR["<ZM>,<0*RFNU!=]LH;I
M#'R.;)_(>B:3]'FA=0%29MQ;N%CX@38I9<3JKW61T[*C_)YD15:J;7U=>1X:
MCC!E%NIY*N\<,;[34$2<TLS7H[D;[=:(]=[Y;,?]*^KKKU6PT5(EH:SQ95TF
MU:FD_06%D'&7!*"T54RWVFJU1BHD$"*]\BZ^BB:\P)5AF5VK+\=@O5FGYZ.1
M%YN?HZ-4[M<GDJ%>7+C)57*]U5JX=8S59)+2OY)ZM'^'3,7W/TN^R^PJVPK=
ML.]&/(JY['T4MYK-TS%32MBD5K57W;1'&P'!NPTF.\-[#1T436<]*R>54[OD
M>U'.5?K4"&P\9+E8;C3TO$C$JJP05#T9'7QR>-3[7R<[2:_27%!+'/"R6%[9
M(GM1S7M7:.1>RHI@\^L%)DV(76U7"-'PSP.UO\%R)M')[T4K[T5KU47;A;%!
M5R+(ZW5+Z-CE[\C4143](%P
M                        (+QCM_RO$EJ&IM]'*V7_ -*^JO\ >GV%&FT%
MZHF7*TU='(FVS1JS]AJ\]%B<K)/5>U>547R5.AWXKVTX<L[["X."]BCBHI;S
M*K'3S;BC1%158Q%Z[]BJJ?85G;,?N]STM#;:J5B_^)X:HW[5Z$^Q' \FMM4E
M2RZ16U%^DQFY>;XMZ-+G9K6TXY=[TML'&)'-C:DCD>]$1%<B:VOMT<CSO0
M                "*\2;%'>\<EZL94TNYH7N5$3:)U:JKV1?V&OB=2Z<ZQ#
M(KY*]T%YCEI=JK*1[5B:GQ5-\WUE9W3$;];5=\IME0YB=Y(6^(W[4._'9)K;
MAR2V^&#+0X'6_FJKG<7M^@UL#%^/5W]R%7*NG*U>CD[HO14+_P"%=O6@PVC<
M]NI*G<[NGDY?5_1HO)=8IQS=2X 'G>@
M                                           /CFHYJHY$5%[HJ'T
M$1$1$1$1$\D/-1V^CHGS/HZ6"!\SE?(Z.-&J]R^:JG=3T@        "$<5<W
M?@MJH[@^S5-TH)9EBJE@3:P,Y57G7HO3?3KHKZTW_A%EV8T.5I=XZ2\4T:1,
MIZIWR=B)U[M<FE^DO5%+VFBCFB=',QLD;DTYKDVBI[T*JR[@%@^0U#ZAMO=;
M:EZ[<ZB=R-5?Z'T?L0"4291@L;%>^\8ZC43:KX\/[2'Y!QWP2PL?3V:;YUK7
M+ZE-;H5T]W]+6O[R-TWHLXQ'.KI[M<I8O)FFM_267A/"K$,.5)+/9X?E:?\
MYS/_  LGU*[>OJT!)<7N-1=\>M]PK**2AJ*F%LKZ:3?-$JIOE7:)U3X&3
M  8S*?O9N_Y'-^HXR9C,I^]F[_D<WZC@*)]"K[S+]^6M_4-B37;T*OO,OWY:
MW]0V)         U2],__ $_B_P#5/_70J1>Z_$MOTS_]/XO_ %3_ -="I%[K
M\3ZW\-^'+[./+YCX #Z3D     @  H  @    "L1D_\ $&_TT/T!X??>)CO^
M[Z?_  VGY^Y/_$&_TT/T"X??>)CO^[Z?_#:?$]O_ *SOQ?"SX /$Z
M     %-\7N-,^ 9'%:H<9JKAS0I+XZO5C%WY-TU=Z\P+D!K'^^AK?Q*F_.'?
M] _?15OXE3?G#O\ H V<!K%^^AK?Q*F_.'?]!UR>E141.:V3#GL<[LCJI45?
M_D VA!K%^^BK?Q)F_.'?] _?15OXE3?G#O\ H V=!K%^^BK?Q*F_.'?]!V4_
MI/5LM1%'^XBI=SN1NF3JKEVODG)U4#9D'73R>-3Q2JU6<[4=RKW3:=E.P
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MT50R-7NC>NW,YG*Y&N]Z(J(OO)F
M                           Q5)CMHI*J6II[?3MGE>LCY.7:JY5VJ]3*
M@ B(B:1-(                          ,;=+%:[JQ6W"A@G1?Y3>OV]SW
M4\,=/3QP0-1D4;48QJ>2(FD0[
M
M      QF4_>S=_R.;]1QDS&93][-W_(YOU' 4#Z&M7%2X+DTTJNY8*E)7HB;
M7E2/?3[%)_@/'#&<UR5MCMD%QBJW-<YKIX41J\O=-HY=?60?T*^N&7Y%[?+6
M_J%[VS'[/:ZN>JMMKH:2IG7<LL,#6.>OO5$VH%?93QSQ;&\Q?C==#<GUD<C(
MGR10(K&N=K7GM>Z=D,UQ/XGV3AU#;Y+W%6R_+5<D:4T:.URZWO:IKNA*:FQ6
MFIN<-RJ+912W"'_-U+X6K(SX.UM#G=[1;KS3)3W:AI:V!'(Y(ZB))&HJ>>E
MBWW2[+]S5,W\.L^:58KDC\+^%^ERZUO7=/;HZ>&?%.Q\0H;C)98JV+Y"B+*E
M1$C=HN]*FE5%[+T)JM%2K1+1K30_)%;R+#R)R<OLY>VCIL]GMMEI5IK104M#
M KN98Z>)L;57VZ1 *XPSCGC&6Y;%C]M@N;*N57M8^:!$8JM15\E54[>:'9GG
M&[&,+R=;%=(;C+6-1BO=!"CFMYNJ=55-]/83^BL%HH;C/7T5KHJ>NG_SM1%
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M?M_O#9<'QGT4W["N.-O$%V%X^L%H9\IR.M:Y*.G:G,K41%5TJI_):B+]8%D
M@7 N]W#(>&-GN=XJ'5-=.UZR2.1$5=.5">@
M
M
M                                  ,9E/WLW?\ (YOU'&3,9E/WLW?\
MCF_4<!1/H5?>9?ORUOZAL2:[>A5]YM^_+6_J&Q(        &J7IH?Z?Q?^J?
M^LA4B]U^);?IG_Z?QC^J?^NA4B]U^)];^&_#E]G'E\Q\ !])Q     4
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MZ
M          \]PK:>W4,]973,@I8&+))(]=-:U.JJH'H!1*>D[AZW;Y-\BNJ4
M?/R?+/#;R_'7-O7Z?<7?;ZRGN%#!644S)Z6=B212,7:/:J;14 [S&93][-W_
M ".;]1QDS&93][-W_(YOU' 43Z%7WF7[\M;^H;$FNWH5?>;?ORUOZAL2
M    !JEZ9_\ I_%_ZI_ZY4B]U^);?IG_ .G\7_JG_K%2+W4^M_#?AR^SCR^8
M^  ^DY        @    "@  P^4?Q!O\ 3/T"X??>)CO^[Z?_  VGY^Y1_$&_
MTS] N'WWB8[_ +OI_P##:?$]O_JN_%\+/@ \3H     !JOZ07_>#PS_X'^*I
MM0:K^D%_W@\,_P#@?XJ@6([Z2_$^'UWTE^)\                 %.>D?\
MQ/'?REW]R%QE.>D?_$\=_*7?W(!N#;_XC3?U;?[CO.BW_P 1IOZMO]QW@
M      J(O=-@  B(B:1-( !U+30+,DRPQK*GX?*G-]IV@ #C+%'*Q62L:]J^
M3DVAR '"&&*!G+#&R-OL8U$3]!S  ZHZ:"*1TD<,;'N[N:U$5?K.U414TJ;0
M  =3:>%LSI6PQI*[N]&IM?K.T $1$32)I#I92T\<JRL@B;(O=Z,1%7ZSN 'Q
MS4<U6N1%:O147S.$5/##&L<44;(U[M:U$3[#L '7!3PTZ*D$4<2+U5&-1N_L
M.:-1$TB)H^@#JAIH(4<D,,<:.7:\K43?Q.W2=.B=  "HBII4V@  !41>Z(H
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M=W2\VIE3R\C]JU[?8J*8N<ETW[O+IN7I.S,@ TP
M /-5U<-*WFGD1J>SS4PTESKJQ_);J=4C_P#,=_\ CH9N4C4QM2($=:R^0>NC
MVR)_)544],%WF3U:RAF8[S5J;11,MEQTS.SC)(R-JND<C6IYJ8^2[0,9]&3F
M_DJU4,'7USZAROD<K6]D::92'YSI>;7B?7KH=R5<"IM)6?:0V%72;7LB=CMV
MY>BHCM>TJZ3)LC'=G(OUG(AR/3LO?V'?'6NCZ)*]ONWT&C25 CL=SG3L]KD]
MYV?.LW\J,FD9X$;DKJF5->*J?#H</&F\WO7_ -2ET:2?9C+Q5+&G@QKI7)ZS
MO8AB9*NJ8WU9'(GEUV>&:J?.JMJ7HNTUS+W)Z+)W[NUM2SQ-,557X]CTNF=4
M4[XUD56^Q>I')J2:"17P;<B]=^P[(;@]J_PO1-:1->9QG-WUD]-]FW-XUZY4
M>QZZ15/K)I$^BG7WGICE22+JB:TG4XKR<QVFJ\VGOM]T=!$K455]B.\E/0V\
M3KK3&+YF)3D7NND[JOL*GH>-D%3FD5H^;%;03U'R>.IY]NYMZ1RI[/<-R"^(
M;JU4_A6Z_HGOCJ(I$]1[5(HDK_Y*!)?73IR_!2Z)-W28;1 G7L0FYY%)9UI_
MX.26"1Z(]R_18FR9P/22)KV]G(BH8F<MU&KQY3&9WQ7, &F
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M+,?5G+"9>6D'SU0_^8[_ (5'SU0_^8[_ (5-W_N/X!^*MM_LQ]Q_ /Q5MO\
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MJN7STAC+);5:C:JHZN5-M;[#.IVZ&.F2[B]>5QF%\0 !ID
M                                             *B*BHJ(J+W10 (=
M]R_"?GGYU_<Q:_EO-S<_@IR\WMY/H[]^B8HB-1$1$1$Z(B
M            :_>F#;:ZY8U866ZBJ:M[*Q5<D$3GJU.1>JZ0O''6.98;<Q[5
M:YM/&BHJ:5%Y4,@                               :X^E?:[A<+]ACJ
M"AJJIL4RJ]88G/1GKM[Z3H;' #A FH8T7ORH<P
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M-[(V_P#,S]/3Q4[.6&-C$_V4.TB.$,;(HT9&U&M3LB(<P
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M?^8O1/\ [DBMEC@I=/EU+.GX2IT3X(9=C6L:C6-1K4\D0^A!.P
M
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M*Y\B].9%]G14UY%X@
M                                   ^*B;V?0!BZNS4LZQJJ<K6R+(Y
MJ?AK[SR6['H(;C)5O7G5KU6)O9&[\_B9_77>PG8Q[O'SITG+G)TR]F)O-K6M
M1LD:ZE8FM>U"*S0RT[E2>-[51?9T+ 5.G<X/B9(WEE:CT]Z&W.(&R=R)I&]/
M:IS;*OGK[26S6>BEWN%&K[6]#S.QVB=_YJ?!P5'/%_V3XV;;=HF_@I(OW-T7
M\J?_ (__ +':E@H=:<QSOBI16EEF_P#RXRE536TI//\ _1*29)&KYF/L=EIY
MN(670,<^-K&4BM5%_P#T:F>J,:J&;6GG21/8[HIOD\_:?LSCX>+G8B?21/B?
M%E3E]545=G5/0U].JH^F?I/-$V>9%<V1%>BHB>[J8:9J--)KW;.F9?X1=>S9
MVPO;,FXW)O793JE14>KN[>RJ!CIEW,FSDU43KU4YSP/<NXVJY5[(B=5.ZDL]
M=4I_F71M]K^@T/$KD:[?,FE^Q#T11;3;G(B>73N2&WX]%#IU4])W?R-::96:
MA@F9RNC:B)VY4UH@C%ME6&JAD77*B\JDN3JFT7HO8C-?;IJ9%?&BS1>Y.N_@
M>-*2\.C21OC<KDVB(_M]1FVQK''J31 87'FUS87_ "QSM-72-?W^TS32R[9L
MT  J                        !USP1SQ.CE;S,=T5%\SL!+-C"5MAIY?E
M4B+_  DK4:W?9FO8=]EM$-L@<D?K2R:61Z_A+^PR>NFMGW1F<>,NV[RYW'IM
M[(O>+-(Q\DU-M[7+S*WS0PFUB=IS7H[V*A82I[U.J:E@F7<L3'+[50VP@[9W
M*GT4T<TEZ=MK[E)1)8Z)Z[2-6_T5T=*XY1+YS)\'?_8*CCIM)VU\0Z;75&[3
MXDC;CE$B[W,OQ><W8_0.32QKOV[ZE$9;,BIV1#DCVKYF;GQF!W^8GEC]R]3&
M5&/5L6UB5LJ>Y=*!T>(Q/PT/L3T?*B)K6CR2P5<7^>IWL]ZMZ'VAE2*95EWU
M RR:Y3Q/548JH>Q$16<S7(K?:>1S53U'=%7L!X&?2>JKYG9MJ-5-]_/V!:6H
M=(J11/D7_939D*6P5DR(LO+"W_:ZK]@&,9U=R(J;\M]-GI9'RHB\VW)Y:)5;
MK/34:(O*DLG\MZ;U\#G6VR&=%<W^#>OFB=R#PX]+RR20N7Z7K(9UJ>\B%525
ML$B1QQN61RZ1[5Z:^)UNI;S$N]SK\'[,VV-3#<WM- >:A29*:/Y0[FD5NU76
MM'I++M@ !0
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M[0
M                                  A.,_\ :;F/]72?X:DVT0G&?^TW
M,?ZND_PU)L;S\_:?LSCX-=-'GFH::?\ ST$;OBAZ 8:>"2U4BL1L<38E\E;T
M,=5T$D?TTYV)V<B?WD@/BIM->065$J"J93U22+ZR-VBDI@F9/&CXW(YJ^:$:
MEL-6Y)I&O:CTDW&W?16^\Y06FYTM4Q8)TY-[5R+T^M/,QU7?ANXR]]I/L^G"
M!'MC1)5:K_-43N<S;F^:^&@C43R39]  (
M               &@ /CFHY-.1%3WH>62V44CN9]-$KO;H]8 QT]JB55=3ZB
M>GDG8PU; Z!'/F9RK[?+ZB5'CN],^JH)8HM>(J>KOVBK*Q5DKHH56*14:CU3
M3E\OB2!%14WY$57'JI',1LK4:YFWJO73O9\#V6>BN=/*Y)I4\+^2Y>9%^'L,
M3*_)JXSS*SZ )V!MA\UM.N@U$3LFCZ
M
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M*.KB26-VM+I?)?>!D0
M                                          $)QG_M-S'^KI/\-2;$
M)QG_ +3<Q_JZ3_#4FQO/S]I^S./@ !AH
M
M
M         1CB?C\V4X#>[+2O1E15T[F1*J].;NB+[MH:I\-.*=]X-P5..Y!C
M+WTR3ND5'[AE:Y=(NG*BHY.G3^\VCXM7J\X[@MQN^.015%;2(DBQR-5R*Q%]
M941/8G4K3AMQ9Q#.<5\/B))98;M"Y6RLKF,1DC?)S.;W+KZ@/#P_KN&/$3B+
M%D-$ZMMV5H]L[:623D;(YJ=5;TT[W]=J0+TDKFEFX^6RY.B=,VDCIYEC:NE?
MRKO2*86\Q6"?T@[)'PP9JC2K@55IU58UD1^WJS_9U]7<D/I U%/1^D39*BO?
M''31)2OE?)]%&HO55]P$M_?2TGXGW#^W3_I)O?<M9FWH_P!_OD5%)0MGHIV^
M#(Y'*WEVG?2'O^Z;POW_ *8LG_ W]AT9MDN/Y'P?R]^+UE+54T%'(Q_R=--:
MY6JH%->C5Q1Q3",1N%#DEPDIZF6K\5C&T[Y/5Y43>VHJ>1&L]O%'Q1XX6B;"
M:*545\+'3)'R.E5C^997)W1$3S7V$S]%K ,6RS#;E59%9:>OJ8JSPV22*Y%1
MO*BZZ*AL3C&%8WBRO=CUEHJ![TTZ2*-.=4]G,O7]($A3L:P^FO<)6T^,VWG<
MVGD?).]$[*J::GV;4FW%SA9E>894ERL.7/M%'X#(OD[996^LF]KIJZZ[0I;C
MAPSR'$\$ME7?+P^]OBK7L=.KI'^&Q[4TFW;UU:OVH!F:KC+BTF-46,5N%U%3
MB,+8X4J%?X:N5O7G1O+WWM=;V7G2X9A&;<.[90T%,DF.*GCTS('JSE5=]?BF
MUZ+V4JK-\UP*X>CRE!0SV_Y<M+%'#0M1J312HJ;7E3JG95V='#_-;QPP]'RS
MW9;*MPAJ*V5$\258TB8Y?4=V7:*J*!T>D7EEIH+)%PSLMJ:Q:5\#$J)5:V.)
M$;M-+_*7?55UYEL87C%RLO J&RV.X1U%V6C>L-33S)R)(]57U']M)ON0CB;Q
M%P#*N#M?52R6Y]XK:=%92(C5J(JCLGO32^?L,WZ(K;BG"O=P65:=:N3Y)XBK
M_F]-^C[N;F_2!K_QJX8S8%8K-6W>XR7"^W.:5U5(KMM;I&KI%7JJ[5=JJ_4;
MK8A]ZEF_(H?U$->?3;_T;B_];/\ W--AL0^]2R_D4/ZB =N27)MGQZYW%_T:
M2FDF_P"%JK_R*#]#^CDN$.5937?PE;7U2,61?K<[7UN0N;B?225W#O)*:#_.
MOH9>7WZ:J_\ (JGT,ZB-_#JXP-UXD5>Y7?!S6Z_N4"$XKQ)XEY/G-_QFPU5/
M-*LLS(YYVHC:2-DBIS=.Z]D\_@>2#B/Q-P+.ZG%KK/'?J^HU'3LF=S)SO^@]
MJIUUONB^SR/9Z,:?_MQS'^C4_P".ASX@HB^EQ9$5$5.:G_N<!Y\SROBGPLR.
MU5^37B*X4M>Y7+3-7<6FJG,Q$_!72]T+'X_<6ZS$['9J7&V,^>+Q$DL;W)S>
M%&J)U1/-RJJ(F_>1#TVO\SB7].?_ .@P7I)T=1;Z[A[D+H7R4$=##&Y43HCV
MZ=R_6F_L SM74\9<!Q2IR&\5\5TI)(5\>GDD1TE)S)IKT7MT54Z)M"9\!,_N
MM[X87R_Y/6?*9:&25W.K4;IC6<VNAY^+_%S$:WA3<8[9=::MK+E3^#%2Q/19
M&*[NKV]VZZ]RI,,O;K)Z+V3^$[4U;7_(V(B]5YT1%_1L"1</[=(OH\<1\AJ6
MKXUY6>5'+YM:O[5<8+A7Q/BX?<%:R&AY)\@KKA(VD@WM6)R,3Q'(G77L3S7Z
MRX[O8TQWT6JRVZ1'QV97O_I/]9?TJ:V85PMK,CX87K+;=5.6KMTVHJ5C=JYK
M$1SW;]J(NT^ &T'#&KRVT8/793Q)N4KW-IG5#*'PVM\*-$YMNUUYE]GD55BF
M1<5^+5VK[KC5TCL]JI).5C$7ECWW1BIU5RZ[KV)MAN5S<4> -[H6O62_TU"^
MFGC1=OD<C%Y':_VM?;LBOHJ9]CV/8Q=+)D-QIK75Q52S-6J>D:/141%1%7S1
M4[ =>/<4L\GXTVC&,A?'1<DJ4U931-162.1JKSHODCNB]%-IS3*DR6BRSTJK
M?=;5MU$^K;'$]4UXB-C5.;X*;/T7$3'*W,IL6IZUSKU$YS7P^&J(BM3:]>P$
MN--<NOM!C?I6U%VN\SH:&FJ$=+(UBN5$6'79.J]5-RC3K);30WSTM);;=J9E
M50SU"-EA?O3D\'?70$DX]<9<)RK *JSV57W&NG>U8W/IW1I"J+OGVY$ZZZ=/
M:1BJ2[8OZ*44-0DM.MXN.D8]%:[P5VO;V+R(OP4V.M_"+ K?4LJ*7%K<DK%V
MU7L61$7X.54,1Z1>(SY3PNK*6V0J^KHG-JH86-ZOY=HK41/<J_8!XO1<QNBL
M_"VWU\,+/EMSW//+I.94VJ-;OV(B=O>IY/2PQVCNG#"IN<D+/EUMD9)%-I.9
M&J[3F[]B[W]1$_1KXNV*AQ&+&LGKHK;4T"N2&6H<C(Y(U7>N9>RHN^B^X\_I
M-<5[)>,7_<OB]8RYU%9*QTTU,[G8UJ+M&HJ=U5==O8!*>!F\S]'B6TW)72M2
M.>BVY=KRHJJW[-I]AC?0XOTM1C%YL%0]7/MM2CX]KV8_IK[6K]I/.!>,SX=P
MEH:2XL\*K?')53L7NU7;72^]$T53Z&M,^2[9C<435.]T<35\E7F<[^Y4 V@
M
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MDJ%72,2=O5?8B]E,K-=K=#<&4,U?21ULFE93NF:DCM[UIN]KV4UE,M]X33W
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M8YKVHYBHYJ]45%VBGT
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MA6N^65#5[L5R)IOU(B%C5='35C6-JZ>&=&+S-25B.Y5]J;\SO
M
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M(L"JK=:3VHA.CR>U98Y\V66/BM\<LQDH #SM@
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MS6XCA-)9[G)!)4Q22O<Z!55JHYZN3NB>TF)CDLN5L6>  &%
M
M
M
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MWOLN_19P*GM'%^A?PVJ;Y<HG1WBB<E)46_M(ZJ[(U&]].7[-+[#T8[4Y!C6
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MJGE2FN5)S>HL3UTDJ)V1S7<O7V;$QN])M/@<8WMDC:^-R.8Y$5')V5/:<B*
M
M
M
M        !6GI&5#X.$5Z2)=>*L,3E3R:LK=EED:XC8]^ZG";Q9D7E?50Z8OL
M>BHYOZ40L[78PG$N%E-P1O<$*(D<5H5C43V(Q$0P./X1CSN"#&RVV"66HM*U
M,L[V[D=(L2NYN9>O1>WL,E8_%S_@O+:TE;2W*6B=;:GQ&JO@SL;RN1R=^Z?I
M)7;;#+28'!8'3,=-';DHEF1J\JN\/EYM>SS-Y6R6;]6<?117CS7SA?PLL=?/
M+\WW6J\.K5':61C%>K6*OLZ)]A/^-.(V.GX:7&LHJ"GHJNTQ)44<\#$8Z)[%
M36E3VZT>JGX60S\+K1BMSK7-K+:OB05]*WE=%*CE5'-1?<NE0\M;P\RK(X:>
MVYCED-58X7M=+!24?@R5:-5%1)'*Y>FT3>D-W*6]KZD[)[A5;-<<0LE95KNH
MJ**&61?:Y6(JJ5IF5'#<?2&L5'4MYH:BPSQ/3VHKI$+?I8(Z:FBIX&(R&)J1
ML:B=&M1-(A$+CAU15\5;5E;:N)M-1T#Z1T"L7F<KE<NT7MKUCGCE)E;^99=?
MV5C:K_66_@W=<5<]/GREKUQR)OFO.Y&-<G_H<JI\#+XI:X[+QXI;9#TCH\:9
M W_TJQ"0S\,DDXLQ98VL:E B)-)0\B^O4(US6R;[=$7XF8CQ"H9Q6ERQ:N):
M9]O^1_)^1>??,B\V]ZUT-]<_O_T:_P!^ZK,(LF27;,<\?CF2NLT<=T5)&)3,
ME\1==%]9%T=-%;:^MXF46.<6KW65LD3TJK4R-K(Z6KUOZ7*B+S;3M]7GUMG
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MR?A%P[CN[WR>)=V4;G[TYT:+R]_AYED.X?9K)9_W/S9NU;'R^&LK:/56Z/\
MD<_-KMTV9>_\.(JBS8K:[)+'1TECK(JA$D:KED:SOU37K+[1,I+WN^\-=D5X
M]XU9[/@UNJ[3;Z>CJJ"NITIY8&(US$WKNG<GG%.".LX87]E1I6NH7/7XHFT_
M2@XIXG49EC'S72U45+(E1'-SR,5R::N]:0Q/&VIF3"&6"@W)=+U+'04[&]U3
M>WNU[$:U=F)>J2>NVNTNV=X4U$E5PWQJ:=561U!#M5\_51"5'AL%MBLUDH+;
M3?YFD@9 U?:C4UO]![C.5WE;#'M  &5
M
M
M                                        &.MUFH+;65]50TS8)JZ1
M):A6*NI'HFN;79%]JIW\S(@
M       ,>EGH&WM]W2F:MR="E.LZJJJD:+OE3?1$WUZ=S(  G8
M  !Y;K;J2[6ZHH;C3LJ*2H8L<D3TVCFJ=E) REIXX(45L4348U%<KE1$[=5Z
MJ=P                                      !CJBS4$]YI[K-3-?7T\
M;HH97*J^&U>^D[(J^W6S(@ G8
M
M
6                         !__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
